﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Tanimoto, S
   Tamura, H
   Ue, T
   Yamane, K
   Maruyama, H
   Kawakami, H
   Kiuchi, Y
AF Tanimoto, Seiji
   Tamura, Hiroki
   Ue, Takahiro
   Yamane, Ken
   Maruyama, Hirofumi
   Kawakami, Hideshi
   Kiuchi, Yoshiaki
TI A polymorphism of LOC387715 gene is associated with age-related macular
   degeneration in the Japanese population
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE age-related macular degeneration (AMD); complement factor H (CFH);
   LOC387715; 10q26; Japanese; polymorphism
ID COMPLEMENT FACTOR-H; RISK-FACTORS; CHOROIDAL NEOVASCULARIZATION;
   CIGARETTE-SMOKING; POOLED FINDINGS; 3 CONTINENTS; MACULOPATHY;
   SUSCEPTIBILITY; VARIANT; PREVALENCE
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness among older adults in developed countries and also in Japan. Previous research suggests that AMD is etiologically a complex disease, caused by multiple genes and environmental factors. Association studies have identified that a complement factor H gene (CFH) variant is a major risk factor for AMD in Caucasians. However, we and two other groups have reported no association between CFH and AMD in the Japanese population. Recent studies have suggested that LOC387715 on chromosome 10q26 may be the second major risk loci for AMD in Caucasians. In this study, we examined the association between LOC387715 and AMD in Japanese, and our results show that polymorphism of the LOC387715 gene is associated with AMD in Japanese as well as in Caucasians. Our data show a disease odds ratio of 6.20 (95% Cl: 2.87-13.40) conferred by homozygosity for risk alleles at LOC387715 compared with the non-risk genotype. A polymorphism of LOC387715 gene is associated with AMD in the Japanese population. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Hiroshima Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Hiroshima 730, Japan.
   Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Epidemiol, Hiroshima 730, Japan.
C3 Hiroshima University; Hiroshima University
RP Tanimoto, S (通讯作者)，1-2-3 Kasumi,Minami Ku, Hiroshima 7348551, Japan.
EM stanimo@hiroshima-u.ac.jp
RI Kawakami, Hideshi/A-2086-2009; Kawakami, Hideshi/ABE-4077-2021;
   Maruyama, Hirofumi/B-9333-2011; Javadzadeh, Alireza/L-6424-2017
OI Kawakami, Hideshi/0000-0002-1405-0901; Kawakami,
   Hideshi/0000-0002-1405-0901; Maruyama, Hirofumi/0000-0001-7613-8717;
   Javadzadeh, Alireza/0000-0002-5151-6125
CR Arden G B, 2006, J Br Menopause Soc, V12, P64, DOI 10.1258/136218006777525703
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 29
TC 40
Z9 41
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD FEB 27
PY 2007
VL 414
IS 1
BP 71
EP 74
DI 10.1016/j.neulet.2006.12.011
PG 4
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 146WR
UT WOS:000244965900015
PM 17194541
DA 2022-11-30
ER

PT J
AU Parmeggiani, F
   Gemmati, D
   Costagliola, C
   Sebastian, A
   Incorvaia, C
AF Parmeggiani, Francesco
   Gemmati, Donato
   Costagliola, Ciro
   Sebastian, Adolfo
   Incorvaia, Carlo
TI Predictive role of C677T MTHFR polymorphism in variable efficacy of
   photodynamic therapy for neovascular age-related macular degeneration
SO PHARMACOGENOMICS
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   endothelium; folate pathway gene polymorphisms; pharmacogenetics;
   photodynamic therapy with verteporfin; thrombophilia
ID METHYLENETETRAHYDROFOLATE REDUCTASE GENE; OCCULT CHOROIDAL
   NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR; NON-HODGKINS-LYMPHOMA;
   VERTEPORFIN THERAPY; NATURAL-HISTORY; FACTOR-XIII; INTRAVITREAL
   BEVACIZUMAB; HOMOCYSTEINE METABOLISM; VAL34LEU POLYMORPHISM
AB Age-related macular degeneration (AMD) complicated by subfoveal choroidal neovascularization (CNV) is the leading cause of severe central blindness in developed countries. AMD-related CNVs are distinguishable in classic and occult subtypes, characterized by variable natural history and different responsiveness to therapeutic procedures. Combined and repeated use of photodynamic therapy with verteporfin (PDT-V) and antiangiogenic drugs represents the most promising strategy against neovascular AMD, but it is unavoidably associated with mounting health-resource utilization. Predictive correlations between peculiar coagulation-balance gene variants and different levels of post-PDT-V benefit have recently been documented in Caucasians with AMD-related CNVs. In particular, methylenetetrahydrofolate reductase C677T substitution, a common thrombophilic folate pathway genotypic polymorphism, influences a better CNV responsiveness to PDT-V in classic-but not in occult-CNV cases. These pharmacogenetic findings indicate the opportunities to optimize the eligibility criteria of PDT-V and/or to perform this intriguing therapy in a customized manner, for finally minimizing the socio-economic burden of neovascular AMD.
C1 [Parmeggiani, Francesco; Sebastian, Adolfo; Incorvaia, Carlo] Univ Ferrara, Sez Clin Oclist, Dipartimento Discipline Med Chirurg Comunicaz & C, I-44100 Ferrara, Italy.
   [Gemmati, Donato] Univ Ferrara, Dept Hematol, Ctr Study Hemostasis & Thrombosis, I-44100 Ferrara, Italy.
   [Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Campobasso, Italy.
C3 University of Ferrara; University of Ferrara; University of Molise
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Sez Clin Oclist, Dipartimento Discipline Med Chirurg Comunicaz & C, Corso Giovecca 203, I-44100 Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Gemmati, Donato/E-5107-2010; Costagliola, Ciro/G-5707-2012
OI Costagliola, Ciro/0000-0001-8477-6188; Gemmati,
   Donato/0000-0001-6213-6120
CR Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Ardissino D, 1997, LANCET, V349, P769, DOI 10.1016/S0140-6736(96)11189-2
   Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Ariens RAS, 2002, BLOOD, V100, P743, DOI 10.1182/blood.V100.3.743
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Attie-Castro FA, 2000, THROMB HAEMOSTASIS, V84, P601, DOI 10.1055/s-0037-1614074
   Austin RC, 2004, CELL DEATH DIFFER, V11, pS56, DOI 10.1038/sj.cdd.4401451
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bernardi F, 2002, PATHOPHYSIOL HAEMO T, V32, P335, DOI 10.1159/000076692
   Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840
   Casas JP, 2005, LANCET, V365, P224, DOI 10.1016/S0140-6736(05)70152-5
   Castoldi E, 2004, CURR OPIN HEMATOL, V11, P176, DOI 10.1097/01.moh.0000130315.41033.32
   Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chambers JC, 1999, CIRCULATION, V99, P1156, DOI 10.1161/01.CIR.99.9.1156
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Coppola A, 2000, SEMIN THROMB HEMOST, V26, P243, DOI 10.1055/s-2000-8469
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   D'Angelo A, 2003, PATHOPHYSIOL HAEMO T, V33, P337, DOI 10.1159/000083824
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   Danckwardt S, 2006, ACTA HAEMATOL-BASEL, V115, P192, DOI 10.1159/000090934
   Dayal S, 2002, ARTERIOSCL THROM VAS, V22, P1996, DOI 10.1161/01.ATV.0000041629.92741.DC
   de Koning ABL, 2003, CLIN BIOCHEM, V36, P431, DOI 10.1016/S0009-9120(03)00062-6
   De Stefano V, 2000, SEMIN THROMB HEMOST, V26, P305, DOI 10.1055/s-2000-8473
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342
   Essex RW, 2003, CLIN EXP OPHTHALMOL, V31, P476, DOI 10.1046/j.1442-9071.2003.00714.x
   Faraci FM, 2004, STROKE, V35, P345, DOI 10.1161/01.STR.0000115161.10646.67
   FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327
   Gemmati D., 2008, Folate-pathway gene variants in cancer: haematological malignancies, P23
   Gemmati D., 2008, Folate-pathway gene variants in cancer: haematological malignancies, P1
   Gemmati D, 2004, CANCER EPIDEM BIOMAR, V13, P787
   Gemmati D, 1999, HAEMATOLOGICA, V84, P824
   Gemmati D, 2007, HAEMATOLOGICA, V92, P478, DOI 10.3324/haematol.10587
   GERMMATI D, 1999, ARTERIOSCLER THROMB, V19, P1761
   Goyette P, 2000, HUM MUTAT, V16, P132, DOI 10.1002/1098-1004(200008)16:2<132::AID-HUMU5>3.0.CO;2-T
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hasan T., 1997, CANC MED, P739
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588
   Holven KB, 2007, J THROMB HAEMOST, V5, P193, DOI 10.1111/j.1538-7836.2006.02275.x
   Holven KB, 2003, J NUTR, V133, P3588, DOI 10.1093/jn/133.11.3588
   Ilhan N, 2008, ARCH MED RES, V39, P125, DOI 10.1016/j.arcmed.2007.07.009
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Isola V, 2006, AM J OPHTHALMOL, V142, P680, DOI 10.1016/j.ajo.2006.04.028
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kanani PM, 1999, CIRCULATION, V100, P1161, DOI 10.1161/01.CIR.100.11.1161
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kolling K, 2004, AM J CARDIOL, V93, P1201, DOI 10.1016/j.amjcard.2004.02.009
   Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Ma J, 1999, CANCER EPIDEM BIOMAR, V8, P825
   MA J, CANC RES, V57, P1098
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   Manku KK, 2007, CLIN EXP OPHTHALMOL, V35, P330, DOI 10.1111/j.1442-9071.2007.01482.x
   Mao RF, 2008, CELL BIOCHEM FUNCT, V26, P352, DOI 10.1002/cbf.1450
   Matthews RG, 2007, CLIN CHEM LAB MED, V45, P1700, DOI 10.1515/CCLM.2007.324
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Molloy AM, 1998, CLIN CHEM, V44, P186
   NEMERSON Y, 1992, SEMIN HEMATOL, V29, P170
   Okumura T, 2003, J THROMB HAEMOST, V1, P1856, DOI 10.1046/j.1538-7836.2003.00339.x
   Parmeggiani F, 2006, OPHTHALMOLOGY, V113, P157
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Peng FY, 2001, INT J MOL MED, V8, P509
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P145
   Postea O, 2006, ARTERIOSCL THROM VAS, V26, P508, DOI 10.1161/01.ATV.0000201039.21705.dc
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rongioletti M, 2005, PLATELETS, V16, P185, DOI 10.1080/09537100400020187
   Rosenberg N, 2002, AM J HUM GENET, V70, P758, DOI 10.1086/338932
   Rosendaal Frits R, 2005, Hematology Am Soc Hematol Educ Program, P1
   Rosenfeld PJ, 2007, AM J OPHTHALMOL, V144, P970, DOI 10.1016/j.ajo.2007.08.017
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523
   Sakurai K, 2003, J PHARMACOL SCI, V91, P182
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schmidt-Erfurth U, 2008, OPHTHALMOLOGY, V115, P134, DOI 10.1016/j.ophtha.2007.02.033
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schwahn B, 2001, Am J Pharmacogenomics, V1, P189, DOI 10.2165/00129785-200101030-00004
   Shemirani AH, 2006, BBA-PROTEINS PROTEOM, V1764, P1420, DOI 10.1016/j.bbapap.2006.06.007
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594
   Ungvari Z, 2003, ARTERIOSCL THROM VAS, V23, P418, DOI 10.1161/01.ATV.0000061735.85377.40
   Virgili G, 2007, COCHRANE DB SYST REV, V3
   Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Weiss N, 2005, CURR DRUG METAB, V6, P27, DOI 10.2174/1389200052997357
   Weiss N, 2002, ARTERIOSCL THROM VAS, V22, P34, DOI 10.1161/hq1201.100456
   Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998
   Wickens J, 2006, DRUG SAFETY, V29, P189, DOI 10.2165/00002018-200629030-00003
   Wilcken B, 2003, J MED GENET, V40, P619, DOI 10.1136/jmg.40.8.619
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamada K, 2001, P NATL ACAD SCI USA, V98, P14853, DOI 10.1073/pnas.261469998
   Yang N, 2006, EYE, V20, P523, DOI 10.1038/sj.eye.6701991
   Ye Z, 2006, LANCET, V367, P651, DOI 10.1016/S0140-6736(06)68263-9
   Zuluaga MF, 2007, INVEST OPHTH VIS SCI, V48, P1767, DOI 10.1167/iovs.06-1224
   2005, RATINA, V25, P119
NR 129
TC 23
Z9 24
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD JAN
PY 2009
VL 10
IS 1
BP 81
EP 95
DI 10.2217/14622416.10.1.81
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 396BR
UT WOS:000262567700014
PM 19102718
OA Green Published
DA 2022-11-30
ER

PT J
AU El Ameen, A
   Cohen, SY
   Semoun, O
   Miere, A
   Srour, M
   Quaranta-El Maftouhi, M
   Oubraham, H
   Blanco-Garavito, R
   Querques, G
   Souied, EH
AF El Ameen, Ala
   Cohen, Salomon Y.
   Semoun, Oudy
   Miere, Alexandra
   Srour, Mayer
   Quaranta-El Maftouhi, Maddalena
   Oubraham, Hassiba
   Blanco-Garavito, Rocio
   Querques, Giuseppe
   Souied, Eric H.
TI TYPE 2 NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
   IMAGED BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; Type 2
   neovascularization; OCT-angiography
ID CLASSIC CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   CLASSIFICATION; MACULOPATHY; MEMBRANES
AB Purpose: Optical coherence tomography angiography is a novel and noninvasive technique for imaging retinal microvasculature by detecting changes in reflectivity that is related to blood flow. The purpose of this study was to describe Type 2 neovascularization characteristics in age-related macular degeneration using optical coherence tomography angiography.
   Methods: Fourteen eyes of 14 consecutive patients with Type 2 neovascularization were prospectively included. All patients underwent a complete ophthalmological examination, including color and infrared fundus photography, fluorescein and indocyanine green angiography, spectral domain optical coherence tomography angiography, and optical coherence tomography angiography.
   Results: In all cases, Type 2 lesions could be detected by optical coherence tomography angiography, presenting as a hyperflow lesion in the outer retina, with a glomerulus (4/14) or medusa shape (10/14), surrounded by a dark halo. The superficial layer and the deep retina showed no abnormal flow. Surprisingly, the Type 2 lesions could also be observed in the presumed choriocapillaris layer. These glomerulus- or medusa-shaped lesions were connected, in 10/14 eyes, to a thicker main branch, which seemed to continue deep into the choroidal layers.
   Conclusion: Optical coherence tomography angiography may be a new imaging method for the diagnosis of Type 2 neovascularization in clinical routine. However, the specificity of the features needs to be investigated in further studies.
C1 [El Ameen, Ala; Cohen, Salomon Y.; Semoun, Oudy; Miere, Alexandra; Srour, Mayer; Quaranta-El Maftouhi, Maddalena; Oubraham, Hassiba; Blanco-Garavito, Rocio; Querques, Giuseppe; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Querques,
   Giuseppe/0000-0002-3292-9581
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gelisken F, 1998, JPN J OPHTHALMOL, V42, P300, DOI 10.1016/S0021-5155(98)00010-0
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   Puliafito CA, 2014, OSLI RETINA, V45, P360, DOI 10.3928/23258160-20140925-01
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Soubrane G, 2004, J FR OPHTALMOL, V27, P79, DOI 10.1016/S0181-5512(04)96098-6
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 16
TC 90
Z9 90
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2015
VL 35
IS 11
BP 2212
EP 2218
DI 10.1097/IAE.0000000000000773
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV5LD
UT WOS:000364311100007
PM 26441269
DA 2022-11-30
ER

PT J
AU Banerjee, A
   Kumar, S
   Kulhara, P
   Gupta, A
AF Banerjee, Anindya
   Kumar, Suresh
   Kulhara, Parmanand
   Gupta, Amod
TI Prevalence of depression and its effect on disability in patients with
   age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; depression; disability;
   vision-specific disability; World Health Organization disability
   assessment schedule
ID IMPAIRED VISION; VISUAL-ACUITY; IMPACT; SCALE
AB Aims: To estimate depression in patients with age-related macular degeneration (AMD) and study the relationships among depression, visual acuity, and disability.
   Materials and Methods: It was a cross-sectional study with consecutive sampling (n = 53) of patients with AMD aged 50 years and above attending the retina clinic of a tertiary care hospital in North India. Depression, general disability and vision-specific disability were assessed in subjects meeting selection criteria. Assessments were done using the fourth edition of Diagnostic and Statistical Manual of mental disorders (DSM- IV) Geriatric Depression Scale (GDS), Structured Clinical Interview for DSM-IV Axis -I Disorders, Clinical Version (SCID-CV), World Health Organization Disability Assessment Schedule-II (WHODAS-II) and Daily Living Tasks dependent on Vision scale (DLTV). Non-parametric correlation analyses and regression analyses were performed.
   Results: Out of 53 participants, 26.4 (n = 14) met DSM-IV criteria for the diagnosis of depressive disorder. Depressed patients had significantly greater levels of general and vision-specific disability than non-depressed patients. General disability was predicted better by depression and vision-specific disability than by visual acuity.
   Conclusion: Depression is a major concern in patients with AMD and contributes more to disability than visual impairment.
C1 [Banerjee, Anindya; Kumar, Suresh; Kulhara, Parmanand] Postgrad Inst Med Educ & Res, Dept Psychiat, Chandigarh 160012, India.
   [Gupta, Amod] Postgrad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh 160012, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh
RP Kumar, S (通讯作者)，Postgrad Inst Med Educ & Res, Dept Psychiat, Sector 12, Chandigarh 160012, India.
EM drsalgotra@yahoo.co.in
RI Gupta, Amod/V-7633-2017
OI Gupta, Amod/0000-0001-8427-5738
CR Almeida OP, 1999, INT J GERIATR PSYCH, V14, P858, DOI 10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO;2-8
   APA, 1994, DIAGNOSTIC STAT MANU
   Babor T.F., 1992, ALCOHOL USE DISORDER
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BLAZER D, 1989, NEW ENGL J MED, V320, P164, DOI 10.1056/NEJM198901193200306
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796
   Cole MG, 2003, AM J PSYCHIAT, V160, P1147, DOI 10.1176/appi.ajp.160.6.1147
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   First MB, 1997, STRUCTURED CLIN INTE
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Ho T., 1997, SMJ, V38, P149
   Jain I S, 1984, Indian J Ophthalmol, V32, P343
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Rovner BW, 2006, OPHTHALMOLOGY, V113, P1743, DOI 10.1016/j.ophtha.2006.05.033
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   SHMUELYDULITZKI Y, 1995, AM J GERIAT PSYCHIAT, V3, P325, DOI 10.1097/00019442-199503040-00007
   ShmuelyDulitzki Y, 1997, AM J GERIAT PSYCHIAT, V5, P216, DOI 10.1097/00019442-199700530-00005
   Tasman W, 2005, CAN J OPHTHALMOL, V40, P389, DOI 10.1016/S0008-4182(05)80082-1
   *WHODAS 2, 2000, DIS ASS SCH TRAIN MA
NR 27
TC 24
Z9 24
U1 0
U2 7
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD NOV-DEC
PY 2008
VL 56
IS 6
BP 469
EP 474
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 363QP
UT WOS:000260282100005
PM 18974517
DA 2022-11-30
ER

PT J
AU Loane, E
   Nolan, JM
   O'Donovan, O
   Bhosale, P
   Bernstein, PS
   Beatty, S
AF Loane, Edward
   Nolan, John M.
   O'Donovan, Orla
   Bhosale, Prakash
   Bernstein, Paul S.
   Beatty, Stephen
TI Transport and retinal capture of lutein and zeaxanthin with reference to
   age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE absorption; age-related macular degeneration; apolipoprotein E;
   lipoproteins; lutein; macular pigment; transport; xanthophyll-binding
   proteins; zeaxanthin
ID APOLIPOPROTEIN-E POLYMORPHISM; DENSITY-LIPOPROTEIN RECEPTORS;
   BETA-CAROTENE; NUTRITIONAL MANIPULATION; PRIMATE RETINAS; E GENE;
   INTESTINAL-ABSORPTION; EPSILON-4 ALLELE; BINDING-PROTEIN; PIGMENT
AB Age-related macular degeneration (AMD) is the most common cause of irreversible blindness in the elderly population in the western world. The etiology and pathogenesis of this disease remain nuclear. However, there is an increasing body of evidence supporting the hypothesis that the macular pigment carotenoids, lutein and zeaxanthin, play an important role in protection against AMD by filtering out blue light at a pre-receptoral level, or by quenching free radicals. Lutein and zeaxanthin are dietary xanthophyll carotenoids, which are delivered to the retina via plasma lipoproteins. The biological mechanisms governing retinal capture and accumulation of lutein and zeaxanthin, to the exclusion of other carotenoids, are still poorly understood. Although these mechanisms remain unclear, it is possible that selective capture of these carotenoids is related to lipoprotein, or apolipoprotein, function and profile. Xanthophyll-binding proteins appear to play an important role in the retinal capture of the xanthophyll carotenoids. The Pi isoform of GSTP1 has been isolated as a specific binding protein for zeaxanthin. The binding protein responsible for retinal uptake of lutein remains elusive. This article reviews the literature germane to the mechanisms involved in the capture, accumulation and stabilization of lutein and zeaxanthin by the retina, and the processes involved in their transport in serum.
C1 [Loane, Edward] Waterford Inst Technol, Macular Pigment Res Grp, Waterford, Ireland.
   [Beatty, Stephen] Waterford Reg Hosp, Dept Ophthalmol, Waterford, Ireland.
   [Bhosale, Prakash; Bernstein, Paul S.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
C3 South East Technological University (SETU); Utah System of Higher
   Education; University of Utah
RP Loane, E (通讯作者)，Waterford Inst Technol, Macular Pigment Res Grp, Waterford, Ireland.
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084; O' Donovan, Orla/0000-0003-3980-8835
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, INVEST OPHTH VIS SCI, V41, pS600
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2004, INVEST OPHTH VIS SCI, V45, pU322
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Billsten HH, 2003, PHOTOCHEM PHOTOBIOL, V78, P138, DOI 10.1562/0031-8655(2003)078<0138:PPOXIC>2.0.CO;2
   BOERWINKLE E, 1988, AM J HUM GENET, V42, P104
   BOERWINKLE E, 1987, AM J MED GENET, V27, P567, DOI 10.1002/ajmg.1320270310
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943
   Chan C, 1998, CURR EYE RES, V17, P890, DOI 10.1076/ceyr.17.9.890.5141
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2
   Dentchev T, 2003, MOL VIS, V9, P184
   During A, 2002, J LIPID RES, V43, P1086, DOI 10.1194/jlr.M200068-JLR200
   During A, 2004, ARCH BIOCHEM BIOPHYS, V430, P77, DOI 10.1016/j.abb.2004.03.024
   Durrington PN, 1989, HYPERLIPIDAEMIA DIAG
   EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566
   ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GOLDSTEIN JL, 1982, MED CLIN N AM, V66, P335, DOI 10.1016/S0025-7125(16)31424-9
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Goulinet S, 1997, ARTERIOSCL THROM VAS, V17, P786, DOI 10.1161/01.ATV.17.4.786
   GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HAYES KC, 1974, INVEST OPHTH VISUAL, V13, P499
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   KRINSKY NI, 1982, J NATL CANCER I, V69, P205
   Kuhrt H, 1997, J BRAIN RES, V38, P223
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Leon AS, 2004, METABOLISM, V53, P108, DOI 10.1016/j.metabol.2003.08.013
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178
   MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1
   MAHLEY RW, 1984, J LIPID RES, V25, P1277
   Mouchel Y, 1995, NEUROREPORT, V7, P205
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   PARRA HJ, 1992, ARTERIOSCLER THROMB, V12, P701, DOI 10.1161/01.ATV.12.6.701
   POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2
   QUARMBY R, 1977, COMP BIOCHEM PHYS B, V56, P55, DOI 10.1016/0305-0491(77)90222-X
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schneeberger SA, 1997, RETINA-J RET VIT DIS, V17, P38, DOI 10.1097/00006982-199701000-00008
   SCHNEIDER WJ, 1981, J CLIN INVEST, V68, P1075, DOI 10.1172/JCI110330
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shanmugaratnam J, 1997, MOL BRAIN RES, V50, P113, DOI 10.1016/S0169-328X(97)00176-9
   Siems WG, 1999, BIOFACTORS, V10, P105, DOI 10.1002/biof.5520100204
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   SNIPS GJ, 1986, P NATL ACAD SCI USA, V83, P1130, DOI 10.1073/pnas.83.4.1130
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   STAHL W, 1992, J NUTR, V122, P2161, DOI 10.1093/jn/122.11.2161
   Stewart JE, 1998, INT J BIOCHEM CELL B, V30, P407, DOI 10.1016/S1357-2725(97)00151-9
   Sugawara T, 2001, J NUTR, V131, P2921, DOI 10.1093/jn/131.11.2921
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   UTERMANN G, 1980, AM J HUM GENET, V32, P339
   van den Berg H, 1998, AM J CLIN NUTR, V68, P82, DOI 10.1093/ajcn/68.1.82
   Viroonudomphol D, 2003, ASIA PAC J CLIN NUTR, V12, P73
   WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518
   Werder M, 2001, BIOCHEMISTRY-US, V40, P11643, DOI 10.1021/bi0109820
   WERNER JS, 1988, J OPT SOC AM A, V5, P2122, DOI 10.1364/JOSAA.5.002122
   WHITE WS, 1994, J AM COLL NUTR, V13, P665
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 100
TC 88
Z9 93
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2008
VL 53
IS 1
BP 68
EP 81
DI 10.1016/j.survophthal.2007.10.008
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 253SR
UT WOS:000252538400006
PM 18191658
OA Green Accepted
DA 2022-11-30
ER

PT J
AU George, AK
   Singh, M
   Homme, RP
   Majumder, A
   Sandhu, HS
   Tyagi, SC
AF George, Akash K.
   Singh, Mahavir
   Homme, Rubens Petit
   Majumder, Avisek
   Sandhu, Harpal S.
   Tyagi, Suresh C.
TI A hypothesis for treating inflammation and oxidative stress with
   hydrogen sulfide during age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE eye diseases; hydrogen sulfide treatment; inflammation; macula;
   oxidative stress; pyroptosis; retinal degeneration
ID RETINAL-PIGMENT EPITHELIUM; MOUSE MODEL; CELL-DEATH; PROTECTS; THERAPY;
   HYPERHOMOCYSTEINEMIA; NEOVASCULARIZATION; BISRETINOIDS; LOCALIZATION;
   HOMOCYSTEINE
AB Age-related macular degeneration (AMD) is a leading cause of blindness and is becoming a global crisis since affected people will increase to 288 million by 2040. Genetics, age, diabetes, gender, obesity, hypertension, race, hyperopia, iris-color, smoking, sun-light and pyroptosis have varying roles in AMD, but oxidative stress-induced inflammation remains a significant driver of pathobiology. Eye is a unique organ as it contains a remarkable oxygengradient that generates reactive oxygen species (ROS) which upregulates inflammatory pathways. ROS becomes a source of functional and morphological impairments in retinal pigment epithelium (RPE), endothelial cells and retinal ganglion cells. Reports demonstrated that hydrogen sulfide (H2S) acts as a signaling molecule and that it may treat ailments. Therefore, we propose a novel hypothesis that H2S may restore homeostasis in the eyes thereby reducing damage caused by oxidative injury and inflammation. Since H2S has been shown to be a powerful antioxidant because of its free-radicals' inhibition properties in addition to its beneficial effects in age-related conditions, therefore, patients may benefit from H2S salubrious effects not only by minimizing their oxidant and inflammatory injuries to retina but also by lowering retinal glutamate excitotoxicity.
C1 [George, Akash K.; Singh, Mahavir; Homme, Rubens Petit] Univ Louisville, Sch Med, Dept Physiol, Eye & Vis Sci Lab, Louisville, KY 40202 USA.
   [George, Akash K.; Singh, Mahavir; Homme, Rubens Petit; Majumder, Avisek; Tyagi, Suresh C.] Univ Louisville, Sch Med, Dept Physiol, Louisville, KY 40202 USA.
   [Majumder, Avisek] Univ Louisville, Sch Med, Dept Biochem & Mol Genet, Louisville, KY 40202 USA.
   [Sandhu, Harpal S.] Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Louisville, KY 40202 USA.
   [Sandhu, Harpal S.] Univ Louisville, Sch Med, Kentucky Lions Eye Ctr, Louisville, KY 40202 USA.
C3 University of Louisville; University of Louisville; University of
   Louisville; University of Louisville; University of Louisville
RP Singh, M (通讯作者)，Univ Louisville, Sch Med, Dept Physiol, Eye & Vis Sci Lab, Louisville, KY 40202 USA.
EM gene2genetics@gmail.com; mahavir.singh@louisville.edu
RI Majumder, Avisek/AAO-9296-2020
OI Majumder, Avisek/0000-0002-6761-2242; Singh, Mahavir/0000-0002-2415-3314
FU NIH Heart, Lung, and Blood Institute [HLO74815]; Institute of
   Neurological Disorders and Stroke [NS-084823]
FX Supported in part by NIH Heart, Lung, and Blood Institute (No.HLO74815);
   Institute of Neurological Disorders and Stroke (No.NS-084823).
CR Abe K, 1996, J NEUROSCI, V16, P1066
   Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Albini TA, 2005, BRIT J OPHTHALMOL, V89, P901, DOI 10.1136/bjo.2004.060293
   Alfadda AA, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/936486
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Bringmann A, 2000, INVEST OPHTH VIS SCI, V41, P2791
   Calvert JW, 2010, CIRCULATION, V122, P11, DOI 10.1161/CIRCULATIONAHA.109.920991
   Cia D, 2016, J CELL MOL MED, V20, P1651, DOI 10.1111/jcmm.12857
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Cottet S, 2009, CURR MOL MED, V9, P375, DOI 10.2174/156652409787847155
   Droge W, 2002, EXP GERONTOL, V37, P1333, DOI 10.1016/S0531-5565(02)00175-4
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Du JB, 2014, J BIOL CHEM, V289, P9741, DOI 10.1074/jbc.M113.517995
   Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104
   Farinati F, 2010, DIGEST DIS, V28, P579, DOI 10.1159/000320052
   Fiorucci S, 2007, BRIT J PHARMACOL, V150, P996, DOI 10.1038/sj.bjp.0707193
   Flannigan KL, 2014, P NATL ACAD SCI USA, V111, P13559, DOI 10.1073/pnas.1413390111
   Gersztenkorn D, 2016, INVEST OPHTH VIS SCI, V57, P3002, DOI 10.1167/iovs.15-18555
   Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006
   Gong QH, 2011, J ALZHEIMERS DIS, V24, P173, DOI 10.3233/JAD-2011-110128
   Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878
   Hughes MN, 2009, FREE RADICAL BIO MED, V47, P1346, DOI 10.1016/j.freeradbiomed.2009.09.018
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jin HL, 2016, J PHARMACEUT BIOMED, V117, P560, DOI 10.1016/j.jpba.2015.10.010
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaneko Y, 2006, DIABETES, V55, P1391, DOI 10.2337/db05-1082
   Kiang AS, 2014, ADV EXP MED BIOL, V801, P783, DOI 10.1007/978-1-4614-3209-8_98
   Kimura H, 2005, ANTIOXID REDOX SIGN, V7, P795, DOI 10.1089/ars.2005.7.795
   Kimura H, 2011, EXP PHYSIOL, V96, P833, DOI 10.1113/expphysiol.2011.057455
   Kimura H, 2011, AMINO ACIDS, V41, P113, DOI 10.1007/s00726-010-0510-x
   Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje
   Kimura Y, 2006, ANTIOXID REDOX SIGN, V8, P661, DOI 10.1089/ars.2006.8.661
   Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282
   Kraus JP, 2001, CYSTATHIONINE SYNTHA, P223
   Kulkarni M, 2011, NEUROCHEM RES, V36, P1540, DOI 10.1007/s11064-011-0482-6
   Lavu M, 2011, CLIN SCI, V120, P219, DOI 10.1042/CS20100462
   Li L, 2007, FREE RADICAL BIO MED, V42, P706, DOI 10.1016/j.freeradbiomed.2006.12.011
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin C, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00001
   Mikami Y, 2011, J BIOL CHEM, V286, P39379, DOI 10.1074/jbc.M111.298208
   Mimoun S, 2012, ANTIOXID REDOX SIGN, V17, P1, DOI 10.1089/ars.2011.4186
   MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6
   Nagai Y, 2004, FASEB J, V18, P557, DOI 10.1096/fj.03-1052fje
   Niedzielska E, 2016, MOL NEUROBIOL, V53, P4094, DOI 10.1007/s12035-015-9337-5
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Perez-H J, 2014, TOXICOLOGY, V319, P38, DOI 10.1016/j.tox.2014.02.009
   Pong WW, 2007, J COMP NEUROL, V505, P158, DOI 10.1002/cne.21468
   Rahal A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/761264
   Rahal S., 2012, J CLIN CELL IMMUNOL, V1, P2012
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Shibuya N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2371
   Singh M, 2017, MED HYPOTHESES, V105, P17, DOI 10.1016/j.mehy.2017.06.012
   Singh M, 2015, CHEM-BIOL INTERACT, V234, P261, DOI 10.1016/j.cbi.2014.12.028
   Smith BJ, 2017, NEUROSCIENCE, V340, P279, DOI 10.1016/j.neuroscience.2016.10.054
   STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267
   Takir S, 2015, EXP EYE RES, V132, P190, DOI 10.1016/j.exer.2015.02.002
   Tang GH, 2010, CLIN EXP PHARMACOL P, V37, P753, DOI 10.1111/j.1440-1681.2010.05351.x
   Tsubota Kazuo, 2007, Nippon Ganka Gakkai Zasshi, V111, P193
   Tyagi N, 2005, AM J PHYSIOL-HEART C, V289, pH2649, DOI 10.1152/ajpheart.00548.2005
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   Wallace JL, 2009, GASTROENTEROLOGY, V137, P569, DOI 10.1053/j.gastro.2009.04.012
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang R, 2012, PHYSIOL REV, V92, P791, DOI 10.1152/physrev.00017.2011
   Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x
   Whiteman M, 2010, DIABETOLOGIA, V53, P1722, DOI 10.1007/s00125-010-1761-5
   Whiteman Matthew, 2011, Expert Rev Clin Pharmacol, V4, P13, DOI 10.1586/ecp.10.134
   Whiteman M, 2009, J CELL MOL MED, V13, P488, DOI 10.1111/j.1582-4934.2009.00645.x
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zayachkivska O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110688
   Zhang HL, 2011, CLIN EXP OPTOM, V94, P528, DOI 10.1111/j.1444-0938.2011.00611.x
   Zhang XM, 2011, AM J PHYSIOL-CELL PH, V301, pC1017, DOI 10.1152/ajpcell.00185.2011
   Zhang Y, 2011, J INT MED RES, V39, P464, DOI 10.1177/147323001103900214
   Zhao H, 2001, PROTEIN SCI, V10, P1113, DOI 10.1110/ps.41701
   Zhao JL, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20734
NR 88
TC 24
Z9 24
U1 0
U2 13
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAY 18
PY 2018
VL 11
IS 5
BP 881
EP 887
DI 10.18240/ijo.2018.05.26
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH2QL
UT WOS:000433246500026
PM 29862191
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Pawlowska, E
   Szczepanska, J
   Blasiak, J
AF Kaarniranta, Kai
   Pawlowska, Elzbieta
   Szczepanska, Joanna
   Blasiak, Janusz
TI DICER1 in the Pathogenesis of Age-related Macular Degeneration (AMD) -
   Alu RNA Accumulation versus miRNA Dysregulation
SO AGING AND DISEASE
LA English
DT Review
DE age-related macular degeneration; DICER1; Alu repeats; miRNA regulation;
   NLRP3 inflammasome
ID NLRP3 INFLAMMASOME ACTIVATION; RETINAL-PIGMENT EPITHELIUM; TRANSPOSABLE
   ELEMENTS; MICRORNA BIOGENESIS; DNA-DAMAGE; CELLS; SURVIVAL; GENE; EYE;
   EPIGENETICS
AB DICER1 deficiency in the retinal pigment epithelium (RPE) was associated with the accumulation of Alu transcripts and implicated in geographic atrophy (GA), a form of age-related macular degeneration (AMD), an eye disease leading to blindness in millions of people. Although the exact mechanism of this association is not fully known, the activation of the NLRP3 inflammasome, maturation of caspase-1 and disruption in mitochondria! homeostasis in RPE cells were shown as critical for it. DICER1 deficiency results in dysregulation of miRNAs and changes in the expression of many genes important for RPE homeostasis, which may also contribute to AMD. DICER1 deficiency can change the functions of the miR-183/96/182 cluster that regulates photoreceptors and their synaptic transmission. Aging, the main AMD risk factor, is associated with decreased expression of DICER1 and changes in its diurnal pattern that are not synchronized with circadian regulation in the retina. The initial insult inducing DICER1 deficiency in AMD may be oxidative stress, another major risk factor of AMD, but further studies on the role of deficient DICER1 in AMD pathogenesis and its therapeutic potential are needed.
C1 [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, PL-92216 Lodz, Poland.
   [Szczepanska, Joanna] Med Univ Lodz, Dept Pediat Dent, PL-92216 Lodz, Poland.
   [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Medical University Lodz; Medical University Lodz;
   University of Lodz
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
EM janusz.blasiak@biol.uni.lodz.pl
OI Blasiak, Janusz/0000-0001-9539-9584; Szczepanska,
   JOANNA/0000-0001-9912-5345; Pawlowska, Elzbieta/0000-0002-5373-4783
CR Allam R, 2014, EMBO REP, V15, P982, DOI 10.15252/embr.201438463
   Arslan J, 2018, PHARMACOGENOMICS, V19, P435, DOI 10.2217/pgs-2017-0183
   Ayarpadikannan S, 2015, GENE, V558, P187, DOI 10.1016/j.gene.2015.01.039
   Ayarpadikannan Selvam, 2014, Genomics & Informatics, V12, P98, DOI 10.5808/GI.2014.12.3.98
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1291, DOI 10.2741/3789
   Busskamp V, 2014, NEURON, V83, P586, DOI 10.1016/j.neuron.2014.06.020
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chong YS, 2018, CUTAN OCUL TOXICOL, V37, P52, DOI 10.1080/15569527.2017.1335748
   Damiani D, 2008, J NEUROSCI, V28, P4878, DOI 10.1523/JNEUROSCI.0828-08.2008
   Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Filipowicz W, 2005, CURR OPIN STRUC BIOL, V15, P331, DOI 10.1016/j.sbi.2005.05.006
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Georgi SA, 2010, J NEUROSCI, V30, P4048, DOI 10.1523/JNEUROSCI.4982-09.2010
   Hasler J, 2006, NUCLEIC ACIDS RES, V34, P5491, DOI 10.1093/nar/gkl706
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haig D, 2016, BIOESSAYS, V38, P1158, DOI 10.1002/bies.201600125
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Hueso M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061734
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim Songmi, 2016, Genomics & Informatics, V14, P70, DOI 10.5808/GI.2016.14.3.70
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Koushan K, 2013, NUTRIENTS, V5, P1823, DOI 10.3390/nu5051823
   Lee HE, 2015, GENES GENET SYST, V90, P245, DOI 10.1266/ggs.15-00016
   Li MY, 2017, HUM MOL GENET, V26, pR68, DOI 10.1093/hmg/ddx219
   Lieberman PM, 2016, BIOESSAYS, V38, P943, DOI 10.1002/bies.201600078
   Liu CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep33947
   Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438
   Lumayag S, 2013, P NATL ACAD SCI USA, V110, pE507, DOI 10.1073/pnas.1212655110
   MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895
   Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Natoli R, 2018, ADV EXP MED BIOL, V1074, P37, DOI 10.1007/978-3-319-75402-4_5
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Pinter R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010021
   Ryan D, 2006, MOL VIS, V12, P1175
   Sanuki R, 2011, NAT NEUROSCI, V14, P1125, DOI 10.1038/nn.2897
   Sawe N, 2008, J NEUROSCI RES, V86, P1659, DOI 10.1002/jnr.21604
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Song MS, 2017, BIOCHEM J, V474, P1603, DOI 10.1042/BCJ20160759
   Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759
   Sundermeier TR, 2017, J BIOL CHEM, V292, P3366, DOI 10.1074/jbc.M116.770024
   Sundermeier TR, 2014, FASEB J, V28, P3780, DOI 10.1096/fj.14-254292
   Sutterwala FS, 2014, ANN NY ACAD SCI, V1319, P82, DOI 10.1111/nyas.12458
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Yan YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080029
   Yu JJ, 2014, P NATL ACAD SCI USA, V111, P15514, DOI 10.1073/pnas.1414859111
   Zhu BJ, 2017, EXP EYE RES, V162, P73, DOI 10.1016/j.exer.2017.07.007
   Zhu QB, 2011, J BIOL CHEM, V286, P31749, DOI 10.1074/jbc.M111.259028
NR 69
TC 6
Z9 7
U1 0
U2 3
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD AUG
PY 2020
VL 11
IS 4
BP 851
EP 862
DI 10.14336/AD.2019.0809
PG 12
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA MV9JM
UT WOS:000556664900014
PM 32765950
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nakata, I
   Yamashiro, K
   Nakanishi, H
   Tsujikawa, A
   Otani, A
   Yoshimura, N
AF Nakata, Isao
   Yamashiro, Kenji
   Nakanishi, Hideo
   Tsujikawa, Akitaka
   Otani, Atsushi
   Yoshimura, Nagahisa
TI VEGF gene polymorphism and response to intravitreal bevacizumab and
   triple therapy in age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Photodynamic therapy; Vascular endothelial growth factor
ID ENDOTHELIAL-GROWTH-FACTOR; COMPLEMENT-FACTOR-H; PHOTODYNAMIC THERAPY;
   DIABETIC-RETINOPATHY; LOC387715 GENOTYPES; JAPANESE POPULATION; NO
   ASSOCIATION; RISK; RANIBIZUMAB; AVASTIN
AB To investigate the association between the vascular endothelial growth factor (VEGF) gene and response to either intravitreal bevacizumab (IVB) or photodynamic therapy with intravitreal triamcinolone acetonide and IVB (triple therapy) for neovascular age-related macular degeneration (AMD).
   The study consisted of 94 patients with neovascular AMD who underwent IVB and 79 patients with neovascular AMD who underwent triple therapy. Genotypes were determined for four selected tagging single-nucleotide polymorphism (SNP)s of the VEGF gene.
   Of the four SNPs studied, one SNP (rs699946) was associated significantly with visual acuity (VA) changes 12 months after treatment-irrespective of whether they received IVB alone (P = 0.044) or triple therapy 0.010). Baseline VA was not significantly different among the three genotypes of rs699946 in either treatment group. There were no significant differences in the number of treatments, incidence of recurrence, or the period until the recurrence according to VEGF rs699946 genetic variant.
   The VEGF gene SNP rs699946 was associated with response to IVB alone and to triple therapy in this study. The G allele in SNP rs699946 can thus be applied as a marker for better visual prognosis in patients with neovascular AMD who receive either IVB or triple therapy.
C1 [Nakata, Isao; Yamashiro, Kenji; Nakanishi, Hideo; Tsujikawa, Akitaka; Otani, Atsushi; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
   [Nakata, Isao; Nakanishi, Hideo] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto 6068507, Japan.
C3 Kyoto University; Kyoto University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
OI Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science, Tokyo, Japan [21249084,
   200791294]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX The authors wish to thank Drs Norimoto Gotoh, Hisako Hayashi, Sotaro
   Ooto, and Hiroshi Tamura for their valuable contributions to this study.
   This study was supported in part by Grants-in-aid for scientific
   research (nos. 21249084 and 200791294) from the Japan Society for the
   Promotion of Science, Tokyo, Japan, and the Japan National Society for
   the Prevention of Blindness, Tokyo, Japan.
CR Abhary S, 2009, INVEST OPHTH VIS SCI, V50, P5552, DOI 10.1167/iovs.09-3694
   Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   Bewick V, 2004, CRIT CARE, V8, P130, DOI 10.1186/cc2836
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Del Bo R, 2009, J NEUROL SCI, V283, P66, DOI 10.1016/j.jns.2009.02.318
   Diao LP, 2009, J CANCER RES CLIN, V135, P1473, DOI 10.1007/s00432-009-0650-0
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Girnita DM, 2008, TRANSPLANTATION, V85, P1632, DOI 10.1097/TP.0b013e3181722edc
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   IMMONEN I, 2009, OPHTHALMOLOGY
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   KIM DH, 2009, ANN ONCOL
   Kim DH, 2008, BRIT J HAEMATOL, V140, P71, DOI 10.1111/j.1365-2141.2007.06887.x
   Kim JG, 2008, CLIN CANCER RES, V14, P62, DOI 10.1158/1078-0432.CCR-07-1537
   Kong SY, 2007, HEPATOLOGY, V46, P446, DOI 10.1002/hep.21720
   Krippl P, 2003, INT J CANCER, V106, P468, DOI 10.1002/ijc.11238
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Okamoto H, 2006, MOL VIS, V12, P156
   PABST S, 2009, CHEST
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Petrovic MG, 2008, MOL VIS, V14, P1382
   Renner W, 2000, J VASC RES, V37, P443, DOI 10.1159/000054076
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   Thorisson GA, 2005, GENOME RES, V15, P1592, DOI 10.1101/gr.4413105
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   Zarbock R, 2009, HUM MOL GENET, V18, P3344, DOI 10.1093/hmg/ddp259
NR 47
TC 29
Z9 32
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2011
VL 55
IS 5
BP 435
EP 443
DI 10.1007/s10384-011-0061-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 828OT
UT WOS:000295512400001
PM 21744122
DA 2022-11-30
ER

PT J
AU Wong, CW
   Wong, TT
AF Wong, Chee Wai
   Wong, Tina T.
TI Posterior segment drug delivery for the treatment of exudative
   age-related macular degeneration and diabetic macular oedema
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID SUBCONJUNCTIVAL INJECTION; ANTI-ANGIOGENESIS; TOPICAL DELIVERY;
   GENE-THERAPY; EYE DROPS; FOLLOW-UP; PHASE-1; PHARMACOKINETICS;
   DEXAMETHASONE; PERMEABILITY
AB Inhibitors of vascular endothelial growth factors are used to treat a myriad of retinal conditions, including exudative age-related macular degeneration (AMD), diabetic macular oedema (DME) and diabetic retinopathy. Although effective, long-term efficacy is limited by the need for frequent and invasive intravitreal injections. The quest for sustained action therapeutics that can be delivered to target tissue in the least invasive manner is an arduous endeavour that has ended in premature failure for several technologies in Phase II or III trials. Nevertheless, there have been promising preclinical studies, and more are on the horizon: port delivery systems for the treatment of exudative AMD have entered Phase III trials and a wide array of preclinical studies have demonstrated the potential for nanoparticles, such as liposomes, dendrimers and cell penetrating peptides to deliver therapeutics into the posterior segment via minimally invasive routes. In this review, we discuss the challenges posed by ocular barriers for drug penetration and present the recent advancements of the most pertinent drug delivery platforms with a focus on the treatment of exudative AMD and DME.
C1 [Wong, Chee Wai] Singapore Natl Eye Ctr, Surg Retina, Singapore, Singapore.
   [Wong, Chee Wai; Wong, Tina T.] Duke NUS Grad Med Sch, Singapore, Singapore.
   [Wong, Tina T.] Singapore Natl Eye Ctr, Glaucoma, Singapore 168751, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center
RP Wong, TT (通讯作者)，Singapore Natl Eye Ctr, Glaucoma, Singapore 168751, Singapore.
EM tina.wong.t.l@snec.com.sg
OI Wong, Chee Wai/0000-0002-0935-2016
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   AHMAD I, 1992, CANCER RES, V52, P4817
   Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
   BARZA M, 1987, INVEST OPHTH VIS SCI, V28, P893
   Beydoun T, 2015, J OCUL PHARMACOL TH, V31, P93, DOI 10.1089/jop.2013.0247
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Chen C, 2017, BIOMATERIALS, V112, P218, DOI 10.1016/j.biomaterials.2016.09.022
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   de Cogan F, 2017, INVEST OPHTH VIS SCI, V58, P2578, DOI 10.1167/iovs.16-20072
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Delventhal R, 2017, SCI REP-UK, V7, DOI 10.1038/srep43754
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Gooch N, 2013, J FUNCT BIOMATER, V4, P14, DOI 10.3390/jfb4010014
   Guidotti G, 2017, TRENDS PHARMACOL SCI, V38, P406, DOI 10.1016/j.tips.2017.01.003
   Gupta SK, 2000, J OCUL PHARMACOL TH, V16, P511, DOI 10.1089/jop.2000.16.511
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hoffmann-La Roche Ltd, INV UPD
   Humayun M, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.6.5
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Lee V H, 1986, J Ocul Pharmacol, V2, P67, DOI 10.1089/jop.1986.2.67
   Liu C, 2014, MOL PHARMACEUT, V11, P1218, DOI 10.1021/mp400681n
   Madni A, 2014, J PHARM PHARM SCI, V17, P401, DOI 10.18433/J3CP55
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mains J, 2013, J OCUL PHARMACOL TH, V29, P143, DOI 10.1089/jop.2012.0138
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Milla P, 2012, CURR DRUG METAB, V13, P105, DOI 10.2174/138920012798356934
   Pescina S, 2018, J CONTROL RELEASE, V284, P84, DOI 10.1016/j.jconrel.2018.06.023
   Prausnitz MR, 1998, J PHARM SCI, V87, P1479, DOI 10.1021/js9802594
   Rajapaksha A, 2015, MOL CELL BIOMECH, V12, P215
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Reissmann S, 2014, J PEPT SCI, V20, P760, DOI 10.1002/psc.2672
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sherje AP, 2018, INT J PHARMACEUT, V548, P707, DOI 10.1016/j.ijpharm.2018.07.030
   Suda K, 2017, J CONTROL RELEASE, V266, P301, DOI 10.1016/j.jconrel.2017.09.036
   Takahashi K, 2017, MOL THER, V25, P296, DOI 10.1016/j.ymthe.2016.10.008
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   URTTI A, 1993, SURV OPHTHALMOL, V37, P435, DOI 10.1016/0039-6257(93)90141-S
   VANROOIJEN N, 1980, IMMUNOL COMMUN, V9, P243, DOI 10.3109/08820138009065997
   Weijtens O, 2000, OPHTHALMOLOGY, V107, P1932, DOI 10.1016/S0161-6420(00)00344-4
   Weijtens O, 1999, AM J OPHTHALMOL, V128, P192, DOI 10.1016/S0002-9394(99)00129-4
   Yellepeddi VK, 2016, J OCUL PHARMACOL TH, V32, P67, DOI 10.1089/jop.2015.0047
   Zhang XK, 2015, BBA-GEN SUBJECTS, V1850, P1140, DOI 10.1016/j.bbagen.2015.01.019
NR 47
TC 11
Z9 11
U1 1
U2 30
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2019
VL 103
IS 10
BP 14
EP 18
DI 10.1136/bjophthalmol-2018-313462
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JZ5SV
UT WOS:000505163800002
PM 31040133
DA 2022-11-30
ER

PT J
AU Mantel, I
   Zografos, L
   Ambresin, A
AF Mantel, Irmela
   Zografos, Leonidas
   Ambresin, Aude
TI Early clinical experience with ranibizumab for occult and minimally
   classic neovascular membranes in age-related macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; ranibizumab; visual acuity; anti-VEGF;
   occult neovascular membrane; minimally classic neovascular membrane
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   VERTEPORFIN; TRIALS
AB Background: In large randomized multicenter trials, ranibizumab has shown its therapeutic efficacy for exudative age-related macular degeneration (AMD). The aim of this paper is to report the real-life clinical experience with this treatment for occult and minimally classic membranes without pigment epithelium detachment. Methods: We conducted a retrospective chart review of 37 patients with occult and minimally classic neovascular membranes in AMD, without pigment epithelium detachment. Results: The mean visual improvement of 2 lines at 3, 6 and 9 months corresponds well with the results of the large trials. A mean number of 5 reinjections was reached by month 8. It may potentially exceed the mean 5.5 injections of the PrONTO study (prospective optical coherence tomography imaging of patients with neovascular AMD treated with intraocular ranibizumab). At months 6-8 recurrence was frequently observed. Conclusion: The early experience of ranibizumab in clinical practice brings similarly good results as the large-scale trials. However, interrupting the treatment too early may be a disadvantage. Copyright (C) 2008 S. Karger AG, Basel.
C1 [Mantel, Irmela; Zografos, Leonidas; Ambresin, Aude] Univ Lausanne, Dept Ophthalmol, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Eye Hosp Jules Gonin, 15 Av France,Case Postale 133, CH-1000 Lausanne, Switzerland.
EM irmela.mantel@ophtal.vd.ch
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 7
TC 17
Z9 17
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2008
VL 222
IS 5
BP 321
EP 323
DI 10.1159/000144075
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 350KU
UT WOS:000259352100005
PM 18617755
DA 2022-11-30
ER

PT J
AU Augustin, AJ
   Schmidt-Erfurth, U
AF Augustin, A. J.
   Schmidt-Erfurth, U.
TI Verteporfin therapy and triamcinolone acetonide: Convergent modes of
   action for treatment of neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularization; age-related macular degeneration;
   photodynamic therapy; verteporfin; triamcinolone acetonide
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; INTRAVITREAL
   TRIAMCINOLONE; PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION;
   VISUAL IMPAIRMENT; INTRAOCULAR-PRESSURE; EXPRESSION; INJECTION;
   ANGIOGENESIS
AB PURPOSE. Choroidal neovascularization associated with age-related macular degeneration is the primary cause of blindness in the elderly in developed countries, due to a number of pathogenic effects, including angiogenesis, cell-mediated inflammation, leukocyte adhesion and extravasation, and matrix remodeling.
   METHODS. By producing photochemical effects at the site of target tissue (lesion), photodynamic therapy (PDT) can induce vascular damage and blood flow stasis, leading to occlusion of vascularization and lesion leakage.
   RESULTS. PDT with verteporfin (Visudyne, Novartis) has been shown to be safe and effective in reducing the risk of vision loss in patients with classic containing subfoveal CNV and occult with no classic CNV However, in predominantly occult CNV, the treatment may be most effective in smaller lesions, and less in larger lesions. Most important, visual acuity rarely is improved.
   CONCLUSIONS. Pilot studies and large case series suggest that a combination of PDT and intravitreal triamcinolone acetonide has the potential to improve visual outcomes and reduce the need for additional treatments. Randomized, prospective clinical trials are underway to confirm the efficacy and safety of this novel treatment modality.
C1 Klinikum Karlsruhe, Dept Ophthalmol, D-76133 Karlsruhe, Germany.
   Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 Municipal Hospital Karlsruhe; University of Vienna
RP Augustin, AJ (通讯作者)，Klinikum Karlsruhe, Dept Ophthalmol, Moltkestr 90, D-76133 Karlsruhe, Germany.
EM 106020.560@compuserve.com
OI Augustin, Prof. Dr. Albert J./0000-0003-1591-0536
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anand R, 2003, ARCH OPHTHALMOL-CHIC, V121, P415
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   AUGUSTINE AJ, 2005, M AAO RET SUBSP DAY
   Bandi N, 2001, EUR J PHARMACOL, V425, P109, DOI 10.1016/S0014-2999(01)01192-X
   BHAVSAR AR, 2004, AM SOC RET SPEC 2004
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brooks HL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1801, DOI 10.1001/archopht.122.12.1801
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Fischer S, 2001, EUR J PHARMACOL, V411, P231, DOI 10.1016/S0014-2999(00)00915-8
   Folkman J, 1997, EXS, V79, P1
   Foran S, 2003, OPHTHALMOLOGY, V110, P41, DOI 10.1016/S0161-6420(02)01295-2
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Hoerauf H, 2000, ARCH OPHTHALMOL-CHIC, V118, P580
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Kang BS, 2001, BIOL PHARM BULL, V24, P701, DOI 10.1248/bpb.24.701
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kent D, 2003, MOL VIS, V9, P747
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   LEWIS GD, 1986, ENDOCRINOLOGY, V119, P62, DOI 10.1210/endo-119-1-62
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   NAVEH N, 1991, PROSTAG LEUKOTR ESS, V42, P101, DOI 10.1016/0952-3278(91)90075-G
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Peyman GA, 2004, RETINA-J RET VIT DIS, V24, P488, DOI 10.1097/00006982-200406000-00032
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   ROTH DB, INTRAVITREAL TRIAMCI
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   SZE PY, 1994, J STEROID BIOCHEM, V48, P179, DOI 10.1016/0960-0760(94)90143-0
   Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
NR 74
TC 13
Z9 13
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2006
VL 16
IS 6
BP 824
EP 834
DI 10.1177/112067210601600607
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 147YD
UT WOS:000245040800007
PM 17191188
DA 2022-11-30
ER

PT J
AU Rasmussen, A
   Sander, B
AF Rasmussen, Annette
   Sander, Birgit
TI Long-term longitudinal study of patients treated with ranibizumab for
   neovascular age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; long-term treatment; vascular
   endothelial growth factor
ID INTRAVITREAL RANIBIZUMAB; CHOROIDAL NEOVASCULARIZATION; DOSING REGIMEN;
   VISUAL-ACUITY; FOLLOW-UP; PREVALENCE; PREDICTORS; BLINDNESS; MARINA;
   TRIAL
AB Purpose of reviewTo review the current literature regarding long-term treatment beyond 2 years with anti-vascular endothelial growth factor (VEGF) inhibition for neovascular age-related macular degeneration (nv-AMD).Recent findingsOnly few studies of anti-VEGF treatment for nv-AMD exist beyond 2 years, and the number of patients followed for 4 years or longer is small. The results of studies show that the majority of patients with nv-AMD can preserve visual acuity compared with baseline, subgroups reveal large variations in visual benefit. Approximately 20-30% of patients seem to respond poorly to the treatment, and 20% obtain a condition with inactivity and good results. The majority of patients will need continuous active treatment. Long-term decline of visual acuity reflects the natural progression of the disease, however, insufficient treatment cannot be excluded leaving a potential for further improvement. Close follow-up to detect recurrent activity of nv-AMD and activity in fellow eye is important. Definitive evidence of systemic side-effects is lacking, but long-term VEGF inhibition seems to be tolerated well with few ocular and systemic complications.SummaryThe majority of patients with nv-AMD can preserve visual acuity and expect long-term treatment beyond 2 years. Ocular complications and systemic adverse events remain few.
C1 [Rasmussen, Annette; Sander, Birgit] Glostrup Cty Hosp, Res Dept Ophthalmol, DK-2600 Glostrup, Denmark.
C3 University of Copenhagen
RP Rasmussen, A (通讯作者)，Glostrup Cty Hosp, Res Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM annette.rasmussen@regionh.dk
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Nentwich MM, 2013, RETINA
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rung L, 2013, CLIN OPHTHALMOL, V7, P395, DOI 10.2147/OPTH.S41585
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 45
TC 23
Z9 23
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2014
VL 25
IS 3
BP 158
EP 163
DI 10.1097/ICU.0000000000000050
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF1GC
UT WOS:000334461400002
PM 24663065
DA 2022-11-30
ER

PT J
AU Skerka, C
   Lauer, N
   Weinberger, AAWA
   Keilhauer, CN
   Suhnel, J
   Smith, R
   Schlotzer-Schrehardt, U
   Fritsche, L
   Heinen, S
   Hartmann, A
   Weber, BHF
   Zipfel, PF
AF Skerka, Christine
   Lauer, Nadine
   Weinberger, Andreas A. W. A.
   Keilhauer, Claudia N.
   Suehnel, Juergen
   Smith, Richard
   Schloetzer-Schrehardt, Ursula
   Fritsche, Lars
   Heinen, Stefan
   Hartmann, Andrea
   Weber, Bernhard H. F.
   Zipfel, Peter F.
TI Defective complement control of Factor H (Y402H) and FHL-1 in
   age-related macular degeneration
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE complement age-related macular degenartion; complement control;
   C-reactive protein; disease mechanisms
ID C-REACTIVE PROTEIN; HEMOLYTIC-UREMIC SYNDROME; ENDOTHELIAL-CELLS;
   BINDING-SITES; HEPARIN; VARIANT; RISK; POLYMORPHISM; REGULATOR; DRUSEN
AB The common variant in the human complement Factor H gene (CFH), with Tyr402His, is linked to age-related macular degeneration (AMD), a prevalent disorder leading to visual impairment and irreversible blindness in elderly patients. Here we show that the risk variant CFH 402His displays reduced binding to C reactive protein (CRP), heparin and retinal pigment epithelial cells. This reduced binding can cause inefficient complement regulation at the cell surface, particularly when CRP is recruited to injured sites and tissue. In addition, we identify the Factor H-like protein 1 (FHL-1), an alternative splice product of the CFH gene as an additional protein that includes the risk residue 402, and thus confers risk for AMD. FHL-1 is expressed in the eye and the FHL-1 402His risk variant shows similar reduced cell binding and likely reduced complement regulatory functions on the cell surface. CFH and FHL-1 may act in concert in the eye and the reduced surface binding may result in inappropriate local complement control, which in turn can lead to inflammation, disturbance of local physiological homeostasis and progression to cell damage. As a consequence, these processes may lead to AMD pathogenesis. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Hans Knoll Inst, Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany.
   Rhein Westfal TH Aachen, Dept Ophthalmol, Aachen, Germany.
   Univ Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   Fritz Lipmann Inst, Leibniz Inst Age Res, Biocomp Grp, Jena, Germany.
   Univ Iowa, Carver Coll Med, Iowa City, IA USA.
   Univ Erlangen Nurnberg, Dept Ophthalmol, Erlangen, Germany.
   Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   Univ Jena, Jena, Germany.
C3 Hans Knoll Institute (HKI); RWTH Aachen University; University of
   Wurzburg; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut
   (FLI); University of Iowa; University of Erlangen Nuremberg; University
   of Regensburg; Friedrich Schiller University of Jena
RP Zipfel, PF (通讯作者)，Hans Knoll Inst, Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11a, D-07745 Jena, Germany.
EM Peter.Zipfel@hki-jena.de
RI Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Heinen,
   Stefan/0000-0001-5800-6593; Smith, Richard/0000-0003-1201-6731; Weber,
   Bernhard H.F./0000-0002-8808-7723
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heinen S, 2007, J AM SOC NEPHROL, V18, P506, DOI 10.1681/ASN.2006091069
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Noris M, 2005, J AM SOC NEPHROL, V16, P1177, DOI 10.1681/ASN.2005010086
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Ranganathan S, 2000, Pac Symp Biocomput, P155
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schlotzer-Schrehardt U, 2005, INVEST OPHTH VIS SCI, V46, P2023, DOI 10.1167/iovs.04-0915
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Wieland HA, 2005, NAT REV DRUG DISCOV, V4, P3
   ZIPFEL P, 2006, COMPLEMENT KIDNEY DI
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
NR 37
TC 151
Z9 158
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD JUL
PY 2007
VL 44
IS 13
BP 3398
EP 3406
DI 10.1016/j.molimm.2007.02.012
PG 9
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA 179EK
UT WOS:000247272200015
PM 17399790
DA 2022-11-30
ER

PT J
AU Piermarocchi, S
   Lo Giudice, G
   Sartore, M
   Friede, F
   Segato, T
   Pilotto, E
   Midena, E
AF Piermarocchi, S
   Lo Giudice, G
   Sartore, M
   Friede, F
   Segato, T
   Pilotto, E
   Midena, E
TI Photodynamic therapy increases the eligibility for feeder vessel
   treatment of choroidal neovascularization caused by age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTOCOAGULATION
AB PURPOSE: To report angiographic observations about feeder vessel identification after photodynamic therapy in patients with choroidal neovascularization caused by age-related macular degeneration.
   DESIGN: Cohort study.
   METHODS: We analyzed fluorescein and indocyanine green dynamic angiography in 156 eyes of 145 patients before and after photodynamic therapy to identify the feeder vessels of the choroidal neovascular membrane.
   RESULTS: Before photodynamic therapy one or more feeder vessel could be detected in 35 (22.4%) out of 156 eyes with choroidal neovascularization. Three months after photodynamic therapy, a feeder vessel could be identified in 112 (84.2%) out of 133 eyes with persistent choroidal neovascularization. Among these, 16 eyes received direct laser photocoagulation of the feeder vessel and did not need any further photodynamic therapy.
   CONCLUSION: Previous photodynamic therapy improves the detection of the feeder vessel of the choroidal neovascularization. A sequential combined therapy (photodynamic and feeder vessel treatment) could be considered as an alternative to multiple photodynamic treatments. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Univ Padua, Dept Ophthalmol, I-35128 Padua, Italy.
C3 University of Padua
RP Piermarocchi, S (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
RI Midena, Edoardo/AAB-6010-2020
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Flower RW, 2000, AM J OPHTHALMOL, V129, P501, DOI 10.1016/S0002-9394(99)00411-0
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
NR 7
TC 8
Z9 21
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2002
VL 133
IS 4
BP 572
EP 575
DI 10.1016/S0002-9394(01)01370-8
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 538DE
UT WOS:000174798200027
PM 11931801
DA 2022-11-30
ER

PT J
AU Atilano, SR
   Udar, N
   Satalich, TA
   Udar, V
   Chwa, M
   Kenney, MC
AF Atilano, Shari R.
   Udar, Nitin
   Satalich, Timothy A.
   Udar, Viraat
   Chwa, Marilyn
   Kenney, M. Cristina
TI Low frequency mitochondrial DNA heteroplasmy SNPs in blood, retina, and
   [RPE plus choroid] of age-related macular degeneration subjects
SO PLOS ONE
LA English
DT Article
ID PIGMENT EPITHELIUM; MUTATIONS; MTDNA; HAPLOGROUPS; VARIANTS; DELETION;
   DISEASES; DAMAGE; MODEL; SUSCEPTIBILITY
AB Purpose
   Mitochondrial (mt) DNA damage is associated with age-related macular degeneration (AMD) and other human aging diseases. This study was designed to quantify and characterize mtDNA low-frequency heteroplasmy single nucleotide polymorphisms (SNPs) of three different tissues isolated from AMD subjects using Next Generation Sequencing (NGS) technology.
   Methods
   DNA was extracted from neural retina, [RPE+choroid] and blood from three deceased age-related macular degeneration (AMD) subjects. Entire mitochondrial genomes were analyzed for low-frequency heteroplasmy SNPs using NGS technology that independently sequenced both mtDNA strands. This deep sequencing method (average sequencing depth of 30,000; range 1,000-100,000) can accurately differentiate low-frequency heteroplasmy SNPs from DNA modification artifacts. Twenty-three 'hot-spot' heteroplasmy mtDNA SNPs were analyzed in 222 additional blood samples.
   Results
   Germline homoplasmy SNPs that defined mtDNA haplogroups were consistent in the three tissues of each subject. Analyses of SNPs with <40% heteroplasmy revealed the blood had significantly greater numbers of heteroplasmy SNPs than retina alone (p <= 0.05) or retina+choroid combined (p = 0.008). Twenty-three 'hot-spot' mtDNA heteroplasmy SNPs were present, with three being non-synonymous (amino acid change). Four 'hot-spot' heteroplasmy SNPs (m.1120C>T, m.1284T>C, m.1556C>T, m.7256C>T) were found in additional samples (n = 222). Five heteroplasmy SNPs (m.4104A>G, m.5320C>T, m.5471G>A, m.5474A>G, m.5498A>G) declined with age. Two heteroplasmy SNPs (m.13095T>C, m.13105A>G) increased in AMD compared to Normal samples. In the heteroplasmy SNPs, very few transversion mutations (purine to pyrimidine or vice versa, associated with oxidative damage) were found and the majority were transition changes (purine to purine or pyrimidine to pyrimidine, associated with replication errors).
   Conclusion
   Within an individual, the blood, retina and [RPE+choroid] contained identical homoplasmy SNPs representing inherited germline mtDNA haplogroup. NGS methodology showed significantly more mtDNA heteroplasmy SNPs in blood compared to retina and [RPE+choroid], suggesting the latter tissues have substantial protection. Significantly higher heteroplasmy levels of m.13095T>C and m.13105A>G may represent potential AMD biomarkers. Finally, high levels of transition mutations suggest that accumulation of heteroplasmic SNPs may occur through replication errors rather than oxidative damage.
C1 [Atilano, Shari R.; Udar, Nitin; Udar, Viraat; Chwa, Marilyn; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.
   [Satalich, Timothy A.] Univ Calif Irvine, Inst Math Behav Sci, Irvine, CA USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.; Kenney, MC (通讯作者)，Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
EM mkenney@hs.uci.edu
OI Atilano, Shari/0000-0002-7729-7864
FU Discovery Eye Foundation; Iris and B. Gerald Cantor Foundation; Max
   Factor Family Foundation; NEI [R01 EY0127363]; Research to Prevent
   Blindness
FX This work was supported by the Discovery Eye Foundation
   (https://discoveryeye.org/), Polly and Michael Smith, Edith and Roy
   Carver, Iris and B. Gerald Cantor Foundation
   (http://cantorfoundation.org/), Max Factor Family Foundation, and NEI
   R01 EY0127363 (MCK). Supported in part by an Unrestricted Departmental
   Grant from Research to Prevent Blindness. MCK was the primary recipient
   of these awards. The Sponsors/Funders did not play any role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akesson LS, 2019, EUR J HUM GENET, V27, P1821, DOI 10.1038/s41431-019-0477-3
   Atilano SR, 2015, HUM MOL GENET, V24, P4491, DOI 10.1093/hmg/ddv173
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chalkia D, 2017, JAMA PSYCHIAT, V74, P1161, DOI 10.1001/jamapsychiatry.2017.2604
   Chinnery PF, 2013, BRIT MED BULL, V106, P135, DOI 10.1093/bmb/ldt017
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Dunn T, 2019, BIOINFORMATICS, V35, P1579, DOI 10.1093/bioinformatics/bty849
   Durham SE, 2007, AM J HUM GENET, V81, P189, DOI 10.1086/518901
   Expert Panel on Neurologic Imaging, 2017, J AM COLL RADIOL, V14, pS550
   Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Hopkins JF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00377-y
   Huang YQ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224677
   Itsara LS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1003974
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kamiya J, 2003, DIABETOLOGIA, V46, P1559, DOI 10.1007/s00125-003-1215-4
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kenney M.C., 2014, HUM MOL GENET
   Kenney MC, 2014, BBA-MOL BASIS DIS, V1842, P208, DOI 10.1016/j.bbadis.2013.10.016
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kopinski PK, 2019, P NATL ACAD SCI USA, V116, P16028, DOI 10.1073/pnas.1906896116
   Li G, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027665
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Long RY, 2007, ECOL ECON, P194
   Lu WW, 2016, MITOCHONDRIAL DNA A, V27, P2303, DOI 10.3109/19401736.2014.971022
   Lu YY, 2017, J NEUROL SCI, V379, P137, DOI 10.1016/j.jns.2017.05.056
   Malik D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099003
   McCormick EM, 2018, CURR GENET MED REP, V6, P52, DOI 10.1007/s40142-018-0137-x
   McFarland R, 2009, J INTERN MED, V265, P210, DOI 10.1111/j.1365-2796.2008.02066.x
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Persad PJ, 2017, INVEST OPHTH VIS SCI, V58, P4027, DOI 10.1167/iovs.17-21734
   Picard M, 2014, P NATL ACAD SCI USA, V111, pE4033, DOI 10.1073/pnas.1414028111
   Preste R, 2019, NUCLEIC ACIDS RES, V47, pD1202, DOI 10.1093/nar/gky1024
   Ramos A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074636
   Sharpley MS, 2012, CELL, V151, P333, DOI 10.1016/j.cell.2012.09.004
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   Singh LN, 2018, INVEST OPHTH VIS SCI, V59, P4598, DOI 10.1167/iovs.18-25085
   Suarez-Villagran MY, 2018, GENOME BIOL EVOL, V10, P1039, DOI 10.1093/gbe/evy060
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Villagran MYS, 2015, SCI REP-UK, V5, DOI 10.1038/srep13571
   WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wallace DC, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a021220
   Wang YQ, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006391
   Wei W, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-016-0404-6
   Yates JR, 2005, NAT REV MOL CELL BIO, V6, P702, DOI 10.1038/nrm1711
   Ziada AS, 2019, AGING CELL, V18, DOI 10.1111/acel.13018
   Zsurka G, 2018, GENES-BASEL, V9, DOI 10.3390/genes9040175
NR 61
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2021
VL 16
IS 1
AR e0246114
DI 10.1371/journal.pone.0246114
PG 24
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QB1HB
UT WOS:000613891400039
PM 33513185
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lazzarini, R
   Nicolai, M
   Lucarini, G
   Pirani, V
   Mariotti, C
   Bracci, M
   Mattioli-Belmonte, M
AF Lazzarini, Raffaella
   Nicolai, Michele
   Lucarini, Guendalina
   Pirani, Vittorio
   Mariotti, Cesare
   Bracci, Massimo
   Mattioli-Belmonte, Monica
TI Oxidative stress in retinal pigment epithelium impairs stem cells: a
   vicious cycle in age-related macular degeneration
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Retinal pigment epithelium; Stem cells; Oxidative stress; Age-related
   macular degeneration (AMD); Inflammation; Senescence-associated
   secretory phenotype (SASP)
ID HUMAN RPE; SENESCENCE
AB Aging, chronic oxidative stress, and inflammation are major pathogenic factors in the development and progression of age-related macular degeneration (AMD) with the loss of retinal pigment epithelium (RPE). The human RPE contains a subpopulation of progenitors (i.e., RPE stem cells-RPESCs) whose role in the RPE homeostasis is under investigation. We evaluated the paracrine effects of mature RPE cells exposed to oxidative stress (H2O2) on RPESCs behavior through co-cultural, morphofunctional, and bioinformatic approaches. RPESCs showed a decline in proliferation, an increase of the senescence-associated beta-galactosidase activity, the acquisition of a senescent-like secretory phenotype (SASP), and the reduction of their stemness and differentiation competencies. IL-6 and Superoxide Dismutase 2 (SOD2) seem to be key molecules in RPESCs response to oxidative stress. Our results get insight into stress-induced senescent-associated molecular mechanisms implicated in AMD pathogenesis. The presence of chronic oxidative stress in the microenvironment reduces the RPESCs abilities, inducing and/or maintaining a pro-inflammatory retinal milieu that in turn could affect AMD onset and progression.
C1 [Lazzarini, Raffaella; Lucarini, Guendalina; Bracci, Massimo; Mattioli-Belmonte, Monica] Univ Politecn Marche, Dept Clin & Mol Sci DISCLIMO, Via Tronto 10-A, I-60126 Ancona, Italy.
   [Nicolai, Michele; Pirani, Vittorio; Mariotti, Cesare] Univ Politecn Marche, Dept Expt & Clin Med, Ophthalmol Clin, Via Tronto 10-A, I-60126 Ancona, Italy.
C3 Marche Polytechnic University; Marche Polytechnic University
RP Nicolai, M (通讯作者)，Univ Politecn Marche, Dept Expt & Clin Med, Ophthalmol Clin, Via Tronto 10-A, I-60126 Ancona, Italy.
EM michele.nicolai@hotmail.it
RI Mattioli-Belmonte, Monica/AAF-6197-2020
OI Mattioli-Belmonte, Monica/0000-0002-2087-2776; Nicolai,
   Michele/0000-0001-8302-6107
FU Universita Politecnica delle Marche
FX This study was supported by a Grant of Universita Politecnica delle
   Marche to Monica Mattioli-Belmonte.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Gupta T, 2017, J HISTOCHEM CYTOCHEM, V65, P567, DOI 10.1369/0022155417726507
   Harris J, 2017, PATHOBIOL AGING AGE, V7, DOI 10.1080/20010001.2017.1398016
   Jacob KD, 2013, MECH AGEING DEV, V134, P139, DOI 10.1016/j.mad.2013.02.008
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Kourtis N, 2011, EMBO J, V30, P2520, DOI 10.1038/emboj.2011.162
   Kultz D, 2005, ANNU REV PHYSIOL, V67, P225, DOI 10.1146/annurev.physiol.67.040403.103635
   Lazzarini R, 2018, AGING-US, V10, P3173, DOI 10.18632/aging.101624
   Lee JS, 2019, BMB REP, V52, P1, DOI 10.5483/BMBRep.2019.52.1.002
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Mariotti C, 2015, CELL TISSUE RES, V362, P21, DOI 10.1007/s00441-015-2185-9
   Meyer P, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005741
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Tower J, 2012, WIRES DEV BIOL, V1, P789, DOI 10.1002/wdev.56
   Ung L, 2017, CLIN SCI, V131, P2865, DOI 10.1042/CS20171246
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SR, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/486263
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
NR 35
TC 2
Z9 2
U1 4
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN
PY 2022
VL 477
IS 1
BP 67
EP 77
DI 10.1007/s11010-021-04258-3
EA SEP 2021
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA YF8IR
UT WOS:000696755000002
PM 34535868
DA 2022-11-30
ER

PT J
AU Tate, PS
   Marquioni-Ramella, MD
   Cerchiaro, C
   Suburo, AM
AF Tate, Pablo S.
   Marquioni-Ramella, Melisa D.
   Cerchiaro, Constanza
   Suburo, Angela M.
TI Ilex paraguariensis Extracts Prevent Oxidative Damage in a Mouse Model
   of Age-Related Macular Degeneration
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE age-related macular degeneration; oxidative stress; polyphenols; retinal
   pigment epithelium; Yerba mate
ID OPTICAL COHERENCE TOMOGRAPHY; PROLIFERATIVE VITREORETINOPATHY; SODIUM
   IODATE; RETINAL DEGENERATION; CIGARETTE-SMOKE; ACTIVATION; CELLS;
   CONSUMPTION; PROTECTION; INJURY
AB Age-related macular degeneration (AMD), a chronic disease of the retina, leads to severe visual loss. AMD affects the retinal pigment epithelium (RPE) and the visual cells (photoreceptors). RPE failure, the first step of this disease, is associated with oxidative stress. Since antioxidants can slow down AMD progression, the intake of foods and drinks rich in antioxidant compounds may reduce retinal damage. Ilex paraguariensis (yerba mate, YM) extracts reduce oxidative damage of RPE cells in vitro as shown in previous study. Here, the effects of YM drinking on RPE and photoreceptor survival after oxidative damage with sodium iodate (NaIO3; SI) in a murine AMD model are described. Funduscopy and histology show that YM treatment prevents RPE and photoreceptor damage. YM also increases the expression of NRF2, the master antioxidant gene, and its effectors HO-1 and SOD2. In mice receiving YM and SI, the antioxidant response is larger than in mice receiving YM or SI alone. The YM drink also increases expression of RPE65, a gene that is involved in the functionality and survival of photoreceptors and RPE cells. The results suggest YM can play an important role in the prevention of retinal damage associated with oxidative stress, such as AMD.
C1 [Tate, Pablo S.; Marquioni-Ramella, Melisa D.; Cerchiaro, Constanza; Suburo, Angela M.] Univ Austral, CONICET, Fac Ciencias Biomed, Inst Invest Med Traslac,IIMT, B1629AHJ, Buenos Aires, DF, Argentina.
C3 Austral University; Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET)
RP Suburo, AM (通讯作者)，Univ Austral, CONICET, Fac Ciencias Biomed, Inst Invest Med Traslac,IIMT, B1629AHJ, Buenos Aires, DF, Argentina.
EM amsuburo@austral.edu.ar
OI Suburo, Angela/0000-0002-5713-3301; Marquioni Ramella, Melisa
   Daniela/0000-0003-3377-9789
CR Arcari DP, 2009, OBESITY, V17, P2127, DOI 10.1038/oby.2009.158
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Bellezza I, 2018, BBA-MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Bracesco N, 2011, J ETHNOPHARMACOL, V136, P378, DOI 10.1016/j.jep.2010.06.032
   Butler JM, 2021, J CELL MOL MED, V25, P5572, DOI 10.1111/jcmm.16569
   Cano M, 2021, AGING CELL, V20, DOI 10.1111/acel.13444
   Cao DF, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.34
   Ceverino GC, 2021, MOL BIOL REP, V48, P13, DOI 10.1007/s11033-020-06096-w
   Chidlow G, 2011, J HISTOCHEM CYTOCHEM, V59, P884, DOI 10.1369/0022155411418115
   Choi EH, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000850
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Chtcheglova L.A., 2020, LIFE-BASEL, V10, P1
   de Oliveira E, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-4331X20187342, 10.1590/1414-431x20187342]
   Emanuele S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157963
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Gebara KS, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010014
   Gebara KS, 2017, J AGR FOOD CHEM, V65, P10093, DOI 10.1021/acs.jafc.7b04093
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Iribarne M, 2008, AM J PATHOL, V172, P1030, DOI 10.2353/ajpath.2008.070605
   Iribarne M, 2007, INVEST OPHTH VIS SCI, V48, P1348, DOI 10.1167/iovs.06-0964
   Jang H, 2015, MOL NUTR FOOD RES, V59, P1918, DOI 10.1002/mnfr.201400897
   Johnson J, 2009, INVEST OPHTH VIS SCI, V50, P2398, DOI 10.1167/iovs.08-2088
   Kiser P.D., 2021, PROG RETIN EYE RES
   KORTE GE, 1994, INT REV CYTOL, V152, P223, DOI 10.1016/S0074-7696(08)62558-9
   Lacroix S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20625-5
   Machalinska A, 2014, CURR EYE RES, V39, P1033, DOI 10.3109/02713683.2014.892996
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marquioni-Ramella MD, 2020, EXP EYE RES, V190, DOI 10.1016/j.exer.2019.107854
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Mudhar HS, 2020, EYE, V34, P246, DOI 10.1038/s41433-019-0724-4
   Ortega JT, 2019, J BIOL CHEM, V294, P8101, DOI 10.1074/jbc.RA119.007808
   Periyasamy P, 2017, PROG RETIN EYE RES, V60, P1, DOI 10.1016/j.preteyeres.2017.08.003
   Reisenhofer MH, 2017, CURR MOL MED, V17, P100, DOI 10.2174/1566524017666170331162048
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Soler MVC, 2002, EXP EYE RES, V75, P491, DOI 10.1006/exer.2002.2031
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tanito M, 2008, EXP EYE RES, V87, P292, DOI 10.1016/j.exer.2008.06.002
   Tate PS, 2020, J FUNCT FOODS, V67, DOI 10.1016/j.jff.2020.103833
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wenick A.S., 2018, RYANS RETINA, P3928
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 47
TC 0
Z9 0
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD MAY
PY 2022
VL 66
IS 10
AR 2100807
DI 10.1002/mnfr.202100807
EA MAR 2022
PG 7
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 1I4CV
UT WOS:000773567400001
PM 35279946
DA 2022-11-30
ER

PT J
AU Sasaki, M
   Miyagawa, N
   Harada, S
   Tsubota, K
   Takebayashi, T
   Nishiwaki, Y
   Kawasaki, R
AF Sasaki, Mariko
   Miyagawa, Naoko
   Harada, Sei
   Tsubota, Kazuo
   Takebayashi, Toru
   Nishiwaki, Yuji
   Kawasaki, Ryo
TI Dietary Patterns and Their Associations with Intermediate Age-Related
   Macular Degeneration in a Japanese Population
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration (AMD); intermediate AMD; dietary
   pattern; principal component analysis; Asian; staple food
ID FOOD FREQUENCY QUESTIONNAIRE; MEDITERRANEAN DIET; GLYCEMIC INDEX; RISK;
   CARBOHYDRATE; PROGRESSION; MACULOPATHY; CONSUMPTION; PREVALENCE;
   ZEAXANTHIN
AB This population-based cross-sectional study investigated the influence of dietary patterns on age-related macular degeneration (AMD) in a Japanese population. The Tsuruoka Metabolomics Cohort Study enrolled a general population aged 35-74 years from among participants in annual health check-up programs in Tsuruoka City, Japan. Eating habits were assessed using a food frequency questionnaire. Principal component analysis was used to identify dietary patterns among food items. The association between quartiles of scores for each dietary pattern and intermediate AMD was assessed using multivariate logistic regression models. Of 3433 participants, 415 had intermediate AMD. We identified four principal components comprising the Vegetable-rich pattern, Varied staple food pattern, Animal-rich pattern, and Seafood-rich pattern. After adjusting for potential confounders, higher Varied staple food diet scores were associated with a lower prevalence of intermediate AMD (fourth vs. first quartile) (OR, 0.63; 95% confidence interval [CI], 0.46-0.86). A significant trend of decreasing ORs for intermediate AMD associated with increasing Varied staple food diet scores was noted (p for trend = 0.002). There was no significant association between the other dietary patterns and intermediate AMD. In a Japanese population, individuals with a dietary pattern score high in the Varied staple food pattern had a lower prevalence of intermediate AMD.
C1 [Sasaki, Mariko; Tsubota, Kazuo] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo 1608582, Japan.
   [Sasaki, Mariko] Tachikawa Hosp, Dept Ophthalmol, Tokyo 1908531, Japan.
   [Sasaki, Mariko] Natl Tokyo Med Ctr, Natl Inst Sensory Organs, Tokyo 1528902, Japan.
   [Miyagawa, Naoko; Harada, Sei; Takebayashi, Toru] Keio Univ, Dept Prevent Med & Publ Hlth, Sch Med, Tokyo 1608582, Japan.
   [Nishiwaki, Yuji] Toho Univ, Dept Environm & Occupat Hlth, Tokyo 1438540, Japan.
   [Kawasaki, Ryo] Osaka Univ, Dept Vis Informat Topcon, Grad Sch Med, Osaka 5650871, Japan.
C3 Keio University; Tachikawa Hospital; Keio University; Toho University;
   Osaka University
RP Sasaki, M (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, Tokyo 1608582, Japan.; Sasaki, M (通讯作者)，Tachikawa Hosp, Dept Ophthalmol, Tokyo 1908531, Japan.; Sasaki, M (通讯作者)，Natl Tokyo Med Ctr, Natl Inst Sensory Organs, Tokyo 1528902, Japan.
EM mariko.sasaki@a2.keio.jp; nmiya@keio.jp; seipeace2u@gmail.com;
   tsubota@z3.keio.jp; ttakebayashi@keio.jp;
   yuuji.nishiwaki@med.toho-u.ac.jp; ryo.kawasaki@ophthal.med.osaka-u.ac.jp
RI ; Tsubota, Kazuo/M-1915-2013
OI Sasaki, Mariko/0000-0001-5608-0546; Tsubota, Kazuo/0000-0002-8874-7111;
   Kawasaki, Ryo/0000-0002-7492-6303
FU Yamagata Prefectural Government; Japan Society for the Promotion of
   Science [JP24390168, JP15H04778, 20K10490, 25670303, 26670340,
   JP15K19231]; city of Tsuruoka
FX This study was supported in part by research funds from the Yamagata
   Prefectural Government (http://www.pref.yamagata.jp/) and the city of
   Tsuruoka (https://www.city.tsuruoka.lg.jp/), and by the Grant-in-Aid for
   Scientific Research (B) (grant numbers JP24390168, JP15H04778), the
   Grant-in-Aid for Scientific Research (C) (grant number 20K10490),
   Grant-in-Aid for Challenging Exploratory Research (grant number
   25670303, 26670340), and Grant-in-Aid for Young Scientists (B) (grant
   number JP15K19231) from the Japan Society for the Promotion of Science
   (http://www.jsps.go.jp/).
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barclay AW, 2008, PUBLIC HEALTH NUTR, V11, P573, DOI 10.1017/S1368980007001103
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2017, INVEST OPHTH VIS SCI, V58, P1404, DOI 10.1167/iovs.16-20454
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Dinu M, 2019, EUR J NUTR, V58, P2123, DOI 10.1007/s00394-018-1771-5
   Francisco SG, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092862
   Harada S, 2016, ENVIRON HEALTH PREV, V21, P18, DOI 10.1007/s12199-015-0494-y
   Henry CJ, 2021, NUTR DIABETES, V11, DOI 10.1038/s41387-020-00145-w
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Imaeda N, 2007, J EPIDEMIOL, V17, P100, DOI 10.2188/jea.17.100
   Imaeda N, 2021, ENVIRON HEALTH PREV, V26, DOI 10.1186/s12199-021-00951-3
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kang KT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44632-2
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kuwabara K, 2016, J ATHEROSCLER THROMB, V23, P477, DOI 10.5551/jat.33100
   Lever J, 2017, NAT METHODS, V14, P641, DOI 10.1038/nmeth.4346
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Matsumoto M, 2021, J EPIDEMIOL, V31, P495, DOI 10.2188/jea.JE20200089
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Newby PK, 2004, NUTR REV, V62, P177, DOI [10.1111/j.1753-4887.2004.tb00040.x, 10.1301/rn.2004.may.177-203]
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Tokudome Y, 2005, J EPIDEMIOL, V15, P135, DOI 10.2188/jea.15.135
   Tsugane S, 2021, EUR J CLIN NUTR, V75, P921, DOI 10.1038/s41430-020-0677-5
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 42
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2022
VL 11
IS 6
AR 1617
DI 10.3390/jcm11061617
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0C2UM
UT WOS:000775174600001
PM 35329943
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Javed, F
   Sculean, A
   Romanos, GE
AF Javed, Fawad
   Sculean, Anton
   Romanos, Georgios E.
TI Association between age-related macular degeneration and periodontal and
   peri-implant diseases: a systematic review
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; clinical; peri-implantitis;
   periodontitis; survey
ID NATIONAL-HEALTH; RISK-FACTOR; PREVALENCE
AB The aim of the present systematic review was to assess the association between age-related macular degeneration (AMD) and periodontal and peri-implant diseases. The focused question was 'Is there a relationship between AMD and periodontal and peri-implant diseases?' Indexed databases were searched up to and including May 2020 to identify pertinent original studies. The Cochrane Collaboration's tool was used to assess the risk of bias. Five observational cohort studies were included that assessed the association between AMD and periodontitis. The number of patients with and without AMD ranged between 54 and 90 and 1697 and 12,171 individuals, respectively. Examiner blinding to the study groups was performed in 1 of the 5 studies. None of the studies were power adjusted. Scrutiny of studies showed that all 5 studies included in the present systematic review had a high risk of bias. Results from all studies reported a direct association between AMD and periodontitis. No studies assessed the association between AMD and peri-implant diseases. The association between AMD and periodontal and peri-implant diseases remains debatable. Further well-designed and power-adjusted studies are needed to determine whether or not a 'true' association exists between AMD and periodontal and peri-implant diseases.
C1 [Javed, Fawad] Univ Rochester, Eastman Inst Oral Hlth, Div Orthodont & Dentofacial Orthoped, Rochester, NY USA.
   [Sculean, Anton] Univ Bern, Sch Dent Med, Dept Periodontol, Bern, Switzerland.
   [Romanos, Georgios E.] SUNY Stony Brook, Sch Dent Med, Dept Periodontol, Lab Periodontal Implant Phototherapy LAPIP, Stony Brook, NY 11794 USA.
C3 University of Rochester; University of Bern; State University of New
   York (SUNY) System; SUNY Community College; State University of New York
   (SUNY) Stony Brook
RP Romanos, GE (通讯作者)，SUNY Stony Brook, Sch Dent Med, Dept Periodontol, Lab Periodontal Implant Phototherapy LAPIP, Stony Brook, NY 11794 USA.
EM georgios.romanos@stonybrook.edu
RI Romanos, Georgios E./A-1742-2014
OI Romanos, Georgios E./0000-0002-7745-5957
CR Brzozowska Aleksandra, 2012, Klin Oczna, V114, P29
   Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Gemmy Cheung CM, 2013, AM J OPHTHALMOL, V155, pe761
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Heitz-Mayfield LJA, 2010, PERIODONTOL 2000, V53, P167, DOI 10.1111/j.1600-0757.2010.00348.x
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Javed F, 2007, J PERIODONTOL, V78, P2112, DOI 10.1902/jop.2007.070186
   Javed F, 2019, PERIODONTOL 2000, V81, P57, DOI 10.1111/prd.12283
   Javed F, 2019, PERIODONTOL 2000, V81, P48, DOI 10.1111/prd.12282
   Javed F, 2015, J PERIODONTOL, V86, P839, DOI 10.1902/jop.2015.150120
   Javed F, 2013, INTERV MED APPL SCI, V5, P116, DOI 10.1556/IMAS.5.2013.3.4
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
   Pockpa ZAD, 2019, PERM J, V23, P18
   Romanos G, 2010, J ORAL IMPLANTOL, V36, P315, DOI 10.1563/AAID-JOI-D-09-00060
   Shin YU, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006418
   Sun KT, 2020, RETINA-J RET VIT DIS, V40, P2312, DOI 10.1097/IAE.0000000000002750
   Viswanathan M., 2013, METHODS RES REPORTS
   Vohra F, 2018, INT J PERIODONT REST, V38, pE119, DOI 10.11607/prd.3411
   Wagley S, 2015, RETINA-J RET VIT DIS, V35, P982, DOI 10.1097/IAE.0000000000000427
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu CM, 2019, ACTA OPHTHALMOL, V97, pE713, DOI 10.1111/aos.14032
NR 28
TC 6
Z9 6
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2021
VL 99
IS 4
BP 351
EP 356
DI 10.1111/aos.14629
EA SEP 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SZ5CP
UT WOS:000573599400001
PM 32996717
DA 2022-11-30
ER

PT J
AU Pondorfer, SG
   Heinemann, M
   Wintergerst, MWM
   Pfau, M
   Stromer, AL
   Holz, FG
   Finger, RP
AF Pondorfer, Susanne G.
   Heinemann, Manuel
   Wintergerst, Maximilian W. M.
   Pfau, Maximilian
   Stroemer, Annika L.
   Holz, Frank G.
   Finger, Robert P.
TI Detecting vision loss in intermediate age-related macular degeneration:
   A comparison of visual function tests
SO PLOS ONE
LA English
DT Article
ID ROBSON CONTRAST SENSITIVITY; MEDIATED DARK-ADAPTATION; OPTIMAL
   CUT-POINT; LOW-LUMINANCE; YOUDEN INDEX; GEOGRAPHIC ATROPHY; ACUITY LOSS;
   MICROPERIMETRY; MACULOPATHY; ASSOCIATIONS
AB The purpose of the study was to evaluate the diagnostic accuracy of visual function tests in intermediate age-related macular degeneration (iAMD). A total of 62 subjects (38 patients with iAMD and 24 controls) were included and underwent several functional assessments: Best-corrected visual acuity (BCVA), low luminance visual acuity (LLVA), visual acuity (VA) measured with the Moorfields Vanishing Optotypes Acuity Charts (MAC), contrast sensitivity with the Pelli-Robson test, reading speed using the International Reading Speed texts (IReST) and mesopic and dark-adapted microperimetry (S-MAIA, CenterVue, Padova, Italy). Groups were compared using non-parametric Wilcoxon rank sum tests and ROC analyses. Linear regression was used to control for confounding. Results showed that all visual function test performances except the IReST were significantly reduced in iAMD patients compared to controls (p < 0.05). These effects did not alter after controlling for age and sex. Best discrimination between iAMD and controls yield the combination of LLVA and contrast sensitivity as well as MAC-VA and contrast sensitivity (ROC area under the curve 0.95 and 0.93, respectively). Our results suggest that LLVA, MAC-VA, contrast sensitivity and mesopic and dark-adapted microperimetry can capture visual impairment characteristic for iAMD. Best discrimination against iAMD is achieved with a combination of two tests.
C1 [Pondorfer, Susanne G.; Heinemann, Manuel; Wintergerst, Maximilian W. M.; Pfau, Maximilian; Stroemer, Annika L.; Holz, Frank G.; Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
C3 University of Bonn
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Bonn, Germany.
EM robert.finger@ukbonn.de
RI Wintergerst, Maximilian/AAW-2972-2021; Wintergerst,
   Maximilian/E-5523-2019
OI Wintergerst, Maximilian/0000-0002-2766-7038; Pfau,
   Maximilian/0000-0001-9761-9640; Finger, Robert P/0000-0003-4253-7597
FU Else Krohner Fresenius Stiftung/German Scholars Organization [GSO/EKFS
   16]
FX R.P.F.: Else Krohner Fresenius Stiftung/German Scholars Organization
   (GSO/EKFS 16) The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], PREV INC HEALTHC NEE
   [Anonymous], 2017, STATA STAT SOFTWARE
   Barteselli G, 2014, EYE, V28, P1231, DOI 10.1038/eye.2014.189
   CAMPBELL FW, 1966, J PHYSIOL-LONDON, V186, P558, DOI 10.1113/jphysiol.1966.sp008056
   Cassels NK, 2018, USE MICROPERIMETRY A
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Choi BCK, 1998, AM J EPIDEMIOL, V148, P1127
   Cleves Mario A, 2002, STATA J, P301
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Mantyjarvi M, 2001, J CATARACT REFR SURG, V27, P261, DOI 10.1016/S0886-3350(00)00562-9
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   McKeague C, 2014, OPTOMETRY VISION SCI, V91, P916, DOI 10.1097/OPX.0000000000000318
   METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2
   Nebbioso M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/671529
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Ruopp MD, 2008, BIOMETRICAL J, V50, P419, DOI 10.1002/bimj.200710415
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, pAMD65, DOI 10.1167/iovs.17-23764
   Schisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tran BK, 2015, KLIN MONATSBL AUGENH, V232, P529, DOI 10.1055/s-0035-1545779
   Trauzettel-Klosinski S, 2012, INVEST OPHTH VIS SCI, V53, P5452, DOI 10.1167/iovs.11-8284
   Varadaraj V, 2018, AM J OPHTHALMOL, V186, P138, DOI 10.1016/j.ajo.2017.11.026
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vujosevic S, 2011, Z AUGENHEILKD, V225, P155, DOI [10.1159/000320340, DOI 10.1159/000320340]
   Vujosevic S, 2016, A VONGRAEFES ARCH KL
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 54
TC 12
Z9 12
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2020
VL 15
IS 4
AR e0231748
DI 10.1371/journal.pone.0231748
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LR9JM
UT WOS:000536011400104
PM 32298375
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Logue, MW
   Schu, M
   Vardarajan, BN
   Farrell, J
   Lunetta, KL
   Jun, G
   Baldwin, CT
   DeAngelis, MM
   Farrer, LA
AF Logue, Mark W.
   Schu, Matthew
   Vardarajan, Badri N.
   Farrell, John
   Lunetta, Kathryn L.
   Jun, Gyungah
   Baldwin, Clinton T.
   DeAngelis, Margaret M.
   Farrer, Lindsay A.
TI A search for age-related macular degeneration risk variants in Alzheimer
   disease genes and pathways
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Alzheimer disease; Age related macular degeneration; Genetic
   association; Gene-based test; Pathway analysis
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; APOLIPOPROTEIN-E GENE;
   COMMON VARIANTS; PERISPINAL ETANERCEPT; SUSCEPTIBILITY LOCI; IDENTIFIES
   VARIANTS; TYPE-4 ALLELE; AMYLOID-BETA; E EPSILON-4
AB Several lines of inquiry point to overlapping molecular mechanisms between late-onset Alzheimer disease (AD) and age-related macular degeneration (AMD). We evaluated summarized results from large genome-wide association studies for AD and AMD to test the hypothesis that AD susceptibility loci are also associated with AMD. We observed association of both disorders with genes in a region of chromosome 7, including PILRA and ZCWPW1 (peak AMD SNP rs7792525, minor allele frequency [MAF] 19%, odds ratio [OR] 1.14, p 2.34 x 10(-6)), and with ABCA7 (peak AMD SNP rs3752228, MAF = 0.054, OR 1.22, p 0.00012). Next, we evaluated association of AMD with genes in AD-related pathways identified by canonical pathway analysis of AD-associated genes. Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF 0.23, OR 0.91, p 7.52 = 10 x 5), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF 0.34, OR 0.89, p 1.17 = 10 x 5), which is a member of the atherosclerosis signaling and the LXR/ RXR activation pathways. Our results suggest that AMD and AD share genetic mechanisms. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Logue, Mark W.; Schu, Matthew; Vardarajan, Badri N.; Farrell, John; Jun, Gyungah; Baldwin, Clinton T.; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA.
   [Logue, Mark W.; Lunetta, Kathryn L.; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
   [DeAngelis, Margaret M.] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
C3 Boston University; Boston University; Boston University; Boston
   University; Boston University; Utah System of Higher Education;
   University of Utah
RP Farrer, LA (通讯作者)，Boston Univ, Sch Med, Biomed Genet E201,72 East Concord St, Boston, MA 02118 USA.
EM farrer@bu.edu
RI DeAngelis, e/J-7863-2015; Farrer, Lindsay/AAS-1035-2020
OI Farrer, Lindsay/0000-0001-5533-4225; Jun, Gyungah/0000-0002-3230-8697;
   Schu, Matthew/0000-0003-0630-1026; Lunetta, Kathryn/0000-0002-9268-810X
FU National Institutes of Health [R01-AG025259, PG30-AG13846, U01-AG032984,
   R01-EY0144581]; Research to Prevent Blindness, Inc NY; Department of
   Ophthalmology and Visual Sciences, University of Utah; Edward and Della
   Thome Memorial Foundation; NATIONAL EYE INSTITUTE [R01EY014458] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG032984,
   R01AG025259, P30AG013846] Funding Source: NIH RePORTER
FX The authors gratefully acknowledge the technical assistance of Grant
   Duclos. This work was supported by National Institutes of Health grants
   R01-AG025259, PG30-AG13846, U01-AG032984, and R01-EY0144581, an
   unrestricted grant from Research to Prevent Blindness, Inc NY, NY to the
   Department of Ophthalmology and Visual Sciences, University of Utah, and
   by a grant from the Edward and Della Thome Memorial Foundation.
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Bando H, 2007, EXP EYE RES, V84, P135, DOI 10.1016/j.exer.2006.09.008
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815
   Casserly I, 2004, LANCET, V363, P1139, DOI 10.1016/S0140-6736(04)15900-X
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Du XM, 2012, CELL REP, V1, P29, DOI 10.1016/j.celrep.2011.10.004
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349
   FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gatta LB, 2008, DEMENT GERIATR COGN, V26, P169, DOI 10.1159/000151050
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036
   He FH, 2010, STRUCTURE, V18, P1127, DOI 10.1016/j.str.2010.06.012
   Hill JM, 2007, EXP EYE RES, V84, P801, DOI 10.1016/j.exer.2006.08.001
   Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803
   Huang J, 2011, BIOINFORMATICS, V27, P1201, DOI 10.1093/bioinformatics/btr116
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Itzhaki RF, 1998, BIOCHEM SOC T, V26, P273, DOI 10.1042/bst0260273
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013950
   Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kennelly Sean P, 2009, Ther Adv Neurol Disord, V2, P241, DOI 10.1177/1756285609103483
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Liu JZ, 2010, AM J HUM GENET, V87, P139, DOI 10.1016/j.ajhg.2010.06.009
   Logue MW, 2011, ARCH NEUROL-CHICAGO, V68, P1569, DOI 10.1001/archneurol.2011.646
   Makhatadze NJ, 1998, HUM IMMUNOL, V59, P571, DOI 10.1016/S0198-8859(98)00056-1
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Miyashita A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058618
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Proitsi P, 2012, NEUROBIOL AGING, V33, P1843, DOI DOI 10.1016/J.NEUR0BI0LAGING.2011.12.036
   Reitz C, 2004, ARCH NEUROL-CHICAGO, V61, P705, DOI 10.1001/archneur.61.5.705
   Reitz C, 2013, JAMA-J AM MED ASSOC, V309, P1483, DOI 10.1001/jama.2013.2973
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943
   Satoh T, 2008, CELL, V132, P935, DOI 10.1016/j.cell.2008.01.043
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seshadri S, 2010, JAMA-J AM MED ASSOC, V303, P1832, DOI 10.1001/jama.2010.574
   Shukla SY, 2009, INVEST OPHTH VIS SCI, V50, P2878, DOI 10.1167/iovs.08-2981
   Solovieff N, 2013, NAT REV GENET, V14, P483, DOI 10.1038/nrg3461
   Tanaka N, 2011, J ATHEROSCLER THROMB, V18, P274, DOI 10.5551/jat.6726
   Tobinick EL, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-27
   Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2
   Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Wu FB, 2009, AGEING RES REV, V8, P147, DOI 10.1016/j.arr.2009.03.002
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 85
TC 35
Z9 35
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JUN
PY 2014
VL 35
IS 6
AR 1510.e7
DI 10.1016/j.neurobiolaging.2013.12.007
PG 12
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA AE4RO
UT WOS:000333970800034
PM 24439028
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sabour-Pickett, S
   Loughman, J
   Nolan, JM
   Stack, J
   Pesudovs, K
   Meagher, KA
   Beatty, S
AF Sabour-Pickett, Sarah
   Loughman, James
   Nolan, John M.
   Stack, Jim
   Pesudovs, Konrad
   Meagher, Katherine A.
   Beatty, Stephen
TI Visual Performance in Patients with Neovascular Age-Related Macular
   Degeneration Undergoing Treatment with Intravitreal Ranibizumab
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CONTRAST SENSITIVITY; CHOROIDAL
   NEOVASCULARIZATION; MICROPERIMETRIC CHANGES; READING SPEED; VISION;
   IMPACT; ACUITY; VERTEPORFIN; IMPAIRMENT
AB Purpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (nv-AMD). Methods. Forty-seven eyes of 47 patients with nv-AMD, and corrected distance visual acuity (CDVA) logMAR 0.7 or better, undergoing intravitreal injections of ranibizumab, were enrolled into this prospective study. Visual function was assessed using a range of psychophysical tests, while mean foveal thickness (MFT) was determined by optical coherence tomography (OCT). Results. Groupmean (+/- sd) MFT reduced significantly from baseline (233 (+/- 59)) to exit (205 (+/- 40)) (P = 0.001). CDVA exhibited no change between baseline and exit visits (P = 0.48 and P = 0.31, resp.). Measures of visual function that did exhibit statistically significant improvements (P < 0.05 for all) included reading acuity, reading speed, mesopic and photopic contrast sensitivity (CS), mesopic and photopic glare disability (GD), and retinotopic ocular sensitivity (ROS) at all eccentricities. Conclusion. Eyes with nv-AMD undergoing intravitreal ranibizumab injections exhibit improvements in many parameters of visual function. Outcome measures other than CDVA, such as CS, GD, and ROS, should not only be considered in the design of studies investigating nv-AMD, but also in treatment and retreatment strategies for patients with the condition.
C1 [Sabour-Pickett, Sarah; Loughman, James] Dublin Inst Technol, Dept Optometry, Dublin, Ireland.
   [Sabour-Pickett, Sarah; Nolan, John M.; Beatty, Stephen] Whitfield Clin, Inst Eye Surg, Waterford, Ireland.
   [Sabour-Pickett, Sarah; Nolan, John M.; Beatty, Stephen] Whitfield Clin, Inst Vis Res, Waterford, Ireland.
   [Sabour-Pickett, Sarah; Nolan, John M.; Stack, Jim; Meagher, Katherine A.; Beatty, Stephen] Waterford Inst Technol, Macular Pigment Res Grp, Waterford, Ireland.
   [Loughman, James] Univ KwaZulu Natal, Fac Hlth Sci, African Vis Res Inst, Durban, South Africa.
   [Pesudovs, Konrad] Flinders Med Ctr, Dept Optometry & Vis Sci, NH & MRC Ctr Clin Eye Res, Bedford Pk, SA, Australia.
   [Pesudovs, Konrad] Flinders Univ South Australia, Bedford Pk, SA, Australia.
C3 Technological University Dublin; South East Technological University
   (SETU); University of Kwazulu Natal; Flinders Medical Centre; Flinders
   University South Australia
RP Sabour-Pickett, S (通讯作者)，Dublin Inst Technol, Dept Optometry, Dublin, Ireland.
EM sarah.sabourpickett@gmail.com
RI Pesudovs, Konrad/T-9403-2019; Nolan, John/N-4921-2014
OI Pesudovs, Konrad/0000-0002-6322-9369; Nolan, John/0000-0002-5503-7084;
   Loughman, James/0000-0003-3130-8991
FU Novartis Pharma AG
FX This study was funded by Novartis Pharma AG.
CR Alexander P, 2012, EYE, V26, P678, DOI 10.1038/eye.2012.7
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Das R, 2009, RETINA-J RET VIT DIS, V29, P1013, DOI 10.1097/IAE.0b013e3181a91dbf
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hohberger B, 2007, GRAEF ARCH CLIN EXP, V245, P1805, DOI 10.1007/s00417-007-0662-x
   Kaiser P. K., 2007, AM J OPHTHALMOL, V144, p850e4
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Kloos P, 2008, KLIN MONATSBL AUGENH, V225, P385, DOI 10.1055/s-2008-1027252
   Koch KR, 2012, GRAEF ARCH CLIN EXP, V250, P201, DOI 10.1007/s00417-011-1792-8
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   LOSHIN DS, 1984, ARCH OPHTHALMOL-CHIC, V102, P1303, DOI 10.1001/archopht.1984.01040031053022
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Owsley Cynthia, 2003, Ophthalmol Clin North Am, V16, P171, DOI 10.1016/S0896-1549(03)00003-8
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Stifter E, 2004, GRAEF ARCH CLIN EXP, V242, P31, DOI 10.1007/s00417-003-0776-8
   Stifter E, 2005, J CATARACT REFR SURG, V31, P2111, DOI 10.1016/j.jcrs.2005.03.080
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Wong T., 2008, OPHTHALMOLOGY, V115, p116e1
NR 42
TC 17
Z9 18
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 268438
DI 10.1155/2013/268438
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 097XC
UT WOS:000315505800001
PM 23533703
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Yu, Y
   Bhangale, TR
   Fagerness, J
   Ripke, S
   Thorleifsson, G
   Tan, PL
   Souied, EH
   Richardson, AJ
   Merriam, JE
   Buitendijk, GHS
   Reynolds, R
   Raychaudhuri, S
   Chin, KA
   Sobrin, L
   Evangelou, E
   Lee, PH
   Lee, AY
   Leveziel, N
   Zack, DJ
   Campochiaro, B
   Campochiaro, P
   Smith, RT
   Barile, GR
   Guymer, RH
   Hogg, R
   Chakravarthy, U
   Robman, LD
   Gustafsson, O
   Sigurdsson, H
   Ortmann, W
   Behrens, TW
   Stefansson, K
   Uitterlinden, AG
   van Duijn, CM
   Vingerling, JR
   Klaver, CCW
   Allikmets, R
   Brantley, MA
   Baird, PN
   Katsanis, N
   Thorsteinsdottir, U
   Ioannidis, JPA
   Daly, MJ
   Graham, RR
   Seddon, JM
AF Yu, Yi
   Bhangale, Tushar R.
   Fagerness, Jesen
   Ripke, Stephan
   Thorleifsson, Gudmar
   Tan, Perciliz L.
   Souied, Eric H.
   Richardson, Andrea J.
   Merriam, Joanna E.
   Buitendijk, Gabrielle H. S.
   Reynolds, Robyn
   Raychaudhuri, Soumya
   Chin, Kimberly A.
   Sobrin, Lucia
   Evangelou, Evangelos
   Lee, Phil H.
   Lee, Aaron Y.
   Leveziel, Nicolas
   Zack, Donald J.
   Campochiaro, Betsy
   Campochiaro, Peter
   Smith, R. Theodore
   Barile, Gaetano R.
   Guymer, Robyn H.
   Hogg, Ruth
   Chakravarthy, Usha
   Robman, Luba D.
   Gustafsson, Omar
   Sigurdsson, Haraldur
   Ortmann, Ward
   Behrens, Timothy W.
   Stefansson, Kari
   Uitterlinden, Andre G.
   van Duijn, Cornelia M.
   Vingerling, Johannes R.
   Klaver, Caroline C. W.
   Allikmets, Rando
   Brantley, Milam A., Jr.
   Baird, Paul N.
   Katsanis, Nicholas
   Thorsteinsdottir, Unnur
   Ioannidis, John P. A.
   Daly, Mark J.
   Graham, Robert R.
   Seddon, Johanna M.
TI Common variants near FRK/COL10A1 and VEGFA are associated with advanced
   age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; GENETIC-ASSOCIATION; RISK;
   SUSCEPTIBILITY; METAANALYSIS; HAPLOTYPE; DISEASE; LOCI; ANGIOGENESIS
AB Despite significant progress in the identification of genetic loci for age-related macular degeneration (AMD), not all of the heritability has been explained. To identify variants which contribute to the remaining genetic susceptibility, we performed the largest meta-analysis of genome-wide association studies to date for advanced AMD. We imputed 6 036 699 single-nucleotide polymorphisms with the 1000 Genomes Project reference genotypes on 2594 cases and 4134 controls with follow-up replication of top signals in 5640 cases and 52 174 controls. We identified two new common susceptibility alleles, rs1999930 on 6q21-q22.3 near FRK/COL10A1 [odds ratio (OR) 0.87; P = 1.1 x 10(-8)] and rs4711751 on 6p12 near VEGFA (OR 1.15; P = 8.7 x 10(-9)). In addition to the two novel loci, 10 previously reported loci in ARMS2/HTRA1 (rs10490924), CFH (rs1061170, and rs1410996), CFB (rs641153), C3 (rs2230199), C2 (rs9332739), CFI (rs10033900), LIPC (rs10468017), TIMP3 (rs9621532) and CETP (rs3764261) were confirmed with genome-wide significant signals in this large study. Loci in the recently reported genes ABCA1 and COL8A1 were also detected with suggestive evidence of association with advanced AMD. The novel variants identified in this study suggest that angiogenesis (VEGFA) and extracellular collagen matrix (FRK/COL10A1) pathways contribute to the development of advanced AMD.
C1 [Yu, Yi; Reynolds, Robyn; Chin, Kimberly A.; Seddon, Johanna M.] Tufts Univ, Sch Med, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Ioannidis, John P. A.] Tufts Univ, Sch Med, Ctr Genet Epidemiol & Modeling, Boston, MA 02111 USA.
   [Ioannidis, John P. A.] Tufts Univ, Sch Med, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA.
   [Ioannidis, John P. A.] Tufts Univ, Sch Med, Tufts Clin & Translat Sci Inst, Boston, MA 02111 USA.
   [Ioannidis, John P. A.; Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Tufts Med Ctr, Boston, MA 02111 USA.
   [Bhangale, Tushar R.] Genentech Inc, Human Genet Grp, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA.
   [Ortmann, Ward; Behrens, Timothy W.; Graham, Robert R.] Genentech Inc, Human Genet Grp, Immunol & Tissue Growth & Repair Dept, San Francisco, CA 94080 USA.
   [Fagerness, Jesen; Ripke, Stephan; Raychaudhuri, Soumya; Lee, Phil H.; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Fagerness, Jesen; Ripke, Stephan; Raychaudhuri, Soumya; Lee, Phil H.; Daly, Mark J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
   [Thorleifsson, Gudmar; Gustafsson, Omar; Stefansson, Kari; Thorsteinsdottir, Unnur] deCODE Genet, IS-101 Reykjavik, Iceland.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC 27710 USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Dept Cell Biol, Durham, NC 27710 USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27710 USA.
   [Souied, Eric H.; Leveziel, Nicolas] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Souied, Eric H.; Leveziel, Nicolas] UPEC, Dept Ophthalmol, Fac Med Henri Mondor, Creteil, France.
   [Richardson, Andrea J.; Guymer, Robyn H.; Robman, Luba D.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Merriam, Joanna E.; Smith, R. Theodore; Barile, Gaetano R.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; van Duijn, Cornelia M.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA.
   [Sobrin, Lucia] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
   [Evangelou, Evangelos; Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.
   [Lee, Aaron Y.; Brantley, Milam A., Jr.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Lee, Aaron Y.; Brantley, Milam A., Jr.] Barnes Retina Inst, St Louis, MO 63144 USA.
   [Zack, Donald J.; Campochiaro, Betsy; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Zack, Donald J.; Campochiaro, Betsy; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
   [Zack, Donald J.; Campochiaro, Betsy] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Mol Biol & Genet, Baltimore, MD 21287 USA.
   [Zack, Donald J.; Campochiaro, Betsy] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA.
   [Hogg, Ruth; Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast, Antrim, North Ireland.
   [Sigurdsson, Haraldur] Natl Univ Hosp Reykjavik, Dept Ophthalmol, IS-101 Reykjavik, Iceland.
   [Sigurdsson, Haraldur; Stefansson, Kari; Thorsteinsdottir, Unnur] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.
   [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
   [Zack, Donald J.] UPMC, Inst Vis, Paris, France.
C3 Tufts University; Tufts University; Tufts University; Tufts University;
   Tufts Medical Center; Tufts University; Roche Holding; Genentech; Roche
   Holding; Genentech; Harvard University; Massachusetts General Hospital;
   Harvard University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Duke University; Duke University; Duke University; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique
   Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   Hopital Universitaire Henri-Mondor - APHP; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   Columbia University; Erasmus University Rotterdam; Erasmus MC; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; Harvard University; Brigham & Women's Hospital; Harvard University;
   Brigham & Women's Hospital; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; University of Ioannina; Washington
   University (WUSTL); Washington University (WUSTL); Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Queens University Belfast;
   Landspitali National University Hospital; University of Iceland;
   Columbia University; Stanford University; Stanford University;
   UDICE-French Research Universities; Sorbonne Universite
RP Seddon, JM (通讯作者)，Tufts Univ, Sch Med, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Stefansson, Kari/AAE-7187-2019; Evangelou, Evangelos/C-3033-2013; Hogg,
   Ruth E./ABC-9602-2020; Ioannidis, John P. A./G-9836-2011; Allikmets,
   Rando/ABD-4533-2021; du, zhao jiang/F-6229-2011; Lee,
   Aaron/AAT-2839-2020; Katsanis, Nicholas/E-1837-2012; Klaver, Caroline
   C.W./A-2013-2016; Daly, Mark J/B-2453-2017; Ripke, Stephan/AAK-5486-2021
OI Evangelou, Evangelos/0000-0002-5488-2999; Hogg, Ruth
   E./0000-0001-9413-2669; Daly, Mark J/0000-0002-0949-8752; Raychaudhuri,
   Soumya/0000-0002-1901-8265; Nicolas, Leveziel/0000-0001-8533-9457;
   smith, theodore/0000-0002-1693-943X; ripke, stephan/0000-0003-3622-835X;
   Guymer, Robyn/0000-0002-9441-4356; Sobrin, Lucia/0000-0003-1575-0819;
   Zack, Don/0000-0002-7966-1973; Baird, Paul/0000-0002-1305-3502; Lee,
   Aaron/0000-0002-7452-1648; Katsanis, Nicholas/0000-0002-2480-0171;
   Klaver, Caroline/0000-0002-2355-5258; Van Duijn,
   Cornelia/0000-0002-2374-9204; Chakravarthy, Usha/0000-0002-2606-3734
FU National Eye Institute; National Institute of Mental Health [R01
   MH67257, R01 MH59588, R01 MH59571, R01 MH59565, R01 MH59587, R01
   MH60870, R01 MH59566, R01 MH59586, R01 MH61675, R01 MH60879, R01
   MH81800, U01 MH46276, U01 MH46289, U01 MH46318, U01 MH79469, U01
   MH79470]; National Institutes of Health, Bethesda, MD, USA [RO1-EY11309,
   RO1-EY13435, R24-EY017404, P30-EY 001765, K12-EY16335]; Massachusetts
   Lions Eye Research Fund, Inc.; Research to Prevent Blindness, Inc., New
   York, NY, USA; Foundation Fighting Blindness, Owing Mills, MD, USA;
   Macula Vision Research Foundation; Kaplen Foundation; Widgeon Point
   Charitable Foundation; Alcon Research Institute; Fight for Sight;
   National Health and Medical Research Council of Australia Centre for
   Clinical Research Excellence [529923]; Victorian Government; American
   Macular Degeneration Foundation; Macular Degeneration Research Fund of
   the Ophthalmic Epidemiology and Genetics Service; New England Eye
   Center; Tufts Medical Center, Tufts University School of Medicine,
   Boston, MA, USA; NATIONAL EYE INSTITUTE [R01EY011309, R24EY017404,
   K12EY016335, P30EY001765, R01EY013435] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
   [K08AR055688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTH [R01MH059586, U01MH079470, R01MH059565, U01MH079469, R01MH059566,
   R01MH059571, R01MH060879, R01MH081800, R01MH059587, U01MH046318,
   R01MH059588, R01MH061675, U01MH046276, R01MH060870, R01MH067257] Funding
   Source: NIH RePORTER
FX We thank the participants, their families and numerous ophthalmologists
   throughout the country who participated in this study, the MIGen study
   group and the Brigham and Women's Hospital PhenoGenetic Project for
   providing DNA samples that were used in this study, the AREDS Research
   Group, and Dr J. Barre, Dr. J. C. Danan and P. Ledudal from the Clinical
   Researches Functional Unit, CHI Creteil, France. The MMAP dataset used
   for the analyses described in this manuscript was obtained from the NEI
   Study of Age-Related Macular Degeneration (NEI-AMD) Database found at
   http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number
   phs000182.v2.p1. Funding support for NEI-AMD was provided by the
   National Eye Institute. We would like to thank NEI-AMD participants and
   the NEI-AMD Research Group for their valuable contribution to this
   research. Funding support for the Genome-Wide Association of
   Schizophrenia Study was provided by the National Institute of Mental
   Health (R01 MH67257, R01 MH59588, R01 MH59571, R01 MH59565, R01 MH59587,
   R01 MH60870, R01 MH59566, R01 MH59586, R01 MH61675, R01 MH60879, R01
   MH81800, U01 MH46276, U01 MH46289 U01 MH46318, U01 MH79469, and U01
   MH79470) and the genotyping of samples was provided through the Genetic
   Association Information Network (GAIN). The datasets used for the
   analyses described in this manuscript were obtained from the database of
   Genotypes and Phenotypes (dbGaP) found at
   http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number
   phs000021.v3.p2. Samples and associated phenotype data for the
   Genome-Wide Association of Schizophrenia Study were provided by the
   Molecular Genetics of Schizophrenia Collaboration (PI: Pablo V. Gejman,
   Evanston Northwestern Healthcare (ENH) and Northwestern University,
   Evanston, IL, USA).; We deeply appreciate the support of a generous
   anonymous donor to the research of J.M.S., without whom the Tufts/MGH
   genome-wide association study would not have been possible. This
   research was also supported in part by grants RO1-EY11309, RO1-EY13435,
   R24-EY017404, P30-EY 001765 and K12-EY16335 from the National Institutes
   of Health, Bethesda, MD, USA; Massachusetts Lions Eye Research Fund,
   Inc.; Unrestricted grants and Career Development Award from Research to
   Prevent Blindness, Inc., New York, NY, USA; Foundation Fighting
   Blindness, Owing Mills, MD, USA; The Macula Vision Research Foundation;
   Kaplen Foundation; Widgeon Point Charitable Foundation; the Alcon
   Research Institute; a Fight for Sight postdoctoral award; the National
   Health and Medical Research Council of Australia Centre for Clinical
   Research Excellence No. 529923-Translational Clinical Research in Major
   Eye Diseases and a Practitioner Fellowship to R. H. G. and Operational
   Infrastructure Support from the Victorian Government; American Macular
   Degeneration Foundation; and the Macular Degeneration Research Fund of
   the Ophthalmic Epidemiology and Genetics Service, New England Eye
   Center, Tufts Medical Center, Tufts University School of Medicine,
   Boston, MA, USA. Funding to pay the Open Access publication charges for
   this article was provided by the Macular Degeneration Research Fund,
   Tufts Medical Center.
CR Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Browning BL, 2009, AM J HUM GENET, V84, P210, DOI 10.1016/j.ajhg.2009.01.005
   Browning SR, 2007, AM J HUM GENET, V81, P1084, DOI 10.1086/521987
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Corbo JC, 2010, GENOME RES, V20, P1512, DOI 10.1101/gr.109405.110
   de Bakker PIW, 2008, HUM MOL GENET, V17, pR122, DOI 10.1093/hmg/ddn288
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Estrada K, 2009, BIOINFORMATICS, V25, P2750, DOI 10.1093/bioinformatics/btp497
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hom G, 2008, NEW ENGL J MED, V358, P900, DOI 10.1056/NEJMoa0707865
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kathiresan S, 2009, NAT GENET, V41, P334, DOI 10.1038/ng.327
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Korn JM, 2008, NAT GENET, V40, P1253, DOI 10.1038/ng.237
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2007, NAT GENET, V39, P1045, DOI 10.1038/ng2127
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Lamas JR, 2010, ANN RHEUM DIS, V69, P1880, DOI 10.1136/ard.2009.122564
   Ribatti D, 2009, LEUKEMIA RES, V33, P638, DOI 10.1016/j.leukres.2008.11.019
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 2011, OPHTHALMOLO IN PRESS
   Seddon JM, 2008, ALBERT JAKOBIECS PRI, V1, P413
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Sudhakar A, 2005, J CLIN INVEST, V115, P2801, DOI 10.1172/JCI24813
   Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008
   Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 51
TC 197
Z9 201
U1 0
U2 26
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD SEP 15
PY 2011
VL 20
IS 18
BP 3699
EP 3709
DI 10.1093/hmg/ddr270
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 814IP
UT WOS:000294442200016
PM 21665990
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Zuluaga, MF
   Mailhos, C
   Robinson, G
   Shima, DT
   Gurny, R
   Lange, N
AF Zuluaga, Maria-Fernanda
   Mailhos, Carolina
   Robinson, Gregory
   Shima, David T.
   Gurny, Robert
   Lange, Norbert
TI Synergies of VEGF inhibition and photodynamic therapy in the treatment
   of age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   INDUCIBLE FACTOR-I; VERTEPORFIN THERAPY; INTRAVITREAL TRIAMCINOLONE;
   VISUAL-ACUITY; EXPRESSION; MEMBRANES; ANGIOGENESIS; HYPOXIA
AB PURPOSE. Photodynamic therapy (PDT) and the administration of compounds acting against vascular endothelial growth factor (anti-VEGF) are approved for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Experimental evidence that the combined use of both treatment options may improve therapeutic outcome is presented.
   METHODS. Fertilized chick eggs were incubated until day 12 of embryo development (EDD12) and were treated by PDT using two different photosensitizing agents (liposomal formulation of BPD-MA; m-THPP encapsulated in polymeric nanoparticles) and were visualized using an epifluorescence microscope. Vascular occlusion of the treated zones of the chorioallantoic membrane (CAM) was assessed by fluorescence angiography 24 and 48 hours after treatment. Alternatively, PDT-treated areas were exposed to a soluble VEGF receptor antagonist (sFIt-1) 6 hours after treatment and were analyzed.
   RESULTS. Vascular occlusion in the PDT-treated areas was observed with both photosensitizers 24 hours after treatment. Reperfusion of preexisting blood vessels and first signs of revascularization were Visible 48 hours after PDT. Topical administration of sFlt-1 to the treated areas augmented occlusion and limited subsequent angiogenesis in a dose-dependent manner.
   CONCLUSIONS. The combined use of PDT and of agents targeting angiogenic cytokines may synergistically improve therapeutic outcome after combined treatment in patients with CNV secondary to AMD.
C1 Univ Geneva, Sect Pharmaceut Sci, Lab Pharmaceut & Biopharmaceut, CH-1211 Geneva, Switzerland.
   Eyetech Res Ctr, Lexington, MA USA.
C3 University of Geneva
RP Lange, N (通讯作者)，Univ Geneva, Sect Pharmaceut Sci, Lab Pharmaceut & Biopharmaceut, 30 Quai Ernest Ansermet, CH-1211 Geneva, Switzerland.
EM norbert.lange@pharm.unige.ch
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Cecic I, 2001, PHOTOCHEM PHOTOBIOL, V74, P712, DOI 10.1562/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Korbelik M, 1999, CANCER LETT, V137, P91, DOI 10.1016/S0304-3835(98)00349-8
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   OSIECKA BJ, 2003, MED SCI MONITOR, V9, P110
   Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rudolf M, 2004, KLIN MONATSBL AUGENH, V221, P1026, DOI 10.1055/s-2004-813851
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Uehara M, 2001, EUR J CANCER, V37, P2111, DOI 10.1016/S0959-8049(01)00243-X
   Vargas A, 2004, INT J PHARMACEUT, V286, P131, DOI 10.1016/j.ijpharm.2004.07.029
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamaguchi S, 2002, BIOCHEM BIOPH RES CO, V291, P554, DOI 10.1006/bbrc.2002.6478
   Zhang XP, 2005, LASER MED SCI, V20, P74, DOI 10.1007/s10103-005-0348-8
   Zhou QY, 2005, CANCER CHEMOTH PHARM, V56, P569, DOI 10.1007/s00280-005-1017-0
NR 35
TC 25
Z9 31
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2007
VL 48
IS 4
BP 1767
EP 1772
DI 10.1167/iovs.06-1224
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 153CB
UT WOS:000245408200043
PM 17389510
DA 2022-11-30
ER

PT J
AU Chakraborty, R
   Pramanik, A
AF Chakraborty, Rivu
   Pramanik, Ankita
TI DCNN-based prediction model for detection of age-related macular
   degeneration from color fundus images
SO MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING
LA English
DT Article
DE Age-related macular degeneration; Retinal image analysis; Color fundus
   image; Deep learning; Convolutional neural network
ID AUTOMATED DETECTION; FEATURES; DRUSEN
AB Age-related macular degeneration (AMD) is a degenerative disorder in the macular region of the eye. AMD is the leading cause of irreversible vision loss in the elderly population. With the increase in aged population in the world, there is an urgent need to develop low-cost, hassle-free, and portable equipment diagnostic and analytical tools for early diagnosis. As AMD detection is done by examining the fundus images, its diagnosis is heavily dependent on medical personnel and their experience. To remove this issue, computer-aided algorithms may be used for AMD detection. The proposed work offers an effective solution to the AMD detection problem. It proposes a novel 13-layer deep convolutional neural network (DCNN) architecture to screen fundus images to spot direct signs of AMD. Five pairs of convolution and maxpool layers and three fully connected layers are utilized in the proposed network. Extensive simulations on original and augmented versions of two datasets (iChallenge-AMD and ARIA) consisting of healthy and diseased cases show a classification accuracy of 89.75%, 91.69%, and 99.45% on original and augmented versions of iChallenge-AMD and 90.00%, 93.03%, and 99.55% on ARIA, using a 10-fold cross-validation technique. It surpasses the best-known algorithm using DCNN by 2%.
C1 [Chakraborty, Rivu; Pramanik, Ankita] Indian Inst Engn Sci & Technol, Sibpur, India.
C3 Indian Institute of Engineering Science Technology Shibpur (IIEST)
RP Chakraborty, R (通讯作者)，Indian Inst Engn Sci & Technol, Sibpur, India.
EM rivuchakraborty17@gmail.com; ankita@telecom.iiests.ac.in
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Acharya UR, 2017, J COMPUT SCI-NETH, V20, P41, DOI 10.1016/j.jocs.2017.03.005
   BASTEK JV, 1982, OPHTHALMOLOGY, V89, P1455
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Broad (Baidu Research Open-Access Dataset), 2019, ICHALLENGE AMD DAT
   Buitinck L., 2013, API DESIGN MACHINE L, P108
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chakraborty Rivu, 2021, Proceedings of International Conference on Frontiers in Computing and Systems. COMSYS 2020. Advances in Intelligent Systems and Computing (AISC 1255), P433, DOI 10.1007/978-981-15-7834-2_41
   Dalal N., 2005, CVPR
   Das S, 2018, J PHYS CONF SER, V1000, DOI 10.1088/1742-6596/1000/1/012053
   Davis J., 2006, P 23 INT C MACH LEAR, P233
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   de la Torre J, 2020, NEUROCOMPUTING, V396, P465, DOI 10.1016/j.neucom.2018.07.102
   Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   Fourcade A, 2019, J STOMATOL ORAL MAXI, V120, P279, DOI 10.1016/j.jormas.2019.06.002
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Gass JD, 1997, STEREOSCOPIC ATLAS M
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Goodfellow I, 2016, ADAPT COMPUT MACH LE, P1
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hosny KM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217293
   HUMPHREY WT, 1984, AM J OPHTHALMOL, V98, P717, DOI 10.1016/0002-9394(84)90686-X
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94
   Masumoto H, 2019, PEERJ, V7, DOI 10.7717/peerj.6900
   Mookiah MRK, 2015, KNOWL-BASED SYST, V89, P654, DOI 10.1016/j.knosys.2015.09.012
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Organization WH, 2015, WORLD REP AG HLTH
   Pacheco KD, 2016, INVEST OPHTH VIS SCI, V57
   Pead E, 2019, SURV OPHTHALMOL, V64, P498, DOI 10.1016/j.survophthal.2019.02.003
   Prince MJ, 2015, LANCET, V385, P549, DOI 10.1016/S0140-6736(14)61347-7
   Saito T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118432
   Sermanet P., 2013, ARXIV PREPRINT ARXIV
   Shen DG, 2017, ANNU REV BIOMED ENG, V19, P221, DOI [10.1146/annurev-bioeng-071516044442, 10.1146/annurev-bioeng-071516-044442]
   Tan JH, 2018, FUTURE GENER COMP SY, V87, P127, DOI 10.1016/j.future.2018.05.001
   Taylor L, 2018, 2018 IEEE SYMPOSIUM SERIES ON COMPUTATIONAL INTELLIGENCE (IEEE SSCI), P1542, DOI 10.1109/SSCI.2018.8628742
   Trucco E, 2013, INVEST OPHTH VIS SCI, V54, P3546, DOI 10.1167/iovs.12-10347
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   2020, ARIA AUTOMATIC RETIN
NR 50
TC 0
Z9 0
U1 2
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0140-0118
EI 1741-0444
J9 MED BIOL ENG COMPUT
JI Med. Biol. Eng. Comput.
PD MAY
PY 2022
VL 60
IS 5
BP 1431
EP 1448
DI 10.1007/s11517-022-02542-y
EA MAR 2022
PG 18
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Mathematical & Computational Biology;
   Medical Informatics
GA 0M9DO
UT WOS:000767038600002
PM 35267149
DA 2022-11-30
ER

PT J
AU Koo, HC
   Baek, YY
   Choi, JS
   Kim, YM
   Sung, B
   Kim, MJ
   Kim, JG
   You, JC
AF Koo, Hye Cheong
   Baek, Yi-Yong
   Choi, Jun-Sup
   Kim, Young-Myeong
   Sung, Bokyung
   Kim, Min-Jung
   Kim, Jae Gyu
   You, Ji Chang
TI Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models
   of Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE acetylated tetrapeptide (Ac-RLYE); neovascular age-related macular
   degeneration; resistance; retinal neovascularization; laser-induced CNV
   model; VEGF; VEGFR-2
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR 2; ANTI-VEGF THERAPY;
   CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR PHARMACOKINETICS;
   DIABETIC-RETINOPATHY; RANIBIZUMAB; AFLIBERCEPT; INHIBITOR;
   IDENTIFICATION
AB It has been shown previously that a novel tetrapeptide, Arg-Leu-Tyr-Glu (RLYE), derived from human plasminogen inhibits vascular endothelial growth factor (VEGF)-induced angiogenesis, suppresses choroidal neovascularization in mice by an inhibition of VEGF receptor-2 (VEGFR-2) specific signaling pathway. In this study, we report that a modified tetrapeptide (Ac-RLYE) showed improved anti-choroidal neovascularization (CNV) efficacy in a number of animal models of neovascular age-related macular degeneration (AMD) which include rat, rabbit, and minipig. The preventive and therapeutic in vivo efficacy of Ac-RLYE via following intravitreal administration was determined to be either similar or superior to that of ranibizumab and aflibercept. Assessment of the intraocular pharmacokinetic and toxicokinetic properties of Ac-RLYE in rabbits demonstrated that it rapidly reached the retina with minimal systemic exposure after a single intravitreal dose, and it did not accumulate in plasma during repetitive dosing (bi-weekly for 14 weeks). Our results suggested that Ac-RLYE has a great potential for an alternative therapeutics for neovascular (wet) AMD. Since the amino acids in human VEGFR-2 targeted by Ac-RLYE are conserved among the animals employed in this study, the therapeutic efficacies of Ac-RLYE evaluated in those animals are predicted to be observed in human patients suffering from retinal degenerative diseases.
C1 [Koo, Hye Cheong; Baek, Yi-Yong; Choi, Jun-Sup; Sung, Bokyung; Kim, Min-Jung; Kim, Jae Gyu; You, Ji Chang] Avixgen Inc, Seoul 06649, South Korea.
   [Kim, Young-Myeong] Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 24341, Gangwon Do, South Korea.
   [You, Ji Chang] Catholic Univ Korea, Sch Med, Dept Pathol, Natl Res Lab Mol Virol, Seoul 06591, South Korea.
C3 Kangwon National University; Catholic University of Korea
RP You, JC (通讯作者)，Avixgen Inc, Seoul 06649, South Korea.; You, JC (通讯作者)，Catholic Univ Korea, Sch Med, Dept Pathol, Natl Res Lab Mol Virol, Seoul 06591, South Korea.
EM koohj99@avixgen.com; yybaek@avixgen.com; mjschoi@daum.net;
   ymkim@kangwon.ac.kr; bsung@avixgen.com; mjkim208@avixgen.com;
   jagkim@avixgen.com; jiyou@catholic.ac.kr
RI Sung, Bokyung/AAX-5697-2021
OI Kim, Young-Myeong/0000-0002-8326-7768
FU Korea Health Industry Development Institute (KHIDI) - Ministry of Health
   & Welfare, Republic of Korea [HI17C2273]; research foundation of Korea
   (NRF) - Korean Government [2017R1A5A1015366, 2020R1F1A1075725]
FX This research was supported by a grant of the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (grant number: HI17C2273). This work was supported in part by a research
   foundation of Korea (NRF) funded by the Korean Government
   (2017R1A5A1015366 and 2020R1F1A1075725).
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aziz MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep24460
   Baek YY, 2017, ONCOTARGET, V8, P11763, DOI 10.18632/oncotarget.14343
   Baek YY, 2015, BIOCHEM BIOPH RES CO, V463, P532, DOI 10.1016/j.bbrc.2015.05.073
   Bee YS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102993
   Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Caldwelll RB, 2003, DIABETES-METAB RES, V19, P442, DOI 10.1002/dmrr.415
   Cao LX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168366
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Conti B, 1997, EUR J PHARM SCI, V5, P287, DOI 10.1016/S0928-0987(97)00023-7
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Forbes JM, 2013, PHYSIOL REV, V93, P137, DOI 10.1152/physrev.00045.2011
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411
   Jo DH, 2017, ONCOTARGET, V8, P45506, DOI 10.18632/oncotarget.17221
   Jo NC, 2007, J KOREAN MED ASSOC, V50, P731, DOI 10.5124/jkma.2007.50.8.731
   Kim EK, 2014, CORNEA, V33, P60, DOI 10.1097/ICO.0000000000000007
   Kim KL, 2017, INVEST OPHTH VIS SCI, V58, P3592, DOI 10.1167/iovs.17-21416
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228
   Leppanen VM, 2010, P NATL ACAD SCI USA, V107, P2425, DOI 10.1073/pnas.0914318107
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   MURATA T, 1995, OPHTHALMIC RES, V27, P48, DOI 10.1159/000267567
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Nuzzi R., 2015, J CLIN EXP OPHTHALMO, V6, P448
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Park W, 2019, BIOMOL THER, V27, P474, DOI 10.4062/biomolther.2019.041
   Rojas J.S., 2015, INT J OPHTHALMOL CLI, V2, P022
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawano A, 1996, CELL GROWTH DIFFER, V7, P213
   Simmons AB, 2018, ANGIOGENESIS, V21, P751, DOI 10.1007/s10456-018-9618-5
   Souied EH, 2016, OPHTHAL EPIDEMIOL, V23, P71, DOI 10.3109/09286586.2015.1090004
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Takahashi H, 2008, CURR EYE RES, V33, P1002, DOI 10.1080/02713680802492440
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2007, GLOB IN EL AV BLINDN
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yun JA, 2019, MOL PHARMACOL, V96, P692, DOI 10.1124/mol.119.117234
NR 48
TC 0
Z9 0
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2021
VL 22
IS 8
AR 3893
DI 10.3390/ijms22083893
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA RT3ML
UT WOS:000644366200001
PM 33918777
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pondorfer, SG
   Terheyden, JH
   Heinemann, M
   Wintergerst, MWM
   Holz, FG
   Finger, RP
AF Pondorfer, Susanne G.
   Terheyden, Jan H.
   Heinemann, Manuel
   Wintergerst, Maximilian W. M.
   Holz, Frank G.
   Finger, Robert P.
TI Association of Vision-related Quality of Life with Visual Function in
   Age-Related Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ROBSON CONTRAST SENSITIVITY; LOW LUMINANCE; FUNCTION-TESTS; ACUITY LOSS;
   QUESTIONNAIRE; MACULOPATHY; PREVALENCE; MICROPERIMETRY; PERFORMANCE;
   DISEASE
AB The purpose of this study was to assess which visual function measures are most strongly associated with vision-related quality of life (VRQoL) in age-related macular degeneration (AMD). A cross-sectional study of subjects with early AMD (n = 10), intermediate AMD (n = 42) and late AMD (n = 38) was conducted. Subjects were interviewed with the Impact of Vision Impairment (IVI) questionnaire. Functional tests performed included best-corrected visual acuity (BCVA), low luminance visual acuity (LLVA), visual acuity measured with the Moorfields Acuity Charts (MAC), contrast sensitivity, reading speed, mesopic and dark-adapted microperimetry. The relationship between VRQoL and visual function was assessed with multiple regressions controlling for confounders. Rasch analysis demonstrated the validity of the IVI to assess VRQoL through three subscales: reading and accessing information, mobility and independence, and emotional well-being. Subjects with late AMD had significant lower IVI scores on all subscales compared with intermediate and early AMD (p < 0.011). In the overall cohort, IVI subscales were associated with BCVA, LLVA, MAC-VA and contrast sensitivity (all p < 0.001). Among the subgroup of early and intermediate AMD subjects, reading and mobility subscales were significantly associated with MAC-VA (p < 0.013). These results suggest that MAC-VA is a useful, patient-relevant measure of visual impairment in AMD.
C1 [Pondorfer, Susanne G.; Terheyden, Jan H.; Heinemann, Manuel; Wintergerst, Maximilian W. M.; Holz, Frank G.; Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
C3 University of Bonn
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM robert.finger@ukbonn.de
RI Wintergerst, Maximilian/E-5523-2019; Wintergerst,
   Maximilian/AAW-2972-2021
OI Wintergerst, Maximilian/0000-0002-2766-7038; 
FU Else Krohner Fresenius Stiftung/German Scholars Organization [GSO/EKFS
   16]
FX We thank the Else Krohner Fresenius Stiftung/German Scholars
   Organization (GSO/EKFS 16) for their support. We thank Jeany Q. Li,
   Matthias M. Mauschitz, Maximilian Pfau, Christopher A. Turski and
   Gabrielle N. Turski for their support.
CR [Anonymous], 2017, STATA STAT SOFTWARE
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bond T. G., 2021, APPL RASCH MODEL FUN, V4th
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger R. P, 2018, J INT OPHTALMOLOGIE, P1, DOI [10.1159/000491402, DOI 10.1159/000491402]
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P8241, DOI 10.1167/iovs.11-7858
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P3613, DOI 10.1167/iovs.10-7127
   Ivers RQ, 2000, CLIN EXP OPHTHALMOL, V28, P41, DOI 10.1046/j.1442-9071.2000.00236.x
   John M, 2006, USERS GUIDE WINSTEPS
   John M Linacre, 2016, WINSTEPS RASCH MEASU
   Keeffe JE, 1999, AUST NZ J OPHTHALMOL, V27, P184, DOI 10.1046/j.1440-1606.1999.00179.x
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Mallinson T, 2004, MED CARE, V42, P17, DOI 10.1097/01.mlr.0000103522.78233.c3
   Mallinson T, 2007, OPTOMETRY VISION SCI, V84, P675, DOI 10.1097/OPX.0b013e3181339f44
   Mantyjarvi M, 2001, J CATARACT REFR SURG, V27, P261, DOI 10.1016/S0886-3350(00)00562-9
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pesudovs K, 2007, OPTOMETRY VISION SCI, V84, P663, DOI 10.1097/OPX.0b013e318141fe75
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Rasch G., 1993, PROBABILISTIC MODELS
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   Tran BK, 2015, KLIN MONATSBL AUGENH, V232, P529, DOI 10.1055/s-0035-1545779
   Trauzettel-Klosinski S, 2012, INVEST OPHTH VIS SCI, V53, P5452, DOI 10.1167/iovs.11-8284
   Trauzettel-Klosinski Susanne, 2011, Handb Clin Neurol, V102, P263, DOI 10.1016/B978-0-444-52903-9.00016-9
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright B.D., 2002, RASCH MEASUREMENT T, V16
   WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
NR 42
TC 20
Z9 21
U1 0
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 25
PY 2019
VL 9
AR 15326
DI 10.1038/s41598-019-51769-7
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JH5RK
UT WOS:000492825800036
PM 31653904
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Haga, A
   Kawaji, T
   Ideta, R
   Inomata, Y
   Tanihara, H
AF Haga, Akira
   Kawaji, Takahiro
   Ideta, Ryuichi
   Inomata, Yasuya
   Tanihara, Hidenobu
TI Treat-and-extend versus every-other-month regimens with aflibercept in
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; age-related macular degeneration; choroidal
   neovascularization; macular degeneration; polypoidal choroidal
   vasculopathy; treat-and-extend
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL ANGIOMATOUS PROLIFERATION;
   ANTI-VEGF AGENTS; INTRAVITREAL AFLIBERCEPT; CLINICAL CHARACTERISTICS;
   PHOTODYNAMIC THERAPY; TREATMENT OUTCOMES; JAPANESE PATIENTS; PROSPECTIVE
   TRIAL; TRAP-EYE
AB PurposeTo compare the 1-year outcomes of treat-and-extend (TAE) and every-other-month (2M) regimens with intravitreal aflibercept in Japanese wet age-related macular degeneration (AMD) patients.
   MethodsProspective, multicenter, randomized clinical trial. The primary outcome measure was the proportion of eyes in which the best-corrected visual acuity (BCVA) was maintained at week 52 [with a loss of <0.3 logarithm of minimum angular of resolution (logMAR) units]. The secondary outcome measures were the mean change from baseline in the central retinal thickness (CRT) and the number of injections.
   ResultsForty-one patients were enrolled. The mean changes in the BCVA from baseline in the TAE and 2M were -0.320.27 and -0.26 +/- 0.30 logMAR units (p=0.46). The TAE group was noninferior to the 2M group in BCVA maintenance. The mean CRT changes from baseline in the TAE and 2M were -161 +/- 133 and -157 +/- 90m (p=0.73). The mean number of injections in the TAE and 2M were 7.5 +/- 1.2 (range, 7-12) and 8.0 +/- 0.0 (p<0.0001).
   ConclusionTreat-and-extend (TAE) regimen with aflibercept improved the BCVA and CRT to the same extent as 2M regimen, with a reduced number of injections.
C1 [Haga, Akira; Kawaji, Takahiro; Inomata, Yasuya; Tanihara, Hidenobu] Kumamoto Univ, Dept Ophthalmol, Fac Life Sci, Kumamoto, Japan.
   [Kawaji, Takahiro] Sato Eye & Internal Med Clin, Kumamoto, Japan.
   [Ideta, Ryuichi] Ideta Eye Hosp, Kumamoto, Japan.
C3 Kumamoto University
RP Haga, A (通讯作者)，Kumamoto Univ, Fac Life Sci, Dept Ophthalmol, Chuo Ku, 1-1-1 Honjo, Kumamoto, Japan.
EM akira10184179@gmail.com
RI Kawaji, Takahiro/AAH-2481-2020
FU Grants-in-Aid for Scientific Research [17H04351] Funding Source: KAKEN
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Barthelmes D, 2017, RETINA
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kume A, 2016, OPHTHALMOLOGY, V123, P1263, DOI 10.1016/j.ophtha.2016.01.042
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Pak KY, 2017, RETINA-J RET VIT DIS, V37, P561, DOI 10.1097/IAE.0000000000001195
   Pedrosa AC, 2016, CLIN OPHTHALMOL, V10, P541, DOI 10.2147/OPTH.S90913
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tomkins-Netzer O, 2017, ACTA OPHTHALMOL, V95, pE342, DOI 10.1111/aos.13251
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 42
TC 30
Z9 30
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2018
VL 96
IS 3
BP E393
EP E398
DI 10.1111/aos.13607
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE0NY
UT WOS:000430912700019
PM 29220114
OA Bronze
DA 2022-11-30
ER

PT J
AU Windisch, R
   Windisch, BK
   Cruess, AE
AF Windisch, Roman
   Windisch, Bettina K.
   Cruess, Alan E.
TI Use of fluorescein and indocyanine green angiography in polypoidal
   choroidal vasculopathy patients following photodynamic therapy
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE polypoidal choroidal vasculopathy; age-related macular degeneration;
   photodynamic therapy
ID MACULAR DEGENERATION; VERTEPORFIN; NEOVASCULARIZATION; VIDEOANGIOGRAPHY
AB Background: Exudative age-related macular degeneration (AMD) is a sight-threatening event in many elderly people. Some patients have a much better outcome in visual acuity (VA) than others after treatment with photodynamic therapy (PDT) with verteporfin. The combination of fluorescein angiography (FA) and indocyanine green (ICG) angiography using the Heidelberg Retina Angiograph II (HRA 2) should make a delineation of distinct pattern(s) possible in order to better select and assess therapy.
   Methods: This is a retrospective, case-control, single-centre study. We identified a total of 168 eyes of 168 patients from July 2003 to June 2006, including 30 eyes of 30 patients with better visual outcome, defined in this study as VA <= 0.48 logMAR (>= 20/60 Snellen chart) at the end of the study. Best-corrected VA, maximal central retinal thickness as measured by optical coherence tomography, and results of the FA/ICG angiography using the HRA 2 were analyzed. In this article, we discuss patients with polypoidal choroidal vasculopathy (PCV) and their characteristics.
   Results: The average follow-up time was 15.3 months (range 4-28 months). Seventeen (57%) of the 30 patients with better visual outcome had PCV. All patients in the group with better visual outcome needed fewer PDT treatments compared with our control group of patients with an exudative AMD.
   Interpretation: Simultaneous FA/ICG angiography using the HRA 2 allowed delineation of a subgroup of patients with PCV who showed a better visual outcome compared with those with other types of exudative AMD, after treatment with PDT
C1 [Windisch, Roman; Windisch, Bettina K.; Cruess, Alan E.] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Ctr Eye, Halifax, NS, Canada.
C3 Dalhousie University
RP Cruess, AE (通讯作者)，Victoria Gen Hosp, Dept Ophthalmol & Visual Sci, Centennial Bldg,1278 Tower Rd, Halifax, NS B3H 2Y9, Canada.
EM alan.cruess@dal.ca
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 12
TC 6
Z9 7
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2008
VL 43
IS 6
BP 678
EP 682
DI 10.3129/i08-153
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 389BC
UT WOS:000262063900012
PM 19020634
DA 2022-11-30
ER

PT J
AU Fukuda, S
   Varshney, A
   Fowler, BJ
   Wang, SB
   Narendran, S
   Ambati, K
   Yasuma, T
   Magagnoli, J
   Leung, H
   Hirahara, S
   Nagasaka, Y
   Yasuma, R
   Apicella, I
   Pereira, F
   Makin, RD
   Magner, E
   Liu, XN
   Sun, J
   Wang, M
   Baker, K
   Marion, KM
   Huang, XW
   Baghdasaryan, E
   Ambati, M
   Ambati, VL
   Pandey, A
   Pandya, L
   Cummings, T
   Banerjee, D
   Huang, PR
   Yerramothu, P
   Tolstonog, GV
   Held, U
   Erwin, JA
   Paquola, ACM
   Herdy, JR
   Ogura, Y
   Terasaki, H
   Oshika, T
   Darwish, S
   Singh, RK
   Mozaffari, S
   Bhattarai, D
   Kim, KB
   Hardin, JW
   Bennett, CL
   Hinton, DR
   Hanson, TE
   Rover, C
   Parang, K
   Kerur, N
   Liu, JZ
   Werner, BC
   Sutton, SS
   Sadda, SR
   Schumann, GG
   Gelfand, BD
   Gage, FH
   Ambati, J
AF Fukuda, Shinichi
   Varshney, Akhil
   Fowler, Benjamin J.
   Wang, Shao-bin
   Narendran, Siddharth
   Ambati, Kameshwari
   Yasuma, Tetsuhiro
   Magagnoli, Joseph
   Leung, Hannah
   Hirahara, Shuichiro
   Nagasaka, Yosuke
   Yasuma, Reo
   Apicella, Ivana
   Pereira, Felipe
   Makin, Ryan D.
   Magner, Eamonn
   Liu, Xinan
   Sun, Jian
   Wang, Mo
   Baker, Kirstie
   Marion, Kenneth M.
   Huang, Xiwen
   Baghdasaryan, Elmira
   Ambati, Meenakshi
   Ambati, Vidya L.
   Pandey, Akshat
   Pandya, Lekha
   Cummings, Tammy
   Banerjee, Daipayan
   Huang, Peirong
   Yerramothu, Praveen
   Tolstonog, Genrich, V
   Held, Ulrike
   Erwin, Jennifer A.
   Paquola, Apua C. M.
   Herdy, Joseph R.
   Ogura, Yuichiro
   Terasaki, Hiroko
   Oshika, Tetsuro
   Darwish, Shaban
   Singh, Ramendra K.
   Mozaffari, Saghar
   Bhattarai, Deepak
   Kim, Kyung Bo
   Hardin, James W.
   Bennett, Charles L.
   Hinton, David R.
   Hanson, Timothy E.
   Rover, Christian
   Parang, Keykavous
   Kerur, Nagaraj
   Liu, Jinze
   Werner, Brian C.
   Sutton, S. Scott
   Sadda, Srinivas R.
   Schumann, Gerald G.
   Gelfand, Bradley D.
   Gage, Fred H.
   Ambati, Jayakrishna
TI Cytoplasmic synthesis of endogenous Alu complementary DNA via reverse
   transcription and implications in age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Alu; retrotransposon; macular degeneration; retina; health insurance
   databases
ID INFLAMMASOME ACTIVATION; NLRP3 INFLAMMASOME; NEGATIVE CONTROLS; RNA;
   RETROTRANSPOSITION; METAANALYSIS; SEQUENCE; EVENTS; TARGET; BIAS
AB Alu retroelements propagate via retrotransposition by hijacking long interspersed nuclear element-1 (L1) reverse transcriptase (RT) and endonuclease activities. Reverse transcription of Alu RNA into complementary DNA (cDNA) is presumed to occur exclusively in the nucleus at the genomic integration site. Whether Alu cDNA is synthesized independently of genomic integration is unknown. Alu RNA promotes retinal pigmented epithelium (RPE) death in geographic atrophy, an untreatable type of age-related macular degeneration. We report that Alu RNA-induced RPE degeneration is mediated via cytoplasmic L1-reverse-transcribed Alu cDNA independently of retrotransposition. Alu RNA did not induce cDNA production or RPE degeneration in L1-inhibited animals or human cells. Alu reverse transcription can be initiated in the cytoplasm via self-priming of Alu RNA. In four health insurance databases, use of nucleoside RT inhibitors was associated with reduced risk of developing atrophic macular degeneration (pooled adjusted hazard ratio, 0.616; 95% confidence interval, 0.493-0.770), thus identifying inhibitors of this Alu replication cycle shunt as potential therapies for a major cause of blindness.
C1 [Fukuda, Shinichi; Varshney, Akhil; Wang, Shao-bin; Narendran, Siddharth; Ambati, Kameshwari; Leung, Hannah; Hirahara, Shuichiro; Nagasaka, Yosuke; Yasuma, Reo; Apicella, Ivana; Pereira, Felipe; Makin, Ryan D.; Sun, Jian; Ambati, Meenakshi; Pandey, Akshat; Pandya, Lekha; Banerjee, Daipayan; Huang, Peirong; Yerramothu, Praveen; Kerur, Nagaraj; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Ctr Adv Vis Sci, Sch Med, Charlottesville, VA 22908 USA.
   [Fukuda, Shinichi; Varshney, Akhil; Wang, Shao-bin; Narendran, Siddharth; Ambati, Kameshwari; Leung, Hannah; Hirahara, Shuichiro; Nagasaka, Yosuke; Yasuma, Reo; Apicella, Ivana; Pereira, Felipe; Makin, Ryan D.; Sun, Jian; Ambati, Meenakshi; Pandey, Akshat; Pandya, Lekha; Banerjee, Daipayan; Huang, Peirong; Yerramothu, Praveen; Kerur, Nagaraj; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.
   [Fukuda, Shinichi; Oshika, Tetsuro] Univ Tsukuba, Dept Ophthalmol, Ibaraki 3058575, Japan.
   [Fowler, Benjamin J.; Yasuma, Tetsuhiro] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.
   [Narendran, Siddharth] Aravind Eye Hosp Syst, Madurai 625020, Tamil Nadu, India.
   [Yasuma, Tetsuhiro; Yasuma, Reo; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4648601, Japan.
   [Magagnoli, Joseph; Cummings, Tammy; Hardin, James W.; Bennett, Charles L.; Sutton, S. Scott] Columbia Vet Affairs Hlth Care Syst, Dorn Res Inst, Columbia, SC 29209 USA.
   [Magagnoli, Joseph; Cummings, Tammy; Bennett, Charles L.; Sutton, S. Scott] Univ South Carolina, Coll Pharm, Dept Clin Pharm & Outcomes Sci, Columbia, SC 29208 USA.
   [Hirahara, Shuichiro; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol, Nagoya, Aichi 4678601, Japan.
   [Pereira, Felipe] Univ Fed Sao Paulo, Dept Oftalmol & Ciencias Visuais, Escola Paulista Med, BR-04023062 Sao Paulo, Brazil.
   [Magner, Eamonn; Liu, Xinan; Huang, Xiwen; Liu, Jinze] Univ Kentucky, Dept Comp Sci, Lexington, KY 40536 USA.
   [Wang, Mo; Baker, Kirstie; Marion, Kenneth M.; Baghdasaryan, Elmira; Sadda, Srinivas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Baghdasaryan, Elmira; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Ambati, Meenakshi; Ambati, Vidya L.] Ctr Digital Image Evaluat, Charlottesville, VA 22901 USA.
   [Tolstonog, Genrich, V] Univ Hosp Lausanne, Dept Otolaryngol Head & Neck Surg, CH-1011 Lausanne, Switzerland.
   [Held, Ulrike; Schumann, Gerald G.] Paul Ehrlich Inst, Dept Med Biotechnol, D-63225 Langen, Germany.
   [Erwin, Jennifer A.; Paquola, Apua C. M.] Johns Hopkins Univ, Sch Med, Lieber Inst Brain Dev, Baltimore, MD 21205 USA.
   [Herdy, Joseph R.; Gage, Fred H.] Salk Inst Biol Studies, Lab Genet, La Jolla, CA 92037 USA.
   [Darwish, Shaban; Singh, Ramendra K.; Mozaffari, Saghar; Parang, Keykavous] Chapman Univ, Ctr Targeted Drug Delivery, Sch Pharm, Dept Biomed & Pharmaceut Sci, Irvine, CA 92618 USA.
   [Darwish, Shaban] Natl Res Ctr, Organometall & Organometalloid Chem Dept, Giza 12622, Egypt.
   [Bhattarai, Deepak; Kim, Kyung Bo] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Hardin, James W.] Univ South Carolina, Dept Epidemiol & Biostat, Columbia, SC 29208 USA.
   [Bennett, Charles L.] Univ South Carolina, Coll Pharm, Ctr Medicat Safety & Efficacy, Columbia, SC 29208 USA.
   [Hinton, David R.] Univ Southern Calif, Univ Southern Calif Roski Eye Inst, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Hanson, Timothy E.] Medtronic Inc, Minneapolis, MN 55432 USA.
   [Hanson, Timothy E.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA.
   [Rover, Christian] Univ Med Ctr Gottingen, Dept Med Stat, D-37073 Gottingen, Germany.
   [Kerur, Nagaraj] Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA.
   [Kerur, Nagaraj; Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.
   [Werner, Brian C.] Univ Virginia, Sch Med, Dept Orthopaed Surg, Charlottesville, VA 22908 USA.
   [Gelfand, Bradley D.] Univ Virginia, Sch Med, Dept Biomed Engn, Charlottesville, VA 22908 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.
C3 University of Virginia; University of Virginia; University of Tsukuba;
   University of Kentucky; Nagoya University; University of South Carolina
   System; University of South Carolina Columbia; Nagoya City University;
   Universidade Federal de Sao Paulo (UNIFESP); University of Kentucky;
   Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of Lausanne;
   Centre Hospitalier Universitaire Vaudois (CHUV); Paul Ehrlich Institute;
   Johns Hopkins University; Salk Institute; Chapman University System;
   Chapman University; Egyptian Knowledge Bank (EKB); National Research
   Centre (NRC); University of Kentucky; University of South Carolina
   System; University of South Carolina Columbia; University of South
   Carolina System; University of South Carolina Columbia; University of
   Southern California; University of Southern California; Medtronic;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Gottingen; University of Virginia; University of Virginia;
   University of Virginia; University of Virginia; University of Virginia
RP Ambati, J (通讯作者)，Univ Virginia, Ctr Adv Vis Sci, Sch Med, Charlottesville, VA 22908 USA.; Ambati, J (通讯作者)，Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.; Gage, FH (通讯作者)，Salk Inst Biol Studies, Lab Genet, La Jolla, CA 92037 USA.; Ambati, J (通讯作者)，Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.; Ambati, J (通讯作者)，Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.
EM gage@salk.edu; ja9qr@virginia.edu
RI Sutton, S. Scott/AAR-7855-2021; Parang, Keykavous/ABC-1584-2021; WANG,
   SHAO-BIN/Z-1810-2018
OI Sutton, S. Scott/0000-0002-3889-6178; Parang,
   Keykavous/0000-0001-8600-0893; WANG, SHAO-BIN/0000-0002-6699-9406;
   Yerramothu, Praveen/0000-0001-6635-6681; Rover,
   Christian/0000-0002-6911-698X
FU NIH [DP1GM114862, R01EY022238, R01EY024068, R01EY028027, R01EY29799,
   R01EY031039, K99EY024336, R00EY024336, R21EY030651, T32HL091812,
   UL1RR033173, R01EY001545]; DuPont Guerry III Professorship; University
   of Virginia Strategic Investment Fund; John Templeton Foundation
   [60763]; Doris Duke Distinguished Clinical Scientist Award; Ellison
   Medical Foundation Senior Scholar in Aging Award; Dr. E. Vernon Smith
   and Eloise C. SmithMacular Degeneration Endowed Chair; Japan Society for
   the Promotion of Science Fund for the Promotion of Joint International
   Research (Home-Returning Researcher Development Research); Japan Eye
   Bank Association; Beckman Initiative for Macular Research; Association
   for Research in Vision and Ophthalmology/Alcon Early Career
   Clinician-Scientist Research Award; Fight for Sight postdoctoral award;
   Fulbright Visiting Scholar Program; Research to Prevent Blindness;
   BrightFocus Foundation; Owens Family Foundation; American Heart
   Association; National Center for Research Resources; National Center for
   Advancing Translational Sciences, NIH [UL1TR000117]; Ministry of Health
   of the Federal Republic of Germany [FKZ2518FSB403]
FX We thank J. L. Goodier and H. H. Kazazian for valuable discussions that
   improved the manuscript; A. P. Jackson, H. H. Kazazian, J. V. Moran, and
   M. A. Reijns for reagents and mice; and D. Robertson, K. Langberg, X.
   Zhou, R. Hankins, G. Pattison, Q. Zhong, K. A. Fox, and C. Spee for
   technical assistance. J.A. received support from NIH grants
   (DP1GM114862, R01EY022238, R01EY024068, R01EY028027, R01EY29799, and
   R01EY031039), the DuPont Guerry III Professorship, the University of
   Virginia Strategic Investment Fund, John Templeton Foundation Grant
   60763, Doris Duke Distinguished Clinical Scientist Award, Ellison
   Medical Foundation Senior Scholar in Aging Award, the DuPont Guerry III
   Professorship, Dr. E. Vernon Smith and Eloise C. SmithMacular
   Degeneration Endowed Chair, and a gift fromMr. andMrs. EliW. Tullis;
   S.F., from Japan Society for the Promotion of Science Fund for the
   Promotion of Joint International Research (Home-Returning Researcher
   Development Research) and Research Grant of Japan Eye Bank Association;
   N.K. received support from NIH Grants K99EY024336, R00EY024336, and
   R21EY030651, and the Beckman Initiative for Macular Research; B.J.F.
   received support from NIH Grants T32HL091812 and UL1RR033173; R.Y.
   received support from Association for Research in Vision and
   Ophthalmology/Alcon Early Career Clinician-Scientist Research Award;
   T.Y. received support from Fight for Sight postdoctoral award; R.K.S.
   received support from the Fulbright Visiting Scholar Program; D.R.H.
   received support from NIH Grant R01EY001545 and an unrestricted
   departmental grant from Research to Prevent Blindness; S.S.S. received
   support from resources and the use of facilities at the W. J. B. Dorn
   Veterans Affairs Medical Center, Dorn Research Institute; B.D.G.
   received support from NIH Grants R01EY028027 and R01EY031039,
   BrightFocus Foundation, the Owens Family Foundation, the American Heart
   Association, and the National Center for Research Resources and the
   National Center for Advancing Translational Sciences, NIH, through Grant
   UL1TR000117; and G.G.S. is supported by a grant from the Ministry of
   Health of the Federal Republic of Germany (FKZ2518FSB403). The content
   of this article is solely the responsibility of the authors and does not
   necessarily represent the official views of the NIH or the US Department
   of Veterans Affairs, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the US government. This
   paper presents, in part, original research conducted using data from the
   Department of Veterans Affairs and is, in part, the result of work
   supported with resources and the use of facilities at the Dorn Research
   Institute, Columbia Veterans Affairs Health Care System (Columbia, SC).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahl V, 2015, MOL CELL, V60, P715, DOI 10.1016/j.molcel.2015.10.003
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J., 2019, US Patent, Patent No. [10,294,220, 10294220]
   Ambati J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18528-z
   An WF, 2011, MOBILE DNA-UK, V2, DOI 10.1186/1759-8753-2-2
   ANELLO C, 1995, J CLIN EPIDEMIOL, V48, P109, DOI 10.1016/0895-4356(94)00084-4
   Arnold BF, 2016, EPIDEMIOLOGY, V27, P637, DOI 10.1097/EDE.0000000000000504
   Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798
   Batzer MA, 1996, J MOL EVOL, V42, P3, DOI 10.1007/BF00163204
   Bennett EA, 2008, GENOME RES, V18, P1875, DOI 10.1101/gr.081737.108
   Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6
   BOGUSLAWSKI SJ, 1986, J IMMUNOL METHODS, V89, P123, DOI 10.1016/0022-1759(86)90040-2
   Carreira PE, 2014, FEBS J, V281, P63, DOI 10.1111/febs.12601
   Conti A, 2015, NUCLEIC ACIDS RES, V43, P817, DOI 10.1093/nar/gku1361
   DAWID AP, 1982, J AM STAT ASSOC, V77, P605, DOI 10.2307/2287720
   Deininger P, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-236
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223
   Dhellin O, 1997, EMBO J, V16, P6590, DOI 10.1093/emboj/16.21.6590
   Di Ruocco F, 2018, ONCOGENE, V37, P627, DOI 10.1038/onc.2017.369
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184
   Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Hagan CR, 2003, NAT GENET, V35, P219, DOI 10.1038/ng1259
   Haukoos JS, 2015, JAMA-J AM MED ASSOC, V314, P1637, DOI 10.1001/jama.2015.13480
   Imai K, 2004, J AM STAT ASSOC, V99, P854, DOI 10.1198/016214504000001187
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kazazian HH, 2017, NEW ENGL J MED, V377, P361, DOI 10.1056/NEJMra1510092
   Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kirilyuk A, 2008, NUCLEIC ACIDS RES, V36, P648, DOI 10.1093/nar/gkm1045
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Konkel MK, 2015, GENOME BIOL EVOL, V7, P2608, DOI 10.1093/gbe/evv167
   KROLEWSKI JJ, 1984, J MOL BIOL, V174, P41, DOI 10.1016/0022-2836(84)90364-4
   Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7
   Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb
   LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758
   Mandal D, 2011, ANGEW CHEM INT EDIT, V50, P9633, DOI 10.1002/anie.201102572
   MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804
   Miyoshi T, 2019, MOL CELL, V75, P1286, DOI 10.1016/j.molcel.2019.07.018
   Narendran S, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.4
   Ohlsson H, 2020, JAMA PSYCHIAT, V77, P637, DOI 10.1001/jamapsychiatry.2019.3758
   Oler AJ, 2012, MOBILE DNA-UK, V3, DOI 10.1186/1759-8753-3-11
   Prasad V, 2013, JAMA-J AM MED ASSOC, V309, P241, DOI 10.1001/jama.2012.96867
   Rodriguez-Martin B, 2020, NAT GENET, V52, P306, DOI 10.1038/s41588-019-0562-0
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0
   Schwertz H, 2018, ARTERIOSCL THROM VAS, V38, P801, DOI 10.1161/ATVBAHA.117.310552
   Shen MR, 1997, NUCLEIC ACIDS RES, V25, P1641, DOI 10.1093/nar/25.8.1641
   Shirazi AN, 2013, MOL PHARMACEUT, V10, P4717, DOI 10.1021/mp400539r
   Sutton AJ, 2001, STAT METHODS MED RES, V10, P277, DOI 10.1191/096228001678227794
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052
   Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang XO, 2019, GENOME RES, V29, P1402, DOI 10.1101/gr.249789.119
NR 59
TC 18
Z9 18
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 9
PY 2021
VL 118
IS 6
AR e2022751118
DI 10.1073/pnas.2022751118
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QG1MR
UT WOS:000617355300089
PM 33526699
OA Green Published
DA 2022-11-30
ER

PT J
AU Ludwig, CA
   Vail, D
   Rajeshuni, NA
   Al-Moujahed, A
   Rosenblatt, T
   Callaway, NF
   Pasricha, MV
   Ji, MRH
   Moshfeghi, DM
AF Ludwig, Cassie A.
   Vail, Daniel
   Rajeshuni, Nitya A.
   Al-Moujahed, Ahmad
   Rosenblatt, Tatiana
   Callaway, Natalia F.
   Veerappan Pasricha, Malini
   Ji, Marco H.
   Moshfeghi, Darius M.
TI Statins and the progression of age-related macular degeneration in the
   United States
SO PLOS ONE
LA English
DT Article
ID 5-YEAR INCIDENCE; RISK; ASSOCIATION; DISEASE; CROSS
AB Purpose To study the effect of statin exposure on the progression from non-exudative to exudative age-related macular degeneration (AMD). Methods Retrospective cohort study of commercially insured patients diagnosed with non-exudative AMD (n = 231,888) from 2007 to 2015. Time-to-event analysis of the association between exposure to lipid-lowering medications and time from non-exudative AMD to exudative AMD diagnosis was conducted. Outcome measures included progression to exudative AMD, indicated by diagnosis codes for exudative AMD or procedural codes for intravitreal injections. Results In the year before and after first AMD diagnosis, 11,330 patients were continuously prescribed lipid-lowering medications and 31,627 patients did not take any lipid-lowering medication. Of those taking statins, 21 (1.6%) patients were on very-high-dose lipophilic statins, 644 (47.6%) on high-dose lipophilic statins, and 689 (50.9%) on low-dose lipophilic statins. We found no statistically significant relationship between exposure to low (HR 0.89, 95% CI 0.83 to 1.38) or high-dose lipophilic statins (HR 1.12, 95% CI 0.86 to 1.45) and progression to exudative AMD. No patients taking very-high-dose lipophilic statins converted from non-exudative to exudative AMD, though this difference was not statistically significant due to the subgroup size (p = .23, log-rank test). Conclusions No statistically significant relationship was found between statin exposure and risk of AMD progression. Interestingly, no patients taking very-high-dose lipophilic statins progressed to exudative AMD, a finding that warrants further exploration.
C1 [Ludwig, Cassie A.; Vail, Daniel; Rajeshuni, Nitya A.; Al-Moujahed, Ahmad; Rosenblatt, Tatiana; Callaway, Natalia F.; Veerappan Pasricha, Malini; Ji, Marco H.; Moshfeghi, Darius M.] Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Palo Alto, CA 94304 USA.
   [Ludwig, Cassie A.] Harvard Med Sch, Massachusetts Eye & Ear, Retina Serv, Dept Ophthalmol, Boston, MA 02115 USA.
C3 Stanford University; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Palo Alto, CA 94304 USA.
EM dariusm@stanford.edu
RI Ji, Marco H./Q-3807-2017
OI Ji, Marco H./0000-0002-7033-7763; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X
FU Research to Prevent Blindness, Inc.; NEI [P30-EY026877]; Society of Heed
   Fellows; Michels Fellowship Foundation; Heed Ophthalmic Foundation
FX Our financial support was as follows: DMM: Research to Prevent
   Blindness, Inc., NEI P30-EY026877 CAL: The Heed Fellowship awarded
   through the Society of Heed Fellows NFC: Heed Ophthalmic Foundation and
   Michels Fellowship Foundation Darius M. Moshfeghi is a co-founder with
   equity and serves on the board of directors of Linc, Inc a company that
   has developed a novel statin molecule that among other things may be
   targeted for AMD. Additionally, Darius M. Moshfeghi has the following
   conflicts of interest: 1800 Contacts (board of directors, equity),
   Akceso Advisors AG (evaluation of DME market), Akebia (scientific
   advisory board for ROP), Alcon (data safety monitoring board for
   HAWK/HARRIER), Aldeyra Therapeutics (Site PI: ADX-2191-PVR-001 GUARD),
   Allegro (scientific advisory board), Apellis (Site PI: APL2-303 DERBY),
   Bayer Pharma AG (ROP imaging committee), CMEOutfitters.com (CME
   consultant), Cole Eye Institute (CME consultant), Congruence medical
   solutions (consultant), dSentz, Inc. (founder, board of directors,
   equity), Genentech (PROPER grant 2019), Grand Legend Technology, LTD
   (equity), Iconic Therapeutics (steering committee, unpaid), Irenix
   (scientific advisory board, unpaid), Northwell Health (grand rounds),
   Novartis Pharmaceuticals (data safety monitoring board for HAWK/HARRIER,
   KITE/KESTREL, China nAMD/DME, pediatric advisory board), Ocular Surgery
   News (consultant), Pr3vent (founder, board of directors, equity), Praxis
   UNS, Inc. (consultant), Prime Medical Education (CME consultant),
   Promisight, Inc. (founder, board of directors, equity), Pykus
   (scientific advisory board, equity), Regeneron (CME consultant, ROP
   steering committee, PI for ROP trial), Retina Technologies LLC (advisor,
   consultant), Retina Today/Pentavision (consultant), Shapiro Law Group
   (ROP expert witness), SLACK, Inc. (CME CoverLetter_Revisions
   consultant), University of Miami (CME consultant), VersI, Inc. (founder,
   equity), Vindico (CME consultant), Visunex (scientific advisory board,
   equity. None of the other authors have any conflicts of interest to
   report. The above funders did not have any additional role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The specific roles of these authors are
   articulated in the `author contributions' section. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Blum A, 2009, ATHEROSCLEROSIS, V203, P325, DOI 10.1016/j.atherosclerosis.2008.08.022
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Fong CW, 2014, EUR J MED CHEM, V85, P661, DOI 10.1016/j.ejmech.2014.08.037
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G. Jr., 2004, American Journal of Ophthalmology, V137, P217, DOI 10.1016/j.ajo.2003.10.014
   Menendez ME, 2014, CLIN ORTHOP RELAT R, V472, P2878, DOI 10.1007/s11999-014-3686-7
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Miyaki K, 2009, CURR EYE RES, V34, P10, DOI 10.1080/02713680802579196
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Peponis V, 2010, CLIN OPHTHALMOL, V4, P865
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Smeeth L., 2006, AM J OPHTHALMOL, V141, P238, DOI [10.1016/j.ajo.2005.11.029, DOI 10.1016/J.AJO.2005.11.029]
   Smith M.K., 2009, ISSUES CULTURAL TOUR
   Terai N, 2011, ACTA OPHTHALMOL, V89, pE500, DOI 10.1111/j.1755-3768.2011.02154.x
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   Tsujinaka H, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00401
   Vail D, 2019, AM J OPHTHALMOL, V207, P378, DOI 10.1016/j.ajo.2019.05.029
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu TH, 2010, J NEUROCHEM, V114, P1734, DOI 10.1111/j.1471-4159.2010.06884.x
NR 37
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 4
PY 2021
VL 16
IS 8
AR e0252878
DI 10.1371/journal.pone.0252878
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UA6IY
UT WOS:000685264900044
PM 34347799
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zeiss, CJ
AF Zeiss, C. J.
TI REVIEW PAPER: Animals as Models of Age-Related Macular Degeneration: An
   Imperfect Measure of the Truth
SO VETERINARY PATHOLOGY
LA English
DT Review
DE Bruch's membrane; choriocapillaris; complement; degeneration; macula;
   retinal pigment epithelium
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL
   GROWTH-FACTOR; EXPERIMENTAL SUBRETINAL NEOVASCULARIZATION; INHIBITS
   CHOROIDAL NEOVASCULARIZATION; HTRA1 PROMOTER POLYMORPHISM; C-REACTIVE
   PROTEIN; BRUCHS MEMBRANE; RHESUS-MONKEYS; INCREASED EXPRESSION
AB Age-related macular degeneration (AMD) is a degenerative condition that begins in Bruch's membrane and progresses to involve the retinal pigment epithelium and ultimately the overlying photoreceptors. The only required etiologic factor is age, and AMD is regarded as the leading cause of blindness in individuals older than 65 years. AMD results from variable contributions of age, environment, and genetic predisposition. Many loci are linked to AMD; in the majority of cases, the disease is associated with polymorphisms within these genes, rather than mutations that ablate gene function. The etiologic complexity of AMD is reflected by the paucity of animal models that entirely replicate the human disease. This review compares the salient anatomy of the primate and rodent retina, particularly in the light of AMD pathology. It next discusses prevailing hypotheses explaining how AMD may develop. These include the role of complement activation and macrophage chemotaxis in AMD, molecular mechanisms of choroidal neovascularization, and the roles of oxidative damage and lipid metabolism. Finally, the article gives an overview of spontaneous and induced nonhuman primate models and describes relevant mouse models in the context of each pathogenetic mechanism.
C1 Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06520 USA.
C3 Yale University
RP Zeiss, CJ (通讯作者)，Yale Univ, Sch Med, Comparat Med Sect, 375 Congress Ave, New Haven, CT 06520 USA.
EM caroline.zeiss@yale.edu
FU National Institutes of Health [K01 RR16090-01A2]; Claude D. Pepper Older
   Americans Independence Center at Yale University School of Medicine
   [P30-AG21342]; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR016090]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG021342]
   Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health (No. K01
   RR16090-01A2) and the Claude D. Pepper Older Americans Independence
   Center at Yale University School of Medicine (No. P30-AG21342 [National
   Institutes of Health / National Institute on Aging; Dr Mary Tinetti,
   principal investigator]).
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BOK D, 1993, J CELL SCI, P189
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Campochiaro PA, 2007, CURR GENE THER, V7, P25, DOI 10.2174/156652307779940252
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Criswell MH, 2005, INVEST OPHTH VIS SCI, V46, P2168, DOI 10.1167/iovs.04-1442
   Criswell MH, 2004, INVEST OPHTH VIS SCI, V45, P625, DOI 10.1167/iovs.03-0718
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dawson W.W., 1989, Puerto Rico Health Sciences Journal, V8, P111
   Dawson WW, 2008, VISION RES, V48, P360, DOI 10.1016/j.visres.2007.08.006
   DAWSON WW, 1989, DOC OPHTHALMOL, V71, P253
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Economou MA, 2008, ACTA OPHTHALMOL, V86, P930, DOI [10.1111/j.1755-3768.2008.01188.x, 10.1111/j.1755-3768.2008.01182.x, 10.1111/j.1755-3768.2008.01185.x, 10.1111/j.1755-3768.2008.01184.x]
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   ELMOFTY AAM, 1980, EXP EYE RES, V31, P147, DOI 10.1016/0014-4835(80)90075-5
   ENGEL HM, 1988, OPHTHALMOLOGICA, V196, P143, DOI 10.1159/000309891
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   GRAVES DT, 1995, CRIT REV ORAL BIOL M, V6, P109, DOI 10.1177/10454411950060020101
   Green W R, 1999, Mol Vis, V5, P27
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OHKUMA H, 1983, ARCH OPHTHALMOL-CHIC, V101, P1102, DOI 10.1001/archopht.1983.01040020104018
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   RODIECK RW, 1973, VERTEBRATE RETINA PR
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   RYAN SJ, 1980, A GRAEF ARCH KLIN EX, V215, P29, DOI 10.1007/BF00413394
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Semkova I, 2003, INVEST OPHTH VIS SCI, V44, P5349, DOI 10.1167/iovs.02-0732
   Singh R, 2008, INT J APPL CERAM TEC, V5, P1, DOI 10.1111/j.1744-7402.2008.02183.x
   Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suzuki MT, 2003, PRIMATES, V44, P291, DOI 10.1007/s10329-002-0016-6
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Trapp C, 2007, ONCOGENE, V26, P4044, DOI 10.1038/sj.onc.1210167
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeiss CJ, 2004, INVEST OPHTH VIS SCI, V45, P971, DOI 10.1167/iovs.03-0301
   Zhang XC, 2006, J CLIN INVEST, V116, P3050, DOI 10.1172/JCI28139
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 124
TC 75
Z9 81
U1 0
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0300-9858
EI 1544-2217
J9 VET PATHOL
JI Vet. Pathol.
PD MAY
PY 2010
VL 47
IS 3
BP 396
EP 413
DI 10.1177/0300985809359598
PG 18
WC Pathology; Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Veterinary Sciences
GA 593SH
UT WOS:000277480400003
PM 20382825
DA 2022-11-30
ER

PT J
AU Cackett, P
   Wong, TY
   Aung, T
   Saw, SM
   Tay, WT
   Rochtchina, E
   Mitchell, P
   Wang, JJ
AF Cackett, Peter
   Wong, Tien Y.
   Aung, Tin
   Saw, Seang-Mei
   Tay, Wan Ting
   Rochtchina, Elena
   Mitchell, Paul
   Wang, Jie Jin
TI Smoking, Cardiovascular Risk Factors, and Age-related Macular
   Degeneration in Asians: The Singapore Malay Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; BLUE-MOUNTAINS-EYE; BEAVER DAM EYE; BODY-MASS
   INDEX; NUTRITION EXAMINATION SURVEY; LONG-TERM INCIDENCE;
   NATIONAL-HEALTH; DIETARY-FAT; MACULOPATHY; DISEASE
AB PURPOSE: To assess associations between smoking and cardiovascular risk factors and prevalent age-related macular degeneration (AMD) in the Singapore Malay population.
   DESIGN: Population-based, cross-sectional study.
   METHODS: A total of 3,280 Malay adults age 40 to 80 years were included in the study. Early and late AMD signs were graded from retinal photographs following Wisconsin system. All participants had interview, systemic examination, and laboratory investigations to determine smoking status and cardiovascular risk factors.
   RESULTS: A total of 3,265 participants had gradable photos, 21 (0.6%) with late AMD and 169 (5.2%) with early AMD. After adjusting for age and gender, current smokers were significantly more likely to have late AMD (odds ratio [OR], 3.79; 95% confidence interval [CI], 1.40 to 10.23). This association was stronger among those who currently smoked >5 packs of cigarettes per week (OR, 9.35; 95% CI, 2.49 to 35.08).
   CONCLUSIONS: Smoking was associated with a higher late AMD prevalence in Malays, consistent with findings from studies in White populations. (Am J Ophthalmol 2008;146:960-967. (C) 2008 by Elsevier Inc. All rights reserved.)
C1 [Wong, Tien Y.; Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Rochtchina, Elena; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Cackett, Peter; Wong, Tien Y.; Aung, Tin; Tay, Wan Ting] Singapore Eye Res Inst, Singapore, Singapore.
   [Cackett, Peter; Wong, Tien Y.; Aung, Tin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Wong, Tien Y.; Aung, Tin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Saw, Seang-Mei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Community Occupat & Family Med, Singapore 117595, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Sydney; National University of Singapore; Singapore National Eye
   Center; Singapore National Eye Center; National University of Singapore;
   National University of Singapore
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; wang, jie/GRS-0942-2022; Mitchell,
   Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Wang, Jie Jin/0000-0001-9491-4898
FU NATIONAL MEDICAL RESEARCH COUNCIL [0796/2003, 0863/2004, CSI/0002/2005];
   Biomedical Research Council [501/l/25-5]; Singapore Tissue Network;
   Ministry Of Health, Singapore; Pfizer Inc, New York, New York
FX THIS STUDY WAS SUPPORTED BY THE NATIONAL MEDICAL RESEARCH COUNCIL GRANTS
   NOS. 0796/2003, 0863/2004, AND CSI/0002/2005, and Biomedical Research
   Council Grant No. 501/l/25-5, with additional support from the Singapore
   Tissue Network and the Ministry Of Health, Singapore, and Pfizer Inc,
   New York, New York. The authors indicate no financial conflict of
   interest. Involved in the design and conduct Of study (T.Y.W., S.M.S.,
   T.A.); collection, management, analysis, and interpretation of the data
   (P.C., T.Y.W., T.W.T., E.R., J.J.W.) and Preparation, review, or
   approved of the manuscript (P.C., T.Y.W., T.A., S.M.S., T.W.T., E.R.,
   P.M., J.J.W.). The Ethics Commit tee of the Singapore Eye Research
   Institute approved the study, and its conduct followed the tenets of the
   Declaration Of Helsinki. Written informed consent was obtained from all
   patients after explaining the nature Of the study. The authors thank the
   staff in the Singapore Malay Eye Study for their important contributions
   in examining and interviewing patients and data entry and to the
   Participants for their time.
CR Carroll T, 2003, TOB CONTROL, V12, P40
   Chan-Yeung M, 2004, INT J TUBERC LUNG D, V8, P2
   Cheng TO, 2003, J NATL MED ASSOC, V95, P1115
   Cheng TO, 2007, INT J CARDIOL, V123, P1, DOI 10.1016/j.ijcard.2006.12.023
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gallagher D, 2000, AM J CLIN NUTR, V72, P694, DOI 10.1093/ajcn/72.3.694
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KAWASAKI R, 2007, OPHTHALMOLO IN PRESS
   KAWASAKI R, 2008, OPHTHALMOLO IN PRESS
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kramer H, 2004, AM J HYPERTENS, V17, P963, DOI 10.1016/j.amjhyper.2004.06.001
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Lee CMY, 2007, OBES REV, V8, P191, DOI 10.1111/j.1467-789X.2006.00292.x
   Liu LS, 2007, BIOCHEM CELL BIOL, V85, P157, DOI 10.1139/O07-004
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Sun C, 2008, INVEST OPHTH VIS SCI, V49, P1784, DOI 10.1167/iovs.07-1450
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wilson N, 2002, NEW ZEAL MED J, V115, P199
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 58
TC 64
Z9 67
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2008
VL 146
IS 6
BP 960
EP 967
DI 10.1016/j.ajo.2008.06.026
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 378UH
UT WOS:000261349200025
PM 18723144
DA 2022-11-30
ER

PT J
AU He, TT
   Zhou, QE
   Zou, YW
AF He, Tingting
   Zhou, Qiaoer
   Zou, Yuanwen
TI Automatic Detection of Age-Related Macular Degeneration Based on Deep
   Learning and Local Outlier Factor Algorithm
SO DIAGNOSTICS
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography; deep
   learning; local outlier factor
ID OPTICAL COHERENCE TOMOGRAPHY; DISEASE; CLASSIFICATION; EDEMA
AB Age-related macular degeneration (AMD) is a retinal disorder affecting the elderly, and society's aging population means that the disease is becoming increasingly prevalent. The vision in patients with early AMD is usually unaffected or nearly normal but central vision may be weakened or even lost if timely treatment is not performed. Therefore, early diagnosis is particularly important to prevent the further exacerbation of AMD. This paper proposed a novel automatic detection method of AMD from optical coherence tomography (OCT) images based on deep learning and a local outlier factor (LOF) algorithm. A ResNet-50 model with L2-constrained softmax loss was retrained to extract features from OCT images and the LOF algorithm was used as the classifier. The proposed method was trained on the UCSD dataset and tested on both the UCSD dataset and Duke dataset, with an accuracy of 99.87% and 97.56%, respectively. Even though the model was only trained on the UCSD dataset, it obtained good detection accuracy when tested on another dataset. Comparison with other methods also indicates the efficiency of the proposed method in detecting AMD.
C1 [He, Tingting; Zhou, Qiaoer; Zou, Yuanwen] Sichuan Univ, Coll Biomed Engn, Chengdu 610065, Peoples R China.
C3 Sichuan University
RP Zou, YW (通讯作者)，Sichuan Univ, Coll Biomed Engn, Chengdu 610065, Peoples R China.
EM 2019223010062@stu.scu.edu.cn; zhou_qiaoer@outlook.com; zyw@scu.edu.cn
OI He, Tingting/0000-0003-1704-7430; Zou, Yuanwen/0000-0002-9228-3698
CR Arabi PM, 2018, IOP CONF SER-MAT SCI, V310, DOI 10.1088/1757-899X/310/1/012096
   Araveti SK, 2020, LASER MED SCI, V35, P213, DOI 10.1007/s10103-019-02847-9
   Balasubramani V, 2021, J IMAGING, V7, DOI 10.3390/jimaging7120252
   Baltruschat IM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42294-8
   Breunig MM, 2000, SIGMOD REC, V29, P93, DOI 10.1145/335191.335388
   Costa RA, 2006, PROG RETIN EYE RES, V25, P325, DOI 10.1016/j.preteyeres.2006.03.001
   Das V, 2019, BIOMED SIGNAL PROCES, V54, DOI 10.1016/j.bspc.2019.101605
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Elsharkawy M, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11122313
   Fang LY, 2019, J VIS COMMUN IMAGE R, V59, P327, DOI 10.1016/j.jvcir.2019.01.022
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Gu JX, 2018, PATTERN RECOGN, V77, P354, DOI 10.1016/j.patcog.2017.10.013
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hussain MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198281
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Kadry S, 2022, J SUPERCOMPUT, V78, P7321, DOI 10.1007/s11227-021-04181-w
   Kaymak S, 2018, INT C INTELL COMP CO, P265, DOI 10.1109/ICCP.2018.8516635
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Khalid S., 2016, IJCSIS, P14
   Khojasteh P, 2019, COMPUT BIOL MED, V104, P62, DOI 10.1016/j.compbiomed.2018.10.031
   Larimer CJ, 2020, APPL OPTICS, V59, P2474, DOI 10.1364/AO.384674
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lu J, 2015, KNOWL-BASED SYST, V80, P14, DOI 10.1016/j.knosys.2015.01.010
   Meng TQ, 2018, CHIN CONTR CONF, P9362, DOI 10.23919/ChiCC.2018.8483036
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Naz S, 2016, INT CONF IMAG PROC
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Ranjan R., 2017, L2 CONSTRAINED SOFTM
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Rosen Joseph, 2021, J Imaging, V7, DOI 10.3390/jimaging7100197
   Schultz NM, 2021, CLIN THER, V43, P1792, DOI 10.1016/j.clinthera.2021.08.011
   Serener A, 2019, 2019 SCIENTIFIC MEETING ON ELECTRICAL-ELECTRONICS & BIOMEDICAL ENGINEERING AND COMPUTER SCIENCE (EBBT)
   Serte S, 2021, COMPUT BIOL MED, V132, DOI 10.1016/j.compbiomed.2021.104306
   Sharif MM, 2018, 2018 IEEE 20TH INTERNATIONAL CONFERENCE ON E-HEALTH NETWORKING, APPLICATIONS AND SERVICES (HEALTHCOM)
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Sun YK, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.1.016012
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
   Thomas A, 2021, COMPUT METH PROG BIO, V209, DOI 10.1016/j.cmpb.2021.106294
   Thomas A, 2021, BIOMED SIGNAL PROCES, V67, DOI 10.1016/j.bspc.2021.102538
   Thomas A, 2021, COMPUT METH PROG BIO, V200, DOI 10.1016/j.cmpb.2020.105822
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   Wang JQ, 2020, BIOMECH MODEL MECHAN, V19, P7, DOI 10.1007/s10237-019-01191-9
   Wang Y, 2016, BIOMED OPT EXPRESS, V7, P4928, DOI 10.1364/BOE.7.004928
   Wong PW, 2021, WATER RES, V205, DOI 10.1016/j.watres.2021.117668
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   Yow AP, 2020, ADV EXP MED BIOL, V1213, P149, DOI 10.1007/978-3-030-33128-3_10
NR 51
TC 2
Z9 2
U1 4
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD FEB
PY 2022
VL 12
IS 2
AR 532
DI 10.3390/diagnostics12020532
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZM1SL
UT WOS:000764144800001
PM 35204621
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Romero-Vazquez, S
   Llorens, V
   Soler-Boronat, A
   Figueras-Roca, M
   Adan, A
   Molins, B
AF Romero-Vazquez, Sara
   Llorens, Victor
   Soler-Boronat, Alba
   Figueras-Roca, Marc
   Adan, Alfredo
   Molins, Blanca
TI Interlink between Inflammation and Oxidative Stress in Age-Related
   Macular Degeneration: Role of Complement Factor H
SO BIOMEDICINES
LA English
DT Review
DE age-related macular degeneration; inflammation; oxidative stress;
   complement factor H; retinal pigment epithelium
ID C-REACTIVE PROTEIN; BRUCHS MEMBRANE IMPLICATIONS; RETINAL-PIGMENT
   EPITHELIUM; LIGHT-INDUCED DAMAGE; CIGARETTE-SMOKING; RISK-FACTORS; HUMAN
   MONOCYTES; END-PRODUCTS; DISEASE; VARIANT
AB Age-related macular degeneration (AMD) heads the list of legal blindness among the elderly population in developed countries. Due to the complex nature of the retina and the variety of risk factors and mechanisms involved, the molecular pathways underlying AMD are not yet fully defined. Persistent low-grade inflammation and oxidative stress eventually lead to retinal pigment epithelium dysfunction and outer blood-retinal barrier (oBRB) breakdown. The identification of AMD susceptibility genes encoding complement factors, and the presence of inflammatory mediators in drusen, the hallmark deposits of AMD, supports the notion that immune-mediated processes are major drivers of AMD pathobiology. Complement factor H (FH), the main regulator of the alternative pathway of the complement system, may have a key contribution in the pathogenesis of AMD as it is able to regulate both inflammatory and oxidative stress responses in the oBRB. Indeed, genetic variants in the CFH gene account for the strongest genetic risk factors for AMD. In this review, we focus on the roles of inflammation and oxidative stress and their connection with FH and related proteins as regulators of both phenomena in the context of AMD.
C1 [Romero-Vazquez, Sara; Llorens, Victor; Soler-Boronat, Alba; Figueras-Roca, Marc; Adan, Alfredo; Molins, Blanca] Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi I Sunyer IDIBAPS, Grp Ocular Inflammat Clin & Expt Studies, Barcelona 08025, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS
RP Molins, B (通讯作者)，Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi I Sunyer IDIBAPS, Grp Ocular Inflammat Clin & Expt Studies, Barcelona 08025, Spain.
EM sromerov@dinic.cat; yllorens@clinic.cat; albasolerboronat@gmail.com;
   mafiguer@clinic.cat; amadan@dinic.cat; bmolins@dinic.cat
RI Llorens Bellés, Víctor/V-3892-2019; Figueras-Roca, Marc/G-9095-2017
OI Llorens Bellés, Víctor/0000-0002-7375-1564; Figueras-Roca,
   Marc/0000-0002-0548-0539
FU Ministry of Science and Innovation of Spain, 'Instituto de Salud Carlos
   III', 'Fondo de Investigacion Sanitaria' [PI19/00265, PI17/00316,
   RD16/0008]; FEDER "Una manera de hacer Europa"; Generalitat of Catalunya
   (Secretaria d'Universitats i Recerca del Departament d'Economia i
   Coneixement de la Generalitat) [2017 SGR 0701]
FX This work was funded by the Ministry of Science and Innovation of Spain,
   'Instituto de Salud Carlos III', 'Fondo de Investigacion Sanitaria'
   (grant numbers PI19/00265, PI17/00316, and RD16/0008), and funds FEDER
   "Una manera de hacer Europa". We thank the support of the Generalitat of
   Catalunya (Secretaria d'Universitats i Recerca del Departament
   d'Economia i Coneixement de la Generalitat, 2017 SGR 0701.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aredo B, 2015, INVEST OPHTH VIS SCI, V56, P3427, DOI 10.1167/iovs.14-16089
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Braig D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14188
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Buch J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218020
   Carroll MC, 2004, MOL IMMUNOL, V41, P141, DOI 10.1016/j.molimm.2004.03.017
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen ZA, 2016, MOL CELL PROTEOMICS, V15, P2730, DOI 10.1074/mcp.M115.056473
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Cserhalmi M, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101341
   Dalvi S, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0171-9
   de Cordoba SR, 1999, MOL IMMUNOL, V36, P803, DOI 10.1016/S0161-5890(99)00100-5
   Dick AD, 2017, EYE, V31, P87, DOI 10.1038/eye.2016.177
   Du Hongjun, 2016, Open J Ophthalmol, V6, P43
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jabbehdari S, 2021, SURV OPHTHALMOL, V66, P423, DOI 10.1016/j.survophthal.2020.09.002
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaplan M, 2010, CLIN CHEM, V56, P1036, DOI 10.1373/clinchem.2009.136838
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Keeling E, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7020016
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krilis M, 2018, FREE RADICAL BIO MED, V129, P237, DOI 10.1016/j.freeradbiomed.2018.09.034
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li HL, 2017, EXPERT OPIN INV DRUG, V26, P1103, DOI 10.1080/13543784.2017.1369042
   Li K, 2012, IMMUNOBIOLOGY, V217, P65, DOI 10.1016/j.imbio.2011.07.033
   Li Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042015
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Lueck K, 2015, OPHTHALMIC RES, V54, P195, DOI 10.1159/000439596
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Makou E, 2013, BIOCHEMISTRY-US, V52, P3949, DOI 10.1021/bi4003452
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   McFadyen JD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01351
   Molday RS, 2015, J CELL SCI, V128, P4039, DOI 10.1242/jcs.175687
   Molins B, 2008, ARTERIOSCL THROM VAS, V28, P2239, DOI 10.1161/ATVBAHA.108.174359
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Naylor RM, 2013, CLIN PHARMACOL THER, V93, P105, DOI 10.1038/clpt.2012.193
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Ogura S, 2020, FASEB J, V34, P10117, DOI 10.1096/fj.202000807R
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Ott C, 2018, MECH AGEING DEV, V170, P72, DOI 10.1016/j.mad.2017.07.007
   Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Romero-Vazquez S, 2020, AGING-US, V12, P13905, DOI 10.18632/aging.103655
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shanmugam N, 2008, DIABETES, V57, P879, DOI 10.2337/db07-1204
   Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sofat R, 2013, J IMMUNOL METHODS, V390, P63, DOI 10.1016/j.jim.2013.01.009
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suzuki M, 2007, MOL VIS, V13, P772
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thiele Geoffrey M, 2004, Comp Hepatol, V3 Suppl 1, pS25, DOI 10.1186/1476-5926-2-S1-S25
   Thiele JR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00675
   Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Winkler BS, 1999, MOL VIS, V5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Wu L, 2014, INVEST OPHTH VIS SCI, V55, P1910, DOI 10.1167/iovs.14-13867
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang W, 2019, CURR EYE RES, V44, P67, DOI 10.1080/02713683.2018.1518458
NR 117
TC 9
Z9 10
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD JUL
PY 2021
VL 9
IS 7
AR 763
DI 10.3390/biomedicines9070763
PG 17
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA TO0MS
UT WOS:000676618100001
PM 34209418
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chen, Y
   Okano, K
   Maeda, T
   Chauhan, V
   Golczak, M
   Maeda, A
   Palczewski, K
AF Chen, Yu
   Okano, Kiichiro
   Maeda, Tadao
   Chauhan, Vishal
   Golczak, Marcin
   Maeda, Akiko
   Palczewski, Krzysztof
TI Mechanism of All-trans-retinal Toxicity with Implications for Stargardt
   Disease and Age-related Macular Degeneration
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RECESSIVE RETINITIS-PIGMENTOSA; NEUTROPHIL NADPH-OXIDASE; ACTIVATED
   PROTEIN-KINASE; VISUAL CYCLE; PHOSPHOLIPASE-C; GENE ABCR; IN-VIVO;
   BINDING-PROPERTIES; 5-HT1A RECEPTORS; OXIDATIVE STRESS
AB Compromised clearance of all-trans-retinal (atRAL), a component of the retinoid cycle, increases the susceptibility of mouse retina to acute light-induced photoreceptor degeneration. Abca4(-/-)Rdh8(-/-) mice featuring defective atRAL clearance were used to examine the one or more underlying molecular mechanisms, because exposure to intense light causes severe photoreceptor degeneration in these animals. Here we report that bright light exposure of Abca4(-/-)Rdh8(-/-) mice increased atRAL levels in the retina that induced rapid NADPH oxidase-mediated overproduction of intracellular reactive oxygen species (ROS). Moreover, such ROS generation was inhibited by blocking phospholipase C and inositol 1,4,5-trisphosphate-induced Ca2+ release, indicating that activation occurs upstream of NADPH oxidase-mediated ROS generation. Because multiple upstream G protein-coupled receptors can activate phospholipase C, we then tested the effects of antagonists of serotonin 2A (5-HT2AR) and M-3-muscarinic (M3R) receptors and found they both protected Abca4(-/-)Rdh8(-/-) mouse retinas from light-induced degeneration. Thus, a cascade of signaling events appears to mediate the toxicity of atRAL in light-induced photoreceptor degeneration of Abca4(-/-)Rdh8(-/-) mice. A similar mechanism may be operative in human Stargardt disease and age-related macular degeneration.
C1 [Chen, Yu; Okano, Kiichiro; Maeda, Tadao; Chauhan, Vishal; Golczak, Marcin; Maeda, Akiko; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Maeda, Tadao; Chauhan, Vishal; Maeda, Akiko] Case Western Reserve Univ, Sch Med, Dept Ophthalmol, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University
RP Palczewski, K (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM kxp65@case.edu
FU National Institutes of Health [EY009339, EY021126, EY019031, EY019880,
   P30 EY11373]; Research to Prevent Blindness Foundation; Ohio Lions Eye
   Research Foundation; NATIONAL EYE INSTITUTE [K08EY019880, R24EY021126,
   R01EY009339, P30EY011373, K08EY019031] Funding Source: NIH RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants EY009339, EY021126, EY019031, EY019880, and P30 EY11373.
   This work was also supported by the Research to Prevent Blindness
   Foundation and the Ohio Lions Eye Research Foundation.
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   ARVIDSSON LE, 1981, J MED CHEM, V24, P921, DOI 10.1021/jm00140a002
   BADWEY JA, 1989, J BIOL CHEM, V264, P14947
   BADWEY JA, 1986, J CELL PHYSIOL, V127, P223, DOI 10.1002/jcp.1041270206
   BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756
   Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200
   DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x
   Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4
   FISHER SK, 1992, J NEUROCHEM, V58, P18, DOI 10.1111/j.1471-4159.1992.tb09273.x
   Fishkin N, 2005, BIOORGAN MED CHEM, V13, P5189, DOI 10.1016/j.bmc.2005.05.001
   Fleisch VC, 2008, J NEUROSCI, V28, P8208, DOI 10.1523/JNEUROSCI.2367-08.2008
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Greene EL, 2000, AM J PHYSIOL-RENAL, V278, pF650, DOI 10.1152/ajprenal.2000.278.4.F650
   Haruta M, 2009, P NATL ACAD SCI USA, V106, P9397, DOI 10.1073/pnas.0808940106
   Hensler JG, 1998, NEUROPSYCHOPHARMACOL, V19, P354, DOI 10.1016/S0893-133X(98)00037-2
   HOYER D, 1994, PHARMACOL REV, V46, P157
   Hsu YC, 2011, CELL SIGNAL, V23, P2013, DOI 10.1016/j.cellsig.2011.07.015
   JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606
   Kim YK, 2008, J BIOL CHEM, V283, P5611, DOI 10.1074/jbc.M708885200
   Kiser P. D., 2011, BIOCHIM BIOPHYS ACTA
   Kiser PD, 2010, PROG RETIN EYE RES, V29, P428, DOI 10.1016/j.preteyeres.2010.03.002
   Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312
   LEYSEN JE, 1985, MOL PHARMACOL, V27, P600
   LEYSEN JE, 1982, MOL PHARMACOL, V21, P301
   LOCHNER JE, 1986, P NATL ACAD SCI USA, V83, P7673, DOI 10.1073/pnas.83.20.7673
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   MICHEL AD, 1989, EUR J PHARMACOL, V166, P459, DOI 10.1016/0014-2999(89)90359-2
   Molday RS, 2006, ADV EXP MED BIOL, V572, P465
   Movitz C, 1997, INFLAMMATION, V21, P531, DOI 10.1023/A:1027363730746
   Naumenko VS, 2010, GENES BRAIN BEHAV, V9, P519, DOI 10.1111/j.1601-183X.2010.00581.x
   ORGANISCIAK DT, 1992, INVEST OPHTH VIS SCI, V33, P1599
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   STEINBECK MJ, 1991, J BIOL CHEM, V266, P16336
   STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tsybovsky Y, 2011, BIOCHEMISTRY-US, V50, P6855, DOI 10.1021/bi200774w
   Usui S, 2009, J NEUROCHEM, V110, P1028, DOI 10.1111/j.1471-4159.2009.06195.x
   von Lintig J, 2010, TRENDS BIOCHEM SCI, V35, P400, DOI 10.1016/j.tibs.2010.01.005
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
   Zhang QJ, 2005, HUM GENET, V118, P356, DOI 10.1007/s00439-005-0054-4
   Zhang YH, 2004, J PHARMACOL EXP THER, V310, P59, DOI 10.1124/jpet.103.062224
   Zhang YH, 2001, J NEUROSCI, V21, P7919, DOI 10.1523/JNEUROSCI.21-20-07919.2001
NR 59
TC 142
Z9 145
U1 0
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 10
PY 2012
VL 287
IS 7
BP 5059
EP 5069
DI 10.1074/jbc.M111.315432
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 896YX
UT WOS:000300608500064
PM 22184108
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Olsen, TW
   Feng, X
   Kasper, TJ
   Rath, PP
   Steuer, ER
AF Olsen, TW
   Feng, X
   Kasper, TJ
   Rath, PP
   Steuer, ER
TI Fluorescein angiographic lesion type frequency in neovascular
   age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   PHOTODYNAMIC THERAPY; LASER PHOTOCOAGULATION; VERTEPORFIN THERAPY;
   VISUAL IMPAIRMENT; MACULOPATHY; PREVALENCE; EYE; POPULATION
AB Objective: To assess the frequency of lesion types using fluorescein angiography (FA) in neovascular age-related macular degeneration (nAMD).
   Design: Cross-sectional study. Participants: Two hundred cases of nAMD.
   Methods: Fluorescein angiograms from 908 patients (university-based, tertiary retinal referral practice [UP] 478; comprehensive, community-based eye clinic [CC] = 430) were reviewed to identify 200 cases of nAMD (100 from each center). Two graders evaluated the frequency of angiographic subtypes.
   Main Outcome Measures: Identifying (1) the frequency of subfoveal nAMD lesions that meet the definition of "predominantly classic," "minimally classic," "occult with no classic"; (2) lesion location, size, and subtype; and (3) the intergrader agreement (K).
   Results: There was little difference in the frequency of lesion type between the UP and the CC. Most nAMD lesions were subfoveal (78.5%, 157 of 200), and of these, 20% (32 of 157) were predominantly classic; whereas 73% (114 of 157)were occult with no classic, and 7% (11 of 157) were minimally classic. Of the 200 angiograms, 33 (16.5%) were juxtafoveal, and 10 (5%) were extrafoveal. Twenty of the 43 juxtafoveal and extrafoveal lesions (47%) were predominantly classic. Classic with no occult subfoveal lesions were smaller than minimally classic or occult with no classic (1.7 vs. 3.7 and 2.8 mm; P = 0.001 and 0.01, respectively). Of 114 subfoveal occult with no classic lesions, 54 (47%) had both smaller lesion size less than or equal to4 disc areas (DA) and lower visual acuity <20/50, whereas 107 (94%) had a smaller lesion or lower visual acuity.
   Conclusions: Most angiographic lesions of patients who undergo FA for nAMD are subfoveal and occult. We estimate that 20% of subfoveal lesions are predominantly classic. Approximately half of the juxtafoveal and extrafoveal lesions are predominantly classic. Nearly 30% of all nAMD lesions have both small occult lesions (size :54 DA) and a visual acuity less than 20/50. We found minimal difference in lesion type between a UP and a CC. (C) 2004 by the American Academy of Ophthalmology.
C1 Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Olsen, TW (通讯作者)，Univ Minnesota, Dept Ophthalmol, MMC Box 493,420 Delaware St SE, Minneapolis, MN 55455 USA.
EM olsen010@tc.umn.edu
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Fleiss J.L., 1981, STAT METHODS RATES P, P212
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   OShea JG, 1996, MED J AUSTRALIA, V165, P561, DOI 10.5694/j.1326-5377.1996.tb138643.x
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 24
TC 63
Z9 67
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2004
VL 111
IS 2
BP 250
EP 255
DI 10.1016/j.ophtha.2003.05.030
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 771UU
UT WOS:000188805100009
PM 15019371
DA 2022-11-30
ER

PT J
AU Eisenbarth, W
   Feucht, N
   Enders, C
   Maier, M
   Lohmann, CP
   MacKeben, M
AF Eisenbarth, Werner
   Feucht, Nikolaus
   Enders, Christian
   Maier, Mathias
   Lohmann, Chris P.
   MacKeben, Manfred
TI Parafoveal contributions to retinal function during ranibizumab therapy
   for age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CONTRAST SENSITIVITY; CHOROIDAL
   NEOVASCULARIZATION; VISUAL FUNCTION; VISION; ACUITY; AMD
AB Objective: The standard measure for the assessment of functional vision in the central retina is best corrected visual acuity (VA). Our aim was to investigate whether it is an advantage to include tests for functional changes in the near retinal periphery to monitor treatment effects in patients receiving multiple injections of anti vascular endothelial growth factor (anti-VEGF) agents for advanced exudative age-related macular degeneration (AMD).
   Design: Prospective pilot study.
   Participants: Our cohort consisted of 24 patients with exudative AMD (mean age +/- SD: 77.46 +/- 7.82 years) treated at an ophthalmology clinic.
   Methods: We compared data from standard functional measurements, VA-near, and contrast sensitivity (CS), with results from the macular mapping test (MMT) at 10% and 100% contrast. Measurements of retinal thickness by optical coherence tomography (OCT) were used to document the morphologic efficacy of the anti-VEGF agent. Tests were performed at baseline and 4 weeks after 3 monthly ranibizumab injections.
   Results: All 4 functional tests yielded successes (equal or better visual performance after treatment) in 79.2% to 83.3% of cases. Including test locations in the near periphery yielded the highest success rate in the MMT at 10% contrast. Values for VA-near and CS also improved in a majority of cases. OCT measurements of retinal thickness indicated that the agent was effective in the fovea and near periphery.
   Conclusions: Our findings indicate that using the MMT adds information about functional changes in the near periphery of the retina and allows more sensitive assessment of treatment effects or disease progression without the high expense of other techniques.
C1 [Eisenbarth, Werner] Univ Appl Sci Munich, Dept Optometry Ophthalm Opt, D-80335 Munich, Germany.
   [Feucht, Nikolaus; Enders, Christian; Maier, Mathias; Lohmann, Chris P.] Tech Univ Munich, Klinikum Rechts Isar, Dept Ophthalmol, D-80290 Munich, Germany.
   [MacKeben, Manfred] Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA.
C3 Technical University of Munich; The Smith-Kettlewell Eye Research
   Institute
RP Eisenbarth, W (通讯作者)，Univ Appl Sci Munich, Lothstr 34, D-80335 Munich, Germany.
EM werner.eisenbarth@hm.edu
RI Feucht, Nikolaus/ABB-2222-2021
OI Feucht, Nikolaus/0000-0001-9848-0070; Eisenbarth,
   Werner/0000-0003-2142-6513; Enders, Christian/0000-0003-3922-3765
CR ABEL LA, 1983, VISION RES, V23, P33, DOI 10.1016/0042-6989(83)90038-X
   Bartlett Hannah, 2005, BMC Ophthalmol, V5, P18, DOI 10.1186/1471-2415-5-18
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Eisenbarth W, 2010, ARVO M MAY 1 6 FORT
   Eisenbarth W, 2012, ARVO M MAY 6 10 FORT
   Feucht N, 2010, WORLD OPHTH C WCO JU
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Gonzalez EG, 2006, CAN J OPHTHALMOL, V41, P333, DOI 10.1139/I06-019
   Hahn GA, 2009, GRAEF ARCH CLIN EXP, V247, P43, DOI 10.1007/s00417-008-0919-z
   Inoue M, 2010, AM J OPHTHALMOL, V150, P834, DOI 10.1016/j.ajo.2010.06.006
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Loughman J, 2010, 1 DUBL I TECHN
   MacKeben M, 2012, ARVO M MAY 6 10 FORT
   MacKeben M, 2008, J VISUAL IMPAIR BLIN, V102, P649, DOI 10.1177/0145482X0810201009
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Oh J, 2010, INVEST OPHTH VIS SCI, V51, P1651, DOI 10.1167/iovs.09-4420
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   SJOSTRAND J, 1979, ACTA OPHTHALMOL, V57, P832
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
NR 26
TC 1
Z9 1
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2015
VL 50
IS 1
BP 37
EP 43
DI 10.1016/j.jcjo.2014.08.004
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE6MP
UT WOS:000351951400020
PM 25677281
DA 2022-11-30
ER

PT J
AU Christen, WG
   Glynn, RJ
   Chew, EY
   Buring, JE
AF Christen, William G.
   Glynn, Robert J.
   Chew, Emily Y.
   Buring, Julie E.
TI Low-Dose Aspirin and Medical Record-Confirmed Age-related Macular
   Degeneration in a Randomized Trial of Women
SO OPHTHALMOLOGY
LA English
DT Article
ID PROTECTS ENDOTHELIAL-CELLS; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE;
   OXIDATIVE STRESS; BETA-CAROTENE; MACULOPATHY; RISK; PATHOGENESIS;
   PROGRESSION; INHIBITION
AB Objective: To test whether alternate-day low-dose aspirin affects incidence of age-related macular degeneration (AMD) in a large-scale randomized trial of women.
   Design: Randomized, double-masked, placebo-controlled trial.
   Participants: Thirty-nine thousand eight hundred seventy-six healthy female health professionals aged 45 years or older.
   Intervention: Participants were assigned randomly to receive either 100 mg aspirin on alternate days or placebo and were followed up for the presence of AMD for an average of 10 years.
   Main Outcome Measures: Incident AMD responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-report confirmed by medical record review.
   Results: After 10 years of treatment and follow-up, there were 111 cases of AMD in the aspirin group and 134 cases in the placebo group (hazard ratio, 0.82; 95% confidence interval, 0.64-1.06).
   Conclusions: In a large-scale randomized trial of female health professionals with 10 years of treatment and follow-up, low-dose aspirin had no large beneficial or harmful effect on risk of AMD.
C1 [Christen, William G.; Glynn, Robert J.; Buring, Julie E.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
   [Glynn, Robert J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Chew, Emily Y.] NEI, Bethesda, MD 20892 USA.
   [Buring, Julie E.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard T.H. Chan School of Public Health; National Institutes of Health
   (NIH) - USA; NIH National Eye Institute (NEI); Harvard University;
   Harvard Medical School
RP Christen, WG (通讯作者)，900 Commonwealth Ave E, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
FU National Institutes of Health, Bethesda, Maryland [CA47988, HL43851,
   EY06633]; NATIONAL CANCER INSTITUTE [R01CA047988] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY006633] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851]
   Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health, Bethesda, Maryland
   (grant nos.: CA47988, HL43851,and EY06633). Pills and packaging were
   provided by Bayer Healthcare and the Natural Source Vitamin E
   Association.
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   ARUOMA OI, 1988, XENOBIOTICA, V18, P459, DOI 10.3109/00498258809041682
   Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206
   Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BURCH JW, 1978, J CLIN INVEST, V61, P314, DOI 10.1172/JCI108941
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Chiang N, 2004, P NATL ACAD SCI USA, V101, P15178, DOI 10.1073/pnas.0405445101
   Christen WG, 2004, OPHTHAL EPIDEMIOL, V11, P401, DOI 10.1080/09286580490515152
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47
   COX DR, 1972, J R STAT SOC B, V187, P220
   Eidelman RS, 2003, ARCH INTERN MED, V163, P2006, DOI 10.1001/archinte.163.17.2006
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gawaz M, 1998, CIRCULATION, V98, P1164, DOI 10.1161/01.CIR.98.12.1164
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grosser N, 2003, ARTERIOSCL THROM VAS, V23, P1345, DOI 10.1161/01.ATV.0000083296.57581.AE
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KINGHAM JD, 1988, NEW ENGL J MED, V318, P1126
   KINSHUCK D, 1992, SURV OPHTHALMOL, V3, P149
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   *NAT EYE I, NAT PLAN EYE VIS RES
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Podhaisky HP, 1997, FEBS LETT, V417, P349, DOI 10.1016/S0014-5793(97)01307-0
   Ridker P M, 1996, J Cardiovasc Risk, V3, P209, DOI 10.1097/00043798-199604000-00013
   RIDKER PM, 1991, AM HEART J, V122, P1588, DOI 10.1016/0002-8703(91)90275-M
   Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073
   SERHAN CN, 2002, PROSTAG OTH LIPID M, V6869, P433
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Steer KA, 1997, HEART, V77, P333, DOI 10.1136/hrt.77.4.333
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 53
TC 41
Z9 45
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2009
VL 116
IS 12
BP 2386
EP 2392
DI 10.1016/j.ophtha.2009.05.031
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530HE
UT WOS:000272579200019
PM 19815293
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Afarid, M
   Torabi-Nami, M
   Nemati, A
   Khosravi, A
   Malekzadeh, M
AF Afarid, Mehrdad
   Torabi-Nami, Mohammad
   Nemati, Alijan
   Khosravi, Amir
   Malekzadeh, Mahyar
TI Brain-derived neurotrophic factor in patients with advanced age-related
   macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; brain-derived neurotrophic factor;
   serum level; pathogenesis
ID NEUROPROTECTIVE EFFICACY; ALZHEIMERS-DISEASE; GENE POLYMORPHISM;
   AMYLOID-BETA; BDNF LEVELS; SERUM; PATHOGENESIS; ASSOCIATION; EXPRESSION;
   VAL66MET
AB AIM: To investigate the serum level of the brain derived neurotrophic factor (BDNF) in age -related macular degeneration (AMD) and healthy control subjects. The disruption in the tight balance of neuroinflammatory and neuroprotective processes in an immune -privileged site like retina is proposed to contribute to the pathogenesis of AMD. One of the main neuroprotective mediators in the central nervous system Is BDNF with its serum level notably affected in several neurodegenerative disorders.
   METHODS: Thirty-six patients'with AMD and 36 age-matched controls were enrolled in this study. The serum level of BDNF was measured using the enzyme -linked immunosorbent assay method. Results were analyzed to compare case and control values. Comparisons were also made between the BDNF level of wet- vsdry-AMD, and male vs female patients and controls. Analysis of variance (ANOVA) and Student's t-test were employed to analyze the data.
   RESULTS: The mean BDNF levels in AMD group were significantly higher than the control group. Furthermore, our analysis revealed greater BDNF values in all AMD subgroups compared to controls (P=0.004, 0.005, 0.001 and 0.02 for male wet-AMD, male dry-AMD, female wetAMD and female dry-AMD vscontrols, respectively). The BDNF level however did not vary between wet- and dryAMD patients (P=0.74). While within-group comparisons in males and females of AMD and control groups did not show any difference in BDNF (P=0.16, 0.64 and 0.85 for wet -AMD, dry -AMD and control groups, respectively), between -group data showed a higher mean BDNF in both male and female AMD subjects than their peer controls.
   CONCLUSION: This study demonstrated that the serum BDNF level is different in patients with AMD as compared to subjects without AMD. Future attempts should be done to unravel beneficial or deleterious effect of this neurotrophin in the pathogenesis of AMD.
C1 [Afarid, Mehrdad] Shiraz Univ Med Sci, Sch Med, Poostchi Eye Res Ctr, Dept Ophthalmol, Shiraz 7134814336, Iran.
   [Torabi-Nami, Mohammad] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Shiraz 7134814336, Iran.
   [Nemati, Alijan] Shiraz Univ Med Sci, Poostchi Eye Res Ctr, Shiraz 7134814336, Iran.
   [Khosravi, Amir] Shiraz Univ Med Sci, Student Res Comm, Shiraz 7134814336, Iran.
   [Khosravi, Amir] Shiraz Univ Med Sci, Sch Med, Poostchi Eye Res Ctr, Shiraz 7134814336, Iran.
   [Malekzadeh, Mahyar] Shiraz Univ Med Sci, Inst Canc Res, Sch Med, Shiraz 7134814336, Iran.
C3 Shiraz University of Medical Science; Shiraz University of Medical
   Science; Shiraz University of Medical Science; Shiraz University of
   Medical Science; Shiraz University of Medical Science; Shiraz University
   of Medical Science
RP Torabi-Nami, M (通讯作者)，Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Shiraz 7134814336, Iran.
EM torabinami@sums.ac.ir
RI Nami, Mohammad/AAL-6280-2021; Nami, Mohammad/S-9435-2018; Khosravi,
   Amir/AAY-8368-2020; Malekzadeh, Mahyar/B-5031-2012; Afarid,
   Mehrdad/K-6921-2016
OI Nami, Mohammad/0000-0003-1410-5340; Nami, Mohammad/0000-0003-1410-5340;
   Khosravi, Amir/0000-0002-8346-215X; Malekzadeh,
   Mahyar/0000-0003-1581-0471; Afarid, Mehrdad/0000-0003-2348-9163
FU Shiraz Institute for Cancer Research
FX Authors would like to acknowledge Shiraz Institute for Cancer Research
   for provided supports, as well as Dr. Abbas Ghaderi (Director of the
   Institute for Cancer Research, School of Medicine, Shiraz University of
   Medical Sciences, Shiraz, Iran) and Narges Rousta (PhD student of
   bio-statistics, School of Medicine, Shiraz University of Medical
   Sciences, Shiraz, Iran) for their invaluable contributions.
CR Ali SS, 2008, NANOMED-NANOTECHNOL, V4, P283, DOI 10.1016/j.nano.2008.05.003
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amoureux Sebastien, 2008, Int J Biomed Sci, V4, P204
   Angelucci F, 2011, NEUROCHEM INT, V59, P1, DOI 10.1016/j.neuint.2011.04.010
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Bejot Y, 2011, NEUROCHEM INT, V58, P102, DOI 10.1016/j.neuint.2010.10.019
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Ciammola A, 2007, AM J MED GENET B, V144B, P574, DOI 10.1002/ajmg.b.30501
   de Geyter D, 2013, NEUROSCIENCE, V250, P253, DOI 10.1016/j.neuroscience.2013.07.016
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Donnici L, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-61
   Veloso CED, 2014, OPHTHALMIC RES, V51, P1, DOI 10.1159/000354328
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   El-Shafei A., 2009, CURR PSYCHIAT, V16, P277
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Goutan E, 1998, MOL BRAIN RES, V59, P154, DOI 10.1016/S0169-328X(98)00156-9
   Haddad WM, 2003, J FR OPHTALMOL, V26, P307
   Herrmann P, 2013, OPHTHALMOLOGE, V110, P377, DOI 10.1007/s00347-012-2779-5
   Huang YZ, 2012, J NEUROSCI, V32, P15521, DOI 10.1523/JNEUROSCI.0755-12.2012
   Laske C, 2007, J PSYCHIATR RES, V41, P387, DOI 10.1016/j.jpsychires.2006.01.014
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Lee JG, 2009, PSYCHIAT INVEST, V6, P299, DOI 10.4306/pi.2009.6.4.299
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lu B, 2013, NAT REV NEUROSCI, V14, P401, DOI 10.1038/nrn3505
   Nieto R., 2013, FRONT PSYCHIATRY, V4, P45, DOI DOI 10.3389/FPSYT.2013.00045
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Patel M, 1996, MOL PSYCHIATR, V1, P362
   Ross Erika K, 2012, Recent Pat CNS Drug Discov, V7, P230
   Rybakowski JK, 2006, MOL PSYCHIATR, V11, P122, DOI 10.1038/sj.mp.4001765
   Schmier JK, 2012, AM J OPHTHALMOL, V154, P675, DOI 10.1016/j.ajo.2012.04.017
   Teche SP, 2013, PSYCHIAT QUART, V84, P485, DOI 10.1007/s11126-013-9261-7
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Xu G, 1998, Zhonghua Yan Ke Za Zhi, V34, P59
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zhang L, 2014, MOL PSYCHIATR, V19, P8, DOI 10.1038/mp.2012.180
   Zhou M, 2007, J NEUROCHEM, V103, P2212, DOI 10.1111/j.1471-4159.2007.04906.x
   Zhu H, 2012, BRAIN RES, V1439, P1, DOI 10.1016/j.brainres.2011.12.035
NR 40
TC 10
Z9 10
U1 0
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD OCT
PY 2015
VL 8
IS 5
BP 991
EP 995
DI 10.3980/j.issn.2222-3959.2015.05.25
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS1WD
UT WOS:000361858600025
PM 26558215
DA 2022-11-30
ER

PT J
AU Guymer, R
   Robman, L
AF Guymer, Robyn
   Robman, Luba
TI Chlamydia pneumoniae and age-related macular degeneration: a role in
   pathogenesis or merely a chance association?
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; Chlamydophila pneumoniae; risk factor
ID FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; VISUAL IMPAIRMENT;
   CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS; SECONDARY PREVENTION;
   COMPLEMENT; PREVALENCE; MACULOPATHY; DRUSEN
AB The role of inflammation in the aetiology of age-related macular degeneration (AMD) has become very topical as the discovery that genetic variation in complement pathway genes influences the risk of developing AMD. Complement factor H gene, an inhibitor of the alternative complement activation pathway along with other complement pathway genes factor F (BF) and C2 show significant contribution to the risk of AMD. The alternative complement pathway is activated by a trigger, which is often microbial in nature. One current model of AMD aetiology implicates aberrant regulation of the alternative pathway of complement, in combination with some unknown infectious agents. Chlamydia pneumoniae could be one such potential trigger of the alternative complement pathway and several investigations have linked C. pneumoniae to AMD. However, there are only a few studies to date and numbers in most studies are small. Also there are many difficulties in verifying laboratory techniques for the detection of C. pneumoniae chronic infection. As such we need to be cautious not to over interpret the current results. However, the findings certainly give impetus for further work on C. pneumoniae and AMD. This paper provides an overview of work in this area.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Guymer, R (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356
CR AbdelRahman YM, 2005, FEMS MICROBIOL REV, V29, P949, DOI 10.1016/j.femsre.2005.03.002
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson JL, 2004, TEX HEART I J, V31, P33
   Apfalter P, 2005, J CLIN MICROBIOL, V43, P5835, DOI 10.1128/JCM.43.12.5835-5841.2005
   BENYAAKOV M, 1994, J CLIN PATHOL, V47, P232, DOI 10.1136/jcp.47.3.232
   Cannon CP, 2005, NEW ENGL J MED, V352, P1646, DOI 10.1056/NEJMoa043528
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fong IW, 2000, CAN MED ASSOC J, V163, P49
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   FREIDANK HM, 1993, J INFECTION, V27, P89, DOI 10.1016/0163-4453(93)94013-2
   Glovsky MM, 2004, ANN ALLERG ASTHMA IM, V93, P513, DOI 10.1016/S1081-1206(10)61257-4
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GRAYSTON J, 2006, 11 INT S HUM CHLAM I, P621
   Grayston JT, 2005, NEW ENGL J MED, V352, P1637, DOI 10.1056/NEJMoa043526
   GRAYSTON JT, 1992, CLIN INFECT DIS, V15, P757, DOI 10.1093/clind/15.5.757
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammerschlag Margaret R, 2003, Expert Rev Anti Infect Ther, V1, P493, DOI 10.1586/14787210.1.3.493
   Hammerschlag MR, 2005, J INFECT DIS, V192, P1305, DOI 10.1086/466533
   Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012
   Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300
   KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841
   KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451
   Leinonen M, 2002, LANCET INFECT DIS, V2, P11, DOI 10.1016/S1473-3099(01)00168-2
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   O'Connor CM, 2003, JAMA-J AM MED ASSOC, V290, P1459, DOI 10.1001/jama.290.11.1459
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Quinn TC, 1999, AM HEART J, V138, pS507, DOI 10.1016/S0002-8703(99)70287-5
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Song WC, 2004, CURR DIRECT AUTOIMMU, V7, P181
   STREBLOW DN, 2001, J NUTR, P131
   Taylor-Robinson D, 2002, J CLIN PATHOL, V55, P218, DOI 10.1136/jcp.55.3.218
   Taylor-Robinson D, 2000, J INFECT DIS, V181, pS437, DOI 10.1086/315614
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   TIKELLIS G, 2006, EYE, V26, P1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Verkooyen RP, 1998, J CLIN MICROBIOL, V36, P2301, DOI 10.1128/JCM.36.8.2301-2307.1998
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WANG JH, 1993, SCAND J INFECT DIS, V25, P565, DOI 10.3109/00365549309008544
NR 65
TC 22
Z9 23
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2007
VL 35
IS 1
BP 89
EP 93
DI 10.1111/j.1442-9071.2006.01392.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131KE
UT WOS:000243866900016
PM 17300581
DA 2022-11-30
ER

PT J
AU Tarita-Nistor, L
   Brent, MH
   Steinbach, MJ
   Gonzalez, EG
AF Tarita-Nistor, Luminita
   Brent, Michael H.
   Steinbach, Martin J.
   Gonzalez, Esther G.
TI Fixation Stability during Binocular Viewing in Patients with Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PREFERRED RETINAL LOCI; SCANNING LASER OPHTHALMOSCOPE; CENTRAL VISION
   LOSS; CENTRAL SCOTOMA; DISEASE; LOCATION; EYE; FOVEA; AMD
AB PURPOSE. The authors examined the fixation stability of patients with age-related macular degeneration (AMD) and large. interocular acuity differences, testing them in monocular and binocular viewing conditions. The relationship between fixation stability and visual performance during monocular and binocular viewing was also studied.
   METHODS. Twenty patients with AMD participated. Their monocular and binocular distance acuities were measured with the ETDRS charts. Fixation stability of the better and worse eye were recorded monocularly with the MP-1 microperimeter (Nidek Technologies Srl., Vigonza, PD, Italy) and binocularly with an EyeLink eye tracker (SR Research Ltd., Mississauga, Ontario, Canada). Additional recordings of monocular fixations were obtained with the EyeLink in viewing conditions when one eye viewed the target while the fellow eye was covered by an infrared filter so it could not see the target.
   RESULTS. Fixation stability of the better eye did not change across viewing conditions. Fixation stability of the worse eye was 84% to 100% better in the binocular condition than in monocular conditions. Fixation stability of the worse eye was significantly larger (P < 0.05) than that of the better eye when recorded monocularly with the MP-1 microperimeter. This difference was dramatically reduced in the binocular condition but remained marginally significant (95% confidence interval, -0.351 to -0.006). For the better eye, there was a moderate relationship between fixation stability and visual acuity, both monocular and binocular, in all conditions in which this eye viewed the target.
   CONCLUSIONS. Fixational ocular motor control and visual acuity are driven by the better-seeing eye when patients with AMD and large interocular acuity differences perform the tasks binocularly. (Invest Ophthalmol Vis Sci. 2011;52:1887-1893) 10.1167/iovs.10-6059
C1 [Gonzalez, Esther G.] Toronto Western Hosp, Toronto Western Res Inst, Vis Sci Res Program, Toronto, ON M5T 2S8, Canada.
   [Tarita-Nistor, Luminita; Steinbach, Martin J.; Gonzalez, Esther G.] York Univ, Ctr Vis Res, Toronto, ON M3J 2R7, Canada.
   [Brent, Michael H.; Steinbach, Martin J.; Gonzalez, Esther G.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; York University - Canada; University of Toronto
RP Gonzalez, EG (通讯作者)，Toronto Western Hosp, Toronto Western Res Inst, Vis Sci Res Program, 399 Bathurst St,FP 6-212, Toronto, ON M5T 2S8, Canada.
EM gonzalez@yorku.ca
FU Milton Harris Fund for Adult Macular Degeneration; Natural Sciences and
   Engineering Research Council of Canada [A7664]; Sir Jules Thorn
   Charitable Trust; Krembil Family Foundation; Toronto Western Hospital
FX Supported by the Milton Harris Fund for Adult Macular Degeneration
   (MHB); the Natural Sciences and Engineering Research Council of Canada
   Grant A7664 (MJS); the Sir Jules Thorn Charitable Trust (MJS); the
   Krembil Family Foundation (MJS); the Vision Science Research Program,
   Toronto Western Hospital; and an anonymous donor.
CR Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2002, OPTOMETRY VISION SCI, V79, P735, DOI 10.1097/00006324-200211000-00011
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Gonzalez EG, 2006, CAN J OPHTHALMOL, V41, P333, DOI 10.1139/I06-019
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Kabanarou SA, 2006, OPTOMETRY VISION SCI, V83, P789, DOI 10.1097/01.opx.0000238642.65218.64
   Kabanarou SA, 2006, OPHTHALMOLOGY, V113, P2251, DOI 10.1016/j.ophtha.2006.06.028
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Martinez-Conde S, 2004, NAT REV NEUROSCI, V5, P229, DOI 10.1038/nrn1348
   MartinezConde S, 2006, V154
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Quillen DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1725
   Reinhard J, 2007, VISION RES, V47, P2076, DOI 10.1016/j.visres.2007.04.012
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   TABACHNICK BG, 2001, USING MULTIVARIATE S, P67
   Tarita-Nistor L, 2006, CAN J OPHTHALMOL, V41, P327, DOI 10.1139/I06-029
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2006, VISION RES, V46, P2487, DOI 10.1016/j.visres.2006.01.035
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
NR 41
TC 35
Z9 35
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2011
VL 52
IS 3
BP 1887
EP 1893
DI 10.1167/iovs.10-6059
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 742SR
UT WOS:000288965300083
PM 21071732
DA 2022-11-30
ER

PT J
AU Seitzman, RL
   Mangione, C
   Ensrud, KE
   Cauley, JA
   Stone, KL
   Cummings, SR
   Hochberg, MC
   Hillier, TA
   Yu, F
   Coleman, AL
AF Seitzman, Robin L.
   Mangione, Carol
   Ensrud, Kristine E.
   Cauley, Jane A.
   Stones, Katie L.
   Cummings, Steven R.
   Hochberg, Marc C.
   Hillier, Teresa A.
   Yu, Fei
   Coleman, Anne L.
CA Study Osteoporotic Fractures Res G
TI Postmenopausal Hormone Therapy and Age-Related Maculopathy in Older
   Women
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; age-related maculopathy; estrogen;
   postmenopausal hormone therapy
ID BEAVER DAM EYE; BLUE-MOUNTAINS EYE; MACULAR DEGENERATION; REPLACEMENT
   THERAPY; CIGARETTE-SMOKING; 5-YEAR INCIDENCE; UNITED-STATES;
   RISK-FACTORS; BONE LOSS; PROGRESSION
AB Purpose: To examine the association between postmenopausal hormone therapy and Age-Related Maculopathy (ARM) in older women and to determine if these associations vary by smoking status. Methods: A cross-sectional analysis of 1065 women of European origin aged >= 74 years attending the year-10 examination of the Study of Osteoporotic Fractures was performed. Fundus photographs were graded for ARM using a modification of the Wisconsin Age-Related Maculopathy Grading System used in NHANES III. Multiple imputation methods were used to examine the associations of type and duration of postmenopausal hormone therapy use with early and late ARM as well as interactions with smoking history. Results: Compared to never users, Neither estrogen alone (E), Estrogen plus progestin (E+P), nor duration of use was significantly associated with early ARM [odds ratio (OR) E=1.01, 95% confidence interval (CI) 0.77-1.34; OR E+P=0.85, 95% CI 0.55-1.35; OR <= 3 years use=1.04, 95% CI 0.74-1.47; OR>3-12 years use=0.93, 95% CI 0.64-1.35; OR >12 years use=0.95, 95% CI 0.65-1.37] or late ARM (OR any E/E+P=0.59, 95% CI 0.29-1.19; OR <= 3 years use=0.73, 95% CI 0.30-1.77; OR>3 years of use = 0.51, 95% CI 0.22-1.17), though power for late ARM was limited. Tests for smoking interactions were not significant. Conclusions: This study found no evidence to support an association between use of E, E+P, or duration of use and ARM risk.
C1 [Coleman, Anne L.; Study Osteoporotic Fractures Res G] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA.
   [Yu, Fei] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
   [Mangione, Carol] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [Seitzman, Robin L.; Yu, Fei; Coleman, Anne L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
   [Hochberg, Marc C.] Univ Maryland, Div Rheumatol, Baltimore, MD 21201 USA.
   [Cummings, Steven R.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Stones, Katie L.; Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
   [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
   [Ensrud, Kristine E.] Univ Minnesota, Dept Epidemiol, Minneapolis, MN 55455 USA.
   [Ensrud, Kristine E.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Kaiser Permanente;
   University System of Maryland; University of Maryland Baltimore;
   University of California System; University of California San Francisco;
   California Pacific Medical Center; California Pacific Medical Center
   Research Institute; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Minnesota System;
   University of Minnesota Twin Cities; University of Minnesota System;
   University of Minnesota Twin Cities; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Minneapolis VA Health Care System
RP Seitzman, RL (通讯作者)，Drug Safety & Risk Management, Biogen Idec,5200 Res Pl, San Diego, CA 92122 USA.
EM seitzman@aucla.edu
RI Cauley, Jane A/N-4836-2015
OI Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036
FU National Institutes of Health [AG05407, AR35582, AG05394, AR35584,
   AR35583, AG08415, AG-02-004]; National Eye Institute [EY07026]; UCLA
   Center for Health Improvement in Minority Elders/Resource Centers for
   Minority Aging Research; NATIONAL EYE INSTITUTE [T32EY007026] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND
   MUSCULOSKELETAL AND SKIN DISEASES [R01AR035584, R01AR035583,
   R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG008415] Funding Source: NIH RePORTER
FX The Study of Osteoporotic Fractures is supported by National Institutes
   of Health funding, under the following grant numbers: AG05407, AR35582,
   AG05394, AR35584, AR35583, and AG08415. Support for Dr. Seitzman was
   also provided by National Institutes of Health, National Eye Institute
   grant number EY07026. Support for Dr. Mangione was also provided by the
   UCLA Center for Health Improvement in Minority Elders/Resource Centers
   for Minority Aging Research, National Institutes of Health, National
   Institute of Aging (AG-02-004).
CR Abramov Y, 2004, MENOPAUSE, V11, P62, DOI 10.1097/01.GME.0000074701.19603.11
   Bjarnason NH, 2000, J CLIN ENDOCR METAB, V85, P590, DOI 10.1210/jc.85.2.590
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   CASSIDENTI DL, 1990, AM J OBSTET GYNECOL, V163, P1953, DOI 10.1016/0002-9378(90)90780-B
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geisler J, 1999, J ENDOCRINOL, V162, P265, DOI 10.1677/joe.0.1620265
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   JENSEN J, 1988, AM J OBSTET GYNECOL, V159, P820, DOI 10.1016/S0002-9378(88)80144-3
   JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602
   KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BE, 1994, T AM OPHTHAL SOC, V92, P295
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Rubin D.B., 1987, MULTIPLE IMPUTATION, P1
   Schafer J.L., 1997, ANAL INCOMPLETE MULT
   Seitzman RL, 2007, J AM GERIATR SOC, V55, P740, DOI 10.1111/j.1532-5415.2007.01138.x
   Smith JP, 1997, J ADV NURS, V25, P1, DOI 10.1046/j.1365-2648.1997.1997025001.x
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Tanko LB, 2004, MENOPAUSE, V11, P104, DOI 10.1097/01.GME.0000079740.18541.DB
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 35
TC 5
Z9 5
U1 0
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD SEP-OCT
PY 2008
VL 15
IS 5
BP 308
EP 316
DI 10.1080/09286580802077724
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 363FD
UT WOS:000260252300005
PM 18850467
DA 2022-11-30
ER

PT J
AU Hyttinen, JMT
   Petrovski, G
   Salminen, A
   Kaarniranta, K
AF Hyttinen, Juha M. T.
   Petrovski, Goran
   Salminen, Antero
   Kaarniranta, Kai
TI 5 '-Adenosine Monophosphate-Activated Protein Kinase-Mammalian Target of
   Rapamycin Axis As Therapeutic Target for Age-Related Macular
   Degeneration
SO REJUVENATION RESEARCH
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS; VEGF EXPRESSION; AUTOPHAGY;
   MTOR; RESVERATROL; AMPK; PATHOGENESIS; INHIBITION; PHOSPHORYLATION
AB Age-related macular degeneration (AMD) is the most common reason for blindness in developed countries. AMD essentially involves chronic oxidative stress, increased accumulation of lipofuscin in retinal pigment epithelial (RPE) cells, and extracellular drusen formation, as well as presence of chronic inflammation in the retina. The capacity to prevent the accumulation of cellular cytotoxic protein aggregates is decreased in senescent cells, which may evoke lipofuscin accumulation into lysosomes in postmitotic RPE cells. The formation of lipofuscin, in turn, decreases the lysosomal enzyme activity and impairs the autophagic clearance of damaged proteins destined for cellular removal. 5'-Adenosine monophosphate-activated protein kinase (AMPK) is a well-known inhibitor of mammalian target of rapamycin (mTOR) that subsequently evokes induction of autophagy. This review examines the novel potential therapeutic targets on the AMPK-mTOR axis and the ways in which autophagy clearance can suppress or prevent RPE degeneration and development of AMD.
C1 [Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, FI-70211 Kuopio, Finland.
   [Petrovski, Goran] Univ Debrecen, Dept Biochem & Mol Biol, Hungarian Acad Sci, Apoptosis & Genom Res Grp, Debrecen, Hungary.
   [Petrovski, Goran] Univ Debrecen, Med & Hlth Sci Ctr, Dept Ophthalmol, Debrecen, Hungary.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; Hungarian Academy of Sciences; University
   of Debrecen; University of Debrecen; University of Eastern Finland;
   Kuopio University Hospital; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland
RP Hyttinen, JMT (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
EM Juha.Hyttinen@uef.fi
RI Petrovski, Goran/A-8983-2012
OI Hyttinen, Juha/0000-0002-3414-4032; Petrovski,
   Goran/0000-0003-2905-9252; Kaarniranta, Kai/0000-0003-2600-8679
CR Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Bai XC, 2010, CELL MOL LIFE SCI, V67, P239, DOI 10.1007/s00018-009-0163-7
   Bergamini E, 2004, INT J BIOCHEM CELL B, V36, P2392, DOI 10.1016/j.biocel.2004.05.007
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Blasiak Janusz, 2009, Klin Oczna, V111, P174
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Brunk UT, 1995, GERONTOLOGY, V41, P201
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Canto C, 2010, CELL MOL LIFE SCI, V67, P3407, DOI 10.1007/s00018-010-0454-z
   Chan EYW, 2009, MOL CELL BIOL, V29, P157, DOI 10.1128/MCB.01082-08
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104
   Dejneka NS, 2004, MOL VIS, V10, P964
   Denzer K, 2000, J CELL SCI, V113, P3365
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886
   Emerling BM, 2009, FREE RADICAL BIO MED, V46, P1386, DOI 10.1016/j.freeradbiomed.2009.02.019
   Eskelinen EL, 2008, BIOCHIM BIOPHYS ACTA, V1793, P664
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hardie DG, 2011, AM J CLIN NUTR, V93, p891S, DOI 10.3945/ajcn.110.001925
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hoyer-Hansen M, 2007, AUTOPHAGY, V3, P381, DOI 10.4161/auto.4240
   Hwang JT, 2008, GENES NUTR, V2, P323, DOI 10.1007/s12263-007-0069-7
   Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507
   Khan AA, 2010, AM J PATHOL, V177, P481, DOI 10.2353/ajpath.2010.090836
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Kubota S, 2010, AM J PATHOL, V177, P1725, DOI 10.2353/ajpath.2010.100098
   Kunchithapautham K, 2011, INVEST OPHTH VIS SCI, V52, P2967, DOI 10.1167/iovs.10-6278
   Kurz T, 2008, BBA-GEN SUBJECTS, V1780, P1291, DOI 10.1016/j.bbagen.2008.01.009
   Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007
   LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778
   Leclerc Gilles M, 2010, J Mol Signal, V5, P15, DOI 10.1186/1750-2187-5-15
   Lee CH, 2007, ANNU REV PHARMACOL, V47, P443, DOI 10.1146/annurev.pharmtox.47.120505.105359
   Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Liu LH, 2010, DEV CELL, V19, P845, DOI 10.1016/j.devcel.2010.11.004
   McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761
   Meares GP, 2010, J BIOL CHEM, V285, P3191, DOI 10.1074/jbc.M109.047365
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mukherjee S, 2010, DOSE-RESPONSE, V8, P478, DOI 10.2203/dose-response.09-015.Mukherjee
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ouchi N, 2005, CIRC RES, V96, P838, DOI 10.1161/01.RES.0000163633.10240.3b
   Petrovski G, 2011, ANN NY ACAD SCI, V1215, P22, DOI 10.1111/j.1749-6632.2010.05843.x
   Petrovski G, 2010, J CELL MOL MED, V14, P2543, DOI 10.1111/j.1582-4934.2010.01196.x
   Puljak L, 2008, EXP CELL RES, V314, P2100, DOI 10.1016/j.yexcr.2008.03.002
   Qin SF, 2008, J BIOL CHEM, V283, P6744, DOI 10.1074/jbc.M708848200
   Qin SF, 2010, EXP EYE RES, V91, P818, DOI 10.1016/j.exer.2010.10.007
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Samari HR, 1998, J BIOL CHEM, V273, P23758, DOI 10.1074/jbc.273.37.23758
   Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x
   Sheu SJ, 2010, J OCUL PHARMACOL TH, V26, P231, DOI 10.1089/jop.2009.0137
   Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005
   Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Viana R, 2008, BIOCHEM BIOPH RES CO, V369, P964, DOI 10.1016/j.bbrc.2008.02.126
   Viiri J, 2010, MOL VIS, V16, P1399
   Vingtdeux V, 2010, J BIOL CHEM, V285, P9100, DOI 10.1074/jbc.M109.060061
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang SB, 2010, J BIOL CHEM, V285, P19976, DOI 10.1074/jbc.M110.102467
   Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200
NR 91
TC 31
Z9 33
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
EI 1557-8577
J9 REJUV RES
JI Rejuv. Res.
PD DEC
PY 2011
VL 14
IS 6
BP 651
EP 660
DI 10.1089/rej.2011.1220
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 865XM
UT WOS:000298344200008
PM 22007913
DA 2022-11-30
ER

PT J
AU Mones, J
   Biarnes, M
   Trindade, F
   Casaroli-Marano, R
AF Mones, Jordi
   Biarnes, Marc
   Trindade, Fabio
   Casaroli-Marano, Ricardo
TI FUSION regimen: ranibizumab in treatment-naive patients with exudative
   age-related macular degeneration and relatively good baseline visual
   acuity
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Exudative age-related macular degeneration; Ranibizumab; PRN regimen;
   Anti-VEGF therapy; FUSION; Treat-and-extend regimen
ID DOSING REGIMEN; TRIAL
AB To investigate the safety and efficacy of a combined fixed-interval and pro re nata regimen of ranibizumab (FUSION regimen) for treatment of exudative age-related macular degeneration in patients with good visual acuity at baseline. To establish whether similar efficacy to monthly regimens can be achieved with fewer injections, even in patients with good visual acuity.
   This was a prospective, open-label, consecutive interventional case series in treatment-na < ve patients with exudative age-related macular degeneration. The FUSION regimen consists of three phases: 1) a loading phase of two or three injections, depending on presence or absence of choroidal neovascularization activity at first follow-up, 2) administration of one injection on disappearance of exudation, and 3) subsequent administration of two separate injections at intervals 2 months apart, and then an injection every 3 months. Endpoints included visual acuity, presence of fluid, adverse events and number of injections administered.
   Seventeen eyes of 17 Caucasian patients were included. Mean patient age was 76 years, and 15 patients were female. Mean baseline visual acuity was 67.5 letters (median 67), with Snellen equivalent 20/50++, ranged between 45 (20/125) and 83 (20/20--). At 3 months, mean change in best-corrected visual acuity (BCVA) was +2.3 letters (median +9) compared with baseline (p = 0.3). At 6 months, mean change in BCVA was +4.2 letters (median +9) compared with baseline (p = 0.02). At 12 months, one patient had discontinued the study. Mean change in BCVA was 5.6 (median +10) compared with baseline (p = 0.04). No patient lost a parts per thousand yen15 letters, and 14 patients (87.5%) lost < 5 letters. The mean number of injections was 6.9. One patient experienced a retinal pigment epithelium tear; no other complications were observed.
   The FUSION regimen for ranibizumab has the potential to maintain visual gains achieved during the loading phase, as reported in studies with monthly injections, even in eyes with a relatively good visual acuity at baseline. These 12-month results warrant validation in a larger, randomized controlled trial.
C1 [Mones, Jordi; Biarnes, Marc; Trindade, Fabio] Ctr Med Teknon, Inst Macula & Retina, Barcelona 08022, Spain.
   [Casaroli-Marano, Ricardo] Univ Barcelona, Fac Med, Dept Cirugia, Barcelona 7, Spain.
C3 University of Barcelona
RP Mones, J (通讯作者)，Ctr Med Teknon, Inst Macula & Retina, Vilana 12, Barcelona 08022, Spain.
EM jmones@institutmacularetina.com
RI mones, jordi/CAJ-2963-2022; Casaroli-Marano, Ricardo Pedro/D-4535-2014
OI mones, jordi/0000-0003-3685-2160; Casaroli-Marano, Ricardo
   Pedro/0000-0003-1812-9323; Trindade, Fabio/0000-0001-9993-5188; Biarnes,
   Marc/0000-0003-2584-4894
FU Novartis Pharma AG; Institut de la Macula i de la Retina; Barcelona
   Macula Foundation
FX The authors would like to acknowledge Chameleon Communications
   International, who provided editorial assistance with funding from
   Novartis Pharma AG. This encompassed editing for language and grammar,
   formatting, referencing, preparing tables and figures, and incorporating
   the authors' revisions. At all stages, the authors have had control over
   the content of this manuscript, for which they have given final approval
   and take full responsibility. As funding sponsors and in accordance with
   "Good Publication Practice for Communicating Company-Sponsored Medical
   Research: the GPP2 guidelines", Novartis Pharma AG had no input into the
   content of this manuscript.; Funding for this study was provided by
   Institut de la Macula i de la Retina, and Barcelona Macula Foundation.
   Clinical trial registration number: NCT01500915, clinicaltrials.gov
CR Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Biswas P, 2011, OPHTHALMOLOGY, V118, P600, DOI 10.1016/j.ophtha.2010.10.027
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mones J, 2008, 26 M CLUB J GONIN ST
   Mones J, 2011, OPHTHALMOLOGICA, V225, P112, DOI 10.1159/000319906
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Pauleikhoff D, 2011, GRAEF ARCH CLIN EXP, V249, P631, DOI 10.1007/s00417-011-1639-3
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   SINGER M, 2009, INVEST OPHTHALMOL VI, V50
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Verbraak F, 2009, 9 EURETINA C NIC FRA
NR 24
TC 16
Z9 17
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2012
VL 250
IS 12
BP 1737
EP 1744
DI 10.1007/s00417-012-2009-5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 040ZP
UT WOS:000311366200004
PM 22527314
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Erke, MG
   Bertelsen, G
   Peto, T
   Sjolie, AK
   Lindekleiv, H
   Njolstad, I
AF Erke, Maja G.
   Bertelsen, Geir
   Peto, Tunde
   Sjolie, Anne K.
   Lindekleiv, Haakon
   Njolstad, Inger
TI Cardiovascular risk factors associated with age-related macular
   degeneration: the Tromso Study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE epidemiology; age-related macular degeneration; smoking; risk factors;
   physical activity; hypertension; body mass index; sex difference
ID BODY-MASS INDEX; VISUAL IMPAIRMENT; PHYSICAL-ACTIVITY; POOLED FINDINGS;
   MACULOPATHY; PREVALENCE; DISEASE; HYPERTENSION; MORTALITY; SMOKING
AB PurposeTo examine associations between cardiovascular risk factors and age-related macular degeneration (AMD).
   MethodsA population-based, cross-sectional study of Caucasians aged 65-87years was conducted in Norway in 2007/2008. Retinal photographs were graded for AMD. Multivariable logistic regression analyses were performed based on questionnaires addressing habits of smoking, alcohol consumption, physical activity, health and medication; and physical examination comprising anthropometric measurements, blood pressure and blood sampling. Cardiovascular disease status was obtained from a validated end-point registry.
   ResultsGradable photographs were available for 2631 participants, of whom 92 (3.5%) subjects had late AMD. In the multivariable analysis of late AMD, significant interactions were found between sex and the variables age, triglyceride level, use of lipid-lowering drugs and physical exercise. Current daily smoking was significantly related to late AMD in both sexes (odds ratio (OR) 4.06, 95% confidence interval (CI) 1.69-9.76 and OR 3.59, 95% CI 1.17-11.04, women and men, respectively) compared with never smokers. Higher number of pack years was associated with the presence of large drusen (>125m) (OR 1.04, 95% CI 1.01-1.09 per 5years). Higher systolic blood pressure (OR 1.06, 95% CI 1.01-1.12 per 5mmHg), overweight (OR 2.87, 95% CI 1.13-7.29) and obesity (OR 2.92, 95% CI 1.06-8.03), physical exercise duration (OR 0.41, 95% 0.18-0.96 for 30min or more compared with less) and frequency (OR 0.46, 95% CI 0.23-0.92 for weekly or more often compared to less) were associated with late AMD in women only.
   ConclusionsSmoking was strongly associated with AMD, in line with results from other populations. Also, late AMD was related to higher systolic blood pressure, physical inactivity, overweight and obesity in women.
C1 [Erke, Maja G.; Bertelsen, Geir] Univ Hosp North Norway, Dept Ophthalmol & Neurosurg, N-9038 Tromso, Norway.
   [Erke, Maja G.; Bertelsen, Geir; Lindekleiv, Haakon; Njolstad, Inger] Univ Tromso, Fac Hlth Sci, Dept Community Med, Res Grp Epidemiol Chron Dis, Tromso, Norway.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Peto, Tunde] UCL Inst Ophthalmol, Head Reading Ctr, London, England.
   [Sjolie, Anne K.] Odense Univ Hosp, Dept Ophthalmol, DK-5000 Odense, Denmark.
   [Sjolie, Anne K.] Univ Tromso, Fac Hlth Sci, Dept Clin Med, Brain & Circulat Res Grp, Tromso, Norway.
C3 UiT The Arctic University of Tromso; University Hospital of North
   Norway; UiT The Arctic University of Tromso; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; University of Southern
   Denmark; Odense University Hospital; UiT The Arctic University of Tromso
RP Erke, MG (通讯作者)，Univ Hosp North Norway, Dept Ophthalmol & Neurosurg, POB 100, N-9038 Tromso, Norway.
EM maja.g.erke@uit.no
RI Bertelsen, Geir/ABB-9865-2021; Njolstad, Inger/X-3784-2019; Peto,
   Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381
FU Northern Norway Regional Health Authority [SFP897-09]; NIHR Biomedical
   Research Centre at Moorfields Eye Hospital NHS Foundation Trust; UCL
   Institute of Ophthalmology, London, UK
FX Financial support: Supported by a PhD grant from The Northern Norway
   Regional Health Authority, Grant Number SFP897-09. Tunde Peto was
   supported by NIHR Biomedical Research Centre at Moorfields Eye Hospital
   NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. The
   funding organizations had no role in the design or conduct of this
   research.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bertelsen G, 2013, ACTA OPHTHALMOL, V91, P635, DOI 10.1111/j.1755-3768.2012.02511.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2011, P NATL ACAD SCI USA, V108, P18569, DOI 10.1073/pnas.1115497108
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Eggen AE, 2013, SCAND J PUBLIC HEALT, V41, P65, DOI 10.1177/1403494812469851
   Erke MG, 2013, BRIT J OPHTHALMOL, V97, P1036, DOI 10.1136/bjophthalmol-2012-302461
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Gulsvik AK, 2012, INT J EPIDEMIOL, V41, P521, DOI 10.1093/ije/dyr205
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jacobsen BK, 2012, INT J EPIDEMIOL, V41, P961, DOI 10.1093/ije/dyr049
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thijssen DHJ, 2012, CLIN SCI, V122, P311, DOI 10.1042/CS20110469
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vitale C, 2009, NAT REV CARDIOL, V6, P532, DOI 10.1038/nrcardio.2009.105
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
NR 42
TC 29
Z9 29
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2014
VL 92
IS 7
BP 662
EP 669
DI 10.1111/aos.12346
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS3FN
UT WOS:000344162700031
PM 24460653
OA Bronze
DA 2022-11-30
ER

PT J
AU Lenoble, Q
   Tran, THC
   Szaffarczyk, S
   Boucart, M
AF Lenoble, Quentin
   Thi Ha Chau Tran
   Szaffarczyk, Sebastien
   Boucart, Muriel
TI Categorization Task over a Touch Screen in Age-Related Macular
   Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE categorization; age-related macular degeneration; aging; recognition;
   touch screen
ID PREFERRED RETINAL LOCI; LOW-VISION; SCENE CATEGORIZATION; GRASPING
   BEHAVIOR; ONLINE CONTROL; PREHENSION; DISEASE; PEOPLE; PSYCHOPHYSICS;
   DISORDERS
AB Purpose In our modern society, many touch screen applications require hand-eye coordination to associate an icon with its specific contextual unit on phones, on computers, or in public transport. We assessed the ability of patients with age-related macular degeneration (AMD) to explore scenes and to associate a target (animal or object) with a unique congruent scene (e.g., to match a fish with the sea) presented between three other distractors on a touch screen computer.
   Methods Twenty-four patients with AMD (64 to 90 years) with best-corrected visual acuity between 20/40 and 20/400 as well as 17 age-matched (60 to 94 years) and 15 young (22 to 34 years) participants with normal visual acuity had to match a target with a congruent scene by moving their index finger on a 22-in touch screen.
   Results Patients were as accurate (98.7% correct responses) as the age-matched control (98.9% correct responses) and young participants (99.3% correct responses) at performing the task. The duration of exploration was significantly longer for the AMD patients (mean, 4.13 seconds) compared with the age-matched group (mean, 2.96 seconds). The young participants were also significantly faster than the old group (mean, 0.93 seconds). The movement parameters of the older participants (patients and old control subjects) were affected compared with the young; the peak speed decreased (-8 cm/s) and the movement duration increased (+0.9 seconds) with age compared with the young group.
   Conclusions People with AMD are able to perform a contextual association task on a touch screen with high accuracy. The AMD patients were specifically affected in the exploration phase; their accuracy and movement parameters did not differ from the old control group. Our study suggests that the decline associated with AMD is more focused on the duration of exploration than on movement parameters in touch screen use.
C1 [Lenoble, Quentin; Szaffarczyk, Sebastien; Boucart, Muriel] Univ Lille, UMR CNRS 9193, SCALab, Lille, France.
   [Thi Ha Chau Tran] Hop St Vincent de Paul, Serv Ophtalmol, Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute
   for Humanities & Social Sciences (INSHS); Universite de Lille - ISITE;
   Universite de Lille
RP Lenoble, Q (通讯作者)，150 Rue Dr Yersin, F-59120 Loos, France.
EM qlenoble.vision@gmail.com
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
FU French National Research Agency (grant SHS2 LowVision); Fondation Visio
FX The study was funded by research grants from the French National
   Research Agency (grant SHS2 LowVision) and by Fondation Visio. The
   sponsors had no role in the design or conduct of this research.
CR Baseler HA, 2011, OPTOMETRY VISION SCI, V88, P1255, DOI 10.1097/OPX.0b013e3182282f13
   Boucart M, 2013, INVEST OPHTH VIS SCI, V54, P1950, DOI 10.1167/iovs.12-9680
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   Bradshaw MF, 2003, SPATIAL VISION, V16, P295, DOI 10.1163/156856803322467545
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Crossland MD, 2014, OPHTHAL PHYSL OPT, V34, P552, DOI 10.1111/opo.12136
   Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   FINE EM, 1995, J OPT SOC AM A, V12, P2286, DOI 10.1364/JOSAA.12.002286
   Gill K, 2013, EYE, V27, P639, DOI 10.1038/eye.2013.14
   Gonzalez EG, 2011, INVEST OPHTH VIS SCI, V52, P4208, DOI 10.1167/iovs.10-7026
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Guyader N, 2004, CR BIOL, V327, P313, DOI 10.1016/j.crvi.2004.02.006
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jeannerod M., 1981, ATTENTION PERFORM, VIX, P153
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Loftus A, 2004, EXP BRAIN RES, V158, P317, DOI 10.1007/s00221-004-1905-2
   Pardhan S, 2013, INVEST OPHTH VIS SCI, V54, P3281, DOI 10.1167/iovs.12-11045
   Pardhan S, 2012, INVEST OPHTH VIS SCI, V53, P6687, DOI 10.1167/iovs.12-9821
   Rand MK, 2007, EXP BRAIN RES, V181, P447, DOI 10.1007/s00221-007-0945-9
   SERVOS P, 1994, EXP BRAIN RES, V98, P119
   Sullivan B, 2008, OPHTHAL PHYSL OPT, V28, P168, DOI 10.1111/j.1475-1313.2008.00546.x
   Thi HCT, 2011, INVEST OPHTH VIS SCI, V52, P1655, DOI 10.1167/iovs.10-6003
   Thibaut M, 2014, VISION RES, V98, P46, DOI 10.1016/j.visres.2014.03.004
   Timberlake GT, 2011, INVEST OPHTH VIS SCI, V52, P2540, DOI 10.1167/iovs.10-6062
   Tran THC, 2012, J FR OPHTALMOL, V35, P58, DOI 10.1016/j.jfo.2011.08.002
   Walker R, 2013, BRIT J OPHTHALMOL, V97, P110, DOI 10.1136/bjophthalmol-2012-302415
   Watt SJ, 2000, NEUROPSYCHOLOGIA, V38, P1473, DOI 10.1016/S0028-3932(00)00065-8
NR 28
TC 2
Z9 2
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD OCT
PY 2015
VL 92
IS 10
BP 986
EP 994
DI 10.1097/OPX.0000000000000694
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA CS5HA
UT WOS:000362107300004
PM 26398350
DA 2022-11-30
ER

PT J
AU Mintz, J
   Labiste, C
   DiCaro, MV
   McElroy, E
   Alizadeh, R
   Xu, KY
AF Mintz, Joel
   Labiste, Chase
   DiCaro, Michael, V
   McElroy, Evan
   Alizadeh, Reza
   Xu, Kunyong
TI Teleophthalmology for age-related macular degeneration during the
   COVID-19 pandemic and beyond
SO JOURNAL OF TELEMEDICINE AND TELECARE
LA English
DT Article
DE COVID-19; age-related macular degeneration; retinal disease;
   telemedicine; teleophthalmology; retinal specialist; coronavirus
ID VISUAL OUTCOMES; RANIBIZUMAB; DISEASE; DELAY; DIAGNOSIS; PROGRESS;
   SYSTEM; ACUITY; TRIAL; STATE
AB Introduction COVID-19 has disrupted how ophthalmic practice is conducted worldwide. One patient population that may suffer from poor outcomes during the pandemic are those with age-related macular degeneration (AMD). Many practices are performing some form of teleophthalmology services for their patients, and guidance is needed on how to maintain continuity of care amongst patients with AMD using teleophthalmology. Methods A literature search was conducted, ending 1 August 2020, to identify AMD outcomes and telecare management strategies that could be used during the COVID-19 pandemic Results 237 total articles were retrieved, 56 of which were included for analysis. Four American Academy of Ophthalmology and Center for Disease Control web resources were also included. Discussion Risk-stratification models have been developed that let providers readily screen existing patients for their future risk of neovascular AMD (nAMD). When used with at-home monitoring devices to detect nAMD, providers may be able to determine who should be contacted via teleophthalmology for screening. Telemedicine triage can be used for new complaints of vision loss to determine who should be referred to a retinal specialist for management of suspected nAMD. To increase access and provider flexibility, smartphone fundus photography images sent to a centralized teleophthalmology service can aid in the detection of nAMD. Considerations should also be made for COVID-19 transmission, and teleophthalmology can be used to screen patients for the presence of COVID-19 prior to in-person office visits. Teleophthalmology has additional utility in connecting with nursing home, rural, and socioeconomically disadvantaged patients in the post-pandemic period.
C1 [Mintz, Joel; Labiste, Chase; McElroy, Evan] Nova Southeastern Univ, Dr Kiran C Patel Coll Allopath Med, 3200 S Univ Dr, Davie, FL 33328 USA.
   [DiCaro, Michael, V] Univ Arizona, Coll Med, Tucson, AZ USA.
   [Alizadeh, Reza; Xu, Kunyong] Univ Arizona, Dept Ophthalmol, Tucson, AZ USA.
C3 Nova Southeastern University; University of Arizona; University of
   Arizona
RP Mintz, J (通讯作者)，Nova Southeastern Univ, Dr Kiran C Patel Coll Allopath Med, 3200 S Univ Dr, Davie, FL 33328 USA.
EM jm4719@mynsu.nova.edu
RI Alizadeh, Reza/AGY-1911-2022
OI Alizadeh, Reza/0000-0003-2414-0764; Mintz, Joel/0000-0002-8121-1736
CR AAO, 2020, IMP COR UPD OPHTH
   Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2018, SMARTPH FUND HOW US
   Bhuiyan A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.25
   Bifolck E, 2018, JAAPA-J AM ACAD PHYS, V31, P34, DOI 10.1097/01.JAA.0000541482.54611.7c
   CDC, 2020, COR DIS 2019 COVID 1
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Coding for Phone Calls Internet and Telehealth Consultations, 2020, COD PHON CALLS INT T
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Forrester JD, 2020, J AM COLL SURGEONS, V230, P1098, DOI 10.1016/j.jamcollsurg.2020.03.030
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Hessellund A, 2012, ACTA OPHTHALMOL, V90, P471, DOI 10.1111/j.1755-3768.2010.02074.x
   Hu K., 2020, OPHTHALMIC MANIFESTA
   Huang JJ, 2011, J GLAUCOMA, V20, P118, DOI 10.1097/IJG.0b013e3181d786f8
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Keane PA, 2014, OPHTHALMOLOGY, V121, P2489, DOI 10.1016/j.ophtha.2014.07.054
   Khachfe HH, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.7313
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Li B, 2015, JAMA OPHTHALMOL, V133, P276, DOI 10.1001/jamaophthalmol.2014.5014
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lord RK, 2010, OPHTHALMOLOGY, V117, P1274, DOI 10.1016/j.ophtha.2010.01.001
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mathew R, 2012, EYE, V26, P389, DOI 10.1038/eye.2011.326
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Parke DW, 2020, JAMA OPHTHALMOL, V138, P599, DOI 10.1001/jamaophthalmol.2020.2004
   Patel ZM, 2020, NEUROSURGERY, V87, pE66, DOI 10.1093/neuros/nyaa125
   Rajalakshmi R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138285
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rathi S, 2017, OPHTHALMOLOGY, V124, P1729, DOI 10.1016/j.ophtha.2017.05.026
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sim PY, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017771
   Singh N, 2017, ASIA-PAC J OPHTHALMO, V6, P520, DOI 10.22608/APO.2017416
   Siu AL, 2016, JAMA-J AM MED ASSOC, V315, P908, DOI 10.1001/jama.2016.0763
   Suto S, 2014, RETINA-J RET VIT DIS, V34, P203, DOI 10.1097/IAE.0000000000000041
   Takahashi H, 2015, RETINA-J RET VIT DIS, V35, P1331, DOI 10.1097/IAE.0000000000000513
   Thornton J, 2020, BMJ, DOI DOI 10.1136/BMJ.M1401
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Toy BC, 2016, RETINA-J RET VIT DIS, V36, P1000, DOI 10.1097/IAE.0000000000000955
   Trevino R, 2008, OPHTHAL PHYSL OPT, V28, P183, DOI 10.1111/j.1475-1313.2008.00561.x
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wilson C, 2005, DIABETES CARE, V28, P318, DOI 10.2337/diacare.28.2.318
   Wintergerst MWM, 2018, OPHTHALMOLOGE, V115, P1035, DOI 10.1007/s00347-017-0610-z
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 60
TC 7
Z9 7
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1357-633X
EI 1758-1109
J9 J TELEMED TELECARE
JI J. Telemed. Telecare
PD OCT
PY 2022
VL 28
IS 9
BP 670
EP 679
AR 1357633X20960636
DI 10.1177/1357633X20960636
EA SEP 2020
PG 10
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA 4H4GA
UT WOS:000575154700001
PM 32990152
OA Green Published
DA 2022-11-30
ER

PT J
AU Wagner, BD
   Patnaik, JL
   Palestine, AG
   Frazer-Abel, AA
   Baldermann, R
   Holers, VM
   Mathias, MT
   Mandava, N
   Lynch, AM
AF Wagner, Brandie D.
   Patnaik, Jennifer L.
   Palestine, Alan G.
   Frazer-Abel, Ashley A.
   Baldermann, Rebecca
   Holers, V. Michael
   Mathias, Marc T.
   Mandava, Naresh
   Lynch, Anne M.
TI Association of Systemic Inflammatory Factors with Progression to
   Advanced Age-related Macular Degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Systems-based analysis; classical and alternative complement pathways;
   reticular pseudodrusen; chronic inflammation
AB Purpose Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly. The role of systemic inflammation in AMD remains unclear specifically in patients with intermediate AMD (iAMD). We sought to determine whether systemic inflammation was associated with future iAMD progression.
   Methods Combinations of 27 circulating inflammatory markers including complement factors, cytokines, chemokines, and high-sensitivity C-reactive protein (hsCRP) were evaluated in iAMD patients recruited into a Colorado AMD registry. Systemic inflammatory markers were combined using principal component analysis. Risk factors for AMD progression were evaluated using Cox regression models.
   Results This study included 99 subjects with iAMD, 21 of which progressed to advanced AMD. Two principal components (PCs) were identified that contributed to the risk of progression to advanced AMD, after adjusting for age and bilateral reticular pseudodrusen. The strongest associated PC was explained largely by the pro-inflammatory cytokine TNF alpha and the anti-inflammatory IL1ra antagonist of IL1. The additional PC was largely explained by IL6, IL8, C3 and factor D in the positive direction and CRP, MCP1, factor B and factor I in the negative direction.
   Conclusion When evaluated through multivariate analyses, combinations of biomarkers distinguished patients who did and did not progress to future advanced AMD. Increased risk could result from different combinations of analyte levels indicating a complex relationship rather than a simple increase in a few markers. This suggests that studying systemic inflammation in iAMD can provide insights into early pathologic events and potentially identify patients at highest risk for the development of severe AMD.
C1 [Wagner, Brandie D.] Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA.
   [Wagner, Brandie D.; Patnaik, Jennifer L.; Palestine, Alan G.; Mathias, Marc T.; Mandava, Naresh; Lynch, Anne M.] Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA.
   [Frazer-Abel, Ashley A.] Univ Colorado, Sch Med, Exsera BioLabs, Aurora, CO USA.
   [Baldermann, Rebecca] Univ Colorado, Colorado Clin & Translat Sci Inst, Anschutz Med Campus, Aurora, CO USA.
   [Holers, V. Michael] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA.
   [Holers, V. Michael] Univ Colorado, Sch Med, Dept Immunol, Aurora, CO USA.
C3 Colorado School of Public Health; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   System; University of Colorado Anschutz Medical Campus; University of
   Colorado System; University of Colorado Anschutz Medical Campus;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus; University of Colorado System; University of Colorado
   Anschutz Medical Campus
RP Wagner, BD (通讯作者)，Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO 80045 USA.
EM brandie.wagner@cuanschutz.edu
FU Macula Society; Regeneron; NIH/NCATS Colorado CTSA [UL1 TR002535];
   Research to Prevent Blindness, Inc.; Frederic C. Hamilton Macular
   Degeneration Center
FX This work was supported by a Macula Society Research Grant supported by
   Regeneron (2018), a Challenge Grant to the Department of Ophthalmology
   from Research to Prevent Blindness, Inc., and the Frederic C. Hamilton
   Macular Degeneration Center. Supported by NIH/NCATS Colorado CTSA Grant
   Number UL1 TR002535. Contents are the authors' sole responsibility and
   do not necessarily represent official NIH views.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bandeen-Roche K, 2009, REJUV RES, V12, P403, DOI 10.1089/rej.2009.0883
   Bjornstad P, 2018, NEPHROL DIAL TRANSPL, V33, P1189, DOI 10.1093/ndt/gfx255
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chew EY, 2020, OPHTHALMOLOGY, V127, pS120, DOI 10.1016/j.ophtha.2019.12.028
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   COX DR, 1972, J R STAT SOC B, V34, P187
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Holers VM, 2014, ANNU REV IMMUNOL, V32, P433, DOI 10.1146/annurev-immunol-032713-120154
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Janeway CA, 2005, IMMUNOBIOLOGY
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Lynch AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.12
   Lynch AM, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000361
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Lynch AM, 2019, RETINA-J RET VIT DIS, V39, P656, DOI 10.1097/IAE.0000000000002023
   Lynch AM, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.14
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Morrisette-Thomas V, 2014, MECH AGEING DEV, V139, P49, DOI 10.1016/j.mad.2014.06.005
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   SIVAPRASAD S, 2007, ARCH OPHTHALMOL-CHIC, V125
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 50
TC 6
Z9 6
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD MAR 4
PY 2022
VL 29
IS 2
BP 139
EP 148
DI 10.1080/09286586.2021.1910314
EA APR 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0U4EZ
UT WOS:000638152500001
PM 33827374
DA 2022-11-30
ER

PT J
AU Chaudhary, V
   Barbosa, J
   Lam, WC
   Mak, M
   Mavrikakis, E
   Mohaghegh, PSM
AF Chaudhary, Varun
   Barbosa, Joshua
   Lam, Wai-Ching
   Mak, Michael
   Mavrikakis, Emmanouil
   Mohaghegh, S. Mohammad P.
TI Ozurdex in age-related macular degeneration as adjunct to ranibizumab
   (The OARA Study)
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID THERAPY
AB Objective: To evaluate the utility of dexamethasone intravitreal implant (DXI; Ozurdex; Allergan, Irvine, Calif.) in combination with ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) versus ranibizumab monotherapy on visual acuity (VA) and anatomical outcomes in a neovascular age-related macular degeneration (nAMD) cohort.
   Design: Multicentred, single-blinded, pilot randomized control trial.
   Participants: Ten patients 50 years or older with subfoveal choroidal neovascularization secondary to AMD were randomized to receive DXI in combination with ranibizumab (group 1) or ranibizumab alone (group 2) after a 3-month ranibizumab loading period.
   Methods: Group 1 patients received 1 DXI after the loading phase with the option of retreatment at months 4 to 6. Ranibizumab was administered pro re nata for 6 months in both study arms. Mean VA and central macular thickness (CMT) reductions from baseline to study endpoint (9 months) were reported in addition to adverse event frequency across study cohorts.
   Results: From baseline to the study endpoint, VA improved by 10.8 +/- 13.2 Early Treatment of Diabetic Retinopathy Study letters in the control arm and 3.0 +/- 10.5 letters in the intervention arm (p = 0.331). CMT decreased by 31.7% +/- 17.5% and 13.3% +/- 27.0% (p = 0.236) for the control and intervention cohorts, respectively. One patient developed intraocular pressure in excess of 30 mm Hg 3 months after DXI administration.
   Conclusions: For this nAMD population, no visual or anatomical benefits were observed when treating with DXI in adjunct to ranibizumab relative to ranibizumab monotherapy. DXI-related adverse events were consistent with those previously documented for dexamethasone.
C1 [Chaudhary, Varun; Barbosa, Joshua; Mohaghegh, S. Mohammad P.] McMaster Univ, Dept Surg, St Josephs Healthcare Hamilton, Hamilton Reg Eye Inst,Eye Res Unit, Hamilton, ON, Canada.
   [Lam, Wai-Ching; Mak, Michael] Univ Toronto, Toronto Western Hosp, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Mavrikakis, Emmanouil] Gen Hosp Athens G Gennimatas, Athens, Greece.
C3 McMaster University; University of Toronto; University Toronto
   Affiliates; University Health Network Toronto
RP Chaudhary, V (通讯作者)，Hamilton Reg Eye Inst, Dept Surg, Div Ophthalmol, 2757 King St East, Hamilton, ON L8G 5E4, Canada.
EM surghrs@mcmaster.ca
RI Chaudhary, Varun/AAQ-2371-2021
OI Chaudhary, Varun/0000-0002-9988-4146; Mohaghegh P, S
   Mohammad/0000-0001-6455-5775; Lam, Wai-Ching/0000-0003-2057-9374
FU Allergan
FX Funding for this study was obtained from Allergan. The funding
   organization had no role in the design or conduct of this research.
   Ethics approval was obtained from the Hamilton Integrated Research
   Ethics Board (Reference No.:10-3388) and the University Health Network
   Research Ethics Board (Reference No.:10-0605-A). This trial was
   registered on clinicaltrials.gov under the identifier NCT01243086.
CR Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
NR 6
TC 16
Z9 17
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2016
VL 51
IS 4
BP 302
EP 305
DI 10.1016/j.jcjo.2016.04.020
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT6GQ
UT WOS:000381582500023
PM 27521672
DA 2022-11-30
ER

PT J
AU Hirai, H
   Yamashita, M
   Matsumoto, M
   Hayakawa, M
   Sakai, K
   Ueda, T
   Ogata, N
AF Hirai, Hiromasa
   Yamashita, Mariko
   Matsumoto, Masanori
   Hayakawa, Masaki
   Sakai, Kazuya
   Ueda, Tetsuo
   Ogata, Nahoko
TI Analysis focusing on plasma von Willebrand factor in pachychoroid
   neovasculopathy and age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMPLEMENT FACTOR-H; ENDOTHELIAL-GROWTH-FACTOR; FACTOR MULTIMERS;
   VONWILLEBRAND-FACTOR; BLOOD-GROUP; PLATELETS; AMD
AB Pachychoroid neovasculopathy (PNV) is a new concept of macular disorder. Some cases diagnosed as age-related macular degeneration (AMD) have been re-diagnosed as PNV. However, the biological features of PNV are still uncertain. The purpose of this study was to compare PNV and AMD by analyses focusing on von Willebrand factor (VWF) and complement factor H (CFH). Ninety-seven patients who were previously diagnosed with treatment naive AMD were enrolled in this study. They were re-classified as either PNV or AMD based on the clinical criteria and 33 patients were classified as PNV and 64 patients as AMD. We examined the clinical data, analyzed VWF multimer and two genetic polymorphisms (I62V and Y402H) in the CFH. PNV group was significantly younger than AMD group (P = 0.001). In both I62V and Y402H, there were no significant differences between PNV and AMD while the recessive homozygous (AA) was found only in PNV group in I62V. The presence of unusually large VWF multimers (UL-VWFMs) and subretinal hemorrhages were significantly higher in PNV than in AMD (P = 0.045, P = 0.020, respectively). Thus, the residual UL-VWFMs may result in platelet thrombosis and hemorrhages in the choriocapillaris of PNV. In conclusion, our results suggest the biological differences between PNV and AMD.
C1 [Hirai, Hiromasa; Ueda, Tetsuo; Ogata, Nahoko] Nara Med Univ, Dept Ophthalmol, 840 Shijo Cho, Kashihara, Nara, Japan.
   [Yamashita, Mariko] Nara City Hosp, Dept Ophthalmol, 1-50-1 Higashikidera Cho, Nara, Japan.
   [Matsumoto, Masanori; Hayakawa, Masaki; Sakai, Kazuya] Nara Med Univ, Dept Blood Transfus Med, 840 Shijo Cho, Kashihara, Nara, Japan.
C3 Nara Medical University; Nara Medical University
RP Ogata, N (通讯作者)，Nara Med Univ, Dept Ophthalmol, 840 Shijo Cho, Kashihara, Nara, Japan.
EM ogata@naramed-u.ac.jp
RI Sakai, Kazuya/M-6602-2019
OI Sakai, Kazuya/0000-0003-0523-7931; Hirai, Hiromasa/0000-0002-7607-0975
CR Baek J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42052-w
   Bicer O, 2020, OSLI RETINA, V51, P640, DOI 10.3928/23258160-20201104-06
   Bowen DJ, 2003, J THROMB HAEMOST, V1, P33, DOI 10.1046/j.1538-7836.2003.00007.x
   Buchtele N, 2018, THROMB HAEMOSTASIS, V118, P959, DOI 10.1055/s-0038-1648251
   BUDDE U, 1990, THROMB HAEMOSTASIS, V63, P312
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Crawley JTB, 2011, BLOOD, V118, P3212, DOI 10.1182/blood-2011-02-306597
   Feng SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073715
   Gallinaro L, 2008, BLOOD, V111, P3540, DOI 10.1182/blood-2007-11-122945
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hosoda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75451-5
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kato S, 2006, TRANSFUSION, V46, P1444, DOI 10.1111/j.1537-2995.2006.00914.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kroll MH, 1996, BLOOD, V88, P1525
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Malukiewicz-Wisniewska Grazyna, 2005, Klin Oczna, V107, P70
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Matsumoto M, 2005, PATHOPHYSIOL HAEMO T, V34, P35, DOI 10.1159/000088546
   Matsushita K, 2005, BLOOD, V105, P207, DOI 10.1182/blood-2004-04-1519
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657
   Nagai N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47738-9
   Nolasco L, 2013, ARTERIOSCL THROM VAS, V33, P2524, DOI 10.1161/ATVBAHA.113.302280
   Ohkuma Y, 2014, CLIN OPHTHALMOL, V8, P143, DOI 10.2147/OPTH.S56483
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rayes J, 2014, BLOOD, V123, P121, DOI 10.1182/blood-2013-04-495853
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tagawa M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73303-w
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Wang ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088324
   Warren CM, 2003, ELECTROPHORESIS, V24, P1695, DOI 10.1002/elps.200305392
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yamashita M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19473-0
   Yoshikawa T, 2019, THROMB RES, V183, P20, DOI 10.1016/j.thromres.2019.09.005
NR 40
TC 0
Z9 0
U1 2
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 7
PY 2021
VL 11
IS 1
AR 19987
DI 10.1038/s41598-021-99557-6
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WF5XG
UT WOS:000706376200058
PM 34620972
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Bashshur, ZF
   Bazarbachi, A
   Schakal, A
   Haddad, ZA
   El Haibi, CP
   Noureddin, BN
AF Bashshur, Ziad F.
   Bazarbachi, Ali
   Schakal, Alexandre
   Haddad, Zeina A.
   El Haibi, Christelle P.
   Noureddin, Baha' N.
TI Intravitreal bevacizumab for the management of choroidal
   neovascularization in age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ANTIBODY; PHARMACOKINETICS; INHIBITION;
   THERAPY; SAFETY; FAB
AB PURPOSE: To investigate the efficacy and safety of intravitreal bevacizumab for managing choroidal neovascularization (CNV) due to age,related macular degeneration (AMD).
   DESIGN: Prospective interventional case series.
   METHODS: Seventeen eyes of 17 patients with subfoveal CNV due to AMD participated in this study at the American University of Beirut Ophthalmology Clinics. All patients had failed, refused, or were not eligible for photodynamic therapy. All eyes received a baseline eye examination, which included best-corrected visual acuity (BCVA), dilated fundus examination, ocular coherence tomography (OCT) imaging, and fluorescein angiography. An intravitreal injection of bevacizumab (2.5 mg/0.1 ml) was given at baseline and followed by two additional injections at four-week intervals. BCVA, OCT, and fluorescein angiography were repeated four weeks after each injection. Main outcome measures were improvement in BCVA and central retinal thickness (CRT).
   RESULTS: Mean baseline BCVA was 20/252 (median 20/200), and baseline CRT was 362 mu m (median 350 mu m). Improvement in VA and CRT occurred by the fourth week. At 12 weeks, mean BCVA was 20/76 (P < .001) and median BCVA was 20/50 (P < .001). Both mean and median CRT decreased to 211 mu m (P < .001). Thirteen (76%) of 17 eyes had total resolution of subretinal fluid, and four eyes (24%) had BCVA better than 20/50. No systemic or ocular side effects were noted at any time.
   CONCLUSION: Eyes with CNV due to AMD treated with intravitreal bevacizumab had marked anatomic and visual improvement. Further studies are necessary to confirm the long,term efficacy and safety of this treatment.
C1 Amer Univ Beirut, Med Ctr, Dept Ophthalmol, Beirut, Lebanon.
   Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon.
   St Joseph Univ, Hotel Dieu, Dept Ophthalmol, Beirut, Lebanon.
C3 American University of Beirut; American University of Beirut; American
   University of Beirut
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 11-0236,B11, Beirut, Lebanon.
EM zb00@aub.edu.lb
OI Bazarbachi, Ali/0000-0002-7171-4997
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   EUGENE WM, 2005, CAN J OPHTHALMOL, V40, P352
   Fernando NH, 2003, SEMIN ONCOL, V30, P39, DOI 10.1016/S0093-7754(03)00124-6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101
   Mulcahy MF, 2005, EXPERT OPIN BIOL TH, V5, P997, DOI 10.1517/14712598.5.7.997
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   *US PHARM, US PHARM
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
NR 24
TC 255
Z9 275
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2006
VL 142
IS 1
BP 1
EP 9
DI 10.1016/j.ajo.2006.02.037
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064HF
UT WOS:000239079100001
PM 16815245
DA 2022-11-30
ER

PT J
AU Dugel, PU
   Koh, A
   Ogura, Y
   Jaffe, GJ
   Schmidt-Erfurth, U
   Brown, DM
   Gomes, AV
   Warburton, J
   Weichselberger, A
   Holz, FG
AF Dugel, Pravin U.
   Koh, Adrian
   Ogura, Yuichiro
   Jaffe, Glenn J.
   Schmidt-Erfurth, Ursula
   Brown, David M.
   Gomes, Andre, V
   Warburton, James
   Weichselberger, Andreas
   Holz, Frank G.
CA HAWK & HARRIER Study Investigators
TI HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials
   of Brolucizumab for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY LOSS; TREAT-AND-EXTEND; INTRAVITREAL RANIBIZUMAB;
   AFLIBERCEPT; BEVACIZUMAB; MANAGEMENT; OUTCOMES; THERAPY; SAFETY
AB Purpose: Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (nAMD).
   Design: Double-masked, multicenter, active-controlled, randomized trials.
   Participants: Patients (N = 1817) with untreated, active choroidal neovascularization due to age-related macular degeneration in the study eye.
   Intervention: Patients were randomized to intravitreal brolucizumab 3 mg (HAWK only) or 6 mg or aflibercept 2 mg. After loading with 3 monthly injections, brolucizumab-treated eyes received an injection every 12 weeks (q12w) and were interval adjusted to every 8 weeks (q8w) if disease activity was present; aflibercept-treated eyes received q8w dosing.
   Main Outcome Measures: The primary hypothesis was noninferiority in mean best-corrected visual acuity (BCVA) change from baseline to Week 48 (margin: 4 letters). Other key end points included the percentage of patients who maintained q12w dosing through Week 48 and anatomic outcomes.
   Results: At Week 48, each brolucizumab arm demonstrated noninferiority to aflibercept in BCVA change from baseline (least squares [LS] mean, +6.6 [6 mg] and +6.1 [3 mg] letters with brolucizumab vs. +6.8 letters with aflibercept [HAWK]; +6.9 [brolucizumab 6 mg] vs. +7.6 [aflibercept] letters [HARRIER]; P < 0.001 for each comparison). Greater than 50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing through Week 48 (56% [HAWK] and 51 % [HARRIER]). At Week 16, after identical treatment exposure, fewer brolucizumab 6 mg-treated eyes had disease activity versus aflibercept in HAWK (24.0% vs. 34.5%; P = 0.001) and HARRIER (22.7% vs. 32.2%; P = 0.002). Greater central subfield thickness reductions from baseline to Week 48 were observed with brolucizumab 6 mg versus aflibercept in HAWK (LS mean -172.8 mu m vs. -143.7 mu m; P = 0.001) and HARRIER (LS mean -193.8 mu m vs. -143.9 mu m; P < 0.001). Anatomic retinal fluid outcomes favored brolucizumab over aflibercept. Overall, adverse event rates were generally similar with brolucizumab and aflibercept.
   Conclusions: Brolucizumab was noninferior to aflibercept in visual function at Week 48, and >50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing interval through Week 48. Anatomic outcomes favored brolucizumab over aflibercept. Overall safety with brolucizumab was similar to aflibercept (C) 2019 by the American Academy of Ophthalmology.
C1 [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Dugel, Pravin U.] Univ Southern Calif, Los Angeles, CA 90007 USA.
   [Koh, Adrian] Eye & Retina Surg, Singapore, Singapore.
   [Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Jaffe, Glenn J.] Duke Eye Ctr, Durham, NC USA.
   [Schmidt-Erfurth, Ursula] Med Univ Vienna, Vienna, Austria.
   [Brown, David M.] Retina Consultants Houston, Houston, TX USA.
   [Gomes, Andre, V] Univ Sao Paulo, Sao Paulo, SP, Brazil.
   [Warburton, James; Weichselberger, Andreas] Novartis Pharma AG, Basel, Switzerland.
   [Holz, Frank G.] Univ Bonn, Bonn, Germany.
C3 University of Southern California; Nagoya City University; Duke
   University; Medical University of Vienna; Universidade de Sao Paulo;
   Novartis; University of Bonn
RP Dugel, PU (通讯作者)，Univ Southern Calif, Keck Sch Med, Retinal Consultants Arizona, Roski Eye Inst, Los Angeles, CA 90033 USA.
EM pdugel@gmail.com
RI Hunter, Allan/AAJ-5848-2020
OI Valverde-Megias, Alicia/0000-0002-6166-114X
FU Novartis Pharma AG
FX The authors thank Aaron Runkle, PhD, and Joelle Suchy, PhD (Nucleus
   Global, Hamilton, NJ), for assistance with medical writing (funded by
   Novartis Pharma AG).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   American Academy of Ophthalmology, AG REL MAC DEG PREF
   [Anonymous], 2017, EYLEA AFL INJ
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro P A, 1999, Mol Vis, V5, P34
   CHONG V, 2013, INVEST OPHTH VIS SCI, V54
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Ehlken C, 2017, CLIN OPHTHALMOL, P1213
   ELDEM MB, 2009, INVEST OPHTH VIS SCI, V50, P2374
   Escher D, 2015, 15 EURETINA C SEPT 1
   European Medicines Agency, 2012, EYLEA AFL ASS REP
   EYLEA (aflibercept), 2014, INJ PACK INS
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Kim BJ, 2014, AM J OPHTHALMOL, V158, P128, DOI 10.1016/j.ajo.2014.04.004
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kiss S, 2014, OSLI RETINA, V45, P285, DOI 10.3928/23258160-20140709-04
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller BR, 2010, PROTEIN ENG DES SEL, V23, P549, DOI 10.1093/protein/gzq028
   Nelson AL, 2010, MABS-AUSTIN, V2, P77, DOI 10.4161/mabs.2.1.10786
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   TBC, BROL UN SINGL CHAIN
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 44
TC 305
Z9 312
U1 4
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2020
VL 127
IS 1
BP 72
EP 84
DI 10.1016/j.ophtha.2019.04.017
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JW7JM
UT WOS:000503224300022
PM 30986442
OA hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Kim, HJ
   Woo, SJ
   Suh, EJ
   Ahn, J
   Park, JH
   Hong, HK
   Lee, JE
   Ahn, SJ
   Hwang, DJ
   Kim, KW
   Park, KH
   Lee, C
AF Kim, Hye-Jung
   Woo, Se Joon
   Suh, Eui Jin
   Ahn, Jeeyun
   Park, Ji Hyun
   Hong, Hye Kyoung
   Lee, Ji Eun
   Ahn, Seong Joon
   Hwang, Duck Jin
   Kim, Ki Woong
   Park, Kyu Hyung
   Lee, Cheolju
TI Identification of Vinculin as a Potential Plasma Marker for Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE plasma marker; vinculin; age-related macular degeneration; 4-dimensional
   protein profiling; proteomics
ID RETINAL-PIGMENT EPITHELIUM; PROTEOME-PROJECT; PROTEINS; COMPLEX; S100A9;
   PATHOGENESIS; PREVALENCE; EXPRESSION; BIOMARKERS; CANCER
AB PURPOSE. To identify plasma protein biomarkers for age-related macular degeneration (AMD) using a large-scale quantitative proteomic discovery procedure.
   METHODS. Plasma proteomes from 20 exudative AMD patients and 20 healthy control patients were comparatively profiled by four-dimensional liquid chromatography-tandem mass spectrometry (LC-MS/MS). Proteins existing at statistically different levels were validated by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 233 case-controlled samples. Newly discovered plasma biomarkers were further confirmed using in vivo and in vitro experiments.
   RESULTS. Out of 320 proteins identified, vinculin, protein S100A9, triosephosphate isomerase, protein S100A8, protein Z-dependent protease inhibitor, C-X-C motif chemokine 7, and tenascin X showed significantly differential expression in AMD patient plasma compared to control plasma. Among these, the area under the curve (AUC) for vinculin was 0.871 for discriminating between exudative AMD and controls (n = 201) and 0.879 for discriminating between AMD and controls (n = 233). A proteogenomic combination model using vinculin and two known risk genotypes in ARMS2 and CFH genes additionally provided excellent discrimination of AMD from controls (AUC = 0.916). The plasma level of vinculin was not associated with any confounding clinical variables, such as age, smoking, and other comorbidities. Additionally, vinculin was strongly expressed in retinal pigment epithelial cells of human eyes, and its expression was elevated when exposed to oxidative stress in vitro.
   CONCLUSIONS. Vinculin was identified as a potential plasma biomarker for AMD. The early detection of AMD using novel plasma biomarkers with genetic modeling may enable timely treatment and vision preservation in the elderly.
C1 [Kim, Hye-Jung; Suh, Eui Jin; Lee, Ji Eun; Lee, Cheolju] Korea Inst Sci & Technol, Theragnosis Res Ctr, Seoul, South Korea.
   [Woo, Se Joon; Ahn, Jeeyun; Park, Ji Hyun; Hong, Hye Kyoung; Ahn, Seong Joon; Hwang, Duck Jin; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Songnam 463707, Gyeonggi Do, South Korea.
   [Ahn, Jeeyun] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Ophthalmol, Seoul, South Korea.
   [Hwang, Duck Jin] HanGil Eye Hosp, Dept Ophthalmol, Inchon, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Bundang Hosp, Dept Neuropsychiat, Songnam 463707, Gyeonggi Do, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Dept Psychiat, Coll Med, Seoul, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Coll Nat Sci, Dept Brain & Cognit Sci, Seoul 151742, South Korea.
   [Lee, Cheolju] Univ Sci & Technol, Dept Biol Chem, Taejon, South Korea.
C3 Korea Institute of Science & Technology (KIST); Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University Hospital; Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University (SNU)
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, 300 Gumi Dong, Songnam 463707, Gyeonggi Do, South Korea.
EM sejoon1@snu.ac.kr; jiani4@snu.ac.kr; clee270@kist.re.kr
OI Ahn, Jeeyun/0000-0001-9017-1652; Hwang, Daniel
   Duck-Jin/0000-0003-1808-3169
FU Korea Health Technology R&D Project, Ministry of Health Welfare, Korea
   [A111161, A092077]; Joint Research Project, Korea Research Council of
   Fundamental Science and Technology, Korea
FX Supported by grants from the Korea Health Technology R&D Project,
   Ministry of Health & Welfare, Korea (A111161 and A092077), and the Joint
   Research Project, Korea Research Council of Fundamental Science and
   Technology, Korea. The authors alone are responsible for the content and
   writing of the paper.
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goldmann WH, 2013, CELL BIOL INT, V37, P397, DOI 10.1002/cbin.10064
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197
   Huveneers S, 2012, J CELL BIOL, V196, P641, DOI 10.1083/jcb.201108120
   Itou H, 2001, ACTA CRYSTALLOGR D, V57, P1174, DOI 10.1107/S090744490100957X
   Jhoo JH, 2008, DEMENT GERIATR COGN, V26, P270, DOI 10.1159/000160960
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kim HJ, 2012, J PROTEOMICS, V75, P2983, DOI 10.1016/j.jprot.2011.12.002
   Kim HJ, 2009, J PROTEOME RES, V8, P1368, DOI 10.1021/pr8007573
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Leanderson T, 2012, ONCOIMMUNOLOGY, V1, P1404, DOI 10.4161/onci.21027
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Omenn GS, 2005, PROTEOMICS, V5, P3226, DOI 10.1002/pmic.200500358
   Rai AJ, 2005, PROTEOMICS, V5, P3262, DOI 10.1002/pmic.200401245
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   States DJ, 2006, NAT BIOTECHNOL, V24, P333, DOI 10.1038/nbt1183
   STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348
   Suh EJ, 2012, EXP MOL MED, V44, P36, DOI 10.3858/emm.2012.44.1.003
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Ziegler WH, 2008, BIOCHEM SOC T, V36, P235, DOI 10.1042/BST0360235
NR 32
TC 16
Z9 19
U1 1
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2014
VL 55
IS 11
BP 7166
EP 7176
DI 10.1167/iovs.14-15168
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX9IR
UT WOS:000347217300018
PM 25298412
DA 2022-11-30
ER

PT J
AU Troutbeck, R
   Bunting, R
   van Heerdon, A
   Cain, M
   Guymer, R
AF Troutbeck, Robyn
   Bunting, Roland
   van Heerdon, Anton
   Cain, Melinda
   Guymer, Robyn
TI Ranibizumab therapy for choroidal neovascularization secondary to
   non-age-related macular degeneration causes
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascular membrane; multifocal choroiditis; myopia;
   ranibizumab
ID RANDOMIZED CLINICAL-TRIAL; INTRAVITREAL BEVACIZUMAB; VERTEPORFIN;
   MACULOPATHY; MYOPIA; INJECTION
AB Background: To investigate the efficacy of ranibizumab therapy for choroidal neovascular (CNV) membranes secondary to conditions other than macular degeneration.
   Design: Prospective case series conducted at the Royal Victorian Eye and Ear Hospital.
   Participants: Twelve-month follow-up data for 41 patients with CNV recruited from the outpatient clinic from May 2008 to April 2010 is presented. Fifteen patients had myopia, seven had multifocal choroiditis, and eight had other primary causes.
   Methods: All patients had visual acuity, fluorescein angiogram and optical coherence tomography performed at the initial visit (baseline). Ranibizumab was injected with a standard sterile technique. Patients were reviewed after 1 month, and further injections were given at the treating doctors' discretion.
   Main Outcome Measures: Change in visual acuity and central macular thickness at 12 months was compared with baseline for each of the groups. Local and systemic adverse outcomes were recorded.
   Results: Analysis was stratified by primary pathology. On average, 40%, 43% and 25% of patients with myopia, multifocal choroiditis and 'other' pathologies, respectively, experienced a three or more line improvement in vision. The average number of injections in 12 months was 4.2 for the entire group. Central macular thickness significantly decreased in the 12-month period for the combined group (P = 0.03). No patient had an adverse systemic side-effect; however, there was one case of endophthalmitis.
   Conclusions: Ranibizumab is an effective treatment for CNV secondary to non-age-related macular degeneration causes, with most patients gaining an improvement in the first 2 months following injection.
C1 [Troutbeck, Robyn; Bunting, Roland; van Heerdon, Anton; Cain, Melinda; Guymer, Robyn] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Guymer, R (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356
CR [Anonymous], 2010, R LANG ENV STAT COMP
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang LK, 2008, ARCH OPHTHALMOL-CHIC, V126, P941, DOI 10.1001/archopht.126.7.941
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gupta B, 2010, EYE, V24, P203, DOI 10.1038/eye.2009.201
   HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heier JS, 2011, OPHTHALMOLOGY, V118, P111, DOI 10.1016/j.ophtha.2010.04.016
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   Lee YA, 2009, EYE, V23, P645, DOI 10.1038/eye.2008.17
   Mansour AM, 2008, AM J OPHTHALMOL, V146, P410, DOI 10.1016/j.ajo.2008.05.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2009, BRIT J OPHTHALMOL, V93, P448, DOI 10.1136/bjo.2008.145391
   Ruiz-Oliva F, 2002, OPHTHALMOLOGY, V109, P1043, DOI 10.1016/S0161-6420(02)00972-7
   Sawa M, 2009, AM J OPHTHALMOL, V148, P584, DOI 10.1016/j.ajo.2009.04.026
   Spaide R F, 1999, Curr Opin Ophthalmol, V10, P177, DOI 10.1097/00055735-199906000-00005
   Tabandeh H, 1999, OPHTHALMOLOGY, V106, P2063, DOI 10.1016/S0161-6420(99)90484-0
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 23
TC 11
Z9 12
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD FEB
PY 2012
VL 40
IS 1
BP 67
EP 72
DI 10.1111/j.1442-9071.2011.02719.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 888JW
UT WOS:000300000800030
PM 22004186
OA Bronze
DA 2022-11-30
ER

PT J
AU Comer, GM
   Ciulla, TA
   Criswell, MH
   Tolentino, M
AF Comer, GM
   Ciulla, TA
   Criswell, MH
   Tolentino, M
TI Current and future treatment options for nonexudative and exudative
   age-related macular degeneration
SO DRUGS & AGING
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR;
   INTRAVITREAL TRIAMCINOLONE ACETONIDE; RETINAL-PIGMENT EPITHELIUM;
   EXPERIMENTAL SUBRETINAL NEOVASCULARIZATION; SUSTAINED-RELEASE
   TRIAMCINOLONE; RANDOMIZED CLINICAL-TRIAL; EXTERNAL-BEAM RADIATION;
   PHOTODYNAMIC THERAPY; TRANSPUPILLARY THERMOTHERAPY
AB Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the industrialised world. Although relatively simple to diagnose through direct visualisation augmented with rapid sequence fluorescein angiography, treatment has presented a far greater challenge because the true aetiology of AMD is largely unknown. Within the past decade, researchers have introduced many new, potentially promising treatment and prevention options in an attempt to minimise the damage imparted from AMD. They capitalise on many of the theoretical and known factors contributing to AMD progression. A high-dose of an orally administered combination of the antioxidants ascorbic acid (vitamin Q, tocopherol (vitamin E) and beta-carotene, in addition to copper and zinc, is the only widely accepted preventive therapy. Thermal laser photocoagulation and verteporfin photodynamic therapy are the only standard treatment options available based on large scale, randomised, prospective, placebo-controlled trials; however, efficacy is limited and only a minority of patients who present with AMD are eligible for these treatments. Many other preventive and treatment options are in all phases of clinical studies and expected to change the entire approach to AMD management in the near future. For example, alternative antioxidants, drusen ablation, apheresis and HMG-CoA reductase inhibitors have shown promise in some studies by preventing or slowing the progression of certain forms of AMD. In addition, alternative photodynamic therapies, low-intensity laser, antiangiogenic medications, radiation treatment and surgery have demonstrated the ability, albeit to differing degrees, to inhibit or possibly even reverse the severe vision loss often associated with AMD charactefised by choroidal neovascularisation.
C1 Midwest Eye Inst, Vitreoretinal Serv, Indianapolis, IN 46280 USA.
   Indiana Univ, Sch Med, Dept Ophthalmol, Indianapolis, IN 46204 USA.
   Indiana Univ, Sch Med, Retina Serv Res Labs, Dept Ophthalmol, Indianapolis, IN 46204 USA.
   Univ Penn, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis; Indiana University System; Indiana University-Purdue
   University Indianapolis; University of Pennsylvania; University of
   Pennsylvania
RP Ciulla, TA (通讯作者)，Midwest Eye Inst, Vitreoretinal Serv, 201 Penn Pkwy, Indianapolis, IN 46280 USA.
EM thomasciulla@yahoo.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Algvere PV, 1997, ACTA OPHTHALMOL SCAN, V75, P1
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   Anders N, 1998, OPHTHALMOLOGE, V95, P760, DOI 10.1007/s003470050349
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   *BAUSCH LOMB INC, BAUSCH LOMB CONTR DE
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BISCHOFF J, 1995, TRENDS CELL BIOL, V5, P69, DOI 10.1016/S0962-8924(00)88949-7
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blumenkranz MS, 2000, INVEST OPHTH VIS SCI, V41, pS531
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BOYER D, CLIN TRIALS ASSESS R
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 2003, INVEST OPHTHALMOL VI, V44
   BROUTYBOYE D, 1980, SCIENCE, V208, P516, DOI 10.1126/science.6154315
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Brunner R, 1995, INT J ARTIF ORGANS, V18, P794, DOI 10.1177/039139889501801208
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CAMPOCHIARO PA, 2003, INVEST OPHTHALMOL VI, V44
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   CHAN CK, 1994, OPHTHALMOLOGY, V101, P289
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   CHARTERS L, 2003, OPHTHALMOLOGY TIMES, V28, P1
   CHARTERS L, 2003, OPHTHALMOLOGY TIMES, V28, P14
   Cheng LY, 2001, J OCUL PHARMACOL TH, V17, P295, DOI 10.1089/108076801750295326
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P3337
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   *CLIN TRIALS GOV, MAC DEG
   *CLIN TRIALS GOV, CEL TREAT MAC DEG PA
   COLLIER MA, 1997, P AM ASSOC CANC RES, V38, pA1491
   *CONTR DEL SYST IN, CONTR DEL SYST
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   DAMORE PA, 1992, AM J RESP CELL MOL, V6, P1
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   Donati G, 1999, BRIT J OPHTHALMOL, V83, P646, DOI 10.1136/bjo.83.6.646
   *E LILL CO, KEY STUD FIND DIAB E
   EAGLE RC, 1984, OPHTHALMOLOGY, V91, P613
   ENGLER C, 1994, BRIT J OPHTHALMOL, V78, P749, DOI 10.1136/bjo.78.10.749
   *EYET PHARM INC, CLIN TRIALS
   EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203
   Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   FUNG WE, 1991, AM J OPHTHALMOL, V112, P349, DOI 10.1016/S0002-9394(14)76743-1
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Garcia CR, 2002, CURR EYE RES, V24, P33, DOI 10.1076/ceyr.24.1.33.5429
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   *GEN, GEN REP SQUAL CONT I
   *GEN INC, GEN ANN PREL POS PHA
   Genaidy M, 2002, RETINA-J RET VIT DIS, V22, P772, DOI 10.1097/00006982-200212000-00014
   *GENVEC INC, PEDF PROGR NEW APPR
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   GONZALEZ J, 2003, OCULAR SURG NEWS, V21, P48
   GONZALEZ J, 2003, OCULAR SURG NEWS, V21, P40
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   HEIER JS, 2003, INVEST OPHTHALMOL VI, V44
   HEIMANN K, 1994, GRAEF ARCH CLIN EXP, V232, P706, DOI 10.1007/BF00184272
   Higgins RD, 2000, INVEST OPHTH VIS SCI, V41, P1507
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   HO AC, ANECORTAVE ACETATE T
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   HOPEROSS MW, 1994, ACTA OPHTHALMOL, V72, P134
   HUDSON HL, 1995, BRIT J OPHTHALMOL, V79, P417, DOI 10.1136/bjo.79.5.417
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   JAAKKOLA A, 1994, ACTA OPHTHALMOL, V72, P545
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3
   Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   KLIMAN GH, 1994, LASER SURG MED, V15, P11, DOI 10.1002/lsm.1900150104
   Krott R, 1998, GRAEF ARCH CLIN EXP, V236, P916, DOI 10.1007/s004170050180
   Kruse FE, 1998, GRAEF ARCH CLIN EXP, V236, P461, DOI 10.1007/s004170050106
   KVANTA A, 1995, CURR EYE RES, V14, P1015, DOI 10.3109/02713689508998523
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Leahy KM, 2002, CANCER RES, V62, P625
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   *LT MERTZ RET RES, STUD COMP EARL STAND
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Maguire MG, 2001, INVEST OPHTH VIS SCI, V42, pS233
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   MANDELCORN MS, 1993, CAN J OPHTHALMOL, V28, P19
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   MARCUS DM, 2003, INVEST OPHTHALMOL VI, V44
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Martidis A, 1999, J OCUL PHARMACOL TH, V15, P425, DOI 10.1089/jop.1999.15.425
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   MILLER JW, 1993, OPHTHALMOLOGY, V100, P9
   *MIR MED TECHN, SNET2 PHAS 3 CLIN TR
   *MIRA 1, AG REL MAC DEG CLIN
   *MIRA 1 STUD GROUP, 2002, T AM OPHTHAL SOC, V100, P85
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 1999, OPHTHALMOLOGY, V106, P1384, DOI 10.1016/S0161-6420(99)00729-0
   MORIARTY AP, 1994, BRIT J OPHTHALMOL, V78, P238, DOI 10.1136/bjo.78.3.238-b
   Moshfeghi DM, 1998, OPHTHALMIC SURG LAS, V29, P663
   NADER N, 2004, OCULAR SURG NEWS, V22, P28
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   *NAT EYE I, ID TREATM FEED VESS
   *NAT EYE I, COMPL AG REL MAC DEG
   Neuringer M, 1999, INVEST OPHTH VIS SCI, V40, pS164
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   *NIH, SUBM SURG TRIALS SST
   Obana A, 1999, LASER SURG MED, V24, P209, DOI 10.1002/(SICI)1096-9101(1999)24:3<209::AID-LSM6>3.0.CO;2-L
   OHKUMA H, 1983, INVEST OPHTH VIS SCI, V24, P481
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   Ozerdem U, 2002, CURR EYE RES, V24, P86, DOI 10.1076/ceyr.24.2.86.8159
   Ozerdem U, 2001, OPHTHALMIC RES, V33, P20, DOI 10.1159/000055636
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Perkins SL, 2000, RETINA-J RET VIT DIS, V20, P514, DOI 10.1097/00006982-200009000-00013
   Peyman GA, 1997, OPHTHALMIC SURG LAS, V28, P409
   PHARM INC, PHARM REG RIGHTS OPT
   Prettenhofer U, 1998, STRAHLENTHER ONKOL, V174, P613, DOI 10.1007/BF03038508
   *QLT INC, OCC AMD
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Reich S, 2003, MOL VIS, V9, P210
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   REICHEL E, 1994, OPHTHALMIC SURG LAS, V25, P195
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   RIDDLE J, 2003, REV OPHTHALMOLOGY, V10, P40
   ROACH L, 2004, EYENET, V8, P29
   Roesen B, 1998, OPHTHALMOLOGE, V95, P461, DOI 10.1007/s003470050297
   ROH M, 2003, INVEST OPHTHALMOL VI, V44
   ROSENFELD PJ, 2004, INVEST OPHTHALMOL VI, V45
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sasai K, 1997, INT J RADIAT ONCOL, V39, P173, DOI 10.1016/S0360-3016(97)00296-4
   SAYAG D, 2003, INVEST OPHTHALMOL VI, V44
   Schalch W, 1992, EXS, V62, P280
   SCHLAEGEL TF, 1977, OCULAR HISTOPLASMOSI
   SEDDON JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P176, DOI 10.1001/archopht.1994.01090140052021
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 2001, RETINA, P1039
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   SIDKY YA, 1987, CANCER RES, V47, P5155
   SINGERMAN LJ, 2004, INVEST OPHTHALMOL VI, V45
   SLAKTER JS, 2003, INVEST OPHTHALMOL VI, V44
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Staar S, 1999, INT J RADIAT ONCOL, V45, P467, DOI 10.1016/S0360-3016(99)00186-8
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STUR M, 2004, INVEST OPHTHALMOL VI, V45
   Subasi M, 1999, Radiat Med, V17, P169
   Takita H, 2003, INVEST OPHTH VIS SCI, V44, P4497, DOI 10.1167/iovs.03-0052
   Thach AB, 2003, ARCH OPHTHALMOL-CHIC, V121, P817, DOI 10.1001/archopht.121.6.817
   Thoelen A, 1995, Ger J Ophthalmol, V4, P137
   Tholen AM, 1998, OPHTHALMOLOGE, V95, P691, DOI 10.1007/s003470050337
   THOMAS EL, 2004, INVEST OPHTHALMOL VI, V45
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1993, AM J OPHTHALMOL, V115, P563, DOI 10.1016/S0002-9394(14)71451-5
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Weinberger AWA, 1999, KLIN MONATSBL AUGENH, V214, P96, DOI 10.1055/s-2008-1034756
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WHITE CW, 1989, NEW ENGL J MED, V320, P1197, DOI 10.1056/NEJM198905043201807
   Widder RA, 1998, BLOOD PURIFICAT, V16, P15, DOI 10.1159/000014308
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Woessner JF, 1998, BIOL EXTRAC, P1
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   ZHANG KE, 1998, P NEW YORK ACAD SCI
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 236
TC 27
Z9 31
U1 0
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2004
VL 21
IS 15
BP 967
EP 992
DI 10.2165/00002512-200421150-00002
PG 26
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 886RY
UT WOS:000226247300001
PM 15631528
DA 2022-11-30
ER

PT J
AU Lindner, M
   Bezatis, A
   Czauderna, J
   Becker, E
   Brinkmann, CK
   Schmitz-Valckenberg, S
   Fimmers, R
   Holz, FG
   Fleckenstein, M
AF Lindner, Moritz
   Bezatis, Athanasios
   Czauderna, Joanna
   Becker, Eva
   Brinkmann, Christian K.
   Schmitz-Valckenberg, Steffen
   Fimmers, Rolf
   Holz, Frank G.
   Fleckenstein, Monika
TI Choroidal Thickness in Geographic Atrophy Secondary to Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE geographic atrophy; choroidal thickness; fundus autofluorescence
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE PATTERNS;
   RETINAL-PIGMENT EPITHELIUM; HEALTHY-SUBJECTS; BRUCHS MEMBRANE;
   MORPHOMETRIC-ANALYSIS; MACULOPATHY; VASCULOPATHY; PROGRESSION;
   PREVALENCE
AB PURPOSE. To analyze choroidal thickness (CT) in eyes with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
   METHODS. A total of 72 eyes of 72 patients (mean age, 75.97 +/- 7.09 years) with GA and 37 eyes of 37 healthy controls (73.89 +/- 6.19 years) were examined by confocal scanning laser ophthalmoscopy and enhanced depth imaging (EDI) spectral-domain optical coherence tomography. Choroidal thickness was measured at 25 defined points in horizontal and vertical scans. Geographic atrophy size was determined in fundus autofluorescence (FAF) images and GA subtypes were classified based on abnormal FAF in the perilesional zone.
   RESULTS. In GA, subfoveal CT (fCT) was significantly thinner compared to controls (173.03 +/- 90.22 vs. 253.95 +/- 69.19 mu m, P < 0.001). Analysis of averaged measurements of all 25 points obtained per patient (mCT) revealed similar results (162.07 +/- 76.26 vs. 228.00 +/- 66.24 mu m, P < 0.001). Spatial differences in CT between both groups were largest superior to the fovea. Addressing "diffuse-trickling'' (n = 15) and "non-diffuse-trickling'' (n = 57) GA independently, fCT was 114.67 +/- 43.32 and 188.39 +/- 93.26 mu m, respectively (P = 0.002), with both groups being significantly thinner than controls (P < 0.001 for "diffuse-trickling'' and P < 0.001 for "non-diffuse-trickling''). Similar results were obtained for mCT, which was 110.21 +/- 29.66 mu m in "diffuse-trickling,'' 175.72 +/- 79.02 mu m in "non-diffuse-trickling'' and 228.00 6 66.24 lm in controls. Differences were significant with P = 0.002 between both GA groups and P <= 0.001 toward controls for each GA group.
   CONCLUSIONS. The results indicate that the choroid in eyes with GA is thinner compared to normal eyes of similar age. Hereby, the extent of thinning is most pronounced in a specific subtype of GA identified by FAF imaging ("diffuse trickling''). Such GA subtype-related differences in choroidal thickness may reflect heterogeneity in the pathogenesis of disease.
C1 [Lindner, Moritz; Bezatis, Athanasios; Czauderna, Joanna; Becker, Eva; Brinkmann, Christian K.; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Fimmers, Rolf] Univ Bonn, Inst Biostat, D-53127 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM monika.fleckenstein@ukb.uni-bonn.de
RI Lindner, Moritz/AAC-8639-2021
OI Lindner, Moritz/0000-0002-4416-3421; Fleckenstein,
   Monika/0000-0001-8321-8037
FU DFG (German Research Council) [Ho 1926/1-3, FL 658/4-1, BONFOR
   0-137-0012]
FX Supported by research grants from DFG (German Research Council): Ho
   1926/1-3, FL 658/4-1; BONFOR 0-137-0012 (MF). The authors alone are
   responsible for the content and writing of the paper.
CR Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Brown JS, 2009, INVEST OPHTH VIS SCI, V50, P5, DOI 10.1167/iovs.08-1779
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Johnstone J, 2014, INVEST OPHTH VIS SCI, V55, P2004, DOI 10.1167/iovs.13-12937
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Mansouri K, 2013, OPHTHALMOLOGY, V120, P2508, DOI 10.1016/j.ophtha.2013.07.040
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Noori Jila, 2012, J Ophthalmic Vis Res, V7, P180
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P332, DOI 10.1097/IAE.0b013e3181eef0ae
   Vural AD, 2014, RETINA-J RET VIT DIS, V34, P1223, DOI 10.1097/IAE.0000000000000043
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Zengin MO, 2014, BRIT J OPHTHALMOL, V98, P233, DOI 10.1136/bjophthalmol-2013-304044
NR 45
TC 67
Z9 67
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2015
VL 56
IS 2
BP 875
EP 882
DI 10.1167/iovs.14-14933
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BC
UT WOS:000352137300022
PM 25587059
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Nadal, J
   Fimmers, R
   Lindner, M
   Holz, FG
   Schmid, M
   Fleckenstein, M
AF Schmitz-Valckenberg, Steffen
   Nadal, Jennifer
   Fimmers, Rolf
   Lindner, Moritz
   Holz, Frank G.
   Schmid, Matthias
   Fleckenstein, Monika
CA Fam Study Grp
TI Modeling Visual Acuity in Geographic Atrophy Secondary to Age-Related
   Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Geographic atrophy; Visual acuity;
   Visual function; Fundus autofluorescence imaging; Natural history
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FUNDUS
   AUTOFLUORESCENCE PATTERNS; BEAVER DAM EYE; NATURAL-HISTORY; JUNCTIONAL
   ZONE; PROGRESSION; DISEASE; ENLARGEMENT; MACULOPATHY
AB Purpose: To analyze and model visual acuity (VA) in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Methods: The course of VA was analyzed using Turnbull's estimator in 226 eyes with uni-or bilateral GA due to AMD (151 patients; mean age 74.0 +/- 7.6 years; mean follow-up time 33.4 +/- 23.4 months) from the natural history FAM (Fundus-Autofluorescence Imaging in AMD) study. The variables 'age at baseline', 'gender', 'lesion size', 'diagnosis of the fellow eye', 'status of the fovea', 'focality of the lesion' and 'pattern' were evaluated for effects on predicting VA using linear mixed-effects models. Results: Mean VA at baseline was 0.6 (Snellen 20/80) +/- 0.4 logMAR [range -0.1 to 1.8 (20/17 to hand motions)], showing an estimated mean increase of 0.181 (95% CI 0.152-0.210) and 0.256 (0.214-0.300) after 2 and 4 years of follow-up, respectively. The percentage of eyes with a loss of >= 3 lines was 34% by 2 years and 47% by 4 years. Linear mixed model analysis suggested that 65% of VA variability could be explained by the assessed predictor variables. The strongest effect was found for the 'status of the fovea' (0.69 logMAR units between 'definitively spared fovea' and 'definitive foveal involvement', p < 0.001). The second strongest effect was identified for 'total lesion size' (effects between 0.02 and 0.09 logMAR units for each mm depending on foveal involvement, p < 0.001, square root transformed values). Conclusions: These findings underscore the importance of GA lesion characteristics as these have the strongest impact on VA. Natural history data and modeling VA to other variables will be helpful for refining outcome parameters and estimating possible benefits of therapeutic interventions. (C) 2016 S. Karger AG, Basel
C1 [Schmitz-Valckenberg, Steffen; Lindner, Moritz; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
   [Nadal, Jennifer; Fimmers, Rolf; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, DE-53127 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
EM Frank.Holz@ukb.uni-bonn.de
RI Lindner, Moritz/AAC-8639-2021
OI Lindner, Moritz/0000-0002-4416-3421; Fleckenstein,
   Monika/0000-0001-8321-8037; Schmid, Matthias/0000-0002-0788-0317
FU German Research Foundation (DFG) [Ho1926/3-1, FL 658/4-1, SCHM 2966/1-2]
FX This study was financially supported by the German Research Foundation
   (DFG): Ho1926/3-1, FL 658/4-1 and SCHM 2966/1-2. The funding
   organization had no role in the design or conduct of this research.
CR [Anonymous], 2011, CTGTAC M 52 JUN 29, V52
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   TURNBULL BW, 1976, J R STAT SOC B, V38, P290
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 34
TC 14
Z9 14
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 235
IS 4
BP 215
EP 224
DI 10.1159/000445217
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP9BR
UT WOS:000378792200006
PM 27089126
DA 2022-11-30
ER

PT J
AU Alves, CH
   Fernandes, R
   Santiago, AR
   Ambrosio, AF
AF Henrique Alves, C.
   Fernandes, Rosa
   Santiago, Ana Raquel
   Ambrosio, Antonio Francisco
TI Microglia Contribution to the Regulation of the Retinal and Choroidal
   Vasculature in Age-Related Macular Degeneration
SO CELLS
LA English
DT Review
DE age-related macular degeneration (AMD); retina; choroid; microglia;
   retinal vasculature; inflammation; neogenesis; angiogenesis
ID PIGMENT EPITHELIAL-CELLS; GLYCATION END-PRODUCTS; ENDOTHELIAL
   GROWTH-FACTOR; RETICULAR PSEUDODRUSEN; COMPLEMENT ACTIVATION;
   ANTIANGIOGENIC FACTORS; BRUCHS MEMBRANE; POTENTIAL ROLE; UP-REGULATION;
   NITRIC-OXIDE
AB The retina is a highly metabolically active tissue with high-level consumption of nutrients and oxygen. This high metabolic demand requires a properly developed and maintained vascular system. The retina is nourished by two systems: the central retinal artery that supplies the inner retina and the choriocapillaris that supplies the outer retina and retinal pigment epithelium (RPE). Pathological neovascularization, characterized by endothelial cell proliferation and new vessel formation, is a common hallmark in several retinal degenerative diseases, including age-related macular degeneration (AMD). A limited number of studies have suggested that microglia, the resident immune cells of the retina, have an important role not only in the pathology but also in the formation and physiology of the retinal vascular system. Here, we review the current knowledge on microglial interaction with the retinal vascular system under physiological and pathological conditions. To do so, we first highlight the role of microglial cells in the formation and maintenance of the retinal vasculature system. Thereafter, we discuss the molecular signaling mechanisms through which microglial cells contribute to the alterations in retinal and choroidal vasculatures and to the neovascularization in AMD.
C1 [Henrique Alves, C.; Fernandes, Rosa; Santiago, Ana Raquel; Ambrosio, Antonio Francisco] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Retinal Dysfunct & Neuroinflammat Lab, P-3000548 Coimbra, Portugal.
   [Henrique Alves, C.; Fernandes, Rosa; Santiago, Ana Raquel; Ambrosio, Antonio Francisco] Univ Coimbra, CIBB, P-3004531 Coimbra, Portugal.
   [Henrique Alves, C.; Fernandes, Rosa; Santiago, Ana Raquel; Ambrosio, Antonio Francisco] Assoc Innovat & Biomed Res Light & Image AIBILI, P-3000548 Coimbra, Portugal.
   [Henrique Alves, C.; Fernandes, Rosa; Santiago, Ana Raquel; Ambrosio, Antonio Francisco] CACC, P-3004561 Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra; Universidade de Coimbra
RP Ambrosio, AF (通讯作者)，Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Retinal Dysfunct & Neuroinflammat Lab, P-3000548 Coimbra, Portugal.; Ambrosio, AF (通讯作者)，Univ Coimbra, CIBB, P-3004531 Coimbra, Portugal.; Ambrosio, AF (通讯作者)，Assoc Innovat & Biomed Res Light & Image AIBILI, P-3000548 Coimbra, Portugal.; Ambrosio, AF (通讯作者)，CACC, P-3004561 Coimbra, Portugal.
EM chalves@fmed.uc.pt; rcfernandes@fmed.uc.pt; asantiago@fmed.uc.pt;
   afambrosio@fmed.uc.pt
RI Fernandes, Rosa/P-1102-2014; Alves, Henrique/AAH-3017-2019; Santiago,
   Ana Raquel/I-6566-2013
OI Fernandes, Rosa/0000-0001-7828-2296; Alves,
   Henrique/0000-0001-9776-5701; Santiago, Ana Raquel/0000-0002-7541-7041;
   Ambrosio, Antonio F/0000-0002-0477-1641
FU National Funds via FCT (Foundation for Science and Technology)
   [UIDB/04539/2020, UIDP/04539/2020, CEECIND/00886/2017]
FX This research was funded by National Funds via FCT (Foundation for
   Science and Technology) through the Strategic Project UIDB/04539/2020
   and UIDP/04539/2020 (CIBB); and CEECIND/00886/2017 to C.H.A.
CR Ahmad I, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100824
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Alliot F, 1999, DEV BRAIN RES, V117, P145, DOI 10.1016/S0165-3806(99)00113-3
   Alvarez Y, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-114
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arrigo A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091425
   ASHWELL KWS, 1989, VISUAL NEUROSCI, V2, P437, DOI 10.1017/S0952523800012335
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   BOULTON M, 1986, BRIT J OPHTHALMOL, V70, P808, DOI 10.1136/bjo.70.11.808
   Camacho P, 2017, OPHTHALMOLOGICA, V238, P31, DOI 10.1159/000468965
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Canto A, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110543
   CAPON MRC, 1988, EYE, V2, P114, DOI 10.1038/eye.1988.23
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chan-Ling T, 2004, INVEST OPHTH VIS SCI, V45, P2020, DOI 10.1167/iovs.03-1169
   Chappell JC, 2019, J DEV BIOL, V7, DOI 10.3390/jdb7030018
   Chaudhary V, 2016, CAN J OPHTHALMOL, V51, P302, DOI 10.1016/j.jcjo.2016.04.020
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089548
   Chen S, 2017, CELL REP, V19, P1378, DOI 10.1016/j.celrep.2017.04.056
   Cheng JP, 2018, ACTA NEUROPATHOL, V136, P507, DOI 10.1007/s00401-018-1893-0
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chiquita S, 2019, MOL NEUROBIOL, V56, P5416, DOI 10.1007/s12035-018-1461-6
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Coughlan MT, 2009, J AM SOC NEPHROL, V20, P742, DOI 10.1681/ASN.2008050514
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Dainichi T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01107
   Daufenbach DR, 1998, OPHTHALMOLOGY, V105, P1455, DOI 10.1016/S0161-6420(98)98028-9
   Ding DM, 2018, BIOCHEM BIOPH RES CO, V503, P2742, DOI 10.1016/j.bbrc.2018.08.034
   Dorey CK, 1996, ARCH OPHTHALMOL-CHIC, V114, P1210, DOI 10.1001/archopht.1996.01100140410008
   Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500
   Dorrell MI, 2006, PROG RETIN EYE RES, V25, P277, DOI 10.1016/j.preteyeres.2006.01.001
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   FLOWER RW, 1985, INVEST OPHTH VIS SCI, V26, P957
   Foulquier S, 2019, ANGIOGENESIS, V22, P481, DOI 10.1007/s10456-019-09671-3
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gasparotto J, 2018, J BIOL CHEM, V293, P226, DOI 10.1074/jbc.M117.786756
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Haupt F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46308-3
   Hayreh SS, 2001, PROG RETIN EYE RES, V20, P563, DOI 10.1016/S1350-9462(01)00004-0
   Heavner W, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008391
   Heng LZ, 2013, DIABETIC MED, V30, P640, DOI 10.1111/dme.12089
   Hong HK, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-87
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hughes S, 2000, INVEST OPHTH VIS SCI, V41, P1217
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kalea AZ, 2009, CLIN SCI, V116, P621, DOI 10.1042/CS20080494
   Karlstetter M, 2017, EMBO MOL MED, V9, P154, DOI 10.15252/emmm.201606627
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kozulin P, 2010, INVEST OPHTH VIS SCI, V51, P4298, DOI 10.1167/iovs.09-4905
   Kozulin P, 2009, MOL VIS, V15, P45
   Krilis M, 2017, ONCOTARGET, V8, P49016, DOI 10.18632/oncotarget.14940
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   Lavine JA, 2017, INVEST OPHTH VIS SCI, V58, P299, DOI 10.1167/iovs.16-20204
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lennikov A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01903
   Li FE, 2019, NEURAL DEV, V14, DOI 10.1186/s13064-019-0137-x
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Loukovaara S, 2013, ACTA OPHTHALMOL, V91, P531, DOI 10.1111/j.1755-3768.2012.02473.x
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Lutty GA, 2018, PROG RETIN EYE RES, V62, P58, DOI 10.1016/j.preteyeres.2017.10.001
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marin-Teva JL, 1998, GLIA, V22, P31, DOI 10.1002/(SICI)1098-1136(199801)22:1<31::AID-GLIA4>3.0.CO;2-B
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mazzitello KI, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.051908
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nag TC, 2019, ANN ANAT, V223, P8, DOI 10.1016/j.aanat.2019.01.006
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nonobe N, 2019, RETINA-J RET VIT DIS, V39, P111, DOI 10.1097/IAE.0000000000001937
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nunes I, 1998, J Am Optom Assoc, V69, P643
   Olson JL, 2009, OCUL IMMUNOL INFLAMM, V17, P195, DOI 10.1080/09273940802710705
   Opatrilova R, 2018, ACTA OPHTHALMOL, V96, P222, DOI 10.1111/aos.13384
   Outtz HH, 2011, BLOOD, V118, P3436, DOI 10.1182/blood-2010-12-327015
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Pau H, 2010, GRAEF ARCH CLIN EXP, V248, P1, DOI 10.1007/s00417-009-1190-7
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PENFOLD PL, 1993, J NEUROIMMUNOL, V45, P183, DOI 10.1016/0165-5728(93)90179-3
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P255, DOI 10.1007/BF00920031
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Provis JM, 2008, ARCH OPHTHALMOL-CHIC, V126, P507, DOI 10.1001/archopht.126.4.507
   PROVIS JM, 1995, GLIA, V14, P243, DOI 10.1002/glia.440140402
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   Quinn PMJ, 2019, GENES-BASEL, V10, DOI 10.3390/genes10120987
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rymo SF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015846
   Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x
   Sandercoe TM, 2003, J COMP NEUROL, V462, P42, DOI 10.1002/cne.10705
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schmetterer L, 2001, PROG RETIN EYE RES, V20, P823, DOI 10.1016/S1350-9462(01)00014-3
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schwarzer P, 2020, AM J PATHOL, V190, P412, DOI 10.1016/j.ajpath.2019.10.011
   Scott A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011863
   Selvam S, 2018, PROG RETIN EYE RES, V63, P1, DOI 10.1016/j.preteyeres.2017.11.001
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   Sugiyama K., 1994, J GLAUCOMA, V3, P45, DOI [10.1097/00061198-199400321-00006, DOI 10.1097/00061198-199400321-00006]
   Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008
   Sun Y, 2018, ANNU REV VIS SCI, V4, P101, DOI 10.1146/annurev-vision-091517-034018
   Tay TL, 2017, NAT NEUROSCI, V20, P793, DOI 10.1038/nn.4547
   Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tremblay S, 2013, INVEST OPHTH VIS SCI, V54, P8125, DOI 10.1167/iovs.13-12496
   Trinh M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.20
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Usman M, 2019, CUREUS, V11, DOI 10.7759/cureus.6485
   Usui V, 2015, J CLIN INVEST, V125, P2335, DOI 10.1172/JCI80297
   van Noort JM, 2010, J NEUROPATH EXP NEUR, V69, P694, DOI 10.1097/NEN.0b013e3181e4939c
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vielma AH, 2012, BRAIN RES, V1430, P112, DOI 10.1016/j.brainres.2011.10.045
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu WK, 2015, AM J PATHOL, V185, P2324, DOI 10.1016/j.ajpath.2015.04.013
   Xie JL, 2013, CELL SIGNAL, V25, P2185, DOI 10.1016/j.cellsig.2013.06.013
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yamamoto H, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00099
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Yeung SC, 2020, SURV OPHTHALMOL, V65, P473, DOI 10.1016/j.survophthal.2019.12.007
   Yin J, 2017, J CELL MOL MED, V21, P3467, DOI 10.1111/jcmm.13256
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhu X, 2016, EXP CELL RES, V348, P87, DOI 10.1016/j.yexcr.2016.09.002
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 189
TC 18
Z9 19
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD MAY
PY 2020
VL 9
IS 5
AR 1217
DI 10.3390/cells9051217
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LW7RF
UT WOS:000539340200151
PM 32423062
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Han, GG
   Wei, PH
   He, MQ
   Teng, H
   Chu, YH
AF Han, Guoge
   Wei, Pinghui
   He, Meiqin
   Teng, He
   Chu, Yanhua
TI Metabolomic Profiling of the Aqueous Humor in Patients with Wet
   Age-Related Macular Degeneration Using UHPLC-MS/MS
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE metabolomic; aqueous humor (AH); age-related macular degeneration (AMD);
   mitochondrial
ID L-CARNITINE; MITOCHONDRIAL ACONITASE; BETAINE; CELLS; SUPPRESSION;
   ISCHEMIA; TARGETS; MODEL; IRON
AB Assessing metabolomic alterations in age-related macular degeneration (AMD) can provide insights into its pathogenesis. We compared the metabolomic profiles of the aqueous humor between wet AMD patients (n = 26) and age- and sex-matched patients undergoing cataract surgery without AMD as controls (n = 20). A global untargeted metabolomics study was performed using ultra-high-performance liquid chromatography tandem mass spectrometry. Univariate analysis after the false discovery correction showed 18 significantly altered metabolites among the 291 metabolites measured. These differential metabolomic profiles pointed to three interconnected metabolic pathways: a compromised carnitine-associated mitochondrial oxidation pathway (carnitine, deoxycarnitine, N6-trimethyl-L-lysine), an altered carbohydrate metabolism pathway (cis-aconitic acid, itaconatic acid, and mesaconic acid), which plays a role in senescence and immunity, and an activated osmoprotection pathway (glycine betaine, creatine), which potentially contributes to the pathogenesis of the disease. These results suggested that metabolic dysfunction in AMD is mitochondrial-centered and may provide new insights into the pathophysiology of wet AMD and novel therapeutic strategies.
C1 [Han, Guoge; Wei, Pinghui; He, Meiqin; Chu, Yanhua] Tianjin Eye Hosp, Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin 300020, Peoples R China.
   [Teng, He] Tianjin Med Univ, Eye Inst, Eye Hosp, Tianjin 300384, Peoples R China.
   [Teng, He] Tianjin Med Univ, Eye Hosp, Sch Optometry & Ophthalmol, Tianjin 300384, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University
RP Han, GG (通讯作者)，Tianjin Eye Hosp, Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin 300020, Peoples R China.
EM dovehanguoge@hotmail.com
OI Wei, Pinghui/0000-0002-2052-6355
FU National Natural Science Foundation of China [81700849]; Natural Science
   Foundation of Tianjin City [18JCQNJC10600]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (81700849) and Natural Science Foundation of Tianjin
   City (18JCQNJC10600).
CR Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alagoz G, 2002, OPHTHALMOLOGICA, V216, P144, DOI 10.1159/000048315
   Almannai M, 2019, MOLECULES, V24, DOI 10.3390/molecules24183251
   Bambouskova M, 2018, NATURE, V556, P501, DOI 10.1038/s41586-018-0052-z
   Barbas-Bernardos C, 2016, J PHARMACEUT BIOMED, V127, P18, DOI 10.1016/j.jpba.2016.03.032
   Bringmann A, 2016, MOL VIS, V22, P1437
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Buisset A, 2019, J PROTEOME RES, V18, P1307, DOI 10.1021/acs.jproteome.8b00915
   Calandrella N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.40
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cheng Z, 2013, BIOCHEM BIOPH RES CO, V433, P145, DOI 10.1016/j.bbrc.2013.02.040
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Figueroa-Soto CG, 2018, BIOCHIMIE, V147, P89, DOI 10.1016/j.biochi.2018.01.002
   Freddo TF, 2013, PROG RETIN EYE RES, V32, P181, DOI 10.1016/j.preteyeres.2012.10.004
   Hollborn M, 2018, MOL VIS, V24, P518
   Ji YH, 2017, EXP EYE RES, V159, P147, DOI 10.1016/j.exer.2017.03.004
   Jin HY, 2019, J PHARMACEUT BIOMED, V174, P414, DOI 10.1016/j.jpba.2019.06.013
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim YG, 2015, MOL MED REP, V12, P1639, DOI 10.3892/mmr.2015.3613
   Lains I, 2019, PROG RETIN EYE RES, V69, P57, DOI 10.1016/j.preteyeres.2018.11.002
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004
   Lenth RV, 2001, AM STAT, V55, P187, DOI 10.1198/000313001317098149
   Liang L, 2020, CARBOHYD POLYM, V229, DOI 10.1016/j.carbpol.2019.115534
   Liu P, 2018, P NATL ACAD SCI USA, V115, P9032, DOI 10.1073/pnas.1807982115
   Mayordomo-Febrer A, 2015, EXP EYE RES, V131, P84, DOI 10.1016/j.exer.2014.11.012
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nashine S, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107701
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Park SW, 2017, VASC PHARMACOL, V90, P19, DOI 10.1016/j.vph.2016.07.007
   PESSOTTO P, 1994, J OCUL PHARMACOL, V10, P643, DOI 10.1089/jop.1994.10.643
   RILEY MV, 1972, INVEST OPHTH VISUAL, V11, P600
   Santos-Fandila A, 2013, TALANTA, V114, P79, DOI 10.1016/j.talanta.2013.03.082
   Spiegel K, 2012, AM J HUM GENET, V90, P518, DOI 10.1016/j.ajhg.2012.01.009
   Spindler J., 2018, PLOS ONE, V13
   Strijbis K, 2010, IUBMB LIFE, V62, P357, DOI 10.1002/iub.323
   Synowiec E, 2012, MOL BIOL REP, V39, P7077, DOI 10.1007/s11033-012-1539-6
   Szabados L, 2010, TRENDS PLANT SCI, V15, P89, DOI 10.1016/j.tplants.2009.11.009
   Tachikawa M, 2010, INVEST OPHTH VIS SCI, V51, P430, DOI 10.1167/iovs.09-4080
   Tang Z, 2016, TALANTA, V152, P119, DOI 10.1016/j.talanta.2016.01.056
   Tong WH, 2007, BIOMETALS, V20, P549, DOI 10.1007/s10534-006-9047-6
   Wang HY, 2020, ACTA DIABETOL, V57, P41, DOI 10.1007/s00592-019-01363-0
   Wei PH, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107919
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yam M, 2019, J BIOL CHEM, V294, P10278, DOI 10.1074/jbc.RA119.007983
   Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168
NR 57
TC 10
Z9 10
U1 0
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD JUN 5
PY 2020
VL 19
IS 6
BP 2358
EP 2366
DI 10.1021/acs.jproteome.0c00036
PG 9
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA LV9NA
UT WOS:000538772300016
PM 32293180
DA 2022-11-30
ER

PT J
AU De Bruyne, S
   Van den Broecke, C
   Vrielinck, H
   Khelifi, S
   De Wever, O
   Bracke, K
   Huizing, M
   Boston, N
   Himpe, J
   Speeckaert, M
   Vral, A
   Van Dorpe, J
   Van Aken, E
   Delanghe, JR
AF De Bruyne, Sander
   Van den Broecke, Caroline
   Vrielinck, Henk
   Khelifi, Samira
   De Wever, Olivier
   Bracke, Ken
   Huizing, Manon
   Boston, Nezahat
   Himpe, Jonas
   Speeckaert, Marijn
   Vral, Anne
   Van Dorpe, Jo
   Van Aken, Elisabeth
   Delanghe, Joris R.
TI Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related
   Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; eye diseases; fructosamine-3-kinase;
   glycation end products; advanced; retinal drusen; therapeutics
ID GLYCATION END-PRODUCT; BRUCHS MEMBRANE; EXPRESSION; IDENTIFICATION;
   HYALURONIDASE; MANAGEMENT; LIPOFUSCIN; SUBSTRATE; DEPOSITS; 3-KINASE
AB Age-related macular degeneration is the leading cause of blindness in the developed world. Since advanced glycation end products (AGEs) are implicated in the pathogenesis of AMD through various lines of evidence, we investigated the potential of fructosamine-3-kinase (FN3K) in the disruption of retinal AGEs, drusenoid material and drusenoid lesions in patients with AMD. AGE-type autofluorescence was measured to evaluate the effects of FN3K on glycolaldehyde-induced AGE-modified neural porcine retinas and unmodified human neural retinas. Eye pairs from cigarette-smoke- and air-exposed mice were treated and evaluated histologically. Automated optical image analysis of human tissue sections was performed to compare control- and FN3K-treated drusen and near-infrared (NIR) microspectroscopy was performed to examine biochemical differences. Optical coherence tomography (OCT) was used to evaluate the effect of FN3K on drusenoid deposits after treatment of post-mortem human eyes. FN3K treatment provoked a significant decrease (41%) of AGE-related autofluorescence in the AGE-modified porcine retinas. Furthermore, treatment of human neural retinas resulted in significant decreases of autofluorescence (-24%). FN3K-treated murine eyes showed less drusenoid material. Pairwise comparison of drusen on tissue sections revealed significant changes in color intensity after FN3K treatment. NIR microspectroscopy uncovered clear spectral differences in drusenoid material (Bruch's membrane) and drusen after FN3K treatment. Ex vivo treatment strongly reduced size of subretinal drusenoid lesions on OCT imaging (up to 83%). In conclusion, our study demonstrated for the first time a potential role of FN3K in the disruption of AGE-related retinal autofluorescence, drusenoid material and drusenoid lesions in patients with AMD.
C1 [De Bruyne, Sander; Himpe, Jonas; Van Dorpe, Jo; Delanghe, Joris R.] Univ Ghent, Dept Diagnost Sci, B-9000 Ghent, Belgium.
   [Van den Broecke, Caroline; Van Dorpe, Jo] Ghent Univ Hosp, Dept Pathol, B-9000 Ghent, Belgium.
   [Vrielinck, Henk; Khelifi, Samira] Univ Ghent, Dept Solid State Sci, B-9000 Ghent, Belgium.
   [De Wever, Olivier; Vral, Anne] Univ Ghent, Dept Human Struct & Repair, B-9000 Ghent, Belgium.
   [Bracke, Ken; Speeckaert, Marijn] Univ Ghent, Dept Internal Med & Pediat, B-9000 Ghent, Belgium.
   [Huizing, Manon; Boston, Nezahat] Antwerp Univ Hosp, Biobank, B-2650 Antwerp, Belgium.
   [Speeckaert, Marijn] Res Fdn Flanders, B-1000 Brussels, Belgium.
   [Van Aken, Elisabeth] Univ Ghent, Dept Head & Skin, B-9000 Ghent, Belgium.
C3 Ghent University; Ghent University; Ghent University Hospital; Ghent
   University; Ghent University; Ghent University; University of Antwerp;
   Ghent University
RP Delanghe, JR (通讯作者)，Univ Ghent, Dept Diagnost Sci, B-9000 Ghent, Belgium.; Van Aken, E (通讯作者)，Univ Ghent, Dept Head & Skin, B-9000 Ghent, Belgium.
EM sanderR.debruyne@ugent.be; caroline.vandenbroecke@azstlucas.be;
   henk.vrielinck@ugent.be; samira.khelifi@ugent.be;
   olivier.dewever@ugent.be; ken.bracke@ugent.be; manon.huizing@uza.be;
   nezahat.boston@uza.be; jonas.himpe@ugent.be; marijn.speeckaert@ugent.be;
   anne.vral@ugent.be; jo.vandorpe@ugent.be; elisabeth.vanaken@ugent.be;
   joris.delanghe@ugent.be
RI Bracke, Ken R/GSN-7630-2022
OI Bracke, Ken R/0000-0001-5906-4605; Vrielinck, Henk/0000-0003-4861-9630;
   De Bruyne, Sander/0000-0002-9041-4404; Khelifi,
   Samira/0000-0001-6908-903X; Speeckaert, Marijn/0000-0001-9183-4390;
   Delanghe, Joris/0000-0002-5702-6792
FU IOF grant [F2018/IOF-Advanced/411]; Research Foundation
   Flanders-Hercules Foundation (FWO-Vlaanderen) [AUGE/13/13: FT-IMAGER]
FX This research was supported by an IOF grant (F2018/IOF-Advanced/411) and
   by the Research Foundation Flanders-Hercules Foundation (FWO-Vlaanderen,
   project number AUGE/13/13: FT-IMAGER).
CR Ashraf JM, 2015, IUBMB LIFE, V67, P897, DOI 10.1002/iub.1450
   Avemaria F, 2015, CLIN CHEM LAB MED, V53, P1315, DOI 10.1515/cclm-2015-0207
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Borrelli E, 2012, INT J OPHTHALMOL-CHI, V5, P708, DOI 10.3980/j.issn.2222-3959.2012.06.11
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Buhren BA, 2016, EUR J MED RES, V21, DOI 10.1186/s40001-016-0201-5
   Conner JR, 2004, BIOCHEM BIOPH RES CO, V323, P932, DOI 10.1016/j.bbrc.2004.08.181
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   De Bruyne S, 2019, BRIT J DERMATOL, V180, P637, DOI 10.1111/bjd.17199
   De Bruyne S, 2018, CRIT REV CL LAB SCI, V55, P1, DOI 10.1080/10408363.2017.1414142
   DEBRUYNE S, 2019, J CLIN MED, V0008
   Delpierre G, 2000, DIABETES, V49, P1627, DOI 10.2337/diabetes.49.10.1627
   Delpierre G, 2002, BIOCHEM J, V365, P801, DOI 10.1042/BJ20020325
   Dunmore SJ, 2018, DIABETES, V67, P131, DOI 10.2337/db17-0441
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Fernandez DC, 2005, NAT BIOTECHNOL, V23, P469, DOI 10.1038/nbt1080
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Garg U, 2004, J FORENSIC SCI, V49, P388
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hayer-Hartl M, 2000, METH MOL B, V140, P127
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Owen Leah A, 2019, Invest Ophthalmol Vis Sci, V60, P1204, DOI 10.1167/iovs.18-24254
   Repetto R, 2010, BIOMECH MODEL MECHAN, V9, P65, DOI 10.1007/s10237-009-0159-0
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Ruschen H, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010368.pub2
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schoonooghe S, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-70
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Semba RD, 2014, JAMA OPHTHALMOL, V132, P464, DOI 10.1001/jamaophthalmol.2013.7664
   Steenbeke M, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10010034
   Szwergold BS, 2001, DIABETES, V50, P2139, DOI 10.2337/diabetes.50.9.2139
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Varma VK, 2016, KIDNEY INT, V89, P1153, DOI 10.1016/j.kint.2015.11.027
   Westenskow Peter D, 2017, Stem Cell Investig, V4, P86, DOI 10.21037/sci.2017.10.01
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
NR 45
TC 2
Z9 2
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2869
DI 10.3390/jcm9092869
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OG9BF
UT WOS:000582169400001
PM 32899850
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Leske, MC
   Wu, SY
   Hennis, A
   Nemesure, B
   Yang, L
   Hyman, L
   Schachat, AP
AF Leske, MC
   Wu, SY
   Hennis, A
   Nemesure, B
   Yang, L
   Hyman, L
   Schachat, AP
CA Barbados Eye Studies Grp
TI Nine-year incidence of age-related macular degeneration in the Barbados
   Eye Studies
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER-DAM EYE; VISUAL IMPAIRMENT PROJECT;
   OPEN-ANGLE GLAUCOMA; 5-YEAR INCIDENCE; RACIAL-DIFFERENCES; 4-YEAR
   INCIDENCE; OLDER AMERICANS; PREVALENCE; MACULOPATHY
AB Objective: To provide 9-year incidence estimates of age-related macular degeneration (AMD) in a population of African descent.
   Design: Population-based cohort study.
   Participants: Two thousand seven hundred ninety-three participants (81% of eligible) after 9 years' follow-up.
   Main Outcome Measures: Nine-year incidence of AMD-related features, based on fundus photographic gradings and/or clinical examinations.
   Results: The overall incidence rate of early AMD was 12.6% (95% confidence interval [Cl], 11.0%-14.1%), and that of late AMD was 0.7% (95% Cl, 0.4%-1.1%). Both increased with age (P<0.05). For early AMD, incidence ranged from 10.7% at 40 to 49 years of age to 16.8% at >= 70 years. For late AMD, incidence increased from 0.1% to 2.3% in the same age groups. Late AMD was more likely to develop in eyes with pigment changes (risk ratio [RR], 5.8; 95% Cl, 2.0-16.8) and retinal pigment epithelial atrophy (RR, 5.4; 95% Cl, 1.9-15.8) at baseline. Crude RRs indicated significant associations of late AMD to elevated systolic blood pressure and diabetes history, but only the diabetes relationship was suggested after adjusting for age, with borderline statistical significance (age-adjusted RR, 2.7; P = 0.054).
   Conclusions: Nine-year data on natural history indicate that early AMD is common in this population of African origin, although late AMD is infrequent. These long-term observations provide further evidence for the lower AMD risk in black populations compared with white populations.
C1 SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA.
   Minist Hlth, Bridgetown, Barbados.
   Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   Univ W Indies, Sch Clin Med & Res, Chron Dis Res Ctr, Bridgetown, Barbados.
C3 State University of New York (SUNY) System; SUNY Community College;
   State University of New York (SUNY) Stony Brook; Johns Hopkins
   University; Johns Hopkins Medicine; University West Indies Mona Jamaica;
   University of the West Indies Open Campus
RP Leske, MC (通讯作者)，SUNY Stony Brook, Dept Prevent Med, HSC L3 086, Stony Brook, NY 11794 USA.
EM cleske@notes.cc.sunysb.edu
FU NATIONAL EYE INSTITUTE [U10EY007625, U10EY007617] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY07625, EY07617] Funding Source: Medline
CR BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Leske MC, 2004, OPHTHALMOLOGY, V111, P483, DOI 10.1016/j.ophtha.2003.06.016
   Leske MC, 2004, OPHTHALMOLOGY, V111, P118, DOI 10.1016/j.ophtha.2003.04.002
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Leske MC, 2001, ARCH OPHTHALMOL-CHIC, V119, P89
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Singer J. D., 2003, APPL LONGITUDINAL DA, DOI 10.1093/acprof:oso/9780195152968.001.0001
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
NR 38
TC 52
Z9 56
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2006
VL 113
IS 1
BP 29
EP 35
DI 10.1016/j.ophtha.2005.08.012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 998JJ
UT WOS:000234314400005
PM 16290049
DA 2022-11-30
ER

PT J
AU Patel, N
   Ohbayashi, M
   Nugent, AK
   Ramchand, K
   Toda, M
   Chau, KY
   Bunce, C
   Webster, A
   Bird, AC
   Ono, SJ
   Chong, V
AF Patel, N
   Ohbayashi, M
   Nugent, AK
   Ramchand, K
   Toda, M
   Chau, KY
   Bunce, C
   Webster, A
   Bird, AC
   Ono, SJ
   Chong, V
TI Circulating anti-retinal antibodies as immune markers in age-related
   macular degeneration
SO IMMUNOLOGY
LA English
DT Article
DE age-related macular degeneration; aging; auto-antibodies; drusen;
   retina; retinal pigment epithelium
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CANCER-ASSOCIATED RETINOPATHY; COMPLEMENT
   ACTIVATION; AUTOIMMUNE-DISEASES; HISTONE ANTIBODIES; DRUSEN FORMATION;
   AUTOANTIBODIES; PROTEIN; ATHEROSCLEROSIS; MACULOPATHY
AB Age-related macular maculopathy (ARM) and age-related macular degeneration (AMD) are the leading causes of blindness in the Western world. Despite the magnitude of this clinical problem, very little is known about the pathogenesis of the disease. In this study, we analysed the sera (using indirect immunohistochemistry and Western blot analysis) from a very large cohort of such patients and normal age-matched controls to detect circulating anti-retinal antibodies. Patients with bilateral drusen (n = 64) and with chorioretinal neovascularization (CNV) (n = 51) were recruited in addition to age-matched control subjects (n = 39). The sera were analysed for anti-retinal immunoglobulins on retinal sections. The data were then correlated with the clinical features graded according to the International Classification and Grading System of ARM and AMD. The sera of patients with drusen (93.75%) and CNV (82.27%) were found to have a significantly (P = 0.02) higher titre of autoantibodies to the retina in comparison with controls (8.69%), indicating significant evidence of involvement of the immune process in early stages of AMD. Subsequent statistical analysis of the drusen group showed significant progressive staining (P = 0.0009) in the nuclei layers from early to late stages of ARM. Western blotting confirmed the presence of anti-retinal immunoglobulins to retinal antigens. As anti-retinal immunoglobulins are present in patients with bilateral drusen and exudative AMD, these antibodies could play a significant role in the pathogenesis of AMD. Whilst we do not have evidence that these antibodies precede disease onset, the possibility that their presence might contribute to disease progression needs to be investigated. Finally, the eventual identification of the target antigens detected by these antibodies may permit the future development of new diagnostic methods for ARM and AMD.
C1 UCL, Dept Immunol, Inst Ophthalmol, London EC1V 9EL, England.
   Kings Coll Hosp London, Retinal Res Unit, London, England.
   Univ London Sch Med, London, England.
C3 University of London; University College London; King's College Hospital
   NHS Foundation Trust; King's College Hospital; University of London
RP Ono, SJ (通讯作者)，UCL, Dept Immunol, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM santa.ono@ucl.ac.uk
RI Toda, Masako/S-9810-2019; Chau, Kai-Yin (David)/C-2845-2011; Chong,
   Ngaihang V/A-5141-2009; Chong, Victor/Q-6565-2018; Chau,
   David/P-8335-2019
OI Chong, Victor/0000-0002-7693-522X; Chau, David/0000-0002-5797-2922;
   Bunce, Catey/0000-0002-0935-3713
CR Adamus G, 1998, J AUTOIMMUN, V11, P671, DOI 10.1006/jaut.1998.0239
   Adamus G, 2003, AUTOIMMUN REV, V2, P63, DOI 10.1016/S1568-9972(02)00127-1
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   BAEKKESKOV S, 1984, SCIENCE, V224, P1348, DOI 10.1126/science.6374896
   BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0
   Betterle C, 2002, ENDOCR REV, V23, P327, DOI 10.1210/er.23.3.327
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen H, 1993, Yan Ke Xue Bao, V9, P113
   Cortes-Hernandez J, 2004, AM J MED, V116, P165, DOI 10.1016/j.amjmed.2003.08.034
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eichen JG, 2001, J NEURO-OPHTHALMOL, V21, P168, DOI 10.1097/00041327-200109000-00003
   GIOUD M, 1982, ARTHRITIS RHEUM, V25, P407, DOI 10.1002/art.1780250408
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lernmark A, 2001, J CLIN INVEST, V108, P1091, DOI 10.1172/JCI200114234
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Notkins AL, 2001, J CLIN INVEST, V108, P1247, DOI 10.1172/JCI200114257
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Schett G, 2002, LUPUS, V11, P704, DOI 10.1191/0961203302lu247oa
   SHOENFELD Y, 1989, CLIN EXP RHEUMATOL, V7, P265
   THIRKILL CE, 1992, INVEST OPHTH VIS SCI, V33, P2768
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wu L, 1996, Yan Ke Xue Bao, V12, P58
   Zanone MM, 2003, METABOLISM, V52, P25, DOI 10.1053/meta.2003.50003
NR 32
TC 96
Z9 101
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD JUL
PY 2005
VL 115
IS 3
BP 422
EP 430
DI 10.1111/j.1365-2567.2005.02173.x
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 934AZ
UT WOS:000229680200015
PM 15946260
OA Green Published
DA 2022-11-30
ER

PT J
AU Carneiro, AM
   Barthelmes, D
   Falcao, MS
   Mendonca, LS
   Fonseca, SL
   Goncalves, RM
   Faria-Correia, F
   Falcao-Reis, FM
AF Carneiro, Angela M.
   Barthelmes, Daniel
   Falcao, Manuel S.
   Mendonca, Luis S.
   Fonseca, Sofia L.
   Goncalves, Rita M.
   Faria-Correia, Fernando
   Falcao-Reis, Fernando M.
TI Arterial Thromboembolic Events in Patients with Exudative Age-Related
   Macular Degeneration Treated with Intravitreal Bevacizumab or
   Ranibizumab
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration, exudative; Arterial thromboembolic
   events; Bevacizumab; Ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; CARDIOVASCULAR-DISEASE;
   MYOCARDIAL-INFARCTION; NITRIC-OXIDE; PHOTODYNAMIC THERAPY;
   CANCER-PATIENTS; VEGF-A; ANGIOGENESIS; PREVALENCE; MACULOPATHY
AB Background/Aims: To compare retrospectively the incidence of arterial thromboembolic events (ATEs) in patients treated with bevacizumab or ranibizumab for exudative age-related macular degeneration. Methods: Charts of 378 patients treated with at least 1 intravitreal injection of ranibizumab or bevacizumab were reviewed to calculate the incidence of ATEs. Only patients under monotherapy were analyzed. Results: ATEs occurred in 15 patients: 12 (12/97) with bevacizumab (12.4%) and 3 (3/219) with ranibizumab (1.4%) - odds ratio 10.16; 95% confidence interval 2.80-36.93; p < 0.0001. ATEs in the bevacizumab and ranibizumab cohorts included stroke, myocardial infarction, angina pectoris, peripheral thromboembolic disease, transient ischemic attack, sudden death and lethal stroke. Conclusion: In this series, bevacizumab raised the risk of ATEs when compared to ranibizumab. In an elderly population with multiple cardiovascular risk factors, the new ATEs may not be attributed exclusively to the intravitreal bevacizumab administration. These findings raise an issue that must be confirmed in randomized clinical trials. Copyright (C) 2011 S. Karger AG, Basel
C1 [Carneiro, Angela M.; Falcao, Manuel S.; Falcao-Reis, Fernando M.] Univ Porto, Dept Ophthalmol, Hosp Sao Joao, Fac Med, P-4200319 Oporto, Portugal.
   [Barthelmes, Daniel] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
C3 Sao Joao Hospital; Universidade do Porto; University of Sydney
RP Carneiro, AM (通讯作者)，Univ Porto, Dept Ophthalmol, Hosp Sao Joao, Fac Med, Al Prof Hernani Monteiro, P-4200319 Oporto, Portugal.
EM angelacarneiro@netcabo.pt
RI Carneiro, Angela/N-9680-2013; Falcao/AAQ-8509-2020
OI Carneiro, Angela/0000-0002-3370-7243; Falcao/0000-0003-4718-0910;
   Falcao-Reis, Fernando/0000-0002-5995-9430; Fonseca,
   Sofia/0000-0001-5365-6220; Faria-Correia, Fernando/0000-0002-8824-7862
FU Sociedade Portuguesa de Oftalmologia; Hospital de Sao Joao; Swiss
   National Foundation; Walter and Gertrud Siegenthaler Foundation, Zurich,
   Switzerland
FX We thank Prof. Eric Souied for helpful criticisms and also the
   technicians Hugo Monteiro, Paulo Rocha and Fatima Matos for their
   dedication and work. This work was supported by grants from the
   Sociedade Portuguesa de Oftalmologia (to A.C.), Hospital de Sao Joao (to
   A.C.), Swiss National Foundation (to D.B.) and the Walter and Gertrud
   Siegenthaler Foundation, Zurich, Switzerland (to D.B.).
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carneiro A, 2009, EXP EYE RES, V88, P522, DOI 10.1016/j.exer.2008.11.011
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Correia M, 2004, STROKE, V35, P2048, DOI 10.1161/01.STR.0000137606.34301.13
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   DEGRAAF JC, 1992, CIRCULATION, V85, P2284, DOI 10.1161/01.CIR.85.6.2284
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gabriel R, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-360
   Gardete-Correia L, 2010, DIABETIC MED, V27, P879, DOI 10.1111/j.1464-5491.2010.03017.x
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hata Y, 2000, J CLIN INVEST, V106, P541, DOI 10.1172/JCI8338
   Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719
   Kuenen BC, 2002, ARTERIOSCL THROM VAS, V22, P1500, DOI 10.1161/01.ATV.0000030186.66672.36
   Labianca R, 2010, CRIT REV ONCOL HEMAT, V74, P106, DOI 10.1016/j.critrevonc.2010.01.010
   Lee K, 2009, RETINA-J RET VIT DIS, V29, P1409, DOI 10.1097/IAE.0b013e3181b21056
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Los M, 2007, ONCOLOGIST, V12, P443, DOI 10.1634/theoncologist.12-4-443
   Macedo ME, 2005, J HYPERTENS, V23, P1661, DOI 10.1097/01.hjh.0000179908.51187.de
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Matsunaga T, 2000, CIRCULATION, V102, P3098
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Meyer T, 2009, J THROMB HAEMOST, V7, P171, DOI 10.1111/j.1538-7836.2008.03212.x
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99
   Nissen NN, 1998, AM J PATHOL, V152, P1445
   Oliveira A, 2010, AM J CLIN NUTR, V92, P211, DOI 10.3945/ajcn.2009.29075
   Pereg D, 2008, EUR HEART J, V29, P2325, DOI 10.1093/eurheartj/ehn384
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sans S, 2005, EUR HEART J, V26, P505, DOI 10.1093/eurheartj/ehi068
   Sassa Y, 2010, CLIN OPHTHALMOL, V4, P275
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Sheybani A, 2009, RETINA-J RET VIT DIS, V29, P1404, DOI 10.1097/IAE.0b013e3181b32d13
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Triano LR, 2010, DRUGS, V70, P167, DOI 10.2165/11532200-000000000-00000
   Valachis A, 2010, BREAST CANCER RES TR, V122, P1, DOI 10.1007/s10549-009-0727-0
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Yannuzzi LA, 1995, THE RETINA ATLAS
   YAO SK, 1992, CIRCULATION, V86, P1302, DOI 10.1161/01.CIR.86.4.1302
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375
NR 72
TC 43
Z9 46
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 4
BP 211
EP 221
DI 10.1159/000323943
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749YO
UT WOS:000289508200005
PM 21336001
DA 2022-11-30
ER

PT J
AU Maberley, DAL
   Chew, H
   Ma, P
   Chang, A
   Hollands, H
   Maberley, A
AF Maberley, DAL
   Chew, H
   Ma, P
   Chang, A
   Hollands, H
   Maberley, A
TI Comparison of photodynamic therapy and transpupillary thermotherapy for
   subfoveal choroidal neovascularization due to age-related macular
   degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; choroidal neovascularization; macular degeneration;
   photodynamic therapy; transpupillary thermotherapy; verteporfin
ID VERTEPORFIN; OCCULT
AB Background: The purpose of this study was to compare photodynamic therapy (PDT) against subthreshold transpupillary thermotherapy (TTT) with a diode laser for subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
   Methods: Patients with subfoveal choroidal neovascularization secondary to AMD were offered PDT as an initial intervention. If they declined PDT, then TTT was offered.
   Results: We evaluated and followed 115 consecutive patients for an average of 1 year. The primary outcome measure was visual acuity, but the interventions were also compared on the basis of lesion size and angiographically determined lesion activity. Baseline comparisons between the 2 treatment groups showed significant differences in pretreatment visual acuity, lesion size, and lesion composition. Univariate analysis of outcomes demonstrated equivalence between the treatment groups in final lesion size, angiographic activity, and visual acuity. Multivariate analysis also demonstrated equivalence between the treatment groups in final visual acuity while controlling for age, pretreatment visual acuity, and lesion category. Predominantly classic lesions were associated with poorer visual outcomes.
   Interpretation: The PDT and TTT groups were equivalent in terms of all outcome parameters evaluated.
C1 Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada.
   Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada.
   Univ British Columbia, Fac Med, Vancouver, BC, Canada.
C3 University of British Columbia; University of Toronto; University of
   British Columbia
RP Maberley, DAL (通讯作者)，2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM crtg_vancouver@hotmail.com
CR Ahuja R M, 2001, Semin Ophthalmol, V16, P81, DOI 10.1076/soph.16.2.81.4215
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   REICHEL E, 2004, RETINA 2004 EVERYTHI
   Tranos P, 2004, ACTA OPHTHALMOL SCAN, V82, P585, DOI 10.1111/j.1600-0420.2004.00327.x
   *TREATM AG REL MAC, 1999, ARCH OPHTHALMOL-CHIC, V118, P488
NR 11
TC 9
Z9 10
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 378
EP 383
DI 10.1016/S0008-4182(05)80080-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400013
PM 15947807
DA 2022-11-30
ER

PT J
AU Ambati, J
   Anand, A
   Fernandez, S
   Sakurai, E
   Lynn, BC
   Kuziel, WA
   Rollins, BJ
   Ambati, BK
AF Ambati, J
   Anand, A
   Fernandez, S
   Sakurai, E
   Lynn, BC
   Kuziel, WA
   Rollins, BJ
   Ambati, BK
TI An animal model of age-related macular degeneration in senescent
   Ccl-2-or Ccr-2-deficient mice
SO NATURE MEDICINE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; GLYCATION
   END-PRODUCTS; CHLAMYDIA-PNEUMONIAE INFECTION; HIGH-FAT DIET; CHOROIDAL
   NEOVASCULARIZATION; BRUCHS MEMBRANE; COMPLEMENT ACTIVATION; TARGETED
   DISRUPTION; DEPOSIT FORMATION
AB The study and treatment of age-related macular degeneration (AMD), a leading cause of blindness, has been hampered by a lack of animal models. Here we report that mice deficient either in monocyte chemoattractant protein-1 (Ccl-2; also known as MCP-1) or its cognate C-C chemokine receptor-2 (Ccr-2) develop cardinal features of AMD, including accumulation of lipofuscin in and drusen beneath the retinal pigmented epithelium (RPE), photoreceptor atrophy and choroidal neovascularization (CNV). Complement and IgG deposition in RPE and choroid accompanies senescence in this model, as in human AMD. RPE or choroidal endothelial production of Ccl-2 induced by complement C5a and IgG may mediate choroidal macrophage infiltration into aged wild-type choroids. Wild-type choroidal macrophages degrade C5 and IgG in eye sections of Ccl2(-/-) or Ccr2(-/-) mice. Impaired macrophage recruitment may allow accumulation of C5a and IgG, which induces vascular endothelial growth factor (VEGF) production by RPE, possibly mediating development of CNV. These models implicate macrophage dysfunction in AMD pathogenesis and may be useful as a platform for validating therapies.
C1 Univ Kentucky, Dept Ophthalmol, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA.
   Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30907 USA.
C3 University of Kentucky; University of Kentucky; University of Kentucky;
   University of Texas System; University of Texas Austin; Harvard
   University; Brigham & Women's Hospital; Dana-Farber Cancer Institute;
   Harvard Medical School; University System of Georgia; Augusta University
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Ophthalmol, 740 S Limestone St, Lexington, KY 40536 USA.
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768; Lynn, Bert/0000-0001-8426-3024
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Bian ZM, 1996, J LEUKOCYTE BIOL, V60, P405, DOI 10.1002/jlb.60.3.405
   Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788
   Brons RH, 2001, ANN RHEUM DIS, V60, P1097, DOI 10.1136/ard.60.12.1097
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kothe H, 2000, CIRCULATION, V101, P1760, DOI 10.1161/01.CIR.101.15.1760
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   LEYS A, 1990, GRAEF ARCH CLIN EXP, V228, P499, DOI 10.1007/BF00918479
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Meda L, 1996, J IMMUNOL, V157, P1213
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919
   Roberts WG, 1997, CANCER RES, V57, P765
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SCHULZE M, 1993, AM J PATHOL, V142, P179
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
NR 47
TC 488
Z9 551
U1 0
U2 34
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2003
VL 9
IS 11
BP 1390
EP 1397
DI 10.1038/nm950
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 739AH
UT WOS:000186319700029
PM 14566334
DA 2022-11-30
ER

PT J
AU Rossi, EA
   Rangel-Fonseca, P
   Parkins, K
   Fischer, W
   Latchney, LR
   Folwell, MA
   Williams, DR
   Dubra, A
   Chung, MM
AF Rossi, Ethan A.
   Rangel-Fonseca, Piero
   Parkins, Keith
   Fischer, William
   Latchney, Lisa R.
   Folwell, Margaret A.
   Williams, David R.
   Dubra, Alfredo
   Chung, Mina M.
TI In vivo imaging of retinal pigment epithelium cells in age related
   macular degeneration
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; FLUORESCENCE
AB Morgan and colleagues demonstrated that the RPE cell mosaic can be resolved in the living human eye non-invasively by imaging the short-wavelength autofluorescence using an adaptive optics (AO) ophthalmoscope. This method, based on the assumption that all subjects have the same longitudinal chromatic aberration (LCA) correction, has proved difficult to use in diseased eyes, and in particular those affected by age-related macular degeneration (AMD). In this work, we improve Morgan's method by accounting for chromatic aberration variations by optimizing the confocal aperture axial and transverse placement through an automated iterative maximization of image intensity. The increase in image intensity after algorithmic aperture placement varied depending upon patient and aperture position prior to optimization but increases as large as a factor of 10 were observed. When using a confocal aperture of 3.4 Airy disks in diameter, images were obtained using retinal radiant exposures of less than 2.44 J/cm(2), which is similar to 22 times below the current ANSI maximum permissible exposure. RPE cell morphologies that were strikingly similar to those seen in postmortem histological studies were observed in AMD eyes, even in areas where the pattern of fluorescence appeared normal in commercial fundus autofluorescence (FAF) images. This new method can be used to study RPE morphology in AMD and other diseases, providing a powerful tool for understanding disease pathogenesis and progression, and offering a new means to assess the efficacy of treatments designed to restore RPE health. (C) 2013 Optical Society of America
C1 [Rossi, Ethan A.; Parkins, Keith; Folwell, Margaret A.; Williams, David R.; Chung, Mina M.] Univ Rochester, Ctr Visual Sci, Rochester, NY 14642 USA.
   [Rangel-Fonseca, Piero] Ctr Invest Opt, Leon 37150, Gto, Mexico.
   [Fischer, William; Latchney, Lisa R.; Chung, Mina M.] Univ Rochester, Flaum Eye Inst, Rochester, NY 14642 USA.
   [Williams, David R.] Univ Rochester, Inst Opt, Rochester, NY 14642 USA.
   [Dubra, Alfredo] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA.
   [Dubra, Alfredo] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA.
C3 University of Rochester; CIO - Centro de Investigaciones en Optica A.C.;
   University of Rochester; University of Rochester; Medical College of
   Wisconsin; Medical College of Wisconsin
RP Rossi, EA (通讯作者)，Univ Rochester, Ctr Visual Sci, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM erossi@cvs.rochester.edu
RI RANGEL-FONSECA, Piero/B-9332-2015; Rossi, Ethan/A-7933-2013; Rossi,
   Ethan/AAC-6204-2019
OI Rossi, Ethan/0000-0003-3210-0551; Rossi, Ethan/0000-0003-3210-0551;
   Rangel-Fonseca, Piero/0000-0002-6254-0550; Williams, David
   R/0000-0003-3227-8333; Dubra, Alfredo/0000-0002-6506-9020
FU NIH [F32EY021669, EY021786, EY014375, EY004367, EY007125]; Fight for
   Sight [FFS-PD-11-020]; Edward N. & Della L. Thome Memorial Foundation;
   Research to Prevent Blindness; NATIONAL EYE INSTITUTE [F32EY021669,
   P30EY001319, T32EY007125, R01EY014375, R01EY021786, R01EY004367] Funding
   Source: NIH RePORTER
FX The authors wish to thank Jennifer J. Hunter, Ph.D. for helpful
   discussions concerning light safety. This work was supported by NIH
   grants F32EY021669, EY021786, EY014375, EY004367, and EY007125, a
   postdoctoral award to Ethan A. Rossi, Ph.D., from Fight for Sight
   (FFS-PD-11-020), a grant from the Edward N. & Della L. Thome Memorial
   Foundation to Mina M. Chung, M.D. Alfredo Dubra-Suarez, Ph.D., holds a
   Career Award at the Scientific Interface from the Burroughs Wellcome
   Fund and a Career Development Award from Research to Prevent Blindness.
   This research was also supported by unrestricted departmental grants
   from Research to Prevent Blindness.
CR Adler R, 1999, MOL VIS, V5
   American National Standards Institute, ANSIZ13612007
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Borggaard J., 2009, NELDER MEAD COMPUTER
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DELORI FC, INVEST OPHTHALMOL VI, V41, P496
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1757, DOI 10.1364/BOE.2.001757
   Dubra A, 2010, LECT NOTES COMPUT SC, V6204, P60, DOI 10.1007/978-3-642-14366-3_6
   Fernandez EJ, 2005, OPT EXPRESS, V13, P400, DOI 10.1364/OPEX.13.000400
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gray DC, 2006, OPT EXPRESS, V14, P7144, DOI 10.1364/OE.14.007144
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Grieve K, 2006, OPT EXPRESS, V14, P12230, DOI 10.1364/OE.14.012230
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kleiner M, 2007, PERCEPTION, V36, P14
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Morgan J. I. W., 2008, IN VIVO IMAGING RETI
   Morgan JIW, 2008, INVEST OPHTH VIS SCI, V49, P3715, DOI 10.1167/iovs.07-1430
   Morgan JIW, 2009, INVEST OPHTH VIS SCI, V50, P6015, DOI 10.1167/iovs.09-3643
   Morgan JIW, 2009, INVEST OPHTH VIS SCI, V50, P1350, DOI 10.1167/iovs.08-2618
   NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Rangel-Fonseca P., AUTOMATED SEGM UNPUB
   Rossi E. A., 2012, INVEST OPHTHALMOL VI, V53
   Rossi E. A., 2013, ROCHESTER EXPOSURE L
   Rossi E. A., 2011, ENG EYE 3 BEN SPAIN, VIII
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Sliney DH, 2010, INVEST OPHTH VIS SCI, V51
   THIBOS LN, 1992, APPL OPTICS, V31, P3594, DOI 10.1364/AO.31.003594
   Von Ruckmann A, 2002, AM J OPHTHALMOL, V133, P780, DOI 10.1016/S0002-9394(02)01428-9
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
NR 39
TC 70
Z9 93
U1 0
U2 14
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD NOV 1
PY 2013
VL 4
IS 11
BP 2527
EP 2539
DI 10.1364/BOE.4.002527
PG 13
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 246ZW
UT WOS:000326582500021
PM 24298413
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Oishi, A
   Mandai, M
   Nishida, A
   Hata, M
   Matsuki, T
   Kurimoto, Y
AF Oishi, Akio
   Mandai, Michiko
   Nishida, Akihiro
   Hata, Masayuki
   Matsuki, Takaaki
   Kurimoto, Yasuo
TI Remission and dropout rate of anti-VEGF therapy for age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Pegaptanib; Ranibizumab
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   VISUAL-ACUITY; RANIBIZUMAB; VERTEPORFIN; TRIAL; OUTCOMES; REGIMEN
AB PURPOSE. Anti-vascular endothelial growth factor (VEGF) therapy is a first-line treatment for age-related macular degeneration (AMD) but frequent visits and injections can be a burden for patients. The purpose of this study is to estimate the remission rate and tolerability of anti-VEGF therapy for AMD in a clinical setting.
   METHODS. We investigated 90 eyes of 87 patients with AMD who underwent anti-VEGF therapy and were followed for more than 6 months. Ranibizumab and pegaptanib were used as anti-VEGF agents. Initial therapy was any of the following: a single injection, 3 consecutive monthly injections, or combination therapy with verteporfin. Additional injections were given as-needed during follow-up. An injection-free period greater than 6 months at the final observation was regarded as cessation; the reason for cessation was studied for each patient. Clinical characteristics were compared between patents with and without cessation.
   RESULTS. The mean follow-up period was 12.8 months. Mean logMAR before and 6 months after the treatment was 0.89 and 0.83, respectively. Cessation was noted in 32 eyes of 31 patients (35.6%). Remission was achieved in 13 (40.6%) of these eyes. The other cases either did not wish to undergo further treatment or dropped out. Poor baseline visual acuity (VA) was associated with cessation.
   CONCLUSIONS. With current anti-VEGF therapy, remission was achieved in a limited number of AMD cases. The high frequency of voluntary cessation warrants consideration of an alternative treatment and/or supportive care for those with poor baseline VA.
C1 [Oishi, Akio] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, Kobe, Hyogo 6500046, Japan.
   [Mandai, Michiko] RIKEN, Ctr Dev Biol, Lab Retinal Regenerat, Kobe, Hyogo, Japan.
C3 Kobe City Medical Center General Hospital; RIKEN
RP Oishi, A (通讯作者)，Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, 4-6 Minatojima Minamimachi, Kobe, Hyogo 6500046, Japan.
EM aquio@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458
FU Japanese Society for the Promotion of Science, Tokyo, Japan [22791706]
FX Supported in part by Grant-In-Aid for Scientific Research (No. 22791706)
   from the Japanese Society for the Promotion of Science, Tokyo, Japan.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1991, Arch Ophthalmol, V109, P1232
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Potter MJ, 2006, GRAEF ARCH CLIN EXP, V244, P1026, DOI 10.1007/s00417-005-0204-3
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
NR 21
TC 36
Z9 40
U1 0
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2011
VL 21
IS 6
BP 777
EP 782
DI 10.5301/EJO.2011.7430
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 926YF
UT WOS:000302868300015
PM 21500186
DA 2022-11-30
ER

PT J
AU Postel, EA
   Agarwal, A
   Schmidt, S
   Fan, YTR
   Scott, WK
   Gilbert, JR
   Haines, JL
   Pericak-Vance, MA
AF Postel, EA
   Agarwal, A
   Schmidt, S
   Fan, YTR
   Scott, WK
   Gilbert, JR
   Haines, JL
   Pericak-Vance, MA
TI Comparing age-related macular degeneration phenotype in probands from
   singleton and multiplex families
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; MACULOPATHY; PREVALENCE; DISEASE; CLASSIFICATION;
   POPULATION; MUTATIONS; HISTORY; PIGMENT; SYSTEM
AB PURPOSE: To compare age-related macular degeneration (AMD) phenotype between probands in singleton and multiplex families to determine whether data from these two groups may be combined for consolidated genetic analyses.
   DESIGN: Retrospective case-control study.
   METHODS: Individuals 55 years of age or older with AMD were identified. Complete histories. and examinations were recorded, 35,mm fundus photographs obtained, and macular findings graded. Detailed information was recorded, including the presence of extramacular and peripheral drusen, peripheral reticular pigmentary change, posterior vitreous detachment, and iris color. Comparisons were performed between probands from singleton and multiplex families.
   RESULTS: There was no statistically significant difference in grade between the 411 singleton and 125 multiplex probands (P = .52), and the distribution of grades was similar between the two groups. No statistically significant difference was found between proband groups with respect to the presence or extent of small (P = .48), intermediate (P = .72), and large drusen (P = .74) and retinal pigment epithelium hyper, (P = .76) and hypo, pigmentation (P = .55); in the presence or grade of peripheral reticular pigment change; the presence of geographic atrophy in exudative disease, extramacular drusen, or posterior vitreous detachment; lens status; iris color; visual acuity; intraocular pressure; optic nerve cupping; and body mass index. A statistically significant difference between the two groups was noted in the presence of peripheral drusen (P = .0001).
   CONCLUSIONS: Singleton and multiplex AMD probands share a similar phenotype. This suggests that multiplex and singleton data can be combined for consolidated genetic analyses. (c) 2005 by Elsevier Inc. All rights reserved.
C1 Duke Univ, Ctr Eye, Durham, NC 27710 USA.
   Vanderbilt Eye Inst, Nashville, TN USA.
   Duke Univ, Ctr Human Genet, Durham, NC 27710 USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
C3 Duke University; Vanderbilt University; Duke University; Vanderbilt
   University
RP Postel, EA (通讯作者)，Duke Univ, Ctr Eye, Box 3802, Durham, NC 27710 USA.
EM poste002@mc.duke.edu
RI Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NATIONAL EYE INSTITUTE [U10EY012118] Funding Source: NIH RePORTER; NEI
   NIH HHS [U10 EY 12118] Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Badano JL, 2003, HUM MOL GENET, V12, P1651, DOI 10.1093/hmg/ddg188
   Bensen JT, 1999, GENET EPIDEMIOL, V17, P141, DOI 10.1002/(SICI)1098-2272(1999)17:2<141::AID-GEPI4>3.0.CO;2-Q
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Daiger Stephen P, 2004, Novartis Found Symp, V255, P17
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   GETTY DJ, 1989, CURR EYE RES, V8, P1, DOI 10.3109/02713688909013889
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Seddon JM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71716-7
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   Young P, 2001, J NEUROL, V248, P410, DOI 10.1007/s004150170183
   Ziogas A, 2003, AM J PREV MED, V24, P190, DOI 10.1016/S0749-3797(02)00593-7
NR 35
TC 24
Z9 25
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2005
VL 139
IS 5
BP 820
EP 825
DI 10.1016/j.ajo.2004.12.029
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 924AJ
UT WOS:000228950500008
PM 15860286
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Kumar, H
   Hodgson, LAB
   Guymer, RH
AF Wu, Zhichao
   Kumar, Himeesh
   Hodgson, Lauren A. B.
   Guymer, Robyn H.
TI Reticular Pseudodrusen on the Risk of Progression in Intermediate
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS;
   GEOGRAPHIC-ATROPHY; FELLOW-EYES; CLINICAL-FEATURES; DARK-ADAPTATION;
   ASSOCIATION; DISEASE; NEOVASCULARIZATION; PREVALENCE
AB PURPOSE: To examine the association between reticular pseudodrusen (RPD) and progression to late age-related macular degeneration (AMD) in individuals with intermediate AMD. DESIGN: Prospective cohort study. METHODS: Two hundred eighty eyes from 140 participants with bilateral large drusen underwent multimodal imaging (MMI), including optical coherence tomography (OCT), near-infrared reflectance (NIR), fundus autofluorescence, and color fundus photography (CFP), at 6 monthly intervals up over a 36-month follow-up period. The presence of RPD per eye was determined based on either a combined MMI criterion, or each individual imaging modality, and their extent measured on combined OCT and NIR imaging. The association between the presence of RPD on different imaging modalities, and their extent, with the development of late AMD (including OCT-defined atrophy) was evaluated. RESULTS: The presence of RPD on MMI, or any of its individual modalities, at baseline was not significantly associated with an increased rate of developing late AMD, with or without adjusting for risk factors for AMD progression (age, drusen volume on OCT, and pigmentary abnormalities on CFP; all P > 0.205). The extent of RPD present was also not significantly associated with an increased rate of developing late AMD, with or without adjustment for risk factors for AMD progression (both P > 0.522). CONCLUSIONS: In this cohort with bilateral large drusen, the presence of RPD was not significantly associated with an increased risk of developing late AMD. Additional longitudinal studies in all stages of AMD are needed to understand the implications of RPD on vision loss in this condition. (C) 2022 Elsevier Inc. All rights reserved.
C1 [Wu, Zhichao; Kumar, Himeesh; Hodgson, Lauren A. B.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Wu, Zhichao; Kumar, Himeesh; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Wu, Zhichao] Ctr Eye Res Australia, Level 7,32 Gisbome St, East Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Centre for Eye Research Australia
RP Wu, ZC (通讯作者)，Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.; Wu, ZC (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisbome St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Kumar, Himeesh/0000-0001-9169-5335;
   Hodgson, Lauren/0000-0002-9492-3927
FU ACKNOWLEDGMENTS/DISCLOSURES [APP1181010, APP1138253, GNT1103013,
   2008382]; National Health & Medical Research Council of Australia;
   Macular Disease Foundation Australia
FX Funding Support: This study was supported by the National Health &
   Medical Research Council of Australia (grants APP1181010 [R.H.G., Z.W.]
   and APP1138253 [R.H.G.] , and fellowship GNT1103013 [R.H.G.] and
   #2008382 [Z.W.] ) and a Macular Disease Foundation Australia grant
   (Z.W., R.H.G.) . The Centre for Eye Research Australia (CERA) receives
   operational infrastructure support from the Victorian Government. The
   funders had no role in the manuscript writing and the decision to submit
   the manuscript for publication.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Cozzi M, 2020, OPHTHALMOL RETINA, V4, P987, DOI 10.1016/j.oret.2020.04.013
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Luu CD, 2018, OPHTHALMOL RETINA, V2, P1206, DOI 10.1016/j.oret.2018.06.016
   Lynch AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.12
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   McCarthy LC, 2012, AM J OPHTHALMOL, V154, P568, DOI 10.1016/j.ajo.2012.03.021
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sample PA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1136, DOI 10.1001/archophthalmol.2009.187
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Thee EF, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.26
   Thiele S, 2020, OPHTHALMOL RETINA, V4, P31, DOI 10.1016/j.oret.2019.08.003
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Wu ZC, 2019, OPHTHALMOL RETINA, V3, P1026, DOI 10.1016/j.oret.2019.07.008
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
   Zhang GY, 2021, LANCET DIGIT HEALTH, V3, pE665, DOI 10.1016/S2589-7500(21)00134-5
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zhou Q, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149030
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2022
VL 239
BP 202
EP 211
DI 10.1016/j.ajo.2022.03.007
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1V7CL
UT WOS:000806243000021
PM 35288077
DA 2022-11-30
ER

PT J
AU Qiu, YY
   Sun, TT
   Xu, FJ
   Gao, P
   Tang, GY
   Peng, Q
AF Qiu, Yaoyan
   Sun, Tingting
   Xu, Feijia
   Gao, Peng
   Tang, Guangyu
   Peng, Qing
TI Correlation of vascular change and cognitive impairment in age-related
   macular degeneration patients
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Optical coherence tomography angiography; cognitive impairment;
   age-related macular degeneration
ID NEOVASCULARIZATION
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness among the elderly. However, the correlation between vascular change and cognitive impairment in AMD disease is still unknown. In our study, we investigate the blood flow change among different layers of the retina in the AMD eye and normal fellow eye of AMD patients and its influence with patients' cognition. Our study applies optical coherence tomography angiography (OCTA) to assess the blood flow of the retina in AMD patients and the healthy controls (HCs). Magnetic resonance imaging (MRI) and Montreal Cognitive Assessment (MoCA) were performed to evaluate the cognitive change of the individuals. The results showed that deep capillary plexus density, superficial capillary plexus density, retina thickness and retinal nerve fiber layer thickness deduction existed in both eyes of the AMD patient compared with the HCs. The reduced vessel density in the choroidal layer only existed in the AMD eye of the patients while the fellow eye of patients and HCs did not change much. Furthermore, the AMD patient got a lower MoCA score compared to the HCs. Our results illustrate that the fellow eye of the AMD patient underwent vessel density change, which may lead to the early stage of AMD. The lower score of the MoCA test in AMD patients refers to the cognitive impairment. These findings show the significance of taking actions to prevent the progress of AMD in the fellow eye, as well as paying more attention to the development of cognitive impairment of these patients.
C1 [Qiu, Yaoyan; Gao, Peng; Peng, Qing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, 301 Yanchang Rd, Shanghai 200072, Peoples R China.
   [Sun, Tingting] Fudan Univ, Dept Ophthalmol, Huashan Hosp, Shanghai 200040, Peoples R China.
   [Xu, Feijia; Tang, Guangyu] Tongji Univ, Shanghai Peoples Hosp 10, Dept Radiol, 301 Yanchang Rd, Shanghai 200072, Peoples R China.
C3 Tongji University; Fudan University; Tongji University
RP Gao, P; Peng, Q (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, 301 Yanchang Rd, Shanghai 200072, Peoples R China.; Tang, GY (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Radiol, 301 Yanchang Rd, Shanghai 200072, Peoples R China.
EM neocloudy@hotmail.com; tgy17@tongji.edu.cn; drqingpeng@126.com
OI Peng, Qing/0000-0002-6991-9432
FU National Natural Science Foundation of China [81470025]; Shanghai
   Municipal Health Commission [ZY(2018-2020)-ZWB-1001-CPJS10]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 81470025), and by Shanghai Municipal Health
   Commission (No. ZY(2018-2020)-ZWB-1001-CPJS10).
CR Ahn SM, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0866-3
   Akil H, 2019, CAN J OPHTHALMOL, V54, P519, DOI 10.1016/j.jcjo.2019.02.010
   Au A, 2019, INVEST OPHTH VIS SCI, V60, P3310, DOI 10.1167/iovs.18-26478
   Bulut M, 2018, BRIT J OPHTHALMOL, V102, P233, DOI 10.1136/bjophthalmol-2017-310476
   Camacho P, 2017, OPHTHALMOLOGICA, V238, P31, DOI 10.1159/000468965
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Choi M, 2020, AM J OPHTHALMOL, V213, P109, DOI 10.1016/j.ajo.2020.01.012
   Choi S, 2020, AM J OPHTHALMOL, V210, P41, DOI 10.1016/j.ajo.2019.11.001
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Cui RX, 2019, IEEE J BIOMED HEALTH, V23, P2099, DOI 10.1109/JBHI.2018.2882392
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Dubois B, 2016, ALZHEIMERS DEMENT, V12, P292, DOI 10.1016/j.jalz.2016.02.002
   Eguchi A, 2019, CURR ALZHEIMER RES, V16, P852, DOI 10.2174/1567205016666190805155230
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Hua DH, 2020, MICROVASC RES, V129, DOI 10.1016/j.mvr.2019.103969
   Iiboshi K, 2020, TELEMED E-HEALTH, V26, P920, DOI 10.1089/tmj.2019.0134
   Invernizzi A, 2019, CLIN EXP OPHTHALMOL, V47, P357, DOI 10.1111/ceo.13470
   Kim JM, 2019, SEMIN OPHTHALMOL, V34, P168, DOI 10.1080/08820538.2019.1620791
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee J, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0811-x
   Liesz A, 2019, SCIENCE, V365, P223, DOI 10.1126/science.aay2720
   Magrath GN, 2017, RETINA-J RET VIT DIS, V37, P2102, DOI 10.1097/IAE.0000000000001458
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   O'Bryhim BE, 2018, JAMA OPHTHALMOL, V136, P1242, DOI 10.1001/jamaophthalmol.2018.3556
   Salobrar-Garcia E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220535
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Trinh M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.20
   Waksmunski AR, 2019, INVEST OPHTH VIS SCI, V60, P4041, DOI 10.1167/iovs.19-27827
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
   Zhang LJ, 2019, HUM MOL GENET, V28, P3475, DOI 10.1093/hmg/ddz159
NR 33
TC 0
Z9 1
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2021
VL 13
IS 1
BP 336
EP 348
PG 13
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA QB4JN
UT WOS:000614106800007
PM 33527028
DA 2022-11-30
ER

PT J
AU de Sisternes, L
   Simon, N
   Tibshirani, R
   Leng, T
   Rubin, DL
AF de Sisternes, Luis
   Simon, Noah
   Tibshirani, Robert
   Leng, Theodore
   Rubin, Daniel L.
TI Quantitative SD-OCT Imaging Biomarkers as Indicators of Age-Related
   Macular Degeneration Progression
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography;
   statistical modeling; risk assessment; prediction
ID OPTICAL COHERENCE TOMOGRAPHY; DRUSEN; PREDICTION; RISK; SEGMENTATION;
   VALIDATION; HAPLOTYPE; MODEL; EYES; AREA
AB PURPOSE. We developed a statistical model based on quantitative characteristics of drusen to estimate the likelihood of conversion from early and intermediate age-related macular degeneration (AMD) to its advanced exudative form (AMD progression) in the short term (less than 5 years), a crucial task to enable early intervention and improve outcomes.
   METHODS. Image features of drusen quantifying their number, morphology, and reflectivity properties, as well as the longitudinal evolution in these characteristics, were automatically extracted from 2146 spectral-domain optical coherence tomography (SD-OCT) scans of 330 AMD eyes in 244 patients collected over a period of 5 years, with 36 eyes showing progression during clinical follow-up. We developed and evaluated a statistical model to predict the likelihood of progression at predetermined times using clinical and image features as predictors.
   RESULTS. Area, volume, height, and reflectivity of drusen were informative features distinguishing between progressing and nonprogressing cases. Discerning progression at follow-up (mean, 6.16 months) resulted in a mean area under the receiver operating characteristic curve (AUC) of 0.74 (95% confidence interval [CI], 0.58, 0.85). The maximum predictive performance was observed at 11 months after a patient's first early AMD diagnosis, with mean AUC 0.92 (95% CI, 0.83, 0.98). Those eyes predicted to progress showed a much higher progression rate than those predicted not to progress at any given time from the initial visit.
   CONCLUSIONS. Our results demonstrate the potential ability of our model to identify those AMD patients at risk of progressing to exudative AMD from an early or intermediate stage.
C1 [de Sisternes, Luis; Rubin, Daniel L.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.
   [Simon, Noah; Tibshirani, Robert] Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
   [Simon, Noah] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94304 USA.
   [Rubin, Daniel L.] Stanford Univ, Dept Med Biomed Informat, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; University of Washington;
   University of Washington Seattle; Stanford University; Stanford
   University
RP Leng, T (通讯作者)，Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM tedleng@stanford.edu; dlrubin@stanford.edu
RI Leng, Theodore/AAQ-7459-2020
OI Leng, Theodore/0000-0002-8461-3562
FU Bio-X Interdisciplinary Initiatives Program of Stanford University;
   Spectrum-SPADA innovation grant of Stanford University
FX Supported by a grant from the Bio-X Interdisciplinary Initiatives
   Program of Stanford University, and the Spectrum-SPADA innovation grant
   of Stanford University. The authors alone are responsible for the
   content and writing of the paper.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Akashi A, 2013, INVEST OPHTH VIS SCI, V54, P6025, DOI 10.1167/iovs.13-12630
   Alexander L, 2004, REV OPTOMETRY, V141, p1CE
   alu T ., 2013, ISRN BIOMEDICAL IMAG, P1, DOI DOI 10.1155/2013/910641
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chen Q, 2014, RETINA-J RET VIT DIS, V34, P996, DOI 10.1097/IAE.0000000000000018
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   COX DR, 1972, J R STAT SOC B, V34, P187
   De Niro JE, 2014, RETINA-J RET VIT DIS, V34, P1163, DOI 10.1097/IAE.0000000000000077
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Feigl B, 2011, CURR MED RES OPIN, V27, P1745, DOI 10.1185/03007995.2011.603301
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fitzmaurice G, 2004, APPL LONGITUDINAL AN, P326
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Friberg TR, 2011, OPHTHAL SURG LAS IM, V42, P369, DOI 10.3928/15428877-20110812-01
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Liu S, 2014, J GLAUCOMA, V23, pE45, DOI 10.1097/IJG.0b013e31829ea2a7
   NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Rubin DL, 2013, OPHTHALMOLOGY, V120, P644, DOI 10.1016/j.ophtha.2012.09.052
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P40, DOI 10.1001/archophthalmol.2010.328
   Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zysk AM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2793736
NR 42
TC 73
Z9 74
U1 1
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2014
VL 55
IS 11
BP 7093
EP 7103
DI 10.1167/iovs.14-14918
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX9IR
UT WOS:000347217300009
PM 25301882
DA 2022-11-30
ER

PT J
AU Iwata, E
   Ueno, S
   Ishikawa, K
   Ito, Y
   Uetani, R
   Piao, CH
   Kondo, M
   Terasaki, H
AF Iwata, Eiji
   Ueno, Shinji
   Ishikawa, Kohei
   Ito, Yasuki
   Uetani, Ruka
   Piao, Chang-Hua
   Kondo, Mineo
   Terasaki, Hiroko
TI Focal Macular Electroretinograms after Intravitreal Injections of
   Bevacizumab for Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; AVASTIN; RANIBIZUMAB
AB PURPOSE. To evaluate the changes in the best-corrected visual acuity (BCVA), macular thickness, and focal macular electroretinograms (FMERGs) after three intravitreal injections of bevacizumab for a choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
   METHODS. The medical records of 18 eyes of 18 patients who had received three consecutive monthly intravitreal injections of bevacizumab were retrospectively studied. The BCVA, macular thickness determined by optical coherence tomography (OCT), and FMERGs were measured before the first injection, and 10 days after each of the intravitreal bevacizumab injections.
   RESULTS. The number of eyes with improvement in BCVA after the first injection was one (6%), after the second injection was four (22%), and after the third injection was five (28%). The number of eyes with reduction in macular thickness was 4 (33%), 8 (44%), and 10 (56%) after each of the three injections. The number of eyes with increase in b-wave amplitude of the FMERGs was 7 (38%), 6 (33%), and 10 (56%) after each of the three each injections. The mean macular thickness was significantly thinner after the first injection, and the mean BCVA was significantly improved after the second injection. The mean amplitude and implicit time of the b-wave of the FMERGs were significantly improved only after the third injection (P < 0.05).
   CONCLUSIONS. All parameters improved but the best was after the third injection, indicating that three monthly intravitreous injections with bevacizumab may be an effective treatment regimen for AMD. (Invest Ophthalmol Vis Sci. 2012;53:4185-4190) DOI:10.1167/iovs.11-9335
C1 [Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Terasaki, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM terasaki@med.nagoya-u.ac.jp
RI Maruko, Ruka/M-4929-2014; Ito, Yasuki/M-4876-2014; Terasaki,
   Hiroko/M-5054-2014; Ueno, Shinji/M-5063-2014
OI Maruko, Ruka/0000-0003-0208-1011; Ito, Yasuki/0000-0001-9219-9261; 
FU Ministry of Education, Science, Sports, and Culture, Japan [2159225,
   20592075, 20390448, 23390401]; Grants-in-Aid for Scientific Research
   [23592603] Funding Source: KAKEN
FX Supported by Grants-in Aid 2159225 (YI), 20592075 (MK), 20390448 (HT),
   and 23390401 (HT) from the Ministry of Education, Science, Sports, and
   Culture, Japan.
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campa C, 2011, INVEST OPHTH VIS SCI, V52, P3446, DOI 10.1167/iovs.10-6588
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hatta Y, 2010, RETINA-J RET VIT DIS, V30, P495, DOI 10.1097/IAE.0b013e3181bcedbe
   Ishikawa K, 2005, OPHTHALMIC RES, V37, P34, DOI 10.1159/000083020
   Ishikawa K, 2008, JPN J OPHTHALMOL, V52, P182, DOI 10.1007/s10384-008-0528-8
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Karanjia R, 2008, BRIT J OPHTHALMOL, V92, P1248, DOI 10.1136/bjo.2008.138800
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Miyake Y, 1988, Nippon Ganka Gakkai Zasshi, V92, P1419
   MIYAKE Y, 1988, INVEST OPHTH VIS SCI, V29, P1631
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pedersen KB, 2010, RETINA-J RET VIT DIS, V30, P1025, DOI 10.1097/IAE.0b013e3181cafc8f
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Terasaki H, 2004, INVEST OPHTH VIS SCI, V45, P567, DOI 10.1167/iovs.03-0187
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P1540
NR 22
TC 14
Z9 14
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2012
VL 53
IS 7
BP 4185
EP 4190
DI 10.1167/iovs.11-9335
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 971CM
UT WOS:000306181200108
PM 22618591
DA 2022-11-30
ER

PT J
AU Lu, F
   Zhao, PQ
   Fan, YC
   Tang, SB
   Hu, JB
   Liu, XQ
   Yang, X
   Chen, YY
   Li, T
   Lei, CT
   Yang, JY
   Lin, Y
   Ma, S
   Li, CY
   Shi, Y
   Yang, ZL
AF Lu, Fang
   Zhao, Peiquan
   Fan, Yinchuan
   Tang, Shibo
   Hu, Jianbin
   Liu, Xiaoqi
   Yang, Xian
   Chen, Yiye
   Li, Tao
   Lei, Chuntao
   Yang, Jiyun
   Lin, Ying
   Ma, Shi
   Li, Chunyong
   Shi, Yi
   Yang, Zhenglin
TI An association study of SERPING1 gene and age-related macular
   degeneration in a Han Chinese population
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; BODY-MASS INDEX;
   ENVIRONMENTAL ASSOCIATIONS; VARIANT INCREASES; COMMON VARIATION; RISK;
   SUSCEPTIBILITY; SMOKING; CFH
AB Purpose: Single nucleotide polymorphisms (SNPs) in the complement component 1 inhibitor (SERPING1) gene have been shown to be significantly associated with age-related macular degeneration (AMD) in Caucasian populations. A replication study of an association between these SNPs and AMD in a Chinese population is reported in this study.
   Methods: Six SNPs, including rs2511990, rs1005510, rs11546660, rs2511989, rs2511988, and rs4926 in SERPING1 were genotyped in a Han Chinese subject group using the SNaPshot method of ABI. This subject group was composed of 194 patients with choroidal neovascularization (CNV or wet) AMD, 78 patients with soft drusen, and 285 matched controls. P values of the SNPs were calculated using an additive model. Haplotype frequencies between cases and controls were compared by chi 2 analysis. The haplotype analysis was performed using Haploview 4.0.
   Results: None of the six SNPs showed significant association with AMD. None of the major haplotypes were observed to be significantly associated with AMD or choroidal neovascularization AMD (CNV) after a stringent Bonferroni correction.
   Conclusions: We demonstrate that SNPs in SERPING1 are not significantly associated with AMD in the mainland Han Chinese population.
C1 [Lu, Fang; Liu, Xiaoqi; Yang, Jiyun; Lin, Ying; Ma, Shi; Li, Chunyong; Shi, Yi; Yang, Zhenglin] Sichuan Acad Med Sci, Ctr Human Mol Biol & Genet, Chengdu, Sichuan, Peoples R China.
   [Lu, Fang; Fan, Yinchuan; Hu, Jianbin; Liu, Xiaoqi; Lei, Chuntao; Yang, Jiyun; Lin, Ying; Ma, Shi; Li, Chunyong; Shi, Yi; Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
   [Zhao, Peiquan; Chen, Yiye] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
   [Fan, Yinchuan; Hu, Jianbin; Lei, Chuntao] Sichuan Acad Med Sci, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
   [Tang, Shibo; Li, Tao] Zhongshan Ophthalm Ctr, Zhongshan, Guangdong, Peoples R China.
   [Yang, Xian] Qingdao Univ, Sch Med, Dept Ophthalmol, Qingdao 266071, Peoples R China.
C3 Sichuan Provincial People's Hospital; Sichuan Provincial People's
   Hospital; Shanghai Jiao Tong University; Sichuan Provincial People's
   Hospital; Qingdao University
RP Yang, ZL (通讯作者)，Sichuan Acad Med Sci, Ctr Human Mol Biol & Genet, 32 1st Round Rd 2 W, Chengdu, Sichuan, Peoples R China.
EM zliny@yahoo.com
RI TANG, Shi/GXH-5719-2022; Yang, Jiyun/AAS-3937-2020; Chen,
   Yi-Chen/GVU-0551-2022
FU Department of Science and Technology of Sichuan Province [04JY029-045,
   05ZQ026-018]; Natural Science Foundation of China [30671182, 30771220]
FX We thank the participating AMD patients and their families. The authors
   acknowledge the following grant support (to Z. Yang): Department of
   Science and Technology of Sichuan Province (04JY029-045, 05ZQ026-018);
   Natural Science Foundation of China (30671182, 30771220).
CR Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   ARLAUD GJ, 1979, BIOCHIM BIOPHYS ACTA, V576, P151, DOI 10.1016/0005-2795(79)90494-X
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kerr FK, 2008, MOL IMMUNOL, V45, P670, DOI 10.1016/j.molimm.2007.07.008
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Murray-Rust TA, 2009, BIOCHEM J, V422, P295, DOI 10.1042/BJ20090198
   Park KH, 2009, MOL VIS, V15, P200
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   ZICCARDI RJ, 1976, J IMMUNOL, V116, P504
NR 34
TC 16
Z9 18
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 10
PY 2010
VL 16
IS 1
BP 1
EP 6
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 570SW
UT WOS:000275699300001
PM 20062564
DA 2022-11-30
ER

PT J
AU Liew, G
   Tse, B
   Ho, IV
   Joachim, N
   White, A
   Pickford, R
   Maltby, D
   Gopinath, B
   Mitchell, P
   Crossett, B
AF Liew, Gerald
   Tse, Benita
   Ho, I-Van
   Joachim, Nichole
   White, Andrew
   Pickford, Russell
   Maltby, David
   Gopinath, Bamini
   Mitchell, Paul
   Crossett, Ben
TI Acylcarnitine Abnormalities Implicate Mitochondrial Dysfunction in
   Patients With Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular degeneration; acylcarnitines; mitochondria
ID RETINAL-PIGMENT EPITHELIUM; COGNITIVE IMPAIRMENT; DNA HAPLOGROUPS;
   FATTY-ACIDS; DISEASE; SUSCEPTIBILITY; METABOLITES; MECHANISMS;
   CARNITINE; OMEGA-3
AB PURPOSE. Abnormalities in lipid metabolism are implicated in age-related macular degeneration (AMD), but the pathways involved remain unclear. We assessed whether acylcarnitine concentrations, a marker of lipid and mitochondrial metabolism, differed between patients with AMD and controls.
   METHODS. In this cross-sectional case-control study, cases (n = 81) had neovascular AMD and controls (n = 79) had cataract with no other ocular pathology. Participants were recruited from eye clinics in Western Sydney, Australia, between 2016 and 2018. Plasma blood samples were collected and liquid chromatography mass spectrometry analyses performed to identify acylcarnitine concentrations. Acylcarnitine levels were adjusted for age, gender and smoking in multivariable models. Confirmation of key acylcarnitine identities was conducted using high mass accuracy liquid chromatography-tandem mass spectrometry.
   RESULTS. After multivariable adjustment, C2-carnitine (acetylcarnitine) levels were significantly lower in patients with neovascular AMD compared to controls (0.810 +/- 0.053 (standard error) compared to 1.060 +/- 0.053), p = 0.002). C18:2-DC carnitine (a dicarboxylic acylcarnitine with a 18 carbon side chain and 2 double bonds), levels were significantly higher in patients with neovascular AMD compared to controls (1.244 +/- 0.046 compared to 1.013 +/- 0.046), p = 0.001). Other acylcarnitines examined were not significantly different between cases and controls.
   CONCLUSIONS. Reduced plasma levels of C2-carnitine (acetylcarnitine) and increased plasma levels of C18:2-DC carnitine were observed in patients with neovascular AMD compared to controls. These findings suggest mitochondrial dysfunction could be involved in the pathogenesis of neovascular AMD.
C1 [Liew, Gerald; Joachim, Nichole; White, Andrew; Gopinath, Bamini; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst Med Res, Westmead Hosp, Ctr Vis Res,Dept Ophthalmol, Sydney, NSW, Australia.
   [Liew, Gerald; Ho, I-Van] Retina Associates, Sydney, NSW, Australia.
   [Tse, Benita] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia.
   [Tse, Benita; Maltby, David; Crossett, Ben] Univ Sydney, Sydney Mass Spectrometry, Sydney, NSW, Australia.
   [Pickford, Russell] Univ New South Wales, Bioanalyt Mass Spectrometry Facil, Kensington, NSW, Australia.
C3 University of Sydney; University of Sydney; University of Sydney;
   University of New South Wales Sydney
RP Liew, G (通讯作者)，Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Westmead, NSW 2145, Australia.
EM gerald.liew@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022; White, Andrew JR/E-8462-2013; Pickford,
   Russell/F-9715-2012
OI Pickford, Russell/0000-0001-8982-7618; Ho, I-Van/0000-0002-7215-1233;
   Tse, Benita/0000-0002-0056-8056
FU Macular Degeneration Foundation Australia (MDFA); Bayer Global
   Ophthalmology Awards Program
FX Supported by grants from the Macular Degeneration Foundation Australia
   (MDFA) and the Bayer Global Ophthalmology Awards Program. The sponsors
   or funding organizations had no role in the design or conduct of this
   research.
CR Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Chew EY, 2017, OPHTHALMOLOGICA, V238, P1, DOI 10.1159/000473865
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Cristofano A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155694
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fu ZJ, 2017, INVEST OPHTH VIS SCI, V58, P3862, DOI 10.1167/iovs.17-21796
   Gallant NM, 2017, MOL GENET METAB, V122, P76, DOI 10.1016/j.ymgme.2017.06.015
   Gong Y, 2017, AM J CLIN NUTR, V106, P16, DOI 10.3945/ajcn.117.153825
   Gonzalez-Dominguez R, 2014, ELECTROPHORESIS, V35, P3321, DOI 10.1002/elps.201400196
   Han GG, 2020, J PROTEOME RES, V19, P2358, DOI 10.1021/acs.jproteome.0c00036
   Indiveri C, 2011, MOL ASPECTS MED, V32, P223, DOI 10.1016/j.mam.2011.10.008
   Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   KLER RS, 1991, J BIOL CHEM, V266, P22932
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Millington DS, 2011, METHODS MOL BIOL, V708, P55, DOI 10.1007/978-1-61737-985-7_3
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Nasca C, 2018, P NATL ACAD SCI USA, V115, P8627, DOI 10.1073/pnas.1801609115
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Ratnayake WMN, 2009, ANN NUTR METAB, V55, P8, DOI 10.1159/000228994
   Riazi-Esfahani Mohammad, 2017, J Ophthalmic Vis Res, V12, P424, DOI 10.4103/jovr.jovr_182_17
   Rinaldo P, 2008, GENET MED, V10, P151, DOI 10.1097/GIM.0b013e3181614289
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Rosca MG, 2009, ADV DRUG DELIVER REV, V61, P1332, DOI 10.1016/j.addr.2009.06.009
   Ruiz-Canela M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005705
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shah SH, 2012, AM HEART J, V163, P844, DOI 10.1016/j.ahj.2012.02.005
   Stahl A, 2011, BRIT J OPHTHALMOL, V95, P1496, DOI 10.1136/bjo.2010.194241
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Sweetman L, 2006, PEDIATRICS, V117, pS308, DOI 10.1542/peds.2005-2633J
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Traina G, 2016, FRONT BIOSCI-LANDMRK, V21, P1314, DOI 10.2741/4459
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
NR 47
TC 0
Z9 0
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2020
VL 61
IS 8
AR 32
DI 10.1167/iovs.61.8.32
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MS8BL
UT WOS:000554499000026
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Shahid, H
   Khan, JC
   Cipriani, V
   Sepp, T
   Matharu, BK
   Bunce, C
   Harding, SP
   Clayton, DG
   Moore, AT
   Yates, JRW
AF Shahid, Humma
   Khan, Jane C.
   Cipriani, Valentina
   Sepp, Tiina
   Matharu, Baljinder K.
   Bunce, Catey
   Harding, Simon P.
   Clayton, David G.
   Moore, Anthony T.
   Yates, John R. W.
CA Genetic Factors AMD Study Grp
TI Age-related macular degeneration: the importance of family history as a
   risk factor
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; BLUE MOUNTAINS EYE; MONOZYGOTIC TWINS; MACULOPATHY;
   PREVALENCE; AGGREGATION; ICELAND
AB Background Family history is considered a risk factor for age-related macular degeneration (AMD). With the advent of effective therapy for the disease, the importance of family history merits further investigation. This study quantifies the risk associated with family history, first, by a case-control study of reported family history and, second, by examining the siblings of AMD cases.
   Methods The authors recruited cases with advanced AMD, spouses and siblings. All subjects were carefully phenotyped. Clinical findings in the siblings were compared with spouses. Information about family history was collected. The ORs for reported family history of AMD were calculated. Analyses were adjusted for age, smoking and genotype.
   Results 495 AMD cases, 259 spouses and 171 siblings were recruited. The OR for AMD was 27.8 (CI 3.8 to 203.0; p=0.001) with a reported family history of an affected parent and 12.0 (CI 3.7 to 38.6; p<0.0001) with a history of an affected sibling. ORs adjusted for age and smoking were higher. Examination of siblings confirmed their increased risk with 23% affected by AMD and an OR of 10.8 (4.5 to 25.8; p<0.0001). Adjusting for age increased the OR to 16.1 (6.2 to 41.8).
   Conclusion The risk of AMD is greatly increased by having an affected first-degree relative. Those at risk need to be made aware of this and AMD patients should advise siblings and children to seek prompt ophthalmological advice if they develop visual symptoms of distortion or reduced vision.
C1 [Shahid, Humma] John Radcliffe Hosp, Oxford Eye Hosp, Oxford OX3 0LU, England.
   [Shahid, Humma; Khan, Jane C.; Sepp, Tiina; Matharu, Baljinder K.; Clayton, David G.; Yates, John R. W.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge, England.
   [Khan, Jane C.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Cipriani, Valentina; Bunce, Catey; Moore, Anthony T.; Yates, John R. W.] UCL, Inst Ophthalmol, London, England.
   [Cipriani, Valentina; Bunce, Catey; Moore, Anthony T.; Yates, John R. W.] Moorfields Eye Hosp, London, England.
   [Harding, Simon P.] Univ Liverpool, Sch Clin Sci, Ophthalmol Res Unit, Liverpool L69 3BX, Merseyside, England.
C3 University of Oxford; University of Cambridge; Royal Perth Hospital;
   University of Western Australia; University of London; University
   College London; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of Liverpool
RP Shahid, H (通讯作者)，John Radcliffe Hosp, Oxford Eye Hosp, West Wing, Oxford OX3 0LU, England.
EM hummashahid@hotmail.com
RI Chong, Victor/Q-6565-2018; Cipriani, Valentina/A-8549-2012; edelsten,
   clive/H-3754-2015
OI Chong, Victor/0000-0002-7693-522X; Cipriani,
   Valentina/0000-0002-0839-9955; Harding, Simon/0000-0003-4676-1158;
   edelsten, clive/0000-0002-5845-3956; Bunce, Catey/0000-0002-0935-3713;
   Bishop, Paul/0000-0001-7937-7932
FU MRC, UK [G0000067]; UK; Macular Disease Society; Guide Dogs for the
   Blind Association; Wellcome Trust; Juvenile Diabetes Research
   Foundation; Department of Health's NIHR Biomedical Research Centre for
   Ophthalmology at Moorfields Eye Hospital; UCL Institute of
   Ophthalmology; MRC [G0000067] Funding Source: UKRI; Medical Research
   Council [G0000067] Funding Source: researchfish
FX MRC programme grant (reference G0000067), 2001-2006, to fund salary and
   material support. This work has been supported by grants from the MRC,
   UK (JRWY, ATM, DGC) and the Macular Disease Society (JRWY, ATM). VC is
   funded by a grant from the Guide Dogs for the Blind Association. DGC is
   supported by the Wellcome Trust and the Juvenile Diabetes Research
   Foundation. This research has received a proportion of its funding from
   the Department of Health's NIHR Biomedical Research Centre for
   Ophthalmology at Moorfields Eye Hospital and UCL Institute of
   Ophthalmology. The views expressed in the publication are those of the
   authors and not necessarily those of the Department of Health.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 24
TC 41
Z9 43
U1 0
U2 21
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2012
VL 96
IS 3
BP 427
EP 431
DI 10.1136/bjophthalmol-2011-300193
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 896XO
UT WOS:000300604900026
PM 21865200
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Hubbard, LD
   Armstrong, J
   Rogers, G
   Jacques, PF
   Chylack, LT
   Hankinson, SE
   Willett, WC
   Taylor, A
AF Chiu, CJ
   Hubbard, LD
   Armstrong, J
   Rogers, G
   Jacques, PF
   Chylack, LT
   Hankinson, SE
   Willett, WC
   Taylor, A
TI Dietary glycemic index and carbohydrate in relation to early age-related
   macular degeneration
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE age-related macular degeneration; retina; maculopathy; nutrition;
   vision; carbohydrate; glycemic index; glycation; aging; epidemiology;
   risk factor; food-frequency questionnaire; drusen; pigment abnormalities
ID C-REACTIVE PROTEIN; PLASMA-CONCENTRATIONS; ATHEROSCLEROSIS RISK;
   ADVANCED GLYCATION; MACULOPATHY; DRUSEN; LOAD; QUESTIONNAIRE;
   PREVALENCE; GLUCOSE
AB Background: Several dietary factors have been linked to agerelated maculopathy (ARM), the early form of age-related macular degeneration, and there is reason to think that dietary carbohydrate may play a role in the development of ARM. O
   bjective: The purpose of the present study was to examine the relation between dietary carbohydrate quality, as measured by dietary glycemic index (GI) or total carbohydrate intake, and ARM.
   Design: From the Nurses' Health Study, 1036 eyes from 526 Boston-area participants without a previous ARM diagnosis were included in the present study. The presence and degree of ARM were classified by the Age-Related Eye Diseases Study system. Longterm dietary information was based on data from an average of 4 food-frequency questionnaires collected over a 10-y period before the assessment of ARM. With eyes as the unit of analysis, we used a generalized estimating approach to logistic regression to estimate the odds ratios for ARM in a manner that accounted for the lack of independence between the 2 eyes from the same subject.
   Results: After multivariate adjustment, dietary GI was related to ARM (specifically to retinal pigmentary abnormalities), whereas total carbohydrate intake was not. The odds ratio for ARM being in the highest tertile of dietary GI (>= 77.0) versus the lowest (< 74.6) was 2.7](95%CI: 1.24, 5.93; P for trend= 0.01). Neither dietary GI nor total carbohydrate intake was related to drusen.
   Conclusion: Our results suggest that dietary GI may be an independent risk factor for ARM.
C1 Tufts Univ, USDA, Human Nutr Res Ctr, Boston, MA 02111 USA.
   Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Ctr Ophthal Res, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Tufts University; United States Department of Agriculture (USDA);
   Harvard University; Harvard Medical School; Harvard University; Brigham
   & Women's Hospital; Harvard University; Harvard T.H. Chan School of
   Public Health; Harvard University; Harvard T.H. Chan School of Public
   Health; University of Wisconsin System; University of Wisconsin Madison
RP Taylor, A (通讯作者)，Tufts Univ, USDA, Human Nutr Res Ctr, 711 Washington St, Boston, MA 02111 USA.
EM allen.taylor@tufts.edu
FU NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R03EY014183, R01EY013250, R01EY009611]
   Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source:
   Medline; NEI NIH HHS [EY R01 13250, EY 09611, EY 014183-01A2] Funding
   Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792
   Chin CJ, 2005, AM J CLIN NUTR, V81, P1411
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Farboud B, 1999, MOL VIS, V5, pU1
   Fong DS, 1997, ARCH OPHTHALMOL-CHIC, V115, P873, DOI 10.1001/archopht.1997.01100160043006
   Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419
   Jacques PF, 2001, ARCH OPHTHALMOL-CHIC, V119, P1009, DOI 10.1001/archopht.119.7.1009
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Jonas CR, 2003, CANCER EPIDEM BIOMAR, V12, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Kumagai AK, 1999, DIABETES-METAB RES, V15, P261, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<261::AID-DMRR43>3.0.CO;2-Z
   Liu SM, 2002, AM J CLIN NUTR, V75, P492, DOI 10.1093/ajcn/75.3.492
   Liu SM, 2000, AM J CLIN NUTR, V71, P1455
   Mares-Perlman J.A., 1999, CRC MOD NUT, P181
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
   SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858
   SAS Institute Inc, 1999, SAS STAT US GUID
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Suji G, 2004, BIOGERONTOLOGY, V5, P365, DOI 10.1007/s10522-004-3189-0
   Taylor A, 2002, AM J CLIN NUTR, V75, P540, DOI 10.1093/ajcn/75.3.540
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WILLETT WC, 1983, AM J CLIN NUTR, V38, P631, DOI 10.1093/ajcn/38.4.631
   WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 46
TC 63
Z9 65
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD APR
PY 2006
VL 83
IS 4
BP 880
EP 886
DI 10.1093/ajcn/83.4.880
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 033AA
UT WOS:000236817100023
PM 16600942
DA 2022-11-30
ER

PT J
AU Cipriani, V
   Lores-Motta, L
   He, F
   Fathalla, D
   Tilakaratna, V
   McHarg, S
   Bayatti, N
   Acar, IE
   Hoyng, CB
   Fauser, S
   Moore, AT
   Yates, JRW
   de Jong, EK
   Morgan, BP
   den Hollander, AI
   Bishop, PN
   Clark, SJ
AF Cipriani, Valentina
   Lores-Motta, Laura
   He, Fan
   Fathalla, Dina
   Tilakaratna, Viranga
   McHarg, Selina
   Bayatti, Nadhim
   Acar, Ilhan E.
   Hoyng, Carel B.
   Fauser, Sascha
   Moore, Anthony T.
   Yates, John R. W.
   de Jong, Eiko K.
   Morgan, B. Paul
   den Hollander, Anneke I.
   Bishop, Paul N.
   Clark, Simon J.
TI Increased circulating levels of Factor H-Related Protein 4 are strongly
   associated with age-related macular degeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; RARE GENETIC-VARIANTS;
   ALTERNATIVE PATHWAY; PLASMA-LEVELS; RISK; CFH; ACTIVATION; EXPRESSION;
   POLYMORPHISM
AB Age-related macular degeneration (AMD) is a leading cause of blindness. Genetic variants at the chromosome 1q31.3 encompassing the complement factor H (CFH, FH) and CFH related genes (CFHR1-5) are major determinants of AMD susceptibility, but their molecular consequences remain unclear. Here we demonstrate that FHR-4 plays a prominent role in AMD pathogenesis. We show that systemic FHR-4 levels are elevated in AMD (P-value=7.1x10(-6)), whereas no difference is seen for FH. Furthermore, FHR-4 accumulates in the choriocapillaris, Bruch's membrane and drusen, and can compete with FH/FHL-1 for C3b binding, preventing FI-mediated C3b cleavage. Critically, the protective allele of the strongest AMD-associated CFH locus variant rs10922109 has the highest association with reduced FHR-4 levels (P-value=2.2x10(-56)), independently of the AMD-protective CFHR1-3 deletion, and even in those individuals that carry the high-risk allele of rs1061170 (Y402H). Our findings identify FHR-4 as a key molecular player contributing to complement dysregulation in AMD.
C1 [Cipriani, Valentina] Queen Mary Univ London, Clin Pharmacol, William Harvey Res Inst, London EC1M 6BQ, England.
   [Cipriani, Valentina; Moore, Anthony T.; Yates, John R. W.] UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
   [Cipriani, Valentina; Moore, Anthony T.; Yates, John R. W.] Moorfields Eye Hosp NHS Fdn Trust, London EC1V 2PD, England.
   [Cipriani, Valentina] UCL, UCL Genet Inst, London WC1E 6BT, England.
   [Lores-Motta, Laura; Acar, Ilhan E.; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, NL-6525 GA Nijmegen, Netherlands.
   [He, Fan; Tilakaratna, Viranga; McHarg, Selina; Bayatti, Nadhim; Bishop, Paul N.; Clark, Simon J.] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Div Evolut & Genom Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.
   [Fathalla, Dina; Morgan, B. Paul] Cardiff Univ, Sch Med, Div Infect & Immun, Syst Immun URI, Cardiff CF14 4XN, Wales.
   [Fathalla, Dina; Morgan, B. Paul] Cardiff Univ, Sch Med, UK DRI Cardiff, Cardiff CF14 4XN, Wales.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, CH-4070 Basel, Switzerland.
   [Moore, Anthony T.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
   [Yates, John R. W.] Univ Cambridge, Dept Med Genet, Cambridge CB2 0QQ, England.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, NL-6525 HR Nijmegen, Netherlands.
   [Bishop, Paul N.] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Royal Eye Hosp, Manchester M13 9WL, Lancs, England.
   [Clark, Simon J.] Univ Manchester, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England.
   [Clark, Simon J.] Eberhard Karls Univ Tubingen, Res Inst Ophthalmol, Dept Ophthalmol, D-72076 Tubingen, Germany.
C3 University of London; Queen Mary University London; University of
   London; University College London; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of London; University College London; Radboud University Nijmegen;
   University of Manchester; Cardiff University; Cardiff University;
   University of Cologne; Roche Holding; University of California System;
   University of California San Francisco; University of Cambridge; Radboud
   University Nijmegen; Manchester Royal Eye Hospital; University of
   Manchester; University of Manchester; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital
RP Cipriani, V (通讯作者)，Queen Mary Univ London, Clin Pharmacol, William Harvey Res Inst, London EC1M 6BQ, England.; Cipriani, V (通讯作者)，UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.; Cipriani, V (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, London EC1V 2PD, England.; Cipriani, V (通讯作者)，UCL, UCL Genet Inst, London WC1E 6BT, England.; Clark, SJ (通讯作者)，Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Div Evolut & Genom Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.; Clark, SJ (通讯作者)，Univ Manchester, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England.; Clark, SJ (通讯作者)，Eberhard Karls Univ Tubingen, Res Inst Ophthalmol, Dept Ophthalmol, D-72076 Tubingen, Germany.
EM v.cipriani@qmul.ac.uk; simon.clark@uni-tuebingen.de
RI Acar, İlhan Erkin/B-7758-2018; Cipriani, Valentina/A-8549-2012
OI Acar, İlhan Erkin/0000-0002-2078-9905; Cipriani,
   Valentina/0000-0002-0839-9955; Fathalla, Dina/0000-0003-3845-529X;
   Clark, Simon/0000-0001-8394-8355
FU Cambridge AMD Study (UK Medical Research Council (MRC)) [G0000067];
   Oogfonds; Landelijke Stichting voor Blinden en Slechtzienden; Stichting
   Blindenhulp, Stichting A.F. Deutman Oogheelkunde Researchfonds;
   Netherlands Organization for Scientific Research (Vidi Innovational
   Research Award) [016.096.309]; European Research Council under the
   European Union [310644 MACULA]; Macular Society UK [12928]; CIDR
   [HHSN268201200008I, EY022310, 1 x 01HG006934-01]; MRC fellowship
   [MR/K024418/1]; Fight for Sight UK [1517/1518]; MRC-supported UK
   Dementia Research Institute - Department of Health's NIHR Biomedical
   Research Centre for Ophthalmology at Moorfields Eye Hospital; MRC
   [MR/P025838/1]; MRC [MR/K024418/1, UKDRI-3002] Funding Source: UKRI
FX We are grateful to all the subjects who kindly participated in this
   research. For the Cambridge AMD Study (UK Medical Research Council (MRC)
   grant G0000067 to J.R.W.Y. and A.T.M.), we gratefully acknowledge help
   with patient recruitment from members of the Genetic Factors in AMD
   Study Group (P. Black, Z. Butt, V. Chong, C. Edelsten, A. Fitt, D.W.
   Flanagan, A. Glenn, S.P. Harding, C. Jakeman, C. Jones, R.J. Lamb, V.
   Moffatt, C.M. Moorman, R.J. Pushpanathan, E. Redmond, T. Rimmer and D.A.
   Thurlby); we thank Jane Khan and Humma Shahid for carrying out the
   clinical evaluation and sampling of subjects and Tunde Peto and
   colleagues at the Reading Centre, Moorfields Eye Hospital, London, for
   grading the fundus photographs. EUGENDA was funded by grants from the
   Oogfonds, MaculaFonds, Landelijke Stichting voor Blinden en
   Slechtzienden, Stichting Blindenhulp, Stichting A.F. Deutman
   Oogheelkunde Researchfonds, the Netherlands Organization for Scientific
   Research (Vidi Innovational Research Award 016.096.309), and the
   European Research Council under the European Union's Seventh Framework
   Programme (FP/2007-2013) (ERC Grant Agreement no. 310644 MACULA). We
   wish to thank the Manchester Eye Tissue Repository for supplying human
   macula tissue, and their funding from the Macular Society UK (12928). We
   also thank the IAMDGC (http://eaglep.case.edu/iamdgc_web/; for a full
   list of consortium members, please see Supplementary Note 1) for
   providing the genotype data. The Cambridge and EUGENDA samples were
   genotyped as part of the IAMDGC exomechip project supported by CIDR
   (contract number HHSN268201200008I) and funded by EY022310 (to Jonathan
   L. Haines, Case Western Reserve University, Cleveland) and 1 x
   01HG006934-01 (to Goncalo R. Abecasis, University of Michigan,
   Department of Biostatistics). We wish to thank Lars Fritsche for
   providing CFH locus-phased genotype data for the IAMDGC primary analysis
   dataset. Other funding sources are as follows: S.J.C./V.T., an MRC
   fellowship (MR/K024418/1); S.M., Fight for Sight UK research grant
   (1517/1518); B.P.M./D.F. supported by a Programme Grant from the
   MRC-supported UK Dementia Research Institute; V.C. was primarily funded
   by the Department of Health's NIHR Biomedical Research Centre for
   Ophthalmology at Moorfields Eye Hospital and UCL Institute of
   Ophthalmology, and an MRC research grant (MR/P025838/1). The funding
   bodies had no role in the design of the study and collection, analysis,
   and interpretation of data and in writing the manuscript.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Cantsilieris S, 2018, P NATL ACAD SCI USA, V115, pE4433, DOI 10.1073/pnas.1717600115
   Chirco KR, 2018, EYE, V32, P1740, DOI 10.1038/s41433-018-0170-8
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   CLARK SJ, 2010, INVEST OPHTH VIS SCI, V51
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FONTAINE M, 1989, BIOCHEM J, V258, P927, DOI 10.1042/bj2580927
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kubista KE, 2011, MOL VIS, V17, P2080
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Sharma NK, 2013, DNA CELL BIOL, V32, P549, DOI 10.1089/dna.2013.2072
   Silva AS, 2012, MOL VIS, V18, P2288
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Strunz T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24219-z
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Wagner AH, 2013, EXP EYE RES, V111, P105, DOI 10.1016/j.exer.2013.03.004
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
NR 69
TC 48
Z9 49
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB 7
PY 2020
VL 11
IS 1
AR 778
DI 10.1038/s41467-020-14499-3
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KL6AP
UT WOS:000513504400005
PM 32034129
OA Green Published, Green Accepted, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Cruess, A
   Zlateva, G
   Xu, X
   Rochon, S
AF Cruess, Alan
   Zlateva, Gergana
   Xu, Xiao
   Rochon, Sophie
TI Burden of illness of neovascular age-related macular degeneration in
   Canada
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE quality of life; health care resource utilization; visual acuity
ID VISUAL FUNCTION QUESTIONNAIRE; HEALTH-STATUS; EYE; IMPAIRMENT; IMPACT;
   COHORT
AB Background: Age-related macular degeneration (AMD) is a retinal disease affecting more than 2 million Canadians over the age of 50. The neovascular form of AMD is responsible for 90% of severe vision loss associated with the disease. This study was conducted to assess the burden of neovascular AMD in the Canadian population.
   Methods: A cross-sectional, observational study was conducted of self-reported functional health, well-being, and disease burden among elderly subjects in Canada with (n = 67) and without (n = 99) neovascular AMD. Subjects completed telephone surveys of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), the EuroQol questionnaire (EQ-5D), and the Hospital Anxiety and Depression Scale (HADS). Subjects also reported their history of falls and fractures and annual health care resource utilization.
   Results: Subjects with neovascular AMD reported significantly worse vision-related functioning and overall wellbeing than controls (adjusted mean scores on the NEI-VFQ-25:48.0 vs.87.5;p < 0.0001) and significantly more depression symptoms than controls (HADS depression: 5.8 vs. 4.3; p = 0.037). Subjects with neovascular AMD also reported more than twice the need for assistance with daily activities compared with controls (19.4% vs. 9.1%; p = 0.013) and a nearly 3 times higher fall rate than the control group (22.4% vs. 8.1 %; p = 0.014). The annual neovascular AMD cost per patient was Can$11 334, which is over 8 times that of elderly subjects without neovascular AMD (Can$1412). Over half of the neovascular AMD costs were direct medical costs.
   Interpretation: Neovascular AMD is associated with significant limitation in functional abilities and quality of life, resulting in increased health care resource utilization and high patient support costs. These findings emphasize the need for new treatments for neovascular AMD that will prevent vision loss and progression to blindness in order to lessen the ensuing economic burden.
C1 Pfizer Inc, Montreal, PQ H9J 2M5, Canada.
   [Cruess, Alan] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.
   [Zlateva, Gergana] Pfizer Inc, New York, NY USA.
   [Xu, Xiao] Covance Market Access Serv Inc, Gaithersburg, MD USA.
C3 Pfizer; Dalhousie University; Pfizer; Covance
RP Rochon, S (通讯作者)，Pfizer Inc, 17300 Trans-Canada Highway, Montreal, PQ H9J 2M5, Canada.
EM Sophie.Rochon@pfizer.com
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   *CAN I HLTH INF, AN 2003 2003 DAT CAN
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Eich D, 1999, VASA-J VASCULAR DIS, V28, P3, DOI 10.1024/0301-1526.28.1.3
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hopley C, 2003, CLIN EXP OPHTHALMOL, V31, P522, DOI 10.1046/j.1442-9071.2003.00715.x
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Legood R, 2002, INJ PREV, V8, P155, DOI 10.1136/ip.8.2.155
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   *ONT MIN HLTH LONG, 2003, ONT DRUG BEN FORM CO
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2004, VALUE HEALTH, V7, P260, DOI 10.1016/S1098-3015(10)62188-2
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   WHO, 2004, MAGN CAUS VIS IMP
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 24
TC 71
Z9 71
U1 0
U2 13
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2007
VL 42
IS 6
BP 836
EP 843
DI 10.3129/i07-153
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 241MJ
UT WOS:000251660200010
PM 18026200
DA 2022-11-30
ER

PT J
AU Ge, Y
   Zhang, A
   Sun, R
   Xu, JW
   Yin, T
   He, HB
   Gou, JX
   Kong, J
   Zhang, Y
   Tang, X
AF Ge, Ying
   Zhang, Anan
   Sun, Rong
   Xu, Jiawen
   Yin, Tian
   He, Haibing
   Gou, Jingxin
   Kong, Jun
   Zhang, Yu
   Tang, Xing
TI Penetratin-modified lutein nanoemulsion in-situ gel for the treatment of
   age-related macular degeneration
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Article
DE Age-related macular degeneration; lutein; nanoemulsion; penetratin;
   in-situ gel; antioxidant
ID CELLULAR UPTAKE; CONTROLLED-RELEASE; POLOXAMER GELS; DELIVERY;
   ACCUMULATION; ANTIOXIDANTS; PATHOGENESIS; STABILITY; HYDROGEN; SYSTEM
AB Background: Lutein is the primary macular pigment with an favorable effect on the treatment of age-related macular degeneration (AMD). However, the poor water solubility of lutein hinders its absorption and delivery. In this study, a penetratin-modified lutein nanoemulsion in-situ gel (GEL) was prepared for the treatment of AMD. Methods: A nanoemulsion (NE) was prepared and modified with penetratin (P-NE) to improve the penetration. The effect of penetratin was evaluated by cell uptake and intraocular distribution assays. A dry AMD model was induced using NaIO3, and the therapeutic effect was evaluated by electroretinography, the number of apoptosis cells and the reactive oxygen species (ROS) level. Results: Lutein showed a good ability to protect ARPE-19 from the damage of H2O2 and the uptake rate of P-NE was significantly higher than NE. In the efficacy experiments, the structure of retina was significantly improved after treatment, the apoptosis rate decreased from 31.98% to 2.05%, and the level of ROS was significantly decreased (p < 0.0001). Conclusions: With the aid of penetratin, lutein could be delivered to the retina effectively. The P-NE GEL could evidently inhibit the apoptosis and ROS, demonstrating that the P-NE GEL has a good application prospect in the treatment of AMD.
C1 [Ge, Ying; Zhang, Anan; Sun, Rong; Xu, Jiawen; He, Haibing; Gou, Jingxin; Zhang, Yu; Tang, Xing] Shenyang Pharmaceut Univ, Coll Pharm, Dept Pharmaceut, Shenyang 110016, Liaoning, Peoples R China.
   [Xu, Jiawen] Chinese Acad Med Sci, Dept Pharm, Fuwai Hosp, Shenzhen, Peoples R China.
   [Yin, Tian] Shenyang Pharmaceut Univ, Sch Funct Food & Wine, Shenyang, Liaoning, Peoples R China.
   [Kong, Jun] China Med Univ, Dept Ophthalmol, Affiliated Hosp 4, Shenyang, Liaoning, Peoples R China.
C3 Shenyang Pharmaceutical University; Chinese Academy of Medical Sciences
   - Peking Union Medical College; Fu Wai Hospital - CAMS; Shenyang
   Pharmaceutical University; China Medical University
RP Zhang, Y (通讯作者)，Shenyang Pharmaceut Univ, Coll Pharm, Dept Pharmaceut, Shenyang 110016, Liaoning, Peoples R China.
EM pharmzy@163.com
RI xu, jia/GSD-6347-2022
FU National Mega-project for Innovative Drugs [2019ZX09721001]; Major
   Project of National Science and Technology 'Creation of Major New Drugs'
   from China [2018ZX09721002-002]; China Postdoctoral Science Foundation
   [2019M651149]; Liaoning Revitalization Talents Program [XLYC1907111,
   XLYC1908031]; Liaoning Province Doctoral Start-up Fund Program
   [2019-BS-226]; Liaoning Province Natural Science Fund Project
   [20180551031]; Overseas Returnees Start-up Fund from Shenyang
   Pharmaceutical University [GGJJ2018102]
FX This work was supported by the National Mega-project for Innovative
   Drugs [2019ZX09721001], Major Project of National Science and Technology
   'Creation of Major New Drugs' from China [2018ZX09721002-002], China
   Postdoctoral Science Foundation Grant [2019M651149], Liaoning
   Revitalization Talents Program [XLYC1907111, XLYC1908031], Liaoning
   Province Doctoral Start-up Fund Program [2019-BS-226], Liaoning Province
   Natural Science Fund Project [20180551031] and Overseas Returnees
   Start-up Fund from Shenyang Pharmaceutical University [GGJJ2018102].
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Bentley MVLB, 1999, INT J PHARM, V193, P49, DOI 10.1016/S0378-5173(99)00313-0
   Bhardwaj R, 1996, J PHARM SCI-US, V85, P915, DOI 10.1021/js960097g
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Chan CM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0531-z
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Cho HY, 2019, ACS APPL MATER INTER, V11, P23909, DOI 10.1021/acsami.9b07483
   Chong YS, 2018, CUTAN OCUL TOXICOL, V37, P52, DOI 10.1080/15569527.2017.1335748
   Cicinelli MV, 2017, SURV OPHTHALMOL, V63, pS0039625717300590
   Constable PA, 2017, DOC OPHTHALMOL, V134, P1, DOI 10.1007/s10633-017-9573-2
   Silva JTD, 2017, FOOD CHEM, V230, P336, DOI 10.1016/j.foodchem.2017.03.059
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Frede K, 2014, J FUNCT FOODS, V8, P118, DOI 10.1016/j.jff.2014.03.011
   Gu X, 2004, AM J OPHTHALMOL, V137, P974
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jackson TL, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5058
   Jiang J, 2018, EUR J PHARM SCI, V121, P251, DOI 10.1016/j.ejps.2018.04.043
   Jiang K, 2017, ACTA BIOMATER, V63, P123, DOI 10.1016/j.actbio.2017.09.023
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klein R, 2019, OPHTHALMOLOGY, V126, P752, DOI 10.1016/j.ophtha.2018.12.026
   Lim C, 2016, J DRUG DELIV SCI TEC, V36, P168, DOI 10.1016/j.jddst.2016.10.009
   Linetsky M, 2018, CHEM RES TOXICOL, V31, P666, DOI 10.1021/acs.chemrestox.8b00028
   Liu C, 2016, ACS APPL MATER INTER, V8, P19256, DOI 10.1021/acsami.6b04551
   Liu YL, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00389
   Lucero-Acuna A, 2015, INT J PHARMACEUT, V494, P249, DOI 10.1016/j.ijpharm.2015.07.049
   Mahajan HS, 2010, DRUG DELIV, V17, P19, DOI 10.3109/10717540903447194
   Phan MAT, 2018, MOLECULES, V23, DOI 10.3390/molecules23082035
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Morsi N, 2017, EUR J PHARM SCI, V104, P302, DOI 10.1016/j.ejps.2017.04.013
   Nolan JM, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2015.35
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Qiu S, 2017, NEUROSCI LETT, V657, P53, DOI 10.1016/j.neulet.2017.07.041
   Reed K, 2016, J OCUL PHARMACOL TH, V32, P574, DOI 10.1089/jop.2016.0084
   Robson AG, 2018, DOC OPHTHALMOL, V136, P1, DOI 10.1007/s10633-017-9621-y
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Suda K, 2017, J CONTROL RELEASE, V266, P301, DOI 10.1016/j.jconrel.2017.09.036
   Tai LY, 2017, INT J PHARMACEUT, V529, P347, DOI 10.1016/j.ijpharm.2017.06.090
   Tai LY, 2017, NANOMED-NANOTECHNOL, V13, P2091, DOI 10.1016/j.nano.2017.04.011
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tao Z, 2013, MOL NEUROBIOL, V47, P241, DOI 10.1007/s12035-012-8366-6
   Teo A, 2017, FOOD CHEM, V221, P1269, DOI 10.1016/j.foodchem.2016.11.030
   Toomey MB, 2010, ARCH BIOCHEM BIOPHYS, V504, P161, DOI 10.1016/j.abb.2010.06.033
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   Verma M, 2020, COLLOID SURFACE A, V587, DOI 10.1016/j.colsurfa.2019.124333
   Vila N, 2017, OPHTHALMIC RES, V57, P48, DOI 10.1159/000449252
   Wagner A, 2019, OPHTHALMOLOGE, V116, P43, DOI 10.1007/s00347-017-0638-0
   Wang LH, 2014, BRIT J CANCER, V110, P341, DOI 10.1038/bjc.2013.752
   Weigel F, 2018, FOOD CHEM, V242, P395, DOI 10.1016/j.foodchem.2017.09.060
   Wu MF, 2019, INT J NANOMED, V14, P2667, DOI 10.2147/IJN.S194068
   Xu JW, 2019, J CONTROL RELEASE, V305, P18, DOI 10.1016/j.jconrel.2019.05.025
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yang C, 2018, FOOD CHEM, V249, P66, DOI 10.1016/j.foodchem.2017.12.055
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yong CS, 2001, INT J PHARM, V226, P195, DOI 10.1016/S0378-5173(01)00809-2
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
NR 57
TC 20
Z9 20
U1 6
U2 52
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD APR 2
PY 2020
VL 17
IS 4
BP 603
EP 619
DI 10.1080/17425247.2020.1735348
EA MAR 2020
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KX0HM
UT WOS:000519176300001
PM 32105151
DA 2022-11-30
ER

PT J
AU Jia, LH
   Shen, XL
   Fan, R
   Sun, Y
   Pan, XY
   Yanh, HM
   Liu, L
AF Jia LiHong
   Shen XueLi
   Fan Rui
   Sun Yan
   Pan XingYue
   Yanh HongMei
   Liu Lu
TI Risk Factors for Age-Related Macular Degeneration in Elderly Chinese
   Population in Shenyang of China
SO BIOMEDICAL AND ENVIRONMENTAL SCIENCES
LA English
DT Article
DE Lifestyle; Dietary habit; Age-related macular degeneration; Chinese
   people
ID PREVALENCE; ASSOCIATION; PROGRESSION
AB Objective The paper aims to evaluate the risk factors for age-related macular degeneration (AMD) in elderly Chinese population in Shenyang, a northeast city of China.
   Methods A case-control study was conducted to investigate the risk factors for the prevalence of AMD. Ninety three AMD patients diagnosed by a complete ophthalmic examination were recruited as cases from the outpatient departments of two eye hospitals in Shenyang, while 108 normal subjects of similar age and sex were recruited as controls. A questionnaire was administered among both cases and controls.
   Results AMD patients aged 60 years and older accounted for 75.3%. There were significantly higher educational levels, shorter smoking history, less sunlight exposure and cataract, and higher proportion of antioxidants intake in controls than in AMD patients. The frequency of intake of fruits, legumes, fish and shrimps was significantly higher in controls than in AMD patients. In a binary logistic regression analysis, smoking and cataract were the risk factors for AMD (OR: 4.44, 95% Cl: 2.27-8.69; OR: 4.47, 95% Cl: 2.26-8.85 respectively). The high educational background was a protective factor for AMD (OR: 0.761, 95% Cl: 0.51-0.98).
   Conclusion A low educational background, smoking and cataract are associated with a higher prevalence of AMD.
C1 [Jia LiHong; Pan XingYue; Yanh HongMei; Liu Lu] China Med Univ, Sch Publ Hlth, Shenyang 110001, Liaoning, Peoples R China.
   [Shen XueLi] China Med Univ, Affiliated Hosp 1, Dept Neurol, Shenyang 110001, Liaoning, Peoples R China.
   [Fan Rui] Shenyang AIER Ophthalmol Hosp, Shenyang 110005, Liaoning, Peoples R China.
   [Sun Yan] Heshi Ophthalmol Hosp, Shenyang 110034, Liaoning, Peoples R China.
C3 China Medical University; China Medical University
RP Jia, LH (通讯作者)，China Med Univ, Sch Publ Hlth, Shenyang 110001, Liaoning, Peoples R China.
EM lhjia@mail.cmu.edu.cn
FU Nutritional Science Foundation of the Chinese Nutrition Society, China
   [07016]
FX This work was supported by a grant from the Nutritional Science
   Foundation of the Chinese Nutrition Society (No. 07016), China.
CR Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kuklina EV, 2010, ANN FAM MED, V8, P327, DOI 10.1370/afm.1137
   Li Li-ming, 2005, Zhonghua Liu Xing Bing Xue Za Zhi, V26, P478
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   Noel SE, 2009, J NUTR, V139, P1360, DOI 10.3945/jn.109.105874
   O'Connell ED, 2008, AM J CLIN NUTR, V87, P712, DOI 10.1093/ajcn/87.3.712
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   The Chinese Nutrition Society, 1999, NUTR TODAY, V34, P106
   The group of Ophthalmology in Chinese Medical Association, 1987, CHINESE J OPHTHALMOL, V23
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Xu L, 2010, GRAEF ARCH CLIN EXP, V248, P49, DOI 10.1007/s00417-009-1204-5
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 29
TC 5
Z9 5
U1 0
U2 19
PU CHINESE CENTER DISEASE CONTROL & PREVENTION
PI BEIJING
PA 155 CHANGBAI RD, CHANGPING DISTRICT, BEIJING, 102206, PEOPLES R CHINA
SN 0895-3988
J9 BIOMED ENVIRON SCI
JI Biomed. Environ. Sci.
PD OCT
PY 2011
VL 24
IS 5
BP 506
EP 511
DI 10.3967/0895-3988.2011.05.008
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 853AV
UT WOS:000297399500008
PM 22108416
DA 2022-11-30
ER

PT J
AU Leuschen, JN
   Schuman, SG
   Winter, KP
   McCall, MN
   Wong, WT
   Chew, EY
   Hwang, T
   Srivastava, S
   Sarin, N
   Clemons, T
   Harrington, M
   Toth, CA
AF Leuschen, Jessica N.
   Schuman, Stefanie G.
   Winter, Katrina P.
   McCall, Michelle N.
   Wong, Wai T.
   Chew, Emily Y.
   Hwang, Thomas
   Srivastava, Sunil
   Sarin, Neeru
   Clemons, Traci
   Harrington, Molly
   Toth, Cynthia A.
TI Spectral-Domain Optical Coherence Tomography Characteristics of
   Intermediate Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; FUNDUS AUTOFLUORESCENCE; NATURAL-HISTORY;
   RISK-FACTORS; FOLLOW-UP; SD-OCT; DRUSEN; MACULOPATHY; EYES; PROGRESSION
AB Purpose: Describe qualitative spectral-domain optical coherence tomography (SD-OCT) characteristics of eyes classified as intermediate age-related macular degeneration (nonadvanced AMD) from Age-Related Eye Disease Study 2 (AREDS2) color fundus photography (CFP) grading.
   Design: Prospective cross-sectional study.
   Participants: We included 345 AREDS2 participants from 4 study centers and 122 control participants who lack CFP features of intermediate AMD.
   Methods: Both eyes were imaged with SD-OCT and CFP. The SD-OCT macular volume scans were graded for the presence of 5 retinal, 5 subretinal, and 4 drusen characteristics. In all, 314 AREDS2 participants with >= 1 category-3 AMD eye and all controls each had 1 eye entered into SD-OCT analysis, with 63 eyes regraded to test reproducibility.
   Main Outcome Measures: We assessed SD-OCT characteristics at baseline.
   Results: In 98% of AMD eyes, SD-OCT grading of all characteristics was successful, detecting drusen in 99.7%, retinal pigment epithelium (RPE) atrophy/absence in 22.9%, subfoveal geographic atrophy in 2.5%, and fluid in or under the retina in 25.5%. Twenty-eight percent of AMD eyes had characteristics of possible advanced AMD on SD-OCT. Two percent of control eyes had drusen on SD-OCT. Vision loss was not correlated with foveal drusen alone, but with foveal drusen that were associated with other foveal pathology and with overlying focal hyperreflectivity. Focal hyperreflectivity over drusen, drusen cores, and hyper- or hyporeflectivity of drusen were also associated with RPE atrophy.
   Conclusions: Macular pathologies in AMD can be qualitatively and reproducibly evaluated with SD-OCT, identifying pathologic features that are associated with vision loss, RPE atrophy, and even possibly the presence of advanced AMD not apparent on CFP. Qualitative and detailed SD-OCT analysis can contribute to the anatomic characterization of AMD in clinical studies of vision loss and disease progression.
C1 [Leuschen, Jessica N.; Schuman, Stefanie G.; Winter, Katrina P.; McCall, Michelle N.; Sarin, Neeru; Toth, Cynthia A.] Duke Eye Ctr, Durham, NC 27710 USA.
   [Wong, Wai T.; Chew, Emily Y.] NEI, Bethesda, MD 20892 USA.
   [Hwang, Thomas] Devers Eye Inst, Portland, OR USA.
   [Srivastava, Sunil] Emory Eye Ctr, Atlanta, GA USA.
   [Clemons, Traci; Harrington, Molly] EMMES Corp, Rockville, MD USA.
C3 Duke University; National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); Devers Eye Institute; Emmes Corporation
RP Toth, CA (通讯作者)，Duke Eye Ctr, Box 3802,Erwin Rd, Durham, NC 27710 USA.
RI toth, cynthia a/F-5614-2011; Hwang, Thomas/AAV-5146-2020; Hwang, Thomas
   S./AAW-6618-2020; Toth, Cynthia/L-5534-2019; Wong, Wai/B-6118-2017
OI Hwang, Thomas S./0000-0002-0535-4823; Toth, Cynthia/0000-0002-2324-0854;
   Wong, Wai/0000-0003-0681-4016
FU Genentech; Sirion Therapeutics; Bioptigen, Inc; Alcon Laboratories, Inc;
   Genentech [IST-4400S]; Alcon Laboratories
FX The authors have made the following disclosures:; Cynthia A. Toth:
   Research support-Genentech, Sirion Therapeutics, Bioptigen, Inc, Alcon
   Laboratories, Inc; potential royalties-Bioptigen, Inc, Alcon
   Laboratories, Inc.; Duke University has an equity and intellectual
   property interest in Bioptigen.; This project (ClinicalTrials.gov
   identifier: NCT00734487, August 13, 2008) was funded in part by
   Genentech grant (IST-4400S), Bioptigen (equipment), and Alcon
   Laboratories (unrestricted startup grant).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Ma W, 2009, PLOS ONE, V4, pe7945
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toth CA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1425, DOI 10.1001/archopht.1997.01100160595012
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Williams MA, 2009, AGE AGEING, V38, P648, DOI 10.1093/ageing/afp136
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 45
TC 73
Z9 74
U1 1
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2013
VL 120
IS 1
BP 140
EP 150
DI 10.1016/j.ophtha.2012.07.004
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 063PI
UT WOS:000313011700021
PM 22968145
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kaiser, PK
   Symons, RCA
   Shah, SM
   Quinlan, EJ
   Tabandeh, H
   Do, DV
   Reisen, G
   Lockridge, JA
   Short, B
   Guerciolini, R
   Nguyen, QD
AF Kaiser, Peter K.
   Symons, R. C. Andrew
   Shah, Syed Mahmood
   Quinlan, Edward J.
   Tabandeh, Homayoun
   Do, Diana V.
   Reisen, Gail
   Lockridge, Jennifer A.
   Short, Brian
   Guerciolini, Roberto
   Nguyen, Quan Dong
CA Sirna-027 Study Investigators
TI RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by
   Sirna-027
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS; OLIGONUCLEOTIDES; SUPPRESSION;
   RECEPTOR-1; VEGF
AB PURPOSE: To assess the safety, tolerability, pharmacokinetics, and dose-limiting toxicity of single intravitreal injection of Sirna-027, a small interfering RNA targeting vascular endothelial growth factor receptor-1, in patients with choroidal neovascularization (CNV) resulting from neovascular age-related macular degeneration (AMD). Secondary objectives included assessment of anatomic changes in retinal thickness, size of CNV, and changes in visual acuity.
   DESIGN: Prospective, open-label, single-dose, dose-escalation phase 1 study.
   METHODS: Twenty-six eyes of 26 patients with a median age of 82 years and CNV resulting from AMD who had previous treatments with other therapies were treated at 2 academic retinal practices. Patients received a single dose of Sirna-027 (100, 200, 400, 800, 1200, or 1600 mu g/eye). Blood was sampled for pharmacokinetic analysis at 1, 4, and 24 hours after injection and on day 7. Patients underwent ophthalmic examinations including visual acuity, fluorescein angiography, and optical coherence tomography at screening and days 7, 14, 28, and 84. The main outcome measures were adverse reactions and dose-limiting toxicities.
   RESULTS: Intravitreal injection of a single dose of Sirna-027 from 100 to 1600 mu g was well tolerated in patients with AMD, with no dose-limiting toxicity found. Adverse events were mild to moderate in severity. Adjusted mean foveal thickness decreased within 2 weeks after study treatment. The decrease was most pronounced in the 100-and 200-mu g doses.
   CONCLUSIONS: A single intravitreal dose of Sirna-027 up to 1600 mu g/eye was well tolerated in patients with CNV resulting from neovascular AMD that had been refractory to other therapies. Stabilization or improvement in visual acuity and foveal thickness was observed. No dose-response or dose-limiting effects were noted. (Am J Ophthalmol 2010;150:33-39. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Symons, R. C. Andrew; Shah, Syed Mahmood; Quinlan, Edward J.; Tabandeh, Homayoun; Do, Diana V.; Nguyen, Quan Dong] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Reisen, Gail; Lockridge, Jennifer A.; Guerciolini, Roberto] Sirna Therapeut Inc, San Francisco, CA USA.
   [Short, Brian] Allergan Pharmaceut Inc, Irvine, CA USA.
C3 Cleveland Clinic Foundation; Johns Hopkins University; Johns Hopkins
   Medicine; AbbVie; Allergan
RP Nguyen, QD (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Eye Inst, 600 N Wolfe St,Maumenee 745, Baltimore, MD 21287 USA.
EM qnguyen4@jhmi.edu
RI Symons, Robert Charles Andrew/C-2040-2017; Shah, Syed/K-2672-2018
OI Symons, Robert Charles Andrew/0000-0002-8104-881X; Kaiser,
   Peter/0000-0001-5126-045X
FU SIRNA THERAPEUTICS, INC, SAN FRANCISO, CALIFORNIA; Allergan; Sirna
   Therapeutics, Inc.
FX SUPPORTED BY SIRNA THERAPEUTICS, INC, SAN FRANCISO, CALIFORNIA. THE COLE
   EYE INSTITUTE, THE EMPLOYER OF DR Kaiser, and the Johns Hopkins
   University, the employer of Drs Symons, Shah, Quinlan, Do, and Nguyen,
   have received research grant support from Allergan and Sirna
   Therapeutics, Inc. Drs Kaiser and Quinlan served on the Scientific
   Advisory Board of Allergan. Drs Lockridge and Guerciolini and Ms Reisen
   were employees of Sirna Therapeutics, Inc. Dr Short is an employee of
   Allergan, Inc. Involved in design and conduct of the study (P.K.K.,
   R.G., Q.D.N.); Collection, management, analysis, and interpretation of
   the data (P.K.K., R.C.A.S., S.M.S., E.J.Q., H.T., D.V.D., OR., J.A.L.,
   B.S., R.G., Q.D.N.); and Preparation, review, or approval of the
   manuscript (P.K.K., S.M.S., E.J.Q., H.T., D.V.D., OR., J.A.L., B.S.,
   R.G., Q.D.N.). The study received institutional review board approval at
   both the Wilmer Eye Institute, Johns Hopkins University, and the Cole
   Eye Institute, Cleveland Clinics. All study sites were compliant with
   the Health Insurance Portability and Accountability Act of 1996. Before
   determination of eligibility for enrollment, patients provided written,
   informed consent for study participation. The study was posted to
   http://www.clinicaltrials.gov (identified no. NCT00363714).
CR Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FloresAguilar M, 1997, J INFECT DIS, V175, P1308, DOI 10.1086/516461
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X
   Monteith DK, 1999, TOXICOL PATHOL, V27, P8, DOI 10.1177/019262339902700103
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Tatlipinar S, 2007, OPHTHALMOLOGICA, V221, P227, DOI 10.1159/000101923
   Tuschl Thomas, 2002, Mol Interv, V2, P158, DOI 10.1124/mi.2.3.158
NR 14
TC 134
Z9 148
U1 0
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2010
VL 150
IS 1
BP 33
EP 39
DI 10.1016/j.ajo.2010.02.006
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624FW
UT WOS:000279803200008
PM 20609706
DA 2022-11-30
ER

PT J
AU Hasegawa, T
   Otani, A
   Sasahara, M
   Gotoh, N
   Ooto, S
   Tamura, H
   Yamashiro, K
   Tsujikawa, A
   Yoshimura, N
AF Hasegawa, Tomoko
   Otani, Atsushi
   Sasahara, Manabu
   Gotoh, Norimoto
   Ooto, Sotaro
   Tamura, Hiroshi
   Yamashiro, Kenji
   Tsujikawa, Akitaka
   Yoshimura, Nagahisa
TI Prognostic Factors of Vitreous Hemorrhage Secondary to Exudative
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PHOTODYNAMIC THERAPY; SUBMACULAR
   HEMORRHAGE; COMPLICATIONS; ASSOCIATION; MANAGEMENT
AB PURPOSE: Vitreous hemorrhage (VH) is a rare but serious complication of the eyes with exudative age-related macular degeneration (AMD). This retrospective study was designed to evaluate various clinical factors that may affect the visual prognosis of patients with VH secondary to exudative AMD.
   DESIGN: Retrospective case study.
   METHODS: We intensively documented 31 cases of VH secondary to exudative AMD and retrospectively analyzed best-corrected visual acuity (BCVA). All eyes underwent standard pars plana vitrectomy (PPV) for treating VH. Three subgroups were created according to the clinical course and treatment history before the occurrence of VH: (1) gas group (7 eyes), pneumatic displacement with sulfur hexafluoride gas performed to treat massive submacular hemorrhage; (2) photodynamic therapy (PDT) group (9 eyes), PDT performed to treat exudative AMD; (3) untreated group (15 eyes), no treatment performed.
   RESULTS: As a whole, BCVA before the occurrence of VH was 1.05 +/- 0.59 (logarithm of the minimal angle of resolution). After the occurrence of VH, BCVA before PPV dropped to 2.61 +/- 0.82. After the operation, final BCVA improved significantly to 1.25 +/- 0.73 (P < 10(-8)). In a subgroup analysis, no statistically significant difference was seen among the 3 subgroups at any time point. We found that the eyes whose fellow eye had exudative AMD showed significantly poor final BCVA compared with the unilateral cases (0.92 +/- 0.57 and 1.49 +/- 0.72; P = .02).
   CONCLUSIONS: PPV can improve visual acuity in the eyes with VH secondary to AMD, although effectiveness is limited. Medical practitioners should be cautious of the visual prognosis, especially in the cases in which the fellow eye has exudative AMD. (Am J Ophthalmol 2010;149:322-329. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Otani, Atsushi] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068386, Japan.
C3 Kyoto University
RP Otani, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068386, Japan.
EM otan@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamashiro, Kenji/0000-0001-9354-8558
CR Azzolini C, 1991, Eur J Ophthalmol, V1, P142
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Gomi Fumi, 1998, Nippon Ganka Gakkai Zasshi, V102, P436
   GOOGE JM, 1987, SURV OPHTHALMOL, V32, P123, DOI 10.1016/0039-6257(87)90104-4
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
NR 20
TC 12
Z9 14
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2010
VL 149
IS 2
BP 322
EP 329
DI 10.1016/j.ajo.2009.09.012
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 551OU
UT WOS:000274219700022
PM 20103057
OA Green Published
DA 2022-11-30
ER

PT J
AU Mrowicka, M
   Mrowicki, J
   Kucharska, E
   Majsterek, I
AF Mrowicka, Malgorzata
   Mrowicki, Jerzy
   Kucharska, Ewa
   Majsterek, Ireneusz
TI Lutein and Zeaxanthin and Their Roles in Age-Related Macular
   Degeneration-Neurodegenerative Disease
SO NUTRIENTS
LA English
DT Article
DE lutein; zeaxanthin; xanthophylls; carotenoid deficiency; age-related
   macular degeneration; oxidative stress
ID PIGMENT OPTICAL-DENSITY; DIETARY CAROTENOIDS; CONTRAST SENSITIVITY;
   OXIDATION-PRODUCTS; MESO-ZEAXANTHIN; VISUAL FUNCTION; CLINICAL-TRIAL;
   GENETIC RISK; VITAMIN-C; SUPPLEMENTATION
AB Lutein and zeaxanthin belong to the xanthophyll family of carotenoids, which are pigments produced by plants. Structurally, they are very similar, differing only slightly in the arrangement of atoms. Key sources of these carotenoids include kale, savoy cabbage, spinach, broccoli, peas, parsley, corn, and egg yolks. The recommended daily intake of lutein is approximately 10.0 mg and that of zeaxanthin is 2 mg. Lutein intake in adults varies, with average intakes being 1-2mg/day. Due to the lack of synthesis of consumption of these compounds in humans, these substances are extremely important for the proper functioning of certain organs of the body (eye, skin, heart, intestines). Eating a lot of dark leafy vegetables and some fruits can help to prevent our bodies from developing diseases. The protective effects of carotenoids are mainly related to their defense against oxidative stress and their ability to scavenge free radicals. Lutein and zeaxanthin are the only dietary carotenoids that accumulate in the retina, specifically the macula, and are called macular pigments. These carotenoids are concentrated by the action of specific binding proteins such as StARD3, which binds lutein, and GSTP1, which binds zeaxanthin and its dietary metabolite, mesozeaxanthin. It has been shown that supportive therapy with lutein and zeaxanthin can have a beneficial effect in delaying the progression of eye diseases such as age-related macular degeneration (AMD) and cataracts. This article presents the current state of knowledge on the role of lutein and zeaxanthin, especially from human studies targeting their metabolism and bioavailability, with recommendations to consume xanthophyll-rich foods.
C1 [Mrowicka, Malgorzata; Mrowicki, Jerzy; Majsterek, Ireneusz] Med Univ Lodz, Dept Clin Chem & Biochem, PL-90419 Lodz, Poland.
   [Kucharska, Ewa] Jesuit Univ Ignatianum, Dept Gerontol Geriatr & Social Work, PL-31501 Krakow, Poland.
C3 Medical University Lodz
RP Majsterek, I (通讯作者)，Med Univ Lodz, Dept Clin Chem & Biochem, PL-90419 Lodz, Poland.
EM malgorzata.mrowicka@umed.lodz.pl; jerzy.mrowicki@umed.lodz.pl;
   ewa.kucharska@ignatianum.edu.pl; ireneusz.majsterek@umed.lodz.pl
OI Majsterek, Ireneusz/0000-0001-6231-3334
FU National Science Center (NCN) [2016/21/B/NZ5/01411]; Department of
   Clinical Chemistry and Biochemistry, Medical University, Lodz, Poland
   [503/5-108-05/503-51-001-19-00]
FX This work was supported by grant no. 2016/21/B/NZ5/01411 OPUS 11 of the
   National Science Center (NCN) and statutory grant no.
   503/5-108-05/503-51-001-19-00 of the Department of Clinical Chemistry
   and Biochemistry, Medical University, Lodz, Poland.
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   [Anonymous], 2012, EFSA J, V10, P2981
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Augustynska D, 2015, CHEM-BIOL INTERACT, V239, P19, DOI 10.1016/j.cbi.2015.06.021
   Aziz E, 2020, LIFE SCI, V240, DOI 10.1016/j.lfs.2019.117104
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Black HS, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9030264
   Blakely S, 2003, J NUTR, V133, P2838, DOI 10.1093/jn/133.9.2838
   Bohm F, 2012, ACTA BIOCHIM POL, V59, P27
   Bone RA, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051321
   Bonyadi MHJ, 2018, ACTA OPHTHALMOL, V96, pe105, DOI 10.1111/aos.13494
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Castenmiller JJM, 1997, PURE APPL CHEM, V69, P2145, DOI 10.1351/pac199769102145
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Contin MA, 2016, EYE, V30, P255, DOI 10.1038/eye.2015.221
   Edge R, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010005
   El-Agamey A, 2007, FREE RADICAL RES, V41, P295, DOI 10.1080/10715760601087558
   Garcia-Layana A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041253
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hammond BR, 2013, INVEST OPHTH VIS SCI, V54, P476, DOI 10.1167/iovs.12-10411
   Harrison EH, 2012, BBA-MOL CELL BIOL L, V1821, P70, DOI 10.1016/j.bbalip.2011.06.002
   Hirdyani H., 2017, J PHARM RES, P528, DOI [10.20959/wjpr20176-8671, DOI 10.20959/WJPR20176-8671]
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Howells O, 2013, GRAEF ARCH CLIN EXP, V251, P871, DOI 10.1007/s00417-012-2127-0
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jaswir I, 2011, J MED PLANTS RES, V5, P7146, DOI 10.5897/JMPR11.018
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Kim JH, 2008, FREE RADICAL BIO MED, V45, P885, DOI 10.1016/j.freeradbiomed.2008.06.019
   Kuijk E.F.V., 2005, INVESTIG OPHTHALMOL, V46, P1787
   Kwiatkowska E., 2010, POST PY FITOTER, V2, P97
   Lakshminarayana R, 2013, CHEM-BIOL INTERACT, V203, P448, DOI 10.1016/j.cbi.2013.03.006
   Lee EH, 2004, J INVEST DERMATOL, V122, P510, DOI 10.1046/j.0022-202X.2004.22227.x
   Lem DW, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10081255
   Li BX, 2020, P NATL ACAD SCI USA, V117, P12352, DOI 10.1073/pnas.1922793117
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lindbergh CA, 2020, BRAIN IMAGING BEHAV, V14, P668, DOI 10.1007/s11682-018-00034-y
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Machida N, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102966
   Maoka T, 2020, J NAT MED-TOKYO, V74, P1, DOI 10.1007/s11418-019-01364-x
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   National Institutes of Health, 2019, FACTS AG REL MAC DEG
   Paradowska D., 2020, WORLD SCI NEWS, V139, P221
   Park HH, 2008, ARCH PHARM RES, V31, P1303, DOI 10.1007/s12272-001-2110-5
   Prokopiou E, 2017, BMJ OPEN OPHTHALMOL, V2, DOI [10.1136/bmjophth-2016-000056corr1, 10.1136/bmjophth-2016-000056]
   Pugazhendhi A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031170
   Qiu S, 2017, NEUROSCI LETT, V657, P53, DOI 10.1016/j.neulet.2017.07.041
   Querques G, 2018, GRAEF ARCH CLIN EXP, V256, P1, DOI 10.1007/s00417-017-3848-x
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   Roberts JE, 2001, PHOTOCHEM PHOTOBIOL, V74, P740, DOI 10.1562/0031-8655(2001)074<0740:POLPWX>2.0.CO;2
   Rodrigues E, 2012, MAR DRUGS, V10, P1784, DOI 10.3390/md10081784
   Sabour-Pickett S, 2014, RETINA-J RET VIT DIS, V34, P1757, DOI 10.1097/IAE.0000000000000174
   Santoyo S, 2012, J APPL PHYCOL, V24, P731, DOI 10.1007/s10811-011-9692-1
   Sawa M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62483-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sharma A, 2020, EYE, V34, P802, DOI 10.1038/s41433-019-0670-1
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stahl W, 2001, BIOFACTORS, V15, P95, DOI 10.1002/biof.5520150209
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2017, INVEST OPHTH VIS SCI, V58, P2291, DOI 10.1167/iovs.16-21087
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Suarez-Barrio C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031021
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Swapnil P, 2021, CURR PLANT BIOL, V26, DOI 10.1016/j.cpb.2021.100203
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tanprasertsuk J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155488
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thurnham DI, 2015, GRAEF ARCH CLIN EXP, V253, P1231, DOI 10.1007/s00417-014-2811-3
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Vishwanathan R, 2016, NUTR NEUROSCI, V19, P95, DOI 10.1179/1476830514Y.0000000141
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Widomska J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051333
   Wolf-Schnurrbusch UEK, 2015, INVEST OPHTH VIS SCI, V56, P8069, DOI 10.1167/iovs.15-17586
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
NR 99
TC 8
Z9 8
U1 7
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD FEB
PY 2022
VL 14
IS 4
AR 827
DI 10.3390/nu14040827
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 2T8XC
UT WOS:000822750100001
PM 35215476
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Schaal, S
   Sherman, MP
   Nesmith, B
   Barak, Y
AF Schaal, Shlomit
   Sherman, Mark P.
   Nesmith, Brooke
   Barak, Yoreh
TI UNTREATED OBSTRUCTIVE SLEEP APNEA HINDERS RESPONSE TO BEVACIZUMAB IN
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; obstructive sleep apnea;
   poor responders
ID RANIBIZUMAB; HYPERTENSION; ASSOCIATION; DISEASE; EYE; PHARMACOTHERAPY;
   TACHYPHYLAXIS; PREVALENCE; PREDICTORS; HYPOXEMIA
AB Purpose:To compare functional and anatomical responses to intravitreal bevacizumab in patients with exudative age-related macular degeneration (AMD) between two groups of patients with obstructive sleep apnea (OSA) with and without treatment with continuous positive airway pressure therapy.Methods:Patients with OSA were categorized into 2 groups: 18 untreated and 20 treated with continuous positive airway pressure therapy. All patients had exudative AMD and received treatment with intravitreal bevacizumab. Central retinal thickness was plotted against time to assess anatomical response. Logarithm of the minimum angle of resolution visual acuity changes determined functional effect. Total number of intravitreal injections administered was assessed.Results:Treated OSA group received 8 7 total injections; untreated OSA group received 16 +/- 4 injections (P < 0.05). Treated OSA group achieved statistically significant better visual acuity (logarithm of the minimum angle of resolution, 0.3 +/- 0.24, 20/40), as opposed to the untreated group (logarithm of the minimum angle of resolution, 0.7 +/- 0.41; P < 0.05). Central retinal thickness improved in the treated OSA group compared with the untreated group: 358 +/- 95 m to 254 +/- 45 m and 350 +/- 75 m to 322 +/- 105 m, respectively (P < 0.05, 20/100).Conclusion:Untreated OSA hinders the response of exudative AMD to intravitreal bevacizumab. Treatment of OSA with continuous positive airway pressure therapy yields a subsequent anatomical response and functional improvement while requiring significantly less injections. Identifying and treating underlying OSA earlier in patients with exudative AMD may yield better functional outcomes.
C1 [Schaal, Shlomit; Sherman, Mark P.; Nesmith, Brooke] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
   [Barak, Yoreh] Rambam Med Ctr, Dept Ophthalmol, Haifa, Israel.
C3 University of Louisville; Rambam Health Care Campus; Technion Israel
   Institute of Technology
RP Schaal, S (通讯作者)，301E Muhammad Ali Blvd, Louisville, KY 40202 USA.
EM s.schaal@louisville.edu
OI Barak, Yoreh/0000-0002-6941-862X
FU Research to Prevent Blindness, Inc, New York, NY
FX Supported in part by an unrestricted grant from Research to Prevent
   Blindness, Inc, New York, NY.
CR Artunay O, 2011, RETINA-J RET VIT DIS, V31, P1279, DOI 10.1097/IAE.0b013e318205b228
   Berg S, 2008, CLIN RESPIR J, V2, P197, DOI 10.1111/j.1752-699X.2008.00076.x
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   Del Rio R, 2011, AM J PHYSIOL-LUNG C, V301, pL702, DOI 10.1152/ajplung.00128.2011
   Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263
   Fanfulla F, 2008, SLEEP, V31, P249, DOI 10.1093/sleep/31.2.249
   Finkel KJ, 2009, SLEEP MED, V10, P753, DOI 10.1016/j.sleep.2008.08.007
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Glacet-Bernard A, 2010, ARCH OPHTHALMOL-CHIC, V128, P1533, DOI 10.1001/archophthalmol.2010.272
   Gonzaga CC, 2010, J CLIN SLEEP MED, V6, P363
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   KRIEGER J, 1989, CHEST, V96, P729, DOI 10.1378/chest.96.4.729
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee Won, 2008, Expert Rev Respir Med, V2, P349, DOI 10.1586/17476348.2.3.349
   Leveque TK, 2007, SLEEP BREATH, V11, P253, DOI 10.1007/s11325-007-0112-3
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mojon DS, 1998, OPHTHALMOLOGY, V105, P874, DOI 10.1016/S0161-6420(98)95030-8
   Mojon DS, 1999, OPHTHALMOLOGY, V106, P1009, DOI 10.1016/S0161-6420(99)00525-4
   Monahan K, 2011, CURR OPIN CARDIOL, V26, P541, DOI 10.1097/HCO.0b013e32834b806a
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Purvin VA, 2000, ARCH OPHTHALMOL-CHIC, V118, P1626, DOI 10.1001/archopht.118.12.1626
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shamsuzzaman ASM, 2003, JAMA-J AM MED ASSOC, V290, P1906, DOI 10.1001/jama.290.14.1906
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Sulit L, 2006, SLEEP, V29, P777, DOI 10.1093/sleep/29.6.777
   Waller EA, 2008, MAYO CLIN PROC, V83, P1251, DOI 10.4065/83.11.1251
   WOOG JJ, 1990, AM J OPHTHALMOL, V110, P314, DOI 10.1016/S0002-9394(14)76357-3
   Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080
   Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893
   Young Terry, 2009, WMJ, V108, P246
NR 40
TC 23
Z9 23
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2016
VL 36
IS 4
BP 791
EP 797
DI 10.1097/IAE.0000000000000981
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DJ0IC
UT WOS:000373884700019
PM 26841211
DA 2022-11-30
ER

PT J
AU Mantel, I
   Ambresin, A
   Moetteli, L
   Droz, I
   Roduit, R
   Munier, FL
   Schorderet, DF
AF Mantel, Irmela
   Ambresin, Aude
   Moetteli, Leila
   Droz, Ivaine
   Roduit, Raphael
   Munier, Francis L.
   Schorderet, Daniel F.
TI Complement Factor B Polymorphism and the Phenotype of Early Age-related
   Macular Degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; complement factor B; drusen;
   genotype-phenotype association; polymorphism
ID FACTOR-H POLYMORPHISM; COMPONENT 2; FAMILIAL AGGREGATION; CHINESE
   POPULATION; MONOZYGOTIC TWINS; SEVERITY SCALE; ASSOCIATION; MACULOPATHY;
   RISK; GENES
AB Purpose: Age-related macular degeneration (AMD) has been associated with a number of polymorphisms in genes in the complement pathway. We examined the potential genotype-phenotype correlation of complement factor B (CFB) (R32Q) polymorphisms in Caucasian patients with AMD.
   Methods: Data from a Central European cohort of 349 patients with early AMD in at least one eye were analyzed for potential associations of the CFB (R32Q/rs641153) polymorphism with phenotypic features of early AMD. Early AMD was classified according to the International Classification and Grading System into predominant drusen size, largest drusen, drusen covered surface, central or ring-like location, peripheral drusen, and pigmentary changes. The potential association with single nucleotide polymorphisms on CFB (R32Q/rs641153) was evaluated for all patients, corrected for age, sex, and the polymorphisms of CFH (Y402H) and ARMS2 (A69S).
   Results: CFB (R32Q) polymorphisms showed a significant association with smaller drusen size (largest drusen <= 250 mu m, p = 0.021, predominant drusen <= 125 mu m, p = 0.016), with smaller surface covered by drusen (<= 10%; p = 0.02), and with more frequent occurrence of peripheral drusen (p = 0.007). No association was found for pigmentary changes.
   Conclusions: The CFB (R32Q) polymorphism was associated with AMD characterized by small drusen only, and appeared to be protective of large drusen (OR 0.48/0.45) and of larger drusen covered area (OR 0.34). Furthermore, peripheral drusen were more frequently found (OR 2.27). This result supports the role of complement components and their polymorphisms in drusen formation and may enable a better understanding of AMD pathogenesis.
C1 [Mantel, Irmela; Ambresin, Aude; Moetteli, Leila; Droz, Ivaine; Munier, Francis L.; Schorderet, Daniel F.] Univ Lausanne, Jules Gonin Eye Hosp, Univ Lausanne, Dept Ophthalmol, CH-1015 Lausanne, Switzerland.
   [Roduit, Raphael; Munier, Francis L.; Schorderet, Daniel F.] Univ Lausanne, Inst Res Ophthalmol, Sion, Switzerland.
   [Roduit, Raphael; Munier, Francis L.; Schorderet, Daniel F.] Swiss Fed Inst Technol, CH-1015 Lausanne, Switzerland.
C3 University of Lausanne; University of Lausanne; Swiss Federal Institutes
   of Technology Domain; Ecole Polytechnique Federale de Lausanne
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, 15 Ave France Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
RI Roduit, Raphael/AAC-3890-2021
OI Roduit, Raphael/0000-0001-7440-2799
FU Pfizer AG (Dublin, Irland) [127RD06IM06]; Grieshaber Ophthalmic Research
   Foundation (Schaffhausen, Switzerland)
FX The authors received financial support for this research from Pfizer AG
   (Dublin, Irland, grant number 127RD06IM06) and the Grieshaber Ophthalmic
   Research Foundation (Schaffhausen, Switzerland). The funding
   organizations had no role in the design or conduct of the study.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Chou WW, 2012, CELL IMMUNOL, V273, P79, DOI 10.1016/j.cellimm.2011.11.003
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hughes AE, 2011, MOL VIS, V17, P983
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   SVERRISSON T, 1995, INVEST OPHTH VIS SCI, V36, pS10
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Thompson CL, 2007, INVEST OPHTH VIS SCI, V48, P3005, DOI 10.1167/iovs.06-1325
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
NR 46
TC 11
Z9 11
U1 0
U2 10
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD MAR
PY 2014
VL 35
IS 1
BP 12
EP 17
DI 10.3109/13816810.2013.766217
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA AA1IZ
UT WOS:000330851100003
PM 23373431
DA 2022-11-30
ER

PT J
AU Puche, N
   Blanco-Garavito, R
   Richard, F
   Leveziel, N
   Zerbib, J
   Tilleul, J
   Mimoun, G
   Querques, G
   Cohen, SY
   Souied, EH
AF Puche, Nathalie
   Blanco-Garavito, Rocio
   Richard, Florence
   Leveziel, Nicolas
   Zerbib, Jennyfer
   Tilleul, Julien
   Mimoun, Gerard
   Querques, Giuseppe
   Cohen, Salomon Y.
   Souied, Eric H.
TI GENETIC AND ENVIRONMENTAL FACTORS ASSOCIATED WITH RETICULAR PSEUDODRUSEN
   IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; epidemiology; genetic; reticular
   pseudodrusen; smoking
ID FACTOR-H POLYMORPHISM; SUBRETINAL DRUSENOID DEPOSITS; RISK; PREVALENCE;
   VARIANT
AB Purpose: To analyze the genetic and environmental factors associated with reticular pseudodrusen (RPD) in age-related macular degeneration (AMD).
   Methods: In a large population, AMD patients (n = 519) with and without RPD were assessed with a standardized examination including infrared images and spectral domain optical coherence tomography scans. Three groups were defined: Group 1: AMD patients with RPD (n = 105); Group 2: AMD patients without RPD (n = 414); and Group 3: controls with no AMD and no RPD (n = 430). Four genes associated with AMD (CFH, ARMS2/HTRA1, C3, apolipoprotein E) and environmental factors were assessed between the 3 groups.
   Results: None of the environmental factors studied were more significantly associated to either Group 1 or Group 2. The odds ratios and 95% confidence intervals for individuals homozygous for the CFH risk allele were 4.0 (2.1-7.7) ([95% confidence interval: 2.1-7.7]; P < 0.0004) in Group 1 and 4.3 ([2.6-7.1]; P < 0.0004) in Group 2, compared with Group 3. The odds ratios for individuals homozygous for the ARMS2 risk allele for Groups 1 and 2 compared with Group 3 were 16.3 ([7.6-35.4]; P < 0.0004) and 11.9 ([6.3-22.3]; P < 0.0004), respectively. None of the genotypes studied were more significantly associated to Group 1 than Group 2.
   Conclusion: Genotypes known to be associated with AMD were similarly observed in patients with and without RPD. RETINA 33: 998-1004, 2013
C1 [Puche, Nathalie; Blanco-Garavito, Rocio; Leveziel, Nicolas; Zerbib, Jennyfer; Tilleul, Julien; Mimoun, Gerard; Querques, Giuseppe; Souied, Eric H.] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Richard, Florence] Univ Lille 2, INSERM, UMR 744, Inst Pasteur Lille, Lille, France.
   [Cohen, Salomon Y.] Ophthalmol Ctr Imaging & Laser, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Le Reseau
   International des Instituts Pasteur (RIIP); Universite de Lille - ISITE;
   Institut Pasteur Lille; Universite de Lille
RP Souied, EH (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
OI Querques, Giuseppe/0000-0002-3292-9581; Nicolas,
   Leveziel/0000-0001-8533-9457
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawkins BS, 1999, MOL VIS, V5
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   Leveziel N, 2007, MOL VIS, V13, P2153
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 31
TC 33
Z9 34
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2013
VL 33
IS 5
BP 998
EP 1004
DI 10.1097/IAE.0b013e31827b6483
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131QY
UT WOS:000318011100016
PM 23549092
DA 2022-11-30
ER

PT J
AU Karagiannis, DA
   Ladas, ID
   Parikakis, E
   Georgalas, I
   Kotsolis, A
   Amariotakis, G
   Soumplis, V
   Mitropoulos, P
AF Karagiannis, Dimitrios A.
   Ladas, Ioannis D.
   Parikakis, Efstratios
   Georgalas, Ilias
   Kotsolis, Athanasios
   Amariotakis, Giorgos
   Soumplis, Vasileios
   Mitropoulos, Panagiotis
TI Changing from bevacizumab to ranibizumab in age-related macular
   degeneration. Is it safe?
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE age-related macular degeneration; bevacizumab; ranibizumab; subretinal
   hemorrhage
AB Objective: To report our experiences in changing from intravitreal bevacizumab to ranibizumab in age-related macular degeneration (AMD).
   Design: Retrospective case series.
   Participants and methods: We retrospectively reviewed the records of 34 patients (36 eyes) who were treated with monthly injections of intravitreal bevacizumab for six months and then switched to monthly injections of ranibizumab for 12 months. Best-corrected visual acuity measurements (BCVA), contact lens biomicroscopy, optical coherence tomography (OCT), and fluorescein angiography were performed at the baseline examination and then monthly. Chi-square test was used for statistical analysis.
   Results: Following bevacizumab treatment, retinal thickness decreased (P = 0.033) while BCVA improved (P = 0.040). Changing from bevacizumab to ranibizumab resulted in a transient decrease in BCVA (P = 0.045) and an increase in retinal thickness (P = 0.042). In addition, three eyes presented with a large subretinal hemorrhage. However, final retinal thickness was better than the initial thickness and the value following the bevacizumab course. No major ocular or systemic side effects were noted.
   Conclusions: Ranibizumab was clinically effective in the long term but the change of treatment from bevacizumab to a half-size molecule with less half-life in the vitreous such as ranibizumab contributed to a transient "instability" in the eye which may have triggered the large subretinal hemorrhage. There is insufficient experience reported in the literature in switching from one agent to another. A prospective study with controls is necessary to determine whether it is safe to change from one medication to another.
C1 [Karagiannis, Dimitrios A.; Parikakis, Efstratios; Amariotakis, Giorgos; Soumplis, Vasileios; Mitropoulos, Panagiotis] Ophthalmiatrio Eye Hosp Athens, Athens, Greece.
   [Ladas, Ioannis D.; Georgalas, Ilias; Kotsolis, Athanasios] Univ Athens, Dept Ophthalmol 1, Sch Med, Gen Hosp Athens, Athens, Greece.
C3 Athens Medical School; General Hospital of N. Ionia Agia Olga; National
   & Kapodistrian University of Athens
RP Karagiannis, DA (通讯作者)，5 Dimokratias Ave, Drosia 14572, Greece.
EM dimitrioskaragiannis@doctors.org.uk
RI Georgalas, Ilias/AAD-5946-2019
OI Georgalas, Ilias/0000-0002-6171-5865
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Buys YM, 2007, CAN J OPHTHALMOL, V42, P789, DOI 10.3129/i07-176
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Devenyi RG, 2006, CAN J OPHTHALMOL, V41, P133, DOI 10.1139/I06-901
   Gatto Barbara, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P287, DOI 10.2174/187152006777698178
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Kaempf S, 2008, INVEST OPHTH VIS SCI, V49, P3164, DOI 10.1167/iovs.07-1265
   Karagiannis DA, 2009, OPHTHALMOLOGICA, V223, P279, DOI 10.1159/000213644
   Klein RM, 2007, RETINA-J RET VIT DIS, V27, P1163, DOI 10.1097/IAE.0b013e31815e9322
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Levine JP, 2009, RETINA-J RET VIT DIS, V29, P1074, DOI 10.1097/IAE.0b013e3181b09443
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Singh Rishi P., 2007, Indian Journal of Ophthalmology, V55, P421
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
NR 30
TC 18
Z9 19
U1 0
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176-9092
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2009
VL 4
BP 457
EP 461
PG 5
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA V21WZ
UT WOS:000208239000049
PM 20054410
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Chen, FK
   Ikeji, F
   Xing, W
   Bunce, C
   Da Cruz, L
   Tufail, A
AF Patel, Praveen J.
   Chen, Fred K.
   Ikeji, Felicia
   Xing, Wen
   Bunce, Catey
   Da Cruz, Lyndon
   Tufail, Adnan
TI Repeatability of stratus optical coherence tomography measures in
   neovascular age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID REPRODUCIBILITY; THICKNESS
AB PURPOSE. To determine the repeatability of Stratus optical coherence tomography (OCT) measures of retinal thickness and volume in patients with neovascular age-related macular degeneration (nAMD)
   METHOD. Fifty-one eyes of 51 consecutive patients with nAMD underwent an OCT imaging session in which two fast macular thickness map (FMTM) protocol scans sets were acquired by a single experienced operator certified for clinical trials work. Coefficients of repeatability for each of nine Early Treatment of Diabetic Retinopathy Study (ETDRS)-like regions, foveolar center-point retinal thickness (CPT) and total macular volume (TMV), were calculated. Scans were analyzed retrospectively for errors in retinal boundary placement by two observers, with revised coefficients of repeatability calculated after excluding any scan sets with significant segmentation error.
   RESULTS. The coefficient of repeatability for the central 1-mm macular subfield was 67 mu m (23%) and was less than 75 mu m for all macular subfields. There was much larger variability in the center-point thickness measure, with a coefficient of repeatability of 88 mu m (32%) for the automated center-point thickness (ACPT). After excluding nine scan set pairs with significant segmentation error, the coefficient of repeatability for the central 1-mm macular subfield was reduced to 50 mu m (19%).
   CONCLUSIONS. OCT-derived retinal thickness measurements are subject to considerable measurement variability in patients with nAMD. Changes in central macular thickness of more than 50 mu m may better reflect true clinical change in scan sets without significant segmentation error and may be used to guide the retreatment of patients with nAMD in clinical trials and clinical practice.
C1 [Patel, Praveen J.; Chen, Fred K.; Ikeji, Felicia; Xing, Wen; Bunce, Catey; Da Cruz, Lyndon; Tufail, Adnan] Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Tufail, A (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM adnan.tufail@moorfields.nhs.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Tufail, Adnan/0000-0001-6131-7640; Bunce,
   Catey/0000-0002-0935-3713
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Browning DJ, 2004, AM J OPHTHALMOL, V138, P477, DOI 10.1016/j.ajo.2004.03.014
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hammer DX, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1896967
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 12
TC 50
Z9 50
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2008
VL 49
IS 3
BP 1084
EP 1088
DI 10.1167/iovs.07-1203
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 271TZ
UT WOS:000253812900036
PM 18326734
DA 2022-11-30
ER

PT J
AU Yaylali, SA
   Akcakaya, AA
   Erbil, HH
   Candemir, B
   Mesci, C
   Acar, H
AF Yaylali, Sevil Ari
   Akcakaya, Aylin Ardagil
   Erbil, Hasan Hasbi
   Candemir, Bahadir
   Mesci, Cem
   Acar, Huseyin
TI The relationship between optical coherence tomography patterns,
   angiographic parameters and visual acuity in age-related macular
   degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Exudative age-related macular degeneration; Fluorescein angiography;
   Optical coherence tomography; Visual acuity
AB To assess the relationships between visual acuity (VA), fluorescein angiographic parameters and optical coherence tomography (OCT) patterns in exudative age-related macular degeneration (AMD). Fifty eyes with confirmed diagnosis of new exudative AMD who underwent fluorescein angiography (FA) and OCT evaluation were reviewed retrospectively. The greatest linear diameter of lesion (GLD) by FA and central foveal thickness (CFT) by OCT were measured. The OCT scans were evaluated for the presence of diffuse retinal thickening (D), cystic spaces (C), subretinal fluid (S) and pigment epithelial detachment (P) and five OCT patterns were detected (D + S; C; C + S; P + C + S; P + D + S). Angiographic classification of choroidal neovascularizations was performed. Correlations were statistically significant for VA and CFT in all patients whereas VA and GLD correlation was statistically significant only in predominantly classic and minimal classic lesions. The lowest VA values were detected in patients with COCT pattern and/or predominantly classic lesion type by FA. The OCT and FA findings when evaluated simultaneously may provide information regarding visual function in AMD.
C1 [Yaylali, Sevil Ari; Akcakaya, Aylin Ardagil; Erbil, Hasan Hasbi; Candemir, Bahadir; Mesci, Cem; Acar, Huseyin] Istanbul Goztepe Educ Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 Istanbul Goztepe Training and Research Hospital
RP Yaylali, SA (通讯作者)，Istanbul Goztepe Educ Hosp, Dept Ophthalmol, Istanbul, Turkey.
EM sevil.yaylali@gmail.com; aardagil@gmail.com; h.h.erbil@hotmail.com;
   bahadircandemir@yahoo.com; cmesci@ttmail.com; skydivercine@hotmail.com
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD FEB
PY 2012
VL 32
IS 1
BP 25
EP 30
DI 10.1007/s10792-012-9519-3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA VJ8EI
UT WOS:000634109500004
DA 2022-11-30
ER

PT J
AU Li, L
   Li, W
   Chen, CZ
   Yi, ZHZ
   Zhou, YY
AF Li, L.
   Li, W.
   Chen, C. Z.
   Yi, Z. H. Z.
   Zhou, Y. Y.
TI Is aspirin use associated with age-related macular degeneration? A
   meta-analysis
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Review
DE age-related macular degeneration; aspirin; meta-analysis;
   neovascularization
ID RISK-FACTORS; CHOROIDAL NEOVASCULARIZATION; DECREASED RATES; INTRAOCULAR
   HEMORRHAGE; 5-YEAR INCIDENCE; MACULOPATHY; THERAPY; STATIN; DRUG;
   PATHOGENESIS
AB What is known and objectivesAspirin is one of the most widely used medications in the world. The evidence on its effect on the risk of age-related macular degeneration (AMD) appears inconsistent across different types of studies. The aim of this meta-analysis was to evaluate the association between aspirin use and the risk of AMD.
   MethodsRelevant studies were searched using databases including PubMed, EMBASE, Cochrane Library and MEDLINE up to March 2014. Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated by random-effects or fixed-effect models. The heterogeneity was assessed by the inconsistency index (I-2). The publication bias was evaluated by Begg's funnel plot and Egger's weighted regression. Sensitivity analysis was also performed in different ways.
   ResultsTen eligible studies including 180834 individuals based on the inclusion criteria were analysed in this meta-analysis. The pooled RR for the aspirin use on the risk of AMD was 1137 (95% CI, 1003-1289; I-2, 684%). The pooled RR for the aspirin use on the risk of early and late AMD was 119 (95% CI, 092-153; I-2, 826%) and 122 (95% CI, 087-172; I-2, 557%), respectively. In different types of late AMD, the pooled RR was 195 (95% CI, 140-272; I-2, 27%) for neovascularization and 084 (95% CI, 062-115; I-2, 0%) for geographic atrophy. The pooled RR in studies with standardized AMD classification was 1307 (95% CI, 1006-1698; I-2, 792%).
   What is new and conclusionThis meta-analysis updates similar reviews that included studies with various types of biases. A rigorous analysis shows a weak but statistically significant association between aspirin use and the risk of AMD; a result which is different to that previously reported.
C1 [Li, L.; Chen, C. Z.; Yi, Z. H. Z.; Zhou, Y. Y.] Wuhan Univ, Renmin Hosp, Dept Ophthalmol, Wuhan 430060, Hubei Province, Peoples R China.
   [Li, W.] Hubei Canc Hosp, Dept Head & Neck Surg, Wuhan, Hubei Province, Peoples R China.
C3 Wuhan University
RP Chen, CZ (通讯作者)，Wuhan Univ, Renmin Hosp, Dept Ophthalmol, 238 Jiefang Rd, Wuhan 430060, Hubei Province, Peoples R China.
EM liluohanxing@163.com
RI Yi, Zuohuizi/HDN-1699-2022
OI Chen, Changzheng/0000-0002-7281-552X
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Battinelli EM, 2011, BLOOD, V118, P1359, DOI 10.1182/blood-2011-02-334524
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Cheung N, 2013, BRIT J OPHTHALMOL, V97, P785, DOI 10.1136/bjophthalmol-2012-302253
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   CHRISTEN WG, 1994, AM J MED, V97, pS14, DOI 10.1016/0002-9343(94)90293-3
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2014, EXPERT OPIN DRUG SAF, V13, P421, DOI 10.1517/14740338.2014.889680
   Christen William G, 2014, Evid Based Med, V19, pe6, DOI 10.1136/eb-2013-101358
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Covinsky KE, 2013, JAMA INTERN MED, V173, P266, DOI 10.1001/jamainternmed.2013.2790
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   de Jong PTVM, 2010, OPHTHALMOLOGY, V117, P1279, DOI 10.1016/j.ophtha.2010.03.011
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gaynes BI, 2004, AM J OPHTHALMOL, V138, P1089, DOI 10.1016/j.ajo.2004.08.048
   Girgis RAM, 2004, AM J OPHTHALMOL, V138, P697, DOI 10.1016/j.ajo.2004.05.063
   Goertz O, 2011, BURNS, V37, P656, DOI 10.1016/j.burns.2011.01.004
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hall Nigel F, 2002, Expert Opin Pharmacother, V3, P803
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holbrook AM, 2005, ARCH INTERN MED, V165, P1095, DOI 10.1001/archinte.165.10.1095
   Hu XQ, 2013, JAMA-J AM MED ASSOC, V309, P1227, DOI 10.1001/jama.2013.2035
   Kahawita SK, 2014, CAN J OPHTHALMOL, V49, P35, DOI 10.1016/j.jcjo.2013.07.016
   Kaul S, 2013, JAMA INTERN MED, V173, P264, DOI 10.1001/jamainternmed.2013.2530
   Keller DL, 2013, JAMA INTERN MED, V173, P1476, DOI 10.1001/jamainternmed.2013.8147
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Mascitelli L, 2010, MED HYPOTHESES, V74, P754, DOI 10.1016/j.mehy.2009.11.009
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Ramaswamy SG, 2013, J AM GERIATR SOC, V61, P1033, DOI 10.1111/jgs.12284
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073
   Rudnicka AR, 2010, EYE, V24, P1199, DOI 10.1038/eye.2010.8
   Samoocha David, 2010, J Med Internet Res, V12, pe23, DOI 10.2196/jmir.1286
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sobrin L, 2013, AM J OPHTHALMOL, V156, P213, DOI 10.1016/j.ajo.2013.04.023
   Swanson MW, 2008, OPTOMETRY VISION SCI, V85, P947, DOI 10.1097/OPX.0b013e31818883e0
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Warner TD, 2002, P NATL ACAD SCI USA, V99, P13371, DOI 10.1073/pnas.222543099
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wu Yan, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P59
   Ye J, 2014, INVEST OPHTH VIS SCI, V55, P2687, DOI 10.1167/iovs.13-13206
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 70
TC 15
Z9 15
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD APR
PY 2015
VL 40
IS 2
BP 144
EP 154
DI 10.1111/jcpt.12241
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CC8UA
UT WOS:000350642600004
PM 25475899
OA Bronze
DA 2022-11-30
ER

PT J
AU Kelly, UL
   Grigsby, D
   Cady, MA
   Landowski, M
   Skiba, NP
   Liu, J
   Remaley, AT
   Klingeborn, M
   Rickman, CB
AF Kelly, Una L.
   Grigsby, Daniel
   Cady, Martha A.
   Landowski, Michael
   Skiba, Nikolai P.
   Liu, Jian
   Remaley, Alan T.
   Klingeborn, Mikael
   Bowes Rickman, Catherine
TI High-density lipoproteins are a potential therapeutic target for
   age-related macular degeneration
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE lipoprotein; heparan sulfate; complement; retinal degeneration; aging;
   high-density lipoprotein (HDL); apolipoprotein; glycosaminoglycan;
   oligosaccharide; age-related macular degeneration; complement factor H;
   heparan sulfate proteoglycans; retinal pigmented epithelium
ID COMPLEMENT FACTOR-H; APOLIPOPROTEIN MIMETIC PEPTIDE; CHOLESTEROL EFFLUX;
   HEPARAN-SULFATE; BRUCHS MEMBRANE; ALTERNATIVE PATHWAY; BINDING; HDL;
   POLYMORPHISM; RISK
AB Strong evidence suggests that dysregulated lipid metabolism involving dysfunction of the retinal pigmented epithelium (RPE) underlies the pathogenesis of age-related macular degeneration (AMD), the leading cause of irreversible blindness in the elderly. A hallmark of AMD is the overproduction of lipid- and protein-rich extracellular deposits that accumulate in the extracellular matrix (Bruch's membrane (BrM)) adjacent to the RPE. We analyzed apolipoprotein A-1 (ApoA-1)-containing lipoproteins isolated from BrM of elderly human donor eyes and found a unique proteome, distinct from high-density lipoprotein (HDL) isolated from donor plasma of the same individuals. The most striking difference is higher concentrations of ApoB and ApoE, which bind to glycosaminoglycans. We hypothesize that this interaction promotes lipoprotein deposition onto BrM glycosaminoglycans, initiating downstream effects that contribute to RPE dysfunction/death. We tested this hypothesis using two potential therapeutic strategies to alter the lipoprotein/protein profile of these extracellular deposits. First, we used short heparan sulfate oligosaccharides to remove lipoproteins already deposited in both the extracellular matrix of RPE cells and aged donor BrM tissue. Second, an ApoA-1 mimetic, 5A peptide, was demonstrated to modulate the composition and concentration of apolipoproteins secreted from primary porcine RPE cells. Significantly, in a mouse model of AMD, this 5A peptide altered the proteomic profile of circulating HDL and ameliorated some of the potentially harmful changes to the protein composition resulting from the high-fat, high-cholesterol diet in this model. Together, these results suggest that targeting HDL interactions with BrM represents a new strategy to slow AMD progression in humans.
C1 [Kelly, Una L.; Grigsby, Daniel; Cady, Martha A.; Landowski, Michael; Skiba, Nikolai P.; Klingeborn, Mikael; Bowes Rickman, Catherine] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Bowes Rickman, Catherine] Duke Univ, Med Ctr, Cell Biol, Durham, NC USA.
   [Liu, Jian] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Chapel Hill, NC 27515 USA.
   [Remaley, Alan T.] NHLBI, Lipoprot Metab Sect, Pulm & Vasc Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Landowski, Michael] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA.
C3 Duke University; Duke University; University of North Carolina;
   University of North Carolina Chapel Hill; National Institutes of Health
   (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI);
   University of Wisconsin System; University of Wisconsin Madison
RP Klingeborn, M; Rickman, CB (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.; Rickman, CB (通讯作者)，Duke Univ, Med Ctr, Cell Biol, Durham, NC USA.
EM mikael.klingeborn@duke.edu; bowes007@duke.edu
OI Klingeborn, Mikael/0000-0003-2907-0371; Bowes Rickman,
   Catherine/0000-0002-8555-9596; Landowski, Michael/0000-0003-0151-0689
FU NEI, National Institutes of Health [R01 EY026161, P30 EY005722]; Edward
   N. and Della L. Thome Memorial Foundation Award in Age-Related Macular
   Degeneration Research; Research to Prevent Blindness/International
   Retinal Research Foundation Catalyst award for Innovative Research
   Approaches for AMD; Research to Prevent Blindness; National Institutes
   of Health [1R01HL094463, R01 HL144970]
FX This work was supported by NEI, National Institutes of Health, Grants
   R01 EY026161 (to C. B. R.) and P30 EY005722 (to Duke Eye Center); an
   Edward N. and Della L. Thome Memorial Foundation Award in Age-Related
   Macular Degeneration Research (to C. B. R.); a Research to Prevent
   Blindness/International Retinal Research Foundation Catalyst award for
   Innovative Research Approaches for AMD (to C. B. R.); and an
   unrestricted grant from Research to Prevent Blindness (to the Duke Eye
   Center). A. R. is supported by intramural NHBLI-DIR funds from the
   National Institutes of Health. J. L. is supported by National Institutes
   of Health Grants 1R01HL094463 and R01 HL144970. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Amar MJA, 2010, J PHARMACOL EXP THER, V334, P634, DOI 10.1124/jpet.110.167890
   AVIRAM M, 1983, BIOCHEM MED METAB B, V30, P111, DOI 10.1016/0006-2944(83)90013-3
   Beebe DC, 2013, INVEST OPHTH VIS SCI, V54, P5720, DOI 10.1167/iovs.13-12873
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Boren J, 2016, CURR OPIN LIPIDOL, V27, P473, DOI 10.1097/MOL.0000000000000330
   Bourdi M, 2018, REGUL TOXICOL PHARM, V100, P59, DOI 10.1016/j.yrtph.2018.10.009
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Calabresi L, 2002, ARTERIOSCL THROM VAS, V22, P656, DOI 10.1161/hq0402.105901
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Flood C, 2004, ARTERIOSCL THROM VAS, V24, P564, DOI 10.1161/01.ATV.0000117174.19078.85
   Fogelstrand P, 2012, NUTR METAB CARDIOVAS, V22, P1, DOI 10.1016/j.numecd.2011.09.007
   Foley EM, 2013, ARTERIOSCL THROM VAS, V33, P2065, DOI 10.1161/ATVBAHA.113.301637
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heinecke JW, 2009, J LIPID RES, V50, pS167, DOI 10.1194/jlr.R800097-JLR200
   Holzer M, 2016, SCI REP-UK, V6, DOI 10.1038/srep38533
   Holzer M, 2013, BBA-MOL CELL BIOL L, V1831, P1442, DOI 10.1016/j.bbalip.2013.06.004
   Holzer M, 2012, J LIPID RES, V53, P1618, DOI 10.1194/jlr.M027367
   Hoofnagle AN, 2012, CLIN CHEM, V58, P777, DOI 10.1373/clinchem.2011.173856
   Hughes CS, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145625
   Iozzo RV, 2015, MATRIX BIOL, V42, P11, DOI 10.1016/j.matbio.2015.02.003
   Islam RM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20965-2
   Jiang JY, 2012, J VIROL, V86, P7256, DOI 10.1128/JVI.07222-11
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Kelly U, 2009, INVEST OPHTH VIS SCI, V50, P1540, DOI 10.1167/iovs.08-2782
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Kontush A, 2015, HANDB EXP PHARMACOL, V224, P3, DOI 10.1007/978-3-319-09665-0_1
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lawrence R, 2008, J BIOL CHEM, V283, P33674, DOI 10.1074/jbc.M804288200
   Liu RP, 2010, J BIOL CHEM, V285, P34240, DOI 10.1074/jbc.M110.159152
   Mahoney DJ, 2004, ANAL BIOCHEM, V330, P123, DOI 10.1016/j.ab.2004.03.055
   Marson A, 2009, GLYCOBIOLOGY, V19, P1537, DOI 10.1093/glycob/cwp132
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McHarg S, 2015, JOVE-J VIS EXP, DOI 10.3791/53382
   MOLD C, 1984, J IMMUNOL, V133, P882
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Murphy A.J., 2013, INT SCH RES NETW PHY, P1
   Nagata KO, 2013, P NATL ACAD SCI USA, V110, P5034, DOI 10.1073/pnas.1220703110
   Navab M, 2000, J LIPID RES, V41, P1495
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Packard RRS, 2008, CLIN CHEM, V54, P24, DOI 10.1373/clinchem.2007.097360
   PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Pertl L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157210
   Phillips MC, 2018, J LIPID RES, V59, P749, DOI 10.1194/jlr.R082313
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Sethi AA, 2008, J BIOL CHEM, V283, P32273, DOI 10.1074/jbc.M804461200
   Shah AS, 2013, J LIPID RES, V54, P2575, DOI 10.1194/jlr.R035725
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Silva JC, 2005, ANAL CHEM, V77, P2187, DOI 10.1021/ac048455k
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Stanford KI, 2009, J CLIN INVEST, V119, P3236, DOI 10.1172/JCI38251
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   Sviridov DO, 2013, J PHARMACOL EXP THER, V344, P50, DOI 10.1124/jpet.112.198143
   Tabet F, 2010, ARTERIOSCL THROM VAS, V30, P246, DOI 10.1161/ATVBAHA.109.200196
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Vaisar T, 2010, CLIN CHIM ACTA, V411, P972, DOI 10.1016/j.cca.2010.03.023
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Weichhart T, 2012, J AM SOC NEPHROL, V23, P934, DOI 10.1681/ASN.2011070668
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zaferani A, 2012, J BIOL CHEM, V287, P31471, DOI 10.1074/jbc.M112.380386
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 90
TC 9
Z9 9
U1 2
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 25
PY 2020
VL 295
IS 39
BP 13601
EP 13616
DI 10.1074/jbc.RA119.012305
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA NY3VI
UT WOS:000576321100014
PM 32737203
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Heinemann, M
   Welker, SG
   Li, JQ
   Wintergerst, MWM
   Turski, GN
   Turski, CA
   Holz, FG
   Finger, RP
AF Heinemann, M.
   Welker, S. G.
   Li, J. Q.
   Wintergerst, M. W. M.
   Turski, G. N.
   Turski, C. A.
   Holz, F. G.
   Finger, Robert P.
TI Awareness of Age-Related Macular Degeneration in Community-Dwelling
   Elderly Persons in Germany
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Screening; age-related eye diseases; awareness; non-mydriatic fundus
   photography; age-related macular degeneration (AMD)
ID PHYSICAL-ACTIVITY; DIABETIC-RETINOPATHY; FOLLOW-UP; PREVALENCE; CARE;
   KNOWLEDGE; GLAUCOMA; EPIDEMIOLOGY; PROGRESSION; MACULOPATHY
AB Background: Due to current demographic trends age-related macular degeneration (AMD) is becoming more prevalent. When disease progresses to late-stage neovascular AMD, rapid initiation of treatment is required to achieve optimal outcomes. However, many affected individuals may be unaware of their disease impeding and delaying care seeking. Therefore, in an exploratory study we assessed whether elderly persons living independently in the community were aware of their AMD.Methods: Participants were recruited in eleven seniors' community centers. Participants underwent a standardized interview followed by non-mydriatic fundus photography of the macula and the optic disc in both eyes (Canon CR-2AF, Canon, New York, USA). The images were graded by an ophthalmologist and the data were analyzed descriptively.Results: A total of 281 participants (73.98.1years; 71.9% women) underwent bilateral fundus photography. The fundus photographs of 208 participants (74%; 73.6 +/- 7.0years; 73.1% women) could be graded. In a third (32.2%, n =67) no pathological changes were detected. AMD was present in 24.5% of the examined subjects (n=51). Half of the cases had early (47.1%), followed by intermediate (41.2%) and late (11.7%) AMD. Only one third (n=16, 31.4%) were aware of their disease.Conclusions: A quarter of community dwelling elderly had AMD but only a third of these were aware of being affected with AMD. This confirms previous studies demonstrating low awareness for age-related eye diseases in the community. Considering the increase in population aging, awareness campaigns for AMD are needed.
C1 [Heinemann, M.; Welker, S. G.; Li, J. Q.; Wintergerst, M. W. M.; Turski, G. N.; Turski, C. A.; Holz, F. G.; Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53121 Bonn, Germany.
C3 University of Bonn
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53121 Bonn, Germany.
EM Robert.Finger@ukbonn.de
RI Wintergerst, Maximilian/AAW-2972-2021; Wintergerst,
   Maximilian/E-5523-2019
OI Wintergerst, Maximilian/0000-0002-2766-7038
FU German Scholars Organization/Else Krohner Fresenius Stiftung [GSO/EKFS
   16]
FX This research was supported by the German Scholars Organization/Else
   Krohner Fresenius Stiftung (GSO/EKFS 16)
CR Altangerel U, 2009, CAN J OPHTHALMOL, V44, P66, DOI 10.3129/i08-175
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Bundesamt S., 2017, STAT JB DEUTSCHLAND
   Cavan D, 2017, DIABETES RES CLIN PR, V129, P16, DOI 10.1016/j.diabres.2017.03.023
   Dlugaj M, 2010, DEMENT GERIATR COGN, V30, P362, DOI 10.1159/000320988
   Fang PP, 2017, OPHTHALMOLOGE, V114, P818, DOI 10.1007/s00347-017-0557-0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gibson DM, 2017, PREV MED, V105, P257, DOI 10.1016/j.ypmed.2017.09.019
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Huang OS, 2015, BRIT J OPHTHALMOL, V99, P1614, DOI 10.1136/bjophthalmol-2014-306492
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Kasthurirangan S, 2006, VISION RES, V46, P1393, DOI 10.1016/j.visres.2005.07.004
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kreft D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195426
   Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780
   Mansouri K, 2006, OPHTHALMOLOGICA, V220, P101, DOI 10.1159/000090574
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Pfeiffer N, 2002, J GLAUCOMA, V11, P458, DOI 10.1097/00061198-200210000-00016
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   Schmalhofer C, 2016, GESUNDHEITSWESEN, V78, pA67, DOI 10.1055/s-0036-1586577
   Schuster AK, 2018, OPHTHALMOLOGE, V115, P832, DOI 10.1007/s00347-018-0694-0
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Welp A, 2016, MAKING EYE HLTH POPU
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Wintergerst MWM, 2018, OPHTHALMOLOGE, V115, P1035, DOI 10.1007/s00347-017-0610-z
NR 31
TC 3
Z9 3
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD JUL 4
PY 2019
VL 26
IS 4
BP 238
EP 243
DI 10.1080/09286586.2019.1597898
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IS7QJ
UT WOS:000482344000003
PM 30917716
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Guymer, RH
   Finger, RP
AF Wu, Zhichao
   Guymer, Robyn H.
   Finger, Robert P.
TI Low luminance deficit and night vision symptoms in intermediate
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; VISUAL-ACUITY; END-POINTS; MACULOPATHY;
   MICROPERIMETRY; QUESTIONNAIRE
AB Background/aims To determine the relationship between self-reported visual difficulties under low luminance conditions (night vision symptoms) and visual function measures in intermediate age-related macular degeneration (AMD).
   Methods One hundred participants with bilateral intermediate AMD were examined in a prospective cross-sectional study with visual function measures including best-corrected visual acuity (BCVA), low luminance visual acuity (LLVA) and microperimetry in both eyes. A 10-item Night Vision Questionnaire (NVQ-10) was then used to determine the degree of self-reported night vision symptoms experienced by each participant. For analyses, low luminance deficit (LLD) was derived as the difference between LLVA and BCVA, and microperimetric mean sensitivity (MS; all points) and central sensitivity (CS; points within the central 1 degrees) were determined. Rasch analysis was used to estimate the person measure of night vision symptoms, and its relationship with visual function parameters was determined.
   Results NVQ-10 person measures were significantly associated with LLD (beta coefficient 0.067, 95% CI 0.005 to 0.130, p=0.034), but not BCVA, LLVA, microperimetric MS or CS (p=0.090). Participants with the highest degree of self-reported night vision symptoms (fourth quartile of person measure) had significantly worse LLD than those with the least difficulty (first quartile of person measure; p=0.019).
   Conclusions In individuals with bilateral intermediate AMD, LLD was associated with self-reported night vision symptoms, suggesting that this measure may better capture the visual difficulties experienced by these individuals under low luminance conditions than the conventional measure of photopic visual acuity.
C1 [Wu, Zhichao; Guymer, Robyn H.; Finger, Robert P.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Finger, Robert P/0000-0003-4253-7597
FU German Research Council [DFG FI 1540/5-1]; National Health and Medical
   Research Council (NHMRC) [590205, 1008979]; Centre for Clinical Research
   Excellence [529923]; Macular Disease Foundation Australia Research
   Grant; BrightFocus Foundation; Charles Viertel Charitable Foundation;
   Lloyd and Kathleen Ansell Ophthalmology Foundation; Mankiewicz-Zelkin
   Fellowship of the University of Melbourne; Menzies Foundation
FX This work was in part supported by the German Research Council (DFG FI
   1540/5-1, grant to RPF) and by National Health and Medical Research
   Council (NHMRC) project grants (#590205 and #1008979) and Centre for
   Clinical Research Excellence grant #529923, a Macular Disease Foundation
   Australia Research Grant (RHG), the BrightFocus Foundation and the
   Charles Viertel Charitable Foundation, the Lloyd and Kathleen Ansell
   Ophthalmology Foundation, the Mankiewicz-Zelkin Fellowship of the
   University of Melbourne and The Menzies Foundation. The funders had no
   role in the design and conduct of the data, preparation, review or
   approval of the manuscript and decision to submit the manuscript for
   publication.
CR Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P8241, DOI 10.1167/iovs.11-7858
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Lesmes Luis Andres, 2013, Drug Discov Today Ther Strateg, V10, pe43, DOI 10.1016/j.ddstr.2012.11.002
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
NR 21
TC 35
Z9 35
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2016
VL 100
IS 3
BP 395
EP 398
DI 10.1136/bjophthalmol-2015-306621
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DE9SN
UT WOS:000370979300020
PM 26250520
DA 2022-11-30
ER

PT J
AU Pras, E
   Kristal, D
   Shoshany, N
   Volodarsky, D
   Vulih, I
   Celniker, G
   Isakov, O
   Shomron, N
   Pras, E
AF Pras, Eran
   Kristal, Dana
   Shoshany, Nadav
   Volodarsky, Dina
   Vulih, Inna
   Celniker, Gershon
   Isakov, Ofer
   Shomron, Noam
   Pras, Elon
TI Rare genetic variants in Tunisian Jewish patients suffering from
   age-related macular degeneration
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID FACTOR-H POLYMORPHISM; COMPLEMENT FACTOR-I; HIGH-RISK; CHROMOSOME 10Q26;
   APOLIPOPROTEIN-E; COMMON VARIANTS; SEQUENCING DATA; LARGE FAMILY;
   FACTOR-B; ASSOCIATION
AB Purpose To explore the molecular basis of familial, early onset, age-related macular degeneration (AMD) with diverse phenotypes, using whole exome sequencing (WES).
   Methods We performed WES on four patients (two sibs from two families) manifesting early-onset AMD and searched for disease-causing genetic variants in previously identified macular degeneration related genes. Validation studies of the variants included bioinformatics tools, segregation analysis of mutations within the families and mutation screening in an AMD cohort of patients.
   Results The index patients were in their 50s when diagnosed and displayed a wide variety of clinical AMD presentations: from limited drusen in the posterior pole to multiple basal-laminar drusen extending peripherally. Severe visual impairment due to extensive geographic atrophy and/or choroidal-neovascularisation was common by the age of 75 years. Approximately, 400 000 genomic variants for each DNA sample were included in the downstream bioinformatics analysis, which ended in the discovery of two novel variants; in one family a single bp deletion was identified in the Hemicentin (HMCN1) gene (c.4162delC), whereas in the other, a missense variant (p.V412M) in the Complement Factor-I (CFI) gene was found. Screening for these variants in a cohort of patients with AMD identified another family with the CFI variant.
   Conclusions This report uses WES to uncover rare genetic variants in AMD. A null-variant in HMCN1 has been identified in one AMD family, and a missense variant in CFI was discovered in two other families. These variants confirm the genetic complexity and significance of rare genetic variants in the pathogenesis of AMD.
C1 [Pras, Eran; Shoshany, Nadav] Assaf Harofeh Med Ctr, Dept Ophthalmol, Matlows Ophthalmogenet Lab, IL-70300 Zerifin, Israel.
   [Pras, Eran; Celniker, Gershon; Isakov, Ofer; Shomron, Noam; Pras, Elon] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Kristal, Dana] Edith Wolfson Med Ctr, Dept Ophthalmol, Holon, Israel.
   [Volodarsky, Dina; Vulih, Inna] Assaf Harofeh Med Ctr, Dyn Labs, IL-70300 Zerifin, Israel.
   [Celniker, Gershon; Isakov, Ofer; Shomron, Noam] Tel Aviv Univ, Fac Med, Funct Genom Lab, IL-69978 Tel Aviv, Israel.
   [Pras, Elon] Tel Aviv Univ, Sheba Med Ctr, Danek Gartener Inst Human Genet, IL-69978 Tel Aviv, Israel.
C3 Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv
   University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf
   Harofeh); Tel Aviv University; Tel Aviv University; Chaim Sheba Medical
   Center; Tel Aviv University
RP Pras, E (通讯作者)，Assaf Harofeh Med Ctr, Dept Ophthalmol, IL-70300 Zerifin, Israel.
EM eranpras@gmail.com
FU Claire and Amedee Maratier Institute for the Study of Blindness and
   Visual Disorders; Miriam and Haim Fogelnest Fund, Sackler Faculty of
   Medicine, Tel-Aviv University, Tel-Aviv, Israel; Chief Scientist Office
   of the Ministry of Health, Israel [7205]; 'Lirot' Association;
   Consortium for Mapping Retinal Degeneration Disorders in Israel
FX This study was supported by the Claire and Amedee Maratier Institute for
   the Study of Blindness and Visual Disorders, and the Miriam and Haim
   Fogelnest Fund, Sackler Faculty of Medicine, Tel-Aviv University,
   Tel-Aviv, Israel. This work was also supported in part by grant no. 7205
   from the Chief Scientist Office of the Ministry of Health, Israel;
   'Lirot' Association and the Consortium for Mapping Retinal Degeneration
   Disorders in Israel.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   LATHROP GM, 1984, AM J HUM GENET, V36, P460
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liu XM, 2013, HUM MUTAT, V34, pE2393, DOI 10.1002/humu.22376
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Richards CS, 2008, GENET MED, V10, P294, DOI 10.1097/GIM.0b013e31816b5cae
   Roversi P, 2011, P NATL ACAD SCI USA, V108, P12839, DOI 10.1073/pnas.1102167108
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
NR 45
TC 12
Z9 13
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD JUL
PY 2015
VL 52
IS 7
BP 484
EP 492
DI 10.1136/jmedgenet-2015-103130
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CL3PH
UT WOS:000356861900007
PM 25986072
DA 2022-11-30
ER

PT J
AU Akagi-Kurashige, Y
   Tsujikawa, A
   Oishi, A
   Ooto, S
   Yamashiro, K
   Tamura, H
   Nakata, I
   Ueda-Arakawa, N
   Yoshimura, N
AF Akagi-Kurashige, Yumiko
   Tsujikawa, Akitaka
   Oishi, Akio
   Ooto, Sotaro
   Yamashiro, Kenji
   Tamura, Hiroshi
   Nakata, Isao
   Ueda-Arakawa, Naoko
   Yoshimura, Nagahisa
TI Relationship between retinal morphological findings and visual function
   in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; External limiting membrane;
   Hyperreflective foci; Optical coherence tomography; Polypoidal choroidal
   vasculopathy
ID OPTICAL COHERENCE TOMOGRAPHY; VERTEPORFIN PHOTODYNAMIC THERAPY; EXTERNAL
   LIMITING MEMBRANE; ULTRAHIGH-RESOLUTION; HYPERREFLECTIVE FOCI; SUBGROUP
   ANALYSIS; RANIBIZUMAB; IDENTIFICATION; PATHOLOGY; ANCHOR
AB We aimed to study the retinal morphological findings associated with exudative age-related macular degeneration (AMD) and their association with visual prognosis.
   We retrospectively reviewed the medical records of 96 consecutive patients (96 eyes) with exudative AMD. Retinal structural changes were examined using optical coherence tomography (OCT).
   Initial OCT examination showed cystoid macular edema in 18 eyes (18.8%), fibrin exudate in 56 eyes (58.3%), and hyperreflective foci within the neurosensory retina in 78 eyes (81.3%). Upon initial examination, an external limiting membrane (ELM) line was detected under the fovea in 64 eyes (66.7%). Using Pearson's correlation analyses, final visual acuity (VA) was correlated with initial VA (r = 0.61, p < 0.001), age (r = 0.34, p < 0.001), initial total foveal thickness (r = 0.41, p < 0.001), presence of hyperreflective foci (r = 0.40, p < 0.001), and detection of a foveal ELM line (r = 0.55, p < 0.001). After multiple regression analysis, final VA correlated with initial VA (r = 0.48, p < 0.001), initial presence of hyperreflective foci (r = 0.23, p = 0.054), and detection of a foveal ELM line (r = 0.36, p = 0.008).
   In eyes with exudative AMD, final VA was most correlated with initial VA. In addition, the initial integrity of the foveal outer retina was partially correlated with the visual prognosis. The initial ELM condition was associated with good final VA, while the initial presence of hyperreflective foci in the foveal neurosensory retina was associated with poor final VA.
C1 [Akagi-Kurashige, Yumiko; Tsujikawa, Akitaka; Oishi, Akio; Ooto, Sotaro; Yamashiro, Kenji; Tamura, Hiroshi; Nakata, Isao; Ueda-Arakawa, Naoko; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011; Oishi, Akio/AAE-9996-2020
OI TAMURA, Hiroshi/0000-0002-7740-2732; Oishi, Akio/0000-0002-0977-9458;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas G, 2009, OPTICAL COHERANCE TO, P171
   Coscas G, 2009, OPTICAL COHERENCE TO, P97
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Gloesmann M, 2003, INVEST OPHTH VIS SCI, V44, P1696, DOI 10.1167/iovs.02-0654
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ota M, 2010, OPHTHALMOLOGY, V117, P1996, DOI 10.1016/j.ophtha.2010.06.019
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Theodossiadis PG, 2011, OPHTHALMOLOGICA, V225, P176, DOI 10.1159/000323322
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
   YANNUZZI LA, 1988, B NEW YORK ACAD MED, V64, P955
NR 28
TC 28
Z9 28
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2012
VL 250
IS 8
BP 1129
EP 1136
DI 10.1007/s00417-012-1928-5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979CE
UT WOS:000306791700002
PM 22290070
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, TW
   Kang, JW
   Ahn, J
   Lee, EK
   Cho, KC
   Han, BNR
   Hong, NY
   Park, J
   Kim, KP
AF Kim, Tae Wan
   Kang, Jeong Won
   Ahn, Jeeyun
   Lee, Eun Kyung
   Cho, Kyung-Cho
   Han, Bit Na Ra
   Hong, Nam Young
   Park, Jisook
   Kim, Kwang Pyo
TI Proteomic Analysis of the Aqueous Humor in Age-related Macular
   Degeneration (AMD) Patients
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE aqueous humor; age-related macular degeneration; mass spectrometry;
   proteomics; multiple reaction monitoring
ID ENDOTHELIAL GROWTH-FACTOR; PROTEIN IDENTIFICATION TECHNOLOGY; FACTOR-H
   POLYMORPHISM; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB;
   STATISTICAL-MODEL; NONHUMAN PRIMATE; PLASMA PROTEOME; GLAUCOMA;
   ASSOCIATION
AB Age-related macular degeneration (AMD) can lead to irreversible central vision loss in the elderly. Although large number of growth factor pathways, including the vascular endothelial growth factor (VEGF), has been implicated in the pathogenesis of AMD, no study has directly assessed the whole proteomic composition in the aqueous humor (AH) among AMID patients. The AR contains proteins secreted from the anterior segment tissue, and these proteins may play an important role in the pathogenesis of AMD. Thus, comparisons between the AR proteomic profiles of AMD patients and non-AMD controls may lead to the verification of novel pathogenic proteins useful as potential clinical biomarkers. In this study, we used discovery-based proteomics and Multiple Reaction Monitoring Mass Spectrometry (MRM-MS) to analyze AR from AMD patients and AH from controls who underwent cataract surgery. A total of 154 proteins with at least two unique peptides were identified in the AH. Of these 154 proteins identified by discovery-based proteomics, 10 AH proteins were novel identifications. The protein composition in the AH was different between AMD patients and non-AMD controls. Subsequently, a systematic MRM-MS assay was performed in seven highly abundant differentially expressed proteins from these groups. Differential expression of three proteins was observed in the AH of AMD patients compared with that of cataract controls (p < 0.0312). Elucidation of the aqueous proteome will establish a foundation for protein function analysis and identify differentially expressed markers associated with AMD. This study demonstrates that integrated proteomic technologies can yield novel biomarkers to detect exudative AMD.
C1 [Kim, Kwang Pyo] Konkuk Univ, Dept Mol Biotechnol, Inst Biomed Sci & Technol, WCU Program, Seoul 143701, South Korea.
   [Kim, Tae Wan; Ahn, Jeeyun] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Ophthalmol, Seoul, South Korea.
   [Kim, Tae Wan; Ahn, Jeeyun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Konkuk University; Seoul National University (SNU); Seoul National
   University Hospital; Seoul National University (SNU)
RP Kim, KP (通讯作者)，Konkuk Univ, Dept Mol Biotechnol, Inst Biomed Sci & Technol, WCU Program, 1 Hwayang Dong, Seoul 143701, South Korea.
EM kpkim@konkuk.ac.kr
RI Kim, Kwang Pyo/AAG-1815-2020
OI Kim, Kwang Pyo/0000-0003-0095-3787; Ahn, Jeeyun/0000-0001-9017-1652
FU National Project for Personalized Genomic Medicine from the Korean
   Ministry of Health and Welfare [A111218-11-CP02]; WCU program from the
   Korean Ministry of Education, Science and Technology [R33-10128]; SNUB
   research fund [04-2010-0410]
FX This study was supported by grants from the National Project for
   Personalized Genomic Medicine (A111218-11-CP02) from the Korean Ministry
   of Health and Welfare, WCU program (Project No. R33-10128) from the
   Korean Ministry of Education, Science and Technology, and the SNUB
   research fund (04-2010-0410).
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bennett KL, 2011, J PROTEOMICS, V74, P151, DOI 10.1016/j.jprot.2010.10.002
   Bouhenni RA, 2011, EXP EYE RES, V92, P67, DOI 10.1016/j.exer.2010.11.004
   Chowdhury UR, 2010, INVEST OPHTH VIS SCI, V51, P4921, DOI 10.1167/iovs.10-5531
   Duan XM, 2008, MOL VIS, V14, P370
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Escoffier P, 2010, J PROTEOME RES, V9, P789, DOI 10.1021/pr9006602
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Funding M, 2005, ACTA OPHTHALMOL SCAN, V83, P31, DOI 10.1111/j.1600-0420.2005.00381.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta MK, 2009, PROTEOMICS, V9, P4834, DOI 10.1002/pmic.200900310
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Izzotti A, 2010, J PROTEOME RES, V9, P4831, DOI 10.1021/pr1005372
   Jackson John K., 2005, Angiogenesis, V8, P229, DOI 10.1007/s10456-005-9018-5
   Janciauskiene S, 2006, EXP EYE RES, V82, P505, DOI 10.1016/j.exer.2005.08.010
   Jeong SK, 2010, PROTEOMICS, V10, P1250, DOI 10.1002/pmic.200900371
   Kanelleas A, 2011, CLIN EXP DERMATOL, V36, P845, DOI 10.1111/j.1365-2230.2011.04131.x
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lange V, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.61
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Pandaranayaka PJE, 2010, MOL VIS, V16, P2891
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Richardson MR, 2009, MOL VIS, V15, P2740
   Ru QHC, 2006, J CHROMATOGR A, V1111, P175, DOI 10.1016/j.chroma.2005.06.080
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sakamoto T, 2001, GRAEF ARCH CLIN EXP, V239, P865, DOI 10.1007/s004170100373
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Strickland N.J., 2011, INT J CANC
   Thambisetty M, 2010, ARCH GEN PSYCHIAT, V67, P739, DOI 10.1001/archgenpsychiatry.2010.78
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
NR 40
TC 47
Z9 50
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD AUG
PY 2012
VL 11
IS 8
BP 4034
EP 4043
DI 10.1021/pr300080s
PG 10
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 982IW
UT WOS:000307037600010
PM 22702841
DA 2022-11-30
ER

PT J
AU Lotery, AJ
   Baas, D
   Ridley, C
   Jones, RPO
   Klaver, CCW
   Stone, E
   Nakamura, T
   Luff, A
   Griffiths, H
   Wang, T
   Bergen, AAB
   Trump, D
AF Lotery, Andrew J.
   Baas, Dominique
   Ridley, Caroline
   Jones, Richard P. O.
   Klaver, Caroline C. W.
   Stone, Edwin
   Nakamura, Tomoyuki
   Luff, Andrew
   Griffiths, Helen
   Wang, Tao
   Bergen, Arthur A. B.
   Trump, Dorothy
TI Reduced secretion of fibulin 5 in age-related macular degeneration and
   cutis laxa
SO HUMAN MUTATION
LA English
DT Article
DE age-related macular degeneration; ARMD; fibulin 5; FBLN5; cutis laxa;
   genotype-phenotype correlation; elastinogenesis
ID FACTOR-H POLYMORPHISM; MALATTIA LEVENTINESE; VISUAL IMPAIRMENT;
   CIGARETTE-SMOKING; IN-VIVO; GENE; MUTATION; PROTEIN; FAMILY;
   ACCUMULATION
AB Age-related macular degeneration (ARMD) is the leading cause of irreversible visual loss in the Western world, affecting approximately 25 million people worldwide. The pathogenesis is complex and missense mutations in FBLN5 have been reported in association with ARMD. We have investigated the role of fibulin 5 in ARMD by completing the first European study of the gene FBLN5 in ARMD (using 2 European cohorts of 805 ARMD patients and 279 controls) and by determining the functional effects of the missense mutations on fibulin 5 expression. We also correlated the FBLN5 genotype with the ARMD phenotype. We found two novel sequence changes in ARMD patients that were absent in controls and expressed these and the other nine reported FBLN5 mutations associated with ARMD and two associated with the autosomal recessive disease cutis laxa. Fibulin 5 secretion was significantly reduced (P < 0.001) for four ARMD (p.G412E, p.G267S, p.I169T, and p.Q124P) and two cutis laxa (p.S227P, p.C217R) mutations. These results suggest that some missense mutations associated with ARMD lead to decreased fibulin 5 secretion with a possible corresponding reduction in elastinogenesis. This study confirms the previous work identifying an association between FBLN5 mutations and ARMD and for the first time suggests a functional mechanism by which these mutations can lead to ARMD. It further demonstrates that FBLN5 mutations can be associated with different phenotypes of ARMD (not limited to the previously described cuticular drusen type). Such knowledge may ultimately lead to the development of novel therapies for this common disease.
C1 Univ Southampton, Div Human Genet, Southampton SO9 5NH, Hants, England.
   Southampton Univ Hosp Trust, Southampton Eye Unit, Southampton, Hants, England.
   Netherlands Ophthalm Res Inst, Dept Clin & Mol Ophthalmogenet, NL-1100 AC Amsterdam, Netherlands.
   Univ Manchester, Sch Med, Acad Unit Med Genet, Manchester M13 9PL, Lancs, England.
   Erasmus Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   Univ Iowa Hosp & Clin, Ctr Macular Degenerat, Iowa City, IA 52242 USA.
   Kyoto Univ, Sch Med, Horizontal Med Res Org, Cardiovasc Dev Unit, Kyoto 606, Japan.
   Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
   Univ Manchester, Fac Med & Hlth Sci, Ctr Mol Med, Manchester M13 9PL, Lancs, England.
C3 University of Southampton; University of Southampton; University
   Hospital Southampton NHS Foundation Trust; Royal Netherlands Academy of
   Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW);
   University of Manchester; Erasmus University Rotterdam; Erasmus MC;
   University of Iowa; Kyoto University; University of Amsterdam; Academic
   Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of
   Manchester
RP Lotery, AJ (通讯作者)，Univ Southampton, Southampton Gen Hosp, Div Human Genet, Duthie Bldg,MP808, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
RI Klaver, Caroline C.W./A-2013-2016; Nakamura, Tomoyuki/AAX-9340-2020;
   Bergen, Arthur/J-3637-2013
OI Stone, Edwin M./0000-0003-3343-4414; Ridley,
   Caroline/0000-0002-5483-0320; Baas, Dominique C./0000-0003-0989-9828;
   Lotery, Andrew/0000-0001-5541-4305; Klaver,
   Caroline/0000-0002-2355-5258; Bergen, Arthur/0000-0002-6333-9576
FU Wellcome Trust [076169] Funding Source: Medline
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FISCHER J, 2004, 3 EUR S EL 2004 30 J
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749
   Jones DT, 1999, PROTEINS, P104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297
   Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113
   Lotery A J, 2001, Ophthalmic Genet, V22, P163, DOI 10.1076/opge.22.3.163.2222
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Lotery AJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P538
   Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Tsuruga E, 2004, INT J BIOCHEM CELL B, V36, P395, DOI 10.1016/S1357-2725(03)00238-3
   Wang T, 2002, HUM MOL GENET, V11, P3097, DOI 10.1093/hmg/11.24.3097
   WELEBER RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1531, DOI 10.1001/archopht.1993.01090110097033
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 34
TC 57
Z9 61
U1 0
U2 6
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD JUN
PY 2006
VL 27
IS 6
BP 568
EP 574
DI 10.1002/humu.20344
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 047GU
UT WOS:000237868600009
PM 16652333
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lundstrom, M
   Brege, KG
   Floren, I
   Lundh, B
   Stenevi, U
   Thorburn, W
AF Lundstrom, M
   Brege, KG
   Floren, I
   Lundh, B
   Stenevi, U
   Thorburn, W
TI Cataract surgery and quality of life in patients with age related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CATQUEST QUESTIONNAIRE; VISUAL FUNCTION; OF-LIFE; OUTCOMES; MACULOPATHY;
   PREDICTORS; VALIDITY; REGISTER; ACUITY; CARE
AB Background: The coexistence of cataract and age related macular degeneration (AMD) is not unusual, especially in the very elderly. The outcome of cataract surgery in these cases depends on the effect of AMD on vision. In this study the authors have compared the outcome of cataract patients with AMD to that of cataract patients with no vision threatening ocular comorbidity, and analysed possible predictors of good or poor outcome.
   Methods: An observational prospective study on consecutive cases operated for cataract during 1 month at six surgical departments affiliated to the Swedish National Cataract Register (NCR). Data were collected according to the protocol of NCR and subjects completed the Catquest questionnaire before and 6 months after surgery. 90 subjects with AMD were compared to 335 subjects with no sight threatening ocular comorbidity.
   Results: Difficulties in performing various daily life activities improved significantly for AMD subjects after surgery (p<0.001, Wilcoxon signed rank test). Satisfaction with vision also improved significantly after surgery (p<0.001, Wilcoxon signed rank test). Activity level and independence were unchanged. Subjects with no ocular comorbidity had a still better outcome. The most important variable related to a good self assessed functional outcome was postoperative visual acuity irrespective of the presence of AMD. AMD subjects scheduled for second eye surgery and AMD subjects dissatisfied with their vision before surgery had a poorer outcome.
   Conclusion: Subjects with various stages of dry AMD and cataract improved their self assessed visual function and satisfaction with vision significantly after cataract extraction.
C1 Blekinge Hosp, Dept Ophthalmol, SE-37185 Karlskrona, Sweden.
   Lake Maelar Hosp, Dept Ophthalmol, SE-63188 Eskilstuna, Sweden.
   Univ Lund Hosp, Dept Ophthalmol, SE-22185 Lund, Sweden.
   Linkoping Univ Hosp, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
   Sahlgrens Univ Hosp, Dept Ophthalmol, SE-43180 Molndal, Sweden.
   Univ Umea Hosp, SE-90185 Umea, Sweden.
C3 Lund University; Skane University Hospital; Linkoping University;
   Sahlgrenska University Hospital; Umea University
RP Lundstrom, M (通讯作者)，Blekinge Hosp, Dept Ophthalmol, SE-37185 Karlskrona, Sweden.
CR Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   *CAT MAN GUID PAN, 1993, AHCPR PUB
   HOLLADAY JT, 1991, AM J OPHTHALMOL, V111, P372, DOI 10.1016/S0002-9394(14)72328-1
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   Laidlaw DAH, 1998, LANCET, V352, P925, DOI 10.1016/S0140-6736(97)12536-3
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Lundstrom M, 2001, J CATARACT REFR SURG, V27, P1176, DOI 10.1016/S0886-3350(01)00772-6
   Lundstrom M, 1998, J CATARACT REFR SURG, V24, P968, DOI 10.1016/S0886-3350(98)80053-9
   Lundstrom M, 2002, ACTA OPHTHALMOL SCAN, V80, P248, DOI 10.1034/j.1600-0420.2002.800304.x
   Lundstrom M, 1997, J CATARACT REFR SURG, V23, P1226, DOI 10.1016/S0886-3350(97)80321-5
   Lundstrom M, 2000, J CATARACT REFR SURG, V26, P101, DOI 10.1016/S0886-3350(99)00324-7
   Lundstrom M, 2001, J CATARACT REFR SURG, V27, P1553, DOI 10.1016/S0886-3350(01)00984-1
   Lundstrom M, 2001, ACTA OPHTHALMOL SCAN, V79, P342, DOI 10.1034/j.1600-0420.2001.079004342.x
   Lundstrom M, 1999, BRIT J OPHTHALMOL, V83, P1272, DOI 10.1136/bjo.83.11.1272
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   McCarty CA, 1999, BRIT J OPHTHALMOL, V83, P62, DOI 10.1136/bjo.83.1.62
   Norregaard JC, 1996, ACTA OPHTHALMOL SCAN, V74, P604
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Taylor HR, 2000, BRIT J OPHTHALMOL, V84, P1, DOI 10.1136/bjo.84.1.1
   TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1312, DOI 10.1001/archopht.1995.01100100100038
   Westcott MC, 2000, BRIT J OPHTHALMOL, V84, P1380, DOI 10.1136/bjo.84.12.1380
NR 23
TC 57
Z9 64
U1 0
U2 3
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2002
VL 86
IS 12
BP 1330
EP 1335
DI 10.1136/bjo.86.12.1330
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 620VQ
UT WOS:000179553700006
PM 12446358
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Bhutto, IA
   McLeod, DS
   Jing, T
   Sunness, JS
   Seddon, JM
   Lutty, GA
AF Bhutto, Imran A.
   McLeod, D. Scott
   Jing, Tian
   Sunness, Janet S.
   Seddon, Johanna M.
   Lutty, Gerard A.
TI Increased choroidal mast cells and their degranulation in age-related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; ENDOTHELIAL-CELLS; MEMBRANE;
   NEOVASCULARIZATION; ANGIOGENESIS; LEUKOCYTES; BASOPHILS; TRYPTASE;
   SYSTEM
AB Background/aims Inflammation has been implicated in age-related macular degeneration (AMD). This study investigates the association of mast cells (MCs), a resident choroidal inflammatory cell, with pathological changes in AMD.
   Methods Human donor eyes included aged controls (n=10), clinically diagnosed with early AMD (n=8), geographic atrophy (GA, n=4) and exudative AMD (n=11). The choroids were excised and incubated for alkaline phosphatase (APase; blood vessels) and nonspecific esterase activities (MCs). Degranulated (DG) and non-degranulated MCs in four areas of posterior choroid (nasal, non-macular, paramacular and submacular) were counted in flat mounts (4-6 fields/area). Choroids were subsequently embedded in JB-4 and sectioned for histological analyses.
   Results The number of MCs was significantly increased in all choroidal areas in early AMD (p=0.0006) and in paramacular area in exudative AMD (139.44 +/- 55.3 cells/mm(2); p=0.0091) and GA (199.08 +/- 82.0 cells/mm(2); p=0.0019) compared with the aged controls. DG MCs were also increased in paramacular (p=0.001) and submacular choroid (p=0.02) in all forms of AMD. Areas with the greatest numbers of DG MCs had loss of choriocapillaris (CC). Sections revealed that the MCs were widely distributed in Sattler's and Haller's layer in the choroidal stroma in aged controls, whereas MCs were frequently found in close proximity with CC in GA and exudative AMD and in choroidal neovascularisation (CNV).
   Conclusion Increased MC numbers and degranulation were observed in all AMD choroids. These results suggest that MC degranulation may contribute to the pathogenesis of AMD: death of CC and retinal pigment epithelial and CNV formation. The proteolytic enzymes released from MC granules may result in thinning of AMD choroid.
C1 [Bhutto, Imran A.; McLeod, D. Scott; Lutty, Gerard A.] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Jing, Tian] Johns Hopkins Univ, Sch Med, Biostat Consulting Ctr, Baltimore, MD USA.
   [Sunness, Janet S.] Greater Baltimore Med Ctr, Hoover Low Vis Rehabil Serv, Baltimore, MD USA.
   [Sunness, Janet S.] Univ Maryland, Sch Med, Dept Ophthalmol & Visual Sci, Baltimore, MD 21201 USA.
   [Seddon, Johanna M.] New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Greater Baltimore Medical Center; University System of
   Maryland; University of Maryland Baltimore; Tufts University
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu
OI Sunness, Janet/0000-0001-8823-0780
FU NIH [EY-01765, R01-EY016151, RO1 EY08552]; Research to Prevent
   Blindness; Arnold and Mabel Beckman Foundation; Foundation Fighting
   Blindness; Bright Focus Foundation; Age-Related Macular Degeneration
   Research Fund Tufts Medical Center, Boston, Massachusetts, USA;
   Altsheler Durell Foundation; RPB Senior Scientific Investigator Award;
   NATIONAL EYE INSTITUTE [P30EY001765, R01EY008552, R01EY016151] Funding
   Source: NIH RePORTER
FX This work was supported by NIH grants EY-01765 (Wilmer), R01-EY016151
   (GAL) and RO1 EY08552 (JSS), unrestricted funds from Research to Prevent
   Blindness (Wilmer), the Arnold and Mabel Beckman Foundation (GAL and
   JMS), the Foundation Fighting Blindness (GAL and JMS), Bright Focus
   Foundation (IAB), Age-Related Macular Degeneration Research Fund Tufts
   Medical Center, Boston, Massachusetts, USA (JMS) and the Altsheler
   Durell Foundation. GAL received an RPB Senior Scientific Investigator
   Award.
CR AZIZKHAN RG, 1980, J EXP MED, V152, P931, DOI 10.1084/jem.152.4.931
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Blair RJ, 1997, J CLIN INVEST, V99, P2691, DOI 10.1172/JCI119458
   Bousquet E, 2015, AM J PATHOL, V185, P2083, DOI 10.1016/j.ajpath.2015.04.002
   Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815
   Dvorak AM, 1997, INT ARCH ALLERGY IMM, V114, P1, DOI 10.1159/000237635
   Galli SJ, 2000, CURR OPIN HEMATOL, V7, P32, DOI 10.1097/00062752-200001000-00007
   GALLI SJ, 1993, NEW ENGL J MED, V328, P257
   Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327
   Godfrey W A, 1987, Trans Am Ophthalmol Soc, V85, P557
   Iddamalgoda A, 2008, ARCH DERMATOL RES, V300, pS69, DOI 10.1007/s00403-007-0806-1
   Lutty GA, 1997, AM J PATHOL, V151, P707
   May CA, 1999, HISTOCHEM CELL BIOL, V112, P381, DOI 10.1007/s004180050420
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   McMenamin PG, 1997, EYE, V11, P183, DOI 10.1038/eye.1997.49
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Muramatsu M, 2000, EUR J PHARMACOL, V402, P181, DOI 10.1016/S0014-2999(00)00350-2
   Nazarov PG, 2012, LIFE SCI, V91, P1053, DOI 10.1016/j.lfs.2012.08.004
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   SMITH RS, 1966, ARCH OPHTHALMOL-CHIC, V75, P390
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Takehana Y, 1999, INVEST OPHTH VIS SCI, V40, P459
   THARP MD, 1989, J INVEST DERMATOL, V93, pS107, DOI 10.1111/1523-1747.ep12581221
   Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014
   Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x
   Xu JM, 2012, ENDOCR REV, V33, P71, DOI 10.1210/er.2011-0013
NR 32
TC 43
Z9 45
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2016
VL 100
IS 5
BP 720
EP 726
DI 10.1136/bjophthalmol-2015-308290
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL0OT
UT WOS:000375333000027
PM 26931413
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Alexander, MS
   Lajoie, K
   Neima, DR
   Strath, RA
   Robinovitch, SN
   Marigold, DS
AF Alexander, M. Scott
   Lajoie, Kim
   Neima, David R.
   Strath, Robert A.
   Robinovitch, Stephen N.
   Marigold, Daniel S.
TI Effects of Age-Related Macular Degeneration and Ambient Light on Curb
   Negotiation
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE macular degeneration; low vision; mobility; obstacle avoidance; curb
ID VISUAL-FIELD LOSS; MEDIATED DARK-ADAPTATION; OLDER-ADULTS; VISION LOSS;
   MOBILITY PERFORMANCE; WATERLOO VISION; INJURIOUS FALLS; EYE DISEASE;
   MACULOPATHY; RISK
AB Purpose. To determine how age-related macular degeneration (AMD) and changes in ambient light affect the ability to negotiate a curb while walking.
   Methods. Ten older adults with AMD and 11 normal-sighted control subjects performed a curb negotiation task under normal light (similar to 600 lux), dim light (similar to 0.7 lux), and following a sudden reduction (similar to 600 to 0.7 lux) of light. In this task, subjects walked and stepped up or down a simulated sidewalk curb. Movement kinematics and ground reaction forces were measured during curb ascent and descent. Habitual visual acuity, contrast sensitivity, and visual fields were also assessed.
   Results. Apart from slower gait speed in those with AMD, there were no differences between groups during curb ascent for any other measure. During curb descent, older adults with AMD frequently used shuffling steps in the approach phase to locate the curb edge and showed prolonged double support duration stepping over the curb compared with control subjects. However, reduced lighting, particularly a sudden reduction, led to several significant changes in movement characteristics in both groups. For instance, toe clearance stepping up the curb was greater, and landing force stepping down was reduced. In addition, slower gait speed and greater double support duration were evident in curb ascent and descent. In AMD subjects, contrast sensitivity, visual acuity, and visual field threshold were associated with several kinematic measures in the three light conditions during curb negotiation.
   Conclusions. Minor AMD-specific changes in movement are seen during curb negotiation. However, attenuated lighting greatly impacts curb ascent and descent, regardless of eye disease, which manifests as a cautious walking strategy and may increase the risk of falling. Environmental enhancements that reduce the deleterious effects of poor lighting are required to improve mobility and quality of life of older adults, particularly those with AMD.
C1 [Alexander, M. Scott; Lajoie, Kim; Strath, Robert A.; Robinovitch, Stephen N.; Marigold, Daniel S.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada.
   [Robinovitch, Stephen N.] Simon Fraser Univ, Sch Engn Sci, Burnaby, BC V5A 1S6, Canada.
C3 Simon Fraser University; Simon Fraser University
RP Marigold, DS (通讯作者)，Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.
EM daniel_marigold@sfu.ca
OI Alexander, Scott/0000-0002-2691-0999; Robinovitch,
   Stephen/0000-0003-3881-6227
FU Canadian National Institute for the Blind (CNIB) Baker Applied Research
   grant
FX The authors thank the staff at Dr. Neima's office and Drs. Lim, Parsons,
   and Tischler and their staff for help with recruiting patients. A
   Canadian National Institute for the Blind (CNIB) Baker Applied Research
   grant supported this study.
CR Berg K., 1992, CAN J PUB HLTH, V2, pS7
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P733
   Buckley JJ, 2005, STUD FUZZ SOFT COMP, V171, P53
   Buckley JG, 2005, GAIT POSTURE, V21, P65, DOI 10.1016/j.gaitpost.2003.12.001
   Buckley JG, 2008, EXP BRAIN RES, V184, P223, DOI 10.1007/s00221-007-1096-8
   Buckley JG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019079
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Cruess AF, 2011, CAN J OPHTHALMOL, V46, P315, DOI 10.1016/j.jcjo.2011.06.006
   Figueiro MG, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-49
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Haymes SA, 2006, OPHTHAL PHYSL OPT, V26, P169, DOI 10.1111/j.1475-1313.2006.00367.x
   Haymes SA, 2002, OPHTHAL PHYSL OPT, V22, P79, DOI 10.1046/j.1475-1313.2002.00016.x
   Heasley K, 2004, INVEST OPHTH VIS SCI, V45, P2122, DOI 10.1167/iovs.03-1199
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Hreljac A, 2000, J BIOMECH, V33, P783, DOI 10.1016/S0021-9290(00)00014-2
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Johnson L, 2008, J AM GERIATR SOC, V56, P178, DOI 10.1111/j.1532-5415.2007.01485.x
   Johnson L, 2007, INVEST OPHTH VIS SCI, V48, P1466, DOI 10.1167/iovs.06-0586
   Kallie CS., 2010, J VIS 0901, V10, P1, DOI [10.1167/10.11.1, DOI 10.1167/10.11.1]
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Leat SJ, 2008, OPTOMETRY VISION SCI, V85, P1049, DOI 10.1097/OPX.0b013e31818b949d
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Marigold DS, 2008, EXERC SPORT SCI REV, V36, P145, DOI 10.1097/JES.0b013e31817bff72
   Moe-Nilssen R, 2006, J MOTOR BEHAV, V38, P118, DOI 10.3200/JMBR.38.2.118-125
   Nelson-Quigg JM, 2000, INVEST OPHTH VIS SCI, V41, P2212
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Patino CM, 2010, OPHTHALMOLOGY, V117, P199, DOI 10.1016/j.ophtha.2009.06.063
   PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   SPAULDING SJ, 1995, GAIT POSTURE, V3, P227
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Timmis MA, 2014, GAIT POSTURE, V39, P252, DOI 10.1016/j.gaitpost.2013.07.115
   Timmis MA, 2012, INVEST OPHTH VIS SCI, V53, P4120, DOI 10.1167/iovs.12-9897
   Turano KA, 1996, INVEST OPHTH VIS SCI, V37, P1483
   VERBAKEN JH, 1986, AM J OPTOM PHYS OPT, V63, P724
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   Wilcox D T, 1989, J Am Optom Assoc, V60, P504
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Zietz D, 2011, GAIT POSTURE, V34, P279, DOI 10.1016/j.gaitpost.2011.05.017
NR 47
TC 13
Z9 13
U1 2
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 975
EP 989
DI 10.1097/OPX.0000000000000286
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500022
PM 24879086
DA 2022-11-30
ER

PT J
AU Kabanarou, SA
   Crossland, MD
   Bellmann, C
   Rees, A
   Culham, LE
   Rubin, GS
AF Kabanarou, Stamatina A.
   Crossland, Michael D.
   Bellmann, Caren
   Rees, Angela
   Culham, Louise E.
   Rubin, Gary S.
TI Gaze changes with binocular versus monocular viewing in age-related
   macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; PREFERRED RETINAL LOCI; PERICENTRAL
   FIXATION TARGETS; CENTRAL SCOTOMA; ECCENTRIC FIXATION; LOW-VISION;
   STABILITY; DISEASE; LOCATION; TEXT
AB Purpose: To determine and explain gaze changes during binocular versus monocular viewing in patients with age-related macular degeneration (AMD).
   Design: Cross-sectional study.
   Participants: Twenty-nine patients with bilateral late-stage AMD.
   Methods: Distance acuity and fundus pathologic features were evaluated. Eye position was recorded while viewing a circular fixation target under monocular and binocular viewing conditions using an infrared eye tracker (SMI Gazetracker, SensoMotoric, Germany; Eyelink Software 2.04). Gaze changes were quantified by calculating the mean x-coordinate and y-coordinate eye position of the center of the bivariate contour ellipse area for a 30-second fixation task under both viewing conditions. Retinal loci used for monocular fixation for each eye were determined using the scanning laser ophthalmoscope (SLO; SLO 101, Rodenstock, Munich, Germany).
   Main Outcome Measure: Gaze position.
   Results: Nine patients showed no shift in gaze position from monocular to binocular viewing. Three patients demonstrated a shift in both eyes, and 17 patients demonstrated a shift in only 1 eye. The mean shift was 4.7 5 (standard deviation). The shift in gaze position in the worse eye was predictive of the distance between the 2 monocular preferred retinal loci (PRLs; better and worse eye; r(2) = 0.59; P < 0.0001), whereas there was no association between the shift in gaze position in the better eye and distance (r(2) = 0.00; P = 0.91).
   Conclusions: Most AMD patients shift gaze position in 1 or both eyes when viewing binocularly compared with monocularly. These changes suggest that different retinal locations are used for fixation under the 2 viewing conditions. The SLO data showed that these patients are likely to demonstrate monocular PRLs that fall on noncorresponding areas. These results may have implications for the effective development of eccentric viewing and binocular behavior of AMD patients.
C1 Inst Ophthalmol, Dept Vis Rehabil, London EC1V 9EL, England.
C3 University of London; University College London
RP Kabanarou, SA (通讯作者)，Inst Ophthalmol, Dept Vis Rehabil, 11-43 Bath St, London EC1V 9EL, England.
EM stamatina_k@hotmail.com
RI Crossland, Michael D/B-5600-2008
OI Crossland, Michael D/0000-0001-6833-6043
CR Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Crossland MD, 2002, OPTOMETRY VISION SCI, V79, P735, DOI 10.1097/00006324-200211000-00011
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Culham L. E., 1997, OPHTHAL PHYSL OPT, V17, P542
   CULHAM LE, 1992, OPHTHAL PHYSL OPT, V12, P281, DOI 10.1111/j.1475-1313.1992.tb00398.x
   CULHAM LE, 1993, CLIN VISION SCI, V8, P551
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Deruaz A, 2004, BRIT J OPHTHALMOL, V88, P461, DOI 10.1136/bjo.2003.025601
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   NACHMIAS J, 1970, J OPT SOC AM, V60, P382, DOI 10.1364/JOSA.60.000382
   NACHMIAS J, 1959, J OPT SOC AM, V49, P901, DOI 10.1364/JOSA.49.000901
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Robinson B, 1997, OPTOMETRY VISION SCI, V74, P79, DOI 10.1097/00006324-199702000-00019
   ROHRSCHNEIDER K, 1995, GRAEF ARCH CLIN EXP, V233, P743, DOI 10.1007/BF00184084
   SCHUCHARD RA, 1995, AM J OCCUP THER, V49, P870, DOI 10.5014/ajot.49.9.870
   SCHUCHARD RA, 1992, CLIN VISION SCI, V7, P511
   SCHUCHARD RA, 1995, VISION SCI ITS APPL, P332
   SCHUCHARD RA, 1994, OPHTHALMOLOGY CLIN N, V7, P243
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   Timberlake GT, 2003, OPTOMETRY VISION SCI, V80, P772, DOI 10.1097/00006324-200311000-00015
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   VONNOORDEN GK, 2002, BINOCULAR VISION OCU, P20
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 38
TC 35
Z9 36
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2006
VL 113
IS 12
BP 2251
EP 2258
DI 10.1016/j.ophtha.2006.06.028
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114KH
UT WOS:000242664600019
PM 16996593
DA 2022-11-30
ER

PT J
AU Roh, MI
   Lim, SJ
   Ahn, JM
   Lim, JB
   Kwon, OW
AF Roh, Mi In
   Lim, Su Jin
   Ahn, Ji Min
   Lim, Jong Baek
   Kwon, Oh Woong
TI Concentration of cytokines in age-related macular degeneration after
   consecutive intravitreal bevacizumab injection
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Aqueous humor; Bevacizumab;
   Interleukin-1; Vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; AQUEOUS-HUMOR LEVELS;
   CHOROIDAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; VITREOUS LEVELS;
   INVOLVEMENT; BEVACKUMAB
AB To evaluate the changes in aqueous humor cytokine levels following consecutive intravitreal bevacizumab (Avastin, Genentech Inc., San Francisco, CA, USA) injections in eyes with choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
   Aqueous humor samples were collected at the time of intravitreal injection of 1.25 mg of bevacizumab every 7.0 (+/- 2.0) weeks from ten eyes with AMD for the AMD group and during cataract surgery in nine eyes for the control group. Visual acuity with Early Treatment of Diabetic Retinopathy Study (ETDRS) letters and central macular thickness (CMT) using optical coherence tomography were measured before each injection in the AMD group. Aqueous cytokine levels were determined by immunoassay using multi-analyte biochip array technology (Evidence investigator cytokine and growth factor biochip array, RANDOX laboratories Ltd., Crumlin, UK).
   In the AMD group, mean +/- standard deviation(SD) aqueous VEGF levels decreased from 68.0 +/- 32.1 pg/ml at baseline to 26.3 +/- 19.0 pg/ml after the first injection (p = 0.028) and to 25.2 +/- 12.8 pg/ml after the second injection (p = 0.005). While CMT decreased from 307.7 +/- 102.0 mu m to 206.8 +/- 141.5 A mu m (p = 0.037), ETDRS visual acuity increased from 17.6 A +/- 11.7 letters to 22.0 A +/- 15.6 letters after three consecutive injections (p = 0.017).
   Significantly decreased VEGF levels were noted after the first injection of bevacizumab. These levels were maintained after the second injection, which paralleled the change in visual acuity and CMT.
C1 [Lim, Su Jin; Kwon, Oh Woong] Nune Eye Hosp, Retina Ctr, Seoul 135841, South Korea.
   [Roh, Mi In; Kwon, Oh Woong] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, Seoul, South Korea.
   [Ahn, Ji Min] Siloam Eye Hosp, Seoul, South Korea.
   [Lim, Jong Baek] Yonsei Univ, Coll Med, Dept Lab Med, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Kwon, OW (通讯作者)，Nune Eye Hosp, Retina Ctr, 907-16 Daechi Dong, Seoul 135841, South Korea.
EM owkwon0301@yuhs.ac
OI Roh, Miin/0000-0003-3346-754X; Lim, Jong-Baeck/0000-0003-0419-0422
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Kowluru RA, 2004, BRIT J OPHTHALMOL, V88, P1343, DOI 10.1136/bjo.2003.038133
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Molloy RM, 2005, CLIN CHEM LAB MED, V43, P1303, DOI 10.1515/CCLM.2005.224
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220
   Song XP, 2003, J IMMUNOL, V171, P6448, DOI 10.4049/jimmunol.171.12.6448
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M
   Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100
   Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P19, DOI 10.1089/jop.2006.22.19
NR 22
TC 29
Z9 29
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2010
VL 248
IS 5
BP 635
EP 640
DI 10.1007/s00417-009-1254-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 575ML
UT WOS:000276071100003
PM 19997926
DA 2022-11-30
ER

PT J
AU Ghorbanihaghjo, A
   Javadzadeh, A
   Rashtchizadeh, N
   Argani, H
   Masoodnia, S
   Nezami, N
AF Ghorbanihaghjo, Amir
   Javadzadeh, Alireza
   Rashtchizadeh, Nadereh
   Argani, Hassan
   Masoodnia, Sima
   Nezami, Nariman
TI High-sensitivity C-reactive protein and endothelin-1 in age-related
   macular degeneration
SO JOURNAL OF MENS HEALTH
LA English
DT Article
DE Age-related macular degeneration (AMD); Endothelin-1 (ET-1);
   High-sensitivity C-reactive protein (hsCRP)
ID CARDIOVASCULAR RISK-FACTORS; POOLED FINDINGS; MACULOPATHY; INFLAMMATION;
   ASSOCIATION; PREVALENCE; FIBRINOGEN; THERAPY; DISEASE; MARKER
AB Background: Age-related macular degeneration (AMD) is the most common cause of elderly irreversible vision loss in the world. Since C-reactive protein (CRP) is a potential risk factor that has been known to induce AMD, this study was designed to explore the relationship between AMD and serum levels of high sensitrvity C-reactive protein (hsCRP), and endothelin-1 (ET-1).
   Methods: The subjects were 48 males with AMD (28 with wet type and 20 with dry type) having a mean age of 69.4 +/- 9.6 years and a matched group of 45 apparently healthy control subjects. The AMD was diagnosed using a slit-lamp with super filled lens, fundus photography and fluorescein angiography. Levels of hsC RP and ET-1 were determined using ELISA methods.
   Results: hsCRP (6.96 +/- 5.15 vs. 3.64 +/- 4.67 mg/l, P<0.0001) and ET-1 levels (0.66 +/- 0.31 vs. 0.52 +/- 0.25 pg/ml, P = 0.025) in the patients were higher than in the controls, but the multivariate analysis also showed a significant difference in cholesterol level (P <0.001). There were no significant differences in the serum levels of hsCRP and ET-1 between the two types of AMD (P>0.05). ET-1 also correlated directly with hsCRP levels (r = 0.284, P < 0.01).
   Conclusions: The results suggest that although the serum levels of ET-1 and hsCRP are higher in the patients with AMD, they are a dependent risk factor. (C) 2009 WPMH GmbH. Published by Elsevier Ireland Ltd.
C1 [Ghorbanihaghjo, Amir; Javadzadeh, Alireza; Argani, Hassan; Masoodnia, Sima] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran.
   [Rashtchizadeh, Nadereh; Nezami, Nariman] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz 51664, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science
RP Javadzadeh, A (通讯作者)，Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran.
EM javadzadehalireza@yahoo.com
RI Argani, Hassan/AAD-8372-2019; Nezami, Nariman/W-3690-2019; Javadzadeh,
   Alireza/L-6424-2017; Rashtchizadeh, Nadereh/L-7691-2017
OI Javadzadeh, Alireza/0000-0002-5151-6125; Rashtchizadeh,
   Nadereh/0000-0003-2878-3847; ghorbanihaghjo, amir/0000-0001-6742-0526
CR AGUI T, 1994, BLOOD, V84, P2531
   Bialek-Szymanska Anna, 2007, Klin Oczna, V109, P127
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Chapman MJ, 2007, PHARMACOL THERAPEUT, V113, P184, DOI 10.1016/j.pharmthera.2006.08.005
   Cosin-Sales J, 2003, J AM COLL CARDIOL, V41, P1468, DOI 10.1016/S0735-1097(03)00243-2
   de Ferranti SD, 2007, CARDIOVASC PATHOL, V16, P14, DOI 10.1016/j.carpath.2006.04.006
   Duerrschmidt N, 2000, BIOCHEM BIOPH RES CO, V269, P713, DOI 10.1006/bbrc.2000.2354
   Ersoy Y, 2006, HEPATOL RES, V34, P111, DOI 10.1016/j.hepres.2005.11.005
   Evans M, 2004, DRUGS, V64, P1181, DOI 10.2165/00003495-200464110-00003
   Ferri C, 2007, CURR PHARM DESIGN, V13, P1631, DOI 10.2174/138161207780831301
   Folsom AR, 2005, EUR J EPIDEMIOL, V20, P1015, DOI 10.1007/s10654-005-3657-0
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gemici G, 2007, CARDIOLOGY, V107, P340, DOI 10.1159/000099048
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Iglarz M, 2003, CURR HYPERTENS REP, V5, P144, DOI 10.1007/s11906-003-0071-4
   Katayama T, 2005, CIRC J, V69, P654, DOI 10.1253/circj.69.654
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kinlay S, 2001, CIRCULATION, V104, P1114, DOI 10.1161/hc3501.095707
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kuehn BM, 2005, JAMA-J AM MED ASSOC, V293, P1841, DOI 10.1001/jama.293.15.1841
   Lee HBH, 2007, CAN J OPHTHALMOL, V42, P131, DOI 10.3129/canjophthalmol.06-101
   Maeda S, 2006, EXP BIOL MED, V231, P1044
   Masaki T, 2004, TRENDS PHARMACOL SCI, V25, P219, DOI 10.1016/j.tips.2004.02.008
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Pfutzner A, 2006, DIABETES TECHNOL THE, V8, P28, DOI 10.1089/dia.2006.8.28
   Ramzy D, 2007, J THORAC CARDIOV SUR, V133, P1137, DOI 10.1016/j.jtcvs.2006.11.034
   Ridker PM, 2007, J AM COLL CARDIOL, V49, P2129, DOI 10.1016/j.jacc.2007.02.052
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shah R, 2007, EUR J INTERN MED, V18, P272, DOI 10.1016/j.ejim.2007.04.002
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Tsui Janice C. S., 2005, Current Vascular Pharmacology, V3, P325, DOI 10.2174/157016105774329444
   Vainas T, 2005, J VASC SURG, V42, P243, DOI 10.1016/j.jvs.2005.03.060
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang XF, 2003, INVEST OPHTH VIS SCI, V44, P2067, DOI 10.1167/iovs.02-0841
   Wunder DM, 2006, EUR J ENDOCRINOL, V155, P137, DOI 10.1530/eje.1.02178
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 53
TC 1
Z9 1
U1 0
U2 0
PU CODON PUBLICATIONS
PI BRISBANE
PA LEVEL 9, 167 EAGLE ST, BRISBANE, QLD 4000, AUSTRALIA
SN 1875-6867
EI 1875-6859
J9 J MENS HEALTH
JI J. Mens Health
PD MAR
PY 2010
VL 7
IS 1
BP 85
EP 91
DI 10.1016/j.jomh.2009.10.003
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA 687WN
UT WOS:000284809000010
DA 2022-11-30
ER

PT J
AU Mauschitz, MM
   Schmitz, MT
   Verzijden, T
   Schmid, M
   Thee, EF
   Colijn, JM
   Delcourt, C
   Cougnard-Gregoire, A
   Merle, BMJ
   Korobelnik, JF
   Gopinath, B
   Mitchell, P
   Elbaz, H
   Schuster, AK
   Wild, PS
   Brandl, C
   Stark, KJ
   Heid, IM
   Gunther, F
   Peters, A
   Klaver, CCW
   Finger, RP
AF Mauschitz, Matthias M.
   Schmitz, Marie-Therese
   Verzijden, Timo
   Schmid, Matthias
   Thee, Eric F.
   Colijn, Johanna M.
   Delcourt, Cecile
   Cougnard-Gregoire, Audrey
   Merle, Benedicte M. J.
   Korobelnik, Jean-Francois
   Gopinath, Bamini
   Mitchell, Paul
   Elbaz, Hisham
   Schuster, Alexander K.
   Wild, Philipp S.
   Brandl, Caroline
   Stark, Klaus J.
   Heid, Iris M.
   Gunther, Felix
   Peters, Annette
   Klaver, Caroline C. W.
   Finger, Robert P.
CA European Eye Epidemiology E3 Conso
TI Physical Activity, Incidence, and Progression of Age-Related Macular
   Degeneration: A Multicohort Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OXIDATIVE STRESS; PREVALENCE; CLASSIFICATION; MACULOPATHY; DIETARY
AB PURPOSE: To investigate the impact of physical activity (PA) on the incidence or progression of age-related macular degeneration (AMD) in the general population.
   DESIGN: Meta-analysis of longitudinal cohort studies.
   METHODS: We included 14,630 adults with no or early AMD at baseline from 7 population-based studies and examined associations of PA with AMD incidence and progression using multistate models (MSM) per study and subsequent random effects meta-analysis. Age effects were assessed using meta-regression. The main outcome measure was the hazard ratio (HR) for incident early or progression to late AMD.
   RESULTS: At baseline, mean age was 60.7 +/- 6.9 to 76.4 +/- 4.3 years, and prevalence of early AMD was 7.7% (range, 3.6%-16.9%) between cohorts. During followup, 1461 and 189 events occurred for early and late AMD, respectively. In meta-analyses, no or low to moderate PA (high PA as reference) was associated with an increased risk for incident early AMD (HR, 1.19; 95% CI, 1.01-1.40; P = .04), but not for late AMD. In subsequent meta-regression, we found no association of age with the effect of PA on incident AMD.
   CONCLUSIONS: Our study suggests high levels of PA to be protective for the development of early AMD across several population-based cohort studies. Our results establish PA as a modifiable risk factor for AMD and inform further AMD prevention strategies to reduce its public health impact. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Mauschitz, Matthias M.; Finger, Robert P.] Univ Hosp Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Schmitz, Marie-Therese; Schmid, Matthias] Univ Bonn, Med Fac, Dept Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Verzijden, Timo; Thee, Eric F.; Colijn, Johanna M.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Delcourt, Cecile; Cougnard-Gregoire, Audrey; Merle, Benedicte M. J.; Korobelnik, Jean-Francois] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, Inst Natl Sante & Rech Med, Unite Mixte Rech 1219,Team Lifelong Exposures Hlt, Bordeaux, France.
   [Gopinath, Bamini; Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   [Gopinath, Bamini] Macquarie Univ, Macquarie Univ Hearing, Dept Linguist, Sydney, NSW, Australia.
   [Elbaz, Hisham; Schuster, Alexander K.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Mainz, Germany.
   [Elbaz, Hisham] Otto von Guericke Univ, Dept Ophthalmol, Magdeburg, Germany.
   [Wild, Philipp S.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Ctr Cardiol, Prevent Cardiol & Prevent Med, Mainz, Germany.
   [Wild, Philipp S.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Ctr Thrombosis & Hemostasis, Mainz, Germany.
   [Wild, Philipp S.] DZHK German Ctr Cardiovasc Res, Partner Site Rhine Main, Mainz, Germany.
   [Brandl, Caroline; Stark, Klaus J.; Heid, Iris M.; Gunther, Felix] Univ Hosp Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Brandl, Caroline] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Gunther, Felix] Ludwig Maximilians Univ Munchen, Dept Stat, Stat Consulting Unit StaBLab, Munich, Germany.
   [Peters, Annette] Helmholtz Ctr Munich, Inst Epidemiol, Munich, Germany.
   [Peters, Annette] Ludwig Maximilians Univ Munchen, Med Fac, Dept Epidemiol, Inst Med Informat Proc Biometry & Epidemiol, Munich, Germany.
   [Klaver, Caroline C. W.] Radboudumc, Dept Opthalmol, Nijmegen, Netherlands.
   [Klaver, Caroline C. W.] Inst Mol & Clin Ophthalmol, Basel, Switzerland.
C3 University of Bonn; University of Bonn; Erasmus University Rotterdam;
   Erasmus MC; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   University of Sydney; Westmead Institute for Medical Research; Macquarie
   University; Johannes Gutenberg University of Mainz; Otto von Guericke
   University; Johannes Gutenberg University of Mainz; Johannes Gutenberg
   University of Mainz; German Centre for Cardiovascular Research;
   University of Regensburg; University of Regensburg; University of
   Munich; Helmholtz Association; Helmholtz-Center Munich - German Research
   Center for Environmental Health; University of Munich; Radboud
   University Nijmegen
RP Mauschitz, MM (通讯作者)，Univ Hosp Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Matthias.Mauschitz@ukbonn.de
RI ; Delcourt, Cecile/I-2627-2013; Merle, Benedicte MJ/F-1247-2015
OI Korobelnik, Jean-Francois/0000-0002-4438-9535; Schmid,
   Matthias/0000-0002-0788-0317; Delcourt, Cecile/0000-0002-2099-0481;
   Merle, Benedicte MJ/0000-0003-1332-0954; Schmitz,
   Marie-Therese/0000-0003-1351-9381; Wild, Philipp/0000-0003-4413-9752
FU government of Rhineland-Palatinate ("Stiftung Rheinland-Pfalz fur
   Innovation") [AZ 961-386261/733]; research program "Wissenschafft
   Zukunft" of the Johannes Gutenberg-University of Mainz; research program
   "Center for Translational Vascular Biology (CTVB)" of the Johannes
   Gutenberg-University of Mainz; Boehringer Ingelheim; Philips Medical
   Systems; Federal Ministry of Education and Research [BMBF 01EO1503];
   Deutsche Ophthalmologische Gesellschaft; Berufsverband der Augenarzte
   Deutschland e.V; Thea Pharma; Fondation Voir et Entendre; Retina France;
   Agence Nationale de la Recherche [ANR 2010-PRSP-011 VISA]; CFSR
   Recherche (Club Francophone des Specialistes de la Retine); French
   Ministry of Health (PHRC) [PHRC12_157 ECLAIR]; CNSA (Caisse Nationale
   pour la Solidariteet l'Autonomie); Institut National de la Santeet de la
   Recherche Medicale (INSERM), Paris, France; Fondation de France, Paris;
   Department of Epidemiology of Ageing, Paris; Fondation pour la Recherche
   Medicale, Paris; Region Languedoc-Roussillon, Montpellier, France;
   Association Retina-France, Toulouse; Rhones Poulenc; Essilor; Specia;
   Horiba ABX Montpellier; Centre de Recherche et d'Information
   Nutritionnelle, Paris; Erasmus Medical Center and Erasmus University,
   Rotterdam; Netherlands Organization for the Health Research and
   Development (ZonMw); Research Institute for Diseases in the Elderly
   (RIDE); Ministry of Education, Culture and Science; Ministry for Health,
   Welfare and Sports; European Commission (DG XII); Municipality of
   Rotterdam; European Union Horizon 2020 [634479]; Royal Dutch Academy of
   Sciences; German Federal Ministry of Education and Research [BMBF
   01ER1206, BMBF 01ER1507]; Deutsche Forschungsgemeinschaft (DFG, German
   Research Foundation) [HE 3690/7-1, BR 6028/2-1]; Australian National
   Health and Medical Research Council [974159, 991407, 211069, 262120,
   457349]; Innovative Medicines Initiative (MACUSTAR project)
FX The Gutenberg Health Study is funded through the government of
   Rhineland-Palatinate ("Stiftung Rheinland-Pfalz fur Innovation,"
   contract AZ 961-386261/733), the research programs "Wissenschafft
   Zukunft" and "Center for Translational Vascular Biology (CTVB)" of the
   Johannes Gutenberg-University of Mainz, and its contract with Boehringer
   Ingelheim and Philips Medical Systems, including an unrestricted grant
   for the Gutenberg Health Study. Funders were involved in the development
   of the study design as scientific consultants. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. Philipp S. Wild is funded by the Federal
   Ministry of Education and Research (BMBF 01EO1503) and is the principle
   investigator of the German Center for Cardiovascular Research (DZHK).
   Alexander K. Schuster holds the professorship for ophthalmic health care
   research endowed by "Stiftung Auge" and financed by "Deutsche
   Ophthalmologische Gesellschaft" and "Berufsverband der Augenarzte
   Deutschland e.V." The Alienor study was supported by Thea Pharma,
   Fondation Voir et Entendre, Retina France, Agence Nationale de la
   Recherche (ANR 2010-PRSP-011 VISA), CFSR Recherche (Club Francophone des
   Specialistes de la Retine), French Ministry of Health (PHRC, 2012,
   PHRC12_157 ECLAIR), and CNSA (Caisse Nationale pour la Solidariteet
   l'Autonomie). The POLA study was supported by the Institut National de
   la Santeet de la Recherche Medicale (INSERM), Paris, France; by grants
   from the Fondation de France, Department of Epidemiology of Ageing,
   Paris, the Fondation pour la Recherche Medicale, Paris, the Region
   Languedoc-Roussillon, Montpellier, France, and the Association
   Retina-France, Toulouse; and by financial support from Rhones Poulenc,
   Essilor, Specia and Horiba ABX Montpellier, and the Centre de Recherche
   et d'Information Nutritionnelle, Paris. The sponsors and funding
   organizations played no role in the design or conduct of this research.
   The Rotterdam Study is funded by Erasmus Medical Center and Erasmus
   University, Rotterdam, Netherlands Organization for the Health Research
   and Development (ZonMw), the Research Institute for Diseases in the
   Elderly (RIDE), the Ministry of Education, Culture and Science, the
   Ministry for Health, Welfare and Sports, the European Commission (DG
   XII), and the Municipality of Rotterdam. Supported by the European Union
   Horizon 2020 grant No. 634479 (EYE-RISK) and Royal Dutch Academy of
   Sciences (Ammodo Award to Caroline C.W. Klaver). AugUR investigations
   and analyses are supported by grants from the German Federal Ministry of
   Education and Research (BMBF 01ER1206, BMBF 01ER1507 to Iris M. Heid)
   and by the Deutsche Forschungsgemeinschaft (DFG, German Research
   Foundation; HE 3690/7-1 to I.M.H., BR 6028/2-1 to Caroline Brandl). The
   Blue Mountains Eye Study was funded by the Australian National Health
   and Medical Research Council (Grant Nos. 974159, 991407, 211069, 262120,
   and 457349). Matthias Schmid received funding paid to the institution
   from Innovative Medicines Initiative (MACUSTAR project).
CR Albrecht M, 2018, EUR J PREV CARDIOL, V25, P1316, DOI 10.1177/2047487318780031
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloomer RJ, 2008, GENDER MED, V5, P218, DOI 10.1016/j.genm.2008.07.002
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Delcourt C, 2016, EUR J EPIDEMIOL, V31, P197, DOI 10.1007/s10654-015-0098-2
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2020, JAMA OPHTHALMOL, V138, P1234, DOI 10.1001/jamaophthalmol.2020.3989
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Gopinath B, 2014, INVEST OPHTH VIS SCI, V55, P7799, DOI 10.1167/iovs.14-15575
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heinemann M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222045
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   McGuinness MB, 2016, BRIT J OPHTHALMOL, V100, P1353, DOI 10.1136/bjophthalmol-2015-307663
   Mekjavic PJ, 2019, VALUE HEALTH REG ISS, V19, P1, DOI 10.1016/j.vhri.2018.11.002
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Mury P, 2018, SPORTS MED, V48, P2725, DOI 10.1007/s40279-018-0996-z
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   Petiot V, 2007, NEUROEPIDEMIOLOGY, V28, P56, DOI 10.1159/000098518
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Saksens NTM, 2014, INVEST OPHTH VIS SCI, V55, P7085, DOI 10.1167/iovs.14-14659
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Thee EF, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.26
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 43
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2022
VL 236
BP 99
EP 106
DI 10.1016/j.ajo.2021.10.008
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4X3ZY
UT WOS:000860785500011
PM 34695401
DA 2022-11-30
ER

PT J
AU Verbraak, FD
   Ponsioen, DL
   Tigchelaar-Besling, OAM
   Nguyen, V
   Gillies, MC
   Barthelmes, D
   Klaver, CCW
AF Verbraak, Frank D.
   Ponsioen, Dirk L.
   Tigchelaar-Besling, Odette A. M.
   Nguyen, Vuong
   Gillies, Mark C.
   Barthelmes, Daniel
   Klaver, Caroline C. W.
TI Real-world treatment outcomes of neovascular Age-related Macular
   Degeneration in the Netherlands
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE neovascular age&#8208; related macular degeneration (nAMD); anti&#8208;
   VEGF treatment; quality registration; real&#8208; world data
ID RANIBIZUMAB; BEVACIZUMAB; AFLIBERCEPT; INJECTIONS
AB Purpose To compare treatment outcomes of treatment-naive eyes with neovascular age-related macular degeneration (nAMD) with bevacizumab as the first-line treatment, according to the guidelines of the Dutch Ophthalmological Society, with those treated first with either ranibizumab or aflibercept, as used in many other countries, all treated using a treat-and-extend strategy.
   Methods Data were obtained from the prospectively designed Fight Retinal Blindness! outcomes registry. The primary outcome was the mean change from baseline in visual acuity of all treated eyes, after 12, 24 and 36 months of treatment. Secondary outcomes were the number of injections, the number of visits and the rate of switching to a second anti-VEGF drug.
   Results The study included 703 treatment-naive eyes with nAMD with 12 months follow-up, 373 eyes with 24 months follow-up, and 171 eyes with 36 months follow-up in the Netherlands, and 1131, 652, and 303 treatment-naive eyes with respectively 12, 24, and 36 months of follow-up in all other countries. The change in visual acuity from baseline did not differ between the Netherlands and the other countries at any follow-up time. The median number of injections, visits and the proportion of eyes switching treatment was significantly higher in the Netherlands than in the other countries.
   Conclusion Starting anti-VEGF treatment for nAMD with bevacizumab, as is mandatory in the Netherlands, delivers outcomes similar to those starting treatment with either ranibizumab or aflibercept, but at a cost of more frequent injections, and visits, and more frequent switching treatment to a second drug.
C1 [Verbraak, Frank D.] Univ Amsterdam, Med Ctr, Dept Ophthalmol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.
   [Ponsioen, Dirk L.] Isala Clin, Dept Ophthalmol, Zwolle, Netherlands.
   [Tigchelaar-Besling, Odette A. M.] Amphia Clin, Dept Ophthalmol, Breda, Netherlands.
   [Nguyen, Vuong; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Barthelmes, Daniel] Zurich Univ, Med Clin, Dept Ophthalmol, Zurich, Switzerland.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen, Med Clin, Dept Ophthalmol, Nijmegen, Netherlands.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
C3 University of Amsterdam; Isala Clinics; University of Sydney; University
   of Zurich; Radboud University Nijmegen; Erasmus University Rotterdam;
   Erasmus MC
RP Verbraak, FD (通讯作者)，Univ Amsterdam, Med Ctr, Dept Ophthalmol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.
EM f.verbraak@amsterdamumc.nl
OI Verbraak, Frank D/0000-0001-7560-1423
FU Bayer B.V.
FX The authors acknowledge the project management support of Nga-Chi Lau,
   PhD (employee of Bayer B.V.) in the start-up phase of the FRB! Registry
   in the Netherlands and acknowledge the financial support of Bayer B.V.
   for the Dutch FRB! Platform.
CR Barthelmes D, 2018, GRAEF ARCH CLIN EXP, V256, P1839, DOI 10.1007/s00417-018-4061-2
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhandari S, 2020, OPHTHALMOLOGY, V127, P369, DOI 10.1016/j.ophtha.2019.10.006
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cleveland W.S., 1992, STAT MODELS S, P309, DOI DOI 10.1201/9780203738535-8
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Gerding H, 2016, KLIN MONATSBL AUGENH, V233, P471, DOI 10.1055/s-0041-111835
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2020, OPHTHALMOLOGY, V127, pE21, DOI 10.1016/j.ophtha.2019.10.031
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Invernizzi A, 2019, AM J OPHTHALMOL, V204, P105, DOI 10.1016/j.ajo.2019.03.001
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nguyen V, 2020, RETINA-J RET VIT DIS, V40, P866, DOI 10.1097/IAE.0000000000002485
   Ohji M, 2020, ADV THER, V37, P2184, DOI 10.1007/s12325-020-01298-x
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Society DO, 2017, GUID AG REL MAC DEG
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
NR 23
TC 6
Z9 6
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2021
VL 99
IS 6
BP E884
EP E892
DI 10.1111/aos.14712
EA DEC 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UO6TY
UT WOS:000600926300001
PM 33354933
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, L
   Wang, B
   Cui, W
   Fang, SF
AF Chen, Ling
   Wang, Bing
   Cui, Wei
   Fang, Shufen
TI Efficacy of ranibizumab combined with photodynamic therapy on wet
   age-related macular degeneration
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; ranibizumab
ID MYOPIC CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; DOSING
   REGIMEN
AB Efficacy and safety of intravitreal ranibizumab (IVR) combined with photodynamic therapy (PDT) in treating wet age-related macular degeneration (wAMD) were studied. A total of 130 eyes were collected from 130 wAMD patients treated in Affiliated to Qingdao University Yuhuangding Hospital of Yantai, of which 65 were given IVR combined with PDT (combination therapy group) and the remaining 65 were treated with simple IVR (ranibizumab group). The differences in best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure, choroidal neovascularization (CNV) leakage, levels of serum vascular endothelial growth factor (VEGF) and transforming growth factor-beta 1 (TGF-beta 1) as well as complication rate were compared before and after treatment between the two groups. At 1, 3, 6 and 12 months after treatment, combination therapy group had remarkably better BCVA and notably smaller CMT than ranibizumab group. Fundus fluorescein angiography (FFA) showed that the area of macular degeneration was reduced markedly after treatment in both groups, and the area in combination therapy group was evidently smaller than that in ranibizumab group at 1, 3 and 6 months after treatment. At 3 months after treatment, the levels of serum VEGF and TGF-beta 1 declined obviously in the two groups compared with those before treatment. The IVR combined with PDT can effectively improve the visual acuity, decrease CMT and prominently reduce the area of macular degeneration of wAMD patients, and its therapeutic effects are long-standing and tolerable for the patients, so it is worthy of clinical popularization.
C1 [Chen, Ling] Qingdao Univ, Yuhuangding Hosp Yantai, Dept Ophthalmol, Yantai 264000, Shandong, Peoples R China.
   [Wang, Bing] Yantaishan Hosp, Dept Ophthalmol, Yantai 264000, Shandong, Peoples R China.
   [Cui, Wei] Qingdao Fuwai Cardiovasc Dis Hosp, Dept Ophthalmol & Otolaryngol, Qingdao 266034, Shandong, Peoples R China.
   [Fang, Shufen] Laizhou Peoples Hosp Yantai, Dept Ophthalmol, 1718 Wuli St, Yantai 261400, Shandong, Peoples R China.
C3 Qingdao University
RP Fang, SF (通讯作者)，Laizhou Peoples Hosp Yantai, Dept Ophthalmol, 1718 Wuli St, Yantai 261400, Shandong, Peoples R China.
EM shufan122@163.com
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Datseris I, 2015, SEMIN OPHTHALMOL, V30, P112, DOI 10.3109/08820538.2013.833268
   Kang EC, 2017, RETINA-J RET VIT DIS, V37, P1775, DOI 10.1097/IAE.0000000000001421
   Kim Hyun Woong, 2011, Korean J Ophthalmol, V25, P231, DOI 10.3341/kjo.2011.25.4.231
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nakamura T, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/154659
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Saviano Sandro, 2016, Digit J Ophthalmol, V22, P46, DOI 10.5693/djo.01.2014.01.004
   Saviano S, 2014, INT J OPHTHALMOL-CHI, V7, P335, DOI 10.3980/j.issn.2222-3959.2014.02.26
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Su YX, 2018, PHOTODIAGN PHOTODYN, V22, P263, DOI 10.1016/j.pdpdt.2018.05.002
   Teper SJ, 2016, PHOTODIAGN PHOTODYN, V13, P108, DOI 10.1016/j.pdpdt.2016.01.006
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
NR 21
TC 2
Z9 2
U1 1
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JUN
PY 2020
VL 19
IS 6
BP 3691
EP 3697
DI 10.3892/etm.2020.8641
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA LU3VL
UT WOS:000537686800031
PM 32346433
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Real, JP
   Luna, JD
   Urrets-Zavalia, JA
   De Santis, MO
   Palma, SD
   Granero, GE
AF Real, Juan P.
   Luna, Jose D.
   Urrets-Zavalia, Julio A.
   De Santis, Mariana O.
   Palma, Santiago D.
   Granero, Gladys E.
TI Accessibility as a conditioning factor in treatment for exudative
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Cohort studies; Health services accessibility; Macular
   degeneration; Ranibizumab
ID PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB;
   VERTEPORFIN; AVASTIN; TRIAMCINOLONE; TRIAL
AB Purpose: Ranibizumab and bevacizumab coexist as the main therapeutic strategies for the treatment of neovascular age-related macular degeneration (NV-AMD). In Argentina, the access pathways to the drugs are different. Patients with different pathways and gatekeepers to access may experience different outcomes. The purpose of this work was to estimate the impact on therapeutic effects and visual outcome of the different accessibilities to NV-AMD treatment.
   Methods: A retrospective analysis of the charts of 78 patients with previously untreated exudative AMD, who were treated with ranibizumab or bevacizumab between January 2009 and December 2011, was conducted. The main outcomes measured included time delay and change in mean best-corrected visual acuity (BCVA) between diagnosis and treatment and mean BCVA change at 1-year follow-ups.
   Results: The delay between diagnosis and treatment and decrease in visual acuity over this time was significantly higher for patients treated with ranibizumab. At 1 year after the initiation of treatment, BCVA had a mean increase from baseline of 0.11 letters in the bevacizumab group with a mean of 4.71 injections, compared with a decrease of 8.87 letters with a mean of 2.98 injections in the ranibizumab group.
   Conclusions: Access to treatment can be a key factor for success of therapy. Waiting times and availability of doses are crucial in the treatment of NV-AMD. Solving the problems related to delayed initiation of therapy and the difficulties in the maintenance phase are more important than define whether bevacizumab or ranibizumab is used.
C1 [Real, Juan P.; Palma, Santiago D.; Granero, Gladys E.] Natl Univ Cordoba, Dept Pharm, Fac Chem Sci, Cordoba, Argentina.
   [Luna, Jose D.] Ctr Privado Ojos Romagosa SA Fdn VER, Vitreoretinal Dept, Cordoba, Argentina.
   [Urrets-Zavalia, Julio A.] Catholic Univ Cordoba, Univ Clin Reina Fabiola, Dept Ophthalmol, Cordoba, Argentina.
   [De Santis, Mariana O.] Natl Univ Cordoba, Sch Econ Sci, Inst Econ & Finance, Cordoba, Argentina.
C3 National University of Cordoba; Catholic University of Cordoba; National
   University of Cordoba
RP Granero, GE (通讯作者)，Natl Univ Cordoba, Dept Pharm, Fac Chem Sci, Ciudad Univ Edif Ciencias 2 X5000HUA, Cordoba, Argentina.
EM glagra@fcq.unc.edu.ar
CR Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Vasudev D, 2009, J OCUL PHARMACOL TH, V25, P453, DOI 10.1089/jop.2009.0036
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
NR 17
TC 5
Z9 5
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2013
VL 23
IS 6
BP 857
EP 864
DI 10.5301/ejo.5000299
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 274LO
UT WOS:000328608100014
PM 23661541
DA 2022-11-30
ER

PT J
AU Ni, JQ
   Yuan, XL
   Gu, JY
   Yue, XZ
   Gu, XR
   Nagaraj, RH
   Crab, JW
AF Ni, Jiaqian
   Yuan, Xianglin
   Gu, Jiayin
   Yue, Xiuzhen
   Gu, Xiaorong
   Nagaraj, Ram H.
   Crab, John W.
CA Clinical Genomic Proteomic AMD
TI Plasma Protein Pentosidine and Carboxymethyllysine, Biomarkers for
   Age-related Macular Degeneration
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID GLYCATION END-PRODUCTS; FACTOR-H POLYMORPHISM; BRUCHS MEMBRANE;
   OXIDATIVE DAMAGE; N-EPSILON-(CARBOXYMETHYL)LYSINE; DRUSEN; RISK;
   RECEPTOR; PROGRESS; VARIANT
AB Age-related macular degeneration (AMD) causes severe vision loss in the elderly; early identification of AMD risk could help slow or prevent disease progression. Toward the discovery of AMD biomarkers, we quantified plasma protein N-epsilon-carboxymethyllysine (CML) and pentosidine from 58 AMD and 32 control donors. CML and pentosidine are advanced glycation end products that are abundant in Bruch membrane, the extracellular matrix separating the retinal pigment epithelium from the blood-bearing choriocapillaris. We measured CML and pentosidine by LC-MS/MS and LC-fluorometry, respectively, and found higher mean levels of CML (similar to 54%) and pentosidine (similar to 64%) in AMD (p < 0.0001) relative to normal controls. Plasma protein fructosyl-lysine, a marker of early glycation, was found by amino acid analysis to be in equal amounts in control and non-diabetic AMD donors, supporting an association between AMD and increased levels of CML and pentosidine independent of other diseases like diabetes. Carboxyethylpyrrole (CEP), an oxidative modification from docosahexaenoate-containing lipids and also abundant in AMD Bruch membrane, was elevated similar to 86% in the AMD cohort, but autoantibody titers to CEP, CML, and pentosidine were not significantly increased. Compellingly higher mean levels of CML and pentosidine were present in AMD plasma protein over a broad age range. Receiver operating curves indicate that CML, CEP adducts, and pentosidine alone discriminated between AMD and control subjects with 78, 79, and 88% accuracy, respectively, whereas CML in combination with pentosidine provided similar to 89% accuracy, and CEP plus pentosidine provided similar to 92% accuracy. Pentosidine levels appeared slightly altered in AMD patients with hypertension and cardiovascular disease, indicating further studies are warranted. Overall this study supports the potential utility of plasma protein CML and pentosidine as biomarkers for assessing AMD risk and susceptibility, particularly in combination with CEP adducts and with concurrent analyses of fructosyl-lysine to detect confounding factors. Molecular & Cellular Proteomics 8: 1921-1933, 2009.
C1 [Ni, Jiaqian; Yuan, Xianglin; Gu, Jiayin; Yue, Xiuzhen; Gu, Xiaorong; Crab, John W.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Ni, Jiaqian; Yuan, Xianglin; Gu, Jiayin; Yue, Xiuzhen; Gu, Xiaorong; Crab, John W.] Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Ni, Jiaqian; Crab, John W.] Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA.
   [Gu, Jiayin; Crab, John W.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Nagaraj, Ram H.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Crab, John W.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Ophthalmol, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; University
   System of Ohio; Cleveland State University; Case Western Reserve
   University; Case Western Reserve University; Case Western Reserve
   University; Cleveland Clinic Foundation
RP Crab, JW (通讯作者)，Cleveland Clin Fdn I 31, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM Crabbj@ccf.org
OI Kaiser, Peter/0000-0001-5126-045X
FU National Institutes of Health [EY015638, EY014239, EY09912]; State of
   Ohio [BRTT 05-29]; Foundation Fighting Blindness center; Research to
   Prevent Blindness; Steinbach Award; Cleveland Clinic Foundation;
   NATIONAL EYE INSTITUTE [R24EY015638, R01EY009912, R29EY009912,
   R01EY014239] Funding Source: NIH RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants EY015638, EY014239, and EY09912. This work was also
   supported by State of Ohio Grant BRTT 05-29, a Foundation Fighting
   Blindness center grant ( to the Cole Eye Institute), a Research to
   Prevent Blindness (RPB) challenge grant ( to the Cole Eye Institute), a
   RPB senior investigator award ( to J.W.C.), a Steinbach Award ( to
   J.W.C.), and the Cleveland Clinic Foundation.
CR Ahmed KA, 2007, J CLIN BIOCHEM NUTR, V41, P97, DOI 10.3164/jcbn.2007014
   Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRABB JW, 1997, CURRENT PROTOCOLS S, V7
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farboud B, 1999, MOL VIS, V5, pU1
   Floridi A, 1999, J CHROMATOGR A, V846, P65, DOI 10.1016/S0021-9673(99)00442-2
   Friedlander MA, 1996, J CLIN INVEST, V97, P728, DOI 10.1172/JCI118471
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Goh SY, 2008, J CLIN ENDOCR METAB, V93, P1143, DOI 10.1210/jc.2007-1817
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu J, 2007, INVEST OPHTHALMOL VI, V48
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   GU X, 2009, INVEST OPHTHALMOL VI, V50
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hassid BG, 2009, J CLIN NEUROSCI, V16, P302, DOI 10.1016/j.jocn.2007.12.011
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Lieuw-A-Fa MLM, 2004, NEPHROL DIAL TRANSPL, V19, P631, DOI 10.1093/ndt/gfg619
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   ODETTI P, 1992, DIABETES, V41, P153, DOI 10.2337/diabetes.41.2.153
   Okamoto T, 2002, MICROVASC RES, V63, P186, DOI 10.1006/mvre.2001.2371
   REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021
   Riviere S, 1998, GLYCOCONJUGATE J, V15, P1039, DOI 10.1023/A:1006902428776
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida N, 2005, METABOLISM, V54, P345, DOI 10.1016/j.metabol.2004.09.014
NR 49
TC 61
Z9 69
U1 4
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD AUG
PY 2009
VL 8
IS 8
BP 1921
EP 1933
DI 10.1074/mcp.M900127-MCP200
PG 13
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 483IX
UT WOS:000268958700013
PM 19435712
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Jacob, J
   Brie, H
   Leys, A
   Levecq, L
   Mergaerts, F
   Denhaerynck, K
   Vancayzeele, S
   Van Craeyveld, E
   Abraham, I
   MacDonald, K
AF Jacob, Julie
   Brie, Heidi
   Leys, Anita
   Levecq, Laurent
   Mergaerts, Filip
   Denhaerynck, Kris
   Vancayzeele, Stefaan
   Van Craeyveld, Eline
   Abraham, Ivo
   MacDonald, Karen
TI Six-year outcomes in neovascular age-related macular degeneration with
   ranibizumab
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE ranibizumab; age-related macular degeneration; visual acuity; central
   retinal thickness; optical coherence tomography; visual function;
   long-term outcome
ID LONG-TERM OUTCOMES; INTRAVITREAL RANIBIZUMAB; THERAPY; VISION;
   PREVALENCE; HORIZON; ATROPHY; ANCHOR; MARINA; TREAT
AB AIM: To evaluate the outcomes of >= 6y ranibizumab therapy in neovascular age-related macular degeneration (AMD).
   METHODS: HELIX was a retrospective, observational effeciveness study using medical records of patients treated in three clinics in Belgium. Patients had neovascular AMD and were initially treated with intravitreal ranibizumab (0.5 mg) between November 1, 2007 and October 31, 2008, had >= 6y of data available, and were treated on an ongoing, as-needed basis. Outcomes included best-corrected visual acuity (BCVA) and central retinal thickness (CRT).
   RESULTS: The sample consisted of 88 eyes from 69 patients. Mean age was 76.4 +/- 6.5y, most patients were female (62.3%). Most eyes (62.5%) were treatment-naive, 33 previously treated eyes had received predominantly other anti-vascular endothelial growth factor agents and verteporfin. Mean baseline BCVA was 57.4 +/- 12.7 ETDRS letters and CRT was 292 +/- 86 mu m. On average, patients received 20.6 +/- 11.9 ranibizumab injections over the >= 6y. Intervals between injections were on average 12.7 +/- 16.1wk. Mean change in BCVA from baseline to last observation for the sample was less than one letter (-0.9 +/- 17.3 letters), with an average loss of-3.2 +/- 15.6 letters in previously treated eyes versus a gain of 0.6 +/- 18.4 letters in treatment-naive eyes. When considering a loss of <15 letters over 6y as stabilization of disease, 75.9% of all eyes showed a positive (improvement or stabilization) outcome. Mean change in CRT from baseline to last observation for the sample was -26.9 +/- 148.4 mu m with the greatest reduction observed in treatment-naive eyes.
   CONCLUSION: This retrospective study of 69 neovascular AMD patients treated for My with ranibizumab demonstrates long-term visual stabilization. In light of the natural evolution of the disease, these data confirm that ranibizumab is effective long-term under real-world conditions of heterogeneity of patients, clinicians, and centers.
C1 [Jacob, Julie; Leys, Anita] Leuven Univ, Hosp Eye, Kapucijnenvoer 33, B-3000 Leuven, Belgium.
   [Brie, Heidi; Vancayzeele, Stefaan; Van Craeyveld, Eline] Novartis Pharmaceut, Medialaan 40, B-1800 Vilvoorde, Belgium.
   [Levecq, Laurent] Catholic Univ Louvain, CHU UCL Namur, B-5530 Yvoir, Belgium.
   [Mergaerts, Filip] Med Ctr Aarschot, Langdorpsesteenweg 129, B-3200 Aarschot, Belgium.
   [Denhaerynck, Kris; Abraham, Ivo; MacDonald, Karen] Matrix45, 6159 W Sunset Rd, Tucson, AZ 85743 USA.
   [Abraham, Ivo] Univ Arizona, Ctr Hlth Outcomes & Pharmacoecon Res, Tucson, AZ 85721 USA.
C3 KU Leuven; Novartis; Universite Catholique Louvain; University of
   Arizona
RP Abraham, I (通讯作者)，Matrix45, 6159 W Sunset Rd, Tucson, AZ 85743 USA.
EM iabraham@matrix45.com; kmacdonald@matrix45.com
OI Jacob, Julie/0000-0002-4716-6820
FU Novartis Pharma
FX The HELIX study was sponsored by Novartis Pharma. Julie Jacob, Anita
   Leys, Laurent Levecq, Filip Mergaerts have served as investigators for
   Novartis. Heidi Brie, Stefaan Vancayzeele, and Eline Van Craeyveld are
   employees of Novartis. Kris Denhaerynck, Ivo Abraham, and Karen
   MacDonald are employees of Matrix45, which was under contract with
   Novartis to consult on study design, study protocol, statistical
   analysis, results reporting, and dissemination. Company policy prohibits
   employees from owning equity in client organizations of Matrix45 (except
   for independently administered collective funds). Matrix45 performs
   similar studies for other pharmaceutical companies on a non-exclusivity
   basis.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Airody A, 2015, ACTA OPHTHALMOL, V93, pE511, DOI 10.1111/aos.12618
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Calvo P, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/820605
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gupta AD, 2014, LUMINOUS DETAILED ST
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2015, INVEST OPHTH VIS SCI, V56
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Novartis, 2015, LUC EUR SMPC
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roh Young-Rae, 2013, Korean J Ophthalmol, V27, P268, DOI 10.3341/kjo.2013.27.4.268
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 42
TC 13
Z9 17
U1 0
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JAN 18
PY 2017
VL 10
IS 1
BP 81
EP 90
DI 10.18240/ijo.2017.01.14
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EH4XU
UT WOS:000391778000014
PM 28149782
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Demirs, JT
   Yang, JZ
   Crowley, MA
   Twarog, M
   Delgado, O
   Qiu, YB
   Poor, S
   Rice, DS
   Dryja, TP
   Anderson, K
   Liao, SM
AF Demirs, John T.
   Yang, Junzheng
   Crowley, Maura A.
   Twarog, Michael
   Delgado, Omar
   Qiu, Yubin
   Poor, Stephen
   Rice, Dennis S.
   Dryja, Thaddeus P.
   Anderson, Karen
   Liao, Sha-Mei
TI Differential and Altered Spatial Distribution of Complement Expression
   in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; complement expression; geographic
   atrophy; RNAscope
ID GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; CFI GENE; FACTOR-I;
   HIGH-RISK; FACTOR-B; ACTIVATION; SYSTEM; VARIANTS; RARE
AB PURPOSE. Dysregulation of the alternative complement pathway is a major pathogenic mechanism in age-related macular degeneration. We investigated whether locally synthesized complement components contribute to AMD by profiling complement expression in postmortem eyes with and without AMD.
   METHODS: AMD severity grade 1 to 4 was determined by analysis of postmortem acquired fundus images and hematoxylin and eosin stained histological sections. TaqMan (donor eyes n = 39) and RNAscope/in situ hybridization (n = 10) were performed to detect complement mRNA. Meso scale discovery assay and Western blot (n = 31) were used to measure complement protein levels.
   RESULTS. The levels of complement mRNA and protein expression were approximately 15- to 100-fold (P < 0.0001-0.001) higher in macular retinal pigment epithelium (RPE)/choroid tissue than in neural retina, regardless of AMD grade status. Complement mRNA and protein levels were modestly elevated in vitreous and the macular neural retina in eyes with geographic atrophy (GA), but not in eyes with early or intermediate AMD, compared to normal eyes. Alternative and classical pathway complement mRNAs (C3, CFB, CFH, CFI, C1QA) identified by RNAscope were conspicuous in areas of atrophy; in those areas C3 mRNA was observed in a subset of IBA1(+) microglia or macrophages.
   CONCLUSIONS. We verified that RPE/choroid contains most ocular complement; thus RPE/choroid rather than the neural retina or vitreous is likely to be the key site for complement inhibition to treat GA or earlier stage of the disease. Outer retinal local production of complement mRNAs along with evidence of increased complement activation is a feature of GA.
C1 [Demirs, John T.; Yang, Junzheng; Crowley, Maura A.; Twarog, Michael; Delgado, Omar; Qiu, Yubin; Poor, Stephen; Rice, Dennis S.; Dryja, Thaddeus P.; Anderson, Karen; Liao, Sha-Mei] Novartis Inst Biomed Res, Dept Ophthalmol, Cambridge, MA USA.
   [Dryja, Thaddeus P.] Massachusetts Eye & Ear, Cogan Eye Pathol Lab, Boston, MA USA.
   [Anderson, Karen] Biogen, Cambridge, MA USA.
C3 Novartis; Harvard University; Massachusetts Eye & Ear Infirmary; Biogen
RP Liao, SM (通讯作者)，22 Windsor St, Cambridge, MA 02139 USA.
EM sha-mei.liao@novartis.com
CR Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Cowan CS, 2019, CELL TYPES HUMAN REI
   Crowley MA, 2018, INVEST OPHTH VIS SCI, V59, P940, DOI 10.1167/iovs.17-22605
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehrlich R, 2017, REFERENCE MODULE NEU
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fakhouri F, 2010, NAT REV NEPHROL, V6, P494, DOI 10.1038/nrneph.2010.85
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fonseca MI, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0814-9
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hu YQ, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000365
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110
   Luo C, 2011, MOL VIS, V17, P1588
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McGeer PL, 2017, NEUROBIOL AGING, V52, P12, DOI 10.1016/j.neurobiolaging.2016.12.017
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Morley BJW, 1999, COMPLEMENT FACTSBOOK, P240
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2016, NAT REV NEPHROL, V12, P383, DOI 10.1038/nrneph.2016.70
   Rohrer B, 2019, MOL VIS, V25, P79
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P4195
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Streilein JW, 1997, EYE, V11, P171, DOI 10.1038/eye.1997.47
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wright AF, 2018, OPHTHALMOLOGY, V125, P962, DOI 10.1016/j.ophtha.2018.03.034
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 77
TC 7
Z9 7
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2021
VL 62
IS 7
AR 26
DI 10.1167/iovs.62.7.26
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UA5JI
UT WOS:000685197200019
PM 34160562
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ratnapriya, R
   Acar, IE
   Geerlings, MJ
   Branham, K
   Kwong, A
   Saksens, NTM
   Pauper, M
   Corominas, J
   Kwicklis, M
   Zipprer, D
   Starostik, MR
   Othman, M
   Yashar, B
   Abecasis, GR
   Chew, EY
   Ferrington, DA
   Hoyng, CB
   Swaroop, A
   den Hollander, AI
AF Ratnapriya, Rinki
   Acar, Ilhan E.
   Geerlings, Maartje J.
   Branham, Kari
   Kwong, Alan
   Saksens, Nicole T. M.
   Pauper, Marc
   Corominas, Jordi
   Kwicklis, Madeline
   Zipprer, David
   Starostik, Margaret R.
   Othman, Mohammad
   Yashar, Beverly
   Abecasis, Goncalo R.
   Chew, Emily Y.
   Ferrington, Deborah A.
   Hoyng, Carel B.
   Swaroop, Anand
   den Hollander, Anneke, I
TI Family-based exome sequencing identifies rare coding variants in
   age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; HIGH-RISK;
   GENETIC-VARIANTS; SUSCEPTIBILITY; MACULOPATHY; DISEASE; SCAN; PROTEIN;
   SYSTEM
AB Genome-wide association studies (GWAS) have identified 52 independent variants at 34 genetic loci that are associated with age-related macular degeneration (AMD), the most common cause of incurable vision loss in the elderly worldwide. However, causal genes at the majority of these loci remain unknown. In this study, we performed whole exome sequencing of 264 individuals from 63 multiplex families with AMD and analyzed the data for rare protein-altering variants in candidate target genes at AMD-associated loci. Rare coding variants were identified in the CFH, PUS7, RXFP2, PHF12 and TACC2 genes in three or more families. In addition, we detected rare coding variants in the C9, SPEF2 and BCAR1 genes, which were previously suggested as likely causative genes at respective AMD susceptibility loci. Identification of rare variants in the CFH and C9 genes in our study validated previous reports of rare variants in complement pathway genes in AMD. We then extended our exome-wide analysis and identified rare protein-altering variants in 13 genes outside the AMD-GWAS loci in three or more families. Two of these genes, SCN10A and KIR2DL4, are of interest because variants in these genes also showed association with AMD in case-control cohorts, albeit not at the level of genome-wide significance. Our study presents the first large-scale, exome-wide analysis of rare variants in AMD. Further independent replications and molecular investigation of candidate target genes, reported here, would assist in gaining novel insights into mechanisms underlying AMD pathogenesis.
C1 [Ratnapriya, Rinki; Kwicklis, Madeline; Zipprer, David; Starostik, Margaret R.; Chew, Emily Y.; Swaroop, Anand] NEI, NNRL, Bethesda, MD 20892 USA.
   [Ratnapriya, Rinki] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
   [Acar, Ilhan E.; Geerlings, Maartje J.; Saksens, Nicole T. M.; Pauper, Marc; Corominas, Jordi; Hoyng, Carel B.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, NL-6500 Nijmegen, Netherlands.
   [Branham, Kari; Othman, Mohammad; Yashar, Beverly] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   [Kwong, Alan; Abecasis, Goncalo R.] Univ Michigan, Ctr Stat Genet, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Baylor College of Medicine; Radboud University Nijmegen;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Minnesota System;
   University of Minnesota Twin Cities
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Philips van Leydenlaan 15,Route 409, NL-6525 EX Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Branham, Kari/AAA-8336-2022; Acar, İlhan Erkin/B-7758-2018; Geerlings,
   Maartje/P-3338-2019; Pauper, Marc/AGZ-0438-2022
OI Acar, İlhan Erkin/0000-0002-2078-9905; Geerlings,
   Maartje/0000-0003-1164-3573; Pauper, Marc/0000-0001-6274-9891; Yashar,
   Beverly M./0000-0003-0807-3258; Ferrington, Deborah/0000-0003-2561-7464;
   Ratnapriya, Rinki/0000-0002-0469-4631
FU Intramural Research Program of the National Eye Institute [EY000450,
   EY000474]; Dutch Organization for Scientific Research [Vici.170.024]
FX This work was supported by the Intramural Research Program of the
   National Eye Institute (EY000450, EY000474 to AS) and Dutch Organization
   for Scientific Research (016.Vici.170.024 to AIdH).
CR Abecasis, 2014, 64 ANN M AM SOC HUM
   Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Auton A., 2015, NATURE, V7571, P68, DOI 10.1038/nature15393
   Bashirova AA, 2006, ANNU REV GENOM HUM G, V7, P277, DOI 10.1146/annurev.genom.7.080505.115726
   Bathgate RAD, 2013, PHYSIOL REV, V93, P405, DOI 10.1152/physrev.00001.2012
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bomba L, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1212-4
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Donizetti A, 2015, J EXP ZOOL PART B, V324, P605, DOI 10.1002/jez.b.22637
   Duvvari MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152047
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Faber CG, 2012, P NATL ACAD SCI USA, V109, P19444, DOI 10.1073/pnas.1216080109
   Feng S, 2014, BIOINFORMATICS, V30, P2828, DOI 10.1093/bioinformatics/btu367
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Giblin JP, 2016, ADV PROTEIN CHEM STR, V104, P157, DOI 10.1016/bs.apcsb.2015.11.006
   Goverdhan SV, 2008, INVEST OPHTH VIS SCI, V49, P5077, DOI 10.1167/iovs.08-1837
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Graveline R, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00522-16
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Keady BT, 2011, MOL BIOL CELL, V22, P921, DOI 10.1091/mbc.E10-09-0792
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kolehmainen J, 2003, AM J HUM GENET, V72, P1359, DOI 10.1086/375454
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Momozawa Y, 2016, HUM MOL GENET, V25, P5027, DOI 10.1093/hmg/ddw335
   O'Brien BJ, 2008, J COMP NEUROL, V508, P940, DOI 10.1002/cne.21701
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Pietraszkiewicz A, 2018, OPHTHALMOLOGY, V125, P398, DOI 10.1016/j.ophtha.2017.10.027
   Pras E, 2015, J MED GENET, V52, P484, DOI 10.1136/jmedgenet-2015-103130
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Riccomagno MM, 2014, NEURON, V81, P779, DOI 10.1016/j.neuron.2014.01.036
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sironen A, 2011, BIOL REPROD, V85, P690, DOI 10.1095/biolreprod.111.091132
   Sironen A, 2010, BIOL REPROD, V82, P580, DOI 10.1095/biolreprod.108.074971
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Welter Danielle, 2014, Nucleic Acids Res, V42, pD1001, DOI 10.1093/nar/gkt1229
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang HJ, 2015, PROG RETIN EYE RES, V46, P1, DOI 10.1016/j.preteyeres.2015.01.005
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zwick ME, 2000, ANNU REV GENOM HUM G, V1, P387, DOI 10.1146/annurev.genom.1.1.387
NR 83
TC 8
Z9 8
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUN 15
PY 2020
VL 29
IS 12
BP 2022
EP 2034
DI 10.1093/hmg/ddaa057
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA PQ8KK
UT WOS:000606792200007
PM 32246154
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Jaffe, GJ
   Ying, GS
   Toth, CA
   Daniel, E
   Grunwald, JE
   Martin, DF
   Maguire, MG
AF Jaffe, Glenn J.
   Ying, Gui-Shuang
   Toth, Cynthia A.
   Daniel, Ebenezer
   Grunwald, Juan E.
   Martin, Daniel F.
   Maguire, Maureen G.
CA Comparison Age Related Macular
TI Macular Morphology and Visual Acuity in Year Five of the Comparison of
   Age-related Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL HYPERREFLECTIVE MATERIAL; RANIBIZUMAB; OUTCOMES; ATROPHY;
   ANCHOR; MARINA; RISK
AB Purpose: To evaluate associations of morphologic features with 5-year visual acuity (VA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
   Design: Cohort study within a randomized clinical trial.
   Participants: Participants in CATT.
   Methods: Eyes with age-related macular degeneration-associated choroidal neovascularization (CNV) and VA between 20/25 and 20/320 were eligible. Treatment was assigned randomly to ranibizumab or bevacizumab and to 3 dosing regimens for 2 years and was at the ophthalmologists' discretion thereafter.
   Main Outcome Measures: Visual acuity, thickness and morphologic features on OCT, and lesion size and foveal composition on fundus photography (FP) and fluorescein angiography (FA).
   Results: Visual acuity and image gradings were available for 523 of 914 participants (57%) alive at 5 years. At 5 years, 60% of eyes had intraretinal fluid (IRF), 38% had subretinal fluid (SRF), 36% had subretinal pigment epithelium (RPE) fluid, and 66% had subretinal hyper-reflective material (SHRM). Mean (standard deviation) foveal center thickness was 148 mm (99) for retina, 5 mm (21) for SRF, 125 mm (107) for subretinal tissue complex, 11 mm (33) for SHRM, and 103 mm (95) for RPE thorn RPE elevation. The SHRM, thinner retina, greater CNV lesion area, and foveal center pathology (all P < 0.001) and IRF (P < 0.05) were independently associated with worse VA. Adjusted mean VA letters were 62 for no pathology in the foveal center; 61 for CNV, fluid, or hemorrhage; 65 for non-geographic atrophy (GA); 64 for nonfibrotic scar; 53 for GA; and 56 for fibrotic scar. Incidence or worsening of 8 pathologic features (foveal GA, foveal scar, foveal CNV, SHRM, foveal IRF, retinal thinning, CNV lesion area, and GA area) between years 2 and 5 was independently associated with greater loss of VA from years 2 to 5 and VA loss from baseline to year 5.
   Conclusions: Associations between VA and morphologic features previously identified through year 1 were maintained or strengthened at year 5. New foveal scar, CNV, intraretinal fluid, SHRM and retinal thinning, development or worsening of foveal GA, and increased lesion size are important contributors to the VA decline from years 2 to 5. A significant need to develop therapies to address these adverse pathologic features remains. (C) 2018 by the American Academy of Ophthalmology
C1 [Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, 2351 Erwin Rd,Box 3802, Durham, NC 27705 USA.
   [Ying, Gui-Shuang; Daniel, Ebenezer; Grunwald, Juan E.; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH USA.
C3 Duke University; University of Pennsylvania; Cleveland Clinic Foundation
RP Jaffe, GJ (通讯作者)，Duke Univ, Dept Ophthalmol, 2351 Erwin Rd,Box 3802, Durham, NC 27705 USA.
EM jaffe001@mc.duke.edu
OI Grunwald, Juan/0000-0002-5973-6616; Maguire, Maureen/0000-0002-4249-2467
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland [U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, U10 EY023530]; NATIONAL EYE
   INSTITUTE [P30EY001583, U10EY023530] Funding Source: NIH RePORTER
FX Supported by Cooperative Agreements U10 EY017823, U10 EY017825, U10
   EY017826, U10 EY017828, and U10 EY023530 from the National Eye
   Institute, National Institutes of Health, Department of Health and Human
   Services, Bethesda, Maryland. The funding organization participated in
   the design and conduct of the study and review of the manuscript.
   ClinicalTrials. gov number NCT00593450.
CR [Anonymous], 2016, REGENERON ANNOUNCES
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Manayath GJ, 2018, RETINA-J RET VIT DIS, V38, P1195, DOI 10.1097/IAE.0000000000001665
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
NR 19
TC 107
Z9 111
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2019
VL 126
IS 2
BP 252
EP 260
DI 10.1016/j.ophtha.2018.08.035
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HI2YI
UT WOS:000456312400022
PM 30189282
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Ayton, LN
   Guymer, RH
   Luu, CD
AF Wu, Zhichao
   Ayton, Lauren N.
   Guymer, Robyn H.
   Luu, Chi D.
TI Low-Luminance Visual Acuity and Microperimetry in Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; RETICULAR PSEUDODRUSEN; EYES; DYSFUNCTION;
   MACULOPATHY
AB Objective: To compare the effectiveness of low-luminance visual acuity (LLVA) and microperimetry as functional measures in early stages of age-related macular degeneration (AMD).
   Design: Prospective cross-sectional study.
   Participants: One hundred seventy-nine participants with a clinical spectrum of non-neovascular AMD and 26 control participants.
   Methods: Best-corrected visual acuity (BVCA), LLVA, and microperimetric retinal sensitivity were measured on 1 eye of all participants. Low-luminance deficit (LLD) was calculated as the difference between LLVA and BCVA. The functional parameters were compared between 6 clinical severity groups (from controls to non-foveal geographic atrophy [GA]), and the relationships and magnitude of these parameters were determined and compared.
   Main Outcome Measures: Visual acuity parameters (BCVA, LLVA, and LLD) and central retinal sensitivity.
   Results: Best-corrected visual acuity, LLVA, and central retinal sensitivity were reduced significantly for all AMD clinical severity groups when compared with control participants (P <= 0.002), except for those with drusen between 63 and 125 mm (P >= 0.107). However, LLD was not significantly different from control participants in all groups (P >= 0.073), except in the non-foveal GA group (P = 0.008). A significant positive relationship between central retinal sensitivity and LLD (R = 0.613; P < 0.001), but not BCVA, suggests that there is a trend for LLVA to detect a greater extent of functional deficit than BCVA in eyes with increasingly poorer retinal sensitivity. However, the results of the linear regression models estimated central retinal sensitivity to be 6.1, 3.7, and 5.1 standard deviations (SDs) less than normal by the time BCVA, LLVA, and LLD, respectively, were 2 SDs less than normal.
   Conclusions: In early stages of AMD, LLVA did not detect a greater extent of functional deficit than BCVA when compared with control participants. Although there was a trend for LLVA to be more effective at detecting foveal deficits than BCVA in eyes with increasingly poorer retinal sensitivity, both visual acuity measures were much less sensitive compared with microperimetry. (C) 2014 by the American Academy of Ophthalmology.
C1 [Wu, Zhichao; Ayton, Lauren N.; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Luu, Chi/0000-0002-7604-7097; Guymer,
   Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (Canberra, ACT, Australia)
   [1027624, 529905]; Macular Disease Foundation (Sydney, NSW, Australia);
   Bupa Health Foundation (Melbourne, VIC, Australia); William Angliss
   Charitable Fund (Melbourne, VIC, Australia); MR & RA Brownless Perpetual
   Charitable Trust (Melbourne, VIC, Australia); Victorian Government;
   National Health and Medical Research Council (Centre for Clinical
   Research Excellence) [529923]
FX Supported by the National Health and Medical Research Council (Canberra,
   ACT, Australia) (Project Grant no.: 1027624; practitioner fellowship
   no.: 529905 [RHG]); the Macular Disease Foundation (Sydney, NSW,
   Australia); the Bupa Health Foundation (Melbourne, VIC, Australia);
   William Angliss Charitable Fund (Melbourne, VIC, Australia); and the MR
   & RA Brownless Perpetual Charitable Trust (Melbourne, VIC, Australia).
   The Centre for Eye Research Australia receives Operational
   Infrastructure Support from the Victorian Government and is supported by
   the National Health and Medical Research Council (Centre for Clinical
   Research Excellence Award no.: 529923).
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   BLAND MJ, 1986, LANCET, V1, P307
   Connolly DM, 2009, AVIAT SPACE ENVIR MD, V80, P933, DOI 10.3357/ASEM.2535.2009
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Dacey D. M., 1994, CIBA F SYMP, V184
   DACEY DM, 1994, CIBA F SYMP, V184, P12
   DACEY DM, 1994, CIBA F SYMP, V184, P28
   Eckmiller MS, 2004, PROG RETIN EYE RES, V23, P495, DOI 10.1016/j.preteyeres.2004.04.005
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gao WH, 2008, OPT EXPRESS, V16, P6486, DOI 10.1364/OE.16.006486
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lesmes LA, DRUG DISCOV IN PRESS
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   WILLIAMS DR, 1986, TRENDS NEUROSCI, V9, P193, DOI 10.1016/0166-2236(86)90058-5
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 30
TC 58
Z9 58
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2014
VL 121
IS 8
BP 1612
EP 1619
DI 10.1016/j.ophtha.2014.02.005
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2KR
UT WOS:000341151100026
PM 24661863
DA 2022-11-30
ER

PT J
AU Zarubina, AV
   Neely, DC
   Clark, ME
   Huisingh, CE
   Samuels, BC
   Zhang, YH
   McGwin, G
   Owsley, C
   Curcio, CA
AF Zarubina, Anna V.
   Neely, David C.
   Clark, Mark E.
   Huisingh, Carrie E.
   Samuels, Brian C.
   Zhang, Yuhua
   McGwin, Gerald, Jr.
   Owsley, Cynthia
   Curcio, Christine A.
TI Prevalence of Subretinal Drusenoid Deposits in Older Persons with and
   without Age-Related Macular Degeneration, by Multimodal Imaging
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER OPHTHALMOSCOPY;
   RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; RETICULAR PSEUDODRUSEN;
   GEOGRAPHIC ATROPHY; DARK-ADAPTATION; AUTOFLUORESCENCE CHARACTERISTICS;
   CHOROIDAL NEOVASCULARIZATION; PHOTORECEPTOR TOPOGRAPHY
AB Purpose: To assess the prevalence of subretinal drusenoid deposits (SDD) in older adults with healthy maculas and early and intermediate age-related macular degeneration (AMD) using multimodal imaging.
   Design: Cross-sectional study.
   Participants: A total of 651 subjects aged >= 60 years enrolled in the Alabama Study of Early Age-Related Macular Degeneration from primary care ophthalmology clinics.
   Methods: Subjects were imaged using spectral domain optical coherence tomography (SD OCT) of the macula and optic nerve head (ONH), infrared reflectance, fundus autofluorescence, and color fundus photographs (CFP). Eyes were assessed for AMD presence and severity using the Age-Related Eye Disease Study (AREDS) 9-step scale. Criteria for SDD presence were identification on >= 1 en face modality plus SD OCT or on >= 2 en face modalities if absent on SD OCT. Subretinal drusenoid deposits were considered present at the person level if present in 1 or both eyes.
   Main Outcome Measures: Prevalence of SDD in participants with and without AMD.
   Results: Overall prevalence of SDD was 32% (197/611), with 62% (122/197) affected in both eyes. Persons with SDD were older than those without SDD (70.6 vs. 68.7 years, P = 0.0002). Prevalence of SDD was 23% in subjects without AMD and 52% in subjects with AMD (P < 0.0001). Among those with early and intermediate AMD, SDD prevalence was 49% and 79%, respectively. After age adjustment, those with SDD were 3.4 times more likely to have AMD than those without SDD (95% confidence interval, 2.3-4.9). By using CFP only for SDD detection per the AREDS protocol, prevalence of SDD was 2% (12/610). Of persons with SDD detected by SD OCT and confirmed by at least 1 en face modality, 47% (89/190) were detected exclusively on the ONH SD OCT volume.
   Conclusions: Subretinal drusenoid deposits are present in approximately one quarter of older adults with healthy maculae and in more than half of persons with early to intermediate AMD, even by stringent criteria. The prevalence of SDD is strongly associated with AMD presence and severity and increases with age, and its retinal topography including peripapillary involvement resembles that of rod photoreceptors. Consensus on SDD detection methods is recommended to advance our knowledge of this lesion and its clinical and biologic significance. (C) 2016 by the American Academy of Ophthalmology.
C1 [Zarubina, Anna V.; Neely, David C.; Clark, Mark E.; Huisingh, Carrie E.; Samuels, Brian C.; Zhang, Yuhua; McGwin, Gerald, Jr.; Owsley, Cynthia; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 1670 Univ Blvd,VH 360, Birmingham, AL 35294 USA.
   [Huisingh, Carrie E.; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, 1670 Univ Blvd,VH 360, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, 1670 Univ Blvd,VH 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
OI Huisingh, Carrie/0000-0002-7010-2024; Samuels, Brian/0000-0003-3860-6879
FU National Institute on Aging [R01AG04212]; National Eye Institute
   [R01EY06109, R01EY024378]; National Institutes of Health, Bethesda,
   Maryland; EyeSight Foundation of Alabama, Birmingham, Alabama; Alfreda
   J. Schueler Trust, Chicago, Illinois; Research to Prevent Blindness
   Inc., New York, New York; NATIONAL EYE INSTITUTE [R01EY006109,
   R01EY024378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
FX Funded by the National Institute on Aging (R01AG04212) and National Eye
   Institute (R01EY06109, R01EY024378), National Institutes of Health,
   Bethesda, Maryland; EyeSight Foundation of Alabama, Birmingham, Alabama;
   Alfreda J. Schueler Trust, Chicago, Illinois; and Research to Prevent
   Blindness Inc., New York, New York.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   De Bats Flore, 2013, ISRN Ophthalmol, V2013, P273085, DOI 10.1155/2013/273085
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Eliasieh K, 2007, INVEST OPHTH VIS SCI, V48, P2824, DOI 10.1167/iovs.06-1228
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Hoffmann EM, 2007, SURV OPHTHALMOL, V52, P32, DOI 10.1016/j.survophthal.2006.10.002
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lally DR, 2014, JAMA OPHTHALMOL, V132, P775, DOI 10.1001/jamaophthalmol.2014.387
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Neely D, 2015, INVEST OPHTH VIS SCI, V56
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Owsley C, 2015, CURR EYE RES, V41, P1
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Vongkulsiri S, 2015, RETINA-J RET VIT DIS, V35, P1211, DOI 10.1097/IAE.0000000000000514
   Vongkulsiri S, 2014, AM J OPHTHALMOL, V158, P710, DOI 10.1016/j.ajo.2014.07.009
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2012, KLIN MONATSBL AUGENH, V229, P399, DOI 10.1055/s-0031-1299404
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 82
TC 47
Z9 47
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2016
VL 123
IS 5
BP 1090
EP 1100
DI 10.1016/j.ophtha.2015.12.034
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL9DS
UT WOS:000375942300030
PM 26875000
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Waldstein, SM
   Philip, AM
   Leitner, R
   Simader, C
   Langs, G
   Gerendas, BS
   Schmidt-Erfurth, U
AF Waldstein, Sebastian M.
   Philip, Ana-Maria
   Leitner, Roland
   Simader, Christian
   Langs, Georg
   Gerendas, Bianca S.
   Schmidt-Erfurth, Ursula
TI Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal
   Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENT;
   RANIBIZUMAB; EDEMA; PREDICTORS
AB IMPORTANCE Robust and sensitive imaging biomarkers for visual function are an unmet medical need in the management of neovascular age-related macular degeneration.
   OBJECTIVE To determine the correlation of 3-dimensionally quantified intraretinal cystoid fluid (IRC) and subretinal fluid (SRF) with best-corrected visual acuity (BCVA) in treatment-naive neovascular age-related macular degeneration and during antiangiogenic therapy.
   DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study between November 2009 and November 2011 at an institutional referral center and reading center of patients with treatment-naive subfoveal choroidal neovascularization receiving intravitreal ranibizumab or aflibercept over 12 months. All individual IRC and SRF lesions were manually delineated on each of the 128 B-scan sections of spectral-domain optical coherence tomographic volume scans at baseline and months 1, 6, and 12. Correlations were computed between the IRC and SRF parameters and the baseline BCVA, final BCVA, and BCVA change. A systematic parameter search was conducted to detect annotation-derived variables with best predictive value. An exponential model for BCVA change balancing for the ceiling effect was constructed.
   MAIN OUTCOMES AND MEASURES Goodness of fit of correlations between the IRC and SRF parameters and the baseline BCVA, final BCVA, and BCVA change.
   RESULTS Thirty-eight patients were included (25 female, 13 male; mean [SD] age at enrollment, 78.49 [8.23] years; mean [SD] BCVA score at baseline, 54 [16] Early Treatment Diabetic Retinopathy Study letters [Snellen equivalent approximately 20/160], with a gain to 63 [19] letters [Snellen equivalent approximately 20/100] at month 12). A total of 19 456 scans underwent complete quantification of IRC and SRF. The best correlation with BCVA at baseline was achieved using a coverage-based, foveal area-weighted IRC parameter (R-2 = 0.59; P < .001). The same baseline parameter also predicted BCVA at 12 months (R-2 = 0.21; P = .003). The BCVA gain correlated with IRC decrease in the exponential model (R-2 = 0.40; P < .001) and linear model (R-2 = 0.25; P = .002). No robust associations were found between SRF and baseline BCVA (R-2 = 0.06; P = .14) or BCVA change (R-2 = 0.14; P = .02).
   CONCLUSIONS AND RELEVANCE In this proof-of-principle study, IRC-derived morphometric variables correlated well with treatment-naive BCVA and BCVA outcomes in antiangiogenic therapy. While IRC reduction was associated with BCVA gains, some IRC-mediated neurosensory damage remained permanent.
C1 [Waldstein, Sebastian M.; Philip, Ana-Maria; Leitner, Roland; Simader, Christian; Gerendas, Bianca S.; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, AT-1090 Vienna, Austria.
   [Langs, Georg] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Computat Imaging Res Lab, Christian Doppler Lab Ophthalm Image Anal, AT-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Spitalgasse 23, AT-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Langs, Georg/0000-0002-5536-6873; Gerendas, Bianca
   S./0000-0001-8940-8130; Waldstein, Sebastian/0000-0003-2899-6279;
   Schmidt-Erfurth, Ursula/0000-0002-7788-7311
FU Austrian Federal Ministry of Economy, Family and Youth; National
   Foundation for Research, Technology and Development; Christian Doppler
   Research Association
FX This study was supported by the Austrian Federal Ministry of Economy,
   Family and Youth and the National Foundation for Research, Technology
   and Development and by a grant from the Christian Doppler Research
   Association.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Liu MM, 2015, INVEST OPHTH VIS SCI, V56
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Montuoro A, 2014, LECT NOTES COMPUT SC, V8674, P130, DOI 10.1007/978-3-319-10470-6_17
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Sophie R, 2015, OPHTHALMOLOGY, V122, P1395, DOI 10.1016/j.ophtha.2015.02.036
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wu J, 2014, OPHTH MED IM AN 1 IN
NR 25
TC 66
Z9 66
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB
PY 2016
VL 134
IS 2
BP 182
EP 190
DI 10.1001/jamaophthalmol.2015.4948
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH1JK
UT WOS:000372540000017
PM 26661463
OA Bronze
DA 2022-11-30
ER

PT J
AU Keel, S
   Li, ZX
   Scheetz, J
   Robman, L
   Phung, J
   Makeyeva, G
   Aung, K
   Liu, C
   Yan, XX
   Meng, W
   Guymer, R
   Chang, R
   He, MG
AF Keel, Stuart
   Li, Zhixi
   Scheetz, Jane
   Robman, Liubov
   Phung, James
   Makeyeva, Galina
   Aung, KhinZaw
   Liu, Chi
   Yan, Xixi
   Meng, Wei
   Guymer, Robyn
   Chang, Robert
   He, Mingguang
TI Development and validation of a deep-learning algorithm for the
   detection of neovascular age-related macular degeneration from colour
   fundus photographs
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE deep-learning algorithm; age-related macular degeneration;
   retinal-imaging
ID DIABETIC-RETINOPATHY; FEATURES; IMAGES
AB Importance Detection of early onset neovascular age-related macular degeneration (AMD) is critical to protecting vision. Background To describe the development and validation of a deep-learning algorithm (DLA) for the detection of neovascular age-related macular degeneration. Design Development and validation of a DLA using retrospective datasets. Participants We developed and trained the DLA using 56 113 retinal images and an additional 86 162 images from an independent dataset to externally validate the DLA. All images were non-stereoscopic and retrospectively collected. Methods The internal validation dataset was derived from real-world clinical settings in China. Gold standard grading was assigned when consensus was reached by three individual ophthalmologists. The DLA classified 31 247 images as gradable and 24 866 as ungradable (poor quality or poor field definition). These ungradable images were used to create a classification model for image quality. Efficiency and diagnostic accuracy were tested using 86 162 images derived from the Melbourne Collaborative Cohort Study. Neovascular AMD and/or ungradable outcome in one or both eyes was considered referable. Main Outcome Measures Area under the receiver operating characteristic curve (AUC), sensitivity and specificity. Results In the internal validation dataset, the AUC, sensitivity and specificity of the DLA for neovascular AMD was 0.995, 96.7%, 96.4%, respectively. Testing against the independent external dataset achieved an AUC, sensitivity and specificity of 0.967, 100% and 93.4%, respectively. More than 60% of false positive cases displayed other macular pathologies. Amongst the false negative cases (internal validation dataset only), over half (57.2%) proved to be undetected detachment of the neurosensory retina or RPE layer. Conclusions and Relevance This DLA shows robust performance for the detection of neovascular AMD amongst retinal images from a multi-ethnic sample and under different imaging protocols. Further research is warranted to investigate where this technology could be best utilized within screening and research settings.
C1 [Keel, Stuart; Scheetz, Jane; Robman, Liubov; Makeyeva, Galina; Aung, KhinZaw; Yan, Xixi; Guymer, Robyn; He, Mingguang] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Li, Zhixi; He, Mingguang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Robman, Liubov; Phung, James] Monash Univ Melbourne, Melbourne, Vic, Australia.
   [Liu, Chi; Meng, Wei] Healgoo Interact Med Technol Co Ltd, Guangzhou, Guangdong, Peoples R China.
   [Chang, Robert] Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Palo Alto, CA 94304 USA.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Sun Yat Sen University; Monash University;
   Stanford University
RP He, MG (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM mingguang.he@unimelb.edu.au
RI He, Mingguang/AAY-5239-2020
OI He, Mingguang/0000-0002-6912-2810
FU National Key R&D Program of China [2018YFC0116500]; Fundamental Research
   Funds of the State Key Laboratory in Ophthalmology; National Natural
   Science Foundation of China [81420108008]; Bupa Health Foundation
   Australia grant; MACH 2018 MRFF Rapid Applied Research Translation
   grant; University of Melbourne at Research Accelerator Program; CERA
   Foundation; Victorian State Government; VicHealth; Cancer Council
   Victoria; National Health & Medical Research Council of Australia
   (NHMRC) [209 057, 251 533, 396 414]; Ophthalmic Research Institute of
   Australia; American Health Assistance Foundation; John Reid Charitable
   Trust; Royal Victorian Eye and Ear Hospital; Jack Brockhoff Foundation;
   Perpetual Trustees
FX This research was supported in part by the National Key R&D Program of
   China (2018YFC0116500), Fundamental Research Funds of the State Key
   Laboratory in Ophthalmology, National Natural Science Foundation of
   China (81420108008), Bupa Health Foundation Australia grant, and a MACH
   2018 MRFF Rapid Applied Research Translation grant. Prof. Mingguang He
   receives support from the University of Melbourne at Research
   Accelerator Program and the CERA Foundation. The Centre for Eye Research
   Australia receives Operational Infrastructure Support from the Victorian
   State Government.; Cohort recruitment in the MCCS was funded by
   VicHealth and The Cancer Council Victoria. Further MCCS funding: the
   National Health & Medical Research Council of Australia (NHMRC) Program
   Grant 209 057, Capacity Building Grant 251 533 and Enabling Grant 396
   414. The ophthalmic component was funded by the Ophthalmic Research
   Institute of Australia; American Health Assistance Foundation, Jack
   Brockhoff Foundation, John Reid Charitable Trust, Perpetual Trustees and
   Royal Victorian Eye and Ear Hospital.
CR Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Castelvecchi D, 2016, NATURE, V537, P20, DOI 10.1038/538020a
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frcophth AT, 2017, OPHTHALMOLOGY, V124, P343, DOI 10.1016/j.ophtha.2016.11.014
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Keel S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22612-2
   Li ZX, 2018, DIABETES CARE, V41, P2509, DOI 10.2337/dc18-0147
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Milne RL, 2017, INT J EPIDEMIOL, V46, P1757, DOI 10.1093/ije/dyx085
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Robman LD, 2015, OPHTHAL EPIDEMIOL, V22, P75, DOI 10.3109/09286586.2015.1010688
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2016, JAMA-J AM MED ASSOC, V316, P2366, DOI 10.1001/jama.2016.17563
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 25
TC 33
Z9 33
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2019
VL 47
IS 8
BP 1009
EP 1018
DI 10.1111/ceo.13575
EA JUL 2019
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JO4BS
UT WOS:000479387700001
PM 31215760
OA Green Published
DA 2022-11-30
ER

PT J
AU Kenealy, SJ
   Schmidt, S
   Agarwal, A
   Postel, EA
   De la Paz, M
   Pericak-Vance, MA
   Haines, JL
AF Kenealy, SJ
   Schmidt, S
   Agarwal, A
   Postel, EA
   De la Paz, M
   Pericak-Vance, MA
   Haines, JL
TI Linkage analysis for age-related macular degeneration supports a gene on
   chromosome 10q26
SO MOLECULAR VISION
LA English
DT Article
ID STARGARDT-DISEASE GENE; APOLIPOPROTEIN-E GENE; ALZHEIMERS-DISEASE;
   GENOME SCAN; MACULOPATHY; ASSOCIATION; ALLELE; MUTATIONS; RISK; ABCR
AB PURPOSE: Age-related macular degeneration (AMD) is a retinal degenerative disease that is the leading cause of blindness worldwide in individuals over the age of 60. Although the etiology of AMD remains largely unknown, numerous studies have suggested both genetic and environmental influences. A previous study of affected multiplex families identified four chromosomal regions that potentially harbor AMD susceptibility genes. The purpose of our study was to further investigate these regions with additional microsatellite marker coverage in our independent data set.
   METHODS: We examined regions on chromosomes 1q, 9p, 10q, and 17q for genetic linkage in our 70 multiplex families (consisting of 133 affected sibpairs). Two point heterogeneity LOD score (HLOD) and nonparametric LOD score (MLS) analyses were performed for disease models defined by the most severe status in either eye. Conditional analyses were performed using apolipoprotein E (APOE) alleles as covariates in semiparametric LOD (LOD*) score calculations.
   RESULTS: Regions on chromosomes 1q, 9p, and 17q did not provide evidence of linkage in our data set. However, markers D10S1230 and D10S1656 on chromosome 10q26 generated maximum HLOD scores of 1.52 and 1.13, respectively. Marker D10S1230 also generated an MLS score of 1.56 in stage 4 and 5 individuals. Controlling for the potential effect of the APOE-epsilon4 allele did not substantially alter these scores.
   CONCLUSIONS: With the inclusion of this study, at least five AMD data sets provide support of genetic linkage to 10q26. Such consistency and confirmation of evidence strongly suggests that this region should be the subject of further detailed genomic efforts for the disease.
C1 Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Nashville, TN 37232 USA.
   Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA.
   Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Vanderbilt University; Vanderbilt University; Duke University; Duke
   University; Duke University
RP Haines, JL (通讯作者)，Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, 519 Light Hall, Nashville, TN 37232 USA.
EM jonathan@chgr.mc.vanderbilt.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728
FU NEI NIH HHS [EY12118] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [U10EY012118, R01EY012118] Funding Source: NIH RePORTER
CR Akimoto A, 2001, GRAEF ARCH CLIN EXP, V239, P66, DOI 10.1007/PL00007900
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   AYYAGARI R, 2002, OPHTHALMIC GENET, V23, P198
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   GORING HHH, 1995, AM J HUM GENET, V57, P1102
   Greenberg DA, 2001, GENET EPIDEMIOL, V21, P299, DOI 10.1002/gepi.1036
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P571
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Klaver C. C. W., 1996, Investigative Ophthalmology and Visual Science, V37, pS413
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   Li YJ, 2002, AM J HUM GENET, V71, P450
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   OTT J, 1986, AM J HUM GENET, V39, P159
   PLOUGHMAN LM, 1989, AM J HUM GENET, V44, P543
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rozen S, 2000, Methods Mol Biol, V132, P365
   SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U
   SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222
   Schmidt S, 2002, AM J HUM GENET, V70, P708, DOI 10.1086/339269
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   SUAREZ BK, 1994, GENETIC APPROACHES M, P23
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213
   WROBLEWSKI JJ, 1994, OPHTHALMOLOGY, V101, P12
   Wu WS, 1998, JAMA-J AM MED ASSOC, V280, P619, DOI 10.1001/jama.280.7.619
NR 52
TC 57
Z9 63
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 26
PY 2004
VL 10
IS 7-9
BP 57
EP 61
PG 5
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 769MG
UT WOS:000188653400002
PM 14758336
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Hegel, MT
   Massof, RW
   Leiby, BE
   Ho, AC
   Tasman, WS
AF Rovner, Barry W.
   Casten, Robin J.
   Hegel, Mark T.
   Massof, Robert W.
   Leiby, Benjamin E.
   Ho, Allen C.
   Tasman, William S.
TI Personality and Functional Vision in Older Adults with Age-Related
   Macular Degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID SOMATIC COMPLAINTS; DEPRESSION; NEUROTICISM; REHABILITATION; VALIDITY;
   OUTCOMES; DISEASE; HEALTH; QUESTIONNAIRE; ASSOCIATION
AB Introduction: The purpose of the study was to determine whether personality traits influence self-reported functional vision in patients with age-related macular degeneration (AMD). Methods: This is a prospective cross-sectional analysis of baseline data from the Low Vision Depression Prevention Trial. Participants (N = 182) over age 65 with bilateral AMD, visual acuity worse than 20/70 in the better-seeing eye, and subthreshold depression were recruited from the Wills Eye Hospital retina practice. Assessments included visual acuity, contrast sensitivity, National Eye Institute Visual Function Questionnaire-25 plus Supplement (NEI VFQ-25) near and distance subscales, depression, and personality testing. Structural equation models were used to investigate the relationship of the NEI VFQ near activities and distance activities with the various demographic, clinical, and psychological predictors. Results: In the single-predictor model for near functional vision, visual acuity at logMAR <= 1 (estimate = -0.33 [95% confidence interval {CI} -0.46, -0.20]; p <= 0.001), neuroticism (estimate = -0.05 [95% CI -0.08, -0.01]; p = 0.01), and education (estimate = -0.08 [95% CI 0.01, 0.15]; p = 0.03) were statistically significant predictors. In the single-predictor model for distance functional vision, only visual acuity at logMAR <= 1 (estimate = -0.49 [95% CI -0.69, -0.29]; p <= 0.001) and neuroticism (estimate = -0.09 [95% CI -0.15, 0.02]; p = 0.008) were statistically significant predictors. Discussion: Self-reported functional vision depends on the severity of vision loss as well as the personality trait of neuroticism. Implications for practitioners: Assessment of personality traits, particularly neuroticism, may increase the precision of rating scales of functional vision and suggest new rehabilitative interventions to improve the functional vision and quality of life of patients with AMD.
C1 [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Hosp Neurosci, Dept Psychiat, Philadelphia, PA 19107 USA.
   [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Hosp Neurosci, Dept Neurol, Philadelphia, PA 19107 USA.
   [Casten, Robin J.] Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Hosp Neurosci, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   [Hegel, Mark T.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03756 USA.
   [Hegel, Mark T.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Dept Community & Family Med, Lebanon, NH 03756 USA.
   [Massof, Robert W.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Baltimore, MD 21205 USA.
   [Leiby, Benjamin E.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA.
   [Ho, Allen C.; Tasman, William S.] Wills Eye Hosp & Res Inst, Philadelphia, PA 19107 USA.
   [Ho, Allen C.; Tasman, William S.] Jefferson Med Coll, Dept Ophthalmol, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Jefferson University;
   Dartmouth College; Dartmouth College; Johns Hopkins University; Johns
   Hopkins Medicine; Jefferson University; Jefferson University; Jefferson
   University
RP Rovner, BW (通讯作者)，Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Hosp Neurosci, Dept Psychiat, 900 Walnut St, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu; robin.casten@jefferson.edu;
   mark.t.hegel@Dartmouth.edu; rmassof@lions.med.jhu.edu;
   benjamin.leiby@jefferson.edu; acho@att.ne; wst1@ureach.com
OI Ho, Allen/0000-0003-3921-608X
CR Alma MA, 2013, J VISUAL IMPAIR BLIN, V107, P5, DOI 10.1177/0145482X1310700101
   Andrews G, 1996, BRIT J PSYCHIAT, V168, P76, DOI 10.1192/S0007125000298449
   [Anonymous], 1990, PERSONALITY ADULTHOO
   Boerner K, 2006, CLIN REHABIL, V20, P478, DOI 10.1191/0269215506cr965oa
   Casten R. J., LOW VISION DEP UNPUB
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Colenbrander A., 2005, INT C SERIES, V1282, P482, DOI DOI 10.1016/J.ICS.2005.05.002
   Costa P.T., 1992, REVISED NEO PERSONAL
   COSTA PT, 1987, J PERS, V55, P299, DOI 10.1111/j.1467-6494.1987.tb00438.x
   COSTA PT, 1985, AM PSYCHOL, V40, P19, DOI 10.1037/0003-066X.40.1.19
   Cuijpers P, 2010, ARCH GEN PSYCHIAT, V67, P1086, DOI 10.1001/archgenpsychiatry.2010.130
   Goldstein JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1028, DOI 10.1001/archophthalmol.2012.1197
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91
   Lockenhoff CE, 2008, J RES PERS, V42, P1334, DOI 10.1016/j.jrp.2008.05.006
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   McCrae RR, 2011, PERS SOC PSYCHOL REV, V15, P28, DOI 10.1177/1088868310366253
   McKean-Cowdin R, 2010, OPHTHALMOLOGY, V117, P1900, DOI 10.1016/j.ophtha.2010.01.059
   Moustaki I, 2003, BRIT J MATH STAT PSY, V56, P337, DOI 10.1348/000711003770480075
   Muthen LK., 2017, MPLUS USERS GUIDE VE, V8
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   Rees G, 2009, OPTOMETRY VISION SCI, V86, P1328, DOI 10.1097/OPX.0b013e3181c07a55
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rovner BW, 2006, OPHTHALMOLOGY, V113, P1743, DOI 10.1016/j.ophtha.2006.05.033
   Rovner BW, 2011, ARCH OPHTHALMOL-CHIC, V129, P885, DOI 10.1001/archophthalmol.2011.146
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Russo J, 1997, PSYCHOSOMATICS, V38, P339, DOI 10.1016/S0033-3182(97)71441-5
   Ryan B, 2008, OPTOMETRY VISION SCI, V85, P112, DOI 10.1097/OPX.0b013e31816225dc
   Skrondal A, 2004, GEN LATENT VARIABLE, V1st, DOI DOI 10.1201/9780203489437
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   Tabrett DR, 2012, INVEST OPHTH VIS SCI, V53, P7227, DOI 10.1167/iovs.12-10404
   Tang TZ, 2009, ARCH GEN PSYCHIAT, V66, P1322, DOI 10.1001/archgenpsychiatry.2009.166
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   Warrian KJ, 2009, BRIT J OPHTHALMOL, V93, P310, DOI 10.1136/bjo.2008.139592
   Whitson HE, 2012, J AM GERIATR SOC, V60, P2087, DOI 10.1111/j.1532-5415.2012.04194.x
   Wray NR, 2008, ARCH GEN PSYCHIAT, V65, P649, DOI 10.1001/archpsyc.65.6.649
   Zhang XC, 2013, ANN I H POINCARE-AN, V30, P573, DOI 10.1016/j.anihpc.2012.10.006
NR 44
TC 2
Z9 2
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD MAY-JUN
PY 2014
VL 108
IS 3
BP 187
EP 199
PG 13
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA CA8RM
UT WOS:000349188600003
DA 2022-11-30
ER

PT J
AU Khurana, RN
   Kunimoto, D
   Yoon, YH
   Wykoff, CC
   Chang, A
   Maturi, RK
   Agostini, H
   Souied, E
   Chow, DR
   Lotery, AJ
   Ohji, M
   Bandello, F
   Belfort, R
   Li, XY
   Jiao, J
   Le, G
   Kim, K
   Schmidt, W
   Hashad, Y
AF Khurana, Rahul N.
   Kunimoto, Derek
   Yoon, Young Hee
   Wykoff, Charles C.
   Chang, Andrew
   Maturi, Raj K.
   Agostini, Hansjuergen
   Souied, Eric
   Chow, David R.
   Lotery, Andrew J.
   Ohji, Masahito
   Bandello, Francesco
   Belfort Jr, Rubens
   Li, Xiao-Yan
   Jiao, Jenny
   Le, Grace
   Kim, Kimmie
   Schmidt, Werner
   Hashad, Yehia
TI Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar
   in Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
DE Abicipar; Anti-VEGF; Choroidal neovascularization; DARPin therapeutic;
   Intravitreal injection; Neovascular age-related macular degeneration;
   Ranibizumab; Treatment burden; Visual acuity
ID MANAGEMENT; BLINDNESS; PEGOL
AB Purpose: To report the 2-year efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) compared with monthly ranibizumab in patients with treatment-naive neovascular age-related macular degeneration (nAMD).
   Design: Two multicenter, randomized, phase 3 clinical trials with identical protocols (CEDAR and SEQUOIA). Analyses used pooled trial data.
   Participants: The trials enrolled 1888 patients (1 eye/patient) with active choroidal neovascularization secondary to age-related macular degeneration and best-corrected visual acuity (BCVA) of 24 to 73 Early Treatment Diabetic Retinopathy Study letters.
   Methods: At enrollment, patients were assigned to study eye treatment with abicipar 2 mg every 8 weeks after initial doses at baseline and weeks 4 and 8 (abicipar Q8, n = 630), abicipar 2 mg every 12 weeks after initial doses at baseline and weeks 4 and 12 (abicipar Q12, n = 628), or ranibizumab 0.5 mg every 4 weeks (ranibizumab Q4, n = 630).
   Main Outcome Measures: Efficacy measures included stable vision(<15-letter loss in BCVA from baseline) and change from baseline in BCVA and central retinal thickness (CRT). Safety measures included adverse events (AEs).
   Results: For patients who completed the study, efficacy of abicipar after initial doses was maintained through week 104. At week 104, the proportion of patients with stable vision was 93.0% (396/426), 89.8% (379/422), and 94.4% (470/498); mean change in BCVA from baseline was +7.8 letters, +6.1 letters, and +8.5 letters, and mean change in CRT from baseline was -147 mu m, -146 mu m, and -142 mu m in the abicipar Q8 (14 injections), abicipar Q12 (10 injections), and ranibizumab Q4 (25 injections) groups, respectively. The overall incidence of intraocular inflammation (IOI) AEs was 15.4%, 15.3%, and 0.3% from baseline through week 52 and 16.2%, 17.6%, and 1.3% from baseline through week 104 in the abicipar Q8, abicipar Q12, and ranibizumab Q4 groups, respectively.
   Conclusions: Two-year results show efficacy of abicipar Q8 and Q12 in nAMD. First onset of IOI events with abicipar was much reduced in the second year and comparable with ranibizumab (0.8% and 2.3% vs. 1.0%). The extended duration of effect of abicipar allows for quarterly dosing and reduced treatment burden. (C) 2020 by the American Academy of Ophthalmology.
C1 [Khurana, Rahul N.] Northern Calif Retina Vitreous Associates, 2495 Hosp Dr,545, Mountain View, CA 94040 USA.
   [Kunimoto, Derek] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Yoon, Young Hee] Univ Ulsan, Asan Med Ctr, Seoul, South Korea.
   [Wykoff, Charles C.] Retina Consultants Houston, Houston, TX USA.
   [Chang, Andrew] Sydney Retina Clin, Sydney, NSW, Australia.
   [Chang, Andrew] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Maturi, Raj K.] Midwest Eye Inst, Indianapolis, IN USA.
   [Maturi, Raj K.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Agostini, Hansjuergen] Univ Freiburg, Fac Med, Eye Ctr, Med Ctr, Freiburg, Germany.
   [Souied, Eric] Serv Univ Ophthalmol, Ctr Hosp Creteil, Creteil, France.
   [Chow, David R.] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada.
   [Chow, David R.] Toronto Retina Inst, N York, ON, Canada.
   [Lotery, Andrew J.] Univ Southampton, Southampton, Hants, England.
   [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Bandello, Francesco] Hosp San Raffaele, Univ Vita Salute Sci Inst, Milan, Italy.
   [Belfort Jr, Rubens] Univ Fed Sao Paulo, Vis Inst, Sao Paulo, Brazil.
   [Li, Xiao-Yan; Jiao, Jenny; Le, Grace; Kim, Kimmie; Schmidt, Werner; Hashad, Yehia] Allergan, Irvine, CA USA.
C3 University of Ulsan; University of Sydney; Indiana University System;
   Indiana University Bloomington; University of Freiburg; Assistance
   Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil; University of Toronto; University
   Toronto Affiliates; Saint Michaels Hospital Toronto; University of
   Southampton; Shiga University of Medical Science; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele; Universidade Federal
   de Sao Paulo (UNIFESP); AbbVie; Allergan
RP Khurana, RN (通讯作者)，Northern Calif Retina Vitreous Associates, 2495 Hosp Dr,545, Mountain View, CA 94040 USA.
EM rnkhurana@gmail.com
OI bandello, francesco/0000-0003-3238-9682; Khurana,
   Rahul/0000-0001-5198-1353
FU Allergan plc, Dublin, Ireland; AbbVie
FX Sponsored by Allergan plc, Dublin, Ireland (before its acquisition by
   AbbVie, Inc, North Chicago, Illinois). The sponsor participated in the
   design of the study, data management, data analysis, interpretation of
   the data, and preparation, review, and approval of the manuscript.
   Evidence Scientific Solutions, Inc, Philadelphia, Pennsylvania, prepared
   a draft of the manuscript under the direction of the authors and
   provided editorial assistance, funded by AbbVie. All authors met the
   ICMJE authorship criteria. Neither honoraria nor payments were made for
   authorship.
CR Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kunimoto D, 2019, OPHTHALMIC SURG LASE, V50, pE22
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
NR 24
TC 14
Z9 14
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2021
VL 128
IS 7
BP 1027
EP 1038
DI 10.1016/j.ophtha.2020.11.017
EA JUN 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TB1BR
UT WOS:000667677700015
PM 33221326
OA hybrid
DA 2022-11-30
ER

PT J
AU Zareparsi, S
   Branham, KEH
   Li, MY
   Shah, S
   Klein, RJ
   Ott, J
   Hoh, J
   Abecasis, GR
   Swaroop, A
AF Zareparsi, S
   Branham, KEH
   Li, MY
   Shah, S
   Klein, RJ
   Ott, J
   Hoh, J
   Abecasis, GR
   Swaroop, A
TI Strong association of the Y402H variant in complement factor H at 1q32
   with susceptibility to age-related macular degeneration
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID C-REACTIVE PROTEIN; GENOMEWIDE-SCAN; MALATTIA LEVENTINESE; GENETIC
   ASSOCIATION; APOLIPOPROTEIN-E; DRUSEN FORMATION; LINKAGE; LOCUS; COMMON;
   POLYMORPHISM
AB Using a large sample of cases and controls from a single center, we show that a T -> C substitution in exon 9 ( Y402H) of the complement factor H gene is strongly associated with susceptibility to age- related macular degeneration, the most common cause of blindness in the elderly. Frequency of the C allele was 0.61 in cases, versus 0.34 in age-matched controls (P < 1x10(-24)). Genotype frequencies also differ markedly between cases and controls ( x(2)=112.68 [ 2 degrees of freedom]; P < 1x10(-24)). A multiplicative model fits the data well, and we estimate the population frequency of the high- risk C allele to be 0.39 ( 95% confidence interval 0.36 - 0.42) and the genotype relative risk to be 2.44 ( 95% confidence interval 2.08 - 2.83) for TC heterozygotes and 5.93 ( 95% confidence interval 4.33 - 8.02) for CC homozygotes.
C1 Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Biostat, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA.
   Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; Rockefeller University; Yale University
RP Swaroop, A (通讯作者)，Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM swaroop@umich.edu
RI Branham, Kari/AAA-8336-2022; Abecasis, Goncalo R/B-7840-2010; Klein,
   Robert/K-1888-2013
OI Klein, Robert/0000-0003-3539-5391; Branham, Kari/0000-0002-2492-254X;
   Swaroop, Anand/0000-0002-1975-1141; Abecasis,
   Goncalo/0000-0003-1509-1825
FU NEI NIH HHS [F32-EY014085, P30-EY007003, R01-EY15771, P30 EY007003, F32
   EY014085, R01 EY015771] Funding Source: Medline; NHGRI NIH HHS
   [K25-HG000060, K25 HG000060] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [P30EY007003, F32EY014085, R01EY015771] Funding Source: NIH
   RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K25HG000060] Funding
   Source: NIH RePORTER
CR Abecasis GR, 2005, HUM HERED, V59, P118, DOI 10.1159/000085226
   Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Goring HHH, 2001, AM J HUM GENET, V69, P1357, DOI 10.1086/324471
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li MY, 2005, AM J HUM GENET, V76, P934, DOI 10.1086/430277
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   RISCH N, 1990, AM J HUM GENET, V46, P222
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wittke-Thompson JK, 2005, AM J HUM GENET, V76, P967, DOI 10.1086/430507
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   ZAREPARSI S, 2005, HUM MOL GENET
NR 35
TC 285
Z9 342
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUL
PY 2005
VL 77
IS 1
BP 149
EP 153
DI 10.1086/431426
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 935PP
UT WOS:000229794500015
PM 15895326
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Zekavat, SM
   Sekimitsu, S
   Ye, YX
   Raghu, V
   Zhao, HY
   Elze, T
   Segre, AV
   Wiggs, JL
   Natarajan, P
   Del Priore, L
   Zebardast, N
   Wang, JC
AF Zekavat, Seyedeh Maryam
   Sekimitsu, Sayuri
   Ye, Yixuan
   Raghu, Vineet
   Zhao, Hongyu
   Elze, Tobias
   Segre, Ayellet, V
   Wiggs, Janey L.
   Natarajan, Pradeep
   Del Priore, Lucian
   Zebardast, Nazlee
   Wang, Jay C.
TI Photoreceptor Layer Thinning Is an Early Biomarker for Age-Related
   Macular Degeneration Epidemiologic and Genetic Evidence from UK Biobank
   OCT Data
SO OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Genetics; OCT; Photoreceptor thinning;
   Epidemiology
ID TISSUE INHIBITOR; THICKNESSES; MACULOPATHY; PREDICTION; MODEL; EYE
AB Purpose: Despite widespread use of OCT, an early-stage imaging biomarker for age-related macular degeneration (AMD) has not been identified. Pathophysiologically, the timing of drusen accumulation in relationship to photoreceptor degeneration in AMD remains unclear, as are the inherited genetic variants contributing to these processes. Herein, we jointly analyzed OCT, electronic health record data, and genomic data to characterize the time sequence of changes in retinal layer thicknesses in AMD, as well as epidemiologic and genetic associations between retinal layer thicknesses and AMD.
   Design: Cohort study.
   Participants: Forty-four thousand eight hundred twenty-three individuals from the UK Biobank (enrollment age range, 40-70 years; 54% women; median follow-up, 10 years).
   Methods: The Topcon Advanced Boundary Segmentation algorithm was used for retinal layer segmentation. We associated 9 retinal layer thicknesses with prevalent AMD (present at enrollment) in a logistic regression model and with incident AMD (diagnosed after enrollment) in a Cox proportional hazards model. Next, we associated AMD-associated genetic alleles, individually and as a polygenic risk score (PRS), with retinal layer thicknesses. All analyses were adjusted for age, age-squared (age(2)), sex, smoking status, and principal components of ancestry.
   Main Outcome Measures: Prevalent and incident AMD.
   Results: Photoreceptor segment (PS) thinning was observed throughout the lifespan of individuals analyzed, whereas retinal pigment epithelium (RPE) and Bruch's membrane (BM) complex thickening started after 57 years of age. Each standard deviation (SD) of PS thinning and RPE-BM complex thickening was associated with incident AMD (PS: hazard ratio [HR], 1.35; 95% confidence interval [CI], 1.23-1.47; P = 3.7 x 10(-11); RPE-BM complex: HR, 1.14; 95% CI, 1.06-1.22; P = 0.00024). The AMD PRS was associated with PS thinning (beta, -0.21 SD per twofold genetically increased risk of AMD; 95% CI, -0.23 to -0.19; P = 2.8 x 10(-74)), and its association with RPE-BM complex was U-shaped (thinning with AMD PRS less than the 92nd percentile and thickening with AMD PRS more than the 92nd percentile). The loci with strongest support for genetic correlation were AMD risk-raising variants Complement Factor H (CFH):rs570618-T, CFH:rs10922109-C, and Age-Related Maculopathy Susceptibility 2 (ARMS2)/High-Temperature Requirement Serine Protease 1 (HTRA1):rs3750846-C on PS thinning and SYN3iTissue Inhibitor of Metalloprotease 3 (T/MP3):rs5754227-T on RPE-BM complex thickening.
   Conclusions: Epidemiologically, PS thinning precedes RPE-BM complex thickening by decades and is the retinal layer most strongly predictive of future AMD risk. Genetically, AMD risk variants are associated with decreased PS thickness. Overall, these findings support PS thinning as an early-stage biomarker for future AMD development. (C) 2022 by the American Academy of Ophthalmology
C1 [Zekavat, Seyedeh Maryam; Del Priore, Lucian; Wang, Jay C.] Yale Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT USA.
   [Zekavat, Seyedeh Maryam; Ye, Yixuan; Zhao, Hongyu] Yale Univ, Computat Biol & Bioinformat Program, New Haven, CT USA.
   [Zekavat, Seyedeh Maryam; Raghu, Vineet; Natarajan, Pradeep] Broad Inst MIT & Harvard, Program Med & Populat Genet & Cardiovasc Dis Init, Cambridge, MA 02142 USA.
   [Zekavat, Seyedeh Maryam; Raghu, Vineet; Natarajan, Pradeep] Harvard Med Sch, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02115 USA.
   [Sekimitsu, Sayuri] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Raghu, Vineet] Harvard Med Sch, Massachusetts Gen Hosp, Cardiovasc Imaging Res Ctr, Boston, MA 02115 USA.
   [Zhao, Hongyu] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
   [Elze, Tobias; Segre, Ayellet, V; Wiggs, Janey L.; Zebardast, Nazlee] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02115 USA.
   [Wang, Jay C.] Northern Calif Retina Vitreous Associates, 2495 Hosp Dr,Suite 545, Mountain View, CA 94040 USA.
C3 Yale University; Yale University; Harvard University; Massachusetts
   Institute of Technology (MIT); Broad Institute; Harvard University;
   Harvard Medical School; Massachusetts General Hospital; Tufts
   University; Harvard University; Harvard Medical School; Massachusetts
   General Hospital; Yale University; Harvard University; Harvard Medical
   School; Massachusetts Eye & Ear Infirmary
RP Wang, JC (通讯作者)，Northern Calif Retina Vitreous Associates, 2495 Hosp Dr,Suite 545, Mountain View, CA 94040 USA.
EM jay.wang@yale.edu
OI Sekimitsu, Sayuri/0000-0002-6480-8880; Ye, Yixuan/0000-0002-2643-665X;
   Natarajan, Pradeep/0000-0001-8402-7435
FU National Heart, Lung, and Blood Institute [1F30HL149180-01, R01HL1427,
   R01HL148565, R01HL148050]; National Eye Institute [R01 EY031424-0,
   R01EY020928, R01EY022305, R01EY031820, R01EY032559, 1K23EY032634];
   National Institutes of Health Medical Scientist Training Program
   Training Grant, Bethesda, Maryland [T32GM136651]; Hassenfeld Scholar
   Award from Massachusetts General Hospital, Boston, Massachusetts
FX Supported by the National Heart, Lung, and Blood Institute (grant nos.:
   1F30HL149180-01 [S.M.Z.], R01HL1427 [P.N.], R01HL148565 [P.N.], and
   R01HL148050 [P.N.]), the National Eye Institute (grant nos.: R01
   EY031424-0 [A.V.S.], R01EY020928 [J.L.W.], R01EY022305 [J.L.W.],
   R01EY031820 [J.L.W.], R01EY032559 [J.L.W.], and 1K23EY032634 N.Z.), and
   the National Institutes of Health Medical Scientist Training Program
   Training Grant, Bethesda, Maryland (grant no.: T32GM136651 [S.M.Z.]);
   and the Hassenfeld Scholar Award from Massachusetts General Hospital,
   Boston, Massachusetts (P.N.). HUMAN SUBJECTS: Human subjects were
   included in this study. Massachusetts General Hospital Institutional
   Review Board (protocol 2021P002040) and facilitated through UK Biobank
   Applications 7089 and 50211. All research adhered to the tenets of the
   Declaration of Helsinki, and all participants provided informed consent.
CR Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Chua SYL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55484-1
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Currant H, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009497
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gao XR, 2019, HUM MOL GENET, V28, P1162, DOI 10.1093/hmg/ddy422
   Ge T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09718-5
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Keane PA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164095
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Macgregor AM, 2009, J HISTOCHEM CYTOCHEM, V57, P207, DOI 10.1369/jhc.2008.952531
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P181, DOI 10.1136/bjo.63.3.181
   McHugh KJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216215
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Oura Y, 2018, AM J PATHOL, V188, P2729, DOI 10.1016/j.ajpath.2018.08.012
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Zebardast N, 2021, OPHTHALMOLOGY, V128, P1300, DOI 10.1016/j.ophtha.2021.03.007
   Zekavat SM, 2021, MED-CAMBRIDGE, V2, P137, DOI 10.1016/j.medj.2020.11.001
   Zekavat SM, 2019, CIRC-GENOM PRECIS ME, V12, DOI 10.1161/CIRCGEN.118.002453
   Zekavat SM, 2019, ARTERIOSCL THROM VAS, V39, P1253, DOI 10.1161/ATVBAHA.119.312626
   Zekavat SM, 2017, J LIPID RES, V58, P1325, DOI 10.1194/jlr.M074088
   Zouache MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78059-x
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 40
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2022
VL 129
IS 6
BP 694
EP 707
DI 10.1016/j.ophtha.2022.02.001
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3E1OX
UT WOS:000829760600019
PM 35149155
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Xu, ZX
   Ruan, ZH
   Huang, XT
   Liu, Q
   Li, ZZ
   Zhou, XY
   Zhang, X
   Shang, L
AF Xu, Zixuan
   Ruan, Zhaohui
   Huang, Xuetao
   Liu, Qiang
   Li, Zhaozhi
   Zhou, Xueyun
   Zhang, Xian
   Shang, Lei
TI Identification of aberrantly methylated differentially expressed genes
   in age-related macular degeneration
SO MEDICINE
LA English
DT Article
DE related macular degeneration; methylation; microarray analysis
ID SINGLE NUCLEOTIDE POLYMORPHISMS
AB DNA methylation plays a significant role in many diseases. Age-related macular degeneration (AMD) is a leading cause of vision loss for people aged 50 years and above, but the etiology and pathogenesis are largely unknown. This study aimed to identify the aberrantly methylated differentially expressed genes (DEGs) in AMD and predict the related pathways on the basis of public data.
   Aberrant methylation can influence the functions of key genes by altering their expression. Here, we found out DEGs by overlapping public microarray data (GSE29801 and GSE102952). Functional and enrichment analyses of selected genes were performed using the DAVID database. Subsequently, protein-protein interaction (PPI) networks were constructed by using STRING and visualized in cytoscape to determine hub genes. Finally, we collected AMD patients' blood samples to identify the methylation statuses of these hub genes by using methylated DNA immunoprecipitation.
   In total, 156 hypermethylation-low expression genes and 127 hypomethylation-high expression genes were predicted. The hypermethylation-low expression genes were enriched in biological processes of response to cardiac conduction, ATP binding, and cell-cell junction assembly. The top 5 hub genes of the PPI network were HSP90AA1, HSPA1L, HSPE1, HSP90B1, and NOP56. Meanwhile, the hypomethylation-high expression genes were enriched in the biological processes of response to positive regulation of the MAPK cascade, actin cytoskeleton reorganization, dentate gyrus development, and cell migration. The top 5 hub genes of this PPI network were PIK3R1, EZR, IGF2, SLC2A1, and CDKN1C. Moreover, the methylation statuses of NOP56, EZR, IGF2, SLC2A1, CDKN1C were confirmed to be altered in the blood of AMD patients.
   This study indicated possible aberrantly methylated DEGs and differentially expressed pathways in AMD by bioinformatics analysis, providing novel insights for unraveling the pathogenesis of AMD. Hub genes, including NOP56, EZR, IGF2, SLC2A1, CDKN1C, might serve as aberrant methylation-based candidate biomarkers for AMD in future applications.
C1 [Xu, Zixuan; Ruan, Zhaohui; Liu, Qiang; Zhou, Xueyun; Zhang, Xian; Shang, Lei] Nanchang Univ, Affiliated Eye Hosp, Jiangxi Res Inst Ophthalmol & Visual Sci, Nanchang 330006, Jiangxi, Peoples R China.
   [Huang, Xuetao] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Zhengzhou, Henan, Peoples R China.
   [Li, Zhaozhi] Sichuang Univ, Coll Life Sci, Key Lab Bioresources & Ecoenvironm, Chengdu, Sichuan, Peoples R China.
C3 Nanchang University; Zhengzhou University; Sichuan University
RP Shang, L (通讯作者)，Nanchang Univ, Affiliated Eye Hosp, Jiangxi Res Inst Ophthalmol & Visual Sci, Nanchang 330006, Jiangxi, Peoples R China.
EM shanglei1986@gmail.com
RI Shang, Lei/W-2984-2019
FU Natural Science Foundation of Jiangxi Province [20161BAB215222];
   Educational Commission of Jiangxi Province of PR China [GJJ150147];
   Cultivation scientific research fund for the junior teachers of medicine
   in NanChang University [PY201826]
FX This work is supported by grants from Natural Science Foundation of
   Jiangxi Province (No. 20161BAB215222), Educational Commission of Jiangxi
   Province of PR China (GJJ150147) and Cultivation scientific research
   fund for the junior teachers of medicine in NanChang University
   (PY201826). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   Baas DC, 2012, MOL VIS, V18, P657
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fries GR, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.32
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Huang-Doran I, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88766
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Iribarne M, 2017, J NEUROGENET, V31, P88, DOI 10.1080/01677063.2017.1358268
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Li X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047600
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Nasare AM, 2015, EUR J MICROBIOL IMMU, V5, P316, DOI 10.1556/1886.2015.00024
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Roy S, 2017, AUTOPHAGY, V13, P2013, DOI 10.1080/15548627.2017.1371397
   SanGiovanni JP, 2017, CLIN CHEM LAB MED, V55, P763, DOI 10.1515/cclm-2016-0898
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Strzalka-Mrozik B, 2017, CLIN INTERV AGING, V12, P1401, DOI 10.2147/CIA.S135030
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Velez G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193250
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X
   Yokosako K, 2014, OPEN OPHTHALMOL J, V8, P39, DOI 10.2174/1874364101408010039
   Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   2016, CURR EYE RES, V41, P1245, DOI DOI 10.3109/02713683.2015.1095933
NR 28
TC 4
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR
PY 2019
VL 98
IS 14
AR e15083
DI 10.1097/MD.0000000000015083
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HX3WF
UT WOS:000467323600052
PM 30946360
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Seitzman, RL
   Mangione, CM
   Cauley, JA
   Ensrud, KE
   Stone, KL
   Cummings, SR
   Hochberg, MC
   Hillier, TA
   Yu, F
   Coleman, AL
AF Seitzman, Robin L.
   Mangione, Carol M.
   Cauley, Jane A.
   Ensrud, Kristine E.
   Stone, Katie L.
   Cummings, Steven R.
   Hochberg, Marc C.
   Hillier, Teresa A.
   Yu, Fei
   Coleman, Anne L.
CA Study Osteoporotic Fractures Res G
TI Bone mineral density and age-related maculopathy in older women
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE age-related macular degeneration; age-related maculopathy; bone density
ID NUTRITION EXAMINATION SURVEY; BLUE-MOUNTAINS EYE; BEAVER DAM EYE;
   MACULAR DEGENERATION; POSTMENOPAUSAL WOMEN; NATIONAL-HEALTH;
   OSTEOPOROTIC FRACTURES; 5-YEAR INCIDENCE; GRADING SYSTEM; UNITED-STATES
AB OBJECTIVES: To determine whether bone mineral density (BMD) is associated with age-related maculopathy (ARM) risk in older women.
   DESIGN: Cross-sectional analysis at Year 10 (1997/98) of the Study of Osteoporotic Fractures (SOF).
   SETTING: Four clinical centers in the United States.
   PARTICIPANTS: One thousand forty-two randomly sampled SOF participants who attended the Year 10 clinic visit.
   MEASUREMENT: ARM status was determined from fundus photographs using a modification of the Wisconsin Age-Related Maculopathy Grading System 6-level severity scale used in the National Health and Nutrition Examination Survey III. Total hip BMD was measured at Year 10 using dual-energy x-ray absorptiometry. Information on potential confounders, including age, reproductive hormone exposures, body mass index, smoking, alcohol consumption, nutrition, education, diabetes mellitus, hypertension, and physical activity, was ascertained with questionnaires.
   RESULTS: The prevalence of ARM was 50% (46% had early ARM and 4% had late ARM). After potential confounder adjustment, greater BMD was associated with lower odds of ARM (odds ratio (OR) per 1 standard deviation increase in BMD=0.82, 95% confidence interval (CI)=0.70-0.96). Women in the highest quartile of BMD had lower odds of ARM than those in the lowest quartile (OR=0.63, 95% CI=0.41-0.97) and those in the lowest three quartiles combined (OR=0.66, 95% CI=0.48-0.91).
   CONCLUSION: Higher levels of BMD may be associated with lower risk for ARM. The underlying mechanism is unknown, although BMD may be a marker for lifetime endogenous estrogen exposure. Future studies are needed to replicate these findings and further investigate the nature of the relationship between BMD and ARM.
C1 Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA.
   Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   Univ Minnesota, Vet Affairs Med Ctr, Minneapolis, MN USA.
   Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Epidemiol, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Community Hlth, Minneapolis, MN 55455 USA.
   Calif Pacific Med Ctr, Inst Res, San Francisco, CA USA.
   Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   Univ Maryland, Div Rheumatol, Baltimore, MD 21201 USA.
   Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California System; University of California Los Angeles; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; University of Minnesota System; University of Minnesota Twin
   Cities; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Minneapolis VA Health Care System; University of
   Minnesota System; University of Minnesota Twin Cities; University of
   Minnesota System; University of Minnesota Twin Cities; University of
   Minnesota System; University of Minnesota Twin Cities; California
   Pacific Medical Center; California Pacific Medical Center Research
   Institute; University of California System; University of California San
   Francisco; University System of Maryland; University of Maryland
   Baltimore; Kaiser Permanente
RP Seitzman, RL (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Dept Ophthalmol, 100 Stein Plaza,Suite 2-118, Los Angeles, CA 90095 USA.
EM seitzman@ucla.edu
RI Cauley, Jane A/N-4836-2015
OI Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036
FU NEI NIH HHS [EY07026] Funding Source: Medline; NIAMS NIH HHS [AR35583,
   AR35582, AR35584] Funding Source: Medline; NIA NIH HHS [AG-02-004,
   AG08415, AG05407, AG05394] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [T32EY007026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035583,
   R01AR035582, R01AR035584] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R01AG008415] Funding Source: NIH RePORTER
CR Abramov Y, 2004, MENOPAUSE, V11, P62, DOI 10.1097/01.GME.0000074701.19603.11
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416
   BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B
   Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404
   CAULEY JA, 1994, AM J EPIDEMIOL, V139, P1035, DOI 10.1093/oxfordjournals.aje.a116943
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   ENSRUD KE, 1995, J BONE MINER RES, V10, P1778
   ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021
   FOX KM, 1993, J BONE MINER RES, V8, P901
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hagemans MLC, 2004, HUM REPROD, V19, P2163, DOI 10.1093/humrep/deh381
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BE, 1994, T AM OPHTHAL SOC, V92, P295
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   NEELY KA, 1993, OPHTHALMOL CLIN N AM, V2, P291
   Nelson HD, 2002, ARCH INTERN MED, V162, P2278, DOI 10.1001/archinte.162.20.2278
   New SA, 2000, AM J CLIN NUTR, V71, P142
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Tucker KL, 2002, AM J CLIN NUTR, V76, P245, DOI 10.1093/ajcn/76.1.245
   Tucker KL, 1999, AM J CLIN NUTR, V69, P727
   TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 47
TC 8
Z9 8
U1 0
U2 4
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2007
VL 55
IS 5
BP 740
EP 746
DI 10.1111/j.1532-5415.2007.01138.x
PG 7
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 161RA
UT WOS:000246031900013
PM 17493194
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Erie, JC
   Good, JA
   Butz, JA
AF Erie, Jay C.
   Good, Jonathan A.
   Butz, John A.
TI Excess Lead in the Neural Retina in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CADMIUM TOXICITY; ZINC; COPPER
AB PURPOSE: To measure lead and cadmium in retinal tissues of human donor eyes with and without age-related macular degeneration (AMD). DESIGN: Laboratory investigation.
   METHODS: Lead and cadmium concentrations in retinal tissues (neural retina and retinal pigment epithelium [RPE]-choroid complex) in 25 subjects with AMD (50 donor eyes) and 36 normal subjects (72 donor eyes) were determined by using inductively coupled plasma-mass spectrometry. Severity of AMD was graded by using color fundus photographs and the Minnesota Grading System. Differences in metal concentrations were compared by using Wilcoxon rank-sum tests.
   RESULTS: The neural retinas of subjects with AMD had increased lead concentrations (median, 12.0 ng/g; 25% to 75% interquartile range, 8 to 18 ng/g; n = 25) compared with normal subjects (median, 8.0 ng/g; 25% to 75% interquartile range, 0 to 11 ng/g; P = .04; n = 36). There was no difference in lead concentration in the RPE-choroid complex between subjects with AMD (median, 198 ng/g; 25% to 75% interquartile range, 87 to 381 ng/g) and normal subjects (median, 172 ng/g; 25% to 75% interquartile range, 100 to 288 ng/g; P = .25). Cadmium concentration in the neural retina (median, 0.9 mu g/g; 25% to 75% interquartile range, 0.7 to 1.8 mu g/g) and RPE-choroid complex (median, 2.2 mu g/g; 25% to 75% interquartile range, 1.8 to 3.7 mu g/g) in subjects with AMD was not different from concentrations in the neural retina (median, 0.9 mu g/g; 25% to 75% interquartile range, 0.7 to 1.4 mu g/g; P = .32) and RPE-choroid complex (median, 1.5 mu g/g; 25% to 75% interquartile range, 0.9 to 2.5 mu g/g; P = .12) of normal subjects.
   CONCLUSIONS: AMD is associated with excess lead in the neural retina, and this relationship suggests that metal homeostasis in AMD eyes is different from normal. (Am J Ophthalmol 2009;148:890-894. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Erie, Jay C.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Good, Jonathan A.; Butz, John A.] Mayo Clin, Met Lab, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic
RP Erie, JC (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM erie.jay@mayo.edu
FU MAYO FOUNDATION, ROCHESTER, MINNESOTA; Research to Prevent Blindness
   Inc, New York, New York
FX THIS STUDY WAS SUPPORTED IN PART BY THE MAYO FOUNDATION, ROCHESTER,
   MINNESOTA (THE ROBERT R. WALLER Career Development Award); and Research
   to Prevent Blindness Inc, New York, New York. The authors indicate no
   financial conflict of interest. Involved in design and conduct of study
   (J.C.E., J.A.G., J.A.B.); collection, management, analysis, and
   interpretation of data (J.C.E., J.A.G., J.A.B.); preparation (J.C.E.),
   review and approval of manuscript (J.C.E., J.A.G., J.A.B.). The Study
   protocol was reviewed and approved by the Institutional Review Board of
   the Mayo Clinic. The study was in accordance with the tenets of the
   Declaration of Helsinki.
CR Agency for Toxic Substances and Disease Registry (ATSDR), 2005, CERCLA PRIOR LIST HA
   ARVIDSON B, 1983, NEUROBIOLOGY TRACE E, P51
   BARRY PSI, 1975, BRIT J IND MED, V32, P119
   BHATTACHARYYA MH, 2000, MOL BIOL TOXICOLOGY, P276
   BIN QH, 1994, MED HYPOTHESES, V42, P380, DOI 10.1016/0306-9877(94)90157-0
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   FOX DA, 1994, NEUROTOXICOLOGY, V15, P503
   GOYER RA, 1993, ENVIRON HEALTH PERSP, V100, P177, DOI 10.2307/3431524
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hyun HJ, 2001, INVEST OPHTH VIS SCI, V42, P460
   JAMALL IS, 1990, BIOL TRACE ELEM RES, V23, P55, DOI 10.1007/BF02917177
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Martelli A, 2006, BIOCHIMIE, V88, P1807, DOI 10.1016/j.biochi.2006.05.013
   Mecocci P, 2004, NEUROL RES, V26, P598, DOI 10.1179/016164104225017659
   Navas-Acien A, 2005, ENVIRON HEALTH PERSP, V113, P164, DOI 10.1289/ehp.7329
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   SARNA T, 1976, SCIENCE, V192, P1132, DOI 10.1126/science.179142
   Schaumberg DA, 2004, JAMA-J AM MED ASSOC, V292, P2750, DOI 10.1001/jama.292.22.2750
   STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H
   Vig EK, 2000, J AM GERIATR SOC, V48, P1501, DOI 10.1111/jgs.2000.48.11.1501
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   YUKI K, 2009, BIOL TRACE ELEM 0424
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 27
TC 18
Z9 18
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2009
VL 148
IS 6
BP 890
EP 894
DI 10.1016/j.ajo.2009.07.001
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530BP
UT WOS:000272564200013
PM 19733830
DA 2022-11-30
ER

PT J
AU White, UE
   Black, AA
   Delbaere, K
   Wood, JM
AF White, Ursula E.
   Black, Alex A.
   Delbaere, Kim
   Wood, Joanne M.
TI Determinants of concern about falling in adults with age-related macular
   degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE falls; fear of falling; macular degeneration; vision impairment
ID QUALITY-OF-LIFE; TO-STAND TEST; OLDER-ADULTS; ACTIVITY RESTRICTION;
   VISION IMPAIRMENT; CONTRAST SENSITIVITY; VISUAL IMPAIRMENT; ELDERLY
   PERSONS; FEAR; DEPRESSION
AB Purpose To investigate the prevalence and level of concern about falling (CF) among older people with vision impairment due to age-related macular degeneration (AMD) compared to a visually normal control group, and to identify determinants of CF for the AMD group.
   Methods Participants included 133 older people: 77 with AMD (mean age = 80.5 +/- 6.2 years), and 56 controls (mean age = 75.4 +/- 5.3 years). Binocular visual acuity, contrast sensitivity and visual fields were measured, and CF was assessed using the Falls Efficacy Scale - International (FES-I). Data were also collected for sensorimotor function (postural sway, sit-to-stand, knee extensions, walking speed, proprioception), and neuropsychological function (reaction time, symptoms of anxiety and depression) using validated tests and scales.
   Results Concern about falling scores were higher for AMD participants compared to control participants (mean +/- S.D. 24.6 +/- 8.0 vs 21.6 +/- 5.7, p = 0.02, respectively), although these findings failed to reach significance when adjusted for age (p = 0.16). Among AMD participants, multivariable models showed that greater CF was associated with reduced contrast sensitivity (p = 0.02), slower sit-to-stand times (p < 0.001) and higher anxiety scores (p < 0.001); these factors explained 40% of the variance in CF (p < 0.01).
   Conclusion Levels of CF in older people with AMD were not found to be elevated by their disease status alone, but rather by the extent of vision loss. Levels of CF in those with AMD were associated with various visual, sensorimotor and neuropsychological factors. These findings will assist clinicians in identifying those at greatest risk of developing high CF and inform the design of future intervention programmes for this population.
C1 [White, Ursula E.; Black, Alex A.; Wood, Joanne M.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Sch Optometry & Vis Sci, Ctr Vis & Eye Res, Brisbane, Qld, Australia.
   [Delbaere, Kim] Neurosci Res Australia, Falls Balance & Injury Res Ctr, Randwick, NSW, Australia.
   [Delbaere, Kim] Univ New South Wales, Sch Publ Hlth & Community Med, Kensington, NSW, Australia.
C3 Queensland University of Technology (QUT); Neuroscience Research
   Australia; University of New South Wales Sydney
RP White, UE (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Sch Optometry & Vis Sci, Ctr Vis & Eye Res, Brisbane, Qld, Australia.
EM ursula.white@qut.edu.au
RI Black, Alex/I-9727-2012
OI Black, Alex/0000-0002-8671-5167; , Joanne/0000-0002-0776-7736; White,
   Ursula/0000-0003-2112-2851; Delbaere, Kim/0000-0002-5655-0234
FU Australian Government Research Training Program scholarship
FX This work was supported by an Australian Government Research Training
   Program scholarship. The authors would also like to thank the OKKO Eye
   Specialist Centre and Queensland Eye Institute for their assistance with
   recruitment. The authors are indebted to the low vision support groups,
   retirement village communities and the University of the Third Age, who
   hosted recruitment talks, and to the study participants who generously
   donated their time to our study.
CR ADAMS N, 2019, PUBLIC HLTH RES, V7, P1
   Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bohannon RW, 2006, PERCEPT MOTOR SKILL, V103, P215, DOI 10.2466/PMS.103.1.215-222
   Bohannon RW, 2011, J STRENGTH COND RES, V25, P3205, DOI 10.1519/JSC.0b013e318234e59f
   Byrne GJ, 2010, AGING MENT HEALTH, V14, P247, DOI 10.1080/13607861003587628
   Campbell AJ, 2005, BMJ-BRIT MED J, V331, P817, DOI 10.1136/bmj.38601.447731.55
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Cheng Y, 2013, CHINESE MED J-PEKING, V126, P1430, DOI 10.3760/cma.j.issn.0366-6999.20123274
   Chong MFA, 2018, CLIN EXP OPTOM, V101, P793, DOI 10.1111/cxo.12805
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x
   Delbaere K, 2004, AGE AGEING, V33, P368, DOI 10.1093/ageing/afh106
   Delbaere K, 2010, AGE AGEING, V39, P210, DOI 10.1093/ageing/afp225
   Deshpande N, 2008, AM J PHYS MED REHAB, V87, P354, DOI 10.1097/PHM.0b013e31815e6e9b
   Duggan E, 2017, J GERONTOL A-BIOL, V72, P1663, DOI 10.1093/gerona/glx021
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman SM, 2002, J AM GERIATR SOC, V50, P1329, DOI 10.1046/j.1532-5415.2002.50352.x
   Guillemin F, 2013, OSTEOPOROSIS INT, V24, P3001, DOI 10.1007/s00198-013-2408-4
   Heesterbeek TJ, 2017, OPHTHAL PHYSL OPT, V37, P385, DOI 10.1111/opo.12388
   Howland J, 1998, GERONTOLOGIST, V38, P549, DOI 10.1093/geront/38.5.549
   Jacob Louis, 2017, Ger Med Sci, V15, pDoc04, DOI 10.3205/000245
   Jung D, 2009, WESTERN J NURS RES, V31, P6, DOI 10.1177/0193945908320466
   Kempen GIJM, 2014, AM J GERIAT PSYCHIAT, V22, P309, DOI 10.1016/j.jagp.2012.08.007
   Kendrick D, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009848.pub2
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Kubicki A, 2014, NEUROSCI LETT, V577, P89, DOI 10.1016/j.neulet.2014.06.014
   Lachman ME, 1998, J GERONTOL B-PSYCHOL, V53, pP43, DOI 10.1093/geronb/53B.1.P43
   Lamoureux EL, 2008, OPHTHAL EPIDEMIOL, V15, P105, DOI 10.1080/09286580701840354
   Lamoureux EL, 2009, OPTOMETRY VISION SCI, V86, P139, DOI 10.1097/OPX.0b013e318194eb47
   Li FZ, 2003, J GERONTOL B-PSYCHOL, V58, pP283, DOI 10.1093/geronb/58.5.P283
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237
   Lord SR, 2002, J GERONTOL A-BIOL, V57, pM539, DOI 10.1093/gerona/57.8.M539
   LORD SR, 1991, J AM GERIATR SOC, V39, P1194, DOI 10.1111/j.1532-5415.1991.tb03574.x
   Martin A, 2006, GEN HOSP PSYCHIAT, V28, P71, DOI 10.1016/j.genhosppsych.2005.07.003
   Murphy SL, 2003, J GERONTOL A-BIOL, V58, P943
   Murphy SL, 2002, J AM GERIATR SOC, V50, P516, DOI 10.1046/j.1532-5415.2002.50119.x
   Nguyen AM, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0062-8
   Pye A, 2017, INT PSYCHOGERIATR, V29, P1771, DOI 10.1017/S104161021700120X
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.037
   Rubin D. B, 2004, MULTIPLE IMPUTATION, V81
   Scheffer AC, 2008, AGE AGEING, V37, P19, DOI 10.1093/ageing/afm169
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Tabrett DR, 2012, OPHTHAL PHYSL OPT, V32, P156, DOI 10.1111/j.1475-1313.2012.00892.x
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   Vellas BJ, 1997, AGE AGEING, V26, P189, DOI 10.1093/ageing/26.3.189
   VERBAKEN JH, 1986, AM J OPTOM PHYS OPT, V63, P724
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   Wittich W, 2010, J VISUAL IMPAIR BLIN, V104, P360, DOI 10.1177/0145482X1010400606
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2008, J AM GERIATR SOC, V56, P986, DOI 10.1111/j.1532-5415.2008.01709.x
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Yardley L, 2005, AGE AGEING, V34, P614, DOI 10.1093/ageing/afi196
   Yuki K, 2013, INVEST OPHTH VIS SCI, V54, P7739, DOI 10.1167/iovs.13-12079
NR 60
TC 1
Z9 1
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAR
PY 2021
VL 41
IS 2
BP 245
EP 254
DI 10.1111/opo.12777
EA DEC 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA QY0PY
UT WOS:000601578800001
PM 33368495
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Mouallem-Beziere, A
   Blanco-Garavito, R
   Richard, F
   Miere, A
   Jung, CM
   Rozet, JM
   Souied, EH
AF Mouallem-Beziere, Alexandra
   Blanco-Garavito, Rocio
   Richard, Florence
   Miere, Alexandra
   Jung, Camille
   Rozet, Jean-Michel
   Souied, Eric H.
TI GENETICS OF LARGE PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retina; age-related macular degeneration; vascularized pigment
   epithelial detachment
ID COMPLEMENT FACTOR-H; VARIABLE-DOSING RANIBIZUMAB; INTRAVITREAL
   RANIBIZUMAB; RISK; POLYMORPHISM; PREVALENCE; MACULOPATHY; VEGF; C3;
   SUSCEPTIBILITY
AB Purpose: We hypothesized that severe forms of neovascular age-related macular degeneration (AMD) such as large pigment epithelial detachments poorly responding to anti-vascular endothelial growth factor therapy might present a distinct genotype compared with overall series of neovascular AMD. Methods: This is a multicenter genetic association study. Sixty-eight patients presenting pigment epithelial detachments resistant to ranibizumab (issued from ARI2 study, register number NCT02157077 on ) were compared with two series of patients derived from previously published clinical studies, presenting neovascular AMD (NAT2 study n = 300 and PHRC study n = 1,127), and with healthy controls (n = 441). The phenotype of neovascular AMD groups was based on visual acuity measurement, fundus examination, spectral-domain optical coherence tomography, and angiographic data. All samples were genotyped for three single-nucleotide polymorphisms: CFH (rs1061170), ARMS2 (rs10490924), and C3 (rs2230199). Significant difference in allele frequency between participants with neovascular AMD and control was the main outcome measurement. Results: The GG genotype of the C3 rs2230199 was significantly more frequent in the ARI2 group (55.9%) than the PHRC group (6.0%, P < 0.0001; odds ratio = 24.0 [95% confidence interval 10.4-55.0]) and the NAT2 group (5.1%, P < 0.0001; odds ratio = 16.1 [95% confidence interval 5.0-51.9]). The repartition of patients carrying a T allele of the ARMS2 (rs10490924) or patients carrying a C allele of the CFH (rs1061170) was similar in the ARI2 group when compared with the NAT2 and PHRC groups. Conclusion: In our series, the genotype GG of C3 rs2230199 was more significantly associated with the phenotype of large vascularized pigment epithelial detachment poorly responding to anti-vascular endothelial growth factor therapy than in global AMD series.
C1 [Mouallem-Beziere, Alexandra; Blanco-Garavito, Rocio; Miere, Alexandra; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
   [Richard, Florence] Univ Lille Nord France, INSERM774, Inst Pasteur Lille, Lille, France.
   [Jung, Camille] Hop Intercommunal Creteil, Ctr Ressources Biol, Creteil, France.
   [Rozet, Jean-Michel] Paris Descartes Univ, INSERM, UMR1163, LGO,Inst Genet Dis,Imagine, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Le Reseau
   International des Instituts Pasteur (RIIP); Universite de Lille - ISITE;
   Institut Pasteur Lille; Universite de Lille; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Institut National de
   la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite Paris Cite
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Miere, Alexandra/AIC-4074-2022; ROZET, Jean-Michel/E-5737-2016
OI Miere, Alexandra/0000-0003-4123-8210; ROZET,
   Jean-Michel/0000-0001-7951-7886; JUNG, Camille/0000-0001-8486-8939
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buermans HPJ, 2014, BBA-MOL BASIS DIS, V1842, P1932, DOI 10.1016/j.bbadis.2014.06.015
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Merle BMJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130816
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Teper SJ, 2010, MOL VIS, V16, P2598
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zhang MX, 2015, GENET MOL RES, V14, P12567, DOI 10.4238/2015.October.16.24
NR 50
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2020
VL 40
IS 4
BP 663
EP 671
DI 10.1097/IAE.0000000000002454
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB2WI
UT WOS:000524497800009
PM 30681643
DA 2022-11-30
ER

PT J
AU Robman, LD
   Islam, FMA
   Chong, EWT
   Adams, MKM
   Simpson, JA
   Aung, KZ
   Makeyeva, GA
   Hopper, JL
   English, DR
   Giles, GG
   Baird, PN
   Guymer, RH
AF Robman, Liubov D.
   Islam, Fakir M. A.
   Chong, Elaine W. T.
   Adams, Madeleine K. M.
   Simpson, Julie A.
   Aung, Khin Zaw
   Makeyeva, Galina A.
   Hopper, John L.
   English, Dallas R.
   Giles, Graham G.
   Baird, Paul N.
   Guymer, Robyn H.
TI Age-Related Macular Degeneration in Ethnically Diverse Australia:
   Melbourne Collaborative Cohort Study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); ethnicity; prevalence
ID BLUE MOUNTAINS EYE; MEDITERRANEAN DIET; VISUAL IMPAIRMENT; GREEK
   MIGRANTS; RISK-FACTORS; PREVALENCE; MACULOPATHY; POPULATION; MORTALITY;
   CLASSIFICATION
AB Purpose: To determine and compare the prevalence of age-related macular degeneration (AMD) in older Australians of Anglo-Celtic and Southern European origin.
   Methods: A total of 21,132 participants of the Melbourne Collaborative Cohort Study, aged 47-86 years, were assessed for AMD in 2003-2007 with non-mydriatic fundus photography. Of these, 14% were born in Southern Europe (Greece, Italy or Malta), with the remaining 86% of Anglo-Celtic origin, born in Australia, the United Kingdom or New Zealand.
   Results: Overall, 2694 participants (12.7%) had early stages of AMD, defined as either one or more drusen >= 125 mu m (with or without pigmentary abnormalities) or one or more drusen 63-124 mu m with pigmentary abnormalities in a 6000-mu m diameter grading grid, in the absence of late AMD in either eye. A total of 122 participants (0.6%) had late AMD, defined as either geographic atrophy or neovascular AMD. In logistic regression analysis, adjusted for age, sex, smoking, education and physical activity, Southern Europeans compared to Anglo-Celts had a higher prevalence of the early stages of AMD (odds ratio, OR, 1.15, 95% confidence interval, CI, 1.00-1.34), and lower prevalence of late AMD (OR 0.36, 95% CI 0.17-0.78).
   Conclusions: Australians of Southern European origin have a higher prevalence of the early stages of AMD and lower prevalence of late AMD compared to those of Anglo-Celtic origin. Although AMD prevalence in the older age group(s) of Southern Europeans could be underestimated due to disparity in participation rates, it is likely that both lifestyle and genetic factors play their parts in differential AMD prevalence in these ethnic groups.
C1 [Robman, Liubov D.; Islam, Fakir M. A.; Chong, Elaine W. T.; Adams, Madeleine K. M.; Aung, Khin Zaw; Makeyeva, Galina A.; Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Simpson, Julie A.; Hopper, John L.; English, Dallas R.; Giles, Graham G.] Univ Melbourne, Sch Publ Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
   [English, Dallas R.; Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; Cancer Council
   Victoria
RP Robman, LD (通讯作者)，Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM lrobman@unimelb.edu.au
RI English, Dallas/AAH-5005-2019; Adams, Madeleine K M/B-7915-2016; Islam,
   Fakir M Amirul/P-6665-2015
OI English, Dallas/0000-0001-7828-8188; Adams, Madeleine K
   M/0000-0002-5277-5487; Islam, Fakir M Amirul/0000-0003-3897-3302; Baird,
   Paul/0000-0002-1305-3502; Giles, Graham/0000-0003-4946-9099; Guymer,
   Robyn/0000-0002-9441-4356
FU VicHealth and The Cancer Council Victoria; National Health & Medical
   Research Council of Australia (NHMRC) [209057, 251533, 396414];
   Ophthalmic Research Institute of Australia; American Health Assistance
   Foundation; Jack Brockhoff Foundation; John Reid Charitable Trust;
   Perpetual Trustees and Royal Victorian Eye and Ear Hospital; NHMRC
   [300052, 529905, 590226, 1028444, 1023434]; Wagstaff Fellowship; Hugh
   Noel Puckle Scholarship; Novartis Medical Retinal Fellowship; NHMRC
   Centre for Clinical Research Excellence Grant [529923]; Victorian
   Government
FX Cohort recruitment was funded by VicHealth and The Cancer Council
   Victoria. Further MCCS funding: the National Health & Medical Research
   Council of Australia (NHMRC) Program Grant 209057, Capacity Building
   Grant 251533 and Enabling Grant 396414. The ophthalmic component was
   funded by the Ophthalmic Research Institute of Australia; American
   Health Assistance Foundation, Jack Brockhoff Foundation, John Reid
   Charitable Trust, Perpetual Trustees and Royal Victorian Eye and Ear
   Hospital. People support was provided through the NHMRC Career
   Development (300052) and Practitioner (529905) Fellowships to RHG,
   Wagstaff Fellowship to LR, NHMRC PhD scholarship (590226) and Hugh Noel
   Puckle Scholarship to MA, NHMRC Senior Research Fellowships to PNB
   (1028444) and JH (1023434), and Novartis Medical Retinal Fellowship to
   EC. Centre for Eye Research Australia is a recipient of the NHMRC Centre
   for Clinical Research Excellence Grant 529923 and Operational
   Infrastructure Support from the Victorian Government. The funding
   organizations did not have any involvement in study design and data
   collection, analysis or interpretation.
CR Access Economics, 2006, CENTR FOC IMP AG MAC
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Australian Bureau of Statistics, 2012, 3235 0 POP AG SEX RE
   BENNETT SA, 1993, AUST J PUBLIC HEALTH, V17, P251
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Carresi C, 2009, CLIN TER, V160
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Deloitte Access Economics, 2011, MAC DEG FDN, P145
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Giles G, 2002, LYON FRANCE, V156, P69
   Giles GG, 1990, P NUTR SOC AUST, V15, P61
   Hodge AM, 2004, DIABETES CARE, V27, P2330, DOI 10.2337/diacare.27.10.2330
   Ireland PD, 1996, AUST NZ J PUBL HEAL, V20, P143, DOI 10.1111/j.1753-6405.1996.tb01808.x
   Kalantar-Zadeh K, 2007, SEMIN DIALYSIS, V20, P593, DOI 10.1111/j.1525-139X.2007.00360.x
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kouris-Blazos A, 2002, ASIA PAC J CLIN NUTR, V11, pS569, DOI 10.1046/j.1440-6047.11.supp3.2.x
   KourisBlazos A, 1996, AGE AGEING, V25, P177, DOI 10.1093/ageing/25.3.177
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Shaw BA, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-803
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stein JD, 2011, INVEST OPHTH VIS SCI, V52, P6842, DOI 10.1167/iovs.11-7179
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Trichopoulou A, 2000, BRIT J NUTR, V84, pS205, DOI 10.1079/096582197388554
   Trichopoulou A, 1994, J Cardiovasc Risk, V1, P9, DOI 10.1097/00043798-199406000-00003
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vasto S, 2012, REJUV RES, V15, P184, DOI 10.1089/rej.2011.1280
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang YY, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2721
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   WHO, 2012, WORLD HLTH STAT 2012
   World Health Organization, CAUS BLINDN VIS IMP
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
NR 51
TC 6
Z9 6
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD APR
PY 2015
VL 22
IS 2
BP 75
EP 84
DI 10.3109/09286586.2015.1010688
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD9EO
UT WOS:000351400700001
PM 25777306
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Chang, ML
   Zhang, FF
   Li, T
   Gensler, G
   Schleicher, M
   Taylor, A
AF Chiu, Chung-Jung
   Chang, Min-Lee
   Zhang, Fang Fang
   Li, Tricia
   Gensler, Gary
   Schleicher, Molly
   Taylor, Allen
TI The Relationship of Major American Dietary Patterns to Age-Related
   Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GLYCEMIC INDEX; VISUAL IMPAIRMENT; RISK; ASSOCIATION; CARBOHYDRATE;
   CONSUMPTION; DISEASE; ANTIOXIDANTS; FAT
AB PURPOSE: We hypothesized that major American dietary patterns are associated with risk for age-related macular degeneration (AMD).
   DESIGN: Cross-sectional study.
   METHODS: We classified 8103 eyes in 4088 eligible participants in the baseline Age-Related Eye Disease Study (AREDS). They were classified into control(n = 2739), early AMD (n = 4599), and advanced AMD (n = 765) by the AREDS AMD Classification System. Food consumption data were collected by using a 90-item food frequency questionnaire.
   RESULTS: Two major dietary patterns were identified by factor (principal component) analysis based on 37 food groups and named Oriental and Western patterns. The Oriental pattern was characterized by higher intake of vegetables, legumes, fruit, whole grains, tomatoes, and seafood. The Western pattern was characterized by higher intake of red meat, processed meat, high-fat dairy products, French fries, refined grains, and eggs. We ranked our participants according to how closely their diets line up with the 2 patterns by calculating the 2 factor scores for each participant. For early AMD, multivariate-adjusted odds ratio (OR) from generalized estimating equation logistic analysis comparing the highest to lowest quintile of the Oriental pattern score was ORE50 = 0.74 (95% confidence interval (CI): 0.59-0.91; P-trend =0.01), and the OR comparing the highest to lowest quintile of the Western pattern score was ORE5w = 1.56 (1.18-2.06; P-trend = 0.01). For advanced AMD, the ORA50 was 0.38 (0.27-0.54; P-trend < 0.0001), and the ORA5w was 3.70 (2.31-5.92; P-trend < 0.0001).
   CONCLUSIONS: Our data indicate that overall diet is significantly associated with the odds of AMD and that dietary management as an AMD prevention strategy warrants further study. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Chiu, Chung-Jung; Chang, Min-Lee; Schleicher, Molly; Taylor, Allen] Jean Mayer United States Dept Agr Human Nutr Res, Boston, MA USA.
   [Chiu, Chung-Jung; Taylor, Allen] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Zhang, Fang Fang] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
   [Li, Tricia] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA.
   [Gensler, Gary] EMMES Corp, Age Related Eye Dis Study Coordinating Ctr, Rockville, MD USA.
C3 Tufts University; Tufts University; Harvard University; Brigham &
   Women's Hospital; Harvard Medical School; Emmes Corporation
RP Chiu, CJ (通讯作者)，Tufts Univ, Jean Mayer United States Dept Agr Human Nutr Res, 711 Washington St, Boston, MA 02111 USA.
EM CJ.Chiu@tufts.edu
OI CHANG, MIN-LEE/0000-0001-9868-4030
FU National Institutes of Health, United States [RO1EY021826, RO1EY013250,
   RO1EY021212]; United States Department of Agriculture
   [1950-5100-060-01A]; NATIONAL EYE INSTITUTE [R01EY021826, R01EY021212,
   R01EY013250] Funding Source: NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST, and none were reported. Financial
   support for this project was provided by RO1EY021826 (C.J.C.),
   RO1EY013250 (AT.) and RO1EY021212 (A.T.) from the National Institutes of
   Health, United States, and the United States Department of Agriculture
   under agreements 1950-5100-060-01A (C.J.C., A.T.). Design and conduct of
   study (C.J.C., A.T.); Collection, management, analysis, and
   interpretation of data (C.J.C., M.L.C., F.F.Z., T.L., G.G.);
   Preparation, review, or approval of the manuscript (C.-J.C., M.-L.C.,
   F.F.Z., G.G., M.S., A.T.); Statistical expertise (C.J.C., F.F.Z., T.L.,
   G.G.); Administrative, technical or logistic support (M.L.C., G.G.,
   M.S.).
CR Abdi H, 2010, WIRES COMPUT STAT, V2, P433, DOI 10.1002/wics.101
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chang ML, 2014, ADV EXP MED BIOL, V801, P609, DOI 10.1007/978-1-4614-3209-8_77
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P1177, DOI 10.1093/ajcn/83.5.1177
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Chiu CJ, 2014, OPHTHALMOLOGY
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fung TT, 2001, AM J CLIN NUTR, V73, P61
   Hu FB, 2000, AM J CLIN NUTR, V72, P912
   Hu FB, 1999, AM J CLIN NUTR, V69, P243
   Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kurinij N, 1998, INT C DIET ASS MEAS
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   McEvoy CT, 2013, INVEST OPHTH VIS SCI, V54, P1337, DOI 10.1167/iovs.12-11065
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Slattery ML, 1998, AM J EPIDEMIOL, V148, P4, DOI 10.1093/aje/148.1.4-a
   Vishwanathan R, 2010, NUTR RES, V30, P747, DOI 10.1016/j.nutres.2010.10.007
   Vishwanathan R, 2009, AM J CLIN NUTR, V90, P1272, DOI 10.3945/ajcn.2009.28013
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 41
TC 67
Z9 67
U1 0
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2014
VL 158
IS 1
BP 118
EP 127
DI 10.1016/j.ajo.2014.04.016
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK0IY
UT WOS:000338097300017
PM 24792100
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gu, JY
   Pauer, GJT
   Yue, XZ
   Narendra, U
   Sturgill, GM
   Bena, J
   Gu, XR
   Peachey, NS
   Salomon, RG
   Hagstrom, SA
   Crabb, JW
AF Gu, Jiayin
   Pauer, Gayle J. T.
   Yue, Xiuzhen
   Narendra, Umadevi
   Sturgill, Gwen M.
   Bena, James
   Gu, Xiaorong
   Peachey, Neal S.
   Salomon, Robert G.
   Hagstrom, Stephanie A.
   Crabb, John W.
CA Clinical Genomic Proteomic AMD Stu
TI Assessing Susceptibility to Age-related Macular Degeneration with
   Proteomic and Genomic Biomarkers
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; BRUCHS MEMBRANE; RISK;
   POLYMORPHISM; VARIANT; LOC387715; DRUSEN; GENES; INFLAMMATION
AB Age-related macular degeneration (AMD) is a progressive disease and major cause of severe visual loss. Toward the discovery of tools for early identification of AMD susceptibility, we evaluated the combined predictive capability of proteomic and genomic AMD biomarkers. We quantified plasma carboxyethylpyrrole (CEP) oxidative protein modifications and CEP autoantibodies by ELISA in 916 AMD and 488 control donors. CEP adducts are uniquely generated from oxidation of docosahexaenoate-containing lipids that are abundant in the retina. Mean CEP adduct and autoantibody levels were found to be elevated in AMD plasma by similar to 60 and similar to 30%, respectively. The odds ratio for both CEP markers elevated was 3-fold greater or more in AMD than in control patients. Genotyping was performed for AMD risk polymorphisms associated with age-related macuiopathy susceptibility 2 (ARMS2), high temperature requirement factor A1 (HTRA1), complement factor H, and complement C3, and the risk of AMD was predicted based on genotype alone or in combination with the CEP markers. The AMD risk predicted for those exhibiting elevated CEP markers and risk genotypes was 2-3-fold greater than the risk based on genotype alone. AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers. The results compellingly demonstrate higher mean CEP marker levels in AMD plasma over a broad age range. Receiver operating characteristic curves suggest that CEP markers alone can discriminate between AMD and control plasma donors with similar to 76% accuracy and in combination with genomic markers provide up to similar to 80% discrimination accuracy. Plasma CEP marker levels were altered slightly by several demographic and health factors that warrant further study. We conclude that CEP plasma biomarkers, particularly in combination with genomic markers, offer a potential early warning system for assessing susceptibility to this blinding, multifactorial disease. Molecular & Cellular Proteomics 8: 1338-1349, 2009.
C1 [Hagstrom, Stephanie A.] Cleveland Clin Fdn, Lerner Res Inst i31, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Gu, Jiayin; Pauer, Gayle J. T.; Yue, Xiuzhen; Narendra, Umadevi; Bena, James; Gu, Xiaorong; Peachey, Neal S.; Hagstrom, Stephanie A.; Crabb, John W.] Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Bena, James] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA.
   [Gu, Jiayin; Salomon, Robert G.; Crabb, John W.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Sturgill, Gwen M.; Peachey, Neal S.] Louis Stokes Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
   [Peachey, Neal S.; Hagstrom, Stephanie A.; Crabb, John W.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland Clin Lerner Coll Med, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland
   Clinic Foundation; Case Western Reserve University; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Case Western
   Reserve University; Louis Stokes Cleveland Veterans Affairs Medical
   Center; Case Western Reserve University; Cleveland Clinic Foundation
RP Hagstrom, SA (通讯作者)，Cleveland Clin Fdn, Lerner Res Inst i31, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM hagstrs@ccf.org
RI Salomon, Robert G/C-3463-2008; Peachey, Neal/G-5533-2010; Wilson,
   Steven/C-6140-2018
OI Peachey, Neal/0000-0002-4419-7226; Kaiser, Peter/0000-0001-5126-045X;
   Dupps, William/0000-0003-0761-8658; Salomon, Robert/0000-0001-9456-3557;
   Wilson, Steven/0000-0001-8121-960X
FU National Institutes of Health [EY015638, EY014239, GM21249, EY016072];
   State of Ohio [BRTT 05-29]; Foundation Fighting Blindness Center;
   Research to Prevent Blindness (RPB); Veterans Affairs Medical Research
   Service; Cleveland Clinic Foundation; NATIONAL CENTER FOR RESEARCH
   RESOURCES [KL2RR024990] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY014239, R24EY015638, R01EY016072] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249]
   Funding Source: NIH RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants EY015638, EY014239, GM21249, and EY016072. This work was
   also supported by Grant BRTT 05-29 from the State of Ohio, a Foundation
   Fighting Blindness Center grant, a Research to Prevent Blindness (RPB)
   center grant, a RPB senior investigator award (to J. W. C.), a Steinbach
   award (to J. W. C.), the Veterans Affairs Medical Research Service, and
   the Cleveland Clinic Foundation.
CR Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GU X, 2004, INVESTIG OPHTHALMOL, V45
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   RENGANATHAN K, 2003, INVESTIG OPHTHALMOL, V44
   Renganathan K, 2008, ADV EXP MED BIOL, V613, P261, DOI 10.1007/978-0-387-74904-4_30
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 41
TC 81
Z9 84
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD JUN
PY 2009
VL 8
IS 6
BP 1338
EP 1349
DI 10.1074/mcp.M800453-MCP200
PG 12
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 457DB
UT WOS:000266904900014
PM 19202148
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Simpson, JM
   Luo, W
   Penfold, P
   Hunyor, ABL
   Chua, W
   Mitchell, P
   Billson, F
AF Gillies, MC
   Simpson, JM
   Luo, W
   Penfold, P
   Hunyor, ABL
   Chua, W
   Mitchell, P
   Billson, F
TI A Randomized clinical trial of a single dose of intravitreal
   triamcinolone acetonide for neovascular age-related macular degeneration
   - One year results
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; PREVALENCE; MODEL; EYE
AB Objective: To determine if a single intravitreal injection of 4 mg of triamcinolone acetonide in patients with classic choroidal neovascularization associated with age-related macular degeneration can safely reduce the risk of severe visual loss.
   Methods: A double-masked, placebo-controlled, randomized clinical trial was performed in patients 60 years or older who had choroidal neovascularization with any classic component, a duration of symptoms of less than 1 year, and a visual acuity of 20/200 or better. Best-corrected visual acuity, intraocular pressure, and cataract grading were performed before the injection and then at 3, 6, and 12 months.
   Main Outcome Measure: The development of severe loss of vision (30 letters) by survival analysis on an intention-to-treat basis.
   Results: One hundred fifty-one eyes were randomized into the study, and follow-up data were obtained for 73 (97%) of the 75 eyes in the treated group and for 70 (92%) of the 76 eyes in the control group. There was no difference between the 2 groups for the development of severe visual loss during the first year of the study (log-rank chi(1)(2)=0.03, P=.90). In both groups, the 12-month risk of severe visual loss was 35%, with a hazard ratio of 1.05 (95% confidence interval, 0.59-1.86). The change in size of the neovascular membranes, however, was significantly less in eyes receiving triamcinolone than in those receiving placebo 3 months after treatment (P=.01), although no difference was noted after 12 months. After 12 months, treated eyes had a significantly higher risk of an elevated intraocular pressure (31/75 [41%] vs 3/76 [4%]; P<.001), but not of cataract progression (P=.29).
   Conclusions: A single dose of intravitreal triamcinolone had no effect on the risk of loss of visual acuity during the first year of the study in eyes with age-related macular degeneration and classic choroidal neovascularization, despite a significant antiangiogenic effect found 3 months after treatment. This biological effect warrants further study.
C1 Univ Sydney, Dept Clin Ophthalmol, Save Sight & Eye Hlth Inst, Sydney, NSW 2001, Australia.
   Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2001, Australia.
   Sydney Eye Hosp, Retina Unit, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney
RP Gillies, MC (通讯作者)，Univ Sydney, Dept Clin Ophthalmol, Save Sight & Eye Hlth Inst, GPO Box 4337, Sydney, NSW 2001, Australia.
RI gillies, mark c/B-3242-2012
OI Simpson, Judy M/0000-0001-5172-3004
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   CHANDLER DB, 1985, AM J OPHTHALMOL, V99, P686, DOI 10.1016/S0002-9394(14)76037-4
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HIDA T, 1986, AM J OPHTHALMOL, V101, P190, DOI 10.1016/0002-9394(86)90593-3
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   *MAC PHOT STUD, 1991, MAN PROC
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   *VERT PHOT THER ST, 2001, ZM J OPHTHALMOL, V131, P541
NR 18
TC 254
Z9 283
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2003
VL 121
IS 5
BP 667
EP 673
DI 10.1001/archopht.121.5.667
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 676XU
UT WOS:000182778500009
PM 12742844
DA 2022-11-30
ER

PT J
AU Song, DW
   Liu, P
   Shang, K
   Ma, YB
AF Song, Dawei
   Liu, Ping
   Shang, Kai
   Ma, YiBin
TI Application and mechanism of anti-VEGF drugs in age-related macular
   degeneration
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Review
DE mechanism; anti-VEGF drugs; age-related macularde; treatment; choroidal
   neovascularization
ID ANGIOGRAPHY; THERAPY
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. The incidence rate increases with age in people over 50 years of age. With the advent of China's aging society, the number of patients is increasing year by year. Although researchers have done a lot of basic research and clinical research on the pathogenesis and treatment of AMD in recent years, the pathogenesis of AMD is still controversialdue to the complexity of the disease itself. AMD is the primary cause of blindness in the elderly over 50 years old. It is characterized by the formation of choroidal neovascularization (CNV) and the over secretion of vascular endothelial growth factor (VEGF) as its main mechanism, which can eventually lead to vision loss or blindness. The occurrence and development of AMD is an extremely complex process, in which a large number of regulatory factors and cytokines are involved. Most of the existing treatments are for its concomitant CNV. Targeted VEGF drugs for neovascularization, such as Lucentis and Aflibercept, are the first-line drugs for AMD. Their application has greatly reduced the blinding rate of patients. However, there are still some patients who have no response to treatment or cannot maintain their vision after long-term treatment. Frequent injection also increases the risk of complications and economic burden. In order to further improve the quality of life and long-term prognosis of AMD patients, a variety of new treatmentshave been or will be applied in clinic, including combined treatment with the same or different targets to improve the curative effect, change or simplify the mode of medication, inhibit VEGF receptor tyrosine protein kinase and so on. This article provides a brief review of the research progress of anti-VEGF drugs and their mechanisms for the treatment of AMD, it is expected to provide a better treatment plan for AMD treatment.
C1 [Song, Dawei; Liu, Ping; Shang, Kai; Ma, YiBin] Taian City Cent Hosp, Tai An, Peoples R China.
RP Ma, YB (通讯作者)，Taian City Cent Hosp, Tai An, Peoples R China.
EM mybzlj1973@163.com
CR Ambati J, 2011, INVEST OPHTH VIS SCI, V52, P2166, DOI 10.1167/iovs.11-7328
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Arjunan P, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020309
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Chu S.J., 2015, J CLIN OPHTHALMOL, V23, P24
   Clearkin L, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000257
   Dor Y, 2001, AM J PHYSIOL-CELL PH, V280, pC1367, DOI 10.1152/ajpcell.2001.280.6.C1367
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guo CH, 2021, MAR DRUGS, V19, DOI 10.3390/md19040193
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hong H., 2010, INT J OPHTHALMOL-CHI, V10, P2176
   Hong HK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.22
   Hu YC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92693-z
   Kc A., 2020, BIOCHEM BIOPH RES CO, V530, P60
   Liu YM, 2021, EXP EYE RES, V204, DOI 10.1016/j.exer.2021.108446
   Ma R, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.641894
   [梅丽霞 MEI Li-xia], 2009, [中国医学影像技术, Chinese Journal of Medical Imaging Technology], V25, P813
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Mohan R.R., 2013, REPRESENTATIVE STERE, P145
   Montorio D, 2021, PHOTODIAGN PHOTODYN, V33, DOI 10.1016/j.pdpdt.2020.102094
   Schopf L., 2013, INVEST OPHTHALMOL VI, V84, P922
   Sharma K., 2021, CONTRIBUTION RARE AL
   Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Stenirri S, 2012, CLIN CHEM LAB MED, V50, P1021, DOI 10.1515/cclm-2011-0854
   Tavakoli Z, 2020, BIOMED PHYS ENG EXPR, V6, DOI 10.1088/2057-1976/ab269a
   Vogl WD, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85110-y
   Wang JL, 2013, INVEST OPHTH VIS SCI, V54, P7983, DOI 10.1167/iovs.13-13068
   Waters SB, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.5
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   Wei CR, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.557429
   Wei Y., 2020, SIMULTANEOUS INFEREN, P105
   Wu MJ, 2019, EXP EYE RES, V182, P93, DOI 10.1016/j.exer.2019.03.018
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
   Yu L., 2015, J OCULAR FUNDUS DIS, V31, P256
   Zarbin MA, 2022, BRIT J OPHTHALMOL, V106, P1561, DOI 10.1136/bjophthalmol-2020-318688
   Zhang Cheng-fen, 2003, Zhonghua Yan Ke Za Zhi, V39, P415
   Zhang M, 2008, MOL VIS, V14, P37
   [章玮 Zhang Wei], 2014, [中国实用眼科杂志, Chinese Journal of Practical Ophthalmology], V32, P428
   Zhu LP, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-1113-z
NR 41
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD SEP 23
PY 2022
VL 10
AR 955787
DI 10.3389/fbioe.2022.943915
PG 7
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 5K8KQ
UT WOS:000869969800001
PM 36213057
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Hykin, P
AF Sivaprasad, Sobha
   Hykin, Philip
TI What is new in the management of wet age-related macular degeneration?
SO BRITISH MEDICAL BULLETIN
LA English
DT Article
DE age-related macular degeneration; VEGF; ranibizumab; aflibercept;
   bevacizumab; radiation
ID VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL RANIBIZUMAB; VISUAL IMPAIRMENT; BLINDNESS; SAFETY; FOCUS;
   DELAY
AB The hallmark of wet age-related macular degeneration (AMD) is choroidal neovascularization (CNV). The key cytokine involved in the pathogenesis of CNV is vascular endothelial growth factor (VEGF). Since 2005, antiVEGF therapy has revolutionized the management of this condition.
   A systematic computerized literature search was conducted on PubMed ().
   AntiVEGF therapy has resulted in improvement in visual function and performance. Currently, practitioners are spoilt for choice of these agents.
   Bevacizumab is unlicensed for intraocular use but has a better market share than ranibizumab in the treatment of wet AMD as it is approximately 40 times cheaper than ranibizumab, if aliquoted into smaller doses for intraocular use. This has stirred up questions on indemnity, safety, dosing, treatment regimen and quality control, despite the fact that well-designed clinical trials have shown that both drugs are equally effective. Another dilemma for the physicians is the choice of treatment regimens with antiVEGF agents that include fixed dosing, optical coherence tomography (OCT)-guided re-treatment, treat and extend or a combination of proactive and reactive dosing. Real-life outcomes of physician-dependent OCT-guided re-treatment with these agents are inferior to outcomes reported in clinical trials.
   A recently food and drug administration-approved antiVEGF agent, aflibercept, is rapidly becoming a popular choice as well-designed randomized clinical trials indicate that eight weekly fixed dosing of aflibercept is non-inferior to monthly ranibizumab.
   Options for reducing the frequency of repeated intravitreal injections are being explored. Combination therapy with photodynamic therapy and epimacular brachytherapy seem scientifically plausible due to their synergistic effects. However, so far the results on these combinations have not shown any superior visual outcomes to antiVEGF monotherapy, and the practicalities of delivering these therapies are formidable. So, research into other novel therapeutic approaches such as pigment epithelium-derived factor and designed ankyrin repeat proteins are gaining momentum.
C1 [Sivaprasad, Sobha; Hykin, Philip] Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Sivaprasad, S (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM sobha.sivaprasad@moorfields.nhs.uk
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
FU Novartis; Bayer; Pfizer; Allergan
FX S.S. and P. H. have received research grants, travel grants, speaker
   fees and have attended advisory board meetings of Novartis, Bayer,
   Pfizer and Allergan.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Kaiser PK, 2012, GRAEF ARCH CLIN EXP, V250, P1563, DOI 10.1007/s00417-012-2123-4
   Kishan AU, 2012, INT J RADIAT ONCOL, DOI [10.1016/j.ijrobp.2012.07.2352, DOI 10.1016/J.IJR0BP.2012.07.2352.[]
   Maguire Maureen G, 2012, LDI Issue Brief, V17, P1
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mones J, 2011, OPHTHALMOLOGICA, V225, P112, DOI 10.1159/000319906
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Williams PD, 2012, CLIN OPHTHALMOL, V6, P1519, DOI 10.2147/OPTH.S31010
NR 30
TC 11
Z9 12
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-1420
EI 1471-8391
J9 BRIT MED BULL
JI Br. Med. Bull.
PD MAR
PY 2013
VL 105
IS 1
BP 201
EP 211
DI 10.1093/bmb/ldt004
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 133CK
UT WOS:000318114800012
PM 23393060
OA Bronze
DA 2022-11-30
ER

PT J
AU Quiram, PA
   Hassan, TS
   Williams, GA
AF Quiram, Polly A.
   Hassan, Tarek S.
   Williams, George A.
TI Treatment of naive lesions in neovascular age-related macular
   degeneration with pegaptanib
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; pegaptanib sodium; Macugen; naive lesions
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN;
   RANIBIZUMAB; EXPRESSION; ANTIBODY; THERAPY
AB Purpose: To evaluate the safety and efficacy of pegaptanib sodium injection (Macugen, OSI Eyetech Pharmaceuticals) as primary therapy for previously untreated choroidal neovascular membranes (CNV) associated with wet age-related macular degeneration (AMD).
   Methods: The authors retrospectively reviewed data of 90 patients with newly diagnosed wet AMD in which pegaptanilb was used as primary therapy. Inclusion criteria included CNV of any angiographic subtype and size. Exclusion criteria included any lesion previously treated with photodynamic therapy (PDT), intravitreal triamcinolone, or thermal laser. Outcome measures included pre and post-treatment changes in best-corrected visual acuity, lesion size, lesion angiographic characteristics, and optical coherence tomography (OCT) measurements. Patients were injected every 6 weeks and fluorescein angiography (FA) and OCT imaging were performed after every three injections. Safety assessment was performed by complete ophthalmologic examination pre- and post-injection.
   Results: Of the patients undergoing primary treatment with pegaptanib, the lesion characteristics were 80% (72/90) occult, 13% (12/90) minimally classic, and 7% (6/90) predominantly classic. Lesion sizes were 50% (45/90): <= 4 disc areas (DA) and 50% (45/90) > 4 DA. The mean follow-up was 9.1 +/- 2 months (range 6-14 months): Gain of >= 3 lines of vision occurred in 20% (18/90) of patients, stabilization of vision (prevention of three lines of vision loss) occurred in 70% (63/90) of patients, and loss of >= 3 lines of vision occurred in 10% (9/90) of patients, resulting in a 90% response rate. In the patients who gained 3 lines of vision, the average number of injections was 3.5. One case of endophthalmitis was recognized.
   Conclusions: Pegaptanib as primary therapy for naive CNV lesions offers a 90% rate of improvement or stabilization of vision-outcomes that exceed those reported in the VISION trial.
C1 William Beaumont Hosp, Royal Oak, MI 48073 USA.
C3 Beaumont Health
RP Quiram, PA (通讯作者)，William Beaumont Hosp, 3535 W 13 Mile Rd,MOB Suite 632, Royal Oak, MI 48073 USA.
EM pollyquiram@yahoo.com
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Presta LG, 1997, CANCER RES, V57, P4593
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Riusala A, 2005, GRAEF ARCH CLIN EXP, V243, P947, DOI 10.1007/s00417-005-1161-6
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 29
TC 21
Z9 21
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2007
VL 27
IS 7
BP 851
EP 856
DI 10.1097/IAE.0b013e31806458f0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 212QT
UT WOS:000249612600008
PM 17891008
DA 2022-11-30
ER

PT J
AU Savastano, MC
   Falsini, B
   Cozzupoli, GM
   Savastano, A
   Gambini, G
   De Vico, U
   Minnella, AM
   Placidi, G
   Piccardi, M
   Rizzo, S
AF Savastano, Maria C.
   Falsini, Benedetto
   Cozzupoli, Grazia M.
   Savastano, Alfonso
   Gambini, Gloria
   De Vico, Umberto
   Minnella, Angelo M.
   Placidi, Giorgio
   Piccardi, Marco
   Rizzo, Stanislao
TI Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related
   Macular Degeneration: Correlation with Macular Function
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE focal electroretinogram; sub-RPE illumination; age-related macular
   degeneration; outer retina and retinal pigment epithelium atrophy
ID VISUAL-ACUITY
AB The purpose of this study was to investigate the relationship between the retinal pigment epithelium (RPE) and outer retina changes, expressed in terms of sub-RPE illumination (SRI) on optical-coherence tomography (OCT), and central retinal function, measured by visual acuity and focal electroretinogram (fERG), in patients with non-exudative age-related macular degeneration (neAMD). In this retrospective study, 29 eyes of 29 patients affected by early (24.14%), intermediate (41.38%), and advanced (34.48%) neAMD were evaluated. All enrolled eyes were studied with OCT to measure the total area of SRI, by using an automated standardized algorithm. Visual acuity and fERG were assessed. The area of SRI was negatively correlated with fERG amplitude (r <= -0.4, p <= 0.02) and best-corrected visual acuity (BCVA) (r <= 0.4, p <= 0.04). Our results indicate that the severity of retinal pigment epithelium and outer retina atrophy (RORA), indirectly quantified through the detection of SRI areas by commercial OCT algorithms, is correlated with central retinal dysfunction, as determined by visual acuity and fERG, supporting the combined use of structural exams and functional tests as valid tools to detect the extent of RPE and photoreceptors' disruption.
C1 [Savastano, Maria C.; Falsini, Benedetto; Cozzupoli, Grazia M.; Savastano, Alfonso; Gambini, Gloria; De Vico, Umberto; Minnella, Angelo M.; Placidi, Giorgio; Piccardi, Marco; Rizzo, Stanislao] Fdn Policlin Univ A Gemelli IRCCS, UOC Oculist, Largo A Gemelli 8, I-00168 Rome, Italy.
   [Savastano, Maria C.; Falsini, Benedetto; Cozzupoli, Grazia M.; Savastano, Alfonso; Gambini, Gloria; De Vico, Umberto; Minnella, Angelo M.; Placidi, Giorgio; Piccardi, Marco; Rizzo, Stanislao] Univ Cattolica Sacro Cuore, UOC Oculist, Largo A Gemelli 8, I-00168 Rome, Italy.
   [Rizzo, Stanislao] CNR, Ist Neurosci, Via G Moruzzi 1, I-56124 Pisa, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze
   (IN-CNR)
RP Cozzupoli, GM (通讯作者)，Fdn Policlin Univ A Gemelli IRCCS, UOC Oculist, Largo A Gemelli 8, I-00168 Rome, Italy.; Cozzupoli, GM (通讯作者)，Univ Cattolica Sacro Cuore, UOC Oculist, Largo A Gemelli 8, I-00168 Rome, Italy.
EM mariacristina.savastano@gmail.com; benedetto.falsini@unicatt.it;
   mgcozzupoli@gmail.com; alfonso.savastano@policlinicogemelli.it;
   gambini.gloria@gmail.com; umbertodevico@gmail.com;
   angelomaria.minnella@policlinicogemelli.it; giorgioplacidi@libero.it;
   piccmarc@tiscali.it; stanislao.rizzo@unicatt.it
RI minnella, angelo maria/AAQ-6250-2020; Savastano, Alfonso/AAJ-4173-2021;
   Gambini, Gloria/AAE-9479-2021; Savastano, Maria Cristina/I-5355-2015;
   Falsini, Benedetto/AAC-5907-2022
OI minnella, angelo maria/0000-0001-5896-5313; Savastano,
   Alfonso/0000-0003-1575-6567; Savastano, Maria
   Cristina/0000-0003-1397-4333; PLACIDI, GIORGIO/0000-0003-2156-7068;
   Falsini, Benedetto/0000-0002-1694-1062
CR Abdel Kader M., 2017, NEW FRONT OPHTHALMOL, V3, P1, DOI [10.15761/NFO.1000156, DOI 10.15761/NFO.1000156]
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Capoluongo E, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2012.03.008
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Galli-Resta L, 2013, INVEST OPHTH VIS SCI, V54, P6560, DOI 10.1167/iovs.13-12676
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Kiernan DF, 2012, RETINA-J RET VIT DIS, V32, P1077, DOI 10.1097/IAE.0b013e31823c23bc
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kraszewska O, 2018, INVEST OPHTH VIS SCI, V59
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
NR 21
TC 3
Z9 3
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2973
DI 10.3390/jcm9092973
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OF4RX
UT WOS:000581198100001
PM 32942540
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Maronas, O
   Garcia-Quintanilla, L
   Luaces-Rodriguez, A
   Fernandez-Ferreiro, A
   Latorre-Pellicer, A
   Abraldes, MJ
   Lamas, MJ
   Carracedo, A
AF Maronas, Olalla
   Garcia-Quintanilla, Laura
   Luaces-Rodriguez, Andrea
   Fernandez-Ferreiro, Anxo
   Latorre-Pellicer, Ana
   Abraldes, Maximino J.
   Lamas, Maria J.
   Carracedo, Angel
TI Anti-VEGF Treatment and Response in Age-related Macular Degeneration:
   Disease's Susceptibility, Pharmacogenetics and Pharmacokinetics
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Susceptibility; pharmacogenetics; pharmacokinetics; treatments;
   age-related macular degeneration; anti-VEGF
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL RANIBIZUMAB TREATMENT;
   COMPLEMENT FACTOR-H; INTRAOCULAR PHARMACOKINETICS; PRECISION MEDICINE;
   GENE POLYMORPHISMS; TREATMENT OUTCOMES; POOLED FINDINGS; NONCODING RNAS;
   FACTOR THERAPY
AB The current review is focussing different factors that contribute and directly correlate to the onset and progression of Age-related Macular Degeneration (AMD). In particular, the susceptibility to AMD due to genetic and non-genetic factors and the establishment of risk scores, based on the analysis of different genes to measure the risk of developing the disease. A correlation with the actual therapeutic landscape to treat AMD patients from the point of view of pharmacokinetics and pharmacogenetics is also exposed. Treatments commonly used, as well as different regimes of administration, will be especially important in trying to classify individuals as "responders" and "non-responders". Analysis of different genes correlated with drug response and also the emerging field of microRNAs (miRNAs) as DOI : possible biomarkers for early AMD detection and response will be also reviewed.
   This article aims to provide the reader a review of different publications correlated with AMD from the molecular and kinetic point of view as well as its commonly used treatments, major pitfalls and future directions that, to our knowledge, could be interesting to assess and follow in order to develop a personalized medicine model for AMD.
C1 [Maronas, Olalla; Carracedo, Angel] Univ Santiago Compostela, Ctr Nacl Genotipado CEGEN PRB3, Grp Med Xenom, Santiago De Compostela, Spain.
   [Garcia-Quintanilla, Laura] Xerencia Xest Integrada Santiago de Compostela SE, Serv Farm, Santiago De Compostela, Spain.
   [Luaces-Rodriguez, Andrea; Fernandez-Ferreiro, Anxo] Univ Santiago de Compostela, Fac Farm, Dept Farm & Tecnol Farmaceut, Santiago De Compostela, Spain.
   [Luaces-Rodriguez, Andrea; Fernandez-Ferreiro, Anxo] Univ Santiago de Compostela, Fac Farm, Inst Farm Ind, Santiago De Compostela, Spain.
   [Luaces-Rodriguez, Andrea; Fernandez-Ferreiro, Anxo; Lamas, Maria J.] Inst Invest Salud Santiago de Compostela IDIS, Grp Farmacol Clin, Santiago De Compostela, Spain.
   [Fernandez-Ferreiro, Anxo] Hosp Clin Univ Santiago de Compostela SERGAS CHUS, Dept Farm, Santiago De Compostela, Spain.
   [Latorre-Pellicer, Ana] Univ Zaragoza, Fac Med, Dept Farmacol Fisiol, Unidad Genet Clin & Genom Func, Zaragoza, Spain.
   [Abraldes, Maximino J.] Xerencia Xest Integrada Santiago de Compostela, Serv Oftalmol, Santiago De Compostela, Spain.
   [Abraldes, Maximino J.] Univ Santiago de Compostela, Dept Ciruxia & Especialidades Med Quirurx, Santiago De Compostela, Spain.
   [Carracedo, Angel] Univ Santiago de Compostela, CIBERER, Grp Med Xenom, Santiago De Compostela, Spain.
   [Carracedo, Angel] SERGAS, Fdn Publ Galega Med Xenom, Santiago De Compostela, Spain.
C3 Universidade de Santiago de Compostela; Universidade de Santiago de
   Compostela; Universidade de Santiago de Compostela; University of
   Zaragoza; Universidade de Santiago de Compostela; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; Universidade de Santiago de
   Compostela
RP Maronas, O (通讯作者)，Univ Santiago Compostela, Ctr Nacl Genotipado CEGEN PRB3, Grp Med Xenom, Santiago De Compostela, Spain.; Garcia-Quintanilla, L (通讯作者)，Xerencia Xest Integrada Santiago de Compostela SE, Serv Farm, Santiago De Compostela, Spain.
EM olalla.maronas@jusc.es; laura.garcia.quintanilla@sergas.es;
   angel.carraeedo@usc.es
RI Garcia-Quintanilla, Laura/AAV-2083-2021; Pellicer, Ana
   Latorre/A-8601-2019; LAMAS, MARIA J/R-2717-2016
OI Pellicer, Ana Latorre/0000-0002-4703-6620; Garcia-Quintanilla,
   Laura/0000-0002-4411-7097; Carracedo, Angel/0000-0003-1085-8986; LAMAS,
   MARIA J/0000-0001-8875-3290; Maronas Amigo, Olalla/0000-0001-6952-3377
FU Instituto de Salud Carlos III-ISCIII [PI17/00940]; FEDER
   [RD16/0008/0003, RD12/0034/0017]; ISCIII [JR18/00014, PT13000/10004];
   Xunta de Galicia; European Union (European Social Fund - ESF); MINECO;
   USC
FX This work was partially supported by Instituto de Salud Carlos
   III-ISCIII (PI17/00940) and (RETICS Oftared, RD16/0008/0003 and
   RD12/0034/0017) co-funded by FEDER. Anxo Fernandez-Ferreiro acknowledges
   the support of ISCIII by research grant (JR18/00014). Ana
   Latorre-Pellicer acknowledges the financial support of the Xunta de
   Galicia and the European Union (European Social Fund - ESF) (predoctoral
   research fellowship). We also like to thank the INNOPHARMA Platform,
   supported by MINECO and USC and cofounded by European Regional
   Development Fund (ERDF), and to the Spanish National Genotyping Center
   (CEGEN), included in the Biomolecular and Bioinformatics Resources
   Platform supported by the ISCIII (PT13000/10004).
CR Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Arias Barquet L, 2012, Arch Soc Esp Oftalmol, V87 Suppl 1, P10, DOI 10.1016/S0365-6691(12)70047-3
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Ayala-Haedo JA, 2010, ANN HUM GENET, V74, P195, DOI 10.1111/j.1469-1809.2010.00570.x
   Bakbak B, 2016, CURR EYE RES, V41, P862, DOI 10.3109/02713683.2015.1067325
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonyadi MHJ, 2017, OPHTHALMIC GENET, V38, P308, DOI 10.1080/13816810.2016.1237664
   Bovier ER, 2013, NUTRIENTS, V5, P750, DOI 10.3390/nu5030750
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Celik N, 2015, INVEST OPHTH VIS SCI, V56, P5574, DOI 10.1167/iovs.15-16418
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cioffi C., 2016, RECENT DEV AGENTS TR, P261, DOI [10.29200/acsmedchemrev-v51.ch16, DOI 10.29200/ACSMEDCHEMREV-V51.CH16]
   Clarke SF, 2012, GUT MICROBES, V3, P186, DOI 10.4161/gmic.20168
   Costa J., 2017, AMD FUTURE PERSPECTI
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   De Guire V, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq354
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Ertekin S, 2014, MOL VIS, V20, P1057
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2014, OPHTHALMOLOGY, V121, P1663, DOI 10.1016/j.ophtha.2014.02.025
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Huang C, 2013, MOL VIS, V19, P1211
   Hung T, 2010, RNA BIOL, V7, P582, DOI 10.4161/rna.7.5.13216
   Jeong SW, 2015, INVEST OPHTH VIS SCI, V56, P2737, DOI 10.1167/iovs.14-14803
   Juan V.T., 2010, REV MED CLIN CONDES, V21, P949, DOI [10.1016/S0716-8640(10)70620-9, DOI 10.1016/S0716-8640(10)70620-9]
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Laude A, 2010, PROG RETIN EYE RES, V29, P466, DOI 10.1016/j.preteyeres.2010.04.003
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lee JT, 2009, GENE DEV, V23, P1831, DOI 10.1101/gad.1811209
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li F, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040478
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lores-Motta L, 2018, MOL DIAGN THER, V22, P315, DOI 10.1007/s40291-018-0332-1
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Mullins RF, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-58
   Mustafi D, 2013, HUM MOL GENET, V22, P2992, DOI 10.1093/hmg/ddt156
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Park UC, 2014, MOL VIS, V20, P1680
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rowan S, 2018, ADV EXP MED BIOL, V1074, P429, DOI 10.1007/978-3-319-75402-4_53
   Sakurai M, 2014, BRIT J OPHTHALMOL, V98, P469, DOI 10.1136/bjophthalmol-2013-304267
   Saltzman ET, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00061
   Saunders DJ, 2015, BRIT J OPHTHALMOL, V99, P1554, DOI 10.1136/bjophthalmol-2015-306771
   Schlottmann PG, 2017, ASIA-PAC J OPHTHALMO, V6, P514, DOI 10.22608/APO.2017258
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schwartz SG, 2005, OPHTHALMOLOGY, V112, P2131, DOI 10.1016/j.ophtha.2005.08.014
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Sun LJ, 2018, PROTEIN CELL, V9, P397, DOI 10.1007/s13238-018-0546-3
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Villarreal G, 2011, INVEST OPHTH VIS SCI, V52, P3391, DOI 10.1167/iovs.10-6165
   Wan PX, 2017, J MED GENET, V54, P450, DOI 10.1136/jmedgenet-2016-104266
   Wang CG, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122659
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wykoff CC, 2018, OSLI RETINA, V49, P913, DOI 10.3928/23258160-20181203-01
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Xu XD, 2014, MOL BIOL REP, V41, P4493, DOI 10.1007/s11033-014-3320-5
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2018, ASIA-PAC J OPHTHALMO, V7, P63, DOI 10.22608/APO.2017495
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 133
TC 5
Z9 5
U1 0
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2020
VL 27
IS 4
BP 549
EP 569
DI 10.2174/0929867326666190711105325
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA KU3AG
UT WOS:000519578800003
PM 31296152
DA 2022-11-30
ER

PT J
AU McGuinness, MB
   Karahalios, A
   Finger, RP
   Guymer, RH
   Simpson, JA
AF McGuinness, Myra B.
   Karahalios, Amalia
   Finger, Robert P.
   Guymer, Robyn H.
   Simpson, Julie A.
TI Age-Related Macular Degeneration and Mortality: A Systematic Review and
   Meta-Analysis
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Review
DE Age-related macular degeneration; cancer; cardiovascular disease;
   meta-analysis; mortality; survival
ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; VISUAL IMPAIRMENT;
   MYOCARDIAL-INFARCTION; EYE DISEASE; CARDIOVASCULAR-DISEASE;
   ATHEROSCLEROSIS RISK; ASSOCIATION; SURVIVAL; PATHOGENESIS
AB Purpose: Age-related macular degeneration (AMD) is the leading cause of severe, irreversible vision loss in older adults. Evidence for an association between AMD and mortality remains inconclusive despite evidence for an association with cardiovascular and inflammatory diseases. We aim to compare all-cause, cardiovascular and cancer mortality between those with early or late AMD and control study participants.Methods: A protocol was registered at PROSPERO (CRD42015020622). A systematic search of Medline (Ovid), PubMed, and Embase (Ovid) was conducted on 6 June 2015. Reference lists from identified studies and four clinical trial registries were searched for additional studies. Participants were required to be over the age of 40 years, and AMD status must have been objectively assessed. The Risk Of Bias In Non-Randomized Studies - of Interventions (ROBINS-I) tool was used to assess the risk of bias. Random-effects meta-analyses were performed.Results: A total of 12 reports from 10 studies were included in the meta-analysis. Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02-1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13-1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98-1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96-1.31). There was no evidence of an association between early or late AMD and cancer mortality (early AMD, three studies, HR 1.17, 95% CI 0.78-1.75; late AMD, three studies, HR 1.01, 95% CI 0.77-1.33).Conclusion: Late AMD is associated with increased rates of all-cause and cardiovascular mortality, suggesting shared pathways between late AMD and systemic disease.
C1 [McGuinness, Myra B.; Finger, Robert P.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [McGuinness, Myra B.; Finger, Robert P.; Guymer, Robyn H.] Univ Melbourne, Dept Ophthalmol, East Melbourne, Australia.
   [McGuinness, Myra B.; Karahalios, Amalia; Simpson, Julie A.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Level 3,207 Bouverie St, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne
RP Simpson, JA (通讯作者)，Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Level 3,207 Bouverie St, Melbourne, Vic 3010, Australia.
EM julieas@unimelb.edu.au
RI McGuinness, Myra/G-4900-2017
OI McGuinness, Myra/0000-0002-5422-040X; Finger, Robert
   P/0000-0003-4253-7597; Guymer, Robyn/0000-0002-9441-4356
FU Australian Postgraduate Award; Victorian Centre for Biostatistics
   (NHMRC: Centre of Research Excellence) [1035261]; Lloyd and Kathleen
   Ansell Ophthalmology Foundation; University of Melbourne
FX This work was supported by an Australian Postgraduate Award and a
   studentship courtesy of the Victorian Centre for Biostatistics (NHMRC:
   Centre of Research Excellence grant 1035261) to MBM; the Lloyd and
   Kathleen Ansell Ophthalmology Foundation and the Mankiewicz-Zelkin
   Fellowship of the University of Melbourne to RPF; and CERA receives
   operational infrastructure support from the Victorian government. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Al-Qureshi S, 2012, CLIN EXP OPHTHALMOL, V40, P3, DOI 10.1111/j.1442-9071.2011.02739.x
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BENGTSSON B, 1984, ACTA OPHTHALMOL, V62, P725
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2005, ARCH OPHTHALMOL-CHIC, V123, P395, DOI 10.1001/archopht.123.3.395
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EW, 2015, PLOS ONE, V10, P11
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Cuijpers P, 2002, J AFFECT DISORDERS, V72, P227, DOI 10.1016/S0165-0327(01)00413-X
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Gohdes DM, 2005, PREVENT CHRONIC DIS, V2, P1
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hernan MA, 2002, AM J EPIDEMIOL, V155, P176, DOI 10.1093/aje/155.2.176
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198-003-1490-4
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P48, DOI 10.1159/000027393
   Lange LA, 2006, JAMA-J AM MED ASSOC, V296, P2703, DOI 10.1001/jama.296.22.2703
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   ROGOT E, 1966, J CHRON DIS, V19, P179, DOI 10.1016/0021-9681(66)90048-8
   Roth DB, 2009, OPHTHALMOLOGY, V116, P1226, DOI 10.1016/j.ophtha.2009.02.011
   Schlomer GL, 2010, J COUNS PSYCHOL, V57, P1, DOI 10.1037/a0018082
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   THOMPSON JR, 1989, AGE AGEING, V18, P83, DOI 10.1093/ageing/18.2.83
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang YX, 2014, ACTA OPHTHALMOL, V92, pE424, DOI 10.1111/aos.12370
   Whitcup SM, 2013, INT J INFLAM, V2013, P1
   Wong D, 2011, GRAEF ARCH CLIN EXP, V249, P161, DOI 10.1007/s00417-010-1574-8
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
   Xu L, 2009, OPHTHALMOLOGY, V116, P732, DOI 10.1016/j.ophtha.2008.11.003
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 64
TC 26
Z9 26
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2017
VL 24
IS 3
BP 141
EP 152
DI 10.1080/09286586.2016.1259422
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EU1RY
UT WOS:000400798900001
PM 28139151
DA 2022-11-30
ER

PT J
AU Shahidatul-Adha, M
   Zunaina, E
   Aini-Amalina, MN
AF Shahidatul-Adha, Mohamad
   Zunaina, Embong
   Aini-Amalina, Mazlan N.
TI Evaluation of vascular endothelial growth factor (VEGF) level in the
   tears and serum of age-related macular degeneration patients
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FLUID; ANGIOGENESIS; PATHOGENESIS; RETINOPATHY; CORRELATE; SMOKING; AMD
AB Age-related macular degeneration (AMD) is an important cause of irreversible central blindness worldwide. Clinical manifestations range from asymptomatic in early and intermediate AMD to significant vision loss in late AMD. Approximately 10% of cases of early AMD eventually progress to the late advanced stage, influenced by the upregulation of vascular endothelial growth factor (VEGF). In this study, we evaluated VEGF concentration in the tears and serum of AMD patients. Our study revealed a significantly higher level of VEGF in the tears of patients with AMD compared with controls. The tear VEGF level has high sensitivity and specificity, and is significantly related to the severity of AMD, whilst serum VEGF level is non-specific and non-predictive of AMD severity. Thus, VEGF level in the tears may be used as a non-invasive biomarker for AMD progression. A large cohort study is needed for further verification.
C1 [Shahidatul-Adha, Mohamad; Zunaina, Embong] Univ Sains Malaysia, Sch Med Sci, Dept Ophthalmol & Visual Sci, Kubang Kerian 16150, Kelantan, Malaysia.
   [Shahidatul-Adha, Mohamad; Zunaina, Embong; Aini-Amalina, Mazlan N.] Hosp Univ Sains Malaysia, Jalan Raja Perempuan Zainab II, Kota Baharu 16150, Kelantan, Malaysia.
C3 Universiti Sains Malaysia; Universiti Sains Malaysia
RP Shahidatul-Adha, M (通讯作者)，Univ Sains Malaysia, Sch Med Sci, Dept Ophthalmol & Visual Sci, Kubang Kerian 16150, Kelantan, Malaysia.; Shahidatul-Adha, M (通讯作者)，Hosp Univ Sains Malaysia, Jalan Raja Perempuan Zainab II, Kota Baharu 16150, Kelantan, Malaysia.
EM shieda@usm.my
OI Shahidatul-Adha, Mohamad/0000-0002-4835-4022
FU Tabung Insentif Pembangunan Siswazah PPSP - School of Medical Sciences,
   Universiti Sains Malaysia
FX This study was partially supported by the Tabung Insentif Pembangunan
   Siswazah PPSP 2016; a monetary incentive funded by School of Medical
   Sciences, Universiti Sains Malaysia.
CR Adigal SS, 2021, EXPERT REV MOL DIAGN, V21, P767, DOI 10.1080/14737159.2021.1941879
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ang WJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221481
   Azkargorta M, 2017, J PROTEOMICS, V150, P359, DOI 10.1016/j.jprot.2016.05.006
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boursiquot BC, 2017, HYPERTENSION, V70, P552, DOI 10.1161/HYPERTENSIONAHA.117.09275
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Denisin AK, 2012, ANALYST, V137, P5088, DOI 10.1039/c2an35821b
   Ghoshal R, 2018, SAINS MALAYS, V47, P2447, DOI 10.17576/jsm-2018-4710-21
   Gomulka K, 2019, ADV CLIN EXP MED, V28, P759, DOI 10.17219/acem/92012
   Haas P, 2011, CURR EYE RES, V36, P143, DOI 10.3109/02713683.2010.533808
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hsu MY, 2015, LAB CHIP, V15, P2357, DOI 10.1039/c4lc01052c
   Kasza M, 2015, GRAEF ARCH CLIN EXP, V253, P1581, DOI 10.1007/s00417-015-3030-2
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Liu YY, 2019, INT J OPHTHALMOL-CHI, V12, P457, DOI 10.18240/ijo.2019.03.17
   Lopez-Cisternas J, 2006, CORNEA, V25, P312
   Ma YH, 2012, J NEUROSCI RES, V90, P1873, DOI 10.1002/jnr.23088
   Matsumoto T, 2017, GRAEF ARCH CLIN EXP, V255, P1981, DOI 10.1007/s00417-017-3756-0
   Mesquita J, 2018, GROWTH FACTORS, V36, P48, DOI 10.1080/08977194.2018.1477140
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oshima Y, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-01816-7
   Pieczynski J, 2021, EUR J OPHTHALMOL, V31, P2245, DOI 10.1177/1120672121998922
   Rentka A, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/573681
   Roszkowska AM, 2013, CURR EYE RES, V38, P335, DOI 10.3109/02713683.2012.745880
   Shahidi-Dadras M, 2016, INT J DERMATOL, V55, P52, DOI 10.1111/ijd.12842
   Sharma K, 2015, ANN NEUROSCI, V22, P232, DOI 10.5214/ans.0972.7531.220408
   Singhal R., 2020, INVESTIG OPHTHALMOL, V61, P2999
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   STUCHELL RN, 1984, INVEST OPHTH VIS SCI, V25, P374
   Tan W, 2007, CANCER BIOL THER, V6, P1211
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tual-Chalot S, 2020, CIRC RES, V126, P243, DOI 10.1161/CIRCRESAHA.119.315974
   Ugur MG, 2018, CLIN RESPIR J, V12, P1912, DOI 10.1111/crj.12755
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   WHITE KM, 1993, ACTA OPHTHALMOL, V71, P524
   Winiarczyk M, 2018, GRAEF ARCH CLIN EXP, V256, P1127, DOI 10.1007/s00417-018-3984-y
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Zakaria N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036451
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zechariah A, 2013, ARTERIOSCL THROM VAS, V33, P1561, DOI 10.1161/ATVBAHA.112.300749
   Zhang JJ, 2021, CURR EYE RES, V46, P1900, DOI 10.1080/02713683.2021.1942070
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
NR 48
TC 0
Z9 0
U1 1
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 15
PY 2022
VL 12
IS 1
AR 4423
DI 10.1038/s41598-022-08492-7
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZT9JZ
UT WOS:000769466200056
PM 35292705
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bilbao-Malave, V
   Gonzalez-Zamora, J
   de la Puente, M
   Recalde, S
   Fernandez-Robredo, P
   Hernandez, M
   Layana, AG
   de Viteri, MS
AF Bilbao-Malave, Valentina
   Gonzalez-Zamora, Jorge
   de la Puente, Miriam
   Recalde, Sergio
   Fernandez-Robredo, Patricia
   Hernandez, Maria
   Garcia Layana, Alfredo
   Saenz de Viteri, Manuel
TI Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Age
   Related Macular Degeneration, Role in Pathophysiology, and Possible New
   Therapeutic Strategies
SO ANTIOXIDANTS
LA English
DT Review
DE age related macular degeneration; mitochondria; endoplasmic reticulum;
   oxidative stress; antioxidants; bile acids; resveratrol; melatonin;
   humanin; coenzyme Q10
ID RETINAL-PIGMENT EPITHELIUM; UNFOLDED PROTEIN RESPONSE; ENDOTHELIAL
   GROWTH-FACTOR; OXIDATIVE STRESS; TAUROURSODEOXYCHOLIC ACID; ER STRESS;
   CHOROIDAL NEOVASCULARIZATION; RESVERATROL PROTECTS; COENZYME Q(10); RPE
   CELLS
AB Age related macular degeneration (AMD) is the main cause of legal blindness in developed countries. It is a multifactorial disease in which a combination of genetic and environmental factors contributes to increased risk of developing this vision-incapacitating condition. Oxidative stress plays a central role in the pathophysiology of AMD and recent publications have highlighted the importance of mitochondrial dysfunction and endoplasmic reticulum stress in this disease. Although treatment with vascular endothelium growth factor inhibitors have decreased the risk of blindness in patients with the exudative form of AMD, the search for new therapeutic options continues to prevent the loss of photoreceptors and retinal pigment epithelium cells, characteristic of late stage AMD. In this review, we explain how mitochondrial dysfunction and endoplasmic reticulum stress participate in AMD pathogenesis. We also discuss a role of several antioxidants (bile acids, resveratrol, melatonin, humanin, and coenzyme Q10) in amelioration of AMD pathology.
C1 [Bilbao-Malave, Valentina; Gonzalez-Zamora, Jorge; de la Puente, Miriam; Garcia Layana, Alfredo; Saenz de Viteri, Manuel] Clin Univ Navarra, Dept Opthalmol, Pamplona 31008, Spain.
   [Recalde, Sergio; Fernandez-Robredo, Patricia; Hernandez, Maria; Garcia Layana, Alfredo; Saenz de Viteri, Manuel] Univ Navarra, Dept Ophthalmol, Expt Ophthalmol Lab, Retinal Pathol & New Therapies Grp, Pamplona 31008, Spain.
   [Recalde, Sergio; Fernandez-Robredo, Patricia; Hernandez, Maria; Garcia Layana, Alfredo; Saenz de Viteri, Manuel] Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain.
   [Recalde, Sergio; Fernandez-Robredo, Patricia; Hernandez, Maria; Garcia Layana, Alfredo; Saenz de Viteri, Manuel] Inst Salud Carlos III, Red Temat Invest Cooperat Salud Prevent Early Det, Minist Ciencia Innovac & Univ, Madrid 28029, Spain.
C3 University of Navarra; University of Navarra; Instituto de Salud Carlos
   III
RP de Viteri, MS (通讯作者)，Clin Univ Navarra, Dept Opthalmol, Pamplona 31008, Spain.; de Viteri, MS (通讯作者)，Univ Navarra, Dept Ophthalmol, Expt Ophthalmol Lab, Retinal Pathol & New Therapies Grp, Pamplona 31008, Spain.; de Viteri, MS (通讯作者)，Navarra Inst Hlth Res, IdiSNA, Pamplona 31008, Spain.; de Viteri, MS (通讯作者)，Inst Salud Carlos III, Red Temat Invest Cooperat Salud Prevent Early Det, Minist Ciencia Innovac & Univ, Madrid 28029, Spain.
EM vbilbao@unav.es; jgzamora@unav.es; mdelapuentec@unav.es;
   srecalde@unav.es; pfrobredo@unav.es; mahersan@unav.es; aglayana@unav.es;
   msaenzdevit@unav.es
RI Recalde, Sergio/D-1815-2017
OI Recalde, Sergio/0000-0002-9328-9725; Gonzalez Zamora,
   Jorge/0000-0002-2826-6842; Saenz-de-Viteri, Manuel/0000-0002-9375-4535
FU Instituto de Salud Carlos III/European Regional Development Fund (ERDF);
   OFTARED: Enfermedades oculares: "Prevencion, deteccion precoz,
   tratamiento y rehabilitacion de las patologias oculares"
   [RD16/0008/0011]; Fundacion Jesus de Gangoiti Barrera; Fundacion
   Multiopticas CUN 2019
FX This research was funded by research grants from the "Instituto de Salud
   Carlos III/European Regional Development Fund (ERDF)" and
   RD16/0008/0011, OFTARED: Enfermedades oculares: "Prevencion, deteccion
   precoz, tratamiento y rehabilitacion de las patologias oculares". This
   work has been partly funded by the Fundacion Jesus de Gangoiti Barrera
   and Fundacion Multiopticas CUN 2019.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2
   Adams CJ, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00011
   Ivanescu AA, 2015, NUTRIENTS, V7, P5423, DOI 10.3390/nu7075229
   Alaimo A, 2020, ARCH TOXICOL, V94, P553, DOI 10.1007/s00204-019-02637-w
   Alhasani RH, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090367
   Ansar M, 2015, HUM GENET, V134, P941, DOI 10.1007/s00439-015-1571-4
   Athanasiou Dimitra, 2017, Hum Mol Genet, V26, P4896, DOI 10.1093/hmg/ddx370
   Bardak H, 2018, CUTAN OCUL TOXICOL, V37, P112, DOI 10.1080/15569527.2017.1354218
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Bechtel TJ, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600391
   Beuers U, 2009, J HEPATOL, V51, P237, DOI 10.1016/j.jhep.2009.04.009
   Bhatt P, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01836-4
   Bhattarai N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062066
   Binet F, 2015, CELL METAB, V22, P560, DOI 10.1016/j.cmet.2015.07.010
   Blasi MA, 2001, OPHTHALMOLOGICA, V215, P51, DOI 10.1159/000050826
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6819736
   Boatright JH, 2006, MOL VIS, V12, P1706
   Boatright Jeffrey H, 2009, J Ocul Biol Dis Infor, V2, P149
   Bodnar NO, 2017, CELL, V169, P722, DOI 10.1016/j.cell.2017.04.020
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Bubenik GA, 2011, J PHYSIOL PHARMACOL, V62, P13
   Cabral-Miranda F, 2018, CURR TOP MICROBIOL, V414, P131, DOI 10.1007/82_2017_52
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851
   Carvalho P, 2010, CELL, V143, P579, DOI 10.1016/j.cell.2010.10.028
   Chakravarthi S, 2006, EMBO REP, V7, P271, DOI 10.1038/sj.embor.7400645
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   Chapman J, 2019, FEBS LETT, V593, P1566, DOI 10.1002/1873-3468.13498
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chino H, 2020, TRENDS CELL BIOL, V30, P384, DOI 10.1016/j.tcb.2020.02.001
   Chong WC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040771
   Christianson JC, 2014, NAT STRUCT MOL BIOL, V21, P325, DOI 10.1038/nsmb.2793
   Christis C, 2008, FEBS J, V275, P4700, DOI 10.1111/j.1742-4658.2008.06590.x
   Colla E, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00560
   Cormenier J, 2018, MECH AGEING DEV, V170, P82, DOI 10.1016/j.mad.2017.08.003
   Cornebise C, 2020, MOLECULES, V25, DOI 10.3390/molecules25235564
   Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063
   Crooke A, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12430
   Daruich A, 2019, MOL VIS, V25, P610
   de Barcelos IP, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020028
   de la Barca JMC, 2016, BRAIN, V139, P2864, DOI 10.1093/brain/aww222
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Delmas D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031295
   Dieguez HH, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12643
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Drack AV, 2012, INVEST OPHTH VIS SCI, V53, P100, DOI 10.1167/iovs.11-8544
   Drogat B, 2007, CANCER RES, V67, P6700, DOI 10.1158/0008-5472.CAN-06-3235
   Druelle C, 2016, ONCOTARGET, V7, P67699, DOI 10.18632/oncotarget.11505
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   Diaz-Casado ME, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092221
   Ellgaard L, 2018, TRENDS BIOCHEM SCI, V43, P32, DOI 10.1016/j.tibs.2017.10.006
   Estebanez B, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01744
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Feher J, 2003, OPHTHALMOLOGICA, V217, P351, DOI 10.1159/000071351
   Fernandes AF, 2006, EXP EYE RES, V83, P1472, DOI 10.1016/j.exer.2006.07.024
   Fernandez-Robredo P, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090838
   Fernandez-Sanchez L, 2011, INVEST OPHTH VIS SCI, V52, P4998, DOI 10.1167/iovs.11-7496
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Zuccato CF, 2019, EXPERT OPIN THER TAR, V23, P117, DOI 10.1080/14728222.2019.1559300
   Garcia-Layana A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041253
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gardner BM, 2011, SCIENCE, V333, P1891, DOI 10.1126/science.1209126
   Garrido-Maraver J, 2014, MOL SYNDROMOL, V5, P187, DOI 10.1159/000360101
   Garrido-Maraver J, 2014, FRONT BIOSCI-LANDMRK, V19, P619, DOI 10.2741/4231
   Gaspar JM, 2013, NEUROSCIENCE, V253, P380, DOI 10.1016/j.neuroscience.2013.08.053
   Gavilan MP, 2006, NEUROBIOL AGING, V27, P973, DOI 10.1016/j.neurobiolaging.2005.05.010
   Ghosh R, 2010, PLOS ONE, V5, pA104, DOI 10.1371/journal.pone.0009575
   Gomez-Vicente V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137826
   Gong ZW, 2018, J CELL BIOL, V217, P635, DOI 10.1083/jcb.201606095
   Gong ZW, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00210
   Grootjans J, 2016, NAT REV IMMUNOL, V16, P469, DOI 10.1038/nri.2016.62
   Han G, 2014, INVEST OPHTH VIS SCI, V55, P5616, DOI 10.1167/iovs.14-14371
   Hernandez M, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051423
   Hernandez-Camacho JD, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00044
   Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580-020-0250-z
   Hetz C, 2017, NAT REV NEUROL, V13, P477, DOI 10.1038/nrneurol.2017.99
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hussain SG, 2007, BIOCHEM BIOPH RES CO, V355, P365, DOI 10.1016/j.bbrc.2007.01.156
   Huyer G, 2004, J BIOL CHEM, V279, P38369, DOI 10.1074/jbc.M402468200
   Ikeyama S, 2003, J BIOL CHEM, V278, P16726, DOI 10.1074/jbc.M300677200
   Josifovska N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030813
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kagan VE, 2000, PROTOPLASMA, V214, P11, DOI 10.1007/BF02524257
   Kanavi MR, 2014, MOLECULES, V19, P17578, DOI 10.3390/molecules191117578
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kang JH, 2016, ARCH PHARM RES, V39, P1703, DOI 10.1007/s12272-016-0839-0
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Kheitan S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181667
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kirkland JL, 2002, EXP GERONTOL, V37, P757, DOI 10.1016/S0531-5565(02)00014-1
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Koyama Y, 2008, INVEST OPHTH VIS SCI, V49, P2376, DOI 10.1167/iovs.07-1067
   Lee CS, 2015, YONSEI MED J, V56, P1678, DOI 10.3349/ymj.2015.56.6.1678
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Li C, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01633
   Li CS, 2020, ADV EXP MED BIOL, V1248, P265, DOI 10.1007/978-981-15-3266-5_12
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Li W, 2020, APPL MICROBIOL BIOT, V104, P6129, DOI 10.1007/s00253-020-10614-y
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Li Z, 2020, NANOMED-NANOTECHNOL, V24, DOI 10.1016/j.nano.2019.102111
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Libby RT, 2010, ADV EXP MED BIOL, V664, P403, DOI 10.1007/978-1-4419-1399-9_46
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Maharjan P, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11110561
   Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245
   Manzar H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239299
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Matsunaga D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165150
   Maugeri A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072118
   Maurel M, 2014, TRENDS BIOCHEM SCI, V39, P245, DOI 10.1016/j.tibs.2014.02.008
   McLaughlin T, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0250-z
   Mehrzadi S, 2020, EXPERT OPIN THER TAR, V24, P359, DOI 10.1080/14728222.2020.1737015
   Merksamer PI, 2008, CELL, V135, P933, DOI 10.1016/j.cell.2008.10.011
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Minakshi R, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.215
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Monte MJ, 2009, WORLD J GASTROENTERO, V15, P804, DOI 10.3748/wjg.15.804
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Murase H, 2015, INVEST OPHTH VIS SCI, V56, P2511, DOI 10.1167/iovs.14-15962
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Naidoo N, 2009, AGEING RES REV, V8, P150, DOI 10.1016/j.arr.2009.03.001
   Nashine S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051102
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Navas P, 2007, MITOCHONDRION, V7, pS34, DOI 10.1016/j.mito.2007.02.010
   Neal SE, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.32
   Nita M, 2020, EXCLI J, V19, P1353, DOI 10.17179/excli2020-2915
   Nociari M. M., 2017, LYSOSOMES ASS DIS ME
   Nuss JE, 2008, BIOCHEM BIOPH RES CO, V365, P355, DOI 10.1016/j.bbrc.2007.10.194
   Okabe M, 2008, MOL CANCER THER, V7, P3081, DOI 10.1158/1535-7163.MCT-08-0539
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Oveson BC, 2011, J NEUROCHEM, V116, P144, DOI 10.1111/j.1471-4159.2010.07092.x
   Patel C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092138
   Perepechaeva ML, 2014, B EXP BIOL MED+, V157, P424, DOI 10.1007/s10517-014-2582-1
   Phillips MJ, 2008, INVEST OPHTH VIS SCI, V49, P2148, DOI 10.1167/iovs.07-1012
   Qin SF, 2014, EXP EYE RES, V118, P100, DOI 10.1016/j.exer.2013.11.010
   Qiu YY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1780-1
   Qu JF, 2009, INVEST OPHTH VIS SCI, V50, P1814, DOI 10.1167/iovs.08-2656
   Rana T, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.539
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Read A, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10050384
   Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480
   Ren J, 2021, NAT REV CARDIOL, V18, P499, DOI 10.1038/s41569-021-00511-w
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   Rosen RB, 2012, MOL VIS, V18, P1640
   Rotig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   de Viteri MS, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090828
   Salminen A, 2020, J MOL MED, V98, P633, DOI 10.1007/s00109-020-01904-z
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Schwarz DS, 2016, CELL MOL LIFE SCI, V73, P79, DOI 10.1007/s00018-015-2052-6
   Shacham T, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00020
   Sharma A, 2012, INDIAN J OPHTHALMOL, V60, P189, DOI 10.4103/0301-4738.95869
   Sheu SJ, 2010, J OCUL PHARMACOL TH, V26, P231, DOI 10.1089/jop.2009.0137
   Shoulders MD, 2013, CELL REP, V3, P1279, DOI 10.1016/j.celrep.2013.03.024
   Solanki A, 2019, CURR DRUG DELIV, V16, P226, DOI 10.2174/1567201815666181031163111
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Sreekumar PG, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101663
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Stepicheva NA, 2019, ADV EXP MED BIOL, V1185, P45, DOI 10.1007/978-3-030-27378-1_8
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subramani M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12496-z
   Suga T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169719
   Surgucheva I, 2005, CELL MOL NEUROBIOL, V25, P1051, DOI 10.1007/s10571-005-8474-1
   Surguchov A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050624
   Suzuki T, 2017, CELL REP, V18, P2045, DOI 10.1016/j.celrep.2017.01.076
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tang BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103364
   Terman A, 2002, ANN NY ACAD SCI, V973, P309, DOI 10.1111/j.1749-6632.2002.tb04657.x
   Tomasetti M, 2001, FASEB J, V15, P1425, DOI 10.1096/fj.00-0694fje
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Vang Sheila, 2014, Glob Adv Health Med, V3, P58, DOI 10.7453/gahmj.2014.017
   Vats S, 2021, AUTOPHAGY, V17, P1037, DOI 10.1080/15548627.2021.1883886
   Vembar SS, 2008, NAT REV MOL CELL BIO, V9, P944, DOI 10.1038/nrm2546
   Villalba JM, 2010, EXPERT OPIN INV DRUG, V19, P535, DOI 10.1517/13543781003727495
   Warden C, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050626
   Warden C, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107974
   Wiechmann AF, 2008, PROG RETIN EYE RES, V27, P137, DOI 10.1016/j.preteyeres.2007.10.001
   Willy JA, 2015, MOL BIOL CELL, V26, P2190, DOI 10.1091/mbc.E15-01-0036
   Woo SJ, 2010, J OCUL PHARMACOL TH, V26, P223, DOI 10.1089/jop.2010.0012
   Wu XD, 2018, CURR OPIN CELL BIOL, V53, P22, DOI 10.1016/j.ceb.2018.04.004
   Xie W, 2010, SEMIN CELL DEV BIOL, V21, P533, DOI 10.1016/j.semcdb.2010.02.007
   Xu Y, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12660
   Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018
   Yang GG, 2018, J TOXICOL SCI, V43, P659, DOI 10.2131/jts.43.659
   Yang Y, 2019, EUR REV MED PHARMACO, V23, P378, DOI 10.26355/eurrev_201901_16786
   Yang Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01612
   Yao JY, 2018, AUTOPHAGY, V14, P1226, DOI 10.1080/15548627.2018.1463121
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zhang HM, 2020, INT J OPHTHALMOL-CHI, V13, P886, DOI 10.18240/ijo.2020.06.05
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhang SX, 2014, EXP EYE RES, V125, P30, DOI 10.1016/j.exer.2014.04.015
   Zhang T, 2012, INVEST OPHTH VIS SCI, V53, P3349, DOI 10.1167/iovs.12-9851
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P3622, DOI 10.1167/iovs.07-1559
   Zhang X, 2017, CURR MED CHEM, V24, P4329, DOI 10.2174/0929867324666170801100516
   Zhong YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038616
   Zhu D, 2009, EYE, V23, P2105, DOI 10.1038/eye.2009.161
NR 212
TC 3
Z9 3
U1 5
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD AUG
PY 2021
VL 10
IS 8
AR 1170
DI 10.3390/antiox10081170
PG 31
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA UF5XV
UT WOS:000688647600001
PM 34439418
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Thomas, J
   Mohammad, S
   Charnigo, R
   Baffi, J
   Abdel-Latif, A
   Ziada, KM
AF Thomas, Joseph
   Mohammad, Sohail
   Charnigo, Richard
   Baffi, Judit
   Abdel-Latif, Ahmed
   Ziada, Khaled M.
TI Age-Related Macular Degeneration and Coronary Artery Disease in a VA
   Population
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Article
DE age-related macular degeneration; coronary artery disease; Veterans
   Affairs patients
ID C-REACTIVE PROTEIN; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   APOLIPOPROTEIN-E; HEART-DISEASE; MACULOPATHY; ATHEROSCLEROSIS;
   ASSOCIATION; HYPERTENSION; ROTTERDAM
AB Objectives Age-related macular degeneration (AMD) is the leading cause of blindness in the United States. Although AMD shares multiple risk factors with coronary artery disease (CAD), the association between AMD and CAD has not been established. The objective of our study was to demonstrate an association between the diagnosis of AMD and CAD and/or major cardiovascular risk factors.
   Methods We performed a retrospective chart review of >13,000 patients at the Lexington Veterans Affairs Medical Center. Patients diagnosed as having AMD served as cases, and patients diagnosed with cataract and no AMD served as controls. We examined the prevalence of CAD and associated risk factors in both groups using univariate analysis followed by multivariate analyses to examine the association between AMD and CAD after adjusting for known common risk factors.
   Results We identified 3950 patients with AMD and 9166 controls. Patients with AMD were on average 6 years older than controls (P < 0.001) and had a significantly higher prevalence of CAD (39% vs 34%) and hypertension (88% vs 83%) but lower incidence of diabetes mellitus and smoking. Estimated odds ratio relating CAD to AMD was 1.22 (95% confidence interval 1.13-1.32; P < 0.001). The association between CAD and AMD remained significant in multivariate analyses in older individuals (76 years and older). When we conducted a secondary analysis and matched the AMD and non-AMD groups based on age, the association between CAD and AMD remained significant (39.4% in the AMD group vs 36.6% in the non-AMD group; P = 0.011).
   Conclusions These findings support the existence of an association between CAD and AMD, particularly in older adult patients in the predominantly male Veterans Affairs population. Such an association between AMD and systemic vascular disease justifies the potential coscreening for these conditions.
C1 Univ Kentucky, Div Cardiovasc Med, Dept Biostat, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Ophthalmol, Lexington, KY 40536 USA.
C3 University of Kentucky; University of Kentucky
RP Thomas, J (通讯作者)，Univ Kentucky, Div Cardiovasc Med, 900 S Limestone St,CT Wethington Bldg,Suite 324, Lexington, KY 40536 USA.
EM Kziad2@uky.edu
RI Abdel-Latif, Ahmed/V-8097-2019
OI Abdel-Latif, Ahmed/0000-0002-8178-7102
FU National Institutes of Health; University of Kentucky Clinical and
   Translational Science Pilot Award [UL1TR000117]; UK COBRE Early Career
   Program [P20 GM103527]; National Institutes of Health [R56 HL124266];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000117]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R56HL124266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [P20GM103527] Funding Source: NIH RePORTER
FX R.C. has received a National Institutes of Health grant. A.A.L. is
   supported by the University of Kentucky Clinical and Translational
   Science Pilot Award (UL1TR000117), the UK COBRE Early Career Program
   (P20 GM103527) and National Institutes of Health grant no. R56 HL124266.
   The remaining authors have no financial relationships to disclose and no
   conflicts of interest to report.
CR Bergstralh EJ, 1996, EPIDEMIOLOGY, V7, P331
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cao JJ, 2007, CIRCULATION, V116, P32, DOI 10.1161/CIRCULATIONAHA.106.645606
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 28
TC 12
Z9 12
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0038-4348
EI 1541-8243
J9 SOUTH MED J
JI South.Med.J.
PD AUG
PY 2015
VL 108
IS 8
BP 502
EP 506
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CP3WC
UT WOS:000359812400013
PM 26280780
DA 2022-11-30
ER

PT J
AU Topouzis, F
   Anastasopoulos, E
   Augood, C
   Bentham, GC
   Chakravarthy, U
   de Jong, PTVM
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Vingerling, JR
   Vioque, J
   Young, IS
   Fletcher, AE
AF Topouzis, F.
   Anastasopoulos, E.
   Augood, C.
   Bentham, G. C.
   Chakravarthy, U.
   de Jong, P. T. V. M.
   Rahu, M.
   Seland, J.
   Soubrane, G.
   Tomazzoli, L.
   Vingerling, J. R.
   Vioque, J.
   Young, I. S.
   Fletcher, A. E.
TI Association of diabetes with age-related macular degeneration in the
   EUREYE study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; BEAVER-DAM EYE; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; VISUAL IMPAIRMENT; NATIONAL-HEALTH; POOLED
   FINDINGS; 3 CONTINENTS; MACULOPATHY; POPULATION
AB Objective: To examine the association between self-reported diabetes history and early or late age-related macular degeneration (AMD) in the European population.
   Methods: Participants aged 65 years and over in the cross-sectional population-based EUREYE study underwent an eye examination including digital retinal photography. The images were graded at a single centre. A structured questionnaire was administered by trained field workers for putative risk factors for AMD including history of diabetes mellitus. Logistic regression models were used to examine the association between diabetes and stages of AMD, taking account of potential demographic, behavioural, dietary and medical (history of cardiovascular disease) confounders.
   Main outcome measures: Photographic images were graded according to the modified International Classification System for AMD and stratified into five exclusive stages from no signs of AMD (AMD stage 0), early AMD (Stages 1-3) and late AMD (Stage 4). Late AMD was subdivided in neovascular AMD (NV-AMD) or geographic atrophy (GA).
   Results: Data on diabetes history and potential confounders were available in 2117 control subjects without AMD, 2182 with early AMD, 49 with GA and 101 with NV-AMD. Of all participants, 13.1% reported a history of diabetes. After adjusting for potential confounders, subjects with neovascular AMD compared with controls had increased odds for diabetes (odds ratio 1.81; 95% confidence interval, 1.10 to 2.98, p = 0.02). Subjects with AMD grades 1 to 3 or GA had no increased odds for diabetes compared with those without AMD.
   Conclusions: In the EUREYE study, after multiple adjustments, positive association of diabetes mellitus with neovascular AMD was found. The hypothesis that diabetes is associated with neovascular AMD but not with geographic atrophy may suggest a different pathogenesis of the two advanced forms of the disease and needs to be further evaluated.
C1 [Topouzis, F.; Anastasopoulos, E.] Aristotle Univ Thessaloniki, Dept Ophthalmol, Sch Med, Thessaloniki 54636, Greece.
   [Augood, C.; Fletcher, A. E.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England.
   [Bentham, G. C.] Univ E Anglia, Ctr Environm Risk, Norwich NR4 7TJ, Norfolk, England.
   [Chakravarthy, U.] Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [de Jong, P. T. V. M.; Vingerling, J. R.] Univ Amsterdam, Acad Med Ctr, Netherlands Ophthalm Res Inst, KNAW, NL-1105 AZ Amsterdam, Netherlands.
   [de Jong, P. T. V. M.; Vingerling, J. R.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Rahu, M.] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   [Seland, J.] Oyeavdelingen Haukeland Sykehus Univ Bergen, Bergen, Norway.
   [Soubrane, G.] Univ Paris 12, Clin Ophthalmol, Paris, France.
   [Tomazzoli, L.] Univ Verona, Clin Oculist, I-37100 Verona, Italy.
   [Vioque, J.] Univ Miguel Hernandez, Dept Salud Publ, Alicante, Spain.
   [Vioque, J.] CIBERESP, Alicante, Spain.
   [Young, I. S.] Queens Univ Belfast, Ctr Clin & Populat Sci, Belfast, Antrim, North Ireland.
C3 Aristotle University of Thessaloniki; University of London; London
   School of Hygiene & Tropical Medicine; University of East Anglia; Queens
   University Belfast; Royal Netherlands Academy of Arts & Sciences;
   Netherlands Institute for Neuroscience (NIN-KNAW); University of
   Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam;
   Academic Medical Center Amsterdam; National Institute for Health
   Development - Estonia; University of Bergen; Haukeland University
   Hospital; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University
   of Verona; Universidad Miguel Hernandez de Elche; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERESP; Queens University Belfast
RP Topouzis, F (通讯作者)，Aristotle Univ Thessaloniki, Dept Ophthalmol, AHEPA Hosp, S Kiriakidi 1, Thessaloniki 54636, Greece.
EM ftopouzis@otenet.gr
RI Rahu, Mati/A-9981-2008; Vioque, Jesus/A-1066-2008
OI Vioque, Jesus/0000-0002-2284-148X; Young, Ian/0000-0003-3890-3152;
   Topouzis, Fotis/0000-0002-8966-537X; Chakravarthy,
   Usha/0000-0002-2606-3734
FU European Commission Vth Framework, Brussels, Belgium
   [QLK6-CT-1999-02094]; Macular Disease Society, Andover, UK; Ministry of
   Education and Science, Tallinn, Estonia [01921112s02]; Spanish Ministry
   of Health [FIS 01/1692E]; Novartis, Basel, Switzerland; Pfizer, New York
FX European Commission Vth Framework, Brussels, Belgium (contract no
   QLK6-CT-1999-02094). Additional funding for cameras was provided by the
   Macular Disease Society, Andover, UK. MR was financed by the Ministry of
   Education and Science, Tallinn, Estonia (target funding no 01921112s02).
   Additional funding in Alicante was received from the Spanish Ministry of
   Health (Grants: FIS 01/1692E; CIBERESP). European Eye investigator
   meetings were supported by travel grants from Novartis, Basel,
   Switzerland, and Pfizer, New York.
CR Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   *EYE DIS CAS CONTR, 1992, ARCH OPHTHALMOL-CHIC, V110, P104
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Martin LM, 2000, AM J PREV MED, V18, P215, DOI 10.1016/S0749-3797(99)00158-0
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow KK, 1999, OPHTHAL EPIDEMIOL, V6, P124
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Weinbrenner T, 2006, GERONTOLOGY, V52, P275, DOI 10.1159/000094608
   Zhang XZ, 2008, ARCH OPHTHALMOL-CHIC, V126, P1421, DOI 10.1001/archopht.126.10.1421
NR 25
TC 41
Z9 45
U1 1
U2 11
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2009
VL 93
IS 8
BP 1037
EP 1041
DI 10.1136/bjo.2008.146316
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 474RP
UT WOS:000268302000011
PM 19429584
OA Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Roquet, W
   Roudot-Thoraval, F
   Coscas, G
   Soubrane, G
AF Roquet, W
   Roudot-Thoraval, F
   Coscas, G
   Soubrane, G
TI Clinical features of drusenoid pigment epithelial detachment in age
   related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY FORM; CLASSIFICATION; ANGIOGRAPHY
AB Aim: To analyse clinical features of drusenoid pigment epithelium detachment (PED) in age related macular degeneration.
   Methods: 61 eyes of 32 patients with untreated drusenoid PED were followed for an average of 4.6 years ( range 1 - 17 years). Drusenoid PED was defined as K disc diameter ( DD) of confluent soft drusen under the centre of the macula. All patients underwent visual acuity measurement, biomicroscopic fundus examination, stereoscopic colour photograph, and fluorescein and indocyanine green angiography. Optical coherence tomography was performed in selected cases at the last examination. Kaplan Meier survival analysis was performed to estimate the probability of complications.
   Results: Three different natural outcomes were identified: persistence of drusenoid PED (38%), development of geographic atrophy ( 49%), and choroidal neovascularisation (CNV) (13%). Based on Kaplan Meier survival analysis, drusenoid PED had a 50% of chance of developing geographic atrophy after 7 years. If the drusenoid PED was greater than 2 DD or was associated with metamorphopsia at initial presentation, progression to atrophy or ingrowth of CNV occurred after 2 years (p< 0.01). Indocyanine green angiography confirmed fluorescein angiographic features or ascertained the presence of CNV when fluorescein angiography was equivocal. Optical coherence tomography was helpful in distinguishing coalescent soft drusen from drusenoid PED and disclosed the accumulation of sub or intraretinal fluid in eyes with CNV.
   Conclusion: Drusenoid PED size greater than 2 DD and metamorphopsia were risk factors identified at presentation which affected prognosis. The evaluation of the eyes at risk requires the use of all imaging means in order to ascertain the diagnosis of CNV. At long term ( over 10 years), geographic atrophy and CNV had occurred in 75% and 25% respectively, with a poor visual outcome.
C1 Univ Paris 12, Clin Ophtalmol, F-94200 Creteil, France.
   Hop Henri Mondor, Serv Sante Publ, F-94010 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique
   Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   Hopital Universitaire Henri-Mondor - APHP
RP Soubrane, G (通讯作者)，Univ Paris 12, Clin Ophtalmol, 40 Ave Verdun, F-94200 Creteil, France.
EM gisele.soubrane@chicreteil.fr
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   COSCAS G, 1991, DEGENERESCENCES MACU, P191
   GASS JDM, 1987, STEREOSCOPIC ATLAS M, P82
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Quaranta M, 1998, J FR OPHTALMOL, V21, P185
   Regillo C D, 1999, Curr Opin Ophthalmol, V10, P189, DOI 10.1097/00055735-199906000-00007
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
NR 16
TC 66
Z9 70
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY 1
PY 2004
VL 88
IS 5
BP 638
EP 642
DI 10.1136/bjo.2003.017632
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 813DF
UT WOS:000220887100011
PM 15090415
OA Bronze, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Douglas, VP
   Garg, I
   Douglas, KAA
   Miller, JB
AF Douglas, Vivian Paraskevi
   Garg, Itika
   Douglas, Konstantinos A. A.
   Miller, John B.
TI Subthreshold Exudative Choroidal Neovascularization (CNV): Presentation
   of This Uncommon Subtype and Other CNVs in Age-Related Macular
   Degeneration (AMD)
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE subthreshold exudative choroidal neovascularization; CNV; age-related
   macular degeneration; AMD; occult CNV; classic CNV; retinal angiomatous
   proliferation; mixed CNV; nonexudative CNV; quiescent; macular
   neovascularization; MNV
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION;
   DOUBLE-LAYER SIGN; CLINICOPATHOLOGICAL CORRELATION; ANGIOGRAPHY;
   PREVALENCE; DISEASE
AB Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in people over the age of 50 worldwide. Exudative or neovascular AMD is a more severe subset of AMD which is characterized by the presence of choroidal neovascularization (CNV). Recent advancements in multimodal ophthalmic imaging, including optical coherence tomography (OCT) and OCT-angiography (OCT-A), have facilitated the detection and characterization of previously undetectable neovascular lesions and have enabled a more refined classification of CNV in exudative as well as nonexudative AMD patients. Subthreshold exudative CNV is a novel subtype of exudative AMD that typically presents asymptomatically with good visual acuity and is characterized by stable persistent or intermittent subretinal fluid (SRF). This review aims to provide an overview of the clinical as well as multimodal imaging characteristics of CNV in AMD, including this new clinical phenotype, and propose effective approaches for management.
C1 [Douglas, Vivian Paraskevi; Garg, Itika; Douglas, Konstantinos A. A.; Miller, John B.] Harvard Med Sch, Harvard Retinal Imaging Lab, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
   [Garg, Itika; Miller, John B.] Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye
   & Ear Infirmary
RP Miller, JB (通讯作者)，Harvard Med Sch, Harvard Retinal Imaging Lab, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.; Miller, JB (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
EM douglasvivianp@gmail.com; itika_garg@meei.harvard.edu;
   douglaskonstantinos@gmail.com; john_miller@meei.harvard.edu
RI Miller, John J/GZG-5663-2022; Garg, Itika/AIE-7779-2022
OI Garg, Itika/0000-0002-9537-8561
CR Bacci T, 2021, GRAEF ARCH CLIN EXP, V259, P1123, DOI 10.1007/s00417-020-05021-y
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Casalino G, 2020, EXPERT REV OPHTHALMO, V15, P83, DOI 10.1080/17469899.2020.1745062
   Chen Katherine G, 2021, Retin Cases Brief Rep, V15, P207, DOI 10.1097/ICB.0000000000000826
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Horner F, 2021, CLIN OPHTHALMOL, V15, P1703, DOI 10.2147/OPTH.S305141
   Invernizzi A, 2019, AM J OPHTHALMOL, V204, P105, DOI 10.1016/j.ajo.2019.03.001
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kloos P, 2011, KLIN MONATSBL AUGENH, V228, P340, DOI 10.1055/s-0031-1273230
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   LE Hoang Mai, 2021, Vision (Basel), V5, DOI 10.3390/vision5020016
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Pece A, 2000, ARCH OPHTHALMOL-CHIC, V118, P630
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roh Miin, 2020, J Vitreoretin Dis, V4, P377, DOI 10.1177/2474126420916607
   Schmidt-Erfurth U, 2007, INVEST OPHTH VIS SCI, V48, P1751, DOI 10.1167/iovs.06-0686
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sharma A, 2022, RETINA-J RET VIT DIS, V42, P107, DOI 10.1097/IAE.0000000000003261
   Sheth J, 2018, INDIAN J OPHTHALMOL, V66, P1796, DOI 10.4103/ijo.IJO_377_18
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Uchida A, 2020, OSLI RETINA, V51, P22, DOI 10.3928/23258160-20191211-03
   Veritti D, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14020265
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 45
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2022
VL 11
IS 8
AR 2083
DI 10.3390/jcm11082083
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0R0RC
UT WOS:000785312800001
PM 35456174
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ores, R
   Puche, N
   Querques, G
   Blanco-Garavito, R
   Merle, B
   Coscas, G
   Oubraham, H
   Semoun, O
   Souied, EH
AF Ores, Raphaelle
   Puche, Nathalie
   Querques, Giuseppe
   Blanco-Garavito, Rocio
   Merle, Benedicte
   Coscas, Gabriel
   Oubraham, Hassiba
   Semoun, Oudy
   Souied, Eric H.
TI Gray Hyper-Reflective Subretinal Exudative Lesions in Exudative
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   FLUORESCEIN ANGIOGRAPHY; BRUCHS MEMBRANE; RANIBIZUMAB; PROGNOSIS
AB PURPOSE: To investigate the effects of ranibizumab 0.5 mg on gray hyper-reflective subretinal lesions diagnosed by spectral-domain optical coherence tomography (SD OCT) in patients with exudative age-related macular degeneration (AMD).
   DESIGN: Retrospective interventional study.
   METHODS: Data from 28 consecutive patients affected with neovascular AMD that presented subretinal hyper-reflective lesions as visualized by SD OCT were collected. Gray hyper-reflective subretinal lesion characteristics were analyzed before and after intravitreal ranibizumab 0.5 mg injection.
   RESULTS: Thirty eyes of 28 patients (5 male, 23 female, aged 57-91 years) were included. At study entry, gray lesion was associated with exudative features in 24 of 30 eyes (80%), including subretinal fluid (SRF) in 20 of 30 eyes (67%) and retinal cystoid spaces in 11 of 30 eyes (37%). Twenty-four eyes with exudative features at study entry received prompt treatment; 6 eyes without exudative features at study entry received deferred treatment (after 1 month observation), when exudative signs emerged (SRF in 3/6 eyes and retinal cystoid spaces in 5/6 eyes). Ninety-three percent of the gray lesions responded to ranibizumab treatment at 2 months and 77% at 6 months. Gray hyper-reflective subretinal lesion thickness was significantly reduced after treatment at both 2 months (from 482 +/- 116 mu m to 367 +/- 102 mu m, P < .0001) and 6 months (from 482 +/- 116 mu m to 369 +/- 71 mu m, P < .0001).
   CONCLUSION: Our findings suggest that gray hyper-reflective subretinal lesions might be considered as a qualitative criterion for retreatment of exudative AM:D. They may represent an early sign of active choroidal neovascularization, and should prompt to early treatment. ((C) 2014 by Elsevier Inc. All rights reserved.)
C1 [Ores, Raphaelle; Puche, Nathalie; Querques, Giuseppe; Blanco-Garavito, Rocio; Merle, Benedicte; Coscas, Gabriel; Oubraham, Hassiba; Semoun, Oudy; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Merle, Benedicte MJ/AAQ-5021-2021; Ores, Raphaëlle/AAC-6071-2020; Merle,
   Benedicte MJ/F-1247-2015
OI Merle, Benedicte MJ/0000-0003-1332-0954; Merle, Benedicte
   MJ/0000-0003-1332-0954; Querques, Giuseppe/0000-0002-3292-9581
FU Allergan; Novartis; Bayer; Fondation Nestle France; Federation des
   aveugles et handicaps visuels and serves on the Speakers' Bureau of
   Thea; Federation des aveugles et handicaps visuels and serves on the
   Speakers' Bureau of BauschLomb
FX Dr Puche has received travel expenses and grants for development of
   educational presentations by Allergan, and grants for manuscript
   preparation from Novartis. Dr Blanco-Garavito has received grants from
   Bayer and travel expenses from Novartis. Benedicte Merle has received
   grants from Fondation Nestle France and Federation des aveugles et
   handicaps visuels and serves on the Speakers' Bureaus of Thea and
   Bausch&Lomb. Dr Coscas is a consultant for Novartis, Bayer, and
   Allergan, and has received occasional travel expenses from Allergan. Dr
   Oubraham is a consultant for Novartis, Allergan, and Bayer and has
   received grants for development of educational presentations from
   Novartis, Allergan, and Bayer. Dr Souied is a consultant for Novartis,
   Bayer, and Allergan; serves on their Speakers' Bureaus; and has received
   travel expenses from Novartis, Allergan and Bayer. Dr Semoun and Dr Ores
   do not have financial disclosures. The authors indicate no funding
   support.
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Coscas F, 2012, RETINA-J RET VIT DIS, V32, P1069, DOI 10.1097/IAE.0b013e318240a529
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Giani A, 2011, RETINA-J RET VIT DIS, V31, P942, DOI 10.1097/IAE.0b013e31820a68cc
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Submacular Surgery Trials Research Group, 2006, OPHTHALMOLOGY, V113
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 29
TC 30
Z9 31
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2014
VL 158
IS 2
BP 354
EP 361
DI 10.1016/j.ajo.2014.04.025
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN6EB
UT WOS:000340686600020
PM 24794284
DA 2022-11-30
ER

PT J
AU Ho, CYD
   Lek, JJ
   Aung, KZ
   McGuinness, MB
   Luu, CD
   Guymer, RH
AF Ho, Chi Y. D.
   Lek, Jia J.
   Aung, Khin Z.
   McGuinness, Myra B.
   Luu, Chi D.
   Guymer, Robyn H.
TI Relationship between reticular pseudodrusen and choroidal thickness in
   intermediate age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal thickness; reticular
   pseudodrusen
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY;
   GEOGRAPHIC-ATROPHY; RISK-FACTOR; PREVALENCE; MACULOPATHY;
   CLASSIFICATION; MAPS; EYES
AB ImportanceReticular pseudodrusen (RPD) is strongly associated with late age-related macular degeneration (AMD) but their aetiology remains unknown. RPD have been associated with reduced choroidal thickness (ChT) but most studies are limited by small sample size and varying severity of AMD.
   BackgroundTo investigate the relationship between choroidal thickness and RPD in eyes with intermediate AMD (iAMD), controlling for variables known to influence ChT.
   DesignRetrospective cohort study.
   ParticipantsParticipants were recruited from Centre for Eye Research Australia.
   MethodsColour fundus photographs, fundus auto fluorescence, near-infrared and spectral-domain ocular coherence tomography (OCT) were graded for RPD. ChT was measured from enhanced-depth imaging OCT scans at the centre of fovea, 1500 and 3000m nasal, temporal, superior and inferior from centre of fovea.
   Main Outcome MeasuresChT between RPD and non-RPD group.
   ResultsA total of 297 eyes from 152 subjects were included. A total of 84 (28%) had RPD and were older than non-RPD group (75.1 5.4 years and 68.7 +/- 6.9 years, respectively; P < 0.001). In unadjusted analysis, the RPD group was significantly associated with thinner choroids across all measured locations (P 0.022). After adjustment for variables, the presence of RPD was no longer associated with ChT (P 0.132 for all locations) but age (P < 0.001) and refractive error (P = 0.002) remained significantly associated with ChT.
   Conclusions and RelevanceAge and refractive error, rather than RPD, was significantly associated with reduced ChT in eyes with iAMD. Choroidal insufficiency may be a less important variable in RPD aetiology than previously considered.
C1 [Ho, Chi Y. D.; Lek, Jia J.; Aung, Khin Z.; McGuinness, Myra B.; Luu, Chi D.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Ho, Chi Y. D.; Lek, Jia J.; Aung, Khin Z.; McGuinness, Myra B.; Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Ho, CYD (通讯作者)，Ctr Eye Res Australia, Macular Res, Level 8,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cy.doreen.ho@gmail.com
RI McGuinness, Myra/G-4900-2017
OI McGuinness, Myra/0000-0002-5422-040X; Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) [1084081]; NHMRC
   Principal Research Fellowship [1103013]
FX This research was supported by the National Health and Medical Research
   Council (NH&MRC) Project Grants (1084081) and NHMRC Principal Research
   Fellowship (RG #1103013). Centre for Eye Research Australia (CERA)
   receives Operational Infrastructure Support from the Victorian
   Government.
CR Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bland JM, 1996, BRIT MED J, V313, P744
   Cheng H, 2016, CURR EYE RES, V41, P1492, DOI 10.3109/02713683.2015.1127391
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Grewal D, 2014, PLOS ONE, V9, P1
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 32
TC 9
Z9 9
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2018
VL 46
IS 5
BP 485
EP 494
DI 10.1111/ceo.13131
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM8QJ
UT WOS:000438497300006
PM 29236343
OA Green Published
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Tokarz, P
   Koskela, A
   Paterno, J
   Blasiak, J
AF Kaarniranta, Kai
   Tokarz, Paulina
   Koskela, Ali
   Paterno, Jussi
   Blasiak, Janusz
TI Autophagy regulates death of retinal pigment epithelium cells in
   age-related macular degeneration
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Review
DE Age-related macular degeneration; Cell death; Apoptosis; Necroptosis;
   Pyroptosis; Alu transcripts
ID NLRP3 INFLAMMASOME ACTIVATION; OXIDATIVE STRESS; ALU RNA; SELECTIVE
   AUTOPHAGY; MITOCHONDRIAL-DNA; PATHWAY; RPE; DYSFUNCTION; APOPTOSIS;
   SUSCEPTIBILITY
AB Age-related macular degeneration (AMD) is an eye disease underlined by the degradation of retinal pigment epithelium (RPE) cells, photoreceptors, and choriocapillares, but the exact mechanism of cell death in AMD is not completely clear. This mechanism is important for prevention of and therapeutic intervention in AMD, which is a hardly curable disease. Present reports suggest that both apoptosis and pyroptosis (cell death dependent on caspase-1) as well as necroptosis (regulated necrosis dependent on the proteins RIPK3 and MLKL, caspase-independent) can be involved in the AMD-related death of RPE cells. Autophagy, a cellular clearing system, plays an important role in AMD pathogenesis, and this role is closely associated with the activation of the NLRP3 inflammasome, a central event for advanced AMD. Autophagy can play a role in apoptosis, pyroptosis, and necroptosis, but its contribution to AMD-specific cell death is not completely clear. Autophagy can be involved in the regulation of proteins important for cellular antioxidative defense, including Nrf2, which can interact with p62/SQSTM, a protein essential for autophagy. As oxidative stress is implicated in AMD pathogenesis, autophagy can contribute to this disease by deregulation of cellular defense against the stress. However, these and other interactions do not explain the mechanisms of RPE cell death in AMD. In this review, we present basic mechanisms of autophagy and its involvement in AMD pathogenesis and try to show a regulatory role of autophagy in RPE cell death. This can result in considering the genes and proteins of autophagy as molecular targets in AMD prevention and therapy.
C1 [Kaarniranta, Kai; Koskela, Ali; Paterno, Jussi] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70210, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70210, Finland.
   [Tokarz, Paulina; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90236 Lodz, Poland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Lodz
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, PL-90236 Lodz, Poland.
EM jblasiak@biol.uni.lodz.pl
RI Paterno, Jussi/AAY-5526-2020; Tokarz, Paulina/L-9983-2013
OI Paterno, Jussi/0000-0002-5442-4314; Tokarz, Paulina/0000-0001-9016-3089;
   Blasiak, Janusz/0000-0001-9539-9584
CR Adler R, 1999, MOL VIS, V5
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]
   Bao L, 2016, DNA CELL BIOL, V35, P385, DOI 10.1089/dna.2016.3259
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016
   Carelli V, 2002, NEUROCHEM INT, V40, P573, DOI 10.1016/S0197-0186(01)00129-2
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Criollo A, 2007, APOPTOSIS, V12, P3, DOI 10.1007/s10495-006-0328-x
   Cuervo AM, 2008, TRENDS GENET, V24, P604, DOI 10.1016/j.tig.2008.10.002
   Czarny P, 2015, INT J MOL SCI, V16, P2641, DOI 10.3390/ijms16022641
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ezaki J, 2011, AUTOPHAGY, V7, P727, DOI 10.4161/auto.7.7.15371
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Filomeni G, 2010, AUTOPHAGY, V6, P999, DOI 10.4161/auto.6.7.12754
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gallagher LE, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020024
   Galluzzi L, 2011, INT REV CEL MOL BIO, V289, P1, DOI 10.1016/B978-0-12-386039-2.00001-8
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Gibbings D, 2013, AUTOPHAGY, V9, P781, DOI 10.4161/auto.23694
   Guha S, 2013, FASEB J, V27, P4500, DOI 10.1096/fj.13-236166
   Guo H, 2014, NAT COMMUN, V5, DOI [10.1038/ncomms5986, 10.1038/ncomms6276]
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hanus J, 2015, INVEST OPHTH VIS SCI, V56, P5048, DOI 10.1167/iovs.15-16401
   Helisalmi S, 2014, ACTA OPHTHALMOL, V92, pE410, DOI 10.1111/aos.12341
   Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Jing K, 2012, EXP MOL MED, V44, P69, DOI 10.3858/emm.2012.44.2.028
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kim JY, 2015, ONCOTARGET, V6, P44161, DOI 10.18632/oncotarget.6592
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kole AJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.220
   Kozlowski MR, 2015, CURR EYE RES, V40, P501, DOI 10.3109/02713683.2014.935440
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Levonen AL, 2014, FREE RADICAL BIO MED, V71, P196, DOI 10.1016/j.freeradbiomed.2014.03.025
   Li YJ, 2015, CELL PHYSIOL BIOCHEM, V35, P1663, DOI 10.1159/000373980
   Linares JF, 2013, MOL CELL, V51, P283, DOI 10.1016/j.molcel.2013.06.020
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizumura K, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00244
   Mizumura K, 2014, J CLIN INVEST, V124, P3987, DOI 10.1172/JCI74985
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Nakahara T, 2013, J PHARMACOL SCI, V123, P79, DOI 10.1254/jphs.13R03CP
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nekova TS, 2014, CELL CYCLE, V13, P2192, DOI 10.4161/cc.29216
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Park J, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500661
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Rodrigues GA, 2011, INVEST OPHTH VIS SCI, V52, P890, DOI 10.1167/iovs.10-5715
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Sarkar S, 2013, BIOCHEM SOC T, V41, P1103, DOI 10.1042/BST20130134
   Sato M, 2013, BBA-MOL CELL RES, V1833, P1979, DOI 10.1016/j.bbamcr.2013.03.010
   Sato M, 2013, TRAFFIC, V14, P479, DOI 10.1111/tra.12050
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Scherz-Shouval R, 2007, AUTOPHAGY, V3, P371, DOI 10.4161/auto.4214
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Sharma S, 2013, MUTAT RES-FUND MOL M, V743, P97, DOI 10.1016/j.mrfmmm.2012.11.002
   Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487
   Singh K, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-70
   SINNETT D, 1991, J BIOL CHEM, V266, P8675
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Taniguchi K, 2016, FEBS LETT, V590, P2375, DOI 10.1002/1873-3468.12301
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tokarz P, 2016, EUR J PHARMACOL, V776, P167, DOI 10.1016/j.ejphar.2016.02.049
   Tsao YP, 2006, LIFE SCI, V79, P545, DOI 10.1016/j.lfs.2006.01.041
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Tsukamoto S, 2008, SCIENCE, V321, P117, DOI 10.1126/science.1154822
   Tsukamoto S, 2008, AUTOPHAGY, V4, P1076, DOI 10.4161/auto.7065
   Ueno T, 2012, BBA-PROTEINS PROTEOM, V1824, P51, DOI 10.1016/j.bbapap.2011.06.019
   Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang L, 2016, ADV EXP MED BIOL, V854, P17, DOI 10.1007/978-3-319-17121-0_3
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010073
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/bse0550105, 10.1042/BSE0550105]
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
   Zhan J, 2016, CURR MOL MED, V16, P487, DOI 10.2174/1566524016666160429121606
   Zhang C, 2013, CANCER LETT, V340, P51, DOI 10.1016/j.canlet.2013.06.021
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang L, 2016, CELL PROLIFERAT, V49, P246, DOI 10.1111/cpr.12247
   Zhou QH, 2011, CELL RES, V21, P1662, DOI 10.1038/cr.2011.182
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26322
NR 114
TC 100
Z9 101
U1 1
U2 28
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0742-2091
EI 1573-6822
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD APR
PY 2017
VL 33
IS 2
BP 113
EP 128
DI 10.1007/s10565-016-9371-8
PG 16
WC Cell Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Toxicology
GA EM0CM
UT WOS:000394986400003
PM 27900566
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Crabb, JW
   Miyagi, M
   Gu, XR
   Shadrach, K
   West, KA
   Sakaguchi, H
   Kamei, M
   Hasan, A
   Yan, L
   Rayborn, ME
   Salomon, RG
   Hollyfield, JG
AF Crabb, JW
   Miyagi, M
   Gu, XR
   Shadrach, K
   West, KA
   Sakaguchi, H
   Kamei, M
   Hasan, A
   Yan, L
   Rayborn, ME
   Salomon, RG
   Hollyfield, JG
TI Drusen proteome analysis: An approach to the etiology of age-related
   macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HEPARIN-BINDING PROPERTIES; GLYCATION END-PRODUCTS; BRUCHS MEMBRANE;
   IN-VIVO; DYSTROPHY; GENE; PATHOGENESIS; IDENTIFICATION; VITRONECTIN;
   MUTATION
AB Drusen are extracellular deposits that accumulate below the retinal pigment epithelium on Bruch's membrane and are risk factors for developing age-related macular degeneration (AMD). The progression of AMD might be slowed or halted if the formation of drusen could be modulated. To work toward a molecular understanding of drusen formation, we have developed a method for isolating microgram quantities of drusen and Bruch's membrane for proteome analysis. Liquid chromatography tandem MS analyses of drusen preparations from 18 normal donors and five AMD donors identified 129 proteins. Immunocytochemical studies have thus far localized approximate to16% of these proteins in drusen. Tissue metalloproteinase inhibitor 3, clusterin, vitronectin, and serum albumin were the most common proteins observed in normal donor drusen whereas crystallin was detected more frequently in AMD donor drusen. Up to 65% of the proteins identified were found in drusen from both AMD and normal donors. However, oxidative protein modifications were also observed, including apparent crosslinked species of tissue metalloproteinase inhibitor 3 and vitronectin, and carboxyethyl pyrrole protein adducts. Carboxyethyl pyrrole adducts are uniquely generated from the oxidation of docosahexaenoate-containing lipids. By Western analysis they were found to be more abundant in AMD than in normal Bruch's membrane and were found associated with drusen proteins. Carboxymethyl lysine, another oxidative modification, was also detected in drusen. These data strongly support the hypothesis that oxidative injury contributes to the pathogenesis of AMD and suggest that oxidative protein modifications may have a critical role in drusen formation.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA.
   Case Western Reserve Univ, Dept Chem, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western
   Reserve University
RP Crabb, JW (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
RI Salomon, Robert G/C-3463-2008; Mitchell, Paul/P-1498-2014
OI Salomon, Robert/0000-0001-9456-3557
FU NATIONAL EYE INSTITUTE [R56EY014240, R01EY002362, R01EY014240,
   R01EY014239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AHMED MU, 1986, J BIOL CHEM, V261, P4889
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   CALL TW, 1990, EXP EYE RES, V51, P451, DOI 10.1016/0014-4835(90)90158-Q
   Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712
   Elgawish A, 1996, J BIOL CHEM, V271, P12964, DOI 10.1074/jbc.271.22.12964
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FRIGUET B, 1994, J BIOL CHEM, V269, P21639
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HOGASEN K, 1992, J BIOL CHEM, V267, P23076
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LEWIS H, 1986, OPHTHALMOLOGY, V93, P1098
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Okamoto T, 2002, MICROVASC RES, V63, P186, DOI 10.1006/mvre.2001.2371
   Pankhurst GJ, 1998, BIOCHEMISTRY-US, V37, P4823, DOI 10.1021/bi972367v
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058
   Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 38
TC 910
Z9 956
U1 1
U2 48
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 12
PY 2002
VL 99
IS 23
BP 14682
EP 14687
DI 10.1073/pnas.222551899
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 615AZ
UT WOS:000179224800016
PM 12391305
OA Green Published
DA 2022-11-30
ER

PT J
AU Finn, AP
   Pistilli, M
   Tai, V
   Daniel, E
   Ying, GS
   Maguire, MG
   Grunwald, JE
   Martin, DF
   Jaffe, GJ
   Toth, CA
AF Finn, Avni P.
   Pistilli, Maxwell
   Tai, Vincent
   Daniel, Ebenezer
   Ying, Gui-Shuang
   Maguire, Maureen G.
   Grunwald, Juan E.
   Martin, Daniel F.
   Jaffe, Glenn J.
   Toth, Cynthia A.
CA Comparison Age-Related Macular Deg
TI Localized Optical Coherence Tomography Precursors of Macular Atrophy and
   Fibrotic Scar in the Comparison of Age-Related Macular Degeneration
   Treatments Trials
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To identify precursors of macular atrophy (MA) and of fibrotic scar (FS) in eyes treated with antivascular endothelial growth factor through pixelmapping analysis of baseline optical coherence tomography (OCT).
   METHODS: DESIGN: Cross-sectional analysis. SETTING: Multicenter clinical trial. PATIENT POPULATION: 68 eyes from the Comparison of Age-Related Macular Degeneration Treatments Trials. INTERVENTION: Treatment with anti-vascular endothelial growth factor agents. MAIN OUTCOME MEASURE: The percentage of MA or FS pixels with each OCT feature at baseline, and the odds ratio for baseline pixels with an OCT feature to develop MA or FS.
   RESULTS: Retinal pigment epithelium atrophy and photoreceptor loss on OCT were highly predictive of MA at that location at years 2 and 5 (P <.0001), but accounted for only 22.5% of the ensuing atrophy at year 2 and less at year 5. Among pixels of MA at year 2, 78% were preceded by thick drusen, 54% by subretinal macular neovascularization (MNV), and 22.5% by no detectable OCT features. MNV, subretinal hyperreflective material, pigment epithelial detachment, intraretinal fluid, and sub-retinal pigment epithelium fluid were predictive of FS at that location (P values <.05). More than 75% of the pixels of FS at years 2 and 5 were preceded by pixels of baseline MNV.
   CONCLUSIONS: Most pixels of FS were preceded by components of neovascularization. Although one- quarter ofMAwas accounted for by pre-existing evidence of atrophy on OCT alone, the development of MA in areas of thick drusen, areas with and without subretinal MNV lesion, and areas without detectable OCT precursors argues that the development of MA is multifactorial and may follow, in part, a non-neovascular pathway. ((C) 2020 Elsevier Inc. All rights reserved.)
C1 [Finn, Avni P.] Northern Calif Retina Vitreous Associates, Mountain View, CA USA.
   [Pistilli, Maxwell; Daniel, Ebenezer; Ying, Gui-Shuang; Maguire, Maureen G.; Grunwald, Juan E.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Tai, Vincent; Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Toth, Cynthia A.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
C3 University of Pennsylvania; Duke University; Cleveland Clinic
   Foundation; Duke University
RP Toth, CA (通讯作者)，Duke Eye Ctr, DUMC 3802, Durham, NC 27710 USA.
EM cynthia.toth@duke.edu
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland [U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, U10 EY023530]
FX The study was supported by cooperative agreements U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, and U10 EY023530 from the National
   Eye Institute, National Institutes of Health, Department of Health and
   Human Services, Bethesda, Maryland. The funding organization
   participated in the design and conduct of the study and review of the
   manuscript. ClinicalTrials.gov number NCT00593450.
CR Abdelfattah NS, 2018, AM J OPHTHALMOL, V192, P84, DOI 10.1016/j.ajo.2018.05.008
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Chen L, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.8
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Domalpally A, 2018, OPHTHALMOL RETINA, V2, P1021, DOI 10.1016/j.oret.2018.04.009
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Folgar FA, 2014, OPHTHALMOLOGY, V121, P1956, DOI 10.1016/j.ophtha.2014.04.020
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Toth CA, 2018, OPHTHALMOL RETINA, V2, P481, DOI 10.1016/j.oret.2017.09.016
   Toth CA, 2019, OPHTHALMOL RETINA, V3, P316, DOI 10.1016/j.oret.2018.11.011
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 34
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2021
VL 223
BP 338
EP 347
DI 10.1016/j.ajo.2020.11.002
EA JAN 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RC2MF
UT WOS:000632638100037
PM 33221285
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Barthelmes, D
   Nguyen, V
   Daien, V
   Campain, A
   Walton, R
   Guymer, R
   Morlet, N
   Hunyor, AP
   Essex, RW
   Arnold, JJ
   Gillies, MC
AF Barthelmes, Daniel
   Vuong Nguyen
   Daien, Vincent
   Campain, Anna
   Walton, Richard
   Guymer, Robyn
   Morlet, Nigel
   Hunyor, Alex P.
   Essex, Rohan W.
   Arnold, Jennifer J.
   Gillies, Mark C.
CA Fight Retinal Blindness Study Grp
TI TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING
   AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; aflibercept; treat and extend;
   neovascular; CNV; choroidal neovascularization
ID 2.0 MG RANIBIZUMAB; PROSPECTIVE TRIAL; EFFICACY; REGIMEN; SAFETY
AB Purpose: To report 24-month outcomes of a treat and extend (T&E) regimen using aflibercept in eyes with neovascular age-related macular degeneration.
   Methods: This was a database observational study that included treatment-naive eyes with neovascular age-related macular degeneration tracked by the Fight Retinal Blindness! outcome registry completing 24 months of sole monotherapy with aflibercept treatment under a T&E regimen between November 1, 2012 and January 31, 2014. Locally weighted scatterplot smoothing curves were used to display visual acuity outcomes. Main outcome measures were change in visual acuity at 24 months and number of injections and visits during the study period.
   Results: The study population, identified by reviewing the database, consisted of 136 eyes from 123 patients completing 24 months of follow-up on aflibercept. Mean (SD) age was 77.2 (7.0) years, 59% were female. Mean visual acuity increased from 61.4 (similar to 20/60; SD 17.4) letters at baseline to 67.4 (similar to 20/45; SD 17.7) letters at 24 months (+6.0 letters [95% confidence interval: 3.3-8.5]; P < 0.001). From baseline to 24 months, the proportion of eyes with visual acuity >= 70 letters (20/40) increased (40%-58%, P < 0.001) and the proportion of eyes with visual acuity <= 35 letters (20/200) remained the same (10%; P = 0.547). Ninety-eight per cent of eyes starting with visual acuity >= 70 letters (20/40) were able to maintain this up to 24 months. From the first to the second year of treatment, the mean number of injections (7.8 [2.1] vs. 5.7 [2.6]; P < 0.001) and visits (8.7 [1.7] vs. 6.5 [2.4]; P, 0.001) decreased for eyes completing 24 months of treatment. When data from 60 eligible eyes that did not complete 2 years follow-up, along with 14 eyes that switched to ranibizumab, were included using last observation carried forward, the mean change in visual acuity from baseline was +5.6 letters (95% confidence interval: 3.3-7.7).
   Conclusion: These data indicate that eyes treated with aflibercept, as a sole therapy, in routine clinical practice with a T&E regimen can achieve good visual outcomes while decreasing the burden of treatments and clinic visits.
C1 [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Barthelmes, Daniel; Vuong Nguyen; Daien, Vincent; Campain, Anna; Walton, Richard; Hunyor, Alex P.; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Daien, Vincent] Montpellier Univ Hosp, Montpellier, France.
   [Guymer, Robyn] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA, Australia.
   [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Acton, ACT, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
C3 University of Zurich; University Zurich Hospital; University of Sydney;
   Universite de Montpellier; CHU de Montpellier; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   University of Western Australia; Australian National University
RP Barthelmes, D (通讯作者)，Univ Hosp Zurich, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM daniel.barthelmes@usz.ch
RI Hunyor, Alex/AAT-8205-2021; DAIEN, Vincent/Z-5516-2019
OI Hunyor, Alex/0000-0002-8182-6167; DAIEN, Vincent/0000-0001-5675-0861;
   Guymer, Robyn/0000-0002-9441-4356; Nguyen, Vuong/0000-0001-9070-9803;
   Essex, Rohan/0000-0001-5323-0334; Campain, Anna/0000-0003-1057-0085
FU Royal Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia (NHMRC); NHMRC
   practitioner fellowship; NHMRC Principal research fellowship; Walter and
   Gertrud Siegenthaler Foundation Zurich, Switzerland; Swiss National
   Foundation; Novartis; Bayer
FX Supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009) and a grant from the
   National Health and Medical Research Council, Australia (NHMRC
   2010-2012).; M. C. Gillies is a Sydney Medical Foundation Fellow and is
   supported by an NHMRC practitioner fellowship, and R. Guymer is
   supported by a NHMRC Principal research fellowship. D. Barthelmes was
   supported by the Walter and Gertrud Siegenthaler Foundation Zurich,
   Switzerland and the Swiss National Foundation. Funding was also provided
   by Novartis and Bayer. These supporting organizations had no role in the
   design or conduct of the research. M. C. Gillies and R. Guymer are
   members of advisory boards for Novartis and Bayer. D. Barthelmes
   received research grants from Novartis and Bayer. V. Daien received
   travel grants from Novartis and Bayer. None of the other authors have no
   any conflicting interests to disclose.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   [Anonymous], 2016, R LANG ENV STAT COMP
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chin-Yee D, 2015, BR J OPHTHALMOL
   CLEVELAND WS, 1988, J ECONOMETRICS, V37, P87, DOI 10.1016/0304-4076(88)90077-2
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah CP, 2013, AAO M
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Unnebrink K, 2001, STAT MED, V20, P3931, DOI 10.1002/sim.1149
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 24
TC 66
Z9 67
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2018
VL 38
IS 1
BP 20
EP 28
DI 10.1097/IAE.0000000000001496
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB0KM
UT WOS:000428734800008
PM 28145976
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mettu, PS
   Sarin, N
   Stinnett, SS
   Toth, CA
AF Mettu, Priyatham S.
   Sarin, Neeru
   Stinnett, Sandra S.
   Toth, Cynthia A.
TI RECOVERY OF THE NEUROSENSORY RETINA AFTER MACULAR TRANSLOCATION SURGERY
   IS INDEPENDENT OF PREOPERATIVE MACULAR SENSITIVITY IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; macular translocation;
   microperimetry; optical coherence tomography; quality of life; choroidal
   neovascularization
ID QUALITY-OF-LIFE; 360-DEGREES PERIPHERAL RETINECTOMY; VISUAL FUNCTION
   QUESTIONNAIRE; CONTRAST SENSITIVITY; NATURAL-HISTORY; RANIBIZUMAB;
   OUTCOMES; IMPACT; PARAMETERS; VISION
AB Purpose: To directly assess the recovery of the retina overlying choroidal neovascularization in neovascular age-related macular degeneration and to understand the relationship between macular sensitivity and visual functional measures and retinal structural alterations as predictive factors for outcome among eyes undergoing macular translocation surgery (MT360).
   Methods: In a prospective, consecutive case series of 55 patients with subfoveal choroidal neovascularization undergoing MT360, we explored the relationship between macular sensitivity on the Nidek microperimeter-1 with pathologic features on optical coherence tomography and with distance and near visual acuity, reading speed, contrast sensitivity, color vision, and National Eye Institute Visual Function Questionnaire-25 composite quality-of-life (QOL) score, both before and at 1 year after MT360.
   Results: On average, there was improvement in all measures of visual function, macular sensitivity, and QOL after MT360. Preoperative median retinal sensitivity score did not predict postoperative measures of visual function, macular sensitivity, and vision-related QOL. Correlation between preoperative median retinal sensitivity score and preoperative measures of visual function and vision-related QOL was generally poor, excepting modest correlation for contrast sensitivity and color vision. However, correlation between postoperative median retinal sensitivity score and postoperative measures of visual function and vision-related QOL was uniformly modest, and change in median retinal sensitivity score correlated modestly with change in most measures of visual function and QOL. Among optical coherence tomography morphologic features, preoperative retinal pigment epithelium elevation predicted reduced postoperative contrast sensitivity (P = 0.04), while preoperative epiretinal membrane or vitreomacular traction predicted increased postoperative contrast sensitivity (P = 0.05). Preoperative cystoid macular edema, subretinal fluid, and subretinal lesion were associated with decreased median retinal sensitivity score (P values <= 0.03).
   Conclusion: The authors' findings demonstrate the resilience and recovery of poorly functioning retina in neovascular age-related macular degeneration but fail to demonstrate a role for macular sensitivity as measured by Nidek microperimeter-1 in identifying irreversibly damaged retina that would not benefit from MT360. RETINA 31: 1637-1649, 2011
C1 [Mettu, Priyatham S.; Sarin, Neeru; Stinnett, Sandra S.; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Duke University
RP Toth, CA (通讯作者)，Box 3802, Durham, NC 27710 USA.
EM toth0004@mc.duke.edu
RI Toth, Cynthia/L-5534-2019; toth, cynthia a/F-5614-2011
OI Toth, Cynthia/0000-0002-2324-0854; Stinnett, Sandra/0000-0001-7192-0195
FU Alice and John Haynes; Grier Family; Alcon; Genentech
FX Supported by grants from Alice and John Haynes and the Grier Family.; C.
   Toth receives royalties from Alcon and research support from Genentech;
   she is a consultant for both Alcon and Genentech. Duke University has an
   equity and intellectual property interest in technology licensed to
   Bioptigen. No other authors have financial disclosures to report.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Chieh JJ, 2008, RETINA-J RET VIT DIS, V28, P1522, DOI 10.1097/IAE.0b013e318186c634
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   GINSBURG AP, 1995, J CATARACT REFR SURG, V21, P82, DOI 10.1016/S0886-3350(13)80485-3
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mruthyunjaya P, 2005, RETINA-J RET VIT DIS, V25, P597, DOI 10.1097/00006982-200507000-00010
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Oyagi T, 2004, RETINA-J RET VIT DIS, V24, P548, DOI 10.1097/00006982-200408000-00007
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   *SST, 1998, PB98166648 SST NTIS
   Talwar D, 2001, CLIN EXP OPHTHALMOL, V29, P17, DOI 10.1046/j.1442-9071.2001.00361.x
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Uppal G, 2007, CLIN EXP OPHTHALMOL, V35, P448, DOI 10.1111/j.1442-9071.2007.01528.x
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ziemssen F, 2008, GRAEF ARCH CLIN EXP, V246, P653, DOI 10.1007/s00417-007-0726-y
NR 25
TC 6
Z9 6
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2011
VL 31
IS 8
BP 1637
EP 1649
DI 10.1097/IAE.0b013e31821800e0
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814LS
UT WOS:000294456100024
PM 21775925
DA 2022-11-30
ER

PT J
AU Schultz, NM
   Braunack-Mayer, L
   Schwartz, J
   Gaspar, L
AF Schultz, Neil M.
   Braunack-Mayer, Lydia
   Schwartz, Jason
   Gaspar, Luis
TI The Patient Experience: Symptoms and Impact of Dry Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Conceptual model; Dry age-related macular degeneration; Dry AMD;
   Patient-reported outcome measure; PROM
ID OUTCOMES PRO INSTRUMENTS
AB Introduction No published literature systematically explores the dry age-related macular degeneration (AMD) patient experience. To inform the development of patient-reported outcome measures (PROMs), the important and relevant signs, symptoms, and impacts for patients with dry AMD were identified. Methods A holistic approach was used to capture, define, and organize the signs, symptoms, and impacts that are important to patients with dry AMD. Qualitative evidence was identified through a targeted literature review and clinician (N = 5) and patient (N = 20) interviews. The targeted review was expanded to include patients with AMD, as few studies specific to dry AMD were identified. The qualitative evidence was incorporated into a conceptual model that included the signs, symptoms, and impacts of dry AMD affecting the patient experience. Results Twenty-nine articles (dry AMD, N = 5; general AMD, N = 24) exploring health-related quality-of-life evidence in patients with AMD were identified. Concepts identified and included in the preliminary, literature-based model included signs and symptoms related to general vision loss and general impacts (e.g., dependency on others, poor spatial perception/mobility, difficulty reading, emotional affects). No concepts unique to dry AMD were identified. Interviewed clinicians refined the literature-based model. Across all visual acuity severities, >= 80% of patients reported difficulty driving, reading, and completing activities of daily living, along with frustration and dependency on others; all patients reported blurred vision. The final model included 35 signs, symptoms, and impacts, with 19 considered salient. Conclusions To better understand the patient experience, we captured, defined, and organized signs, symptoms, and impacts into a dry AMD conceptual model. This model can aid in the development of PROMs reflecting the experience of patients with dry AMD.
C1 [Schultz, Neil M.; Schwartz, Jason] Astellas Pharma Inc, Northbrook, IL 60062 USA.
   [Braunack-Mayer, Lydia] IQVIA, Basel, Switzerland.
   [Gaspar, Luis] IQVIA, Reading, Berks, England.
C3 Astellas Pharmaceuticals; IQVIA; IQVIA
RP Schultz, NM (通讯作者)，Astellas Pharma Inc, Northbrook, IL 60062 USA.
EM neil.schultz@astellas.com
FU Astellas Pharma, Inc.
FX This study and the journal's publication fees were funded by Astellas
   Pharma, Inc.
CR [Anonymous], 2020, LASTACAFT PACKAGE IN
   [Anonymous], 2020, IKERVIS SUMMARY PROD
   [Anonymous], 2016, LUCENTIS SUMMARY PRO
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Braithwaite T, 2019, PATIENT-RELAT OUTCOM, V10, P9, DOI 10.2147/PROM.S162802
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79
   Food and drug administration, 2020, ATIENT FOCUSED DRUG
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pascolini D, 2010, GLOBAL DATA VISUAL I
   Patrick DL, 2011, VALUE HEALTH, V14, P978, DOI 10.1016/j.jval.2011.06.013
   Patrick DL, 2011, VALUE HEALTH, V14, P967, DOI 10.1016/j.jval.2011.06.014
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 16
TC 4
Z9 4
U1 1
U2 1
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD MAR
PY 2021
VL 10
IS 1
BP 151
EP 164
DI 10.1007/s40123-020-00325-y
EA JAN 2021
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI3UY
UT WOS:000612876700001
PM 33512689
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Muftuoglu, IK
   Lin, TZ
   Bartsch, DU
   Freeman, WR
AF Muftuoglu, Ilkay Kilic
   Lin, Tiezhu
   Bartsch, Dirk-Uwe
   Freeman, William R.
TI Influence of vitrectomy on the progression of dry age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; Dry AMD; Drusen volume; PPV; Pars plana vitrectomy; AMD
   progression; OCT
ID DRUSEN VOLUME; VITREOMACULAR TRACTION; TREATMENT OUTCOMES; RISK
AB Purpose To demonstrate whether pars plana vitrectomy (PPV) changes the progression of dry age-related macular degeneration (AMD) by assessing longitudinal changes in drusen volume over follow-up. Methods Dry AMD patients who had undergone unilateral PPV for symptomatic vitreomacular disorders were evaluated for the progression of disease by spectral domain-optical coherence tomography (SD-OCT) features including drusen volume, development of geographic atrophy, or choroidal neovascularization during follow-up. Drusen volume was manually calculated using an image processing software (ImageJ, NIH) on raster SD-OCT scans. Mean change in drusen volume of surgery eyes was compared with values of the fellow eyes of the same subjects (control group). Results Among 183 eyes with both vitreoretinal disorder and dry AMD, 48 eyes of 24 patients met the inclusion criteria and were included. The mean drusen volume change during a mean of 25.49 +/- 23.35 months of follow-up (range: 6.00-86.87 months) was 4.236.899 +/- 20.488.913 mu m(3)in the study eye and 7.796.357 +/- 34.798.519 mu m(3)in the fellow eye (p= 0.297). Best-corrected visual acuity (BCVA) significantly increased from 0.40 +/- 0.18 logMAR (approximate to 20/50 Snellen equivalent) to 0.32 +/- 0.31 (approximate to 20/41 Snellen equivalent) after surgery (p= 0.012) in the study group while BCVA remained stable in the control group (0.19 +/- 0.34 logMAR [approximate to 20/30 Snellen equivalent] at baseline and 0.20 +/- 0.31 logMAR [approximate to 20/31 Snellen equivalent],p= 0.432). Choroidal neovascularization developed in 1 vitrectomized eye (4.54%) and in 1 eye (4.54%) from the control group during follow-up. Conclusion Vitrectomy did not seem to worsen dry AMD progression; even more visual acuity may improve despite a slight increase in drusen volume following surgery.
C1 [Muftuoglu, Ilkay Kilic; Lin, Tiezhu; Bartsch, Dirk-Uwe; Freeman, William R.] Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, Dept Ophthalmol, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
   [Muftuoglu, Ilkay Kilic] Istanbul Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Lin, Tiezhu] He Univ, He Eye Specialists Hosp, Shenyang, Liaoning, Peoples R China.
C3 University of California System; University of California San Diego;
   Istanbul Training & Research Hospital
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, Dept Ophthalmol, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM wrfreeman@ucsd.edu
RI lin, Tiezhu/AAY-1971-2020
FU NIH [R01 EY01632309A1]; National Eye Institute [P30 EY022589]; Research
   to Prevent Blindness, NY
FX This research is supported in part byNIHgrant R01 EY01632309A1 (D.
   U.B.), a core grant from the National Eye Institute P30 EY022589, and an
   unrestricted grant from Research to Prevent Blindness, NY (WRF).
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Kimura S, 2016, GRAEF ARCH CLIN EXP, V254, P1731, DOI 10.1007/s00417-016-3314-1
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krishnan R, 2015, RETINA-J RET VIT DIS, V35, P1750, DOI 10.1097/IAE.0000000000000714
   Maggio E, 2017, OPHTHALMOLOGY, V124, P657, DOI 10.1016/j.ophtha.2017.01.018
   Obeid A, 2018, OPHTHALMOL RETINA, V2, P765, DOI 10.1016/j.oret.2018.01.004
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thiele S, 2018, OPHTHALMOLOGICA, V239, P110, DOI 10.1159/000485260
   Ziada J, 2018, RETINA-J RET VIT DIS, V38, P531, DOI 10.1097/IAE.0000000000001573
NR 15
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2021
VL 259
IS 4
BP 847
EP 853
DI 10.1007/s00417-020-04943-x
EA OCT 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RH0XW
UT WOS:000579253000001
PM 33064198
DA 2022-11-30
ER

PT J
AU Kong, M
   Kim, S
   Ham, DI
AF Kong, Mingui
   Kim, Sungmin
   Ham, Don-Il
TI INCIDENCE OF LATE AGE-RELATED MACULAR DEGENERATION IN EYES WITH
   RETICULAR PSEUDODRUSEN
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; reticular pseudodrusen
ID GEOGRAPHIC-ATROPHY; 5-YEAR INCIDENCE; CLINICAL-FEATURES; 10-YEAR
   INCIDENCE; FELLOW-EYES; PROGRESSION; ASSOCIATION; PREVALENCE;
   MACULOPATHY; CLASSIFICATION
AB Purpose: To investigate the incidence of late age-related macular degeneration (AMD) over 3 years and risk factors for the development of late AMD in Korean patients having reticular pseudodrusen (RPD).
   Methods: Clinical records of Korean RPD patients with no late AMD at first examination and completion of 3 years of regular follow-up were retrospectively reviewed. All patients underwent complete ocular examinations, including multimodal imaging. Reticular pseudodrusen were classified as a separate lesion different from other early AMD lesions, and RPD were not considered a sign of early AMD. Risk factors for the development of late AMD were assessed.
   Results: One hundred and ninety-two RPD eyes of 104 patients were included in this study. Mean age of patients was 69.4 +/- 8.9 years, and other early AMD lesions were accompanied in 152 eyes (79.2%) at baseline. During 3 years, late AMD occurred in 30 eyes (15.6%); geographic atrophy in 24 eyes (12.5%); and neovascular AMD in 6 eyes (3.1%). Eyes having early AMD at baseline revealed significantly higher incidence for late AMD than those eyes having no early AMD at baseline (18.4% vs. 5%, P = 0.048). Late AMD occurred in 5 eyes (38.5%) from 13 fellow RPD eyes of unilateral late AMD at baseline. In logistic regression analysis, thin choroidal thickness, diffuse distribution of RPD, and the presence of late AMD on fellow eye at baseline were significant risk factors for developing late AMD in RPD eyes.
   Conclusion: Reticular pseudodrusen eyes revealed various progression rates to late AMD according to AMD status of both eyes. More frequent monitoring should be considered for patients with RPD at risk of progression to late AMD.
C1 [Kong, Mingui] Hangil Eye Hosp, Retina Ctr, Incheon, South Korea.
   [Kong, Mingui] Catholic Kwandong Univ, Coll Med, Dept Ophthalmol, Incheon, South Korea.
   [Kim, Sungmin; Ham, Don-Il] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
C3 Catholic Kwandong University; Sungkyunkwan University (SKKU); Samsung
   Medical Center
RP Ham, DI (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM oculus@naver.com
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 37
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2019
VL 39
IS 10
BP 1945
EP 1952
DI 10.1097/IAE.0000000000002263
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EX
UT WOS:000507475300014
PM 30048384
DA 2022-11-30
ER

PT J
AU Clemens, CR
   Alten, F
   Baumgart, C
   Heiduschka, P
   Eter, N
AF Clemens, Christoph R.
   Alten, Florian
   Baumgart, Christine
   Heiduschka, Peter
   Eter, Nicole
TI QUANTIFICATION OF RETINAL PIGMENT EPITHELIUM TEAR AREA IN AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium tear;
   confocal scanning laser ophthalmoscopy; near-infrared reflectance;
   fundus autofluorescence; spectral domain optical coherence tomography;
   retinal atrophy quantification; semiautomated software; RegionFinder
ID OCCULT CHOROIDAL NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE IMAGES;
   SCANNING LASER OPHTHALMOSCOPE; MEASURING GEOGRAPHIC ATROPHY;
   PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; SECONDARY; AMD;
   RANIBIZUMAB; DETACHMENT
AB Purpose: To compare different quantification tools based on confocal scanning laser ophthalmoscopy for assessment of retinal pigment epithelium (RPE) tear area size.
   Methods: Confocal scanning laser ophthalmoscopy fundus autofluorescence (FAF) and near-infrared reflectance (IR) images were retrospectively evaluated in 23 patients with RPE tear after intravitreal injection for pigment epithelium detachment due to exudative age-related macular degeneration at baseline and additionally in 11 patients after 5.1 +/- 1.8 months of follow-up. Retinal pigment epithelium tear area was measured by three independent readers using three methods: manually on confocal scanning laser ophthalmoscopy FAF images, manually on confocal scanning laser ophthalmoscopy IR images, and using an FAF-based semiautomated software.
   Results: Confidence intervals were 0.08 and 0.12 for FAF, 0.11 and 0.09 for FAF-based semiautomated software, and 0.25 and 0.27 for IR for intraobserver (Reader 1) and interobserver agreements (Readers 1 and 2), respectively. The average values of the square errors of the quantification methods were 0.040 +/- 0.033 mm(2) (FAF), 0.035 +/- 0.060 mm(2) (software), and 0.187 +/- 0.219 mm(2) (IR). Mean area of RPE tears at baseline given as the average measurement of all 3 readers using FAF-based semiautomated software was 5.77 +/- 4.62 mm(2) (range, 0.13-14.74 mm(2)). Follow-up measurements of unilobular RPE tears (8 patients) showed no change in lesion area size (0.14 +/- 0.33 mm(2)); in contrast, multilobular RPE tears (3 patients) showed a progression in lesion area size of 1.80 +/- 0.74 mm(2).
   Conclusion: Manual FAF-based and semiautomated FAF-based quantifications of RPE tear area are accurate and reproducible and superior to manual IR-based measurement. Retinal pigment epithelium tear area quantification is clinically relevant regarding further intravitreal treatment, particularly in multilobular RPE tears.
C1 [Clemens, Christoph R.; Alten, Florian; Baumgart, Christine; Heiduschka, Peter; Eter, Nicole] Univ Munster, Med Ctr, Dept Ophthalmol, D-48149 Munster, Germany.
C3 University of Munster
RP Clemens, CR (通讯作者)，Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM christoph.clemens@ukmuenster.de
RI Heiduschka, Peter/AAX-3882-2021
CR Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Caramoy A, 2011, ARCH OPHTHALMOL-CHIC, V129, P575, DOI 10.1001/archophthalmol.2011.105
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Karadimas P, 2006, EUR J OPHTHALMOL, V16, P767, DOI 10.1177/112067210601600520
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
NR 34
TC 12
Z9 13
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2014
VL 34
IS 1
BP 24
EP 31
DI 10.1097/IAE.0b013e3182947811
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6CZ
UT WOS:000336958700006
PM 23743641
DA 2022-11-30
ER

PT J
AU Millen, AE
   Voland, R
   Sondel, SA
   Parekh, N
   Horst, RL
   Wallace, RB
   Hageman, GS
   Chappell, R
   Blodi, BA
   Klein, ML
   Gehrs, KM
   Sarto, GE
   Mares, JA
AF Millen, Amy E.
   Voland, Rick
   Sondel, Sherie A.
   Parekh, Niyati
   Horst, Ronald L.
   Wallace, Robert B.
   Hageman, Gregory S.
   Chappell, Rick
   Blodi, Barbara A.
   Klein, Michael L.
   Gehrs, Karen M.
   Sarto, Gloria E.
   Mares, Julie A.
CA CAREDS Study Grp
TI Vitamin D Status and Early Age-Related Macular Degeneration in
   Postmenopausal Women
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID 3RD NATIONAL-HEALTH; EYE DISEASE; VISUAL IMPAIRMENT; NUCLEAR CATARACT;
   SUN EXPOSURE; RISK-FACTORS; MACULOPATHY; SERUM; CAROTENOIDS; PREVALENCE
AB Objective: The relationship between serum 25-hydroxyvitamin D (25[OH]D) concentrations (nmol/L) and the prevalence of early age-related macular degeneration (AMD) was investigated in participants of the Carotenoids in Age-Related Eye Disease Study.
   Methods: Stereoscopic fundus photographs, taken from 2001 to 2004, assessed AMD status. Baseline (1994-1998) serum samples were available for 25(OH)D assays in 1313 women with complete ocular and risk factor data. Odds ratios (ORs) and 95% confidence intervals (CIs) for early AMD (n = 241) of 1287 without advanced disease were estimated with logistic regression and adjusted for age, smoking, iris pigmentation, family history of AMD, cardiovascular disease, diabetes, and hormone therapy use.
   Results: In multivariate models, no significant relationship was observed between early AMD and 25(OH)D (OR for quintile 5 vs 1, 0.79; 95% CI, 0.50-1.24; P for trend = .47). A significant age interaction (P = .002) suggested selective mortality bias in women aged 75 years and older: serum 25(OH)D was associated with decreased odds of early AMD in women younger than 75 years (n = 968) and increased odds in women aged 75 years or older (n = 319) (OR for quintile 5 vs 1, 0.52; 95% CI, 0.29-0.91; P for trend = .02 and OR, 1.76; 95% CI, 0.77-4.13; P for trend = .05, respectively). Further adjustment for body mass index and recreational physical activity, predictors of 25(OH)D, attenuated the observed association in women younger than 75 years. Additionally, among women younger than 75 years, intake of vitamin D from foods and supplements was related to decreased odds of early AMD in multivariate models; no relationship was observed with self-reported time spent in direct sunlight.
   Conclusions: High serum 25(OH)D concentrations may protect against early AMD in women younger than 75 years.
C1 [Millen, Amy E.] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14214 USA.
   [Voland, Rick; Sondel, Sherie A.; Mares, Julie A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   [Chappell, Rick] Univ Wisconsin, Ctr Clin Sci, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53706 USA.
   [Sarto, Gloria E.] Univ Wisconsin, Dept Obstet & Gynecol, Sch Med & Publ Hlth, Madison, WI 53706 USA.
   [Parekh, Niyati] NYU, Dept Nutr Food Studies & Publ Hlth, New York, NY USA.
   [Horst, Ronald L.] Iowa State Univ, Dept Anim Sci, Ames, IA USA.
   [Wallace, Robert B.] Univ Iowa, Gen Hosp Off, Dept Epidemiol, Iowa City, IA USA.
   [Hageman, Gregory S.] Univ Utah, John A Moran Eye Ctr, Translat Res Inst, Salt Lake City, UT USA.
   [Blodi, Barbara A.] Fundus Photograph Reading Ctr, Madison, WI USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97201 USA.
   [Gehrs, Karen M.] Ctr Retina & Macular Dis, Winter Haven, FL USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; University of Wisconsin System; University of Wisconsin
   Madison; University of Wisconsin System; University of Wisconsin
   Madison; University of Wisconsin System; University of Wisconsin
   Madison; New York University; Iowa State University; University of Iowa;
   Utah System of Higher Education; University of Utah; Oregon Health &
   Science University
RP Millen, AE (通讯作者)，SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Ferber Hall 240, Buffalo, NY 14214 USA.
EM aemillen@buffal.edu
RI Parekh, Niyati/ABF-4933-2020
OI Parekh, Niyati/0000-0002-1334-0528; Gehrs, Karen/0000-0003-4510-9678
FU National Institutes of Health [EY13018, EY016886, DK07665]; Research to
   Prevent Blindness; National Heart, Lung, and Blood Institute; US
   Department of Health and Human Services [N01WH22110, 24152, 32100-2,
   32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26,
   42129-32, 44221]; NATIONAL EYE INSTITUTE [R01EY016886, U10EY013018,
   P30EY014800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007665] Funding Source:
   NIH RePORTER; WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR
   NIH [N01WH042114, N01WH042119, N01WH042111, N01WH032115, N01WH042115,
   N01WH032100, N01WH032109, N01WH042123, N01WH042107, N01WH042121,
   N01WH042126, N01WH042109, N01WH042116, N01WH032111, N01WH042108,
   N01WH032118, N01WH042124, N01WH042110, N01WH032101, N01WH042113,
   N01WH032106, N01WH032112, N01WH042118, N01WH042132, N01WH042130,
   N01WH042117, N01WH032102, N01WH022110, N01WH032105, N01WH042131,
   N01WH042112, N01WH042125, N01WH042122, N01WH042129, N01WH032119,
   N01WH032108, N01WH032122, N01WH042120, N01WH032113] Funding Source: NIH
   RePORTER
FX This study was supported by grants EY13018, EY016886, and DK07665 from
   the National Institutes of Health and by Research to Prevent Blindness.
   It was part of the Carotenoids and Age-Related Eye Disease Study
   (CAREDS), an ancillary study of the Women's Health Initiative (WHI). The
   WHI program is funded by the National Heart, Lung, and Blood Institute,
   National Institutes of Health, and the US Department of Health and Human
   Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9,
   32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.
CR Agborsangaya C, 2010, NUTR CANCER, V62, P51, DOI 10.1080/01635580903191460
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7
   Antoniucci DM, 2005, CLIN CHEM, V51, P258
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508
   BIDMON HJ, 1995, HISTOCHEM J, V27, P516
   Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18
   Choi Dongseok, 2008, J Ocul Biol Dis Infor, V1, P37, DOI 10.1007/s12177-008-9007-1
   Craig TA, 2008, J BONE MINER RES, V23, P1486, DOI 10.1359/jbmr.080403
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Duncan DD, 2002, DEV OPHTHALMOL, V35, P76
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FLETCHER AE, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hartweg J, 2007, CLIN CHEM, V53, P1858, DOI 10.1373/clinchem.2006.076380
   Holick MF, 2006, MAYO CLIN PROC, V81, P353, DOI 10.4065/81.3.353
   Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Institute of Medicine, 2011, DIETARY REFERENCE IN
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaplan George A., 1992, P20
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   MARES JA, ARCH OPHTHALMOL
   Mares JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P738, DOI 10.1001/archophthalmol.2010.84
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Millen AE, 2010, AM J CLIN NUTR, V91, P1324, DOI 10.3945/ajcn.2009.28908
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Mullin GE, 2007, NUTR CLIN PRACT, V22, P305, DOI 10.1177/0115426507022003305
   OCKE MC, 1995, J CLIN EPIDEMIOL, V48, P1077, DOI 10.1016/0895-4356(94)00232-F
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6
   Patterson RE, 1998, AM J EPIDEMIOL, V148, P643, DOI 10.1093/aje/148.7.643
   Patterson RE, 1999, PUBLIC HEALTH NUTR, V2, P273, DOI 10.1017/S1368980099000361
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   *SAS, 2001, SAS STAT R 9 2 US GU
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   SHOKRAVI MT, 1995, INVEST OPHTH VIS SCI, V36, P83
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   West Emily S., 2005, International Ophthalmology Clinics, V45, P41
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 60
TC 94
Z9 95
U1 0
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2011
VL 129
IS 4
BP 481
EP 489
DI 10.1001/archophthalmol.2011.48
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 748GT
UT WOS:000289378900013
PM 21482873
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Fleckenstein, M
   Mitchell, P
   Freund, KB
   Sadda, S
   Holz, FG
   Brittain, C
   Henry, EC
   Ferrara, D
AF Fleckenstein, Monika
   Mitchell, Paul
   Freund, K. Bailey
   Sadda, SriniVas
   Holz, Frank G.
   Brittain, Christopher
   Henry, Erin C.
   Ferrara, Daniela
TI The Progression of Geographic Atrophy Secondary to Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; OUTER
   RETINAL TUBULATION; FUNDUS AUTOFLUORESCENCE PATTERNS; SUBFOVEAL
   CHOROIDAL THICKNESS; VISUAL FUNCTION QUESTIONNAIRE; RETICULAR
   PSEUDODRUSEN; PIGMENT EPITHELIUM; EYE DISEASE; FIXATION PATTERNS
AB Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible loss of visual function. Geographic atrophy is defined by the presence of sharply demarcated atrophic lesions of the outer retina, resulting from loss of photoreceptors, retinal pigment epithelium (RPE), and underlying choriocapillaris. These lesions typically appear first in the perifoveal macula, initially sparing the foveal center, and over time often expand and coalesce to include the fovea. Although the kinetics of GA progression are highly variable among individual patients, a growing body of evidence suggests that specific characteristics may be important in predicting disease progression and outcomes. This review synthesizes current understanding of GA progression in AMD and the factors known or postulated to be relevant to GA lesion enlargement, including both affected and fellow eye characteristics. In addition, the roles of genetic, environmental, and demographic factors in GA lesion enlargement are discussed. Overall, GA progression rates reported in the literature for total study populations range from 0.53 to 2.6 mm(2)/year (median, similar to 1.78 mm(2)/year), assessed primarily by color fundus photography or fundus autofluorescence (FAF) imaging. Several factors that could inform an individual's disease prognosis have been replicated in multiple cohorts: baseline lesion size, lesion location, multifocality, FAF patterns, and fellow eye status. Because best-corrected visual acuity does not correspond directly to GA lesion enlargement due to possible foveal sparing, alternative assessments are being explored to capture the relationship between anatomic progression and visual function decline, including microperimetry, low-luminance visual acuity, reading speed assessments, and patient-reported outcomes. Understanding GA progression and its individual variability is critical in the design of clinical studies, in the interpretation and application of clinical trial results, and for counseling patients on how disease progression may affect their individual prognosis. (C) 2017 by the American Academy of Ophthalmology.
C1 [Fleckenstein, Monika; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Sadda, SriniVas] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Sadda, SriniVas] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Brittain, Christopher] F Hoffmann La Roche Ltd, Basel, Switzerland.
   [Henry, Erin C.; Ferrara, Daniela] Genentech Inc, San Francisco, CA 94080 USA.
C3 University of Bonn; University of Sydney; University of Sydney; Westmead
   Institute for Medical Research; Vitreous Retina Macula Consultants of
   New York; New York University; Doheny Eye Institute; University of
   California System; University of California Los Angeles; Roche Holding;
   Roche Holding; Genentech
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Monika.Fleckenstein@ukb.uni-bonn.de
RI ; Freund, K. Bailey/V-7488-2018
OI Ferrara, Daniela/0000-0002-1380-7562; Fleckenstein,
   Monika/0000-0001-8321-8037; Freund, K. Bailey/0000-0002-7888-9773
FU Acucela; Alcon; Allergan; Bayer; Formycon; Genentech; Novartis; Roche;
   Heidelberg Engineering; Genentech/Roche; German Research Foundation
   (DFG) [FL 658/4-1, FL 658/4-2]; Genentech, Inc.; Carl Zeiss Meditec,
   Inc.; Optos plc
FX The author(s) have made the following disclosure(s): M.F.: Personal fees
   - Bayer, Heidelberg Engineering, Novartis, Genentech/Roche; Patent
   US20140303013 A1 pending; Research grant - German Research Foundation
   (DFG): FL 658/4-1 and FL 658/4-2.; F.G.H.: Consulting fees - Acucela,
   Allergan, Bayer, GSK, Heidelberg Engineering, Novartis,
   Genentech/Roche.; S.S.: Consultant - Genentech, Inc., Allergan, Alcon,
   Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Carl Zeiss
   Meditec, Inc., Optos plc; Research support - Genentech, Inc., Allergan,
   Carl Zeiss Meditec, Inc., Optos plc.; The Department of Ophthalmology at
   the University of Bonn has received nonfinancial support through the
   supply of technical equipment by several imaging device manufacturers,
   including Heidelberg Engineering, Optos, and Zeiss Meditec. The
   Department of Ophthalmology at the University of Bonn has received
   research grants from Acucela, Alcon, Allergan, Bayer, Formycon,
   Genentech, Novartis, and Roche.
CR Abdillahi H, 2014, OPHTHALMOLOGY, V121, P1734, DOI 10.1016/j.ophtha.2014.03.036
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Allingham MJ, 2016, INVEST OPHTH VIS SCI, V57, P2283, DOI 10.1167/iovs.15-19008
   American Academy of Ophthalmology (AAO), 2016, ICD10 CM SUBSP ICD 1
   AREDS Research Group, 2000, AREDS STUD DES
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Brown JC, 2014, OPHTHALMOLOGY, V121, P1655, DOI 10.1016/j.ophtha.2014.02.030
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   CDC, 2017, INT CLASS DIS 10 REV
   Centers for Disease Control (CDC), 2016, INT CLASS DIS 10 REV
   Chaikitmongkol V, 2016, CURR OPIN OPHTHALMOL, V27, P217, DOI 10.1097/ICU.0000000000000259
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dolz-Marco R, 2016, INVEST OPHTH VIS SCI, V57, P6440, DOI 10.1167/iovs.16-20265
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57
   European Medicines Agency (EMA), 2016, LETT SUPP READ SPEED
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Giocanti-Auregan A, 2015, INVEST OPHTH VIS SCI, V56, P8325, DOI 10.1167/iovs.14-15480
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Hanout M, 2015, CURR OPIN OPHTHALMOL, V26, P149, DOI 10.1097/ICU.0000000000000153
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Kimel M, 2016, INVEST OPHTH VIS SCI, V57, P6298, DOI 10.1167/iovs.16-20361
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Pilotto E, 2015, BRIT J OPHTHALMOL, V99, P1082, DOI 10.1136/bjophthalmol-2014-306338
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2016, ICD 10 VERS 2016
   World Health Organization, 2017, ICD 11 BET DRAFT MOR
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2015, OSLI RETINA, V46, P772, DOI 10.3928/23258160-20150730-15
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 124
TC 181
Z9 182
U1 2
U2 34
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2018
VL 125
IS 3
BP 369
EP 390
DI 10.1016/j.ophtha.2017.08.038
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW5SE
UT WOS:000425377300016
PM 29110945
OA hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Gerding, H
AF Gerding, H.
TI Functional and Anatomic Efficacy of a Conversion to Aflibercept in Eyes
   with Age-Related Macular Degeneration after Long-Term Ranibizumab
   Treatment
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE aflibercept; ranibizumab; age-related macular degeneration; anti-VEGF;
   intravitreal injections; anti-PIGF; retina; choroidal neovascularisation
ID INTRAVITREAL AFLIBERCEPT; OUTCOMES; RESPONDERS; RESISTANT; THERAPY;
   FLUID
AB Background: It was the aim of this retrospective study to analyse the functional and anatomic efficacy of a conversion from ranibizumab to aflibercept treatment in eyes with exsudative age-related macular degeneration (AMD) with recently unsatisfactory response to a ranibizumab treatment.
   Material, Patients and Methods: 40 eyes of 37 patients (age: 80.6 +/- 7.7 years [mean +/- 1 standard deviation (SD)] were included. The average visual acuity (VA) was 0.56 +/- 0.33 logMAR [mean +/- standard error (SE)] at the time of the first aflibercept injection. The eyes had received a mean of 21.5 +/- 11.7 (mean +/- SD) injections of ranibizumab within 3.15 +/- 1.79 (mean +/- SD) years. Follow-up covered 6 months in all patients. Before and after treatment and conversion of treatment, a PRN regimen with monthly visual acuity and OCT examinations was applied.
   Results: After conversion to aflibercept the mean gain of VA was 0.45 +/- 1.26 lines at month 1 (mean +/- SE, p = 0.04), 0.26 +/- 1.60 at months 3 (p = 0.067), and 0.65 +/- 1.77 (p = 0.03) at month 6. Total OCT central foveal point thickness decreased from 417 +/- 215 mu m (mean +/- 1 SD) before the first injection of aflibercept to 299 +/- 139 (p < 0.001), 325 +/- 174 at month 3 (p < 0.001), and 321 +/- 150 mu m at month 6 (p < 0.001). The average number of aflibercept injections was 4.0 +/- 1.1 (mean +/- SD). At the end of follow up 61% of eyes had gained >= 1 line, 22% >= 2 lines, and 12% >= 3 lines. 10% had lost >= 1 line, 5% >= 2 lines, and 2% >= 3 lines.
   Conclusions: The results of this case series show that conversion from ranibizumab to aflibercept can significantly reduce retinal thickness and improve visual acuity in patients with age-related macular degeneration with increasingly unsatisfactory response to long-term ranibizumab treatment.
C1 [Gerding, H.] Pallas Kliniken, Dept Ophthalmol, Olten, Switzerland.
   [Gerding, H.] Univ Munster, Dept Ophthalmol, D-48149 Munster, Germany.
C3 University of Munster
RP Gerding, H (通讯作者)，Augenzentrum Klin Pallas, Louis Giroud Str 20, CH-4600 Olten, Switzerland.
EM hgerding@klinik-pallas.ch
RI Gerding, Heinrich/M-2363-2019
OI Gerding, Heinrich/0000-0003-3968-5601
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Gerding H, 2014, KLIN MONATSBL AUGENH, V231, P427, DOI 10.1055/s-0034-1368241
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Hall LB, 2014, J OCUL PHARMACOL TH, V30, P346, DOI 10.1089/jop.2013.0188
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 22
TC 4
Z9 5
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2015
VL 232
IS 4
BP 560
EP 563
DI 10.1055/s-0035-1545775
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG7RB
UT WOS:000353501000055
PM 25902122
DA 2022-11-30
ER

PT J
AU Dreyhaupt, J
   Mansmann, U
   Pritsch, M
   Dolar-Szczasny, J
   Bindewald, A
   Holz, FG
AF Dreyhaupt, J
   Mansmann, U
   Pritsch, M
   Dolar-Szczasny, J
   Bindewald, A
   Holz, FG
TI Modelling the natural history of geographic atrophy in patients with
   age-related macular degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; mixed effects
   models; model assessment; natural history
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   TRIAMCINOLONE; PHOTODYNAMIC THERAPY; VISUAL-ACUITY; PREVALENCE;
   TRANSPLANTATION; MACULOPATHY
AB Purpose: To model the natural course of geographic atrophy (GA) in patients with age-related macular degeneration (AMD). Methods: Data on the natural course of GA were collected in the multi-center, longitudinal, prospective observational FAM study. The size of GA was measured by autofluorescence scanning laser ophthalmoscopy. The natural course of GA is modelled by two different mixed effect models (MEM). Both models are compared with respect to the correctness of the model assumptions, goodness of fit, and predictive behavior. Results: The linear model results in better prediction, the non-linear model is more in agreement with the model assumptions. The non-linear model fits the data for small and large areas of GA better, while the linear model seems to be more adequate for the medial areas. More data will be needed to study the interplay of both models in more detail. Conclusions: The natural course of GA varies extremely between individuals. However, reliable factors for the explanation of this variability have so far not been established. MEM are useful for describing "Inter-individual" as well as "Intra-individual" influences without the need for precise knowledge of the influencing factors. Using MEM to evaluate data on the natural history of GA allows one to derive parameter estimates, which could be used to design interventional trials for modes of therapy with a potential to reduce or stop the progression of GA in patients with AMD.
C1 Heidelberg Univ, Dept Med Biometry & Informat, D-69120 Heidelberg, Germany.
   Med Univ Lublin, Hosp Eye 1, Lublin, Poland.
   Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
C3 Ruprecht Karls University Heidelberg; Medical University of Lublin;
   University of Bonn
RP Dreyhaupt, J (通讯作者)，Heidelberg Univ, Dept Med Biometry & Informat, INF 305, D-69120 Heidelberg, Germany.
EM dreyhaupt@imbi.uni-heidelberg.de
OI Dolar-Szczasny, Joanna/0000-0003-4206-4371; Bindewald-Wittich,
   Almut/0000-0002-8151-3953
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BINDEWALD A, ARVO2004
   BINDEWALD A, ARVO2003
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Burnham K.P., 2002, MODEL SELECTION MULT, V2nd, DOI 10.1007/b97636
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   EVANS JR, 2000, COCHRANE DB SYST REV
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   GREHN F, 2003, AUGENHEIKUNDE
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   JORZIK JJ, ARVO2004
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MACCLEARY R, 1980, APPL TIME SERIE ANAL
   MITCHELL RA, 1993, J EPIDEMIOL COMMUN H, V47, P42, DOI 10.1136/jech.47.1.42
   Molenberghs G., 2000, LINEAR MIXED MODELS
   Pinheiro J.C., 2000, MIXED EFFECTS MODELS
   ROTH F, ARVO2004
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1993, AM J OPHTHALMOL, V115, P563, DOI 10.1016/S0002-9394(14)71451-5
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WAHRENDORF J, 1987, J R STAT SOC C-APPL, V36, P72
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
NR 38
TC 47
Z9 47
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD DEC
PY 2005
VL 12
IS 6
BP 353
EP 362
DI 10.1080/09286580591005723
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 989MQ
UT WOS:000233678500001
PM 16283987
DA 2022-11-30
ER

PT J
AU Rechtman, E
   Danis, RP
   Pratt, LM
   Harris, A
AF Rechtman, E
   Danis, RP
   Pratt, LM
   Harris, A
TI Intravitreal triamcinolone with photodynamic therapy for subfoveal
   choroidal neovascularisation in age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; LASER PHOTOCOAGULATION; VERTEPORFIN THERAPY;
   ACETONIDE; LESIONS
AB Aims: To report the effects of intravitreal triamcinolone acetonide (iTAAC) injections as an adjunctive treatment to photodynamic therapy (PDT) with verteporfin for new subfoveal choroidal neovascularisation (CNV) in age related macular degeneration (AMD).
   Methods: We retrospectively reviewed the records of all AMD patients who had iTAAC within 6 weeks of their first PDT and had a follow up of one year or longer. The proportion of eyes after one year follow up that lost or gained greater than or equal to15 and greater than or equal to30 ETDRS letters, baseline and one year lesion greatest linear dimension (GLD), number of PDTs, and side effects were assessed.
   Results: Fourteen patients were evaluated. Eleven received one initial combined treatment and three received an additional combined treatment after 6 months. Median follow up was 18 months ( range 12 to 25 months). Overall, 7% gained greater than or equal to30 letters, 50% maintained stable vision, 14% lost 15 - 29 letters, and 29% lost greater than or equal to30 letters. Overall, mean GLD increased from 2580 (SD 1088) mm to 3946 (SD 1503) mum ( p = 0.01). The mean number of PDTs during the first year was 2.57. Side effects were mild intraocular pressure elevation in 28.5% and cataract progression in 50% of phakic eyes.
   Conclusions: iTAAC with PDT in AMD was found to be relatively safe and had reasonable results for lesions with some classic component.
C1 Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN USA.
   Kaplan Med Ctr, Dept Ophthalmol, Rehovot, Israel.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53711 USA.
C3 Indiana University System; Indiana University Bloomington; Hebrew
   University of Jerusalem; Kaplan Medical Center; University of Wisconsin
   System; University of Wisconsin Madison
RP Danis, RP (通讯作者)，Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Park W 1,406 Sci Dr,Suite 400, Madison, WI 53711 USA.
EM ehudrechtman@yahoo.com; rdanis@rc.ophth.wisc.edu
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BAKRI SJ, 2002, AM ACAD OPHTHALMOLOG, P157
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
NR 19
TC 127
Z9 145
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR 1
PY 2004
VL 88
IS 3
BP 344
EP 347
DI 10.1136/bjo.2003.027177
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 776EY
UT WOS:000189104800009
PM 14977766
OA Bronze, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Nittala, MG
   Song, YE
   Sardell, R
   Adams, LD
   Pan, S
   Velaga, SB
   Horst, V
   Dana, D
   Caywood, L
   Laux, R
   Fuzzell, D
   Fuzzell, S
   Scott, WK
   Bailey, JNC
   Igo, RP
   Haines, J
   Pericak-Vance, MA
   Sadda, SR
   Stambolian, D
AF Nittala, Muneeswar G.
   Song, Yeunjoo E.
   Sardell, Rebecca
   Adams, Larry D.
   Pan, Samuel
   Velaga, Swetha B.
   Horst, Violet
   Dana, Debra
   Caywood, Laura
   Laux, Renee
   Fuzzell, Denise
   Fuzzell, Sarada
   Scott, William K.
   Bailey, Jessica N. Cooke
   Igo, Robert P., Jr.
   Haines, Jonathan
   Pericak-Vance, Margaret A.
   Sadda, Srinivas R.
   Stambolian, Dwight
TI Baseline Spectral Domain Optical Coherence Tomography Characteristics of
   Age-Related Macular Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Amish population; spectral domain optical coherence tomography;
   subretinal drusenoid deposits
ID SUBRETINAL DRUSENOID DEPOSITS; COMPLEMENT FACTOR-H; RETICULAR
   PSEUDODRUSEN; GEOGRAPHIC-ATROPHY; SEVERITY SCALE; RISK-FACTOR;
   PREVALENCE; EYES; SEGMENTATION; PROGRESSION
AB Purpose: To describe spectral domain optical coherence tomography (SD-OCT) findings in an Amish cohort to assess SD-OCT markers for early age-related macular degeneration (AMD).
   Methods: The authors performed a family-based prospective cohort study of 1,146 elderly Amish subjects (age range 50-99 years) (2,292 eyes) who had a family history of at least 1 individual with AMD. All subjects underwent complete ophthalmic examinations, SD-OCT using both Cirrus and Spectralis (20 x 20 degrees scan area) instruments, fundus autofluorescence, infrared imaging, and color fundus photography. Spectral domain optical coherence tomography characteristics were analyzed in subjects with AMD (with and without subretinal drusenoid deposits [SDDs]) and normal healthy cohorts.
   Results: Participants' mean age was 65.2 years (SD +/- 11). Color fundus photographic findings in 596 (53%) subjects (1,009 eyes) were consistent with AMD; the remaining 478 (43%) subjects showed no signs of AMD. The choroid was significantly thinner on OCT (242 +/- 76 mu m, P < 0.001) in those with AMD compared with those without (263 +/- 63 mu m). Subretinal drusenoid deposits were found in 143 eyes (7%); 11 of the 143 eyes (8%) had no other manifestations of AMD. Drusen volume (P < 0.001) and area of geographic atrophy (P > 0.001) were significantly greater, and choroid was significantly (P < 0.001) thinner in subjects with SDDs versus those without SDDs.
   Conclusion: The authors describe spectral domain optical coherence tomography characteristics in an elderly Amish population with and without AMD, including the frequency of SDD. Although relatively uncommon in this population, the authors confirmed that SDDs can be found in the absence of other features of AMD and that eyes with SDDs have thinner choroids.
C1 [Nittala, Muneeswar G.; Velaga, Swetha B.; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Song, Yeunjoo E.; Laux, Renee; Fuzzell, Denise; Fuzzell, Sarada; Bailey, Jessica N. Cooke; Igo, Robert P., Jr.; Haines, Jonathan] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.
   [Sardell, Rebecca; Adams, Larry D.; Pan, Samuel; Caywood, Laura; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Horst, Violet; Dana, Debra; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Haines, Jonathan] Case Western Reserve Univ, Inst Computat Biol, Cleveland, OH 44106 USA.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 Doheny Eye Institute; Case Western Reserve University; University of
   Miami; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; Case Western Reserve University;
   University of Pennsylvania; Pennsylvania Medicine
RP Stambolian, D (通讯作者)，Univ Penn, Perelman Sch Med, Room 313 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM stamboli@pennmedicine.upenn.edu
RI Nittala, Muneeswar/AAT-7533-2020; Bailey, Jessica Cooke/Q-5062-2019;
   Cooke Bailey, Jessica Nicole/AFQ-5925-2022
OI Bailey, Jessica Cooke/0000-0002-4001-8702; Cooke Bailey, Jessica
   Nicole/0000-0002-4001-8702; Scott, William/0000-0001-9336-6404; Song,
   Yeunjoo/0000-0002-7452-3731
FU National Eye Institute, Bethesda, Maryland [RO1 EY023164]; Department of
   Ophthalmology at the Perelman School of Medicine, University of
   Pennsylvania, Philadelphia, Pennsylvania; John P. Hussman Institute of
   Human Genomics at the University Of Miami Miller School Of Medicine,
   Miami, Florida; Institute for Computational Biology, Case Western
   Reserve University, Cleveland, Ohio; F. M. Kirby Foundation; Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY023164] Funding Source:
   NIH RePORTER
FX Supported by the National Eye Institute, Bethesda, Maryland (Grant #RO1
   EY023164), the Department of Ophthalmology at the Perelman School of
   Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, John
   P. Hussman Institute of Human Genomics at the University Of Miami Miller
   School Of Medicine, Miami, Florida and the Institute for Computational
   Biology, Case Western Reserve University, Cleveland, Ohio. Funds also
   were received from the F. M. Kirby Foundation and Research to Prevent
   Blindness.
CR Amish Heritage Committee, 1990, ELKH LAGR COUNT AM H
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   Beachy, 2011, UNSER LEIT STORY AMI
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Diniz B, 2015, EYE, V29, P272, DOI 10.1038/eye.2014.260
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hahs DW, 2006, AM J MED GENET B, V141B, P160, DOI 10.1002/ajmg.b.30257
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Hostetler J. A., 1993, AMISH SOC, DOI 10.2307/539066
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keen KJ, 2003, STAT MED, V22, P3229, DOI 10.1002/sim.1559
   Klein BEK, 2007, AM J OPHTHALMOL, V144, P961, DOI 10.1016/j.ajo.2007.08.016
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Mathew G, 2011, STAT APPL GENET MOL, V10, DOI 10.2202/1544-6115.1573
   McCauley JL, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-19
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Meleth AD, 2011, CURR OPIN OPHTHALMOL, V22, P190, DOI 10.1097/ICU.0b013e32834594b0
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   S. A. G. E, 2016, 6 4 STAT AN GEN EP
   Sardell RJ, 2016, OPHTHALMOLOGY, V123, P2537, DOI 10.1016/j.ophtha.2016.09.001
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 50
TC 11
Z9 11
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2019
VL 39
IS 8
BP 1540
EP 1550
DI 10.1097/IAE.0000000000002210
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ5AL
UT WOS:000480763200018
PM 29746403
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Govindaiah, A
   Baten, A
   Smith, RT
   Balasubramanian, S
   Bhuiyan, A
AF Govindaiah, Arun
   Baten, Abdul
   Smith, R. Theodore
   Balasubramanian, Siva
   Bhuiyan, Alauddin
TI Optimized Prediction Models from Fundus Imaging and Genetics for Late
   Age-Related Macular Degeneration
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE macular degeneration; genetics; fundus imaging; deep learning
ID GENOTYPES; ZINC
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the developed world. In this study, we compare the performance of retinal fundus images and genetic-information-based machine learning models for the prediction of late AMD. Using data from the Age-related Eye Disease Study, we built machine learning models with various combinations of genetic, socio-demographic/clinical, and retinal image data to predict late AMD using its severity and category in a single visit, in 2, 5, and 10 years. We compared their performance in sensitivity, specificity, accuracy, and unweighted kappa. The 2-year model based on retinal image and socio-demographic (S-D) parameters achieved a sensitivity of 91.34%, specificity of 84.49% while the same for genetic and S-D-parameters-based model was 79.79% and 66.84%. For the 5-year model, the retinal image and S-D-parameters-based model also outperformed the genetic and S-D parameters-based model. The two 10-year models achieved similar sensitivities of 74.24% and 75.79%, respectively, but the retinal image and S-D-parameters-based model was otherwise superior. The retinal-image-based models were not further improved by adding genetic data. Retinal imaging and S-D data can build an excellent machine learning predictor of developing late AMD over 2-5 years; the retinal imaging model appears to be the preferred prognostic tool for efficient patient management.
C1 [Govindaiah, Arun; Bhuiyan, Alauddin] iHealthscreen Inc, New York, NY 11418 USA.
   [Baten, Abdul] AgResearch, Palmerston North 4442, New Zealand.
   [Smith, R. Theodore] New York Eye & Ear Infirm, New York, NY 10003 USA.
   [Balasubramanian, Siva] Genetech, San Francisco, CA 94080 USA.
C3 AgResearch - New Zealand; New York Eye & Ear Infirmary of Mount Sinai;
   Roche Holding
RP Bhuiyan, A (通讯作者)，iHealthscreen Inc, New York, NY 11418 USA.
EM arun@ihealthscreen.org; Abdul.Baten@agresearch.co.nz; rts1md@gmail.com;
   balasiva@gene.com; bhuiyan@ihealthscreen.org
OI smith, theodore/0000-0002-1693-943X; Baten, Abdul/0000-0003-4673-0685
FU National Institutes of Health (NIH) Small Business Innovation Research
   (SBIR) [EY031202]
FX This project is funded by National Institutes of Health (NIH) Small
   Business Innovation Research (SBIR) and the project number EY031202.
CR Alauddin S, 2020, INVEST OPHTH VIS SCI, V61
   [Anonymous], GENOME WIDE GENOTYPI
   [Anonymous], AGE RELATED MACULAR
   Bhuiyan A., 2013, J CLIN EXP OPHTHALMO, V4, P1
   Bhuiyan A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.25
   Breiman L., 1996, MACH LEARN, V24, P123, DOI 10.1007/BF00058655
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chollet F, 2017, PROC CVPR IEEE, P1800, DOI 10.1109/CVPR.2017.195
   Dietterich TG, 2000, LECT NOTES COMPUT SC, V1857, P1, DOI 10.1007/3-540-45014-9_1
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman N, 1997, MACH LEARN, V29, P131, DOI 10.1023/A:1007465528199
   Geneva II, 2016, INT J OPHTHALMOL-CHI, V9, P145, DOI 10.18240/ijo.2016.01.24
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Govindaiah A, 2018, I S BIOMED IMAGING, P1525, DOI 10.1109/ISBI.2018.8363863
   Guymer R., 2019, OPHTHALMOLOGY, P126
   Hosmer DW, 2013, WILEY SER PROBAB ST, P1
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Landwehr N, 2005, MACH LEARN, V59, P161, DOI 10.1007/s10994-005-0466-3
   LeCun Y., 2015, NATURE, V521, P436, DOI DOI 10.1038/NATURE14539
   Liutkeviciene R, 2019, GENE, V686, P8, DOI 10.1016/j.gene.2018.11.004
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Rajendran A, 2018, BRIT J OPHTHALMOL, V102, P1213, DOI 10.1136/bjophthalmol-2017-311384
   SAFAVIAN SR, 1991, IEEE T SYST MAN CYB, V21, P660, DOI 10.1109/21.97458
   Seddon J.M., 2011, INVESTIG OPHTHALMOL, V52, P5235
   Souied E, 2013, INVEST OPHTH VIS SCI, V54
   Szegedy C., 2016, ARXIV
   Szegedy C, 2016, PROC CVPR IEEE, P2818, DOI 10.1109/CVPR.2016.308
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2021, OPHTHALMOL RETINA, V5, P118, DOI 10.1016/j.oret.2020.06.026
   Yan Q, 2020, NAT MACH INTELL, V2, P141, DOI 10.1038/s42256-020-0154-9
   Zoph B, 2018, PROC CVPR IEEE, P8697, DOI 10.1109/CVPR.2018.00907
NR 36
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD NOV
PY 2021
VL 11
IS 11
AR 1127
DI 10.3390/jpm11111127
PG 14
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA 3C5TE
UT WOS:000828684800001
PM 34834479
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Baas, DC
   Ho, L
   Tanck, MWT
   Fritsche, LG
   Merriam, JE
   Van het Slot, R
   Koeleman, BPC
   Gorgels, TGMF
   van Duijn, CM
   Uitterlinden, AG
   de Jong, PTVM
   Hofman, A
   ten Brink, JB
   Vingerling, JR
   Klaver, CCW
   Dean, M
   Weber, BHF
   Allikmets, R
   Hageman, GS
   Bergen, AAB
AF Baas, Dominique C.
   Ho, Lintje
   Tanck, Michael W. T.
   Fritsche, Lars G.
   Merriam, Joanna E.
   Van het Slot, Ruben
   Koeleman, Bobby P. C.
   Gorgels, Theo G. M. F.
   van Duijn, Cornelia M.
   Uitterlinden, Andre G.
   de Jong, Paulus T. V. M.
   Hofman, Albert
   ten Brink, Jacoline B.
   Vingerling, Johannes R.
   Klaver, Caroline C. W.
   Dean, Michael
   Weber, Bernhard H. F.
   Allikmets, Rando
   Hageman, Gregory S.
   Bergen, Arthur A. B.
TI Multicenter cohort association study of SLC2A1 single nucleotide
   polymorphisms and age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID TRANSPORTER GLUT1 GENE; COMPLEMENT FACTOR-H; DEPENDENT
   DIABETES-MELLITUS; BLOOD-BRAIN-BARRIER; GLUCOSE-TRANSPORTER; SERPING1
   GENE; SUSCEPTIBILITY; NEPHROPATHY; RISK; EXPRESSION
AB Purpose: Age-related macular degeneration (AMD) is a major cause of blindness in older adults and has a genetically complex background. This study examines the potential association between single nucleotide polymorphisms (SNPs) in the glucose transporter 1 (SLC2A1) gene and AMD. SLC2A1 regulates the bioavailability of glucose in the retinal pigment epithelium (RPE), which might influence oxidative stress-mediated AMD pathology.
   Methods: Twenty-two SNPs spanning the SLC2A1 gene were genotyped in 375 cases and 199 controls from an initial discovery cohort (the Amsterdam-Rotterdam-Netherlands study). Replication testing was performed in The Rotterdam Study (the Netherlands) and study populations from Wurzburg (Germany), the Age Related Eye Disease Study (AREDS; United States), Columbia University (United States), and Iowa University (United States). Subsequently, a meta-analysis of SNP association was performed.
   Results: In the discovery cohort, significant genotypic association between three SNPs (rs3754219, rs4660687, and rs841853) and AMD was found. Replication in five large independent (Caucasian) cohorts (4,860 cases and 4,004 controls) did not yield consistent association results. The genotype frequencies for these SNPs were significantly different for the controls and/or cases among the six individual populations. Meta-analysis revealed significant heterogeneity of effect between the studies.
   Conclusions: No overall association between SLC2A1 SNPs and AMD was demonstrated. Since the genotype frequencies for the three SLC2A1 SNPs were significantly different for the controls and/or cases between the six cohorts, this study corroborates previous evidence that population dependent genetic risk heterogeneity in AMD exists.
C1 [Baas, Dominique C.; Gorgels, Theo G. M. F.; de Jong, Paulus T. V. M.; ten Brink, Jacoline B.; Bergen, Arthur A. B.] NIN, Dept Clin & Mol Ophthalmogenet, Amsterdam, Netherlands.
   [Ho, Lintje; van Duijn, Cornelia M.; Uitterlinden, Andre G.; de Jong, Paulus T. V. M.; Hofman, Albert; Vingerling, Johannes R.; Klaver, Caroline C. W.] EMC, Dept Epidemiol, Rotterdam, Netherlands.
   [Ho, Lintje; Vingerling, Johannes R.; Klaver, Caroline C. W.] EMC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Tanck, Michael W. T.] AMC, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands.
   [Fritsche, Lars G.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Merriam, Joanna E.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol Pathol & Cell Biol, New York, NY USA.
   [Van het Slot, Ruben; Koeleman, Bobby P. C.] UMC, Dept Med Genet, Res Sect, Utrecht, Netherlands.
   [de Jong, Paulus T. V. M.; Bergen, Arthur A. B.] AMC, Dept Ophthalmol, Amsterdam, Netherlands.
   [Uitterlinden, Andre G.] EMC, Dept Internal Med, Rotterdam, Netherlands.
   [Dean, Michael] NCI, Lab Expt Immunol, Canc & Inflammat Program, Frederick, MD 21701 USA.
   [Hageman, Gregory S.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Hageman, Gregory S.] Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   [Bergen, Arthur A. B.] AMC, Dept Clin Genet, Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Amsterdam;
   Academic Medical Center Amsterdam; University of Regensburg; Columbia
   University; University of Amsterdam; Academic Medical Center Amsterdam;
   Erasmus University Rotterdam; Erasmus MC; National Institutes of Health
   (NIH) - USA; NIH National Cancer Institute (NCI); University of Iowa;
   University of California System; University of California Santa Barbara;
   University of Amsterdam; Academic Medical Center Amsterdam
RP Bergen, AAB (通讯作者)，Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM a.bergen@nin.knaw.nl
RI Bergen, Arthur/J-3637-2013; Klaver, Caroline C.W./A-2013-2016; Fritsche,
   Lars G/AAF-9387-2019; Dean, Michael/R-7501-2019; Dean, Michael
   C/G-8172-2012; Allikmets, Rando/ABD-4533-2021
OI Fritsche, Lars G/0000-0002-2110-1690; Dean, Michael
   C/0000-0003-2234-0631; Van Duijn, Cornelia/0000-0002-2374-9204; Bergen,
   Arthur/0000-0002-6333-9576; Tanck, Michael/0000-0001-9828-4459; Weber,
   Bernhard H.F./0000-0002-8808-7723; Baas, Dominique
   C./0000-0003-0989-9828; Klaver, Caroline/0000-0002-2355-5258
FU Merck Sharpe and Dohme; Algemene Nederlandse Vereniging ter Voorkoming
   van Blindheid; Netherlands Macula Fund; LSBS; Netherlands Organization
   for Scientific Research (NWO) Investments [175.010.2005.011,
   911-03-012]; Research Institute for Diseases in the Elderly [014-93-015,
   RIDE2]; Netherlands Genomics Initiative (NGI)/NWO [050-060-810]; EMC and
   Erasmus University, Netherlands Organization for Health Research and
   Development (ZonMw); Ministries of Education, Culture and Science, and
   Health, Welfare and Sports; European Commission; Municipality of
   Rotterdam; National Cancer Institute, National Institutes of Health;
   National Eye Institute [EY13435, EY017404]; Macula Vision Research
   Foundation; Kaplen Foundation; Wigdeon Point Charitable Foundations;
   Research to Prevent Blindness; Department of Ophthalmology & Visual
   Sciences, University of Utah [NIHR24]; Research to Prevent Blindness,
   Inc. Baltimore, MD, USA; NATIONAL CANCER INSTITUTE [ZIABC011301] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY014800, R01EY013435,
   R24EY017404] Funding Source: NIH RePORTER
FX This study was in part financed by an unrestricted research grant from
   Merck Sharpe and Dohme and by the Algemene Nederlandse Vereniging ter
   Voorkoming van Blindheid, The Netherlands Macula Fund and LSBS (all to
   A.A.B). GWAS genotype data for the Rotterdam Study is supported by the
   Netherlands Organization for Scientific Research (NWO) Investments (nr.
   175.010.2005.011, 911-03-012). This study is funded by the Research
   Institute for Diseases in the Elderly (014-93-015; RIDE2), the
   Netherlands Genomics Initiative (NGI)/NWO project nr. 050-060-810, the
   EMC and Erasmus University, Netherlands Organization for Health Research
   and Development (ZonMw), the Ministries of Education, Culture and
   Science, and Health, Welfare and Sports, the European Commission, and
   the Municipality of Rotterdam. The Franconian AMD study would like to
   thank Claudia N. Keilhauer (Department of Ophthalmology, University of
   Wurzburg, Germany) for recruiting individuals with AMD and the control
   subjects. Kerstin Meier (Institute of Human Genetics, University of
   Regensburg, Germany) for technical assistance. AREDS was supported (in
   part) by the Intramural Research Program of the National Cancer
   Institute, National Institutes of Health. The Columbia University study
   is supported in part by the grants from the National Eye Institute
   EY13435 and EY017404; the Macula Vision Research Foundation; Kaplen
   Foundation; Wigdeon Point Charitable Foundations and an unrestricted
   grant from Research to Prevent Blindness. G.S.H is supported by an
   unrestricted NIHR24 grant to the Department of Ophthalmology & Visual
   Sciences, University of Utah and a Senior Scientist Award (GSH) from
   Research to Prevent Blindness, Inc. Baltimore, MD, USA. The University
   of Iowa would like to thank Chris Pappas for technical assistance.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Attia J, 2009, JAMA-J AM MED ASSOC, V301, P191, DOI 10.1001/jama.2008.946
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Booij JC, BMC GENOMICS UNPUB
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Diehn JJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r74
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fernandes R, 2011, AM J PHYSIOL-CELL PH, V300, pC927, DOI 10.1152/ajpcell.00140.2010
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grzeszczak W, 2001, KIDNEY INT, V59, P631, DOI 10.1046/j.1523-1755.2001.059002631.x
   Gutierrez C, 1998, DIABETES RES CLIN PR, V41, P113, DOI 10.1016/S0168-8227(98)00050-3
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Hodgkinson AD, 2005, J DIABETES COMPLICAT, V19, P65, DOI 10.1016/j.jdiacomp.2004.07.002
   Hodgkinson AD, 2001, KIDNEY INT, V59, P985, DOI 10.1046/j.1523-1755.2001.00581.x
   Hofman A, 2011, EUR J EPIDEMIOL, V26, P657, DOI 10.1007/s10654-011-9610-5
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Janigro D, 1999, EPILEPSY RES, V37, P223, DOI 10.1016/S0920-1211(99)00074-1
   KALARIA RN, 1989, J NEUROCHEM, V53, P1083, DOI 10.1111/j.1471-4159.1989.tb07399.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   KUMAGAI AK, 1994, INVEST OPHTH VIS SCI, V35, P2887
   Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133
   Liu ZH, 1999, KIDNEY INT, V55, P1843, DOI 10.1046/j.1523-1755.1999.00449.x
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Makni K, 2008, ANN HUM BIOL, V35, P490, DOI 10.1080/03014460802247142
   MANTYCH GJ, 1993, ENDOCRINOLOGY, V133, P600, DOI 10.1210/en.133.2.600
   MICELI MV, 1990, INVEST OPHTH VIS SCI, V31, P277
   Miller MB, 2008, ADV GENET, V60, P141, DOI 10.1016/S0065-2660(07)00406-3
   Ng DPK, 2002, DIABETES, V51, P2264, DOI 10.2337/diabetes.51.7.2264
   Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje
   Obrosova IG, 2006, DIABETOLOGIA, V49, P2525, DOI 10.1007/s00125-006-0356-7
   Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631
   Page T, 2005, CANCER GENET CYTOGEN, V163, P151, DOI 10.1016/j.cancergencyto.2005.07.004
   Pontiroli AE, 1996, ACTA DIABETOL, V33, P193
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roy MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P605, DOI 10.1001/archophthalmol.2009.48
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takagi H, 1998, DIABETES, V47, P1480, DOI 10.2337/diabetes.47.9.1480
   TAO T, 1995, DIABETOLOGIA, V38, P942, DOI 10.1007/BF00400583
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zintzaras E, 2005, J HUM GENET, V50, P84, DOI 10.1007/s10038-004-0224-6
NR 63
TC 5
Z9 5
U1 0
U2 8
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 17
PY 2012
VL 18
IS 72
BP 657
EP 674
PG 18
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 947JC
UT WOS:000304425300001
PM 22509097
DA 2022-11-30
ER

PT J
AU Mastropasqua, L
   Toto, L
   Borrelli, E
   Carpineto, P
   Di Antonio, L
   Mastropasqua, R
AF Mastropasqua, Leonardo
   Toto, Lisa
   Borrelli, Enrico
   Carpineto, Paolo
   Di Antonio, Luca
   Mastropasqua, Rodolfo
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY ASSESSMENT OF VASCULAR EFFECTS
   OCCURRING AFTER AFLIBERCEPT INTRAVITREAL INJECTIONS IN TREATMENT-NAIVE
   PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; wet AMD; aflibercept; intravitreal injection; optical coherence
   tomography angiography; OCTA; flow density; superficial plexus
ID ENDOTHELIAL GROWTH-FACTOR; FIBER LAYER THICKNESS; SOURCE OCT
   ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; ULTRASOUND ASSESSMENT;
   RANIBIZUMAB; BEVACIZUMAB; THERAPY; EYES; EFFICACY
AB Purpose: To investigate vessel changes occurring after aflibercept injections in treatment-naive exudative age-related macular degeneration patients.
   Methods: Fifteen eyes of 15 patients affected by wet age-related macular degeneration were enrolled in the study. All the patients had a diagnosis of Type 1 choroidal neovascularization and were treated with 3 monthly aflibercept intravitreal injections (IVI). Subjects were evaluated by means of optical coherence tomography angiography at baseline, the day after the first injection and one month after both the first and the second IVI. At last, all the patients were followed up to 2 months after the third IVI.
   Results: Foveal superficial vascular plexus flow density was 29.01% (21.13-37.32%) at baseline and was significantly reduced as soon as 1 month after the first IVI (median: 20.78%; interquartile range: 14.75-23.13%; P = 0.017). Parafoveal superficial vascular plexus flow density was 47.09% (44.91-51.72%) at baseline and significantly decreased as soon as 1 month after the second IVI (median: 44.40%; interquartile range: 41.59-49.29%; P = 0.034). Choroidal neovascularization lesion area remained stable throughout the follow-up. Nevertheless, interestingly, choroidal neovascularization flow area was significantly reduced as soon as the next day the first IVI (median: 0.37 mm(2) and interquartile range: 0.27-0.72 mm(2) at baseline; median: 0.30 mm(2) and interquartile range: 0.24-0.64 mm(2) at 1 day after the first IVI; P = 0.047).
   Conclusion: Intravitreal aflibercept injections are associated with a significant change in native retinal and choroidal vasculature. Moreover, the treatment did not cause a reduction in lesion area, but rather reduced the flow in the choroidal neovascularization.
C1 [Mastropasqua, Leonardo; Toto, Lisa; Borrelli, Enrico; Carpineto, Paolo; Di Antonio, Luca] Univ G dAnnunzio, Ophthalmol Clin, Dept Med & Sci Ageing, I-66100 Chieti, Italy.
   [Mastropasqua, Rodolfo] Univ Verona, Dept Neurol Neuropsychol Morphol & Movement Sci, Ophthalmol Unit, Verona, Italy.
C3 G d'Annunzio University of Chieti-Pescara; University of Verona
RP Toto, L (通讯作者)，Univ G dAnnunzio, Ophthalmol Clin, Dept Med & Sci Ageing, I-66100 Chieti, Italy.
EM l.toto@unich.it
RI Borrelli, Enrico/AAR-3693-2020; Mastropasqua, Rodolfo/AAC-6453-2022;
   Toto, Lisa/K-3473-2018; Carpineto, Paolo/AAN-9688-2020
OI Borrelli, Enrico/0000-0003-2815-5031; Toto, Lisa/0000-0001-5311-5184; 
CR [Anonymous], EYL
   Bambo MP, 2015, ACTA OPHTHALMOL, V93, pE507, DOI 10.1111/aos.12635
   Bonnin P, 2014, ACTA OPHTHALMOL, V92, pE382, DOI 10.1111/aos.12356
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Brar VS, 2010, MOL VIS, V16, P1848
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lumbroso B, 2015, CLIN GUIDE ANGIO OCT
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Sehi M, 2009, AM J OPHTHALMOL, V148, P597, DOI 10.1016/j.ajo.2009.05.030
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Wei E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081343
   Yu JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085718
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
NR 40
TC 28
Z9 31
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2017
VL 37
IS 2
BP 247
EP 256
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK1FO
UT WOS:000393671400013
PM 27628926
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Yanagi, Y
   Mohla, A
   Lee, SY
   Mathur, R
   Chan, CM
   Yeo, I
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Yanagi, Yasuo
   Mohla, Aditi
   Lee, Shu Yen
   Mathur, Ranjana
   Chan, Choi Mun
   Yeo, Ian
   Wong, Tien Yin
TI CHARACTERIZATION AND DIFFERENTIATION OF POLYPOIDAL CHOROIDAL
   VASCULOPATHY USING SWEPT SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE diagnosis; optical coherence tomography angiography; polypoidal
   choroidal vasculopathy; recurrence; treatment response
ID MACULAR DEGENERATION; SPECTRAL-DOMAIN; QUANTITATIVE-ANALYSIS;
   NEOVASCULARIZATION; RANIBIZUMAB; PREVALENCE; THERAPY; DISEASE; OCT
AB Purpose: To determine the correlation and agreement between swept-source optical coherence tomography angiography (SS-OCT-A) with fluorescein angiography (FA), indocyanine green angiography (ICGA) and spectral domain OCT (SD-OCT) in characterizing polypoidal choroidal vasculopathy (PCV) and in differentiating eyes with typical age-related macular degeneration (t-AMD).
   Methods: This study included 32 and 54 eyes with t-AMD and PCV, respectively, who underwent SS-OCT-A, SD-OCT, fluorescein angiography, and indocyanine green angiography. The images from these four techniques were compared.
   Results: On SS-OCT-A, flow signals with vascular network configuration were detected in 81.2% and 77.8% of eyes with t-AMD and PCV, respectively. 40.4% of polyps were detected as flow signals with polypoidal configuration. Compared with indocyanine green angiography, SS-OCT-A had sensitivity and specificity of 83.0% and 57.1%, respectively, for vascular network, and 40.5% and 66.7% for polyps. Longitudinal changes were in agreement between SS-OCT-A and SD-OCT in 90% of eyes. 88.2% of eyes with dry retina on SD-OCT had persistent vascular net on SS-OCT-A. In two cases with reactivation of PCV, SS-OCT-A was more sensitive at detecting recurrence than SD-OCT.
   Conclusion: Swept-source optical coherence tomography angiography is effective at detecting vascular network that correlate to conventional angiography in eyes with t-AMD and PCV. Swept-source optical coherence tomography angiography is inferior to indocyanine green angiography in detecting polyps and cannot replace indocyanine green angiography for differentiating PCV from t-AMD; however, SS-OCT-A may be more sensitive than SD-OCT in detecting early recurrence.
C1 [Cheung, Chui Ming Gemmy; Yanagi, Yasuo; Mohla, Aditi; Lee, Shu Yen; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian; Wong, Tien Yin] Singapore Natl Eye Ctr, Med Retina Serv, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Yanagi, Yasuo; Lee, Shu Yen; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian; Wong, Tien Yin] Singapore Eye Res Inst, Med Retina Serv, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Yanagi, Yasuo/AAF-2670-2020; Yanagi,
   Yasuo/AAA-5441-2022
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Yanagi, Yasuo/0000-0002-0362-7285
FU National Medical Research Council [NMRC/NIG/1003/2009]; BMRC Grant
   [10/1/35/19/671]
FX Supported by National Medical Research Council grant NMRC/NIG/1003/2009
   and BMRC Grant No. 10/1/35/19/671.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Chen FK, 2016, CLIN EXP OPHTHALMOL, V44, P388, DOI 10.1111/ceo.12683
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ng WY, 2014, OPTOMETRY VISION SCI, V91, P872, DOI 10.1097/OPX.0000000000000283
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Saxena S, 2014, CLIN OPHTHALMOL, V8, P2507, DOI 10.2147/OPTH.S72132
   Sayanagi K, 2014, GRAEF ARCH CLIN EXP, V252, P3, DOI 10.1007/s00417-013-2474-5
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Srour M, 2016, BR J OPHTHALMOL
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 25
TC 34
Z9 36
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2017
VL 37
IS 8
BP 1464
EP 1474
DI 10.1097/IAE.0000000000001391
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FB4JU
UT WOS:000406108700006
PM 27828911
DA 2022-11-30
ER

PT J
AU Utheim, OA
   Ritland, JS
   Utheim, TP
   Espeseth, T
   Lydersen, S
   Rootwelt, H
   Semb, SO
   Elsas, T
AF Utheim, Oygunn A.
   Ritland, Jon Stale
   Utheim, Tor P.
   Espeseth, Thomas
   Lydersen, Stian
   Rootwelt, Helge
   Semb, Svein Ove
   Elsas, Tor
TI Apolipoprotein E genotype and risk for development of cataract and
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; Alzheimer's disease; APOE; cataract;
   genotype; OCT
ID ALZHEIMERS-DISEASE; GENE; EXPRESSION
AB Purpose: To study whether apolipoprotein E (APOE) genotypes are associated with risk for developing cataract and age-related macular degeneration (AMD).
   Methods: A sample of 88 healthy adults (50-75 years) genotyped for polymorphisms of APOE underwent an eye examination which included visual acuity (VA) testing, slit-lamp cataract evaluation, optical coherence tomography (OCT) and fundus photography, the last of which was analysed and graded for macular pathology at the Reading Centre, Moorfields Eye Hospital, London. Two-by-two cross tables were analysed using the Fisher-Boschloo unconditional full multinomial test. Two-sample t-tests were used for comparing means of scale variables.
   Results: Thirty-two participants were diagnosed with cataract or had undergone cataract surgery in one or both eyes, and 56 participants demonstrated no signs of cataract. We found that APOE4 carriers were less likely to have cataract than non-APOE4 carriers (p = 0.039). No correlation between APOE genotypes and morphologic changes in the macular region was revealed. However, APOE3 carriers disclosed significantly higher average macular thickness in both eyes than non-APOE3 carriers (p = 0.012), and APOE3 carriers also had significantly better VA than non-APOE3 carriers (p = 0.041).
   Conclusions: We found no association between AMD and APOE polymorphism in a population of 96 individuals aged 50-75 years. A weak negative association between APOE4 and cataract was uncovered in the same population. Apolipoprotein E3 may be a protective factor against the loss of nerve fibres in the macular region.
C1 [Utheim, Oygunn A.; Utheim, Tor P.; Semb, Svein Ove] Ullevaal Univ Hosp, Eye Dept, N-0407 Oslo, Norway.
   [Ritland, Jon Stale] Alesund Hosp, Eye Dept, Alesund, Norway.
   [Espeseth, Thomas] Univ Oslo, Dept Psychol, Oslo, Norway.
   [Lydersen, Stian] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, Unit Appl Clin Res, N-7034 Trondheim, Norway.
   [Rootwelt, Helge] Univ Oslo, Rikshosp, Radiumhosp Med Ctr, Dept Med Biochem, N-0027 Oslo, Norway.
   [Elsas, Tor] Norwegian Univ Sci & Technol, Eye Dept, N-7034 Trondheim, Norway.
C3 University of Oslo; University of Oslo; Norwegian University of Science
   & Technology (NTNU); University of Oslo; National Hospital Norway;
   Norwegian University of Science & Technology (NTNU)
RP Utheim, OA (通讯作者)，Ullevaal Univ Hosp, Eye Dept, N-0407 Oslo, Norway.
EM utyg@uus.no
CR Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BENJAMIN R, 1994, LANCET, V343, P1565, DOI 10.1016/S0140-6736(94)92961-0
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Frederikse PH, 1998, CURR EYE RES, V17, P947, DOI 10.1076/ceyr.17.9.947.5135
   Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Mehrotra DV, 2003, BIOMETRICS, V59, P441, DOI 10.1111/1541-0420.00051
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Zetterberg M, 2004, BRIT J OPHTHALMOL, V88, P716, DOI 10.1136/bjo.2003.032698
NR 11
TC 17
Z9 17
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2008
VL 86
IS 4
BP 401
EP 403
DI 10.1111/j.1600-0420.2007.01070.x
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 309YT
UT WOS:000256496800009
PM 18498549
DA 2022-11-30
ER

PT J
AU Nakata, I
   Yamashiro, K
   Kawaguchi, T
   Gotoh, N
   Nakanishi, H
   Akagi-Kurashige, Y
   Miyake, M
   Tsujikawa, A
   Oishi, A
   Saito, M
   Iida, T
   Yamada, R
   Matsuda, F
   Yoshimura, N
AF Nakata, Isao
   Yamashiro, Kenji
   Kawaguchi, Takahisa
   Gotoh, Norimoto
   Nakanishi, Hideo
   Akagi-Kurashige, Yumiko
   Miyake, Masahiro
   Tsujikawa, Akitaka
   Oishi, Akio
   Saito, Masaaki
   Iida, Tomohiro
   Yamada, Ryo
   Matsuda, Fumihiko
   Yoshimura, Nagahisa
CA Nagahama Study Grp
TI Association Between the Cholesteryl Ester Transfer Protein Gene and
   Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE PCV; lipid; CETP; case-control study
ID COMPLEMENT FACTOR-H; DENSITY-LIPOPROTEIN-CHOLESTEROL; GENOME-WIDE
   ASSOCIATION; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   CARDIOVASCULAR-DISEASE; JAPANESE POPULATION; CLINICAL CHARACTERISTICS;
   PHOTODYNAMIC THERAPY; RISK-FACTORS
AB PURPOSE. To determine whether genetic variants in the lipid-associated genes are related to the risk of developing polypoidal choroidal vasculopathy (PCV) in a Japanese population.
   METHODS. Five hundred eighty-one patients with PCV and 793 controls were enrolled in the study. Association analysis of allele and genotype frequencies was performed for the following single-nucleotide polymorphisms (SNPs) that are associated with high-density lipoprotein cholesterol levels in blood: rs493258 at the hepatic lipase gene (LIPC), rs3764261 at the cholesteryl ester transfer protein gene (CETP), and rs12678919 at the lipoprotein lipase gene (LPL). A further model adjusting for age-related maculopathy susceptibility 2 (ARMS2) A69S, complement factor H (CFH) I62V, age, sex, and smoking status was used to confirm the independent association of these SNPs with other covariates.
   RESULTS. CETP rs3764261 was significantly associated with the development of PCV; the frequency of the minor allele A was higher in the PCV cases (24.0%) than in the control subjects (18.5%) (P = 0.0025; odds ratio [OR], 1.41; 95% confidence interval, 1.13-1.75). Furthermore, we found an independent association of CETP variants with age, sex, smoking status, and genetic background of ARMS2 A69S, CFH I62V, LIPC rs493258, and LPL rs12678919 (P 0.0013; OR, 1.50). LIPC rs493258 and LPL rs12678919 did not show significant associations with the development of PCV (P > 0.05).
   CONCLUSION. CETP variants are associated a risk of developing PCV among the Japanese population.
C1 [Nakata, Isao; Yamashiro, Kenji; Gotoh, Norimoto; Nakanishi, Hideo; Akagi-Kurashige, Yumiko; Miyake, Masahiro; Tsujikawa, Akitaka; Oishi, Akio; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto 6068507, Japan.
   [Nakata, Isao; Kawaguchi, Takahisa; Gotoh, Norimoto; Nakanishi, Hideo; Akagi-Kurashige, Yumiko; Miyake, Masahiro; Yamada, Ryo; Matsuda, Fumihiko] Kyoto Univ, Ctr Genom Med, Inst Natl Sante & Rech Med Unit 852, Grad Sch Med, Kyoto 6068507, Japan.
   [Saito, Masaaki] Fukushima Med Univ, Dept Ophthalmol, Sch Med, Fukushima, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
C3 Kyoto University; Kyoto University; Fukushima Medical University; Tokyo
   Women's Medical University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019; KOSUGI, Shinji/GYR-2946-2022; Oishi,
   Akio/AAE-9996-2020
OI Miyake, Masahiro/0000-0001-7410-3764; Oishi, Akio/0000-0002-0977-9458;
   Yamashiro, Kenji/0000-0001-9354-8558; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamada, Ryo/0000-0002-1587-630X
FU Ministry of Education, Culture, Sports, Science, and Technology of
   Japan; Japan Society for the Promotion of Science [19390442, 22791706,
   22791653]; Japanese National Society for the Prevention of Blindness;
   Takeda Science Foundation
FX Supported by grants-in-aid from the following organizations: the
   Ministry of Education, Culture, Sports, Science, and Technology of Japan
   (2006-2012); Grants 19390442, 22791706, and 22791653 from the Japan
   Society for the Promotion of Science; the Japanese National Society for
   the Prevention of Blindness; and Takeda Science Foundation (2008-2012).
CR CHAJEK T, 1978, P NATL ACAD SCI USA, V75, P3445, DOI 10.1073/pnas.75.7.3445
   Chasman DI, 2008, CIRC-CARDIOVASC GENE, V1, P21, DOI 10.1161/CIRCGENETICS.108.773168
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   GLOMSET JA, 1968, J LIPID RES, V9, P155
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Hiura Y, 2009, CIRC J, V73, P1119, DOI 10.1253/circj.CJ-08-1101
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kooner JS, 2008, NAT GENET, V40, P149, DOI 10.1038/ng.2007.61
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sarzynski MA, 2011, J CLIN ENDOCR METAB, V96, pE953, DOI 10.1210/jc.2010-2227
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   SWENSON TL, 1988, J BIOL CHEM, V263, P5150
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Wallace C, 2008, AM J HUM GENET, V82, P139, DOI 10.1016/j.ajhg.2007.11.001
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshimura K, 2012, NEUROUROL URODYNAM, V31, P1266, DOI 10.1002/nau.22250
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   ZILVERSMIT DB, 1975, BIOCHIM BIOPHYS ACTA, V409, P393, DOI 10.1016/0005-2760(75)90036-3
NR 49
TC 20
Z9 23
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2013
VL 54
IS 9
BP 6068
EP 6073
DI 10.1167/iovs.13-11605
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 228EV
UT WOS:000325169500019
PM 23950155
DA 2022-11-30
ER

PT J
AU Gocuk, SA
   McKendrick, AM
   Downie, LE
AF Gocuk, Sena A.
   McKendrick, Allison M.
   Downie, Laura E.
TI Point-of-care tools to support optometric care provision to people with
   age-related macular degeneration: A randomised, placebo-controlled trial
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; clinical audit; clinical tool;
   optometry
ID CLINICAL DECISION-SUPPORT; ATTENTION CONTROL; PACK-YEARS; RISK;
   ATTITUDES; SMOKING; QUALITY; INTERVENTION; PERSPECTIVES; ADHERENCE
AB Purpose Age-related macular degeneration (AMD) is a leading cause of vision impairment. This randomised placebo-controlled trial investigated whether point-of-care tools can improve optometrists' AMD knowledge and/or care provision. Methods Australian optometrists (n = 31) completed a demographics survey and theoretical AMD case study multiple-choice questions (MCQs) to assess their confidence in AMD care provision and AMD knowledge. Participants were then randomly assigned to one of three point-of-care tools (online 'Classification of Age-related macular degeneration and Risk Assessment Tool' (CARAT), paper CARAT, or 'placebo') to use when providing care to their subsequent 5-10 AMD patients. Participants self-audited the compliance of their AMD care to best practice for these patients, and a similar number of consecutive patients seen prior to enrolment. Post-intervention, participants retook the AMD knowledge MCQs and confidence survey. Results A total of 29 participants completed the study. At the study endpoint, clinical confidence relative to baseline improved with the paper CARAT, relative to placebo, for knowledge of AMD risk factors, asking patients about these factors and referring for medical retinal sub-specialist care. There were no between-group differences for the change in AMD knowledge scores. Considering record documentation for patients with any AMD severity, there were no significant between-group differences for documenting patient risk factors, AMD severity, clinical examination techniques or management. In a sub-analysis, the change from baseline in compliance for documenting discussions about patient smoking behaviours for early AMD patients was higher with use of the online CARAT relative to placebo (p = 0.04). For patients with intermediate AMD, the change from baseline in documenting the risk of progression to late AMD was greater among practitioners who used the paper CARAT, relative to placebo (p = 0.04). Conclusions This study demonstrates that point-of-care clinical tools can improve practitioner confidence and aspects of the documentation of AMD clinical care by optometrists as assessed by self-audit.
C1 [Gocuk, Sena A.; McKendrick, Allison M.; Downie, Laura E.] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic, Australia.
C3 University of Melbourne
RP Downie, LE (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic, Australia.
EM ldownie@unimelb.edu.au
OI Downie, Laura/0000-0002-1596-2259; McKendrick,
   Allison/0000-0003-1972-1222; Gocuk, Sena/0000-0002-0618-343X
FU 2015 Macular Disease Foundation Australia Blackmores research grant;
   NHMRC Translating Research Into Practice (TRIP) Fellowship [APP1091833]
FX This project was partially funded by a 2015 Macular Disease Foundation
   Australia Blackmores research grant (Principal Investigator: Downie),
   and a NHMRC Translating Research Into Practice (TRIP) Fellowship
   (APP1091833 Downie).
CR Aycock DM, 2018, RES NURS HEALTH, V41, P320, DOI 10.1002/nur.21870
   Aycock DM, 2017, RES NURS HEALTH, V40, P153, DOI 10.1002/nur.21776
   Bonner C, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-019-0927-x
   Bright TJ, 2012, ANN INTERN MED, V157, P29, DOI 10.7326/0003-4819-157-1-201207030-00450
   Campbell JM, 2015, WORLDV EVID-BASED NU, V12, P313, DOI 10.1111/wvn.12114
   Dawes Martin, 2005, BMC Med Educ, V5, P1
   DICKSON WJ, 1966, COUNSELING ORG SEQUE
   Douthit BJ, 2020, J PERS MED, V10, DOI 10.3390/jpm10040142
   Downie LE, 2017, OPHTHAL PHYSL OPT, V37, P202, DOI 10.1111/opo.12353
   Downie LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124533
   Efron N, 1998, OPHTHAL PHYSL OPT, V18, P182, DOI 10.1016/S0275-5408(97)00066-5
   Farquhar CM, 2002, MED J AUSTRALIA, V177, P502, DOI 10.5694/j.1326-5377.2002.tb04920.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frijling BD, 2003, QUAL SAF HEALTH CARE, V12, P181, DOI 10.1136/qhc.12.3.181
   Frijling BD, 2002, DIABETIC MED, V19, P836, DOI 10.1046/j.1464-5491.2002.00810.x
   Gocuk SA, 2021, OPHTHAL PHYSL OPT, V41, P53, DOI 10.1111/opo.12754
   Goo SJ, 2020, PAIN MED, V21, P794, DOI 10.1093/pm/pnz081
   Granger BB, 2015, AM HEART J, V169, P539, DOI 10.1016/j.ahj.2015.01.006
   Hart KM, 2020, CLIN EXP OPTOM, V103, P254, DOI 10.1111/cxo.12964
   Henshall C, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1406-z
   Hrobjartsson A, 2004, J INTERN MED, V256, P91, DOI 10.1111/j.1365-2796.2004.01355.x
   Hudson P, 2016, PALLIAT SUPPORT CARE, V14, P161, DOI 10.1017/S1478951515000565
   Kang E, 2020, J PAIN SYMPTOM MANAG, V59, P1239, DOI 10.1016/j.jpainsymman.2019.12.353
   Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   LaFave SE, 2019, RES NURS HEALTH, V42, P476, DOI 10.1002/nur.21992
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   McCambridge J, 2014, J CLIN EPIDEMIOL, V67, P267, DOI 10.1016/j.jclinepi.2013.08.015
   Mertz E, 2017, J EVID-BASED DENT PR, V17, P1, DOI 10.1016/j.jebdp.2016.10.001
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Mitchell P., 2008, GUIDELINES MANAGEMEN
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Murphy Elizabeth V., 2014, Yale Journal of Biology and Medicine, V87, P187
   National Health and Medical Research Council, 2010, NHMRC GUID SCREEN PR
   National Health Medical Research Council, 2009, NHMRC ADD LEV EV GRA
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   O'Connor PM, 2012, MED J AUSTRALIA, V196, P646, DOI 10.5694/mja11.10856
   Optometry Australia, 2016, CLIN PRACT GUID DIAG
   Optometry Australia, 2018, EX MAN PAT DIAB
   Optometry Australia, 2018, CLIN PRACT GUID DIAG
   Palmer R, 2020, HEALTH TECHNOL ASSES, V24, P1, DOI 10.3310/hta24190
   Quit Victoria, 2020, TRAIN RES EYE HLTH P
   Royal Australian and New Zealand College of Ophthalmologists, 2018, RANZCO REF PATHW AMD
   Ryan MA, 2017, OTOLARYNG HEAD NECK, V157, P548, DOI 10.1177/0194599817718822
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   Schnipper JL, 2008, J AM MED INFORM ASSN, V15, P513, DOI 10.1197/jamia.M2501
   Sequist TD, 2005, J AM MED INFORM ASSN, V12, P431, DOI 10.1197/jamia.M1788
   Sequist TD, 2009, ARCH INTERN MED, V169, P364, DOI 10.1001/archinternmed.2008.564
   Shah R, 2009, OPHTHAL PHYSL OPT, V29, P383, DOI 10.1111/j.1475-1313.2009.00656.x
   Srinivasan S, 2017, CUTAN OCUL TOXICOL, V36, P253, DOI 10.1080/15569527.2016.1265548
   Sutton RT, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0221-y
   Ten Teije A., 2008, COMPUTER BASED MED G
   Thompson B Taylor, 2007, Proc Am Thorac Soc, V4, P577, DOI 10.1513/pats.200706-072JK
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wilson BJ, 2006, FAM PRACT, V23, P537, DOI 10.1093/fampra/cml026
NR 57
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JUL
PY 2022
VL 42
IS 4
BP 814
EP 827
DI 10.1111/opo.12970
EA MAR 2022
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1V5WQ
UT WOS:000768307600001
PM 35285531
OA Green Published
DA 2022-11-30
ER

PT J
AU Samkoe, KS
   Cramb, DT
AF Samkoe, KS
   Cramb, DT
TI Application of an ex ovo chicken chorioallantoic membrane model for
   two-photon excitation photodynamic therapy of age-related macular
   degeneration
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE chorioallantoic membrane; photodynamic therapy; two-photon excitation;
   age-related macular degeneration
ID CHORIO-ALLANTOIC MEMBRANE; SHELL-LESS CULTURE; TRANSPORT FUNCTIONS;
   CALCIUM-TRANSPORT; EMBRYO; ANGIOGENESIS; GROWTH; CAM; PHOTOSENSITIZERS;
   QUANTITATION
AB Two-photon excitation photodynamic therapy (TPE-PDT) is being investigated as a clinical treatment for age-related macular degeneration (AMD). TPE-PDT has the potential to provide a more specific and therefore advantageous therapy regime than traditional one-photon excitation PDT. The highly vascularized 8 to 9-day-old chicken chorioallantoic membrane (CAM) is used to model the rapid growth of blood vessels in the wet form of AMD. Using an ex ovo model system for the CAM, ablation studies were successful in mimicking the leaky vessels found in AMD. In addition, the distribution and localization of liposomal Verteporfin were investigated in order to characterize the photosensitizing drug in vivo. Localization of the photosensitizer appears to be greatest on the upper vessel wall, which indicates a potentially strong treatment locale for TPE-PDT. (C) 2003 Society of Photo-optical Instrumentation Engineers.
C1 Univ Calgary, Dept Chem, Calgary, AB T2N 1N4, Canada.
C3 University of Calgary
RP Samkoe, KS (通讯作者)，Univ Calgary, Dept Chem, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.
CR AKINS RE, 1993, J CELL SCI, V105, P381
   Bhawalkar J D, 1997, J Clin Laser Med Surg, V15, P201
   Campochiaro P A, 1999, Mol Vis, V5, P34
   DUNN BE, 1979, DEV BIOL, V71, P216, DOI 10.1016/0012-1606(79)90165-9
   DUNN BE, 1974, POULTRY SCI, V53, P409, DOI 10.3382/ps.0530409
   DUNN BE, 1976, POULTRY SCI, V55, P1067, DOI 10.3382/ps.0551067
   Fisher WG, 1997, PHOTOCHEM PHOTOBIOL, V66, P141, DOI 10.1111/j.1751-1097.1997.tb08636.x
   Frederiksen PK, 2001, J AM CHEM SOC, V123, P1215, DOI 10.1021/ja003468a
   GOTTFRIED V, 1995, J PHOTOCH PHOTOBIO B, V30, P115, DOI 10.1016/1011-1344(95)07180-A
   Goyan R, 2001, J PHYS CHEM B, V105, P2322, DOI 10.1021/jp0026235
   GOYAN R, 2002, THESIS U CALGARY
   Goyan RL, 2000, PHOTOCHEM PHOTOBIOL, V72, P821, DOI 10.1562/0031-8655(2000)072<0821:NITPEO>2.0.CO;2
   Hammer-Wilson MJ, 1999, J PHOTOCH PHOTOBIO B, V53, P44, DOI 10.1016/S1011-1344(99)00124-4
   Hornung R, 1999, J PHOTOCH PHOTOBIO B, V49, P41, DOI 10.1016/S1011-1344(99)00014-7
   Kirchner LM, 1996, MICROVASC RES, V51, P2, DOI 10.1006/mvre.1996.0002
   Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38
   Leonenko ZV, 2000, BBA-BIOMEMBRANES, V1509, P131, DOI 10.1016/S0005-2736(00)00288-1
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Lusimbo WS, 2000, ANAT REC, V259, P25, DOI 10.1002/(SICI)1097-0185(20000501)259:1<25::AID-AR3>3.0.CO;2-Y
   NARBAITZ R, 1977, J ANAT, V124, P347
   NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003
   Ossewaarde-Van Norel J, 2002, J BIOMED OPT, V7, P190, DOI 10.1117/1.1462034
   Ribatti D, 2001, ANAT RECORD, V264, P317, DOI 10.1002/ar.10021
   SANDAU K, 1994, J MICROSC-OXFORD, V175, P205, DOI 10.1111/j.1365-2818.1994.tb03486.x
   Schlatter P, 1997, MICROVASC RES, V54, P65, DOI 10.1006/mvre.1997.2022
   STEWART ME, 1969, EXP CELL RES, V58, P93, DOI 10.1016/0014-4827(69)90119-0
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   TEREPKA AR, 1969, EXP CELL RES, V58, P107, DOI 10.1016/0014-4827(69)90120-7
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 29
TC 44
Z9 47
U1 0
U2 17
PU SPIE-INT SOCIETY OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD JUL
PY 2003
VL 8
IS 3
BP 410
EP 417
DI 10.1117/1.1577117
PG 8
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 709CD
UT WOS:000184606400012
PM 12880346
DA 2022-11-30
ER

PT J
AU Kimura, S
   Morizane, Y
   Hosokawa, M
   Shiode, Y
   Kawata, T
   Doi, S
   Matoba, R
   Hosogi, M
   Fujiwara, A
   Inoue, Y
   Shiraga, F
AF Kimura, Shuhei
   Morizane, Yuki
   Hosokawa, Mio
   Shiode, Yusuke
   Kawata, Tetsuhiro
   Doi, Shinichiro
   Matoba, Ryo
   Hosogi, Mika
   Fujiwara, Atsushi
   Inoue, Yasushi
   Shiraga, Fumio
TI Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy Treated by
   Vitrectomy and Subretinal Tissue Plasminogen Activator
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; NATURAL-HISTORY; PNEUMATIC DISPLACEMENT;
   INTRAVITREAL INJECTION; RANIBIZUMAB; BEVACIZUMAB; GAS; PHARMACOKINETICS;
   EYES
AB PURPOSE: To evaluate vitrectomy with subretinal tissue plasminogen activator (t-PA) injection, and air tamponade, followed by intravitreal anti-vascular endothelial growth factor (VEGF) therapy for submacular hemorrhage in polypoidal choroidal vasculopathy (PCV).
   DESIGN: Prospective, interventional case series.
   METHODS: SETTING: Two clinics. PATIENTS: Fifteen eyes of 15 consecutive patients (mean age 72 7 years) with submacular hemorrhage attributable to PCV. INCLUSION CRITERIA: PCV diagnosis with unorganized submacular hemorrhage greater than 500 pm thick. EXCLUSION CRITERIA: Submacular hemorrhage attributable to macular diseases (eg, high myopia, typical age-related macular degeneration, retinal angiomatous proliferation, and angioid streaks). INTERVENTION: Vitrectomy with 4000 IU t-PA injected subretinally and fluid/air exchange. Patients remained facedown for 3 days after surgery. Anti-VEGF drugs were administered as exudative changes required. MAIN OUTCOME MEASURES: Submacular hemorrhage displacement from the macula and changes in best-corrected visual acuities (BCVAs).
   RESULTS: Mean time from onset to surgery was 9.5 4.5 (range, 5-21) days. Mean follow-up period was 9.4 +/- 3.1 (range, 6-17) months. Surgery successfully displaced submacular hemorrhages from the macula in all eyes. Mean BCVA at baseline (0.98 +/- 0.44) had improved significantly both 1 month after surgery (0.41 +/- 0.25, P < .01) and at final visits (0.23 +/- 0.25, P < .001). In all eyes, exudative retinal changes relapsed after surgery but were completely resolved by anti-VEGF injections. No complications occurred in any patients.
   CONCLUSION: Treating submacular hemorrhage with vitrectomy and subretinal t-PA injection, followed by intravitreal anti-VEGF therapy, is a promising strategy for improving visual acuity in PCV patients warranting further investigation. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Kimura, Shuhei; Morizane, Yuki; Hosokawa, Mio; Shiode, Yusuke; Kawata, Tetsuhiro; Doi, Shinichiro; Matoba, Ryo; Hosogi, Mika; Fujiwara, Atsushi; Shiraga, Fumio] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, Okayama, Okayama 7008558, Japan.
   [Inoue, Yasushi] Inoue Eye Clin, Okayama, Japan.
C3 Okayama University
RP Kimura, S (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, 2-5-1 Shikata Cho Kita Ku, Okayama, Okayama 7008558, Japan.
EM shuheik@cc.okayama-u.ac.jp
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   [Anonymous], 1909, ARCH OPHTHALMOL-CHIC, V117, P1329
   Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Matsuo T, 2001, ACTA OPHTHALMOL SCAN, V79, P533, DOI 10.1034/j.1600-0420.2001.790522.x
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Spaide RF, 1994, RETINA, V15, P100
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Tsymanava A, 2012, ACTA OPHTHALMOL, V90, P633, DOI 10.1111/j.1755-3768.2011.02115.x
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 34
TC 29
Z9 31
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2015
VL 159
IS 4
BP 683
EP 689
DI 10.1016/j.ajo.2014.12.020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE4FV
UT WOS:000351787400009
PM 25555798
DA 2022-11-30
ER

PT J
AU Moss, SE
   Klein, R
   Klein, BEK
AF Moss, SE
   Klein, R
   Klein, BEK
TI Ankle-brachial index and the prevalence of age-related maculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ATHEROSCLEROSIS; ROTTERDAM
AB PURPOSE: To examine the association of ankle,brachial blood pressure index (ABI) with prevalence of age-related maculopathy (ARM).
   DESIGN: A cross-sectional cohort study.
   METHODS: ABI was measured in 2447 subjects aged 53 to 97 years. ARM was determined from 30,degree color stereoscopic fundus photographs.
   RESULTS: Low ABI (<= 0.9) was present in 5.4% of subjects. Early ARM was present in 22.1% of subjects with and 18.8% without low ABI. Late ARM was present in 5.3% of subjects with and 1.7% without low ABI. This result was not statistically significant.
   CONCLUSIONS: Low ABI does not appear to be a risk factor for ARM.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53762 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Moss, SE (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 610 N Walnut St,4th Floor WARF, Madison, WI 53762 USA.
EM moss@epi.ophth.wisc.edu
FU NEI NIH HHS [EY 06594] Funding Source: Medline
CR KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Zheng ZJ, 1997, ATHEROSCLEROSIS, V131, P115, DOI 10.1016/S0021-9150(97)06089-9
NR 5
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2005
VL 140
IS 6
BP 1159
EP 1161
DI 10.1016/j.ajo.2005.07.029
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 000QA
UT WOS:000234475900041
PM 16376678
DA 2022-11-30
ER

PT J
AU Loukovaara, S
   Auvinen, A
   Haukka, J
AF Loukovaara, Sirpa
   Auvinen, Anssi
   Haukka, Jari
TI Associations between systemic medications and development of wet
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE atorvastatin; bicalutamide; calcium channel blockers; estradiol;
   pharmacoepidemiology; real-world evidence; wet age-related macular
   degeneration
ID PROGRESSION; POPULATION; DISEASE
AB Purpose To examine whether systemic medications are associated with the subsequent development of wet age-related macular degeneration (AMD). Methods A retrospective study of 259 562 individuals based on registry data, from January 1, 2001, to December 31, 2017. End-point event was the International Classification of Diseases (ICD)-10 diagnosis for wet AMD. Association between use of systemic medication covering 85 generic drugs categorized according to Anatomical Therapeutic Chemical (ATC) codes and the incidence of wet AMD was evaluated using multivariate Poisson regression model (adjusted for age, sex, diabetes, cancer and socioeconomic group) and nested case-control design. Results The mean length of follow-up was 9.84 years. The number of cases with wet AMD was 2947 and incidence rate was 1.15 per 1000 person-years. After adjustment, we observed an increased risk for the development of wet AMD for patients exposed to amlodipine (IRR 1.33, 95% CI 1.16-1.53), or felodipine (1.24, 95% CI 1.02-1.50). Similarly, an increased risk of wet AMD was associated with the use of bicalutamide (2.14, 95% CI 1.14-4.02), estradiol (1.20, 95% CI 1.03-1.40) and atorvastatin (1.22, 95% CI 1.05-1.43). Of note, digoxin (0.72, 95% CI 0.57-0.91), and ramipril (0.80, 95% CI 0.65-0.99) users had a lower incidence of wet AMD. Conclusions Our findings suggest that the use of second-generation calcium channel blockers could be associated with an increased risk for wet AMD development. Of note, the incidence of wet AMD seemed to be lower in patients using ramipril and digoxin. More studies are needed to elucidate the associations further.
C1 [Loukovaara, Sirpa] Univ Helsinki, Unit Vitreoretinal Surg, Dept Ophthalmol, Helsinki Univ Hosp, Helsinki, Finland.
   [Loukovaara, Sirpa] Univ Helsinki, Individualized Drug Therapy Res Program, Helsinki, Finland.
   [Auvinen, Anssi] Tampere Univ, Fac Social Sci, Hlth Sci, Tampere, Finland.
   [Haukka, Jari] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
   [Haukka, Jari] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; Tampere University; University of Helsinki; Tampere
   University
RP Loukovaara, S (通讯作者)，Univ Helsinki, Unit Vitreoretinal Surg, Dept Ophthalmol, Haartmaninkatu 4 C, Helsinki 00290, Finland.; Loukovaara, S (通讯作者)，Helsinki Univ Hosp, Haartmaninkatu 4 C, Helsinki 00290, Finland.
EM sirpa.loukovaara@hus.fi
RI Haukka, Jari/G-1484-2014
OI Haukka, Jari/0000-0003-1450-6208; Auvinen, Anssi/0000-0003-1125-4818
FU University of Helsinki, Finland
FX This study was funded by University of Helsinki, Finland (JH).
CR Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   [Anonymous], NOMESCO CLASS SURG P
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cho BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102816
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Delcoigne B, 2018, INT J EPIDEMIOL, V47, P841, DOI 10.1093/ije/dyx282
   Dryja TP, 2016, JAMA OPHTHALMOL, V134, P1281, DOI 10.1001/jamaophthalmol.2016.3031
   Elliott WJ, 2011, J CLIN HYPERTENS, V13, P687, DOI 10.1111/j.1751-7176.2011.00513.x
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Evans AJ, 2018, MODERN PATHOL, V31, pS110, DOI 10.1038/modpathol.2017.158
   Fraser-Bell S, 2017, CLIN EXP OPHTHALMOL, V45, P45, DOI 10.1111/ceo.12905
   Gail MH, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031031
   Galappatthy P, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0350-z
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Gehlbach P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub4
   Gissler M., 2004, NOR EPIDEMIOL, V14, P113, DOI DOI 10.5324/NJE.V14I1.284
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1647, DOI 10.1016/j.ophtha.2019.06.023
   Khotcharrat Rossukon, 2015, Journal of the Medical Association of Thailand, V98, P790
   Kolomeyer AM, 2019, RETINA-J RET VIT DIS, V39, P918, DOI 10.1097/IAE.0000000000002059
   LANGHOLZ B, 1991, BIOMETRICS, V47, P1563, DOI 10.2307/2532407
   Lawlor DA, 2016, INT J EPIDEMIOL, V45, P1866, DOI 10.1093/ije/dyw314
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2019, MOL THER-NUCL ACIDS, V17, P113, DOI 10.1016/j.omtn.2019.05.012
   Loukovaara S, 2022, ACTA OPHTHALMOL, V100, pE609, DOI 10.1111/aos.14546
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Montero JA, 2013, RETINA-J RET VIT DIS, V33, P508, DOI 10.1097/IAE.0b013e3182695ba0
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Niskanen L, 2020, J EPIDEMIOL COMMUN H, V74, P950, DOI 10.1136/jech-2019-213602
   Ren C, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4252031
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Team RC, 2013, R LANG ENV STAT COMP
   TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Wang SV, 2021, OPHTHALMOLOGY, V128, P248, DOI 10.1016/j.ophtha.2020.08.004
   Wilkinson-Berka JL, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107766
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105
NR 42
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2022
VL 100
IS 5
BP 572
EP 582
DI 10.1111/aos.15056
EA NOV 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2R9UK
UT WOS:000718200000001
PM 34779110
DA 2022-11-30
ER

PT J
AU Mcguinness, MB
   Le, J
   Mitchell, P
   Gopinath, B
   Cerin, E
   Saksens, NTM
   Schick, T
   Hoyng, CB
   Guymer, RH
   Finger, RP
AF Mcguinness, Myra B.
   Le, Jerome
   Mitchell, Paul
   Gopinath, Bamini
   Cerin, Ester
   Saksens, Nicole T. M.
   Schick, Tina
   Hoyng, Carel B.
   Guymer, Robyn H.
   Finger, Robert P.
TI Physical Activity and Age-related Macular Degeneration: A Systematic
   Literature Review and Meta-analysis
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID BEAVER DAM EYE; 7-YEAR FOLLOW-UP; RISK-FACTORS; GRADING SYSTEM;
   PREVALENCE; ASSOCIATION; MACULOPATHY; HEALTH; COHORT; MORTALITY
AB PURPOSE: To better understand the association, in a white population, of physical activity and age-related macular degeneration (AMD)-the main cause of irreversible severe vision loss in developed countries-given the suggestion that a healthy lifestyle may assist in delaying the onset and progression of AMD.
   DESIGN: Systematic review and meta-analysis.
   METHODS: Medline, EMBASE, and Google Scholar were systematically searched for studies up to May 2015. Reference lists of published articles were hand searched and study authors were contacted to provide additional data. Those in the lowest category of activity in each study were compared with all other participants to assess the association between physical activity and both early and late AMD using random-effects meta-analysis.
   RESULTS: Nine studies (subject age range 30-97 years) were included in the meta-analysis. Physical activity was found to have a protective association with both early AMD (8 studies, n = 38 112, odds ratio (OR) 0.92, 95% confidence interval [CI] 0.86-0.98) and late AMD (7 studies, n = 28 854, OR 0.59, 95% CI 0.49-0.72).
   CONCLUSIONS: Physical activity is associated with lower odds of early and late AMD in white populations. These findings have important implications, reinforcing the public health message of staying active throughout life. However, further longitudinal studies are required to confirm and further characterize a protective effect of physical activity on the onset and/or progression of AMD. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Mcguinness, Myra B.; Le, Jerome; Guymer, Robyn H.; Finger, Robert P.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Australia.
   [Mcguinness, Myra B.; Le, Jerome; Guymer, Robyn H.; Finger, Robert P.] Univ Melbourne, Ophthalmol, Dept Surg, Melbourne, Australia.
   [Mitchell, Paul; Gopinath, Bamini] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   [Mitchell, Paul; Gopinath, Bamini] Univ Sydney, Westmead Millennium Inst, Sydney, NSW, Australia.
   [Cerin, Ester] Australian Catholic Univ, Melbourne, Vic, Australia.
   [Saksens, Nicole T. M.; Hoyng, Carel B.] Radboud Univ Nijmegen, Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Schick, Tina] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; University of Sydney;
   University of Sydney; Westmead Institute for Medical Research;
   Australian Catholic University; Radboud University Nijmegen; University
   of Cologne; University of Bonn
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM robertfinger@gmx.net
RI Cerin, Ester/Z-2011-2019; Gopinath, Bamini/K-4286-2019; Cerin,
   Ester/L-1271-2015; McGuinness, Myra/G-4900-2017; Mitchell,
   Paul/P-1498-2014
OI Cerin, Ester/0000-0002-7599-165X; Gopinath, Bamini/0000-0003-3573-359X;
   Cerin, Ester/0000-0002-7599-165X; McGuinness, Myra/0000-0002-5422-040X;
   Guymer, Robyn/0000-0002-9441-4356; Finger, Robert P/0000-0003-4253-7597
FU LLOYD AND KATHLEEN ANSELL OPHTHALMOLOGY FOUNdation (Australia);
   Mankiewicz-Zelkin Fellowship of the University of Melbourne (Australia);
   National Institutes of Health (USA) - Research to Prevent Blindness
   (USA)
FX SOME FUNDING SUPPORT WAS PROVIDED THE LLOYD AND KATHLEEN ANSELL
   OPHTHALMOLOGY FOUNdation (Australia) and the Mankiewicz-Zelkin
   Fellowship of the University of Melbourne (Australia) to R.P.F. The
   Centre for Eye Research Australia receives Operational Infrastructure
   Support from the Victorian Government (Australia). The Beaver Dam Eye
   Study is funded by the National Institutes of Health (USA) and partly by
   Research to Prevent Blindness (USA).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bauman AE, 2002, AM J PREV MED, V23, P5, DOI 10.1016/S0749-3797(02)00469-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DiPietro L, 2001, J GERONTOL A-BIOL, V56, P13, DOI 10.1093/gerona/56.suppl_2.13
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Gopinath B, 2014, INVEST OPHTH VIS SCI, V55, P7799, DOI 10.1167/iovs.14-15575
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   McGuinness MB, 2016, BRIT J OPHTHALMOL, V100, P1353, DOI 10.1136/bjophthalmol-2015-307663
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   Nigam A, 2011, LANCET, V378, P1202, DOI 10.1016/S0140-6736(11)61029-5
   PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Radak Z, 2001, EXERC IMMUNOL REV, V7, P90
   Saksens NTM, 2014, INVEST OPHTH VIS SCI, V55, P7085, DOI 10.1167/iovs.14-14659
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Wells GA., NEWCASTLE OTTAWA SCA
   Wen CP, 2011, LANCET, V378, P1244, DOI 10.1016/S0140-6736(11)60749-6
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P95, DOI 10.1167/iovs.08-1797
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 43
TC 40
Z9 41
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2017
VL 180
BP 29
EP 38
DI 10.1016/j.ajo.2017.05.016
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC6ZK
UT WOS:000406990000006
PM 28549846
DA 2022-11-30
ER

PT J
AU Cheung, N
   Shankar, A
   Klein, R
   Folsom, AR
   Couper, DJ
   Wong, TY
AF Cheung, Ning
   Shankar, Anoop
   Klein, Ronald
   Folsom, Aaron R.
   Couper, David J.
   Wong, Tien Yin
CA ARIC Study Investigators
TI Age-related macular degeneration and cancer mortality in the
   atherosclerosis risk in communities study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; CHLAMYDIA-PNEUMONIAE INFECTION; BEAVER DAM EYE;
   CHOROIDAL NEOVASCULARIZATION; VISUAL IMPAIRMENT; OXIDATIVE STRESS;
   LUNG-CANCER; DISEASE; ASSOCIATION; MACULOPATHY
AB Objective: To examine the prospective association of early age-related macular degeneration (AMD) with cancer mortality.
   Methods: A population-based cohort study of 10 029 persons aged 49 to 73 years free of cancer. The AMD signs were evaluated from retinal photographs taken in 1993 through 1995. Cancer mortality was determined from death records.
   Results: There were 464 cases of early AMD. Over 10 years, there were 234 cancer deaths (71 lung cancer deaths). After controlling for age, sex, race, field center, education, smoking status, pack-years of smoking, body mass index (calculated as weight in kilograms divided by height in meters squared), and diabetes mellitus, early AMD was associated with cancer mortality (rate ratio [RR], 1.68; 95% confidence interval [CI], 1.03-2.73). This association was overall stronger in African American individuals (RR, 3.93; 95% CI, 1.67-9.22) than white individuals (RR, 1.28; 95% CI, 0.71-2.32) and for lung cancer deaths (RR, 2.14; 95% CI, 0.97-4.72) than nonlung cancer deaths (RR, 1.50; 95% CI, 0.81-2.78). In African American individuals, early AMD was associated with a 5-fold higher risk of lung cancer deaths (RR, 5.28; 95% CI, 1.52-18.40).
   Conclusions: Middle-aged African American individuals with early AMD may be at increased risk of dying of cancer, particularly lung cancer. This association was not present in white individuals and needs confirmation in other studies.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Royal Melbourne Hosp, Victoria, BC, Canada.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Commun Occupat & Family Med, Singapore 117548, Singapore.
   Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
   Univ Minnesota, Div Epidemiol & Commun Hlth, Minneapolis, MN USA.
   Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Wisconsin System; University of Wisconsin Madison; National
   University of Singapore; National University of Singapore; Singapore
   National Eye Center; University of Minnesota System; University of
   Minnesota Twin Cities; University of North Carolina; University of North
   Carolina Chapel Hill
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Reddy, K P J/T-7936-2019; Cheung, Ning
   Danny/F-2043-2013; Arunan, Elangannan/D-4612-2009
OI Wong, Tien Yin/0000-0002-8448-1264; Arunan,
   Elangannan/0000-0001-9669-4307; Couper, David/0000-0002-4313-9235
FU NHLBI NIH HHS [N01-HC-55021, N01-HC-55016, N01-HC-55022, N01-HC-55019,
   N01-HC-55015, N01-HC-55020, N01-HC-55018] Funding Source: Medline;
   DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055015,
   N01HC055021, N01HC055016, N01HC055018, N01HC055022, N01HC055019,
   N01HC055020] Funding Source: NIH RePORTER
CR Ajona D, 2004, CANCER RES, V64, P6310, DOI 10.1158/0008-5472.CAN-03-2328
   *ARIC, 1989, AM J EPIDEMIOL, V129, P957
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Borrell LN, 2004, INT J EPIDEMIOL, V33, P398, DOI 10.1093/ije/dyh063
   Brigati C, 2002, CLIN EXP METASTAS, V19, P247, DOI 10.1023/A:1015587423262
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1
   Cheng ZZ, 2005, CLIN CHEM, V51, P856, DOI 10.1373/clinchem.2004.042192
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Figueiras A, 2001, AM J EPIDEMIOL, V154, P264, DOI 10.1093/aje/154.3.264
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hastie T., 1990, GEN ADDITIVE MODELS
   Jackson R, 1996, J CLIN EPIDEMIOL, V49, P1441, DOI 10.1016/0895-4356(95)00047-X
   Junnikkalla S, 2002, BRIT J CANCER, V87, P1119, DOI 10.1038/sj.bjc.6600614
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1487
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Kovacic P, 2001, CURR MED CHEM, V8, P773, DOI 10.2174/0929867013373084
   Littman AJ, 2005, CANCER EPIDEM BIOMAR, V14, P773, DOI 10.1158/1055-9965.EPI-04-0599
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   *NAT HEART LUNG BL, 1988, ATH RISK COMM STUD
   Newman LA, 2006, J CLIN ONCOL, V24, P1342, DOI 10.1200/JCO.2005.03.3472
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   Taylor HR, 2008, T AM OPHTHAL SOC, V98, P96
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 43
TC 20
Z9 20
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2007
VL 125
IS 9
BP 1241
EP 1247
DI 10.1001/archopht.125.9.1241
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 208TM
UT WOS:000249342100013
PM 17846365
OA Bronze
DA 2022-11-30
ER

PT J
AU Corvi, F
   Tiosano, L
   Corradetti, G
   Nittala, MG
   Lindenberg, S
   Alagorie, AR
   McLaughlin, JA
   Lee, TK
   Sadda, SR
AF Corvi, Federico
   Tiosano, Liran
   Corradetti, Giulia
   Nittala, Muneeswar Gupta
   Lindenberg, Sophiana
   Alagorie, Ahmed Roshdy
   McLaughlin, John Adam
   Lee, Thomas K.
   Sadda, Srinivas R.
TI CHORIOCAPILLARIS FLOW DEFICITS AS A RISK FACTOR FOR PROGRESSION OF
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choriocapillaris; drusen volume;
   hyporeflective drusen cores; intraretinal hyperreflective foci; optical
   coherence tomography angiography; subretinal drusenoid deposits
ID GEOGRAPHIC ATROPHY; NATURAL-HISTORY; EYES
AB Purpose: To evaluate the association between choriocapillaris (CC) flow deficits and structural optical coherence tomography biomarkers and the progression of intermediate age-related macular degeneration (iAMD) to complete retinal pigment epithelial and outer retinal atrophy. Methods: Retrospective analysis of consecutive patients with iAMD with a minimum follow-up of 12 months. Odds ratios of intraretinal hyperreflective foci, hyporeflective drusen cores, subretinal drusenoid deposits, the presence of drusen volume >= 0.03 mm(3) within a central 3-mm circle, fellow eye with late stage of AMD, and CC flow deficits at baseline and months of follow-up were estimated from logistic regression. Results: A total of 112 eyes with iAMD were included. Eyes that progressed were significantly more likely to show intraretinal hyperreflective foci, hyporeflective drusen cores, and drusen volume >= 0.03 mm(3). The CC flow deficit was also significantly greater in eyes that developed complete retinal pigment epithelial and outer retinal atrophy. Intraretinal hyperreflective foci, hyporeflective drusen cores, drusen volume >= 0.03 mm(3), and higher CC flow deficits were significantly and independently associated with the development of complete retinal pigment epithelial and outer retinal atrophy. Conclusion: The CC flow deficit was significantly greater in iAMD eyes that progressed to complete retinal pigment epithelial and outer retinal atrophy and remained an independent risk factor when structural optical coherence tomography biomarkers were considered. CC flow deficits may be useful for enhancing risk stratification and prognostication of patients with iAMD.
C1 [Corvi, Federico; Tiosano, Liran; Corradetti, Giulia; Nittala, Muneeswar Gupta; Lindenberg, Sophiana; Alagorie, Ahmed Roshdy; Sadda, Srinivas R.] Doheny Eye Inst, Dept Ophthalmol, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Corvi, Federico; Corradetti, Giulia; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Corvi, Federico] Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Tiosano, Liran] Hadassah Hebrew Univ, Dept Ophthalmol, Med Ctr, Jerusalem, Israel.
   [Alagorie, Ahmed Roshdy] Tanta Univ, Fac Med, Dept Ophthalmol, Tanta, Egypt.
   [McLaughlin, John Adam; Lee, Thomas K.] Univ Ottawa, Retina Ctr Ottawa, Dept Ophthalmol, Ottawa, ON, Canada.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of Milan;
   Luigi Sacco Hospital; Hebrew University of Jerusalem; Hadassah
   University Medical Center; Egyptian Knowledge Bank (EKB); Tanta
   University; University of Ottawa
RP Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Dept Ophthalmol, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Corradetti, Giulia/Q-5400-2019
OI Corradetti, Giulia/0000-0001-9213-5575; Corvi,
   Federico/0000-0002-2661-5500
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Alagorie AR, 2020, GRAEF ARCH CLIN EXP, V258, P995, DOI 10.1007/s00417-020-04615-w
   Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Byon I, 2020, AM J OPHTHALMOL, V219, P21, DOI 10.1016/j.ajo.2020.05.027
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jack LS, 2016, DEV OPHTHALMOL, V55, P302, DOI 10.1159/000438954
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Rinella NT, 2019, OSLI RETINA, V50, pE229, DOI 10.3928/23258160-20190905-14
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 31
TC 21
Z9 22
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2021
VL 41
IS 4
BP 686
EP 693
DI 10.1097/IAE.0000000000002990
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5KP
UT WOS:000711806600004
PM 33009219
DA 2022-11-30
ER

PT J
AU Blanco-Garavito, R
   Jung, C
   Uzzan, J
   Quaranta-ElMaftouhi, M
   Coscas, F
   Sahel, J
   Korobelnik, JF
   Bechet, S
   Querques, G
   Souied, EH
AF Blanco-Garavito, Rocio
   Jung, Camille
   Uzzan, Joel
   Quaranta-ElMaftouhi, Maddalena
   Coscas, Florence
   Sahel, Jose
   Korobelnik, Jean-Francois
   Bechet, Stephane
   Querques, Giuseppe
   Souied, Eric H.
TI AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE
   AGE-RELATED MACULAR DEGENERATION The ARI2 Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF therapy; pigment epithelial detachment; switch therapy; wet
   age-related macular degeneration; ranibizumab; aflibercept
ID PIGMENT EPITHELIAL DETACHMENT; POSTERIOR VITREOMACULAR ADHESION;
   BEVACIZUMAB; EYES; THERAPY; AMD; TACHYPHYLAXIS; INTERFACE; RESISTANT;
   SECONDARY
AB Purpose: To analyze the efficacy of aflibercept switch treatment for regression of pigment epithelial detachment (PED) in patients previously treated with ranibizumab.
   Methods: Multicenter, prospective, nonrandomized clinical trial. One eye of patients presenting neovascular age-related macular degeneration with PED of more than 250 mu m in height, with persistent fluid, was included. Patients had to have received at least six ranibizumab intravitreal injections during the 12 months before enrollment. Patients were switched from ranibizumab pro re nata to aflibercept (fixed regimen, 3 monthly intravitreal injections, and then Q6). Main outcome measure was change in PED height from baseline to Week 12 after switch. Secondary outcomes were best-corrected visual acuity and PED volume changes.
   Results: Eighty four patients were included. Mean delay between last ranibizumab intravitreal injection and switch was 44.7 days. Mean maximal PED height at baseline visit was 347 mu m (+/- 109) and reduced to a mean of 266 mu m (+/- 114) at Week 12 (P < 0.001) and 288.2 mu m at Week 32 (P < 0.001). Mean PED volume was reduced from 1.3 mm(3) to 0.98 mm3 at Week 12 (P < 0.001). Best-corrected visual acuity improved by 3.3 Early Treatment Diabetic Retinopathy Study letters at Week 32 (P = 0.003).
   Conclusion: Aflibercept switch therapy seems to be effective on large PED in patients previously treated with pro re nata ranibizumab.
C1 [Blanco-Garavito, Rocio; Jung, Camille; Coscas, Florence; Querques, Giuseppe; Souied, Eric H.] Hop Intercommunal Creteil, Serv Univ Ophtalmol, Creteil, France.
   [Blanco-Garavito, Rocio; Jung, Camille; Querques, Giuseppe; Souied, Eric H.] Univ Paris Est Creteil, Ctr Rech Clin Macula, Creteil, France.
   [Jung, Camille] Hop Intercommunal Creteil, Ctr Ressources Biol, Creteil, France.
   [Uzzan, Joel] Clin Mathilde, Rouen, France.
   [Quaranta-ElMaftouhi, Maddalena] Clin Rabelais, Lyon, France.
   [Sahel, Jose] Hop Quinze Vingts, Paris, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux, Serv Ophtalmol, CHU Bordeaux, ISPED, Bordeaux, France.
   [Korobelnik, Jean-Francois] Bordeaux Populat Hlth Res Ctr, INSERM, U1219, Bordeaux, France.
   [Bechet, Stephane] Assoc Clin & Therapeut Infantile Val de Marne, St Maur, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; CHNO des
   Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite;
   CHU Bordeaux; UDICE-French Research Universities; Universite de
   Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI KOROBELNIK, Jean-Francois/A-5448-2016
OI Querques, Giuseppe/0000-0002-3292-9581; JUNG,
   Camille/0000-0001-8486-8939
FU Bayer (Loos, France)
FX This study was performed through a research grant from the sponsor Bayer
   (Loos, France). The sponsor had no role in the design and conduct of the
   study, nor in the writing of this report or in the decision to submit
   this research.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Barteselli G, 2013, AM J OPHTHALMOL, V155, P727, DOI 10.1016/j.ajo.2012.10.019
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2012, EYE, V26, P882, DOI 10.1038/eye.2012.90
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Choi CS, 2016, OSLI RETINA, V47, P245, DOI 10.3928/23258160-20160229-07
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Despreaux R, 2016, GRAEF ARCH CLIN EXP, V254, P639, DOI 10.1007/s00417-015-3084-1
   El-Hifnawy MA, 2017, INT J OPHTHALMOL-CHI, V10, P246, DOI 10.18240/ijo.2017.02.11
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gattoussi S, 2017, INVEST OPHTH VIS SCI, V58, P2180, DOI 10.1167/iovs.16-20741
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   He LM, 2016, RETINA-J RET VIT DIS, V36, P492, DOI 10.1097/IAE.0000000000000749
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lehne RA, 2013, PHARM NURSING CARE, P81
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Maier M, 2012, KLIN MONATSBL AUGENH, V229, P1030, DOI 10.1055/s-0032-1315305
   Major JC, 2015, CAN J OPHTHALMOL, V50, P373, DOI 10.1016/j.jcjo.2014.12.012
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Palacio AC, 2017, RETINA-J RET VIT DIS, V37, P118, DOI 10.1097/IAE.0000000000001115
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schaal S, 2016, RETINA-J RET VIT DIS, V36, P791, DOI 10.1097/IAE.0000000000000981
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Witkin AJ, 2015, SEMIN OPHTHALMOL, V4, P1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 41
TC 8
Z9 8
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2018
VL 38
IS 12
BP 2285
EP 2292
DI 10.1097/IAE.0000000000001928
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1WG
UT WOS:000454008700007
PM 29190241
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Fauser, S
   Weber, BHF
AF Grassmann, Felix
   Fauser, Sascha
   Weber, Bernhard H. F.
TI The genetics of age-related macular degeneration (AMD) - Novel targets
   for designing treatment options?
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Age-related macular degeneration (AMD); Geographic atrophy; Neovascular
   AMD; Genetic predisposition; Complement cascade; Therapeutic approaches;
   Clinical trials
ID COMPLEMENT FACTOR-H; GEOGRAPHIC ATROPHY; HIGH-RISK; STARGARDT-DISEASE;
   SUSCEPTIBILITY; PROGRESSION; VARIANTS; MODELS; C3; POLYMORPHISM
AB Age-related macular degeneration (AMD) is a progressive disease of the central retina and the main cause of legal blindness in industrialized countries. Risk to develop the disease is conferred by both individual as well as genetic factors with the latter being increasingly deciphered over the last decade. Therapeutically, striking advances have been made for the treatment of the neovascular form of late stage AMD while for the late stage atrophic form of the disease, which accounts for almost half of the visually impaired, there is currently no effective therapy on the market. This review highlights our current knowledge on the genetic architecture of early and late stage AMD and explores its potential for the discovery of novel, target-guided treatment options. We reflect on current clinical and experimental therapies for all forms of AMD and specifically note a persisting lack of efficacy for treatment in atrophic AMD. We further explore the current insight in AMD-associated genes and pathways and critically question whether this knowledge is suited to design novel treatment options. Specifically, we point out that known genetic factors associated with AMD govern the risk to develop disease and thus may not play a role in its severity or progression. Treatments based on such knowledge appear appropriate rather for prevention than treatment of manifest disease. As a consequence, future research in AMD needs to be greatly focused on approaches relevant to the patients and their medical needs. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Fauser, Sascha] Univ Hosp, Dept Ophthalmol, Cologne, Germany.
C3 University of Regensburg; University of Cologne
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
OI Grassmann, Felix/0000-0003-1390-7528; Weber, Bernhard
   H.F./0000-0002-8808-7723
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Benjamini Y, 2001, ANN STAT, V29, P1165
   Bertolotti E, 2014, PROG RETIN EYE RES, V42, P130, DOI 10.1016/j.preteyeres.2014.06.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Casaroli-Marano RP, 2014, CLIN OPHTHALMOL, V8, P1661, DOI 10.2147/OPTH.S46068
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Edwards SL, 2013, AM J HUM GENET, V93, P779, DOI 10.1016/j.ajhg.2013.10.012
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Fife RS, 1998, CANCER LETT, V127, P37, DOI 10.1016/S0304-3835(98)00003-2
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grassmann F, 2014, ADV EXP MED BIOL, V801, P291, DOI 10.1007/978-1-4614-3209-8_37
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hermann M, 2012, ACTA OPHTHALMOL, V90, pe500, DOI 10.1111/j.1755-3768.2011.02347.x
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Kjeldsen MJ, 2001, EPILEPSY RES, V44, P167, DOI 10.1016/S0920-1211(01)00196-6
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krakauer T, 2003, ANTIMICROB AGENTS CH, V47, P3630, DOI 10.1128/AAC.47.11.3630-3633.2003
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McKay GJ, 2011, AM J EPIDEMIOL, V173, P1357, DOI 10.1093/aje/kwr015
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pauly D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096371
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Quaggin SE, 2012, J CLIN INVEST, V122, P3849, DOI 10.1172/JCI65509
   Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ristau T, 2014, ACTA OPHTHALMOL, V92, pE494, DOI 10.1111/aos.12347
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Steiner T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092404
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Streiner DL, 2011, CHEST, V140, P16, DOI 10.1378/chest.11-0523
   TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990
   van Beek J, 2001, NEUROREPORT, V12, P289, DOI 10.1097/00001756-200102120-00022
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Walley AJ, 2006, HUM MOL GENET, V15, pR124, DOI 10.1093/hmg/ddl215
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wood JPM, 2013, INVEST OPHTH VIS SCI, V54, P2305, DOI 10.1167/iovs.12-11203
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 97
TC 29
Z9 30
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2015
VL 95
BP 194
EP 202
DI 10.1016/j.ejpb.2015.04.039
PN B
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CU8WH
UT WOS:000363824300005
PM 25986585
DA 2022-11-30
ER

PT J
AU Coral, K
   Raman, R
   Rathi, S
   Rajesh, M
   Sulochana, KN
   Angayarkanni, N
   Paul, PG
   Ramakrishnan, S
AF Coral, K
   Raman, R
   Rathi, S
   Rajesh, M
   Sulochana, KN
   Angayarkanni, N
   Paul, PG
   Ramakrishnan, S
TI Plasma homocysteine and total thiol content in patients with exudative
   age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; homocysteine; glutathione; thiol
   content; oxidative stress
ID ENDOTHELIAL-CELL INJURY; LIPID-PEROXIDATION; NITRIC-OXIDE; RISK-FACTORS;
   PATHOGENESIS; HYPERHOMOCYSTEINEMIA; MALONDIALDEHYDE; ASSOCIATION;
   GLUTATHIONE
AB Purpose Exudative age-related macular degeneration (ARMD) is one of the debilitating ocular complications, which results in permanent blindness. Elevated homocysteine (Hcys) levels have been associated in the development of several vascular diseases. Vascular and oxidative stress theories have been implicated for the development of choroidal neovascularization in exudative ARMD. The aim of the present study was to investigate the possible role of plasma Hcys and thiol content (tSH) as a risk factor for the development of exudative ARMD.
   Method A total of 16 patients with exudative ARMD and 20 age-matched controls were recruited for the study. Plasma Hcys levels were analysed using Reverse Phase High Performance Liquid Chromatography. Plasma glutathione (GSH) content was determined using o-phthalaldehyde (OPA) derivatization and subsequent detection by fluorimeter. Plasma tSH levels were determined by using thiol-specific reagent dithionitrobenzoic acid (DTNB) spectrophotometrically.
   Results Plasma Hcys levels in exudative ARMD were elevated three- fold (18 +/- 5.0 mu M) when compared to healthy controls (6.7 +/- 1.8 mu M). There was a two-fold decrease in the GSH and tSH in exudative ARMD when compared with controls. Negative correlation was observed between diminished tSH and Hcys levels (r-0.4837, P=0.05). Similarly plasma Hcys levels negatively correlated with GSH content (r-0.6620, P < 0.05).
   Conclusion Results from our present study revealed that there is an elevated Hcys level and diminished thiol pool content in exudative ARMD that are significant.
C1 Vis Res Fdn, Biochem Res Dept, Madras 600006, Tamil Nadu, India.
   Vitreoretinal Serv, Dept Ophthalmol, Madras, Tamil Nadu, India.
   NYU, Edgemont High Sch, New York, NY USA.
   Natl Heart Ctr, Singapore, Singapore.
   John Hopkins Singapore, Vasc Biol Lab, Singapore, Singapore.
   Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore.
C3 New York University; National Heart Centre Singapore; National
   University of Singapore
RP Ramakrishnan, S (通讯作者)，Vis Res Fdn, Biochem Res Dept, Sankara Nethralaya,18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM drrk@sankaranethralaya.org
RI Coral, Karunakaran/AAK-2880-2021; Raman, Rajiv/A-7234-2009
OI Raman, Rajiv/0000-0001-5842-0233; Mohanraj, Rajesh/0000-0003-2660-2184
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   COMPOCHIARO PA, 1999, MOL VIS, V5, P34
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520
   HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588
   IAN F, 2000, J NUTR, V30, pS369
   JAYATILLEKE E, 1993, ANAL BIOCHEM, V214, P452, DOI 10.1006/abio.1993.1522
   Jones D. P., 1997, FASEB Journal, V11, pA150
   MIUOLIN H, 1994, METHOD ENZYMOL, V233, P381
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Winkler B S, 1999, Mol Vis, V5, P32
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zappacosta B, 2001, FREE RADICAL RES, V35, P499, DOI 10.1080/10715760100301511
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 27
TC 54
Z9 56
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2006
VL 20
IS 2
BP 203
EP 207
DI 10.1038/sj.eye.6701853
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 009SO
UT WOS:000235133200012
PM 15803172
OA Bronze
DA 2022-11-30
ER

PT J
AU Cameron, DJ
   Yang, ZL
   Gibbs, D
   Chen, HY
   Kaminoh, Y
   Jorgensen, A
   Zeng, J
   Luo, L
   Brinton, E
   Brinton, G
   Brand, JM
   Bernstein, PS
   Zabriskie, NA
   Tang, SB
   Constantine, R
   Tong, ZZ
   Zhang, K
AF Cameron, D. Joshua
   Yang, Zhenglin
   Gibbs, Daniel
   Chen, Haoyu
   Kaminoh, Yuuki
   Jorgensen, Adam
   Zeng, Jesse
   Luo, Ling
   Brinton, Eric
   Brinton, Gregory
   Brand, John M.
   Bernstein, Paul S.
   Zabriskie, Norman A.
   Tang, Shibo
   Constantine, Ryan
   Tong, Zongzhong
   Zhang, Kang
TI HTRA1 variant confers similar risks to geographic atrophy and
   neovascular age-related macular degeneration
SO CELL CYCLE
LA English
DT Article
DE age-related macular degeneration; HTRA1; geographic atrophy; drusen;
   genetics; association
ID COMPLEMENT FACTOR-H; DRUSEN; GENE; DISEASE; SUSCEPTIBILITY;
   POLYMORPHISM; ACTIVATION; COMMON
AB Age-related macular degeneration (AMD) is the most common cause of irreversible visual impairment in the developed world. The two forms of advanced AMD, geographic atrophy (GA) and choroidal neovascularization (wet AMD), represent two types of degenerative processes in the macula that lead to loss of central vision. Soft confluent drusen, characterized by deposits in macula without visual loss are considered a precursor of advanced AMD. A single nucleotide polymorphism, rs11200638, in the promoter of HTRA1 has been shown to increases the risk for wet AMD. However, its impact on soft confluent drusen and GA or the relationship between them is unclear. To better under stand the role the HTRA1 polymorphism plays in AMD subtypes, we genotyped an expanded Utah population with 658 patients having advanced AMD or soft confluent drusen and 294 normal controls and found that the rs11200638 was significantly associated with GA. This association remains significant conditional on LOC387715 rs10490924. In addition, rs11200638 was significantly associated with soft confluent drusen, which are strongly immunolabeled with HTRA1 antibody in an AMD eye with GA similar to wet AMD. Two-locus analyses were performed for CFH Y402H variant at 1q31 and the HTRA1 polymorphism. Together CFH and HTRA1 risk variants increase the odds of having AMD by more than 40 times. These findings expand the role of HTRA1 in AMD. Understanding the underlying molecular mechanism will provide an important insight in pathogenesis of AMD.
C1 Univ Utah, Moran Eye Ctr, Sch Med, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   Sichuan Med Sci Acad, Sichuan, Peoples R China.
   Sichuan Prov Peoples Hosp, Sichuan, Peoples R China.
   Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou, Peoples R China.
   Retina Associates Utah, Holladay, UT USA.
C3 Utah System of Higher Education; University of Utah; Sichuan Provincial
   People's Hospital; Sun Yat Sen University
RP Zhang, K (通讯作者)，Univ Utah, Moran Eye Ctr, Sch Med, Dept Ophthalmol & Visual Sci, 65 N Med Dr, Salt Lake City, UT 84132 USA.
EM kang.zhang@hsc.utah.edu
RI Zhang, Kang/Y-2740-2019; Chen, Haoyu/A-7432-2013; Chu, Kai
   On/E-2325-2016; TANG, Shi/GXH-5719-2022
OI Zhang, Kang/0000-0002-4549-1697; Chen, Haoyu/0000-0003-0676-4610; 
FU NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY014428, P30EY014800, R01EY014448]
   Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00064] Funding Source:
   Medline; NEI NIH HHS [P30EY014800, R01EY14448, R01EY14428] Funding
   Source: Medline
CR Anderson RE, 2002, MOL VIS, V8, P351
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines J.L, 2005, SCIENCE
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klein R.J., 2005, SCIENCE
   LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 22
TC 92
Z9 99
U1 0
U2 5
PU LANDES BIOSCIENCE
PI GEORGETOWN
PA 810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD MAY 1
PY 2007
VL 6
IS 9
BP 1122
EP 1125
DI 10.4161/cc.6.9.4157
PG 4
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 163GV
UT WOS:000246148300019
PM 17426452
OA Bronze
DA 2022-11-30
ER

PT J
AU Ro-Mase, T
   Ishiko, S
   Yoshida, A
AF Ro-Mase, Tomoko
   Ishiko, Satoshi
   Yoshida, Akitoshi
TI Effect of illumination on reading performance in Japanese patients with
   age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Illumination; Reading performance;
   Macular function; Japanese
ID LOW-VISION; EYE-MOVEMENTS; PSYCHOPHYSICS; SIZE; DISEASES; ACUITY; SPEED
AB Purpose Several studies of Western patients with age-related macular degeneration (AMD) have investigated reading performance that improved at high levels of illumination; however, the relation between reading performance and macular function has not been evaluated in detail in Japan. The goals of this study were to evaluate the effect of different levels of illumination on reading performance in Japanese patients with AMD and determine the factors, such as macular function, that affect these results. Study design Cross-sectional study. Methods We prospectively included 39 patients with bilateral AMD or maculopathy. We evaluated reading performance; reading acuity (RA), critical print size (CPS), and maximal reading speed (MRS) using charts with Japanese sentences based on the MNREAD-J in 500-7500 lx. Patients were classified into two groups based on the presence of a central scotoma (CS) or no CS (NCS) diagnosed by microperimetry. Results The RA improved significantly in 500-7500 lx in both groups (NCS,p = 0.001; CS,p = 0.046). The RA improvement differed significantly (2000 lx,p = 0.021; 5,000 lx;p = 0.021; 7500 lx,p = 0.047) between 500 lx and other illumination levels only in the NCS group and then plateaued over 2000 lx. The CPS and MRS did not improve significantly at any illumination level. Conclusions These results suggest that the difference in macular function was related to improvement in the RA with increased illumination in Japanese patients with AMD.
C1 [Ro-Mase, Tomoko; Yoshida, Akitoshi] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.
   [Ishiko, Satoshi] Asahikawa Med Univ, Dept Med, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.
   [Ishiko, Satoshi] Asahikawa Med Univ, Engn Combined Res Inst, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.
C3 Asahikawa Medical College; Asahikawa Medical College; Asahikawa Medical
   College
RP Ishiko, S (通讯作者)，Asahikawa Med Univ, Dept Med, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.; Ishiko, S (通讯作者)，Asahikawa Med Univ, Engn Combined Res Inst, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.
EM ishiko@asahikawa-med.ac.jp
FU Japan Society for the Promotion of Science [JP26462676]
FX This work was supported by the Japan Society for the Promotion of
   Science (KAKENHI grant number JP26462676).
CR [Anonymous], 2010, Z9110 JIS, V9110
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   CORNELISSEN FW, 1991, DOC OPHTHALMOL, V78, P195, DOI 10.1007/BF00165681
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   ELDRED KB, 1992, OPTOMETRY VISION SCI, V69, P46, DOI 10.1097/00006324-199201000-00007
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Legge GE, 2001, VISION RES, V41, P725, DOI 10.1016/S0042-6989(00)00295-9
   LIE I, 1977, AM J OPTOM PHYS OPT, V54, P528
   Lovie-Kitchin J, 2011, CLIN EXP OPTOM, V94, P121, DOI 10.1111/j.1444-0938.2010.00565.x
   Matsumoto Y, 2005, JPN J OPHTHALMOL, V49, P462, DOI 10.1007/s10384-005-0242-8
   ODA K, 1995, INVEST OPHTH VIS SCI, V36, pS671
   Oda K, 1996, 7 ANN M JAP ASS REH, P157
   OSAKA N, 1992, J OPT SOC AM A, V9, P5, DOI 10.1364/JOSAA.9.000005
   SLOAN LL, 1973, AM J OPHTHALMOL, V76, P745, DOI 10.1016/0002-9394(73)90572-2
   SLOAN LL, 1969, DOC OPHTHALMOL, V26, P384, DOI 10.1007/BF00943999
   SOLOMON JA, 1994, NATURE, V369, P395, DOI 10.1038/369395a0
   2005, NIPPON GANKA GAKKAI, V109, P83
NR 23
TC 1
Z9 1
U1 1
U2 6
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2020
VL 64
IS 6
BP 597
EP 604
DI 10.1007/s10384-020-00769-6
EA SEP 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH8VD
UT WOS:000566039500001
PM 32888091
DA 2022-11-30
ER

PT J
AU Budiene, B
   Liutkeviciene, R
   Gustiene, O
   Ugenskiene, R
   Laukaitiene, D
   Savukaityte, A
   Vilkeviciute, A
   Steponaviciute, R
   Rocyte, A
   Zaliuniene, D
AF Budiene, Brigita
   Liutkeviciene, Rasa
   Gustiene, Olivija
   Ugenskiene, Rasa
   Laukaitiene, Danguole
   Savukaityte, Aiste
   Vilkeviciute, Alvita
   Steponaviciute, Rasa
   Rocyte, Aurelija
   Zaliuniene, Dalia
TI The association of matrix metalloproteinases polymorphisms and
   interleukins in advanced age-related macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; gene polymorphism; interleukins;
   matrix metalloproteinases
ID RETINAL-PIGMENT EPITHELIUM; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   ENDOTHELIAL GROWTH-FACTOR; BASAL LAMINAR DEPOSIT; HUMAN RPE CELLS;
   BRUCHS MEMBRANE; EXTRACELLULAR-MATRIX; NEOVASCULAR MEMBRANES;
   ELECTRON-MICROSCOPY; GENE POLYMORPHISMS
AB Purpose: To assess the impact of matrix metalloproteinase (MMP)1-1607 1G/2G (rs1799750), MMP7-181 A/G (rs11568818) single-nucleotide polymorphism and systemic cytokins interleukin-1 beta (IL-1 beta), IL-6 levels on the development of exudative age-related macular degeneration (eAMD)
   Methodology: The study group comprised 282 patients with eAMD, and the control group enrolled 379 randomly selected persons. The genotyping of MMP1-1607 (rs1799750) and MMP7-181 (rs11568818) was performed by using the polymerase chain reaction-based restriction fragment length polymorphism method. To determine IL-1 beta and IL-6 serum levels, the immunoenzymatic method with monoclonal antibodies coated plates was performed.
   Results: MMP1 rs1799750 1G/2G genotype was more frequently found in the development of eAMD. It was associated with a 4.3-fold increased risk for eAMD under the codominant model and a 4.9-fold increased risk for eAMD under the overdominant model. The effect was more pronounced at the age of less than 65 years. IL-1 beta concentration was significantly higher for MMP1 rs1799750 1G/1G genotype and MMP7 rs11568818 A/G genotype in eAMD patients compared with control group subjects.
   Conclusions: MMP1 rs1799750 1G/2G genotype was found to play a significant role in the development of eAMD at the age of less than 65 years. IL-1 beta concentration was significantly higher in eAMD patients for MMP1 rs1799750 1G/1G genotype and MMP7 rs11568818 A/G genotype compared with control group subjects.
C1 [Budiene, Brigita; Liutkeviciene, Rasa; Zaliuniene, Dalia] Lithuanian Univ Hlth Sci, Dept Ophthalmol, Eiveniu 2, Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Vilkeviciute, Alvita] Lithuanian Univ Hlth Sci, Dept Cardiol, Kaunas, Lithuania.
   [Gustiene, Olivija] Lithuanian Univ Hlth Sci, Inst Oncol, Oncol Res Lab, Kaunas, Lithuania.
   [Ugenskiene, Rasa; Laukaitiene, Danguole; Savukaityte, Aiste] Lithuanian Univ Hlth Sci, Neurosci Inst, Kaunas, Lithuania.
   [Steponaviciute, Rasa; Rocyte, Aurelija] Lithuanian Univ Hlth Sci, Dept Lab Med, Lab Clin Chem & Genet, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences; Lithuanian
   University of Health Sciences; Lithuanian University of Health Sciences
RP Budiene, B (通讯作者)，Lithuanian Univ Hlth Sci, Dept Ophthalmol, Eiveniu 2, Kaunas, Lithuania.
EM brigita.budiene@lsmuni.lt
OI Ugenskiene, Rasa/0000-0001-7905-8106
CR ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], IND PSYCHIAT J, DOI DOI 10.4103/0972-6748.98407
   [Anonymous], 2011, AM J OPHTHALMOL, V132, P668
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)02122-5
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chung HY, 2006, ANTIOXID REDOX SIGN, V8, P572, DOI 10.1089/ars.2006.8.572
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Dhaliwal BS, 1999, CLIN CHIM ACTA, V286, P191, DOI 10.1016/S0009-8981(99)00101-1
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Endrighi R, 2016, ANN BEHAV MED, V50, P564, DOI 10.1007/s12160-016-9783-y
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Forrester JV, 2013, EYE, V27, P340, DOI 10.1038/eye.2012.265
   Green W R, 1999, Mol Vis, V5, P27
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   HUNT RC, 1993, INVEST OPHTH VIS SCI, V34, P3179
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones LL, 2011, IMMUNOL RES, V51, P5, DOI 10.1007/s12026-011-8209-y
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lim CS, 2010, CURR VASC PHARMACOL, V8, P75, DOI 10.2174/157016110790226697
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lukens JR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00315
   Miao H, 2012, MOL VIS, V18, P574
   Moreno-Ortiz JM, 2014, GENET MOL RES, V13, P3537, DOI 10.4238/2014.February.14.1
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Papageorgiou N, 2012, CURR TOP MED CHEM, V12, P1206, DOI 10.2174/1568026611208011206
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Rahimi Z, 2016, IMMUNOL INVEST, V45, P543, DOI 10.1080/08820139.2016.1180303
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Steer SA, 2006, PLOS MED, V3, P253, DOI 10.1371/journal.pmed.0030017
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tanaka T, 2012, ANNU REV PHARMACOL, V52, P199, DOI 10.1146/annurev-pharmtox-010611-134715
   Tsironi EE, 2009, MOL VIS, V15, P2890
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Yazama F, 2002, J ELECTRON MICROSC, V51, P127, DOI 10.1093/jmicro/51.2.127
   Zeng RP, 2013, MOL VIS, V19, P729
NR 71
TC 9
Z9 9
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2018
VL 39
IS 4
BP 463
EP 472
DI 10.1080/13816810.2018.1484928
PG 10
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA GK9PB
UT WOS:000436582700008
PM 29947568
DA 2022-11-30
ER

PT J
AU Waisbourd, M
   Loewenstein, A
   Goldstein, M
   Leibovitch, I
AF Waisbourd, Michael
   Loewenstein, Anat
   Goldstein, Michaella
   Leibovitch, Igal
TI Targeting vascular endothelial growth factor - A promising strategy for
   treating age-related macular degeneration
SO DRUGS & AGING
LA English
DT Review
ID INTRAVITREAL BEVACIZUMAB AVASTIN; EXPERIMENTAL CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; PEGAPTANIB SODIUM; VERTEPORFIN
   PDT; NATURAL-HISTORY; RANIBIZUMAB; INJECTION; SAFETY; PHARMACOKINETICS
AB Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the industrialised world. While treatment options for advanced AMD have been rather limited until recently, the introduction of intravitreal injections of anti-angiogenic agents appears to be a promising and revolutionary mode of treatment for this blinding disease. Vascular endothelial growth factor (VEGF) appears to play a pivotal role in the pathogenesis of choroidal neovascularisation, one of the cornerstones of advanced AMD. Pegaptanib, the first antiVEGF treatment approved for AMD patients, is a VEGF-neutralising aptamer that specifically inhibits one isoform of VEGF (VEGF-165). Although evidence suggested that pegaptanib was superior to previous treatment options, results with this agent were still unsatisfactory. Ranibizumab is a humanised anti-VEGF monoclonal antibody fragment that inhibits all isotypes of VEGF. This new drug has demonstrated a high efficacy profile in terms of inhibiting disease progression and even improving visual acuity. Bevacizumab is a full-length anti-VEGF antibody that was originally approved for use in metastatic colon cancer and is under investigation as a low-cost off-label alternative for patients with AMD. There is growing evidence that this drug may be an effective and safe alternative to the more expensive ranibizumab, although prospective multicentre trials are required to fully investigate this issue. Undoubtedly, the concept of directly injecting anti-VEGF drugs into the vitreal cavity brings new hope to many AMD patients.
C1 Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine
RP Waisbourd, M (通讯作者)，Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM mwaisbourd@hotmail.com
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P713, DOI 10.1111/j.1600-0420.2006.00759.x
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Beer PM, 2006, RETINA-J RET VIT DIS, V26, P871, DOI 10.1097/01.iae.0000233327.68433.02
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   *FDA SAF INF ADV E, 2007, 2007 SAF AL DRUGS BI
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gillies MC, 2006, ARCH OPHTHALMOL-CHIC, V124, P1478, DOI 10.1001/archopht.124.10.1478
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lim JI, 2006, RETINA-J RET VIT DIS, V26, pS17, DOI 10.1097/00006982-200607001-00005
   Malecki M, 2005, GENE THER, V12, pS159, DOI 10.1038/sj.gt.3302621
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   *NAT EY I NIH, 2006, NEWS EV NEI STAT
   ORTEGA N, 1999, FRONT BIOSCI, V4, P141
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.OPHTHA.2006.01.027
   Schachat AP, 2005, OPHTHALMOLOGY, V112, P531, DOI 10.1016/j.ophtha.2005.01.018
   Schuman S, 2006, OPHTHALMOLOGY, V113, P501, DOI 10.1016/j.ophtha.2005.12.016
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Vinores SA, 2003, CURR OPIN MOL THER, V5, P673
   Zachary I, 1998, EXP NEPHROL, V6, P480
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P922, DOI 10.1136/bjo.2006.092262
NR 70
TC 38
Z9 41
U1 0
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2007
VL 24
IS 8
BP 643
EP 662
DI 10.2165/00002512-200724080-00003
PG 20
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 203WT
UT WOS:000249005400003
PM 17702534
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Jeon, YJ
   Yoon, W
   Yoon, J
   Kim, J
   Kim, JW
AF Cho, Han Joo
   Jeon, Young Joon
   Yoon, Wontae
   Yoon, Jihyun
   Kim, Jaemin
   Kim, Jong Woo
TI Neovascular age-related macular degeneration without exudative
   recurrence over 24 months after initial remission
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TREAT-AND-EXTEND; OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB;
   BEVACIZUMAB; PREDICTORS; OUTCOMES; THERAPY
AB We investigated the characteristics of neovascular age-related macular degeneration (AMD), which rarely recurs after initial remission. This study retrospectively analyzed 392 neovascular AMD patients treated with anti-vascular endothelial growth factor (VEGF). All patients received three monthly loading doses of anti-VEGF injections, followed by a pro re nata (as needed) regimen for 24 months. The baseline characteristics associated with the odds of having no recurrence within 24 months were evaluated using multivariate modeling. After the initial three loading injections over 24 months, 58 (14.8%) eyes showed no exudative recurrence and did not require additional anti-VEGF injections. These patients without exudative recurrence had significantly better best-corrected visual acuity (P = 0.003) and lower central subfoveal thickness (P = 0.035) at 24 months than those with exudative recurrence. Additionally, the incidence of macular atrophy was significantly lower in the former than in the latter (8.6% vs. 21.9%; P = 0.020). Multivariate analysis revealed that younger age (odds ratio [OR], 0.901; P = 0.033), smaller lesion size (OR, 0.589; P = 0.016), and absence of fibrovascular pigment epithelial detachment (PED) (OR, 1.349; P = 0.028) were associated with higher odds of no recurrence during follow-up. Approximately 15% of the neovascular AMD patients showed no exudative recurrence after initial remission during the 24-month follow-up. The infrequent recurrence after initial remission correlated with younger age, smaller lesion size, and absence of fibrovascular PED.
C1 [Cho, Han Joo; Jeon, Young Joon; Yoon, Wontae; Yoon, Jihyun; Kim, Jaemin; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Coll Med, 156,4Ga Yeongdeungpo Dong, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Konyang Univ, Kims Eye Hosp, Coll Med, 156,4Ga Yeongdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Aslanis S, 2022, OPHTHALMOL RETINA, V6, P15, DOI 10.1016/j.oret.2021.03.010
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2022, AM J OPHTHALMOL, V234, P6, DOI 10.1016/j.ajo.2021.07.026
   Cho HJ, 2021, ACTA OPHTHALMOL, V99, pE540, DOI 10.1111/aos.14631
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Fu DJ, 2021, JAMA OPHTHALMOL, V139, P57, DOI 10.1001/jamaophthalmol.2020.5044
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holmes JP, 2011, CANCER-AM CANCER SOC, V117, P463, DOI 10.1002/cncr.25586
   Hwang RY, 2020, RETINA-J RET VIT DIS, V40, P679, DOI 10.1097/IAE.0000000000002446
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P1183, DOI 10.1007/s00417-019-04306-1
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lin TZ, 2020, BRIT J OPHTHALMOL, V104, P58, DOI 10.1136/bjophthalmol-2018-313447
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P516, DOI 10.1097/IAE.0000000000001572
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Skondra D, 2012, SEMIN OPHTHALMOL, V27, P209, DOI 10.3109/08820538.2012.708807
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 29
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 19
PY 2022
VL 12
IS 1
AR 15662
DI 10.1038/s41598-022-19400-4
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4P6FD
UT WOS:000855488300031
PM 36123375
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nielsen, MK
   Hector, SM
   Allen, K
   Subhi, Y
   Sorensen, TL
AF Nielsen, Marie Krogh
   Hector, Sven Magnus
   Allen, Kelly
   Subhi, Yousif
   Sorensen, Torben Lykke
TI Altered activation state of circulating neutrophils in patients with
   neovascular age-related macular degeneration
SO IMMUNITY & AGEING
LA English
DT Article
DE Neutrophils; Age-related macular degeneration; Choroidal
   neovascularization; Flow cytometry; Inflammation
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; C-REACTIVE PROTEIN;
   CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; INDUCED ARTHRITIS; INFLAMMATION;
   CELLS; RISK; MYELOPEROXIDASE; INHIBITION
AB Background: Neutrophil dysfunction plays a key role in the development of diseases characterized by inflammation and angiogenesis. Here, we studied the systemic expression of neutrophil markers reflecting activation, adhesion, and resolution of inflammation in patients with neovascular age-related macular degeneration (AMD).
   Results: This was a prospective case-control study of patients with neovascular AMD and age-matched healthy control individuals. Patients were recruited from an outpatient program, and control individuals were recruited amongst patients' relatives. Current smokers and individuals with either active immune-disease or ongoing cancer were not included, as these factors are known to affect neutrophil function. Fresh-drawn venous blood was processed for flow cytometric analysis of neutrophil markers. We determined percentages of positive cells and compared expression levels using fluorescence intensity measures. We found conditional differences on marker expression between patients with neovascular AMD (n = 29) and controls (n = 28): no differences were found when looking broadly, but several differences emerged when focusing on non-smokers. Here, patients with neovascular AMD had increased expression of the activity marker cluster of differentiation (CD) 66b (P = 0.003; Mann-Whitney U test), decreased expression of adhesion marker CD162 (P = 0.044; Mann-Whitney U test), and lower expression of the resolution of inflammation marker C-X-C chemokine receptor 2 (P = 0.044; Mann-Whitney U test).
   Conclusions: We present novel evidence suggesting that the activity of circulating neutrophils, sensitive to smoking, may differ in patients with neovascular AMD.
C1 [Nielsen, Marie Krogh; Hector, Sven Magnus; Allen, Kelly; Subhi, Yousif; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Nielsen, Marie Krogh; Subhi, Yousif; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Nielsen, MK (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.; Nielsen, MK (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
EM mrrm@regionsjaelland.dk
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
FU Synoptik-fonden
FX This project was supported by a grant from Synoptik-fonden, which had no
   influence on the design of the study, the analysis of data, the
   preparation of the manuscript, or the decision to publish.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   BD BioSciences, HUM MOUS CD MARK HDB
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011
   Burgisser P, 2007, CYTOM PART A, V71A, P632, DOI 10.1002/cyto.a.20414
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   CARLOS TM, 1994, BLOOD, V84, P2068
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Doodes PD, 2009, ARTHRITIS RHEUM-US, V60, P2945, DOI 10.1002/art.24842
   Doz E, 2008, J IMMUNOL, V180, P1169, DOI 10.4049/jimmunol.180.2.1169
   Dyer DP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42681
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750
   Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974
   Holmannova D, 2017, PERFUSION-UK, V32, P141, DOI 10.1177/0267659116669586
   Ilhan N, 2015, OCUL IMMUNOL INFLAMM, V23, P287, DOI 10.3109/09273948.2014.921715
   Jacobs JP, 2010, ARTHRITIS RHEUM-US, V62, P1921, DOI 10.1002/art.27470
   Jamieson T, 2012, J CLIN INVEST, V122, P3127, DOI 10.1172/JCI61067
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keenan TDL, 2015, RETINA-J RET VIT DIS, V35, P2613, DOI 10.1097/IAE.0000000000000651
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lerner L, 2009, J PHYSIOL PHARMACOL, V60, P81
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marsik C, 2004, J CLIN IMMUNOL, V24, P62, DOI 10.1023/B:JOCI.0000018064.13793.83
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murphy PM, 1997, SEMIN HEMATOL, V34, P311
   Pruenster M, 2009, NAT IMMUNOL, V10, P101, DOI 10.1038/ni.1675
   Ray RS, 2016, NEUROSCI BIOBEHAV R, V68, P611, DOI 10.1016/j.neubiorev.2016.06.031
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rifai N, 2001, CLIN CHEM, V47, P28
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schinke C, 2015, BLOOD, V125, P3144, DOI 10.1182/blood-2015-01-621631
   Schmidt T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132703
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sengul EA, 2017, INT J OPHTHALMOL-CHI, V10, P754, DOI 10.18240/ijo.2017.05.16
   Shimizu K, 2015, J IMMUNOL, V194, P3156, DOI 10.4049/jimmunol.1402155
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Soubhye J, 2016, CURR MED CHEM, V23, P3975, DOI 10.2174/0929867323666160607111806
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2016, DAN MED J, V63
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Urban CF, 2006, CELL MICROBIOL, V8, P1687, DOI 10.1111/j.1462-5822.2006.00792.x
   Woodfin A, 2010, CURR OPIN HEMATOL, V17, P9, DOI 10.1097/MOH.0b013e3283333930
   Yogalingam G, 2017, J BIOL CHEM, V292, P4255, DOI 10.1074/jbc.M116.739441
   Zhang DC, 2015, NATURE, V525, P528, DOI 10.1038/nature15367
   Zhou JH, 2005, MOL VIS, V11, P414
NR 59
TC 11
Z9 12
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4933
J9 IMMUN AGEING
JI Immun. Ageing
PD JUL 27
PY 2017
VL 14
AR 18
DI 10.1186/s12979-017-0100-9
PG 9
WC Geriatrics & Gerontology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Immunology
GA FC2VV
UT WOS:000406697900001
PM 28769990
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tatar, O
   Shinoda, K
   Adam, A
   Rohrbach, JM
   Lucke, K
   Henke-Fahle, S
   Bartz-Schmidt, KU
   Grisanti, S
AF Tatar, Olcay
   Shinoda, Kei
   Adam, Annemarie
   Rohrbach, Jens Martin
   Lucke, Klaus
   Henke-Fahle, Sigrid
   Bartz-Schmidt, Karl Ulrich
   Grisanti, Salvatore
TI Expression of endostatin in human choroidal neovascular membranes
   secondary to age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   angiogenesis; endostatin; E-selectin
ID ENDOTHELIAL-CELL MIGRATION; GROWTH-FACTOR; COLLAGEN-XVIII; E-SELECTIN;
   MATRIX-METALLOPROTEINASE; ENDOGENOUS INHIBITOR; ADHESION MOLECULES;
   TUMOR-GROWTH; ANGIOGENESIS; VEGF
AB Endostatin is an endogenous angiogenesis inhibitor which requires E-selectin for its antiangiogenic activity. The aim of this study was to investigate the expression of endostatin in human choroidal neovascular membranes (CNV) secondary to age-related macular degeneration (AMD) with regard to vascularization and proliferative activity. An interventional case series of 36 patients who underwent removal of CNV were retrospectively investigated. Thirty-six CNV were analyzed by light microscopic immunohistochemistry for the expression of CD34 (endothelial cells, EC), CD105 (activated EC), Ki-67 (cell proliferation), Cytokeratin 18 (epithelial cells), VEGF (vascular endothelial growth factor), E-selectin and endostatin. Donor eyes (n = 7) including one with AMD were used as controls. Endostatin immunoreactivity was present in choroidal vessels of five as well as in the retinal pigment epithelium (RPE)-Bruch's membrane complex of two donor eyes without AMD. In one eye with AMD, endostatin was detected in RPE, Bruch's membrane and choroidal vessels. Ninety-two percent (33/36) of CNV disclosed endostatin staining. RPE-Bruch's membrane complex, choroidal vessels and stroma were positive in 50% (18/36), 72% (26/36), and 78% (28/36) of the membranes, respectively. Both control eyes and CNV expressed all the investigated markers except E-selectin being positive only in membranes. Endostatin, an endogenous angiogenesis inhibitor, is expressed in CNV and its therapeutic up-regulation may be a new strategy in the treatment of neovascular AMD. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Tubingen, Eye Clin, D-71076 Tubingen, Germany.
   Univ Tubingen, Ctr Ophthalmol, D-71076 Tubingen, Germany.
   Tokyo Med Ctr, Natl Hosp Org, Natl Inst Sensory Organs, Lab Visual Physiol, Tokyo, Japan.
   Univ Tubingen, Dept Pathol, Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Eberhard Karls University
   of Tubingen; Eberhard Karls University Hospital
RP Grisanti, S (通讯作者)，Univ Tubingen, Eye Clin, Schleicherstr 12-15, D-71076 Tubingen, Germany.
EM salvatore.grisanti@med.uni-tuebingen.de
RI Shinoda, Kei/ABC-7993-2020
OI Shinoda, Kei/0000-0002-1543-9345
CR Abdollahi A, 2003, CANCER RES, V63, P8890
   Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721
   Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411
   Dixelius J, 2002, CANCER RES, V62, P1944
   Ergun S, 2001, ANGIOGENESIS, V4, P193, DOI DOI 10.1023/A:1014027218980
   Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6
   Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3
   Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x
   Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535
   Green W., 1996, OPHTHALMIC PATHOLOGY, P982
   Grisanti S, 2004, EXP EYE RES, V78, P207, DOI 10.1016/j.exer.2003.11.008
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Kim YM, 2000, CANCER RES, V60, P5410
   Kivela T, 1995, BRIT J BIOMED SCI, V52, P325
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   LANZER RC, 1987, NATURE, V325, P253
   Lee SJ, 2002, FEBS LETT, V519, P147, DOI 10.1016/S0014-5793(02)02742-4
   Luo JY, 1998, BIOCHEM BIOPH RES CO, V245, P906, DOI 10.1006/bbrc.1998.8529
   Luo JY, 1999, BLOOD, V93, P3785, DOI 10.1182/blood.V93.11.3785.411a44_3785_3791
   Lutty G, 1999, MOL VIS, V5
   Makitie T, 1998, GRAEF ARCH CLIN EXP, V236, P415, DOI 10.1007/s004170050099
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Noma H, 2002, ARCH OPHTHALMOL-CHIC, V120, P1075
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249
   Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Skovseth DK, 2005, BLOOD, V105, P1044, DOI 10.1182/blood-2004-03-1164
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wang YD, 2004, EUR PHYS J B, V40, P321, DOI 10.1140/epjb/e2004-00280-0
   Wang YS, 2005, CURR EYE RES, V30, P479, DOI 10.1080/02713680590959358
   Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Yu Y, 2004, P NATL ACAD SCI USA, V101, P8005, DOI 10.1073/pnas.0402551101
   Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97
NR 45
TC 15
Z9 16
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2006
VL 83
IS 2
BP 329
EP 338
DI 10.1016/j.exer.2005.12.017
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 061ND
UT WOS:000238878400012
PM 16584730
DA 2022-11-30
ER

PT J
AU Suzuki, M
   Nagai, N
   Izumi-Nagai, K
   Shinoda, H
   Koto, T
   Uchida, A
   Mochimaru, H
   Yuki, K
   Sasaki, M
   Tsubota, K
   Ozawa, Y
AF Suzuki, Misa
   Nagai, Norihiro
   Izumi-Nagai, Kanako
   Shinoda, Hajime
   Koto, Takashi
   Uchida, Atsuro
   Mochimaru, Hiroshi
   Yuki, Kenya
   Sasaki, Mariko
   Tsubota, Kazuo
   Ozawa, Yoko
TI Predictive factors for non-response to intravitreal ranibizumab
   treatment in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; ENDOTHELIAL GROWTH-FACTOR;
   PHOTODYNAMIC THERAPY; BEVACIZUMAB; VERTEPORFIN
AB Background/aims To study the initial characteristics and response to intravitreal ranibizumab (IVR) treatment of age-related macular degeneration (AMD).
   Methods We reviewed the clinical records of 141 eyes in 141 AMD patients who received monthly IVR for 3 months and thereafter pro re nata (PRN) injections for 9 months as the first treatment for AMD. Patients whose best corrected visual acuity (BCVA) worsened at month 12, and those with increased exudative fundus findings after IVR or an increased central retinal thickness of more than 100 m at month 12, were considered to be non-responders as judged by BCVA and fundus findings, respectively. Non-responders' initial characteristics were analysed using logistic regression models.
   Results 14.9% of eyes were non-responders as judged by BCVA, and 17.0% were non-responders as judged by fundus findings. Initial fibrovascular pigment epithelial detachment (PED) (OR 22.9, 95% CI 2.61 to 201) and serous PED (OR 4.12, 95% CI 1.08 to 15.8) were associated with non-response as judged by BCVA. Initial fibrovascular PED (OR 33.5, 95% CI 2.95 to 381) and type 1 choroidal neovascularization (OR 6.46, 95% CI 1.39 to 30.0) were associated with non-response, as judged by fundus findings.
   Conclusions Although most AMD responded to IVR, non-responders had initial clinical characteristics that might be informative for managing their treatment.
C1 [Suzuki, Misa; Nagai, Norihiro; Izumi-Nagai, Kanako; Shinoda, Hajime; Koto, Takashi; Uchida, Atsuro; Mochimaru, Hiroshi; Yuki, Kenya; Sasaki, Mariko; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo 1608582, Japan.
C3 Keio University
RP Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Lab Retinal Cell Biol, Dept Ophthalmol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Ozawa, Yoko/AAH-9888-2020; Uchida, Atsuro/GVT-8593-2022
OI Uchida, Atsuro/0000-0002-1378-7151
FU Grants-in-Aid for Scientific Research [23592588] Funding Source: KAKEN
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Gharbiya M, 2009, RETINA-J RET VIT DIS, V29, P740, DOI 10.1097/IAE.0b013e3181a0be1d
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   MARMOR MF, 1990, EYE, V4, P340, DOI 10.1038/eye.1990.46
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2012, AM J OPHTHALMOL, V153, P504, DOI 10.1016/j.ajo.2011.08.038
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 17
TC 59
Z9 61
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2014
VL 98
IS 9
BP 1186
EP 1191
DI 10.1136/bjophthalmol-2013-304670
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN3QW
UT WOS:000340504400007
PM 24711658
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Furino, C
   Boscia, F
   Recchimurzo, N
   Besozzi, G
   Cardascia, N
   Sborgia, L
   Niro, A
   Sborgia, C
AF Furino, Claudio
   Boscia, Francesco
   Recchimurzo, Nicola
   Besozzi, Gianluca
   Cardascia, Nicola
   Sborgia, Luigi
   Niro, Alfredo
   Sborgia, Carlo
TI Intravitreal bevacizumab for treatment-naive subfoveal occult choroidal
   neovascularization in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; bevacizumab; occult
   choroidal neovascularization
ID PIGMENT EPITHELIAL TEAR; AVASTIN TREATMENT; INJECTION; THERAPY
AB This study aimed to evaluate the efficacy of multiple injections of intravitreal bevacizumab for treatment-naive subfoveal occult choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
   Twelve eyes of 12 patients (mean age 76 +/- 6 years) with mean best corrected visual acuity (BCVA) of 20/100 and occult subfoveal CNV at fluorescein angiography (FA), indocyanine-green (ICG) angiography and optical coherence tomography (OCT), showing intra- or subretinal fluid with or without retinal pigment epithelial detachment (PED), underwent multiple intravitreal injections (mean 2.4 +/- 0.7) of 1.25 mg (0.05 ml) bevacizumab. Visual acuity and OCT findings were assessed at the end of follow-up.
   After a mean follow-up of 5.7 +/- 2 months, BCVA improved from 20/100 (range 20/50-20/303) to 20/60 (range 20/28-20/200) (p = 0.038). Five eyes (42%) increased BCVA by >= 3 lines, six eyes (50%) increased BCVA by < 3 lines and one eye (8%) remained stable. Macular thickness decreased from 298 +/- 71 mu m to 223 +/- 72 mu m (p = 0.017). No ocular or systemic side-effects were observed.
   Short-term results suggest that multiple intravitreal injections of 1.25 mg bevacizumab are well tolerated and associated with significant improvements in BCVA and decreased retinal thickness by OCT in most patients with treatment-naive occult CNV. Further evaluation of intravitreal bevacizumab for the treatment of occult CNV is warranted.
C1 [Furino, Claudio; Boscia, Francesco; Recchimurzo, Nicola; Besozzi, Gianluca; Cardascia, Nicola; Sborgia, Luigi; Niro, Alfredo; Sborgia, Carlo] Univ Bari, Dept Ophthalmol & Otorhinolaryngol, I-70124 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro
RP Furino, C (通讯作者)，Univ Bari, Dept Ophthalmol & Otorhinolaryngol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.
EM caf.furino@libero.it
RI Niro, Alfredo/S-2609-2019; Cardascia, Nicola/AAC-3306-2019; Boscia,
   Francesco/AAC-7729-2022
OI Niro, Alfredo/0000-0002-7951-3591; Boscia,
   Francesco/0000-0002-5478-060X; Sborgia, Luigi/0000-0003-4433-9527
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kernt M, 2007, ACTA OPHTHALMOL SCAN, V85, P119, DOI 10.1111/j.1600-0420.2006.00819.x
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosiak Jean, 2005, Clin J Oncol Nurs, V9, P407
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stefansson E, 2006, ACTA OPHTHALMOL SCAN, V84, P449, DOI 10.1111/j.1600-0420.2006.00725.x
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 20
TC 21
Z9 21
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2009
VL 87
IS 4
BP 404
EP 407
DI 10.1111/j.1755-3768.2008.01262.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 450SI
UT WOS:000266420700008
PM 18782335
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhang, Q
   Zhang, FB
   Guo, YC
   Liu, YY
   Pan, NX
   Chen, H
   Huang, J
   Yu, BF
   Sang, AM
AF Zhang, Qi
   Zhang, Fengbin
   Guo, Yangchen
   Liu, Yanyan
   Pan, Ningxin
   Chen, Hong
   Huang, Ju
   Yu, Bifan
   Sang, Aimin
TI Regulator of G-protein signaling 1 promotes choroidal neovascularization
   in age-related macular degeneration
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Regulator of G-protein signaling; age-related macular degeneration
   (AMD); vascular endothelial growth factor (VEGF); proliferation;
   choroidal neovascularization (CNV)
ID DATABASE; INJURY; CELLS; RGS1
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness, and is associated with oxidative stress and the development of new blood vessels. At present, the main clinical treatment for AMD includes intraocular injection of vascular endothelial growth factor (VEGF). However, treatment includes repeated injections with significant side-effects. Therefore, new treatment options are required. The aim of the present study was to discover the new treatment target of AMD from the gene level.
   Methods: The Gene Expression Omnibus (GEO) database was used to analyze the differential gene expression in AMD, and the regulator of G-protein signaling 1 (RGS1) was obtained by bioassay. Western blotting and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to detect the expression levels of RGS1, VEGF, and other related molecules in human microvascular endothelial cells (HMECs) under different conditions. Cell viability, apoptosis, and proliferation of HMECs were measured by Cell Counting Kit-8 proliferation assay. Immunofluorescence and immunohistochemistry detected the interaction between RGS1, platelet endothelial cell adhesion molecule-1, and VEGF.
   Results: RGS1 was found to closely associated with the proliferation of vascular endothelial cells, and therefore, with angiogenesis. The expression of RGS1, VEGF, and platelet endothelial cell adhesion molecule-1 was upregulated in laser model mice and hypoxia model HMECs. Knockout of RGS1 inhibits the expression of VEGF and HMEC proliferation, thereby inhibiting AMD angiogenesis.
   Conclusions: Our results support the use of RGS1 as a new potential target for the future treatment of AMD.
C1 [Zhang, Qi; Zhang, Fengbin; Liu, Yanyan; Chen, Hong; Huang, Ju; Yu, Bifan] Dalian Med Univ, Grad Sch, Dalian, Peoples R China.
   [Zhang, Qi; Liu, Yanyan; Chen, Hong; Huang, Ju; Yu, Bifan; Sang, Aimin] Nantong Univ, Dept Ophthalmol, Affiliated Hosp, 20 Xisi Rd, Nantong 226006, Peoples R China.
   [Guo, Yangchen; Pan, Ningxin] Nantong Univ, Dept Ophthalmol, Sch Med, Nantong, Peoples R China.
C3 Dalian Medical University; Nantong University; Nantong University
RP Sang, AM (通讯作者)，Nantong Univ, Dept Ophthalmol, Affiliated Hosp, 20 Xisi Rd, Nantong 226006, Peoples R China.
EM sangam@ntu.edu.cn
RI liu, yan/HCI-5542-2022
FU Nantong Ractigen Therapeutics [133720631294]; Nantong Municipal Bureau
   of Science and Technology [MS12020031]
FX This study was funded by Nantong Ractigen Therapeutics (grant No.
   133720631294) and Nantong Municipal Bureau of Science and Technology
   (grant No. MS12020031), led by Professor Aimin Sang of Affiliated
   Hospital of Nantong University.
CR Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Chaudhry MA, 2008, J BIOMED BIOTECHNOL, DOI 10.1155/2008/541678
   Chen SL, 2019, PEERJ, V7, DOI 10.7717/peerj.7873
   Cho H, 2003, FASEB J, V17, P440, DOI 10.1096/fj.02-0340fje
   Desideri LF, 2022, EXPERT OPIN THER TAR, V26, P145, DOI 10.1080/14728222.2022.2036121
   Do JY, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.12.24
   Feng YF, 2021, ANGIOGENESIS, V24, P489, DOI 10.1007/s10456-020-09760-8
   Ghosh S, 2020, CELL MOL LIFE SCI, V77, P835, DOI 10.1007/s00018-019-03423-8
   Gupta U, 2022, AUTOPHAGY, DOI 10.1080/15548627.2022.2062887
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hu XM, 2019, J CELL PHYSIOL, V234, P20432, DOI 10.1002/jcp.28645
   Hu YX, 2021, GENOMICS, V113, P2134, DOI 10.1016/j.ygeno.2021.04.012
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Li L, 2020, J CELL PHYSIOL, V235, P1259, DOI 10.1002/jcp.29041
   Masuho I, 2020, CELL, V183, P503, DOI 10.1016/j.cell.2020.08.052
   Morris JH, 2014, NAT PROTOC, V9, P2539, DOI 10.1038/nprot.2014.164
   Nashine S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092483
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Nicolo M, 2020, OPHTHALMOLOGICA, V243, P453, DOI 10.1159/000507711
   Pak HK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124793
   Peluzzo AM, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11030587
   Rangel J, 2008, AM J SURG PATHOL, V32, P1207, DOI 10.1097/PAS.0b013e31816fd53c
   Ranjpour M, 2021, PROTOPLASMA, V258, P1133, DOI 10.1007/s00709-021-01632-2
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Sun J, 2018, THERANOSTICS, V8, P4695, DOI 10.7150/thno.26203
   Sun MY, 2018, ONCOL REP, V39, P2673, DOI 10.3892/or.2018.6341
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tanaka K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87340-6
   Tian Y, 2021, NAT BIOMED ENG, V5, P968, DOI 10.1038/s41551-021-00764-3
   Wang S, 2021, BIOENGINEERED, V12, P7079, DOI 10.1080/21655979.2021.1976503
   Wen XW, 2022, BIOENGINEERED, V13, P11767, DOI 10.1080/21655979.2022.2071023
   Wenkstern AR, 2021, KLIN MONATSBL AUGENH, V238, P396, DOI 10.1055/a-1403-3224
   Wu GT, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.146
   Xie ZH, 2016, AAPS J, V18, P294, DOI 10.1208/s12248-015-9847-0
   Yamamoto T, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.22
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Zhang L, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-4949
   Zhang XZ, 2020, J CANCER, V11, P3124, DOI 10.7150/jca.38057
   Zhao NM, 2021, BIOENGINEERED, V12, P10187, DOI 10.1080/21655979.2021.2001217
NR 41
TC 0
Z9 0
U1 0
U2 0
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD SEP
PY 2022
VL 10
IS 18
AR 982
DI 10.21037/atm-22-3992
EA AUG 2022
PG 17
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 6G2OU
UT WOS:000858585600001
PM 36267780
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Thiele, S
   Pfau, M
   Larsen, PP
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Thiele, Sarah
   Pfau, Maximilian
   Larsen, Petra P.
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Multimodal Imaging Patterns for Development of Central Atrophy Secondary
   to Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE conversion; multimodal imaging; biomarker; geographic atrophy; image
   analysis
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC-ATROPHY; RETICULAR
   PSEUDODRUSEN; 7-YEAR OUTCOMES; EYE DISEASE; PROGRESSION; DRUSEN; RISK;
   PREVALENCE; FEATURES
AB PURPOSE. To evaluate the development of central atrophy in eyes with age-related macular degeneration (AMD). METHODS. Six-year longitudinal multimodal retinal imaging data (MODIAMD study) from 98 eyes of 98 subjects with non-late-stage AMD in the study eye at baseline were analyzed for the presence of central atrophy at each annual follow-up visit. Development, manifestation, and further progression of complete retinal pigment epithelium and outer retinal atrophy (cRORA) by multimodal imaging data were compared with atrophy detection based on color fundus photography only. RESULTS. Seventeen study eyes with development of central cRORA within 6 years (cumulative rate: 17.4%) were identified based on multimodal imaging. In 10 (60%) of these eyes, presence of central manifest atrophy was initially not detectable by color fundus photography. In six (35%) eyes, central cRORA occurred by the spread of existing paracentral atrophy toward the fovea. Drusen-associated atrophy development was noted in eight eyes. In two eyes, atrophy development was associated with refractile deposits, while only pigmentary changes in absence of large drusen or refractile deposits were detectable before atrophy occurrence in one eye. CONCLUSIONS. The earlier and more precise detection of central cRORA by multimodal imaging as compared to atrophy detection solely based on color fundus photography allows for more accurate detection and identification of different pathways for atrophy development. In accordance with previous clinical and histopathologic reports, the results confirm that different precursor lesions may independently proceed to central cRORA in AMD.
C1 [Thiele, Sarah; Pfau, Maximilian; Larsen, Petra P.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
C3 University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukbonn.de
RI Larsen, Petra/AAV-3114-2020; Pfau, Maximilian/N-1888-2019
OI Larsen, Petra/0000-0003-2486-632X; Pfau, Maximilian/0000-0001-9761-9640
FU Federal Ministry of Education and Research of Germany (BMBF) [FKZ
   13N10285]; BONFOR GEROK Program, Faculty of Medicine, University of Bonn
   [O-137.0026, O-137.0022, O-137.0025]
FX Supported by Federal Ministry of Education and Research of Germany
   (BMBF), Scholarship FKZ 13N10285, BONFOR GEROK Program, Faculty of
   Medicine, University of Bonn, Grant No. O-137.0026 (ST), and BONFOR
   GEROK Program, Faculty of Medicine, University of Bonn, Grant No.
   O-137.0022 and Grant No. O-137.0025 (MP).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio C, 2017, INVEST OPHTH VIS SCI, V58
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mones J, 2017, OPHTHALMOL RETINA, V1, P461, DOI 10.1016/j.oret.2017.02.006
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schaal KB, 2017, AM J OPHTHALMOL, V174, P145, DOI 10.1016/j.ajo.2016.11.002
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2017, OPHTHALMOLOGICA, V237, P11, DOI 10.1159/000455074
   Schmitz-Valckenberg S, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.3
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2016, RETINA-J RET VIT DIS, V36, P1548, DOI 10.1097/IAE.0000000000000951
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
NR 51
TC 14
Z9 14
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
AR 59
DI 10.1167/iovs.17-23315
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB4CK
UT WOS:000429007900001
PM 29558532
OA gold
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Bremond-Gignac, D
   Quentel, G
   Mimoun, G
   Citterio, T
   Bisot-Locard, S
   Beresniak, A
AF Cohen, S. Y.
   Bremond-Gignac, D.
   Quentel, G.
   Mimoun, G.
   Citterio, T.
   Bisot-Locard, S.
   Beresniak, A.
TI Cost-effectiveness sequential modeling of ranibizumab versus usual care
   in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; cost-effectiveness; ranibizumab;
   modelling
ID PHOTODYNAMIC THERAPY; PEGAPTANIB
AB Aims To assess effectiveness, cost, and cost-effectiveness of ranibizumab versus the current medical practices of treating age-related macular degeneration in France.
   Methods A simulation decision framework over 1 year compared ranibizumab versus the usual care using two effectiveness criteria: the "visual acuity improvement rate" (greater than 15 letters on the ETDRS scale) and the "rate of legal blindness avoided". Two decision trees included various sequences of current treatments, with or without ranibizumab.
   Results Ranibizumab appeared significantly more effective than the usual care (p < 0.001), providing greater treatment success rate of visual acuity improvement (48.8% versus 33.9%). The cost of the ranibizumab strategy was higher (9,123 euros ((sic)) over 1 year for ranibizumab versus 7,604 (sic) for the usual care) but the average cost-effectiveness was lower - 18,721 (sic) /success for ranibizumab versus 22,543 (sic)/success for usual care (p < 0.001). Considering the "legal blindness avoided" success criterion, the ranibizumab strategy appeared significantly more effective (p < 0.001), providing greater treatment success rate for of legal blindness avoided than usual care (99.7% versus 93.1%) although it was more expensive (9,196 (sic) over 1 year for ranibizumab versus 5,713 (sic) for the usual care).
   Conclusion Ranibizumab significantly improved the rate of visual acuity improvement and reduced the rate of legal blindness. Ranibizumab appeared significantly more cost-effective than the usual treatments in terms of visual acuity improvement.
C1 [Bremond-Gignac, D.] Hop Robert Debre, AP HP, Dept Ophthalmol, Paris, France.
   [Bremond-Gignac, D.] Univ Paris 07, INSERM UMRS592, Paris, France.
   [Mimoun, G.] Hop Intercommunal Creteil, AP HP, Dept Ophthalmol, Creteil, France.
   [Citterio, T.; Bisot-Locard, S.] Novartis Grp France SA, Rueil Malmaison, France.
   [Beresniak, A.] Univ Paris 05, LIRAES, Paris, France.
   [Beresniak, A.] Data Mining Int, Geneva, Switzerland.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Robert-Debre - APHP; UDICE-French Research Universities; Universite
   Paris Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil; Novartis; UDICE-French Research
   Universities; Universite Paris Cite
RP Bremond-Gignac, D (通讯作者)，Hop Robert Debre, AP HP, Dept Ophthalmol, Paris, France.
EM dominique.bremond@rdb.aphp.fr
OI BREMOND-GIGNAC, Dominique/0000-0002-3563-5482
FU Creative Commons Attribution Noncommercial License
FX This article is distributed under the terms of the Creative Commons
   Attribution Noncommercial License which permits any noncommercial use,
   distribution, and reproduction in any medium, provided the original
   author(s) and source are credited.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMICO DJ, 2006, OPHTHALMOLOGY, V113, P992
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bremond-Gignac D, 2002, PRESSE MED, V31, P1607
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown GC, 2007, CURR OPIN OPHTHALMOL, V18, P206, DOI 10.1097/ICU.0b013e328129089e
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Chaine G, 2007, J FR OPHTALMOL, V30, pS5
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Duru G, 2002, PHARMACOECONOMICS, V20, P463, DOI 10.2165/00019053-200220070-00004
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   KAISER PK, 2007, OPHTHALMOLOGY, V11
   Kegan B, 2005, MATH BIOSCI, V195, P179, DOI 10.1016/j.mbs.2005.02.004
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   McGregor M, 2006, PHARMACOECONOMICS, V24, P947, DOI 10.2165/00019053-200624100-00002
   PINA JP, 2007, MEDECINE, V3, P443
   Polsky D, 1997, HEALTH ECON, V6, P243, DOI 10.1002/(SICI)1099-1050(199705)6:3<243::AID-HEC269>3.0.CO;2-Z
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rajczi A, 2007, BIOETHICS, V21, P316, DOI 10.1111/j.1467-8519.2007.00559.x
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Schmidt-Erfurth U, 1998, OPHTHALMOLOGE, V95, P725, DOI 10.1007/s003470050343
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Weinstein MC, 2006, PHARMACOECONOMICS, V24, P1043, DOI 10.2165/00019053-200624110-00002
NR 28
TC 17
Z9 18
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2008
VL 246
IS 11
BP 1527
EP 1534
DI 10.1007/s00417-008-0890-8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 358RW
UT WOS:000259936200003
PM 18642019
OA hybrid
DA 2022-11-30
ER

PT J
AU Kashi, AK
   Souied, E
   Fares, S
   Borrelli, E
   Capuano, V
   Jung, C
   Querques, G
   Mouallem, A
   Miere, A
AF Kashi, Alexis Khorrami
   Souied, Eric
   Fares, Selim
   Borrelli, Enrico
   Capuano, Vittorio
   Jung, Camille
   Querques, Giuseppe
   Mouallem, Alexandra
   Miere, Alexandra
TI The Spectrum of Central Choriocapillaris Abnormalities on Swept-Source
   Optical Coherence Tomography Angiography in the Fellow Eye of Unilateral
   Exudative Age-Related Macular Degeneration Patients: From Flow Deficits
   to Subclinical Non-Exudative Neovascularization
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE AMD; oct-angiography; fellow eye; choriocapillaris; quiescent macular
   neovascularization
ID AMD
AB We evaluated the spectrum of choriocapillaris (CC) abnormalities in the fellow eyes of unilateral exudative age-related macular degeneration (AMD) patients using swept-source optical coherence tomography angiography (SS-OCTA). Fellow eyes of unilateral exudative AMD patients were prospectively included between May 2018 and October 2018. Patients underwent a multimodal imaging including a SS-OCTA. Demographics and clinical findings were analyzed. The estimated prevalence of macular neovascularization (MNV) was computed. Number and size of flow deficits (FDs) and percentage of flow deficits (FD%) were computed on the compensated CC flow images with the Fiji software. We included 97 eyes of 97 patients (mean age was 80 +/- 7.66 years, 39 males, 58 females). The prevalence of MNV in the studied eyes was 8.25% (8/97 eyes). In the 89 non-neovascular eyes, FD% averaged 45.84% +/- 11.63%, with a corresponding total area of FDs of 4.19 +/- 1.12 mm(2). There was a higher prevalence of drusenoid pigment epithelial detachment in eyes with subclinical neovascularization (p = 0.021). Fellow eyes with unilateral exudative AMD encompassed a series of CC abnormalities, from FDs of the aging CC to subclinical non-exudative MNV.
C1 [Kashi, Alexis Khorrami; Souied, Eric; Fares, Selim; Capuano, Vittorio; Querques, Giuseppe; Mouallem, Alexandra; Miere, Alexandra] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Souied, Eric; Jung, Camille] Ctr Hosp Intercommunal Creteil, Clin Res Ctr, GRC Macula, F-94000 Creteil, France.
   [Souied, Eric; Jung, Camille] Ctr Hosp Intercommunal Creteil, Biol Ressources Ctr, F-94000 Creteil, France.
   [Borrelli, Enrico; Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Miere, A (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
EM alexis.khorrami@gmail.com; eric.souied@chicreteil.fr;
   selimfares8@gmail.com; borrelli.enrico@yahoo.com;
   vittorio.capuano@gmail.com; camille.jung@chicreteil.fr;
   giuseppe.querques@hotmail.it; alexandra.mouallem@gmail.com;
   alexandramiere@gmail.com
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; JUNG, Camille/0000-0001-8486-8939;
   KHORRAMI KASHI, Alexis/0000-0001-7286-5984; Querques,
   Giuseppe/0000-0002-3292-9581
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sacconi R, 2019, BRIT J OPHTHALMOL, V103, P1320, DOI 10.1136/bjophthalmol-2018-313004
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 29
TC 2
Z9 2
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2021
VL 10
IS 12
AR 2658
DI 10.3390/jcm10122658
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SZ3BI
UT WOS:000666444600001
PM 34208728
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Boyer, D
   Brown, DM
   Chaudhry, N
   Elman, M
   Liang, C
   O'Shaughnessy, D
   Parsons, EC
   Patel, S
   Slakter, JS
   Rosenfeld, PJ
AF Jackson, Timothy L.
   Boyer, David
   Brown, David M.
   Chaudhry, Nauman
   Elman, Michael
   Liang, Chris
   O'Shaughnessy, Denis
   Parsons, Edward C.
   Patel, Sunil
   Slakter, Jason S.
   Rosenfeld, Philip J.
TI Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular
   Degeneration A Phase 1 Dose-Escalation Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID PREVALENCE
AB IMPORTANCE An oral treatment for neovascular age-related macular degeneration would be less burdensome than repeated intravitreous injections. X-82 is an oral tyrosine kinase inhibitor active against vascular endothelial growth factor (VEGF) and platelet-derived growth factor.
   OBJECTIVE To undertake safety testing of oral X-82 administered for the treatment of neovascular AMD.
   DESIGN, SETTING, AND PARTICIPANTS Phase 1, open-label, uncontrolled, dose-escalation study at 5 US retinal clinics between November 2012 and March 2015 (Retina-Vitreous Associates Medical Group, Beverly Hills, California; Blanton Eye Institute, Houston Methodist Hospital, Retina Consultants of Houston, Houston, Texas; New England Retina Associates, Guilford, Connecticut; Elman Retina Group, Baltimore, Maryland; and Retina Research Institute of Texas, Abilene). Thirty-five participants with neovascular age-related macular degeneration, 7 of whom were treatment naive.
   INTERVENTIONS Participants received oral X-82 for 24 weeks at 50 mg alternate days (n = 3), 50 mg daily (n = 8), 100 mg alternate days (n = 4), 100 mg daily (n = 10), 200 mg daily (n = 7), and 300 mg daily (n = 3), with intravitreous anti-VEGF therapy using predefined retreatment criteria. Every 4 weeks, participants underwent best-corrected visual acuity measurement, fundus examination, and spectral-domain optical coherence tomography.
   MAIN OUTCOMES AND MEASURES The main outcome was adverse events. Other outcomes included visual acuity, central subfield retinal thickness, and number of anti-VEGF injections.
   RESULTS Of the 35 participants, the mean age was 76.8 years, 16 were men and 19 were women, and 33 were white and 2 were nonwhite. Of 25 participants (71%) who completed the 24 weeks of X-82 treatment, all except 1 maintained or improved their visual acuity (mean [SD], +3.8 [9.6] letters). Fifteen participants (60%) required no anti-VEGF injections (mean, 0.68). Mean [SD] central subfield thickness reduced by -50 [97] mu m, with 8 participants (all receiving at least 100 mg daily) demonstrating sustained reductions despite no anti-VEGF injections. The most common adverse events attributed to X-82 were diarrhea (n = 6), nausea (n = 5), fatigue (n = 5), and transaminase elevation (n = 4). A dose relationship to the transaminase elevations was not identified; all normalized when X-82 was discontinued. All but 1 were asymptomatic. Ten participants withdrew consent or discontinued prematurely, 6 owing to adverse events attributed to X-82 including leg cramps (n = 2), elevated alanine aminotransferase (n = 2), diarrhea (n = 1), and nausea/anorexia (n = 1).
   CONCLUSIONS AND RELEVANCE X-82 can be associated with reversible, elevated liver enzymes; hence, liver function testing is needed to identify those unsuited to treatment. Although 17% of participants discontinued X-82 owing to AEs, those who completed the study had lower than expected anti-VEGF injection rates. Further studies appear justified, with a phase 2 randomized clinical study under way.
C1 [Jackson, Timothy L.] Kings Coll London, Sch Med, London, England.
   [Boyer, David] Retina Vitreous Assoc Med Grp, Beverly Hills, CA USA.
   [Brown, David M.] Houston Methodist Hosp, Blanton Eye Inst, Retina Consultants Houston, Houston, TX USA.
   [Chaudhry, Nauman] New England Retina Assoc, Guilford, CT USA.
   [Elman, Michael] Elman Retina Grp, Baltimore, MD USA.
   [Liang, Chris; O'Shaughnessy, Denis; Parsons, Edward C.] Tyrogenex Inc, Rockville, MD USA.
   [Patel, Sunil] Retina Res Inst Texas, Abilene, TX USA.
   [Slakter, Jason S.] Digital Angiog Reading Ctr, New York, NY USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 University of London; King's College London; Retina Vitreous Associates
   Medical Group; The Methodist Hospital System; The Methodist Hospital -
   Houston; Bascom Palmer Eye Institute; University of Miami
RP Jackson, TL (通讯作者)，Kings Coll London, Dept Ophthalmol, Sch Med, Kings Coll Hosp, London SE5 9RS, England.
EM t.jackson1@nhs.net
OI Jackson, Timothy/0000-0001-7618-1555; Elman, Michael/0000-0001-7726-9508
FU Tyrogenex Inc, Rockville, Maryland
FX Funded by Tyrogenex Inc, Rockville, Maryland.
CR Alliance JL., 2013, SETTING PRIORITIES E
   Brown EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018-199920020-00002
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cicenas J, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0758-4
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Detry B, 2013, INVEST OPHTH VIS SCI, V54, P3082, DOI 10.1167/iovs.12-10856
   European Medicines Agency, 2009, SUT SUMM PROD CHAR
   Huang D., 2009, INVEST OPHTHALMOL VI, V50, P2966
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Liang C, 2013, ANN M ASS RES VIS OP
   McLaughlin MM, 2013, JAMA OPHTHALMOL, V131, P1595, DOI 10.1001/jamaophthalmol.2013.5002
   Moore KN, 2012, ANN M AM SOC CLIN ON
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Perez-Santonja JJ, 2010, AM J OPHTHALMOL, V150, P519, DOI 10.1016/j.ajo.2010.04.024
   Pfizer, 2016, SUT FULL PRESCR INF
NR 15
TC 21
Z9 26
U1 1
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2017
VL 135
IS 7
BP 761
EP 767
DI 10.1001/jamaophthalmol.2017.1571
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA6CU
UT WOS:000405531700019
PM 28570723
OA Green Published
DA 2022-11-30
ER

PT J
AU Koh, A
   Lai, TYY
   Wei, WB
   Mori, R
   Wakiyama, H
   Park, KH
   Ngah, F
   Macfadden, W
   Dunger-Baldauf, C
   Parikh, S
AF Koh, Adrian
   Lai, Timothy Y. Y.
   Wei, Wen Bin
   Mori, Ryusaburo
   Wakiyama, Harumi
   Park, Kyu Hyung
   Ngah, Fariza
   Macfadden, Wayne
   Dunger-Baldauf, Cornelia
   Parikh, Soumil
CA Luminous Study Steering Comm
TI REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS
   WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY Twelve-Month Results
   From the LUMINOUS Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE visual acuity; central retinal thickness; effectiveness; LUMINOUS;
   neovascular age-related macular degeneration; polypoidal choroidal
   vasculopathy; ranibizumab; real-world outcomes; safety; vascular
   endothelial growth factor
ID VERTEPORFIN PHOTODYNAMIC THERAPY; ANTI-VEGF AGENTS; MACULAR
   DEGENERATION; VISUAL-ACUITY; INTRAVITREAL RANIBIZUMAB; OUTCOMES;
   NEOVASCULARIZATION; COMBINATION; DIAGNOSIS; EFFICACY
AB Purpose: To evaluate the real-world effectiveness and safety of intravitreal ranibizumab 0.5 mg in treatment-naive patients with and without polypoidal choroidal vasculopathy (PCV). Methods: Assessment of neovascular age-related macular degeneration patients with or without PCV after 12 months of ranibizumab treatment during the LUMINOUS study. Outcome measures were visual acuity and central retinal thickness changes from baseline and the rate of ocular adverse events. Results: At baseline, 572 and 5,644 patients were diagnosed with and without PCV, respectively. The mean visual acuity gain from baseline at Month 12 in the PCV and non-PCV groups was +5.0 and +3.0 letters, respectively; these gains were achieved with a mean of 4.4 and 5.1 ranibizumab injections. Eighty percent of PCV patients and 72.2% of non-PCV patients who had baseline visual acuity >= 73 letters maintained this level of vision at Month 12; 20.6% and 17.9% of patients with baseline visual acuity <73 letters achieved visual acuity >= 73 letters in these groups. Greater reductions in central retinal thickness from baseline were also observed for the PCV group versus the non-PCV group. The rate of serious ocular adverse events was 0.7% (PCV group) and 0.9% (non-PCV group). Conclusion: LUMINOUS confirms the effectiveness and safety of ranibizumab in treatment-naive patients with PCV.
C1 [Koh, Adrian] Camden Med Ctr, Singapore, Singapore.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Wei, Wen Bin] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
   [Mori, Ryusaburo] Nihon Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Wakiyama, Harumi] Japanese Red Cross Nagasaki Genbaku Hosp, Nagasaki, Japan.
   [Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Kyeonggi, South Korea.
   [Ngah, Fariza] Hosp Selayang, Dept Ophthalmol, Lebuhraya Selayang Kepong, Batu Caves, Selangor, Malaysia.
   [Macfadden, Wayne; Dunger-Baldauf, Cornelia; Parikh, Soumil] Novartis Pharma AG, Basel, Switzerland.
C3 Chinese University of Hong Kong; Capital Medical University; Nihon
   University; Seoul National University (SNU); Novartis
RP Koh, A (通讯作者)，13-03 Camden Med Ctr,1 Orchard Blvd, Singapore 248649, Singapore.
EM ahckoh@yahoo.com
RI Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428
FU Novartis Pharma AG [NCT01318941]
FX This study was funded and sponsored by Novartis Pharma AG and is
   registered with www.clinicaltrials.gov (NCT01318941). The sponsor
   participated in the study design, conducting the study, and data
   collection, management, analysis, and interpretation.
CR Alasil T, 2017, INT J RETIN VITR, V3, P9
   [Anonymous], 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   [Anonymous], 2016, PHARMACOEPIDEMIOL DR, V25, p2e10, DOI 10.1002/pds.3891.
   [Anonymous], 2016, EYE, DOI DOI 10.1038/EYE.2015.217
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Dixon J R Jr, 1998, Qual Assur, V6, P65
   Eldem B, 2018, GRAEF ARCH CLIN EXP, V256, P963, DOI 10.1007/s00417-017-3890-8
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Genentech Inc, 2017, LUC PRESCR INF
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Iida T, 2007, BRIT J OPHTHALMOL, V91, P1103, DOI 10.1136/bjo.2007.116160
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Li X, 2016, EMERGING MEDIA USES
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 38
TC 6
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2020
VL 40
IS 8
BP 1529
EP 1539
DI 10.1097/IAE.0000000000002624
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NA3ZC
UT WOS:000559752400021
PM 31385918
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Cerniauskas, E
   Kurzawa-Akanbi, M
   Xie, L
   Hallam, D
   Moya-Molina, M
   White, K
   Steer, D
   Doherty, M
   Whitfield, P
   Al-Aama, J
   Armstrong, L
   Kavanagh, D
   Lambris, JD
   Korolchuk, VI
   Harris, C
   Lako, M
AF Cerniauskas, Edvinas
   Kurzawa-Akanbi, Marzena
   Xie, Long
   Hallam, Dean
   Moya-Molina, Marina
   White, Kathryn
   Steer, David
   Doherty, Mary
   Whitfield, Phil
   Al-Aama, Jumana
   Armstrong, Lyle
   Kavanagh, David
   Lambris, John D.
   Korolchuk, Viktor, I
   Harris, Claire
   Lako, Majlinda
TI Complement modulation reverses pathology inY402H-retinal pigment
   epithelium cell model of age-related macular degeneration by restoring
   lysosomal function
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE autophagy; C3; C3b; C5b-9; complement activation; complement factor H;
   human induced pluripotent stem cells; lysosome; retinal pigment
   epithelium; Y402H polymorphism
ID DRUSEN FORMATION; AUTOPHAGY; ACTIVATION; RETINA; RPE; PATHOGENESIS;
   RANIBIZUMAB; PEGAPTANIB; LIPOFUSCIN; INHIBITOR
AB Age-related macular degeneration (AMD) is a multifactorial disease, which is characterized by loss of central vision, affecting one in three people by the age of 75. The Y402H polymorphism in the complement factor H (CFH) gene significantly increases the risk of AMD. We show that Y402H-AMD-patient-specific retinal pigment epithelium (RPE) cells are characterized by a significant reduction in the number of melanosomes, an increased number of swollen lysosome-like-vesicles with fragile membranes, Cathepsin D leakage into drusen-like deposits and reduced lysosomal function. The turnover of C3 is increased significantly in high-risk RPE cells, resulting in higher internalization and deposition of the Terminal Complement ComplexC5b-9at the lysosomes. Inhibition of C3 processing via the compstatin analogue Cp40 reverses the disease phenotypes by relieving the lysosomes of their overburden and restoring their function. These findings suggest that modulation of the complement system represents a useful therapeutic approach for AMD patients associated with complement dysregulation.
C1 [Cerniauskas, Edvinas; Kurzawa-Akanbi, Marzena; Hallam, Dean; Moya-Molina, Marina; White, Kathryn; Steer, David; Armstrong, Lyle; Korolchuk, Viktor, I; Lako, Majlinda] Newcastle Univ, Fac Med Sci, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Xie, Long; Kavanagh, David; Harris, Claire] Newcastle Univ, Fac Med Sci, Clin & Translat Res Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Doherty, Mary; Whitfield, Phil] Univ Highlands & Isl, Inverness, Scotland.
   [Al-Aama, Jumana] King Abdulaziz Univ, Fac Med, Dept Genet Med, Jeddah, Saudi Arabia.
   [Al-Aama, Jumana] King Abdulaziz Univ, Fac Med, Princess Al Jawhara Ctr Excellence Res Hereditary, Jeddah, Saudi Arabia.
   [Kavanagh, David; Harris, Claire] Royal Victoria Infirm, Natl Renal Complement Therapeut Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Lambris, John D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 Newcastle University - UK; Newcastle University - UK; UHI Millennium
   Institute; King Abdulaziz University; King Abdulaziz University;
   Newcastle University - UK; University of Pennsylvania
RP Lako, M (通讯作者)，Newcastle Univ, Int Ctr Life, Biosci Inst, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM majlinda.lako@ncl.ac.uk
RI Al-aama, Jumana/AAA-8653-2021; Kavanagh, David/E-8498-2011; Steel,
   David/I-8053-2015
OI Doherty, Mary/0000-0002-3480-4088; Kavanagh, David/0000-0003-4718-0072;
   Steel, David/0000-0001-8734-3089; Kurzawa-Akanbi,
   Marzena/0000-0002-2482-2741; Cerniauskas, Edvinas/0000-0001-5863-0986;
   Hallam, Dean/0000-0001-9165-3020; MOYA MOLINA,
   MARINA/0000-0002-4787-3015
FU Newcastle upon Tyne Hospitals NHS Charity [BH182022]; Newcastle
   University; BBSRC [BB/R013942/1]; Macular Society UK
FX Newcastle upon Tyne Hospitals NHS Charity, Grant/Award Number: BH182022;
   Newcastle University; BBSRC, Grant/Award Number: BB/R013942/1; Macular
   Society UK
CR Baek KH, 2012, CHEM SOC REV, V41, P3245, DOI 10.1039/c2cs15328a
   Berger N, 2018, J MED CHEM, V61, P6153, DOI 10.1021/acs.jmedchem.8b00560
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   El-Asrag ME, 2015, AM J HUM GENET, V96, P948, DOI 10.1016/j.ajhg.2015.04.006
   ELHIFNAWI E, 1994, ANN ANAT, V176, P505, DOI 10.1016/S0940-9602(11)80384-5
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gouras P, 2011, EXP EYE RES, V93, P937, DOI 10.1016/j.exer.2011.10.011
   Hess C, 2016, IMMUNITY, V45, P240, DOI 10.1016/j.immuni.2016.08.003
   Horikawa T, 2000, BRIT J DERMATOL, V143, P635, DOI 10.1046/j.1365-2133.2000.03725.x
   Hung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3111
   Jia JY, 2019, AUTOPHAGY, V15, P169, DOI 10.1080/15548627.2018.1505155
   Jia JY, 2018, MOL CELL, V70, P120, DOI 10.1016/j.molcel.2018.03.009
   Jin ML, 2002, INVEST OPHTH VIS SCI, V43, P2782
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   King BC, 2019, CELL METAB, V29, P202, DOI 10.1016/j.cmet.2018.09.009
   Lakkaraju A, 2012, ADV EXPT MED BIOL
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   Liu WP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42308
   MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x
   Manuscript A, 2006, ARCH OPHTHALMOL-CHIC, V121, P1621
   Mastellos DC, 2019, NAT REV DRUG DISCOV, V18, P707, DOI 10.1038/s41573-019-0031-6
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ophthalmology M, 1999, EXP EYE RES, V69, P367
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Puertollano Rosa, 2014, F1000Prime Rep, V6, P52, DOI 10.12703/P6-52
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258
   Reis ES, 2015, IMMUNOBIOLOGY, V220, P476, DOI 10.1016/j.imbio.2014.10.026
   REME CE, 1977, INVEST OPHTH VIS SCI, V16, P815
   Ricklin D, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.1239.1239
   Rogiska D, 2017, OXIDAT MED CELL LONG, V2017, P1
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Smith EN, 2019, STEM CELL REP, V12, P1342, DOI 10.1016/j.stemcr.2019.04.012
   Thurston TLM, 2012, NATURE, V482, P414, DOI 10.1038/nature10744
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang A.L., 2009, PLOS ONE, V4
   Wang AL, 2009, AUTOPHAGY, V5, P1190, DOI 10.4161/auto.5.8.10087
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
NR 60
TC 20
Z9 20
U1 2
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD DEC
PY 2020
VL 9
IS 12
BP 1585
EP 1603
DI 10.1002/sctm.20-0211
EA AUG 2020
PG 19
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OX5SG
UT WOS:000560745000001
PM 32815311
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chirco, KR
   Sohn, EH
   Stone, EM
   Tucker, BA
   Mullins, RF
AF Chirco, K. R.
   Sohn, E. H.
   Stone, E. M.
   Tucker, B. A.
   Mullins, R. F.
TI Structural and molecular changes in the aging choroid: implications for
   age-related macular degeneration
SO EYE
LA English
DT Review
ID C-REACTIVE PROTEIN; COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM;
   MEMBRANE ATTACK COMPLEX; BRUCHS MEMBRANE; HUMAN CHORIOCAPILLARIS;
   RETICULAR PSEUDODRUSEN; GEOGRAPHIC ATROPHY; ENDOTHELIAL-CELLS;
   HLA-ANTIGENS
AB Age-related macular degeneration (AMD) is a devastating disease-causing vision loss in millions of people around the world. In advanced stages of disease, death of photoreceptor cells, retinal pigment epithelial cells, and choroidal endothelial cells (CECs) are common. Loss of endothelial cells of the choriocapillaris is one of the earliest detectable events in AMD, and, because the outer retina relies on the choriocapillaris for metabolic support, this loss may be the trigger for progression to more advanced stages. Here we highlight evidence for loss of CECs, including changes to vascular density within the choriocapillaris, altered abundance of CEC markers, and changes to overall thickness of the choroid. Furthermore, we review the key components and functions of the choroid, as well as Bruch's membrane, both of which are vital for healthy vision. We discuss changes to the structure and molecular composition of these tissues, many of which develop with age and may contribute to AMD pathogenesis. For example, a crucial event that occurs in the aging choriocapillaris is accumulation of the membrane attack complex, which may result in complement-mediated CEC lysis, and may be a primary cause for AMD-associated choriocapillaris degeneration. The actions of elevated monomeric C-reactive protein in the choriocapillaris in at-risk individuals may also contribute to the inflammatory environment in the choroid and promote disease progression. Finally, we discuss the progress that has been made in the development of AMD therapies, with a focus on cell replacement.
C1 [Chirco, K. R.; Sohn, E. H.; Stone, E. M.; Tucker, B. A.; Mullins, R. F.] Univ Iowa, Stephen A Wynn Inst Vis Res, Iowa City, IA USA.
   [Chirco, K. R.; Sohn, E. H.; Stone, E. M.; Tucker, B. A.; Mullins, R. F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
C3 University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Stephen A Wynn Inst Vis Res, 4130 MERF,375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891; Tucker, Budd/0000-0003-2178-1742;
   Sohn, Elliott/0000-0002-3778-9362; Stone, Edwin M./0000-0003-3343-4414
FU NIH [EY024605, EY0026547]; Carver Chair in Ocular Cell Biology; Elmer
   and Sylvia Sramek Charitable Foundation; NATIONAL EYE INSTITUTE
   [R01EY024605, R01EY026547] Funding Source: NIH RePORTER
FX We thank the members of the Iowa Lions Eye Bank and the eye donors and
   their families who so generously support this research. This study was
   supported in part by NIH grants EY024605 and EY0026547, the Carver Chair
   in Ocular Cell Biology, and the Elmer and Sylvia Sramek Charitable
   Foundation.
CR ABIHANNA D, 1988, TRANSPLANTATION, V45, P610, DOI 10.1097/00007890-198803000-00021
   Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Arora KS, 2012, INVEST OPHTH VIS SCI, V53, P6393, DOI 10.1167/iovs.12-10224
   Baba T, 2009, INVEST OPHTH VIS SCI, V50, P3503, DOI 10.1167/iovs.08-2614
   BAKKER M, 1986, DOC OPHTHALMOL, V61, P271, DOI 10.1007/BF00142353
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BOK D, 1993, J CELL SCI, P189
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089548
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fukushima I, 1997, AM J OPHTHALMOL, V124, P473, DOI 10.1016/S0002-9394(14)70863-3
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Godfrey W A, 1987, Trans Am Ophthalmol Soc, V85, P557
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P2716, DOI 10.1073/pnas.88.7.2716
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasegawa T, 2007, DEV DYNAM, V236, P2089, DOI 10.1002/dvdy.21231
   Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jordan SC, 2016, CURR OPIN ORGAN TRAN, V21, P447, DOI 10.1097/MOT.0000000000000336
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim DY, 2013, ACTA OPHTHALMOL, V91, P183, DOI 10.1111/j.1755-3768.2011.02305.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kutoglu T, 2005, CLIN ANAT, V18, P269, DOI 10.1002/ca.20092
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Makou E, 2013, BIOCHEMISTRY-US, V52, P3949, DOI 10.1021/bi4003452
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   May CA, 1999, HISTOCHEM CELL BIOL, V112, P381, DOI 10.1007/s004180050420
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   NAKAIZUMI Y, 1964, ARCH OPHTHALMOL-CHIC, V72, P395, DOI 10.1001/archopht.1964.00970020395018
   Nazarov PG, 2012, LIFE SCI, V91, P1053, DOI 10.1016/j.lfs.2012.08.004
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nilsson B, 2012, IMMUNOBIOLOGY, V217, P1106, DOI 10.1016/j.imbio.2012.07.008
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pasceri V, 2000, CIRCULATION, V102, P2165
   Perkins SJ, 2010, BIOCHEM SOC T, V38, P894, DOI 10.1042/BST0380894
   Rhodes B, 2011, NAT REV RHEUMATOL, V7, P283, DOI 10.1038/nrrheum.2011.37
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rohrer B, 2010, ADV EXP MED BIOL, V703, P137, DOI 10.1007/978-1-4419-5635-4_10
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Scholfield CN, 2007, MICROCIRCULATION, V14, P11, DOI 10.1080/10739680601072115
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Songstad AE, 2015, INVEST OPHTH VIS SCI, V56, P8258, DOI 10.1167/iovs.15-17073
   Stein MP, 2000, J IMMUNOL, V164, P1514, DOI 10.4049/jimmunol.164.3.1514
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   WALLMAN J, 1995, VISION RES, V35, P37, DOI 10.1016/0042-6989(94)E0049-Q
   Wang JCC, 2015, MOL VIS, V21, P264
   Wang Q, 2016, INT J OPHTHALMOL-CHI, V9, P298, DOI 10.18240/ijo.2016.02.23
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2005, HUM MOL GENET, V14, P255, DOI 10.1093/hmg/ddi023
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
NR 111
TC 93
Z9 95
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2017
VL 31
IS 1
BP 10
EP 25
DI 10.1038/eye.2016.216
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EL1AU
UT WOS:000394353700002
PM 27716746
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Mendez, KM
   Kim, J
   Lains, I
   Nigalye, A
   Katz, R
   Pundik, S
   Kim, IK
   Liang, LM
   Vavvas, DG
   Miller, JB
   Miller, JW
   Lasky-Su, JA
   Husain, D
AF Mendez, Kevin M.
   Kim, Janice
   Lains, Ines
   Nigalye, Archana
   Katz, Raviv
   Pundik, Shrinivas
   Kim, Ivana K.
   Liang, Liming
   Vavvas, Demetrios G.
   Miller, John B.
   Miller, Joan W.
   Lasky-Su, Jessica A.
   Husain, Deeba
TI Association of Human Plasma Metabolomics with Delayed Dark Adaptation in
   Age-Related Macular Degeneration
SO METABOLITES
LA English
DT Article
DE age-related macular degeneration; dark adaptation; rod-intercept time;
   area under the dark adaption curve; metabolomics; mass spectrometry
ID FATTY-ACIDS; DISEASE
AB The purpose of this study was to analyze the association between plasma metabolite levels and dark adaptation (DA) in age-related macular degeneration (AMD). This was a cross-sectional study including patients with AMD (early, intermediate, and late) and control subjects older than 50 years without any vitreoretinal disease. Fasting blood samples were collected and used for metabolomic profiling with ultra-performance liquid chromatography-mass spectrometry (LC-MS). Patients were also tested with the AdaptDx (MacuLogix, Middletown, PA, USA) DA extended protocol (20 min). Two measures of dark adaptation were calculated and used: rod-intercept time (RIT) and area under the dark adaptation curve (AUDAC). Associations between dark adaption and metabolite levels were tested using multilevel mixed-effects linear modelling, adjusting for age, gender, body mass index (BMI), smoking, race, AMD stage, and Age-Related Eye Disease Study (AREDS) formulation supplementation. We included a total of 71 subjects: 53 with AMD (13 early AMD, 31 intermediate AMD, and 9 late AMD) and 18 controls. Our results revealed that fatty acid-related lipids and amino acids related to glutamate and leucine, isoleucine and valine metabolism were associated with RIT (p < 0.01). Similar results were found when AUDAC was used as the outcome. Fatty acid-related lipids and amino acids are associated with DA, thus suggesting that oxidative stress and mitochondrial dysfunction likely play a role in AMD and visual impairment in this condition.
C1 [Mendez, Kevin M.; Lains, Ines; Nigalye, Archana; Katz, Raviv; Kim, Ivana K.; Vavvas, Demetrios G.; Miller, John B.; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
   [Mendez, Kevin M.; Lasky-Su, Jessica A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02114 USA.
   [Mendez, Kevin M.; Kim, Janice; Lasky-Su, Jessica A.] Harvard Med Sch, Boston, MA 02114 USA.
   [Pundik, Shrinivas] Harvard Med Sch, Schepens Eye Res Inst, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Program Genet Epidemiol & Stat Genet, Boston, MA 02114 USA.
   [Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Brigham & Women's Hospital; Harvard
   University; Harvard Medical School; Harvard University; Harvard Medical
   School; Massachusetts Eye & Ear Infirmary; Schepens Eye Research
   Institute; Harvard University; Harvard T.H. Chan School of Public
   Health; Harvard University; Harvard T.H. Chan School of Public Health
RP Husain, D (通讯作者)，Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
EM kevin.mendez@channing.harvard.edu; janicekim93@gmail.com;
   Ines_Lains@meei.harvard.edu; Archana_Nigalye@meei.harvard.edu;
   Raviv_Katz@meei.harvard.edu; Shrinivas_Pundlik@meei.harvard.edu;
   Ivana_Kim@meei.harvard.edu; lliang@hsph.harvard.edu;
   Demetrios_Vavvas@meei.harvard.edu; John_Miller@meei.harvard.edu;
   Joan_Miller@meei.harvard.edu; jessica.su@channing.harvard.edu;
   Deeba_Husain@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
FU Miller Retina Research Fund (Mass. Eye and Ear); Champalimaud Vision
   Award, National Institutes of Health (NIH) [R01EY030088-01A1]; Research
   to Prevent Blindness, Inc. New York, NY, USA; Commonwealth Unrestricted
   Grant for Eye Research [R01HL123915, R01HL141826]
FX This work was supported by the Miller Retina Research Fund (Mass. Eye
   and Ear), the Champalimaud Vision Award, National Institutes of Health
   (NIH) R01EY030088-01A1, the unrestricted departmental Grant from
   Research to Prevent Blindness, Inc. New York, NY, USA, the Commonwealth
   Unrestricted Grant for Eye Research, R01HL123915 and R01HL141826. The
   funding sources were used for research fellows and other support staff,
   expenses needed for patient recruitment, and metabolomics sample
   analysis. All the above-mentioned funding organizations had no role in
   the conceptualization, design, analysis, decision to publish, or
   preparation of the manuscript design or conduct of this research.
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Catala A, 2006, INT J BIOCHEM CELL B, V38, P1482, DOI 10.1016/j.biocel.2006.02.010
   Chen GB, 2017, ANAL CHEM, V89, P4897, DOI 10.1021/acs.analchem.6b05006
   Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507
   CHIOU WL, 1978, J PHARMACOKINET BIOP, V6, P539, DOI 10.1007/BF01062108
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Cruzat V, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111564
   Curi R, 2007, FRONT BIOSCI-LANDMRK, V12, P344, DOI 10.2741/2068
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Dantzer R, 2017, CURR TOP BEHAV NEURO, V31, P117, DOI 10.1007/7854_2016_6
   Duan YH, 2016, AMINO ACIDS, V48, P41, DOI 10.1007/s00726-015-2067-1
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fu WJJ, 2005, J NUTR, V135, P714, DOI 10.1093/jn/135.4.714
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jeffrey BG, 2001, LIPIDS, V36, P859, DOI 10.1007/s11745-001-0796-3
   Jobgen WS, 2006, J NUTR BIOCHEM, V17, P571, DOI 10.1016/j.jnutbio.2005.12.001
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   KLENK E., 1965, ADVANCE LIPID RES, V3, P1
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2019, PROG RETIN EYE RES, V69, P57, DOI 10.1016/j.preteyeres.2018.11.002
   Lains I, 2018, RETINA-J RET VIT DIS, V38, P1145, DOI 10.1097/IAE.0000000000001659
   Lains I, 2018, AM J OPHTHALMOL, V190, P113, DOI 10.1016/j.ajo.2018.03.035
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Leipnitz G, 2008, LIFE SCI, V82, P652, DOI 10.1016/j.lfs.2007.12.024
   Leipnitz G, 2008, J NEUROSCI RES, V86, P683, DOI 10.1002/jnr.21527
   Leipnitz G, 2015, J INHERIT METAB DIS, V38, P1021, DOI 10.1007/s10545-015-9863-3
   Leveillard T, 2017, CELL MOL LIFE SCI, V74, P3649, DOI 10.1007/s00018-016-2318-7
   Li MX, 2012, HUM GENET, V131, P747, DOI 10.1007/s00439-011-1118-2
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Ventura ALM, 2019, BRAIN RES BULL, V151, P92, DOI 10.1016/j.brainresbull.2018.10.016
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pujol-Lereis LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200739
   Ramchani-Ben Othman K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128395
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schror Karsten, 2007, Paediatr Drugs, V9, P195, DOI 10.2165/00148581-200709030-00008
   Simon MV, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000972
   Singh Meharban, 2005, Indian Journal of Pediatrics, V72, P239, DOI 10.1007/BF02859265
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Stiles M, 2016, J LIPID RES, V57, P818, DOI 10.1194/jlr.M063719
   Tahir Humza J, 2018, Invest Ophthalmol Vis Sci, V59, pAMD202, DOI 10.1167/iovs.18-24227
   Tekwe CD, 2013, BIOFACTORS, V39, P552, DOI 10.1002/biof.1113
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   Simon MV, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00246
   Wang SP, 1998, HUM MOL GENET, V7, P2057, DOI 10.1093/hmg/7.13.2057
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu GY, 2013, AMINO ACIDS, V45, P241, DOI 10.1007/s00726-013-1515-z
NR 72
TC 3
Z9 3
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-1989
J9 METABOLITES
JI Metabolites
PD MAR
PY 2021
VL 11
IS 3
AR 183
DI 10.3390/metabo11030183
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA RE0OH
UT WOS:000633864600001
PM 33801085
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wang, L
   Lee, AYW
   Wigg, JP
   Peshavariya, H
   Liu, P
   Zhang, H
AF Wang, Lei
   Lee, Amy Yi Wei
   Wigg, Jonathan P.
   Peshavariya, Hitesh
   Liu, Ping
   Zhang, Hong
TI miR-126 Regulation of Angiogenesis in Age-Related Macular Degeneration
   in CNV Mouse Model
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE miR-126; age-related macular degeneration; choroidal neovascularization;
   human microvascular endothelial cell (HMEC)
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; CHOROIDAL
   NEOVASCULARIZATION; GENE-EXPRESSION; VEGF FUNCTION; MICRORNAS; PEDF;
   VITRECTOMY; SPROUTY; TARGETS
AB miR-126 has recently been implicated in modulating angiogenic factors in vascular development. Understandings its biological significance might enable development of therapeutic interventions for diseases like age-related macular degeneration (AMD). We aimed to determine the role of miR-126 in AMD using a laser-induced choroidal neovascularization (CNV) mouse model. CNV was induced by laser photocoagulation in C57BL/6 mice. The CNV mice were transfected with scrambled miR or miR-126 mimic. The expression of miR-126, vascular endothelial growth factor-A (VEGF-A), Kinase insert domain receptor (KDR) and Sprouty-related EVH1 domain-containing protein 1 (SPRED-1) in ocular tissues were analyzed by qPCR andWestern blot. The overexpression effects of miR-126 were also proven on human microvascular endothelial cells (HMECs). miR-126 showed a significant decrease in CNV mice (p < 0.05). Both mRNA and protein levels of VEGF-A, KDR and SPRED-1 were upregulated with CNV; these changes were ameliorated by restoration of miR-126 (p < 0.05). CNV was reduced after miR-126 transfection. Transfection of miR-126 reduced the HMECs 2D-capillary-like tube formation (p < 0.01) and migration (p < 0.01). miR-126 has been shown to be a negative modulator of angiogenesis in the eye. All together these results high lights the therapeutic potential of miR-126 suggests that it may contribute as a putative therapeutic target for AMD in humans.
C1 [Wang, Lei; Liu, Ping; Zhang, Hong] Harbin Med Univ, Affiliated Hosp 1, Hosp Eye, Harbin 150001, Peoples R China.
   [Lee, Amy Yi Wei] Univ Melbourne, Ctr Eye Res Australia, Drug Delivery Unit, Dept Pharmacol & Therapeut, East Melbourne, Vic 3000, Australia.
   [Wigg, Jonathan P.; Peshavariya, Hitesh; Zhang, Hong] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3000, Australia.
C3 Harbin Medical University; Centre for Eye Research Australia; University
   of Melbourne; Centre for Eye Research Australia; Royal Victorian Eye &
   Ear Hospital; University of Melbourne
RP Liu, P; Zhang, H (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Hosp Eye, Harbin 150001, Peoples R China.; Zhang, H (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3000, Australia.
EM wangleiPHD@126.com; amylee1192@gmail.com; jonathanwigg@outlook.com;
   hiteshp@163.com; pingliu53@126.com; hong.zhang@unimelb.edu.au
RI Zhang, Hong/AAX-9632-2020
CR Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Anand S, 2013, VASC CELL, V5, DOI 10.1186/2045-824X-5-2
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016
   Bai YY, 2009, J PATHOL, V219, P446, DOI 10.1002/path.2611
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Caporali A, 2012, CARDIOL RES PRACT, V2012, DOI 10.1155/2012/486702
   Caporali A, 2011, CIRCULATION, V123, P282, DOI 10.1161/CIRCULATIONAHA.110.952325
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0
   Chen HX, 2014, ONCOTARGET, V5, P11873, DOI 10.18632/oncotarget.2662
   Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133
   Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002
   Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Nadal E, 2011, NAT REV GENET, V12, P833, DOI 10.1038/nrg3055
   Dull RO, 2001, MICROVASC RES, V61, P203, DOI 10.1006/mvre.2000.2298
   Farnoodian M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12266
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Fish JE, 2009, SCI SIGNAL, V1, DOI 10.1126/scisignal.252pe1
   Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148
   Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8
   Han ZC, 2013, INVEST OPHTH VIS SCI, V54, P574, DOI 10.1167/iovs.12-10959
   Hsieh CH, 2010, EXP CELL RES, V316, P1119, DOI 10.1016/j.yexcr.2009.11.013
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kamal K, 1998, J CELL BIOCHEM, V71, P491, DOI 10.1002/(SICI)1097-4644(19981215)71:4<491::AID-JCB4>3.0.CO;2-P
   Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6
   Kramer A, 2002, DEV OPHTHALMOL, V33, P2
   Kuehbacher A, 2008, TRENDS PHARMACOL SCI, V29, P12, DOI 10.1016/j.tips.2007.10.014
   Kuhnert F, 2008, DEVELOPMENT, V135, P3989, DOI 10.1242/dev.029736
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Larsson E, 2009, GENOME MED, V1, DOI 10.1186/gm108
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Liu MM, 2013, CURR GENOMICS, V14, P166, DOI 10.2174/1389202911314030002
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Neely KA, 1998, AM J PATHOL, V153, P665, DOI 10.1016/S0002-9440(10)65607-6
   Ng YS, 2006, EXP CELL RES, V312, P527, DOI 10.1016/j.yexcr.2005.11.008
   Ohkuma Y, 2014, CLIN OPHTHALMOL, V8, P143, DOI 10.2147/OPTH.S56483
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Schlenker MB, 2015, AM J OPHTHALMOL, V160, P569, DOI 10.1016/j.ajo.2015.06.011
   Schulze S, 2012, ACTA OPHTHALMOL, V90, P244, DOI 10.1111/j.1755-3768.2010.01929.x
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Spirin KS, 1999, CURR EYE RES, V18, P490, DOI 10.1076/ceyr.18.6.490.5267
   Takeyama M, 2015, BIOL RES, V48, DOI [10.1186/s40659-015-0034-7, 10.1186/S40659-015-0034-7]
   Taniguchi K, 2007, MOL CELL BIOL, V27, P4541, DOI 10.1128/MCB.01600-06
   Tombran-Tink J, 2010, CURR MOL MED, V10, P267, DOI 10.2174/156652410791065336
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   van Romunde SHM, 2015, OPHTHALMOLOGY, V122, P1366, DOI 10.1016/j.ophtha.2015.03.012
   Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Wang SS, 2009, CURR OPIN GENET DEV, V19, P205, DOI 10.1016/j.gde.2009.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ye PP, 2014, INT J MED SCI, V11, P17, DOI 10.7150/ijms.7329
   Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zhu N, 2011, MOL CELL BIOCHEM, V351, P157, DOI 10.1007/s11010-011-0723-7
NR 69
TC 22
Z9 26
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2016
VL 17
IS 6
AR 895
DI 10.3390/ijms17060895
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DP9EK
UT WOS:000378799300109
PM 27338342
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Nebbioso, M
   Lambiase, A
   Cerini, A
   Limoli, PG
   La Cava, M
   Greco, A
AF Nebbioso, Marcella
   Lambiase, Alessandro
   Cerini, Alberto
   Limoli, Paolo Giuseppe
   La Cava, Maurizio
   Greco, Antonio
TI Therapeutic Approaches with Intravitreal Injections in Geographic
   Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and
   Potential Molecules
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; anti-inflammatory agents; complement
   inhibitors; dry AMD; geographic atrophy; intravitreal injection;
   neuroprotective agents; non-exudative AMD
ID CILIARY NEUROTROPHIC FACTOR; BRIMONIDINE; TECHNOLOGY; THERAPIES;
   IMPLANTS; DELIVERY; DISEASE; NERVE
AB The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called immunomodulatory or anti-inflammatory agents. A systematic literature search was performed to identify randomized controlled trials published prior to January 2019. Patients affected by dry AMD treated with intravitreal therapeutic agents were included. Changes in the correct visual acuity and reduction in geographic atrophy progression were evaluated. Several new drugs have shown promising results, including those targeting the complement cascade and neuroprotective agents. The potential action of the two groups of drugs is to block complement cascade upregulation of immunomodulating agents, and to prevent the degeneration and apoptosis of ganglion cells for the neuroprotectors, respectively. Our analysis indicates that finding treatments for dry AMD will require continued collaboration among researchers to identify additional molecular targets and to fully interrogate the utility of pluripotent stem cells for personalized therapy.
C1 [Nebbioso, Marcella; Lambiase, Alessandro; Cerini, Alberto; La Cava, Maurizio; Greco, Antonio] Sapienza Univ Rome, Umberto I Policlin, Fac Med & Odontol, Dept Sense Organs, Ple A Moro 5, I-00185 Rome, Italy.
   [Limoli, Paolo Giuseppe] Low Vis Res Ctr Milan, Piazza Sempione 3, I-20145 Milan, Italy.
C3 Sapienza University Rome; University Hospital Sapienza Rome
RP Nebbioso, M (通讯作者)，Sapienza Univ Rome, Umberto I Policlin, Fac Med & Odontol, Dept Sense Organs, Ple A Moro 5, I-00185 Rome, Italy.
EM marcella.nebbioso@uniroma1.it; alessandro.lambiase@uniroma1.it;
   cerinialberto@hotmail.it; paololimoli@libero.it;
   maurizio.lacava@uniroma1.it; antonio.greco@uniroma1.it
RI Limoli, Paolo/AAB-9828-2021; Nebbioso, Marcella/K-6878-2018; Lambiase,
   Alessandro/K-3902-2016
OI Nebbioso, Marcella/0000-0002-5512-0849; Lambiase,
   Alessandro/0000-0002-8974-991X
CR Al-Shahwan S, 2005, OPHTHALMOLOGY, V112, P2143, DOI 10.1016/j.ophtha.2005.06.035
   American Academy of Ophthalmology (AAO), 2016, ICD10 CM SUBSP ICD 1
   Bianchi E, 2016, INT J IMMUNOPATH PH, V29, P40, DOI 10.1177/0394632015615592
   Blumenkranz MS, 2013, RETINA, P1213
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Cavallotti C, 2004, CAN J OPHTHALMOL, V39, P61, DOI 10.1016/S0008-4182(04)80054-1
   CDC, 2017, INT CLASS DIS 10 REV
   Centers for Disease Control (CDC), 2016, INT CLASS DIS 10 REV
   Cheng W. S., 2017, YIXUE YANJIU, V37, P121
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cocco L, 1999, BBA-MOL CELL BIOL L, V1438, P295, DOI 10.1016/S1388-1981(99)00061-X
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Doozandeh Azadeh, 2016, J Ophthalmic Vis Res, V11, P209, DOI 10.4103/2008-322X.183923
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Dukles NA, 2017, INVEST OPHTH VIS SCI, V58
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fuhrmann S, 2003, J COMP NEUROL, V461, P111, DOI 10.1002/cne.10701
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jha KA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072016
   Kandasamy R, 2017, ASIA-PAC J OPHTHALMO, V6, P508, DOI 10.22608/APO.2017262
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Kaushal S., 2009, INVEST OPHTH VIS SCI, V50, P5010
   Kimura A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091584
   Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298
   Lambiase A, 2009, ANN I SUPER SANITA, V45, P439
   Li HL, 2017, EXPERT OPIN INV DRUG, V26, P1103, DOI 10.1080/13543784.2017.1369042
   Limoli PG, 2018, JOVE-J VIS EXP, DOI 10.3791/56469
   Limoli PG, 2016, ONCOTARGET, V7, P46913, DOI 10.18632/oncotarget.10442
   Limoli PG, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000355
   Nebbioso M, 2017, CRIT REV FOOD SCI, V57, P559, DOI 10.1080/10408398.2014.893504
   Nebbioso M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/671529
   Nizari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.397
   Patel HR, 2015, OSLI RETINA, V46, P8, DOI 10.3928/23258160-20150101-01
   Ricklin D, 2016, SEMIN IMMUNOL, V28, P208, DOI 10.1016/j.smim.2016.06.001
   Sagar A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187373
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Sun HG, 2015, MOLECULES, V20, P11959, DOI 10.3390/molecules200711959
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Taskintuna I, 2016, MIDDLE EAST AFR J OP, V23, P13, DOI 10.4103/0974-9233.173134
   Thanos CG, 2004, TISSUE ENG, V10, P1617, DOI 10.1089/ten.2004.10.1617
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Wei YL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010422
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2016, ICD 10 VERS 2016
   World Health Organization, 2017, ICD 11 BET DRAFT MOR
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 57
TC 30
Z9 30
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR 4
PY 2019
VL 20
IS 7
AR 1693
DI 10.3390/ijms20071693
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HU0RD
UT WOS:000464977600005
PM 30987401
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Cheng, S
   Leng, T
AF Cheng, Sarah
   Leng, Theodore
TI Factors Associated With Poor Response to Aflibercept After Switching
   From Ranibizumab or Bevacizumab in Neovascular Age-related Macular
   Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; FACTOR TRAP-EYE; INTRAVITREAL
   RANIBIZUMAB; VEGF-TRAP; RISK-FACTORS; VITAMIN-C; THERAPY; OUTCOMES;
   REGIMEN
AB BACKGROUND AND OBJECTIVE: The purpose of this study was to analyze demographic and ocular features of patients with age-related macular degeneration who failed aflibercept (Eylea; Regeneron, Tarrytown, NY) treatment after switching from ranibizumab (Lucentis; Genentech, South San Francisco, CA) or bevacizumab (Avastin; Genentech, South San Francisco, CA).
   PATIENTS AND METHODS: Retrospective chart review of patients treated with aflibercept at the Byers Eye Institute from November 2011 to August 2014. Patient visual acuity was noted prior to aflibercept; after 1, 3, and 12 months; and on the most recent visit. Patients who improved vision after switching were compared to patients who lost vision. Demographic and imaging features were analyzed using univariate and multivariate statistics.
   RESULTS: Patients who lost vision had significantly higher BMI (P = .013, multivariate) and geographic atrophy (P = .0381, univariate; P = .1, multivariate) compared to patients who improved vision.
   CONCLUSION: BMI and geographic atrophy may be considered as potential indicators for poor response to aflibercept after switching from ranibizumab or bevacizumab.
C1 [Cheng, Sarah; Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.
C3 Stanford University
RP Leng, T (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM tedleng@stanford.edu
RI Leng, Theodore/AAQ-7459-2020
OI Leng, Theodore/0000-0002-8461-3562
FU Medical Scholars Research Program at Stanford
FX Supported by the Medical Scholars Research Program at Stanford.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang W, 2013, MOL VIS, V19, P702
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He LM, 2015, OSLI RETINA, V46, P542, DOI 10.3928/23258160-20150521-05
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Stewart Michael W., 2011, Inflammation & Allergy Drug Targets, V10, P497
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Teper SJ, 2010, MOL VIS, V16, P2598
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 54
TC 3
Z9 4
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUN
PY 2016
VL 47
IS 5
BP 458
EP 465
DI 10.3928/23258160-20160419-09
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9VX
UT WOS:000378847000007
PM 27183550
DA 2022-11-30
ER

PT J
AU Invernizzi, A
   Benatti, E
   Cozzi, M
   Erba, S
   Vaishnavi, S
   Vupparaboina, KK
   Staurenghi, G
   Chhablani, J
   Gillies, M
   Viola, F
AF Invernizzi, Alessandro
   Benatti, Eleonora
   Cozzi, Mariano
   Erba, Stefano
   Vaishnavi, Shiva
   Vupparaboina, Kiran Kumar
   Staurenghi, Giovanni
   Chhablani, Jay
   Gillies, Mark
   Viola, Francesco
TI Choroidal Structural Changes Correlate With Neovascular Activity in
   Neovascular Age Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE choroid; neovascular age related macular degeneration; EDI-OCT;
   choroidal vascularity index; CNV activity
ID RETINAL ANGIOMATOUS PROLIFERATION; THICKNESS; THERAPY; RANIBIZUMAB
AB PURPOSE. To correlate changes in choroidal thickness and vascularity index with disease activity in patients with neovascular age-related macular degeneration (nAMD).
   METHODS. Eyes diagnosed with AMD that had two sequential visits within 12 months and that had no choroidal neovascularization (CNV) or had inactive CNV at the first visit were included. Those that had active CNV at follow-up were enrolled as cases. Eyes that did not developed a CNV or that were still inactive at the second visit were enrolled as controls. Disease activity was based on optical coherence tomography (OCT) and fluorescein angiography findings. Subfoveal choroidal thickness (SCT), mean choroidal thickness (MCT), and choroidal vascularity index (CVI) were assessed on enhanced depth imaging OCT and compared between the baseline and follow-up visit. Subgroup analysis accounting for lesion type and previous treatment, if any, were performed.
   RESULTS. Sixty-five eyes from 60 patients (35 females) and 50 age-and sex-matched controls were included. At the active visit, cases had an increase from 164 +/- 67 mu m to 175 +/- 70 mu m in mean +/- SD SCT and from 144 +/- 45 mu m to 152 +/- 45 mu m in MCT (both P < 0.0001). The mean CVI also increased at from 54.5% +/- 3.3% to 55.4% +/- 3.8% (P = 0.04). Controls did not show significant changes in choroidal measurements between the two visits. Mean SCT, MCT, and CVI values were similar for previously treated and treatment-naive eyes.
   CONCLUSIONS. Choroidal thickness and CVI significantly increased with active disease in nAMD eyes. Changes in choroidal thickness may predict CNV development or recurrence before they are otherwise evident clinically.
C1 [Invernizzi, Alessandro; Cozzi, Mariano; Erba, Stefano; Staurenghi, Giovanni] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Luigi Sacco Hosp, Via GB Grassi 74, I-20157 Milan, Italy.
   [Invernizzi, Alessandro; Gillies, Mark] Univ Sydney, Save Sight Inst, Sydney Eye Hosp, Sydney, NSW, Australia.
   [Benatti, Eleonora; Viola, Francesco] Univ Milan, Dept Clin Sci & Community Hlth, Ophthalmol Unit, IRCCS Ca Granda Fdn,Osped Maggiore Policlin, Milan, Italy.
   [Vaishnavi, Shiva; Vupparaboina, Kiran Kumar; Chhablani, Jay] LV Prasad Eye Inst, Hyderabad, Telangana, India.
C3 University of Milan; Luigi Sacco Hospital; University of Sydney; IRCCS
   Ca Granda Ospedale Maggiore Policlinico; University of Milan; L. V.
   Prasad Eye Institute
RP Invernizzi, A (通讯作者)，Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Luigi Sacco Hosp, Via GB Grassi 74, I-20157 Milan, Italy.
EM alessandro.invernizzi@gmail.com
RI viola, francesco/AAK-5583-2020
OI viola, francesco/0000-0003-1208-913X; Chhablani,
   Jay/0000-0003-1772-3558; Cozzi, Mariano/0000-0001-7777-2461
CR Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Ahn SJ, 2015, INVEST OPHTH VIS SCI, V56, P5794, DOI 10.1167/iovs.14-16006
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BILL A, 1990, EYE, V4, P319, DOI 10.1038/eye.1990.43
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Kim YK, 2016, RETINA-J RET VIT DIS, V36, P1516, DOI 10.1097/IAE.0000000000000952
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Koizumi H, 2008, GRAEF ARCH CLIN EXP, V246, P515, DOI 10.1007/s00417-007-0705-3
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Strauss O, 2016, EUR J PHARMACOL, V787, P84, DOI 10.1016/j.ejphar.2016.03.066
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Vupparaboina KK, 2015, COMPUT MED IMAG GRAP, V46, P315, DOI 10.1016/j.compmedimag.2015.09.008
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 24
TC 30
Z9 31
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2018
VL 59
IS 10
BP 3836
EP 3841
DI 10.1167/iovs.18-23960
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP9ZB
UT WOS:000441273800006
PM 30073357
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lamoureux, EL
   Mitchell, P
   Rees, G
   Cheung, G
   Yeo, I
   Lee, SY
   Liu, E
   Wong, TY
AF Lamoureux, Ecosse L.
   Mitchell, Paul
   Rees, Gwyn
   Cheung, Gemmy
   Yeo, Ian
   Lee, Shu Yen
   Liu, Erica
   Wong, Tien Y.
TI Impact of early and late age-related macular degeneration on
   vision-specific functioning
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MALAY POPULATION; PREVALENCE; IMPAIRMENT; MACULOPATHY; RASCH
AB Aim To assess the impact of early and late age-related macular degeneration (AMD) on vision-specific functioning in Singapore Malays.
   Methods AMD was assessed from fundus photographs. The following endpoints were considered for (a) AMD: no AMD, early AMD, and late AMD; (b) drusen: absence and presence; and (c) retinal pigment epithelium (RPE) abnormality: absence and presence. Vision functioning was assessed using the modified VF-11 scale validated using the Rasch analysis. The overall functioning score was used as the main outcome measure.
   Results Retinal photographs and vision functioning data were available only for 3252 participants. After age standardisation, the prevalence of early AMD was 3.5% and late AMD 0.34%. In multivariate models, after adjusting for age, gender, education, level of income, smoking status, ocular condition and hypertension, only late AMD was independently associated with poorer vision functioning when compared with no AMD or early AMD (b (b regression coefficient)=-6.4 (CI - 11.7 to -2.1; p=0.01)). Early AMD or its principal components, drusen or RPE abnormality, were not independently associated with vision functioning (p>0.05). In adjusted multinomial logistic regression models, people with late AMD were twice as likely (OR=2.23; 95% CI 1.16 to 7.11) to have low overall functioning than those without AMD.
   Conclusions Late AMD has a significant impact on visual functioning, but early AMD, drusen and RPE changes have no impact. These data highlight the importance of preventive public health strategies targeting patients with early AMD signs in order to prevent progression to late AMD when visual function is compromised.
C1 [Lamoureux, Ecosse L.; Rees, Gwyn; Wong, Tien Y.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Lamoureux, Ecosse L.; Cheung, Gemmy; Yeo, Ian; Lee, Shu Yen; Liu, Erica; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; National University of Singapore; Singapore
   National Eye Center; University of Sydney; Westmead Institute for
   Medical Research; National University of Singapore
RP Lamoureux, EL (通讯作者)，Univ Melbourne, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM ecosse@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Mitchell, Paul/P-1498-2014; Lamoureux,
   Ecosse/Z-5482-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
CR ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814
   [Anonymous], 1991, Ophthalmology, V98, P786
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Garamendi E, 2006, VISION RES, V46, P1375, DOI 10.1016/j.visres.2005.07.007
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lamoureux EL, 2008, OPHTHAL EPIDEMIOL, V15, P105, DOI 10.1080/09286580701840354
   Lamoureux EL, 2009, INVEST OPHTH VIS SCI, V50, P2614, DOI 10.1167/iovs.08-2164
   Lamoureux EL, 2009, INVEST OPHTH VIS SCI, V50, P2607, DOI 10.1167/iovs.08-2359
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pesudovs Konrad, 2006, BMC Ophthalmol, V6, P25, DOI 10.1186/1471-2415-6-25
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Sloan Jeff A, 2005, COPD, V2, P57
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
NR 23
TC 33
Z9 33
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2011
VL 95
IS 5
BP 666
EP 670
DI 10.1136/bjo.2010.185207
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 752TN
UT WOS:000289717300017
PM 20956281
DA 2022-11-30
ER

PT J
AU Ferrara, D
   Silver, RE
   Louzada, RN
   Novais, EA
   Collins, GK
   Seddon, JM
AF Ferrara, Daniela
   Silver, Rachel E.
   Louzada, Ricardo N.
   Novais, Eduardo A.
   Collins, Giliann K.
   Seddon, Johanna M.
TI Optical Coherence Tomography Features Preceding the Onset of Advanced
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   geographic atrophy; optical coherence tomography; progression
ID GENOME-WIDE ASSOCIATION; GEOGRAPHIC ATROPHY; CHOROIDAL
   NEOVASCULARIZATION; DRUSEN VOLUME; PROGRESSION; CHORIOCAPILLARIS;
   OUTCOMES; EYES
AB PURPOSE. Age-related macular degeneration (AMD) is a progressive disease with multifactorial etiology. There is a need to identify clinical features that are harbingers of advanced disease. We evaluated morphologic features of the retina and choroid on optical coherence tomography (OCT) to determine if they predict progression to advanced disease.
   METHODS. Progressors transitioned from early or intermediate AMD to advanced disease (n = 40 eyes), and were matched on baseline AMD grade and follow-up interval to nonprogressors who did not develop advanced AMD (n = 40 eyes). Features of the neurosensory retina, photoreceptors, retinal pigment epithelium (RPE), and choroid were evaluated. Logistic regression was used to evaluate univariate associations between features and progression to overall advanced AMD, geographic atrophy (GA), and neovascular disease (NV). Multivariate associations based on stepwise regression models were also assessed.
   RESULTS. Ellipsoid zone disruption was associated with progression to overall advanced AMD and NV (odds ratios [ORs]: 17.9 and 30.6; P < 0.001), with a similar trend observed for GA. Drusenoid RPE detachment, RPE thickening, and retinal pigmentary hyperreflective material were significantly associated with higher risk of progression to advanced AMD (ORs: 5.0-8.5) and NV (ORs: 10.8-17.2). Pigmentary hyperreflective material was associated with progression to GA (OR: 7.5, P = 0.009). Total retinal thickness, pigmentary hyperreflective material, nascent GA features, and choroidal vessel abnormalities were independently associated with progression to advanced AMD in a multivariate stepwise model.
   CONCLUSIONS. Abnormalities in the photoreceptors, retinal thickness, RPE, and choroid were associated with higher risk of developing advanced AMD. These findings provide insights into disease progression, and may be helpful to identify earlier endpoints for clinical studies.
C1 [Ferrara, Daniela; Louzada, Ricardo N.; Novais, Eduardo A.; Seddon, Johanna M.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Silver, Rachel E.; Collins, Giliann K.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Louzada, Ricardo N.] Univ Fed Goias, Dept Ophthalmol, Goiania, Go, Brazil.
   [Novais, Eduardo A.] Univ Fed Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
C3 Harvard University; Harvard Medical School; Tufts Medical Center;
   Universidade Federal de Goias; Universidade Federal de Sao Paulo
   (UNIFESP); Tufts University; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
FU National Institutes of Health [R01-EY011309]; Massachusetts Lions Eye
   Research Fund, Inc., New Bedford, MA, USA; International Retinal
   Research Foundation, Inc., Birmingham, AL, USA; American Macular
   Degeneration Foundation, Northampton, MA, USA; Age-Related Macular
   Degeneration Research Fund, Ophthalmic Epidemiology and Genetics
   Service, Tufts Medical Center, Tufts University School of Medicine,
   Boston, MA, USA; CAPES Foundation, Ministry of Education of Brazil,
   Brasilia, DF, Brazil; NATIONAL EYE INSTITUTE [R01EY011309] Funding
   Source: NIH RePORTER
FX Supported by Grant R01-EY011309 from the National Institutes of Health;
   the Massachusetts Lions Eye Research Fund, Inc., New Bedford, MA, USA;
   the International Retinal Research Foundation, Inc., Birmingham, AL,
   USA; the American Macular Degeneration Foundation, Northampton, MA, USA;
   and the Age-Related Macular Degeneration Research Fund, Ophthalmic
   Epidemiology and Genetics Service, Tufts Medical Center, Tufts
   University School of Medicine, Boston, MA, USA (JMS). RNL and EAN were
   supported by CAPES Foundation, Ministry of Education of Brazil,
   Brasilia, DF, Brazil.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lutty G, 1999, MOL VIS, V5
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Pilotto E, 2016, JAMA OPHTHALMOL, V134, P873, DOI 10.1001/jamaophthalmol.2016.1535
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Saade C, 2014, BRIT J OPHTHALMOL, V98, P1729, DOI 10.1136/bjophthalmol-2014-305005
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shim SH, 2016, OPHTHAL EPIDEMIOL, V23, P80, DOI 10.3109/09286586.2015.1129425
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 35
TC 37
Z9 39
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2017
VL 58
IS 9
BP 3519
EP 3529
DI 10.1167/iovs.17-21696
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH1WU
UT WOS:000410931200028
PM 28715590
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cho, EY
   Hankinson, SE
   Rosner, B
   Willett, WC
   Colditz, GA
AF Cho, Eunyoung
   Hankinson, Susan E.
   Rosner, Bernard
   Willett, Walter C.
   Colditz, Graham A.
TI Prospective study of lutein/zeaxanthin intake and risk of age-related
   macular degeneration
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; TOTAL-ENERGY-INTAKE;
   PIGMENT DENSITY; CAROTENOID CONTENT; ALPHA-TOCOPHEROL; OPTICAL-DENSITY;
   PRIMATE RETINAS; DIETARY-INTAKE; ASCORBIC-ACID
AB Background: The association between lutein/zeaxanthin intake and age-related macular degeneration (AMD) risk may differ by smoking status, vitamin C and E intakes, and body fatness.
   Objective: The objective was to evaluate the association between lutein/zeaxanthin intake and AMD risk by smoking status, intake of antioxidant vitamins, and body fatness.
   Design: We conducted a prospective follow-up study of 71494 women and 41 564 men aged >= 50 y and had no diagnosis of AMD or cancer. Diet was assessed with a validated semiquantitative food-frequency questionnaire.
   Results: During up to 18 y of follow-up, we documented 673 incident cases of early AMD and 442 incident cases of neovascular AMD with a visual loss of 20/30 or worse due primarily to AMD. Lutein/zeaxanthin intake was not associated with the risk of self-reported early AMD. There was a statistically nonsignificant and nonlinear inverse association between lutein/zeaxanthin intake and neovascular AMD risk; the pooled multivariate relative risks for increasing quintiles of intake were 1.00 (referent), 0.80, 0.84, 0.97, and 0.72 (95% CI: 0.53,0.99) (P for trend = 0.14). For early AMD, the association with lutein/zeaxanthin intake did not vary by smoking status, intakes of vitamins C and E, or body mass index. For neovascular AMD, a nonlinear inverse association was found among never smokers.
   Conclusions: These data do not support a protective role of lutein/zeaxanthin intake on risk of self-reported early AMD. The suggestion of inverse associations related to the risk of neovascular AMD needs to be examined further.
C1 [Cho, Eunyoung; Hankinson, Susan E.; Rosner, Bernard; Willett, Walter C.] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA.
   [Cho, Eunyoung; Hankinson, Susan E.; Rosner, Bernard; Willett, Walter C.] Harvard Univ, Sch Med, Boston, MA USA.
   [Hankinson, Susan E.; Rosner, Bernard; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Rosner, Bernard] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Cho, Eunyoung; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Colditz, Graham A.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
   [Colditz, Graham A.] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Harvard University; Harvard T.H. Chan School of
   Public Health; Harvard University; Harvard T.H. Chan School of Public
   Health; Harvard University; Harvard T.H. Chan School of Public Health;
   Washington University (WUSTL); Siteman Cancer Center; Washington
   University (WUSTL)
RP Cho, EY (通讯作者)，Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM eunyoung.cho@channing.harvard.edu
RI Colditz, Graham/A-3963-2009; Cho, Eunyoung/AAV-4469-2020
OI Colditz, Graham/0000-0002-7307-0291; Cho, Eunyoung/0000-0001-6594-2582
FU NATIONAL CANCER INSTITUTE [P01CA055075, P01CA087969] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY009611] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464]
   Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA087969, P01
   CA087969-07, P01 CA055075-17, CA87969, P01 CA055075, P01
   CA087969-090007, CA55075] Funding Source: Medline; NEI NIH HHS [R01
   EY009611-09, EY09611, R01 EY009611] Funding Source: Medline; NHLBI NIH
   HHS [R01 HL035464, HL35464, R01 HL035464-20] Funding Source: Medline
CR Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blakely S, 2003, J NUTR, V133, P2838, DOI 10.1093/jn/133.9.2838
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   CHUNGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318
   Cox DavidRoxbee., 1984, ANAL SURVIVAL DATA, DOI [10.1201/9781315137438/analysis-survival-data-cox-oakes, DOI 10.1201/9781315137438/ANALYSIS-SURVIVAL-DATA-COX-OAKES]
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabriel HE, 2006, CANCER EPIDEM BIOMAR, V15, P993, DOI 10.1158/1055-9965.EPI-05-0664
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gruber M, 2004, J NUTR, V134, P2387, DOI 10.1093/jn/134.9.2387
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   LUNN M, 1995, BIOMETRICS, V51, P524, DOI 10.2307/2532940
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Rosner B., 2000, FUNDAMENTALS BIOSTAT, V5th ed.
   Rothman KJ, 1986, MODERN EPIDEMIOLOGY
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SAS Institute, 1991, SAS STAT SOFTW PHREG
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Therneau TM., 1997, P 1 SEATTL S BIOST S, V123, P51
   TONUCCI LH, 1995, J AGR FOOD CHEM, V43, P579, DOI 10.1021/jf00051a005
   *USDA, 1993, AGR HDB SER, V8
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   Wrona M, 2004, FREE RADICAL BIO MED, V36, P1094, DOI 10.1016/j.freeradbiomed.2004.02.005
   Wrona M, 2003, FREE RADICAL BIO MED, V35, P1319, DOI 10.1016/j.freeradbiomed.2003.07.005
NR 58
TC 71
Z9 77
U1 0
U2 20
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUN
PY 2008
VL 87
IS 6
BP 1837
EP 1843
DI 10.1093/ajcn/87.6.1837
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 313ET
UT WOS:000256724600034
PM 18541575
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Ethen, CM
   Reilly, C
   Feng, X
   Olsen, TW
   Ferrington, DA
AF Ethen, Cheryl M.
   Reilly, Cavan
   Feng, Xiao
   Olsen, Timothy W.
   Ferrington, Deborah A.
TI Age-related macular degeneration and retinal protein modification by
   4-hydroxy-2-nonenal
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID GLUTATHIONE S-TRANSFERASES; GLYCATION END-PRODUCTS; LIPID-PEROXIDATION;
   PIGMENT EPITHELIUM; PROTEOMIC ANALYSIS; ALDOSE REDUCTASE; OXIDATIVE
   STRESS; ALDEHYDE DEHYDROGENASES; RAT; IDENTIFICATION
AB PURPOSE. Oxidative damage to proteins, lipids, and DNA has been suggested to be a mechanism for age- related macular degeneration (AMD). The retina is particularly susceptible to lipid peroxidation due to high concentrations of easily oxidized polyunsaturated fatty acids in the presence of abundant oxygen. One of the most toxic products of lipid peroxidation, 4-hydroxy-2-nonenal (HNE), can modify and inactivate proteins. The hypothesis was that 4-HNE-modified proteins would accumulate and serve as a marker for progressive stages of AMD.
   METHODS. Proteins containing HNE adducts were identified in both the macular and peripheral regions during four progressive stages of AMD. The proteins were resolved by two-dimensional (2-D) gel electrophoresis before detection of HNE-adducted proteins. Modified proteins were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS). The total content of HNE adducts was compared using a slot blot immunoassay. One-dimensional Western blot analysis was used to measure levels of proteins involved in HNE detoxification.
   RESULTS. Nineteen proteins that were consistently modified regardless of stage of AMD or retinal region were identified. These proteins are involved in two main functions: energy production and stress response. No change in total HNE-adducted protein was observed between regions or stages. Modest increases in content of proteins involved in HNE detoxification were observed.
   CONCLUSIONS. Consistently modified proteins indicate preferred protein targets for oxidation by HNE. HNE-modified proteins were not different between regions or stages, suggesting that pathways for detoxification of HNE or removal of damaged proteins are adequate. Consistent levels of HNE-modified proteins suggest that HNE is not a sensitive retinal biomarker for AMD.
C1 Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Biol Mol, Minneapolis, MN USA.
   Univ Minnesota, Dept Biophys, Minneapolis, MN USA.
   Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
   Univ Minnesota, Div Biostat, Minneapolis, MN USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU NEI NIH HHS [EY014176, T32-EY07133] Funding Source: Medline; NIA NIH HHS
   [AG025392, R01 AG025392] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [T32EY007133, R03EY014176] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R01AG025392] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEECKMANS S, 1990, J CELL BIOCHEM, V43, P297, DOI 10.1002/jcb.240430402
   Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890
   Cheng JZ, 2001, J BIOL CHEM, V276, P41213, DOI 10.1074/jbc.M106838200
   Choudhary S, 2003, INVEST OPHTH VIS SCI, V44, P2675, DOI 10.1167/iovs.02-0965
   Coles BF, 2005, METHOD ENZYMOL, V401, P9, DOI 10.1016/S0076-6879(05)01002-5
   Colvis C, 2002, ARCH BIOCHEM BIOPHYS, V397, P319, DOI 10.1006/abbi.2001.2669
   Crabb JW, 2002, PROTEIN SCI, V11, P831, DOI 10.1110/ps.4400102
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Del Corso A, 1998, ARCH BIOCHEM BIOPHYS, V350, P245
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   DeLaPaz MA, 1996, CURR EYE RES, V15, P273, DOI 10.3109/02713689609007621
   Desmots F, 2001, J HISTOCHEM CYTOCHEM, V49, P1573, DOI 10.1177/002215540104901211
   DUNBAR BS, 1988, 2 DIMENSIONAL ELECTR, P77
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   Ferrington DA, 2004, FEBS LETT, V578, P217, DOI 10.1016/j.febslet.2004.11.003
   Fratelli M, 2003, PROTEOMICS, V3, P1154, DOI 10.1002/pmic.200300436
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Grune Tilman, 2003, Molecular Aspects of Medicine, V24, P195, DOI 10.1016/S0098-2997(03)00014-1
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   HARTMANN CM, 1993, EUR J BIOCHEM, V218, P905, DOI 10.1111/j.1432-1033.1993.tb18446.x
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Horakova L, 2002, GEN PHYSIOL BIOPHYS, V21, P327
   Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175
   Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h
   Hussain SNA, 2006, AM J PHYSIOL-LUNG C, V290, pL996, DOI 10.1152/ajplung.00337.2005
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Ishii T, 2003, BIOCHEMISTRY-US, V42, P3474, DOI 10.1021/bi027172o
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kathmann EC, 2000, BIOCHEMISTRY-US, V39, P11170, DOI 10.1021/bi001120m
   Keightley JA, 2004, MOL CELL PROTEOMICS, V3, P167, DOI 10.1074/mcp.M300119-MCP200
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koh YH, 2000, FREE RADICAL RES, V33, P739, DOI 10.1080/10715760000301261
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   McGuire S, 1996, INVEST OPHTH VIS SCI, V37, P833
   Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200
   Negre-Salvayre Anne, 2003, Molecular Aspects of Medicine, V24, P251, DOI 10.1016/S0098-2997(03)00020-7
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Perluigi M, 2005, FREE RADICAL BIO MED, V38, P960, DOI 10.1016/j.freeradbiomed.2004.12.021
   Petrash JM, 2004, CELL MOL LIFE SCI, V61, P737, DOI 10.1007/s00018-003-3402-3
   Rex TS, 2004, HUM GENE THER, V15, P960, DOI 10.1089/hum.2004.15.960
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   SINGHAL SS, 1994, ARCH BIOCHEM BIOPHYS, V311, P242, DOI 10.1006/abbi.1994.1233
   SINGHAL SS, 1994, BBA-PROTEIN STRUCT M, V1204, P279, DOI 10.1016/0167-4838(94)90019-1
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835
   Stagsted J, 2004, J AGR FOOD CHEM, V52, P3967, DOI 10.1021/jf035503d
   STEPHAN P, 1986, BIOCHIM BIOPHYS ACTA, V873, P127, DOI 10.1016/0167-4838(86)90198-6
   SZWEDA LI, 1993, J BIOL CHEM, V268, P3342
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tezel G, 2005, INVEST OPHTH VIS SCI, V46, P3177, DOI 10.1167/iovs.05-0208
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742
   Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   Vasiliou V, 2000, CHEM-BIOL INTERACT, V129, P1, DOI 10.1016/S0009-2797(00)00211-8
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Warburton S, 2005, MOL VIS, V11, P1122
   Wihlmark U, 1996, APMIS, V104, P272, DOI 10.1111/j.1699-0463.1996.tb00717.x
   WINKLER BS, 1995, SEM OPHTALM, V6, P78
   Winkler BS, 1999, MOL VIS, V5
NR 79
TC 71
Z9 72
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2007
VL 48
IS 8
BP 3469
EP 3479
DI 10.1167/iovs.06-1058
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 199VF
UT WOS:000248722600008
PM 17652714
DA 2022-11-30
ER

PT J
AU Ben Moussa, N
   Georges, A
   Capuano, V
   Merle, B
   Souied, EH
   Querques, G
AF Ben Moussa, Naima
   Georges, Anouk
   Capuano, Vittorio
   Merle, Benedicte
   Souied, Eric H.
   Querques, Giuseppe
TI MultiColor imaging in the evaluation of geographic atrophy due to
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE; FLUORESCENCE;
   AREAS
AB Purpose To compare different imaging modalities and to investigate the ability of MultiColor to evaluate geographic atrophy (GA) due to age-related macular degeneration (AMD).
   Methods Twenty-two consecutive patients with GA underwent MultiColor, colour fundus photography, blue fundus autofluorescence (FAF) (excitation= 488 nm; emission > 500 nm), near-infrared FAF (NIR-FAF) (excitation= 787 nm; emission > 800 nm) and spectral-domain optical coherence tomography (SD-OCT) (Spectralis HRA+OCT; Heidelberg Engineering) imaging. Two readers independently measured the size (area) and the width of GA (on horizontal SD-OCT scan cutting the fovea), and evaluated the foveal sparing in each examination.
   Results A total of 32 eyes (22 patients, mean age 79.2 +/- 8 years) with GA were included. Intragrader and intergrader agreement considering the evaluation of the size and width of GA was high for all the examinations. MultiColor and FAF showed the greatest intergrader agreement for GA area measurement (intraclass correlation (ICC)= 0.990, 95% CI 0.980 to 0.995; ICC= 0.998, 95% CI 0.996 to 0.999, respectively). SD-OCT showed the highest intergrader agreement of foveal involvement (k= 1), followed by MultiColor and NIR-FAF (k= 0.68).
   Conclusions We demonstrated that several different imaging modalities currently available in clinical practice are reliable for evaluating GA due to AMD. MultiColor is an excellent tool for the measurement of GA area and width, and for the detection of foveal sparing.
C1 [Ben Moussa, Naima; Georges, Anouk; Capuano, Vittorio; Merle, Benedicte; Souied, Eric H.; Querques, Giuseppe] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI Merle, Benedicte MJ/AAQ-5021-2021; Merle, Benedicte MJ/F-1247-2015
OI Merle, Benedicte MJ/0000-0003-1332-0954; Merle, Benedicte
   MJ/0000-0003-1332-0954; Querques, Giuseppe/0000-0002-3292-9581
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Gibbs D, 2009, INVEST OPHTH VIS SCI, V50, P4386, DOI 10.1167/iovs.09-3471
   Helb HM, 2010, KLIN MONATSBL AUGENH, V227, pR107, DOI 10.1055/s-0030-1250269
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
NR 20
TC 44
Z9 48
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2015
VL 99
IS 6
BP 842
EP 847
DI 10.1136/bjophthalmol-2014-305643
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI7NO
UT WOS:000354950600023
PM 25586715
DA 2022-11-30
ER

PT J
AU Garriga, C
   Pazianas, M
   Hawley, S
   Delmestri, A
   Prieto-Alhambra, D
   Cooper, C
   Judge, A
AF Garriga, Cesar
   Pazianas, Michael
   Hawley, Samuel
   Delmestri, Antonella
   Prieto-Alhambra, Daniel
   Cooper, Cyrus
   Judge, Andrew
TI Oral bisphosphonate use and age-related macular degeneration:
   retrospective cohort and nested case-control study
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article
DE oral bisphosphonates; age-related macular degeneration; hip fracture;
   propensity score matching; nested case-control study
ID RISK; PREVALENCE; ENGLAND; WALES
AB Our objective here was to determine whether oral bisphosphonate (BP) use is associated with the incidence of age-related macular degeneration (AMD). We performed a population-based study using electronic health records from UK primary care (Clinical Practice Research Datalink). A cohort of 13,974 hip fracture patients (1999-2013) was used to conduct (1) a propensity score-matched cohort analysis and (2) a nested case-control analysis. Hip fracture patients were aged >= 50 years without AMD diagnosis before hip fracture date or in the first year of follow-up. Among 6208 matched patients and during 22,142 person-years of follow-up, 57 (1.8%) and 42 (1.4%) AMD cases occurred in BP users and non-BP users, respectively. The survival analysis model did not provide significant evidence of a higher risk of AMD in BP users (subhazard ratio: 1.60; 95% confidence interval (CI): 0.95-2.72; P = 0.08), although there was a significant increased risk among BP users with high medication possession ratio (MPR) (top quartile) relative to non-BP users (odds ratio: 5.08, 95% CI: 3.11-8.30; P < 0.001, respectively). Overall, oral BP use was not associated with an increased risk of AMD in this cohort of hip fracture patients, although the risk increased significantly with higher MPR. More data are needed to confirm these findings.
C1 [Garriga, Cesar; Pazianas, Michael; Hawley, Samuel; Delmestri, Antonella; Prieto-Alhambra, Daniel; Cooper, Cyrus; Judge, Andrew] Univ Oxford, Nuffield Orthopaed Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Musculoskeletal Theme,Oxford NIHR Biomed Res Ctr, Oxford, England.
   [Garriga, Cesar; Hawley, Samuel; Prieto-Alhambra, Daniel; Judge, Andrew] Univ Oxford, Nuffield Orthopaed Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Ctr Stat Med, Oxford, England.
   [Prieto-Alhambra, Daniel; Cooper, Cyrus; Judge, Andrew] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
C3 Nuffield Orthopaedic Centre; University of Oxford; Nuffield Orthopaedic
   Centre; University of Oxford; University of Southampton
RP Garriga, C (通讯作者)，Univ Oxford, Botnar Res Ctr, Windmill Rd, Oxford OX3 7LD, England.
EM cesar.garriga-fuentes@ndorms.ox.ac.uk
RI Garriga, Cesar/AEV-9080-2022; Pazianas, Michael/ABE-4572-2020
OI Garriga, Cesar/0000-0001-7073-3611; Pazianas,
   Michael/0000-0002-4670-0016; Cooper, Cyrus/0000-0003-3510-0709;
   Delmestri, Antonella/0000-0003-0388-3403; Judge,
   Andrew/0000-0003-3015-0432; Hawley, Samuel/0000-0002-7034-6168
FU MRC [MC_U147585819, MC_U147585827, G0400491] Funding Source: UKRI;
   Medical Research Council [MC_UU_12011/1, MC_UP_A620_1014, MC_U147585827,
   MC_U147585824, G0400491, MC_U147585819] Funding Source: Medline; Medical
   Research Council [U1475000001] Funding Source: researchfish; National
   Institute for Health Research [NF-SI-0513-10085, NF-SI-0508-10082]
   Funding Source: researchfish
CR Andersen PK, 2012, INT J EPIDEMIOL, V41, P861, DOI 10.1093/ije/dyr213
   Austin PC, 2014, STAT MED, V33, P1242, DOI 10.1002/sim.5984
   Austin PC, 2011, STAT MED, V30, P1292, DOI 10.1002/sim.4200
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Brown CL, 2017, J AM MED INFORM ASSN, V24, P432, DOI 10.1093/jamia/ocw119
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   GREEN J, 2010, BMJ-BRIT MED J, V341, DOI DOI 10.1136/BMJ.C4444
   Grzybowski A, 2017, AM J OPHTHALMOL, V176, P255, DOI 10.1016/j.ajo.2016.12.028
   Hawley S, 2016, J BONE MINER RES, V31, P2008, DOI 10.1002/jbmr.2882
   Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098
   Ho DE, 2011, J STAT SOFTW, V42
   Honda S, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/206837
   Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205
   Kanis JA., 2008, ASSESSMENT OSTEOPORO
   Kleinbaum DG, 2012, STAT BIOL HEALTH, P1, DOI 10.1007/978-1-4419-6646-9
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mammo Z, 2016, AM J OPHTHALMOL, V168, P62, DOI 10.1016/j.ajo.2016.04.022
   Maraka S, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3783
   Mathur R, 2014, J PUBLIC HEALTH-UK, V36, P684, DOI 10.1093/pubmed/fdt116
   McCullagh P., 1989, GEN LINEAR MODELS MO
   Miki A, 2013, BRIT J OPHTHALMOL, V97, P770, DOI 10.1136/bjophthalmol-2012-303007
   Minassian D., 2009, EXECUTIVE SUMMARY
   Or C, 2013, BRIT J OPHTHALMOL, V97, P1074, DOI 10.1136/bjophthalmol-2013-303355
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pazianas M, 2013, J BONE MINER RES, V28, P455, DOI 10.1002/jbmr.1783
   Rees A, 2014, EYE, V28, P832, DOI 10.1038/eye.2014.103
   Royal College of Physicians, 2015, NAT HIP FRACT DAT AN
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sekhon J., 2011, J STAT SOFTW, V42, P52, DOI DOI 10.18637/jss.v042.i07
   Suissa S, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P811
   Theodoropoulou Sofia, 2015, Lancet, V385 Suppl 1, pS97, DOI 10.1016/S0140-6736(15)60412-3
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   VINOGRADOVA Y, 2013, BMJ-BRIT MED J, V346, DOI DOI 10.1136/BMJ.F114
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang SR, 2015, INFLAMMATION, V38, P658, DOI 10.1007/s10753-014-9973-3
NR 42
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0077-8923
EI 1749-6632
J9 ANN NY ACAD SCI
JI Ann. N.Y. Acad. Sci.
PD MAR
PY 2018
VL 1415
IS 1
SI SI
BP 34
EP 46
DI 10.1111/nyas.13589
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GA5DA
UT WOS:000428351100004
PM 29363763
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Mueller, EE
   Schaier, E
   Brunner, SM
   Eder, W
   Mayr, JA
   Egger, SF
   Nischler, C
   Oberkofler, H
   Reitsamer, HA
   Patsch, W
   Sperl, W
   Kofler, B
AF Mueller, Edith E.
   Schaier, Elena
   Brunner, Susanne M.
   Eder, Waltraud
   Mayr, Johannes A.
   Egger, Stefan F.
   Nischler, Christian
   Oberkofler, Hannes
   Reitsamer, Herbert A.
   Patsch, Wolfgang
   Sperl, Wolfgang
   Kofler, Barbara
TI Mitochondrial Haplogroups and Control Region Polymorphisms in
   Age-Related Macular Degeneration: A Case-Control Study
SO PLOS ONE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; COMPLEMENT FACTOR-H; DNA HAPLOGROUPS; HUMAN
   MTDNA; DISEASE; DYSFUNCTION; RETINOPATHY; MUTATION; CANCER; DAMAGE
AB Background: Onset and development of the multifactorial disease age-related macular degeneration (AMD) are highly interrelated with mitochondrial functions such as energy production and free radical turnover. Mitochondrial dysfunction and overproduction of reactive oxygen species may contribute to destruction of the retinal pigment epithelium, retinal atrophy and choroidal neovascularization, leading to AMD. Consequently, polymorphisms of the mitochondrial genome (mtDNA) are postulated to be susceptibility factors for this disease. Previous studies from Australia and the United States detected associations of mitochondrial haplogroups with AMD. The aim of the present study was to test these associations in Middle European Caucasians.
   Methodology/Principal Findings: Mitochondrial haplogroups (combinations of mtDNA polymorphisms) and mitochondrial CR polymorphisms were analyzed in 200 patients with wet AMD (choroidal neovascularization, CNV), in 66 patients with dry AMD, and in 385 controls from Austria by means of multiplex primer extension analysis and sequencing, respectively. In patients with CNV, haplogroup H was found to be significantly less frequent compared to controls, and haplogroup J showed a trend toward a higher frequency compared to controls. Five CR polymorphisms were found to differ significantly in the two study populations compared to controls, and all, except one (T152C), are linked to those haplogroups.
   Conclusions/Significance: It can be concluded that haplogroup J is a risk factor for AMD, whereas haplogroup H seems to be protective for AMD.
C1 [Mueller, Edith E.; Schaier, Elena; Brunner, Susanne M.; Eder, Waltraud; Mayr, Johannes A.; Sperl, Wolfgang; Kofler, Barbara] Paracelsus Med Univ, Dept Pediat, Res Program Receptor Biochem & Tumor Metab, Salzburg, Austria.
   [Egger, Stefan F.; Nischler, Christian; Reitsamer, Herbert A.] Paracelsus Med Univ, Dept Ophthalmol, Salzburg, Austria.
   [Oberkofler, Hannes; Patsch, Wolfgang] Paracelsus Med Univ, Dept Lab Med, Salzburg, Austria.
C3 Paracelsus Private Medical University; Paracelsus Private Medical
   University; Paracelsus Private Medical University
RP Mueller, EE (通讯作者)，Paracelsus Med Univ, Dept Pediat, Res Program Receptor Biochem & Tumor Metab, Salzburg, Austria.
EM b.kofler@salk.at
OI Mayr, Johannes/0000-0001-6970-336X; Kofler, Barbara/0000-0002-1198-4776;
   Brunner, Susanne Maria/0000-0002-9623-1115
FU Vereinigung zur Forderung Padiatrischer Forschung und Fortbildung,
   Salzburg
FX The study was supported by the "Vereinigung zur Forderung Padiatrischer
   Forschung und Fortbildung, Salzburg'' (www.mito-center.org). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Brandstatter A, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-191
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ebner S, 2009, PLOS ONE IN PRESS
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Isashiki Y, 1998, ACTA OPHTHALMOL SCAN, V76, P6, DOI 10.1034/j.1600-0420.1998.760103.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kofler B, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-35
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Loueslati BY, 2010, GENET MOL RES, V9, P1690, DOI 10.4238/vol9-3gmr778
   Meyer S, 1999, GENETICS, V152, P1103
   Mueller EE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016455
   Mueller EE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006370
   Pereira L, 2005, INT J ANDROL, V28, P241, DOI 10.1111/j.1365-2605.2005.00539.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Schmuczerova J, 2009, MUTAT RES-FUND MOL M, V666, P1, DOI 10.1016/j.mrfmmm.2009.03.002
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wiesbauer M, 2006, ELECTROPHORESIS, V27, P3864, DOI 10.1002/elps.200600086
NR 27
TC 46
Z9 49
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 13
PY 2012
VL 7
IS 2
AR e30874
DI 10.1371/journal.pone.0030874
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 925BB
UT WOS:000302733900016
PM 22348027
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU de la Barca, JMC
   Rondet-Courbis, B
   Ferre, M
   Muller, J
   Buisset, A
   Leruez, S
   Plubeau, G
   Mace, T
   Moureauzeau, L
   Chupin, S
   Tessier, L
   Blanchet, O
   Lenaers, G
   Procaccio, V
   Mirebeau-Prunier, D
   Simard, G
   Gohier, P
   Milea, D
   Reynier, P
AF de la Barca, Juan M. Chao
   Rondet-Courbis, Barnabe
   Ferre, Marc
   Muller, Jeanne
   Buisset, Adrien
   Leruez, Stephanie
   Plubeau, Guillaume
   Mace, Thibaut
   Moureauzeau, Laurie
   Chupin, Stephanie
   Tessier, Lydie
   Blanchet, Odile
   Lenaers, Guy
   Procaccio, Vincent
   Mirebeau-Prunier, Delphine
   Simard, Gilles
   Gohier, Philippe
   Milea, Dan
   Reynier, Pascal
TI A Plasma Metabolomic Profiling of Exudative Age-Related Macular
   Degeneration Showing Carnosine and Mitochondrial Deficiencies
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; lipidomics; metabolomics
ID PREVALENCE
AB To determine the plasma metabolomic profile of exudative age-related macular degeneration (AMD), we performed a targeted metabolomics study on the plasma from patients (n = 40, mean age = 81.1) compared to an age- and sex-matched control group (n = 40, mean age = 81.8). All included patients had documented exudative AMD, causing significant visual loss (mean logMAR visual acuity = 0.63), compared to the control group. Patients and controls did not differ in terms of body mass index and co-morbidities. Among the 188 metabolites analyzed, 150 (79.8%) were accurately measured. The concentrations of 18 metabolites were significantly modified in the AMD group, but only six of them remained significantly different after Benjamini-Hochberg correction. Valine, lysine, carnitine, valerylcarnitine and proline were increased, while carnosine, a dipeptide disclosing anti-oxidant and anti-glycating properties, was, on average, reduced by 50% in AMD compared to controls. Moreover, carnosine was undetectable for 49% of AMD patients compared to 18% in the control group (p-value = 0.0035). Carnitine is involved in the transfer of fatty acids within the mitochondria; proline, lysine and valerylcarnitine are substrates for mitochondrial electrons transferring flavoproteins, and proline is one of the main metabolites supplying energy to the retina. Overall, our results reveal six new metabolites involved in the plasma metabolomic profile of exudative AMD, suggesting mitochondrial energetic impairments and carnosine deficiency.
C1 [de la Barca, Juan M. Chao; Chupin, Stephanie; Tessier, Lydie; Procaccio, Vincent; Mirebeau-Prunier, Delphine; Simard, Gilles; Reynier, Pascal] CHU Angers, Dept Biochim & Genet, F-49933 Angers, France.
   [de la Barca, Juan M. Chao; Ferre, Marc; Lenaers, Guy; Procaccio, Vincent; Mirebeau-Prunier, Delphine; Reynier, Pascal] Univ Angers, CNRS 6015, INSERM, Unite Mixte Rech MITOVASC,Equipe Mitolab,U1083, F-49933 Angers, France.
   [Rondet-Courbis, Barnabe; Muller, Jeanne; Buisset, Adrien; Leruez, Stephanie; Plubeau, Guillaume; Mace, Thibaut; Moureauzeau, Laurie; Gohier, Philippe; Milea, Dan] CHU Angers, Dept Ophtalmol, F-49933 Angers, France.
   [Blanchet, Odile] CHU Angers, Ctr Ressources Biol, BB-0033-00038, F-49933 Angers, France.
   [Milea, Dan] Duke NUS Med Sch, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
C3 Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   d'Angers; Universite d'Angers; Centre Hospitalier Universitaire
   d'Angers; Universite d'Angers; Centre Hospitalier Universitaire
   d'Angers; National University of Singapore; Singapore National Eye
   Center
RP Reynier, P (通讯作者)，CHU Angers, Dept Biochim & Genet, F-49933 Angers, France.; Reynier, P (通讯作者)，Univ Angers, CNRS 6015, INSERM, Unite Mixte Rech MITOVASC,Equipe Mitolab,U1083, F-49933 Angers, France.
EM JMChaoDeLaBarca@chu-angers.fr; ophtalmopontarlier@gmail.com;
   marc.ferre@univ-angers.fr; Jeanne.Muller@chu-angers.fr;
   Adrien.Buisset@chu-angers.fr; stephanieleruez@hotmail.fr;
   Guillaume.Plubeau@chu-angers.fr; Thibault.Mace@chu-angers.fr;
   Laurie.Mourozeau@chu-angers.fr; Stephanie.Chupin@chu-angers.fr;
   LyTessier@chu-angers.fr; OdBlanchet@chu-angers.fr;
   guy.lenaers@inserm.fr; ViProcaccio@chu-angers.fr;
   DePrunier@chu-angers.fr; GiSimard@chu-angers.fr; PhGohier@chu-angers.fr;
   dan.milea@snec.com.sg; pareynier@chu-angers.fr
RI FERRE, Marc/B-4103-2010; Milea, Dan/AAT-8661-2021
OI FERRE, Marc/0000-0001-8265-7249; Reynier, Pascal/0000-0003-0802-4608;
   BLANCHET, Odile/0000-0002-8275-8741
FU Institut National de la Sante et de la Recherche Medicale (INSERM);
   Centre National de la Recherche Scientifique (CNRS); University of
   Angers; Angers University Hospital
FX We are thankful to the individuals participating in this study. We
   acknowledge support from the Institut National de la Sante et de la
   Recherche Medicale (INSERM), the Centre National de la Recherche
   Scientifique (CNRS), the University of Angers, and the Angers University
   Hospital.
CR Babizhayev MA, 2009, AM J THER, V16, P517, DOI 10.1097/MJT.0b013e318195e327
   Boldyrev AA, 2010, REJUV RES, V13, P156, DOI 10.1089/rej.2009.0923
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Elner SG, 2008, T AM OPHTHAL SOC, V106, P222
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Gao XR, 2019, HUM MOL GENET, V28, P1162, DOI 10.1093/hmg/ddy422
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Kelley RA, 2017, J BIOL CHEM, V292, P21023, DOI 10.1074/jbc.M117.785105
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Leruez S, 2018, INVEST OPHTH VIS SCI, V59, P1025, DOI 10.1167/iovs.17-23055
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   Macedo LW, 2016, MOL NEUROBIOL, V53, P5582, DOI 10.1007/s12035-015-9475-9
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   Reddy V Prakash, 2005, Sci Aging Knowledge Environ, V2005, ppe12, DOI 10.1126/sageke.2005.18.pe12
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Yam M, 2019, J BIOL CHEM, V294, P10278, DOI 10.1074/jbc.RA119.007983
   Zhao B, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0498-z
NR 27
TC 10
Z9 10
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2020
VL 9
IS 3
AR 631
DI 10.3390/jcm9030631
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LF2UT
UT WOS:000527278800020
PM 32120889
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Peeters, A
   Magliano, DJ
   Stevens, J
   Duncan, BB
   Klein, R
   Wong, TY
AF Peeters, Anna
   Magliano, Dianna J.
   Stevens, June
   Duncan, Bruce B.
   Klein, Ronald
   Wong, Tien Y.
TI Changes in Abdominal Obesity and Age-Related Macular Degeneration The
   Atherosclerosis Risk in Communities Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BODY-MASS INDEX; BEAVER DAM EYE; WAIST-HIP RATIO;
   CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; WEIGHT CHANGE; MACULOPATHY;
   MEN; HYPERTENSION; PATHOGENESIS
AB Objective: To examine the association between changes in waist-hip ratio (WHR), a measure of abdominal obesity, and age-related macular degeneration (AMD).
   Methods: A total of 12 515 persons from a population-based cohort study, aged 45 to 64 years in 1987 to 1989, were followed up over 6 years. The percentage change in WHR during follow-up was ranked into sex-specific deciles; an increase in WHR was defined as the top 10% of change and a decrease in WHR as the bottom 10%. The association of increased or decreased WHR and presence of AMD at follow-up was determined using logistic regression adjusting for potential confounders.
   Results: The average change in WHR was an increase of 2%, ranging from a decrease of 44% to an increase of 102%. Adecrease in WHR of 3% or more was associated with 29% lower odds of any AMD (odds ratio=0.71; 95% confidence interval, 0.52-0.97). This effect was most pronounced among obese participants at baseline, where a decrease in WHR was associated with 59% lower odds of AMD (odds ratio=0.41; 95% confidence interval, 0.20-0.82).
   Conclusions: Middle- aged persons who had a 3% or greater reduction in WHR over time were less likely to have AMD, particularly among those who were initially obese.
C1 [Peeters, Anna; Magliano, Dianna J.] Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic 3800, Australia.
   [Stevens, June] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Stevens, June] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA.
   [Duncan, Bruce B.] Univ Fed Rio Grande do Sul, Sch Med, Grad Studies Program Epidemiol, Porto Alegre, RS, Brazil.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117595, Singapore.
C3 Monash University; University of North Carolina; University of North
   Carolina Chapel Hill; University of North Carolina; University of North
   Carolina Chapel Hill; Universidade Federal do Rio Grande do Sul;
   University of Wisconsin System; University of Wisconsin Madison; Centre
   for Eye Research Australia; University of Melbourne; National University
   of Singapore; Singapore National Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Peeters, Anna/M-8284-2019; Duncan, Bruce B/L-4140-2016; Wong, Tien
   Yin/AAC-9724-2020; PEETERS, ANNA/B-3663-2013
OI Peeters, Anna/0000-0003-4340-9132; Duncan, Bruce B/0000-0002-7491-2630;
   Wong, Tien Yin/0000-0002-8448-1264; PEETERS, ANNA/0000-0003-4340-9132;
   Klein, Ronald/0000-0002-4428-6237; Magliano, Dianna
   Josephine/0000-0002-6026-5065
FU National Heart, Lung, and Blood Institute [N01-HC-55015, N01-HC-55016,
   N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022];
   VicHealth Research Fellowship; National Heart Foundation, Australia;
   DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055015,
   N01HC055022, N01HC055020, N01HC055019, N01HC055021, N01HC055016,
   N01HC055018] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [R41HL055018, R41HL055019, R42HL055018] Funding Source:
   NIH RePORTER
FX Atherosclerosis Risk in Communities Study is carried out as a
   collaborative study supported by National Heart, Lung, and Blood
   Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018,
   N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. Additional
   support was provided by a VicHealth Research Fellowship (Dr Peeters) and
   the National Heart Foundation, Australia (Dr Wong).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936
   Brancati FL, 2000, JAMA-J AM MED ASSOC, V283, P2253, DOI 10.1001/jama.283.17.2253
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Duncan BB, 2000, OBES RES, V8, P279, DOI 10.1038/oby.2000.33
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   *NAT HEART LUNG BL, 1988, ATH RISK COMM STUD O
   Paunksnis A, 2005, EUR J OPHTHALMOL, V15, P255, DOI 10.1177/112067210501500213
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Stevens J, 2006, INT J OBESITY, V30, P391, DOI 10.1038/sj.ijo.0803175
   Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wannamethee SG, 1999, DIABETES CARE, V22, P1266, DOI 10.2337/diacare.22.8.1266
   Wannamethee SG, 2005, J EPIDEMIOL COMMUN H, V59, P134, DOI 10.1136/jech.2003.015651
   Wannamethee SG, 2005, ARCH INTERN MED, V165, P1035, DOI 10.1001/archinte.165.9.1035
   Welborn TA, 2003, MED J AUSTRALIA, V179, P580, DOI 10.5694/j.1326-5377.2003.tb05704.x
   WHO, 1997, OB PREV MAN GLOB EP
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 37
TC 41
Z9 41
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2008
VL 126
IS 11
BP 1554
EP 1560
DI 10.1001/archopht.126.11.1554
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 370XV
UT WOS:000260797300011
PM 19001224
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Pinna, A
   Solinas, G
   Giancipoli, E
   Porcu, T
   Zinellu, A
   Damico-Ricci, G
   Boscia, F
   Lanzetta, P
   Avitabile, T
   Schwartz, AG
   Carru, C
AF Pinna, Antonio
   Solinas, Giuliana
   Giancipoli, Ermete
   Porcu, Tiziana
   Zinellu, Angelo
   Damico-Ricci, Giuseppe
   Boscia, Francesco
   Lanzetta, Paolo
   Avitabile, Teresio
   Schwartz, Arthur G.
   Carru, Ciriaco
TI Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Late-stage
   Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE age-related macular degeneration (AMD); Glucose-6-Phosphate
   Dehydrogenase (G6PD) deficiency; observational case-control study;
   stepwise logistic regression analysis
ID LONG-TERM INCIDENCE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; SARDINIAN
   POPULATION; CIGARETTE-SMOKING; MACULOPATHY; CATARACT; SUSCEPTIBILITY;
   POLYMORPHISM; ASSOCIATION
AB Purpose: Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in Western Countries. Evidence indicates that Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, a common genetic abnormality, may protect against ischemic heart and cerebrovascular disease, ocular vascular disorders, and colorectal cancer. This study was undertaken to ascertain whether G6PD deficiency may protect against AMD.
   Materials and Methods: 79 men with late-stage AMD and 79 male, age-matched cataract controls without AMD were recruited in March-December 2016. Smoking status, clinical history, and drug use were recorded. A blood sample was taken from each participant. Complete blood count, hemoglobin, glucose, creatinine, cholesterol, triglycerides, transaminases, bilirubin, and erythrocyte G6PD activity were measured. Stepwise logistic regression was used to investigate the association between G6PD deficiency and AMD.
   Results: G6PD deficiency was found in 7 (8.9%) AMD patients and 8 (10.1%) controls, a not statistically significant difference. Stepwise logistic regression disclosed that AMD was significantly associated with increased diastolic blood pressure (OR=1.09, 95% CI=1.03-1.15, P=0.02) and LDL-cholesterol (OR=1.02, 95% CI=1.0001-1.03, P=0.049) and lower values of white blood cell (WBC) count (OR=0.71, 95% CI=0.56-0.88, P=0.02) and aspartate aminotransferase (AST) (OR=0.92, 95% CI=0.85-0.99, P=0.044).
   Conclusion: Results suggest that G6PD deficiency has no protective effect on nor is a risk factor for AMD. Larger studies are necessary to confirm whether increased diastolic blood pressure and LDL-cholesterol and lower values of WBC count and AST are risk factors for AMD.
C1 [Pinna, Antonio; Porcu, Tiziana; Boscia, Francesco] Univ Sassari, Dept Med Surg & Expt Sci, Sassari, Italy.
   [Solinas, Giuliana; Giancipoli, Ermete; Zinellu, Angelo; Damico-Ricci, Giuseppe; Carru, Ciriaco] Univ Sassari, Dept Biomed Sci, Sassari, Italy.
   [Pinna, Antonio; Boscia, Francesco; Carru, Ciriaco] Azienda Osped Univ Sassari, Sassari, Italy.
   [Lanzetta, Paolo] Univ Udine, Dept Med Ophthalmol, Udine, Italy.
   [Avitabile, Teresio] Univ Catania, Dept Ophthalmol, Catania, Italy.
   [Schwartz, Arthur G.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA.
C3 University of Sassari; University of Sassari; University of Sassari;
   University of Udine; University of Catania; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); Temple University
RP Carru, C (通讯作者)，Univ Sassari, Dept Biomed Sci, Sassari, Italy.; Pinna, A; Carru, C (通讯作者)，Azienda Osped Univ Sassari, Sassari, Italy.; Pinna, A (通讯作者)，Univ Sassari, Ophthalmol Unit, Dept Med Surg & Expt Sci, Viale San Pietro 43 A, I-07100 Sassari, Italy.
EM apinna@uniss.it
RI Pinna, Antonio/H-5067-2018; Avitabile, Teresio/AAC-6076-2022; Carru,
   Ciriaco/AAI-9996-2021; Ricci, Giuseppe D'Amico/O-6051-2019; Boscia,
   Francesco/AAC-7729-2022
OI Pinna, Antonio/0000-0003-3052-2662; Ricci, Giuseppe
   D'Amico/0000-0002-9022-4790; Solinas, Giuliana/0000-0003-2174-0983;
   Carru, Ciriaco/0000-0002-6985-4907
FU "Regione Autonoma della Sardegna," Italy [7, RAS 2010, CRP-25871 ANTONIO
   PINNA]
FX This study was partially supported by a grant funded by the "Regione
   Autonoma della Sardegna," Italy, according to the LR August 7, 2007, n.
   7 (#RAS 2010, CRP-25871 ANTONIO PINNA). The funding organization had no
   role in the design or conduct of this research.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1989, B WORLD HEALTH ORGAN, V67, P601
   Batetta B, 2002, CELL PROLIFERAT, V35, P143
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613
   CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989
   Cocco P, 1998, BLOOD, V91, P706, DOI 10.1182/blood.V91.2.706.706_706_709
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dore MP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005254
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gupte SA, 2008, CURR OPIN INVEST DR, V9, P993
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   INHOFFEN W, 1990, GRAEF ARCH CLIN EXP, V228, P316, DOI 10.1007/BF00920054
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein B E, 1999, Ophthalmic Epidemiol, V6, P247
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488
   Maida A, 1973, HAEMATOLOGICA, V58, P1265
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MELONI T, 1990, AM J OPHTHALMOL, V110, P661, DOI 10.1016/S0002-9394(14)77064-3
   Olea JL, 2012, EUR J OPHTHALMOL, V22, P404, DOI 10.5301/ejo.5000023
   Pes GM, 2018, ANN MED, V50, P68, DOI 10.1080/07853890.2017.1390247
   Pes Giovanni Mario, 2017, Asian Pac J Cancer Prev, V18, P2403, DOI 10.22034/APJCP.2017.18.9.2403
   Pinna A, 2008, INVEST OPHTH VIS SCI, V49, P1328, DOI 10.1167/iovs.07-1115
   Pinna A, 2007, INVEST OPHTH VIS SCI, V48, P2747, DOI 10.1167/iovs.06-1064
   Pinna A, 2013, INT J MED SCI, V10, P1907, DOI 10.7150/ijms.6776
   Pinna A, 2009, OPHTHAL EPIDEMIOL, V16, P395, DOI 10.3109/09286580903312293
   Robman L, 2005, EYE, V19, P1074, DOI 10.1038/sj.eye.6701964
   Ruwende C, 1998, J MOL MED, V76, P581, DOI 10.1007/s001090050253
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   1997, HAEMATOLOGICA, V82, P440
NR 50
TC 3
Z9 3
U1 0
U2 1
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2019
VL 16
IS 5
BP 623
EP 629
DI 10.7150/ijms.30155
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HY2IU
UT WOS:000467944400001
PM 31217728
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Sung, HJ
   Han, JI
   Lee, JW
   Uhm, KB
   Heo, K
AF Sung, Ho Jin
   Han, Jung Il
   Lee, Ji Won
   Uhm, Ki Bang
   Heo, Kyun
TI TCCR/WSX-1 is a novel angiogenic factor in age-related macular
   degeneration
SO MOLECULAR VISION
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; C-REACTIVE PROTEIN; CHOROIDAL
   NEOVASCULARIZATION; INTERLEUKIN-27; EPIDEMIOLOGY; INFLAMMATION;
   PROGRESSION; CELLS
AB Purpose: Age-related macular degeneration (AMD) is the major cause of blindness among persons aged 60 years and older. The current approved therapies for AMD are exclusively limited to inhibiting vascular endothelial growth factor. However, substantial improvement in vision occurs in only one-third of patients treated with vascular endothelial growth factor antagonists, and one-sixth of treated patients still progress to legal blindness. Therefore, more specific targets are needed to treat AMD. Our goal was to find secretory proteins that change in number in the aqueous humor and that cause exudative AMD disease.
   Methods: The number of molecules changed in the aqueous humor of patients with AMD compared to the control group was determined using antibody array analysis. The levels of angiopoietin-2 and insulin-like growth factor binding protein-related protein 7 were measured using enzyme-linked immunosorbent assay. The levels of T-cell cytokine receptor (TCCR/WSX-1) were determined using western blot. Potential TCCR/WSX-1-mediated effects on tube formation as well as phosphorylation of extracellular signal-regulated kinase in human umbilical vein endothelial cells were determined.
   Results: We found that the numbers of several molecules were changed in the aqueous humor of patients with AMD compared to the control group. Among them, angiopoietin-2 was reduced by 20% and TCCR/WSX-1 was increased twofold. Moreover, exogenous TCCR protein induced tube formation and phosphorylation of extracellular signal-regulated kinase in human umbilical vein endothelial cells.
   Conclusions: Our study suggests that TCCR/WSX-1 is closely associated with angiogenesis and could serve as a novel therapeutic target in patients with AMD.
C1 [Sung, Ho Jin; Lee, Ji Won; Heo, Kyun] Natl Canc Ctr, Div Convergence Technol, Funct Genom Branch, Goyang Si 410769, Gyeonggi Do, South Korea.
   [Sung, Ho Jin] Ewha Womans Univ, Dept Life Sci, Div Life & Pharmaceut Sci, Seoul, South Korea.
   [Sung, Ho Jin] Ewha Womans Univ, Ctr Cell Signaling & Drug Discovery Res, Seoul, South Korea.
   [Han, Jung Il] Konyang Univ, Sch Med, Kims Eye Hosp, Dept Ophthalmol,Retina Ctr, Seoul, South Korea.
   [Uhm, Ki Bang] Hanyang Univ, Coll Med, Dept Ophthalmol, Seoul 133791, South Korea.
C3 National Cancer Center - Korea (NCC); Ewha Womans University; Ewha
   Womans University; Konyang University; Hanyang University
RP Heo, K (通讯作者)，Natl Canc Ctr, Div Convergence Technol, Funct Genom Branch, 323 Ilsan Ro, Goyang Si 410769, Gyeonggi Do, South Korea.
EM hk@ncc.re.kr
RI Klets, Dmytro/P-3547-2018
OI Klets, Dmytro/0000-0001-7463-1030; Uhm, Ki Bang/0000-0002-7649-3695
FU National Cancer Center [NCC1010224]
FX This work was supported by research grants from the National Cancer
   Center Grant (NCC1010224).
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Augustin AJ, 2009, CLIN OPHTHALMOL, V3, P175
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Coukos G, 2005, BRIT J CANCER, V92, P1182, DOI 10.1038/sj.bjc.6602476
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Feng XM, 2007, HUM IMMUNOL, V68, P965, DOI 10.1016/j.humimm.2007.10.004
   Jankowski M, 2010, ARCH IMMUNOL THER EX, V58, P417, DOI 10.1007/s00005-010-0098-6
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lacotte S, 2009, ANN NY ACAD SCI, V1173, P310, DOI 10.1111/j.1749-6632.2009.04813.x
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Noonan DM, 2008, CANCER METAST REV, V27, P31, DOI 10.1007/s10555-007-9108-5
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Sozzani S, 2007, TRENDS IMMUNOL, V28, P385, DOI 10.1016/j.it.2007.07.006
   STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348
   Villarino AV, 2004, J IMMUNOL, V173, P715, DOI 10.4049/jimmunol.173.2.715
   Yoshida H, 2008, IMMUNOL REV, V226, P234, DOI 10.1111/j.1600-065X.2008.00710.x
   Zhang J, 2006, J PATHOL, V208, P453, DOI 10.1002/path.1937
NR 26
TC 12
Z9 12
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 28
PY 2012
VL 18
IS 25-28
BP 234
EP 240
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 905AB
UT WOS:000301242000003
PM 22312192
DA 2022-11-30
ER

PT J
AU Seitsonen, S
   Jarvela, I
   Meri, S
   Tommila, P
   Ranta, P
   Immonen, I
AF Seitsonen, Sanna
   Jarvela, Irma
   Meri, Seppo
   Tommila, Petri
   Ranta, Paivi
   Immonen, Ilkka
TI Complement factor HY402H polymorphism and characteristics of exudative
   age-related macular degeneration lesions
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   complement factor H; polymorphism
ID FACTOR-H POLYMORPHISM; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   PHOTODYNAMIC THERAPY; STRUCTURAL FINDINGS; VARIANT; RISK; GENE; CFH;
   SUSCEPTIBILITY; VERTEPORFIN
AB Purpose: The Y402H polymorphism of the complement factor H (CFH) gene is associated with age-related macular degeneration (AMD) in many populations. The reported genotype-phenotype correlations in the CFH Y402H polymorphism have not been pronounced and no studies on the effect of the polymorphism on the subgroups within wet AMD have been performed. In this study, we wanted to evaluate whether the CFH Y402H polymorphism has an effect on clinical variables in recent exudative AMD lesions.
   Methods: The study included 172 patients with exudative AMD. The size of AMD lesions and the presence and area of other AMD lesion variables were recorded in fluorescein angiography (FA) and analysed in relation to the Y402H genotypes.
   Results: The median lesion size (classic + occult choroidal neovascularization [CNV] + serous pigment epithelium detachment [PED] + haemorrhage, if present) was 8.15 mm(2) in patients homozygous for the CFH risk allele (CC), 7.50 mm(2) in heterozygous patients (CT), and 7.05 mm(2) in those with the normal genotype (TT) (p = 0.599). Areas of classic and occult CNV, combined, without serous PED or haemorrhage were 6.37 mm(2), 5.00 mm(2) and 5.18 mm(2), respectively (p = 0.407). There was a trend for CC patients to have more frequently minimally classic and less frequently predominantly classic lesion composition than CT or TT subjects.
   Conclusions: We detected no clear impact of the CFH Y402H polymorphism on recent exudative AMD lesion characteristics. Although the complement cascade is implicated in CNV formation and scarring processes in the retina, the Y402H polymorphism appears relatively neutral in these functions.
C1 [Seitsonen, Sanna; Tommila, Petri; Ranta, Paivi; Immonen, Ilkka] Univ Helsinki, Cent Hosp, Dept Ophthalmol, Helsinki 00029, Finland.
   [Jarvela, Irma] Univ Helsinki, Dept Med Genet, Helsinki 00029, Finland.
   [Meri, Seppo] Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, Helsinki 00029, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; University of Helsinki
RP Seitsonen, S (通讯作者)，Univ Helsinki, Cent Hosp, Dept Ophthalmol, Box 220, Helsinki 00029, Finland.
EM sanna.seitsonen@hus.fi
RI Jarvela, Irma E/L-5836-2013
OI Jarvela, Irma E/0000-0002-1770-6187; Meri, Seppo/0000-0001-9142-501X
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Riusala A, 2005, GRAEF ARCH CLIN EXP, V243, P947, DOI 10.1007/s00417-005-1161-6
   Riusala AM, 2004, AM J OPHTHALMOL, V138, P245, DOI 10.1016/j.ajo.2004.03.007
   Seitsonen S, 2006, MOL VIS, V12, P796
   Souied EH, 2005, MOL VIS, V11, P1135
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 24
TC 21
Z9 21
U1 0
U2 4
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2008
VL 86
IS 4
BP 390
EP 394
DI 10.1111/j.1600-0420.2007.01050.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 309YT
UT WOS:000256496800007
PM 17995985
DA 2022-11-30
ER

PT J
AU Clark, SJ
   Higman, VA
   Mulloy, B
   Perkins, SJ
   Lea, SM
   Sim, RB
   Day, AJ
AF Clark, Simon J.
   Higman, Victoria A.
   Mulloy, Barbara
   Perkins, Stephen J.
   Lea, Susan M.
   Sim, Robert B.
   Day, Anthony J.
TI His-384 allotypic variant of factor H associated with age-related
   macular degeneration has different heparin binding properties from the
   non-disease-associated form.
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID COMPLEMENT FACTOR-H; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; BOUND
   C3B; SULFATE; IDENTIFICATION; POLYMORPHISM; PROTEIN; COMMON; MEMBRANE
AB A polymorphism in complement factor H has recently been associated with age-related macular degeneration (AMD), the leading cause of blindness in the elderly. A histidine rather than a tyrosine at residue position 384 in the mature protein increases the risk of AMD. Here, using a recombinant construct, we show that amino acid 384 is adjacent to a heparin-binding site in CCP7 of factor H and demonstrate that the allotypic variants differentially recognize heparin. This functional alteration may affect binding of factor H to polyanionic patterns on host surfaces, potentially influencing complement activation, immune complex clearance, and inflammation in the macula of AMD patients.
C1 Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England.
   Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England.
   Univ Oxford, Dept Biochem, Mol Biophys Lab, Oxford OX1 3QU, England.
   Natl Inst Biol Stand & Controls, Blanche Lane, Potters Bar EN6 3QG, Herts, England.
   UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England.
C3 University of Manchester; University of Oxford; University of Oxford;
   National Institute for Biological Standards & Control; University of
   London; University College London
RP Day, AJ (通讯作者)，Univ Manchester, Fac Life Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.
EM anthony.day@manchester.ac.uk
RI Higman, Victoria/H-3795-2011; Day, Anthony/O-1658-2015; Sim,
   Bob/A-1354-2008; Lea, Susan M/B-7678-2009
OI Higman, Victoria/0000-0002-3204-2665; Day, Anthony/0000-0002-1415-3134;
   Sim, Bob/0000-0002-2855-7455; Lea, Susan M/0000-0001-9287-8053; Clark,
   Simon/0000-0001-8394-8355
FU MRC [MC_U138274352] Funding Source: UKRI; Medical Research Council
   [MC_U138274352] Funding Source: Medline
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR
   CARRENO MP, 1989, EUR J IMMUNOL, V19, P2145, DOI 10.1002/eji.1830191126
   Carrino DA, 2003, J BIOL CHEM, V278, P17566, DOI 10.1074/jbc.M300124200
   Cavallotti C, 2004, OPHTHALMIC RES, V36, P211, DOI 10.1159/000078779
   Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Girardin EP, 2005, J BIOL CHEM, V280, P38059, DOI 10.1074/jbc.M507997200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Lauder RM, 1998, BIOCHEM J, V330, P753
   Mahoney DJ, 2005, J BIOL CHEM, V280, P27044, DOI 10.1074/jbc.M502068200
   Mahoney DJ, 2004, ANAL BIOCHEM, V330, P123, DOI 10.1016/j.ab.2004.03.055
   Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   MULLOY B, 1994, CARBOHYD RES, V255, P1, DOI 10.1016/S0008-6215(00)90968-6
   Mulloy B, 2000, THROMB HAEMOSTASIS, V84, P1052
   Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147
   NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T
   Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Saito A, 2005, J BIOCHEM, V137, P225, DOI 10.1093/jb/mvi025
   SIM E, 1983, BIOSCIENCE REP, V3, P1119, DOI 10.1007/BF01120205
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   THOMAS DP, 1984, THROMB HAEMOSTASIS, V52, P148
   White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604
NR 44
TC 148
Z9 153
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 25
PY 2006
VL 281
IS 34
BP 24713
EP 24720
DI 10.1074/jbc.M605083200
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 074YF
UT WOS:000239847800067
PM 16787919
OA hybrid
DA 2022-11-30
ER

PT J
AU Joeres, S
   Tsong, JW
   Updike, PG
   Collins, AT
   Dustin, L
   Walsh, AC
   Romano, PW
   Sadda, SR
AF Joeres, Sandra
   Tsong, Jerry W.
   Updike, Paul G.
   Collins, Allyson T.
   Dustin, Laurie
   Walsh, Alexander C.
   Romano, Peggy W.
   Sadda, SriniVas R.
TI Reproducibility of quantitative optical coherence tomography subanalysis
   in neovascular age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL THICKNESS MEASUREMENTS; CHOROIDAL NEOVASCULARIZATION;
   RESOLUTION; EDEMA
AB PURPOSE. To determine the intergrader reproducibility for computer-assisted grading of optical coherence tomography (OCT) images in eyes with neovascular age-related macular degeneration (AMD), by using a standardized grading procedure.
   METHODS. Sixty OCT image sets ( of six radial lines each) were independently analyzed by two graders using validated custom software (OCTOR) to draw boundaries manually on OCT B-scans. Spaces delineated by these boundaries included retina, subretinal fluid, subretinal tissue, and pigment epithelial detachments (PEDs). Volume measurements for the nine Early Treatment of Diabetic Retinopathy Study (ETDRS) subfields and the mean foveal center point (FCP) thickness were calculated by the software and compared by using weighted kappa statistics and intraclass correlation coefficients (ICCs).
   RESULTS. Intergrader comparison of the foveal central subfield (FCS) volume, total volume, and mean FCP thickness showed a high level of agreement and strong correlation between measurements for all spaces (kappa(weighted) = 0.72-0.97; ICC = 0.92-0.99). The best agreement was observed for total volume of the combination of all four graded spaces (kappa(weighted) = 0.97, mean difference = 0.31 mm(3), or 2.51%). The highest ICCs were seen for FCP thickness measurements. The poorest agreement was found for grading of subretinal tissue. Eyes with advanced choroidal neovascularization (CNV) and poor visibility of the retinal pigment epithelium (RPE) band appeared to show the greatest intergrader discrepancies.
   CONCLUSIONS. Analysis of OCT images by trained graders using computer-assisted grading software allows for highly reproducible quantitative measurements, even in eyes with complex diseases such as neovascular AMD. Quantitative subanalysis may be useful in studying the differential morphologic effect of therapies on various anatomic components.
C1 Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA USA.
   Univ So Calif, Keck Sch Med, Doheny Eye Inst, Dept Prevent Med, Los Angeles, CA USA.
C3 Doheny Eye Institute; Doheny Eye Institute; University of Southern
   California; Doheny Eye Institute; University of Southern California
RP Sadda, SR (通讯作者)，Doheny Eye Inst, DEI 3623,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
FU NEI NIH HHS [EY03040, R01 EY014375] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [R01EY014375, P30EY003040] Funding Source: NIH RePORTER
CR Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Fukuchi T, 2001, JPN J OPHTHALMOL, V45, P252, DOI 10.1016/S0021-5155(00)00381-6
   Gallemore RP, 2000, RETINA-J RET VIT DIS, V20, P115, DOI 10.1097/00006982-200003000-00001
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hee MR, 2005, AM J OPHTHALMOL, V139, P154, DOI 10.1016/j.ajo.2004.08.066
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   LANDIS JR, 1977, BIOMETRICS, V104, P7
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Panozzo Giacomo, 2003, Semin Ophthalmol, V18, P74, DOI 10.1076/soph.18.2.74.15854
   PARK HM, 2003, P 3 INT C QUAL SOFTW, P1
   Pons ME, 2005, OPHTHALMOLOGY, V112, P1079, DOI 10.1016/j.ophtha.2004.11.061
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rivellese M, 2000, OPHTHALMIC SURG LAS, V31, P192
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   SCHUMAN JS, 2004, OPTICAL COHERENCE TO
   Toth CA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1425, DOI 10.1001/archopht.1997.01100160595012
   Voo Irene, 2004, Ophthalmol Clin North Am, V17, P21, DOI 10.1016/j.ohc.2003.12.002
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Zawadzki RJ, 2005, OPT EXPRESS, V13, P8532, DOI 10.1364/OPEX.13.008532
NR 26
TC 90
Z9 93
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2007
VL 48
IS 9
BP 4300
EP 4307
DI 10.1167/iovs.07-0179
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 204RO
UT WOS:000249061900055
PM 17724220
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Pawlowska, E
   Szczepanska, J
   Jablkowska, A
   Blasiak, J
AF Kaarniranta, Kai
   Pawlowska, Elzbieta
   Szczepanska, Joanna
   Jablkowska, Aleksandra
   Blasiak, Janusz
TI Role of Mitochondrial DNA Damage in ROS-Mediated Pathogenesis of
   Age-Related Macular Degeneration (AMD)
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; mitochondria; mtDNA damage; DNA damage
   response; reactive oxygen species
ID RETINAL-PIGMENT EPITHELIUM; BASE EXCISION-REPAIR; OXIDATIVE STRESS;
   HUMAN RPE; PROGRESSIVE STAGES; POTENT SOURCES; REPLICATION; DISEASE;
   CELLS; 7,8-DIHYDRO-8-OXOGUANINE
AB Age-related macular degeneration (AMD) is a complex eye disease that affects millions of people worldwide and is the main reason for legal blindness and vision loss in the elderly in developed countries. Although the cause of AMD pathogenesis is not known, oxidative stress-related damage to retinal pigment epithelium (RPE) is considered an early event in AMD induction. However, the precise cause of such damage and of the induction of oxidative stress, including related oxidative effects occurring in RPE and the onset and progression of AMD, are not well understood. Many results point to mitochondria as a source of elevated levels of reactive oxygen species (ROS) in AMD. This ROS increase can be associated with aging and effects induced by other AMD risk factors and is correlated with damage to mitochondrial DNA. Therefore, mitochondrial DNA (mtDNA) damage can be an essential element of AMD pathogenesis. This is supported by many studies that show a greater susceptibility of mtDNA than nuclear DNA to DNA-damaging agents in AMD. Therefore, the mitochondrial DNA damage reaction (mtDDR) is important in AMD prevention and in slowing down its progression as is ROS-targeting AMD therapy. However, we know far less about mtDNA than its nuclear counterparts. Further research should measure DNA damage in order to compare it in mitochondria and the nucleus, as current methods have serious disadvantages.
C1 [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, PL-92216 Lodz, Poland.
   [Szczepanska, Joanna] Med Univ Lodz, Dept Pediat Dent, PL-92216 Lodz, Poland.
   [Jablkowska, Aleksandra] W Bieganski Hosp, Dept Infect & Liver Dis, PL-91347 Lodz, Poland.
   [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Medical University Lodz; Medical University Lodz;
   University of Lodz
RP Blasiak, J (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
EM kai.kaarniranta@kuh.fi; elzbieta.pawlowska@umed.lodz.pl;
   joanna.szczepanska@umed.lodz.pl; jablkowska@pro.onet.pl;
   janusz.blasiak@biol.uni.lodz.pl
OI Blasiak, Janusz/0000-0001-9539-9584; Kaarniranta,
   Kai/0000-0003-2600-8679; Pawlowska, Elzbieta/0000-0002-5373-4783;
   Szczepanska, JOANNA/0000-0001-9912-5345
FU National Science Centre, Poland [2017/27/B/NZ3/00872]
FX This work was supported by National Science Centre, Poland grant number
   2017/27/B/NZ3/00872.
CR Aamann MD, 2010, FASEB J, V24, P2334, DOI 10.1096/fj.09-147991
   Alexeyev M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012641
   Armstrong JS, 2007, METHOD CELL BIOL, V80, P355, DOI 10.1016/S0091-679X(06)80018-X
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Beckman KB, 1999, MUTAT RES-FUND MOL M, V424, P51, DOI 10.1016/S0027-5107(99)00007-X
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Brand RM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00920
   Sanchez MC, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7080098
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Caston RA, 2017, FREE RADICAL BIO MED, V107, P146, DOI 10.1016/j.freeradbiomed.2016.11.025
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Chocron ES, 2019, BBA-MOL BASIS DIS, V1865, P285, DOI 10.1016/j.bbadis.2018.09.035
   Cline SD, 2012, BBA-GENE REGUL MECH, V1819, P979, DOI 10.1016/j.bbagrm.2012.06.002
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dahal S, 2018, CELL MOL LIFE SCI, V75, P1641, DOI 10.1007/s00018-017-2702-y
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davalli P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3565127
   Dieguez HH, 2019, FREE RADICAL BIO MED, V131, P72, DOI 10.1016/j.freeradbiomed.2018.11.035
   Dunn JD, 2015, REDOX BIOL, V6, P472, DOI 10.1016/j.redox.2015.09.005
   Elfawy HA, 2019, LIFE SCI, V218, P165, DOI 10.1016/j.lfs.2018.12.029
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   Guo MY, 2019, ACTA OPHTHALMOL, V97, pE1, DOI 10.1111/aos.13825
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Henderson PT, 2003, BIOCHEMISTRY-US, V42, P9257, DOI 10.1021/bi0347252
   Henderson PT, 2002, BIOCHEMISTRY-US, V41, P914, DOI 10.1021/bi0156355
   Hiona A, 2008, EXP GERONTOL, V43, P24, DOI 10.1016/j.exger.2007.10.001
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jezek P, 2019, INT J BIOCHEM CELL B, V106, P21, DOI 10.1016/j.biocel.2018.10.012
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kamenisch Y, 2010, J EXP MED, V207, P379, DOI 10.1084/jem.20091834
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kenney MC, 2014, HUM MOL GENET, V23, P3537, DOI 10.1093/hmg/ddu065
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kim JS, 2018, CLIN EXP PHARMACOL P, V45, P547, DOI 10.1111/1440-1681.12914
   Kiyuna LA, 2018, FREE RADICAL BIO MED, V129, P155, DOI 10.1016/j.freeradbiomed.2018.09.019
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Lawrenson J.G., 2017, COCHRANE DB SYST REV, V2017
   Leung W, 2019, GENES-BASEL, V10, DOI 10.3390/genes10010010
   Li XY, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-19
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu P, 2008, MOL CELL BIOL, V28, P4975, DOI 10.1128/MCB.00457-08
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Medeiros TC, 2018, J CELL BIOL, V217, P1601, DOI 10.1083/jcb.201801168
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Moldogazieva NT, 2018, FREE RADICAL RES, V52, P507, DOI 10.1080/10715762.2018.1457217
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Murphy MP, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003386
   Nakamura J, 1999, CANCER RES, V59, P2522
   Nanayakkara GK, 2019, ARCH BIOCHEM BIOPHYS, V662, P68, DOI 10.1016/j.abb.2018.12.002
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nogueira C, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-34
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olivas-Aguirre M, 2019, J LEUKOCYTE BIOL, V105, P935, DOI 10.1002/JLB.5VMR0818-330RR
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Phillips AF, 2017, MOL CELL, V65, P527, DOI 10.1016/j.molcel.2016.12.014
   Pinto M, 2015, FREE RADICAL BIO MED, V85, P250, DOI 10.1016/j.freeradbiomed.2015.05.005
   Plesca D, 2008, METHOD ENZYMOL, V446, P107, DOI 10.1016/S0076-6879(08)01606-6
   Pohjoismaki JLO, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201800102
   Prakash A, 2015, J CELL BIOCHEM, V116, P1490, DOI 10.1002/jcb.25103
   Rothfuss O, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1082
   Russell O, 2014, EXP CELL RES, V325, P38, DOI 10.1016/j.yexcr.2014.03.012
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Shadel GS, 2015, CELL, V163, P560, DOI 10.1016/j.cell.2015.10.001
   Shen L, 2015, INVEST OPHTH VIS SCI, V56, P4290, DOI 10.1167/iovs.15-16533
   Shokolenko I, 2009, NUCLEIC ACIDS RES, V37, P2539, DOI 10.1093/nar/gkp100
   Shokolenko IN, 2013, DNA REPAIR, V12, P488, DOI 10.1016/j.dnarep.2013.04.023
   Siguroardottir S, 2000, AM J HUM GENET, V66, P1599, DOI 10.1086/302902
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015
   Stefano GB, 2017, ADV EXP MED BIOL, V982, P577, DOI 10.1007/978-3-319-55330-6_30
   Suliman HB, 2016, PHARMACOL REV, V68, P20, DOI 10.1124/pr.115.011502
   Tadi SK, 2016, MOL BIOL CELL, V27, P223, DOI 10.1091/mbc.E15-05-0260
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tilleul J, 2013, MOL VIS, V19, P1132
   Torregrosa-Munumer R, 2017, P NATL ACAD SCI USA, V114, P11398, DOI 10.1073/pnas.1705367114
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vasileiou PVS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081821
   Wang AL, 2008, MOL VIS, V14, P644
   Wang AL, 2010, NEUROBIOL AGING, V31, P2002, DOI 10.1016/j.neurobiolaging.2008.10.019
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yasuhira S, 2000, J BIOL CHEM, V275, P11824, DOI 10.1074/jbc.275.16.11824
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 112
TC 84
Z9 84
U1 4
U2 19
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY 2
PY 2019
VL 20
IS 10
AR 2374
DI 10.3390/ijms20102374
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IC5IP
UT WOS:000471001400005
PM 31091656
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Scoles, D
   Ying, GS
   Pan, W
   Hua, PY
   Grunwald, JE
   Daniel, E
   Jaffe, GJ
   Toth, CA
   Martin, DF
   Maguire, MG
AF Scoles, Drew
   Ying, Gui-shuang
   Pan, Wei
   Hua, Peiying
   Grunwald, Juan E.
   Daniel, Ebenezer
   Jaffe, Glenn J.
   Toth, Cynthia A.
   Martin, Daniel F.
   Maguire, Maureen G.
CA Comparison AMD Treatments Trials R
TI Characteristics of Eyes With Good Visual Acuity at 5 Years After
   Initiation of Treatment for Age-Related Macular Degeneration but Not
   Receiving Treatment From Years 3 to 5 Post Hoc Analysis of the CATT
   Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BASE-LINE PREDICTORS; RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; RISK
AB This case-control study examines the baseline data and 5-year outcomes of participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) who retained good vision despite receiving no therapy for 3 years after release from the 2-year CATT treatment protocol.
   Importance Identifying the characteristics of eyes with neovascular age-related macular degeneration (nAMD) that maintain good vision without anti-vascular endothelial growth factor treatment for at least 3 years after management, as occurred in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), may have prognostic importance and help in understanding the disease and its treatment. Objectives To ascertain the characteristics of eyes in the CATT that retained good vision despite receiving no therapy for 3 years after release from the 2-year CATT treatment protocol. Design, Setting and Participants This case-control study analyzed the baseline and follow-up characteristics of eyes with nAMD that were enrolled in the CATT from 43 US clinical centers between February 20, 2008, and December 9, 2009. After initial randomization to 1 of 4 treatment groups (ranibizumab monthly, bevacizumab monthly, ranibizumab as needed, or bevacizumab as needed), at year 1, participants in the monthly groups were rerandomized to continue monthly treatment or to switch to as-needed treatment using the same drug as originally assigned. At year 2, participants were released from the protocol to treatment at the discretion of their ophthalmologist. At year 5, participants were recalled for examination. This present analysis, conducted from December 1, 2018, to September 30, 2019, compared the eyes of 40 participants (referred to as the cessation of treatment with good visual acuity, or CTGVA, group) with the eyes of the remainder of the CATT Follow-up Study (referred to as the other group). Main Outcomes and Measures Visual acuity, morphologic characteristics, and number of treatments over 5 years. Results Among 625 eyes with nAMD at baseline and a visual acuity measurement at year 5, 40 (6.4%; 95% CI, 4.7%-8.7%) were included in the analysis. These 40 participants, compared with the other group (n = 585), had a lower mean (SD) age of 74.7 (7.3) years (vs 77.7 [7.3] years; P = .01) and included 26 women (65.0%). Baseline characteristics were similar between eyes in the CTGVA and other groups, except for better visual acuity letter score in the study eye (68.8 vs 61.8; P = .001) and the fellow eye (78.4 vs 68.0; P = .01) as well as the presence of blocked fluorescence seen more often in participants in the CTGVA vs the other group (27.5% vs 13.8%; P = .02). Eyes in the CTGVA group with as-needed treatment received fewer mean (SD) injections in year 1 (5.8 [4.0] vs 8.1 [3.5]) and year 2 (7.7 [5.7] vs 13.8 [6.8]) than eyes in the other as-needed group. Mean (SD) visual acuity letter score at 5 years was 79.0 (5.5; Snellen 20/25) in the CTGVA group and 57.5 (24.2; Snellen 20/80) in the other group. Conclusions and Relevance These findings suggest that a small proportion of eyes with nAMD can retain good visual acuity with no treatment for at least 3 years after the initial 2 years of treatment. Unique characteristics of eyes that could discontinue treatment while maintaining good visual acuity could not be identified at baseline, but data suggest that not all eyes with this disease may need treatment forever.
   Question In the Comparison of Age-Related Macular Degeneration Treatments Trials, what was the frequency of retained good vision at 5 years when no treatment was given after 2 years from treatment initiation? Findings In this case-control study of 625 eyes with neovascular age-related macular degeneration that were enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials, a small percentage (40 [6.4%]) retained a visual acuity letter score of 68 (Snellen 20/40) or better with no treatment for at least 3 years. Meaning Findings of this study demonstrated that a minority of participants with neovascular age-related macular degeneration retained good vision even without treatment after 2 years of protocol management, suggesting that not all eyes with this disease will need treatment forever.
C1 [Scoles, Drew; Ying, Gui-shuang; Pan, Wei; Hua, Peiying; Grunwald, Juan E.; Daniel, Ebenezer; Maguire, Maureen G.] Univ Penn, Perelman Sch Med, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
   [Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Duke Eye Ctr, Durham, NC USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Duke University;
   Cleveland Clinic Foundation
RP Scoles, D (通讯作者)，Univ Penn, Perelman Sch Med, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM drew.scoles@pennmedicine.upenn.edu
OI Folk, James/0000-0002-6271-2906; Russell, Stephen/0000-0003-3776-1367;
   Scoles, Drew/0000-0002-8942-5456
FU NEI, NIH, US Department of Health and Human Services [U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, U10 EY023530, R21EY028998]
FX This study was funded by cooperative agreements U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, U10 EY023530, and R21EY028998 from
   the NEI, NIH, US Department of Health and Human Services.
CR Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Haddad WM, 2017, RETINA-J RET VIT DIS, V37, P951, DOI 10.1097/IAE.0000000000001282
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P516, DOI 10.1097/IAE.0000000000001572
   Nguyen V, 2019, OPHTHALMOL RETINA, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 23
TC 3
Z9 3
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2020
VL 138
IS 3
BP 276
EP 284
DI 10.1001/jamaophthalmol.2019.5831
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW1MQ
UT WOS:000520936000007
PM 31999297
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Sardell, RJ
   Bailey, JNC
   Courtenay, MD
   Whitehead, P
   Laux, RA
   Adams, LD
   Fortun, JA
   Brantley, MA
   Kovach, JL
   Schwartz, SG
   Agarwal, A
   Scott, WK
   Haines, JL
   Pericak-Vance, MA
AF Sardell, Rebecca J.
   Bailey, Jessica N. Cooke
   Courtenay, Monique D.
   Whitehead, Patrice
   Laux, Renee A.
   Adams, Larry D.
   Fortun, Jorge A.
   Brantley, Milam A., Jr.
   Kovach, Jaclyn L.
   Schwartz, Stephen G.
   Agarwal, Anita
   Scott, William K.
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
TI Whole exome sequencing of extreme age-related macular degeneration
   phenotypes
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; COMPONENT 2; FACTOR-B;
   MISSING HERITABILITY; GENETIC ASSOCIATION; VISUAL IMPAIRMENT;
   APOLIPOPROTEIN-E; INCREASES RISK; RARE VARIANTS
AB Purpose: Demographic, environmental, and genetic risk factors for age-related macular degeneration (AMD) have been identified; however, a substantial portion of the variance in AMD disease risk and heritability remains unexplained. To identify AMD risk variants and generate hypotheses for future studies, we performed whole exome sequencing for 75 individuals whose phenotype was not well predicted by their genotype at known risk loci. We hypothesized that these phenotypically extreme individuals were more likely to carry rare risk or protective variants with large effect sizes.
   Methods: A genetic risk score was calculated in a case-control set of 864 individuals (467 AMD cases, 397 controls) based on 19 common (>= 1% minor allele frequency, MAF) single nucleotide variants previously associated with the risk of advanced AMD in a large meta-analysis of advanced cases and controls. We then selected for sequencing 39 cases with bilateral choroidal neovascularization with the lowest genetic risk scores to detect risk variants and 36 unaffected controls with the highest genetic risk score to detect protective variants. After minimizing the influence of 19 common genetic risk loci on case-control status, we targeted single variants of large effect and the aggregate effect of weaker variants within genes and pathways. Single variant tests were conducted on all variants, while gene-based and pathway analyses were conducted on three subsets of data: 1) rare (<= 1% MAF in the European population) stop, splice, or damaging missense variants, 2) all rare variants, and 3) all variants. All analyses controlled for the effects of age and sex.
   Results: No variant, gene, or pathway outside regions known to be associated with risk for advanced AMD reached genome-wide significance. However, we identified several variants with substantial differences in allele frequency between cases and controls with strong additive effects on affection status after controlling for age and sex. Protective effects trending toward significance were detected at two loci identified in single-variant analyses: an intronic variant in FBLN7 (the gene encoding fibulin 7) and at three variants near pyridoxal (pyridoxine, vitamin B-6) kinase (PDXK). Aggregate rare-variant analyses suggested evidence for association at ASRGL1, a gene previously linked to photoreceptor cell death, and at BSDC1. In known AMD loci we also identified 29 novel or rare damaging missense or stop/splice variants in our sample of cases and controls.
   Conclusions: Identified variants and genes may highlight regions important in the pathogenesis of AMD and are key targets for replication.
C1 [Sardell, Rebecca J.; Courtenay, Monique D.; Whitehead, Patrice; Adams, Larry D.; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, 1501 NW 10th Ave,BRB 319, Miami, FL 33136 USA.
   [Bailey, Jessica N. Cooke; Laux, Renee A.; Haines, Jonathan L.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Fortun, Jorge A.; Kovach, Jaclyn L.; Schwartz, Stephen G.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Brantley, Milam A., Jr.; Agarwal, Anita] Vanderbilt Univ, Sch Med, Dept Ophthalmol & Visual Sci, Nashville, TN 37212 USA.
C3 University of Miami; Case Western Reserve University; Bascom Palmer Eye
   Institute; University of Miami; Vanderbilt University
RP Pericak-Vance, MA (通讯作者)，Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, 1501 NW 10th Ave,BRB 319, Miami, FL 33136 USA.
EM MPericak@med.miami.edu
RI Fortún, Jesús/H-1816-2017; Cooke Bailey, Jessica Nicole/AFQ-5925-2022;
   Haines, Jonathan/C-3374-2012
OI Fortún, Jesús/0000-0002-6959-5263; Cooke Bailey, Jessica
   Nicole/0000-0002-4001-8702; Haines, Jonathan/0000-0002-4351-4728; Scott,
   William/0000-0001-9336-6404
FU Alcon; Genentech; NIH Center Core Grant [P30EY014801]; Research to
   Prevent Blindness, New York, NY; NEI T32 training grant [5T32EY023194];
   PhRMA Informatics Fellowship;  [R01EY012118]; NATIONAL EYE INSTITUTE
   [R01EY012118, T32EY023194, P30EY014801] Funding Source: NIH RePORTER
FX We thank all the participants of this study. We thank Drs. Michael
   Hauser and Eric Postel for their assistance ascertaining participants.
   JAF has been a consultant for Allergan and Dorc, and received financial
   support from Alcon and Genentech. This work was presented at ARVO (2015)
   and ASHG (2014 and 2015) annual meetings. Grants: R01EY012118 (to MAP-V,
   WKS, JLH, AA), NIH Center Core Grant P30EY014801 (University of Miami)
   and by an unrestricted grant from Research to Prevent Blindness, New
   York, NY (University of Miami). RJS was supported by NEI T32 training
   grant (5T32EY023194). JNCB was supported by a PhRMA Informatics
   Fellowship..
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Biswas P, 2016, HUM MOL GEN IN PRESS
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Cirulli ET, 2010, NAT REV GENET, V11, P415, DOI 10.1038/nrg2779
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330
   de Vega S, 2014, ARCH BIOCHEM BIOPHYS, V545, P148, DOI 10.1016/j.abb.2014.01.013
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Exome Variant Server, 2014, NHLBI GO EX SEQ PROJ
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Flammer J, 2013, EUR HEART J, V34, P1270, DOI 10.1093/eurheartj/eht023
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guey LT, 2011, GENET EPIDEMIOL, V35, P236, DOI 10.1002/gepi.20572
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Hollborn M, 2011, MOL VIS, V17, P2738
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jostins L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076328
   Kim C, 2006, MOL VIS, V12, P1640
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007
   Lee S, 2014, AM J HUM GENET, V95, P5, DOI 10.1016/j.ajhg.2014.06.009
   Li DL, 2011, GENET EPIDEMIOL, V35, P790, DOI 10.1002/gepi.20628
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Ma WC, 2014, INVEST OPHTH VIS SCI, V55, P6187, DOI 10.1167/iovs.14-14352
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   National Eye Institute, 2010, AG REL MAC DEG AMD
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rotstein NP, 2010, J LIPID RES, V51, P1247, DOI 10.1194/jlr.R003442
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stitziel NO, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-227
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Vance Jeffery M., 1998, P201
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wu GD, 2013, GENET EPIDEMIOL, V37, P478, DOI 10.1002/gepi.21728
   Xu SB, 1999, J BIOL CHEM, V274, P35676, DOI 10.1074/jbc.274.50.35676
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhu J, 2014, FRONT GENET, V5, DOI [10.3389/fgene.2014.00149, 10.3389/fgene.2014.00187]
   Zuk O, 2014, P NATL ACAD SCI USA, V111, pE455, DOI 10.1073/pnas.1322563111
NR 86
TC 12
Z9 12
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 29
PY 2016
VL 22
BP 1062
EP 1076
PG 15
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA DX7NM
UT WOS:000384574600001
PM 27625572
DA 2022-11-30
ER

PT J
AU Nigalye, AK
   Hess, K
   Pundlik, SJ
   Jeffrey, BG
   Cukras, CA
   Husain, D
AF Nigalye, Archana K.
   Hess, Kristina
   Pundlik, Shrinivas J.
   Jeffrey, Brett G.
   Cukras, Catherine A.
   Husain, Deeba
TI Dark Adaptation and Its Role in Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE dark adaptation (DA); phototransduction; cone-rod break (CRB);
   rod-intercept time (RIT); age-related macular degeneration (AMD);
   subretinal drusenoid deposits (SDD); longitudinal monitoring; spatial
   gradient
ID SUBRETINAL DRUSENOID DEPOSITS; RETICULAR PSEUDODRUSEN; VITAMIN-A; NIGHT
   BLINDNESS; VISUAL FUNCTION; LOW LUMINANCE; GEOGRAPHIC-ATROPHY;
   STRUCTURAL-CHANGES; INTERMEDIATE AMD; HUMAN RETINA
AB Dark adaptation (DA) refers to the slow recovery of visual sensitivity in darkness following exposure to intense or prolonged illumination, which bleaches a significant amount of the rhodopsin. This natural process also offers an opportunity to understand cellular function in the outer retina and evaluate for presence of disease. How our eyes adapt to darkness can be a key indicator of retinal health, which can be altered in the presence of certain diseases, such as age-related macular degeneration (AMD). A specific focus on clinical aspects of DA measurement and its significance to furthering our understanding of AMD has revealed essential findings underlying the pathobiology of the disease. The process of dark adaptation involves phototransduction taking place mainly between the photoreceptor outer segments and the retinal pigment epithelial (RPE) layer. DA occurs over a large range of luminance and is modulated by both cone and rod photoreceptors. In the photopic ranges, rods are saturated and cone cells adapt to the high luminance levels. However, under scotopic ranges, cones are unable to respond to the dim luminance and rods modulate the responses to lower levels of light as they can respond to even a single photon. Since the cone visual cycle is also based on the Muller cells, measuring the impairment in rod-based dark adaptation is thought to be particularly relevant to diseases such as AMD, which involves both photoreceptors and RPE. Dark adaptation parameters are metrics derived from curve-fitting dark adaptation sensitivities over time and can represent specific cellular function. Parameters such as the cone-rod break (CRB) and rod intercept time (RIT) are particularly sensitive to changes in the outer retina. There is some structural and functional continuum between normal aging and the AMD pathology. Many studies have shown an increase of the rod intercept time (RIT), i.e., delays in rod-mediated DA in AMD patients with increasing disease severity determined by increased drusen grade, pigment changes and the presence of subretinal drusenoid deposits (SDD) and association with certain morphological features in the peripheral retina. Specifications of spatial testing location, repeatability of the testing, ease and availability of the testing device in clinical settings, and test duration in elderly population are also important. We provide a detailed overview in light of all these factors.
C1 [Nigalye, Archana K.; Husain, Deeba] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
   [Hess, Kristina; Jeffrey, Brett G.; Cukras, Catherine A.] NEI, NIH, Bethesda, MD 20892 USA.
   [Pundlik, Shrinivas J.] Harvard Med Sch, Schepens Eye Res Inst Mass Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Harvard University; Harvard Medical School
RP Husain, D (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Retina Serv, 243 Charles St, Boston, MA 02114 USA.; Cukras, CA (通讯作者)，NEI, NIH, Bethesda, MD 20892 USA.
EM archana_nigalye@meei.harvard.edu; kristina.hess@nih.gov;
   shrinivas_pundlik@meei.harvard.edu; brett.jeffrey@nih.gov;
   cukrasc@nei.nih.gov; deeba_husain@meei.harvard.edu
CR Abbott-Johnson WJ, 2011, BRIT J OPHTHALMOL, V95, P544, DOI 10.1136/bjo.2009.179176
   AdaptDx, 2014, USER MANUAL
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ANDERSON SJ, 1991, J PHYSIOL-LONDON, V442, P47, DOI 10.1113/jphysiol.1991.sp018781
   Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Barbur JL., 2010, ENCY EYE, P323, DOI [10.1016/B978-0-12-374203-2.00233-5, DOI 10.1016/B978-0-12-374203-2.00233-5]
   Bavinger JC, 2016, INVEST OPHTH VIS SCI, V57, P208, DOI 10.1167/iovs.15-17281
   BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613
   Binns AM, 2018, INVEST OPHTH VIS SCI, V59, pAMD114, DOI 10.1167/iovs.18-24211
   BLOMBERG LARS-H., 1959, ACTA OPHTHALMOL, V37, P274
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Burns ME, 2005, NEURON, V48, P387, DOI 10.1016/j.neuron.2005.10.014
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cukras C, 2016, RETINA-J RET VIT DIS, V36, P2348, DOI 10.1097/IAE.0000000000001113
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1991, PROGR RETINAL RES, V10, P89, DOI DOI 10.1016/0278-4327(91)90010-Y
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Demb JB, 2012, VISUAL NEUROSCI, V29, P51, DOI 10.1017/S0952523811000368
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Dong ZZ, 2018, INT J OPHTHALMOL-CHI, V11, P747, DOI 10.18240/ijo.2018.05.06
   Dowling J.E., 1987, RETINA APPROACHABLE
   DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648
   DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0
   Echols BS, 2020, OPHTHALMOL RETINA, V4, P1059, DOI 10.1016/j.oret.2020.05.001
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Feldman JB, 1938, ARCH OPHTHALMOL-CHIC, V19, P882, DOI 10.1001/archopht.1938.00850180034002
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P8241, DOI 10.1167/iovs.11-7858
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Flynn OJ, 2017, INVEST OPHTH VIS SCI, V58
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Gorin MB, 2014, J CLIN MED, V3, P1335, DOI 10.3390/jcm3041335
   Gramatikov B, 2013, INVEST OPHTH VIS SCI, V54
   Hecht S, 1937, J GEN PHYSIOL, V20, P831, DOI 10.1085/jgp.20.6.831
   Hecht S, 1920, J GEN PHYSIOL, V2, P499, DOI 10.1085/jgp.2.5.499
   Hess K, 2020, RETINA-J RET VIT DIS, V40, P1988, DOI 10.1097/IAE.0000000000002689
   Higgins BE, 2021, OPHTHALMOL THER, V10, P21, DOI 10.1007/s40123-020-00323-0
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hogg RE, 2009, OPHTHALMOLOGY, V116, P263, DOI 10.1016/j.ophtha.2008.09.002
   Iannaccone A, 2014, INVEST OPHTH VIS SCI, V55, P4790, DOI 10.1167/iovs.14-15135
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Jeyakumar SM, 2015, INDIAN J MED RES, V141, P275, DOI 10.4103/0971-5916.156554
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kelly J.M., PARAMETERS DARK ADAP
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kolb H., 1995, WEBVISION ORG RETINA
   Lains I, 2021, RETINA-J RET VIT DIS, V41, P2098, DOI 10.1097/IAE.0000000000003152
   Lains I, 2018, RETINA-J RET VIT DIS, V38, P1145, DOI 10.1097/IAE.0000000000001659
   Lains I, 2018, AM J OPHTHALMOL, V190, P113, DOI 10.1016/j.ajo.2018.03.035
   Lamb TD, 2016, EYE, V30, P179, DOI 10.1038/eye.2015.236
   LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Lamb TD, 2017, DEV BIOL, V431, P77, DOI 10.1016/j.ydbio.2017.03.018
   Lesmes Luis Andres, 2013, Drug Discov Today Ther Strateg, V10, pe43, DOI 10.1016/j.ddstr.2012.11.002
   Luu CD, 2018, OPHTHALMOL RETINA, V2, P1206, DOI 10.1016/j.oret.2018.06.016
   Mandelbaum J, 1941, ARCH OPHTHALMOL-CHIC, V26, P203, DOI 10.1001/archopht.1941.00870140053003
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   McGuinness MB, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.6.30
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Munch IC, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0273-6
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Owsley C, 2011, VISION RES, V51, P1610, DOI 10.1016/j.visres.2010.10.020
   Patnaik JL, 2019, OPHTHALMOL RETINA, V3, P336, DOI 10.1016/j.oret.2018.11.004
   Patryas L, 2013, GRAEF ARCH CLIN EXP, V251, P1821, DOI 10.1007/s00417-013-2324-5
   Pereira SE, 2012, OBES SURG, V22, P602, DOI 10.1007/s11695-011-0522-y
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Pokorny J, 2006, VISUAL NEUROSCI, V23, P525, DOI 10.1017/S0952523806233492
   PRICE MJ, 1985, BRIT J OPHTHALMOL, V69, P205, DOI 10.1136/bjo.69.3.205
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P413, DOI 10.1113/jphysiol.1975.sp010982
   Pundlik S, 2022, BRIT J OPHTHALMOL, V106, P1450, DOI 10.1136/bjophthalmol-2021-318806
   Pundlik S, 2018, INVEST OPHTH VIS SCI, V59
   Purves D, 2004, PSYCHOL REV, V111, P142, DOI 10.1037/0033-295X.111.1.142
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Reeves A, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00008
   Renner AB, 2015, DOC OPHTHALMOL, V131, P221, DOI 10.1007/s10633-015-9516-8
   Reuter T, 2011, VISION RES, V51, P2243, DOI 10.1016/j.visres.2011.08.021
   Rodrigo-Diaz E, 2019, INVEST OPHTH VIS SCI, V60, P5070, DOI 10.1167/iovs.19-27971
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   RUSSELL RM, 1980, AM J CLIN NUTR, V33, P2741, DOI 10.1093/ajcn/33.12.2741
   Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337
   Sahel JA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017111
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tahir Humza J, 2018, Invest Ophthalmol Vis Sci, V59, pAMD202, DOI 10.1167/iovs.18-24227
   Tahir HJ, 2017, EXP EYE RES, V155, P47, DOI 10.1016/j.exer.2016.11.016
   Tan RS, 2019, INVEST OPHTH VIS SCI, V60, P1511, DOI 10.1167/iovs.18-26385
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Trasino SE, 2015, SCI REP-UK, V5, DOI 10.1038/srep15893
   Uddin D, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.31
   van Hateren JH, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-34
   Wang JS, 2014, J NEUROSCI, V34, P11212, DOI 10.1523/JNEUROSCI.1245-14.2014
   WINN B, 1994, INVEST OPHTH VIS SCI, V35, P1132
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wyszecki G., 2000, COLOR SCI CONCEPTS M, Vsecond
   Yang GQ, 2015, INT J OPHTHALMOL-CHI, V8, P1245, DOI 10.3980/j.issn.2222-3959.2015.06.31
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   ZEAVIN BH, 1956, AM J OPHTHALMOL, V42, P253, DOI 10.1016/0002-9394(56)90377-4
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 137
TC 1
Z9 1
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2022
VL 11
IS 5
AR 1358
DI 10.3390/jcm11051358
PG 24
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZS1YO
UT WOS:000768267600001
PM 35268448
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bek, T
   Klug, SE
AF Bek, Toke
   Klug, Sidsel Ehlers
TI Incidence and risk factors for neovascular age-related macular
   degeneration in the fellow eye
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Anti-VEGF treatment;
   Fellow eye; Risk factors
ID CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; RANIBIZUMAB; PROGRESSION;
   TRIALS; AFLIBERCEPT; PREVALENCE; THICKNESS; THERAPY; DISEASE
AB PurposeThe epidemiology, risk factors, and the effect of anti-VEGF treatment on neovascular age-related macular degeneration (nAMD) have primarily been studied in the first eye developing the disease. The understanding of pathophysiology and planning of follow-up examinations can be improved by knowledge of incidence and risk factors for development of the disease in the fellow eye.MethodsIn a prospective observational cohort study, epidemiological and clinical risk factors for the development of nAMD in the fellow eye among 2516 patients consecutively diagnosed with the disease from a population of 0.9 million citizens during a period of more than 10years were studied.ResultsnAMD had been diagnosed in the fellow eye of 541 (21.5%) of the patients. The incidence of fellow-eye involvement increased from approximately 5% in patients initially presenting with bilateral disease to approximately 28% more than 6years after the diagnosis in the first eye. Visual acuity (VA) was higher and central retinal thickness (CRT) was lower in fellow eyes with nAMD diagnosed later than the first eye. Male gender, increasing leakage area, and peripapillary location of the subretinal neovascular membrane in the first eye reduced the risk of developing disease in the fellow eye.ConclusionsThe planning of follow-up examinations of patients diagnosed with nAMD in one eye should consider that the risk of fellow-eye involvement is higher within the first 6years, in women, and when the leakage area in the first eye is small and not located peripapillary.
C1 [Bek, Toke; Klug, Sidsel Ehlers] Aarhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus, Denmark.
C3 Aarhus University
RP Bek, T (通讯作者)，Aarhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus, Denmark.
EM toke.bek@mail.tele.dk
OI Bek, Toke/0000-0002-0409-2534
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Bek T, 2018, INT OPHTHALMOL, V12, P473
   Bek T, 2016, INVEST OPHTH VIS SCI, V57, P5429, DOI 10.1167/iovs.16-20305
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bressler SB, 2016, JAMA OPHTHALMOL, V134, P278, DOI 10.1001/jamaophthalmol.2015.5346
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chevreaud O, 2016, EUR J OPHTHALMOL, V26, P44, DOI 10.5301/ejo.5000649
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Gamulescu MA, 2010, J OCUL PHARMACOL TH, V26, P213, DOI 10.1089/jop.2009.0126
   Govetto A, 2017, BRIT J OPHTHALMOL, V101, P764, DOI 10.1136/bjophthalmol-2016-309281
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Ibrahim MA, 2012, EYE, V26, P454, DOI 10.1038/eye.2011.293
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jonas JB, 2011, J OCUL PHARMACOL TH, V27, P401, DOI 10.1089/jop.2011.0080
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schick T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156778
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
NR 28
TC 9
Z9 9
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2018
VL 256
IS 11
BP 2061
EP 2068
DI 10.1007/s00417-018-4100-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GX8NF
UT WOS:000448042400006
PM 30097785
DA 2022-11-30
ER

PT J
AU Lains, I
   Pundlik, SJ
   Nigalye, A
   Katz, R
   Luo, G
   Kim, IK
   Vavvas, DG
   Miller, JW
   Miller, JB
   Husain, D
AF Lains, Ines
   Pundlik, Shrinivas J.
   Nigalye, Archana
   Katz, Raviv
   Luo, Gang
   Kim, Ivana K.
   Vavvas, Demetrios G.
   Miller, Joan W.
   Miller, John B.
   Husain, Deeba
TI BASELINE PREDICTORS ASSOCIATED WITH 3-YEAR CHANGES IN DARK ADAPTATION IN
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; dark adaptation; hyperreflective foci;
   optical coherence tomography; retinal atrophy
ID HYPERREFLECTIVE FOCI; PROGRESSION; DISEASE
AB Purpose: To assess the relationship between baseline age-related macular degeneration (AMD) and disease stage, as well as optical coherence tomography features seen in AMD, with 3-year changes in dark adaptation (DA). Methods: Prospective longitudinal study including patients with AMD and a comparison group (n = 42 eyes, 27 patients). At baseline and 3 years, we obtained color fundus photographs, spectral-domain optical coherence tomography, and rod-mediated DA (20 minutes protocol). Multilevel mixed-effect models were used for analyses, with changes in rod intercept time at 3 years as the primary outcome. As some eyes (n = 11) reached the DA testing ceiling value at baseline, we used 3-year changes in area under the DA curve as an additional outcome. Results: Baseline AMD, AMD stage, and hyperreflective foci on optical coherence tomography were associated with larger changes in rod intercept time at 3 years. When change in area under the DA curve was used as an outcome, in addition to these features, the presence of retinal atrophy and drusenoid pigment epithelial detachment had significant associations. New subretinal drusenoid deposits at 3 years were also associated with more pronounced changes in rod intercept time and area under the DA curve. Conclusion: Specific optical coherence tomography features are associated with DA impairments over time, which supports that structural changes predict functional loss over 3 years.
C1 [Lains, Ines; Pundlik, Shrinivas J.; Nigalye, Archana; Katz, Raviv; Luo, Gang; Kim, Ivana K.; Vavvas, Demetrios G.; Miller, Joan W.; Miller, John B.; Husain, Deeba] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02115 USA.
   [Pundlik, Shrinivas J.; Luo, Gang] Schepens Eye Res Inst Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Husain, D (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
EM Deeba_Husain@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
FU Miller Retina Research Fund (Mass. Eye and Ear); Champalimaud Vision
   Award; National Institutes of Health (NIH) [R01EY030088-01A1]; Research
   to Prevent Blindness, Inc., New York; Commonwealth Unrestricted Grant
   for Eye Research
FX Supported by the Miller Retina Research Fund (Mass. Eye and Ear), the
   Champalimaud Vision Award, National Institutes of Health (NIH)
   R01EY030088-01A1, the unrestricted departmental grant from Research to
   Prevent Blindness, Inc., New York, and the Commonwealth Unrestricted
   Grant for Eye Research. The funding sources were used for research
   fellows and other support staff, expenses needed for patient
   recruitment, and metabolomics sample analysis. All the above mentioned
   funding organizations had no role in the conceptualization, design,
   analysis, decision to publish, or preparation of the manuscript design
   or conduct of this research. We have not been paid to write this article
   by a pharmaceutical company or agency.
CR Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   CHIOU WL, 1978, J PHARMACOKINET BIOP, V6, P539, DOI 10.1007/BF01062108
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Echols BS, 2020, OPHTHALMOL RETINA, V4, P1059, DOI 10.1016/j.oret.2020.05.001
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Garlipp MA, 2013, EXP EYE RES, V113, P192, DOI 10.1016/j.exer.2013.02.003
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Oliphant, 2006, A GUIDE TO NUMPY
   Owsley C, 2015, CURR EYE RES, V41, P1
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Tan RS, 2019, INVEST OPHTH VIS SCI, V60, P1511, DOI 10.1167/iovs.18-26385
   Tiosano L, 2020, GRAEF ARCH CLIN EXP, V258, P2353, DOI 10.1007/s00417-020-04837-y
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 29
TC 3
Z9 3
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2021
VL 41
IS 10
BP 2098
EP 2105
DI 10.1097/IAE.0000000000003152
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5GS
UT WOS:000711796500013
PM 33625114
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Valmaggia, C
   Haueter, I
   Kloos, P
   Lang, C
   Niederberger, H
AF Valmaggia, C.
   Haueter, I.
   Kloos, P.
   Lang, C.
   Niederberger, H.
TI The Treatment of Choroidal Neovascularizations in Age-Related Macular
   Degeneration using either Avastin or Lucentis
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; Avastin; Lucentis
ID BEVACIZUMAB; RANIBIZUMAB; VERTEPORFIN
AB Background: Either Avastin or Lucentis was used in our clinic to treat choroidal neovascularizations in age-related macular degeneration. The number of injections necessary for drying the macular findings was especially assessed.
   Patients and Methods: From April 2006 to August 2008 324 eyes were treated with Avastin, and from January 2007 to August 2008 348 eyes were treated with Lucentis. The intravitreal injections with Avastin (1.25 mg in 0.05 mL) were performed every six weeks, and with Lucentis (0.05 mg in 0.05 mL) every four weeks until the macular findings were considered to be dry. Fluorescein angiography and optical coherence tomography were used for the diagnosis and for the checks which were carried out every twelve weeks. The visual acuity was measured with an ETDRS chart.
   Results: The treatment with Avastin is completed in 319 eyes with an average improvement of the visual acuity of 5.1 letters after 3.3 injections, and with Lucentis in 226 eyes with an average improvement of the visual acuity of 6.4 letters after 3.4 injections (p = 0.24; one way ANOVA).
   Conclusion: Both of the drugs allow the drying of the macular findings in the great majority of the cases after a short time and lead to a quite similar improvement of the visual acuity. A definitive stabilization of the disease after stopping the treatment is not foreseeable.
C1 [Valmaggia, C.; Haueter, I.; Kloos, P.; Lang, C.; Niederberger, H.] Cantonal Hosp, Dept Ophthalmol, CH-9007 St Gallen, Switzerland.
C3 Kantonsspital St. Gallen
RP Valmaggia, C (通讯作者)，Cantonal Hosp, Dept Ophthalmol, CH-9007 St Gallen, Switzerland.
EM christophe.valmaggia@kssg.ch
CR Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P240, DOI 10.1089/jop.2006.0146
   KLETTNER AK, 2008, INVEST OPTHALMOL VIS
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Moreno SF, 2008, BRIT J OPHTHALMOL, V92, P866
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Quiroz-Mercado Hugo, 2007, Semin Ophthalmol, V22, P109, DOI 10.1080/08820530701420082
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Valmaggia C, 2008, KLIN MONATSBL AUGENH, V225, P380, DOI 10.1055/s-2008-1027266
   WU L, 2007, GRAEFES ARCH CLIN EX
NR 18
TC 3
Z9 6
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2009
VL 226
IS 4
BP 294
EP 298
DI 10.1055/s-0028-1109298
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 441CW
UT WOS:000265747900019
PM 19384786
DA 2022-11-30
ER

PT J
AU Mitchell, P
   Annemans, L
   White, R
   Gallagher, M
   Thomas, S
AF Mitchell, Paul
   Annemans, Lieven
   White, Richard
   Gallagher, Meghan
   Thomas, Simu
TI Cost Effectiveness of Treatments for Wet Age-Related Macular
   Degeneration
SO PHARMACOECONOMICS
LA English
DT Review
ID PHOTODYNAMIC THERAPY; RANIBIZUMAB LUCENTIS; UTILITY ANALYSIS; CHOROIDAL
   NEOVASCULARIZATION; LASER PHOTOCOAGULATION; CONTRAST SENSITIVITY; VISUAL
   IMPAIRMENT; NONMEDICAL COSTS; VERTEPORFIN; BEVACIZUMAB
AB Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems. This systematic review examined the cost-effectiveness data for current therapeutic options for wet AMD. PubMed and EMBASE databases were searched for all articles reporting original cost-effectiveness analyses of wet AMD treatments. The Centre for Reviews and Dissemination and Cochrane Library databases were searched for all wet AMD health technology assessments (HTAs). Overall, 44 publications were evaluated in full and included in this review.
   A broad range of cost-effectiveness analyses were identified for the most commonly used therapies for wet AMD (pegaptanib, ranibizumab and photodynamic therapy [PDT] with verteporfin). Three studies evaluated the cost effectiveness of bevacizumab in wet AMD. A small number of analyses of other treatments, such as laser photocoagulation and antioxidant vitamins, were also found.
   Ranibizumab was consistently shown to be cost effective for wet AMD in comparison with all the approved wet AMD therapies (four of the five studies identified showed ranibizumab was cost effective vs usual care, PDT or pegaptanib); however, there was considerable variation in the methodology for cost-effectiveness modelling between studies. Findings from the HTAs supported those from the PubMed and EM BASE searches; of the seven HTAs that included ranibizumab, six (including HTAs for Australia, Canada and the UK) concluded that ranibizumab was cost effective for the treatment of wet AMD; most compared ranibizumab with PDT and/or pegaptanib. By contrast, HTAs at best generally recommended pegaptanib or PDT for restricted use in subsets of patients with wet AMD. In the literature analyses, pegaptanib was found to be cost effective versus usual/best supportive care (including PDT) or no treatment in one of five studies; the other four studies found pegaptanib was of borderline cost effectiveness depending on the stage of disease and time horizon. PDT was shown to be cost effective versus usual/best supportive care or no treatment in five of nine studies; two studies showed that PDT was of borderline cost effectiveness depending on baseline visual acuity, and two showed that PDT was not cost effective. We identified no robust studies that properly evaluated the cost effectiveness of bevacizumab in wet AMD.
C1 [Mitchell, Paul] Univ Sydney, Westmead Hosp, Eye Clin B4A, Discipline Ophthalmol, Westmead, NSW 2145, Australia.
   [Annemans, Lieven] Univ Ghent, Dept Publ Hlth, Fac Med, B-9000 Ghent, Belgium.
   [White, Richard] Oxford PharmaGenesis Ltd, Res Evaluat Unit, Oxford, England.
   [Gallagher, Meghan] Novartis Pharma AG, Basel, Switzerland.
   [Thomas, Simu] Novartis Pharmaceut, E Hanover, NJ USA.
C3 University of Sydney; Ghent University; Novartis; Novartis
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Eye Clin B4A, Discipline Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul.mitchell@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; White, Richard/D-5407-2009
OI White, Richard/0000-0002-6494-8162; White, Richard/0000-0003-4410-6635
FU Novartis Pharma AG, Basel, Switzerland; Novartis Pharma AG; Pfizer;
   Allergan; Solvay; Novartis
FX All authors participated in the development and writing of the
   manuscript, and approved the final article for publication. The authors
   take full responsibility for the content of the article and would like
   to thank Dr Annette Keith (Oxford PharmaGenesis (TM) Ltd) for carrying
   out the initial literature searches, providing the authors with an
   overview of the search findings, and collating and incorporating
   comments from all authors. This editorial assistance was funded by
   Novartis Pharma AG, Basel, Switzerland. This analysis was supported by
   Novartis Pharma AG, Basel, Switzerland.; PM has received consultancy
   fees from Novartis Pharma AG, Pfizer, Allergan and Solvay and has also
   been paid lecture fees/honoraria by these companies. LA has received an
   unrestricted grant from Novartis. RW is an employee of Oxford
   PharmaGenesis (TM) Ltd, which has received project funding from Novartis
   Pharma AG. MG and ST are employees of Novartis Pharma AG.
CR *AFSSAPS, UT HORS AMM DAV POIN
   *ANAES, 2001, TREATM AG REL MAC DE
   Andriolo RB, 2009, SAO PAULO MED J, V127, P84, DOI 10.1590/S1516-31802009000200006
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   AUGUSTOVSKI F, 2007, VASCULAR ENDOTHELIAL
   *AUSTR GOV DEP HLT, 2001, PHOT THER VERT MAC D
   *AUSTR GOV DEP HLT, 2007, PUBL SUMM DOC RAN
   *AUSTR GOV DEP HLT, 2005, PUBL SUMM DOC VERT
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   *BAND GROUP, LUC VERS AV NEEDS MU
   Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007
   Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown A, 2008, MANAGEMENT NEOVASCUL
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   *CAN AG DRUGS TECH, 2008, COMM DRUG REV RAN LU
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Donati G, 2007, J FR OPHTALMOL, V30, P837, DOI 10.1016/S0181-5512(07)92619-4
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Lafuma A, 2006, PHARMACOECONOMICS, V24, P193, DOI 10.2165/00019053-200624020-00007
   Lafuma Antoine, 2006, Eur J Health Econ, V7, P158, DOI 10.1007/s10198-006-0346-1
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larouche K., 2005, EVALUATION PHOTODYNA
   MEADS C, 2003, HEALTH TECHNOL ASSES, V7, pR1
   MEADS C, 2001, CLIN EFFECTIVENESS C
   MHRA, 2009, DRUG SAFETY UPDATE, V2, P6
   Muslera E., 2006, Arch Soc Esp Oftalmol, V81, P199
   *NEI, COMP AG REL MAC DEG
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   OLIVA G, 2006, PHOTODYNAMIC THERAPY
   Olsen TW, 2007, AM J OPHTHALMOL, V144, P281, DOI 10.1016/j.ajo.2007.05.005
   OShea JG, 1996, MED J AUSTRALIA, V165, P561, DOI 10.5694/j.1326-5377.1996.tb138643.x
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   *SCOTT MED CONS, 2007, RAN 10MG ML SOL INTR
   *SCOTT MED CONS, 2006, PEG 0 3MG SOL INTR I
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   *SWED COUNC TECHN, 2001, PHOT TREATM MAC DEG
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   *UK ROYAL GROUP HO, RAND CONTR ALT TREAT
   WILLIAMS G, 2007, RETINA TODAY     JAN, P43
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   YANG YC, DEV TREATMENT AMD TH
NR 74
TC 40
Z9 45
U1 0
U2 27
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-7690
EI 1179-2027
J9 PHARMACOECONOMICS
JI Pharmacoeconomics
PY 2011
VL 29
IS 2
BP 107
EP 131
DI 10.2165/11585520-000000000-00000
PG 25
WC Economics; Health Care Sciences & Services; Health Policy & Services;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services; Pharmacology &
   Pharmacy
GA 720HO
UT WOS:000287271700003
PM 21244102
OA Green Published
DA 2022-11-30
ER

PT J
AU Arslan, S
   Kadayifcilar, S
   Samur, G
AF Arslan, Sedat
   Kadayifcilar, Sibel
   Samur, Gulhan
TI The Potential Role of Dietary Antioxidant Capacity in Preventing
   Age-Related Macular Degeneration
SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
LA English
DT Article
DE Dietary total antioxidant capacity; nutrition; age-related macular
   degeneration; nutrient intake; glycemic index
ID BODY-MASS INDEX; ABDOMINAL OBESITY; EYE DISEASE; MACULOPATHY;
   PROGRESSION; RISK; ASSOCIATION; FAT
AB Objectives: Age-related macular degeneration (AMD) is a progressive disorder among people aged >= 50 years. Some dietary factors associated with the susceptibility to AMD include dietary glycemic index and glycemic load, as well as intake of antioxidants and other nutrients, such as vitamins, minerals, and dietary fatty acids. Methods: This case-control study was conducted between July 2015 and February 2016 on 100 case subjects with AMD and 100 healthy controls without AMD. The participants were recruited from the Department of Ophthalmology of Hacettepe University Hospitals in Ankara, Turkey. Dietary intake was estimated from a 3-day food intake record and food frequency questionnaire, and anthropometric measurements were recorded. The relationship between nutritional factors and AMD was assessed using logistic regression. Results: Dietary total antioxidant intake of AMD group was found to be lower (p < 0.05) than that of healthy individuals. In a multivariate analysis, smoking, daily red meat intake, omega-6 intake, and higher glycemic index were identified as risk factors for AMD development. Meanwhile, daily fruit intake, daily fish intake, omega-3 intake, and zinc intake were associated with a protective effect. However, no difference was found in dietary total antioxidant capacity. Conclusions: In this study, a high dietary intake of carotenoids, vitamins C and E, zinc, and omega-3, as well as maintaining optimal waist circumference, were found to substantially reduce the risk of developing AMD in people aged >50 years. By contrast, in addition to smoking and old age, obesity, high red meat intake, and omega-6 intake might increase the risk of developing AMD. Therefore, a better understanding of nutritional risk factors is necessary for preventing AMD.
C1 [Arslan, Sedat] Kastamonu Univ, Nutr & Dietet, Kastamonu, Turkey.
   [Kadayifcilar, Sibel] Hacettepe Univ, Dept Ophthalmol, Ankara, Turkey.
   [Samur, Gulhan] Hacettepe Univ, Nutr & Dietet, Ankara, Turkey.
C3 Kastamonu University; Hacettepe University; Hacettepe University
RP Samur, G (通讯作者)，Hacettepe Univ, Nutr & Dietet, Ankara, Turkey.; Samur, G (通讯作者)，Hacettepe Univ, Sihhiye Kampusu Saglik Bilimleri Fak, Beslenme & Diyetetik Bolumu, Altindag Ankara, Turkey.
EM gsamur@hacettepe.edu.tr
RI ARSLAN, Sedat/HCI-2518-2022
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   [Anonymous], 2014, DIETARY GUIDELINES T
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Carlsen MH, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-3
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Defay R, 2001, INT J OBESITY, V25, P512, DOI 10.1038/sj.ijo.0801570
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN R, 1994, OPHTHALMOLOGY, V101, P1969
   Mance TC, 2011, COLLEGIUM ANTROPOL, V35, P307
   Mariotti SP, 2012, GLOBAL DATA VISUAL I, P20
   Marventano S, 2016, INT J FOOD SCI NUTR, V67, P857, DOI 10.1080/09637486.2016.1198893
   Merdol T, 2003, STANDART YEMEK TARIF
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Organization WH, 2011, WAIST CIRC WAIST HIP
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Pekcan G, 2018, DIYET EL KITABI, P67
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schmid M., 2011, BESLENME BILGI SISTE
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Suter PM, 1998, AM J HYPERTENS, V11, P1305, DOI 10.1016/S0895-7061(98)00162-9
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tamburrino MB, 2002, PANMINERVA MED, V44, P301
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   World Health Organization, 2004, BMI CLASS 2004
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 39
TC 8
Z9 8
U1 0
U2 7
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0731-5724
EI 1541-1087
J9 J AM COLL NUTR
JI J. Am. Coll. Nutr.
PD JUL 4
PY 2019
VL 38
IS 5
BP 424
EP 432
DI 10.1080/07315724.2018.1538830
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA IF3GV
UT WOS:000472969800005
PM 30570376
DA 2022-11-30
ER

PT J
AU Baxter, JM
   Fotheringham, AJ
   Foss, AJE
AF Baxter, J. M.
   Fotheringham, A. J.
   Foss, A. J. E.
TI Determining patient preferences in the management of neovascular
   age-related macular degeneration: a conjoint analysis
SO EYE
LA English
DT Article
ID GLAUCOMA PATIENTS; RANIBIZUMAB; VIEWS; BEVACIZUMAB; INJECTIONS; STAGE;
   CARE
AB Purpose To determine the opinions from a patient perspective on relevant variables in the delivery of treatment for neovascular age-related macular degeneration (nAMD).
   Methods Pilot interviews with patients and doctors were conducted to identify what variables in the provision of a nAMD service were important. This led to the generation of two sets of scenario options. Subsequently 100 patients undergoing active treatment for nAMD in the National Health Service University Hospital, United Kingdom underwent interview assessment. They were asked to rank their preferences for provision of their care with reference to these two sets of scenario options. Using conjoint analysis, percentage preferences, and utility scores for each variable in each scenario design were calculated.
   Results Ninety-five patients completed the preference ranking for both scenarios. Eight patients ranked worse vision as preferable to better vision and were excluded on the basis that they had not understood the task. The results of the remaining 87 patients are presented. The most important factor to patients was having good vision, followed by a one-stop service and less frequent follow up. The least important factors were label status of the drug, cost to the health service, and grade of the injector.
   Conclusion Patients regard good vision and minimal visits to the hospital above the status of injector, label status of drug, or cost to the NHS.
C1 [Baxter, J. M.; Fotheringham, A. J.; Foss, A. J. E.] Queens Med Ctr, Dept Ophthalmol, Derby Rd, Nottingham NG7 2UH, England.
C3 University of Nottingham
RP Foss, AJE (通讯作者)，Queens Med Ctr, Dept Ophthalmol, Derby Rd, Nottingham NG7 2UH, England.
EM alexander.foss@nuh.nhs.uk
OI Foss, Alexander/0000-0001-9649-0072
CR [Anonymous], 2014, NHS SHOULD US CANC D
   Bhargava JS, 2008, BRIT J OPHTHALMOL, V92, P1601, DOI 10.1136/bjo.2008.140483
   Bhargava JS, 2006, INVEST OPHTH VIS SCI, V47, P2885, DOI 10.1167/iovs.05-1244
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Danner M, 2016, PATIENT, V9, P47, DOI 10.1007/s40271-015-0122-3
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Hawkes N, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6867
   Health and Social Care Information Centre UK, HOSP PRESCR ENGL 201
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lotery A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6887
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michelotti MM, 2014, CLIN OPHTHALMOL, V8, P755, DOI 10.2147/OPTH.S59982
   NHS England, PUTT PAT 1 NHS ENGL
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   PARKER BR, 1976, OPER RES, V24, P991, DOI 10.1287/opre.24.5.991
   Rodriguez Ramirez M, 2014, Arch Soc Esp Oftalmol, V89, P477, DOI 10.1016/j.oftal.2014.05.010
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross MA, 2003, QUAL SAF HEALTH CARE, V12, P13, DOI 10.1136/qhc.12.1.13
   Ryan M, 2000, BMJ-BRIT MED J, V320, P1530, DOI 10.1136/bmj.320.7248.1530
   Simcock P, 2014, EYE, V28, P1161, DOI 10.1038/eye.2014.153
NR 26
TC 23
Z9 23
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2016
VL 30
IS 5
BP 698
EP 704
DI 10.1038/eye.2016.18
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL5UL
UT WOS:000375702400008
PM 26915744
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Sogut, E
   Ortak, H
   Aydogan, L
   Benli, I
AF Sogut, Erkan
   Ortak, Huseyin
   Aydogan, Leyla
   Benli, Ismail
TI ASSOCIATION OF PARAOXONASE 1 L55M AND Q192R SINGLE-NUCLEOTIDE
   POLYMORPHISMS WITH AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; PON1 polymorphism; real-time PCR
ID LOW-DENSITY-LIPOPROTEIN; GENE POLYMORPHISMS; CARDIOVASCULAR-DISEASE;
   CIGARETTE-SMOKING; PON1; MACULOPATHY; PREVALENCE; CORONARY; RISK;
   HOMOCYSTEINE
AB Purpose: To determine if paraoxonase 1 (PON1) gene polymorphisms have an effect on the risk of having age-related macular degeneration (AMD).
   Methods: The study population consisted of 142 patients who were diagnosed with either exudative or atrophic AMD and 138 sex-and age-matched controls without AMD. Genotyping of the PON1 L55M and Q192R single-nucleotide polymorphisms was performed using real-time polymerase chain reaction and commercially produced kits. A full ophthalmic evaluation was performed in each subject, and all subjects were screened for hypertension, diabetes, hypercholesterolemia, and smoking history.
   Results: The PON1 MM and QQ genotypes were less frequent in patients with AMD than in control subjects (MM: 4 vs. 13%, P = 0.015; QQ: 15 vs. 27%, P = 0.020). A multivariate logistic regression analysis was also conducted. After adjusting for age, gender, and the prevalence of smoking, hypertension, diabetes, and hypercholesterolemia, the MM and QQ genotypes (MM/QQ vs. LL + LM/QR + RR) were found to be associated with a decreased risk of AMD (MM: odds ratio = 0.24, P = 0.007, 95% confidence interval: 0.09-0.68; QQ: odds ratio = 0.46, P = 0.013, 95% confidence interval: 0.25-0.85).
   Conclusion: The authors found that subjects with the PON1 MM and QQ genotypes had a lower risk of AMD.
C1 [Sogut, Erkan; Aydogan, Leyla; Benli, Ismail] Gaziosmanpasa Univ, Fac Med, Dept Biochem, Tokat, Turkey.
   [Ortak, Huseyin] Gaziosmanpasa Univ, Fac Med, Dept Ophthalmol, Tokat, Turkey.
C3 Gaziosmanpasa University; Gaziosmanpasa University
RP Sogut, E (通讯作者)，Gaziosmanpasa Univ, Fac Med, Dept Biochem, Tokat, Turkey.
EM erkanchems@yahoo.com
RI benli, ismail/A-7441-2016
CR ADKINS S, 1993, AM J HUM GENET, V52, P598
   ALDER VA, 1985, CURR EYE RES, V4, P121, DOI 10.3109/02713688508999977
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Barbieri M, 2002, J CLIN ENDOCR METAB, V87, P222, DOI 10.1210/jc.87.1.222
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x
   Brophy VH, 2001, AM J HUM GENET, V68, P1428, DOI 10.1086/320600
   Carmine A, 2002, MOVEMENT DISORD, V17, P764, DOI 10.1002/mds.10172
   Dantoine TF, 2002, ANN NY ACAD SCI, V977, P239, DOI 10.1111/j.1749-6632.2002.tb04821.x
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   Draganov DI, 2004, N-S ARCH PHARMACOL, V369, P78, DOI 10.1007/s00210-003-0833-1
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134
   HARATS D, 1989, ATHEROSCLEROSIS, V79, P245, DOI 10.1016/0021-9150(89)90130-5
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Ito T, 2002, HUM GENET, V110, P89, DOI 10.1007/s00439-001-0654-6
   Jaouad L, 2003, FREE RADICAL RES, V37, P77, DOI 10.1080/1071576021000036614
   Javadzadeh A, 2012, RETINA-J RET VIT DIS, V32, P658, DOI 10.1097/IAE.0b013e31822529b1
   Kao YL, 1998, J CLIN ENDOCR METAB, V83, P2589, DOI 10.1210/jc.83.7.2589
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mackness B, 1998, FEBS LETT, V423, P57, DOI 10.1016/S0014-5793(98)00064-7
   Mackness MI, 1997, LANCET, V349, P851, DOI 10.1016/S0140-6736(05)61755-2
   Mahadesh, 2010, WORLD APPL SCI J, V9, P194
   Marchegiani F, 2008, REJUV RES, V11, P113, DOI 10.1089/rej.2007.0582
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mouhamed Dhouha Haj, 2012, Environmental Health and Preventive Medicine, V17, P316, DOI 10.1007/s12199-011-0256-4
   Nowak Michal, 2005, Klin Oczna, V107, P715
   Otocka-Kmiecik A, 2009, POSTEP HIG MED DOSW, V63, P668
   Pauer GJT, 2010, AM J OPHTHALMOL, V149, P513, DOI 10.1016/j.ajo.2009.09.024
   Pocsai Z, 2003, CLIN CHIM ACTA, V332, P31, DOI 10.1016/S0009-8981(03)00083-4
   PrimoParmo SL, 1996, GENOMICS, V33, P498, DOI 10.1006/geno.1996.0225
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Watzinger N, 2002, CARDIOLOGY, V98, P116, DOI 10.1159/000066321
   Winkler BS, 1999, MOL VIS, V5
NR 51
TC 2
Z9 2
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1836
EP 1842
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500011
PM 23538572
DA 2022-11-30
ER

PT J
AU Rein, DB
   Wittenborn, JS
   Zhang, XZ
   Honeycutt, AA
   Lesesne, SB
   Saaddine, J
AF Rein, David B.
   Wittenborn, John S.
   Zhang, Xinzhi
   Honeycutt, Amanda A.
   Lesesne, Sarah B.
   Saaddine, Jinan
CA Vision Hlth Cost-Effectiveness
TI Forecasting Age-Related Macular Degeneration Through the Year 2050 The
   Potential Impact of New Treatments
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COST-EFFECTIVENESS; VISUAL IMPAIRMENT; SEVERITY SCALE; PREVALENCE;
   MACULOPATHY; RANIBIZUMAB; BEVACIZUMAB; THERAPY
AB Objective: To forecast age-related macular degeneration (AMD) and its consequences in the United States through the year 2050 with different treatment scenarios.
   Methods: We simulated cases of early AMD, choroidal neovascularization (CNV), geographic atrophy (GA), and AMD-attributable visual impairment and blindness with 5 universal treatment scenarios: ( 1) no treatment; ( 2) focal laser and photodynamic therapy (PDT) for CNV; ( 3) vitamin prophylaxis at early-AMD incidence with focal laser/PDT for CNV; ( 4) no vitamin prophylaxis followed by focal laser treatment for extra and juxtafoveal CNV and anti-vascular endothelial growth factor treatment; and ( 5) vitamin prophylaxis at early-AMD incidence followed by CNV treatment, as in scenario 4.
   Results: Cases of early AMD increased from 9.1 million in 2010 to 17.8 million in 2050 across all scenarios. In non-vitamin-receiving scenarios, cases of CNV and GA increased from 1.7 million in 2010 to 3.8 million in 2050 (25% lower in vitamin-receiving scenarios). Cases of visual impairment and blindness increased from 620 000 in 2010 to 1.6 million in 2050 when given no treatment and were 2.4%, 22.0%, 16.9%, and 34.5% lower in scenarios 2, 3, 4, and 5, respectively.
   Conclusion: Prevalence of AMD will increase substantially by 2050, but the use of new therapies can mitigate its effects.
C1 [Rein, David B.; Wittenborn, John S.; Zhang, Xinzhi; Honeycutt, Amanda A.; Lesesne, Sarah B.] Res Triangle Inst RTI Int, Res Triangle Pk, NC USA.
   [Zhang, Xinzhi; Saaddine, Jinan] Ctr Dis Control & Prevent, Natl Ctr Chron Dis & Prevent, Atlanta, GA USA.
C3 Research Triangle Institute; Centers for Disease Control & Prevention -
   USA
RP Rein, DB (通讯作者)，Res Triangle Inst RTI Int, 2951 Flowers Rd,Ste 119, Atlanta, GA 30306 USA.
EM drein@rti.org
OI Rein, David/0000-0002-1271-5789; Honeycutt, Amanda/0000-0003-0166-1399
FU Centers for Disease Control and Prevention's Division of Diabetes
   Translation through US Federal [200-2002-00776]
FX This study was supported by the Centers for Disease Control and
   Prevention's Division of Diabetes Translation through US Federal
   Contract 200-2002-00776.
CR *AAO, 2006, AG REL MAC DEG PREF
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang CW, 2003, CAN J OPHTHALMOL, V38, P27, DOI 10.1016/S0008-4182(03)80005-4
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Chung PY, 1998, AM J OPHTHALMOL, V126, P185, DOI 10.1016/S0002-9394(98)00151-2
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitka M, 2007, JAMA-J AM MED ASSOC, V297, P1538, DOI 10.1001/jama.297.14.1538
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   PECK P, 2007, MEDPAGE TODAY   1101
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   US Census Bureau Population Division, 2000, NAT POP PROJ SUMM TA
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   *VIT, VIT HLTH INC WEB SIT
NR 38
TC 243
Z9 253
U1 1
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2009
VL 127
IS 4
BP 533
EP 540
DI 10.1001/archophthalmol.2009.58
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 431ZN
UT WOS:000265103400027
PM 19365036
OA Bronze
DA 2022-11-30
ER

PT J
AU Rahimy, E
   Ying, GS
   Pan, W
   Hsu, J
AF Rahimy, Ehsan
   Ying, Gui-Shuang
   Pan, Wei
   Hsu, Jason
CA CATT Res Grp
TI EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF
   AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; aqueous outflow; beta blockers;
   carbonic anhydrase inhibitors; choroidal neovascularization;
   dorzolamide; intraocular pressure; timolol
ID SYSTEMIC BETA-BLOCKERS; TOPICAL DORZOLAMIDE THERAPY; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; ADRENERGIC SYSTEM; MOUSE
   MODEL; RANIBIZUMAB; TIMOLOL; EFFICACY; EDEMA
AB Purpose: To evaluate the effect of intraocular pressure-lowering medications on treatment outcomes in the Comparison of AMD Treatments Trials.
   Methods: Secondary analysis of Comparison of AMD Treatments Trials data. Medication logs were reviewed for continuous 2-year use of agents that increased aqueous outflow (Group A: topical prostaglandins) or suppressed aqueous production (Group B: topical beta blockers and carbonic anhydrase inhibitors). Eyes were excluded if mixed-mechanism intraocular pressure-lowering agents or medications from more than one group were taken. Anatomical and vision responses to treatment at years 1, 2, and over the entire 2-year period in each group were compared with controls (no intraocular pressure-lowering medications).
   Results: Inclusion criteria were met by 28 Group A patients, 19 Group B patients, and 857 controls. After 2 years, the control group had a mean visual acuity improvement of +6.3 letters from baseline, compared with +3.5 letters in Group A (P = 0.38), and +13.8 letters in Group B (P = 0.052). Mean retinal thickness change from baseline was -54.9 mu m in controls, -80.6 mu m in Group A (P = 0.26), and -96.8 mu m in Group B (P = 0.13). Mean total thickness change from baseline was -163 mu m in controls, -180 mu m in Group A (P = 0.63), and -238 mu m in Group B (P = 0.08). In longitudinal analysis with adjustment by their baseline values, anti-vascular endothelial growth factor treatment drug and regimen, Group B had more visual acuity improvement (difference of 2.6 letters, 95% confidence interval: -3.4-8.5 letters), more reduction in the retinal thickness (-17.9 mu m, 95% confidence interval: -36.5 to 0.7 mu m), and total thickness from baseline (mean difference of -54.7 mu m, 95% confidence interval: -103 to 6.2 mu m) compared with the control group.
   Conclusion: Concurrent aqueous suppressant use during anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration was associated with a trend toward greater reductions in retinal and total thickness as well as improved visual outcomes over 2 years. A similar effect was not observed to the same extent with agents that increase aqueous outflow. Because of the small sample size and secondary analysis, these findings must be cautiously interpreted and perhaps serve as a basis for future prospective studies.
C1 [Rahimy, Ehsan] Palo Alto Med Fdn, Dept Ophthalmol, Palo Alto, CA USA.
   [Rahimy, Ehsan; Hsu, Jason] Wills Eye Hosp & Res Inst, Retina Serv, Mid Atlantic Retina, Philadelphia, PA USA.
   [Ying, Gui-Shuang; Pan, Wei] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 Palo Alto Medical Foundation Research Institute; Jefferson University;
   University of Pennsylvania; Pennsylvania Medicine
RP Hsu, J (通讯作者)，Thomas Jefferson Univ, Mid Atlantic Retina, Retina Serv, Wills Eye Hosp, Philadelphia, PA 19107 USA.
EM jhsu@midatlanticretina.com
OI Rahimy, Ehsan/0000-0001-8446-7078
FU NIH [U10 EY0\17823, U10 EY017825, U10 EY017826, U10 EY017828,
   R21EY023689]
FX Supported by NIH U10 EY0\17823, U10 EY017825, U10 EY017826, U10 EY017828
   and R21EY023689.
CR Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brubaker RF, 2000, OPHTHALMOLOGY, V107, P283, DOI 10.1016/S0161-6420(99)00044-5
   Byeon SH, 2009, GRAEF ARCH CLIN EXP, V247, P35, DOI 10.1007/s00417-008-0917-1
   Casini G, 2014, PROG RETIN EYE RES, V42, P103, DOI 10.1016/j.preteyeres.2014.06.001
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Dwivedi R1, 2016, RETIN CASES BRIEF RE, V12, P75
   Ehlers JP, 2013, EYE, V27, P102, DOI 10.1038/eye.2012.228
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Genead MA, 2012, RETINA-J RET VIT DIS, V32, P826, DOI 10.1097/IAE.0b013e3182215ae9
   Genead MA, 2010, ARCH OPHTHALMOL-CHIC, V128, P190, DOI 10.1001/archophthalmol.2009.398
   Grover S, 2006, AM J OPHTHALMOL, V141, P850, DOI 10.1016/j.ajo.2005.12.030
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Harris A, 1996, ACTA OPHTHALMOL SCAN, V74, P569
   Harris A, 2003, BRIT J OPHTHALMOL, V87, P753, DOI 10.1136/bjo.87.6.753
   Harris A, 2001, AM J OPHTHALMOL, V132, P490, DOI 10.1016/S0002-9394(01)01158-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ikeda Y, 2012, GRAEF ARCH CLIN EXP, V250, P809, DOI 10.1007/s00417-011-1904-5
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   Lavine JA, 2013, JAMA OPHTHALMOL, V131, P376, DOI 10.1001/jamaophthalmol.2013.1476
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martini D, 2011, J NEUROCHEM, V119, P1317, DOI 10.1111/j.1471-4159.2011.07530.x
   Montero JA, 2013, RETINA-J RET VIT DIS, V33, P508, DOI 10.1097/IAE.0b013e3182695ba0
   Ristori C, 2011, INVEST OPHTH VIS SCI, V52, P155, DOI 10.1167/iovs.10-5536
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sridhar J, 2016, JAMA OPHTHALMOL, V134, P437, DOI 10.1001/jamaophthalmol.2016.0045
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Terashima H, 1996, JPN J OPHTHALMOL, V40, P142
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   Traband A, 2017, RETINA-J RET VIT DIS, V37, P41, DOI 10.1097/IAE.0000000000001226
   Ying GS, 2017, OPHTHAL EPIDEMIOL, V24, P130, DOI 10.1080/09286586.2016.1259636
NR 37
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2019
VL 39
IS 4
BP 636
EP 647
DI 10.1097/IAE.000000000002124
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4TY
UT WOS:000480744900002
PM 29517580
DA 2022-11-30
ER

PT J
AU Lad, EM
   Hammill, BG
   Qualls, LG
   Wang, F
   Cousins, SW
   Curtis, LH
AF Lad, Eleonora M.
   Hammill, Bradley G.
   Qualls, Laura G.
   Wang, Fang
   Cousins, Scott W.
   Curtis, Lesley H.
TI Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular
   Degeneration Among Medicare Beneficiaries
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RESOURCE USE; RANIBIZUMAB; VERTEPORFIN; TRENDS; TRIAL
AB PURPOSE: To examine the use of anti-vascular endothelial growth factor (VEGF) therapy in clinical practice among patients with neovascular age-related macular degeneration (AMD).
   DESIGN: Retrospective cohort study.
   METHODS: Among 459 237 Medicare beneficiaries, we identified anti-VEGF treatment using claims for intravitreal injections of anti-VEGF medications with a supporting diagnosis of neovascular AMD. We used the cumulative incidence function to calculate the frequency of anti-VEGF treatments and treatment visits for neovascular AMD per treated eye in the first and second year after the initial anti-VEGF injection. We calculated the mean number of treatments and treatment visits per eye using the mean frequency function. Rates of discontinuation were estimated using Kaplan-Meier methods.
   RESULTS: The mean number of injections was 4.3 in the first year, with 58% of patients receiving 1-4 injections, 20% receiving 5-6 injections, and 22% receiving 7 or more injections. Among patients who received 7 or more injections during the first year, 31% received a comparable number during the second year, and 12% received no injections. Of patients who received 1-4 injections during the first year, 70% received no injections and 24% received 1-4 injections during the second year. Rates of anti-VEGF discontinuation were 57% within 12 months and 71% within 24 months.
   CONCLUSIONS: The frequency of anti-VEGF injections for neovascular AMD was lower than that recommended by large-scale clinical trials, and rates of discontinuation were high. National practice patterns in anti-VEGF therapy for patients with neovascular AMD do not reflect optimal treatment strategies suggested by recent clinical trial evidence. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Lad, Eleonora M.; Cousins, Scott W.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA.
   [Curtis, Lesley H.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
   [Hammill, Bradley G.; Qualls, Laura G.; Curtis, Lesley H.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
   [Wang, Fang] GlaxoSmithKline, King Of Prussia, PA USA.
C3 Duke University; Duke University; Duke University; GlaxoSmithKline
RP Curtis, LH (通讯作者)，Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.
EM lesley.curtis@duke.edu
FU Heidelberg Engineering; Kala; Pfizer; Valeant Ophthalmics; Boston
   Scientific Corporation; Bristol-Myers Squibb; GlaxoSmithKline; GE
   Healthcare; Johnson Johnson; Medtronic; Merck; Novartis Pharmaceuticals
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. Dr Cousins reported receiving
   funding from Heidelberg Engineering, Kala, Pfizer, and Valeant
   Ophthalmics. Dr Curtis reported receiving research support from Boston
   Scientific Corporation, Bristol-Myers Squibb, GlaxoSmithKline, GE
   Healthcare, Johnson & Johnson, Medtronic, Merck, and Novartis
   Pharmaceuticals. Dr Wang is an employee of GlaxoSmithKline. No other
   authors reported conflicts of interest. This study was supported by a
   research agreement between GlaxoSmithKline and Duke University.
   Contributions of the authors: design and conduct of the study (E.M.L.,
   B.G.H., L.G.Q., F.W., L.H.C.); collection and management of the data
   (B.G.H., L.H.C.); analysis and interpretation of the data (E.M.L.,
   B.G.H., L.G.Q., F.W., S.W.C., L.H.C.); preparation, review, and approval
   of the manuscript (E.M.L., B.G.H., L.G.Q., F.W., S.W.C., L.H.C.).
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Centers for Medicare & Medicaid Services, MED ENR AG BEN JUL 2
   Chronic Conditions Warehouse Categories, CHRON COND WAR CAT
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kalbfleisch D., 1980, STAT ANAL FAILURE TI, DOI DOI 10.1016/0197-2456(81)90009-X
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salm M, 2006, AM J OPHTHALMOL, V142, P976, DOI 10.1016/j.ajo.2006.07.057
   Shea AM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1748, DOI 10.1001/archopht.126.12.1748
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stein JD, 2012, AM J OPHTHALMOL, V154, P452, DOI 10.1016/j.ajo.2012.03.032
NR 20
TC 46
Z9 50
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2014
VL 158
IS 3
BP 537
EP 543
DI 10.1016/j.ajo.2014.05.014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2CZ
UT WOS:000341124400017
PM 24857687
DA 2022-11-30
ER

PT J
AU Mundo, L
   Tosi, G
   Lazzi, S
   Pertile, G
   Parolini, B
   Neri, G
   Posarelli, M
   De Benedetto, E
   Bacci, T
   Silvestri, E
   Siciliano, M
   Barbera, S
   Orlandini, M
   Greenwood, J
   Moss, S
   Galvagni, F
AF Mundo, Lucia
   Tosi, Gian
   Lazzi, Stefano
   Pertile, Grazia
   Parolini, Barbara
   Neri, Giovanni
   Posarelli, Matteo
   De Benedetto, Elena
   Bacci, Tommaso
   Silvestri, Ennio
   Siciliano, Maria
   Barbera, Stefano
   Orlandini, Maurizio
   Greenwood, John
   Moss, Stephen
   Galvagni, Federico
TI LRG1 Expression Is Elevated in the Eyes of Patients with Neovascular
   Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE LRG1; age-related macular degeneration; AMD; VEGF; choroidal neovascular
   membranes
ID PROMOTES ANGIOGENESIS; COLORECTAL-CANCER; PROTEOMICS; THERAPY
AB Leucine-rich a-2-glycoprotein 1 (LRG1) is a candidate therapeutic target for treating the neovascular form of age-related macular degeneration (nvAMD). In this study we examined the expression of LRG1 in eyes of nvAMD patients. Choroidal neovascular membranes (CNVMs) from patients who underwent submacular surgery for retinal pigment epithelium-choroid graft transplantation were collected from 5 nvAMD patients without any prior intravitreal anti-VEGF injection, and from six patients who received intravitreal anti-VEGF injections before surgery. As controls free of nvAMD, retina sections were obtained from the eyes resected from a patient with lacrimal sac tumor and from a patient with neuroblastoma. CNVMs were immunostained for CD34, LRG1, and alpha-smooth muscle actin (alpha-SMA). Aqueous humor samples were collected from 58 untreated-naive nvAMD patients prior to the intravitreal injection of anti-VEGF and 51 age-matched cataract control patients, and LRG1 concentration was measured by ELISA. The level of LRG1 immunostaining is frequently high in both the endothelial cells of the blood vessels, and myofibroblasts in the surrounding tissue of CNVMs of treatment-naive nvAMD patients. Furthermore, the average concentration of LRG1 was significantly higher in the aqueous humor of nvAMD patients than in controls. These observations provide a strong experimental basis and scientific rationale for the progression of a therapeutic anti-LRG1 monoclonal antibody into clinical trials with patients with nvAMD.
C1 [Mundo, Lucia; Lazzi, Stefano; Siciliano, Maria] Univ Siena, Dept Med Biotechnol, Sect Pathol, I-53100 Siena, Italy.
   [Mundo, Lucia] Univ Limerick, Hlth Res Inst, Limerick V94 T9PX, Ireland.
   [Tosi, Gian; Neri, Giovanni; Posarelli, Matteo; De Benedetto, Elena; Bacci, Tommaso] Univ Siena, Dept Med Surg & Neurosci, Ophthalmol Unit, I-53100 Siena, Italy.
   [Pertile, Grazia] IRCCS Sacro Cuore Don Calabria Hosp, I-37024 Negrar, Italy.
   [Parolini, Barbara] St Anna Hosp, Vitroretinal Unit, I-25127 Brescia, Italy.
   [Silvestri, Ennio; Barbera, Stefano; Orlandini, Maurizio; Galvagni, Federico] Univ Siena, Dept Biotechnol Chem & Pharm, Via A Moro 2, I-53100 Siena, Italy.
   [Greenwood, John; Moss, Stephen] UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
C3 University of Siena; University of Limerick; University of Siena; IRCCS
   Sacro Cuore Don Calabria; University of Ferrara; Arcispedale Sant'Anna;
   University of Siena; University of London; University College London
RP Galvagni, F (通讯作者)，Univ Siena, Dept Biotechnol Chem & Pharm, Via A Moro 2, I-53100 Siena, Italy.; Moss, S (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM lucia.mundo.ml@gmail.com; gianmarco.tosi@unisi.it; lazzi2@unisi.it;
   grazia.pertile@gmail.com; parolinibarbara@gmail.com;
   gio.neri2009@libero.it; mposarelli@gmail.com;
   elenadebenedetto1992@gmail.com; osammot.iccab@gmail.com;
   ennio.silvestri@unige.ch; siciliano10@student.unisi.it;
   stefano.barbera@student.unisi.it; maurizio.orlandini@unisi.it;
   j.greenwood@ucl.ac.uk; s.moss@ucl.ac.uk; federico.galvagni@unisi.it
RI Lazzi, Stefano/P-8265-2018; Bacci, Tommaso/GQA-8840-2022; Mundo,
   Lucia/ABE-8599-2021; Pertile, Grazia/AAC-4956-2022
OI Lazzi, Stefano/0000-0002-2218-3771; Bacci, Tommaso/0000-0001-7477-2263;
   Barbera, Stefano/0000-0001-9544-455X; Galvagni,
   Federico/0000-0003-1967-9554; Greenwood, John/0000-0003-4496-2984;
   POSARELLI, MATTEO/0000-0002-3983-0381
FU MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca) grant;
   I.Ri.Fo.R Onlus (Institute for Research, Training, and Rehabilitation)
   [2747]; Wellcome Trust [206413/B/17/Z]
FX This study was supported by MIUR (Ministero dell'Istruzione,
   dell'Universita e della Ricerca) grant "Dipartimento di Eccellenza"
   2018-2022 to the Department of Biotechnology, Chemistry and Pharmacy
   grant (F.G. and M.O.), I.Ri.Fo.R Onlus (Institute for Research,
   Training, and Rehabilitation) (grant number prot. 2747, 08/08/2019,
   G.M.T.), and Wellcome Trust (Investigator award 206413/B/17/Z, S.E.M.
   and J.G.).
CR Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Arruabarrena C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153281
   Bajka A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115846
   Castellino N, 2018, AGING-US, V10, P4241, DOI 10.18632/aging.101727
   Dolar-Szczasny J, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.656774
   Elfalah M, 2021, CLIN OPHTHALMOL, V15, P661, DOI 10.2147/OPTH.S289068
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g
   Gao Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0600-6
   Guldvik IJ, 2020, EUR UROL OPEN SCI, V21, P51, DOI 10.1016/j.euros.2020.08.007
   Honda H, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13556
   Iglicki M, 2021, EYE, V35, P1111, DOI 10.1038/s41433-020-01309-9
   Kallenberg D., 2020, HUMANIZED ANTIBODY L, V55, P137, DOI DOI 10.1101/2020.07.25.218149
   Kodeboyina SK, 2020, PROTEOMES, V8, DOI 10.3390/proteomes8040034
   Ladd JJ, 2012, CANCER PREV RES, V5, P655, DOI 10.1158/1940-6207.CAPR-11-0412
   Li ZF, 2019, MOL THER-ONCOLYTICS, V14, P313, DOI 10.1016/j.omto.2019.08.001
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Nobl M, 2016, EXP EYE RES, V146, P107, DOI 10.1016/j.exer.2016.01.001
   O'Connor M.N., 2020, LRG1 DESTABILIZES TU, DOI [10.1101/2020.10.12.334359, DOI 10.1101/2020.10.12.334359]
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Qu SC, 2019, INT J OPHTHALMOL-CHI, V12, P1758, DOI 10.18240/ijo.2019.11.15
   Sng MK, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0014-5
   Wang XM, 2013, NATURE, V499, P306, DOI 10.1038/nature12345
   Wang YY, 2019, CURR CANCER DRUG TAR, V19, P756, DOI 10.2174/1568009619666190204095942
   Yang Y, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-01782-0
   Zhang AF, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.01064
   Zhang JJ, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0306-2
   Zhang Q, 2018, ONCOTARGETS THER, V11, P2745, DOI 10.2147/OTT.S153375
NR 29
TC 5
Z9 5
U1 4
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2021
VL 22
IS 16
AR 8879
DI 10.3390/ijms22168879
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UG3QZ
UT WOS:000689172700001
PM 34445590
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kucukevcilioglu, M
   Patel, CB
   Stone, EM
   Russell, SR
AF Kucukevcilioglu, Murat
   Patel, Chetankumar B.
   Stone, Edwin M.
   Russell, Stephen R.
TI Clinically detectable drusen domains in fibulin-5-associated age-related
   macular degeneration (AMD)
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Drusen; Fibulin 5; Fluorescein
   angiography; Fundus photography
ID OPTICAL COHERENCE TOMOGRAPHY; BRUCHS MEMBRANE; UNESTERIFIED CHOLESTEROL;
   IN-VIVO; FIBULIN-5; SUBSTRUCTURE; DEPOSITS; MUTATION; BINDING
AB To evaluate whether drusen of subjects with fibulin-5 mutation-associated age-related macular degeneration (AMD) have clinically demonstrable drusen domains as evidenced by differences between color and fluorescein angiographic profiles. Of seven patients we identified with AMD due to mutations in the fibulin-5 gene (Fib-5 AMD), five had color fundus photography and fluorescein angiography (FA). One had bilateral choroidal neovascularization and no drusen. For each eye, the green channel (GC) of the digital RGB (Red-Green-Blue) color image and hyperfluorescent domain (HD) intensity of the FA image were registered and drusen were manually segmented and measured. Totally 75 small (a parts per thousand currency sign62 mu m), 110 intermediate (63-125 mu m), and 30 large (> 125 mu m) drusen were measured in four patients within the 6 x 6 mm central macular areas. All four subjects demonstrated central or paracentral HDs within each drusen perimeter. HDs were found in association with each druse, with a HD/GC ratio of 0.82, 0.76, and 0.72 respectively for small, intermediate, and large drusen (Student T Test: P < 0.01, P < 0.01, P < 0.01). A statistical difference was found for the HD/GC ratios between small- and intermediate-sized drusen and small- and large-sized drusen but not between intermediate-sized and large-sized drusen (P = 0.001, P < 0.001, P > 0.05, respectively). AMD patients with mutations in fibulin-5 share drusen phenotypic structure and have HD/GC ratios that are similar to individuals with cuticular or basal laminar drusen. Drusen substructure may reflect similarities in drusen stage and/or genesis and appear to vary among AMD genotypes.
C1 [Kucukevcilioglu, Murat] Gulhane Mil Med Acad, Dept Ophthalmol, GATA Goz Klin, TR-06010 Ankara, Turkey.
   [Patel, Chetankumar B.] Greater Potomac Retina, Frederick, MD 21704 USA.
   [Stone, Edwin M.; Russell, Stephen R.] Univ Iowa, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, Carver Coll Med, Iowa City, IA 52242 USA.
C3 Gulhane Military Medical Academy; University of Iowa
RP Kucukevcilioglu, M (通讯作者)，Gulhane Mil Med Acad, Dept Ophthalmol, GATA Goz Klin, TR-06010 Ankara, Turkey.
EM eyedrmuratk@gmail.com
RI Kucukevcilioglu, Murat/AAH-3033-2021
OI Russell, Stephen/0000-0003-3776-1367; Stone, Edwin
   M./0000-0003-3343-4414
CR Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Friedman D, 2012, RETINA-J RET VIT DIS, V32, P19, DOI 10.1097/IAE.0b013e318219e5e9
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Rudolf M, 2014, BRIT J OPHTHALMOL, V98, P698, DOI 10.1136/bjophthalmol-2013-304226
   Russell SR, 2004, AM J OPHTHALMOL, V137, P924, DOI 10.1016/j.ajo.2003.12.043
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Sohn EH, 2014, RETINA, V35, P48
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WOLFE DR, 1986, OPHTHALMOLOGY, V93, P1617
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
NR 24
TC 4
Z9 4
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD AUG
PY 2016
VL 36
IS 4
BP 569
EP 575
DI 10.1007/s10792-015-0164-5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DQ6OO
UT WOS:000379324900016
PM 26694911
DA 2022-11-30
ER

PT J
AU Zeng, BZ
   Zhang, HN
   Peng, YT
   Yu, H
   Li, WH
   Li, ZQ
   Xie, YJ
   Qiu, SJ
   Wu, PX
   Zhang, W
   Liu, YW
   Chen, YM
   Liu, X
   Huang, B
AF Zeng, Baozhu
   Zhang, Hening
   Peng, Yuting
   Yu, Huan
   Li, Weihua
   Li, Zhiquan
   Xie, Yaojue
   Qiu, Sujuan
   Wu, Peixin
   Zhang, Wang
   Liu, Yanwei
   Chen, Yanming
   Liu, Xing
   Huang, Bing
TI Spontaneous fundus lesions in elderly monkeys: An ideal model for
   age-related macular degeneration and high myopia clinical research
SO LIFE SCIENCES
LA English
DT Article
DE Animal model; Fundus diseases; Age-related macular degeneration; High
   myopia; Cynomolgus monkeys
ID RHESUS-MONKEYS; MACACA-MULATTA; ANIMAL-MODEL; LIFE-SPAN; MACULOPATHY;
   WEAR
AB Aims: Age-related macular degeneration (AMD) and high myopia are frequent causes of progressive visual impairment, so it is critical to identify animal models with resembling human retinal physiology, AMD and high myopia pathological features for therapeutic studies. Main methods: We screened elderly cynomolgus monkeys for fundus lesions by slit-lamp biomicroscope combined with fundus pre-set lens and further examined positive cases by color fundus photography (CFP), optical coherence tomography (OCT), fundus fluorescein angiography (FFA), streak retinoscopy, and A-scan ultrasonography. Key findings: Among the 156 animals examined, 10 males and 5 females (30 eyes) exhibited fundus abnormalities (9.6% prevalence). Multi-modal imaging revealed drusen in 20 eyes of 11 animals (prevalence rate of 7.1%), tessellated fundus in 22 eyes of 11 animals, and myopia choroidal neovascularization (CNV) in 4 eyes of 3 animals. Significance: Aged cynomolgus monkeys exhibit spontaneous fundus lesions resembling human AMD and high myopia, which could be an ideal model for clinical research.
C1 [Zeng, Baozhu; Zhang, Hening; Yu, Huan; Li, Weihua; Li, Zhiquan; Xie, Yaojue; Qiu, Sujuan; Wu, Peixin; Zhang, Wang; Liu, Xing; Huang, Bing] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Peng, Yuting] Guangdong Prov Hosp Chinese Med, Dept Ophthalmol, Guangzhou, Peoples R China.
   [Liu, Yanwei] Chuangyao Biotechnol Co Ltd, Zhaoqing, Peoples R China.
   [Chen, Yanming] Xiangguan Biotechnol Co Ltd, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Guangzhou University of Chinese Medicine
RP Liu, X; Huang, B (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
EM drliuxing@163.com; huangbing2000@hotmail.com
OI Yu, Huan/0000-0003-4626-977X
FU Fundamental Research Funds of the State Key Laboratory of Ophthalmology
   (Guangzhou, China) [303060202400201018, 303010303018]; Science and
   Technology Planning Project of Guangdong Province, China
   [2019A030317002, 2017A030303013]
FX This research was funded in part by the Fundamental Research Funds of
   the State Key Laboratory of Ophthalmology (Guangzhou, China) [grant
   numbers 303060202400201018 and 303010303018], and the Science and
   Technology Planning Project of Guangdong Province, China [grant numbers
   2019A030317002 and 2017A030303013].
CR Bradley DV, 1999, INVEST OPHTH VIS SCI, V40, P214
   Bringmann A, 2018, PROG RETIN EYE RES, V66, P49, DOI 10.1016/j.preteyeres.2018.03.006
   Collery RF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110699
   DAWSON WW, 1989, DOC OPHTHALMOL, V71, P253
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   ELMOFTY AAM, 1980, EXP EYE RES, V31, P147, DOI 10.1016/0014-4835(80)90075-5
   ENGEL HM, 1988, OPHTHALMOLOGICA, V196, P143, DOI 10.1159/000309891
   Ferguson B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-43
   Fernandes A, 2003, INVEST OPHTH VIS SCI, V44, P2373, DOI 10.1167/iovs.02-0944
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Graham B, 1999, VISION RES, V39, P189, DOI 10.1016/S0042-6989(98)00189-8
   Grunert U, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100844
   Hafezi F, 2000, BRIT J OPHTHALMOL, V84, P922, DOI 10.1136/bjo.84.8.922
   He MG, 2015, JAMA-J AM MED ASSOC, V314, P1142, DOI 10.1001/jama.2015.10803
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang XY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20272-w
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Peng YR, 2019, CELL, V176, P1222, DOI 10.1016/j.cell.2019.01.004
   Picaud S, 2019, P NATL ACAD SCI USA, V116, P26280, DOI 10.1073/pnas.1902292116
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   RAVIOLA E, 1985, NEW ENGL J MED, V312, P1609, DOI 10.1056/NEJM198506203122505
   Roth GS, 2004, SCIENCE, V305, P1423, DOI 10.1126/science.1102541
   Schaeffel F, 2004, OPTOMETRY VISION SCI, V81, P99, DOI 10.1097/00006324-200402000-00008
   Shaikh AW, 1999, OPTOMETRY VISION SCI, V76, P308, DOI 10.1097/00006324-199905000-00019
   Sinha R, 2017, CELL, V168, P413, DOI 10.1016/j.cell.2017.01.005
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   TIGGES J, 1988, AM J PRIMATOL, V15, P263, DOI 10.1002/ajp.1350150308
   Tschulakow AV, 2018, PEERJ, V6, DOI 10.7717/peerj.4482
   ULSHAFER RJ, 1987, RETINA-J RET VIT DIS, V7, P198, DOI 10.1097/00006982-198700730-00011
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Veth KN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001310
   WALLMAN J, 1978, SCIENCE, V201, P1249, DOI 10.1126/science.694514
   WIESEL TN, 1977, NATURE, V266, P66, DOI 10.1038/266066a0
   Yiu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14715-z
NR 42
TC 1
Z9 1
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD OCT 1
PY 2021
VL 282
AR 119811
DI 10.1016/j.lfs.2021.119811
EA JUL 2021
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA UB0BZ
UT WOS:000685519400001
PM 34256039
DA 2022-11-30
ER

PT J
AU Weaver, C
   Cyr, B
   Vaccari, JCD
   Vaccari, JPD
AF Weaver, Cailey
   Cyr, Brianna
   Vaccari, Juan Carlos de Rivero
   Vaccari, Juan Pablo de Rivero
TI Inflammasome Proteins as Inflammatory Biomarkers of Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE macular degeneration; biomarkers; inflammasome; ASC, IL-18
ID C-REACTIVE PROTEIN; NLRP3 INFLAMMASOME; ALZHEIMERS-DISEASE; VEGF-A;
   PREVALENCE; INTERLEUKIN-18; PATHOGENESIS; MACULOPATHY; TIME
AB Purpose: Age-related macular degeneration (AMD) can result in severe vision loss and blurriness in the older population. The early and intermediate stages of AMD typically start without noticeable symptoms and can only be detected with a comprehensive eye exam. Because of the quiet onset of the disease, it is necessary to identify potential biomarkers to aid in the diagnosis, staging, and association with disease onset. Inflammasome signaling proteins are prominent biomarkers in the central nervous system, and the inflammasome has been shown to play a role in the innate inflammatory response in aging and AMD.
   Methods: Serum from healthy controls and AMD patients were analyzed for the protein levels of Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), interleukin (IL)-18 and C-reactive protein (CRP) to determine cutoff points, positive and negative predictive values, and receiver operator characteristic curves, as well as univariate and multivariate linear and logistic regression models.
   Results: ASC, IL-18, and CRP were elevated in the serum of AMD patients when compared to healthy controls. The area under the curve (AUC) for ASC was 0.98 with a cutoff point of 365.6 pg/mL, whereas IL-18 had an AUC of 0.73 and a cutoff point of 242.4 pg/mL, and the AUC for CRP was 0.67 with a cutoff point of 8,684,152 pg/mL. Levels of IL-18 had a statistically significant linear correlation with that of ASC with an adjusted R-2 of 0.1906, indicating that 19% of IL-18 could be explained by ASC protein levels in serum. Moreover, a logistic regression model for the diagnosis of AMD consists of ASC and having a diagnosis of hypertension, indicating that these two factors (elevated levels of ASC and a diagnosis of hypertension [HTN]) are associated with the diagnosis of AMD.
   Conclusions: ASC, IL-18, and CRP are elevated in patients with AMD, and the protein levels of IL-18 are partially the result of ASC protein expression. Moreover, elevated protein levels of ASC in serum and a diagnosis of HTN increase the odds of patients having a diagnosis of AMD.
   Translational Relevance: Biomarkers of AMD may be used to monitor disease risk, response to treatment and disease progression.
C1 [Weaver, Cailey; Cyr, Brianna; Vaccari, Juan Pablo de Rivero] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Weaver, Cailey; Cyr, Brianna; Vaccari, Juan Pablo de Rivero] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA.
   [Vaccari, Juan Pablo de Rivero] Univ Miami, Miller Sch Med, Ctr Cognit Neurosci, Miami, FL 33136 USA.
   [Vaccari, Juan Pablo de Rivero] Univ Miami, Miller Sch Med, Aging Univ, Miami, FL 33136 USA.
   [Vaccari, Juan Pablo de Rivero] InflamaCORE LLC, Miami, FL USA.
   [Vaccari, Juan Carlos de Rivero] DRV Ventures LLC, Miami, FL USA.
C3 University of Miami; University of Miami; University of Miami;
   University of Miami
RP Vaccari, JPD (通讯作者)，Lois Pope LIFE Ctr, Dept Neurol Surg, 1095 NW 14th Terrace,3-25, Miami, FL 33136 USA.
EM jderivero@med.miami.edu
OI Cyr, Brianna/0000-0002-2924-7416
FU Stanley J. Glaser Foundation Research Award
FX Supported by the 2019 Stanley J. Glaser Foundation Research Award to
   JPdRV.
CR Aden K, 2017, IMMUNITY, V46, P173, DOI 10.1016/j.immuni.2017.02.009
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Belkin M, 2013, AM J OPHTHALMOL, V155, P404, DOI 10.1016/j.ajo.2012.09.017
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brand FJ, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0137-0
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Forouzandeh M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01238
   Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Ildefonso CJ, 2016, ADV EXP MED BIOL, V854, P59, DOI 10.1007/978-3-319-17121-0_9
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Keane RW, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00135
   Kerr N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210128
   Kerr N, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00309
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Latz E, 2018, SEMIN IMMUNOL, V40, P61, DOI 10.1016/j.smim.2018.09.001
   Marneros AG, 2016, ADV EXP MED BIOL, V854, P79, DOI 10.1007/978-3-319-17121-0_12
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Mawhinney LJ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-123
   Mejias NH, 2018, J INFLAMM-LOND, V15, DOI 10.1186/s12950-018-0198-3
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Pawelec G, 2014, CURR OPIN IMMUNOL, V29, P23, DOI 10.1016/j.coi.2014.03.007
   Perez-Barcena J, 2021, J NEUROSURG, V134, P1644, DOI 10.3171/2020.2.JNS193079
   Platnich JM, 2019, ARCH BIOCHEM BIOPHYS, V670, P4, DOI 10.1016/j.abb.2019.02.008
   Puren AJ, 1999, P NATL ACAD SCI USA, V96, P2256, DOI 10.1073/pnas.96.5.2256
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Schwaber EJ, 2020, J ALZHEIMERS DIS, V76, P207, DOI 10.3233/JAD-200111
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Scott XO, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134674
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Shen JK, 2014, J CELL PHYSIOL, V229, P974, DOI 10.1002/jcp.24575
   Tan HD, 2020, MOL NEUROBIOL, V57, P4488, DOI 10.1007/s12035-020-02024-y
   Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 47
TC 6
Z9 6
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD DEC
PY 2020
VL 9
IS 13
AR 27
DI 10.1167/tvst.9.13.27
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG6UM
UT WOS:000617719900018
PM 33364081
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Niazi, S
   Nielsen, MK
   Sorensen, TL
   Subhi, Y
AF Niazi, Siar
   Nielsen, Marie Krogh
   Sorensen, Torben Lykke
   Subhi, Yousif
TI Neutrophil-to-lymphocyte ratio in age-related macular degeneration: a
   systematic review and meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization; drusen;
   geographic atrophy; lymphocytes; neutrophils
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CIRCULATING MONOCYTES; CELLS;
   NEUTROPHIL/LYMPHOCYTE; INFLAMMATION; PREVALENCE; EXPRESSION; PROPORTION;
   THICKNESS; RESPONSES
AB Age-related macular degeneration (AMD) is aetiologically linked to immunological ageing and dysfunction. One aspect of this is the altered neutrophil-to-lymphocyte ratio (NLR), which in other domains have been associated with inflammation and angiogenesis, and therefore investigated in patients with AMD in several papers. In this systematic review and meta-analysis, we summarize findings in patients with AMD in relation to NLR, both qualitatively and quantitatively. We searched PubMed/MEDLINE, EMBASE, Web of Science, and the Cochrane Central and identified six studies from where we extracted data on 1178 individuals (777 patients with AMD and 401 healthy controls). Patients with AMD had a higher NLR (weighted mean difference: 0.37, CI 95% 0.08 to 0.66, p = 0.013) when compared to healthy controls. In subgroup analyses, we did not find a significant difference between patients with dry AMD and healthy controls (weighted mean difference: 0.34, CI 95% -0.03 to 0.69, p = 0.068), but did find a strong significant difference between patients with neovascular AMD and healthy controls (weighted mean difference: 0.54, CI 95% 0.23 to 0.86, p = 0.00068). Hence, we find that the association between AMD and elevated NLR may have stronger relevance to the neovascular subtype of AMD. However, the clinical value of measuring the NLR remains unclear.
C1 [Niazi, Siar; Nielsen, Marie Krogh; Sorensen, Torben Lykke; Subhi, Yousif] Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Niazi, Siar; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
CR Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Askou AL, 2018, ACTA OPHTHALMOL, V96, P9, DOI 10.1111/aos.13407
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Dyer Douglas P, 2017, Sci Rep, V7, P42681, DOI 10.1038/srep42681
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Faria SS, 2016, ECANCERMEDICALSCIENC, V10, DOI 10.3332/ecancer.2016.702
   Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Harris J, 2017, PATHOBIOL AGING AGE, V7, DOI 10.1080/20010001.2017.1398016
   Hector SM, 2017, CLIN OPHTHALMOL, V11, P179, DOI 10.2147/OPTH.S121332
   Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750
   Ilhan N, 2015, OCUL IMMUNOL INFLAMM, V23, P287, DOI 10.3109/09273948.2014.921715
   Krogh Nielsen M, 2017, IMMUN AGEING, V14, P18, DOI DOI 10.1186/s12979-017-0100-9
   Kurtul Bengi Ece, 2016, Korean J Ophthalmol, V30, P377
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Lorentzen TD, 2018, ACTA OPHTHALMOL, V96, P475, DOI 10.1111/aos.13646
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Marsik C, 2004, J CLIN IMMUNOL, V24, P62, DOI 10.1023/B:JOCI.0000018064.13793.83
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Nielsen MK, 2019, CLIN EXP OPHTHALMOL, V47, P69, DOI 10.1111/ceo.13362
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990
   Pinna A, 2019, OCUL IMMUNOL INFLAMM, V27, P932, DOI 10.1080/09273948.2018.1485960
   Rembach A, 2014, J NEUROIMMUNOL, V273, P65, DOI 10.1016/j.jneuroim.2014.05.005
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Schmidt T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132703
   Sengul EA, 2017, INT J OPHTHALMOL-CHI, V10, P754, DOI 10.18240/ijo.2017.05.16
   SHAU H, 1988, J IMMUNOL, V141, P4395
   Shen EM, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43027
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Tamhane UU, 2008, AM J CARDIOL, V102, P653, DOI 10.1016/j.amjcard.2008.05.006
   Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Yu Y, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0251-z
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   Zhou JH, 2005, MOL VIS, V11, P414
NR 53
TC 25
Z9 25
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2019
VL 97
IS 6
BP 558
EP 566
DI 10.1111/aos.14072
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IP7VT
UT WOS:000480256800002
PM 30811869
OA Bronze
DA 2022-11-30
ER

PT J
AU Lommatzsch, A
   Hermans, P
   Weber, B
   Pauleikhoff, D
AF Lommatzsch, Albrecht
   Hermans, Pia
   Weber, Bernhard
   Pauleikhoff, Daniel
TI Complement factor H variant Y402H and basal laminar deposits in
   exudative age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE complement factor H polymorphism; basal laminar deposits; age-related
   macular degeneration; CFH genotype; histopathology
ID CHOROIDAL NEOVASCULAR MEMBRANES; RISK; DIFFERENTIATION; SUSCEPTIBILITY;
   POLYMORPHISM; INCREASES; DRUSEN; GENE
AB Complement factor H (CFH) polymorphism Y402H has been shown to be significantly associated with age-related macular degeneration (AMD). Furthermore, histopathological studies in AMD have implicated basal laminar deposits (BLD) in the development of choroidal neovascularization (CNV) membranes. The purpose of this study was to correlate CFH staining in BLD with the CFH genotype at the tyrosine 402 histidine (Y402H) polymorphism.
   During macular translocation, 21 angiographically confirmed CNV membranes were extracted in 21 patients. The specimens were analysed histologically for BLD. The presence of CFH, complement proteins, and vitronectin was determined by immunohistochemistry. Finally, the CFH Y402H genotype was established by direct sequencing analysis.
   Histological examination demonstrated BLD in all of the excised CNV membranes. By immunostaining CFH was detected in the peripheral aspect at the inner and outer surface of BLD, which colocalized with other proteins of the complement cascade (C3, C5b-9). Similarly, vitronectin was detected in all of the BLD investigated. Four patients were noncarriers of CFH Y402H polymorphism, nine patients were heterozygous and eight patients homozygous for the CFH Y402H polymorphism.
   BLD are composed of different complement factors (factor H, C3, C5b-9) and extracellular matrix proteins such as vitronectin. The prevalence of homozygous carriers in regard to CFH Y402H polymorphism, which is suspicious for AMD, might be associated with increased secretion of vitronectin in response to dysregulation of the complement cascade.
C1 Univ Regensburg, Inst Human Genet, D-8400 Regensburg, Germany.
   St Franziskus Hosp, Dept Ophthalmol, D-48145 Munster, Germany.
C3 University of Regensburg; St. Franziskus-Hospital
RP Pauleikhoff, D (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
EM dapauleikhoff@muenster.de
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   DEBOER HC, 1992, J BIOL CHEM, V267, P2264
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   PODACK ER, 1979, J BIOL CHEM, V254, P9908
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 18
TC 18
Z9 19
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2007
VL 245
IS 11
BP 1713
EP 1716
DI 10.1007/s00417-007-0649-7
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 215BK
UT WOS:000249782200018
PM 17704937
DA 2022-11-30
ER

PT J
AU Dedania, VS
   Bakri, SJ
AF Dedania, Vaidehi S.
   Bakri, Sophie J.
TI Systemic safety of intravitreal anti-vascular endothelial growth factor
   agents in age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE adverse events; bevacizumab; ranibizumab; vascular endothelial growth
   factor
ID VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION
   SECONDARY; ARTERIAL THROMBOEMBOLIC EVENTS; FACTOR TRAP-EYE; BEVACIZUMAB
   AVASTIN; OCULAR NEOVASCULARIZATION; RANIBIZUMAB LUCENTIS; PEGAPTANIB
   SODIUM; PLASMA-LEVELS; PHASE-II
AB Purpose of review
   The purpose of review is to summarize the literature addressing nonocular adverse events in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor (VEGF) inhibitors and to present possible mechanisms of effect.
   Recent findings
   The incidence of overall nonocular serious adverse events varied from 0 to 39.3% and nonocular adverse events ranged from 0 to 86.9%. Few studies have reported a significant association between use of intravitreal anti-VEGF agents and overall incidence of adverse events, stroke, myocardial infarction, nonocular hemorrhage and death, with overall greater concern in patients treated with bevacizumab. Additionally, history of stroke or other arterial thromboembolic event may be a risk factor for future stroke in patients treated with intravitreal anti-VEGF agents. Theories explaining the mechanisms of increased risk of nonocular adverse events secondary to anti-VEGF agent use surround the necessity of VEGF for the normal functioning of the endothelium and the damage incurred with use of anti-VEGF agents.
   Summary
   Current data are insufficient to definitively conclude that intravitreal anti-VEGF agents are safe, although there is a trend toward an overall favorable systemic safety profile. Caution should be exerted in patients with a history of cardiovascular disease, as these patients may be at greater risk for nonocular serious adverse events.
C1 [Dedania, Vaidehi S.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, 200 First St NW, Rochester, MN 55905 USA.
C3 University of Michigan System; University of Michigan; Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St NW, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
FU Research to Prevent Blindness, New York, NY
FX S.J.B. was supported by Research to Prevent Blindness, New York, NY.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   BOYER DS, 2008, ANN M AM AC OPHTH NO
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Heier JS, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Kaiser PK, 2012, GRAEF ARCH CLIN EXP, V250, P1563, DOI 10.1007/s00417-012-2123-4
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kilickap S, 2003, J CLIN ONCOL, V21, P3542, DOI 10.1200/JCO.2003.99.046
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kwon OW, 2012, GRAEF ARCH CLIN EXP, V250, P1467, DOI 10.1007/s00417-012-1970-3
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Liu EM, 2015, OSLI RETINA, V46, P1021, DOI 10.3928/23258160-20151027-06
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Mourad JJ, 2008, ANN ONCOL, V19, P927, DOI 10.1093/annonc/mdm550
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Saeed MU, 2013, CLIN OPHTHALMOL, V7, P533, DOI 10.2147/OPTH.S31016
   Sane David C., 2004, Angiogenesis, V7, P193, DOI 10.1007/s10456-004-2699-3
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schrijvers BF, 2004, KIDNEY INT, V65, P2003, DOI 10.1111/j.1523-1755.2004.00621.x
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Vinores SA, 1999, DOC OPHTHALMOL, V97, P217, DOI 10.1023/A:1002136712070
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 76
TC 11
Z9 11
U1 0
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2016
VL 27
IS 3
BP 224
EP 243
DI 10.1097/ICU.0000000000000257
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK2TJ
UT WOS:000374767000008
PM 26871657
DA 2022-11-30
ER

PT J
AU Kyosseva, SV
   Seal, S
   McGinnis, JF
AF Kyosseva, Svetlana V.
   Seal, Sudipta
   McGinnis, James F.
TI CERIUM OXIDE NANOPARTICLES INHIBIT MAP KINASES ACTIVATION IN THE RETINA
   OF VLDLR MOUSE MODEL OF AGE-RELATED MACULAR DEGENERATION
SO COMPTES RENDUS DE L ACADEMIE BULGARE DES SCIENCES
LA English
DT Article
DE cerium oxide nanoparticles; age-related macular degeneration; retina;
   Vldlr; MAP kinases
ID SUBRETINAL NEOVASCULARIZATION; NANOCERIA; INFLAMMATION; EXPRESSION;
   PATHWAY
AB Age-related macular degeneration (AMD) damages the central region of the retina and is the leading cause of blindness in the elderly. The retina provides an ideal environment for the generation of toxic reactive oxygen species (ROS) and resultant oxidative damage due to the retina's specific anatomical and metabolic characteristics. Decreasing ROS is, therefore, a target in the prevention and treatment of AMD. Cerium oxide nanoparticles or nanoceria are antioxidants that catalytically scavenge ROS. We have previously shown that a single intravitreal injection of nanoceria into the eye of a P28 Vldlr-/- mouse, an AMD model, inhibits the activation of mitogen-activated protein (MAP) kinases ERK, JNK, and p38 within one week. In this study we extended the endpoint for analysis to 3 months and demonstrated that injection of nanoceria in P28 Vldlr-/- mice produced sustained inhibition of the three MAP kinases down to the level of control wild type mice.
C1 [Kyosseva, Svetlana V.; McGinnis, James F.] Univ Oklahoma, Hlth Sci Ctr, Dean McGee Eye Inst, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
   [Kyosseva, Svetlana V.; McGinnis, James F.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Neurosci, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Seal, Sudipta] Univ Cent Florida, Nanosci Technol Ctr, Adv Mat Proc Anal Ctr, Mat Sci & Engn, Orlando, FL 32816 USA.
   [Seal, Sudipta] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; State University System of Florida; University of
   Central Florida; State University System of Florida; University of
   Central Florida
RP Kyosseva, SV (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dean McGee Eye Inst, Dept Ophthalmol, Oklahoma City, OK 73104 USA.; Kyosseva, SV (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Neurosci, Dept Cell Biol, Oklahoma City, OK 73104 USA.
EM svkiosseva@yahoo.com
RI Seal, Sudipta/A-7698-2012
FU NIH [COBRE-P20 RR017703, P30-EY 12190, R01EY18724, R01EY022111]
FX This work was supported by NIH grants: COBRE-P20 RR017703, P30-EY 12190,
   R01EY18724, R01EY022111.
CR Cai X, 2016, MOL VIS, V22, P1176
   Cai X, 2014, BIOMATERIALS, V35, P249, DOI 10.1016/j.biomaterials.2013.10.022
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Karakoti AS, 2008, JOM-US, V60, P33, DOI 10.1007/s11837-008-0029-8
   Kyosseva SV, 2004, INT REV NEUROBIOL, V59, P201
   Kyosseva SV, 2013, EXP EYE RES, V116, P63, DOI 10.1016/j.exer.2013.08.003
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775
   Nelson BC, 2016, ANTIOXIDANTS-BASEL, V5, DOI 10.3390/antiox5020015
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071239
   Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978-0-12-405881-1.00002-1
   Weng CY, 2009, CURR EYE RES, V34, P867, DOI 10.3109/02713680903177890
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
NR 20
TC 0
Z9 0
U1 1
U2 6
PU PUBL HOUSE BULGARIAN ACAD SCI
PI SOFIA
PA ACADEMICIAN G BONCEV ST, 1113 SOFIA, BULGARIA
SN 1310-1331
J9 CR ACAD BULG SCI
JI C. R. Acad. Bulg. Sci.
PY 2018
VL 71
IS 11
BP 1488
EP 1494
DI 10.7546/CRABS.2018.11.07
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HF4DB
UT WOS:000454182300007
DA 2022-11-30
ER

PT J
AU Balasubramanian, SA
   Kumar, KK
   Baird, PN
AF Balasubramanian, Sivaraman A.
   Kumar, Kaavya Krishna
   Baird, Paul N.
TI The role of proteases and inflammatory molecules in triggering
   neovascular age-related macular degeneration: basic science to clinical
   relevance
SO TRANSLATIONAL RESEARCH
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   RETINAL-PIGMENT EPITHELIUM; MATRIX-METALLOPROTEINASE ACTIVITY; HTRA1
   PROMOTER POLYMORPHISM; AQUEOUS-HUMOR LEVELS; BRUCHS MEMBRANE;
   SERINE-PROTEASE; VEGF-A; GEOGRAPHIC ATROPHY
AB Age-related macular degeneration (AMD) causes severe vision impairment in aged individuals. The health impact and cost of the disease will dramatically increase over the years, with the increase in the aging population. Currently, antivascular endothelial growth factor agents are routinely used for managing late-stage AMD, and recent data have shown that up to 15%-33% of patients do not respond to this treatment. Henceforth, there is a need to develop better treatment options. One avenue is to investigate the role proteases and inflammatory molecules might have in regulating and being regulated by vascular endothelial growth factor. Moreover, emerging data indicate that proteases and inflammatory molecules might be critical in the development and progression of AMD. This article reviews recent literature that investigates proteases and inflammatory molecules involved in the development of AMD. Gaining insights into the proteolytic and inflammatory pathways associated with the pathophysiology of AMD could enable the development of additional or alternative drug strategies for the treatment of AMD.
C1 Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.
   Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Walter & Eliza Hall Institute; University of
   Melbourne
RP Balasubramanian, SA (通讯作者)，32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM siva.bala@unimelb.edu.au
OI Baird, Paul/0000-0002-1305-3502
FU Centre for Clinical Research and Excellence; National Health and Medical
   Research Council Centre [529923]; NHMRC [1028444]
FX The corresponding author (S.A.B.) is supported by Centre for Clinical
   Research and Excellence Fellowship for Translational Research. We
   acknowledge support from the National Health and Medical Research
   Council Centre for Clinical Research Excellence #529923-Translational
   Clinical Research in Major Eye Diseases and NHMRC Senior Research
   Fellowship #1028444 to P.N.B. The Centre for Eye Research Australia
   receives operational infrastructure support from the Victorian
   Government, Australia.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Balasubramanian SA, 2012, ACTA OPHTHALMOL, V90, pE303, DOI 10.1111/j.1755-3768.2011.02369.x
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   BERMAN M, 1982, INVEST OPHTH VIS SCI, V22, P191
   Bingaman DP, Patent, Patent No. [WO 2009006460 A1, 2009006460]
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bode W, 1999, ANN NY ACAD SCI, V878, P73, DOI 10.1111/j.1749-6632.1999.tb07675.x
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Cao SJ, 2013, MOL VIS, V19, P718
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Cavallaro U, 2001, J CELL BIOCHEM, V82, P619, DOI 10.1002/jcb.1190
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000
   Chang SH, 2009, CANCER RES, V69, P4537, DOI 10.1158/0008-5472.CAN-08-4539
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen H, Patent, Patent No. [WO 2009046405 A3, 2009046405]
   CHESNOKOVA NB, 1994, DOC OPHTHALMOL, V85, P275, DOI 10.1007/BF01664935
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Conti SM, 2006, CURR OPIN OPHTHALMOL, V17, P235, DOI 10.1097/01.icu.0000193107.00089.ee
   Davuluri G, 2009, ARCH OPHTHALMOL-CHIC, V127, P613, DOI 10.1001/archophthalmol.2009.88
   Day CL, 2002, STRUCTURE, V10, P737, DOI 10.1016/S0969-2126(02)00782-7
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   dell'Omo R, 2012, AM J OPHTHALMOL, V153, pe2
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ecker SM, 2012, MOL VIS, V18, P1658
   Eisenach PA, 2010, J CELL SCI, V123, P4182, DOI 10.1242/jcs.062711
   Eye Research Australia, 2006, CENTR FOC IMP AG REL
   Feng YQ, 2002, BBA-PROTEINS PROTEOM, V1598, P10, DOI 10.1016/S0167-4838(02)00307-2
   Fernandes AF, 2006, EXP EYE RES, V83, P1472, DOI 10.1016/j.exer.2006.07.024
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrero-Miliani L, 2007, CLIN EXP IMMUNOL, V147, P227, DOI 10.1111/j.1365-2249.2006.03261.x
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   GROSS J, 1962, P NATL ACAD SCI USA, V48, P1014, DOI 10.1073/pnas.48.6.1014
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Gupta Satya P, 2012, Exp Suppl, V103, P35, DOI 10.1007/978-3-0348-0364-9_2
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Hahn P, 2003, INVEST OPHTH VIS SCI, V44, P3598, DOI 10.1167/iovs.02-1113
   Hanemaaijer R, 1998, Adv Dent Res, V12, P114
   HARPER E, 1971, BIOCHEMISTRY-US, V10, P3035, DOI 10.1021/bi00792a008
   Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x
   Hedstrom L, 2002, CURRENT PROTOCOLS PR
   Ho AC, 2011, AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT, P1, DOI 10.1007/978-1-4614-0125-4
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hollborn M, 2008, INVEST OPHTH VIS SCI, V49, P1262, DOI 10.1167/iovs.07-0879
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Holz F.G., 2012, AGE RELATED MACULAR
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Honorati MC, 2004, OSTEOARTHR CARTILAGE, V12, P683, DOI 10.1016/j.joca.2004.05.009
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029
   Im E, 2007, EXP EYE RES, V84, P383, DOI 10.1016/j.exer.2006.05.017
   Ito TK, 2007, ONCOGENE, V26, P7194, DOI 10.1038/sj.onc.1210535
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jiang SN, 2008, INVEST OPHTH VIS SCI, V49, P1345, DOI 10.1167/iovs.07-0308
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2002, OPHTHALMOLOGY, V110, P1273
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Kohri T, 2003, GRAEF ARCH CLIN EXP, V241, P943, DOI 10.1007/s00417-003-0761-2
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   KVANTA A, 1995, CURR EYE RES, V14, P1015, DOI 10.3109/02713689508998523
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liutkeviciene R, OPHTHALMIC GENET
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145
   Makrides SC, 1998, PHARMACOL REV, V50, P59
   Miao H, 2012, MOL VIS, V18, P574
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Murata E, 2003, CURR EYE RES, V26, P271, DOI 10.1076/ceyr.26.4.271.15429
   Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x
   MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nair KS, 2011, NAT GENET, V43, P579, DOI 10.1038/ng.813
   Nakata K, 2004, AM J OPHTHALMOL, V137, P760, DOI 10.1016/S0002-9394(03)01123-1
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   OMAR R, 1993, EUR ARCH PSY CLIN N, V242, P262, DOI 10.1007/BF02190384
   OMAR RF, 1993, BIOCHEM PHARMACOL, V46, P2073, DOI 10.1016/0006-2952(93)90650-L
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Paraoan L, 2003, EXP EYE RES, V76, P753, DOI 10.1016/S0014-4835(03)00061-7
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Phipps JA, 2009, HYPERTENSION, V53, P175, DOI 10.1161/HYPERTENSIONAHA.108.117663
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Rimm EB, 2000, MED CLIN N AM, V84, P239, DOI 10.1016/S0025-7125(05)70216-9
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sang QXA, 2006, CURR TOP MED CHEM, V6, P289, DOI 10.2174/156802606776287045
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Sheybani A, 2010, EXPERT REV OPHTHALMO, V5, P35, DOI 10.1586/EOP.09.67
   Siemerink MJ, 2010, DEV OPHTHALMOL, V46, P4, DOI 10.1159/000320006
   Singh N, 2011, ARCH BIOCHEM BIOPHYS, V516, P85, DOI 10.1016/j.abb.2011.10.007
   Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Sung HJ, 2012, MOL VIS, V18, P234
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Takehana Y, 1999, INVEST OPHTH VIS SCI, V40, P459
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tandon A, 2011, BIOINFORMATION, V5, P310, DOI 10.6026/97320630005310
   Tanihara H, 1997, PROG RETIN EYE RES, V16, P271, DOI 10.1016/S1350-9462(96)00028-6
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tochowicz A, 2007, J MOL BIOL, V371, P989, DOI 10.1016/j.jmb.2007.05.068
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C
   Urbak Larke, 2010, Int J Proteomics, V2010, P479571, DOI 10.1155/2010/479571
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Wang YJ, 2013, ASN NEURO, V5, DOI 10.1042/AN20130028
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Ward C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012543
   Willems LI, 2010, MED RES REV, V30, P778, DOI 10.1002/med.20181
   Winkler B S, 1999, Mol Vis, V5, P32
   Woessner JF, 2002, MOL BIOTECHNOL, V22, P33, DOI 10.1385/MB:22:1:033
   Yang P, 2005, INVEST OPHTH VIS SCI, V46, P1755, DOI 10.1167/iovs.04-1039
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhou M, 2007, T AM OPHTHAL SOC, V105, P7
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
   Ziche M, 1997, LAB INVEST, V76, P517
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 174
TC 10
Z9 11
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1931-5244
EI 1878-1810
J9 TRANSL RES
JI Transl. Res.
PD SEP
PY 2014
VL 164
IS 3
BP 179
EP 192
DI 10.1016/j.trsl.2014.04.005
PG 14
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA AN6WD
UT WOS:000340738200001
PM 24794954
DA 2022-11-30
ER

PT J
AU Hooper, CY
   Lamoureux, EL
   Lim, L
   Fraser-Bell, S
   Yeoh, J
   Harper, CA
   Keeffe, JE
   Guymer, RH
AF Hooper, Claire Y.
   Lamoureux, Ecosse L.
   Lim, Lyndell
   Fraser-Bell, Samantha
   Yeoh, Jonathan
   Harper, Colin A.
   Keeffe, Jill E.
   Guymer, Robyn H.
TI Cataract surgery in high-risk age-related macular degeneration: a
   randomized controlled trial
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; cataract surgery; choroidal
   neovascularization; quality of life
ID BLUE MOUNTAINS EYE; VISION IMPAIRMENT QUESTIONNAIRE; QUALITY-OF-LIFE;
   VISUAL IMPAIRMENT; RASCH ANALYSIS; BEAVER DAM; MACULOPATHY; EXTRACTION;
   IMPACT; ASSOCIATION
AB P>Background:
   To investigate if cataract surgery causes progression, from high-risk early age-related macular degeneration (AMD) to choroidal neovascularization (CNV), in the postoperative period.
   Methods:
   Randomized controlled trial. Patients, with visually significant cataract and fundus features of early AMD at high risk of progression to CNV, were randomized into two groups and were evaluated at baseline and 6 months. The study patients (n = 27) underwent immediate cataract surgery. The control group (n = 29) comprised patients who had cataract surgery deferred until after the 6-month visit. Assessment included visual acuity, quality of life (QoL) and fundus fluorescein angiography (FFA).
   Results:
   Of 68 eligible eyes, 60 participated and 56 completed the study. Three referred eyes (3.2%) were ineligible on the basis of a pre-existing, unsuspected occult CNV that was detected by baseline FFA. All three cases had end-stage exudative AMD in the fellow eye. Of the study eyes in the immediate surgery arm (n = 27), one (3.7%) developed CNV compared with none (0/29) in the deferred arm (KH2; P = 1.0) at 6 months. In the operated group, there was a 2.8-line improvement in logMAR visual acuity and 2.1-fold average gain in QoL at 6 months.
   Conclusions:
   No increased short-term risk of progression of AMD to CNV in high-risk fundi following uncomplicated phacoemulsification surgery was found. A low threshold for performing preoperative imaging in patients with AMD, especially in those with exudative AMD in the fellow eye, to exclude undetected CNV is recommended. Provided there is no CNV, there are distinct benefits of cataract surgery in people with early AMD.
C1 [Hooper, Claire Y.; Lamoureux, Ecosse L.; Lim, Lyndell; Yeoh, Jonathan; Harper, Colin A.; Keeffe, Jill E.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 8002, Australia.
   [Hooper, Claire Y.; Fraser-Bell, Samantha] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Lamoureux, Ecosse L.; Keeffe, Jill E.] Vis CRC, Sydney, NSW, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Sydney
RP Lamoureux, EL (通讯作者)，Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Locked Bag 8, Melbourne, Vic 8002, Australia.
EM ecosse@unimelb.edu.au
RI Lamoureux, Ecosse/Z-5482-2019; Fraser-Bell, Samantha/ABE-8574-2020
OI Fraser-Bell, Samantha/0000-0001-5646-9359; Lim,
   Lyndell/0000-0003-2491-685X; Guymer, Robyn/0000-0002-9441-4356
FU Centre for Eye Research Australia; Leon Mow Foundation; CYH, the
   National Health and Medical Research Council Public Health Fellowship
   (ELL); National Helath and Medical Research Council career development
   award (RHG); Royal Victorian Eye and Ear Hospital Wagstaff Fellowship
   (JEK)
FX Centre for Eye Research Australia gratefully acknowledges the support of
   the Leon Mow Foundation in providing an ophthalmology research
   scholarship for CYH, the National Health and Medical Research Council
   Public Health Fellowship (ELL), the National Helath and Medical Research
   Council career development award (RHG) and the Royal Victorian Eye and
   Ear Hospital Wagstaff Fellowship (JEK).
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chee SP, 1999, J CATARACT REFR SURG, V25, P1280, DOI 10.1016/S0886-3350(99)00161-3
   Cugati S, 2007, OPHTHAL EPIDEMIOL, V14, P408, DOI 10.1080/09286580701316124
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   MARTIN DF, 2002, INVEST OPHTHALMOL VI, V43
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   OLIVER M, 1966, AM J OPHTHALMOL, V62, P1145, DOI 10.1016/0002-9394(66)92567-0
   OSHIKA T, 1992, J CATARACT REFR SURG, V18, P56
   PANDE MW, 1996, J CATARACT REFR SURG, V22, P771
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Vingerling J. R., 1997, Investigative Ophthalmology and Visual Science, V38, pS472
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Wong TY, 2000, BRIT J OPHTHALMOL, V84, P1337, DOI 10.1136/bjo.84.12.1337
NR 35
TC 32
Z9 34
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2009
VL 37
IS 6
BP 570
EP 576
DI 10.1111/j.1442-9071.2009.02095.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 478KQ
UT WOS:000268587600007
PM 19702706
DA 2022-11-30
ER

PT J
AU de Souza, SOL
   Guerra, MCA
   Heneine, LGD
   de Oliveira, CR
   Cunha, AD
   Fialho, SL
   Orefice, RL
AF Lamas de Souza, Sarah Oliveira
   Andrade Guerra, Maria Carolina
   Dias Heneine, Luiz Guilherme
   de Oliveira, Carolina Reis
   Cunha Junior, Armando da Silva
   Fialho, Silvia Ligorio
   Orefice, Rodrigo Lambert
TI Biodegradable core-shell electrospun nanofibers containing bevacizumab
   to treat age-related macular degeneration
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
AB Age-related macular degeneration (AMD) is a degenerative ocular disease that affects the central retina. It is considered the main cause of blindness and loss of vision worldwide. Angiogenic factors are associated with AMD, which has led to the use of antiangiogenic drugs, such as bevacizumab, to treat the disease using frequent intravitreal injections. In the present study, biodegradable core shell nanofibers containing bevacizumab were prepared by the coaxial electrospinning technique. It is thought that the shell could control the release of the drug, while the core would protect and store the drug. Poly(caprolactone) (PCL) and gelatin were used to form the shell of the nanofibers, while poly(vinyl alcohol) (PVA) and bevacizumab comprised the core. The nanofibers were characterized using microscopy techniques, thermal analysis, and FTIR. The results showed that core-shell nanofibers were produced as designed. Bevacizumab activity was evaluated using a chicken embryo chorioallantoic membrane (CAM) assay. An enzyme-linked immunosorbent assay was used to quantify the amount of the drug released from the different nanofibers in vitro. The toxicity of the nanofibers was evaluated in human retinal pigment epithelial (ARPE) cells. The CAM results demonstrated that bevacizumab maintained its antiangiogenic activity when incorporated into the nanofibers. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tests revealed that the nanofibers showed no cellular toxicity, even in the presence of bevacizumab. The core-shell structure of the nanofibers reduced the release rate of bevacizumab compared with PVA nanofibers. The bevacizumab-loaded biodegradable nanofibers presented interesting properties that would potentially constitute an alternative therapy to intravitreal injections to treat AMD.
   [GRAPHICS]
   .
C1 [Lamas de Souza, Sarah Oliveira; Orefice, Rodrigo Lambert] Fed Univ Minas Gerais UFMG, Sch Engn, Ave Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
   [Andrade Guerra, Maria Carolina; Dias Heneine, Luiz Guilherme; Fialho, Silvia Ligorio] Ezequiel Dias Fdn, Belo Horizonte, MG, Brazil.
   [de Oliveira, Carolina Reis] Fed Univ Minas Gerais UFMG, Sch Biol Sci, Belo Horizonte, MG, Brazil.
   [Cunha Junior, Armando da Silva] Fed Univ Minas Gerais UFMG, Sch Pharm, Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais
RP de Souza, SOL (通讯作者)，Fed Univ Minas Gerais UFMG, Sch Engn, Ave Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM sarahlamas@gmail.com
RI Cunha, Armando/G-1157-2012; Orefice, Rodrigo L/N-8055-2018; Fialho, S.
   L./G-1540-2012; Heneine, Luiz Guilherme Dias/F-1822-2018
OI Cunha, Armando/0000-0002-1161-8936; Orefice, Rodrigo
   L/0000-0002-6046-4056; Fialho, S. L./0000-0001-8068-5211; Heneine, Luiz
   Guilherme Dias/0000-0003-0707-2691; Andrade Guerra, Maria
   Carolina/0000-0003-0847-3737
FU CNPq; CAPES; FAPEMIG; SAo Paulo Research Foundation (FAPESP, Brazil)
   [2014/50928-2]; "Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico" (CNPq, Brazil) [465687/2014-8]
FX The authors acknowledge the financial support of CNPq, CAPES and
   FAPEMIG. This study is part of the National Institute of Science and
   Technology in Pharmaceutical Nanotechnology: a transdisciplinary
   approach INCT-NANOFARMA, which is supported by SAo Paulo Research
   Foundation (FAPESP, Brazil) Grant #2014/50928-2, and by "Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico" (CNPq, Brazil)
   Grant # 465687/2014-8.
CR Aguirre-Chagala YE, 2017, MAT SCI ENG C-MATER, V76, P897, DOI 10.1016/j.msec.2017.03.118
   Conley SM, 2010, PROG RETIN EYE RES, V29, P376, DOI 10.1016/j.preteyeres.2010.04.004
   de Avila J, 2013, POLIMEROS, V23, P74, DOI 10.1590/S0104-14282012005000077
   Garg K, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3567097
   Gatne DP, 2016, MICROVASC RES, V103, P11, DOI 10.1016/j.mvr.2015.09.002
   Greiner A, 2006, APPL MICROBIOL BIOT, V71, P387, DOI 10.1007/s00253-006-0356-z
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Islam MS, 2013, COLLOID SURFACE A, V436, P279, DOI 10.1016/j.colsurfa.2013.07.001
   Jiang HL, 2014, J CONTROL RELEASE, V193, P296, DOI 10.1016/j.jconrel.2014.04.025
   Medeiros ES, 2009, J APPL POLYM SCI, V113, P2322, DOI 10.1002/app.30275
   Nowak-Sliwinska P, 2012, J CELL MOL MED, V16, P1553, DOI 10.1111/j.1582-4934.2011.01440.x
   Spitzer MS, 2006, J OPHTHALMOL, V90, P316
   Suarez I, 2016, J CHROMATOGR B, V1032, P155, DOI 10.1016/j.jchromb.2016.05.045
   Tian JH, 2006, POLYMER, V47, P7962, DOI 10.1016/j.polymer.2006.09.042
   Turaga U, 2014, IND ENG CHEM RES, V53, P6951, DOI 10.1021/ie5005465
NR 15
TC 17
Z9 17
U1 0
U2 28
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-4530
EI 1573-4838
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD NOV
PY 2018
VL 29
IS 11
AR 173
DI 10.1007/s10856-018-6187-5
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA GZ3LN
UT WOS:000449288200011
PM 30392064
DA 2022-11-30
ER

PT J
AU Mackay, AM
   Brown, MC
   Grierson, I
   Harding, SP
AF Mackay, Alison M.
   Brown, Malcolm C.
   Grierson, Ian
   Harding, Simon P.
TI Multifocal electroretinography as a predictor of maintenance of vision
   after photodynamic therapy for neovascular age-related macular
   degeneration
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE multifocal electroretinogram; fluoroscein angiogram; photodynamic
   therapy; age-related macular degeneration; logistic regression
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; LESION SIZE; VERTEPORFIN
   THERAPY; TAP; IMPACT; MFERG
AB Purpose To investigate the role of multifocal electroretinography (mfERG) in predicting the outcome of photodynamic therapy (PDT) for neovascular age-related macular degeneration (AMD).
   Methods Participants underwent refraction protocol VA assessment using the ETDRS logMAR chart at 1 m, Contrast Sensitivity (CS) using the Pelli-Robson chart at 1 m, fundus fluorescein angiography (FA) and mfERGs in response to 19 segments. Response to PDT was binary (1 = the loss of less than 15 letters at 12 months, 0 = the loss of 15 letters or more) and was used as the dependent variable for logistic regression analysis.
   Results Logistic regression modelling identified mfERG central segment amplitude, lesion size on FA, VA and CS as predictors of outcome (P = 0.05, 0.02, 0.01, 0.03). The model is stable and has excellent discriminability.
   Conclusion The outcomes of this study are particularly relevant to patients in the UK who are sometimes treated with PDT alone. A larger prospective study would facilitate development of an index to predict outcome of future treatments for AMD.
C1 [Mackay, Alison M.; Brown, Malcolm C.] Royal Liverpool Univ Hosp, Dept Clin Engn, Liverpool, Merseyside, England.
   [Grierson, Ian] Univ Liverpool, Dept Med, Unit Ophthalmol, Liverpool L69 3BX, Merseyside, England.
   [Harding, Simon P.] Royal Liverpool Univ Hosp, St Pauls Eye Inst, Liverpool L7 8XP, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust;
   Royal Liverpool University Hospital; University of Liverpool
RP Mackay, AM (通讯作者)，Royal Liverpool Univ Hosp, Dept Clin Engn, Liverpool, Merseyside, England.
EM alison.mackay70@ntlworld.com
OI Mackay, Alison/0000-0002-6652-1154; Harding, Simon/0000-0003-4676-1158
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   David W, 2000, APPL LOGISTIC REGRES, P26, DOI 10.1002/0471722146
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Hagan RP, 2006, DOC OPHTHALMOL, V113, P21, DOI 10.1007/s10633-006-9009-x
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   MACKAY AM, 2007, IN PRESS DOC OPHTHAL
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   Michels S, 2002, OPHTHALMOLOGE, V99, P96, DOI 10.1007/s003470100532
   Neveu MM, 2006, DOC OPHTHALMOL, V113, P71, DOI 10.1007/s10633-006-9016-y
   Shao J, 1996, JACKKNIFE BOOTSTRAP
   Sivaprasad S, 2006, EYE, V20, P43, DOI 10.1038/sj.eye.6701787
   Soubrane G, 2004, J FR OPHTALMOL, V27, P79, DOI 10.1016/S0181-5512(04)96098-6
NR 18
TC 4
Z9 6
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD JAN
PY 2008
VL 116
IS 1
BP 13
EP 18
DI 10.1007/s10633-007-9071-z
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 254YN
UT WOS:000252624000002
PM 17885777
DA 2022-11-30
ER

PT J
AU Schaal, KB
   Rosenfeld, PJ
   Gregori, G
   Yehoshua, Z
   Feuer, WJ
AF Schaal, Karen B.
   Rosenfeld, Philip J.
   Gregori, Giovanni
   Yehoshua, Zohar
   Feuer, William J.
TI Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; GEOGRAPHIC
   ATROPHY; EYE DISEASE; SD-OCT; FUNDUS AUTOFLUORESCENCE; 5-YEAR INCIDENCE;
   NATURAL-HISTORY; COMPLEMENT INHIBITION; 10-YEAR INCIDENCE
AB Topic: To review the role of anatomic endpoints in clinical trials for the study of nonexudative age-related macular degeneration (AMD) with an emphasis on a novel composite endpoint for the study of emerging therapies for intermediate AMD (iAMD).
   Clinical Relevance: Unlike clinical trials for exudative AMD, it is impractical to use the change in visual acuity (VA) as a primary endpoint for the study of nonexudative AMD. By the time VA has been lost in nonexudative AMD, proof-of-concept early-stage clinical trials would take years to run, and drug development would be a near impossible task. Surrogate endpoints are needed that reliably predict future vision loss and can be easily measured. Anatomic changes that correlate with disease progression in nonexudative AMD offer the greatest promise as primary endpoints.
   Methods: In preparation for this review, the electronic PubMed database was searched for relevant research pertaining to anatomic endpoints for the study of nonexudative AMD. Paper selection was based on our knowledge of the field with the goal to be as inclusive as possible. Whenever possible, recent review articles and results from large clinical trials, preferably with outcomes from many years of follow-up were favored over trials of short duration.
   Results: The most commonly used anatomic endpoint for the study of late, nonexudative AMD is the growth of geographic atrophy (GA). The advantages of studying GA include the appreciation that its enlargement through the foveal center leads to significant vision loss through the availability of natural history studies, the understanding that prevention of this growth would preserve vision in the future, the ability to reliably measure GA using different imaging strategies, and the development appropriate statistical tools that reliably predict the growth of GA over time. The major disadvantage of using GA is that significant, irreversible disease progression has already occurred. The use of drusen volume as a predictor of disease progression and the use of a composite endpoint that incorporates drusen growth, formation of GA, and formation of neovascularization offers an opportunity to study therapies at an earlier stage of AMD with a greater likelihood of preserving better vision over a lifetime.
   Conclusions: Anatomic endpoints for the study of nonexudative AMD are needed to accelerate drug development, and the availability of optical coherence tomography algorithms capable of reliably measuring drusen morphology offer the best opportunity to study therapies for iAMD. (C) 2016 by the American Academy of Ophthalmology.
C1 [Schaal, Karen B.; Rosenfeld, Philip J.; Gregori, Giovanni; Yehoshua, Zohar; Feuer, William J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
FU DFG (German Research Foundation) [SCHA 1869/1-1]; Carl Zeiss Meditec,
   Inc.; Acucela; Apellis; Genentech/Roche; GlaxoSmithKline; Neurotech;
   Ocata Therapeutics; Tyrogenex; National Eye Institute, Research to
   Prevent Blindness; Department of Defense
FX The author(s) have made the following disclosure(s): K.B.S.: Funding -
   the DFG (German Research Foundation) Grant SCHA 1869/1-1.; P.J.R. and
   G.G.: Research support - Carl Zeiss Meditec, Inc.; P.J.R. and Z.Y.:
   Research support - Acucela and Apellis.; P.J.R.: Research support -
   Genentech/Roche, GlaxoSmithKline, Neurotech, Ocata Therapeutics, and
   Tyrogenex; Consultant - Achillion, Acucela, Alcon, Bayer, Chengdu
   Kanghong Biotech, CoDa Therapeutics, Genentech/Roche, Healios K.K.,
   Merck, Regeneron, Stealth, and Tyrogenex.; W.J.F.: Grants - National Eye
   Institute, Research to Prevent Blindness, and Department of Defense.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Busse Jason W, 2012, J Bone Joint Surg Am, V94 Suppl 1, P65, DOI 10.2106/JBJS.K.01287
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   Chen Q, 2014, RETINA-J RET VIT DIS, V34, P996, DOI 10.1097/IAE.0000000000000018
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Complications of Age-related Macular Degeneration Prevention Trial Research G, 2008, OPHTHALMOLOGY, V115
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Diniz B, 2015, EYE, V29, P272, DOI 10.1038/eye.2014.260
   Diniz B, 2014, RETINA-J RET VIT DIS, V34, P55, DOI 10.1097/IAE.0b013e31829d0015
   Dithmar S, 2013, EYE, V27, P779, DOI 10.1038/eye.2013.35
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Friberg TR, 2007, OPHTHAL SURG LAS IM, V38, P126, DOI 10.3928/15428877-20070301-07
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuseya Miki, 2007, Retin Cases Brief Rep, V1, P160, DOI 10.1097/01.ICB.0000279649.37443.70
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krishnan R, 2010, CAN J OPHTHALMOL, V45, P83, DOI 10.3129/i09-187
   Lavinsky D, 2015, RETINA-J RET VIT DIS, V35, P213, DOI 10.1097/IAE.0000000000000340
   Lavinsky D, 2014, RETINA-J RET VIT DIS, V34, P87, DOI 10.1097/IAE.0b013e3182993edc
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Margolis Ron, 2010, Retin Cases Brief Rep, V4, P254, DOI 10.1097/ICB.0b013e3181af5582
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Medeiros FA, 2015, BRIT J OPHTHALMOL, V99, P599, DOI 10.1136/bjophthalmol-2014-305550
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   PELI E, 1986, OPHTHALMOLOGY, V93, P1575
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Schutze C, 2011, ACTA OPHTHALMOL, V89, P235, DOI 10.1111/j.1755-3768.2010.01955.x
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Tomlinson G, 2010, JAMA-J AM MED ASSOC, V303, P267, DOI 10.1001/jama.2009.2017
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 107
TC 70
Z9 70
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2016
VL 123
IS 5
BP 1060
EP 1079
DI 10.1016/j.ophtha.2016.01.034
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL9DS
UT WOS:000375942300028
PM 26952592
OA Bronze
DA 2022-11-30
ER

PT J
AU Palejwala, NV
   Jia, YL
   Gao, SS
   Liu, L
   Flaxel, CJ
   Hwang, TS
   Lauer, AK
   Wilson, DJ
   Huang, D
   Bailey, ST
AF Palejwala, Neal V.
   Jia, Yali
   Gao, Simon S.
   Liu, Liang
   Flaxel, Christina J.
   Hwang, Thomas S.
   Lauer, Andreas K.
   Wilson, David J.
   Huang, David
   Bailey, Steven T.
TI DETECTION OF NONEXUDATIVE CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED
   MACULAR DEGENERATION WITH OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   diagnostic retinal; imaging; optical coherence tomography angiography
ID AMPLITUDE-DECORRELATION ANGIOGRAPHY; FLUORESCEIN ANGIOGRAPHY;
   RISK-FACTORS; EYE; DETACHMENT
AB Purpose: To evaluate eyes with age-related macular degeneration and high-risk characteristics for choroidal neovascularization (CNV) with optical coherence tomographic (OCT) angiography to determine whether earlier detection of CNV is possible.
   Methods: Eyes with drusen, pigmentary changes, and with CNV in the fellow eye were scanned with a 70-kHz spectral domain OCT system (Optovue RTVue-XR Avanti). The split-spectrum amplitude-decorrelation angiography (SSADA) algorithm was used to distinguish blood flow from static tissue. Two masked graders reviewed scans for CNV, defined as flow in the outer retinal/sub-RPE slab. Choroidal neovascularization flow area repeatability and between-grader reproducibility were calculated.
   Results: Of 32 eyes, 2 (6%) were found to have Type 1 CNV with OCT angiography. The lesions were not associated with leakage on fluorescein angiography or fluid on OCT. One case was followed for 8 months without treatment, and the CNV flow area enlarged slightly without fluid buildup on OCT or vision loss. Between-grader reproducibility of the CNV flow area was 9.4% (coefficient of variation) and within-visit repeatability was 5.2% (pooled coefficient of variation).
   Conclusion: Optical coherence tomographic angiography can detect the presence of nonexudative CNV, lesions difficult to identify with fluorescein angiography and OCT. Further study is needed to understand the significance and natural history of these lesions.
C1 [Palejwala, Neal V.; Jia, Yali; Gao, Simon S.; Liu, Liang; Flaxel, Christina J.; Hwang, Thomas S.; Lauer, Andreas K.; Wilson, David J.; Huang, David; Bailey, Steven T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
C3 Oregon Health & Science University
RP Bailey, ST (通讯作者)，Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM bailstev@ohsu.edu
RI Hwang, Thomas S./AAW-6618-2020; Hwang, Thomas/AAV-5146-2020
OI Hwang, Thomas S./0000-0002-0535-4823; Bailey,
   Steven/0000-0003-4949-1464; Gao, Simon/0000-0002-7020-037X; Jia,
   Yali/0000-0002-2784-1905
FU NIH [R01EY024544, DP3 DK104397, R01EY023285, P30 EY010572, T32EY23211];
   Clinical and Translational Science Awards [UL1TR000128]; Research to
   Prevent Blindness; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [UL1TR000128] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY023285, R01EY024544, T32EY023211, P30EY010572] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [DP3DK104397] Funding Source: NIH RePORTER
FX Supported by NIH Grants R01EY024544, DP3 DK104397, R01EY023285, P30
   EY010572, and T32EY23211; Clinical and Translational Science Awards
   (UL1TR000128); and an unrestricted grant from Research to Prevent
   Blindness.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   Coscas F, 2012, INVEST OPHTH VIS SCI, V53, P4147, DOI 10.1167/iovs.12-9878
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Gao SS, 2015, OPT LETT, V40, P2305, DOI 10.1364/OL.40.002305
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P204
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Rush RB, 2015, OSLI RETINA, V46, P718, DOI 10.3928/23258160-20150730-05
   Rush RB, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/642624
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
NR 25
TC 111
Z9 116
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2015
VL 35
IS 11
BP 2204
EP 2211
DI 10.1097/IAE.0000000000000867
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV5LD
UT WOS:000364311100006
PM 26469533
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Das, S
   Tiwari, GJ
   Ghosh, A
AF Das, Srijan
   Tiwari, Gopal J.
   Ghosh, Anindita
TI In silico analysis of new flavonoids from Pongamia pinnata with a
   therapeutic potential for age-related macular degeneration
SO 3 BIOTECH
LA English
DT Article
DE Macular degeneration; Receptors; Flavonoids; Docking; ADME; Antioxidant;
   Radical scavenging
AB Age-related macular degeneration (AMD) leads to progressive degeneration of the macula which ultimately results in the complete loss of central vision. The present study aims to identify the new therapeutic agents for curing AMD. In the present study we have isolated, and compared the activity of natural flavonoids (Karanjin, Karanjachromene, Pongachromene, Pongapin) from plant species Pongamia pinnata (L.) Pierre (Family: Fabaceae) with known flavonol, Quercetin, and a drug Pazopanib through in silico approaches. Chemical structures of isolated flavonoids passed the ADME and PASS analysis, showed drug-like properties without violation of Lipinski parameters. Molecular docking studies were also performed for all isolated flavonoids with the receptors responsible for AMD viz. P2X7, PPAR, RAGE, and TLR3. Docking scores of the flavonoids with the receptors were found to be comparable to that of Quercetin, and Pazopanib (drugs already known for AMD treatment). Among all the flavonoids, Karanjachromene [P2X7 (- 31.39)] and Pongachromene [PPAR (- 65.13), RAGE (- 43.42)] showed a very good binding affinity with receptors predicting them to be the new potent chemical entities for the treatment of AMD.
C1 [Das, Srijan] Med Coll & Hosp Kolkata, 88 Coll St, Kolkata 700073, W Bengal, India.
   [Tiwari, Gopal J.] CSIR Natl Bot Res Inst, Rana Pratap Marg,POB 436, Lucknow 226001, Uttar Pradesh, India.
   [Ghosh, Anindita] Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, 37 SP Mukherjee Rd, Kolkata 700026, W Bengal, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   National Botanical Research Institute (NBRI)
RP Ghosh, A (通讯作者)，Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, 37 SP Mukherjee Rd, Kolkata 700026, W Bengal, India.
EM johndghosh18@gmail.com; gopal.jt@gmail.com; aninschem@gmail.com
FU Department of Science and Technology
FX AG thanks the Department of Science and Technology for funds and
   Director, Chittaranjan National Cancer Institute, Kolkata for support.
CR Bolton EE, 2010, ANN REP COMP CHEM, V4, P217, DOI 10.1016/S1574-1400(08)00012-1
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chen J., 2014, AUSTIN J CLIN OPHTHA, V1, P1012
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chuah YK, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/403460
   Ciudin A, 2013, PPAR RES, V2013, DOI 10.1155/2013/686525
   Daina A, 2016, CHEMMEDCHEM, V11, P1117, DOI 10.1002/cmdc.201600182
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   Truong DH, 2019, J FOOD QUALITY, DOI 10.1155/2019/8178294
   Filimonov DA, 2014, CHEM HETEROCYCL COM+, V50, P444, DOI 10.1007/s10593-014-1496-1
   Ghosh A, 2009, NAT PROD COMMUN, V4, p1934578X0900400207
   Ghosh A, 2010, NAT PROD COMMUN, V5, P1213
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Patel AK, 2013, MOL IMMUNOL, V54, P122, DOI 10.1016/j.molimm.2012.11.005
   Rahimi N, 2006, FRONT BIOSCI-LANDMRK, V11, P818
   SATAM PGN, 1973, INDIAN J CHEM, V11, P1188
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Yadav PP, 2004, PHYTOCHEMISTRY, V65, P439, DOI 10.1016/j.phytochem.2003.09.011
   Zhuang Pei, 2011, Eye Sci, V26, P23, DOI 10.3969/j.issn.1000-4432.2011.01.006
NR 22
TC 1
Z9 1
U1 1
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-572X
EI 2190-5738
J9 3 BIOTECH
JI 3 Biotech
PD NOV 16
PY 2020
VL 10
IS 12
AR 536
DI 10.1007/s13205-020-02537-2
PG 6
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA OY8CJ
UT WOS:000594468800001
PM 33224705
OA Green Published
DA 2022-11-30
ER

PT J
AU Zakaria, N
   Guerard, N
   Emanuelli, A
   Dugel, P
   Watts, J
   Liew, M
   Gekkieva, M
   Hinder, M
AF Zakaria, Nadia
   Guerard, Nicolas
   Emanuelli, Andres
   Dugel, Pravin
   Watts, Jen
   Liew, Melissa
   Gekkieva, Margarita
   Hinder, Markus
TI Evaluation of cardiac parameters and other safety outcomes of
   brolucizumab treatment in patients with neovascular age-related macular
   degeneration
SO PHARMACOLOGY RESEARCH & PERSPECTIVES
LA English
DT Article
DE anti-VEGF; brolucizumab; cardiovascular; intravitreal; nAMD
ID ANTI-VEGF; RANIBIZUMAB; AFLIBERCEPT; MANAGEMENT; EVENTS
AB This was a prospective, single-dose, single-arm, open-label, non-randomized, multicenter clinical study to determine cardiovascular safety after a single brolucizumab 6 mg intravitreal injection in neovascular age-related macular degeneration patients (N = 14). Electrocardiogram (ECG) data were collected at different time points using 12-lead Hotter and standard ECG, and patients were followed up to 8 days (end of study) for any signs of ocular and non-ocular adverse events (AEs). No clinically meaningful changes were observed in cardiac parameters. No patient had a >= 30 msec change from baseline in heart rate-corrected QT using Fridericia's formula (QTcF), and no patient had a new QTcF value of >= 450 msec between 20 and 24 h after treatment. No deaths or serious AEs were reported during the study period. These results are in line with the absence of new cardiovascular safety signal based on the ECG recordings collected over the first year of the pivotal studies performed with brolucizumab in DME.
C1 [Zakaria, Nadia; Liew, Melissa] Novartis Inst BioMed Res, Translat Med, Cambridge, MA 02139 USA.
   [Guerard, Nicolas; Gekkieva, Margarita] Novartis Pharma AG, Global Drug Dev, Basel, Switzerland.
   [Emanuelli, Andres] Emanuelli Res & Dev Ctr, Arecibo, PR USA.
   [Dugel, Pravin] IVERIC Bio, New York, NY USA.
   [Watts, Jen] Novartis Pharmaceut, East Hannover, NJ USA.
   [Hinder, Markus] Novartis Inst BioMed Res, Translat Med, Basel, Switzerland.
C3 Novartis; Novartis; Novartis; Novartis
RP Zakaria, N (通讯作者)，Novartis Inst BioMed Res, 250 Massachusetts Ave, Cambridge, MA 02139 USA.
EM nadia.zakaria@novartis.com
OI Hinder, Markus/0000-0003-2293-8342; Zakaria, Nadia/0000-0003-4862-5491
FU Novartis
FX The study was funded by Novartis.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakraborty D, 2021, CLIN OPHTHALMOL, V15, P3787, DOI 10.2147/OPTH.S328160
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   FDA, BLA 761094 BEOVU BRO
   Georgakopoulos CD., 2020, CURR CLIN PHARMACOL, V137, P483
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Malik M, 2010, DRUG SAFETY, V33, P1, DOI 10.2165/11319160-000000000-00000
   Mladenka P, 2018, MED RES REV, V38, P1332, DOI 10.1002/med.21476
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Simo R, 2008, DIABETOLOGIA, V51, P1574, DOI 10.1007/s00125-008-0989-9
   Starr Matthew R, 2019, Ophthalmic Surg Lasers Imaging Retina, V50, pe140, DOI 10.3928/23258160-20190503-14
   Thulliez M, 2018, JAMA OPHTHALMOL, V136, P557, DOI 10.1001/jamaophthalmol.2018.0002
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 21
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2052-1707
J9 PHARMACOL RES PERSPE
JI Pharmacol. Res. Perspect.
PD APR
PY 2022
VL 10
IS 2
AR e00897
DI 10.1002/prp2.897
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 0I7RE
UT WOS:000779612600010
PM 35301822
OA Green Published
DA 2022-11-30
ER

PT J
AU Kanagasingam, Y
   Bhuiyan, A
   Abramoff, MD
   Smith, RT
   Goldschmidt, L
   Wong, TY
AF Kanagasingam, Yogesan
   Bhuiyan, Alauddin
   Abramoff, Michael D.
   Smith, R. Theodore
   Goldschmidt, Leonard
   Wong, Tien Y.
TI Progress on retinal image analysis for age related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Fundus photograph; Age related macular degeneration; Population
   screening; Optical coherence tomography; Automation and disease grading;
   Telemedicine; Expert system
ID OPTICAL COHERENCE TOMOGRAPHY; DIABETIC-RETINOPATHY; CHOROIDAL
   NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; DRUSEN
   DETECTION; PIGMENT EPITHELIUM; INDOCYANINE GREEN; INTRAVITREAL
   BEVACIZUMAB; RETICULAR PSEUDODRUSEN
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in those over the age of 50 years in the developed countries. The number is expected to increase by similar to 1.5 fold over the next ten years due to an increase in aging population. One of the main measures of AMD severity is the analysis of drusen, pigmentary abnormalities, geographic atrophy (GA) and choroidal neovascularization (CNV) from imaging based on color fundus photograph, optical coherence tomography (OCT) and other imaging modalities. Each of these imaging modalities has strengths and weaknesses for extracting individual AMD pathology and different imaging techniques are used-in combination for capturing and/or quantification of different pathologies. Current dry AMD treatments cannot cure or reverse vision loss. However, the Age-Related Eye Disease Study (AREDS) showed that specific anti-oxidant vitamin supplementation reduces the risk of progression from intermediate stages (defined as the presence of either many medium-sized drusen or one or more large drusen) to late AMD which allows for preventative strategies in properly identified patients. Thus identification of people with early stage AMD is important to design and implement preventative strategies for late AMD, and determine their cost-effectiveness. A mass screening facility with teleophthalmology or telemedicine in combination with computer-aided analysis for large rural-based communities may identify more individuals suitable for early stage AMD prevention.
   In this review, we discuss different imaging modalities that are currently being considered or used for screening AMD. In addition, we look into various automated and semi-automated computer-aided grading systems and related retinal image analysis techniques for drusen, geographic atrophy and choroidal neovascularization detection and/or quantification for measurement of AMD severity using these imaging modalities. We also review the existing telemedicine studies which include diagnosis and management of AMD, and how automated disease grading could benefit telemedicine. As there is no treatment for dry AMD and only early intervention can prevent the late AMD, we emphasize mass screening through a telemedicine platform to enable early detection of AMD. We also provide a comparative study between the imaging modalities and identify potential study areas for further improvement and future research direction in automated AMD grading and screening. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Kanagasingam, Yogesan; Bhuiyan, Alauddin] CSIRO, Australian E Hlth Res Ctr, Wembly, WA 6014, Australia.
   [Bhuiyan, Alauddin; Wong, Tien Y.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
   [Abramoff, Michael D.] Univ Iowa, Iowa City, IA 52242 USA.
   [Smith, R. Theodore] NYU, Sch Med, Dept Ophthalmol, Retinal Image Anal Lab, New York, NY 10016 USA.
   [Goldschmidt, Leonard] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.
C3 Commonwealth Scientific & Industrial Research Organisation (CSIRO);
   Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Iowa; New York University; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care
   System
RP Kanagasingam, Y (通讯作者)，CSIRO, Australian E Hlth Res Ctr, 65 Brockway Rd,Underwood Ave, Wembly, WA 6014, Australia.
EM kan063@csiro.au
RI Abramoff, Michael D/A-5836-2009; Kanagasingam, Yogesan/C-4631-2011;
   Wong, Tien Yin/AAC-9724-2020
OI Abramoff, Michael D/0000-0002-3490-0037; Kanagasingam,
   Yogesan/0000-0001-7321-7495; Wong, Tien Yin/0000-0002-8448-1264; smith,
   theodore/0000-0002-1693-943X
FU NATIONAL EYE INSTITUTE [R01EY019112] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY019112] Funding Source: Medline
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Abramoff MD, 2005, TELEMED J E-HEALTH, V11, P668, DOI 10.1089/tmj.2005.11.668
   Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   [Anonymous], 2012, HED COMP DAT
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barakat M.R., 2004, INVEST OPHTHALMOL VI, V45
   Barriga E.S., 2009, MULTISCALE AM FM LES
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Baumann B., 2010, J BIOMED OPT, V15, P1
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bhuiyan A, 2007, IEEE IMAGE PROC, P2773
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chang AA, 2005, INVEST OPHTH VIS SCI, V46, P1463, DOI 10.1167/iovs.04-0825
   Chang AA, 2004, BRIT J OPHTHALMOL, V88, P307, DOI 10.1136/bjo.2003.024893
   Chew E.Y., 2013, OPHTHALMOLOGY
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Davis B, 2007, PROC SPIE, V6426, DOI 10.1117/12.701391
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Devisetti K., 2011, 33 ANN INT C IEEE EM, P3358
   Diaconu V, 2009, APPL OPTICS, V48, pD52, DOI 10.1364/AO.48.000D52
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Domalpally Amitha, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS34, DOI 10.3928/15428877-20100325-01
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Dzurinko Victoria L, 2004, Optometry, V75, P743, DOI 10.1016/S1529-1839(04)70234-1
   Eccles N., 2012, HARVARD COLL PERIODI
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Fawzi AA, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3640813
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2010, REV OPHTHALMOL
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Framme C, 2005, CURR MED IMAGING, V1, P89, DOI 10.2174/1573405052952994
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Freund K.B., 2008, AGE RELATED MACULAR
   Gao L, 2012, BIOMED OPT EXPRESS, V3, P48, DOI 10.1364/BOE.3.000048
   Ghorbel I, 2011, PATTERN RECOGN, V44, P1590, DOI 10.1016/j.patcog.2011.01.012
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gonzalez R. C., 2008, DIGITAL IMAGE PROCES
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Gupta V, 2008, AM J OPHTHALMOL, V145, P1018, DOI 10.1016/j.ajo.2008.01.021
   Hand DJ, 2006, STAT SCI, V21, P1, DOI 10.1214/088342306000000060
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   He JY, 2006, IEEE T NANOBIOSCI, V5, P46, DOI 10.1109/TNB.2005.864021
   Hijazi M.H.A., 2010, P SGAI C, P325
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Johnson WR, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2434950
   Joshi G. D., 2011, J DIABETES SCI TECHN, V5, P1
   Kaiser P.K., 2011, REV OPHTHALMOL, P6
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Khoobehi B, 2004, INVEST OPHTH VIS SCI, V45, P1464, DOI 10.1167/iovs.03-1069
   Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037
   Klais C.M., 2004, RETIN PHYS       AUG
   KLEIN R, 1992, DIABETES CARE, V15, P1875, DOI 10.2337/diacare.15.12.1875
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kolar R, 2008, INT J BIOMED IMAGING, V2008, DOI 10.1155/2008/513478
   Koozekanani D, 2001, IEEE T MED IMAGING, V20, P900, DOI 10.1109/42.952728
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Kruizinga P, 1999, IEEE T IMAGE PROCESS, V8, P1395, DOI 10.1109/83.791965
   Lavik EB, 2013, DRUG DELIV, V1, P734
   Lee N, 2010, IEEE ENG MED BIO, P5363, DOI 10.1109/IEMBS.2010.5626463
   Lee N., 2007, 29 ANN INT C IEEE EM
   Lee N, 2008, I S BIOMED IMAGING, P1215, DOI 10.1109/ISBI.2008.4541221
   Li HK, 2011, TELEMED J E HLTH
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Liesenfeld B, 2000, DIABETES CARE, V23, P345, DOI 10.2337/diacare.23.3.345
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu YY, 2011, INVEST OPHTH VIS SCI, V52, P8316, DOI 10.1167/iovs.10-7012
   Loduca AL, 2010, AM J OPHTHALMOL, V150, P849, DOI 10.1016/j.ajo.2010.06.034
   Lorenz B, 2009, GRAEF ARCH CLIN EXP, V247, P1251, DOI 10.1007/s00417-009-1077-7
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meleth AD, 2011, CURR OPIN OPHTHALMOL, V22, P190, DOI 10.1097/ICU.0b013e32834594b0
   Miki Norito, 2007, Osaka City Medical Journal, V53, P35
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480
   Murakami Y, 2010, ACTA OPHTHALMOL, V88, P317, DOI 10.1111/j.1755-3768.2009.01715.x
   Narasimha-Iyer H., 2006, C P IEEE ENG MED BIO
   National-Eye-Institute, 2004, PREV BLINDN DAT
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Nishiyama Y, 2001, Jpn J Ophthalmol, V45, P116, DOI 10.1016/S0021-5155(00)00309-9
   Parvathi S.S., 2007, INT C C COMP INT MUL
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Pirbhai A., 2004, INVEST OPHTHALMOL VI
   Priya R., 2011, 2011 3rd International Conference on Electronics Computer Technology (ICECT 2011), P227, DOI 10.1109/ICECTECH.2011.5941690
   Quellec G, 2011, IEEE T MED IMAGING, V30, P523, DOI 10.1109/TMI.2010.2089383
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rapantzikos K., 2001, P INT C IM PROC GREE, DOI DOI 10.1109/ICIP.2001.958308
   Remeseiro B, 2009, LECT NOTES COMPUT SC, V5717, P187, DOI 10.1007/978-3-642-04772-5_25
   Ripley B. D., 1996, PATTERN RECOGNITION
   Rosen RB, 2009, INVEST OPHTH VIS SCI, V50, P851, DOI 10.1167/iovs.08-1855
   Rosenfeld P., 2011, COMP DRUSEN AREA DET
   Rosenfeld P.J.L., 2009, RETIN PHYS       NOV
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sbeh Z.B, 2002, IEEE T MED IMAGING, V20, P1321
   Schardosim L., 2011, 2011 IEEE C INSTR ME, P1
   Schimel Andrew M, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS41, DOI 10.3928/15428877-20110627-04
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Sohrab MA, 2011, SEMIN OPHTHALMOL, V26, P156, DOI 10.3109/08820538.2011.570848
   Soliz P, 2002, P SOC PHOTO-OPT INS, V4681, P159, DOI 10.1117/12.466917
   Song Y, 2012, RETINA-J RET VIT DIS, V32, P569, DOI 10.1097/IAE.0b013e31821f5d69
   Sonka M., 2014, IMAGE PROCESSING ANA
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Tatrai E, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3573817
   Taylor CR, 2007, DIABETES CARE, V30, P574, DOI 10.2337/dc06-1509
   Thaibaoui A., 2000, INT C PATT REC IEEE, DOI DOI 10.1109/ICPR.2000.903025
   Theelen T, 2009, GRAEF ARCH CLIN EXP, V247, P1625, DOI 10.1007/s00417-009-1148-9
   Ulrich JN, 2009, BRIT J OPHTHALMOL, V93, P698, DOI 10.1136/bjo.2008.151357
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yehoshua Zohar, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS6, DOI 10.3928/15428877-20101031-19
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Yogesan K, 2006, TELEOPHTHALMOLOGY
   Yogesan K, 2012, DIGITAL TELERETINAL
   Yogesan K, 2010, AUTOMATED IMAGE DETECTION OF RETINAL PATHOLOGY, P339
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
   Zimmer-Galler IE, 2005, OPHTHAL SURG LAS IM, V36, P228, DOI 10.3928/1542-8877-20050501-09
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 158
TC 106
Z9 108
U1 0
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2014
VL 38
BP 20
EP 42
DI 10.1016/j.preteyeres.2013.10.002
PG 23
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 298PF
UT WOS:000330336000002
PM 24211245
OA hybrid
DA 2022-11-30
ER

PT J
AU Plestina-Borjan, I
   Katusic, D
   Medvidovic-Grubisic, M
   Supe-Domic, D
   Bucan, K
   Tandara, L
   Rogosic, V
AF Plestina-Borjan, Ivna
   Katusic, Damir
   Medvidovic-Grubisic, Maria
   Supe-Domic, Daniela
   Bucan, Kajo
   Tandara, Leida
   Rogosic, Veljko
TI Association of Age-Related Macular Degeneration with Erythrocyte
   Antioxidant Enzymes Activity and Serum Total Antioxidant Status
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID OXIDATIVE STRESS; RISK-FACTOR; RETINA; PATHOGENESIS; RADIATION;
   CATARACT; EXPOSURE; DAMAGE
AB The aim was to estimate association of the oxidative stress with the occurrence of age-related macular degeneration (AMD). The activities of erythrocyte antioxidant enzymes: superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) and additionally serum total antioxidant status (TAS) were used as indicators of the oxidative stress level. 57 AMD patients (32 early and 25 late AMD) and 50 healthy, age and gender matched controls were included. GPx activity (P < 0.001) and serum TAS (P = 0.015) were significantly lower in AMD patients. The difference was not significant for SOD or CAT activities. Significant interaction between GPx and SOD was detected (P = 0.003). At high levels of SOD activity (over 75th percentile), one standard deviation decrease in GPx increases the odds for AMD for six times (OR = 6.22; P < 0.001). ROC analysis revealed that combined values of GPx activity and TAS are significant determinants of AMD status. Accuracy, sensitivity, specificity, and positive and negative predictive values were 75%, 95%, 52%, 69%, and 90%, respectively. The study showed that low GPx activity and TAS are associated with AMD. SOD modulates the association of GPx and AMD. The results suggest that erythrocyte antioxidant enzymes activity and serum TAS could be promising markers for the prediction of AMD.
C1 [Plestina-Borjan, Ivna; Bucan, Kajo; Rogosic, Veljko] Univ Split, Sch Med, Dept Ophthalmol, Split 21000, Croatia.
   [Katusic, Damir] Univ Zagreb, Sch Med, Dept Ophthalmol, Zagreb 10000, Croatia.
   [Medvidovic-Grubisic, Maria] Inst Navy Med, Dept Ophthalmol, Split 21000, Croatia.
   [Supe-Domic, Daniela; Tandara, Leida] Univ Split, Sch Med, Dept Med Lab Diagnost, Split 21000, Croatia.
C3 University of Split; University of Zagreb; University of Zagreb, School
   of Dental Medicine; University of Split
RP Plestina-Borjan, I (通讯作者)，Univ Split, Sch Med, Dept Ophthalmol, Spinciceva 1, Split 21000, Croatia.
EM ivna.plestina@gmail.com
RI Bucan, Kajo/H-6144-2017; Šupe-Domić, Daniela/Y-3169-2019
OI Bucan, Kajo/0000-0003-2684-3447; Šupe-Domić, Daniela/0000-0002-5584-3182
CR Anand A, 2013, OXID MED CELL LONGEV, V2013, DOI DOI 10.1155/2013/365046
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonett DG, 2002, PSYCHOL METHODS, V7, P370, DOI 10.1037//1082-989X.7.3.370
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Khandhadia S., 2014, SYSTEMS BIOL FREE RA, P3625
   Lamont J, 1997, CLIN CHEM, V43, P852
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu ZB, 2007, J NEUROCHEM, V103, P2690, DOI 10.1111/j.1471-4159.2007.04954.x
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Usui S, 2011, FREE RADICAL BIO MED, V51, P1347, DOI 10.1016/j.freeradbiomed.2011.06.010
   WINTERBOURN CC, 1975, J LAB CLIN MED, V85, P337
   World Health Organization, 2013, VIS 2020 RIGHT SIGHT
   World Health Organization, 2004, VIS 2020 RIGHT SIGHT
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 41
TC 13
Z9 13
U1 2
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2015
VL 2015
AR 804054
DI 10.1155/2015/804054
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CD9TJ
UT WOS:000351441000001
PM 25815109
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Schlunck, G
   Martin, G
   Agostini, HT
   Camatta, G
   Hansen, LL
AF Schlunck, G
   Martin, G
   Agostini, HT
   Camatta, G
   Hansen, LL
TI Cultivation of retinal pigment epithelial cells from human choroidal
   neovascular membranes in age related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE retinal pigment epithelium; retinal cell culture; age related macular
   degeneration; neovascularization; immunocytochemistry; RT-PCR
ID ENDOTHELIAL GROWTH-FACTOR; SUBRETINAL NEOVASCULARIZATION; EXPRESSION;
   CULTURE; MODEL
AB A method is described for cultivating retinal pigment epithelial cells from choroidal neovascular membrane (CNV) specimens that were surgically removed in patients with age-related macular degeneration (AMD). CNV specimens of 43 patients were available for cultivation. They were incubated in supplemented DMEM/Ham's F12 cell culture medium on microporous semipermeable filter membranes. Thirty-four specimens gave rise to cell cultures. 28 of which could be subcultivated for up to 15 passages. The membrane type as classified by fluorescence angiography was compared with cellular growth in vitro. Immunocytochemistry revealed a uniform expression of cytokeratin 18 and vimentin, while factor 8, glial fibrillary acidic protein and alpha smooth muscle actin were absent in all 21 cultures stained. The expression of RPE markers cellular retinaldehyde binding protein (CRALBP) and RPE65 was detected by RT-PCR in all cultures tested. An epithelial character of the cultures was supported by the presence of apical microvilli as determined by electron microscopical studies. Therefore, the cell cultures from CNV in AMD bear characteristics of retinal pigment epithelial cells. For the first time. this cell culture system holds the potential to study human RPE cells in the context of neovascular AMD in vitro. (C) 2002 Elsevier Science Ltd.
C1 Univ Freiburg Klinikum, Dept Ophthalmol, Freiburg, Germany.
C3 University of Freiburg
RP Martin, G (通讯作者)，Univ Freiburg, Augenklin, Killianstr 5, D-790106 Freiburg, Germany.
EM martin@aug.ukl.uni-freiburg.de
RI Hansen, Lutz L/A-1390-2011
CR Abe T, 1998, CURR EYE RES, V17, P1103, DOI 10.1076/ceyr.17.12.1103.5126
   ALBERT DM, 1972, ARCH OPHTHALMOL-CHIC, V88, P63
   Ando A, 2000, BRIT J OPHTHALMOL, V84, P1306, DOI 10.1136/bjo.84.11.1306
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   CAPETANDES A, 1990, INVEST OPHTH VIS SCI, V31, P1738
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   FRANK RN, 1989, CURR EYE RES, V8, P239, DOI 10.3109/02713688908997565
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   HETH CA, 1987, CURR EYE RES, V6, P1007, DOI 10.3109/02713688709034872
   HOGAN MJ, 1971, HIST HUMAN EYE, V1, P370
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Jaeger RG, 1997, ORAL SURG ORAL MED O, V84, P663, DOI 10.1016/S1079-2104(97)90369-3
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MANNAGH J, 1973, INVEST OPHTH VISUAL, V12, P52
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Smith RF, 2000, J CARD FAIL, V6, P97, DOI 10.1054/jcaf.2000.7871
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 22
TC 19
Z9 20
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2002
VL 74
IS 5
BP 571
EP 576
DI 10.1006/exer.2001.1148
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 570XQ
UT WOS:000176686100003
PM 12076078
DA 2022-11-30
ER

PT J
AU Klettner, A
   Roider, J
AF Klettner, Alexa
   Roider, Johann
TI Retinal Pigment Epithelium Expressed Toll-like Receptors and Their
   Potential Role in Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retinal pigment epithelium (RPE); toll-like receptors (TLR); age-related
   macular degeneration (AMD); microglia
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL GROWTH-FACTOR;
   NF-KAPPA-B; GEOGRAPHIC ATROPHY; OXIDATIVE STRESS; INNATE IMMUNITY;
   NEOVASCULAR MEMBRANES; BRUCHS MEMBRANE; AQUEOUS-HUMOR; AMYLOID-BETA
AB (1) Background: Inflammation is a major pathomechanism in the development and progression of age-related macular degeneration (AMD). The retinal pigment epithelium (RPE) may contribute to retinal inflammation via activation of its Toll-like receptors (TLR). TLR are pattern recognition receptors that detect the pathogen- or danger-associated molecular pattern. The involvement of TLR activation in AMD is so far not understood. (2) Methods: We performed a systematic literature research, consulting the National Library of Medicine (PubMed). (3) Results: We identified 106 studies, of which 54 were included in this review. Based on these studies, the current status of TLR in AMD, the effects of TLR in RPE activation and of the interaction of TLR activated RPE with monocytic cells are given, and the potential of TLR activation in RPE as part of the AMD development is discussed. (4) Conclusion: The activation of TLR2, -3, and -4 induces a profound pro-inflammatory response in the RPE that may contribute to (long-term) inflammation by induction of pro-inflammatory cytokines, reducing RPE function and causing RPE cell degeneration, thereby potentially constantly providing new TLR ligands, which could perpetuate and, in the long run, exacerbate the inflammatory response, which may contribute to AMD development. Furthermore, the combined activation of RPE and microglia may exacerbate neurotoxic effects.
C1 [Klettner, Alexa; Roider, Johann] Univ Kiel, Univ Med Ctr, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr, Dept Ophthalmol, D-24105 Kiel, Germany.
EM AlexaKarina.Klettner@uksh.de; Johann.Roider@uksh.de
OI Klettner, Alexa/0000-0002-2709-1059
FU DFG
FX We acknowledge financial support by DFG within the funding programme
   Open Access Publizieren.
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bernard JJ, 2012, NAT MED, V18, P1286, DOI 10.1038/nm.2861
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonini S, 2005, OPHTHALMOLOGY, V112, P1528, DOI 10.1016/j.ophtha.2005.04.009
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Brosig A, 2015, MOL VIS, V21, P1000
   Chen C, 2017, MOL MED REP, V15, P2289, DOI 10.3892/mmr.2017.6252
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Cheng Y, 2014, GENET MOL RES, V13, P302, DOI 10.4238/2014.January.17.15
   Chintala SK, 2015, INVEST OPHTH VIS SCI, V56, P505, DOI 10.1167/iovs.14-15539
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Crowley MA, 2018, INVEST OPHTH VIS SCI, V59, P940, DOI 10.1167/iovs.17-22605
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Dietrich L, 2020, EXP EYE RES, V199, DOI 10.1016/j.exer.2020.108167
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Duncan RS, 2020, CELL SIGNAL, V66, DOI 10.1016/j.cellsig.2019.109494
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Elner SG, 2005, INVEST OPHTH VIS SCI, V46, P4627, DOI 10.1167/iovs.05-0658
   Feng LL, 2017, AM J PATHOL, V187, P2208, DOI 10.1016/j.ajpath.2017.06.015
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Gounarides J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111472
   Gregerson DS, 2007, INVEST OPHTH VIS SCI, V48, P4654, DOI 10.1167/iovs.07-0286
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guven M, 2016, CURR EYE RES, V41, P856, DOI 10.3109/02713683.2015.1067326
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hettich C, 2014, GRAEF ARCH CLIN EXP, V252, P1747, DOI 10.1007/s00417-014-2742-z
   Hooks JJ, 2008, J IMMUNOL, V180, P3789, DOI 10.4049/jimmunol.180.6.3789
   Huang JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100985
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Johnson AC, 2005, INVEST OPHTH VIS SCI, V46, P589, DOI 10.1167/iovs.04-1077
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Klettner A., 2015, RECENT ADV EYE RES, P31
   Klettner A, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108214
   Klettner A, 2014, ACTA OPHTHALMOL, V92, pe621, DOI 10.1111/aos.12472
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Klettner A, 2013, ACTA OPHTHALMOL, V91, pE211, DOI 10.1111/aos.12031
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Kumagai N, 2005, INVEST OPHTH VIS SCI, V46, P114, DOI 10.1167/iovs.04-0922
   Kumar A, 2006, CURR MOL MED, V6, P327, DOI 10.2174/156652406776894572
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lewin AS, 2009, NEW ENGL J MED, V360, P2251, DOI 10.1056/NEJMc082233
   Liew G, 2009, NEW ENGL J MED, V360, P2252
   Ling Y, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015583
   Liu XC, 2020, OPHTHALMIC GENET, V41, P31, DOI 10.1080/13816810.2020.1723117
   Ma L, 2016, SCI REP-UK, V6, DOI 10.1038/srep19718
   Maloney SC, 2010, OPHTHALMIC RES, V44, P237, DOI 10.1159/000313989
   Miao H, 2012, MOL VIS, V18, P574
   Micera A, 2005, CURR OPIN ALLERGY CL, V5, P451, DOI 10.1097/01.all.0000182537.55650.99
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mulfaul K, 2020, CELL REP, V30, P2209, DOI 10.1016/j.celrep.2020.01.064
   Mulfaul K, 2018, ADV EXP MED BIOL, V1074, P19, DOI 10.1007/978-3-319-75402-4_3
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Novosad BD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028619
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Patel AK, 2014, MOL CELL NEUROSCI, V63, P38, DOI 10.1016/j.mcn.2014.09.004
   Patel AK, 2013, MOL IMMUNOL, V54, P122, DOI 10.1016/j.molimm.2012.11.005
   Redfern RL, 2010, EXP EYE RES, V90, P679, DOI 10.1016/j.exer.2010.03.012
   Saeed AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106421
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406
   Sharma NK, 2014, MOL CELL BIOCHEM, V393, P1, DOI 10.1007/s11010-014-2040-4
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Sng CCA, 2011, OPHTHALMIC RES, V45, P191, DOI 10.1159/000321387
   Stewart EA, 2015, EXP EYE RES, V138, P114, DOI 10.1016/j.exer.2015.06.012
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugita S, 2009, INVEST OPHTH VIS SCI, V50, P2862, DOI 10.1167/iovs.08-2846
   Talreja D, 2015, INVEST OPHTH VIS SCI, V56, P1719, DOI 10.1167/iovs.14-16087
   Terheyden L, 2021, GRAEF ARCH CLIN EXP, V259, P413, DOI 10.1007/s00417-020-04930-2
   Tezel G, 2008, PROG BRAIN RES, V173, P409, DOI 10.1016/S0079-6123(08)01128-X
   Tode J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.2
   VERSTEEGTIJMES NT, 1982, GRAEF ARCH CLIN EXP, V218, P271, DOI 10.1007/BF02175896
   Wang H, 2014, CHEM RES TOXICOL, V27, P2015, DOI 10.1021/tx500216a
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Will-Orrego A, 2018, J OCUL PHARMACOL TH, V34, P489, DOI 10.1089/jop.2017.0131
   Wornle M, 2011, INVEST OPHTH VIS SCI, V52, P6536, DOI 10.1167/iovs.10-6993
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080288
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou JY, 2020, OPHTHALMIC GENET, V41, P579, DOI 10.1080/13816810.2020.1814348
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
   Zhu Y, 2015, MOL VIS, V21, P1122
   Zhu Y, 2013, MOL VIS, V19, P1826
NR 110
TC 4
Z9 4
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2021
VL 22
IS 16
AR 8387
DI 10.3390/ijms22168387
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UG4GB
UT WOS:000689211900001
PM 34445096
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fernandez, AB
   Ballard, KD
   Wong, TY
   Guo, M
   McClelland, RL
   Burke, G
   Cotch, MF
   Klein, B
   Allison, M
   Klein, R
AF Fernandez, Antonio B.
   Ballard, Kevin D.
   Wong, Tien Y.
   Guo, Mengye
   McClelland, Robyn L.
   Burke, Gregory
   Cotch, Mary Frances
   Klein, Barbara
   Allison, Matthew
   Klein, Ronald
TI Age-related macular degeneration and progression of coronary artery
   calcium: The Multi-Ethnic Study of Atherosclerosis
SO PLOS ONE
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; HEART-DISEASE; RISK-FACTORS; EYE DISEASE;
   INTERVENTION; MORTALITY; ADULTS; PLAQUE; MESA; CT
AB Background
   Age-related macular degeneration (AMD) shares many similarities with cardiovascular disease (CVD) pathophysiology. We sought to determine the relationship of AMD to the progression of coronary artery calcium (CAC) using data from the Multi-Ethnic Study of Atherosclerosis (MESA).
   Methods
   Our cohort consisted of 5803 adults aged 45 to 84 years free of known cardiovascular disease (CVD). Retinal photographs were taken during visit 2 (Aug 2002-Jan 2004). CAC was measured with computed tomography at visit 1 (July 2000-Aug 2002) and visit 5 (April 2010-Dec 2011) and changes between visits were determined.
   Results
   Participants were categorized as with (n = 244) and without AMD (n = 5559) at visit 2. At visit 5, 92 participants with and 2684 without AMD had CAC scores. Among those with detectable CAC at baseline (>0 at visit 1), CAC progression was greater in persons with compared to those without AMD after multivariable adjustment (530 +/- 537 vs. 339 +/- 426 Agatston units, P<0.01).
   Conclusions
   The presence of AMD in a diverse population without known clinical CVD independently predicted higher 10-year CAC progression in participants with baseline CAC >0. The retinal exam might be a useful tool for pre-clinical assessment and prevention of CVD events.
C1 [Fernandez, Antonio B.] Hartford Hosp, Inst Heart & Vasc, Div Cardiol, Hartford, CT 06115 USA.
   [Fernandez, Antonio B.] Univ Connecticut, Dept Med, Farmington, CT 06032 USA.
   [Ballard, Kevin D.] Miami Univ, Dept Kinesiol & Hlth, Oxford, OH 45056 USA.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Natl Eye Ctr, Duke NUS Med Sch, Singapore Eye Res Inst, Singapore, Singapore.
   [Guo, Mengye; McClelland, Robyn L.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Burke, Gregory] Wake Forest Univ Hlth Sci, Dept Publ Hlth Sci, Winston Salem, NC USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH Intramural Res Program, NIH, Bethesda, MD 20892 USA.
   [Klein, Barbara; Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Allison, Matthew] Univ Calif San Diego, La Jolla, CA 92093 USA.
C3 Hartford Hospital; University of Connecticut; University System of Ohio;
   Miami University; National University of Singapore; Singapore National
   Eye Center; University of Washington; University of Washington Seattle;
   Wake Forest University; Wake Forest University School of Medicine;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Wisconsin System; University of Wisconsin Madison;
   University of California System; University of California San Diego
RP Fernandez, AB (通讯作者)，Hartford Hosp, Inst Heart & Vasc, Div Cardiol, Hartford, CT 06115 USA.; Fernandez, AB (通讯作者)，Univ Connecticut, Dept Med, Farmington, CT 06032 USA.
EM antonio.fernandez@hhchealth.org
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cotch, Mary
   Frances/0000-0002-2046-4350; Klein, Ronald/0000-0002-4428-6237;
   Fernandez, Antonio/0000-0003-4517-9123
FU National Heart, Lung, and Blood Institute [HL69979-03, N01-HC-95159,
   N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164,
   N01-HC-95165, N01-HC-95166]; NATIONAL EYE INSTITUTE [ZIAEY000403]
   Funding Source: NIH RePORTER
FX This research was supported by grant #: HL69979-03 to Dr. Klein and Dr.
   Wong and by contracts N01-HC-95159 through N01-HC-95166 from the
   National Heart, Lung, and Blood Institute. The funding agency had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Budoff MJ, 2010, JACC-CARDIOVASC IMAG, V3, P1229, DOI 10.1016/j.jcmg.2010.08.018
   Carr JJ, 2005, RADIOLOGY, V234, P35, DOI 10.1148/radiol.2341040439
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Criqui MH, 2014, JAMA-J AM MED ASSOC, V311, P271, DOI 10.1001/jama.2013.282535
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Detrano RC, 2005, RADIOLOGY, V236, P477, DOI 10.1148/radiol.2362040513
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fernandez AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142968
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Goff DC, 2014, J AM COLL CARDIOL, V63, P2935, DOI [10.1161/01.cir.0000437741.48606.98, 10.1016/j.jacc.2013.11.005]
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Hughes-Austin JM, 2014, VASC MED, V19, P264, DOI 10.1177/1358863X14537545
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   McClelland RL, 2015, J AM COLL CARDIOL, V66, P1643, DOI 10.1016/j.jacc.2015.08.035
   McEvoy JW, 2010, J AM COLL CARDIOL, V56, P1613, DOI 10.1016/j.jacc.2010.06.038
   Pulido JS, 2007, MAYO CLIN PROC, V82, P301, DOI 10.4065/82.3.301
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yeboah J, 2016, J AM COLL CARDIOL, V67, P139, DOI 10.1016/j.jacc.2015.10.058
NR 33
TC 8
Z9 8
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 18
PY 2018
VL 13
IS 7
AR e0201000
DI 10.1371/journal.pone.0201000
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GN4SJ
UT WOS:000439022400089
PM 30020999
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Wolff, B
   Matet, A
   Vasseur, V
   Sahel, JA
   Mauget-Faysse, M
AF Wolff, Benjamin
   Matet, Alexandre
   Vasseur, Vivien
   Sahel, Jose-Alain
   Mauget-Faysse, Martine
TI En Face OCT Imaging for the Diagnosis of Outer Retinal Tubulations in
   Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Purpose. "En face" is an emerging imaging technique derived from spectral domain optical coherence tomography (OCT). It produces frontal sections of retinal layers, also called "C-scan OCT." Outer retinal tubulations (ORTs) in age-related macular degeneration (AMD) are a recent finding evidenced by spectral-domain OCT. The aim of this study is to characterize the morphology of ORT according to the form of AMD, using "en-face" spectral domain OCT. Methods. "En face" OCT imaging was prospectively performed in 26 consecutive eyes with AMD that also had ORT. Results. There were 15 neovascular, 8 atrophic, and 3 eyes with amixed (fibrotic and atrophic) form of AMD. Among the neovascular group, the most frequent tubulation pattern on "en-face" OCT was a branching network emanating from a fibrovascular scar; we term this pattern as "pseudodendritic." It did not require treatment when observed as an isolated finding. In all cases of atrophic AMD, the tubular network was located at the edge of the geographic atrophy area, and formed a "perilesional" pattern. Six atrophic cases showed tubular invaginations inside this area. Conclusion. "En face" OCT is a valuable technique in the diagnosis and followup of macular disease. It revealed the main characteristic patterns of ORT associated with neovascular and atrophic AMD.
C1 [Wolff, Benjamin; Matet, Alexandre; Vasseur, Vivien; Sahel, Jose-Alain; Mauget-Faysse, Martine] Rothschild Ophthalmol Fdn, F-75019 Paris, France.
RP Wolff, B (通讯作者)，Rothschild Ophthalmol Fdn, 25 Rue Manin, F-75019 Paris, France.
EM bwolff@hotmail.fr
RI Sahel, Jose-Alain/F-3172-2017; Matet, Alexandre/H-5227-2019
OI Sahel, Jose-Alain/0000-0002-4831-1153; Matet,
   Alexandre/0000-0002-9721-777X; wolff, benjamin/0000-0003-4709-692X
CR Maftouhi MQE, 2010, J FR OPHTALMOL, V33, P605, DOI 10.1016/j.jfo.2010.09.015
   Podoleanu AG, 1997, OPT LETT, V22, P1039, DOI 10.1364/OL.22.001039
   Wolff B, 2011, ACTA OPHTHALMOL, V89, pE496, DOI 10.1111/j.1755-3768.2011.02144.x
   WOLTER J R, 1955, Klin Monbl Augenheilkd Augenarztl Fortbild, V127, P687
   Yannuzi LA, 2010, RETINAL ATLAS, P158
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 6
TC 46
Z9 54
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2012
VL 2012
AR 542417
DI 10.1155/2012/542417
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 001WZ
UT WOS:000308492300001
PM 22970349
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lin, XL
   Lou, LX
   Miao, Q
   Wang, YJ
   Jin, K
   Shan, PF
   Xu, YF
AF Lin, Xiling
   Lou, Lixia
   Miao, Qi
   Wang, Yijie
   Jin, Kai
   Shan, Pengfei
   Xu, Yufeng
TI The pattern and gender disparity in global burden of age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; RETINA; preventive medicine;
   Screening; socioeconomics and education in medicine; ophthalmology;
   retina; medical therapies
ID VISION LOSS; PREVALENCE; HEALTH; RANIBIZUMAB; ASSOCIATION; MACULOPATHY;
   IMPAIRMENT; INEQUALITY; BLINDNESS; SURGERY
AB Purpose:
   To explore the trend patterns and gender disparity in global burden of age-related macular degeneration (AMD) by year, age, and socioeconomic status using disability-adjusted life-years (DALYs) from Global Burden of Disease (GBD) study 2017.
   Methods:
   DALYs and impairment data caused by AMD were extracted from GBD Study 2017. World Bank income level (WBIL) and human development index (HDI) in 2017 were cited as indicators of socioeconomic status. The Gini coefficients and the concentration indexes were calculated to unveil trends in between-country inequality. The association between gender inequality and socioeconomic levels was analyzed by Pearson correlation.
   Results:
   Total age-standardized DALYs of AMD showed a slightly descending pattern in recent years. However, gender disparity has existed since 1990 for almost three decades, with female being more heavily impacted. This pattern became more obvious with aging and varied among different WHO and WBIL regions. Meanwhile, female subjects tended to have higher vision impairments. Gini coefficients of AMD burden increased from 0.423 to 0.448, while the ones of female-to-male ratio fluctuated around 0.11 between 1990 and 2017, with concentration indexes changing from 0.024 to -0.057 and 0.046 to 0.029 respectively. Female-minus-male difference (r = 0.1721, p = 0.0195) and female-to-male ratio (r = 0.2072, p = 0.0048) of age-standardized DALYs rates were positively related to HDI.
   Conclusions:
   Though global AMD health care is progressing, gender imbalance in disease burden of AMD distribution barely improved. Gender sensitive health policy should be emphasized for the increasing elder population and relieving the higher AMD burden of females.
C1 [Lin, Xiling; Shan, Pengfei] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Endocrinol, Hangzhou, Zhejiang, Peoples R China.
   [Lou, Lixia; Miao, Qi; Wang, Yijie; Jin, Kai; Xu, Yufeng] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Ophthalmol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Xu, YF (通讯作者)，Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Ophthalmol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM xuyufeng0216@zju.edu.cn
FU National Natural Science Foundation of China [81900853, 81670744,
   81870564]; Science Technology Department of Zhejiang Province of China
   [2017C33037]; China Postdoctoral Science Fund [2019M652107]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by National Natural Science Foundation of China (81900853,
   81670744, 81870564), Science Technology Department of Zhejiang Province
   of China (2017C33037) and China Postdoctoral Science Fund (2019M652107).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bank W., 2019, WORLD BANK COUNTR LE
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bleichrodt H, 2006, J HEALTH ECON, V25, P945, DOI 10.1016/j.jhealeco.2006.01.002
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Costa-Font J, 2012, HEALTH POLICY, V106, P195, DOI 10.1016/j.healthpol.2012.04.007
   Courtright Paul, 2009, Community Eye Health, V22, P17
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Finger RP, 2017, CLIN EXP OPHTHALMOL, V45, P143, DOI 10.1111/ceo.12804
   GHDx, 2017, GBD RES TOOL GLOB BU
   Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Jonsson PM, 2006, HEALTH POLICY, V77, P24, DOI 10.1016/j.healthpol.2005.07.012
   Khairallah M, 2014, BRIT J OPHTHALMOL, V98, P605, DOI 10.1136/bjophthalmol-2013-304068
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   Kyu HH, 2018, LANCET, V392, P1859, DOI [10.1016/S0140-6736(18)32335-3, 10.1016/s0140-6736(18)32335-3]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lou LX, 2019, AM J OPHTHALMOL, V198, P1, DOI 10.1016/j.ajo.2018.09.020
   Lou LX, 2018, JAMA OPHTHALMOL, V136, P116, DOI 10.1001/jamaophthalmol.2017.5668
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mokdad AH, 2018, INT J PUBLIC HEALTH, V63, P199, DOI 10.1007/s00038-017-1000-7
   Moller AP, 2009, AM J HUM BIOL, V21, P357, DOI 10.1002/ajhb.20879
   Ono K, 2010, AM J PUBLIC HEALTH, V100, P1784, DOI 10.2105/AJPH.2009.187930
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Patel Ilesh, 2009, Community Eye Health, V22, P27
   Programme UND, HUM DEV REP 2017 HUM
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Smirthwaite G, 2014, ACTA OPHTHALMOL, V92, P432, DOI 10.1111/aos.12230
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Wang DC, 2019, CURR EYE RES, V44, P657, DOI 10.1080/02713683.2019.1576907
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 47
TC 5
Z9 5
U1 2
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2021
VL 31
IS 3
BP 1161
EP 1170
AR 1120672120927256
DI 10.1177/1120672120927256
EA JUN 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA TZ2CF
UT WOS:000538261300001
PM 32498618
DA 2022-11-30
ER

PT J
AU Mousa, SA
   Mousa, SS
AF Mousa, Shaker A.
   Mousa, Shaymaa S.
TI Current Status of Vascular Endothelial Growth Factor Inhibition in
   Age-Related Macular Degeneration
SO BIODRUGS
LA English
DT Review
ID TYROSINE KINASE INHIBITOR; INTRAVITREAL BEVACIZUMAB AVASTIN; VERTEPORFIN
   PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; PERMEABILITY FACTOR;
   PHASE-II; MULTIKINASE INHIBITOR; ANTITUMOR-ACTIVITY; COST-EFFECTIVENESS;
   FACTOR RECEPTOR-2
AB Angiogenesis, the process by which new vessels are created from pre-existing vasculature, has become the subject of intense research in recent years. Increased rates of angiogenesis are associated with several disease states, including cancer, age-related macular degeneration (AMD), psoriasis, rheumatoid arthritis, and diabetic retinopathy. Vascular endothelial growth factor (VEGF) is an important modulator of angiogenesis, and has been implicated in the pathology of a number of conditions, including AMD, diabetic retinopathy, and cancer. AMD is a progressive disease of the macula and the third major cause of blindness worldwide. If not treated appropriately, AMD can progress to involve both eyes. Until recently, the treatment options for AM D have been limited, with photodynamic therapy (PDT) the mainstay of treatment. Although PDT is effective at slowing disease progression, it rarely results in improved vision. Several therapies have been or are now being developed for neovascular AMD, with the goal of inhibiting VEGF. These VEGF inhibitors include the RNA aptamer pegaptanib, partial and full-length antibodies ranibizumab and bevacizumab, the VEGF receptor decoy aflibercept, small interfering RNA-based therapies bevasiranib and AGN 211745, sirolimus, and tyrosine kinase inhibitors, including vatalanib, pazopanib, TG 100801, TG 101095, AG 013958, and AL 39324. At present, established therapies have met with great success in reducing the vision loss associated with neovascular AMD, whereas those still under investigation offer the potential for further advances. In AMD patients, these therapies slow the rate of vision loss and in some cases increase visual acuity. Although VEGF-inhibitor therapies are a milestone in the treatment of these disease states, several concerns need to be addressed before their impact can be fully realized.
C1 [Mousa, Shaker A.] Albany Coll Pharm & Hlth Sci, PRI, Rensselaer, NY 12144 USA.
   [Mousa, Shaymaa S.] Vasc Vis Pharmaceut Inc, Wynantskill, NY USA.
C3 Albany College of Pharmacy & Health Sciences
RP Mousa, SA (通讯作者)，Albany Coll Pharm & Hlth Sci, PRI, 1 Discovery Dr, Rensselaer, NY 12144 USA.
EM Shaker.mousa@acphs.edu
RI Mousa, Shaker A/A-7151-2017
OI Mousa, Shaker A/0000-0002-9294-015X
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Awada A, 2005, BRIT J CANCER, V92, P1855, DOI 10.1038/sj.bjc.6602584
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BROWN LF, 1997, EXS, V79, P233
   Busch T, 2009, RETINA-J RET VIT DIS, V29, pS36, DOI 10.1097/IAE.0b013e3181ad25e8
   Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Ciardiello F, 2003, CLIN CANCER RES, V9, P1546
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   de Jong FA, 2006, ONCOLOGIST, V11, P944, DOI 10.1634/theoncologist.11-8-944
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Drevs J, 2007, J CLIN ONCOL, V25, P3045, DOI 10.1200/JCO.2006.07.2066
   Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   ESKENS FA, 2006, J CLIN ONCOL, V24, P2034
   Faivre S, 2006, J CLIN ONCOL, V24, P25, DOI 10.1200/JCO.2005.02.2194
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928
   Fink AM, 2007, CLIN EXP RHEUMATOL, V25, P305
   Forooghian F, 2007, AM J OPHTHALMOL, V144, P761, DOI 10.1016/j.ajo.2007.07.022
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Hayek S, 2007, KLIN MONATSBL AUGENH, V224, P279, DOI 10.1055/s-2007-962848
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hirawat S, 2007, J CLIN ONCOL, V25
   Hutson TE, 2007, J CLIN ONCOL, V25
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H
   Kaiser PK, 2009, RETINA-J RET VIT DIS, V29, pS34, DOI 10.1097/IAE.0b013e3181ad242f
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Kymes SN, 2009, MINERVA MED, V100, P69
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Maier MM, 2009, KLIN MONATSBL AUGENH, V226, P496, DOI 10.1055/s-0028-1109463
   Marx J, 2002, SCIENCE, V295, P1444
   Michaelis LC, 2005, J CLIN ONCOL, V23, p542S
   Miller KD, 2005, CLIN CANCER RES, V11, P3369, DOI 10.1158/1078-0432.CCR-04-1923
   Mousa SA, 2004, CURR PHARM DESIGN, V10, P1, DOI 10.2174/1381612043453531
   MOUSA SA, 2000, MED INTELL UNIT, V20, P1
   Murakami M, 2006, BLOOD, V108, P1849, DOI 10.1182/blood-2006-04-016030
   Nakamura K, 2006, CANCER RES, V66, P9134, DOI 10.1158/0008-5472.CAN-05-4290
   Nemunaitis J, 2006, J CLIN ONCOL, V24, P4721, DOI 10.1200/JCO.2005.05.5335
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013
   Polverino A, 2006, CANCER RES, V66, P8715, DOI 10.1158/0008-5472.CAN-05-4665
   POTTER MJ, BR J OPHTHALMOL
   Raez LE, 2004, J CLIN ONCOL, V22, P2800, DOI 10.1200/JCO.2004.10.197
   Relf M, 1997, CANCER RES, V57, P963
   Rixe O, 2007, LANCET ONCOL, V8, P975, DOI 10.1016/S1470-2045(07)70285-1
   ROSEN L, 2005, J CLIN ONCOL, V23, P3013
   Rosen LS, 2007, J CLIN ONCOL, V25, P2369, DOI 10.1200/JCO.2006.07.8170
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960
   Singerman L, 2009, RETINA-J RET VIT DIS, V29, pS49, DOI 10.1097/IAE.0b013e3181ad2341
   Sonpavde G, 2008, EXPERT OPIN INV DRUG, V17, P253, DOI 10.1517/13543784.17.2.253
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124
   SUTTLE AB, 2004, J CLIN ONCOL S, V22, P3054
   Suzuki E, 2004, CLIN CANCER RES, V10, P5907, DOI 10.1158/1078-0432.CCR-03-0611
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Thomas AL, 2007, ANN ONCOL, V18, P782, DOI 10.1093/annonc/mdl469
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   Xia XB, 2008, CURR EYE RES, V33, P892, DOI 10.1080/02713680802416670
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 76
TC 43
Z9 48
U1 0
U2 25
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-8804
EI 1179-190X
J9 BIODRUGS
JI Biodrugs
PY 2010
VL 24
IS 3
BP 183
EP 194
DI 10.2165/11318550-000000000-00000
PG 12
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA 606EY
UT WOS:000278406400005
PM 20210371
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Chen, FK
   da Cruz, L
   Tufail, A
AF Patel, Praveen J.
   Chen, Fred K.
   da Cruz, Lyndon
   Tufail, Adnan
TI Segmentation Error in Stratus Optical Coherence Tomography for
   Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL THICKNESS MEASUREMENTS; PATHOLOGY
AB PURPOSE. To describe the rate of automated segmentation error in Stratus optical coherence tomography (OCT) scans in consecutive patients with neovascular age-related macular degeneration (nAMD) receiving treatment and to investigate the effect of the segmentation error on automated retinal thickness measures and whether further imaging reduces the rate of segmentation error.
   METHODS. A retrospective analysis of fast macular thickness map (FMTM) protocol OCT scans of 50 eyes of 50 consecutive patients with nAMD. Each line scan was analyzed for segmentation error with manual measurement of the center-point retinal thickness allowing calculation of the percentage error in automated thickness. OCT scanning was repeated to overcome segmentation error.
   RESULTS. Segmentation error was detected in 45 (90%) of the 50 patients with 37 (74%) patients having an error affecting the central 1-mm subfield. Scan sets with a high central segmentation error score (two or more line scans affected of six) had a significantly greater error in automated center-point retinal thickness than scan sets with a low error score (20% compared with 3%, P < 0.000005). Central subfield segmentation error persisted in 30 (60%) patients despite repeat scanning.
   CONCLUSIONS. There is a high rate of segmentation error in OCT scans of patients with nAMD who are undergoing treatment, leading to errors in automated central retinal thickness measurement. The authors recommend manual measurement of central macular thickness when two or more line scans are affected by segmentation error in the central 1-mm subfield. Repeated scanning reduced the rate of error but did not eliminate the problem. (Invest Ophthalmol Vis Sci. 2009; 50: 399-404) DOI:10.1167/iovs.08-1697
C1 [Patel, Praveen J.; Chen, Fred K.; da Cruz, Lyndon; Tufail, Adnan] Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Tufail, A (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM adnan.tufail@moorfields.nhs.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Tufail, Adnan/0000-0001-6131-7640
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gloesmann M, 2003, INVEST OPHTH VIS SCI, V44, P1696, DOI 10.1167/iovs.02-0654
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
NR 9
TC 45
Z9 45
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2009
VL 50
IS 1
BP 399
EP 404
DI 10.1167/iovs.08-1697
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 390YP
UT WOS:000262199900052
PM 18676631
DA 2022-11-30
ER

PT J
AU Vukicevic, M
   Heraghty, J
   Cummins, R
   Gopinath, B
   Mitchell, P
AF Vukicevic, M.
   Heraghty, J.
   Cummins, R.
   Gopinath, B.
   Mitchell, P.
TI Caregiver perceptions about the impact of caring for patients with wet
   age-related macular degeneration
SO EYE
LA English
DT Article
ID QUALITY-OF-LIFE
AB Purpose Caregivers of older persons with eye disease, namely age-related macular degeneration (AMD), have been reported to have a higher than expected distress. Very few studies have explored caregiver perceptions as to what is important when providing care. The aim of this study was to explore the perceptions of caregivers of persons with neovascular AMD in relation to the most important aspects of caring, as described in extended answers to self-administered survey questions.
   Methods A cross-sectional, self-administered survey of 643 caregivers of people with neovascular AMD, comprising 27 closed-response questions and 2 open ended questions. The latter were analysed as part of this study utilising and 'inductive' Grounded Theory approach.
   Results Six-hundred and forty-three caregiver responses to 2 open ended questions were analysed using an inductive approach and sorted into thematic networks. Three discrete categories arose: The Impact of Caring; Injections and Information and Activities of Daily Living.
   Conclusions Most caregivers were family caregivers and were found to be compassionate and self-sacrificing. They accepted additional responsibility whilst providing an encouraging environment for their care recipient. As a result, they experience distress and consider their own needs as secondary. Very few seek or receive respite and this added burden can have a negative impact upon the relationship between caregiver and care recipient.
C1 [Vukicevic, M.] La Trobe Univ, Dept Clin & Community Allied Hlth, Sch Allied Hlth, Discipline Orthopt, Melbourne, Vic 3086, Australia.
   [Heraghty, J.; Cummins, R.] Macular Dis Fdn Australia, Sydney, NSW, Australia.
   [Gopinath, B.; Mitchell, P.] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Gopinath, B.; Mitchell, P.] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
C3 La Trobe University; University of Sydney; University of Sydney;
   Westmead Institute for Medical Research
RP Vukicevic, M (通讯作者)，La Trobe Univ, Discipline Orthopt, Sch Allied Hlth, Coll Sci Hlth & Engn, Melbourne, Vic 3086, Australia.
EM m.vukicevic@latrobe.edu.au
RI Gopinath, Bamini/K-4286-2019; Mitchell, Paul/P-1498-2014
OI Gopinath, Bamini/0000-0003-3573-359X; Vukicevic,
   Meri/0000-0002-0887-6248
FU Bayer Australia; Macular Disease Foundation Australia; Orthoptics
   Australia
FX Funding for this survey and data analysis was provided by Bayer
   Australia, Macular Disease Foundation Australia, and Orthoptics
   Australia.
CR Attride-Stirling J., 2001, QUAL RES, V1, P385, DOI DOI 10.1177/146879410100100307
   Bambara JK, 2009, INVEST OPHTH VIS SCI, V50, P1585, DOI 10.1167/iovs.08-2744
   Barnhart R, 1996, WORLD BOOK DICT
   Bialon LN, 2012, AM J HOSP PALLIAT ME, V29, P210, DOI 10.1177/1049909111416494
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Bradshaw Ann, 2011, Nurs Times, V107, P12
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cain C.J., 2000, J FAMILY NURSING, V6, P46, DOI DOI 10.1177/107484070000600104
   Cole-King A, 2001, PSYCHOSOM MED, V63, P216, DOI 10.1097/00006842-200103000-00004
   Cornwell Jocelyn, 2009, Nurs Times, V105, P14
   Epstein RM, 2005, ANN FAM MED, V3, P415, DOI 10.1370/afm.348
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gopinath B, 2015, AGING MENT HEALTH, V19, P239, DOI 10.1080/13607863.2014.924477
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Schulz R, 2007, GERONTOLOGIST, V47, P4, DOI 10.1093/geront/47.1.4
NR 17
TC 21
Z9 22
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2016
VL 30
IS 3
BP 413
EP 421
DI 10.1038/eye.2015.235
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI4SV
UT WOS:000373490500013
PM 26611848
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Menke, MN
   Dabov, S
   Sturm, V
AF Menke, M. N.
   Dabov, S.
   Sturm, V.
TI Features of age-related macular degeneration assessed with
   three-dimensional Fourier-domain optical coherence tomography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; ULTRAHIGH-RESOLUTION; CHOROIDAL
   NEOVASCULARIZATION; HIGH-SPEED; PHOTODYNAMIC THERAPY;
   CLINICAL-APPLICATION; BEVACIZUMAB; OCT
AB Background/aims: Age-related macular degeneration (AMD) is among the leading causes of severe visual loss in individuals over 60 years old. Retinal changes associated with AMD were previously studied by time-domain optical coherence tomography (OCT). Recently, Fourier-domain OCT (FD-OCT) has been introduced. FD-OCT provides increased scan resolution and scanning speed, and generates three-dimensional (3D) OCT images. The purpose of this study was to demonstrate features of AMD assessed with high-density scanning 3D-FD-OCT (Topcon 3D-OCT1000).
   Methods: The study was designed as a prospective, observational case series. Five patients with typical morphological changes due to AMD were chosen based on funduscopic findings. Eyes with non-exudative-and exudative AMD were included. 3D-FD-OCT images were obtained, and typical morphological changes associated with AMD were presented.
   Results: FD-OCT provided detailed 3D-images of retinal structure. In addition, FD-OCT showed improved retinal coverage and image quality. FD-OCT B-scan imaging identified typical retinal changes associated with AMD. In addition, FD-OCT imaging revealed information about the extent and the 3D shape of retinal lesions.
   Conclusion: 3D-FD-OCT imaging is useful for diagnosing and following patients with AMD. In addition, 3D-FD-OCT provided information about the extent and 3D shape of retinal pathologies and showed improved retinal coverage.
C1 [Menke, M. N.; Sturm, V.] Univ Zurich, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Dabov, S.] Univ Munster, Sch Med, Munster, Germany.
C3 University of Zurich; University of Munster
RP Menke, MN (通讯作者)，Univ Zurich, Dept Ophthalmol, Frauenklinikstr 24, CH-8091 Zurich, Switzerland.
EM marcel.menke@gmail.com
OI Menke, Marcel/0000-0002-6561-6178
CR Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Eter N, 2004, OPHTHALMOLOGE, V101, P794, DOI 10.1007/s0034-004-1052-y
   Evans J., 1995, STUDIES MED POPULATI, V57
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Menke MN, 2005, OPHTHAL SURG LAS IM, V36, P310, DOI 10.3928/1542-8877-20050701-10
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Spraul CW, 1998, KLIN MONATSBL AUGENH, V212, P141, DOI 10.1055/s-2008-1034850
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   Wojtkowski M, 2005, 2005 Conference on Lasers & Electro-Optics (CLEO), Vols 1-3, P2058
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
NR 25
TC 18
Z9 19
U1 1
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2008
VL 92
IS 11
BP 1492
EP 1497
DI 10.1136/bjo.2008.141242
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 364MZ
UT WOS:000260341100014
PM 18703554
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lee, H
   Choi, AJ
   Kang, GY
   Park, HS
   Kim, HC
   Lim, HJ
   Chung, H
AF Lee, Hyungwoo
   Choi, Ae Jin
   Kang, Gum-Yong
   Park, Hyung Soon
   Kim, Hyung Chan
   Lim, Hyunjung Jade
   Chung, Hyewon
TI Increased 26S proteasome non-ATPase regulatory subunit 1 in the aqueous
   humor of patients with age-related macular degeneration
SO BMB REPORTS
LA English
DT Article
DE Age-related macular degeneration; Aqueous humor; Mass spectrometry;
   Proteomics; Ubiquitin-proteasome system
ID PROTEOMIC ANALYSIS; OXIDATIVE-STRESS; 20S PROTEASOME; DAMAGE
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the world. Evidence indicates that the suppression of the ubiquitin-proteasome system (UPS) contributes to the accumulation of toxic proteins and inflammation in retinal pigment epithelium (RPE), the functional abnormalities and/or the degeneration of which are believed to be the initiators and major pathologies of AMD. To identify new protein associations with the altered UPS in AMD, we used LC-ESI-MS/ MS to perform a proteomic analysis of the aqueous humor (AH) of AMD patients and matched control subjects. Six UPS-related proteins were present in the AH of the patients and control subjects. Four of the proteins, including 26S proteasome non-ATPase regulatory subunit 1 (Rpn2), were increased in patients, according to semi-quantitative proteomic profiling. An LC-MRM assay revealed a significant increase of Rpn2 in 15 AMD patients compared to the control subjects, suggesting that this protein could be a biomarker for AMD.
C1 [Lee, Hyungwoo; Choi, Ae Jin; Kim, Hyung Chan; Chung, Hyewon] Konkuk Univ, Sch Med, Dept Ophthalmol, Seoul 143729, South Korea.
   [Kang, Gum-Yong; Park, Hyung Soon] Diatech Korea Co Ltd, Seoul 138826, South Korea.
   [Lim, Hyunjung Jade] Konkuk Univ, Dept Biomed Sci & Technol, Seoul 143729, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Konkuk University
RP Chung, H (通讯作者)，Konkuk Univ, Sch Med, Dept Ophthalmol, Seoul 143729, South Korea.
EM hchung@kuh.ac.kr
RI Lim, Hyunjung J/D-5343-2011
OI Lim, Hyunjung J/0000-0003-2191-666X; Park, Hyung
   Soon/0000-0003-0558-2874
FU Konkuk University Medical Center Research Grant
FX This work was supported by Konkuk University Medical Center Research
   Grant 2012.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1291, DOI 10.2741/3789
   Brooks WS, 2008, J BIOL CHEM, V283, P22304, DOI 10.1074/jbc.M803238200
   Campello L, 2013, MOL NEUROBIOL, V47, P790, DOI 10.1007/s12035-012-8391-5
   Chen R, 2010, CELL RES, V20, P802, DOI 10.1038/cr.2010.41
   Chowdhury UR, 2010, INVEST OPHTH VIS SCI, V51, P4921, DOI 10.1167/iovs.10-5531
   Duan XM, 2008, MOL VIS, V14, P370
   Endo A, 2009, J BIOL CHEM, V284, P27918, DOI 10.1074/jbc.M109.037218
   Escoffier P, 2010, J PROTEOME RES, V9, P789, DOI 10.1021/pr9006602
   Fautsch MP, 2006, INVEST OPHTH VIS SCI, V47, P4181, DOI 10.1167/iovs.06-0830
   Fernandes AF, 2006, EXP EYE RES, V83, P1472, DOI 10.1016/j.exer.2006.07.024
   Fernandes AF, 2009, MOL BIOL CELL, V20, P3690, DOI 10.1091/mbc.E08-10-1068
   Funding M, 2005, ACTA OPHTHALMOL SCAN, V83, P31, DOI 10.1111/j.1600-0420.2005.00381.x
   Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194
   Kim MS, 2011, J CELL BIOCHEM, V112, P498, DOI 10.1002/jcb.22940
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Macknight ADC, 2000, CLIN EXP PHARMACOL P, V27, P100, DOI 10.1046/j.1440-1681.2000.03208.x
   Motegi A, 2006, J CELL BIOL, V175, P703, DOI 10.1083/jcb.200606145
   Muether PS, 2013, RETINA-J RET VIT DIS, V33, P1809, DOI 10.1097/IAE.0b013e318285cd9e
   Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503
   Pickering AM, 2010, BIOCHEM J, V432, P585, DOI 10.1042/BJ20100878
   Ramakrishna S, 2011, J BIOL CHEM, V286, P10505, DOI 10.1074/jbc.M110.162321
   Richardson MR, 2009, MOL VIS, V15, P2740
   Sakamoto T, 2001, GRAEF ARCH CLIN EXP, V239, P865, DOI 10.1007/s004170100373
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Shang F, 2011, FREE RADICAL BIO MED, V51, P5, DOI 10.1016/j.freeradbiomed.2011.03.031
   Sorokin AV, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1411, DOI 10.1134/S000629790913001X
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Wunderlich K, 2002, MOL VIS, V8, P431
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P3622, DOI 10.1167/iovs.07-1559
NR 33
TC 8
Z9 9
U1 0
U2 7
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635-4 , YEOKSAM-DONG,
   KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA
SN 1976-6696
EI 1976-670X
J9 BMB REP
JI BMB Rep.
PD MAY 31
PY 2014
VL 47
IS 5
BP 292
EP 297
DI 10.5483/BMBRep.2014.47.5.193
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AI4KX
UT WOS:000336835300009
PM 24286321
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Habibi, I
   Sfar, I
   Kort, F
   Bouraoui, R
   Chebil, A
   Limaiem, R
   Ayed, S
   Ben Abdallah, T
   El Matri, L
   Gorgi, Y
AF Habibi, Imen
   Sfar, Imen
   Kort, Fedra
   Bouraoui, Rim
   Chebil, Ahmed
   Limaiem, Rim
   Ayed, Saloua
   Ben Abdallah, Taieb
   El Matri, Leila
   Gorgi, Yousr
TI Complement Component C3 Variant (R102G) and the Risk of Neovascular
   Age-Related Macular Degeneration in a Tunisian Population
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE AMD; C3; complement
ID ASSOCIATION; POLYMORPHISMS
AB Purpose To explore the association between the polymorphism (S/F) p.R102G in the complement component 3 (C3) gene and age-related macular degeneration (AMD) in a Tunisian population.
   Methods The molecular study was performed by polymerase chain reaction using sequence-specific primers (PCR-SSP) in 207 control subjects free of any eye disease (fundus normal) and 145 patients with exudative AMD. The CH50 activity and quantification of C3 and C4 have been made by technical home method and nephelometry, respectively.
   Results The prevalence of C3 GG genotype polymorphism was significantly higher in AMD patients compared to controls (OR: 2.41, IC 95% [1.90-3.05], p = 0.0007). However, no correlation was found between this allelic variant and the type of neovascularization. Similarly, there is no association between this polymorphism and the presence of functional and/or quantitative hypocomplementemia.
   Conclusions The C3 GG genotype of the gene could be a susceptibility factor for AMD in the Tunisian population. However, it does not seem to influence the clinical profile of the disease.
C1 [Habibi, Imen; Sfar, Imen; Ayed, Saloua; Ben Abdallah, Taieb; Gorgi, Yousr] Univ Tunis El Manar, Charles Nicolle Hosp, Res Lab Renal Transplantat & Immunopathol LR03SP0, Tunis, Tunisia.
   [Habibi, Imen; Kort, Fedra; Bouraoui, Rim; Chebil, Ahmed; Limaiem, Rim; El Matri, Leila] Hedi Rais Inst Ophthalmol, Dept Ophthalmol B, Res Lab Oculogenet LR14SP01, Tunis, Tunisia.
C3 Universite de Tunis-El-Manar; Hopital Charles Nicolle; Universite de
   Tunis-El-Manar; Institut Hedi Raies d'ophtalmologie de Tunis
RP Gorgi, Y (通讯作者)，Charles Nicolle Hosp, Res Lab Renal Transplantat & Immunopathol LR03SP0, Blvd 9 Avril 1938, Tunis 1006, Tunisia.
EM gorgi.yousr@gmail.com
FU Tunisian Immunology Research Laboratory [LR03SP01];
   Oculo-genetic-research Laboratory [LR14SP01]
FX This work was supported by the Tunisian Immunology Research Laboratory
   (LR03SP01) and the Oculo-genetic-research Laboratory (LR14SP01). Tunis
   El Manar, University. Tunisia.
CR Bonyadi M, 2017, OPHTHALMIC GENET, V38, P61, DOI 10.3109/13816810.2015.1126612
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu QQ, 2015, GENE, V561, P249, DOI 10.1016/j.gene.2015.02.039
NR 10
TC 3
Z9 3
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2017
VL 234
IS 4
BP 478
EP 482
DI 10.1055/s-0043-104419
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV8BZ
UT WOS:000402006600016
PM 28470643
DA 2022-11-30
ER

PT J
AU Tian, J
   Qin, XY
   Fang, K
   Chen, Q
   Hou, J
   Li, J
   Yu, WZ
   Chen, DF
   Hu, YH
   Li, XX
AF Tian, Jun
   Qin, Xueying
   Fang, Kai
   Chen, Qing
   Hou, Jing
   Li, Juan
   Yu, Wenzhen
   Chen, Dafang
   Hu, Yonghua
   Li, Xiaoxin
TI Association of genetic polymorphisms with response to bevacizumab for
   neovascular age-related macular degeneration in the Chinese population
SO PHARMACOGENOMICS
LA English
DT Article
DE ARMS2; bevacizumab; CFH; HTRA1; neovascular age-related; macular
   degeneration; pharmacogenetics
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; HTRA1 PROMOTER
   POLYMORPHISM; INTRAVITREAL BEVACIZUMAB; RISK; RANIBIZUMAB; VARIANT;
   MULTICENTER; SERPING1; SMOKING
AB Aims: To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). Materials & methods: This was a multicenter prospective study. One hundred and forty four patients with neovascular AMD treated with bevacizumab were recruited from 13 centers. Twelve SNPs were genotyped using Sequenom. Visual acuity score (VAS), central retinal thickness and maximum thickness of lesion were measured at each visit. Results: For the CFH rs800292 polymorphism, mean VAS changes were 4.4, 8.7 and 15.5 letters in the CC, CT and TT genotype carriers (p = 0.009). For ARMS2 rs10490924, mean VAS changes were 3.6, 12.1 and 9.6 letters for the TT, TG and GG genotypes (p = 0.001). For HTRA1 rs11200638, mean VAS changes were 3.6, 12.3 and 9.6 letters for the AA, AG and GG genotypes (p < 0.001). Conclusion: CFH, ARMS2 and HTRA1 genotypes may influence patient response to treatment with intravitreal bevacizumab for neovascular AMD.
C1 [Tian, Jun; Qin, Xueying; Fang, Kai; Chen, Dafang; Hu, Yonghua] Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China.
   [Chen, Qing] Third Mil Med Univ, Prevent Med Coll, Dept Hyg Toxicol, Changqing, Peoples R China.
   [Hou, Jing; Yu, Wenzhen; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Hou, Jing; Yu, Wenzhen; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Li, Juan] Beijing Ctr Dis Control & Prevent, Beijing, Peoples R China.
C3 Peking University; Army Medical University; Peking University
RP Hu, YH (通讯作者)，Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China.
EM yhhu@bjmu.edu.cn
RI 陈, 卿/Q-5601-2019
OI 陈, 卿/0000-0003-4108-7977
FU Ministry of Science and Technology of the People's Republic of China,
   Beijing, China [2006BAI02B05]
FX This research was supported by the National Key Technology Research and
   Development Program in the 11th Five-Year Plan from The Ministry of
   Science and Technology of the People's Republic of China, Beijing, China
   (2006BAI02B05). The finding organization had no role in the design or
   conduct of this research. The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR [Anonymous], BEVACIZUMAB NEOVASCU
   [Anonymous], PLINK WHOLE GENOME A
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shastry B, 2010, GRAEF ARCH CLIN EXP, V248, P1057, DOI 10.1007/s00417-010-1333-x
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Wu LC, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-10
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 36
TC 37
Z9 42
U1 0
U2 7
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD MAY
PY 2012
VL 13
IS 7
BP 779
EP 787
DI 10.2217/PGS.12.53
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 937WQ
UT WOS:000303694800015
PM 22594510
DA 2022-11-30
ER

PT J
AU Vazquez-Alfageme, C
   Nicholson, L
   Hamilton, RD
   Patel, PJ
AF Vazquez-Alfageme, Clara
   Nicholson, Luke
   Hamilton, Robin D.
   Patel, Praveen J.
TI INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT
   EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium tears;
   intravitreal anti-VEGF
ID ANTI-VEGF THERAPY; RANIBIZUMAB; DETACHMENT; AFLIBERCEPT; INJECTION
AB Purpose: To report the incidence of retinal pigment epithelium tears in eyes treated with aflibercept for neovascular age-related macular degeneration and compare it with ranibizumab, and to describe long-term visual outcomes of retinal pigment epithelium tears after intensive anti-vascular endothelial growth factor treatment.
   Methods: Retrospective analysis of clinical charts, spectral domain optical coherence tomography and fundus fluorescein angiography imaging of consecutive naive patients treated with intravitreal aflibercept or ranibizumab for neovascular age-related macular degeneration.
   Results: Eight hundred consecutive eyes were included in the study (300 treated with ranibizumab and 500 with aflibercept) with 34.0 +/- 9.1 months of follow-up. The incidence of tears in the aflibercept group was 3.2% and 2.3% after ranibizumab (P = 0.52). Twenty-nine eyes with retinal pigment epithelium tears were followed for a mean of 30.76 months. Visual acuity at baseline was 20/100 (50.7 +/- 19.3 Early Treatment Diabetic Retinopathy Study letters) and 20/200 (36.1 +/- 26.1 Early Treatment Diabetic Retinopathy Study letters) at the end of follow-up. The mean number of injection was 7.3 at 12 months and 13.9 +/- 8.1 at the end of the study. The number of injections positively correlated with the final visual outcome.
   Conclusion: There was a low rate of retinal pigment epithelium tears after aflibercept injections, similar to ranibizumab. The correlation between the number of anti-vascular endothelial growth factors received and visual outcomes supports the need for continuing anti-vascular endothelial growth factor therapy.
C1 [Vazquez-Alfageme, Clara; Nicholson, Luke; Hamilton, Robin D.; Patel, Praveen J.] Univ Coll London UCL Inst Ophthalmol, Natl Inst Hlth & Res NIHR Biomed Ctr, Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Vazquez-Alfageme, C (通讯作者)，Univ Coll London UCL Inst Ophthalmol, Natl Inst Hlth & Res NIHR Biomed Ctr, Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM Clara.alfageme@outlook.com
OI Nicholson, Luke/0000-0001-6685-4402
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Moorfields Eye Hospital NHS Foundation Trust; University
   College London Institute of Ophthalmology
FX Supported by the National Institute for Health Research (NIHR)
   Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust and University College London Institute of
   Ophthalmology. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR or the Department of Health.
CR Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Ishida Y, 2004, RETINA-J RET VIT DIS, V24, P633, DOI 10.1097/00006982-200408000-00028
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P1083, DOI 10.1097/IAE.0b013e318207d1a3
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sato T, 2015, OSLI RETINA, V46, P87, DOI 10.3928/23258160-20150101-16
   Shin JY, 2015, GRAEF ARCH CLIN EXP, V253, P2151, DOI 10.1007/s00417-015-2977-3
NR 18
TC 8
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2019
VL 39
IS 4
BP 664
EP 669
DI 10.1097/IAE.0000000000002029
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4TY
UT WOS:000480744900005
PM 29324593
DA 2022-11-30
ER

PT J
AU Wygnanski-Jaffe, T
   Desatnik, H
   Alhalel, A
   Goldstein, M
   Lowenstein, A
   Moisseiev, J
AF Wygnanski-Jaffe, Tamara
   Desatnik, Howard
   Alhalel, Amir
   Goldstein, Michaela
   Lowenstein, Anat
   Moisseiev, Joseph
TI ICG angiography-guided photodynamic therapy for large pigment epithelial
   detachments in age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID INDOCYANINE-GREEN VIDEOANGIOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   LASER PHOTOCOAGULATION; NATURAL-HISTORY; SEROUS DETACHMENTS
AB BACKGROUND AND OBJECTIVE: To evaluate the role of photodynamic therapy (PDT) in the management of vascularized pigment epithelial detachment in age-related macular degeneration (AMD) when the pigment epithelial detachment is the predominant component of the neovascular complex.
   PATIENTS AND METHODS: Seventeen eyes of 17 patients underwent indocyanine green angiography-guided PDT and had at least 6 months of follow-up. Data retrieved included visual acuity and angiographic features prior to the treatment, number of PDT sessions, visual acuity, angiographic outcomes at the end of the follow-up, length of follow-up, and status of the fellow eye.
   RESULTS: Eleven women and 6 men were included in the series, with an average age of 77 years and a mean follow-up time of 11 months. Six (35%) of the patients lost less than 3 lines of visual acuity, 6 (35%) lost between 3 and 6 lines, and 5 (30%) lost 6 or more lines. Angiographic outcomes were categorized as failures in 14 (82%) of the treated eyes and successful in 3 (17%) eyes.
   CONCLUSIONS: In 82% of the eyes, PDT failed to flatten the pigment epithelial detachment or prevent growth of the choroidal neovascular membrane. Visual acuity outcomes correlated poorly with angiographic outcomes. PDT does not seem to improve the prognosis of eyes with large pigment epithelial detachments in AMD.
C1 Chaim Sheba Med Ctr, Goldschleger Eye Inst, Dept Ophthalmol, IL-52621 Tel Hashomer, Israel.
   Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
   Zriffin Med Ctr, Dept Ophthalmol, Beer Yaagov, Israel.
C3 Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of
   Medicine; Tel Aviv Sourasky Medical Center
RP Moisseiev, J (通讯作者)，Chaim Sheba Med Ctr, Goldschleger Eye Inst, Dept Ophthalmol, IL-52621 Tel Hashomer, Israel.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   Baumal CR, 1997, OPHTHALMOLOGY, V104, P761, DOI 10.1016/S0161-6420(97)30236-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brancato R, 2000, RETINA-J RET VIT DIS, V20, P134, DOI 10.1097/00006982-200003000-00004
   BRAUNSTEIN RA, 1979, AM J OPHTHALMOL, V88, P652, DOI 10.1016/0002-9394(79)90660-3
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1992, ARCH OPHTHALMOL-CHIC, V110, P761
   Lim JI, 1997, AM J OPHTHALMOL, V123, P524, DOI 10.1016/S0002-9394(14)70178-3
   LIM JI, 1995, AM J OPHTHALMOL, V120, P75, DOI 10.1016/S0002-9394(14)73761-4
   MAGUIRE JI, 1990, AM J OPHTHALMOL, V109, P523, DOI 10.1016/S0002-9394(14)70681-6
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   SCHATZ H, 1973, ARCH OPHTHALMOL-CHIC, V90, P183, DOI 10.1001/archopht.1973.01000050185003
   SINGERMAN LJ, 1988, RETINA-J RET VIT DIS, V8, P115, DOI 10.1097/00006982-198808020-00006
   SINGERMAN LJ, 1989, GRAEF ARCH CLIN EXP, V227, P501, DOI 10.1007/BF02169440
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   SORENSON JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P473, DOI 10.1001/archopht.1994.01090160049021
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
NR 30
TC 14
Z9 14
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2006
VL 37
IS 5
BP 358
EP 363
DI 10.3928/15428877-20060901-01
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 087BE
UT WOS:000240716400001
PM 17017194
DA 2022-11-30
ER

PT J
AU Zhou, T
   Hu, Y
   Chen, Y
   Zhou, KK
   Zhang, B
   Gao, GQ
   Ma, JX
AF Zhou, Ti
   Hu, Yang
   Chen, Ying
   Zhou, Kevin K.
   Zhang, Bin
   Gao, Guoquan
   Ma, Jian-xing
TI The Pathogenic Role of the Canonical Wnt Pathway in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DENSITY LIPOPROTEIN RECEPTOR; FACTOR-H
   POLYMORPHISM; OXIDATIVE STRESS; BETA-CATENIN; ADHESION MOLECULES;
   SIGNALING PATHWAY; INDUCED APOPTOSIS; MOUSE MODEL; INFLAMMATION
AB PURPOSE. The authors' previous studies showed that the Wnt signaling pathway is activated in the retinas and retinal pigment epithelia of animal models of age-related macular degeneration (AMD) and diabetic retinopathy (DR). The purpose of this study was to investigate the role of the canonical Wnt pathway in pathogenesis of these diseases.
   METHODS. The Wnt pathway was activated using the Wnt3a-conditioned medium and adenovirus expressing a constitutively active mutant of beta-catenin (Ad-S37A) in ARPE19, a cell line derived from human RPE. Ad-S37A was injected into the vitreous of normal rats to activate the Wnt pathway in the retina. Accumulation of beta-catenin was determined by Western blot analysis, and its nuclear translocation was revealed by immunocytochemistry. Inflammatory factors were quantified by Western blot analysis and ELISA. Oxidative stress was determined by measuring intracellular reactive oxygen species (ROS) generation and nitrotyrosine levels.
   RESULTS. The Wnt3a-conditioned medium and Ad-S37A both increased beta-catenin levels and its nuclear translocation in ARPE19 cells, suggesting activation of the canonical Wnt pathway. Activation of the Wnt pathway significantly upregulated the expression of VEGF, NF-kappa B, and TNF-alpha. Further, Ad-S37A induced ROS generation in a dose-dependent manner. Wnt3a also induced a twofold increase of ROS generation. Intravitreal injection of Ad-S37A upregulated the expression of VEGF, ICAM-1, NF-kappa B, and TNF-alpha and increased protein nitrotyrosine levels in the retinas of normal rats.
   CONCLUSIONS. Activation of the canonical Wnt pathway is sufficient to induce retinal inflammation and oxidative stress and plays a pathogenic role in AMD and DR. (Invest Ophthalmol Vis Sci. 2010;51:4371-4379) DOI:10.1167/iovs.09-4278
C1 [Zhou, Ti; Hu, Yang; Chen, Ying; Zhou, Kevin K.; Zhang, Bin; Ma, Jian-xing] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Zhou, Ti; Gao, Guoquan] Sun Yat Sen Univ, Zhongshan Med Sch, Dept Biochem, Guangzhou 510275, Guangdong, Peoples R China.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; Sun Yat Sen University
RP Ma, JX (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Med, Dept Cell Biol, 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.
EM gaogq@mail.sysu.edu.cn; jian-xing-ma@ouhsc.edu
RI Zhou, Kelu/C-1322-2017
OI Zhou, Kelu/0000-0001-6751-942X
FU National Institutes of Health [EY012231, EY019309, EY018659]; National
   Center for Research Resources [P20RR024215]; Oklahoma Center for the
   Advancement of Science and Technology and American Diabetes Association;
   NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR024215] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY019309, R01EY018659, R01EY012231]
   Funding Source: NIH RePORTER
FX Supported by National Institutes of Health Grants EY012231, EY019309,
   EY018659, and P20RR024215 from the National Center for Research
   Resources and by grants from the Oklahoma Center for the Advancement of
   Science and Technology and American Diabetes Association.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barile GR, 1999, CURR EYE RES, V19, P219, DOI 10.1076/ceyr.19.3.219.5314
   Bjorklund P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-53
   Bjorklund P, 2007, J CLIN ENDOCR METAB, V92, P338, DOI 10.1210/jc.2006-1197
   Chan CM, 2008, MOL VIS, V14, P2528
   Chang CK, 2004, ANN THORAC SURG, V77, P1222, DOI 10.1016/j.athoracsur.2003.09.128
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2009, AM J PATHOL, V175, P2676, DOI 10.2353/ajpath.2009.080945
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   DUGUID IGM, 1992, CURR EYE RES, V11, P153, DOI 10.3109/02713689208999526
   Easwaran V, 2003, CANCER RES, V63, P3145
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eleuteri E, 2009, FRONT BIOSCI-LANDMRK, V14, P2230, DOI 10.2741/3375
   ELNER SG, 1992, LAB INVEST, V66, P200
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujimori M, 2001, CANCER RES, V61, P6656
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Matsumoto K, 2002, DIABETIC MED, V19, P822, DOI 10.1046/j.1464-5491.2002.00799.x
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak Mariusz, 2005, Klin Oczna, V107, P537
   Nowak Michal, 2005, Klin Oczna, V107, P715
   Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Onorato JM, 1998, ANN NY ACAD SCI, V854, P277, DOI 10.1111/j.1749-6632.1998.tb09909.x
   PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schutt F, 2007, KLIN MONATSBL AUGENH, V224, P580, DOI 10.1055/s-2007-963339
   Takahashi A, 2004, BRAIN RES BULL, V62, P497, DOI 10.1016/j.brainresbull.2003.07.009
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Wylegala Edward, 2007, Klin Oczna, V109, P94
   Wylegala Edward, 2007, Klin Oczna, V109, P97
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Ye JP, 2003, AM J PHYSIOL-LUNG C, V284, pL386, DOI 10.1152/ajplung.00134.2002
   Zhang XB, 2001, CANCER RES, V61, P6050
NR 72
TC 78
Z9 82
U1 0
U2 15
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2010
VL 51
IS 9
BP 4371
EP 4379
DI 10.1167/iovs.09-4278
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 645YS
UT WOS:000281502700004
PM 19875668
OA Green Published
DA 2022-11-30
ER

PT J
AU Fong, DS
   Custis, P
   Howes, J
   Hsu, JW
AF Fong, Donald S.
   Custis, Peter
   Howes, Jennifer
   Hsu, Jin-Wen
TI Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular
   Degeneration A Multicenter, Retrospective Study
SO OPHTHALMOLOGY
LA English
DT Article
ID AVASTIN; VERTEPORFIN; INJECTION
AB Objective: To compare visual acuity (VA) outcomes after bevacizumab or ranibizumab treatment for AMD.
   Design: Comparative, retrospective case series.
   Participants: We followed 452 patients in a retrospective study of exudative AMD treated with anti-vascular endothelial growth factor drugs; 324 patients were treated with bevacizumab and 128 patients with ranibizumab.
   Methods: All treatment-nave patients who received either bevacizumab or ranibizumab were followed for 1 year. Baseline characteristics and VA were recorded using standard descriptive statistics.
   Main Outcome Measures: Visual acuity.
   Results: At 12 months, the distribution of VA improved in both groups with 22.9% of bevacizumab and 25.0% of ranibizumab attaining >= 20/40. Improvement in vision was observed in 27.3% of the bevacizumab group and 20.2% of the ranibizumab group. The mean number of injections at 12 months was 4.4 for bevacizumab and 6.2 for ranibizumab. There were 8 (2%) deaths in the bevacizumab group and 4 (3%) in the ranibizumab group. Two patients developed endophthalmitis in the bevacizumab group and the ranibizumab group. The bevacizumab group had slightly worse acuity at baseline, but both groups showed improvement and stability of vision over time.
   Conclusions: Both treatments seem to be effective in stabilizing VA loss. There was no difference in VA outcome between the 2 treatment groups. Because the study is a nonrandomized comparison, selection bias could mask a true treatment difference. Results from the Comparison of the Age-related Macular Degeneration Treatment Trials will provide more definitive information about the comparative effectiveness of these drugs.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2010; 117: 298-302 (C) 2010 by the American Academy of Ophthalmology.
C1 [Fong, Donald S.; Howes, Jennifer; Hsu, Jin-Wen] So Calif Permanente Med Grp, Dept Res & Evaluat, Pasadena, CA 91101 USA.
   [Fong, Donald S.] So Calif Permanente Med Grp, Dept Ophthalmol, Baldwin Pk, CA USA.
   [Custis, Peter] So Calif Permanente Med Grp, Dept Ophthalmol, San Diego, CA 92120 USA.
C3 Kaiser Permanente; Southern California Permanente Medical Group (SCPMG);
   Permanente Medical Groups; Kaiser Permanente; Southern California
   Permanente Medical Group (SCPMG); Permanente Medical Groups; Kaiser
   Permanente; Southern California Permanente Medical Group (SCPMG);
   Permanente Medical Groups
RP Fong, DS (通讯作者)，So Calif Permanente Med Grp, Dept Res & Evaluat, 100 S Los Robles, Pasadena, CA 91101 USA.
EM donald.s.fong@kp.org
FU Southern California Permanente Medical Group
FX Funded by the Southern California Permanente Medical Group.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen FM, 1998, AM J EPIDEMIOL, V148, P1212, DOI 10.1093/oxfordjournals.aje.a009611
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 11
TC 73
Z9 74
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2010
VL 117
IS 2
BP 298
EP 302
DI 10.1016/j.ophtha.2009.07.023
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 555RB
UT WOS:000274530300016
PM 19969368
DA 2022-11-30
ER

PT J
AU Coscas, F
   Coscas, G
   Souied, E
   Tick, S
   Soubrane, G
AF Coscas, Florence
   Coscas, Gabriel
   Souied, Eric
   Tick, Sarah
   Soubrane, Gisele
TI Optical coherence tomography identification of occult choroidal
   neovascularization in age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; GUIDED LASER PHOTOCOAGULATION;
   FLUORESCEIN ANGIOGRAPHY; ULTRAHIGH-RESOLUTION; VESSELS; SIGN
AB PURPOSE: To evaluate and describe the various optical coherence tomography (OCT) features of occult choroidal neovascularization (CNV) in age-related macular degeneration (AMD) at the time of diagnosis.
   DESIGN: Prospective, consecutive, observational case series.
   METHODS: One hundred and fifty-three eyes of 130 consecutive patients with subfoveal occult CNV diagnosed on scanning laser ophthalmoscope (SLO) fluorescein angiography (FA) and SLO indocyanine green angiography (ICGA) were evaluated with OCT. The diagnostic criteria for occult CNV on angiography were heterogeneous hyperfluorescence with late leakage in the macular region associated with pigment epithelial detachment (PED), stippled hyperfluorescent dots, and signs of deterioration. OCT findings were evaluated and described.
   RESULTS: A PED was observed on OCT in 98% (150 eyes) either as a limited retinal pigment epithelium (RPE) elevation (54 eyes [35.3%1) or a complete detachment (96 eyes [62.7%]). Occult CNV corresponded to zones of hyperreflectivity in contact with the RPE band and was detected in 62.7% of eyes. In fibrovascular PED (63 eyes [65.5%]), the elevated RPE was highlighted posteriorly by a moderately reflective band overlying a hyporeflective cavity. In serous PED, the cavity remained optically empty. The RPE in the detached zone showed changes such as fragmentation (13 7 eyes [89.5 %]). OCT also showed intraretinal (122 eyes [79.7%]) and subretinal (64 eyes [41.8%]) fluid.
   CONCLUSIONS: Analysis of the various OCT features observed in this study confirms the polymorphic nature of occult CNV in AMD, their exudative reactions, the almost constant presence of PED, and the different changes in the RPE band. OCT examination, therefore, provides valuable data to confirm the features of subepithelial occult CNV.
C1 Univ Paris 12, Creteil Eye Clin, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Coscas, F (通讯作者)，Univ Paris 12, Serv Hosp, Practicien Hosp, 40 Ave Verdun, F-94000 Creteil, France.
EM coscas.f@wanadoo.fr
CR Ahlers C, 2005, EUR J OPHTHALMOL, V15, P774, DOI 10.1177/112067210501500619
   Baumal CR, 1997, OPHTHALMOLOGY, V104, P761, DOI 10.1016/S0161-6420(97)30236-X
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Chan A, 2005, ARCH OPHTHALMOL-CHIC, V123, P939, DOI 10.1001/archopht.123.7.939
   Coscas G, 2004, J FR OPHTALMOL, V27, P81, DOI 10.1016/S0181-5512(04)96099-8
   COSCAS G, 1991, 1991 SFO, P487
   COSCAS G, 2004, J FR OPHTHALMOL, V27
   COSFAS G, 2005, ICG ANGIOGRAPHY OCT, P383
   Costa RA, 2005, AM J OPHTHALMOL, V140, P107, DOI 10.1016/j.ajo.2005.02.042
   Desatnik H, 2000, RETINA-J RET VIT DIS, V20, P143, DOI 10.1097/00006982-200003000-00005
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Guyer DR, 1996, ARCH OPHTHALMOL-CHIC, V114, P693, DOI 10.1001/archopht.1996.01100130685008
   Hee MR, 2005, AM J OPHTHALMOL, V139, P154, DOI 10.1016/j.ajo.2004.08.066
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   LUMBROSO B, 2006, OCT SLO FACE OPTICAL, P110
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   PULIAFITO CA, 1996, OCULAR COHERENT TOMO, P74
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   ROSEN RB, 2003, RETINA OPTIC NERVE I, P119
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   SCHUMAN JS, 2004, OPTICAL COHERENCE TO, P768
   Shakoor A, 2006, RETINA-J RET VIT DIS, V26, P44, DOI 10.1097/00006982-200601000-00008
   Soubrane G, 1987, Bull Soc Ophtalmol Fr, V87, P1051
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   VANVELHOVEN ME, 2006, ARCH CLIN EXP OPHTHA, V244, P1119
NR 31
TC 122
Z9 126
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2007
VL 144
IS 4
BP 592
EP 599
DI 10.1016/j.ajo.2007.06.014
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 217GW
UT WOS:000249937400018
PM 17698019
DA 2022-11-30
ER

PT J
AU Park, KH
   Fridley, BL
   Ryu, EJ
   Tosakulwong, N
   Edwards, AO
AF Park, Kyu Hyung
   Fridley, Brooke L.
   Ryu, Euijung
   Tosakulwong, Nirubol
   Edwards, Albert O.
TI Complement Component 3 (C3) Haplotypes and Risk of Advanced Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MOLECULAR ANALYSIS; ASSOCIATION; ALLOTYPES;
   LINKAGE; VARIANT; LOC387715/ARMS2; MACULOPATHY; INCREASES; DRUSEN
AB PURPOSE. Nonsynonymous coding single nucleotide polymorphisms (nsSNPs) in complement component 3 (C3) alter the risk of age-related macular degeneration (AMD). This was a study of the effect of haplotypes across C3 on AMD risk.
   METHODS. Nine SNPs tagging haplotypes across C3 were genotyped on 738 subjects at the Mayo Clinic. Haplotype analyses were performed with and without conditioning on individual SNPs. Replication studies were performed using 1541 subjects from the age-related eye disease study (AREDS).
   RESULTS. Two nsSNPs located 5125 bp apart in the 5' end of C3 showed the highest association (rs1047286 or P314L, P=9.2E-05; rs2230199 or R102G, P=4.1E-05) with AMD. The minor alleles of both SNPs tagged a single risk haplotype. The effects of the two nsSNPs could not be distinguished due to high linkage disequilibrium. The risk SNPs preferentially promoted the development of advanced AMD relative to early AMD in both the Mayo and AREDS subjects. Haplotypes in the 3' end of the C3 locus were associated with AMD in both the Mayo and AREDS subjects. The effect persisted after conditioning on the nsSNPs only in the Mayo subjects. No interaction was found between rs2230199 and smoking or other AMD loci.
   CONCLUSIONS. nsSNPs in C3 increased the risk of developing AMD 1.8-fold for 1 risk allele or 2.4-fold for two risk alleles and were preferentially associated with advanced AMD. Further study is needed to determine whether haplotypes in the 3' end of C3 have an independent association with AMD. (Invest Ophthalmol Vis Sci. 2009;50:3386-3393) DOI:10.1167/iovs.08-3231
C1 [Park, Kyu Hyung; Tosakulwong, Nirubol; Edwards, Albert O.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Fridley, Brooke L.; Ryu, Euijung] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic
RP Edwards, AO (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM edwardslab@mayo.edu
RI Fridley, Brooke L/D-8315-2015; Park, Kyu Hyung/J-5481-2012
OI Fridley, Brooke L/0000-0001-7739-7956; 
FU National Eye Institute [EY014467]; Foundation Fighting Blindness, Owing
   Mills, MD; American Health Assistance Foundation, Clarksburg, MD;
   Research to Prevent Blindness, New York, NY; Mayo Clinic Foundation;
   Seoul National University Bundang Hospital; NATIONAL EYE INSTITUTE
   [R01EY014467] Funding Source: NIH RePORTER
FX Supported by National Eye Institute Grant EY014467, the Foundation
   Fighting Blindness, Owing Mills, MD; the American Health Assistance
   Foundation, Clarksburg, MD; unrestricted departmental grants from
   Research to Prevent Blindness, New York, NY; the Mayo Clinic Foundation,
   and Seoul National University Bundang Hospital.
CR ALPER CA, 1968, J CLIN INVEST, V47, P2181, DOI 10.1172/JCI105904
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Brown KM, 2006, NEW ENGL J MED, V354, P2014, DOI 10.1056/NEJMoa052825
   Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564
   FRANCIS PJ, J MED GENET
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Messias-Reason IJ, 2003, TISSUE ANTIGENS, V62, P308, DOI 10.1034/j.1399-0039.2003.00101.x
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   RAMBAUSEK M, 1987, Nephrology Dialysis Transplantation, V2, P208
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   SISSONS JGP, 1976, NEW ENGL J MED, V294, P461, DOI 10.1056/NEJM197602262940902
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   SRIVASTAVA N, 1985, HUM HERED, V35, P268, DOI 10.1159/000153559
   Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 40
TC 55
Z9 71
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2009
VL 50
IS 7
BP 3386
EP 3393
DI 10.1167/iovs.08-3231
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 461SP
UT WOS:000267292100046
PM 19234341
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Tai, ES
   Kawasaki, R
   Tay, WT
   Lee, JL
   Hamzah, H
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Tai, E. Shyong
   Kawasaki, Ryo
   Tay, Wan Ting
   Lee, Jeannette L.
   Hamzah, Haslina
   Wong, Tien Y.
TI Prevalence of and Risk Factors for Age-Related Macular Degeneration in a
   Multiethnic Asian Cohort
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; CARDIOVASCULAR RISK; REFRACTIVE ERROR; JAPANESE
   POPULATION; CHINESE POPULATION; ADULT-POPULATION; POOLED FINDINGS;
   MACULOPATHY; SINGAPORE; DISEASE
AB Objective: To describe the prevalence of and risk factors for age-related macular degeneration (AMD) in a multiethnic Asian cohort of Chinese, Malay, and Indian persons.
   Methods: In this population-based study, 3172 persons of Chinese, Malay, and Indian ethnicities 40 years and older were included. Participants underwent comprehensive systemic and ocular examination, retinal photography, and laboratory investigations. Early and late AMD signs were graded from retinal photographs. Age-standardized prevalence estimates were calculated using the 2010 Singapore adult population as the standard population. Association with a range of systemic risk factors was analyzed.
   Results: Of 3172 participants, AMD was present in 211 subjects. Age-standardized prevalence of AMD was 7.0% in persons 40 years and older. The age-standardized prevalence was similar in all 3 Asian ethnic groups: Chinese, 7.3%; Malay, 7.7%; and Indian, 5.7% (P value=.44). The prevalence increased with age and was higher in men. Of the range of risk factors evaluated, only myopic refractive error (<-0.5 D) was significantly associated with a lower risk for AMD (odds ratio, 0.44; P<.001, compared with emmetropia) in Chinese men.
   Conclusions: The prevalence of AMD was similar in the 3 major ethnic groups in Asia and comparable with white populations. Myopic refractive error was associated with reduced risk of AMD in Chinese men.
C1 [Cheung, Chui Ming Gemmy; Tay, Wan Ting; Hamzah, Haslina; Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Tai, E. Shyong; Wong, Tien Y.] Natl Univ Singapore, Dept Med, Singapore 168751, Singapore.
   [Lee, Jeannette L.] Natl Univ Singapore, Dept Epidemiol & Publ Hlth, Singapore 168751, Singapore.
   [Wong, Tien Y.] Natl Univ Singapore, Dept Ophthalmol, Singapore 168751, Singapore.
   [Kawasaki, Ryo] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore; Centre for Eye Research Australia;
   University of Melbourne
RP Wong, TY (通讯作者)，Natl Univ Singapore, Singapore Eye Res Inst, Singapore Natl Eye Ctr, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI Kawasaki, Ryo/H-9716-2019; Wong, Tien Yin/AAC-9724-2020; Kawasaki,
   Ryo/B-7266-2009; Tai, E Shyong/J-9831-2013
OI Wong, Tien Yin/0000-0002-8448-1264; Kawasaki, Ryo/0000-0002-7492-6303;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516; Tai, E
   Shyong/0000-0003-2929-8966
FU Biomedical Research Council [03/1/27/18/216, 08/1/35/19/550,
   501/1/25-5]; National Medical Research Council [0838/2004, 0796/2003];
   Singapore Bioimaging Consortium [C-011/2006]; Singapore Prospective
   Study Program; Singapore Tissue Network, A*STAR
FX The Singapore Prospective Study Program/Singapore Cardiovascular Cohort
   Study 2 was supported by Biomedical Research Council grants
   03/1/27/18/216 and 08/1/35/19/550, National Medical Research Council
   grant 0838/2004, and Singapore Bioimaging Consortium grant C-011/2006.
   The Singapore Malay Eye Study was funded by National Medical Research
   Council grant 0796/2003 and Biomedical Research Council grant
   501/1/25-5, with support from the Singapore Prospective Study Program
   and the Singapore Tissue Network, A*STAR.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CYL, 2010, AM J EPIDEMIOL, V171, P206, DOI 10.1093/aje/kwp357
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cutter J, 2001, B WORLD HEALTH ORGAN, V79, P908
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317
   Hughes K, 1997, J EPIDEMIOL COMMUN H, V51, P394, DOI 10.1136/jech.51.4.394
   HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P29, DOI 10.1136/jech.44.1.29
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Leng GC, 1996, BMJ-BRIT MED J, V313, P1440, DOI 10.1136/bmj.313.7070.1440
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liu J, 2004, JAMA-J AM MED ASSOC, V291, P2591, DOI 10.1001/jama.291.21.2591
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Sabanayagam C, 2010, NEPHROL DIAL TRANSPL, V25, P2564, DOI 10.1093/ndt/gfq084
   Sabanayagam C, 2009, J HYPERTENS, V27, P2209, DOI 10.1097/HJH.0b013e328330141d
   Singapore Department of Statistics, CENS POP 2010 ADV CE
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan CE, 1999, DIABETES CARE, V22, P241, DOI 10.2337/diacare.22.2.241
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Tavintharan S, 2009, DIABETES VASC DIS RE, V6, P80, DOI 10.1177/1479164109336043
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
NR 47
TC 61
Z9 63
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2012
VL 130
IS 4
BP 480
EP 486
DI 10.1001/archophthalmol.2011.376
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 922OK
UT WOS:000302557100009
PM 22159171
OA Bronze
DA 2022-11-30
ER

PT J
AU Michalska-Malecka, K
   Slowinska, L
   Dorecka, M
   Romaniuk, W
AF Michalska-Malecka, Katarzyna
   Slowinska, Ludmila
   Dorecka, Mariola
   Romaniuk, Wanda
TI Correlations in some pathogenetic factors and values of hemorheological
   parameters in age-related macular degeneration
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article
DE blood viscosity; plasma viscosity; retinal degeneration change;
   aggregation of red cells; deformability of red cells
ID MEMBRANE DIFFERENTIAL FILTRATION; CARDIOVASCULAR RISK-FACTORS;
   FIBRINOGEN LEVELS; 5-YEAR INCIDENCE; BLOOD-VISCOSITY; MACULOPATHY;
   SMOKING; DISEASE; HYPERTENSION; ASSOCIATION
AB The aim of this study was to correlate some pathogenetic factor with the hemorheological parameters in ills with age-related macular degeneration. The studies were performed on 52 patients suffering from AMD. The control group consisted of 42 healthy persons. Blood samples were taken from patients immediately after ophthalmological examination from antecubital vein and anticoagulated with K(3)EDTA. The symptoms of macular degeneration were drusen; changes in retinal pigmentation, areolar atrophy, neovascularization. Blood viscosity measurements were performed with use of cone-plate Brookfield viscometer at sheer rate 150 s(-1) and plasma viscosity with capillary Ubbelohde's viscometer. Fibrinogen concentration has been measured according to Clauss method, and level of triglycerides was measured using coupled enzymatic reactions. Haematocrit level was measured with the help of micromethod. The viscosity of whole blood, corrected viscosity and plasma viscosity were respectively 6.9%, 14.6% and 15.7% higher in the patient group than in the control group, while fibrinogen-plasma factor was 16% higher. Aggregation amplitude and time t(1/2) were 89.3% and 28.6% lower in AMD group. Erythrocyte deformability was 18% lower. The aggregation index was 7.6% higher in the AMD group then in the control group. Summing up in people suffering from AMD rheological disturbances is observed increased blood and plasma viscosity.
C1 [Michalska-Malecka, Katarzyna; Dorecka, Mariola; Romaniuk, Wanda] Silesian Univ, St Barbaras Hosp Sosnowiec, Dept & Clin Ward Ophthalmol, PL-41200 Sosnowiec, Poland.
   [Slowinska, Ludmila] Silesian Med Univ, Fac Med, Dept Biophys, PL-41800 Zabrze, Poland.
C3 Medical University Silesia
RP Michalska-Malecka, K (通讯作者)，Sybirakow 18, PL-44203 Rybnik, Poland.
EM Kasia@marat.com.pl
OI Dorecka, Mariola/0000-0003-1768-9628; MICHALSKA-MALECKA,
   KATARZYNA/0000-0002-0550-8386
CR BELDASANCHIS JI, 2001, ARCH SOC EXP OFTALMO, V76, P7
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHIEN S, 1973, MICROVASC RES, V5, P155, DOI 10.1016/0026-2862(73)90068-X
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   DINTENFASS L, 1975, MED J AUSTRALIA, V1, P617, DOI 10.5694/j.1326-5377.1975.tb111612.x
   EGAN KM, 1994, PRINCIPLES PARCTICE, V101, P1522
   Egan KM, 1994, PRINCIPLES PRACTICE, P1266
   Ercan M, 2006, CLIN HEMORHEOL MICRO, V35, P441
   ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008
   Ernst E, 1995, J Cardiovasc Risk, V2, P435
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gorin MB, 1999, MOL VIS, V5, pU31
   Green W R, 1999, Mol Vis, V5, P27
   HARDEMAN MR, 1994, CLIN HEMORHEOL, V14, P619
   HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN L, 1992, PRINCIPLES PRACTICE, V99, P933
   HYMAN L, 1992, PRINCIPLES PRACTICE, P1
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KANSKI JJ, 1997, OKULISTYKA KLINICZNA
   Kesmarky G, 2006, CLIN HEMORHEOL MICRO, V35, P67
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   MATRAI A, 1987, CLIN HEMORHEOL, V7, P261
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Rossi M, 2007, CLIN HEMORHEOL MICRO, V36, P163
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   TSO MOM, 1985, OPHTHALMOLOGY, V92, P628
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weber U., 1993, Ophthalmologe, V90, P486
   Widder RA, 1999, KLIN MONATSBL AUGENH, V215, P43, DOI 10.1055/s-2008-1034668
   Wiewiora M, 2006, CLIN HEMORHEOL MICRO, V34, P499
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 51
TC 17
Z9 17
U1 0
U2 4
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386-0291
EI 1875-8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2008
VL 38
IS 3
BP 209
EP 216
PG 8
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 259HT
UT WOS:000252931100008
PM 18239263
DA 2022-11-30
ER

PT J
AU Haan, MN
   Klein, R
   Klein, BE
   Deng, YZ
   Blythe, LK
   Seddon, JM
   Musch, DC
   Kuller, LH
   Hyman, LG
   Wallace, RB
AF Haan, Mary N.
   Klein, Ronald
   Klein, Barbara E.
   Deng, Yingzi
   Blythe, Lynn K.
   Seddon, Johanna M.
   Musch, David C.
   Kuller, Lewis H.
   Hyman, Leslie G.
   Wallace, Robert B.
TI Hormone therapy and age-related macular degeneration - The women's
   health initiative sight exam study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; ESTROGEN REPLACEMENT THERAPY; RANDOMIZED
   CONTROLLED-TRIAL; BEAVER DAM EYE; POSTMENOPAUSAL WOMEN; REPRODUCTIVE
   FACTORS; VISUAL IMPAIRMENT; 5-YEAR INCIDENCE; UNITED-STATES;
   RISK-FACTORS
AB Objective: To determine the effectiveness of treatment with conjugated equine estrogens (CEE) or with CEE combined with progestin (CEE + P) on age-related macular degeneration (AMD).
   Methods: In an ancillary study to the Women's Health Initiative clinical trial of hormone therapy, 4262 women 65 years and older underwent fundus photography for the determination of AMD. Participants were recruited from April 2000 to June 2002 at 21 clinical sites an average of 5 years after randomization. Participants were randomized to treatment with CEE, CEE + P, or placebo. Participants had been treated for an average of 5 years at the ophthalmic evaluation for AMD.
   Results: The overall prevalence of any AMD was 21.0%. No association was found between CEE + P (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.75-1.11) or CEE alone (OR, 0.98; 95% CI, 0.78-1.25) and early-stage AMD. The CEE + P was associated with a reduced risk of soft drusen (OR, 0.83; 95% CI, 0.68-1.00) after adjustment for covariates and with a reduced risk of neovascular AMD (OR, 0.29; 95% CI, 0.09-0.92).
   Conclusions: Treatment with CEE alone or CEE + P does not affect early- or late-stage AMD. Treatment with CEE + P may reduce the risk of soft drusen or neovascular AMD.
C1 Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48104 USA.
   Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48104 USA.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Epidemiol, Boston, MA 02115 USA.
   Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA.
   Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Wisconsin System;
   University of Wisconsin Madison; Harvard University; Harvard Medical
   School; Massachusetts Eye & Ear Infirmary; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; State
   University of New York (SUNY) System; SUNY Community College; State
   University of New York (SUNY) Stony Brook; University of Iowa
RP Haan, MN (通讯作者)，Univ Michigan, Dept Epidemiol, 611 Church St,Room 311, Ann Arbor, MI 48104 USA.
EM mnhaan@umich.edu
RI Haan, Mary N/Y-9354-2018
OI Haan, Mary N/0000-0001-9312-4501; Musch, David/0000-0002-4164-3841
FU WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH
   [N01WH032113] Funding Source: NIH RePORTER
CR Abramov Y, 2004, MENOPAUSE, V11, P62, DOI 10.1097/01.GME.0000074701.19603.11
   Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7
   Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   Barnes JF, 2005, MENOPAUSE, V12, P92, DOI 10.1097/00042192-200512010-00016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cumming RG, 1997, AM J EPIDEMIOL, V145, P242
   Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Defay R, 2001, INT J OBESITY, V25, P512, DOI 10.1038/sj.ijo.0801570
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   KLELN RKB, 1991, BEAVER DAM EYE STUDY
   Kwok S, 2004, CLIN ENDOCRINOL, V61, P760, DOI 10.1111/j.1365-2265.2004.02166.x
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   Prestwood KM, 2004, J GERONTOL A-BIOL, V59, P827
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith JP, 1997, J ADV NURS, V25, P1, DOI 10.1046/j.1365-2648.1997.1997025001.x
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wong TY, 2005, OPHTHALMOLOGY, V112, P553, DOI 10.1016/j.ophtha.2004.11.026
   Yilmazer M, 2003, MATURITAS, V46, P245, DOI 10.1016/S0378-5122(03)00217-2
NR 40
TC 45
Z9 45
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2006
VL 124
IS 7
BP 988
EP 992
DI 10.1001/archopht.124.7.988
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064XE
UT WOS:000239123200007
PM 16832022
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Spandau, UHM
   Kamppeter, BA
   Degenring, RF
   Kreissig, I
   Akkoyun, I
   Vossmerbaeumer, U
AF Jonas, Jost B.
   Spandau, Ulrich H. M.
   Kamppeter, Bernd A.
   Degenring, Robert F.
   Kreissig, Ingrid
   Akkoyun, Imren
   Vossmerbaeumer, Urs
TI Duration of the effect of intravitreal triamcinolone acetonide in eyes
   with exudative age-related macular degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; RAT MODEL;
   INJECTION; INHIBITION; VERTEPORFIN; RECURRENCE; EXPRESSION; EDEMA
AB Objective: The aim of this study was to evaluate the duration of the effect of an intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA) on visual acuity and intraocular pressure (IOP) in patients with exudative age-related macular degeneration (AMD) with subfoveal choroidal neovascularization.
   Participants: The prospective, clinical, interventional, case series study included 69 patients (71 eyes) with exudative AMD who showed an increase in visual acuity by at least 2 Snellen lines after an intravitreal injection of approximately 20 mg TA. Mean follow-up was 11.5 +/- 7.4 months (3.3-35.7 months). The main outcome measure was visual acuity.
   Results: Within the first week after the injection, visual acuity and IOP started to increase significantly (P < 0.001) by reaching a plateau-like maximum at 1-6 months after the injection. Visual acuity and IOP returned to baseline values 7-9 months after the injection. Increase of IOP was statistically (P = 0.72) independent of the change in visual acuity.
   Conclusions: In patients with exudative AMD, who have shown an increase of at least 2 Snellen lines in visual acuity, the effect of intravitreal TA (dosage approximately 20 mg) lasts 7-9 months with respect to an increase in visual acuity and IOP.
C1 Heidelberg Univ, Fac Clin Med, Dept Ophthalmol, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Mannheim, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
RI AKKOYUN, IMREN VARDARLI/AAK-7713-2021
OI AKKOYUN, IMREN VARDARLI/0000-0002-2860-7424
CR Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   AUGUSTIN AJ, 2006, IN PRESS AM J OPHTHA
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P158, DOI 10.1016/j.ajo.2004.02.025
   Jonas JB, 2004, AM J OPHTHALMOL, V137, P560, DOI 10.1016/j.ajo.2003.08.012
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, J CATARACT REFR SURG, V28, P2040, DOI 10.1016/S0886-3350(02)01295-6
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2001, J GLAUCOMA, V10, P284, DOI 10.1097/00061198-200108000-00007
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Martidis A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1380
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spandau UHM, 2005, BRIT J OPHTHALMOL, V89, P745, DOI 10.1136/bjo.2004.052563
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
NR 38
TC 11
Z9 13
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUN
PY 2006
VL 22
IS 3
BP 194
EP 199
DI 10.1089/jop.2006.22.194
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 061LQ
UT WOS:000238874300007
PM 16808681
DA 2022-11-30
ER

PT J
AU Garcia-Layana, A
   Recalde, S
   Hernandez, M
   Abraldes, MJ
   Nascimento, J
   Hernandez-Galilea, E
   Olmedilla-Alonso, B
   Escobar-Barranco, JJ
   Zapata, MA
   Silva, R
   Arredondo, MC
   Lopez-Sabater, MC
   Mendez-Martinez, S
   Pardinas-Baron, N
   Calvo, P
   Fernandez-Robredo, P
AF Garcia-Layana, Alfredo
   Recalde, Sergio
   Hernandez, Maria
   Abraldes, Maximino J.
   Nascimento, Joao
   Hernandez-Galilea, Emiliano
   Olmedilla-Alonso, Begona
   Juan Escobar-Barranco, Jose
   Angel Zapata, Miguel
   Silva, Rufino
   Caballero Arredondo, Mariana
   Carmen Lopez-Sabater, Maria
   Mendez-Martinez, Silvia
   Pardinas-Baron, Nieves
   Calvo, Pilar
   Fernandez-Robredo, Patricia
TI A Randomized Study of Nutritional Supplementation in Patients with
   Unilateral Wet Age-Related Macular Degeneration
SO NUTRIENTS
LA English
DT Article
DE age-related macular degeneration; AREDS; Theavit (R); Retilut (R);
   carotenoids; polyunsaturated; fatty acids; inflammatory markers;
   angiogenic factors at month 12
ID POLYUNSATURATED FATTY-ACIDS; PIGMENT EPITHELIAL-CELLS; QUALITY-OF-LIFE;
   EYE DISEASE; OXIDATIVE STRESS; OMEGA-3-FATTY-ACIDS; ZEAXANTHIN; MARKERS;
   LUTEIN
AB The purpose of this study is evaluate the efficacy and safety of medicinal products containing the original Age-Related Eye Disease group (AREDS) formulation at doses approved in Europe (EU, control group; n = 59) with a product that adds DHA, lutein, zeaxanthin, resveratrol and hydroxytyrosol to the formula (intervention group; n = 50). This was a multicenter, randomized, observer-blinded trial conducted in patients aged 50 years or older diagnosed with unilateral exudative Age related Macular Degeneration AMD. At month 12, the intervention did not have a significant differential effect on visual acuity compared with the control group, with an estimated treatment difference in Early Treatment Diabetic Retinopathy Study (ETDRS) of -1.63 (95% CI -0.83 to 4.09; p = 0.192). The intervention exhibited a significant and, in most cases, relevant effect in terms of a reduction in some inflammatory cytokines and a greater improvement in the fatty acid profile and serum lutein and zeaxantin concentration. In patients with unilateral wet AMD, the addition of lutein, zeaxanthin, resveratrol, hydroxytyrosol and DHA to the AREDS EU recommended doses in the short-term did not have a differential effect on visual acuity compared to a standard AREDS EU formula but, in addition to improving the fatty acid profile and increasing carotenoid serum levels, may provide a beneficial effect in improving the proinflammatory and proangiogenic profile of patients with AMD.
C1 [Garcia-Layana, Alfredo; Recalde, Sergio; Hernandez, Maria; Fernandez-Robredo, Patricia] Clin Univ Navarra, Dept Ophthalmol, Expt Ophthalmol Lab, Retinal Pathol & New Therapies Grp, Av Pio 12 36, Pamplona 31008, Spain.
   [Garcia-Layana, Alfredo; Recalde, Sergio; Hernandez, Maria; Fernandez-Robredo, Patricia] IdiSNA, Navarra Inst Hlth Res, C Irunlarrea 3, Pamplona 31008, Spain.
   [Garcia-Layana, Alfredo; Recalde, Sergio; Hernandez, Maria; Abraldes, Maximino J.; Fernandez-Robredo, Patricia] Inst Salud Carlos III, Red Temat Invest Cooperat Sanitaria Enfer Medades, Av Monforte de Lemos 5, Madrid 28029, Spain.
   [Abraldes, Maximino J.] Univ Santiago de Compostela, Complexo Hosp Univ Santiago de Compostela, Dept Ophthalmol, Santiago De Compostela 15706, Spain.
   [Nascimento, Joao] Retina Lisbon Inst, Retinal Dept, Ophthalmol, Av Duque de Louie 5, P-1050085 Lisbon, Portugal.
   [Hernandez-Galilea, Emiliano] Univ Salamanca, Univ Hosp Salamanca, Dept Ophthalmol, Paseo San Vicente 182, Salamanca 37007, Spain.
   [Olmedilla-Alonso, Begona] Inst Food Sci Technol & Nutr ICTAN CSIC, Dept Metab & Nutr, Jose Antonio Novais 10, Madrid 28040, Spain.
   [Juan Escobar-Barranco, Jose] Hosp Dos de Maig, Dept Ophthalmol, Carrer Dos Maig 301, Barcelona 08025, Spain.
   [Angel Zapata, Miguel] Hosp Valle De Hebron, Dept Ophthalmol, Passeig Vall dHebron 119, Barcelona 08035, Spain.
   [Silva, Rufino] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, P-3004531 Coimbra, Portugal.
   [Silva, Rufino] Ctr Hosp & Univ Coimbra CHUC, Ophthalmol Dept, Praceta Prof Mota Pinto, P-3004561 Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, P-3000548 Coimbra, Portugal.
   [Caballero Arredondo, Mariana; Carmen Lopez-Sabater, Maria] Univ Barcelona, Nutr Food Sci & Gastron, Joan 23 27-31, Barcelona 08028, Spain.
   [Mendez-Martinez, Silvia; Pardinas-Baron, Nieves; Calvo, Pilar] Miguel Servet Univ Hosp, Dept Ophthalmol, Paseo Isabel Catolica 1-3, Zaragoza 50009, Spain.
   [Mendez-Martinez, Silvia; Pardinas-Baron, Nieves; Calvo, Pilar] Univ Zaragoza, Aragon Hlth Res Inst IIS Aragon, Miguel Servet Ophthalmol Res Grp GIMSO, Avda De Juan Bosco 13, Zaragoza 50009, Spain.
C3 University of Navarra; Instituto de Salud Carlos III; Complexo
   Hospitalario Universitario de Santiago de Compostela; Universidade de
   Santiago de Compostela; University of Salamanca; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia y
   Tecnologia de Alimentos y Nutricion (ICTAN); Hospital Universitari Vall
   d'Hebron; Universidade de Coimbra; Universidade de Coimbra; Centro
   Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra;
   University of Barcelona; Miguel Servet University Hospital; University
   of Zaragoza
RP Recalde, S (通讯作者)，Clin Univ Navarra, Dept Ophthalmol, Expt Ophthalmol Lab, Retinal Pathol & New Therapies Grp, Av Pio 12 36, Pamplona 31008, Spain.; Recalde, S (通讯作者)，IdiSNA, Navarra Inst Hlth Res, C Irunlarrea 3, Pamplona 31008, Spain.; Recalde, S (通讯作者)，Inst Salud Carlos III, Red Temat Invest Cooperat Sanitaria Enfer Medades, Av Monforte de Lemos 5, Madrid 28029, Spain.
EM aglayana@unav.es; srecalde@unav.es; mahersan@unav.es;
   maxiabraldes@gmail.com; joaocnascimento@sapo.pt; egalilea@usal.es;
   BOlmedilla@ictan.csic.es; escobarjou@yahoo.es;
   zapatavictori@hotmail.com; rufino.silva@oftalmologia.co.pt;
   mariana.cbllro@gmail.com; mclopez@ub.edu;
   silviamendezmartinez@hotmail.com; npardinasb@yahoo.com;
   xenatrance@yahoo.es; pfrobredo@unav.es
RI Olmedilla-Alonso, Begoña/D-1337-2012; Méndez-Martínez,
   Silvia/U-2803-2019; Caballero Arredondo, Mariana/R-3612-2017; Recalde,
   Sergio/D-1815-2017
OI Olmedilla-Alonso, Begoña/0000-0002-4913-5171; Méndez-Martínez,
   Silvia/0000-0001-6072-1545; Hernandez-Galilea,
   Emiliano/0000-0002-5927-0836; Lopez-Sabater, Maria
   Carmen/0000-0002-8670-7044; Caballero Arredondo,
   Mariana/0000-0003-1873-3977; Zapata, Miguel Angel/0000-0002-0096-4569;
   Silva, Rufino/0000-0001-8676-0833; Recalde, Sergio/0000-0002-9328-9725
FU Laboratorios Thea (Barcelona, Spain); Instituto de Salud Carlos
   III/European Regional Development Fund (ERDF); OFTARED: Enfermedades
   oculares: "Prevencion, deteccion precoz, tratamiento y rehabilitacion de
   las patologias oculares" [RD16/0008/0011]
FX The research was funded by Laboratorios Thea (Barcelona, Spain) and by
   research grants from the "Instituto de Salud Carlos III/European
   Regional Development Fund (ERDF)" and RD16/0008/0011, OFTARED:
   Enfermedades oculares: "Prevencion, deteccion precoz, tratamiento y
   rehabilitacion de las patologias oculares".
CR Aslam Tariq, 2014, Clin Ophthalmol, V8, P2045, DOI 10.2147/OPTH.S63937
   Barnes TC, 2011, INT J RHEUMATOL, V2011, DOI 10.1155/2011/721608
   Bondia-Pons I, 2004, J CHROMATOGR B, V809, P339, DOI 10.1016/j.jchromb.2004.07.002
   Campisi J, 2011, CURR OPIN GENET DEV, V21, P107, DOI 10.1016/j.gde.2010.10.005
   Chatziralli I, 2017, SEMIN OPHTHALMOL, V32, P772, DOI 10.1080/08820538.2016.1181192
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Colak E, 2017, J CLIN BIOCHEM NUTR, V60, P100, DOI 10.3164/jcbn.16-30
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dinu M, 2019, EUR J NUTR, V58, P2123, DOI 10.1007/s00394-018-1771-5
   Elshout M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0514-3
   Eynard AR, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-1049-9
   Fernandez-Vega B, 2016, CASE REP OPHTHAL, V7, P154, DOI 10.1159/000445102
   Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003
   Fu WX, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032127, 10.1371/journal.pone.0040003, 10.1371/journal.pone.0036949, 10.1186/1746-1596-7-49]
   Garcia-Layana A, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/9821509
   Garcia-Layana A., 2015, P 12 ISOPT CLIN INT, P7
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hernandez M, 2019, MOL THER-METH CLIN D, V15, P403, DOI 10.1016/j.omtm.2019.10.013
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lane J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209218
   Latruffe N, 2015, ANN NY ACAD SCI, V1348, P97, DOI 10.1111/nyas.12819
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Liu AH, 2011, CLIN LIPIDOL, V6, P593, DOI 10.2217/CLP.11.41
   Liu JH, 2020, AGING CLIN EXP RES, V32, P2703, DOI 10.1007/s40520-020-01501-7
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Liu ZB, 2007, J NEUROCHEM, V103, P2690, DOI 10.1111/j.1471-4159.2007.04954.x
   Marion-Letellier R, 2015, IUBMB LIFE, V67, P659, DOI 10.1002/iub.1428
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Mirshahi Alireza, 2012, J Ophthalmic Vis Res, V7, P39
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Olmedilla-Alonso B, 2018, NUTRIENTS, V10, DOI 10.3390/nu10080959
   Olmedilla-Alonso B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-52
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Touhami S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1106-8
   Wang HB, 2016, MOL VIS, V22, P116
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wu L, 2013, J OCUL PHARMACOL TH, V29, P366, DOI 10.1089/jop.2012.0203
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P19, DOI 10.1089/jop.2006.22.19
NR 58
TC 7
Z9 7
U1 4
U2 14
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD APR
PY 2021
VL 13
IS 4
AR 1253
DI 10.3390/nu13041253
PG 16
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA RR9JF
UT WOS:000643404600001
PM 33920232
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Habibi, I
   Sfar, I
   Kort, F
   Aounallah-Skhiri, H
   Chebil, A
   Chouchene, I
   Bouraoui, R
   Limaiem, R
   Largheche, L
   Jendoubi-Ayed, S
   Makhlouf, M
   Ben Abdallah, T
   Ayed, K
   El Matri, L
   Gorgi, Y
AF Habibi, I.
   Sfar, I.
   Kort, F.
   Aounallah-Skhiri, H.
   Chebil, A.
   Chouchene, I.
   Bouraoui, R.
   Limaiem, R.
   Largheche, L.
   Jendoubi-Ayed, S.
   Makhlouf, M.
   Ben Abdallah, T.
   Ayed, K.
   El Matri, L.
   Gorgi, Y.
TI Y402H Polymorphism in Complement Factor H and Age-Related Macular
   Degeneration in the Tunisian Population
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Complement factor H; Polymorphisms
ID GEOGRAPHIC ATROPHY; RISK-FACTORS; ASSOCIATION; CFH; GENOTYPE; VARIANT;
   HTRA1; GENE; SUSCEPTIBILITY; PATHOGENESIS
AB To evaluate a possible association between the complement factor H (CFH) Y402H polymorphism and susceptibility to age-related macular degeneration (AMD) in the Tunisian population, as well as the impact of the genotype distribution among different phenotypes and the response to treatment with intravitreal bevacizumab, exon 9 of CFH was analyzed for the Y402H polymorphism by direct sequencing in 135 healthy controls and 127 sporadic unrelated AMD patients classified into the following groups: 12 atrophic AMD (group G1), 115 exudative AMD (G2) and 10 AMD patients who had fibrovascular scarring (G3) that did not allow a precise grading of the phenotype. Seventy patients in G2 were treated with 1.25 mg intravitreal bevacizumab at 6-week intervals until choroidal neovascularization (CNV) was no longer active. The frequency of the CFH 402H allele was significantly higher in AMD patients than in controls (p = 2.62 x 10(-16)). However, subgroup analysis does not reveal any association between the variant allele H and phenotypes of AMD or CNV. Also, there was no significant difference in response to bevacizumab treatment according to Y402H CFH genotype (p = 0.59). A strong association of the 402H allele with susceptibility to AMD in the Tunisian population was confirmed; however, this variant does not appear to be involved in the clinical progression of this disease or in the postintravitreal bevacizumab response. Copyright (c) 2013 S. Karger AG, Basel
C1 [Habibi, I.; Sfar, I.; Jendoubi-Ayed, S.; Makhlouf, M.; Ben Abdallah, T.; Ayed, K.; Gorgi, Y.] Univ Tunis El Manar, Charles Nicolle Hosp, Immunol Res Lab Kidney Transplantat & Immunopatho, Tunis 1006, Tunisia.
   [Kort, F.; Chebil, A.; Chouchene, I.; Bouraoui, R.; Limaiem, R.; Largheche, L.; El Matri, L.] Hedi Rais Inst Ophthalmol, Oculogenet Res Unit, Tunis, Tunisia.
   [Aounallah-Skhiri, H.] Natl Inst Hlth, Tunis, Tunisia.
C3 Universite de Tunis-El-Manar; Hopital Charles Nicolle; Universite de
   Tunis-El-Manar; Institut Hedi Raies d'ophtalmologie de Tunis
RP Gorgi, Y (通讯作者)，Charles Nicolle Hosp, Immunol Lab, Blvd 9 Avril, Tunis 1006, Tunisia.
EM gorgi.yousr@gmail.com
FU Tunisian Immunology Research Laboratory Fund [LR03SP01]
FX This study was supported by a grant from the Tunisian Immunology
   Research Laboratory (LR03SP01) Fund.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Souied EH, 2005, MOL VIS, V11, P1135
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 48
TC 8
Z9 8
U1 0
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2013
VL 49
IS 4
BP 177
EP 184
DI 10.1159/000345068
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 155YI
UT WOS:000319786100002
PM 23306536
DA 2022-11-30
ER

PT J
AU Lin, LY
   Zhou, Q
   Hagstrom, S
   Maguire, MG
   Daniel, E
   Grunwald, JE
   Martin, DF
   Ying, GS
AF Lin, Lisa Y.
   Zhou, Qiang
   Hagstrom, Stephanie
   Maguire, Maureen G.
   Daniel, Ebenezer
   Grunwald, Juan E.
   Martin, Daniel F.
   Ying, Gui-shuang
CA CATT Res Grp
TI Association of Single-Nucleotide Polymorphisms in Age-Related Macular
   Degeneration With Pseudodrusen Secondary Analysis of Data From the
   Comparison of AM D Treatments Trials
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID RETICULAR PSEUDODRUSEN; PREVALENCE; DRUSEN; CATT
AB IMPORTANCE: Previous studies investigating the association of single-nucleotide polymorphisms (SNPs) that confer increased risk of age-related macular degeneration (AMD) with pseudodrusen have yielded conflicting results and have not evaluated other AMD SNPs or pseudodrusen subtypes.
   OBJECTIVE: To determine the association of SNPs in the complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), HtrA serine peptidase 1 (HTRA1), complement C2 (C2), complement C3 (C3), lipase C (LIPC), and complement factor B (CFB) genes with the presence of pseudodrusen and pseudodrusen subtypes (ie, dot, reticular, and confluent).
   DESIGN, SETTING, AND PARTICIPANTS: In this post hoc analysis of cross-sectional data from US participants in the Comparison of AMD Treatments Trials, genotyping was performed in 835 participants with TaqMan assays for the SNPs rs1061170 (Y402H variant in CFH), rs800292 (I62V variant in CFH), rs10490924 (A69S variant in ARMS2), rs11200638 (HTRA1), rs547154 (C2), rs2230199 (R102G variant in C3), rs10468017 (LIPC), and rs4151667 (L9H variant in CFB).
   MAIN OUTCOMES AND MEASURES: Presence and subtype of baseline pseudodrusen in either eye determined using color fundus photography, red-free images, and fluorescein angiograms.
   RESULTS: Among 835 participants enrolled for genotyping, 755 (90.4%) were evaluated for pseudodrusen. Of these, 471 (62.4%) were female and 750 (99.3%) were white, and the mean (SD) age was 78.3 (7.5) years. A total of 213 of 755 participants (28.2%) had pseudodrusen (107 [14.2%] had dot pseudodrusen, 180 [23.8%] had reticular pseudodrusen, and 102 [13.5%] had confluent pseudodrusen). After adjusting for age, sex, and smoking status, the ARMS2 risk allele T was associated with higher risk of pseudodrusen (odds ratio [OR], 1.93; 95% CI, 1.19-3.12) for TT vs GG (P = .04). A similar association was found for HTRA1 (OR, 2.04; 95% CI, 1.26-3.31) for AA vs GG (P = .03). The CFH Y402H risk allele C was associated with lower risk of pseudodrusen (OR, 0.61; 95% CI, 0.38-0.97) for CC vs TT but was not statistically significant after correcting for multiple comparison (P = .20). CFH Y402H, ARMS2, HTRA1, and C3 were significantly associated with reticular pseudodrusen.
   CONCLUSIONS AND RELEVANCE: Among patients with neovascular AMD, the AMD risk alleles ARMS2 and HTRA1 were associated with an increased risk of pseudodrusen and the risk allele CFH Y402H was associated with lower risk of pseudodrusen, supporting findings from previous studies. Understanding the role of these SNPs in the development of pseudodrusen might improve our understanding of the pathogenesis of AMD and help develop future therapies.
C1 [Lin, Lisa Y.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Zhou, Qiang] Capital Med Univ, Dept Ophthalmol, Beijing Chaoyang Hosp, Beijing, Peoples R China.
   [Hagstrom, Stephanie; Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Maguire, Maureen G.; Daniel, Ebenezer; Grunwald, Juan E.; Ying, Gui-shuang] Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Perelman Sch Med, 3535 Market St,Ste 700, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Capital Medical
   University; Cleveland Clinic Foundation; University of Pennsylvania;
   Pennsylvania Medicine
RP Ying, GS (通讯作者)，Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Perelman Sch Med, 3535 Market St,Ste 700, Philadelphia, PA 19104 USA.
EM gsying@pennmedicine.upenn.edu
OI Zhou, Qiang/0000-0002-2351-3621
FU National Eye Institute of the National Institutes of Health [U10
   EY017823, U10 EY017825, U10 EY017826, U10 EY017828, R21EY023689]; US
   Department of Health and Human Services; NATIONAL EYE INSTITUTE
   [P30EY001583] Funding Source: NIH RePORTER
FX The Comparison of AMD Treatment Trials is supported by grants U10
   EY017823, U10 EY017825, U10 EY017826, U10 EY017828, and R21EY023689 from
   the National Eye Institute of the National Institutes of Health and the
   US Department of Health and Human Services.
CR Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Elfandi S, 2016, OPHTHALMOLOGY, V123, P2205, DOI 10.1016/j.ophtha.2016.06.052
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Shijo T, 2017, GRAEF ARCH CLIN EXP, V255, P1125, DOI 10.1007/s00417-017-3622-0
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 15
TC 13
Z9 14
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2018
VL 136
IS 6
BP 682
EP 688
DI 10.1001/jamaophthalmol.2018.1231
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GJ4NZ
UT WOS:000435359100020
PM 29801032
OA Green Published
DA 2022-11-30
ER

PT J
AU Thee, EF
   Meester-Smoor, MA
   Luttikhuizen, DT
   Colijn, JM
   Enthoven, CA
   Haarman, AEG
   Rizopoulos, D
   Klaver, CCW
AF Thee, Eric F.
   Meester-Smoor, Magda A.
   Luttikhuizen, Daniel T.
   Colijn, Johanna M.
   Enthoven, Clair A.
   Haarman, Annechien E. G.
   Rizopoulos, Dimitris
   Klaver, Caroline C. W.
CA EyeNED Reading Ctr
TI Performance of Classification Systems for Age-Related Macular
   Degeneration in the Rotterdam Study
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE AMD; classification systems; screening; artificial intelligence;
   clinical trials
ID SEVERITY SCALE; EYE DISEASE; MACULOPATHY; PREVALENCE
AB Purpose: To compare frequently used classification systems for age-related macular degeneration (AMD) in their abilty to predict late AMD.
   Methods: In total, 9066 participants from the population-based Rotterdam Study were followed up for progression of AMD during a study period up to 30 years. AMD lesions were graded on color fundus photographs after confirmation on other image modalities and grouped at baseline according to six classification systems. Late AMD was defined as geographic atrophy or choroidal neovascularization. Incidence rate (IR) and cumulative incidence (Cul) of late AMD were calculated, and Kaplan-Meier plots and area under the operating characteristics curves (AUCs) were constructed.
   Results: A total of 186 persons developed incident late AMD during a mean follow-up time of 8.7 years. The AREDS simplified scale showed the highest IR for late AMD at 104 cases/1000 py for ages <75 years. The Rotterdam classification showed the highest IR at 89 cases/1000 py >75 years. The 3-Continent harmonization classification provided the most stable progression. Drusen area >10% ETDRS grid (hazard ratio 30.05, 95% confidence interval [CI] 19.25-46.91) was most prognostic of progression. The highest AUC of late AMD (0.8372, 95% CI: 0.8070-0.8673) was achieved when all AMD features present at baseline were included.
   Conclusions: Highest turnover rates from intermediate to late AMD were provided by the AREDS simplified scale and the Rotterdam classification. The 3-Continent harmonization classification showed the most stable progression. All features, especially drusen area, contribute to late AMD prediction.
   Translational Relevance: Findings will help stakeholders select appropriate classification systems for screening, deep learning algorithms, or trials.
C1 [Thee, Eric F.; Meester-Smoor, Magda A.; Luttikhuizen, Daniel T.; Colijn, Johanna M.; Enthoven, Clair A.; Haarman, Annechien E. G.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Thee, Eric F.; Meester-Smoor, Magda A.; Luttikhuizen, Daniel T.; Colijn, Johanna M.; Enthoven, Clair A.; Haarman, Annechien E. G.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Rizopoulos, Dimitris] Erasmus MC, Dept Biostat, Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Radboudumc, Dept Ophthalmol, Nijmegen, Netherlands.
   [Klaver, Caroline C. W.] Univ Basel, Inst Mol & Clin Ophthalmol, Basel, Switzerland.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Radboud University
   Nijmegen; University of Basel
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, Dept Epidemiol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI Thee, Eric Ferdinand/ABB-9370-2020
FU Erasmus Medical Center, Rotterdam; Erasmus University, Rotterdam;
   Netherlands Organization for the Health Research and Development
   (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry
   of Education, Culture and Science; Ministry for Health, Welfare and
   Sports; European Commission (DG XII); Municipality of Rotterdam;
   MaculaFonds through Uitzicht [2018-34]; Oogfonds through Uitzicht
   [2018-34]; Landelijkse Stichting voor Blinden en Slechtzienden through
   Uitzicht [2018-34]; Royal Dutch Academy of Sciences (Ammodo Award);
   European Union's Horizon 2020 research and innovation programme [634479]
FX The Rotterdam Study is funded by Erasmus Medical Center and Erasmus
   University, Rotterdam, Netherlands Organization for the Health Research
   and Development (ZonMw), the Research Institute for Diseases in the
   Elderly (RIDE), the Ministry of Education, Culture and Science, the
   Ministry for Health, Welfare and Sports, the European Commission (DG
   XII), and the Municipality of Rotterdam. Additionally, the ophthalmic
   research within the Rotterdam Study was supported by the following
   foundations: MaculaFonds, Oogfonds, and Landelijkse Stichting voor
   Blinden en Slechtzienden that contributed through Uitzicht (grant
   2018-34), Royal Dutch Academy of Sciences (Ammodo Award to C.C.W.
   Klaver), and the European Union's Horizon 2020 research and innovation
   programme (grant no.:634479; EYE-RISK).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gattoussi S, 2019, ACTA OPHTHALMOL, V97, P364, DOI 10.1111/aos.13883
   Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4
   Kapoor R, 2019, SURV OPHTHALMOL, V64, P233, DOI 10.1016/j.survophthal.2018.09.002
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 21
TC 12
Z9 12
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2020
VL 9
IS 2
AR 26
DI 10.1167/tvst.9.2.26
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PG1FX
UT WOS:000599489500012
PM 32818087
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Pan, CW
   Ikram, MK
   Cheung, CY
   Choi, HW
   Cheung, CMG
   Jonas, JB
   Saw, SM
   Wong, TY
AF Pan, Chen-Wei
   Ikram, M. Kamran
   Cheung, Carol Y.
   Choi, Hyung-Won
   Cheung, Chiu-Ming Gemmy
   Jonas, Jost B.
   Saw, Seang-Mei
   Wong, Tien-Yin
TI Refractive Errors and Age-related Macular Degeneration: A Systematic
   Review and Meta-Analysis
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; SINGAPORE MALAY EYE; GRADING SYSTEM; MACULOPATHY;
   PREVALENCE; SUNLIGHT; MYOPIA; BIAS; ASSOCIATIONS; POPULATION
AB Objective: To evaluate the association between refractive errors and age-related macular degeneration (AMD).
   Main Outcome Measures: A clear understanding of the relationship between refractive error and AMD provides insights into the pathophysiology of AMD.
   Methods: We searched PubMed and Embase from their inception to July 2012 for population-based studies with data on refractive error and AMD assessed from retinal photographs at baseline and follow-up. We performed separate meta-analyses for cross-sectional studies and cohort studies using adjusted odds ratios (ORs) and hazard ratios (HRs) under random effects models, respectively.
   Results: Analysis of the 6 cross-sectional studies showed that hyperopia was associated with higher odds of prevalent AMD (pooled OR hyperopia vs. emmetropia: 1.16; 95% confidence interval [CI], 1.04-1.29) and that myopia was associated with lower odds of prevalent AMD (pooled OR myopia vs. emmetropia: 0.75; 95% CI, 0.61-0.92). Analysis from the 3 cohort studies showed nonsignificant associations. Analysis of the 5 cross-sectional and 2 cohort studies showed that each diopter increase in spherical equivalent was associated with increased odds of both prevalent (pooled OR, 1.09; 95% CI, 1.06-1.12) and incident (pooled HR, 1.06; 95% CI, 1.02-1.10) AMD. In 3 cross-sectional studies with data on axial length, each millimeter increase in axial length was associated with a decreased odd of prevalent AMD (pooled OR, 0.76; 95% CI, 0.69-0.85).
   Conclusions: Refractive error is associated with AMD, although a temporal relationship cannot be determined on the basis of current evidence. Ophthalmologists should be aware that risk of AMD clinically seems to vary by refractive status.
C1 [Pan, Chen-Wei; Choi, Hyung-Won; Saw, Seang-Mei; Wong, Tien-Yin] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Ikram, M. Kamran; Cheung, Carol Y.; Cheung, Chiu-Ming Gemmy; Saw, Seang-Mei; Wong, Tien-Yin] Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Ikram, M. Kamran; Cheung, Carol Y.; Cheung, Chiu-Ming Gemmy; Saw, Seang-Mei; Wong, Tien-Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Ikram, M. Kamran; Cheung, Carol Y.; Cheung, Chiu-Ming Gemmy; Saw, Seang-Mei; Wong, Tien-Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Mannheim, Germany.
C3 National University of Singapore; National University of Singapore;
   Singapore National Eye Center; Singapore National Eye Center; National
   University of Singapore; Ruprecht Karls University Heidelberg
RP Wong, TY (通讯作者)，Singapore Eye Res Inst, 11 3rd Hosp Ave,05-00, Singapore 168751, Singapore.
EM tien_yin_wong@nuhs.edu.sg
RI Cheung, Carol Y./G-7895-2016; Pan, Chen-Wei/E-6205-2015; Pan,
   Chen-Wei/L-7174-2019; Wong, Tien Yin/AAC-9724-2020; Choi,
   Hyungwon/S-8824-2019; Cheung, Carol/AAF-1101-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Choi, Hyungwon/0000-0002-6687-3088;
   Cheung, Carol/0000-0002-9672-1819; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Cheung, Carol/0000-0003-0869-859X; Ikram,
   Mohammad Kamran/0000-0003-0173-9571; Pan, Chen-Wei/0000-0003-3362-4613
FU Biomedical Research Council [08/1/35/19/550]; National Medical Research
   Council, Singapore [STaR/0003/2008]
FX This study was funded by the Biomedical Research Council,
   08/1/35/19/550, and National Medical Research Council, STaR/0003/2008,
   Singapore.
CR AKIBA J, 1990, OPHTHALMOLOGY, V97, P889
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Porta MS, 2008, DICT EPIDEMIOLOGY, P187
   Sanderson S, 2007, INT J EPIDEMIOL, V36, P666, DOI 10.1093/ije/dym018
   Saw SM, 2005, OPHTHAL PHYSL OPT, V25, P381, DOI 10.1111/j.1475-1313.2005.00298.x
   VANNORREN D, 1990, ARCH OPHTHALMOL-CHIC, V108, P1670, DOI 10.1001/archopht.1990.01070140024009
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Vurgese S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029692
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   West Emily S., 2005, International Ophthalmology Clinics, V45, P41
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
NR 35
TC 30
Z9 30
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2013
VL 120
IS 10
BP 2058
EP 2065
DI 10.1016/j.ophtha.2013.03.028
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 227CQ
UT WOS:000325086400023
PM 23706699
DA 2022-11-30
ER

PT J
AU Hibbs, SP
   Smith, A
   Chow, LP
   Downes, SM
AF Hibbs, S. P.
   Smith, A.
   Chow, L. P.
   Downes, S. M.
TI Colour photographs for screening in neovascular age-related macular
   degeneration: are they necessary?
SO EYE
LA English
DT Article
DE age-related macular degeneration; AMD; retinal imaging; choroidal
   neovascularisation; exudative AMD, OCT
ID RANIBIZUMAB; IDENTIFICATION
AB Aims To investigate whether optical coherence tomography (OCT) with associated infra-red images provide enough information to determine treatment decisions in the management of neovascular age-related macular degeneration (nAMD), or whether retinal colour photography is also necessary.
   Methods In all, 87 OCT scans of 82 eyes with nAMD undergoing monitoring post ranibizumab treatment were taken using the Zeiss Stratus (Carl Zeiss Meditec, Jena, Germany; n = 87) together with their corresponding infra-red images. Fundus colour photographs were also taken. These images were reviewed by an experienced assessor, and a ranibizumab treatment decision was made during a multidisciplinary team retinal image review meeting.
   Results In all, 30 OCT scans (34.5%) showed intraretinal or subretinal oedema. A total of 24 colour photographs (19.5%) demonstrated retinal haemorrhage. Corresponding OCT infra-red images gave poor sensitivity in detecting haemorrhages (0.176). In 16.7% of decisions to treat, haemorrhage alone was the deciding factor. Signs of disease activity seen only on colour photography were the deciding factor in clinical decisions for 8% of scans assessed.
   Conclusions The presence or increase of intra-retinal oedema is an important sign of activity triggering ranibizumab retreatment, but some eyes show signs of retinal haemorrhage without coexisting oedema. These haemorrhages are often only seen on either colour imaging or fundoscopy and are unclear or invisible on OCT scans and infrared images. Therefore, although retinal colour photography creates additional expense, it is indispensable for making informed retreatment decisions, if patients are monitored using retinal imaging alone. Eye (2011) 25, 918-921; doi: 10.1038/eye.2011.90; published online 13 May 2011
C1 [Chow, L. P.; Downes, S. M.] John Radcliffe Hosp, Oxford Eye Hosp, Oxford OX3 9DU, England.
   [Smith, A.] Royal Berkshire Hosp, Eye Dept, Reading RG1 5AN, Berks, England.
   [Hibbs, S. P.] Univ Oxford, Div Med Sci, Oxford, England.
C3 University of Oxford; Royal Berkshire Hospital; University of Oxford
RP Downes, SM (通讯作者)，John Radcliffe Hosp, Oxford Eye Hosp, Headley Way, Oxford OX3 9DU, England.
EM susan.downes@orh.nhs.uk
RI Hibbs, Stephen/ABF-2314-2021
OI Hibbs, Stephen/0000-0002-3663-2742
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Maberley DAL, 2005, EYE, V19, P611, DOI 10.1038/sj.eye.6701584
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 7
TC 7
Z9 7
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JUL
PY 2011
VL 25
IS 7
BP 917
EP 920
DI 10.1038/eye.2011.90
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 793ZH
UT WOS:000292862500013
PM 21587273
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Jyothi, S
   Chowdhury, H
   Elagouz, M
   Sivaprasad, S
AF Jyothi, S.
   Chowdhury, H.
   Elagouz, M.
   Sivaprasad, S.
TI Intravitreal bevacizumab (Avastin) for age-related macular degeneration:
   a critical analysis of literature
SO EYE
LA English
DT Article
DE bevacizumab; age-related macular degeneration (ARMD); choroidal
   neovascularisation (CNV); treatment regimen; anti-VEGF (Vascular
   Endothelial Growth Factor); avastin
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; VERTEPORFIN PHOTODYNAMIC
   THERAPY; PIGMENT-EPITHELIUM DETACHMENT; ENDOTHELIAL GROWTH-FACTOR;
   TRIAMCINOLONE ACETONIDE; RANIBIZUMAB; EFFICACY; REGIMEN; 6-MONTH; SAFETY
AB Purpose The current medical environment demands that quality health care is delivered at an affordable cost through the use of objective, unbiased clinical data. This study was undertaken to review the current literature on bevacizumab for age-related macular degeneration and its value in determining best clinical practice.
   Methods Randomised controlled trials (RCTs) and observational studies that met the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria were identified from the current literature for further analysis. Data concerning treatment dosing regimens, response to treatment, complications, and factors influencing outcome and safety were extracted and compiled into a database.
   Results As of January 2009, there were 5 RCTs that compared the outcomes of bevacizumab to other treatment options and 50 studies that met the STROBE criteria with similar visual and anatomical outcomes between RCTs and observational studies. Although the doses and dosing frequencies varied between the studies, the mean gain in vision at 3 months was +7.76 +/- 5.4 ETDRS letters (range +2 to +14.4); an effect that was maintained at 6 months in studies with longer follow-up. Predominantly classic lesions were the most responsive of all lesion subtypes. The complication profiles/rates were similar to those reported with other anti-vascular endothelial agents.
   Conclusions There is sufficient scientific and statistical evidence to advocate the effective use of OCT-guided administration of intravitreal bevacizumab for neovascular AMD. This is reflected in our study outcome measures that are comparable to findings published from recent well-conducted RCTs on intravitreal ranibizumab at the same time point. Eye (2010) 24, 816-824; doi:10.1038/eye.2009.219; published online 14 August 2009
C1 [Sivaprasad, S.] Kings Coll Hosp London, Laser & Retinal Res Unit, Dept Ophthalmol, London SE5 9RS, England.
   [Elagouz, M.] Sohag Univ Hosp, Dept Ophthalmol, Sohag, Egypt.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   Egyptian Knowledge Bank (EKB); Sohag University
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Laser & Retinal Res Unit, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P713, DOI 10.1111/j.1600-0420.2006.00759.x
   Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Ahmadieh H, 2008, EUR J OPHTHALMOL, V18, P297, DOI 10.1177/112067210801800222
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   AVERY RL, 2006, OPHTHALMOLOGY, V113
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   De Clercq C, 2007, Bull Soc Belge Ophtalmol, P15
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   EHRLICH R, 2008, RETINA, V28, P302
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Fung AE, 2009, OPHTHALMOLOGY, V116, P286, DOI 10.1016/j.ophtha.2008.09.014
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Geitzenauer W, 2006, KLIN MONATSBL AUGENH, V223, P822, DOI 10.1055/s-2006-926875
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Hughes MS, 2006, OPHTHAL SURG LAS IM, V37, P446, DOI 10.3928/15428877-20061101-01
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   KREBS I, 2008, ACTA OPHTHALMOL
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P77
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P71
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   LEVY J, 2008, INT OPHTHALMOL
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Mackiewicz Jerzy, 2007, Klin Oczna, V109, P146
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2
   Mones JM, 2007, OPHTHAL SURG LAS IM, V38, P226, DOI 10.3928/15428877-20070501-07
   Navea A, 2009, RETINA-J RET VIT DIS, V29, P13, DOI 10.1097/IAE.0b013e31818a1fd3
   PEDERSEN KB, 2008, ACTA OPHTHALMOL
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SACU S, 2009, EYE
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   *STROBE STAT, 2007, STRENGTH REP OBS STU
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
   Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 74
TC 30
Z9 30
U1 0
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2010
VL 24
IS 5
BP 816
EP 824
DI 10.1038/eye.2009.219
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 595EG
UT WOS:000277592900011
PM 19680279
OA Bronze
DA 2022-11-30
ER

PT J
AU Sohn, EH
   Wang, K
   Thompson, S
   Riker, MJ
   Hoffmann, JM
   Stone, EM
   Mullins, RF
AF Sohn, Elliott H.
   Wang, Kai
   Thompson, Stewart
   Riker, Megan J.
   Hoffmann, Jeremy M.
   Stone, Edwin M.
   Mullins, Robert F.
TI COMPARISON OF DRUSEN AND MODIFYING GENES IN AUTOSOMAL DOMINANT RADIAL
   DRUSEN AND AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; ARMS2; autosomal dominant radial
   drusen; CFH; drusen; extracellular matrix; genetics; histology;
   modifying genes
ID COMPLEMENT FACTOR-H; EXTRACELLULAR-MATRIX; ABERRANT ACCUMULATION;
   MALATTIA LEVENTINESE; TISSUE INHIBITOR; MUTATIONS; EFEMP1; ARMS2; RISK;
   POLYMORPHISM
AB Background: Autosomal dominant radial drusen (ADRD), also termed Malattia Leventinese and Doyne honeycomb retinal dystrophy, causes early-onset vision loss because of mutation in EFEMP1. Drusen in an exceedingly rare ADRD human donor eye was compared with eyes affected with age-related macular degeneration (AMD). This study also elucidated whether variations in high-risk AMD genotypes modify phenotypic severity of ADRD.
   Methods: Morphologic and histochemical analyses of drusen in one ADRD donor and seven AMD donors. Evaluation of complement factor H (CFH) and ARMS2/HTRA1 alleles in a cohort of 25 subjects with ADRD.
   Results: Autosomal dominant radial drusen had unique onion skin-like lamination but otherwise shared many compositional features with hard, nodular drusen and/or diffuse soft drusen with basal deposits. Autosomal dominant radial drusen also possessed collagen type IV, an extracellular matrix protein that is absent in age-related drusen. Antibodies directed against the membrane attack complex showed robust labeling of ADRD. Vitronectin and amyloid P were present in drusen of both types. High-risk alleles in the CFH and ARMS2/HTRA1 genes were not associated with increasing ADRD severity.
   Conclusion: Drusen from ADRD and AMD exhibit overlap of some major constituents, but ADRD exhibit distinct alterations in the extracellular matrix that are absent in AMD.
C1 [Sohn, Elliott H.; Wang, Kai; Thompson, Stewart; Riker, Megan J.; Hoffmann, Jeremy M.; Stone, Edwin M.; Mullins, Robert F.] Univ Iowa, Stephen A Wynn Inst Vis Res, Iowa City, IA 52242 USA.
   [Sohn, Elliott H.; Thompson, Stewart; Riker, Megan J.; Hoffmann, Jeremy M.; Stone, Edwin M.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Wang, Kai] Univ Iowa, Dept Biostat, Iowa City, IA 52242 USA.
   [Stone, Edwin M.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa; Howard
   Hughes Medical Institute; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Stephen A Wynn Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA.
EM Robert-Mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891; Stone, Edwin
   M./0000-0003-3343-4414; Thompson, Stewart/0000-0003-4784-8386; Sohn,
   Elliott/0000-0002-3778-9362
FU National Institutes of Health [EY017451, EY016822]; Howard Hughes
   Medical Institute; Hansjoerg E.J.W. Kolder Professorship for Best
   Disease Research; NATIONAL EYE INSTITUTE [R01EY017451, R01EY016822]
   Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health Grants EY017451 and
   EY016822, the Howard Hughes Medical Institute, and the Hansjoerg E.J.W.
   Kolder Professorship for Best Disease Research.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Curcio CA, 2012, STRUCTURE FUNCTION P
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fawzi AA, 2009, BRIT J OPHTHALMOL, V93, P1606, DOI 10.1136/bjo.2009.158089
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102
   Lenassi E, 2013, AM J OPHTHALMOL, V155, P190, DOI 10.1016/j.ajo.2012.07.003
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Michaelides M, 2006, INVEST OPHTH VIS SCI, V47, P3085, DOI 10.1167/iovs.05-1600
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   NEWSOME DA, 1988, EXP EYE RES, V46, P305, DOI 10.1016/S0014-4835(88)80022-8
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297
   Roybal CN, 2005, INVEST OPHTH VIS SCI, V46, P3973, DOI 10.1167/iovs.05-0070
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sohn EH, 2012, RETINA, P852
   Sohn EH, 2011, ARCH OPHTHALMOL-CHIC, V129, P1626, DOI 10.1001/archophthalmol.2011.338
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
NR 39
TC 20
Z9 20
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2015
VL 35
IS 1
BP 48
EP 57
DI 10.1097/IAE.0000000000000263
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX6WX
UT WOS:000347060000016
PM 25077532
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zweifel, SA
   Saroj, N
   Shapiro, H
   Freund, KB
AF Zweifel, Sandrine A.
   Saroj, Namrata
   Shapiro, Howard
   Freund, K. Bailey
TI THE EFFECT OF FELLOW EYE VISUAL ACUITY ON VISUAL ACUITY OF STUDY EYES
   RECEIVING RANIBIZUMAB FOR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular AMD; anti-vascular endothelial growth factor; intravitreal
   injections; MARINA trial; ANCHOR trial; eccentric fixation
ID GROWTH-FACTOR THERAPY; ANTI-VEGF THERAPY; CHOROIDAL NEOVASCULARIZATION;
   DOSING REGIMEN; IMPROVEMENT; VERTEPORFIN; PREVALENCE; TREAT
AB Purpose: To investigate whether extremes in visual acuity (very good or very poor) of the fellow eye (FE) influence visual acuity of the study eye in patients receiving intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
   Methods: From 2 randomized, controlled, clinical trials (MARINA and ANCHOR), we performed a retrospective analysis of ranibizumab-treated patients who maintained stable FE visual acuity (+/- 5 letters from baseline at each of Months 1, 4, 6, and 12), comparing patients with untreated FE visual acuity that was either 20/32 or better (very good) or 20/200 or worse (very poor). Visual acuity of the treated study eyes, which received monthly intravitreal ranibizumab (0.3 mg or 0.5 mg), was compared between the 2 FE cohorts at the Month 6 and Month 12 visits.
   Results: A total of 145 patients were analyzed. In the cohort with very poor FE visual acuity (n = 55), there were 35 patients in MARINA and 20 patients in ANCHOR; in the cohort with very good FE visual acuity (n = 90), there were 52 patients in MARINA and 38 patients in ANCHOR. The mean (standard deviation) gain of the study eye visual acuity in the very good FE cohort was 10.3 (13.3) and 10.8 (13.7) letters at Months 6 and 12, respectively, compared with a lesser mean visual acuity gain of 4.6 (12.2) and 6.7 (11.7) letters at Months 6 and 12 in the very poor vision FE cohort. There was no statistically significant difference (adjusted) in the study eye visual acuity change between the 2 cohorts at either 6 months (P = 0.11) or 12 months (P = 0.26).
   Conclusion: This retrospective analysis of the MARINA and ANCHOR study data did not support the hypothesis that FE visual acuity plays a significant role in driving visual acuity of patients receiving monthly intravitreal ranibizumab injections for neovascular age-related macular degeneration. Visual acuity of the FE by itself is, therefore, not a useful parameter in predicting visual acuity in a majority of ranibizumab-treated patients. RETINA 32:1243-1249, 2012
C1 [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Zweifel, Sandrine A.] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Saroj, Namrata; Shapiro, Howard] Genentech Inc, San Francisco, CA 94080 USA.
C3 Vitreous Retina Macula Consultants of New York; University of Zurich;
   University Zurich Hospital; Roche Holding; Genentech
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Zweifel, Sandrine/AAX-5045-2020; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc.; Genentech, Inc, South San Francisco, CA;
   Novartis Pharma, AG, Basel, Switzerland
FX Supported in part by the Macula Foundation, Inc. The ANCHOR and MARINA
   studies were funded by Genentech, Inc, South San Francisco, CA, and
   Novartis Pharma, AG, Basel, Switzerland. Genentech designed and oversaw
   the conduct of the ANCHOR and MARINA studies and managed and
   statistically analyzed the data.
CR Behrendt CE, 2004, OPHTHAL EPIDEMIOL, V11, P359, DOI 10.1080/09286580490515125
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Heimes B, 2011, OPHTHALMOLOGE, V108, P124, DOI 10.1007/s00347-010-2210-z
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Ishiko S, 2010, CURR EYE RES, V35, P651, DOI 10.3109/02713681003707235
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   SINGERMAN LJ, 1985, RETINA-J RET VIT DIS, V5, P135, DOI 10.1097/00006982-198500530-00001
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 24
TC 2
Z9 2
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2012
VL 32
IS 7
BP 1243
EP 1249
DI 10.1097/IAE.0b013e3182469064
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 965QK
UT WOS:000305782100003
PM 22466461
DA 2022-11-30
ER

PT J
AU Tikellis, G
   Sun, C
   Gorin, MB
   Klein, R
   Klein, BEK
   Larsen, EKM
   Siscovick, DS
   Hubbard, LD
   Wong, TY
AF Tikellis, Gabriella
   Sun, Cong
   Gorin, Michael B.
   Klein, Ronald
   Klein, Barbara E. K.
   Larsen, Emily K. Marino
   Siscovick, David S.
   Hubbard, Larry D.
   Wong, Tien Y.
TI Apolipoprotein E gene and age-related maculopathy in older individuals -
   The Cardiovascular Health Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; E EPSILON-4;
   BLOOD-PRESSURE; RISK; ASSOCIATION; POPULATION; APOE; EYE; PREVALENCE
AB Objective: To examine the association between the apolipoprotein E (APOE) gene and age-related maculopathy (ARM) in an older population.
   Methods: Two thousand one hundred seventy persons 65 years and older sampled from 4 US communities had ARM signs assessed from retinal photographs using a modified Wisconsin Age-Related Maculopathy Grading System. DNA extracted from blood samples was analyzed for common APOE alleles.
   Results: After controlling for age, sex, cigarette smoking, and other factors, white participants carrying the epsilon 2 allele had an increased risk of late ARM (odds ratio, 2.53 [95% confidence interval, 1.08-5.90]) while carriers of the epsilon 4 allele had a lower risk of late ARM (odds ratio, 0.69 [95% confidence interval, 0.19-2.50]). There were too few late ARM cases in African American individuals for analysis.
   Conclusion: APOE polymorphism is associated with late ARM in older white persons 65 years and older. Consistent with previous studies, the APOE epsilon 2 allele is associated with a significant increased risk of late ARM development, whereas the epsilon 4 allele may confer some protection.
C1 Univ Melbourne, Ctr Eye Res Australia, Retinal Vasc Imaging Ctr, Melbourne, Vic 3002, Australia.
   Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15260 USA.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   Univ Washington, Dept Med & Epidemiol, Seattle, WA 98195 USA.
   Natl Univ Singapore, Eye Res Inst, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; University of Wisconsin System; University of Wisconsin
   Madison; University of Washington; University of Washington Seattle;
   University of Washington; University of Washington Seattle; National
   University of Singapore
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Retinal Vasc Imaging Ctr, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU NHLBI NIH HHS [R21-HL077166, HC-97-06] Funding Source: Medline; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTE [R21HL077166] Funding Source: NIH
   RePORTER
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   CUSHMAN M, 1995, CLIN CHEM, V41, P264
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans DA, 1997, JAMA-J AM MED ASSOC, V277, P822, DOI 10.1001/jama.277.10.822
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   Gorin MB, 1999, MOL VIS, V5, pU31
   Haan MN, 1999, JAMA-J AM MED ASSOC, V282, P40, DOI 10.1001/jama.282.1.40
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HIXSON JE, 1990, J LIPID RES, V31, P545
   Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   ROBBINS J, 1995, J AM GERIATR SOC, V43, P855, DOI 10.1111/j.1532-5415.1995.tb05526.x
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9
   TELL GS, 1994, HYPERTENSION, V23, P59, DOI 10.1161/01.HYP.23.1.59
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Wong TY, 2002, BRIT J OPHTHALMOL, V86, P1007, DOI 10.1136/bjo.86.9.1007
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 36
TC 25
Z9 25
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2007
VL 125
IS 1
BP 68
EP 73
DI 10.1001/archopht.125.1.68
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ZQ
UT WOS:000243336800009
PM 17210854
OA Bronze
DA 2022-11-30
ER

PT J
AU Huang, PR
   Wang, FH
   Sah, BK
   Jiang, JH
   Ni, ZT
   Wang, JS
   Sun, XD
AF Huang, Peirong
   Wang, Fenghua
   Sah, Birendra Kumar
   Jiang, Junhai
   Ni, Zhentian
   Wang, Jentso
   Sun, Xiaodong
TI Homocysteine and the risk of age-related macular degeneration: a
   systematic review and meta-analysis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PLASMA HOMOCYSTEINE; FOLIC-ACID; B-VITAMINS; MACULOPATHY; ANTIOXIDANT;
   MARKERS; FOLATE; WOMEN
AB Contrasting results have been reported regarding the associations between plasma total homocysteine (tHcy) and B vitamin levels and age-related macular degeneration (AMD) risk. Thus, we aimed to systematically evaluate these associations. Relevant case control studies in English were identified via a thorough search of the PubMed, Medline, and Embase databases from inception to June 2014. The results were pooled using Review Manager 5.2.1. Eleven studies (including 1072 cases and 1202 controls) were eligible for analysis of tHcy levels; additionally, 3 studies (including 152 cases and 98 controls) were eligible for analysis of folic acid and vitamin B-12 levels. The cumulative results demonstrated that the plasma tHcy level among the AMD cases was 2.67 mu mol/L (95% confidence interval [CI], 1.60-3.74) higher than that among the controls. In contrast, the vitamin B-12 level among the AMD cases was 64.16 pg/mL (95% CI, 19.32-109.00) lower than that among the controls. Subgroup analyses showed that the folic acid level was 1.66 ng/mL (95% CI, 0.10-3.21) lower for the wet type. Together, the results demonstrated that AMD is associated with elevated tHcy levels and decreased vitamin B-12 levels. Plasma tHcy may act as a modulator of the risk for AMD based on the current evidence.
C1 [Huang, Peirong; Wang, Fenghua; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China.
   [Huang, Peirong; Wang, Fenghua; Sun, Xiaodong] Shanghai Jiao Tong Univ, Eye Res Inst, Shanghai 200030, Peoples R China.
   [Sah, Birendra Kumar; Ni, Zhentian; Wang, Jentso] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Shanghai 200030, Peoples R China.
   [Jiang, Junhai] Univ Texas Hlth Sci Ctr Houston, Div Biostat, Houston, TX 77030 USA.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; University of Texas System; University of Texas
   Health Science Center Houston
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China.
EM xdsun@sjtu.edu.cn
RI NI, ZHENTIAN/GSJ-2311-2022
FU National Basic Research Program of China "973 Program" [2011CB707506];
   National Natural Science Foundation of China [81271030]; Shanghai Key
   Basic Research Grant [11JC141601]; Shanghai Scholar Leadership Grant
   [12XD1404100, XBR2013081]; Shanghai Creative Key Medical Research Grant
   [1341195400]
FX This study was supported by the National Basic Research Program of China
   "973 Program" (2011CB707506), the National Natural Science Foundation of
   China (81271030), a Shanghai Key Basic Research Grant (11JC141601), a
   Shanghai Scholar Leadership Grant (12XD1404100, XBR2013081), and a
   Shanghai Creative Key Medical Research Grant (1341195400).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Evans J, 2013, AM J CLIN NUTR, V98, P4, DOI 10.3945/ajcn.113.064899
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Huang PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082454
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marti-Carvajal AJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006612.pub3
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Mulero J, 2014, CLIN HEMORHEOL MICRO, V58, P447, DOI 10.3233/CH-141807
   Nappo F, 1999, JAMA-J AM MED ASSOC, V281, P2113, DOI 10.1001/jama.281.22.2113
   Niu WQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017052
   Niu WQ, 2009, HYPERTENS RES, V32, P1060, DOI 10.1038/hr.2009.164
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Obeid R, 2013, CLIN CHEM LAB MED, V51, P657, DOI 10.1515/cclm-2012-0402
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Silverman MD, 2002, ARTERIOSCL THROM VAS, V22, P587, DOI 10.1161/01.ATV.0000014221.30108.08
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xue P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045849
NR 39
TC 36
Z9 36
U1 0
U2 11
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 21
PY 2015
VL 5
AR 10585
DI 10.1038/srep10585
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN2FP
UT WOS:000358236500001
PM 26194346
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Raman, R
   Lahane, S
   Gupta, A
   Sandeep, D
   Sharma, T
AF Raman, Rajiv
   Lahane, Sayalee
   Gupta, Aditi
   Sandeep, D.
   Sharma, Tarun
TI Foveal slope measurements in subjects with high-risk of age-related
   macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Configuration; choroidal neovascular membrane; foveal slope; foveal
   thickness; neovascular age-related macular degeneration; macular pigment
ID RETINAL THICKNESS; LUTEIN SUPPLEMENTATION; SPATIAL-DISTRIBUTION; AXIAL
   LENGTH; PIGMENT; SEX; PROFILE
AB Background: Recent reports indicated that the slope of the foveal depression influences the macular pigment (MP) spatial profile. MP has been shown to confer possible protection against age-related macular degeneration (ARMD) because of its antioxidant properties. Aims: To study the configuration of foveal slope and the foveal thickness in fellow eyes of subjects with unilateral neovascular ARMD. Settings and design: Case-control series. Materials and Methods: The study population consisted of 30 cases aged >50, who had unilateral choroidal neovascular membrane (CNVM) or disciform scar in the fellow eye and 29 controls aged >50, who had no sign of ARMD in the either eye. Using spectral-domain optical coherence tomography, foveal thickness at different locations including the central subfield foveal thickness (CSFT) was noted. The foveal slopes were calculated in the six radial scans (between 0.25 degrees and 1 +/- retinal eccentricity) as well as the 3D scan. Results: Cases had a significantly higher CSFT when compared to controls (215.1 +/- 36.19 +/- vs. 193.0 +/- 17.38 +/-, P = 0.004). On the 3D scan, the cases had shallower superior (cases 1.32 +/- 0.32 vs. controls 1.45 +/- 0.13, P = 0.04) and temporal slopes (cases 1.27 +/- 0.21 vs. controls 1.39 +/- 0.12, P = 0.01) in comparison to the controls. Conclusions: We noted a shallower superior and temporal foveal slope and a higher CSFT in the fellow eyes of subjects with a unilateral neovascular ARMD. Prospective studies observing the development of CNVM in subjects with altered foveal slope might provide more information on this optical coherence tomography finding.
C1 [Raman, Rajiv; Lahane, Sayalee; Gupta, Aditi; Sharma, Tarun] Sankara Nethralaya, Shri Bhagwan Mahavir Dept Vitreoretinal Serv, Madras 600006, Tamil Nadu, India.
   [Sandeep, D.] Sankara Nethralaya, Dept Optometry, Madras 600006, Tamil Nadu, India.
RP Sharma, T (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM drtaruns@gmail.com
RI Raman, Rajiv/A-7234-2009
OI Raman, Rajiv/0000-0001-5842-0233
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Duncan JL, 2002, EXP EYE RES, V74, P371, DOI 10.1006/exer.2001.1126
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Grover S, 2010, INVEST OPHTH VIS SCI, V51, P2644, DOI 10.1167/iovs.09-4774
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Liew SHM, 2006, EXP EYE RES, V82, P915, DOI 10.1016/j.exer.2005.10.014
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Ooto S, 2011, INVEST OPHTH VIS SCI, V52, P8769, DOI 10.1167/iovs.11-8388
   Palomo-Alvarez C, 2010, ACTA OPHTHALMOL, P88
   Pryor W, 1987, MODERN BIOL THEORIES, P42
   Sayanagi K, 2009, AM J OPHTHALMOL, V148, P431, DOI 10.1016/j.ajo.2009.04.008
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Song WK, 2010, INVEST OPHTH VIS SCI, V51, P3913, DOI 10.1167/iovs.09-4189
   Van Der Veen RLP, 2009, EUR J OPHTHALMOL, V19, P836, DOI 10.1177/112067210901900524
   Wagner-Schuman M, 2011, INVEST OPHTH VIS SCI, V52, P625, DOI 10.1167/iovs.10-5886
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 26
TC 1
Z9 1
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD SEP
PY 2013
VL 61
IS 9
BP 507
EP 510
DI 10.4103/0301-4738.119437
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 239PR
UT WOS:000326038400007
PM 24104710
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Meng, XL
   Huang, YF
   Jiang, YM
AF Meng, Xiaoli
   Huang, Yifei
   Jiang, Yanming
TI The association of FBLN5 polymorphisms with age-related macular
   degeneration susceptibility in the population of northern China
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE FBLN5; AMD; polymorphism
ID NEOVASCULAR AMD; FIBULIN-5; VARIANTS; PREVALENCE; INVASION; MATRIX
AB Objectives: This study are intended to explore the effect of FBLN5 polymorphisms on age-related macular degeneration (AMD) susceptibility and provide evidence for the pathogenesis of AMD. Methods: This case-control study was conducted in 138 patients with AMD and 152 healthy persons frequency-match with the former by age and gender. FBLN5 1087G>A and 506T>C polymorphisms were genotyped through polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The X-2 test was used to check hardy-weinberg equilibrium (HWE) and calculate odds ratio (OR) with 95% confidence interval (CI) which evaluated the association between polymorphisms and AMD risk. Results: HWE test showed that the selection of control group conformed to requirement. As a result, mutant genotypes TC, CC of FBLN5 506T>C polymorphism both had the higher frequencies in cases compared with controls (P=0.006 and 0.029, respectively). Furthermore its mutant allele C also was associated with the increased risk of AMD (OR=1.725, 95% CI=1.210-2.459). Conclusions: FBLN5 506T>C polymorphism significantly increased the susceptibility to AMD in population of northern China, but 1087G>A might be not an independent risk factor for AMD development.
C1 [Meng, Xiaoli; Huang, Yifei] Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Meng, Xiaoli] Sekwa Eye Hosp, Sekwa Inst Med, Beijing, Peoples R China.
   [Jiang, Yanming] Rocket Force Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Huang, YF (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China.
EM manglit@126.com
RI Huang, Yifei/ABE-7566-2020; Huang, Yifei/ABE-4692-2020
OI Huang, Yifei/0000-0002-7089-6426
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cezario SM, 2015, ARQ BRAS OFTALMOL, V78, P85, DOI 10.5935/0004-2749.20150023
   Chen XJ, 2015, ONCOTARGET, V6, P15022, DOI 10.18632/oncotarget.3609
   Chen XJ, 2014, CARCINOGENESIS, V35, P1707, DOI 10.1093/carcin/bgu023
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Hwang CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084218
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Khan M., 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/608390
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kowal RC, 1999, CYTOGENET CELL GENET, V87, P2, DOI 10.1159/000015382
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Owen LA, 2014, INVEST OPHTH VIS SCI, V55, P3543, DOI 10.1167/iovs.14-14047
   Park UC, 2014, MOL VIS, V20, P1680
   Shi XY, 2014, ASIAN PAC J TROP MED, V7, P787, DOI 10.1016/S1995-7645(14)60137-1
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tu KS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-938
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Volz C, 2015, EUR J PHARM BIOPHARM
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Zhang R, 2015, GENE, V567, P51, DOI 10.1016/j.gene.2015.04.068
NR 28
TC 0
Z9 0
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 3
BP 3722
EP 3726
PG 5
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA ER8PR
UT WOS:000399083300147
DA 2022-11-30
ER

PT J
AU Zarbin, MA
   Rosenfeld, PJ
AF Zarbin, Marco A.
   Rosenfeld, Philip J.
TI PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION An
   Integrated Survey of Emerging Treatment Alternatives
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; angiogenesis; choroidal
   neovascularization; complement; geographic atrophy; neuroprotection;
   oxidative damage; treatment
ID FIBROBLAST-GROWTH-FACTOR; SYNTHETIC RETINOID FENRETINIDE; COMPLEMENT
   FACTOR-H; CILIARY NEUROTROPHIC FACTOR; EPITHELIUM-DERIVED FACTOR;
   PHOTORECEPTOR CELL DEGENERATION; MEDIATED GENE-TRANSFER; PHASE-I TRIAL;
   PIGMENT EPITHELIUM; LIGHT DAMAGE
AB Purpose: To review treatments under development for age-related macular degeneration (AMD) in the context of current knowledge of AMD pathogenesis.
   Methods: Review of the scientific literature published in English.
   Results: Steps in AMD pathogenesis that appear to be good targets for drug development include 1) oxidative damage; 2) lipofuscin accumulation; 3) chronic inflammation; 4) mutations in the complement pathway; and 5) noncomplement mutations that influence chronic inflammation and/or oxidative damage (e. g., mitochondria and extracellular matrix structure). Steps in neovascularization that can be targeted for drug development and combination therapy include 1) angiogenic factor production; 2) factor release; 3) binding of factors to extracellular receptors (and activation of intracellular signaling after receptor binding); 4) endothelial cell activation (and basement membrane degradation); 5) endothelial cell proliferation; 6) directed endothelial cell migration; 7) extracellular matrix remodeling; 8) tube formation; and 9) vascular stabilization.
   Conclusion: The era of pathway-based therapy for the early and late stages of AMD has begun. At each step in the pathway, a new treatment could be developed, but complete inhibition of disease progression will likely require a combination of the various treatments. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical benefits (visual acuity and frequency of treatment) will likely be superior to monotherapy in preventing the late-stage complications of AMD.
   RETINA 30: 1350-1367, 2010
C1 [Zarbin, Marco A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Doctors Off Ctr, Newark, NJ 07103 USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center; Bascom Palmer Eye Institute; University of Miami
RP Zarbin, MA (通讯作者)，Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Doctors Off Ctr, Room 6156,90 Bergen St, Newark, NJ 07103 USA.
EM zarbin@umdnj.edu
OI Zarbin, Marco/0000-0002-7811-7132
FU Lincy Foundation; Foundation Fighting Blindness; National Eye Institute;
   Advanced Cell Technology; Research to Prevent Blindness; Janice Mitchell
   Vassar and Ashby John Mitchell Fellowship; Joseph J. and Marguerite
   DiSepio Retina Research Fund; New Jersey Lions Eye Research Foundation;
   Eye Institute of New Jersey; Alexion Pharmaceuticals; Carl Zeiss
   Meditec; Potentia Pharmaceuticals; CoMentis
FX M. A. Zarbin received grant support from the Lincy Foundation,
   Foundation Fighting Blindness, National Eye Institute, Advanced Cell
   Technology, Research to Prevent Blindness, Janice Mitchell Vassar and
   Ashby John Mitchell Fellowship, Joseph J. and Marguerite DiSepio Retina
   Research Fund, the New Jersey Lions Eye Research Foundation, and the Eye
   Institute of New Jersey. P. J. Rosenfeld received grant support from
   National Eye Institute, Alexion Pharmaceuticals, Othera Pharmaceuticals,
   Carl Zeiss Meditec, Potentia Pharmaceuticals, and CoMentis.
CR Ahlemeyer B, 1997, BRAIN RES, V777, P179
   AIZUSS DH, 1985, INVEST OPHTH VIS SCI, V26, P1262
   Akimoto M, 1999, INVEST OPHTH VIS SCI, V40, P273
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Amara U, 2008, ADV EXP MED BIOL, V632, P71, DOI 10.1007/978-0-387-78952-1_6
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   AVERY RL, 2006, OPHTHALMOLOGY, V363
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353
   Azadi S, 2007, BRAIN RES, V1129, P116, DOI 10.1016/j.brainres.2006.10.031
   Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200
   Beltran WA, 2005, MOL VIS, V11, P232
   Beltran WA, 2009, INVEST OPHTH VIS SCI, V50, P5355, DOI 10.1167/iovs.09-3741
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156
   Camerini T, 2001, J CLIN ONCOL, V19, P1664, DOI 10.1200/JCO.2001.19.6.1664
   Campochiaro PA, 1996, J NEUROSCI, V16, P1679
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Caruso RC, 1998, ARCH OPHTHALMOL-CHIC, V116, P759, DOI 10.1001/archopht.116.6.759
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chalmel F, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-74
   Chaum E, 2003, J CELL BIOCHEM, V88, P57, DOI 10.1002/jcb.10354
   Conley B, 2000, J CLIN ONCOL, V18, P275, DOI 10.1200/JCO.2000.18.2.275
   COSTA A, 1989, EUR J CANCER CLIN ON, V25, P805, DOI 10.1016/0277-5379(89)90124-7
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Decensi A, 2000, CANCER EPIDEM BIOMAR, V9, P1071
   Decensi A, 1997, EUR J CANCER, V33, P80, DOI 10.1016/S0959-8049(96)00351-6
   DECENSI A, 1994, J NATL CANCER I, V86, P105, DOI 10.1093/jnci/86.2.105
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Engelbert M, 2005, INVEST OPHTH VIS SCI, V46, P2479, DOI 10.1167/iovs.04-1139
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554
   Farjo KM, 2009, INVEST OPHTH VIS SCI, V50, P5089, DOI 10.1167/iovs.09-3797
   Follen M, 2001, CLIN CANCER RES, V7, P3356
   FORMELLI F, 1989, CANCER RES, V49, P6149
   FORMELLI F, 1993, J CLIN ONCOL, V11, P2036, DOI 10.1200/JCO.1993.11.10.2036
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022
   Garaventa A, 2003, CLIN CANCER RES, V9, P2032
   GIESE MJ, 1994, INVEST OPHTH VIS SCI, V35, P1026
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOUREAU O, 1993, NEUROREPORT, V5, P233, DOI 10.1097/00001756-199312000-00012
   Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Joseph RM, 1996, INVEST OPHTH VIS SCI, V37, P2434
   KAISER PK, 2009, OPHTHALMOLOGY, V116
   KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P69
   Kaldi I, 2003, EXP EYE RES, V76, P453, DOI 10.1016/S0014-4835(02)00334-2
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lee CG, 2000, CANCER RES, V60, P5565
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li Y, 2003, INVEST OPHTH VIS SCI, V44, P1299, DOI 10.1167/iovs.02-0235
   Machida S, 2001, INVEST OPHTH VIS SCI, V42, P1087
   Maeda A, 2006, J BIOL CHEM, V281, P37697, DOI 10.1074/jbc.M608375200
   Maeda A, 2009, INVEST OPHTH VIS SCI, V50, P5435, DOI 10.1167/iovs.09-3944
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mariani L, 1996, TUMORI, V82, P444, DOI 10.1177/030089169608200506
   Mitchell TS, 2008, ANGIOGENESIS, V11, P141, DOI 10.1007/s10456-007-9085-x
   Miyazaki M, 2003, GENE THER, V10, P1503, DOI 10.1038/sj.gt.3302028
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neuner-Jehle M, 2000, HUM GENE THER, V11, P1875, DOI 10.1089/10430340050129495
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nir I, 2000, J NEUROSCI, V20, P2150
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Orecchia A, 2003, J CELL SCI, V116, P3479, DOI 10.1242/jcs.00673
   Organisciak DT, 2003, INVEST OPHTH VIS SCI, V44, P486, DOI 10.1167/iovs.02-0708
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Puduvalli VK, 2004, J CLIN ONCOL, V22, P4282, DOI 10.1200/JCO.2004.09.096
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Ranchon I, 2003, J NEUROSCI, V23, P6050, DOI 10.1523/JNEUROSCI.23-14-06050.2003
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Raz-Prag D, 2009, INVEST OPHTH VIS SCI, V50, P3897, DOI 10.1167/iovs.08-3153
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Russell RM, 2004, J NUTR, V134, p262S, DOI 10.1093/jn/134.1.262S
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P934, DOI 10.1016/0006-291X(87)90340-8
   Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Sun CP, 2009, INTEGR BIOL-UK, V1, P123, DOI 10.1039/b815225j
   TAKAGI H, 1994, INVEST OPHTH VIS SCI, V35, P916
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   TORRISO R, 1994, CANCER EPIDEM BIOMAR, V3, P507
   Uteza Y, 1999, P NATL ACAD SCI USA, V96, P3126, DOI 10.1073/pnas.96.6.3126
   Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927
   Wahlin KJ, 2001, EXP EYE RES, V73, P693, DOI 10.1006/exer.2001.1078
   WALDBILLIG RJ, 1991, J NEUROCHEM, V57, P1522, DOI 10.1111/j.1471-4159.1991.tb06347.x
   Wen R, 1996, J NEUROSCI, V16, P5986
   WEN R, 1995, J NEUROSCI, V15, P7377
   Wen R, 1998, CURR EYE RES, V17, P494, DOI 10.1076/ceyr.17.5.494.5186
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wong PK, 2008, P NATL ACAD SCI USA, V105, P5105, DOI 10.1073/pnas.0800823105
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Q, 2001, MOL VIS, V7, P48
   Zarbin M, 2006, ARCH OPHTHALMOL-CHIC, V124, P563, DOI 10.1001/archopht.124.4.563
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeiss CJ, 2006, EXP EYE RES, V82, P395, DOI 10.1016/j.exer.2005.07.014
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 164
TC 117
Z9 119
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2010
VL 30
IS 9
BP 1350
EP 1367
DI 10.1097/IAE.0b013e3181f57e30
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 659JC
UT WOS:000282561800002
PM 20924259
DA 2022-11-30
ER

PT J
AU Nashine, S
   Cohen, P
   Wan, JX
   Kenney, MC
AF Nashine, Sonali
   Cohen, Pinchas
   Wan, Junxiang
   Kenney, M. Cristina
TI Effect of Humanin G (HNG) on inflammation in age-related macular
   degeneration (AMD)
SO AGING-US
LA English
DT Article
DE Humanin G; HNG; AMD; inflammation; age-related macular degeneration
ID TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; ALPHA GENE
   POLYMORPHISMS; P-SELECTIN; AMYLOID-BETA; IFN-GAMMA; LEUKOCYTE ADHESION;
   RPE CELLS; IN-VITRO; EXPRESSION
AB Inflammation plays a crucial role in the etiology and pathogenesis of AMD (Age-related Macular Degeneration). Humanin G (HNG) is a Mitochondrial Derived Peptide (MDP) that is cytoprotective in AMD and can protect against mitochondrial and cellular stress induced by damaged AMD mitochondria. The goal of this study was to test our hypothesis that inflammation-associated marker protein levels are increased in AMD and treatment with HNG leads to reduction in their protein levels. Humanin protein levels were measured in the plasma of AMD patients and normal subjects using ELISA assay. Humanin G was added to AMD and normal (control) cybrids which had identical nuclei from mitochondria-deficient ARPE-19 cells but differed in mitochondrial DNA (mtDNA) content derived from clinically characterized AMD patients and normal (control) subjects. Cell lysates were extracted from untreated and HNG-treated AMD and normal cybrids, and the Luminex XMAP multiplex assay was used to measure the levels of inflammatory proteins. AMD plasma showed reduced Humanin protein levels, but higher protein levels of inflammation markers compared to control plasma samples. In AMD RPE cybrid cells, Humanin G reduced the CD62E/ E-Selectin, CD62P/ P-Selectin, ICAM-1, TNF-alpha, MIP-1 alpha, IFN-gamma, IL-1 beta, IL-13, and IL-17A protein levels, thereby suggesting that Humanin G may rescue from mtDNA-mediated inflammation in AMD cybrids. In conclusion, we present novel findings that: A) show reduced Humanin protein levels in AMD plasma vs. normal plasma; B) suggest the role of inflammatory markers in AMD pathogenesis, and C) highlight the positive effects of Humanin G in reducing inflammation in AMD.
C1 [Nashine, Sonali; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Cohen, Pinchas; Wan, Junxiang] Univ Southern Calif, Davis Sch Gerontol, Los Angeles, CA 90007 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University of Southern California; University of California System;
   University of California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.; Kenney, MC (通讯作者)，Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
EM mkenney@hs.uci.edu
FU Arnold and Mabel Beckman foundation; Discovery Eye Foundation; Iris and
   B. Gerald Cantor Foundation; Research to Prevent Blindness; NEI [R01
   EY027363]; UCI School of Medicine; Institute for Clinical and
   Translational Science (ICTS) at University of California Irvine; 2017
   Genentech/ARVO AMD Translational Research Fellowship; 2016 RPB pilot
   research grant
FX This research was funded by Arnold and Mabel Beckman foundation,
   Discovery Eye Foundation, Polly and Michael Smith, Edith and Roy Carver,
   Iris and B. Gerald Cantor Foundation, Unrestricted Departmental Grant
   from Research to Prevent Blindness and NEI R01 EY027363, UCI School of
   Medicine, and support of the Institute for Clinical and Translational
   Science (ICTS) at University of California Irvine. S.N. is a recipient
   of the 2017 Genentech/ARVO AMD Translational Research Fellowship and the
   2016 RPB pilot research grant.
CR Abiko T, 2003, DIABETES, V52, P829, DOI 10.2337/diabetes.52.3.829
   Afonina IS, 2015, IMMUNITY, V42, P991, DOI 10.1016/j.immuni.2015.06.003
   Angiari S, 2013, IMMUNOTHERAPY-UK, V5, P1207, DOI [10.2217/imt.13.122, 10.2217/IMT.13.122]
   Appelbaum T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177224
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Baba T, 2020, ELIFE, V9, DOI 10.7554/eLife.54257
   Balne PK, 2018, DATA BRIEF, V19, P1570, DOI 10.1016/j.dib.2018.05.085
   Bhavsar I., 2015, GEN METHODS BIOMARK, P223
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Byrne EM, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070831
   Campanella GSV, 2008, P NATL ACAD SCI USA, V105, P4814, DOI 10.1073/pnas.0801544105
   Chakrabarty P, 2010, J IMMUNOL, V184, P5333, DOI 10.4049/jimmunol.0903382
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Charles-Messance H, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-019-1655-5
   Chatziralli I, 2017, INVEST OPHTH VIS SCI, V58, pBIO99, DOI 10.1167/iovs.17-21713
   Chen H, 2018, INVEST OPHTH VIS SCI, V59, P978, DOI 10.1167/iovs.17-22816
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen Y, 2018, MOL MED REP, V17, P4627, DOI 10.3892/mmr.2018.8460
   Chernykh V, 2019, INT J OPHTHALMOL-CHI, V12, P25, DOI 10.18240/ijo.2019.01.04
   Chin YP, 2013, ENDOCRINOLOGY, V154, P3739, DOI 10.1210/en.2012-2004
   Cleator JH, 2006, BLOOD, V107, P2736, DOI 10.1182/blood-2004-07-2698
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, DOI [10.1167/iovs.18-23893, DOI 10.1167/I0VS.18-23893]
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005
   Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621
   Dong N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/126984
   Du ZJ, 2016, GRAEF ARCH CLIN EXP, V254, P2469, DOI 10.1007/s00417-016-3508-6
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   El-Tahan RR, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3197-y
   Elahi MM, 2009, BBA-MOL BASIS DIS, V1792, P163, DOI 10.1016/j.bbadis.2009.01.007
   Ertenli I, 1998, J RHEUMATOL, V25, P1054
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Fabricius HA, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.642761
   Fernandez-Vega B, 2016, CASE REP OPHTHAL, V7, P154, DOI 10.1159/000445102
   Fu B, 2017, INT J OPHTHALMOL-CHI, V10, P535, DOI 10.18240/ijo.2017.04.06
   Gadani SP, 2012, J IMMUNOL, V189, P4213, DOI 10.4049/jimmunol.1202246
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gidlund EK, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.13063
   Gonzalez-Amaro R, 1998, DRUGS, V56, P977, DOI 10.2165/00003495-199856060-00003
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   GUYER DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P350, DOI 10.1001/archopht.1993.01090030068041
   Hernandez M, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051423
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Huang H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173716
   Huang Y, 2001, EUR J IMMUNOL, V31, P3676, DOI 10.1002/1521-4141(200112)31:12<3676::AID-IMMU3676>3.0.CO;2-K
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Joo JH, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-02152-6
   Kataoka K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.73
   Kawano T, 1996, AM J GASTROENTEROL, V91, P309
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Khan AH, 2022, EYE, V36, P2192, DOI 10.1038/s41433-021-01824-3
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088
   Lemaitre C, 2001, INVEST OPHTH VIS SCI, V42, P2022
   Ley K, 2001, Results Probl Cell Differ, V33, P177
   Li YJ, 2019, TOHOKU J EXP MED, V247, P87, DOI 10.1620/tjem.247.87
   Lillard JW, 2003, BLOOD, V101, P807, DOI 10.1182/blood-2002-07-2305
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu BY, 2010, MOL VIS, V16, P184
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu Y, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031406, 10.1371/journal.pone.0048083]
   Ludwig RJ, 2007, EXPERT OPIN THER TAR, V11, P1103, DOI 10.1517/14728222.11.8.1103
   Ma ST, 2016, SCI REP-UK, V6, DOI 10.1038/srep22910
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Markiewicz L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/812503
   de la Camara CMF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11764
   McEver RP, 2015, CARDIOVASC RES, V107, P331, DOI 10.1093/cvr/cvv154
   Mehta HH, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1549-7
   Merten M, 2000, CIRCULATION, V102, P1931, DOI 10.1161/01.CIR.102.16.1931
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Moromizato Y, 2000, AM J PATHOL, V157, P1277, DOI 10.1016/S0002-9440(10)64643-3
   Mullins RF, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-58
   Muzumdar RH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006334
   NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994
   Nagy V, 2013, GRAEF ARCH CLIN EXP, V251, P917, DOI 10.1007/s00417-012-2196-0
   Nakazawa T, 2006, MOL VIS, V12, P867
   Nashine S, 2020, AGING-US, V12, P9031, DOI 10.18632/aging.103164
   Nashine S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051102
   Nashine S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010159
   Nashine S, 2019, AGING-US, V11, P6691, DOI 10.18632/aging.102179
   Nashine S, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107701
   Nashine S, 2019, AGING-US, V11, P1177, DOI 10.18632/aging.101820
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Olivares-Gonzalez L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042096
   Olivares-Gonzalez L, 2020, FASEB J, V34, P13839, DOI 10.1096/fj.202000044RR
   Olson JL, 2009, OCUL IMMUNOL INFLAMM, V17, P195, DOI 10.1080/09273940802710705
   Ponnappan S, 2011, ANTIOXID REDOX SIGN, V14, P1551, DOI 10.1089/ars.2010.3228
   Qidwai T, 2011, SCAND J IMMUNOL, V74, P522, DOI 10.1111/j.1365-3083.2011.02602.x
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Saxena S, 2011, PATHOBIOLOGY, V78, P261, DOI 10.1159/000329589
   Scuderi S, 2015, J MOL NEUROSCI, V56, P431, DOI 10.1007/s12031-015-0505-x
   Shwu-Jiuan S, 2012, TAIWAN J OPHTHALMOLO, V2, P51, DOI [10.1016/j.tjo.2012.02.002, DOI 10.1016/J.TJO.2012.02.002]
   Silva M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01878
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Srividya G, 2018, EYE, V32, P820, DOI 10.1038/eye.2017.285
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Strzelak A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051033
   Takahashi H, 2005, IMMUNOL LETT, V98, P189, DOI 10.1016/j.imlet.2004.11.012
   Tau GZ, 2000, J EXP MED, V192, P977, DOI 10.1084/jem.192.7.977
   Tawwab HR, 2019, EGYPT RETINA J, V6, P38
   Torres Rogil José de Almeida, 2014, Rev. bras.oftalmol., V73, P210, DOI 10.5935/0034-7280.20140046
   Touhami S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1106-8
   Tsai T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194603
   van der Wijk AE, 2017, J LEUKOCYTE BIOL, V102, P993, DOI 10.1189/jlb.3RU0417-139
   vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069
   Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181
   Wan L, 2010, RETINA-J RET VIT DIS, V30, P1595, DOI 10.1097/IAE.0b013e3181dc58a6
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Watanabe T, 2016, BRIT J OPHTHALMOL, V100, P425, DOI 10.1136/bjophthalmol-2015-306924
   Wei TT, 2022, FEBS J, V289, P1968, DOI 10.1111/febs.16272
   Woodhead JST, 2020, J APPL PHYSIOL, V128, P1346, DOI 10.1152/japplphysiol.00032.2020
   Wu HL, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/9402198
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Ye EA, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0771-8
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Yen K, 2020, AGING-US, V12, P11185, DOI 10.18632/aging.103534
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
   Zhao MX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122210
   Zhao RJ, 2014, INT IMMUNOPHARMACOL, V22, P285, DOI 10.1016/j.intimp.2014.06.041
   Zhou JZ, 2012, CURR EYE RES, V37, P416, DOI 10.3109/02713683.2012.661114
   Zhou TWE, 2016, AM J PATHOL, V186, P3100, DOI 10.1016/j.ajpath.2016.08.004
NR 137
TC 1
Z9 1
U1 3
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD MAY 31
PY 2022
VL 14
IS 10
BP 4247
EP 4269
PG 23
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 4J5XM
UT WOS:000851337000026
PM 35576057
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kapran, Z
   Ozkaya, A
   Uyar, OM
AF Kapran, Ziya
   Ozkaya, Abdullah
   Uyar, O. Murat
TI Hemorrhagic Age-Related Macular Degeneration Managed With Vitrectomy,
   Subretinal Injection of Tissue Plasminogen Activator, Gas Tamponade, and
   Upright Positioning
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID CHOROIDAL NEOVASCULAR LESIONS; THICK SUBMACULAR HEMORRHAGE; PNEUMATIC
   DISPLACEMENT; NATURAL-HISTORY; RANIBIZUMAB; SECONDARY
AB BACKGROUND AND OBJECTIVE: To investigate the outcomes of vitrectomy, subretinal tissue plasminogen (tPA) injection, gas tamponade, and upright positioning in patients with hemorrhagic neovascular age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Retrospective, noncomparative case series. Records of patients who were diagnosed with submacular hemorrhage secondary to neovascular AMD and underwent treatment with the combined method between 2004 and 2010 were reviewed. The main outcome measure was the difference between preoperative and postoperative best corrected visual acuity (BCVA).
   RESULTS: In 10 eyes of 10 patients, mean preoperative and postoperative BCVA values were 1.75 and 1.23 logMAR, respectively (P = .011), after a mean follow-up time of 38.7 +/- 26.5 months (range: 10 to 71 months). Eight of 10 patients (80%) gained at least three lines.
   CONCLUSION: In patients with hemorrhagic neovascular AMD, treatment with vitrectomy, subretinal tPA injection, gas tamponade, and upright positioning was associated with better visual outcomes than those reported for patients with untreated disease.
C1 [Kapran, Ziya] Bahchesehir Univ, Dept Ophthalmol, Istanbul, Turkey.
   [Ozkaya, Abdullah] Beyoglu Eye Training & Res Hosp, TR-34421 Istanbul, Turkey.
   [Uyar, O. Murat] Maltepe Univ, Dept Ophthalmol, Istanbul, Turkey.
C3 Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research
   Hospital; Maltepe University
RP Ozkaya, A (通讯作者)，Beyoglu Eye Training & Res Hosp, TR-34421 Istanbul, Turkey.
EM abdozkaya@gmail.com
RI Ozkaya, Abdullah/L-5745-2013
OI Ozkaya, Abdullah/0000-0002-1940-8669
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bakri SJ, 2007, GRAEF ARCH CLIN EXP, V245, P609, DOI 10.1007/s00417-006-0349-8
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Frampton JE, 2012, DRUGS, V72, P509, DOI 10.2165/11208410-000000000-00000
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   HANSCOM TA, 1987, ARCH OPHTHALMOL-CHIC, V105, P1722
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Johnson M W, 2000, Curr Opin Ophthalmol, V11, P201, DOI 10.1097/00055735-200006000-00009
   Lincoff H, 2008, RETINA-J RET VIT DIS, V28, P56, DOI 10.1097/IAE.0b013e31806e60db
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   NASRALLAH F, 1989, AM J OPHTHALMOL, V107, P38, DOI 10.1016/0002-9394(89)90812-X
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Polito A, 2007, INVEST OPHTH VIS SCI, V48, P3318, DOI 10.1167/iovs.06-1526
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shah SP, 2009, OPHTHAL SURG LAS IM, V40, P308, DOI 10.3928/15428877-20090430-16
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Stopa M, 2007, RETINA-J RET VIT DIS, V27, P370, DOI 10.1097/IAE.0b013e3180439bc9
   Todorich B, 2011, RETINA-J RET VIT DIS, V31, P1749, DOI 10.1097/IAE.0b013e31821504df
   Tsymanava A, 2012, ACTA OPHTHALMOL, V90, P633, DOI 10.1111/j.1755-3768.2011.02115.x
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 38
TC 13
Z9 13
U1 1
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP-OCT
PY 2013
VL 44
IS 5
BP 471
EP 476
DI 10.3928/23258160-20130909-09
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 296NS
UT WOS:000330192400008
PM 24044710
DA 2022-11-30
ER

PT J
AU Roberts, PK
   Baumann, B
   Schlanitz, FG
   Sacu, S
   Bolz, M
   Pircher, M
   Hagmann, M
   Hitzenberger, CK
   Schmidt-Erfurth, U
AF Roberts, Philipp K.
   Baumann, Bernhard
   Schlanitz, Ferdinand G.
   Sacu, Stefan
   Bolz, Matthias
   Pircher, Michael
   Hagmann, Michael
   Hitzenberger, Christoph K.
   Schmidt-Erfurth, Ursula
TI Retinal pigment epithelial features indicative of neovascular
   progression in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; FELLOW EYE;
   DRUSEN; MEMBRANES; OCT
AB Background/aims To identify characteristic retinal pigment epithelium (RPE) changes in fellow eyes of patients with neovascular age-related macular degeneration (nAMD) using polarisation-sensitive optical coherence tomography (PS-OCT).
   Methods Thirty-one fellow eyes of 31 patients with unilateral nAMD were evaluated in this cohort study of a prospective interventional trial. PS-OCT as well as conventional imaging including spectral-domain (SD)-OCT and fluorescein angiography (FA) were performed using a standardised protocol. Monitoring visits were performed continuously at 1-month intervals. Morphological RPE features associated with the development of choroidal neovascularisation (CNV) were systematically analysed.
   Results Mean follow-up was 29 months (+/- 17, SD). Thirteen (42%) of 31 eyes developed de novo CNV: 9 eyes type I CNV, 2 eyes type II CNV, 2 eyes a retinal angiomatous proliferation lesion. RPE thickening and reticular pseudodrusen (RPD) were observed significantly more often in eyes that developed CNV than in eyes without CNV development (p<0.01). Monthly increase in drusen volume was higher in the CNV group with a median increase of +2.2% in area and +2.9% in volume compared with +0.8% and +0.6% in the non-progressing group. RPE migration within the neurosensory retina and at the level of the RPE resulting in RPE thickening was seen topographically and chronologically associated with CNV development.
   Conclusions Conversion to CNV is associated with RPE-related changes such as RPE migration, RPE thickening, drusen volume or the presence of RPD. Early detection of these features may allow more efficient screening in risk eyes and timely vision-preserving treatment in eyes developing neovascular disease.
C1 [Roberts, Philipp K.; Schlanitz, Ferdinand G.; Sacu, Stefan; Bolz, Matthias; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Baumann, Bernhard; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
   [Hagmann, Michael] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM Ursula.schmidt-erfurth@meduniwien.ac.at
RI Bolz, Matthias/HCI-0622-2022
OI Michael, Pircher/0000-0001-9285-7527; Hitzenberger,
   Christoph/0000-0002-6608-8821; Baumann, Bernhard/0000-0001-6419-1932;
   Schmidt-Erfurth, Ursula/0000-0002-7788-7311
FU FWF grant, Austrian Science Fund, Vienna, Austria [P19624-B02]; European
   Union, FUN-OCT, Brussels, Belgium [201880]; Canon (Tokyo, Japan)
FX CKH has received support by an independent scientific grant (FWF grant
   P19624-B02, Austrian Science Fund, Vienna, Austria), the European Union
   (FP7 HEALTH programme grant 201880, FUN-OCT, Brussels, Belgium) and
   Canon (Tokyo, Japan).
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Cense B, 2004, INVEST OPHTH VIS SCI, V45, P2606, DOI 10.1167/iovs.03-1160
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Stern Jeffrey, 2014, F1000Res, V3, P293, DOI 10.12688/f1000research.5683.1
   Toju R, 2012, AM J OPHTHALMOL, V153, P314, DOI 10.1016/j.ajo.2011.06.026
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zotter S, 2012, BIOMED OPT EXPRESS, V3, P2720, DOI 10.1364/BOE.3.002720
NR 25
TC 13
Z9 13
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2017
VL 101
IS 10
BP 1361
EP 1366
DI 10.1136/bjophthalmol-2016-310004
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI1GT
UT WOS:000411681700012
PM 28270492
DA 2022-11-30
ER

PT J
AU Yau, GL
   Campbell, RJ
   Li, C
   Sharma, S
AF Yau, Gary L.
   Campbell, Robert J.
   Li, Cody
   Sharma, Sanjay
TI Peripapillary RNFL thickness in nonexudative versus chronically treated
   exudative age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID INTRAOCULAR-PRESSURE CHANGES; GROWTH-FACTOR AGENTS; FIBER LAYER
   THICKNESS; INTRAVITREAL INJECTIONS; RANIBIZUMAB; BEVACIZUMAB; GLAUCOMA;
   TRIALS; EDEMA; EYES
AB Objective: To compare the peripapillary retinal nerve fibre layer (RNFL) thickness in nonexudative versus exudative age-related macular degeneration (wet AMD) eyes treated chronically with intravitreal injections of anti vascular endothelial growth factor (anti-VEGF).
   Design: Cross-sectional study.
   Participants: Twenty-nine patients with unilateral wet AMD with at least 12 prior intravitreal anti-VEGF injections and 2 years of therapy were analyzed. The fellow eye with nonexudative (dry) AMD with no prior treatment served as the control group.
   Methods: All patients were prospectively enrolled from a single academic subspecialist practice. Bilateral spectral-domain optical coherence tomography (Cirrus SD-OCT; Carl Zeiss Meditec, Dublin, Calif.) of the peripapillary RNFL was performed on all pairs of eyes. Optic nerve head (ONH) parameters were also computed. The primary outcome was mean difference in peripapillary RNFL thickness compared between the treated and the nontreated eyes.
   Results: Mean RNFL in the chronically treated eyes (95.0 [95% CI 89.8-100.2] mu m) was significantly greater than the nontreated fellow eyes (89.9 [95% CI 85.5-94.3] mu m) (p = 0.01). Quadrantic optic nerve analysis revealed the temporal RNFL to be greater in the treated group (p = 0.02), whereas all other locations were similar. No significant differences were found between the 2 groups in any ONH parameters.
   Conclusions: This study demonstrated no deleterious optic nerve RNFL thinning in a series of wet AMD eyes with long-term repetitive exposure to intravitreal anti-VEGF injections. Furthermore, we observed that those with wet AMD have a relatively thickened temporal peripapillary RNFL layer, which is an important association for all observers of optic nerve disease.
C1 [Yau, Gary L.; Campbell, Robert J.; Li, Cody; Sharma, Sanjay] Queens Univ, Hotel Dieu Hosp, Dept Ophthalmol, Kingston, ON K7L 5G2, Canada.
C3 Queens University - Canada
RP Sharma, S (通讯作者)，Queens Univ, Hotel Dieu Hosp, Dept Ophthalmol, 166 Brock St, Kingston, ON K7L 5G2, Canada.
EM sanjay_sharma60@hotmail.com
FU Physicians' Services Inc. Foundation
FX This work was supported by The Physicians' Services Inc. Foundation,
   which had no involvement in any of the components of the study.
CR Abedi G, 2013, SEMIN OPHTHALMOL, V28, P126, DOI 10.3109/08820538.2013.771195
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Heimann H, 2007, MED RETINA ESSENTIAL, P67
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Leung CKS, 2009, OPHTHALMOLOGY, V116, P1257, DOI 10.1016/j.ophtha.2009.04.013
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Mwanza JC, 2010, INVEST OPHTH VIS SCI, V51, P5724, DOI 10.1167/iovs.10-5222
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Nouri-Mahdavi K, 2004, OPHTHALMOLOGY, V111, P1627, DOI 10.1016/j.ophtha.2004.02.017
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Seth RK, 2009, RETINA-J RET VIT DIS, V29, P956, DOI 10.1097/IAE.0b013e3181a91dfd
   Varma R, 2012, OPHTHALMOLOGY, V119, P2108, DOI 10.1016/j.ophtha.2012.05.017
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
NR 22
TC 6
Z9 6
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2015
VL 50
IS 5
BP 345
EP 349
DI 10.1016/j.jcjo.2015.01.008
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW0UN
UT WOS:000364705100017
PM 26455968
DA 2022-11-30
ER

PT J
AU Yonekawa, Y
   Andreoli, C
   Miller, JB
   Loewenstein, JI
   Sobrin, L
   Eliott, D
   Vavvas, DG
   Miller, JW
   Kim, IK
AF Yonekawa, Yoshihiro
   Andreoli, Christopher
   Miller, John B.
   Loewenstein, John I.
   Sobrin, Lucia
   Eliott, Dean
   Vavvas, Demetrios G.
   Miller, Joan W.
   Kim, Ivana K.
TI Conversion to Aflibercept For Chronic Refractory Or Recurrent
   Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB; VEGF TRAP; 2.0 MG; BEVACIZUMAB; TACHYPHYLAXIS;
   THERAPY
AB PURPOSE: To explore the visual and anatomic outcomes of patients with refractory or recurrent neovascular age-related macular degeneration (AMD) who were converted from bevacizumab and/or ranibizumab to aflibercept.
   DESIGN: Two-center, retrospective chart review.
   METHODS: Treatment history, visual acuity (VA), and central macular thickness (CMT) on spectral-domain optical coherence tomography were collected. Patients were divided into "refractory" (persistent exudation despite monthly injections) or "recurrent" (exudation suppressed, but requiring frequent injections).
   RESULTS: One hundred and two eyes of 94 patients were included; 68 were refractory and 34 were recurrent. Eyes received a mean of 20.4 prior bevacizumab/ranibizumab injections and a mean of 3.8 aflibercept injections. Mean follow-up was 18 weeks. Mean VA was 20/50-1 before conversion, 20/50-2 after 1 aflibercept injection (P = .723), and 20/50 + 2 after the final injection (P = .253). Subgroup analysis of refractory and recurrent cases also showed stable VA. Of the refractory cases, mean CMT had improved after 1 injection (P < .001) and the final injection (P < .001). Intraretinal (P < .001) and subretinal (P < .001) fluid decreased after 1 injection, and the mean injection interval was extended from 5.2 to 6.2 weeks (P = .003). Of the recurrent cases, mean CMT improved after 1 injection (P < .001) and the final injection (P < .001). Intraretinal (P = .003) and subretinal (P = .046) fluid decreased after 1 injection, and the mean injection interval was extended from 7.2 to 9.5 weeks (P = .001).
   CONCLUSIONS: Converting patients with chronic neovascular AMD to aflibercept results in stabilized vision and improved anatomic outcomes, while allowing injection intervals to be extended. (C) 2013 by Elsevier Inc. All rights reserved.
C1 [Yonekawa, Yoshihiro; Andreoli, Christopher; Miller, John B.; Loewenstein, John I.; Sobrin, Lucia; Eliott, Dean; Vavvas, Demetrios G.; Miller, Joan W.; Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA.
   [Andreoli, Christopher] Harvard Vanguard Med Associates, Dept Ophthalmol, Retina Serv, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard Vanguard Medical Associates
RP Kim, IK (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM Ivana_Kim@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
OI Vavvas, Demetrios/0000-0002-8622-6478; Kim, Ivana/0000-0003-0310-6129;
   Miller, Joan/0000-0003-2046-3996; Sobrin, Lucia/0000-0003-1575-0819
FU Genentech
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. The authors report the following
   disclosures: D. Eliott: consultant for Acucela, ArcticDx, Genentech,
   Glaukos, Ophthotech, Regeneron, Salutaris; I.K. Kim: consultant for
   ArticDx, Sequenom, SalutarisMD, Genzyme, Regeneron, and Genentech, and
   research support from Genentech; J.W. Miller: board member for Alcon
   (ended May 2011), consultant for Alcon and KalVista. The Massachusetts
   Eye and Ear Infirmary has an ownership interest in 3 U.S. patents
   directed to the use of verteporfin (Quadra Logic Technologies). In
   addition, the Massachusetts Eye and Ear Infirmary has ownership interest
   in certain patent applications directed to the selective destruction of
   subretinal choroidal neovasculature for the treatment of macular
   degeneration and other disorders. The Massachusetts Eye and Ear
   Infirmary receives royalties as a result of these patents and patent
   applications and J.W.M. receives a share of the same in accordance With
   the Massachusetts Eye and Ear Infirmary's institutional Patent Policy
   and Procedures, which includes royalty-sharing provisions. The authors
   indicate no funding support. Contributions of authors: design and
   conduct of the study (Y.Y., C.A., I.K.K.); collection, management,
   analysis, and interpretation of data (Y.Y., C.A., J.B.M., J.I.L., L.S.,
   D.E., D.G.V., J.W.M., I.K.K.); and preparation, review, or approval of
   the manuscript (Y.Y., CA., J.B.M., J.I.L., L.S., D.E., D.G.V., J.W.M.,
   I.K.K.).
CR Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ehlers JP, 2010, OPHTHAL SURG LAS IM, V41, P182, DOI 10.3928/15428877-20100303-05
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
NR 19
TC 132
Z9 137
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2013
VL 156
IS 1
BP 29
EP 35
DI 10.1016/j.ajo.2013.03.030
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 179OT
UT WOS:000321531900006
PM 23668679
DA 2022-11-30
ER

PT J
AU Gupta, N
   Brown, KE
   Milam, AH
AF Gupta, N
   Brown, KE
   Milam, AH
TI Activated microglia in human retinitis pigmentosa, late-onset retinal
   degeneration, and age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE human retinal diseases; microglia; rods; cones; retinitis pigmentosa;
   age-related macular degeneration; late-onset retinal degeneration;
   immunocytochemistry
ID PHOTORECEPTOR DEGENERATION; RCS RAT; APOPTOSIS; CELLS; DYSTROPHY; GENE;
   PHOSPHOTYROSINE; MACROPHAGES; EXPRESSION; PATHWAYS
AB Many gaps exist in our knowledge of human retinal microglia in health and disease. We address the hypothesis that primary death of rod photoreceptors leads to activation of resident microglia in human retinas with retinitis pigmentosa (RP), late-onset retinal degeneration (L-ORD), or age-related macular degeneration (AMD). Regions of ongoing photoreceptor cell death were studied by immunocytochemistry with microglia- and other retinal cell-specific markers. In normal human retinas, quiescent microglia were small, stellate cells associated with inner retinal blood vessels. In retinas with RP, L-ORD, or AMD, numerous activated microglia were present in the outer nuclear layer in regions of ongoing rod cell death. These microglia were enlarged, amoeboid cells that contained rhodopsin-positive cytoplasmic inclusions. We conclude that activated microglia migrate to the outer nuclear layer and remove rod cell debris. In other central nervous system diseases such as stroke, activated microglia phagocytose debris from the primary injury and also secrete molecules that kill nearby normal neurons. By analogy with these diseases, we suggest that microglia activated by primary rod cell death may kill adjacent photoreceptors. Activated microglia may be a missing link in understanding why initial rod cell death in the human diseases RP, L-ORD, and AMD leads to death of the cones that are critical for high acuity daytime vision. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   Univ Penn, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine
RP Milam, AH (通讯作者)，Univ Penn, Scheie Eye Inst, 51 N 39th St, Philadelphia, PA 19104 USA.
EM annmilam@mail.med.upenn.edu
CR Adler R, 1999, MOL VIS, V5
   Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106
   BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0
   BOYA J, 1991, J ANAT, V175, P229
   BROSNAHAN DM, 1994, OPHTHALMOLOGY, V101, P38
   Bucur O, 2001, J CELL MOL MED, V5, P438, DOI 10.1111/j.1582-4934.2001.tb00181.x
   CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   DUVALL J, 1986, GRAEF ARCH CLIN EXP, V224, P299, DOI 10.1007/BF02143075
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Grossmann R, 2002, GLIA, V37, P229, DOI 10.1002/glia.10031
   Gupta N, 2002, EXP EYE RES, V75, P233, DOI 10.1006/exer.2002.2005
   Hull M, 2002, CURR MED CHEM, V9, P83, DOI 10.2174/0929867023371292
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   KARP HL, 1994, GLIA, V11, P284, DOI 10.1002/glia.440110310
   Kong GY, 2002, GLIA, V37, P191, DOI 10.1002/glia.10030
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253
   LI ZY, 1995, RETINAL DEGENERATION, V2, P1
   Mertsch K, 2001, J COMP NEUROL, V431, P217
   Milam AH, 2001, METH MOLEC MED, V47, P71, DOI 10.1385/1-59259-085-3:71
   Milam AH, 2001, EXP EYE RES, V73, P493, DOI 10.1006/exer.2001.1059
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Ng YK, 1999, NEUROSCI LETT, V262, P207, DOI 10.1016/S0304-3940(99)00076-2
   Papermaster DS, 1997, CELL DEATH DIFFER, V4, P21, DOI 10.1038/sj.cdd.4400210
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1993, J NEUROIMMUNOL, V45, P183, DOI 10.1016/0165-5728(93)90179-3
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pierce EA, 2001, BIOESSAYS, V23, P605, DOI 10.1002/bies.1086
   PROVIS JM, 1995, GLIA, V14, P243, DOI 10.1002/glia.440140402
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Roque RS, 1996, INVEST OPHTH VIS SCI, V37, P196
   SAHEL JA, 2001, PROG BRAIN RES, V1313, P649
   Steinberg Roy H., 1994, Current Opinion in Neurobiology, V4, P515, DOI 10.1016/0959-4388(94)90052-3
   Streit WJ, 2001, NEUROTOXICOLOGY, V22, P619, DOI 10.1016/S0161-813X(01)00033-X
   Sunness JS, 1999, MOL VIS, V5
   SUZUKI H, 1988, NEUROPATH APPL NEURO, V14, P221, DOI 10.1111/j.1365-2990.1988.tb00883.x
   Thanos S, 1996, PROG RETIN EYE RES, V15, P331, DOI 10.1016/1350-9462(96)00006-7
   THANOS S, 1994, TINS, V5, P177
   TILLOTSON ML, 1989, GLIA, V2, P412
   TSO MOM, 1994, INVEST OPHTH VIS SCI, V35, P2693
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Williams KC, 2002, ANNU REV NEUROSCI, V25, P537, DOI 10.1146/annurev.neuro.25.112701.142822
   Wong A, 2001, BRAIN RES, V920, P32, DOI 10.1016/S0006-8993(01)02872-4
   WOOD PL, 1995, NEUROL RES, V17, P242, DOI 10.1080/01616412.1995.11740321
   XU GZ, 1997, HONG KONG J OPHTHALM, V1, P8
   Yang PZ, 2002, INVEST OPHTH VIS SCI, V43, P1488
NR 54
TC 408
Z9 433
U1 1
U2 22
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2003
VL 76
IS 4
BP 463
EP 471
DI 10.1016/S0014-4835(02)00332-9
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 661RE
UT WOS:000181902900008
PM 12634111
DA 2022-11-30
ER

PT J
AU De, S
   Sakmar, TP
AF De, S
   Sakmar, TP
TI Interaction of A2E with model membranes. Implications to the
   pathogenesis of age-related macular degeneration
SO JOURNAL OF GENERAL PHYSIOLOGY
LA English
DT Article
DE lipofuscin; cellular dysfunction; lipid vesicles; fluorescence studies;
   membrane solubilization
ID PIGMENT EPITHELIAL-CELLS; N-RETINYLIDENE ETHANOLAMINE; LIPOFUSCIN
   FLUOROPHORE; GENE-THERAPY; DISC MEMBRANES; MICE; PHOSPHOLIPIDS;
   BIOSYNTHESIS; CHOLESTEROL; INVOLVEMENT
AB Deposition of a fluorophoric material, known as lipofuscin, in retinal pigment epithelium cells has been speculated to be one of the biomarkers of age-related macular degeneration. One of the fluorophores of lipofuscin has been characterized as A2E, a pyridinium bisretinoid. Its cationic nature along with two hydrophobic retinal chains suggests that it can disrupt the membrane integrity by its detergent-like activity and can thus cause cellular damage. With this notion, we studied in detail the interaction between A2E and the model membranes of different lipid compositions rising fluorescence steady-state and fluorescence anisotropy measurements. A transition from vesicular to micellar structure occurred upon incorporation of A2E into the lipid bilayer. However, the A2E concentration at which this transition occurred depends on the lipid composition. A lipid mixture containing 10% phosphatidylserine (PS) (close to disc membrane PS content) behaved similarly to a lipid mixture having no PS. In contrast, vesicles containing 20% PS showed significantly different behavior. Membrane solubilization by A2E was also confirmed by vesicle leakage experiments. A2E also showed significant activity in liposome-mediated gene transfection. A lipid formulation containing 40% A2E and a helper lipid showed plasmid DNA transfection efficiency comparable to commercially available transfection reagents with no evidence of cytotoxicity. These results contribute to understanding the mechanism underlying the A2E-induced cellular dysfunction.
C1 Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Biol & Biochem, New York, NY 10021 USA.
C3 Howard Hughes Medical Institute; Rockefeller University
RP Sakmar, TP (通讯作者)，Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Biol & Biochem, Box 284,1230 York Ave, New York, NY 10021 USA.
RI Sakmar, Thomas P/D-1833-2015
OI Sakmar, Thomas P/0000-0002-2836-8953
CR Abul-Hassan K, 2000, CURR EYE RES, V20, P361, DOI 10.1076/0271-3683(200005)20:5;1-1;FT361
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Albert AD, 1996, BBA-BIOMEMBRANES, V1285, P47, DOI 10.1016/S0005-2736(96)00145-9
   Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Dejneka NS, 2001, BIOESSAYS, V23, P662, DOI 10.1002/bies.1092
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FELGNER JH, 1994, J BIOL CHEM, V269, P2550
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FRALEY R, 1980, BIOCHEMISTRY-US, V19, P6021, DOI 10.1021/bi00567a012
   Haque ME, 2001, BIOCHEMISTRY-US, V40, P4340, DOI 10.1021/bi002030k
   Hessel E, 2000, EUR J BIOCHEM, V267, P1473, DOI 10.1046/j.1432-1327.2000.01147.x
   Hessel E, 2001, J BIOL CHEM, V276, P2538, DOI 10.1074/jbc.M009061200
   Lamb LE, 2001, J PHYS CHEM B, V105, P11507, DOI 10.1021/jp0123177
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Okayama R, 1997, FEBS LETT, V408, P232, DOI 10.1016/S0014-5793(97)00431-6
   PARISH EJ, 1998, RRD ORG CHEM 1, V2, P95
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Safinya CR, 2001, CURR OPIN STRUC BIOL, V11, P440, DOI 10.1016/S0959-440X(00)00230-X
   SAKAI N, 1996, J AM CHEM SOC, V119, P3619
   Shaban H, 2001, ARCH BIOCHEM BIOPHYS, V394, P111, DOI 10.1006/abbi.2001.2535
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
NR 34
TC 69
Z9 71
U1 0
U2 2
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1295
J9 J GEN PHYSIOL
JI J. Gen. Physiol.
PD AUG
PY 2002
VL 120
IS 2
BP 147
EP 157
DI 10.1085/jgp.20028566
PG 11
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA 582DL
UT WOS:000177334400003
PM 12149277
OA Bronze, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Elmore, A
   Harris, WS
   Mu, LN
   Brady, WE
   Hovey, KM
   Mares, JA
   Espeland, MA
   Haan, MN
   Millen, AE
AF Elmore, Andrea
   Harris, William S.
   Mu, Lina
   Brady, William E.
   Hovey, Kathleen M.
   Mares, Julie A.
   Espeland, Mark A.
   Haan, Mary N.
   Millen, Amy E.
TI Red blood cell fatty acids and age-related macular degeneration in
   postmenopausal women
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Cohort; Fatty acids; Age-related macular degeneration; Post-menopausal
   women; Epidemiology; Retinal disease; Diet
ID HEALTH INITIATIVE MEMORY; DIETARY-FAT; EICOSAPENTAENOIC ACID;
   DOCOSAHEXAENOIC ACID; SECONDARY ANALYSES; FISH CONSUMPTION;
   HORMONE-THERAPY; RISK-FACTORS; OMEGA-3-FATTY-ACIDS; BIOMARKERS
AB Purpose To evaluate the relationship between red blood cell (RBC) polyunsaturated fatty acid (PUFA) levels, and dietary PUFA and fish intake, with prevalent and incident age-related macular degeneration (AMD) in a US cohort of postmenopausal women. Methods This analysis included 1456 postmenopausal women from the Women's Health Initiative (WHI) Clinical Trials. RBC PUFAs were measured from fasting serum samples collected at WHI baseline. Dietary PUFAs and fish intake were assessed via food frequency questionnaires at baseline. There were 240 women who had prevalent AMD and 138 who self-reported AMD development over 9.5 years. Adjusted odds ratios and 95% confidence intervals were estimated for prevalent AMD by RBC PUFA levels, dietary PUFA intake, and frequency of fish consumption. Adjusted hazard ratios and 95% confidence intervals were estimated for incident AMD. A p-for-trend was estimated for continuous measures of dietary PUFA and fish intake. Results No significant association was found between prevalent or incident AMD and RBC docosahexaenoic acid (DHA) + eicosapentaenoic acid (EPA), EPA, DHA, alpha-linolenic acid (ALA), linoleic acid (LA), or arachidonic acid (AA). A positive association was found between dietary intake of AA and odds of prevalent AMD (p-for-trend for continuous AA intake = 0.02) and between intake of LA/ALA and incident AMD (p-for-trend for continuous ratio of LA/ALA intake = 0.03). No statistically significant associations were found between AMD and dietary intake of PUFAs or fish. Conclusions RBC PUFAs were not associated with AMD in this cohort. Overall, dietary analyses of PUFAs supported this, excepting dietary AA intake and intake of LA in proportion to ALA of which there were trends of increased risk.
C1 [Elmore, Andrea; Mu, Lina; Hovey, Kathleen M.; Millen, Amy E.] Univ Buffalo State Univ New York, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, 270 Farber Hall, Buffalo, NY 14214 USA.
   [Harris, William S.] OmegaQuant Analyt LLC, Sioux Falls, SD USA.
   [Harris, William S.] Univ South Dakota, Sanford Sch Med, Sioux Falls, SD USA.
   [Brady, William E.] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA.
   [Mares, Julie A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC 27101 USA.
   [Haan, Mary N.] Univ Calif San Francisco, Div Clin Trials, San Francisco, CA 94143 USA.
   [Haan, Mary N.] Univ Calif San Francisco, MultiCtr Studies, Dept Epidemiol Sr Biostat, San Francisco, CA 94143 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; University of South Dakota; University of Wisconsin
   System; University of Wisconsin Madison; Wake Forest University;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco
RP Millen, AE (通讯作者)，Univ Buffalo State Univ New York, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, 270 Farber Hall, Buffalo, NY 14214 USA.
EM aemillen@buffalo.edu
FU National Heart Lung and Blood Institute, Broad Area Announcement 19; NIH
   [HHSN268200900036C]; National Heart, Lung, and Blood Institute, National
   Institutes of Health, U.S. Department of Health and Human Services
   [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
   HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]
FX Funding provided by National Heart Lung and Blood Institute, Broad Area
   Announcement 19; NIH contract HHSN268200900036C. The WHI program is
   funded by the National Heart, Lung, and Blood Institute, National
   Institutes of Health, U.S. Department of Health and Human Services
   through contracts HHSN268201100046C, HHSN268201100001C,
   HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and
   HHSN271201100004C.
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Ammann EM, 2017, PROSTAG LEUKOTR ESS, V121, P68, DOI 10.1016/j.plefa.2017.06.006
   Ammann EM, 2013, NEUROLOGY, V81, P1484, DOI 10.1212/WNL.0b013e3182a9584c
   Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7
   Anil E, 2007, P NUTR SOC, V66, P60, DOI 10.1017/S0029665107005307
   [Anonymous], 2016, OLDER AM 2016 KEY IN
   Arab L, 2003, J NUTR, V133, p925S, DOI 10.1093/jn/133.3.925S
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Calder PC, 2002, EUR J CLIN NUTR, V56, pS14, DOI 10.1038/sj.ejcn.1601478
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Godley PA, 1996, CANCER EPIDEM BIOMAR, V5, P115
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Harris William S, 2006, Curr Atheroscler Rep, V8, P453, DOI 10.1007/s11883-006-0019-7
   Harris WS, 2017, J CLIN LIPIDOL, V11, P250, DOI 10.1016/j.jacl.2016.12.013
   Harris WS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147894
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Mares JA, 2017, NUTRITION IN THE PREVENTION AND TREATMENT OF DISEASE, 4TH EDITION, P393, DOI 10.1016/B978-0-12-802928-2.00019-9
   Merle BMJ, 2017, ACTA OPHTHALMOL, V95, pe763, DOI 10.1111/aos.13408
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Ng ALK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081720
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6
   Persons JE, 2014, INT J GERIATR PSYCH, V29, P747, DOI 10.1002/gps.4058
   Pottala JV, 2014, NEUROLOGY, V82, P435, DOI 10.1212/WNL.0000000000000080
   Pottala JV, 2012, LIPIDS, V47, P835, DOI 10.1007/s11745-012-3693-y
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni John Paul, 2008, Arch Ophthalmol, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SAS Institute Inc, 2015, SAS STAT 14 1 USERS
   Sassa T, 2014, BIOMOL THER, V22, P83, DOI 10.4062/biomolther.2014.017
   Schmitz G, 2008, PROG LIPID RES, V47, P147, DOI 10.1016/j.plipres.2007.12.004
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5
   Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Subar AF, 2015, J NUTR, V145, P2639, DOI 10.3945/jn.115.219634
   Sun Q, 2007, AM J CLIN NUTR, V86, P74, DOI 10.1093/ajcn/86.1.74
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Vajaranant TS, 2016, AM J OPHTHALMOL, V165, P115, DOI 10.1016/j.ajo.2016.02.025
   van Asten F, 2019, OPHTHALMOLOGY, V126, P1541, DOI 10.1016/j.ophtha.2019.06.004
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Women's Health Initiative, DEV PUBL WHI MAN PRO
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
NR 66
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD APR
PY 2022
VL 61
IS 3
BP 1585
EP 1594
DI 10.1007/s00394-021-02746-2
EA JAN 2022
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA ZT0WD
UT WOS:000739221500002
PM 34988653
DA 2022-11-30
ER

PT J
AU Nair, AA
   Finn, AP
   Sternberg, P
AF Nair, Archana A.
   Finn, Avni P.
   Sternberg, Paul
TI Spotlight on Faricimab in the Treatment of Wet Age-Related Macular
   Degeneration: Design, Development and Place in Therapy
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE neovascular age-related macular degeneration; nAMD; macular
   degeneration; anti-vascular endothelial growth factor; anti-VEGF;
   faricimab; choroidal neovascularization; CNVM
ID ENDOTHELIAL GROWTH-FACTOR; EXTEND REGIMEN; RANIBIZUMAB; AFLIBERCEPT;
   OUTCOMES; ANGIOGENESIS; VERTEPORFIN; BEVACIZUMAB; BURDEN; EYE
AB The advent of anti-vascular endothelial growth factor (VEGF) agents has revolutionized the treatment of retinal neovas-cular diseases including neovascular age-related macular degeneration (nAMD), a leading cause of irreversible blindness. Multiple agents and methods for drug delivery are emerging to increase the duration of treatment effect and treatment interval, reducing the overall treatment burden on patients and clinicians. The newest agent on the market is faricimab. This medication targets two distinct pathways in retinal angiogenesis, VEGF-A and Ang-2, to create a more durable effect. Phase 3 trials for this drug compared treatment intervals up to 16 weeks against aflibercept dosed at 8-week intervals for both nAMD and diabetic macular edema (DME). While the drug shows similar functional and anatomic outcomes with a low adverse effect profile and trial data demonstrating increased treatment duration, its exact place in the VEGF marketplace is yet to be determined. In this article, we discuss the mechanism of action, pivotal clinical trials leading to approval, and the anticipated role for faricimab in the treatment of retinal neovascular disease.
C1 [Nair, Archana A.; Finn, Avni P.; Sternberg, Paul] Vanderbilt Univ Sch Med, Vanderbilt Eye Inst, Nashville, TN USA.
   [Sternberg, Paul] Vanderbilt Univ Sch Med, Vanderbilt Eye Inst, Ophthalmol & Visual Sci, 2311 Pierce Ave, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University
RP Sternberg, P (通讯作者)，Vanderbilt Univ Sch Med, Vanderbilt Eye Inst, Ophthalmol & Visual Sci, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM Paul.sternberg@vumc.org
OI Nair, Archana/0000-0003-1583-5396
CR Apte RS, 2020, CELL, V180, P1033, DOI 10.1016/j.cell.2020.02.028
   ASRS, 2021, PREF TRENDS SURV ASR
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Bontzos G, 2020, OPHTHALMOL RETINA, V4, P1138, DOI 10.1016/j.oret.2019.11.004
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Danzig C., 2022, REAL WORLD EFFICACY
   Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Giannakaki-Zimmermann H, 2016, OPHTHALMOLOGICA, V236, P201, DOI 10.1159/000452929
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Joussen AM, 2021, EYE, V35, P1305, DOI 10.1038/s41433-020-01377-x
   Kaiser PK, 2021, RETINA-J RET VIT DIS, V41, P1579, DOI 10.1097/IAE.0000000000003194
   Khanani AM, 2021, INVEST OPHTH VIS SCI, V62
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P1911, DOI 10.1097/IAE.0000000000003128
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Thurston G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006650
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   Wykoff CC, 2022, LANCET, V399, P741, DOI 10.1016/S0140-6736(22)00018-6
   Yerramothu Praveen, 2018, Vision (Basel), V2, DOI 10.3390/vision2030031
   YOKOTA T, 1992, CANCER RES, V52, P3402
NR 45
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2022
VL 16
BP 3395
EP 3400
DI 10.2147/DDDT.S368963
PG 6
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 5K3GM
UT WOS:000869617500001
PM 36199631
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yuan, DQ
   Yuan, DL
   Liu, XY
   Yuan, ST
   Xie, P
   Liu, QH
AF Yuan, Dongqing
   Yuan, Donglan
   Liu, Xiaoyi
   Yuan, Songtao
   Xie, Ping
   Liu, Qinghuai
TI Genetic Association with Response to Intravitreal Ranibizumab for
   Neovascular Age-Related Macular Degeneration in the Han Chinese
   Population
SO OPHTHALMOLOGICA
LA English
DT Article
DE Genetic polymorphisms; Ranibizumab; Response; Neovascular age-related
   macular degeneration
ID COMPLEMENT-FACTOR-H; LOC387715 GENOTYPES; Y402H POLYMORPHISM; VEGF;
   SUSCEPTIBILITY; BEVACIZUMAB; BLINDNESS; THERAPY
AB Purpose: To investigate a possible association between gene variants and patient response to treatment with intravitreal ranibizumab for neovascular age-related macular degeneration (AMD). Methods: Visual acuity score (VAS) was recorded at baseline and a subsequent visit at 6 months. Genotypes of 3 polymorphisms in known AMD susceptibility loci (rs1061170 in complement factor H (CFH), rs11200638 in HTRA1 and rs1413711 in VEGF) were determined. Central retinal thickness and maximum thickness of the lesion were also measured. Results: A total of 168 neovascular AMD patients treated with intravitreal ranibizumab were included in our study. For HTRA1 rs11200638, mean VAS changes were 3.5, 9.4 and 10.6 letters for the AA, AG and GG genotypes, respectively (p = 0.022). In contrast, for CFH rs1061170 and VEGF rs1413711, mean VAS changes were not significant. However, there was no significant difference in the changes in central retinal thickness and maximum lesion thickness among the genotypes of the tested single-nucleotide polymorphisms. Conclusions: HTRA1 gene polymorphism may influence patient response to treatment with intravitreal ranibizumab for neovascular AMD. (C) 2013 S. Karger AG, Basel
C1 [Yuan, Dongqing; Liu, Xiaoyi; Yuan, Songtao; Xie, Ping; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
   [Yuan, Donglan] Nanjing Med Univ, Affiliated Hosp 1, Dept Nucl Med, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
EM wuyuleng@126.com
OI Xie, Ping/0000-0003-4257-8970; Liu, Qinghuai/0000-0003-1605-1964
FU National Basic Research Program of China (973 Program) [2011CB510200];
   General Project of the National Natural Science Fund [81170855];
   Research and Innovation Project for College Graduates of Jiangsu
   Province [CXZZ12_0586]
FX This research project was supported by the National Basic Research
   Program of China (973 Program, No. 2011CB510200,
   http://www.973.gov.cn/AreaAppl.aspx), General Project of the National
   Natural Science Fund (No. 81170855,
   http://www.nsfc.gov.cn/Portal0/default152.htm) and Research and
   Innovation Project for College Graduates of Jiangsu Province (No.
   CXZZ12_0586). The funders had no role in study design, data collection
   and analysis, decision to publish or preparation of the manuscript.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Chowers I, 2008, MOL VIS, V14, P1829
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Wu LC, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-10
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 27
TC 10
Z9 13
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 230
IS 4
BP 227
EP 232
DI 10.1159/000355068
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 253TO
UT WOS:000327112400009
PM 24080590
DA 2022-11-30
ER

PT J
AU Tsaousis, KT
   Empeslidis, T
   Konidaris, VE
   Kapoor, B
   Deane, J
AF Tsaousis, Konstantinos T.
   Empeslidis, Theodoros
   Konidaris, Vasileios E.
   Kapoor, Bharat
   Deane, James
TI The concept of virtual clinics in monitoring patients with age-related
   macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography; virtual
   clinics
ID OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB; REPRODUCIBILITY;
   REPEATABILITY; BEVACIZUMAB
AB PurposeTo present clinical results regarding the treatment of patients with age-related macular degeneration (neovascular form) after the implementation of a virtual' type of follow-up in a single retina service centre.
   MethodsRetrospective study based on the clinical records of the Leicester Royal Infirmary Retina department. Two periods were compared, the 2-year period of 2011-2012 and the following one of 2012-2013 when the virtual' clinics model applied in the department. Primary outcomes were as follows: the time between two appointments, follow-up or treatment and the number of patients with significant (>15 letters) improvement of their best corrected distance visual acuity. Secondary parameters of interest were as follows: mean number of injections per patient/year and the average duration of a virtual' vs. a regular visit.
   ResultsThe mean time interval between two appointments was 5.3weeks following the implementation of the virtual' clinics compared to 6.9weeks in the previous period of regular appointments. Mean visual acuity improvement >15 letters was achieved in 6.9% of the patients compared to 23.1% of the virtual' appointments period. The results regarding injections/patient/year were as follows: 5.6 before the model of virtual' appointments and 5.9 after the implementation. The average time a patient spent for a conventional visit was 71.424.1min, and the respective time needed in the virtual clinic was 47.3 +/- 18.6min.
   ConclusionThe model of virtual' (without actual consultation) follow-up appointments assisted our service to contend with the increased number of patient. In general, the specific pattern of patients' management could be widely considered obviously after comprehensive and all-embracing assessment of its safety and efficiency.
C1 [Tsaousis, Konstantinos T.; Empeslidis, Theodoros; Konidaris, Vasileios E.; Kapoor, Bharat; Deane, James] Leicester Royal Infirm, Dept Ophthalmol, Med Retina, Infirm Sq, Leicester LE1 5WW, Leics, England.
C3 University of Leicester
RP Tsaousis, KT (通讯作者)，Leicester Royal Infirm, Dept Ophthalmol, Med Retina, Infirm Sq, Leicester LE1 5WW, Leics, England.
EM konstantinos.tsaousis@gmail.com
OI Konidaris, Vasileios/0000-0001-5219-5805
FU Hellenic Society of Intraocular Implants and Refractive Surgery
FX Dr. Tsaousis received a scholarship (2015) from the Hellenic Society of
   Intraocular Implants and Refractive Surgery for postgraduate training.
CR Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kiss S, 2014, OSLI RETINA, V45, P285, DOI 10.3928/23258160-20140709-04
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Matlach J, 2014, INVEST OPHTH VIS SCI, V55, P6536, DOI 10.1167/iovs.14-15072
   Pinilla I, 2013, RETINA-J RET VIT DIS, V33, P1448, DOI 10.1097/IAE.0b013e3182807683
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Trikha S, 2012, EYE, V26, P1288, DOI 10.1038/eye.2012.120
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 16
TC 28
Z9 28
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2016
VL 94
IS 5
BP e353
EP e355
DI 10.1111/aos.12832
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR8IZ
UT WOS:000380142900015
PM 26385270
OA Bronze
DA 2022-11-30
ER

PT J
AU Ma, X
   Takahashi, Y
   Wu, WJ
   Chen, JL
   Dehdarani, M
   Liang, WT
   Shin, YH
   Benyajati, S
   Ma, JX
AF Ma, Xiang
   Takahashi, Yusuke
   Wu, Wenjing
   Chen, Jianglei
   Dehdarani, Marcus
   Liang, Wentao
   Shin, Young-Hwa
   Benyajati, Siribhinya
   Ma, Jian-xing
TI Soluble very low-density lipoprotein receptor (sVLDLR) inhibits fibrosis
   in neovascular age-related macular degeneration
SO FASEB JOURNAL
LA English
DT Article
DE fibrosis; macular degeneration; TGF-beta signaling pathway; very
   low-density lipoprotein receptor; Wnt signaling pathway
ID WNT SIGNALING PATHWAY; PATHOGENIC ROLE; TGF-BETA; PROTEIN;
   ISOMEROHYDROLASE; MECHANISMS; EXPRESSION; REGULATOR; RPE65; LRP6
AB Subretinal fibrosis is a key pathological feature in neovascular age-related macular degeneration (nAMD). Previously, we identified soluble very low-density lipoprotein receptor (sVLDLR) as an endogenous Wnt signaling inhibitor. This study investigates whether svLDLR plays an anti-fibrogenic role in nAMD models, including Vldlr(-/-) mice and laser-induced choroidal neovascularization (CNV). We found that fibrosis factors including P-Smad 2/3. alpha-SMA, and CTGF were upregulated in the subretinal area of Vldlr(-/-) mice and the laser-induced CNV model. The antibody blocking Wnt co-receptor LRP6 significantly attenuated the overexpression of fibrotic factors in these two models. Moreover, there was a significant reduction of sVLDLR in the interphotoreceptor matrix (IPM) in the laser-induced CNV model. A transgenic strain (sVLDLR-Tg) with sVLDLR overexpression in the IPM was generated. Overexpression of sVLDLR ameliorated the profibrotic changes in the subretinal area of the laser-induced CNV model. In addition, Wnt and TG F-beta signaling synergistically promoted fibrogenesis in human primary retinal pigment epithelium (RPE) cells. CRISPR/Cas9-mediated LRP6 gene knockout (KO) attenuated this synergistic effect. The disruption of VLDLR expression promoted, while the overexpression of sVLDLR inhibited TGF-beta-induced fibrosis. These findings suggest that overactivated Wnt signaling enhances the TGF-beta pathway in subretinal fibrosis. sVLDLR confers an antifibrotic effect, at least partially, through the inhibition of Wnt signaling and thus, has therapeutic potential for fibrosis.
C1 [Ma, Xiang; Takahashi, Yusuke; Wu, Wenjing; Chen, Jianglei; Dehdarani, Marcus; Liang, Wentao; Shin, Young-Hwa; Benyajati, Siribhinya; Ma, Jian-xing] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, BSEB 328B,941 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center
RP Ma, JX (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, BSEB 328B,941 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.
EM jian-xing-ma@ouhsc.edu
OI Liang, Wentao/0000-0002-0609-6280
FU National Institutes of Health (NIH) [EY019309, EY012231, EY028949,
   EY032930, EY032931]; Diabetic Animal Core and Histology and Image Core
   of diabetic COBRE [GM122744]; NEI P30 [EY021725]
FX National Institutes of Health (NIH), Grant/Award Number: EY019309,
   EY012231, EY028949, EY032930 and EY032931; Diabetic Animal Core and
   Histology and Image Core of diabetic COBRE, Grant/Award Number:
   GM122744; NEI P30, Grant/Award Number: EY021725
CR Akhmetshina A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1734
   Argraves WS, 2001, FRONT BIOSCI, V6, pD406, DOI 10.2741/Argraves
   Burgy O, 2018, MATRIX BIOL, V68-69, P67, DOI 10.1016/j.matbio.2018.03.017
   Chen Q, 2016, MOL CELL BIOL, V36, P2645, DOI 10.1128/MCB.00235-16
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dejana E, 2010, CIRC RES, V107, P943, DOI 10.1161/CIRCRESAHA.110.223750
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Han JW, 2015, INVEST OPHTH VIS SCI, V56, P8314, DOI 10.1167/iovs.15-18359
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Ishikawa M, 2015, EXP EYE RES, V133, P3, DOI 10.1016/j.exer.2015.02.017
   Klapholz-Brown Z, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000945
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lee K, 2014, J CELL SCI, V127, P4857, DOI 10.1242/jcs.149302
   Lee K, 2012, DIABETES, V61, P2948, DOI 10.2337/db11-0300
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2019, MOL THER-NUCL ACIDS, V17, P113, DOI 10.1016/j.omtn.2019.05.012
   Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137
   Luo XT, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032060
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Ma X, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101185
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Masckauchan T. Nestor H., 2005, Angiogenesis, V8, P43, DOI 10.1007/s10456-005-5612-9
   Masuzaki H, 1996, CIRC RES, V78, P8, DOI 10.1161/01.RES.78.1.8
   Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48
   Meyers EA, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022244
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   NAN W, 1993, INVEST OPHTH VIS SCI, V34, P101
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Qiu FF, 2020, CLIN SCI, V134, P1613, DOI 10.1042/CS20200085
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Reddy SS, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-30
   Ren Q, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.670960
   Ren SY, 2013, P NATL ACAD SCI USA, V110, P1440, DOI 10.1073/pnas.1211179110
   Saika S, 2006, LAB INVEST, V86, P106, DOI 10.1038/labinvest.3700375
   Singh HD, 2021, BIOCHEM BIOPH RES CO, V545, P8, DOI 10.1016/j.bbrc.2021.01.068
   Sun Y, 2017, J EXP MED, V214, P1753, DOI 10.1084/jem.20161645
   TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252
   Takahashi Sadao, 2004, J Atheroscler Thromb, V11, P200
   Takahashi Y, 2005, FEBS LETT, V579, P5414, DOI 10.1016/j.febslet.2005.09.002
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Wang ZX, 2015, ARTERIOSCL THROM VAS, V35, P855, DOI 10.1161/ATVBAHA.114.304627
   Wu D, 2019, FASEB J, V33, P2498, DOI 10.1096/fj.201801227R
   Xia CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075186
   Yang X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191279
   Yang YH, 2020, FASEB J, V34, P8428, DOI 10.1096/fj.201903149R
NR 55
TC 1
Z9 1
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2021
VL 35
IS 12
AR e22058
DI 10.1096/fj.202101334R
PG 19
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA XC9HG
UT WOS:000722321300032
PM 34820908
OA Green Published
DA 2022-11-30
ER

PT J
AU Paul, SK
   Pan, I
   Sobol, WM
AF Paul, Samantha K.
   Pan, Ian
   Sobol, Warren M.
TI A SYSTEMATIC REVIEW OF DEEP LEARNING APPLICATIONS FOR OPTICAL COHERENCE
   TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE deep learning; artificial intelligence; age-related macular
   degeneration; optical coherence tomography
ID VISUAL OUTCOMES; PREDICTION; DELAY
AB Purpose: To survey the current literature regarding applications of deep learning to optical coherence tomography in age-related macular degeneration (AMD). Methods: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses systematic review was conducted from January 1, 2000, to May 9, 2021, using PubMed and EMBASE databases. Original research investigations that applied deep learning to optical coherence tomography in patients with AMD or features of AMD (choroidal neovascularization, geographic atrophy, and drusen) were included. Summary statements, data set characteristics, and performance metrics were extracted from included articles for analysis. Results: We identified 95 articles for this review. The majority of articles fell into one of six categories: 1) classification of AMD or AMD biomarkers (n = 40); 2) segmentation of AMD biomarkers (n = 20); 3) segmentation of retinal layers or the choroid in patients with AMD (n = 7); 4) assessing treatment response and disease progression (n = 13); 5) predicting visual function (n = 6); and 6) determining the need for referral to a retina specialist (n = 3). Conclusion: Deep learning models generally achieved high performance, at times comparable with that of specialists. However, external validation and experimental parameters enabling reproducibility were often limited. Prospective studies that demonstrate generalizability and clinical utility of these models are needed.
C1 [Paul, Samantha K.; Sobol, Warren M.] Case Western Reserve Univ, Dept Ophthalmol, Univ Hosp Cleveland Med Ctr, Sch Med, Cleveland, OH 44106 USA.
   [Pan, Ian] Harvard Med Sch, Dept Radiol, Brigham & Womens Hosp, Boston, MA 02115 USA.
C3 Case Western Reserve University; University Hospitals of Cleveland;
   Harvard University; Brigham & Women's Hospital; Harvard Medical School
RP Paul, SK (通讯作者)，Univ Hosp Cleveland Med Ctr, Dept Ophthalmol, 11100 Euclid Ave, Cleveland, OH 44106 USA.
EM samantha.paul2@uhhospitals.org
CR Antony BJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0203726
   Banerjee I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72359-y
   Caron M., 2020, ARXIV
   Choy G, 2018, RADIOLOGY, V288, P318, DOI 10.1148/radiol.2018171820
   Christopher M, 2020, OPHTHALMOLOGY, V127, P346, DOI 10.1016/j.ophtha.2019.09.036
   Cob E, 2021, RADIOL-ARTIF INTELL, V3, DOI 10.1148/ryai.2021200254
   Cooray A, 2016, ROY SOC OPEN SCI
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Eng DK, 2021, RADIOLOGY, V301, P692, DOI 10.1148/radiol.2021204021
   Flanders AE, 2020, RADIOL-ARTIF INTELL, V2, DOI 10.1148/ryai.2020190211
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   He K., 2020, P C COMPUTER VISION
   Henaff O.J., 2019, ARXIV, DOI [10.48550/arXiv.1905.09272, DOI 10.48550/ARXIV.1905.09272]
   Iizuka O, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58467-9
   Kawczynski MG, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.51
   Khan SM, 2021, LANCET DIGIT HEALTH, V3, pE51, DOI 10.1016/S2589-7500(20)30240-5
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Kuo BI, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.53
   Lee H, 2021, RETINA-J RET VIT DIS, V41, P572, DOI 10.1097/IAE.0000000000002898
   Liefers B, 2017, BIOMED OPT EXPRESS, V8, P5160, DOI 10.1364/BOE.8.005160
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Liu HR, 2019, JAMA OPHTHALMOL, V137, P1353, DOI 10.1001/jamaophthalmol.2019.3501
   Liu Y, 2020, NAT MED, V26, P900, DOI 10.1038/s41591-020-0842-3
   Midena E, 2016, GRAEF ARCH CLIN EXP, V254, P1661, DOI 10.1007/s00417-016-3361-7
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   National Institute for Health and Care Excellence (NICE), 2018, NICE GUID NG 82 AG R
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rasti R, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.3.035005
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Sacconi R, 2018, EYE, V32, P734, DOI 10.1038/eye.2017.295
   Schmidhuber J, 2015, NEURAL NETWORKS, V61, P85, DOI 10.1016/j.neunet.2014.09.003
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Shih G, 2019, RADIOL-ARTIF INTELL, V1, DOI 10.1148/ryai.2019180041
   Ting DSJ, 2021, BRIT J OPHTHALMOL, V105, P158, DOI 10.1136/bjophthalmol-2019-315651
   Told R, 2020, RETINA-J RET VIT DIS, V40, P2010, DOI 10.1097/IAE.0000000000002695
   Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7
   Vaswani A, 2017, ADV NEUR IN, V30
   Waldstein SM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69814-1
   Wang MY, 2020, OPHTHALMOLOGY, V127, P731, DOI 10.1016/j.ophtha.2019.12.004
   Xu XY, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8445-y
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Zheng C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.29
NR 44
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2022
VL 42
IS 8
BP 1417
EP 1424
DI 10.1097/IAE.0000000000003535
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3D9GA
UT WOS:000829601100008
PM 35877964
DA 2022-11-30
ER

PT J
AU Yu, HJ
   Wykoff, CC
AF Yu, Hannah J.
   Wykoff, Charles C.
TI Investigational Agents in Development for the Treatment of Geographic
   Atrophy Secondary to Age-Related Macular Degeneration
SO BIODRUGS
LA English
DT Review
ID CILIARY NEUROTROPHIC FACTOR; RETINAL-PIGMENT EPITHELIUM; GENOME-WIDE
   ASSOCIATION; RARE GENETIC-VARIANTS; COMPLEMENT FACTOR-H;
   QUALITY-OF-LIFE; VISUAL IMPAIRMENT; NATURAL-HISTORY; CELL-DEATH;
   HIGH-RISK
AB Geographic atrophy (GA) is an advanced form of age-related macular degeneration, a late-onset, complex, genetic degenerative disease of the retina. Multiple environmental and genetic factors have been implicated in the development of GA, a pathology ultimately defined by loss of photoreceptors and the underlying retinal pigment epithelium and choriocapillaris. The personal burden of GA has been documented to have a substantial negative impact on quality of life, with progressive and cumulative loss of visual function each year. Currently, there are no treatments to prevent or slow the development or progression of GA. Multiple genetic and histopathologic studies have implicated dysregulation of the complement cascade in GA pathogenesis, leading to the development of several investigational pharmaceuticals targeting key factors in this inflammatory pathway. Several other biochemical pathways have also been implicated in GA development and progression, such as mitochondrial components, mediators of apoptosis and molecules involved in extracellular matrix remodeling, many of which are also being investigated for their potential value as therapeutic targets for GA treatment. Recent advancements in our understanding of GA pathogenesis and the progression of multiple potential therapeutics into later-stage human clinical trials hold great promise for a clinically effective therapeutic for patients with GA to emerge within the near future.
C1 [Yu, Hannah J.; Wykoff, Charles C.] Retina Consultants Amer, Retina Consultants Texas, 4460 Bissonnet St,Suite 200, Bellaire, TX 77401 USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX 77030 USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston
RP Wykoff, CC (通讯作者)，Retina Consultants Amer, Retina Consultants Texas, 4460 Bissonnet St,Suite 200, Bellaire, TX 77401 USA.; Wykoff, CC (通讯作者)，Houston Methodist Hosp, Blanton Eye Inst, Houston, TX 77030 USA.
EM charleswykoff@gmail.com
CR Alkeus Pharm, ONGOING CLIN TRIALS
   American Academy of Ophthalmology, 2015, RETINAVITREOUS PANEL
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Annex. Biosci, ANX007
   [Anonymous], 2020, PROGRAMS PIPELINES
   [Anonymous], 2020, PHASE 3 SAFETY EFFIC
   [Anonymous], 2020, STUDY COMPARE EFFICA
   [Anonymous], 2020, CLIN TRIAL DESIGNED
   [Anonymous], 2020, EXPLORE PHASE 2 STUD
   [Anonymous], 2015, PHASE 1 SAFETY STUDY
   [Anonymous], 2020, STUDY EVALUATE SAFET
   [Anonymous], 2020, SAFETY TOLERABILITY
   [Anonymous], 2020, AGE RELATED MACULAR
   [Anonymous], 2020, 1 HUMAN STUDY EVALUA
   [Anonymous], 2020, STUDY DETERMINE SAFE
   [Anonymous], 2020, WHAT IS HMR59
   [Anonymous], 2020, MONOCLONAL ANTIBODY
   [Anonymous], 2018, CLIN STUDY EVALUATE
   [Anonymous], 2019, CLG561 PROOF OF CONC
   [Anonymous], 2020, STUDY ANX007 PARTICI
   [Anonymous], 2019, FDA APPROVES 1 TREAT
   [Anonymous], 2020, MULTIPLE DOSE STUDY
   [Anonymous], 2019, SAFETY EFFICACY STUD
   [Anonymous], 2020, OPEN LABEL PHASE 1 C
   [Anonymous], 2019, TREATMENT ADV DRY AG
   [Anonymous], 2020, APELLIS COMPLETES EN
   [Anonymous], 2021, STUDY INVESTIGATING
   [Anonymous], 2020, PHASE 3 STUDY ALK 00
   [Anonymous], 2021, HORIZON PHASE 2 STUD
   [Anonymous], 2016, ANTICOMPLEMENT C5 MO
   [Anonymous], 2020, INTRAVITREAL AAVCAGS
   [Anonymous], 2020, FOCUS 1 HUMAN STUDY
   [Anonymous], 2019, EYEWIRE NEWS
   [Anonymous], 2020, GEMINI THERAPEUTICS
   [Anonymous], 2020, RECLAIM 2 STUDY EVAL
   [Anonymous], 2020, STUDY NGM621 PARTICI
   [Anonymous], 2019, INTRAVITREAL LFG316
   [Anonymous], 2020, STUDY ASSESSING SAFE
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bianchi E, 2013, INT J MOL MED, V31, P232, DOI 10.3892/ijmm.2012.1164
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bonilha VL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.15
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brinkmann CK, 2010, OPHTHALMOLOGE, V107, P999, DOI 10.1007/s00347-010-2158-z
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Cantor Louis B, 2006, Ther Clin Risk Manag, V2, P337, DOI 10.2147/tcrm.2006.2.4.337
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Charters L., 2020, OPHTHALMOL TIMES
   Chew EY, 2019, OPHTHALMOLOGY, V126, P540, DOI 10.1016/j.ophtha.2018.09.041
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chinskey ND, 2014, CURR OPIN OPHTHALMOL, V25, P228, DOI 10.1097/ICU.0000000000000043
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Ciferri C, 2015, BIOCHEM J, V472, P169, DOI 10.1042/BJ20150601
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cousins S, 2019, RECLAIM PHASE 1 CLIN
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Di Caprio R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/329418
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dugel, 2020, CLIN TRIAL DOWNLOAD
   Dugel P, 2014, PHASE SINGLE ASCENDI
   Ellis S., 2020, GT005 GENE THERAPY T
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freeman W, 2018, BRIMONIDINE DDS SAFE
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galanopoulos A, 2009, CLIN OPHTHALMOL, V3, P117
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gemini Ther, COMPLEMENT FACTOR H
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Gyroscope, GENE THERAPIES
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P673, DOI 10.1016/j.oret.2020.01.019
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200
   Iveric Bio, THERAPEUTICS
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Karaa A, 2018, NEUROLOGY, V90, pE1212, DOI 10.1212/WNL.0000000000005255
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kirkner R., 2020, TARGETING NOVEL ENZY
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kunzel SH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.63
   Kuppermann BD, 2021, RETINA-J RET VIT DIS, V41, P144, DOI 10.1097/IAE.0000000000002789
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Lo ACY, 2011, OPHTHALMOLOGICA, V226, P10, DOI 10.1159/000328206
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mihai DM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.314
   Natl. Hum. Genome Res. Inst, GENOME WIDE ASS STUD
   Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001
   Paradies G, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070728
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pasquin S, 2015, CYTOKINE GROWTH F R, V26, P507, DOI 10.1016/j.cytogfr.2015.07.007
   Patel PJ, 2020, CLIN OPHTHALMOL, V14, P15, DOI 10.2147/OPTH.S226425
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Sivaprasad S, 2019, OPHTHALMOL THER, V8, P115, DOI 10.1007/s40123-019-0160-3
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Stieger K, 2007, GENE THER, V14, P1668, DOI 10.1038/sj.gt.3303034
   Szeto HH, 2018, PROTEIN PEPTIDE LETT, V25, P1108, DOI 10.2174/0929866525666181101105209
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thanos CG, 2004, TISSUE ENG, V10, P1617, DOI 10.1089/ten.2004.10.1617
   Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Wykoff CC., 2020, INHIBITION COMPLEMEN
   Xiao JH, 2017, INVEST OPHTH VIS SCI, V58, P1801, DOI 10.1167/iovs.16-21392
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhou D., 2020, MECH ACTION RISUTEGA
NR 156
TC 1
Z9 1
U1 3
U2 5
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-8804
EI 1179-190X
J9 BIODRUGS
JI Biodrugs
PD MAY
PY 2021
VL 35
IS 3
BP 303
EP 323
DI 10.1007/s40259-021-00481-y
EA APR 2021
PG 21
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA RV2CW
UT WOS:000643179100001
PM 33893984
DA 2022-11-30
ER

PT J
AU Maaijwee, K
   Van den Beesen, KR
   Missotten, T
   Van Meurs, JC
AF Maaijwee, Kristel
   Van den Beesen, Keter R.
   Missotten, Tom
   Van Meurs, Jan C.
TI Angiographic evidence for revascularization of an RPE-choroid graft in
   patients with age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; angiography; perfusion; RPE-choroid
   graft; translocation; revascularization; surgery
ID RETINAL-PIGMENT EPITHELIUM; SCANNING LASER OPHTHALMOSCOPE; INDOCYANINE
   GREEN; SODIUM FLUORESCEIN; VISUAL IMPAIRMENT; TRANSLOCATION; VESSELS;
   PLASMA
AB Purpose: To study graft perfusion using fluorescein angiography (FA) and indocyanine green angiography (ICG) after the translocation of an autologous retinal pigment epithelium (RPE)-choroid graft in patients with exudative age-related macular degeneration (AMD).
   Methods: Retrospective observational case series of 31 patients with AMD who had FA and/or ICG performed after an RPE-choroid graft translocation. The FAs (n = 25) and ICGs (n = 23) were assessed by an independent masked reader for the presence of early fluorescence of the graft in FA, and for perfusion of the choroidal vessels of the graft and recipient bed in ICG.
   Results: Early fluorescence of the graft was present in 23 of the 25 FAs. Perfusion of the graft vasculature was observed in 12 of the 23 ICGs. The two grafts that lacked early fluorescence in FA also had no signs of choroidal perfusion of the graft and the recipient bed with ICG.
   Conclusion: Revascularization of the RPE-choroid graft was observed in all but 2 of the 31 patients either by early fluorescence of the graft by FA or by identification of perfused choroidal graft vessels with ICG from 1 week up to 3 years after surgery. For assessment of revascularization of the graft evaluation of the early phase of the FA is recommended.
C1 [Maaijwee, Kristel; Missotten, Tom; Van Meurs, Jan C.] Rotterdam Eye Hosp, NL-3011 BH Rotterdam, Netherlands.
   [Van den Beesen, Keter R.] Univ Med Ctr Utrecht, Dept Ophthalmol, Rotterdam, Netherlands.
   [Van Meurs, Jan C.] Erasmus Univ, Dept Ophthalmol, Rotterdam, Netherlands.
C3 Rotterdam Eye Hospital; Utrecht University; Utrecht University Medical
   Center; Erasmus University Rotterdam
RP Maaijwee, K (通讯作者)，Rotterdam Eye Hosp, Schiedamse Vest 180, NL-3011 BH Rotterdam, Netherlands.
EM kmaaijwee@hotmail.com
CR Capla JM, 2006, PLAST RECONSTR SURG, V117, P836, DOI 10.1097/01.prs.0000201459.91559.7f
   CONVERSE JM, 1956, ANN SURG, V143, P306, DOI 10.1097/00000658-195603000-00003
   DELORI FC, 1978, EXP EYE RES, V27, P417, DOI 10.1016/0014-4835(78)90020-9
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   FLOWER RW, 1980, INT OPHTHALMOL, V2, P143, DOI 10.1007/BF00137959
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   Gelisken F, 1998, RETINA-J RET VIT DIS, V18, P37
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   KIRYU J, 1994, INVEST OPHTH VIS SCI, V35, P3724
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Maaijwee KJM, 2007, BRIT J OPHTHALMOL, V91, P546, DOI 10.1136/bjo.2006.103259
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   O'Ceallaigh S, 2006, PLAST RECONSTR SURG, V117, P140, DOI 10.1097/01.prs.0000185611.87601.b8
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHNEIDER A, 1992, AM J OPHTHALMOL, V113, P45
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   van den Biesen PR, 1997, RETINA-J RET VIT DIS, V17, P540
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Van Meurs JC, 2005, ESSENT OPHTHALMOL, P73
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   VANDENBIESEN PR, 1994, ANN BIOMED ENG, V22, P456, DOI 10.1007/BF02367082
   VANDENBIESEN PR, 1995, ANN BIOMED ENG, V23, P475, DOI 10.1007/BF02584447
   YONEYA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P681
   YOUNG CMA, 1982, PLAST RECONSTR SURG, V70, P455, DOI 10.1097/00006534-198210000-00008
NR 29
TC 17
Z9 17
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2008
VL 28
IS 3
BP 498
EP 503
DI 10.1097/IAE.0b013e318159ec24
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 273SH
UT WOS:000253951500016
PM 18327145
DA 2022-11-30
ER

PT J
AU Dhalla, MS
   Shah, GK
   Blinder, KJ
   Ryan, EH
   Mittra, RA
   Tewari, A
AF Dhalla, Mandeep S.
   Shah, Gaurav K.
   Blinder, Kevin J.
   Ryan, Edwin H., Jr.
   Mittra, Robert A.
   Tewari, Asheesh
TI Combined photodynamic therapy with verteporfin and intravitreal
   bevacizumab for choroidal neovascularization in age-related macular
   degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; intravitreal triamcinolone; monoclonal antibody;
   pegaptanib; photodynamic therapy; ranibizumab; subretinal
   neovascularization; vascular endothelial derived growth factor;
   verteporfin
ID COHERENCE TOMOGRAPHY FINDINGS; TRIAMCINOLONE ACETONIDE; INJECTION;
   EXPRESSION; VEGF
AB Purpose: To examine the 7-month results for patients treated with combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Methods: This is a retrospective series of 24 eyes with juxtafoveal or subfoveal CNV secondary to AMD. Patients were treated with PDT with verteporfin and 1.25 mg of intravitreal bevacizumab. All patients were naive to treatment and had either treatment within a 14-day interval. Main outcome measures were visual acuity stabilization (defined as no change or a gain in visual acuity) and retreatment rate.
   Results: At the 7-month follow-up, 20 (83%) of 24 patients had stabilization of visual acuity. Sixteen eyes (67%) had improvement in visual acuity. Mean improvement in visual acuity (n = 24) was 2.04 Snellen lines. Fifteen eyes (63%) required only a single combined treatment for CNV resolution. There were no complications, including endophthalmitis, uveitis, and ocular hypertension.
   Conclusion: The results of this study suggest that combined treatment of PDT with verteporfin and intravitreal bevacizumab may be useful in treating neovascular AMD by reducing retreatment rates and improving visual acuity. Further investigation with large, controlled trials is warranted to outline the appropriate treatment paradigm for combination therapy.
C1 Barnes Retina Inst, St Louis, MO USA.
   Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA.
   Vitreoretinal Surg, Edina, MN USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Shah, GK (通讯作者)，1600 S Brentwood Blvd,Suite 800, St Louis, MO 63144 USA.
EM gkshah1@gmail.com
RI Mittra, Robert/AAC-8249-2021
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bucher RS, 2005, ARCH OPHTHALMOL-CHIC, V123, P649, DOI 10.1001/archopht.123.5.649
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Hashimoto Ichiro, 2002, Journal of Medical Investigation, V49, P61
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   MILLER JW, 2005, AM SOC RET SPEC ANN
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
NR 25
TC 88
Z9 100
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2006
VL 26
IS 9
BP 988
EP 993
DI 10.1097/01.iae.0000247164.70376.91
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 175AZ
UT WOS:000246985700002
PM 17151484
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Piechota, M
   Pawlowska, E
   Szatkowska, M
   Sikora, E
   Kaarniranta, K
AF Blasiak, Janusz
   Piechota, Malgorzata
   Pawlowska, Elzbieta
   Szatkowska, Magdalena
   Sikora, Ewa
   Kaarniranta, Kai
TI Cellular Senescence in Age-Related Macular Degeneration: Can Autophagy
   and DNA Damage Response Play a Role?
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; INDUCED PREMATURE SENESCENCE; OXIDATIVE
   STRESS; MITOCHONDRIAL-DNA; SECRETORY PHENOTYPE; HYDROGEN-PEROXIDE;
   CHRONIC INFLAMMATION; CELLS-IMPLICATIONS; GLOBAL PREVALENCE; CANCER
AB Age-related macular degeneration (AMD) is the main reason of blindness in developed countries. Aging is the main AMD risk factor. Oxidative stress, inflammation and some genetic factors play a role in AMD pathogenesis. AMD is associated with the degradation of retinal pigment epithelium (RPE) cells, photoreceptors, and choriocapillaris. Lost RPE cells in the central retina can be replaced by their peripheral counterparts. However, if they are senescent, degenerated regions in the macula cannot be regenerated. Oxidative stress, a main factor of AMD pathogenesis, can induce DNA damage response (DDR), autophagy, and cell senescence. Moreover, cell senescence is involved in the pathogenesis of many age-related diseases. Cell senescence is the state of permanent cellular division arrest and concerns only mitotic cells. RPE cells, although quiescent in the retina, can proliferate in vitro. They can also undergo oxidative stress-induced senescence. Therefore, cellular senescence can be considered as an important molecular pathway of AMD pathology, resulting in an inability of the macula to regenerate after degeneration of RPE cells caused by a factor inducing DDR and autophagy. It is too early to speculate about the role of the mutual interplay between cell senescence, autophagy, and DDR, but this subject is worth further studies.
C1 [Blasiak, Janusz; Szatkowska, Magdalena] Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Piechota, Malgorzata] Polish Acad Sci, Nencki Inst Expt Biol, Lab Mol Basis Behav, Pasteura 3, PL-02093 Warsaw, Poland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, Pomorska 251, PL-92216 Lodz, Poland.
   [Sikora, Ewa] Polish Acad Sci, Nencki Inst Expt Biol, Lab Mol Bases Aging, Pasteura 3, PL-02093 Warsaw, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
C3 University of Lodz; Polish Academy of Sciences; Nencki Institute of
   Experimental Biology of the Polish Academy of Sciences; Medical
   University Lodz; Polish Academy of Sciences; Nencki Institute of
   Experimental Biology of the Polish Academy of Sciences; University of
   Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
EM janusz.blasiak@biol.uni.lodz.pl
OI Piechota, Malgorzata/0000-0001-7511-8626; Blasiak,
   Janusz/0000-0001-9539-9584; Sikora, Ewa/0000-0002-1111-1748; Pawlowska,
   Elzbieta/0000-0002-5373-4783
CR Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Alster O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104964
   Arend N, 2015, OPHTHALMOLOGICA, V234, P73, DOI 10.1159/000381726
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]
   Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Bandyopadhyay D, 2001, EXP GERONTOL, V36, P1265, DOI 10.1016/S0531-5565(01)00098-5
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bielak-Zmijewska A, 2014, BIOGERONTOLOGY, V15, P47, DOI 10.1007/s10522-013-9477-9
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112
   Brzezinska A, 2004, EXP GERONTOL, V39, P539, DOI 10.1016/j.exger.2003.09.026
   Burtner CR, 2010, NAT REV MOL CELL BIO, V11, P567, DOI 10.1038/nrm2944
   Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Chang YC, 2015, TOXICOL IN VITRO, V29, P1358, DOI 10.1016/j.tiv.2015.05.014
   CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Correia-Melo C, 2016, EMBO J, V35, P724, DOI 10.15252/embj.201592862
   Correia-Melo C, 2015, BBA-BIOENERGETICS, V1847, P1373, DOI 10.1016/j.bbabio.2015.05.017
   di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440
   ELIOPOULOS AG, 2016, FRONTIERS GENETICS, V7
   Erusalimsky J D, 2006, Handb Exp Pharmacol, P213
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Filomeni G, 2010, AUTOPHAGY, V6, P999, DOI 10.4161/auto.6.7.12754
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69
   Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003
   Gallagher LE, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020024
   Gewirtz DA, 2013, AUTOPHAGY, V9, P808, DOI 10.4161/auto.23922
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Gorenne I, 2006, CARDIOVASC RES, V72, P9, DOI 10.1016/j.cardiores.2006.06.004
   Grabowska W, 2017, BIOGERONTOLOGY, V18, P447, DOI 10.1007/s10522-017-9685-9
   Gramajo AL, 2010, INVEST OPHTH VIS SCI, V51, P1164, DOI 10.1167/iovs.09-3443
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446
   Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225
   Hewitt G, 2017, TRENDS CELL BIOL, V27, P340, DOI 10.1016/j.tcb.2016.11.011
   Hoare M, 2013, NAT CELL BIOL, V15, P887, DOI 10.1038/ncb2811
   Hubackova S, 2012, AGING-US, V4, P932, DOI 10.18632/aging.100520
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Ioannidou A, 2016, FRONT GENET, V7, DOI 10.3382/fgene.2016.00187
   Jarrett SG, 2007, OPHTHALMIC RES, V39, P213, DOI 10.1159/000104683
   Jarrett Stuart G, 2013, Methods Mol Biol, V935, P227, DOI 10.1007/978-1-62703-080-9_16
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jeyapalan JC, 2008, MECH AGEING DEV, V129, P467, DOI 10.1016/j.mad.2008.04.001
   Jeyapalan JC, 2007, MECH AGEING DEV, V128, P36, DOI 10.1016/j.mad.2006.11.008
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Jurk D, 2012, AGING CELL, V11, P996, DOI 10.1111/j.1474-9726.2012.00870.x
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kang C, 2016, AUTOPHAGY, V12, P898, DOI 10.1080/15548627.2015.1121361
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kreiling JA, 2011, AGING CELL, V10, P292, DOI 10.1111/j.1474-9726.2010.00666.x
   Ksiazek K, 2006, J APPL PHYSIOL, V100, P988, DOI 10.1152/japplphysiol.01086.2005
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156
   Labbe K, 2014, ANNU REV CELL DEV BI, V30, P357, DOI 10.1146/annurev-cellbio-101011-155756
   Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195
   Levonen AL, 2014, FREE RADICAL BIO MED, V71, P196, DOI 10.1016/j.freeradbiomed.2014.03.025
   Li LC, 2015, ONCOL LETT, V10, P3293, DOI 10.3892/ol.2015.3727
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Madeo F, 2010, NAT CELL BIOL, V12, P842, DOI 10.1038/ncb0910-842
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marzetti E, 2010, THESCIENTIFICWORLDJO, V10, P340, DOI 10.1100/tsw.2010.27
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   MOORHEAD PS, 1974, J BIOL STAND, V2, P95, DOI 10.1016/0092-1157(74)90023-7
   Mosieniak G, 2015, NEOPLASIA, V17, P882, DOI 10.1016/j.neo.2015.11.008
   Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272
   Nakamura AJ, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-6
   Naylor RM, 2013, CLIN PHARMACOL THER, V93, P105, DOI 10.1038/clpt.2012.193
   Ovadya Y, 2014, BIOGERONTOLOGY, V15, P627, DOI 10.1007/s10522-014-9529-9
   Piechota M, 2016, ONCOTARGET, V7, P81099, DOI 10.18632/oncotarget.12752
   Pospelova TV, 2009, CELL CYCLE, V8, P4112, DOI 10.4161/cc.8.24.10215
   Przybylska D, 2016, ONCOTARGET, V7, P66429, DOI 10.18632/oncotarget.12079
   Reibaldi M., 2016, AM J OPHTHALMOL, V161
   Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Roggia MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134870
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Sagiv A, 2013, BIOGERONTOLOGY, V14, P617, DOI 10.1007/s10522-013-9473-0
   Salminen A, 2012, CELL SIGNAL, V24, P835, DOI 10.1016/j.cellsig.2011.12.006
   Sample A, 2017, PHOTOCHEM PHOTOBIOL, V93, P943, DOI 10.1111/php.12691
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Scherz-Shouval R, 2007, AUTOPHAGY, V3, P371, DOI 10.4161/auto.4214
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095
   Sedelnikova OA, 2008, AGING CELL, V7, P89, DOI 10.1111/j.1474-9726.2007.00354.x
   Sharma S, 2013, MUTAT RES-FUND MOL M, V743, P97, DOI 10.1016/j.mrfmmm.2012.11.002
   Shibata KR, 2007, STEM CELLS, V25, P2371, DOI 10.1634/stemcells.2007-0225
   Sikora E, 2016, CURR DRUG TARGETS, V17, P377, DOI 10.2174/1389450116666151019094724
   Sikora E, 2014, CURR VASC PHARMACOL, V12, P698
   Sikora E, 2013, EXP GERONTOL, V48, P661, DOI 10.1016/j.exger.2012.09.008
   Sikora E, 2011, AGEING RES REV, V10, P146, DOI 10.1016/j.arr.2010.10.002
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   Testa U, 2016, EXP HEMATOL, V44, P540, DOI 10.1016/j.exphem.2016.04.012
   Tokarz P, 2016, EUR J PHARMACOL, V776, P167, DOI 10.1016/j.ejphar.2016.02.049
   Toussaint O, 2000, ANN NY ACAD SCI, V908, P85, DOI 10.1111/j.1749-6632.2000.tb06638.x
   Tsunemi T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003799
   van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193
   Van Houten B, 2016, FRONT BIOSCI-LANDMRK, V21, P42, DOI 10.2741/4375
   Wang AL, 2008, MOL VIS, V14, P644
   Wang CF, 2009, AGING CELL, V8, P311, DOI 10.1111/j.1474-9726.2009.00481.x
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   White RR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7790
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia HM, 2011, EXP EYE RES, V93, P862, DOI 10.1016/j.exer.2011.09.020
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yu B, 2014, INVEST OPHTH VIS SCI, V55, P8638, DOI 10.1167/iovs.14-14758
   Zhang C, 2013, CANCER LETT, V340, P51, DOI 10.1016/j.canlet.2013.06.021
   Zhu Y, 2014, CURR OPIN CLIN NUTR, V17, P324, DOI 10.1097/MCO.0000000000000065
   Zhu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26322
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
NR 144
TC 54
Z9 54
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2017
VL 2017
AR 5293258
DI 10.1155/2017/5293258
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FL2MV
UT WOS:000414050600001
PM 29225722
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Katsi, VK
   Marketou, ME
   Vrachatis, DA
   Manolis, AJ
   Nihoyannopoulos, P
   Tousoulis, D
   Vardas, PE
   Kallikazaros, I
AF Katsi, Vasiliki K.
   Marketou, Maria E.
   Vrachatis, Dimitrios A.
   Manolis, Athanasios J.
   Nihoyannopoulos, Petros
   Tousoulis, Dimitrios
   Vardas, Panos E.
   Kallikazaros, Ioannis
TI Essential hypertension in the pathogenesis of age-related macular
   degeneration: a review of the current evidence
SO JOURNAL OF HYPERTENSION
LA English
DT Review
DE age-related macular degeneration; essential hypertension;
   neovascularization
ID CARDIOVASCULAR RISK-FACTORS; ANGIOTENSIN-II; BLOOD-PRESSURE; CHOROIDAL
   NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; SYSTEMIC HYPERTENSION;
   TERM INCIDENCE; MACULOPATHY; DISEASE; PREVALENCE
AB Age-related macular degeneration (AMD) is one of the main causes of vision loss, especially in the elderly. The involvement of essential hypertension in its pathogenesis has been well covered in the literature since it was first recognized. Hemodynamic abnormalities appear to contribute to AMD, with the renin-angiotensin system playing a significant role. Many studies have demonstrated that high blood pressure is associated with lower choroidal blood flow and disturbed vascular homeostasis in these patients. In addition, AMD is characterized by abnormal neovascularization, to which angiotensin II and growth factors make a large contribution. Most epidemiological studies have found essential hypertension to be a risk factor for AMD. However, although all agree that the strongest predisposing factors are age and smoking, overall there is some inconsistency regarding the exact role of hypertension in its pathogenesis. In particular, there are no data in the literature to support the view that antihypertensive medication and the successful management of hypertension have a positive effect on the clinical outcome of AMD. This reinforces the data indicating that the cause of AMD is multifactorial and suggests that, although essential hypertension probably plays a role, in itself it is unlikely to be a major contributor to the future occurrence of AMD.
C1 [Katsi, Vasiliki K.; Kallikazaros, Ioannis] Hippokrateion Hosp, Dept Cardiol, Athens, Greece.
   [Marketou, Maria E.; Vardas, Panos E.] Heraklion Univ Hosp, Dept Cardiol, Iraklion, Greece.
   [Vrachatis, Dimitrios A.; Nihoyannopoulos, Petros; Tousoulis, Dimitrios] Natl & Kapodistrian Univ Athens, Hippokrat Hosp, Cardiol Dept 1, Athens 11528, Greece.
   [Manolis, Athanasios J.] Asklepie Gen Hosp, Dept Cardiol, Athens, Greece.
C3 Hippokration General Hospital; University Hospital of Heraklion;
   Hippokration General Hospital; National & Kapodistrian University of
   Athens
RP Marketou, ME (通讯作者)，Heraklion Univ Hosp, Dept Cardiol, POB 1352, Iraklion, Greece.
EM maryemarke@yahoo.gr
RI Vrachatis, Dimitrios/H-3399-2019; vardas, panos/ABF-7144-2020; Vardas,
   Panos/AAP-5694-2021; Vardas, Panos/AAD-5219-2022
OI Vrachatis, Dimitrios/0000-0002-2385-5365; 
CR Belkin M, 2013, AM J OPHTHALMOL, V155, P404, DOI 10.1016/j.ajo.2012.09.017
   Benigni A, 2010, EMBO MOL MED, V2, P247, DOI 10.1002/emmm.201000080
   BERKA JL, 1995, INVEST OPHTH VIS SCI, V36, P1450
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen P, 2006, EXP EYE RES, V83, P1041, DOI 10.1016/j.exer.2006.05.009
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4
   Harrison DG, 2009, MED CLIN N AM, V93, P621, DOI 10.1016/j.mcna.2009.02.015
   Hikichi T, 2001, AM J OPHTHALMOL, V132, P587, DOI 10.1016/S0002-9394(01)01139-4
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jonas JB, 2003, GRAEF ARCH CLIN EXP, V241, P125, DOI 10.1007/s00417-002-0615-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Kulkarni PS, 1999, INVEST OPHTH VIS SCI, V40, P721
   Kurihara T, 2006, INVEST OPHTH VIS SCI, V47, P5545, DOI 10.1167/iovs.06-0478
   Matsugi T, 1997, INVEST OPHTH VIS SCI, V38, P652
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Miller AG, 2010, DIABETES, V59, P3208, DOI 10.2337/db10-0552
   Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Otani A, 1998, CIRC RES, V82, P619, DOI 10.1161/01.RES.82.5.619
   Otani A, 2001, DIABETES, V50, P867, DOI 10.2337/diabetes.50.4.867
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KHC, 2004, ACTA OPHTHALMOL SCAN, V82, P298, DOI 10.1111/j.1600-0420.2004.00265.x
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yamagishi S, 2005, INT J TISSUE REACT, V27, P125
   Yang K, 2014, RETINA-J RET VIT DIS, V34, P1539, DOI 10.1097/IAE.0000000000000118
NR 57
TC 14
Z9 14
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0263-6352
EI 1473-5598
J9 J HYPERTENS
JI J. Hypertens.
PD DEC
PY 2015
VL 33
IS 12
BP 2382
EP 2388
DI 10.1097/HJH.0000000000000766
PG 7
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA DB4BW
UT WOS:000368458700003
PM 26536087
DA 2022-11-30
ER

PT J
AU Fletcher, EL
AF Fletcher, Erica Lucy
TI 2016 Glenn A. Fry Award Lecture: Mechanisms and Potential Treatments of
   Early Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID INDUCED PHOTORECEPTOR DEATH; SPINAL-CORD-INJURY; EXTRACELLULAR ATP;
   RETICULAR PSEUDODRUSEN; SCAVENGER RECEPTOR; IMPROVES RECOVERY; P2X(7)
   RECEPTORS; APOPTOTIC CELLS; VISUAL FUNCTION; ANIMAL-MODELS
AB Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in those older than 80 years. Understanding the mechanisms that cause this condition or its progression is critical for developing novel treatments. Here we summarize our studies evaluating the role of purine, adenosine triphosphate (ATP), in early AMD as well as photoreceptor loss and have also provided some insights to our investigations of a new laser treatment for those with early AMD. One of the receptors that are activated by ATP, P2X7, is expressed by neurons and immune cells and has a different function in each cell type. In neurons, P2X7 receptors forma ligand-gated ion channel, whereas on immune cells P2X7 receptors act as a scavenger receptor. These distinct functions have provided new insights to the mechanisms of AMD. On the one hand, high concentrations of ATP can cause photoreceptor death, most likely via stimulation of P2X7 receptors localized on photoreceptor terminals. On the other hand, P2X7 receptors mediate removal of dead and dying cells by monocytes. By understanding the fundamental cell biological changes that occur in patients and animal models of disease, we have uncovered mechanisms that may help us manage and treat patients in the future. Copyright (C) 2017 American Academy of Optometry
C1 [Fletcher, Erica Lucy] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic, Australia.
C3 University of Melbourne
RP Fletcher, EL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic, Australia.
EM elf@unimelb.edu.au
RI Fletcher, Erica/E-6364-2012
OI Fletcher, Erica/0000-0001-9412-9523
FU NHMRC [APP1061419]
FX NH&MRC grant no. APP1061419 (to Erica Lucy Fletcher).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aplin FP, 2014, INVEST OPHTH VIS SCI, V55, P8319, DOI 10.1167/iovs.14-15732
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eter N, 2008, INVEST OPHTH VIS SCI, V49, P3649, DOI 10.1167/iovs.07-1322
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Fletcher EL, 2011, PROG MOL BIOL TRANSL, V100, P211, DOI 10.1016/B978-0-12-384878-9.00006-6
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Gu BJ, 2011, J IMMUNOL, V187, P2365, DOI 10.4049/jimmunol.1101178
   Gu BJ, 2010, BLOOD, V115, P1621, DOI 10.1182/blood-2009-11-251744
   Gu BJ, 2009, AM J PHYSIOL-CELL PH, V297, pC430, DOI 10.1152/ajpcell.00079.2009
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Ho T, 2014, NEUROSCIENCE, V277, P55, DOI 10.1016/j.neuroscience.2014.06.055
   Ho T, 2016, J OCUL PHARMACOL TH, V32, P509, DOI 10.1089/jop.2015.0158
   Ho T, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00389
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Housley GD, 2009, TRENDS NEUROSCI, V32, P128, DOI 10.1016/j.tins.2009.01.001
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106
   Plithussery T, 2007, NEUROSCIENCE, V146, P403, DOI 10.1016/j.neuroscience.2007.01.055
   Puthussery T, 2004, J COMP NEUROL, V472, P13, DOI 10.1002/cne.20045
   Puthussery T, 2006, EUR J NEUROSCI, V24, P7, DOI 10.1111/j.1460-9568.2006.04895.x
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Vessey KA, 2017, AM J PATHOL IN PRESS
   Vessey KA, 2014, J COMP NEUROL, V522, P2928, DOI 10.1002/cne.23558
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082
   Wiley JS, 2012, PURINERG SIGNAL, V8, P579, DOI 10.1007/s11302-012-9308-5
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
NR 58
TC 1
Z9 1
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD OCT
PY 2017
VL 94
IS 10
BP 939
EP 945
DI 10.1097/OPX.0000000000001124
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI7GN
UT WOS:000412165100003
PM 28858048
DA 2022-11-30
ER

PT J
AU Kost'al, M
   Blaha, M
   Rencova, E
   Lanska, M
   Rozsival, P
   Kratochvilova, V
   Langrova, H
AF Kost'al, Milan
   Blaha, Milan
   Rencova, Eva
   Lanska, Miriam
   Rozsival, Pavel
   Kratochvilova, Vera
   Langrova, Hana
TI Dynamics of Blood Count after Rheohemapheresis in Age-Related Macular
   Degeneration: Possible Association with Clinical Changes
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID MEAN PLATELET VOLUME; DRY FORM; CELL COUNT; RISK; RHEOPHERESIS;
   PARAMETERS; THERAPY; APHERESIS
AB Background. Rheohemapheresis (RHF) is a method that can stop the activity of the dry form of age-related macular degeneration (AMD). The pathophysiologic mechanisms are not well understood, and the effects of the RHF procedures extend beyond the time of the individual procedures. Patients and Methods. We present the data for 46 patients with AMD treated with a series of 8 rheohemapheretic procedures. Blood count parameters were measured before the first and the last procedures. The clinical effect was judged by changes in the drusenoid pigment epithelium detachment (DPED) area before and after the rheopheretic sessions. Results. Rheopheresis caused a decrease in hemoglobin (P < 0.001), a decrease in leukocytes (P < 0.034), and an increase in platelets (P < 0.005). We found a negative correlation between the amount of platelets and their volume (P < 0.001, Pearson correlation coefficient: -0.509). We identified the platelet/MPV ratio as a good predictor of the clinical outcome. Patients with a platelet/MPV ratio greater than 21.5 (before the last rheopheresis) had a significantly better outcome (P = 0.003, sensitivity of 76.9% and specificity of 80%). Conclusion. Several basic blood count parameters after RHF can be concluded to significantly change, with some of those changes correlating with the clinical results (reduction of the DPED area).
C1 [Kost'al, Milan; Blaha, Milan; Lanska, Miriam] Hradec Kralove Charles Univ Prague, Fac Med, Fac Hosp, Dept Internal Med Hematol 4, Hradec Kralove 50005, Czech Republic.
   [Rencova, Eva; Rozsival, Pavel; Kratochvilova, Vera; Langrova, Hana] Hradec Kralove Charles Univ Prague, Fac Med, Fac Hosp, Dept Ophthalmol, Hradec Kralove 50005, Czech Republic.
C3 Charles University Prague; Charles University Prague
RP Blaha, M (通讯作者)，Hradec Kralove Charles Univ Prague, Fac Med, Fac Hosp, Dept Internal Med Hematol 4, Sokolska St 581, Hradec Kralove 50005, Czech Republic.
EM blaham@email.cz
RI Kostal, Milan/GRS-9847-2022; Blaha, Milan/H-8955-2016; Rozsival,
   Pavel/N-9978-2017; Kostal, Milan/S-8157-2018; Kostal,
   Milan/ABE-3938-2020
OI Kostal, Milan/0000-0002-0686-5852; Blaha, Milan/0000-0003-2330-5838;
   Rozsival, Pavel/0000-0001-6628-7954; Kostal, Milan/0000-0002-0686-5852;
   Langrova, Hana/0000-0001-8488-7208
FU Ministry of Health, Czech Republic [NT/14037, NT/13475, Prvouk P37/12,
   00179906]; Grant Agency of Charles University (GAUK) [373611]
FX This work was supported by Ministry of Health, Czech Republic, nos.
   NT/14037, NT/13475, Prvouk P37/12, 00179906, and Grant Agency of Charles
   University (GAUK) 373611.
CR Bath P, 2004, STROKE, V35, P622, DOI 10.1161/01.STR.0000116105.26237.EC
   Bath PMW, 1996, BLOOD COAGUL FIBRIN, V7, P157, DOI 10.1097/00001721-199603000-00011
   Bekwelem W, 2011, ANN EPIDEMIOL, V21, P739, DOI 10.1016/j.annepidem.2011.06.005
   Blaha M, 2008, ATHEROSCLEROSIS, V197, P264, DOI 10.1016/j.atherosclerosis.2007.04.022
   Blaha M, 2012, CLIN HEMORHEOL MICRO, V50, P245, DOI 10.3233/CH-2011-1431
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   Braekkan SK, 2010, J THROMB HAEMOST, V8, P157, DOI 10.1111/j.1538-7836.2009.03498.x
   Chen JJ, 2010, ANGIOLOGY, V61, P382, DOI 10.1177/0003319709344575
   Chu SG, 2010, J THROMB HAEMOST, V8, P148, DOI 10.1111/j.1538-7836.2009.03584.x
   Fell AJ, 2002, OPHTHALMOLOGE, V99, P780, DOI 10.1007/s00347-002-0614-0
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klingel R, 2005, THER APHER DIAL, V9, P473, DOI 10.1111/j.1744-9987.2005.00276.x
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Klingel R, 2010, THER APHER DIAL, V14, P276, DOI 10.1111/j.1744-9987.2010.00807.x
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720
   Liu Quo, 2008, Zhonghua Xinxueguanbing Zazhi, V36, P453
   Macher S, 2012, VOX SANG, V103, P194, DOI 10.1111/j.1423-0410.2012.01609.x
   Mahlknecht U, 2010, EXP THER MED, V1, P1019, DOI 10.3892/etm.2010.150
   Michalska-Malecka K, 2008, CLIN HEMORHEOL MICRO, V38, P209
   Muscari A, 2009, THROMB RES, V123, P587, DOI 10.1016/j.thromres.2008.03.025
   Otto C, 2000, METABOLISM, V49, P810, DOI 10.1053/meta.2000.6264
   Ramunni Alfonso, 2012, Clin Res Cardiol Suppl, V7, P41
   Ramunni A, 2010, BLOOD PURIFICAT, V29, P383, DOI 10.1159/000314650
   Ramunni A, 2009, ATHEROSCLEROSIS SUPP, V10, P53, DOI 10.1016/S1567-5688(09)71811-2
   Rencova E, 2013, ACTA OPHTHALMOL, V91, pE406, DOI 10.1111/j.1755-3768.2012.02503.x
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Studnicka J, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/135798
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Twig G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047183
   Vizioli L, 2009, INT J CLIN PRACT, V63, P1509, DOI 10.1111/j.1742-1241.2009.02070.x
   Yeh JH, 2008, THER APHER DIAL, V12, P500, DOI 10.1111/j.1744-9987.2008.00641.x
NR 33
TC 1
Z9 1
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 858219
DI 10.1155/2014/858219
PG 5
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AD0OA
UT WOS:000332932500001
PM 24734249
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wang, YF
   Wang, MX
   Zhang, XQ
   Zhang, QY
   Nie, J
   Zhang, M
   Liu, XH
   Ma, L
AF Wang, Yafeng
   Wang, Mingxu
   Zhang, Xiaoqing
   Zhang, Qianyu
   Nie, Jing
   Zhang, Ming
   Liu, Xiaohong
   Ma, Le
TI The Association between the Lipids Levels in Blood and Risk of
   Age-Related Macular Degeneration
SO NUTRIENTS
LA English
DT Article
DE age-related macular degeneration; blood lipids levels; HDL;
   meta-analysis
ID NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH; HDL-CHOLESTEROL;
   PREVALENCE; ATHEROSCLEROSIS; SUSCEPTIBILITY; MACULOPATHY; PROGRESSION
AB Lipid metabolism may be involved in the pathogenic mechanism of age-related macular degeneration (AMD). However, conflicting results have been reported in the associations of AMD with blood lipids. We performed a meta-analysis including a total of 19 studies to evaluate associations between blood lipids and this disease. The result reported that the high level of high-density lipoprotein cholesterol (HDL-C) obtained with an increment of 1 mmol/L could result in a significantly increase in the AMD risk of approximately 18% (relative risk (RR), 1.18; 95% confidence interval (CI), 1.01 to 1.35; I-2 = 53.8%; p = 0.007). High levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) were significantly associated with a decreased risk of AMD (RRs ranging from 0.92 to 0.95; all p < 0.05). The stratified analysis based on AMD subtypes showed that these blood lipids were only significantly associated with the risk of early AMD (all p < 0.05). The association between the blood lipids and AMD risk did not differ substantially based on the other characteristics of the participants. A high HDL-C level was associated with an increased AMD risk, whereas participants with high TC, LDL-C, and TG concentrations may show a decreased risk for this disease. Further well-designed large studies are warranted to confirm the conclusions.
C1 [Wang, Yafeng; Liu, Xiaohong] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian 710061, Peoples R China.
   [Wang, Yafeng; Ma, Le] Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian 710004, Peoples R China.
   [Wang, Yafeng; Wang, Mingxu; Zhang, Qianyu; Ma, Le] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian 710049, Peoples R China.
   [Zhang, Xiaoqing] Xian Med Univ, Dept Publ Hlth, Xian 710021, Peoples R China.
   [Nie, Jing] Xi An Jiao Tong Univ, Sch Humanities, Xian 710049, Peoples R China.
   [Zhang, Ming] Xian Honghui Hosp, Xian 710054, Peoples R China.
   [Ma, Le] Xi An Jiao Tong Univ, Minist Educ China, Key Lab Environm & Genes Related Dis, Xian 710049, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University; Xi'an Medical University; Xi'an Jiaotong University;
   Ministry of Education, China; Xi'an Jiaotong University
RP Liu, XH (通讯作者)，Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian 710061, Peoples R China.; Ma, L (通讯作者)，Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian 710004, Peoples R China.; Ma, L (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian 710049, Peoples R China.; Zhang, M (通讯作者)，Xian Honghui Hosp, Xian 710054, Peoples R China.; Ma, L (通讯作者)，Xi An Jiao Tong Univ, Minist Educ China, Key Lab Environm & Genes Related Dis, Xian 710049, Peoples R China.
EM wyf.90.25.wyf@stu.xjtu.edu.cn; wangmx601@xjtu.edu.cn;
   dyzhou@nwpu.edu.cn; MICHELLE921019@stu.xjtu.edu.cn;
   boraisrighthere@sina.com; xgcgfd@126.com; liuxiaoh@mail.xjtu.edu.cn;
   male@mail.xjtu.edu.cn
RI wang, yafeng/J-4829-2017
OI ma, le/0000-0001-7592-9779
FU National Natural Science Foundation of China [NSFC-81202198,
   NSFC-81473059]; Natural Science Foundation of Shaanxi Province of China
   [2013JQ4008]; New-Star Plan of Science and Technology of Shaanxi
   Province [2015LJXX-07]; China Postdoctoral Science Special Foundation
   [2015T81036]; Fundamental Research Funds for the Central Universities
   [qngz2016004]; China Postdoctoral Science Foundation [2014M560790]
FX This study was partially supported by grants from the National Natural
   Science Foundation of China (NSFC-81202198, NSFC-81473059); the Natural
   Science Foundation of Shaanxi Province of China (2013JQ4008); New-Star
   Plan of Science and Technology of Shaanxi Province (2015LJXX-07); the
   China Postdoctoral Science Special Foundation (2015T81036); the
   Fundamental Research Funds for the Central Universities (qngz2016004);
   and the China Postdoctoral Science Foundation Funded Project
   (2014M560790).
CR Andrade IGA, 2015, ANN NUTR METAB, V66, P196, DOI 10.1159/000430790
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bindu GH, 2011, CHOLESTEROL, DOI 10.1155/2011/274629
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eren Esin, 2012, Open Biochem J, V6, P78, DOI 10.2174/1874091X01206010078
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Mei XH, 2015, ARCH MED RES, V46, P351, DOI 10.1016/j.arcmed.2015.05.012
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ngai LY, 2011, EYE, V25, P784, DOI 10.1038/eye.2011.56
   Parhofer KG, 2015, ATHEROSCLEROSIS SUPP, V18, P109, DOI 10.1016/j.atherosclerosissup.2015.02.020
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rader DJ, 2012, NAT MED, V18, P1344, DOI 10.1038/nm.2937
   Rizk NM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/678924
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Wang YF, 2016, GRAEF ARCH CLIN EXP, V254, P323, DOI 10.1007/s00417-015-3211-z
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yin LL, 2012, AM J PATHOL, V180, P541, DOI 10.1016/j.ajpath.2011.10.015
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
NR 46
TC 27
Z9 28
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2016
VL 8
IS 10
AR 663
DI 10.3390/nu8100663
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA ED2HT
UT WOS:000388665300079
PM 27782072
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Chong, EWT
   Wong, TY
   Kreis, AJ
   Simpson, JA
   Guymer, RH
AF Chong, Elaine W-T
   Wong, Tien Y.
   Kreis, Andreas J.
   Simpson, Julie A.
   Guymer, Robyn H.
TI Dietary antioxidants and primary prevention of age related macular
   degeneration: systematic review and meta-analysis
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Review
ID CIGARETTE-SMOKING; VISUAL IMPAIRMENT; VITAMIN-E; PREVALENCE;
   MACULOPATHY; QUALITY; RANIBIZUMAB; CAROTENOIDS; PROGRESSION; TRIALS
AB Objective To evaluate the effectiveness of dietary antioxidants in the primary prevention of age related macular degeneration (AMD).
   Design Systematic review and meta-analysis.
   Data sources Search of seven databases without limits on year or language of publication, and retrieval of references in pertinent reviews and articles.
   Methods Two reviewers independently searched the databases and selected the studies, using standardised criteria. Randomised clinical trials and prospective cohort studies were included. Of the 4192 abstracts initially identified, 12 studies (nine prospective cohort studies and three randomised clinical trials) met the selection criteria and were included. Data extraction and study quality evaluation were independently reviewed, using standardised criteria. Results were pooled quantitatively using meta-analytic methods.
   Results The nine prospective cohort studies included 149 203 people, with 1878 incident cases of early AMD. The antioxidants investigated differed across studies, and not all studies contributed to the meta-analysis of each antioxidant. Pooled results from prospective cohort studies indicated that vitamin A, vitamin C, vitamin E, zinc, lutein, zeaxanthin, a carotene, P carotene, P cryptoxanthin, and lycopene have little or no effect in the primary prevention of early AMD. The three randomised clinical trials did not show that antioxidant supplements prevented early AMD.
   Conclusions There is insufficient evidence to support the role of dietary antioxidants, including the use of dietary antioxidant supplements, for the primary prevention of early AMD.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Melbourne
RP Chong, EWT (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Simpson, Julie A/P-7299-2014; Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Simpson, Julie/0000-0002-2660-2013;
   Guymer, Robyn/0000-0002-9441-4356
CR Arroyo JG, 2006, JAMA-J AM MED ASSOC, V295, P2394, DOI 10.1001/jama.295.20.2394
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   BRODY JE, 2001, NY TIMES        0313
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, BMJ-BRIT MED J, V333, P869, DOI 10.1136/bmj.39009.366736.80
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Clarke M, 2000, LANCET, V355, P756, DOI 10.1016/S0140-6736(05)72172-3
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Deeks J J, 2003, Health Technol Assess, V7, piii
   Dickersin K, 2002, INT J EPIDEMIOL, V31, P6, DOI 10.1093/ije/31.1.6
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7
   Egger M, 1998, BRIT MED J, V316, P140
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hall NF, 2002, BRIT MED J, V325, P1, DOI 10.1136/bmj.325.7354.1
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HOROWITZ JM, 2001, TIME MAGAZINE   1029
   Jampol LM, 2001, JAMA-J AM MED ASSOC, V286, P2466
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly SP, 2004, BRIT MED J, V328, P537, DOI 10.1136/bmj.328.7439.537
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mares JA, 2004, ARCH OPHTHALMOL-CHIC, V122, P628, DOI 10.1001/archopht.122.4.628
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   National Institutes of Health (NIH) United States National Library of Medicine, CLIN TRIALS DAT
   *NIH, CLIN TRIAL DAT
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHMITZ HH, 1993, METHOD ENZYMOL, V214, P102
   SEDDON JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P176, DOI 10.1001/archopht.1994.01090140052021
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 49
TC 150
Z9 159
U1 0
U2 38
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD OCT 13
PY 2007
VL 335
IS 7623
BP 755
EP 759
DI 10.1136/bmj.39350.500428.47
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 224AX
UT WOS:000250418600033
PM 17923720
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Kurt, MM
   Cekic, O
   Akpolat, C
   Aslankurt, M
   Elcioglu, MN
AF Kurt, Muhammed Mustafa
   Cekic, Osman
   Akpolat, Cetin
   Aslankurt, Murat
   Elcioglu, Mustafa Nuri
TI Comparative Retinal Vessel Size Study of Intravitreal Ranibizumab and
   Bevacizumab in Eyes with Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Ranibizumab; Bevacizumab;
   Retinal vessel diameter
ID ENDOTHELIAL GROWTH-FACTOR; RETROBULBAR BLOOD-FLOW; BEAVER DAM EYE;
   PIGMENT EPITHELIUM; VASCULAR CALIBER; INJECTION; AVASTIN(R); DIAMETERS;
   VEGF; SINGAPORE
AB Purpose: The aim of this paper was to assess and compare the effects of intravitreal ranibizumab and bevacizumab on retinal vessel diameter in eyes with neovascular age-related macular degeneration (AMD). Methods: Patients with neovascular AMD who underwent intravitreal injection of either ranibizumab or bevacizumab were included. Noninjected fellow eyes served as a control. The main outcome measures were central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and the artery-vein ratio (AVR). Results: In the ranibizumab group, the mean CRAE value decreased significantly at 1 week and 1 month (p = 0.002). The AVR value decreased significantly at 1 month (p = 0.028). CRVE values did not change at 1 week and 1 month (p = 0.083). In the bevacizumab group, the preinjection CRAE, CRVE, and AVR values did not change through the study period (p = 0.128, p = 0.600, and p = 0.734, respectively). Conclusion: These results suggest that intravitreal ranibizumab led to significant retinal arteriolar vasoconstriction in eyes with neovascular AMD. (C) 2017 S. Karger AG, Basel
C1 [Kurt, Muhammed Mustafa; Cekic, Osman; Akpolat, Cetin; Aslankurt, Murat; Elcioglu, Mustafa Nuri] Okmeydani Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 Istanbul Okmeydani Training & Research Hospital
RP Akpolat, C (通讯作者)，Siverek Community Hosp, Eye Clin, TR-63600 Siverek, Sanliurfa, Turkey.
EM akpolatcetin@yahoo.com
RI Cekic, Osman/H-3027-2019; kurt, muhammed mustafa/AAI-6225-2020
OI Cekic, Osman/0000-0003-0911-8649; 
CR Aslankurt M, 2013, EUR J OPHTHALMOL, V23, P553, DOI 10.5301/ejo.5000268
   Bakbak B, 2013, J OCUL PHARMACOL TH, V29, P728, DOI 10.1089/jop.2013.0049
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chen E, 2009, OPHTHAL SURG LAS IM, V40, P68, DOI 10.3928/15428877-20090101-04
   Chin YC, 2014, OPHTHAL EPIDEMIOL, V21, P224, DOI 10.3109/09286586.2014.926941
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Hwang DJ, 2012, J KOREAN MED SCI, V27, P1580, DOI 10.3346/jkms.2012.27.12.1580
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kelkar A, 2014, CASE REP OPHTHALM, V5, P411, DOI 10.1159/000368343
   Kim KS, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2008.01175.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lee CS, 2008, ACTA OPHTHALMOL, V86, P812, DOI 10.1111/j.1600-0420.2007.01111.x
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Mulcahy MF, 2005, EXPERT OPIN BIOL TH, V5, P997, DOI 10.1517/14712598.5.7.997
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Pekel G, 2015, INT OPHTHALMOL, V35, P657, DOI 10.1007/s10792-014-9991-z
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Tatlipinar S, 2012, CLIN EXP OPTOM, V95, P94, DOI 10.1111/j.1444-0938.2011.00662.x
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
   Wickremasinghe SS, 2012, CLIN EXP OPHTHALMOL, V40, P59, DOI 10.1111/j.1442-9071.2011.02613.x
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2004, OPHTHALMOLOGY, V111, P1183, DOI 10.1016/j.ophtha.2003.09.039
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
   Yokoyama K, 2008, ACTA OPHTHALMOL, V86, P927, DOI 10.1111/j.1755-3768.2008.01187.x
NR 40
TC 6
Z9 7
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 3
BP 147
EP 153
DI 10.1159/000477180
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG4EA
UT WOS:000410182000005
PM 28601887
DA 2022-11-30
ER

PT J
AU Detaram, HD
   Joachim, N
   Liew, G
   Van Vu, K
   Burlutsky, G
   Mitchell, P
   Gopinath, B
AF Detaram, Harshil Dharamdasani
   Joachim, Nichole
   Liew, Gerald
   Van Vu, Kim
   Burlutsky, George
   Mitchell, Paul
   Gopinath, Bamini
TI Smoking and treatment outcomes of neovascular age-related macular
   degeneration over 12 months
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Epidemiology; Macula; Degeneration; Neovascularisation; Public health
ID INTRAVITREAL RANIBIZUMAB THERAPY; VISUAL-ACUITY; POOLED FINDINGS;
   RISK-FACTORS; MACULOPATHY; YOUNGER; CFH; EYE
AB Background To assess the association of smoking with age of onset of neovascular age-related macular degeneration (nAMD), visual acuity (VA), central macular thickness (CMT) and the presence of fluid in patients with nAMD. Methods 547 patients with nAMD were recruited from a tertiary eye clinic during 2012-2015; of these, 490 patients were followed up 12 months later. Clinical diagnosis of nAMD was confirmed by a retinal specialist. Smoking was determined from self-reported history as never, past or current. Age of onset was defined as date of first recorded diagnosis of nAMD in either eye or date of first anti-vascular endothelial growth factor injection. CMT and presence of fluid were recorded from spectral-domain optical coherence tomography images. VA was recorded as number of letters read at 3 m. Results After multivariable adjustment, current smokers developed nAMD at an average 5.5 years younger age than never smokers and 4.4 years younger age than past smokers (p<0.0001 and p=0.0008, respectively). At baseline, adjusted mean CMT was significantly higher in current compared with past smokers (259.2 mu m vs 231.9 mu m, respectively, p=0.04). Current smokers versus never smokers had greater odds of presence of subretinal fluid at 12-month follow-up: multivariable-adjusted OR 1.99 (95% CI 1.09 to 3.67). Smoking status was not significantly associated with VA over 12 months. Conclusions Current smoking was associated with a younger age of nAMD onset and key treatment outcomes such as higher mean CMT and greater odds of subretinal fluid presence. These findings suggest that smoking cessation may benefit patients being treated for nAMD.
C1 Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.
   Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research
RP Gopinath, B (通讯作者)，Univ Sydney, Ctr Vis Res, Sydney, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022
OI Dharamdasani Detaram, Harshil/0000-0002-6095-5963
FU Macular Disease Foundation Australia Research Grant
FX This work was supported by a Macular Disease Foundation Australia
   Research Grant.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Campbell M, 2010, PATHOPHYSIOLOGY CIGA
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   Hernandez Luis, 2018, J Manag Care Spec Pharm, P1, DOI 10.18553/jmcp.2018.17416
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P18, DOI 10.1186/1478-7547-6-18
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wittenborn JS, 2013, OPHTHALMOLOGY, V120, P1728, DOI 10.1016/j.ophtha.2013.01.068
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 28
TC 2
Z9 2
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2020
VL 104
IS 7
BP 893
EP 898
DI 10.1136/bjophthalmol-2019-314849
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MG3WX
UT WOS:000545965300003
PM 31558491
DA 2022-11-30
ER

PT J
AU Kuehlewein, L
   Bansal, M
   Lenis, TL
   Iafe, NA
   Sadda, SR
   Bonin, MA
   De Carlo, TE
   Waheed, NK
   Duker, JS
   Sarraf, D
AF Kuehlewein, Laura
   Bansal, Mayank
   Lenis, Tamara L.
   Iafe, Nicholas A.
   Sadda, Srinivas R.
   Bonin Filho, Marco A.
   De Carlo, Talisa E.
   Waheed, Nadia K.
   Duker, Jay S.
   Sarraf, David
TI Optical Coherence Tomography Angiography of Type 1 Neovascularization in
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; MOTION
   CORRECTION; EYES; AMD; CLASSIFICATION
AB PURPOSE: To analyze type 1 neovascular membranes in age-related macular degeneration (AMD) using optical coherence tomography (OCT) angiography, to correlate morphologic characteristics with imaging and clinical criteria, and to analyze structural features of type 1 neovascularization sequentially after anti-vascular endothelial growth factor (VEGF) therapy.
   DESIGN: Prospective interventional Case series.
   METHODS: Macular OCT angiography images were acquired using the RTVue XR Avanti with AngioVue. Distinct morphologic patterns and quantifiable features of the neovascular membranes were studied on en face projection images at baseline and follow-up.
   RESULTS: Thirty-three eyes of 25 patients were included. In 75% of the eyes, a highly organized vascular complex could be identified. A large main central vessel trunk/feeder vessel could be seen in 72% of these eyes, with vessels radiating in a branching pattern either in all directions from the center of the lesion ("medusa" pattern), or from one side of the lesion ("seafan" pattern). Of the 18 eyes with follow-up OCT angiography, the lesion area and vessel density remained unchanged, even after anti-vascular endothelial growth factor (VEGF) therapy, indicating a more mature longstanding neovascular complex resistant to anti-VEGF therapy.
   CONCLUSIONS: OCT angiography provides a unique opportunity to study the morphology of occult type 1 neovascular membranes in AMP and allows precise structural and vascular assessment noninvasively. We identified a large mature neovascular complex in approximately 75% of eyes, typically consisting of a feeder vessel and large branching vessels resistant to anti-VEGF therapy. OCT angiography may better guide evaluation and treatment of neovascular AMD, and may contribute to the development of improved therapies. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Kuehlewein, Laura; Sadda, Srinivas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Kuehlewein, Laura; Bansal, Mayank; Lenis, Tamara L.; Iafe, Nicholas A.; Sadda, Srinivas R.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Bansal, Mayank; Lenis, Tamara L.; Iafe, Nicholas A.; Sarraf, David] Jules Stein Eye Inst, Los Angeles, CA 90024 USA.
   [Bonin Filho, Marco A.; De Carlo, Talisa E.; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, New England Eye Ctr, Boston, MA 02111 USA.
   [Bonin Filho, Marco A.; De Carlo, Talisa E.; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, Tufts Med Ctr, Boston, MA 02111 USA.
   [Bonin Filho, Marco A.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil.
   [De Carlo, Talisa E.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [De Carlo, Talisa E.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Tufts University; Tufts
   Medical Center; Tufts University; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES); Massachusetts Institute of Technology
   (MIT); Massachusetts Institute of Technology (MIT); US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los
   Angeles Healthcare System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI BONINI FILHO, MARCO/GLR-8943-2022
OI BONINI FILHO, MARCO/0000-0003-0796-8025
FU Allergan, Irvine, California, USA; Carl Zeiss Meditec, Dublin,
   California, USA; Genentech, South San Francisco, California, USA; Optos,
   Marlborough, Massachusetts, USA; Carl Zeiss Meditec; Massachusetts Lions
   Club, South Attleboro, Massachusetts, USA; OptoVue, Fremont, California,
   USA; Research to Prevent Blindness, Columbia, Maryland, USA; Genentech;
   OptoVue; Regeneron, Tarrytown, New York, USA
FX SriniVas R. Sadda: Research support, Allergan, Irvine, California, USA;
   Carl Zeiss Meditec, Dublin, California, USA; Genentech, South San
   Francisco, California, USA; and Optos, Marlborough, Massachusetts, USA;
   Nadia K. Waheed: Research support, Carl Zeiss Meditec; Jay S. Duker:
   Research support, Carl Zeiss Meditec; Grant, Massachusetts Lions Club,
   South Attleboro, Massachusetts, USA; Research support, OptoVue, Fremont,
   California, USA; Grant, Research to Prevent Blindness, Columbia,
   Maryland, USA; David Sarraf: Research grant, Genentech; OptoVue; and
   Regeneron, Tarrytown, New York, USA. All authors attest that they meet
   the current ICIvIJE requirements to qualify as authors.
CR Bellou S, 2013, CANCER LETT, V338, P219, DOI 10.1016/j.canlet.2013.05.015
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   BENNETT AG, 1994, GRAEF ARCH CLIN EXP, V232, P361, DOI 10.1007/BF00175988
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Mendis KR, 2010, INVEST OPHTH VIS SCI, V51, P5864, DOI 10.1167/iovs.10-5333
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Ruiz de Almodovar C, 2007, RETINAL VASCULAR DIS, P46
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   WILLIAMS TD, 1992, OPTOMETRY VISION SCI, V69, P717, DOI 10.1097/00006324-199209000-00009
NR 27
TC 230
Z9 241
U1 3
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2015
VL 160
IS 4
BP 739
EP 748
DI 10.1016/j.ajo.2015.06.030
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR7BR
UT WOS:000361503400016
PM 26164826
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Zayit-Soudry, S
   Alfasi, M
   Goldstein, M
   Moisseiev, J
   Axer-Siegel, R
   Pollack, A
   Yassur, Y
   Loewenstein, A
AF Zayit-Soudry, Shiri
   Alfasi, Meirav
   Goldstein, Michaella
   Moisseiev, Joseph
   Axer-Siegel, Ruth
   Pollack, Ayala
   Yassur, Yuval
   Loewenstein, Anat
TI Variability among retina specialists in evaluating fluorescein
   angiograms of patients with neovascular age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   fluorescein angiogram grading; reproducibility
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY
AB Purpose: To determine the rate of agreement among five retina specialists in classifying various angiographic features of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), as evaluated on printed digital fluorescein angiogram (FA) frames, as well as determination of eligibility for photodynamic treatment (PDT) according to established guidelines.
   Methods: Ninety-two digital FAs demonstrating subfoveal CNV secondary to AMD were evaluated independently by five retina specialists. The pattern of classic component could be classified as no classic component, minimally classic, predominantly classic, or classic only. Each grader was asked to determine eligibility of each case to PDT according to established treatment guidelines, national health insurance guidelines, and one's own personal judgment.
   Results: The kappa coefficient of concordance calculated for all five observers regarding CNV localization was 0.285, indicating fair overall agreement, and was 0.295, indicating fair agreement, regarding classification of leakage pattern. The kappa coefficient of agreement calculated for all five graders regarding eligibility for treatment according to established international guidelines, national health insurance, and each grader's own personal judgment was 0.163, 0.33, and 0.164, respectively, indicating slight to fair overall agreement.
   Conclusion: Considerable variability may exist among retina specialists interpreting FAs and should be considered in the assessment of treatment guidelines.
C1 Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
   Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
   Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel.
   Chaim Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel.
   Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
   Kaplan Med Ctr, Dept Ophthalmol, Rehovot, Israel.
   Mor Eye Inst, Ramat Gan, Israel.
   Hebrew Univ Jerusalem, Jerusalem, Israel.
   Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Technion
   Israel Institute of Technology; Rappaport Faculty of Medicine; Chaim
   Sheba Medical Center; Rabin Medical Center; Hebrew University of
   Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Tel
   Aviv University; Sackler Faculty of Medicine
RP Zayit-Soudry, S (通讯作者)，Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM shirizayit@gmail.com
OI Zayit Soudry, Shiri/0000-0002-8736-1823
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   GRADOUDAS ES, 2004, NEW ENGL J MED, V351, P2805
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Rosner B., 2016, FUNDAMENTALS BIOSTAT
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
NR 18
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2007
VL 27
IS 6
BP 798
EP 803
DI 10.1097/IAE.0b013e31802c50a3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 189NT
UT WOS:000247996400020
PM 17621192
DA 2022-11-30
ER

PT J
AU DeAngelis, MM
   Lane, AM
   Shah, CP
   Ott, J
   Dryja, TP
   Miller, JW
AF DeAngelis, MM
   Lane, AM
   Shah, CP
   Ott, J
   Dryja, TP
   Miller, JW
TI Extremely discordant sib-pair study design to determine risk factors for
   neovascular age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID QUANTITATIVE TRAIT LOCI; ALCOHOL-CONSUMPTION; MACULOPATHY; SMOKING
AB Objective: To search for factors that contribute to the development of neovascular age-related macular degeneration (AMD).
   Methods: In a matched-pair case-control study, we studied sib pairs in which the index sibling had neovascular AMD in at least 1 eye and the unaffected sibling had normal maculae (or at most only a few small drusen) and was past the age at which the index case was diagnosed. Factors studied included sex, iris color, education, alcohol consumption, body mass index, vitamin use, smoking history, hypercholesterolemia, aspirin use, hypertension, other cardiovascular disease, any autoimmune disease, and non-insulin-dependent diabetes mellitus. Conditional logistic regression was performed to identify predictors of neovascular AMD.
   Results: On the basis of 73 sib pairs, multivariate regression analysis revealed statistically significant 2% increase in risk of neovascular AMD with each pack-year of smoking (odds ratio, 1.02; 95% confidence interval, 1.01-1.04; P=.007). Suggestive but nonsignificant associations were also observed for mean lifetime alcohol consumption, adult lifetime body mass index, and hypertension in multivariate regression analyses.
   Conclusion: Using extremely discordant sib pairs to study risk factors for AMD, a novel approach in epidemiological design, we found evidence that smoking is a risk factor for neovascular AMD.
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Ocular Mol Genet Inst, Boston, MA USA.
   Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Rockefeller
   University
RP Miller, JW (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM jwmiller@meei.harvard.edu
RI DeAngelis, e/J-7863-2015
OI Miller, Joan/0000-0003-2046-3996
FU NEI NIH HHS [EY 07076] Funding Source: Medline; NHGRI NIH HHS [HG 00008]
   Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857
   Risch NJ, 1996, AM J HUM GENET, V58, P836
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 18
TC 36
Z9 39
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2004
VL 122
IS 4
BP 575
EP 580
DI 10.1001/archopht.122.4.575
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812GT
UT WOS:000220828700017
PM 15078676
DA 2022-11-30
ER

PT J
AU Moschos, MM
   Chatziralli, IP
   Stamatakis, G
   Papakonstantinou, VD
   Demopoulos, CA
AF Moschos, Marilita M.
   Chatziralli, Irini P.
   Stamatakis, George
   Papakonstantinou, Vasiliki D.
   Demopoulos, Constantinos A.
TI In vitro effects of vitamin supplements on platelet-activating factor
   and its metabolism in age-related macular degeneration
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Age-related macular degeneration; InShape; metabolism; Nutrof; Ocuvite;
   platelet-activating factor; Vitalux; vitamin
ID GROWTH-FACTOR; ANGIOGENESIS; RECEPTOR; RELEASE; VIVO; CAROTENOIDS;
   ANTAGONIST; MEDIATOR; BLOOD
AB Objective: The purpose of our study was to investigate for the first time a series of vitamin supplements used for age-related macular degeneration (AMD) as potential inhibitors of platelet-activating factor (PAF).
   Materials and methods: Various vitamin supplements were tested in washed rabbit platelets (WRPs), in order to investigate the interaction between vitamin supplements (InShape, Nutrof, Ocuvite, Vitalux) and inhibition of PAF-induced platelet aggregation. Additionally, we examined their ability to affect PAF-metabolism, through their in vitro effect on PAF basic metabolic enzymes (PAF-CPT, lyso PAF-AT, and PAF-AH).
   Results: Nutrof exhibited the strongest anti-PAF activity, while Vitalux was the most potent anti-inflammatory factor.
   Conclusion: This is the first study to bring in surface potent anti-inflammatory and anti-angiogenic activities of some vitamin supplements used against AMD, through their in vitro anti-PAF effects in WRPs and the rabbit plasma and leukocyte PAF metabolism, suggesting a promising role of vitamin supplements and especially resveratrol, concerning its potent anti-angiogenic activity in AMD.
C1 [Moschos, Marilita M.; Chatziralli, Irini P.] Univ Athens, Lab Electrophysiol, Dept Ophthalmol 1, Athens 14578, Greece.
   [Stamatakis, George; Papakonstantinou, Vasiliki D.; Demopoulos, Constantinos A.] Univ Athens, Fac Chem, Biochem Lab, Athens 14578, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens
RP Moschos, MM (通讯作者)，Univ Athens, Lab Electrophysiol, Dept Ophthalmol 1, 6 Ikarias St, Athens 14578, Greece.
EM moschosmarilita@yahoo.fr
RI Demopoulos, Constantinos/AAC-6148-2020; Chatziralli, Irini/AAG-4779-2020
OI Demopoulos, Constantinos/0000-0003-2038-4411; Chatziralli,
   Irini/0000-0001-8523-1024; Stamatakis, George/0000-0002-3459-4383
CR ANTONOPOULOU S, 1994, INT J BIOCHEM, V26, P1157, DOI 10.1016/0020-711X(94)90138-4
   Antonopoulou S, 2006, J MED FOOD, V9, P356, DOI 10.1089/jmf.2006.9.356
   BAZAN HEP, 1994, J OCUL PHARMACOL, V10, P319, DOI 10.1089/jop.1994.10.319
   Beauchamp MH, 2002, INVEST OPHTH VIS SCI, V43, P3327
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CAMUSSI G, 1995, J IMMUNOL, V154, P6492
   Camussi G, 1997, J IMMUNOL, V158, P1302
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Demopoulos C., 1997, INFORM, V8, P776
   DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355
   Esquenazi S, 2010, MOL NEUROBIOL, V42, P32, DOI 10.1007/s12035-010-8129-1
   FLETCHER JR, 1990, ANN SURG, V211, P312
   Fragopoulou E, 2000, J AGR FOOD CHEM, V48, P1234, DOI 10.1021/jf990554p
   Gimenez R, 2001, NEUROSCI LETT, V299, P209, DOI 10.1016/S0304-3940(01)01513-0
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   HEUER HO, 1991, LIPIDS, V26, P1369, DOI 10.1007/BF02536569
   Izquierdo I, 2003, DRUG TODAY, V39, P451, DOI 10.1358/dot.2003.39.6.799450
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Ma L, 2011, BR J NUTR, V8, P1
   MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377
   Montrucchio G, 2000, ARTERIOSCL THROM VAS, V20, P80, DOI 10.1161/01.ATV.20.1.80
   Mori M, 1997, INVEST OPHTH VIS SCI, V38, P2672
   Negro Alvarez J M, 1997, Allergol Immunopathol (Madr), V25, P249
   Pratt S, 1999, J Am Optom Assoc, V70, P39
   Prescott SM, 1996, J BIOL CHEM, V268, P17381
   PROUD D, 1990, J ALLERGY CLIN IMMUN, V85, P896, DOI 10.1016/0091-6749(90)90075-F
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sharif NA, 2009, MOL VIS, V15, P1153
   SHENG YH, 1992, CURR EYE RES, V11, P1067, DOI 10.3109/02713689209015078
   SMITH D, 1994, EXP EYE RES, V59, P425, DOI 10.1006/exer.1994.1127
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tsantila N, 2011, ANGIOLOGY, V62, P209, DOI 10.1177/0003319710375089
   Tsoupras A. B., 2009, Infectious Disorders - Drug Targets, V9, P390
   Tsoupras AB, 2012, ANGIOLOGY, V63, P343, DOI 10.1177/0003319711420608
   Tsoupras AB, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-17
   Tsoupras AB, 2010, BIOINORG CHEM APPL, V2010, DOI 10.1155/2010/731202
   Tsoupras AB, 2008, AIDS RES HUM RETROV, V24, P1079, DOI 10.1089/aid.2007.0263
   Tsoupras AB, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/27683
   VERBEY NL, 1989, INVEST OPHTH VIS SCI, V30, P1101
NR 44
TC 2
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PD SEP
PY 2014
VL 33
IS 3
BP 235
EP 241
DI 10.3109/15569527.2013.835818
PG 7
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA AO4EK
UT WOS:000341288800014
PM 24147947
DA 2022-11-30
ER

PT J
AU Caballe-Fontanet, D
   Alvarez-Peregrina, C
   Busquet-Duran, N
   Pedemonte-Sarrias, E
   Sanchez-Tena, MA
AF Caballe-Fontanet, Daniel
   Alvarez-Peregrina, Cristina
   Busquet-Duran, Neus
   Pedemonte-Sarrias, Eduard
   Sanchez-Tena, Miguel Angel
TI Improvement of the Quality of Life in Patients with Age-Related Macular
   Degeneration by Using Filters
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE age-related macular degeneration; NEI VFQ-25; selective cut optical
   filters; quality of life
ID VISUAL-ACUITY; PERFORMANCE; VALIDATION; OUTCOMES; VISION; LENSES; DARK
AB Background: Age-related macular degeneration (AMD) is a disease with an increasing incidence due to the general aging of the population that decreases the patient's quality of life. This work aims to study whether selective cut optical filters improve the AMD patient's quality of life. Methods: Prospective and longitudinal study in 79 patients. Visual acuity, contrast sensitivity, and the line differences in the Colenbrander test were measured. Patients answered The National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25), which measures the quality of life related to vision before and after using cut optical filters. Results: There was an improvement of 5.99 points (3.7-8.3) in NEI VFQ-25 after wearing filters. This improvement was 4.0 points for 450-nm filters and 12.7 points for 511-nm filters. For patients with visual acuity (VA) < 0.25, results of NEI VFQ-25 increased by 10.11 points (1.19-19.02) and for patients with late AMDs, results increased by 5.33 points (1.31-9.35). Conclusions: Selective filters improve the quality of life of patients with AMD. The success rate in the fitting of filters is better for those with VA lower than 0.25 and those with late or advanced AMD.
C1 [Caballe-Fontanet, Daniel; Alvarez-Peregrina, Cristina; Sanchez-Tena, Miguel Angel] Univ Europea Madrid, Sch Biomed & Hlth Sci, Madrid 28670, Spain.
   [Busquet-Duran, Neus; Pedemonte-Sarrias, Eduard] Althaia Xarxa Assistencial Univ Manresa, Dept Ophthalmol, Manresa 08243, Spain.
   [Pedemonte-Sarrias, Eduard] Cent Univ Catalonia UVic UCC, Univ Vic, Fac Med, Vic 08500, Spain.
C3 European University of Madrid; Universitat de Vic - Universitat Central
   de Catalunya (UVic-UCC)
RP Sanchez-Tena, MA (通讯作者)，Univ Europea Madrid, Sch Biomed & Hlth Sci, Madrid 28670, Spain.
EM opticavisiocaballe@gmail.com; cristina.alvarez@universidadeuropea.es;
   nbusquet@althaia.cat; epedemonte@althaia.cat;
   miguelangel.sanchez@universidadeuropea.es
RI Álvarez-Peregrina, Cristina/AAI-1053-2019; Pedemonte-Sarrias,
   Eduard/E-3156-2015
OI Álvarez-Peregrina, Cristina/0000-0003-1097-4581; Pedemonte-Sarrias,
   Eduard/0000-0002-4581-7028; Caballe Fontanet,
   Daniel/0000-0001-8371-5527; Sanchez-Tena, Miguel
   Angel/0000-0002-2583-1789
FU ophthalmologists and professionals of Althaia
FX Special acknowledge for the great support of ophthalmologists and
   professionals of Althaia.
CR Alvarez-Peregrina C, 2018, Arch Soc Esp Oftalmol (Engl Ed), V93, P586, DOI 10.1016/j.oftal.2018.05.017
   Bailey IL, 2013, VISION RES, V90, P2, DOI 10.1016/j.visres.2013.05.004
   Biarnes Perez M., 2016, GAC OPTOM OPTICA OFT, V519, P48
   Brussee T, 2015, OPHTHAL PHYSL OPT, V35, P324, DOI 10.1111/opo.12204
   Buari Noor Halilah, 2014, J Optom, V7, P210, DOI 10.1016/j.optom.2013.12.009
   Caballe-Fontanet D., 2019, GAC OPTOM OPITCA OFT, V546, P50
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Casser L., 2005, COMPREHENSIVE ADULT
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245
   Colenbrander A., 1999, LOW VISION TEST CHAR, P1
   Eperjesi F, 2002, OPHTHAL PHYSL OPT, V22, P68, DOI 10.1046/j.1475-1313.2002.00004.x
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Haegerstrom-Portnoy G, 1999, OPTOMETRY VISION SCI, V76, P141, DOI 10.1097/00006324-199903000-00014
   Herberich E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009788
   Khadka J, 2012, INVEST OPHTH VIS SCI, V53, P1276, DOI 10.1167/iovs.12-9541
   Lin JC, 2010, J EVAL CLIN PRACT, V16, P619, DOI 10.1111/j.1365-2753.2009.01253.x
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Mollazadegan K, 2014, J CATARACT REFR SURG, V40, P774, DOI 10.1016/j.jcrs.2013.10.040
   Ord LM, 2015, J CLIN MED, V4, P1841, DOI 10.3390/jcm4091841
   Perez Jimenez D., 2016, GAC OPTOM OPTICA OFT, V521, P48
   Royal College of Ophthalmologists, 2013, AG REL MAC DEG GUID, V1, P145
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   The Mars Perceptrix Corporation, 2016, MARS LETT CONTRAST S, P1
   Valentincic NV, 2007, RETINA-J RET VIT DIS, V27, P483, DOI 10.1097/01.iae.0000243031.81022.a2
   Wang LL, 2015, CHINESE MED J-PEKING, V128, P1154, DOI 10.4103/0366-6999.156083
   Wolffsohn JS, 2002, OPHTHAL PHYSL OPT, V22, P300, DOI 10.1046/j.1475-1313.2002.00036.x
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 29
TC 0
Z9 0
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD SEP
PY 2020
VL 17
IS 18
AR 6751
DI 10.3390/ijerph17186751
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OF5TM
UT WOS:000581269800001
PM 32947984
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Maruyama-Inoue, M
   Inoue, T
   Mohamed, S
   Kitajima, Y
   Ikeda, S
   Ito, A
   Kadonosono, K
AF Maruyama-Inoue, Maiko
   Inoue, Tatsuya
   Mohamed, Shaheeda
   Kitajima, Yoko
   Ikeda, Shoko
   Ito, Arisa
   Kadonosono, Kazuaki
TI Incidence of elevated intraocular pressure after intravitreal injection
   in Japanese patients with age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROWTH-FACTOR INJECTIONS; OCULAR HYPERTENSION; SUSTAINED ELEVATION;
   FACTOR THERAPY; BEVACIZUMAB; RANIBIZUMAB; PREVALENCE; MACULOPATHY;
   POPULATION; EYE
AB The purpose of this study was to report the incidence of elevated intraocular pressure (IOP) after intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) in Japanese patients with age-related macular degeneration (AMD). A retrospective study of chart review of patients who underwent >= 10 intravitreal anti-VEGF injections between April 2009 and December 2019 was conducted. Elevated IOP was defined as IOP >= 25 mmHg at one visit. Cases with elevated IOP resulting from IVI were identified. Furthermore, the association between elevated IOP and some parameters, as the risk factors that influence elevated IOP, was investigated. A total of 402 eyes of 370 patients were included in this study. Twenty-eight eyes of 26 patients (7.0%) were identified as cases with elevated IOP after IVI. The mean time of elevation after baseline was 50.6 +/- 26.5 months. History of glaucoma (p=0.021; odds ratio, 5.85), treatment modality (p=0.019; odds ratio, 6.32), and total number of injections (p=0.003; odds ratio, 1.03) were significantly associated with elevated IOP. A late complication of elevated IOP is associated with IVI in patients with AMD. Particularly, history of glaucoma and treat and extend regimen with frequent injections were found to be risk factors of elevated IOP.
C1 [Maruyama-Inoue, Maiko; Inoue, Tatsuya; Ikeda, Shoko; Ito, Arisa; Kadonosono, Kazuaki] Yokohama City Univ, Dept Ophthalmol, Med Ctr, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
   [Mohamed, Shaheeda] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Kitajima, Yoko] Kanto Rosai Hosp, Dept Ophthalmol, Kawasaki, Kanagawa, Japan.
C3 Yokohama City University; Chinese University of Hong Kong
RP Maruyama-Inoue, M (通讯作者)，Yokohama City Univ, Dept Ophthalmol, Med Ctr, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Agard E, 2015, CAN J OPHTHALMOL, V50, P127, DOI 10.1016/j.jcjo.2014.11.004
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Frenkel REP, 2007, AM J OPHTHALMOL, V143, P1034, DOI 10.1016/j.ajo.2007.01.052
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kim YJ, 2014, AM J OPHTHALMOL, V157, P1266, DOI 10.1016/j.ajo.2014.02.035
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Menke MN, 2013, OPHTHALMOLOGICA, V229, P168, DOI 10.1159/000346397
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morshedi RG, 2016, J GLAUCOMA, V25, P291, DOI 10.1097/IJG.0000000000000173
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
   Wen JC, 2017, INVEST OPHTH VIS SCI, V58, P1893, DOI 10.1167/iovs.16-20786
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
NR 28
TC 1
Z9 1
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 10
PY 2021
VL 11
IS 1
AR 12246
DI 10.1038/s41598-021-91832-w
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SV4IR
UT WOS:000663784500016
PM 34112856
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU La Cunza, N
   Tan, LX
   Thamban, T
   Germer, CJ
   Rathnasamy, G
   Toops, KA
   Lakkaraju, A
AF La Cunza, Nilsa
   Tan, Li Xuan
   Thamban, Thushara
   Germer, Colin J.
   Rathnasamy, Gurugirijha
   Toops, Kimberly A.
   Lakkaraju, Aparna
TI Mitochondria-dependent phase separation of disease-relevant proteins
   drives pathological features of age-related macular degeneration
SO JCI INSIGHT
LA English
DT Article
ID APOLIPOPROTEIN-E; LIQUID-PHASE; OXIDATIVE STRESS; LIPOFUSCIN
   FLUOROPHORE; ALZHEIMER-DISEASE; EPITHELIAL-CELLS; REDOX STATUS; RPE;
   ASSOCIATION; APOE
AB Age-related macular degeneration (AMD) damages the retinal pigment epithelium (RPE), the tissue that safeguards photoreceptor health, leading to irreversible vision loss. Polymorphisms in cholesterol and complement genes are implicated in AMD, yet mechanisms linking risk variants to RPE injury remain unclear. We sought to determine how allelic variants in the apolipoprotein E cholesterol transporter modulate RPE homeostasis and function. Using live-cell imaging, we show that inefficient cholesterol transport by the AMD risk-associated ApoE2 increases RPE ceramide, leading to autophagic defects and complement-mediated mitochondrial damage. Mitochondrial injury drives redox state-sensitive cysteine-mediated phase separation of ApoE2, forming biomolecular condensates that could nucleate drusen. The protective ApoE4 isoform lacks these cysteines and is resistant to phase separation and condensate formation. In Abca(-/-) Stargardt macular degeneration mice, mitochondrial dysfunction induces liquid-liquid phase separation of p62/SQSTM1, a multifunctional protein that regulates autophagy. Drugs that decrease RPE cholesterol or ceramide prevent mitochondrial injury and phase separation in vitro and in vivo. In AMD donor RPE, mitochondrial fragmentation correlates with ApoE and p62 condensates. Our studies demonstrate that major AMD genetic and biological risk pathways converge upon RPE mitochondria, and identify mitochondrial stress-mediated protein phase separation as an important pathogenic mechanism and promising therapeutic target in AMD.
C1 [La Cunza, Nilsa; Tan, Li Xuan; Thamban, Thushara; Germer, Colin J.; Rathnasamy, Gurugirijha; Lakkaraju, Aparna] Univ Calif San Francisco, Dept Ophthalmol, Sch Med, San Francisco, CA 94143 USA.
   [La Cunza, Nilsa; Germer, Colin J.; Lakkaraju, Aparna] Univ Calif San Francisco, Grad Div, Pharmaceut Sci & Pharmacogen Grad Program, San Francisco, CA 94143 USA.
   [Toops, Kimberly A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Lakkaraju, Aparna] Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.
   [Rathnasamy, Gurugirijha] TurtleTree Labs, Singapore, Singapore.
   [Toops, Kimberly A.] Zeiss Microscopy, White Plains, NY USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of Wisconsin System; University of Wisconsin Madison;
   University of California System; University of California San Francisco
RP Lakkaraju, A (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,Room 233, San Francisco, CA 94143 USA.
EM Aparna.Lakkaraju@ucsf.edu
FU National Eye Institute (NEI)/NIH) [R01EY023299, R01EY030668]; Research
   to Prevent Blindness/American Macular Degeneration Foundation Catalyst
   Award for Innovative Research Approaches; BrightFocus Foundation
   [M2015350]; Macular Society UK; Retina Research Foundation Rebecca Meyer
   Brown Professorship; NEI/NIH P30 core grants for vision research
   [P30EY016665, P30EY002162]; NEI/NIH Diversity Supplement Fellowship [R01
   EY030668-01S1]
FX We thank Joachim Herz for the human APOE2, APOE3, and APOE4 constructs
   and Jimmy Pham for help with Matlab analyses. This research was
   supported by National Eye Institute (NEI)/NIH grants R01EY023299 and
   R01EY030668 (to AL), the Research to Prevent Blindness/American Macular
   Degeneration Foundation Catalyst Award for Innovative Research
   Approaches to AMD (to AL), the BrightFocus Foundation Award for AMD
   research M2015350 (to AL), AMD research grant from the Macular Society
   UK (to AL), the Retina Research Foundation Rebecca Meyer Brown
   Professorship (to AL), and NEI/NIH P30 core grants for vision research
   to the University of Wisconsin-Madison (P30EY016665) and to the
   University of California, San Francisco (P30EY002162). NLC is the
   recipient of an NEI/NIH Diversity Supplement Fellowship (R01
   EY030668-01S1).
CR Abbas RO, 2013, OPHTHALMIC GENET, V34, P209, DOI 10.3109/13816810.2012.762934
   Alberti S, 2019, ANNU REV GENET, V53, P171, DOI 10.1146/annurev-genet-112618-043527
   Alberti S, 2019, CELL, V176, P419, DOI 10.1016/j.cell.2018.12.035
   Alberti S, 2016, BIOESSAYS, V38, P959, DOI 10.1002/bies.201600042
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Aragones G, 2020, AGING CELL, V19, DOI 10.1111/acel.13257
   Belloy ME, 2019, NEURON, V101, P820, DOI 10.1016/j.neuron.2019.01.056
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Biarnes M, 2020, OPHTHALMOL RETINA, V4, P1129, DOI 10.1016/j.oret.2020.04.014
   Bracha D, 2019, NAT BIOTECHNOL, V37, P1435, DOI 10.1038/s41587-019-0341-6
   Caceres PS, 2020, CURR OPIN CELL BIOL, V62, P37, DOI 10.1016/j.ceb.2019.08.001
   Carroll B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02746-z
   Chen XY, 2020, CURR EYE RES, V45, P1390, DOI 10.1080/02713683.2020.1740744
   Chen Y, 2010, P NATL ACAD SCI USA, V107, P12011, DOI 10.1073/pnas.0914984107
   Chen Y, 2021, NEURON, V109, P205, DOI 10.1016/j.neuron.2020.10.008
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dolgin E, 2021, NAT BIOTECHNOL, V39, P123, DOI 10.1038/s41587-021-00828-4
   Dolgin E, 2017, NAT BIOTECHNOL, V35, P1000, DOI 10.1038/nbt1117-1000
   Elliott DA, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-23
   Fan DP, 2007, J BIOL CHEM, V282, P13746, DOI 10.1074/jbc.M611754200
   Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Frieden C, 2017, P NATL ACAD SCI USA, V114, P6292, DOI 10.1073/pnas.1705080114
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gopal PP, 2017, P NATL ACAD SCI USA, V114, pE2466, DOI 10.1073/pnas.1614462114
   Guziewicz KE, 2017, PROG RETIN EYE RES, V58, P70, DOI 10.1016/j.preteyeres.2017.01.005
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008
   Huang ZH, 2011, J LIPID RES, V52, P1733, DOI 10.1194/jlr.M017160
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kara E, 2017, J BIOL CHEM, V292, P14720, DOI 10.1074/jbc.M117.784264
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289
   Leduc Valerie, 2011, Int J Alzheimers Dis, V2011, P974361, DOI 10.4061/2011/974361
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Lewandowski CT, 2020, NEUROBIOL DIS, V139, DOI 10.1016/j.nbd.2020.104811
   Lin YT, 2018, NEURON, V98, P1294, DOI 10.1016/j.neuron.2018.06.011
   Listenberger LL, 2007, CURR PROTOC CELL BIO
   Long JM, 2019, CELL, V179, P312, DOI 10.1016/j.cell.2019.09.001
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Meszaros B, 2018, NUCLEIC ACIDS RES, V46, pW329, DOI 10.1093/nar/gky384
   Milovanovic D, 2018, SCIENCE, V361, P604, DOI 10.1126/science.aat5671
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Molliex A, 2015, CELL, V163, P123, DOI 10.1016/j.cell.2015.09.015
   Patel A, 2015, CELL, V162, P1066, DOI 10.1016/j.cell.2015.07.047
   Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298
   Rawat V, 2019, J NEUROSCI, V39, P9611, DOI 10.1523/JNEUROSCI.1400-19.2019
   Sabaretnam T, 2009, CLIN EXP PHARMACOL P, V36, pe96, DOI 10.1111/j.1440-1681.2009.05306.x
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sanchez-Martin P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.222836
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Toops KA, 2014, EXP EYE RES, V124, P74, DOI 10.1016/j.exer.2014.05.003
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   van der Reest J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04003-3
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wheeler RJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0193
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodruff JB, 2018, TRENDS BIOCHEM SCI, V43, P81, DOI 10.1016/j.tibs.2017.11.005
   Yamauchi K, 2020, BIOL CHEM, V401, P617, DOI 10.1515/hsz-2019-0414
   Yamauchi K, 2017, CLIN BIOCHEM, V50, P777, DOI 10.1016/j.clinbiochem.2017.03.021
   Yamazaki Y, 2019, NAT REV NEUROL, V15, P501, DOI 10.1038/s41582-019-0228-7
   Yang P, 2017, INVEST OPHTH VIS SCI, V58, P3073, DOI 10.1167/iovs.16-20083
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 81
TC 6
Z9 6
U1 3
U2 8
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD MAY 10
PY 2021
VL 6
IS 9
AR e142254
DI 10.1172/jci.insight.142254
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA SE8PT
UT WOS:000652331300012
PM 33822768
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Weng, XL
   Zhang, H
   Kan, MY
   Ye, JY
   Liu, FT
   Wang, T
   Deng, JY
   Tan, YF
   He, L
   Liu, Y
AF Weng, Xiaoling
   Zhang, Hong
   Kan, Mengyuan
   Ye, Junyi
   Liu, Fatao
   Wang, Ting
   Deng, Jiaying
   Tan, Yanfang
   He, Lin
   Liu, Yun
TI Leukocyte telomere length is associated with advanced age-related
   macular degeneration in the Han Chinese population
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE Age-related macular degeneration; Leukocyte telomere length
ID FACTOR-H POLYMORPHISM; COMPLEMENT FACTOR-I; CARDIOVASCULAR-DISEASE;
   RISK-FACTORS; MACULOPATHY; PROGRESSION; PREVALENCE; VARIANT; CANCER;
   GENE
AB Telomeres located at the ends of chromosomes are involved in genomic stability and play a key role in various cancers and age-related diseases. Age-related macular degeneration (AMD) is a late-onset, age-associated progressive neurodegenerative disease, which includes the geographic atrophy (GA) subtype and the choroidal neovascularization (CNV) subtype. To better understand how leukocyte telomere length (LTL) is related to AMD, we conducted an association study in 197 AMD patients and 259 healthy controls using the established quantitative PCR technique. Logistic regression was performed to evaluate the association of LTL and AMD with the age-adjusted ratio of the telomere length to the copy number of a single-copy gene (T/S). Notably, we found a significant association between AMD and LTL (OR = 2.24; 95% CI = 1.68-3.07; P = 0.0001) after adjusting for age and sex. Furthermore, the results showed a strongly significant association between the GA subtype and the LTL (OR = 4.81; 95% CI = 3.15-7.82; P = 0.0001) after adjusting for age and sex. Our findings provide evidence of the role that LTL plays in the pathological mechanisms of AMD, mainly in the GA subgroup but not the CNV subgroup. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Weng, Xiaoling; Zhang, Hong; Ye, Junyi; Tan, Yanfang; He, Lin; Liu, Yun] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
   [Kan, Mengyuan; Liu, Fatao; Wang, Ting; He, Lin] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China.
   [Deng, Jiaying] Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai 200032, Peoples R China.
   [He, Lin] Shanghai Jiao Tong Univ, BioX Ctr, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, Shanghai 200030, Peoples R China.
   [Liu, Yun] Fudan Univ, Shanghai Med Coll, Dept Biochem & Mol Biol, Key Lab Mol Med,Minist Educ, Shanghai 200032, Peoples R China.
C3 Fudan University; Chinese Academy of Sciences; Shanghai Institutes for
   Biological Sciences, CAS; Fudan University; Shanghai Jiao Tong
   University; Fudan University
RP He, L (通讯作者)，Shanghai Jiao Tong Univ, BioX Inst, Small White House,1954 Hua Shan Rd, Shanghai 200030, Peoples R China.
EM helin@bio-x.cn; superliuyun@gmail.com
FU National Natural Science Foundation of China [81121001, 81370728,
   31200954]; National Program on Key Basic Research Project of China (973
   Program) [2011CB504000]; National Key Technology RD Program
   [2012BAI01B09]; Wu Jieping Medical Foundation [320.67001118]; China
   postdoctoral science foundation [2012M510110, 2013T60440]
FX This work was supported by the National Natural Science Foundation of
   China (81121001, 81370728 and 31200954), the National Program on Key
   Basic Research Project of China (973 Program, 2011CB504000), the
   National Key Technology R&D Program (2012BAI01B09), the Wu Jieping
   Medical Foundation (320.67001118), and the China postdoctoral science
   foundation funded project (2012M510110, 2013T60440).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armanios M, 2013, J CLIN INVEST, V123, P996, DOI 10.1172/JCI66370
   Aviv A., 2004, SCI AGING KNOWLEDGE, V2004, P43, DOI DOI 10.1126/SAGEKE.2004.51.PE43
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5
   BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0
   Blackburn EH, 2010, ANGEW CHEM INT EDIT, V49, P7405, DOI 10.1002/anie.201002387
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Der G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045166
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Epel ES, 2009, AGING-US, V1, P81
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fitzpatrick AL, 2007, AM J EPIDEMIOL, V165, P14, DOI [10.1093/aje/kw346, 10.1093/aje/kwj346]
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gil ME, 2004, MOL BIOTECHNOL, V27, P169, DOI 10.1385/MB:27:2:169
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Harley CB, 1997, CIBA F SYMP, V211, P129
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Immonen I, 2013, ACTA OPHTHALMOL, V91, P453, DOI 10.1111/j.1755-3768.2012.02427.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kajstura J, 2000, AM J PATHOL, V156, P813, DOI 10.1016/S0002-9440(10)64949-8
   Kan MY, 2015, EXP BIOL MED, V240, P230, DOI 10.1177/1535370214553770
   Kan MY, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-73
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Liang GY, 2011, CANCER EPIDEM BIOMAR, V20, P1043, DOI 10.1158/1055-9965.EPI-11-0072
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin TT, 2014, BRIT J HAEMATOL, V167, P214, DOI 10.1111/bjh.13023
   Liu ZS, 2011, CANCER EPIDEM BIOMAR, V20, P2642, DOI 10.1158/1055-9965.EPI-11-0890
   Lundblad V, 2012, GENE DEV, V26, P1123, DOI 10.1101/gad.195339.112
   Ma HX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020466
   Malaspina D, 2014, MOL GENET GENOM MED, V2, P326, DOI 10.1002/mgg3.71
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martinez-Delgado B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002182
   McKay GJ, 2011, AM J EPIDEMIOL, V173, P1357, DOI 10.1093/aje/kwr015
   MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622
   Muezzinler A, 2013, AGEING RES REV, V12, P509, DOI 10.1016/j.arr.2013.01.003
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ning XH, 2014, CANCER RES, V74, P3802, DOI 10.1158/0008-5472.CAN-14-0024
   Pallini R, 2006, INT J CANCER, V118, P2158, DOI 10.1002/ijc.21613
   Qian DG, 2014, EUR J HUM GENET, V22, P1417, DOI 10.1038/ejhg.2014.37
   Rajaraman S, 2007, P NATL ACAD SCI USA, V104, P17747, DOI 10.1073/pnas.0706485104
   Rane G., 2014, REJUVENATION RES
   Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Serrano AL, 2004, CIRC RES, V94, P575, DOI 10.1161/01.RES.0000122141.18795.9C
   Shen J, 2007, CANCER RES, V67, P5538, DOI 10.1158/0008-5472.CAN-06-3490
   Shen Q, 2012, J CLIN ENDOCR METAB, V97, P1371, DOI 10.1210/jc.2011-1562
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Tedone E, 2014, EXP GERONTOL, V58, P90, DOI 10.1016/j.exger.2014.06.018
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Willeit P, 2010, JAMA-J AM MED ASSOC, V304, P69, DOI 10.1001/jama.2010.897
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 59
TC 8
Z9 10
U1 0
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD SEP
PY 2015
VL 69
BP 36
EP 40
DI 10.1016/j.exger.2015.06.004
PG 5
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA CQ0XD
UT WOS:000360320200005
PM 26049047
DA 2022-11-30
ER

PT J
AU Zhang, SR
   Liu, YH
   Lu, SL
   Cai, XM
AF Zhang, Shaoru
   Liu, Yonghua
   Lu, Shilin
   Cai, Xinmeng
TI Genetic Variants of Interleukin 17A Are Functionally Associated with
   Increased Risk of Age-Related Macular Degeneration
SO INFLAMMATION
LA English
DT Article
DE IL-17A; polymorphism; age-related macular degeneration
ID SUSCEPTIBILITY; POLYMORPHISMS; ARTHRITIS
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in elderly populations worldwide. Inflammation, among many factors, has been suggested to play an important role in AMD pathogenesis. Interleukin 17 (IL-17) is a proinflammatory cytokine that has been implicated in the pathogenesis of various autoimmune diseases. In the current study, we examined two single nucleotide polymorphisms (SNPs), rs2275913G/A and rs3748067C/T, in the IL-17A gene between AMD patients and healthy controls. Results showed that rs2275913AA genotype and rs3748067TT genotype were associated with increased susceptibility to AMD (hazard ratio [HR], 1.75; 95 % confidence interval [CI], 1.07 to 3.02; P = 0.023, and HR, 2.12; 95 % CI, 1.26 to 4.01; P = 0.004; data were adjusted for age and sex). Next, we investigated the functional relevance of the two SNPs. In vitro stimulated peripheral blood mononuclear cells (PBMCs) from subjects possessing the rs2275913AA genotype produced significantly more IL-17 than those with the GG genotype. However, PBMCs with rs3748067TT genotype revealed significantly higher IL-17 production than those with rs3748067CC genotype only in AMD patients but not in controls. These data indicate IL-17A polymorphisms are associated with increased risk of AMD probably by affecting gene expression.
C1 [Zhang, Shaoru; Liu, Yonghua] Liaocheng Peoples Hosp, Dept Ophthalmol, Liaocheng 252000, Shandong, Peoples R China.
   [Lu, Shilin; Cai, Xinmeng] Liaocheng 3 Peoples Hosp, Dept Ophthalmol, Liaocheng 252000, Shandong, Peoples R China.
RP Zhang, SR (通讯作者)，Liaocheng Peoples Hosp, Dept Ophthalmol, 67 Dong Chang Xi Rd, Liaocheng 252000, Shandong, Peoples R China.
EM zhangshaorulc@126.com
CR Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Bar E, 2014, IMMUNITY, V40, P117, DOI 10.1016/j.immuni.2013.12.002
   Benedetti G, 2014, EUR J IMMUNOL, V44, P339, DOI 10.1002/eji.201344184
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Espinoza JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026229
   Frleta M, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0414-y
   Ocejo-Vinyals JG, 2013, CYTOKINE, V64, P58, DOI 10.1016/j.cyto.2013.05.022
   Gu CF, 2013, CYTOKINE, V64, P477, DOI 10.1016/j.cyto.2013.07.022
   Hayashi R, 2013, CLIN EXP MED, V13, P239, DOI 10.1007/s10238-012-0206-5
   Kerami Z, 2014, J CROHNS COLITIS, V8, P1208, DOI 10.1016/j.crohns.2014.02.009
   Kwa FAA, 2014, DRUG DISCOV TODAY, V19, P1387, DOI 10.1016/j.drudis.2014.03.026
   Lam M, 2013, INT FORUM ALLERGY RH, V3, P121, DOI 10.1002/alr.21082
   Li N, 2014, MOL CARCINOGEN, V53, P447, DOI 10.1002/mc.21992
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Maalmi H, 2014, J ASTHMA, V51, P348, DOI 10.3109/02770903.2013.876647
   Moon SJ, 2014, ARTHRITIS RHEUMATOL, V66, P874, DOI 10.1002/art.38310
   Ng Tsz Kin, 2014, World J Stem Cells, V6, P111, DOI 10.4252/wjsc.v6.i2.111
   Omrane I, 2014, TUMOR BIOL, V35, P6627, DOI 10.1007/s13277-014-1890-4
   Sato DK, 2014, J NEUROIMMUNOL, V268, P95, DOI 10.1016/j.jneuroim.2014.01.008
   Taylor PR, 2014, NAT IMMUNOL, V15, P143, DOI 10.1038/ni.2797
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Yu HH, 2013, DNA CELL BIOL, V32, P717, DOI 10.1089/dna.2013.2127
   Yu XH, 2014, CLIN CHIM ACTA, V431, P33, DOI 10.1016/j.cca.2014.01.012
   Zhu QH, 2014, GENE, V537, P328, DOI 10.1016/j.gene.2013.11.007
NR 24
TC 14
Z9 14
U1 0
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD APR
PY 2015
VL 38
IS 2
BP 658
EP 663
DI 10.1007/s10753-014-9973-3
PG 6
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA CC7NC
UT WOS:000350553800022
PM 25028103
DA 2022-11-30
ER

PT J
AU Yan, RJ
   Zhao, J
   Zhang, XA
   Wang, W
   Jiang, ZY
AF Yan, Ruijia
   Zhao, Jing
   Zhang, Xinai
   Wang, Wei
   Jiang, Zhengyao
TI Association Between Aspirin Usage and Age-Related Macular Degeneration:
   An Updated Systematic Review and Meta-analysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE long-term use; aspirin; association; age-related macular degeneration;
   meta-analysis
ID RISK-FACTORS; MACULOPATHY; PROGRESSION; DISEASE
AB Purpose: To investigate the association between long-term use of aspirin and age-related macular degeneration (AMD). Methods: An updated systematic literature search was conducted in PubMed, Medline, Cochrane Library, and embase from conception to February 26, 2021, without any language restriction. All studies that evaluated the relationship between long-term aspirin use and AMD were included. Results: In the current study, 16 articles were pooled. Overall, no significant association was observed (estimate ratio = 1.108, 95% confidence interval (CI): 0.886-1.385). When the subgroups were evaluated according to various standards, aspirin use was significantly correlated with AMD in studies with volunteer participants (estimate ratio = 0.899, 95% CI: 0.830-0.974, p < 0.01), studies followed up for > 10 years (estimate ratio = 2.206, 95% CI: 2.124-2.292, p < 0.01), duration of aspirin use > 10 years (estimate ratio = 2.323, 95% CI: 2.234-2.416, p < 0.01), and cohort studies (estimate ratio = 1.961, 95% CI: 1.893-2.032, p < 0.01). Conclusion: Therefore, the association of aspirin and AMD can be demonstrated with a long-term follow-up or aspirin use, appropriate study design and participant source. The findings in our study might provide practical information on intervention strategies.
C1 [Yan, Ruijia; Zhao, Jing; Zhang, Xinai; Wang, Wei; Jiang, Zhengyao] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Ophthalmol, Qingdao, Peoples R China.
C3 Shandong University
RP Jiang, ZY (通讯作者)，Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Ophthalmol, Qingdao, Peoples R China.
EM qlykjzy@163.com
CR Arruabarrena C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153281
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Cheung N, 2013, BRIT J OPHTHALMOL, V97, P785, DOI 10.1136/bjophthalmol-2012-302253
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Dolar-Szczasny J, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.656774
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Kahawita SK, 2014, CAN J OPHTHALMOL, V49, P35, DOI 10.1016/j.jcjo.2013.07.016
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1647, DOI 10.1016/j.ophtha.2019.06.023
   Khanani AM, 2022, EYE, V36, P303, DOI 10.1038/s41433-021-01842-1
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Lee WJA, 2021, PHARMACOEPIDEM DR S, V30, P178, DOI 10.1002/pds.5145
   Li L, 2015, J CLIN PHARM THER, V40, P144, DOI 10.1111/jcpt.12241
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Modjtahedi BS, 2018, AM J OPHTHALMOL, V188, P111, DOI 10.1016/j.ajo.2018.01.012
   Montgomery S, 2021, HEART, DOI 10.1136/heartjnl-2021-320154
   Ning N, 2013, HUM EXP TOXICOL, V32, P1164, DOI 10.1177/0960327112472997
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Rim TH, 2019, OPHTHALMOLOGY, V126, P274, DOI 10.1016/j.ophtha.2018.09.014
   Rudnicka AR, 2010, EYE, V24, P1199, DOI 10.1038/eye.2010.8
   Wells G., 2000, NEWCASTLE OTTAWA SCA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ye J, 2014, INVEST OPHTH VIS SCI, V55, P2687, DOI 10.1167/iovs.13-13206
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 37
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 25
PY 2022
VL 13
AR 824745
DI 10.3389/fphar.2022.824745
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 1X8HT
UT WOS:000807690300001
PM 35401184
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, AY
   Raya, AK
   Kymes, SM
   Shiels, A
   Brantley, MA
AF Lee, A. Y.
   Raya, A. K.
   Kymes, S. M.
   Shiels, A.
   Brantley, M. A., Jr.
TI Pharmacogenetics of complement factor H (Y402H) and treatment of
   exudative age-related macular degeneration with ranibizumab
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYMORPHISM; ASSOCIATION; LOC387715; GENOTYPES; SMOKING
AB Aims: To determine whether complement factor H (CFH) genotypes have a pharmacogenetic effect on the treatment of exudative age-related macular degeneration (AMD) with ranibizumab.
   Methods: A retrospective study of 156 patients with exudative AMD treated with intravitreal ranibizumab monotherapy was conducted. AMD phenotypes were characterised by clinical examination, visual acuity, fundus photography, fluorescein angiography and injection timing. Patients received intravitreal ranibizumab injections as part of routine ophthalmological care and were followed for a minimum of 9 months. Each patient was genotyped for the single nucleotide polymorphism rs1061170 (Y402H) in the CFH gene.
   Results: Baseline lesion size and angiographic type, as well as mean visual acuities at baseline, 6 months, and 9 months were similar among the three CFH genotypes. Over 9 months, patients with both risk alleles received approximately one more injection (p=0.09). In a recurrent event analysis, patients homozygous for the CFH Y402H risk allele had a 37% significantly higher risk of requiring additional ranibizumab injections (p=0.04).
   Conclusions: In this study cohort, the response to treatment of AMD with ranibizumab differed according to CFH genotype, suggesting that determining patients' CFH genotype may be helpful in the future in tailoring treatment for exudative AMD with intravitreal ranibizumab.
C1 [Lee, A. Y.; Raya, A. K.; Kymes, S. M.; Shiels, A.; Brantley, M. A., Jr.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Brantley, M. A., Jr.] Barnes Retina Inst, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Brantley, MA (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Campus Box 8096,660 S Euclid Ave, St Louis, MO 63110 USA.
EM brantley@vision.wustl.edu
RI Lee, Aaron/AAT-2839-2020
OI Lee, Aaron/0000-0002-7452-1648
FU NIH [T32RR023255, UL1RR024992]; American Geriatrics Society; Carl M &
   Mildred A Reeves Foundation; NEI [EY012284]; NEI Core [5 P30 EY02687];
   Research to Prevent Blindness; NATIONAL CENTER FOR RESEARCH RESOURCES
   [T32RR023255, UL1RR024992] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [P30EY002687, R01EY012284] Funding Source: NIH RePORTER
FX This work was supported by NIH grant T32RR023255 and UL1RR024992 to
   Washington University School of Medicine (AYL and AKR), the Jahnigen
   Career Development. Award from the American Geriatrics Society (MAB),
   the Carl M & Mildred A Reeves Foundation (MAB), NEI grant EY012284 (AS),
   NEI Core Grant 5 P30 EY02687, and a grant from Research to Prevent
   Blindness to the Department of Ophthalmology and Visual Sciences at
   Washington University School of Medicine.
CR BRANTLEY MA, EYE
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Souied EH, 2005, MOL VIS, V11, P1135
NR 15
TC 105
Z9 118
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2009
VL 93
IS 5
BP 610
EP 613
DI 10.1136/bjo.2008.150995
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 438BE
UT WOS:000265530100012
PM 19091853
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shaikh, AH
   Toussaint, BW
   Miller, DM
   Petersen, MR
   Foster, RE
   Riemann, CD
   Hutchins, RK
   Sisk, RA
AF Shaikh, Adeel H.
   Toussaint, Brian W.
   Miller, Daniel M.
   Petersen, Michael R.
   Foster, Robert E.
   Riemann, Christopher D.
   Hutchins, Robert K.
   Sisk, Robert A.
TI Cost Comparison of Intravitreal Aflibercept With Bevacizumab and
   Ranibizumab for the Treatment of Wet Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID VERTEPORFIN; THERAPY
AB BACKGROUND AND OBJECTIVE: To test the hypothesis that although intravitreal aflibercept (IVA) is expected to be more expensive, the extra cost of treatment would not result in additional vision gain compared with intravitreal bevacizumab (IVB) for the treatment of wet age-related macular degeneration (AMD).
   PATIENTS AND METHODS: A retrospective chart review of patients receiving IVB or intravitreal ranibizumab (IVR) who were subsequently changed to IVA for active wet AMD.
   RESULTS: Thirty-three eyes were included in the study. The mean number of IVB, IVR, and IVA injections per eye over a 6-month period was seven, six, and five, respectively. Visual outcomes were similar in all three groups at the end of the study period. The average drug cost of IVB, IVR, and IVA injections per eye over 6 months was $326, $11,400, and $9,720, respectively.
   CONCLUSION: Aflibercept may allow a modest extension of the treatment interval, but cost makes IVA an expensive alternative without a visual benefit compared with IVB in patients with active wet AMD.
C1 [Shaikh, Adeel H.; Toussaint, Brian W.; Miller, Daniel M.; Riemann, Christopher D.; Hutchins, Robert K.; Sisk, Robert A.] Univ Cincinnati, Coll Med, Dept Ophthalmol, Cincinnati, OH USA.
   [Shaikh, Adeel H.; Toussaint, Brian W.; Miller, Daniel M.; Petersen, Michael R.; Foster, Robert E.; Riemann, Christopher D.; Hutchins, Robert K.; Sisk, Robert A.] Cincinnati Eye Inst, Cincinnati, OH 45242 USA.
C3 University System of Ohio; University of Cincinnati
RP Sisk, RA (通讯作者)，Cincinnati Eye Inst, 1945 CEI Dr, Cincinnati, OH 45242 USA.
EM rsisk@cincinnatieye.com
OI Riemann, Christopher/0000-0003-2022-0951
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2012, RETINA, V32, P343
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
NR 13
TC 12
Z9 13
U1 0
U2 11
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JAN
PY 2015
VL 46
IS 1
BP 62
EP 66
DI 10.3928/23258160-20150101-10
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CG5TO
UT WOS:000353358500009
PM 25559511
DA 2022-11-30
ER

PT J
AU Park, DH
   Sun, HJ
   Lee, SJ
AF Park, Dae Hyun
   Sun, Hae Jung
   Lee, Sung Jin
TI A comparison of responses to intravitreal bevacizumab, ranibizumab, or
   aflibercept injections for neovascular age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Ranibizumab; Aflibercept; Anti-vascular endothelial growth
   factor (anti-VEGF); Neovascular age-related macular degeneration (AMD)
ID ENDOTHELIAL GROWTH-FACTOR; TRAP-EYE; AMD; RESISTANT; OUTCOMES; THERAPY
AB To compare the responses of intravitreal injections of bevacizumab, ranibizumab, or aflibercept for the treatment of neovascular age-related macular degeneration (nAMD).
   This retrospective study examined 232 eyes of 232 patients who received intravitreal anti-vascular endothelial growth factor (VEGF) injections due to treatment-na < ve nAMD. All patients, who were followed-up for at least 1 year, were treated with intravitreal injections monthly until 3 months, and then as needed. We evaluated the effects of intravitreal injections for treatment of nAMD using the central macular thickness (CMT), subretinal fluid (SRF), pigment epithelial detachment (PED) size, and best-corrected visual acuity (BCVA).
   CMT, SRF, PED size, and BCVA (LogMAR) were significantly decreased after treatment with all three anti-VEGF agents. Overall, the bevacizumab, ranibizumab, and aflibercept treatments showed no significant differences in their responses. However, the aflibercept injections decreased PED size more quickly than bevacizumab injections (P = 0.034).
   Bevacizumab, ranibizumab, and aflibercept injections are effective treatments for nAMD and have similar responses, although the number of injections of aflibercept was fewer than other anti-VEGF agents. In addition, aflibercept injections may be a better choice than other anti-VEGF agents for cases of severe increases in PED height.
C1 [Park, Dae Hyun; Sun, Hae Jung; Lee, Sung Jin] Soonchunhyang Univ Hosp, Coll Med, Dept Opthalmol, 59 Daesagwan Ro, Seoul 140743, South Korea.
C3 Soonchunhyang University; Soonchunhyang University Hospital
RP Lee, SJ (通讯作者)，Soonchunhyang Univ Hosp, Coll Med, Dept Opthalmol, 59 Daesagwan Ro, Seoul 140743, South Korea.
EM wismile@schmc.ac.kr
FU Soonchunhyang University
FX This study was supported by Soonchunhyang University Research Fund. No
   grants or sponsoring organizations were involved in the work presented
   in this submission.
CR Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Batioglu F, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0025-z
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Christoforidis JB, 2013, CURR EYE RES, V38, P761, DOI 10.3109/02713683.2013.763988
   De Bats F, 2012, J FR OPHTALMOL, V35, P661, DOI 10.1016/j.jfo.2012.01.015
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gamulescu Maria-Andreea, 2010, International Ophthalmology, V30, P261, DOI 10.1007/s10792-009-9318-7
   Gisladottir S, 2009, GRAEF ARCH CLIN EXP, V247, P1677, DOI 10.1007/s00417-009-1141-3
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Ho QT, 2007, INT J BIOCHEM CELL B, V39, P1349, DOI 10.1016/j.biocel.2007.04.010
   Jorstad OK, 2015, ACTA OPHTHALMOL, V93, pE510, DOI 10.1111/aos.12681
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Ladewig MS, 2006, OPHTHALMOLOGE, V103, P463, DOI 10.1007/s00347-006-1352-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
NR 26
TC 21
Z9 21
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2017
VL 37
IS 5
BP 1205
EP 1214
DI 10.1007/s10792-016-0391-4
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ3WG
UT WOS:000412662600016
PM 27826933
DA 2022-11-30
ER

PT J
AU Chen, ZL
   Li, DB
   Shen, HL
   Mo, HL
   Zeng, ZY
   Wei, H
AF Chen, Zailiang
   Li, Dabao
   Shen, Hailan
   Mo, Hailan
   Zeng, Ziyang
   Wei, Hao
TI Automated segmentation of fluid regions in optical coherence tomography
   B-scan images of age-related macular degeneration
SO OPTICS AND LASER TECHNOLOGY
LA English
DT Article
DE SEUNet; AMD; OCT image; Fluid regions; Segmentation
ID EDEMA; QUANTIFICATION
AB Age-related macular degeneration (AMD) is a common eye disease that causes progressive vision loss in people older than 50 years. Fluid regions in retina are the most characteristic of AMD. Accurately segmenting fluid regions is crucial for the early diagnosis of AMD, and assessment of treatment efficacy. In this paper, we propose an automatic deep learning method constructed by integrating Squeeze-and-Excitation blocks with U-Net named SEUNet to segment fluid regions and classify OCT B-scan images to AMD or normal image. The proposed method comprises three stages: (1) preprocessing stage that includes image noise removal, locating the image on the area of interest, and image color-reversing; (2) fluid region segmentation stage which is based on U-Net and constructed by integrating Squeeze-and-Excitation block to segment fluid region; and (3) image classification stage that classifies image to AMD or normal image. Experimental results show that the proposed method have an average IOU coefficient of 0.9035, an average Dice coefficient of 0.9421, an average precision of 0.9446, and an average recall of 0.9464. Therefore, the proposed method can effectively segment fluid regions in OCT B-scan images.
C1 [Chen, Zailiang; Li, Dabao; Shen, Hailan; Mo, Hailan; Zeng, Ziyang; Wei, Hao] Cent South Univ, Sch Comp Sci & Engn, Changsha 410083, Peoples R China.
   [Chen, Zailiang; Li, Dabao; Mo, Hailan; Zeng, Ziyang; Wei, Hao] Hunan Engn Res Ctr Machine Vis & Intelligent Med, Changsha 410083, Peoples R China.
C3 Central South University
RP Shen, HL (通讯作者)，Cent South Univ, Sch Comp Sci & Engn, Changsha 410083, Peoples R China.
EM xxxyczl@163.com; lidabao@csu.edu.cn; hn_shl@126.com;
   xiaomianhua@csu.edu.cn; zengziyang@csu.edu.cn; csuweihao@csu.edu.cn
FU National Natural Science Foundation of China, China [61672542];
   Fundamental Research Funds for the Central Universities of Central South
   University, China [2018zzts566]
FX This research was supported by the National Natural Science Foundation
   of China, China, under Grant No. 61672542 and supported by the
   Fundamental Research Funds for the Central Universities of Central South
   University, China, under Grant No. 2018zzts566.
CR [Anonymous], 2017, CNNS ENABLE ACCURATE
   [Anonymous], IEEE J BIOMED HLTH I
   Badrinarayanan V, 2017, IEEE T PATTERN ANAL, V39, P2481, DOI 10.1109/TPAMI.2016.2644615
   Bogunovic H, 2015, P OPHTH MED IM AN, P49
   Chen ZL, 2019, IET IMAGE PROCESS, V13, P1824, DOI 10.1049/iet-ipr.2018.5304
   Chen ZL, 2019, MED BIOL ENG COMPUT, V57, P953, DOI 10.1007/s11517-018-1927-8
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Dabov K., 2009, P WORKSH SIGN PROC A, V49, P1
   Hu J, 2018, PROC CVPR IEEE, P7132, DOI [10.1109/TPAMI.2019.2913372, 10.1109/CVPR.2018.00745]
   Khalil T, 2018, IEEE ACCESS, V6, P4560, DOI 10.1109/ACCESS.2018.2791427
   Lang A, 2015, BIOMED OPT EXPRESS, V6, P155, DOI 10.1364/BOE.6.000155
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Poddar R, 2018, OPT LASER TECHNOL, V102, P130, DOI 10.1016/j.optlastec.2017.12.033
   Rashno A, 2018, IEEE T BIO-MED ENG, V65, P989, DOI 10.1109/TBME.2017.2734058
   Rashno A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186949
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmitt JM, 1999, J BIOMED OPT, V4, P95, DOI 10.1117/1.429925
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wintergerst MWM, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.10
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Zhang L, 2015, I S BIOMED IMAGING, P1494, DOI 10.1109/ISBI.2015.7164160
NR 25
TC 13
Z9 13
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0030-3992
EI 1879-2545
J9 OPT LASER TECHNOL
JI Opt. Laser Technol.
PD FEB
PY 2020
VL 122
AR 105830
DI 10.1016/j.optlastec.2019.105830
PG 8
WC Optics; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics; Physics
GA LA0JY
UT WOS:000523644700004
DA 2022-11-30
ER

PT J
AU Zimmer-Galler, IE
   Zeimer, R
AF Zimmer-Galler, IE
   Zeimer, R
TI Feasibility of screening for high-risk age-related macular degeneration
   with an Internet-based automated fundus camera
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID DIABETIC-RETINOPATHY; MACULOPATHY; ZINC
AB BACKGROUND AND OBJECTIVE: The objective of this pilot study was to determine whether a new screening system, the DigiScope (EyeTel Imaging, Inc., Columbia, MD), can detect the presence of age-related macular degeneration (AMD) at a level requiring referral to an ophthalmologist for further evaluation and possible treatment.
   PATIENTS AND METHODS: The DigiScope is an Internet-based semi-automated digital imaging system designed to be in primary care physicians' offices. Forty-two eyes of 21 patients with different categories of AMD were imaged with both the DigiScope and a standard color fundus camera. The imaging capability of the two modalities was compared for identification of lesions associated with AMD and classification into stages.
   RESULTS: There was good agreement for low-risk lesions and excellent agreement for high-risk lesions. Thirty-five of 36 eyes with intermediate or advanced disease were correctly identified with DigiScope images. Choroidal neovascularization was identified in all cases with the DigiScope due to the presence of subretinal hemorrhage or subretinal fibrosis. The DigiScope was found less capable of detecting subretinal fluid than standard stereo fundus photographs.
   CONCLUSIONS: This pilot study suggests that the DigiScope may be a useful screening tool for AMD.
C1 Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Ophthalm Phys Lab, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Zimmer-Galler, IE (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Ophthalm Phys Lab, Wilmer Woods Bldg355,600 N Wolfe St, Baltimore, MD 21287 USA.
FU NATIONAL EYE INSTITUTE [P30EY001765] Funding Source: NIH RePORTER; NEI
   NIH HHS [P30 EY01765] Funding Source: Medline
CR Bresnick GH, 2000, OPHTHALMOLOGY, V107, P19, DOI 10.1016/S0161-6420(99)00010-X
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Lee PP, 2003, OPHTHALMOLOGY, V110, P1952, DOI 10.1016/S0161-6420(03)00817-0
   Lim JI, 2002, RETINA-J RET VIT DIS, V22, P59, DOI 10.1097/00006982-200202000-00011
   Mukamel D B, 1999, Ophthalmic Epidemiol, V6, P61
   Pandit RJ, 2000, DIABETIC MED, V17, P693, DOI 10.1046/j.1464-5491.2000.00368.x
   Rosenthal Bruce, 2003, Optometry, V74, P16
   Schiffman RM, 2005, OPHTHAL SURG LAS IM, V36, P46
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Zeimer R, 2002, INVEST OPHTH VIS SCI, V43, P1581
NR 13
TC 11
Z9 11
U1 0
U2 4
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1082-3069
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2005
VL 36
IS 3
BP 228
EP 236
DI 10.3928/1542-8877-20050501-09
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 926KO
UT WOS:000229122300007
PM 15957480
DA 2022-11-30
ER

PT J
AU Wang, J
   Xue, YJ
   Thapa, S
   Wang, LP
   Tang, JF
   Ji, KT
AF Wang, Jie
   Xue, Yangjing
   Thapa, Saroj
   Wang, Luping
   Tang, Jifei
   Ji, Kangting
TI Relation between Age-Related Macular Degeneration and Cardiovascular
   Events and Mortality: A Systematic Review and Meta-Analysis
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID VISUAL IMPAIRMENT; MYOCARDIAL-INFARCTION; EYE DISEASE; RISK; SURVIVAL;
   STROKE; ADULTS; WOMEN
AB Data on the association between age-related macular degeneration (AMD) and cardiovascular disease and mortality are conflicting. The purpose of this report is to conduct a systematic review to better understand the role of AMD as a risk factor for CVD events and mortality. We searched Medline (Ovid) and Embase (Ovid) for trials published from 1980 to 2015. We included 20 cohort studies that reported relative risks with 95% confidence intervals for the association of AMD and cardiovascular events and mortality, involving 29,964,334 participants. In a random-effects model, the adjusted RR (95% confidence interval [CI]) associated with AMD was 1.08 (1.00-1.117) for all-cause mortality (8 studies) and 1.18 (0.98-1.43) for cardiovascular disease mortality (5 studies). The pooled RR (95% CI) was 1.17 (0.94-1.45) for coronary heart disease (CHD; 3 studies) and 1.13 (0.93-1.36) for stroke (8 studies). Findings from this systematic review support that AMD is associated with increased risk of all-cause mortality. The evidence that AMD predicts incident CVD events or CVD mortality remains inclusive and warrants further study in the future.
C1 [Ji, Kangting] Wenzhou Med Univ, Affiliated Hosp 2, Dept Cardiol, Xueyuanxi Rd 109, Wenzhou 325000, Zhejiang, Peoples R China.
   Wenzhou Med Univ, Yuying Childrens Hosp, Xueyuanxi Rd 109, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Ji, KT (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Cardiol, Xueyuanxi Rd 109, Wenzhou 325000, Zhejiang, Peoples R China.
EM jikingt@163.com
FU Second Affiliated Hospital, Wenzhou Medical University
FX The authors acknowledge the Second Affiliated Hospital, Wenzhou Medical
   University, for supporting the work of their study.
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Chou R, 2009, ANN INTERN MED, V151, P44, DOI 10.7326/0003-4819-151-1-200907070-00008
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Kulmala J, 2008, AGING CLIN EXP RES, V20, P25
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
NR 33
TC 13
Z9 13
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2016
VL 2016
AR 8212063
DI 10.1155/2016/8212063
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA EF7WC
UT WOS:000390539100001
PM 28070519
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Barchitta, M
   Maugeri, A
AF Barchitta, Martina
   Maugeri, Andrea
TI Association between Vascular Endothelial Growth Factor Polymorphisms and
   Age-Related Macular Degeneration: An Updated Meta-Analysis
SO DISEASE MARKERS
LA English
DT Review
ID FACTOR GENE POLYMORPHISMS; VEGF POLYMORPHISMS; SUSCEPTIBILITY; RISK
AB Age-related macular degeneration (AMD) is the most common cause of blindness in elderly people worldwide and the major degenerative disease of the retina that leads to progressive impairment of central vision. Several polymorphisms in different genes have been proposed as factors that increase the disease susceptibility. The aim of the present study is to carry out a systematic review and an updated meta-analysis in order to summarize the current published studies and to evaluate the associations between four common vascular endothelial growth factor (VEGF) polymorphisms (rs833061, rs1413711, rs3025039, and rs2010963) and AMD risk, also stratifying for AMD subtypes and ethnicity. A systematic literature search in the Medline database, using PubMed, was carried out for epidemiological studies, published before June 2016. Associations of VEGF polymorphisms with AMD were estimated by calculating pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) based on different models. Twelve articles were included in the analysis. The present meta-analysis constitutes a useful guide for readers to study AMD and adds new evidence to the growing literature on the role of VEGF polymorphisms in the risk of AMD. Significant associations with AMD risk were showed for rs833061, rs1413711, and rs3025039 polymorphisms but not for rs2010963.
C1 [Barchitta, Martina; Maugeri, Andrea] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Via S Sofia 87, I-95123 Catania, Italy.
C3 University of Catania
RP Barchitta, M (通讯作者)，Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Via S Sofia 87, I-95123 Catania, Italy.
EM martina.barchitta@unict.it
RI Barchitta, Martina/A-1362-2015; Barchitta, Martina/AFV-8723-2022;
   Maugeri, Andrea/K-1018-2017
OI Barchitta, Martina/0000-0002-0905-5003; Maugeri,
   Andrea/0000-0003-2655-8574
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Bulgu Y, 2014, INT J OPHTHALMOL-CHI, V7, P773, DOI [10.3980/j.issn.2222-3959.2014.05.06, 10.3980/j.issn.2222-3959.2014.06]
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cruz-Gonzalez F, 2013, CURR EYE RES, V38, P1274, DOI 10.3109/02713683.2013.819926
   Deeks JJ., 2008, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fang AM, 2009, MOL VIS, V15, P2710
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Goncalves FM, 2010, DNA CELL BIOL, V29, P357, DOI 10.1089/dna.2010.1025
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Huang C, 2013, MOL VIS, V19, P1211
   Gonalves FTI, 2015, ARQ BRAS OFTALMOL, V78, P290, DOI 10.5935/0004-2749.20150077
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Jager R. D., 2008, NEW ENGL J MED, V358, P2544
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Jiang YM, 2013, J INT MED RES, V41, P317, DOI 10.1177/0300060513475570
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Liu Yuqing, 2014, Genet Test Mol Biomarkers, V18, P245, DOI 10.1089/gtmb.2013.0368
   Lu Y, 2012, MOL BIOL REP, V39, P6547, DOI 10.1007/s11033-012-1483-5
   Mckay GJ, 2009, OPHTHALMOLOGY, V116, P1227, DOI 10.1016/j.ophtha.2009.01.008
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Sacca SC, 2009, MUTAT RES-FUND MOL M, V667, P98, DOI 10.1016/j.mrfmmm.2008.11.002
   Stevens A, 2003, CANCER RES, V63, P812
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Szaflik Jacek P, 2009, Klin Oczna, V111, P125
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tong Y, 2010, MOL VIS, V16, P1958
   Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 44
TC 15
Z9 15
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278-0240
EI 1875-8630
J9 DIS MARKERS
JI Dis. Markers
PY 2016
VL 2016
AR 8486406
DI 10.1155/2016/8486406
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine; Pathology
GA EE1UE
UT WOS:000389368200001
PM 27999450
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Bok, D
AF Bok, Dean
TI Contributions of genetics to our understanding of inherited monogenic
   retinal diseases and age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; DOMINANT RETINITIS-PIGMENTOSA; CIGARETTE-SMOKING;
   EPITHELIAL-CELLS; GYRATE ATROPHY; VISUAL CYCLE; ONE FORM; RPE65;
   PROTEIN; LOCALIZATION
AB Molecular genetics has contributed greatly to our understanding of inherited ocular disease. Prior to the development of recombinant DNA technology, basic and clinical scientists were limited to a description and classification of phenotypes based on morphology, biochemistry, and physiology. Progress was severely hampered by the dearth of genetic information. The pace of progress accelerated in the 1990s after the first disease-causing allele for retinitis pigmentosa was reported. The years 1990 through 2000 featured the identification and characterization of multiple gene alleles underlying retinitis pigmentosa and allied monogenic diseases. A second leap in our understanding occurred in the past year. Age-related macular degeneration-which was, until now, refractory to the identification of genes involving significant segments of the patient population-is finally yielding its secrets. However, some genes have no known function.. Indeed this is the case for the majority of genes putatively identified by the Human Genome Project. Answers to these questions will come through an amalgamation of genetics, cell biology, physiology, and other disciplines. Collaboration among investigators in these disciplines is already occurring out of sheer fascination over this interesting and important topic. In the end, patients with inherited ocular disease will be the final and highly deserving beneficiaries.
C1 Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Neurobiol, Los Angeles, CA 90024 USA.
   Univ Calif Los Angeles, Brain Res Inst, David Geffen Sch Med, Los Angeles, CA 90024 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Bok, D (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Neurobiol, Los Angeles, CA 90024 USA.
EM bok@jsei.ucla.edu
FU NATIONAL EYE INSTITUTE [P30EY000331, R37EY000444, R01EY000444] Funding
   Source: NIH RePORTER; NEI NIH HHS [EY 00444, EY 00331] Funding Source:
   Medline
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   BAVIK CO, 1993, J BIOL CHEM, V268, P20540
   Becerra SP, 2006, EXP EYE RES, V82, P739, DOI 10.1016/j.exer.2005.10.016
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fan BJ, 2006, CLIN BIOCHEM, V39, P249, DOI 10.1016/j.clinbiochem.2005.11.001
   Fan BJ, 2006, CLIN BIOCHEM, V39, P231, DOI 10.1016/j.clinbiochem.2005.11.010
   FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 1999, MOL VIS, V5, pU31
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0
   Karan G, 2004, MOL VIS, V10, P248
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lavail Matthew M, 2005, Retina, V25, pS25, DOI 10.1097/00006982-200512001-00009
   Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967
   MacDonald IM, 2004, SURV OPHTHALMOL, V49, P159, DOI 10.1016/j.survophthal.2003.12.003
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   MCWILLIAM P, 1989, GENOMICS, V5, P619, DOI 10.1016/0888-7543(89)90031-1
   MITCHELL GA, 1988, J CLIN INVEST, V81, P630, DOI 10.1172/JCI113365
   Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200
   NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851
   PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   RAMESH V, 1988, P NATL ACAD SCI USA, V85, P3777, DOI 10.1073/pnas.85.11.3777
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sullivan LS, 2006, INVEST OPHTH VIS SCI, V47, P3052, DOI 10.1167/iovs.05-1443
   TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0
   *U TEX HOUST HLTH, RETNET RET INF NETW
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   Vincent AL, 2005, CLIN EXP OPHTHALMOL, V33, P303, DOI 10.1111/j.1442-9071.2005.01011.x
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weleber Richard G, 2005, Retina, V25, pS4, DOI 10.1097/00006982-200512001-00002
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 55
TC 17
Z9 17
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2007
VL 125
IS 2
BP 160
EP 164
DI 10.1001/archopht.125.2.160
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 134FR
UT WOS:000244069400002
PM 17296891
OA Bronze
DA 2022-11-30
ER

PT J
AU Wong, DT
   Berger, AR
   Bourgault, S
   Chen, J
   Colleaux, K
   Cruess, AF
   Dookeran, RI
   Gauthier, D
   Hurley, B
   Kapusta, MA
   Kertes, PJ
   Qian, CX
   Samad, A
   Sheidow, T
   Whelan, JH
AF Wong, David T.
   Berger, Alan R.
   Bourgault, Serge
   Chen, John
   Colleaux, Kevin
   Cruess, Alan F.
   Dookeran, Ravi I.
   Gauthier, Danny
   Hurley, Bernard
   Kapusta, Michael A.
   Kertes, Peter J.
   Qian, Cynthia X.
   Samad, Arif
   Sheidow, Thomas
   Whelan, James H.
TI Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in
   the Management of Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Neovascular age-related macular degeneration; Biomarkers; Fluid;
   Intraretinal; Subretinal
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENT;
   TREAT-AND-EXTEND; CHOROIDAL NEOVASCULARIZATION; INDOCYANINE GREEN;
   FLUORESCEIN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; SUBRETINAL FLUID;
   VISUAL-ACUITY; INTRAVITREAL RANIBIZUMAB
AB These recommendations, produced by a group of Canadian retina experts, have been developed to assist both retina specialists and general ophthalmologists in the management of vision-threatening neovascular age-related macular degeneration (nAMD). The recommendations are based on published evidence as well as collective experience and expertise in routine clinical practice. We provide an update on practice principles for optimal patient care, focusing on identified imaging biomarkers, in particular retinal fluid, as well as current and emerging therapeutic approaches. Algorithms for delivering high-quality care and improving long-term patient outcomes are provided, with an emphasis on timely and appropriate treatment to preserve and maintain vision. In the context of nAMD, increasing macular fluid or leakage on fluorescein angiography (FA) may indicate disease activity regardless of its location. Early elimination of intraretinal fluid (IRF) is of particular relevance as it is a prognostic indicator of worse visual outcomes. Robust referral pathways for second opinion and peer-to-peer consultations must be in place for cases not responding to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.
C1 [Wong, David T.; Berger, Alan R.; Kertes, Peter J.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Bourgault, Serge] Univ Laval, Dept Ophthalmol, Quebec City, PQ, Canada.
   [Chen, John; Kapusta, Michael A.] McGill Univ, Dept Ophthalmol, Montreal, PQ, Canada.
   [Colleaux, Kevin] Univ Saskatchewan, Dept Ophthalmol, Saskatoon, SK, Canada.
   [Cruess, Alan F.; Samad, Arif] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.
   [Dookeran, Ravi I.] Univ Manitoba, Dept Ophthalmol, Winnipeg, MB, Canada.
   [Gauthier, Danny; Qian, Cynthia X.] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Hurley, Bernard] Univ Ottawa, Dept Ophthalmol, Ottawa, ON, Canada.
   [Sheidow, Thomas] Western Univ, Dept Ophthalmol, London, ON, Canada.
   [Whelan, James H.] Mem Univ, Fac Med, St John, NF, Canada.
C3 University of Toronto; Laval University; McGill University; University
   of Saskatchewan; Dalhousie University; University of Manitoba;
   Universite de Montreal; University of Ottawa; Western University
   (University of Western Ontario); Memorial University Newfoundland
RP Wong, DT (通讯作者)，Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
EM david.wong@unityhealth.to
RI Bourgault, Serge/ABC-2569-2021
FU Novartis Pharmaceuticals Canada
FX All authors received an honorarium from Novartis Pharmaceuticals Canada.
   Novartis retained SNELL Medical Communication and provided financial
   assistance to organize the author conference, perform the literature
   research, and prepare a draft manuscript. The authors were provided
   complete editorial independence in the development of this article, and
   no Novartis personnel participated or were present during the author
   meeting.
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Arias-Barquet L, FLUORESCEIN ANGIOGRA
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Bonte CA, 1998, RETINA-J RET VIT DIS, V18, P476, DOI 10.1097/00006982-199805000-00018
   Borrelli E, 2019, OPHTHALMOL THER, V8, P215, DOI 10.1007/s40123-019-0178-6
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Camacho N, 2015, BRIT J OPHTHALMOL, V99, P1277, DOI 10.1136/bjophthalmol-2014-306226
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Evans RN., 2019, ARVO ANN M VANC BC
   Fang PP, 2019, RETINA-J RET VIT DIS, V39, P150, DOI 10.1097/IAE.0000000000001918
   Fernandez M, DIAGNOSTIC USEFULNES
   Flores-Moreno I, 2015, BRIT J OPHTHALMOL, V99, P1260, DOI 10.1136/bjophthalmol-2014-306422
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Giani A, 2011, RETINA-J RET VIT DIS, V31, P942, DOI 10.1097/IAE.0b013e31820a68cc
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Guyer DR, 1996, ARCH OPHTHALMOL-CHIC, V114, P693, DOI 10.1001/archopht.1996.01100130685008
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jhaveri CD., 2019, ASRS 37 ANN SCI M CH
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Klimscha S, 2017, INVEST OPHTH VIS SCI, V58, P4039, DOI 10.1167/iovs.16-20201
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koustenis A, 2017, BRIT J OPHTHALMOL, V101, P16, DOI 10.1136/bjophthalmol-2016-309389
   Kramann CA, 2012, ACTA OPHTHALMOL, V90, P487, DOI 10.1111/j.1755-3768.2010.01952.x
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lam WC, 2020, CAN J OPHTHALMOL, V55, P199, DOI 10.1016/j.jcjo.2019.10.011
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Meira J, 2020, CLIN OPHTHALMOL, V14, P171, DOI 10.2147/OPTH.S234858
   Michalewski J, 2014, CAN J OPHTHALMOL, V49, P339, DOI 10.1016/j.jcjo.2014.04.018
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Montero JA, 2009, EUR J OPHTHALMOL, V19, P448, DOI 10.1177/112067210901900320
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Novartis AG., BEOVU BROLUCIZUMAB G
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Rangasamy S, 2011, INVEST OPHTH VIS SCI, V52, P3784, DOI 10.1167/iovs.10-6386
   Regillo CD, 1998, OPHTHALMOLOGY, V105, P1821, DOI 10.1016/S0161-6420(98)91022-3
   Roche, 2020, PHAS 3 DAT SHOW ROCH
   Rodriguez FJ, 2018, GRAEF ARCH CLIN EXP, V256, P2019, DOI 10.1007/s00417-018-4109-3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sasaki M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186955
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Seidel G, 2013, ACTA OPHTHALMOL, V91, pe482, DOI 10.1111/aos.12111
   Sharma A, 2020, EYE, V34, P424, DOI 10.1038/s41433-019-0582-0
   Silva N, 2020, CASE REP OPHTHALM, V11, P493, DOI 10.1159/000509139
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Soomro T, 2018, EYE, V32, P662, DOI 10.1038/eye.2018.2
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Vardarinos A, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0451-1
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
   Zhao Z, 2019, OPHTHALMOLOGICA, V242, P178, DOI 10.1159/000497491
NR 92
TC 1
Z9 1
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD SEP
PY 2021
VL 244
IS 4
BP 265
EP 280
DI 10.1159/000516108
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UL6QG
UT WOS:000692773000002
PM 33823520
OA Bronze
DA 2022-11-30
ER

PT J
AU Hu, P
   Herrmann, R
   Bednar, A
   Saloupis, P
   Dwyer, MA
   Yang, P
   Qi, XP
   Thomas, RS
   Jaffe, GJ
   Boulton, ME
   McDonnell, DP
   Malek, G
AF Hu, Peng
   Herrmann, Rolf
   Bednar, Amanda
   Saloupis, Peter
   Dwyer, Mary A.
   Yang, Ping
   Qi, Xiaoping
   Thomas, Russell S.
   Jaffe, Glenn J.
   Boulton, Michael E.
   McDonnell, Donald P.
   Malek, Goldis
TI Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix
   metabolism and age-related macular degeneration-like pathology
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE retinal pigment epithelium; retinal disease; toxin metabolism; oxidized
   low density lipoprotein
ID DIOXIN RECEPTOR; DRUSEN; MODEL; DENSITY; GENE; PATHOGENESIS;
   DYSFUNCTION; PROGRESSION; ASSOCIATION; INHIBITION
AB The aryl hydrocarbon receptor (AhR) is a nuclear receptor that regulates xenobiotic metabolism and detoxification. Herein, we report a previously undescribed role for the AhR signaling pathway as an essential defense mechanism in the pathogenesis of early dry age-related macular degeneration (AMD), the leading cause of vision loss in the elderly. We found that AhR activity and protein levels in human retinal pigment epithelial (RPE) cells, cells vulnerable in AMD, decrease with age. This finding is significant given that age is the most established risk factor for development of AMD. Moreover, AhR(-/-) mice exhibit decreased visual function and develop dry AMD-like pathology, including disrupted RPE cell tight junctions, accumulation of RPE cell lipofuscin, basal laminar and linear-like deposit material, Bruch's membrane thickening, and progressive RPE and choroidal atrophy. High-serum low-density lipoprotein levels were also observed in AhR(-/-) mice. In its oxidized form, this lipoprotein can stimulate increased secretion of extracellular matrix molecules commonly found in deposits from RPE cells, in an AhR-dependent manner. This study demonstrates the importance of cellular clearance via the AhR signaling pathway in dry AMD pathogenesis, implicating AhR as a potential target, and the mouse model as a useful platform for validating future therapies.
C1 [Hu, Peng; Herrmann, Rolf; Bednar, Amanda; Saloupis, Peter; Yang, Ping; Jaffe, Glenn J.; Malek, Goldis] Duke Univ, Dept Ophthalmol, Durham, NC 27710 USA.
   [Malek, Goldis] Duke Univ, Dept Pathol, Durham, NC 27710 USA.
   [Dwyer, Mary A.; McDonnell, Donald P.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
   [Qi, Xiaoping; Boulton, Michael E.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.
   [Thomas, Russell S.] Hamner Inst Hlth Sci, Res Triangle Pk, NC 27709 USA.
C3 Duke University; Duke University; Duke University; State University
   System of Florida; University of Florida; The Hamner Institutes for
   Health Sciences
RP Malek, G (通讯作者)，Duke Univ, Dept Ophthalmol, Durham, NC 27710 USA.
EM gmalek@duke.edu
OI Thomas, Russell/0000-0002-2340-0301; Malek, Goldis/0000-0003-0026-2388
FU US National Institutes of Health [EY02868, P30 EY005722, EY019688,
   EY021626, DK48807]; Research to Prevent Blindness, Inc.; American Health
   Assistance Research Foundation-Macular Degeneration; RPB Special
   Scholars Award; Alcon Young Investigator Award; NATIONAL EYE INSTITUTE
   [P30EY005722, R01EY020868, R21EY021626, R01EY019688] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [R01DK048807, R37DK048807] Funding Source: NIH RePORTER
FX We thank the North Carolina Eye Bank, the eye donors, and their families
   for their generosity. We give sincere thanks to Drs. Steven Fliesler,
   Boris Reidel, and Joel Meyer for scientific discussions and helpful
   comments, Dr. Ying Hao for assistance with electron microscopy, Dr.
   Mayur Choudhary for technical assistance, Mr. Jim Ahrendsen and Mr.
   Scott Johnston from Phoenix Research Laboratories for support with
   brightfield and OCT imaging of mice, and Dr. Chad Grotegut for
   assistance with the cigarette smoke extract protocol. This work was
   supported by the US National Institutes of Health Grants EY02868 (to G.
   M.), P30 EY005722 (to Duke Eye Center), EY019688 and EY021626 (to M. E.
   B.), and DK48807 (to D. P. M.), by Research to Prevent Blindness, Inc.
   (RPB) core grants to the Duke Eye Center, by the American Health
   Assistance Research Foundation-Macular Degeneration (G. M.), by an RPB
   Special Scholars Award (to G. M.), and by an Alcon Young Investigator
   Award (to G. M.).
CR Abdelsamie SA, 2011, CLIN IMMUNOL, V139, P258, DOI 10.1016/j.clim.2011.01.016
   Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Angrish MM, 2013, TOXICOL SCI, V131, P108, DOI 10.1093/toxsci/kfs277
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084
   Chevallier A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053520
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   De Abrew KN, 2010, TOXICOL SCI, V118, P454, DOI 10.1093/toxsci/kfq265
   de Souza AR, 2011, J BIOL CHEM, V286, P43214, DOI 10.1074/jbc.M111.258764
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   DuSell CD, 2010, MOL ENDOCRINOL, V24, P33, DOI 10.1210/me.2009-0339
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Herrmann R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027573
   Hillegass JM, 2006, BIOL CHEM, V387, P1159, DOI 10.1515/BC.2006.144
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   JAFFE GJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P1163, DOI 10.1001/archopht.1990.01070100119046
   JIMI S, 1995, ATHEROSCLEROSIS, V116, P15, DOI 10.1016/0021-9150(95)05515-X
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Kung T, 2009, BIOCHEM PHARMACOL, V77, P536, DOI 10.1016/j.bcp.2008.09.031
   Lahvis GP, 2005, MOL PHARMACOL, V67, P714, DOI 10.1124/mol.104.008888
   Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8
   Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev
   Lee JH, 2010, GASTROENTEROLOGY, V139, P653, DOI 10.1053/j.gastro.2010.03.033
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   McIntosh BE, 2010, ANNU REV PHYSIOL, V72, P625, DOI 10.1146/annurev-physiol-021909-135922
   McMillan BJ, 2007, P NATL ACAD SCI USA, V104, P1412, DOI 10.1073/pnas.0607296104
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683
   Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sato S, 2008, TOXICOL APPL PHARM, V229, P10, DOI 10.1016/j.taap.2007.12.029
   Savouret JF, 2001, J BIOL CHEM, V276, P3054, DOI 10.1074/jbc.M005988200
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shin S, 2007, MOL CELL BIOL, V27, P7188, DOI 10.1128/MCB.00915-07
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Tanos R, 2012, TOXICOL SCI, V129, P372, DOI 10.1093/toxsci/kfs204
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yin LL, 2011, CURR EYE RES, V36, P379, DOI 10.3109/02713683.2010.537427
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 58
TC 65
Z9 65
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 22
PY 2013
VL 110
IS 43
BP E4069
EP E4078
DI 10.1073/pnas.1307574110
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 238JU
UT WOS:000325943300006
PM 24106308
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Leat, SJ
   Si, FF
   Gold, D
   Pickering, D
   Gordon, K
   Hodge, W
AF Leat, Susan J.
   Si, Francis Fengqin
   Gold, Deborah
   Pickering, Dawn
   Gordon, Keith
   Hodge, William
TI The Experience of a Randomized Clinical Trial of Closed-Circuit
   Television Versus Eccentric Viewing Training for People with Age-Related
   Macular Degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID LOW-VISION REHABILITATION; INTERVENTION TRIAL; SCOTOMAS; FIXATION;
   SERVICES; DISEASE
AB Introduction: In addition to optical devices, closed-circuit televisions (CCTVs) and eccentric viewing training are both recognized interventions to improve reading performance in individuals with vision loss secondary to age-related macular degeneration. Both are relatively expensive, however, either in the cost of the device or in the amount of time personnel need to provide training. In this randomized trial, we compared the effectiveness of these two interventions. Methods: Participants with age-related macular degeneration and visual acuity between 6/48 (20/160) and 6/120 (20/400) first received basic low vision care, including optical devices. At the subsequent baseline visit, they undertook a battery of measures including logMAR visual acuity; reading speed and accuracy for text in 1.3M and 1M fonts; reading information on medicine bottles, utility bills, and food packages; the NEI-VFQ; the Geriatric Depression Scale; and a reading inventory questionnaire. They were then randomized to either obtaining a CCTV for home use or eccentric viewing training over the following six weeks. Results: Recruitment was more difficult than expected for this population. Of 145 patients referred, 29 met the inclusion-exclusion criteria, 14 were willing to enroll, and 10 completed the trial. For the primary outcome (reading speed for 1.3M print), there was a significant improvement between baseline and outcome for the CCTV group (p = 0.005), but not for the eccentric viewing training group (p = 0.28), and the CCTV group showed significantly greater change (p = 0.04). There was a nonsignificant improvement in reading speed for 1M text and a decrease in the amount of time taken to read utility bill information in the CCTV group. There was a significant improvement in near visual acuity with current glasses with eccentric viewing training. The other measures did not reach statistical significance. Discussion: Randomized clinical trials for low vision rehabilitation, particularly in the elderly population with vision loss, are challenging, but such trials are important for the allocation of resources. This trial showed early indications of more impact on reading performance from CCTV than eccentric viewing training.
C1 [Leat, Susan J.] Univ Waterloo, Sch Optometry & Vis Sci, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
   [Si, Francis Fengqin] Western Univ, Family Med, SJFMC, 346 Platts Lane, London, ON N6G 1J1, Canada.
   [Gold, Deborah] BALANCE Blind Adults, Crossways Complex,2340 Dundas St West,Unit G-06, Toronto, ON M6P 4A9, Canada.
   [Pickering, Dawn] CARF, 1 Yonge St,Suite 1801, Toronto, ON M5E 1W7, Canada.
   [Gordon, Keith] CNIB, 1929 Bayview Ave, Toronto, ON M4G 3E8, Canada.
   [Hodge, William] Western Univ, Ophthalmol & Epidemiol, 268 Grosvenor St, London, ON N4A 4V2, Canada.
C3 University of Waterloo; Western University (University of Western
   Ontario); Western University (University of Western Ontario)
RP Leat, SJ (通讯作者)，Univ Waterloo, Sch Optometry & Vis Sci, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
EM leat@uwaterloo.ca; francie.si@lhsc.on.ca; d.gold@balancefba.org;
   dpickering@carf.org; keith.gordon@cnib.ca; whodgemd1@yahoo.ca
OI Leat, Susan/0000-0002-7082-035X
FU Lawson Research Institute in London, Ontario [Lawson IRF-063-08]; Lawson
   Research Institute in London, Ontario (SJHC Foundation-Jarmain Family
   Fund)
FX Funded by Lawson Research Institute in London, Ontario (Lawson
   IRF-063-08 and SJHC Foundation-Jarmain Family Fund). Our thanks go to
   Shampa Bose for coordinating the study and Julia Baryla (University of
   Western Ontario), Jane Chen, Susan Nieto, Suzanne Decary and Roxanne
   Hazell at CNIB (formerly Canadian National Institute for the Blind),
   Toronto, and Lisa Hamm, Betty Leeson, Sherry Malcho at CNIB, London,
   Ontario, for help in recruiting participants and collecting data. Alex
   Mao aided with data analysis and Optelec contributed towards the cost of
   CCTVs.
CR ClinicalTrials.gov, 2017, LOW VIS STUD COMP EV
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Dougherty BE, 2009, OPTOMETRY VISION SCI, V86, P955, DOI 10.1097/OPX.0b013e3181b180a6
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Fine EM, 1999, VISION RES, V39, P1039, DOI 10.1016/S0042-6989(98)00208-9
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Gaffney AJ, 2014, OPHTHAL PHYSL OPT, V34, P427, DOI 10.1111/opo.12132
   Goodrich G L, 2001, Optometry, V72, P519
   Goodrich GL, 2006, J VISUAL IMPAIR BLIN, V100, P164
   Hamade N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159254
   Kasten E, 2010, J VISUAL IMPAIR BLIN, V104, P303, DOI 10.1177/0145482X1010400506
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Leat SJ, 2016, OPTOMETRY VISION SCI, V93, P77, DOI 10.1097/OPX.0000000000000750
   Lovie-Kitchin J, 2011, CLIN EXP OPTOM, V94, P121, DOI 10.1111/j.1444-0938.2010.00565.x
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Ontario Ministry of Health and Long Term Care, 2008, ASS DEV PROGR
   Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55
   Peterson RC, 2003, AM J OPHTHALMOL, V136, P1129, DOI 10.1016/S0002-9394(03)00567-1
   Petre KL, 2000, OPTOMETRY VISION SCI, V77, P34, DOI 10.1097/00006324-200001000-00011
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Stelmack JA, 2004, J REHABIL RES DEV, V41, P729, DOI 10.1682/JRRD.2003.08.0136
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Stelmack JA, 2012, ARCH OPHTHALMOL-CHIC, V130, P1162, DOI 10.1001/archophthalmol.2012.1820
   Verdina T, 2013, EUR J OPHTHALMOL, V23, P723, DOI 10.5301/ejo.5000291
   Vukicevic M., 2005, INT C SERIES, V1282, P544, DOI DOI 10.1016/j.ics.2005.04.024
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
NR 28
TC 3
Z9 3
U1 0
U2 11
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY
   10121 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD JUL-AUG
PY 2017
VL 111
IS 4
BP 354
EP 368
PG 15
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA FC5XJ
UT WOS:000406914700005
DA 2022-11-30
ER

PT J
AU Veritti, D
   Sarao, V
   Soppelsa, V
   Danese, C
   Chhablani, J
   Lanzetta, P
AF Veritti, Daniele
   Sarao, Valentina
   Soppelsa, Valentina
   Danese, Carla
   Chhablani, Jay
   Lanzetta, Paolo
TI Managing Neovascular Age-Related Macular Degeneration in Clinical
   Practice: Systematic Review, Meta-Analysis, and Meta-Regression
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE aflibercept; age-related macular degeneration; anti-VEGF; bevacizumab;
   brolucizumab; meta-analysis; meta-regression; ranibizumab
ID TREAT-AND-EXTEND; ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE
   TOMOGRAPHY; VISUAL-ACUITY OUTCOMES; PIGMENT EPITHELIAL DETACHMENTS;
   PRO-RE-NATA; INTRAVITREAL RANIBIZUMAB TREATMENT; TREATMENT-NAIVE
   PATIENTS; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; FLUENCE PHOTODYNAMIC
   THERAPY
AB The use of anti-vascular endothelial growth factor (VEGF) agents has profoundly changed the prognosis of neovascular age-related macular degeneration (nAMD). As clinical experiences have accumulated, it has become mandatory to summarize data to give information that can be useful in everyday practice. We conducted a systematic review to identify randomized controlled trials (RCTs) and observational studies that reported 12-month changes in best-corrected visual acuity (BCVA) in patients with nAMD on anti-VEGF monotherapy. Data were analyzed in a random-effects meta-analysis with BCVA change as the primary outcome. Meta-regression was conducted to evaluate the impact of multiple covariates. Four hundred and twelve heterogeneous study populations (109,666 eyes) were included. Anti-VEGFs induced an overall improvement of +5.37 ETDRS letters at 12 months. Meta-regression showed that mean BCVA change was statistically greater for RCTs (p = 0.0032) in comparison with observational studies. Populations following a proactive regimen had better outcomes than those following a reactive treatment regimen. Mean BCVA change was greater in younger populations, with lower baseline BCVA and treated with a higher number of injections (p < 0.001). Our results confirm that anti-VEGFs may produce a significant functional improvement at 12 months in patients with nAMD.
C1 [Veritti, Daniele; Sarao, Valentina; Soppelsa, Valentina; Danese, Carla; Lanzetta, Paolo] Univ Udine, Dept Med Ophthalmol, I-33100 Udine, Italy.
   [Sarao, Valentina; Lanzetta, Paolo] Ist Europeo Microchirurg Oculare IEMO, I-33100 Udine, Italy.
   [Chhablani, Jay] Univ Pittsburgh, Sch Med, Med Retina & Vitreoretinal Surg, Pittsburgh, PA 15261 USA.
C3 University of Udine; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Med Ophthalmol, I-33100 Udine, Italy.; Lanzetta, P (通讯作者)，Ist Europeo Microchirurg Oculare IEMO, I-33100 Udine, Italy.
EM daniele.veritti@uniud.it; valentina.sarao@uniud.it;
   soppelsa.valentina@spes.uniud.it; carla.danese@gmail.com;
   jay.chhablani@gmail.com; paolo.lanzetta@uniud.it
RI Danese, Carla/AHE-2872-2022
OI Danese, Carla/0000-0001-7603-7502; Sarao, Valentina/0000-0003-0041-5073;
   Lanzetta, Paolo/0000-0003-3746-141X; Chhablani, Jay/0000-0003-1772-3558
CR Abdin AD, 2019, GRAEF ARCH CLIN EXP, V257, P1671, DOI 10.1007/s00417-019-04360-9
   Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Alkin Z, 2013, SCI WORLD J, DOI 10.1155/2013/958724
   Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Amarakoon S, 2019, ACTA OPHTHALMOL, V97, P107, DOI 10.1111/aos.13774
   Arai Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229342
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Arias L, 2009, RETINA-J RET VIT DIS, V29, P1444, DOI 10.1097/IAE.0b013e3181ae712d
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Aurell S, 2019, ACTA OPHTHALMOL, V97, P519, DOI 10.1111/aos.13989
   Axer-Siegel R, 2012, RETINA-J RET VIT DIS, V32, P1811, DOI 10.1097/IAE.0b013e31825db771
   Baek JS, 2013, RETINA-J RET VIT DIS, V33, P467, DOI 10.1097/IAE.0b013e3182753b2a
   Bandello F, 2016, BRIT J OPHTHALMOL, V100, P1611, DOI 10.1136/bjophthalmol-2016-308400
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Barakat A, 2018, J FR OPHTALMOL, V41, P603, DOI 10.1016/j.jfo.2018.01.005
   Barikian A, 2015, AM J OPHTHALMOL, V159, P131, DOI 10.1016/j.ajo.2014.10.005
   Basheer K, 2015, CLIN OPHTHALMOL, V9, P959, DOI 10.2147/OPTH.S76754
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bellerive C, 2012, CAN J OPHTHALMOL, V47, P165, DOI 10.1016/j.jcjo.2012.01.011
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bohni SC, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0101-4
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Jelstrup AB, 2020, OPHTHALMOLOGICA, V243, P461, DOI 10.1159/000508902
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Calvo P, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/820605
   Canan H, 2014, CLIN INTERV AGING, V9, P141, DOI 10.2147/CIA.S56863
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Castro-Navarro V, 2017, Arch Soc Esp Oftalmol, V92, P112, DOI 10.1016/j.oftal.2016.09.005
   Cebeci Z, 2018, INT J OPHTHALMOL-CHI, V11, P267, DOI 10.18240/ijo.2018.02.15
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Chatziralli I, 2018, EYE, V32, P1523, DOI 10.1038/s41433-018-0114-3
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Chew JK, 2017, OPHTHALMOLOGICA, V238, P23, DOI 10.1159/000469652
   Chhablani J, 2012, RETINA-J RET VIT DIS, V32, P1465, DOI 10.1097/IAE.0b013e3182475aea
   Chiam PJ, 2016, INT J OPHTHALMOL-CHI, V9, P551, DOI 10.18240/ijo.2016.04.12
   Cho HJ, 2017, J OCUL PHARMACOL TH, V33, P452, DOI 10.1089/jop.2016.0178
   Cho HJ, 2016, RETINA-J RET VIT DIS, V36, P1851, DOI 10.1097/IAE.0000000000001009
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   Chrapek O, 2015, BIOMED PAP, V159, P407, DOI 10.5507/bp.2015.017
   Clemens CR, 2017, ACTA OPHTHALMOL, V95, P683, DOI 10.1111/aos.13359
   Coco RM, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-138
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Cohen SY, 2014, OPHTHALMOLOGICA, V231, P80, DOI 10.1159/000356401
   Coscas F, 2012, RETINA-J RET VIT DIS, V32, P1069, DOI 10.1097/IAE.0b013e318240a529
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Datseris I, 2015, SEMIN OPHTHALMOL, V30, P112, DOI 10.3109/08820538.2013.833268
   De Bats F, 2012, J FR OPHTALMOL, V35, P661, DOI 10.1016/j.jfo.2012.01.015
   de Massougnes S, 2018, RETINA-J RET VIT DIS, V38, P717, DOI 10.1097/IAE.0000000000001613
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Veloso CED, 2014, OPHTHALMIC RES, V51, P1, DOI 10.1159/000354328
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Duval MV, 2017, J FR OPHTALMOL, V40, P270, DOI 10.1016/j.jfo.2016.11.012
   Ebneter A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76354-1
   El-Mollayess GM, 2013, RETINA-J RET VIT DIS, V33, P1828, DOI 10.1097/IAE.0b013e3182877a0d
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   Eldem BM, 2015, ACTA OPHTHALMOL, V93, pE458, DOI 10.1111/aos.12540
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Epstein D, 2016, RETINA-J RET VIT DIS, V36, P1773, DOI 10.1097/IAE.0000000000000978
   Erden B, 2020, INT J OPHTHALMOL-CHI, V13, P104, DOI 10.18240/ijo.2020.01.15
   Feng XF, 2011, INT J OPHTHALMOL-CHI, V4, P85, DOI 10.3980/j.issn.2222-3959.2011.01.20
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Figueras-Roca M, 2021, GRAEF ARCH CLIN EXP, V259, P1463, DOI 10.1007/s00417-020-05016-9
   Figurska M, 2020, EUR J OPHTHALMOL, V30, P586, DOI 10.1177/1120672119874598
   Figurska M, 2012, MED SCI MONITOR, V18, pCR32, DOI 10.12659/MSM.882198
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Fulcher C, 2020, EUR J OPHTHALMOL, V30, P543, DOI 10.1177/1120672119839299
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Galvez MIL, 2020, ACTA OPHTHALMOL, V98, pE820, DOI 10.1111/aos.14399
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P773, DOI 10.1089/jop.2017.0006
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P567, DOI 10.1089/jop.2017.0031
   Gascon P, 2022, EUR J OPHTHALMOL, V32, P356, DOI 10.1177/11206721211005703
   Giacomelli Giovanni, 2014, Retina, V34, P860, DOI 10.1097/IAE.0000000000000007
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Grenga PL, 2013, CAN J OPHTHALMOL, V48, P394, DOI 10.1016/j.jcjo.2013.04.006
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Habibi I, 2016, KLIN MONATSBL AUGENH, V233, P465, DOI 10.1055/s-0041-111801
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P1320, DOI 10.1097/IAE.0000000000001370
   Hatz K, 2017, RETINA-J RET VIT DIS, V37, P1185, DOI 10.1097/IAE.0000000000001318
   Hautamaki A, 2016, RETINA-J RET VIT DIS, V36, P2183, DOI 10.1097/IAE.0000000000001061
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Horner F, 2019, CLIN OPHTHALMOL, V13, P2461, DOI 10.2147/OPTH.S218378
   Husum YS, 2021, ACTA OPHTHALMOL, V99, pE1354, DOI 10.1111/aos.14825
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   Inan S, 2019, CURR EYE RES, V44, P908, DOI 10.1080/02713683.2019.1600195
   Inan UU, 2019, INT OPHTHALMOL, V39, P2721, DOI 10.1007/s10792-019-01116-6
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Inoue M, 2014, CLIN OPHTHALMOL, V8, P1711, DOI 10.2147/OPTH.S68293
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Iordanous Y, 2014, CAN J OPHTHALMOL, V49, P367, DOI 10.1016/j.jcjo.2014.05.010
   Itagaki K, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01542-6
   Ito A, 2017, OPHTHALMOLOGICA, V238, P236, DOI 10.1159/000479937
   Jaggi D, 2022, BRIT J OPHTHALMOL, V106, P246, DOI 10.1136/bjophthalmol-2020-316514
   Jain N, 2017, ASIA-PAC J OPHTHALMO, V6, P488, DOI 10.22608/APO.2017125
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Rodriguez FJ, 2019, TAIWAN J OPHTHALMOL, V9, P243, DOI 10.4103/tjo.tjo_72_19
   Kalouda P, 2015, SEMIN OPHTHALMOL, V30, P6, DOI 10.3109/08820538.2013.807852
   Kang S, 2011, JPN J OPHTHALMOL, V55, P123, DOI 10.1007/s10384-010-0910-1
   Karagiannis D, 2017, CLIN INTERV AGING, V12, P1829, DOI 10.2147/CIA.S145893
   Kato A, 2015, OPHTHALMOLOGICA, V233, P27, DOI 10.1159/000368249
   Katz G, 2012, RETINA-J RET VIT DIS, V32, P293, DOI 10.1097/IAE.0b013e31821e20b0
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Kim M, 2016, INDIAN J OPHTHALMOL, V64, P427, DOI 10.4103/0301-4738.187659
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kodjikian L, 2018, RETINA-J RET VIT DIS, V38, P1492, DOI 10.1097/IAE.0000000000001736
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koizumi H, 2020, JPN J OPHTHALMOL, V64, P338, DOI 10.1007/s10384-020-00745-0
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kucuk B, 2018, INT J OPHTHALMOL-CHI, V11, P645, DOI 10.18240/ijo.2018.04.18
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Kwon OW, 2012, GRAEF ARCH CLIN EXP, V250, P1467, DOI 10.1007/s00417-012-1970-3
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Leung King Fai Calvin, 2018, Vision (Basel), V2, DOI 10.3390/vision2010005
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Maberley DAL, 2018, CAN J OPHTHALMOL, V53, P627, DOI 10.1016/j.jcjo.2018.01.013
   Makri OE, 2019, HELL J NUCL MED, V22, P55
   Makri OE, 2017, OPEN OPHTHALMOL J, V11, P368, DOI 10.2174/1874364101711010368
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Michalewski J, 2014, INDIAN J OPHTHALMOL, V62, P554, DOI 10.4103/0301-4738.133485
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P1911, DOI 10.1097/IAE.0000000000003128
   Modjtahedi BS, 2020, CLIN OPHTHALMOL, V14, P187, DOI 10.2147/OPTH.S228618
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   Mori R, 2017, OPHTHALMOLOGICA, V238, P17, DOI 10.1159/000468950
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nemcansky J, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/2635689
   Nghiem-Buffet S, 2017, RETINA-J RET VIT DIS, V37, P53, DOI 10.1097/IAE.0000000000001134
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Nishimura T, 2020, DOC OPHTHALMOL, V141, P137, DOI 10.1007/s10633-020-09758-z
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Nunes RP, 2019, ARQ BRAS OFTALMOL, V82, P225, DOI 10.5935/0004-2749.20190043
   Oca LuYzaro AI., 2019, ARCH SOC ESP OFTALMO, V94, P430, DOI DOI 10.1016/J.OFTAL.2019.05.007
   Ogasawara M, 2018, JPN J OPHTHALMOL, V62, P584, DOI 10.1007/s10384-018-0605-6
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Ono A, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011737
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Ozkaya Abdullah, 2017, Korean J Ophthalmol, V31, P424, DOI 10.3341/kjo.2016.0125
   Ozkaya A, 2015, SAUDI J OPHTHALMOL, V29, P182, DOI 10.1016/j.sjopt.2014.12.002
   Ozkaya A, 2014, NEPAL J OPHTHALMOL, V6, P145, DOI 10.3126/nepjoph.v6i2.11706
   Ozkaya A, 2013, J OCUL PHARMACOL TH, V29, P865, DOI 10.1089/jop.2013.0106
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Papavasileiou E, 2015, HELL J NUCL MED, V18, P29
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Providencia J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9276580
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Raja MSA, 2010, BRIT J OPHTHALMOL, V94, P1543, DOI 10.1136/bjo.2009.174763
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rasmussen A, 2017, ACTA OPHTHALMOL, V95, P128, DOI 10.1111/aos.13233
   Razi F, 2016, CLIN OPHTHALMOL, V10, P313, DOI 10.2147/OPTH.S97775
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reinsberg M, 2017, CLIN OPHTHALMOL, V11, P621, DOI 10.2147/OPTH.S123513
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Rudnisky CJ, 2010, RETINA-J RET VIT DIS, V30, P548, DOI 10.1097/IAE.0b013e3181bcf1b8
   Rush RB, 2016, ASIA-PAC J OPHTHALMO, V5, P171, DOI 10.1097/APO.0000000000000157
   Rush RB, 2014, AM J OPHTHALMOL, V158, P337, DOI 10.1016/j.ajo.2014.05.007
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Sakai T, 2018, CLIN OPHTHALMOL, V12, P719, DOI 10.2147/OPTH.S156162
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Sawada T, 2014, GRAEF ARCH CLIN EXP, V252, P1545, DOI 10.1007/s00417-014-2612-8
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scholler A, 2014, WIEN KLIN WOCHENSCHR, V126, P355, DOI 10.1007/s00508-014-0539-z
   Selid PD, 2014, OSLI RETINA, V45, P275, DOI 10.3928/23258160-20140709-03
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singh SR, 2020, BRIT J OPHTHALMOL, V104, P678, DOI 10.1136/bjophthalmol-2019-314542
   Smit C, 2018, J COMP EFFECT RES, V7, P561, DOI 10.2217/cer-2017-0099
   Sodhi SK, 2021, INT OPHTHALMOL, V41, P1697, DOI 10.1007/s10792-021-01726-z
   Sonmez K, 2011, RETINA-J RET VIT DIS, V31, P645, DOI 10.1097/IAE.0b013e3182012d18
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Stepanov A, 2021, EUR J OPHTHALMOL, V31, P2488, DOI 10.1177/1120672120971190
   Studnicka J, 2013, OPHTHALMOLOGICA, V230, P34, DOI 10.1159/000350802
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Sul S, 2019, TURK OFTALMOL DERG, V49, P15, DOI 10.4274/tjo.galenos.2018.76429
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Suzuki M, 2010, JPN J OPHTHALMOL, V54, P124, DOI 10.1007/s10384-009-0775-3
   Taipale C, 2020, ADV THER, V37, P2256, DOI 10.1007/s12325-020-01312-2
   Takahashi M, 2010, JPN J OPHTHALMOL, V54, P565, DOI 10.1007/s10384-010-0864-3
   Takayama K, 2017, OPHTHALMOLOGICA, V237, P105, DOI 10.1159/000461785
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tarakcioglu HN, 2019, J FR OPHTALMOL, V42, P22, DOI 10.1016/j.jfo.2018.06.005
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Tsunekawa Y, 2021, JPN J OPHTHALMOL, V65, P69, DOI 10.1007/s10384-020-00783-8
   Tuerksever C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86348-2
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Udaondo P, 2016, OPHTHALMOLOGICA, V236, P29, DOI 10.1159/000445724
   Unsal E, 2019, J CURR OPHTHALMOL, V31, P66, DOI 10.1016/j.joco.2018.11.002
   Vardarinos A, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0451-1
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Verbraak FD, 2021, ACTA OPHTHALMOL, V99, pE884, DOI 10.1111/aos.14712
   Veritti D, 2019, RETINA-J RET VIT DIS, V39, P2077, DOI 10.1097/IAE.0000000000002299
   Veritti D, 2017, EUR J OPHTHALMOL, V27, P74, DOI 10.5301/ejo.5000880
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Veritti D, 2013, RETINA-J RET VIT DIS, V33, P982, DOI 10.1097/IAE.0b013e31826d8ff4
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wakuta M, 2020, GRAEF ARCH CLIN EXP, V258, P1663, DOI 10.1007/s00417-020-04745-1
   Wang FH, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/7530458
   Warwick AN, 2016, INT J OPHTHALMOL-CHI, V9, P1156, DOI 10.18240/ijo.2016.08.12
   Weingessel B, 2012, WIEN KLIN WOCHENSCHR, V124, P750, DOI 10.1007/s00508-012-0249-3
   Westborg I, 2017, RETINA-J RET VIT DIS, V37, P2035, DOI 10.1097/IAE.0000000000001431
   Wickremasinghe SS, 2012, EYE, V26, P958, DOI 10.1038/eye.2012.72
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Williams GS, 2015, SAUDI J OPHTHALMOL, V29, P187, DOI 10.1016/j.sjopt.2015.02.004
   Williams PD, 2012, CLIN OPHTHALMOL, V6, P1519, DOI 10.2147/OPTH.S31010
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wu WC, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01715-3
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
   Yamamoto A, 2013, CLIN OPHTHALMOL, V7, P757, DOI 10.2147/OPTH.S42189
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yang Y, 2017, OPHTHALMOL THER, V6, P175, DOI 10.1007/s40123-017-0091-9
   Yildirim S, 2018, TURK OFTALMOL DERG, V48, P27, DOI 10.4274/tjo.44370
   Zhao C, 2016, MED SCI MONITOR, V22, P833, DOI 10.12659/MSM.895528
   Zhao JL, 2014, BIODRUGS, V28, P527, DOI 10.1007/s40259-014-0106-1
NR 282
TC 2
Z9 2
U1 4
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JAN
PY 2022
VL 11
IS 2
AR 325
DI 10.3390/jcm11020325
PG 22
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YL6MM
UT WOS:000746003200001
PM 35054021
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dunaief, JL
AF Dunaief, Joshua L.
TI Iron induced oxidative damage as a potential factor in age-related
   macular degeneration: The Cogan Lecture
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; TRANSFERRIN RECEPTOR; PIGMENTARY DEGENERATION;
   RETINAL DEGENERATION; INCREASED EXPRESSION; PHOTIC INJURY; RABBIT EYE;
   CERULOPLASMIN; ACERULOPLASMINEMIA; DISEASE
AB Iron is a potent generator of oxidative damage whose levels increase with age, potentially exacerbating age-related diseases. Several lines of evidence suggest that iron accumulation may be a factor in age-related macular degeneration (AMD). AMD retinas have more iron within the photoreceptors, RPE, and drusen than do age-matched control retinas. Accelerated AMD-like maculopathy develops in patients with retinal iron overload from the hereditary disease aceruloplasminemia. Mice with retinal iron overload resulting from knockout of ceruloplasmin and its homologue hephaestin exhibit retinal degeneration with some features of AMD, including subretinal neovascularization, accumulation of RPE lipofuscin and sub-RPE deposits, and RPE/photoreceptor death. Increased understanding of the mechanisms of retinal iron homeostasis may help in the development of therapies to prevent iron overload. For example, herein it is shown that one regulator of systemic iron homeostasis, HFE, is expressed in the RPE. Thus, patients with the common disease hereditary hemochromatosis, which is often caused by an HFE mutation, may have retinal iron overload predisposing to AMD. Preliminary data suggest that iron chelation can reduce RPE iron overload in mice and protect them from degeneration, suggesting that iron-binding drugs may one day prove useful in reducing RPE oxidative stress and decreasing the risk of AMD progression.
C1 Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，305 Stellar Chance Labs, 422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
FU NEI NIH HHS [EY 015240] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY015240] Funding Source: NIH RePORTER
CR Albert DM, 2000, PRINCIPLES PRACTICE
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ARDEN GB, 1984, BRIT J OPHTHALMOL, V68, P873, DOI 10.1136/bjo.68.12.873
   Bacon B R, 1999, Adv Intern Med, V44, P91
   Burdo JR, 2003, BIOMETALS, V16, P63, DOI 10.1023/A:1020718718550
   Chen L, 2003, MOL VIS, V9, P151
   CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   DAVIES SC, 1983, LANCET, V2, P181
   DAVIS AA, 1993, J CELL PHYSIOL, V156, P280, DOI 10.1002/jcp.1041560209
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   DOLY M, 1986, OPHTHALMIC RES, V18, P21, DOI 10.1159/000265409
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farkas RH, 2004, INVEST OPHTH VIS SCI, V45, P1410, DOI 10.1167/iovs.03-0872
   Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472
   Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298
   Gerhardinger C, 2005, INVEST OPHTH VIS SCI, V46, P349, DOI 10.1167/iovs.04-0860
   Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris ZL, 1998, AM J CLIN NUTR, V67, p972S, DOI 10.1093/ajcn/67.5.972S
   Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989
   LAKHANPAL V, 1984, OPHTHALMOLOGY, V91, P443
   Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4
   Leure-duPree A E, 1987, Prog Clin Biol Res, V247, P517
   Levin LA, 1998, INVEST OPHTH VIS SCI, V39, P157
   LI ZL, 1991, CURR EYE RES, V10, P133, DOI 10.3109/02713689109001741
   MCGAHAN MC, 1986, CURR EYE RES, V5, P641, DOI 10.3109/02713688609015131
   Miyahara T, 2003, INVEST OPHTH VIS SCI, V44, P4347, DOI 10.1167/iovs.02-1032
   Miyajima H, 2002, BLOOD CELL MOL DIS, V29, P433, DOI 10.1006/bcmd.2002.0561
   Moos T, 2002, DAN MED BULL, V49, P279
   NEWELL FW, 1979, AM J OPHTHALMOL, V88, P467, DOI 10.1016/0002-9394(79)90648-2
   OSAKI S, 1966, J BIOL CHEM, V241, P5053
   Patel BN, 2002, J NEUROSCI, V22, P6578
   Perry G, 2002, CNS DRUGS, V16, P339, DOI 10.2165/00023210-200216050-00006
   Rattner A, 2005, J NEUROSCI, V25, P4540, DOI 10.1523/JNEUROSCI.0492-05.2005
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Richardson DR, 2004, ANN NY ACAD SCI, V1012, P326, DOI 10.1196/annals.1306.026
   ROTH AM, 1972, ARCH OPHTHALMOL-CHIC, V87, P507
   Rouault TA, 2001, NAT GENET, V28, P299, DOI 10.1038/91036
   TAWARA A, 1986, INVEST OPHTH VIS SCI, V27, P226
   VERGARA O, 1989, EXP EYE RES, V49, P1115, DOI 10.1016/S0014-4835(89)80030-2
   Waugh WH, 2004, J APPL RES, V4, P208
   WETZEL MG, 1991, EXP EYE RES, V53, P437, DOI 10.1016/0014-4835(91)90161-7
   Yamaguchi K, 1998, OPHTHALMOLOGICA, V212, P11, DOI 10.1159/000027251
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zheng HL, 2005, BIOORGAN MED CHEM, V13, P773, DOI 10.1016/j.bmc.2004.10.037
NR 55
TC 124
Z9 130
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2006
VL 47
IS 11
BP 4660
EP 4664
DI 10.1167/iovs.06-0568
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 098XS
UT WOS:000241557500002
PM 17065470
DA 2022-11-30
ER

PT J
AU Hewitt, AW
   Jeganathan, VS
   Kidd, JE
   Pesudovs, K
   Verma, N
AF Hewitt, Alex W.
   Jeganathan, V. Swetha
   Kidd, Juanita E.
   Pesudovs, Konrad
   Verma, Nitin
TI Influence of photodynamic therapy for age related macular degeneration
   upon subjective vision related quality of life
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularisation; visual disability; Rasch analysis; visual
   function; verteporfin
ID FUNCTION INDEX VF-14; VISUAL FUNCTION; CHOROIDAL NEOVASCULARIZATION;
   5-YEAR INCIDENCE; VERTEPORFIN; IMPAIRMENT; MACULOPATHY; VALIDITY;
   OUTCOMES; ACUITY
AB Background: Photodynamic therapy (PDT) has been used in the treatment of choroidal neovascularisation secondary to age-related macular degeneration (AMD). This study prospectively investigated patients' subjective change in visual function following PDT as treatment for AMD. Methods: Eighty-two consecutive patients receiving PDT in Tasmania, Australia, between May and November 2003 were recruited. In conjunction with a comprehensive clinical examination, the Visual Function-14 (VF-14) questionnaire was administered. Final follow-up occurred between February and March 2005. The VF-14 was scored by traditional summary scoring and by Rasch analysis. Results: Five of the 82 (6.1%) subjects recruited were excluded from analysis. PDT was performed on average 5.7 +/- 2.6 times per patient. Raw VF-14 scores tended towards being significantly lower at follow-up than at baseline (67.6 +/- 27.2 against 64.5 +/- 27.7; P=0.052), and did significantly deteriorate using a collapsed Rasch analysis (P=0.0102). Following treatment, 38 (47.5%) eyes had lost three or more Snellen lines of best-corrected visual acuity. Conclusion: Patients undergoing PDT typically report reasonable visual function. In parallel with visual acuity, self-reported visual function may deteriorate slightly after PDT for AMD, but not as much as reported in untreated AMD.
C1 Royal Hobart Hosp, Dept Ophthalmol, Hobart, Tas 7000, Australia.
   Flinders Med Ctr, Ctr Clin Eye Res, NH&MRC, Dept Ophthalmol, Bedford Pk, SA, Australia.
   Flinders Univ S Australia, Bedford Pk, SA 5042, Australia.
C3 Royal Hobart Hospital; Flinders Medical Centre; Flinders University
   South Australia
RP Hewitt, AW (通讯作者)，Royal Hobart Hosp, Dept Ophthalmol, Hobart, Tas 7000, Australia.
EM hewitt.alex@gmail.com
RI Pesudovs, Konrad/T-9403-2019; Hewitt, Alex W/D-1936-2013
OI Pesudovs, Konrad/0000-0002-6322-9369; Hewitt, Alex W/0000-0002-5123-5999
CR Alonso J, 1997, OPHTHALMOLOGY, V104, P799, DOI 10.1016/S0161-6420(97)30230-9
   ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Essex RW, 2003, CLIN EXP OPHTHALMOL, V31, P476, DOI 10.1046/j.1442-9071.2003.00714.x
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Foran S, 2000, CLIN EXP OPHTHALMOL, V28, P143, DOI 10.1046/j.1442-9071.2000.00292.x
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Krummenauer F, 2005, EUR J OPHTHALMOL, V15, P74, DOI 10.1177/112067210501500112
   Linacre J. M, 2004, FACETS RASCH MEASURE
   LINACRE JM, 1999, J OUTCOME MEAS, V3, P122
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   NORQUIST J, 2005, MED CARE, V42, P125
   Pesudovs K, 2004, OPTOMETRY VISION SCI, V81, P769, DOI 10.1097/00006324-200410000-00009
   Pesudovs K, 2003, INVEST OPHTH VIS SCI, V44, P2892, DOI 10.1167/iovs.02-1075
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   Talks SJ, 2004, EYE, V18, P588, DOI 10.1038/sj.eye.6700709
   Valderas JM, 2004, QUAL LIFE RES, V13, P35, DOI 10.1023/B:QURE.0000015298.09085.b0
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Velozo C A, 2000, J Outcome Meas, V4, P667
   Weih L, 2000, CLIN EXP OPHTHALMOL, V28, P153, DOI 10.1046/j.1442-9071.2000.00303.x
   Wolfe E W, 1999, J Outcome Meas, V3, P134
NR 36
TC 13
Z9 15
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2006
VL 244
IS 8
BP 972
EP 977
DI 10.1007/s00417-005-0218-x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 070XE
UT WOS:000239559000010
PM 16411103
DA 2022-11-30
ER

PT J
AU Zajac-Pytrus, HM
   Pilecka, A
   Turno-Krecicka, A
   Adamiec-Mroczek, J
   Misiuk-Hojlo, M
AF Zajac-Pytrus, Hanna M.
   Pilecka, Agnieszka
   Turno-Krecicka, Anna
   Adamiec-Mroczek, Joanna
   Misiuk-Hojlo, Marta
TI The Dry Form of Age-Related Macular Degeneration (AMD): The Current
   Concepts of Pathogenesis and Prospects for Treatment
SO ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Review
DE dry AMD pathogenesis; dry AMD treatment; dry AMD prophylaxis
ID VITAMIN-D; OIL-SPILL; DRUSEN; HEALTH; OMEGA-3-FATTY-ACIDS; ASSOCIATION;
   BIOLOGY; RISK
AB Age-related macular degeneration (AMD) is a disease that causes varying degrees of blindness, which afflicts millions of adults in their later years. Preliminary changes occur during normal aging, but in some individuals the pathology leads to the development of AMD. The pathology seems to be a mixture of biochemical, cellular, and molecular events. Lipofuscinogenesis and early drusen genesis are in the early stages of AMD and their inhibition or reversal would dramatically increase the quality of vision in elderly people. The disease is characterized by abnormal extracellular deposits, known as drusen, which accumulate along the basal surface of the retinal pigmented epithelium RPE. Widespread drusen deposition is associated with retinal pigmented epithelial cell dysfunction and degeneration of the photoreceptors. Recent studies have shown that drusen contain a variety of immunomodulatory molecules, suggesting that the process of drusen formation involves local inflammatory events, including activation of the complement cascade. Molecular pathways involved in the etiology of this disease and the potential prospects of its treatment will be presented on the basis of the results of the current studies.
C1 [Zajac-Pytrus, Hanna M.; Turno-Krecicka, Anna; Adamiec-Mroczek, Joanna; Misiuk-Hojlo, Marta] Wroclaw Med Univ, Dept Ophthalmol, Borowska 213, PL-50556 Wroclaw, Poland.
   [Pilecka, Agnieszka] Higher Sch Humanities, Leszno, Poland.
C3 Wroclaw Medical University
RP Zajac-Pytrus, HM (通讯作者)，Wroclaw Med Univ, Dept Ophthalmol, Borowska 213, PL-50556 Wroclaw, Poland.
EM hzp@spektrum.wroc.pl
RI Adamiec-Mroczek, Joanna/ABA-1121-2021
OI Adamiec-Mroczek, Joanna/0000-0002-6804-358X; Misiuk - Hojlo,
   Marta/0000-0002-4020-3203; Zajac-Pytrus, Hanna/0000-0003-0165-5108;
   Turno-Krecicka, Anna/0000-0001-6732-1851
CR Armstrong RA, 2009, FOLIA NEUROPATHOL, V47, P289
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Curcio CA, 2012, OPHTHALMOLOGICA, V228, P23
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   DeBlack Susan Sanders, 2003, Optometry, V74, P99
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Kang MY, 2012, ALBUMIN DIFFUSION HU, P215
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee V, 2012, NEUROBIOL AGING
   Merle B, 2012, PLASMA OMEGA 3 FATTY, P370
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Stahl A, 2011, BRIT J OPHTHALMOL, V95, P1496, DOI 10.1136/bjo.2010.194241
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Wang A.L, 2009, PLOS ONE, V4, pe5304, DOI DOI 10.1371/JOURNAL.PONE.0004160
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
NR 33
TC 36
Z9 38
U1 1
U2 17
PU WROCLAW MEDICAL UNIV
PI WROCLAW
PA UL K MARCINKOWSKIEGO 2-6, WROCLAW, 50-368, POLAND
SN 1899-5276
EI 2451-2680
J9 ADV CLIN EXP MED
JI Adv. Clin. Exp. Med.
PD SEP-OCT
PY 2015
VL 24
IS 6
BP 1099
EP 1104
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DB4UG
UT WOS:000368508500022
PM 26771984
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kessler, W
   Jantos, CA
   Dreier, J
   Pavlovic, S
AF Kessler, W
   Jantos, CA
   Dreier, J
   Pavlovic, S
TI Chlamydia pneumoniae is not detectable in subretinal neovascular
   membranes in the exudative stage of age-related macular degeneration
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related macular degeneration; subretinal membrane; Chlamydia
   pneumoniae; polymerase chain reaction
ID BEAVER DAM EYE; ISCHEMIC-HEART-DISEASE; RISK-FACTORS; ATHEROSCLEROTIC
   PLAQUE; CARDIOVASCULAR-DISEASE; SEROLOGICAL EVIDENCE; CORONARY-ARTERY;
   INFECTION; MACULOPATHY; ASSOCIATION
AB Purpose: Age-related macular degeneration (AMD) is the most frequent cause of severe visual impairment in western countries, but its aetiology remains unclear. A growing body of evidence suggests that inflammation contributes to the pathogenesis of AMD, similarly to that shown for atherosclerosis. In view of a number of shared risk factors between the two entities and the hypothesized link between Chlamydia pneumoniae infection and atherosclerosis, we investigated whether C. pneumoniae might be involved in exudative AMD.
   Methods: To examine whether C. pneumoniae contributes to the development of subretinal neovascular (SRNV) membranes in AMD, 13 consecutive SRNV membranes surgically excised from patients with exudative AMD were collected and assayed for the presence of C. pneumoniae or other bacterial pathogens by means of polymerase chain reaction (PCR).
   Results: The age of patients ranged from 68 to 85 years (median 73.5 years). In all 13 SRNV membranes, no DNA of either C. pneumoniae or other pathogens was found by PCR.
   Conclusions: These findings indicate that C. pneumoniae is not associated with the development of SRNV membranes in exudative AMD.
C1 Univ Giessen, Dept Ophthalmol, D-35385 Giessen, Germany.
   Evangel Hosp Bielefeld, Inst Lab Med, Bielefeld, Germany.
   Heart & Diabet Ctr N Rhine Westfalia, Inst Lab & Transfus Med, Bad Oeynhausen, Germany.
C3 Justus Liebig University Giessen; Ruhr University Bochum
RP Kessler, W (通讯作者)，Univ Giessen, Dept Ophthalmol, Friedrichstr 18, D-35385 Giessen, Germany.
EM Werner.Kessler@augen.med.unigiessen.de
RI Dreier, Jens/F-1134-2013
OI Dreier, Jens/0000-0002-1337-7750
CR Anderson JL, 1999, CIRCULATION, V99, P1540, DOI 10.1161/01.CIR.99.12.1540
   Bodetti TJ, 2000, INFECT IMMUN, V68, P2744, DOI 10.1128/IAI.68.5.2744-2747.2000
   CAMPBELL LA, 1995, J INFECT DIS, V172, P585, DOI 10.1093/infdis/172.2.585
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642
   Daugherty A, 1997, J CLIN INVEST, V100, P1575, DOI 10.1172/JCI119681
   Dimitrova G, 2002, EYE, V16, P580, DOI 10.1038/sj.eye.6700161
   EINARSSON S, 1994, SCAND J INFECT DIS, V26, P393, DOI 10.3109/00365549409008610
   EMRE U, 1994, ARCH PEDIAT ADOL MED, V148, P727, DOI 10.1001/archpedi.1994.02170070065013
   Espinola-Klein C, 2002, STROKE, V33, P2581, DOI 10.1161/01.STR.0000034789.82859.A4
   GAYDOS CA, 1994, J CLIN MICROBIOL, V32, P903, DOI 10.1128/JCM.32.4.903-905.1994
   Gibbs RGJ, 2000, STROKE, V31, P2930, DOI 10.1161/01.STR.31.12.2930
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kalayoglu MV, 1998, J INFECT DIS, V177, P725, DOI 10.1086/514241
   KALAYOGLU MV, 2003, DETECTION CHLAMYDIA
   KAUKORANTATOLVANEN SS, 1994, MICROB PATHOGENESIS, V16, P313, DOI 10.1006/mpat.1994.1032
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300
   KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841
   KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451
   LaBiche R, 2001, STROKE, V32, P855, DOI 10.1161/01.STR.32.4.855
   Ley BE, 1998, EUR J CLIN MICROBIOL, V17, P247, DOI 10.1007/BF01699981
   Mayr M, 1999, CIRCULATION, V99, P1560, DOI 10.1161/01.CIR.99.12.1560
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Miyashita N, 2001, CHEST, V119, P1416, DOI 10.1378/chest.119.5.1416
   Ong G, 1996, J CLIN PATHOL, V49, P102, DOI 10.1136/jcp.49.2.102
   Ramirez JA, 1996, ANN INTERN MED, V125, P979, DOI 10.7326/0003-4819-125-12-199612150-00008
   SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6
   Sessa R, 2001, ATHEROSCLEROSIS, V159, P521, DOI 10.1016/S0021-9150(01)00537-8
   Smieja M, 2001, CAN J CARDIOL, V17, P270
   Steinhoff D, 1996, CLIN INFECT DIS, V22, P958, DOI 10.1093/clinids/22.6.958
   TONG CYW, 1993, J CLIN PATHOL, V46, P313, DOI 10.1136/jcp.46.4.313
   Torzewski J, 1996, ARTERIOSCL THROM VAS, V16, P673, DOI 10.1161/01.ATV.16.5.673
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Virok D, 2003, J INFECT DIS, V188, P1310, DOI 10.1086/379047
   Weiss SM, 1996, J INFECT DIS, V173, P957, DOI 10.1093/infdis/173.4.957
   Wiesli P, 2002, CIRCULATION, V105, P2646, DOI 10.1161/01.CIR.0000017862.08503.15
   Yamaguchi H, 2002, INFECT IMMUN, V70, P2392, DOI 10.1128/IAI.70.5.2392-2398.2002
NR 54
TC 13
Z9 14
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD JUN
PY 2006
VL 84
IS 3
BP 333
EP 337
DI 10.1111/j.1600-0420.2005.00591.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 043NO
UT WOS:000237608100012
PM 16704694
OA Bronze
DA 2022-11-30
ER

PT J
AU Verdina, T
   Piaggi, S
   Ferraro, V
   Russolillo, V
   Peschiera, R
   Chester, J
   Mastropasqua, R
   Cavallini, GM
AF Verdina, Tommaso
   Piaggi, Stefania
   Ferraro, Vanessa
   Russolillo, Valeria
   Peschiera, Riccardo
   Chester, Johanna
   Mastropasqua, Rodolfo
   Cavallini, Gian Maria
TI Efficacy of biofeedback rehabilitation based on visual evoked potentials
   analysis in patients with advanced age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PREFERRED RETINAL LOCI; FIXATION; PLASTICITY; SCOTOMA; AMD
AB Age-related macular degeneration (AMD) is a progressive and degenerative disorder of the macula. In advanced stages, it is characterized by the formation of areas of geographic atrophy or fibrous scars in the central macula, which determines irreversible loss of central vision. These patients can benefit from visual rehabilitation programmes with acoustic "biofeedback" mechanisms that can instruct the patient to move fixation from the central degenerated macular area to an adjacent healthy area, with a reorganization of the primary visual cortex. In this prospective, comparative, non-randomized study we evaluated the efficacy of visual rehabilitation with an innovative acoustic biofeedback training system based on visual evoked potentials (VEP) real-time examination (Retimax Vision Trainer, CSO, Florence), in a series of patients with advanced AMD compared to a control group. Patients undergoing training were subjected to ten consecutive visual training sessions of 10 min each, performed twice a week. Patients in the control group did not receive any training. VEP biofeedback rehabilitation seems to improve visual acuity, reading performances, contrast sensitivity, retinal fixation and sensitivity and quality of life in AMD patients.
C1 [Verdina, Tommaso; Piaggi, Stefania; Ferraro, Vanessa; Russolillo, Valeria; Peschiera, Riccardo; Mastropasqua, Rodolfo; Cavallini, Gian Maria] Univ Modena & Reggio Emilia, Inst Ophthalmol, Modena, Italy.
   [Chester, Johanna] Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy.
C3 Universita di Modena e Reggio Emilia; Universita di Modena e Reggio
   Emilia
RP Verdina, T (通讯作者)，Univ Modena & Reggio Emilia, Inst Ophthalmol, Modena, Italy.
EM tommaso.verdina@gmail.com
RI Mastropasqua, Rodolfo/AAC-6453-2022
OI Ferraro, Vanessa/0000-0002-5018-1853
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Amore FM, 2013, CAN J OPHTHALMOL, V48, P431, DOI 10.1016/j.jcjo.2013.07.013
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Chiari M, 2014, NEUROPSYCHOL TRENDS, DOI [10.7358/neur-2014-015-chia, DOI 10.7358/NEUR-2014-015-CHIA]
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   Daibert-Nido M, 2019, CAN J OPHTHALMOL, V54, P328, DOI 10.1016/j.jcjo.2018.10.016
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Hamade N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159254
   Huxin KR, 2008, VISION RES, V48, P2154, DOI 10.1016/j.visres.2008.05.022
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Morales MU, 2020, INT OPHTHALMOL, V40, P305, DOI 10.1007/s10792-019-01180-y
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Parmeggiani F., 2002, GESTIONE CLIN RIABIL
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Veneruso PE, 2014, DOC OPHTHALMOL, V129, P177, DOI 10.1007/s10633-014-9462-x
   Verdina T, 2017, GRAEF ARCH CLIN EXP, V255, P1307, DOI 10.1007/s00417-017-3637-6
   Verdina T, 2013, EUR J OPHTHALMOL, V23, P723, DOI 10.5301/ejo.5000291
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2013, APPL PSYCHOPHYS BIOF, V38, P11, DOI 10.1007/s10484-012-9203-4
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 26
TC 2
Z9 2
U1 1
U2 4
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 30
PY 2020
VL 10
IS 1
AR 20886
DI 10.1038/s41598-020-78076-w
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PU3KL
UT WOS:000609203500015
PM 33257759
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Plestina-Borjan, I
   Klinger-Lasic, M
AF Plestina-Borjan, Ivna
   Klinger-Lasic, Mery
TI Long-term exposure to solar ultraviolet radiation as a risk factor for
   age-related macular degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE ultraviolet radiation; age-related macular degeneration
ID LIGHT; PREVALENCE; DAMAGE
AB A clinical epidemiological study has been conducted as apart of research project investigating chronic exposure to solar ultraviolet radiation (UVR) as a factor contributing to the onset of age-related macular degeneration (ARMD). The study included 623 subjects older than 50 from two different geographic areas, one with high solar radiation (the island of Solta - Region 1) and the other (Zagreb and its surroundings - Region 2) with low solar radiation. Individual exposure to UVR was assessed according to global exposure to sunlight, on the basis detailed history of life-long exposure to sunlight, with special reference to professional history and geophysical specificities of the respective areas. Different grades of ARMD were based on the fundus photographs and flourescein angiography. Statistically significant relation was found between ARMD and mean daily exposure (in hours) to solar radiation in Region 1 (chi(2) =186.22; p =0.000), Region w2 (chi(2) =25.66; p =0.000) and in both regions together (chi(2) =216.43; p =0.000). ARMD is more frequent in the subjects belonging to the Region 1 and with the same exposure to sunlight (8 hours and more) which goes in favor of their increased UVR exposure. The results support a relationship between long-term sunlight exposure and increased risk of ARMD.
C1 Split Univ, Sch Med, Dept Ophthalmol, Split, Croatia.
   Univ Zagreb, Sch Med, Zagreb 41001, Croatia.
C3 University of Split; University of Zagreb; University of Zagreb, School
   of Dental Medicine
RP Plestina-Borjan, I (通讯作者)，Clin Hosp Split, Dept Ophthalmol, Spinciceva 1, Split 21000, Croatia.
EM iplestina@krizine.kbsplit.hr
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRILLIANT LB, 1983, AM J EPIDEMIOL, V118, P250, DOI 10.1093/oxfordjournals.aje.a113632
   Duke-Elder SMPA., 1972, SYSTEM OPHTHALMOLOGY, V14
   GARIO PS, 1993, MACULA SENIL
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   LLOYD SA, 1993, LANCET, V342, P1156, DOI 10.1016/0140-6736(93)92130-L
   MAINSTER MA, 1978, AM J OPHTHALMOL, V85, P167, DOI 10.1016/S0002-9394(14)75943-4
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P927
   MARSHALL J, 1985, OPHTHAL PHYSL OPT, V5, P241, DOI 10.1111/j.1475-1313.1985.tb00666.x
   MILLER D, 1987, CLIN LIGHT DAMAGE EY
   MOM T, 1983, OPHTHALMOLOGY, V90, P952
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   PENZAR I, 1990, CROAT SAVEZ ENERGETC
   PENZAR I, 1991, 3 S NOV TEHN OPO
   Taylor H R, 1989, Trans Am Ophthalmol Soc, V87, P802
   WAXLER M, 1988, OPHTHALMIC RES, V20, P179, DOI 10.1159/000266583
   Yannuzzi L A, 1987, Trans Am Ophthalmol Soc, V85, P120
   YANNUZZI LA, 1988, B NEW YORK ACAD MED, V64, P955
   YANNUZZI LA, 1987, RETINA, V9, P28
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 22
TC 29
Z9 29
U1 0
U2 13
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD JAN
PY 2007
VL 31
SU 1
BP 33
EP 38
PG 6
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 143XD
UT WOS:000244758800008
PM 17469746
DA 2022-11-30
ER

PT J
AU Popp, NA
   Agron, E
   Hageman, GS
   Tuo, JS
   Chew, EY
   Chan, CC
AF Popp, Nicholas A.
   Agron, Elvira
   Hageman, Gregory S.
   Tuo, Jingsheng
   Chew, Emily Y.
   Chan, Chi-Chao
TI No Sex Differences in the Frequencies of Common Single Nucleotide
   Polymorphisms Associated with Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; SNPs; sex; genetics
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; RISK-FACTORS;
   REPRODUCTIVE FACTORS; JAPANESE POPULATION; CANDIDATE GENES; CODING
   VARIANT; GENDER; SUSCEPTIBILITY; PREVALENCE
AB Purpose: Since some studies have reported differences in the association of age-related macular degeneration (AMD) with biological sex, we set out to determine whether the difference in the disease susceptibility is afforded by common single nucleotide polymorphisms (SNPs) associated with AMD.Methods: We genotyped 2067 Caucasian subjects from the Age-Related Eye Disease Study cohort for commonly associated AMD SNPs, including those in CFH (rs1061170, rs1410996, and rs3766404), ARMS2 (rs10490924), and C3 (rs2230199) using either a Sequenom MassARRAY MALDI-TOF mass spectrometer or using Taqman genotyping reagents. A Cox proportional hazards model was used to determine the effect of genotype, age, sex, and smoking status on the development of AMD.Results: All tested SNPs genotyped are associated strongly with AMD (p < 0.0001), in concordance with previous studies. However, we found no observable differences in any of the SNPs studied when categorized by sex. Interactions between SNPs and sex were found to be not statistically significant (p = 0.38-0.79).Conclusions: The difference between male and female incidence of AMD is not explained by the most commonly AMD-associated SNPs, though it does not exclude the possibility that other, less common SNPs contribute to this difference.
C1 [Popp, Nicholas A.; Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
   [Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Hageman, Gregory S.] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Hageman, Gregory S.] Univ Utah, John A Moran Eye Ctr, Ctr Translat Med, Salt Lake City, UT USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Utah System of Higher Education; University of Utah;
   Utah System of Higher Education; University of Utah
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
OI Popp, Nicholas/0000-0001-9374-3070
FU National Eye Institute Intramural Research Program; John A. Moran Center
   for Translational Medicine; NATIONAL EYE INSTITUTE [ZIAEY000489] Funding
   Source: NIH RePORTER
FX The National Eye Institute Intramural Research Program and John A. Moran
   Center for Translational Medicine provided funding support.
CR Abou-Gareeb I, 2001, Ophthalmic Epidemiol, V8, P39, DOI 10.1076/opep.8.1.39.1540
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Bond GL, 2007, ONCOGENE, V26, P1317, DOI 10.1038/sj.onc.1210199
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Greer JM, 2012, BIOL-TARGETS THER, V6, P307, DOI 10.2147/BTT.S24067
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kaarniranta K, 2014, CURR EYE RES, P1
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, AM J OPHTHALMOL, V156, P1010, DOI 10.1016/j.ajo.2013.06.004
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09424
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Markle JGM, 2013, SCIENCE, V339, P1084, DOI 10.1126/science.1233521
   Menger Y, 2010, EPIGENOMICS-UK, V2, P807, DOI 10.2217/EPI.10.60
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Pellegrini P, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/819724
   Quintero OL, 2012, J AUTOIMMUN, V38, pJ109, DOI 10.1016/j.jaut.2011.10.003
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shen EY, 2015, EXP NEUROL, V268, P21, DOI 10.1016/j.expneurol.2014.08.006
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wang KS, 2013, J GENET, V92, P395, DOI 10.1007/s12041-013-0279-2
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yurkovetskiy L, 2013, IMMUNITY, V39, P400, DOI 10.1016/j.immuni.2013.08.013
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 54
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2017
VL 42
IS 3
BP 470
EP 475
DI 10.1080/02713683.2016.1196708
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES4EY
UT WOS:000399484000021
PM 27420564
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Halawa, OA
   Lin, JB
   Miller, JW
   Vavvas, DG
AF Halawa, Omar A.
   Lin, Jonathan B.
   Miller, Joan W.
   Vavvas, Demetrios G.
TI A Review of Completed and Ongoing Complement Inhibitor Trials for
   Geographic Atrophy Secondary to Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE complement inhibitors; age-related macular degeneration; AMD; exudation;
   exudative AMD; wet AMD; C3; C5; Factor D
ID FACTOR-H POLYMORPHISM; PROGRESSION; RISK; C3
AB Age-related macular degeneration (AMD) is a leading cause of irreversible blindness among older adults in the Western world. While therapies exist for patients with exudative AMD, there are currently no approved therapies for non-exudative AMD and its advanced form of geographic atrophy (GA). The discovery of genetic variants in complement protein loci with increased susceptibility to AMD has led to the investigation of the role of complement inhibition in AMD with a focus on GA. Here, we review completed and ongoing clinical trials evaluating the safety and efficacy of these studies. Overall, complement inhibition in GA has yielded mixed results. The inhibition of complement factor D has failed pivotal phase 3 trials. Studies of C3 and C5 inhibition meeting their primary endpoint are limited by high rates of discontinuation and withdrawal in the treatment arm and higher risks of conversion to exudative AMD. Studies evaluating other complement members (CFB, CFH, CFI and inhibitors of membrane attack complex-CD59) are ongoing and could offer other viable strategies.
C1 [Miller, Joan W.; Vavvas, Demetrios G.] Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02115 USA.
   Harvard Med Sch, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School
RP Miller, JW; Vavvas, DG (通讯作者)，Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02115 USA.
EM Omar_Halawa@hms.harvard.edu; jblin6@gmail.com;
   joan_miller@meei.harvard.edu; demetrios_vavvas@meei.harvard.edu
CR Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ellis S, 2020, INVEST OPHTH VIS SCI, V61
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Henzan IM, 2010, OPHTHALMOLOGY, V117, P1720, DOI 10.1016/j.ophtha.2010.01.045
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Iveric Bio Inc., 2020, FORM 8 K SEC EXCH CO
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2020, INVEST OPHTH VIS SCI, V61
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Miller ME, 2001, STAT MED, V20, P2383, DOI 10.1002/sim.904.abs
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Steinle NC, 2021, AM J OPHTHALMOL, V227, P116, DOI [10.1016/i.aio.2021.02.031, 10.1016/j.ajo.2021.02.031]
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2021, OPHTHALMOLOGY, V128, P1325, DOI 10.1016/j.ophtha.2021.02.025
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 23
TC 12
Z9 12
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2021
VL 10
IS 12
AR 2580
DI 10.3390/jcm10122580
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SY8IT
UT WOS:000666125400001
PM 34208067
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tong, JP
   Chan, WM
   Liu, DTL
   Lai, TYY
   Choy, KW
   Pang, CP
   Lam, DSC
AF Tong, JP
   Chan, WM
   Liu, DTL
   Lai, TYY
   Choy, KW
   Pang, CP
   Lam, DSC
TI Aqueous humor levels of vascular endothelial growth factor and pigment
   epithelium-derived factor in polypoidal choroidal vasculopathy and
   choroidal neovascularization
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; VITREOUS LEVELS; DIABETIC-RETINOPATHY; FACTOR
   EXPRESSION; MEMBRANES; VEGF; ANGIOGENESIS; PROGRESSION; PREVALENCE; PEDF
AB PURPOSE: To determine the aqueous levels of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in patients with active polypoidal choroidal vasculopathy (PCV) and choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and pathologic myopia.
   DESIGN: Prospective, comparative control study.
   METHODS: Aqueous humors were collected from 32 eyes of 32 patients for either active PCV or CNV. Among them, 11 eyes had active and symptomatic PCV, 12 eyes had active CNV secondary to AMD, and nine eyes had active CNV of pathologic myopia. Levels of VEGF and PEDF were determined by commercially available enzyme-linked immunosorbent assay kits. A group of 10 aqueous samples from 10 patients who underwent cataract surgery without other ocular or systemic diseases comprised the controls.
   RESULTS: VEGF concentrations in aqueous humor were markedly increased in patients with PCV, CNV of AMD, and CNV of myopia when compared with the controls (analysis of variance [ANOVAI, P <.001). VEGF levels in eyes with PCV were, however, significantly lower than those of exudative AMD (P =.045). The PEDF levels were also significantly different among the groups (ANOVA, P =.001), and we observed increased levels in PCV, CNV of AMD, and CNV of myopia.
   CONCLUSIONS: VEGF and PEDF factors were coexpressed and increased with positive correlation in aqueous humor of eyes with active PCV. The different levels of both factors in eyes of PCV and AMD might suggest distinct clinical entities or different angiogenesis courses between PCV and AMD.
C1 Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
   Zhejiang Univ, Affiliated Hosp 1, Coll Med, Zheyi Eye Ctr, Hangzhou 310027, Zhejiang, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Zhejiang University; Chinese University
   of Hong Kong; Prince of Wales Hospital
RP Chan, WM (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 3-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cwm6373@netvigator.com
RI Choy, Richard/AAW-8230-2020; Lam, Dennis/AAL-1211-2020; Pang, Chi
   P/I-5388-2014; Lai, Timothy Y Y/AAC-2120-2020
OI Choy, Richard/0000-0002-3616-6200; Lai, Timothy Y Y/0000-0002-7832-6428
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Boehm BO, 2003, DIABETOLOGIA, V46, P394, DOI 10.1007/s00125-003-1040-9
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Noma H, 2005, AM J OPHTHALMOL, V140, P256, DOI 10.1016/j.ajo.2005.03.003
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
NR 43
TC 292
Z9 321
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2006
VL 141
IS 3
BP 456
EP 462
DI 10.1016/j.ajo.2005.10.012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 022LS
UT WOS:000236057900004
PM 16490490
DA 2022-11-30
ER

PT J
AU Machalinska, A
   Dziedziejko, V
   Mozolewska-Piotrowska, K
   Karczewicz, D
   Wiszniewska, B
   Machalinski, B
AF Machalinska, Anna
   Dziedziejko, Violetta
   Mozolewska-Piotrowska, Katarzyna
   Karczewicz, Danuta
   Wiszniewska, Barbara
   Machalinski, Boguslaw
TI Elevated Plasma Levels of C3a Complement Compound in the Exudative Form
   of Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; C3a-desArg complement compound;
   Inflammatory response
ID INDUCED CHOROIDAL NEOVASCULARIZATION; POPULATION-BASED COHORT; FACTOR-H
   POLYMORPHISM; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE;
   RISK-FACTOR; FACTOR-B; 2 PARTS; ACTIVATION; VARIANT
AB Aim: Recent findings suggest that chronic inflammatory processes play a role in the progression of age-related macular degeneration (AMD). Here we asked whether the development of different forms of AMD is connected with the elevation of plasma C3a-desArg concentration. Methods: We recruited 30 subjects with a clinical diagnosis of exudative AMD with newly diagnosed choroidal neovascularization (CNV), 30 subjects with dry AMD and 30 age- and sex-matched volunteers without AMD. The concentration of C3a-desArg complement compound was measured in the subjects' peripheral blood. We evaluated the association between the level of C3a-desArg and age, sex, smoking, atherosclerosis, and hypertension. Results: We found that the levels of C3a-desArg were significantly elevated in patients with exudative AMD compared to the control group. The concentrations of C3a-desArg in patients with dry AMD were similar to those of controls. Additionally, patients and controls with documented atherosclerosis (AS) displayed significantly higher levels of C3a-desArg compared to subjects without AS. Conclusions: Our results suggest an association between systemic complement activation and the development of CNV. Moreover, we found an association of complement activation with atherosclerosis and confirmed the hypothesis that AMD can be a local manifestation of systemic disease. Copyright (c) 2009 S. Karger AG, Basel
C1 [Machalinska, Anna; Machalinski, Boguslaw] Pomeranian Med Univ, Dept Physiopathol, PL-70111 Szczecin, Poland.
   [Machalinska, Anna; Wiszniewska, Barbara] Pomeranian Med Univ, Dept Histol & Embryol, PL-70111 Szczecin, Poland.
   [Dziedziejko, Violetta] Pomeranian Med Univ, Dept Biochem & Med Chem, PL-70111 Szczecin, Poland.
   [Mozolewska-Piotrowska, Katarzyna; Karczewicz, Danuta] Pomeranian Med Univ, Dept Clin Ophthalmol, PL-70111 Szczecin, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University; Pomeranian Medical University
RP Machalinski, B (通讯作者)，Pomeranian Med Univ, Dept Gen Pathol, 72 Powstancow Wlkp St, PL-70111 Szczecin, Poland.
EM machalin@sci.pam.szczecin.pl
RI Wiszniewska, Barbara/O-3644-2014; Machaliński, Bogusław/P-3025-2014;
   Dziedziejko, Violetta V./A-7626-2015; Machalinska, Anna/P-6701-2014
OI Wiszniewska, Barbara/0000-0002-9064-6969; Dziedziejko, Violetta
   V./0000-0003-4809-415X; Machalinski, Boguslaw/0000-0002-6013-0419
CR Ajjan R, 2005, THROMB HAEMOSTASIS, V94, P1048, DOI 10.1160/TH05-06-0384
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Engstrom G, 2007, J HUM HYPERTENS, V21, P276, DOI 10.1038/sj.jhh.1002129
   Engstrom G, 2005, DIABETES, V54, P570, DOI 10.2337/diabetes.54.2.570
   Engstrom G, 2007, EUR J CARDIOV PREV R, V14, P392, DOI 10.1097/01.hjr.0000244582.30421.b2
   Fleisig AJ, 2005, EXPERT OPIN BIOL TH, V5, P833, DOI 10.1517/14712598.5.6.833
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Mollnes TE, 2007, MOL IMMUNOL, V44, P3838, DOI 10.1016/j.molimm.2007.06.150
   MUSCARI A, 1995, AM J MED, V98, P357, DOI 10.1016/S0002-9343(99)80314-3
   Niculescu F, 2004, IMMUNOL RES, V30, P73, DOI 10.1385/IR:30:1:073
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Onat A, 2005, CLIN SCI, V108, P129, DOI 10.1042/CS20040198
   Palikhe A, 2007, AM J CARDIOL, V99, P890, DOI 10.1016/j.amjcard.2006.11.034
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 35
TC 45
Z9 47
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2009
VL 42
IS 1
BP 54
EP 59
DI 10.1159/000219686
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 461PN
UT WOS:000267280600009
PM 19478542
DA 2022-11-30
ER

PT J
AU Hopley, C
   Salkeld, G
   Wang, JJ
   Mitchell, P
AF Hopley, C
   Salkeld, G
   Wang, JJ
   Mitchell, P
TI Cost utility of screening and treatment for early age related macular
   degeneration with zinc and antioxidants
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; VISUAL IMPAIRMENT; DIABETIC-RETINOPATHY; SMOKING
   PREVALENCE; BLINDNESS; MACULOPATHY; GUIDELINES; AUSTRALIA; IMPACT;
   VALUES
AB Aim: To assess the cost effectiveness of high dose zinc and antioxidants for delaying and reducing the progression of early age related macular degeneration ( AMD).
   Background: AMD is the leading cause of severe vision impairment and blindness in older people throughout the developed world. It currently affects around 420 000 people in the United Kingdom.
   Methods: A cost utility analysis (CUA) was conducted to estimate the cost per quality adjusted life year ( QALY) for screening a cohort of men and women, aged 55 years and over, for early AMD and then treating them with zinc and antioxidants. The incremental CUA was based on a decision analytic model, comparing screening with a no screening comparator ( current practice). Extensive one way sensitivity analysis of parameters was conducted to determine the robustness of the model.
   Results: In this model the cost effectiveness of screening for early AMD was pound 22 722 per quality adjusted life year ( QALY) saved. The cost per QALY decreased to pound 18 948 if photodynamic therapy with verteporfin savings were included.
   Conclusions: Screening for, and prophylactic treatment of, early AMD is estimated to cost around pound 22 700 per QALY saved. This cost falls within accepted levels to warrant further investigation. These findings have implications for ophthalmic practice and healthcare planning.
C1 Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney; University of Sydney
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR *AUSTR BUR STAT, 1997, DEATHS AUSTR 1996, P62
   Barratt A, 1999, JAMA-J AM MED ASSOC, V281, P2029, DOI 10.1001/jama.281.21.2029
   BISHOP BMP, 1999, NATL STRATEGY AGEING, P1
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown G C, 2001, Trans Am Ophthalmol Soc, V99, P199
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062
   Drummond MF., 2015, METHODS EC EVALUATIO, V4
   Foran S, 2002, ARCH OPHTHALMOL-CHIC, V120, P613, DOI 10.1001/archopht.120.5.613
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Marques-Vidal P, 2003, EUR J PUBLIC HEALTH, V13, P168, DOI 10.1093/eurpub/13.2.168
   MCLENNAN W, 1998, AUSTR STAT POPULATIO, P1
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mitchell P, 1999, MED J AUSTRALIA, V171, P173, DOI 10.5694/j.1326-5377.1999.tb123591.x
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   *MMWR, 2003, MMWR-MORBID MORTAL W, V52, P303
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Sharma S, 2003, BRIT J OPHTHALMOL, V87, P259, DOI 10.1136/bjo.87.3.259
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Weinstein MC, 2003, VALUE HEALTH, V6, P9, DOI 10.1046/j.1524-4733.2003.00234.x
   White V, 2003, TOB CONTROL, V12, P67, DOI 10.1136/tc.12.suppl_2.ii67
   Wright SE, 2000, CLIN EXP OPHTHALMOL, V28, P140, DOI 10.1046/j.1442-9071.2000.00296.x
   Younis N, 2003, LANCET, V361, P195, DOI 10.1016/S0140-6736(03)12267-2
NR 32
TC 36
Z9 37
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR 1
PY 2004
VL 88
IS 4
BP 450
EP 454
DI 10.1136/bjo.2003.035279
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 804MI
UT WOS:000220302400005
PM 15031152
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hyttinen, JMT
   Kannan, R
   Felszeghy, S
   Niittykoski, M
   Salminen, A
   Kaarniranta, K
AF Hyttinen, Juha M. T.
   Kannan, Ram
   Felszeghy, Szabolcs
   Niittykoski, Minna
   Salminen, Antero
   Kaarniranta, Kai
TI The Regulation of NFE2L2 (NRF2) Signalling and Epithelial-to-Mesenchymal
   Transition in Age-Related Macular Degeneration Pathology
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; epithelial-to-mesenchymal transition;
   hypoxia; nuclear factor erythroid 2-related factor; oxidative stress;
   reactive oxygen species; retinal pigment epithelium
ID TRANSCRIPTION FACTOR NRF2; RETINAL-PIGMENT EPITHELIUM; NF-KAPPA-B;
   LUNG-CANCER CELLS; INDUCED PREMATURE SENESCENCE; OXIDATIVE
   STRESS-RESPONSE; POSITIVE FEEDBACK LOOP; ANTIOXIDANT RESPONSE;
   MITOCHONDRIAL BIOGENESIS; AUTOPHAGIC DEGRADATION
AB Age-related macular degeneration (AMD) is a mounting cause of loss of sight in the elderly in the developed countries, a trend enhanced by the continual ageing of the population. AMD is a multifactorial and only partly understood, malady. Unfortunately, there is no effective treatment for most AMD patients. It is known that oxidative stress (OS) damages the retinal pigment epithelium (RPE) and contributes to the progression of AMD. We review here the potential importance of two OS-related cellular systems in relation to AMD. First, the nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2)-mediated OS response signalling pathway is important in the prevention of oxidative damage and a failure of this system could be critical in the development of AMD. Second, epithelial-to-mesenchymal transition (EMT) represents a change in the cellular phenotype, which ultimately leads to the fibrosis encountered in RPE, a characteristic of AMD. Many of the pathways triggering EMT are promoted by OS. The possible interconnections between these two signalling routes are discussed here. From a broader perspective, the control of NFE2L2 and EMT as ways of preventing OS-derived cellular damage could be potentially valuable in the therapy of AMD.
C1 [Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
   [Kannan, Ram] Doheny Eye Inst, Stephen J Ryan Initiat Macular Res RIMR, DVRC 203,1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Felszeghy, Szabolcs] Univ Eastern Finland, Inst Biomed, POB 1627, FI-70211 Kuopio, Finland.
   [Felszeghy, Szabolcs] Univ Eastern Finland, Inst Dent, POB 1627, FI-70211 Kuopio, Finland.
   [Niittykoski, Minna] Univ Eastern Finland, AI Virtanen Inst Mol Sci, POB 1627, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, POB 1627, FI-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, POB 100, Kys Kuopio 70029, Finland.
C3 University of Eastern Finland; Doheny Eye Institute; University of
   Eastern Finland; University of Eastern Finland; University of Eastern
   Finland; University of Eastern Finland; Kuopio University Hospital
RP Hyttinen, JMT (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
EM Juha.Hyttinen@uef.fi; rkannan@doheny.org; Szabolcs.Felszeghy@uef.fi;
   Minna.Niittykoski@uef.fi; Antero.Salminen@uef.fi; Kai.Kaarniranta@uef.fi
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; Niittykoski, Minna/0000-0002-2816-9874;
   Hyttinen, Juha/0000-0002-3414-4032
FU Kuopio University Hospital [5503743]; Finnish Eye Foundation; Health
   Research Council of the Academy of Finland [296840]; Paivikki and Sakari
   Sohlberg Foundation; Sigrid Juselius Foundation; University of Eastern
   Finland
FX This work was supported by the Kuopio University Hospital (Grant Number
   5503743), the Finnish Eye Foundation, the Health Research Council of the
   Academy of Finland (Grant Number 296840), the Paivikki and Sakari
   Sohlberg Foundation, Sigrid Juselius Foundation and University of
   Eastern Finland strategical support.
CR Abba ML, 2016, J CLIN MED, V5, DOI 10.3390/jcm5010008
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Alarcon-Aguilar A, 2014, NEUROBIOL AGING, V35, P1901, DOI 10.1016/j.neurobiolaging.2014.01.143
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Alonso IGD, 2018, CANCERS, V10, DOI 10.3390/cancers10040093
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aquilano K, 2013, ANTIOXID REDOX SIGN, V18, P386, DOI 10.1089/ars.2012.4615
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Arunkumar R, 2018, EYE, V32, P992, DOI 10.1038/s41433-018-0044-0
   Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Bai XP, 2016, DRUG METAB REV, V48, P541, DOI 10.1080/03602532.2016.1197239
   Baldelli S, 2013, BBA-GEN SUBJECTS, V1830, P4137, DOI 10.1016/j.bbagen.2013.04.006
   Bales KL, 2016, EXP EYE RES, V150, P71, DOI 10.1016/j.exer.2015.11.007
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Bellezza I, 2018, BBA-MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bertrand M, 2015, CELL CYCLE, V14, P364, DOI 10.4161/15384101.2014.987619
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bitto A, 2014, AGE, V36, P1123, DOI 10.1007/s11357-014-9626-3
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Brown SL, 2008, CANCER RES, V68, P364, DOI 10.1158/0008-5472.CAN-07-2170
   Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737
   Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216
   Cao Y, 2013, CELL MOL LIFE SCI, V70, P2305, DOI 10.1007/s00018-012-1170-7
   Alfredo SIC, 2018, PHARMACOL RES, V134, P92, DOI 10.1016/j.phrs.2018.06.013
   Chaharbakhshi E, 2016, GENESIS, V54, P505, DOI 10.1002/dvg.22964
   Chen QM, 2018, PHYSIOL GENOMICS, V50, P77, DOI 10.1152/physiolgenomics.00041.2017
   Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029
   Chen X, 2018, CELL PHYSIOL BIOCHEM, V50, P1201, DOI 10.1159/000494547
   Chen ZW, 2014, BRIT J PHARMACOL, V171, P3196, DOI 10.1111/bph.12661
   Cheng ZX, 2014, ONCOL REP, V31, P1891, DOI 10.3892/or.2014.3022
   Cherry AD, 2014, J BIOL CHEM, V289, P41, DOI 10.1074/jbc.M113.512483
   Chio IIC, 2016, CELL, V166, P963, DOI 10.1016/j.cell.2016.06.056
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388
   CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467
   Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038
   Copple IM, 2010, J BIOL CHEM, V285, P16782, DOI 10.1074/jbc.M109.096545
   Cuadrado A, 2014, J BIOL CHEM, V289, P15244, DOI 10.1074/jbc.M113.540633
   Cubillo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059948
   Cui YH, 2015, ONCOGENE, V34, P5372, DOI 10.1038/onc.2014.466
   Cunha ES, 2012, EXP CELL RES, V318, P1913, DOI 10.1016/j.yexcr.2012.05.019
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Darvekar SR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085262
   Davies KJA, 2019, FREE RADICAL BIO MED, V134, P708, DOI 10.1016/j.freeradbiomed.2019.01.028
   De Francesco EM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072011
   De Paepe B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9091017
   Deakin Nicholas O, 2012, Genes Cancer, V3, P362, DOI 10.1177/1947601912458582
   Delcourt C, 2014, INVEST OPHTH VIS SCI, V55, P7619, DOI 10.1167/iovs.14-14471
   Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899
   Dodson M, 2015, BIOCHEM J, V469, P347, DOI 10.1042/BJ20150568
   Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6
   Thuan DTB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01985
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Ebrahimi KB, 2018, ANTIOXID REDOX SIGN, V29, P389, DOI 10.1089/ars.2017.7084
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Faraonio R, 2006, J BIOL CHEM, V281, P39776, DOI 10.1074/jbc.M605707200
   Favre C, 2010, ONCOGENE, V29, P3964, DOI 10.1038/onc.2010.146
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Feng H, 2019, INT J BIOL SCI, V15, P507, DOI 10.7150/ijbs.30575
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005
   Gammons M, 2018, CURR OPIN CELL BIOL, V51, P42, DOI 10.1016/j.ceb.2017.10.008
   Gao B, 2014, CLIN PHARMACOL-ADV A, V6, P19, DOI 10.2147/CPAA.S35078
   Ghavami S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.36
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Giannoni E, 2012, ANTIOXID REDOX SIGN, V16, P1248, DOI 10.1089/ars.2011.4280
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong WY, 2018, FREE RADICAL BIO MED, V115, P338, DOI 10.1016/j.freeradbiomed.2017.12.013
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Gunaratne A, 2013, CELL ADHES MIGR, V7, P357, DOI 10.4161/cam.25651
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   He K, 2016, CELL MOL LIFE SCI, V73, P2105, DOI 10.1007/s00018-015-2122-9
   He XQ, 2009, MOL PHARMACOL, V76, P1265, DOI 10.1124/mol.109.058453
   He XY, 2018, DIABETOLOGIA, V61, P881, DOI 10.1007/s00125-017-4523-9
   Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138
   Hsieh CY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-12
   Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200
   Huang KP, 2017, EXP CELL RES, V361, P63, DOI 10.1016/j.yexcr.2017.09.042
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Hyttinen JMT, 2014, AGEING RES REV, V18, P16, DOI 10.1016/j.arr.2014.07.002
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Ichimura Y, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00210
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Ishikawa M, 2005, FREE RADICAL BIO MED, V38, P1344, DOI 10.1016/j.freeradbiomed.2005.01.021
   Iso T, 2016, MOL CELL BIOL, V36, P3100, DOI 10.1128/MCB.00389-16
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Jaffer OA, 2015, AM J RESP CELL MOL, V52, P106, DOI 10.1165/rcmb.2013-0519OC
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jeong Y, 2017, CANCER DISCOV, V7, P86, DOI 10.1158/2159-8290.CD-16-0127
   Jian Z, 2011, J INVEST DERMATOL, V131, P1420, DOI 10.1038/jid.2011.56
   Jiang JW, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.36
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Jo C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4496
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Jobling ME, 2006, RADIAT RES, V166, P839, DOI 10.1667/RR0695.1
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Joo MS, 2016, MOL CELL BIOL, V36, P1931, DOI 10.1128/MCB.00118-16
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawai Y, 2011, J BIOL CHEM, V286, P7629, DOI 10.1074/jbc.M110.208173
   Keeling E, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7020016
   Kent D, 2003, MOL VIS, V9, P747
   Ki SH, 2005, MOL CELL BIOL, V25, P4150, DOI 10.1128/MCB.25.10.4150-4165.2005
   Kim JH, 2013, ONCOGENE, V32, P514, DOI 10.1038/onc.2012.59
   Kim KH, 2010, NUCLEIC ACIDS RES, V38, P48, DOI 10.1093/nar/gkp865
   Kim SM, 2018, FOOD CHEM TOXICOL, V121, P657, DOI 10.1016/j.fct.2018.09.023
   Kim S, 2016, SCI REP-UK, V6, DOI 10.1038/srep24933
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Kiser PD, 2016, ANNU REV VIS SCI, V2, P197, DOI 10.1146/annurev-vision-111815-114407
   Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   KORYTOWSKI W, 1987, PHOTOCHEM PHOTOBIOL, V45, P185, DOI 10.1111/j.1751-1097.1987.tb05362.x
   Koskela A, 2014, MOL VIS, V20, P760
   Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Larabee CM, 2016, MOL VIS, V22, P1503
   Lastres-Becker I, 2016, ANTIOXID REDOX SIGN, V25, P61, DOI 10.1089/ars.2015.6549
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025
   Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy S, 2010, IUBMB LIFE, V62, P237, DOI 10.1002/iub.314
   Lewis KN, 2010, INTEGR COMP BIOL, V50, P829, DOI 10.1093/icb/icq034
   Li W, 2016, ONCOL REP, V35, P1718, DOI 10.3892/or.2015.4504
   Li W, 2008, BBA-MOL CELL RES, V1783, P1847, DOI 10.1016/j.bbamcr.2008.05.024
   Li WG, 2006, J BIOL CHEM, V281, P27251, DOI 10.1074/jbc.M602746200
   Li WJ, 2014, FEBS LETT, V588, P2115, DOI 10.1016/j.febslet.2014.04.046
   Liu D, 2018, NEUROTOXICOLOGY, V69, P84, DOI 10.1016/j.neuro.2018.09.005
   Liu KH, 2018, ANTICANCER RES, V38, P6299, DOI 10.21873/anticanres.12986
   Liu MN, 2017, J CELL MOL MED, V21, P1248, DOI 10.1111/jcmm.13060
   Liu RM, 2010, FREE RADICAL BIO MED, V48, P1, DOI 10.1016/j.freeradbiomed.2009.09.026
   Lo SC, 2006, MOL CELL BIOL, V26, P1235, DOI 10.1128/MCB.26.4.1235-1244.2006
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Mallano T, 2016, ANN RHEUM DIS, V75, P586, DOI 10.1136/annrheumdis-2014-206214
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Maresca V, 2008, PIGM CELL MELANOMA R, V21, P200, DOI 10.1111/j.1755-148X.2007.00432.x
   Marrot L, 2008, PIGM CELL MELANOMA R, V21, P79, DOI 10.1111/j.1755-148X.2007.00424.x
   Maugeri A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072118
   McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200
   Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6
   Movafagh S, 2015, J CELL BIOCHEM, V116, P696, DOI 10.1002/jcb.25074
   Nag TC, 2015, MICRON, V79, P16, DOI 10.1016/j.micron.2015.08.001
   Naidu SD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11262-5
   Nakagami Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7469326
   Namani A, 2014, BBA-MOL CELL RES, V1843, P1875, DOI 10.1016/j.bbamcr.2014.05.003
   National Guideline Alliance, 2018, AG REL MAC DEG DIAGN
   Ni BB, 2014, CYTOKINE, V70, P87, DOI 10.1016/j.cyto.2014.07.249
   Nioi P, 2005, MOL CELL BIOL, V25, P10895, DOI 10.1128/MCB.25.24.10895-10906.2005
   Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003
   O'Connell MA, 2015, BIOCHEM SOC T, V43, P687, DOI 10.1042/BST20150069
   O'Mealey GB, 2017, J CELL SCI, V130, P3467, DOI 10.1242/jcs.203216
   Overstreet JM, 2014, CELL SIGNAL, V26, P1427, DOI 10.1016/j.cellsig.2014.02.017
   Paimela T, 2011, PHARMACOL RES, V64, P501, DOI 10.1016/j.phrs.2011.05.027
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Park JS, 2015, BIOCHEM BIOPH RES CO, V466, P499, DOI 10.1016/j.bbrc.2015.09.059
   Perepechaeva ML, 2016, EXP MOL PATHOL, V101, P124, DOI 10.1016/j.yexmp.2016.07.008
   Piera-Velazquez S, 2019, PHYSIOL REV, V99, P1281, DOI 10.1152/physrev.00021.2018
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Priglinger CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146887
   Pursiheimo JP, 2009, ONCOGENE, V28, P334, DOI 10.1038/onc.2008.392
   Qu J, 2019, J CELL PHYSIOL, V234, P8862, DOI 10.1002/jcp.27548
   Rachakonda G, 2008, CHEM RES TOXICOL, V21, P705, DOI 10.1021/tx700302s
   Raghunath A, 2018, REDOX BIOL, V17, P297, DOI 10.1016/j.redox.2018.05.002
   Riazi-Esfahani Mohammad, 2017, J Ophthalmic Vis Res, V12, P424, DOI 10.4103/jovr.jovr_182_17
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Roehlecke C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071570
   Rossler OG, 2017, J CELL BIOCHEM, V118, P127, DOI 10.1002/jcb.25619
   Rosales MAB, 2019, LIFE SCI ALLIANCE, V2, DOI [10.26508/lsa.201800212, 10.26508/lsa.201900436]
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632
   Ryoo IG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093265
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105
   Saito R, 2016, MOL CELL BIOL, V36, P271, DOI 10.1128/MCB.00868-15
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Saitoh M, 2015, CANCER SCI, V106, P481, DOI 10.1111/cas.12630
   Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Sanchez-Martin P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.222836
   Satoh T, 2015, ASN NEURO, V7, DOI 10.1177/1759091415593294
   Scanlon CS, 2013, J DENT RES, V92, P114, DOI 10.1177/0022034512467352
   Sekine H, 2016, MOL CELL BIOL, V36, P407, DOI 10.1128/MCB.00785-15
   Shagieva G, 2017, ONCOTARGET, V8, P4901, DOI 10.18632/oncotarget.13612
   Shah SZA, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00310
   Shin JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096035
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037
   Sihvola V, 2017, ARCH BIOCHEM BIOPHYS, V617, P94, DOI 10.1016/j.abb.2016.10.010
   Silva-Palacios A, 2018, AGEING RES REV, V47, P31, DOI 10.1016/j.arr.2018.06.003
   Singh CK, 2018, ANTIOXID REDOX SIGN, V28, P643, DOI 10.1089/ars.2017.7290
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Stepkowski TM, 2011, FREE RADICAL BIO MED, V50, P1186, DOI 10.1016/j.freeradbiomed.2011.01.033
   Stone RC, 2016, CELL TISSUE RES, V365, P495, DOI 10.1007/s00441-016-2464-0
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su CY, 2017, TOXICOLOGY, V387, P17, DOI 10.1016/j.tox.2017.06.006
   Sun Z, 2007, MOL CELL BIOL, V27, P6334, DOI 10.1128/MCB.00630-07
   Sun Z, 2009, MOL CELL BIOL, V29, P2658, DOI 10.1128/MCB.01639-08
   Suzuki T, 2015, FREE RADICAL BIO MED, V88, P93, DOI 10.1016/j.freeradbiomed.2015.06.006
   Sykiotis GP, 2011, CURR OPIN CLIN NUTR, V14, P41, DOI 10.1097/MCO.0b013e32834136f2
   Synowiec E, 2013, FRONT BIOSCI-LANDMRK, V18, P80, DOI 10.2741/4088
   Taguchi K, 2012, P NATL ACAD SCI USA, V109, P13561, DOI 10.1073/pnas.1121572109
   Takaya K, 2012, FREE RADICAL BIO MED, V53, P817, DOI 10.1016/j.freeradbiomed.2012.06.023
   Tang LY, 2012, DERMATOLOGY, V224, P145, DOI 10.1159/000336777
   Tao SS, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00660-16
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Theodore M, 2008, J BIOL CHEM, V283, P8984, DOI 10.1074/jbc.M709040200
   Tian W, 2018, J BIOL CHEM, V293, P2029, DOI 10.1074/jbc.RA117.000428
   Tong KI, 2006, MOL CELL BIOL, V26, P2887, DOI 10.1128/MCB.26.8.2887-2900.2006
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06
   United Nations Department of Economic and Social Affairs Population Division, 2013, WORLD POP PROSP 2012
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Viiri J, 2010, MOL VIS, V16, P1399
   Vu KT, 2017, EXP EYE RES, V164, P31, DOI 10.1016/j.exer.2017.08.001
   Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006
   Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200
   Wang HY, 2013, CANCER RES, V73, P3097, DOI 10.1158/0008-5472.CAN-12-3386
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang XJ, 2007, P NATL ACAD SCI USA, V104, P19589, DOI 10.1073/pnas.0709483104
   Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361
   Winkler B S, 1999, Mol Vis, V5, P32
   Winkler TW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194321
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wu D, 2019, FASEB J, V33, P2498, DOI 10.1096/fj.201801227R
   Wu J, 2018, MOL MED REP, V17, P3607, DOI 10.3892/mmr.2017.8360
   Xiang Y, 2019, EUR J PHARMACOL, V848, P140, DOI 10.1016/j.ejphar.2019.01.015
   Xu YH, 2017, BIOCHEM BIOPH RES CO, V490, P535, DOI 10.1016/j.bbrc.2017.06.074
   Yaekashiwa M, 2003, DNA CELL BIOL, V22, P479, DOI 10.1089/10445490360708883
   Yan GG, 2018, INT J BIOCHEM CELL B, V103, P81, DOI 10.1016/j.biocel.2018.08.006
   Zavattari P, 2015, HEPATOLOGY, V62, P851, DOI 10.1002/hep.27790
   Zenkov NK, 2017, BIOCHEMISTRY-MOSCOW+, V82, P556, DOI 10.1134/S0006297917050030
   Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003
   Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004
   Zhang HS, 2019, J CELL MOL MED, V23, P3451, DOI 10.1111/jcmm.14241
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang JX, 2018, FREE RADICAL RES, V52, P1432, DOI 10.1080/10715762.2018.1500020
   Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46763
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou HJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1004-y
   Zhou W, 2007, MOL CELL ENDOCRINOL, V278, P52, DOI 10.1016/j.mce.2007.08.011
   Zhou WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep38646
   Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
   Zou MJ, 2016, ONCOTARGET, V7, P13122, DOI 10.18632/oncotarget.7536
   Zou XZ, 2017, EUR J PHARMACOL, V796, P190, DOI 10.1016/j.ejphar.2016.12.003
NR 268
TC 26
Z9 26
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2019
VL 20
IS 22
AR 5800
DI 10.3390/ijms20225800
PG 35
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JW0YW
UT WOS:000502786800282
PM 31752195
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Othman, R
   Berbari, S
   Vaucher, E
   Couture, R
AF Othman, Rahmeh
   Berbari, Simon
   Vaucher, Elvire
   Couture, Rejean
TI Differential Expression of Kinin Receptors in Human Wet and Dry
   Age-Related Macular Degeneration Retinae
SO PHARMACEUTICALS
LA English
DT Article
DE age-related macular degeneration; bradykinin type 1 receptor; fibrosis;
   gliosis; iNOS; kallikrein-kinin system; microglia; vascular endothelial
   growth factor (VEGF); retina
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS;
   B-1 RECEPTORS; UP-REGULATION; BRADYKININ; INFLAMMATION;
   NEOVASCULARIZATION; ANGIOGENESIS; ACTIVATION
AB Kinins are vasoactive peptides and mediators of inflammation, which signal through two G protein-coupled receptors, B1 and B2 receptors (B1R, B2R). Recent pre-clinical findings suggest a primary role for B1R in a rat model of wet age-related macular degeneration (AMD). The aim of the present study was to investigate whether kinin receptors are differentially expressed in human wet and dry AMD retinae. The cellular distribution of B1R and B2R was examined by immunofluorescence and in situ hybridization in post-mortem human AMD retinae. The association of B1R with inflammatory proteins (inducible nitric oxide synthase (iNOS) and vascular endothelial growth factor A (VEGFA)), fibrosis markers and glial cells was also studied. While B2R mRNA and protein expression was not affected by AMD, a significant increase of B1R mRNA and immunoreactivity was measured in wet AMD retinae when compared to control and dry AMD retinae. B1R was expressed by Muller cells, astrocytes, microglia and endothelial/vascular smooth muscle cells, and colocalized with iNOS and fibrosis markers, but not with VEGFA. In conclusion, the induction and upregulation of the pro-inflammatory and pro-fibrotic kinin B1R in human wet AMD retinae support previous pre-clinical studies and provide a clinical proof-of-concept that B1R represents an attractive therapeutic target worth exploring in this retinal disease.
C1 [Othman, Rahmeh; Vaucher, Elvire] Univ Montreal, Sch Optometry, Montreal, PQ H3T 1P1, Canada.
   [Othman, Rahmeh; Berbari, Simon; Couture, Rejean] Univ Montreal, Fac Med, Dept Pharmacol & Physiol, Montreal, PQ H3T 1P1, Canada.
C3 Universite de Montreal; Universite de Montreal
RP Couture, R (通讯作者)，Univ Montreal, Fac Med, Dept Pharmacol & Physiol, Montreal, PQ H3T 1P1, Canada.
EM Rahmeh.othman@umontreal.ca; Simon.berbari@umontreal.ca;
   Elvire.vaucher@umontreal.ca; rejean.couture@umontreal.ca
OI Vaucher, Elvire/0000-0001-7075-5263
FU Canadian Institutes of Health Research [MOP-125962]; FRQS Vision Health
   Research Network; Antoine-Turmel Foundation; Graduate Program of
   Physiology; Faculty of Graduate Studies, Universite de Montreal
FX This research was funded by the Canadian Institutes of Health Research
   (MOP-125962) and the FRQS Vision Health Research Network in partnership
   with the Antoine-Turmel Foundation to E.V. and R.C. R.O. received PhD
   Studentship Awards from the Graduate Program of Physiology, and the
   Faculty of Graduate Studies, Universite de Montreal.
CR Abdouh M, 2003, BRIT J PHARMACOL, V140, P33, DOI 10.1038/sj.bjp.0705210
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Albert-Weissenberger C, 2012, J CEREBR BLOOD F MET, V32, P1747, DOI 10.1038/jcbfm.2012.62
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson AA, 2008, J CELL PHYSIOL, V215, P82, DOI 10.1002/jcp.21288
   Bhat Menakshi, 2014, Prog Drug Res, V69, P111
   Coorey NJ, 2012, CLIN EXP OPTOM, V95, P266, DOI 10.1111/j.1444-0938.2012.00741.x
   Couture R, 2014, CURR VASC PHARMACOL, V12, P223, DOI 10.2174/1570161112666140226121627
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040318
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040307
   Donato L, 2018, FEBS OPEN BIO, V8, P219, DOI 10.1002/2211-5463.12360
   Dutra RC, 2013, NEUROBIOL DIS, V54, P82, DOI 10.1016/j.nbd.2013.02.007
   Emanueli C, 2002, CIRCULATION, V105, P360, DOI 10.1161/hc0302.102142
   Feilchenfeld Z, 2008, EXP EYE RES, V87, P409, DOI 10.1016/j.exer.2008.07.011
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hachana S, 2020, CURR EYE RES, V45, P965, DOI 10.1080/02713683.2020.1712730
   Hachana S, 2020, BRIT J PHARMACOL, V177, P1949, DOI 10.1111/bph.14962
   Hachana S, 2018, BRIT J PHARMACOL, V175, P968, DOI 10.1111/bph.14138
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   HU DE, 1993, BRIT J PHARMACOL, V109, P14, DOI 10.1111/j.1476-5381.1993.tb13525.x
   Huart A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00008
   Ifuku M, 2007, J NEUROSCI, V27, P13065, DOI 10.1523/JNEUROSCI.3467-07.2007
   Ikeda Y, 2004, CANCER RES, V64, P5178, DOI 10.1158/0008-5472.CAN-03-3589
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Johansen JS, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-5
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Klein J, 2009, FASEB J, V23, P134, DOI 10.1096/fj.08-115600
   Lacoste B, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-57
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Marceau F, 2004, NAT REV DRUG DISCOV, V3, P845, DOI 10.1038/nrd1522
   MCALLISTER BS, 1993, AM J PHYSIOL, V265, pC477, DOI 10.1152/ajpcell.1993.265.2.C477
   McLean PG, 2000, CARDIOVASC RES, V48, P194, DOI 10.1016/S0008-6363(00)00184-X
   Moreno-Garcia A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00464
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Ohlmann A, 2016, HISTOCHEM CELL BIOL, V146, P769, DOI 10.1007/s00418-016-1461-4
   Othman R, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00300
   Parenti A, 2001, FASEB J, V15, P1487, DOI 10.1096/fj.00-0503fje
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pouliot M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033864
   Rashid Khalid, 2019, Front Immunol, V10, P1975, DOI 10.3389/fimmu.2019.01975
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Smith RS, 2008, BIOL CHEM, V389, P725, DOI 10.1515/BC.2008.084
   Souied EH, 2020, AM J OPHTHALMOL, V214, P151, DOI 10.1016/j.ajo.2020.02.016
   Sun JK, 2019, OPHTHALMOL RETINA, V3, P1107, DOI 10.1016/j.oret.2019.07.006
   Talbot S, 2011, PEPTIDES, V32, P1447, DOI 10.1016/j.peptides.2011.05.005
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Terzuoli E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020330
   Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200
   Tisdale AK, 2019, JAMA OPHTHALMOL, V137, P543, DOI 10.1001/jamaophthalmol.2019.0292
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tsujinaka H, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00401
   Wang MH, 2014, ADV EXP MED BIOL, V801, P333, DOI 10.1007/978-1-4614-3209-8_42
   Westermann D, 2009, DIABETES, V58, P1373, DOI 10.2337/db08-0329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 68
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD JUN
PY 2020
VL 13
IS 6
AR 130
DI 10.3390/ph13060130
PG 20
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MO0TH
UT WOS:000551249100024
PM 32599742
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Terao, N
   Koizumi, H
   Kojima, K
   Yamagishi, T
   Yamamoto, Y
   Yoshii, K
   Kitazawa, K
   Hiraga, A
   Toda, M
   Kinoshita, S
   Sotozono, C
   Hamuro, J
AF Terao, Nobuhiro
   Koizumi, Hideki
   Kojima, Kentaro
   Yamagishi, Tetsuya
   Yamamoto, Yuji
   Yoshii, Kengo
   Kitazawa, Koji
   Hiraga, Asako
   Toda, Munetoyo
   Kinoshita, Shigeru
   Sotozono, Chie
   Hamuro, Junji
TI Distinct Aqueous Humour Cytokine Profiles of Patients with Pachychoroid
   Neovasculopathy and Neovascular Age-related Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   MONOCYTE CHEMOATTRACTANT PROTEIN-1; ENDOTHELIAL GROWTH-FACTORS;
   INTRAVITREAL BEVACIZUMAB; MACROPHAGES; SEVERITY; DISEASE; STRESS; TYPE-1
AB This study investigated the pathophysiological features of pachychoroid neovasculopathy (PNV) and neovascular age-related macular degeneration (nAMD) by analysing and comparing cytokine profiles in aqueous humour (AH) collected from 18 PNV, 18 nAMD and 11 control patients. Responses to intravitreal injection of aflibercept were also analysed in the PNV and nAMD groups. In the PNV group, vascular endothelial growth factor (VEGF)-A was significantly lower than in the nAMD group (p = 0.03) but was almost identical to that in the control group (p = 0.86). The nAMD group showed positive correlations between interleukin (IL)-6 and IL-8 (r = 0.78, p < 0.001), IL-6 and monocyte chemoattractant protein (MCP)-1 (r = 0.68, p = 0.002) and IL-8 and MCP-1 (r = 0.68, p = 0.002). In the nAMD group, eyes with dry maculae one month after the first aflibercept injection showed significantly lower VEGF-A and placental growth factor (PlGF) at baseline than those with wet maculae (p = 0.02 for both). However, there was no significant difference between dry and wet maculae in the PNV group. The results suggest that angiogenic factors and proinflammatory cytokines may play the distinct roles in the pathogenesis of PNV and nAMD.
C1 [Terao, Nobuhiro; Kojima, Kentaro; Yamagishi, Tetsuya; Yamamoto, Yuji; Kitazawa, Koji; Sotozono, Chie; Hamuro, Junji] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan.
   [Koizumi, Hideki] Univ Ryukyus, Dept Ophthalmol, Okinawa, Japan.
   [Yoshii, Kengo] Kyoto Prefectural Univ Med, Dept Math & Stat Med Sci, Kyoto, Japan.
   [Hiraga, Asako; Toda, Munetoyo; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Frontier Med Sci & Technol Ophthalmol, Kyoto, Japan.
C3 Kyoto Prefectural University of Medicine; University of Ryukyus; Kyoto
   Prefectural University of Medicine; Kyoto Prefectural University of
   Medicine
RP Koizumi, H (通讯作者)，Univ Ryukyus, Dept Ophthalmol, Okinawa, Japan.
EM hkoizumi@med.u-ryukyu.ac.jp
OI Kojima, Kentaro/0000-0003-2347-4789
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Dong N, 2013, MOL VIS, V19, P1734
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kitazawa K, 2017, BRIT J OPHTHALMOL, V101, P548, DOI 10.1136/bjophthalmol-2016-309650
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Kwon SH, 2015, OPHTHALMOLOGY, V122, P968, DOI 10.1016/j.ophtha.2015.01.007
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   METCALF D, 1987, EXP HEMATOL, V15, P1
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yamawaki T, 2016, INVEST OPHTH VIS SCI, V57, P5945, DOI 10.1167/iovs.16-20604
   Yamazaki Y, 2009, J BIOL CHEM, V284, P9885, DOI 10.1074/jbc.M809071200
NR 41
TC 45
Z9 46
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 12
PY 2018
VL 8
AR 10520
DI 10.1038/s41598-018-28484-w
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GM7ET
UT WOS:000438343600030
PM 30002400
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tadayoni, R
   Sararols, L
   Weissgerber, G
   Verma, R
   Clemens, A
   Holz, FG
AF Tadayoni, Ramin
   Sararols, Laura
   Weissgerber, Georges
   Verma, Rohini
   Clemens, Andreas
   Holz, Frank G.
TI Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of
   Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Brolucizumab; Anti-VEGF; Neovascular age-related macular degeneration
   (AMD); Single-chain antibody fragment
ID PHARMACOKINETICS; RANIBIZUMAB; AFLIBERCEPT; MANAGEMENT; OUTCOMES
AB Background: Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD). Purpose: To review the milestones in the molecular and clinical development of brolucizumab, the first single-chain antibody fragment (scFv) designed specifically for intraocular use in humans. Methods: In this article, we summarize the preclinical and current clinical evidence of brolucizumab administration with an overview of the other treatment regimens and additional indications under investigation. Results: The unique molecular design of brolucizumab led to a low molecular weight of only 26 kDa, allowing for a concentrated molar dose of 1 intravitreal injection compared with other anti-VEGF agents. Phase I and II clinical trial outcomes validated the efficacy of brolucizumab in the treatment of nAMD with signals of a more durable treatment effect. The pivotal phase III trials, HAWK and HARRIER, which included a total of 1,817 patients, established that brolucizumab can be administered every 3 months while maintaining disease control. Conclusions: The preclinical and clinical data on brolucizumab provide evidence of sustained disease control with longer injection intervals, thus potentially reducing the treatment burden in patients with nAMD.
C1 [Tadayoni, Ramin] Univ Paris, Hop Lariboisiere, AP HP, Dept Ophthalmol, Paris, France.
   [Sararols, Laura] Hosp Gen Cataluna, Barcelona, Spain.
   [Weissgerber, Georges; Verma, Rohini; Clemens, Andreas] Novartis Pharma AG, Basel, Switzerland.
   [Clemens, Andreas] Univ Freiburg, Dept Cardiol & Angiol 1, Ctr Heart, Fac Med, Freiburg, Germany.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Novartis; University of Freiburg; University of
   Hamburg; University Medical Center Hamburg-Eppendorf; University of Bonn
RP Clemens, A (通讯作者)，Novartis Pharma AG, Basel, Switzerland.
EM andreas.clemens@novartis.com
OI Clemens, Andreas/0000-0001-6192-1557
FU Novartis Pharma AG, Basel, Switzerland
FX The sponsorship of this study and article processing charges were funded
   by Novartis Pharma AG, Basel, Switzerland.
CR Agostini H, 2020, CURR EYE RES, V45, P1298, DOI 10.1080/02713683.2020.1731832
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borras L, BROLUCIZUMAB U UNPUB
   Borras L, 2010, J BIOL CHEM, V285, P9054, DOI 10.1074/jbc.M109.072876
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Escher D., 2014, EURETINA SEPT 17 20
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Holz FG., 2017, EURETINA
   Holz FG., 2019, 19 EURETINA C SEPT 5
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Miller BR, 2010, PROTEIN ENG DES SEL, V23, P549, DOI 10.1093/protein/gzq028
   Nimz EL, 2016, INVEST OPHTH VIS SCI, V57
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma A, 2020, EYE, V34, P611, DOI 10.1038/s41433-019-0583-z
   Szabo Emese, 2018, J Pharmacol Exp Ther, V365, P422, DOI 10.1124/jpet.117.246249
   Tietz J., 2015, ASS RES VIS OPHTH AR
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
NR 31
TC 21
Z9 22
U1 1
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2021
VL 244
IS 2
BP 93
EP 101
DI 10.1159/000513048
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RY0TU
UT WOS:000647629000001
PM 33197916
OA Bronze
DA 2022-11-30
ER

PT J
AU Cassels, NK
   Wild, JM
   Margrain, TH
   Blyth, C
   Chong, V
   Acton, JH
AF Cassels, Nicola K.
   Wild, John M.
   Margrain, Tom H.
   Blyth, Chris
   Chong, Victor
   Acton, Jennifer H.
TI Microperimetry in Age-Related Macular Degeneration: An Evidence-Base for
   Pattern Deviation Probability Analysis in Microperimetry
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; perimetry; microperimetry; visual
   fields
ID CENTRAL VISUAL-FIELD; RETINAL SENSITIVITY; FULL THRESHOLD; NORMAL
   VALUES; VARIABILITY; PERIMETRY; CLASSIFICATION; FASTPAC; MAIA
AB Purpose: The "traffic light'' color designation of differential light sensitivity used in a number of microperimeters does not encompass the conventional Total and Pattern Deviation probability analyses adopted by standard automated perimetry. We determined whether the color designation is indicative of abnormality as represented by the "gold standard'' Pattern Deviation probability analysis.
   Methods: Total and Pattern Deviation probability levels, using two different methods, were derived at each of 40 stimulus locations, within 7 degrees eccentricity, from 66 ocular healthy individuals (66 eyes) who had undergone microperimetry with the Macular Integrity Assessment microperimeter. The probability levels were applied to the corresponding fields from each of 45 individuals (45 eyes) with age-related macular degeneration (AMD) and evaluated in relation to the color designation.
   Results: Sensitivities designated in orange encompassed the entire range of Pattern Deviation probability levels (from normal to P <= 1%). Those designated in green were mostly normal; those in red/black generally corresponded to the <= 1% probability level.
   Conclusions: The green and the red/black designations are generally indicative of normal and abnormal probability values, respectively. The orange designation encompassed all probability outcomes and should not be relied upon for visual field interpretation. The evidence base indicates replacement of the color designation of sensitivity in AMD by Total Deviation and Pattern Deviation analyses.
C1 [Cassels, Nicola K.; Wild, John M.; Margrain, Tom H.; Acton, Jennifer H.] Cardiff Univ, Coll Biol & Life Sci, Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.
   [Blyth, Chris] Univ Hosp Wales, Dept Ophthalmol, Cardiff, S Glam, Wales.
   [Chong, Victor] Univ Oxford, Dept Ophthalmol, Oxford, England.
C3 Cardiff University; Cardiff University; University of Oxford
RP Acton, JH (通讯作者)，Cardiff Univ, Coll Biol & Life Sci, Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.
EM actonj@cardiff.ac.uk
RI Acton, Jennifer/AAU-3307-2021; Chong, Victor/Q-6565-2018
OI Acton, Jennifer/0000-0002-0347-7651; Chong, Victor/0000-0002-7693-522X
FU Fight for Sight [1463/64]; Cardiff University
FX Jennifer H. Acton was in receipt of a Fight for Sight award (Award
   Number 1463/64). Nicola K. Cassels was in receipt of a graduate research
   scholarship from Cardiff University.
CR Acton JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039944
   Acton JH, 2011, OPTOMETRY VISION SCI, V88, P1288, DOI 10.1097/OPX.0b013e31822b3746
   Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Adams CW, 1999, OPTOMETRY VISION SCI, V76, P582, DOI 10.1097/00006324-199908000-00027
   Altman DG, 1990, PRACTICAL STAT MED R, V12
   Anderson AJ, 2005, INVEST OPHTH VIS SCI, V46, P1540, DOI 10.1167/iovs.04-0968
   Asman P, 2004, INVEST OPHTH VIS SCI, V45, P3099, DOI 10.1167/iovs.03-0617
   Astle AT, 2016, DATA BRIEF, V9, P673, DOI 10.1016/j.dib.2016.07.061
   Balasubramanian S, 2018, BRIT J OPHTHALMOL, V102, P109, DOI 10.1136/bjophthalmol-2017-310258
   Bengtsson B, 1999, ACTA OPHTHALMOL SCAN, V77, P125, DOI 10.1034/j.1600-0420.1999.770201.x
   Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Denniss J, 2017, INVEST OPHTH VIS SCI, V58, P2652, DOI 10.1167/iovs.16-21086
   Denniss J, 2016, INVEST OPHTH VIS SCI, V57, P5449, DOI 10.1167/iovs.16-20222
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FLANAGAN JG, 1993, GRAEF ARCH CLIN EXP, V231, P465, DOI 10.1007/BF02044233
   Fortune B, 2004, DOC OPHTHALMOL, V109, P87, DOI 10.1007/s10633-004-3300-5
   Grobbel J, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.5
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Harrell Frank, REGRESSION MODELING
   HEIJL A, 1987, ARCH OPHTHALMOL-CHIC, V105, P1544
   Heijl A, 1987, DOC OPHTHALMOL PROC, P153
   Hermann A, 2008, ACTA OPHTHALMOL, V86, P446, DOI 10.1111/j.1600-0420.2007.01055.x
   International Organization for Standardization, 2008, 12866 ISO
   JOHNSON CA, 1988, J OPT SOC AM A, V5, P2131, DOI 10.1364/JOSAA.5.002131
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Mojon DS, 2003, OPHTHALMOLOGICA, V217, P260, DOI 10.1159/000070632
   Molina-Martin A, 2017, EUR J OPHTHALMOL, V27, P607, DOI 10.5301/ejo.5000930
   Montesano G, 2019, OPHTHALMOLOGY, V126, P242, DOI 10.1016/j.ophtha.2018.08.010
   Pacey IE, 1998, THESIS
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Phu J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.1
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   Vonthein R, 2007, OPHTHALMOLOGY, V114, P1065, DOI 10.1016/j.ophtha.2006.09.030
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wild JM, 1999, INVEST OPHTH VIS SCI, V40, P1152
   WILD JM, 1995, INVEST OPHTH VIS SCI, V36, P1398
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 50
TC 3
Z9 4
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD NOV
PY 2019
VL 8
IS 6
AR 48
DI 10.1167/tvst.8.6.48
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JZ5PZ
UT WOS:000505155800001
PM 31921516
OA gold, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Srinivasan, S
   Swaminathan, G
   Kulothungan, V
   Ganesan, S
   Sharma, T
   Raman, R
AF Srinivasan, S.
   Swaminathan, G.
   Kulothungan, V.
   Ganesan, S.
   Sharma, T.
   Raman, R.
TI Age-related macular degeneration in a South Indian population, with and
   without diabetes
SO EYE
LA English
DT Article
ID CHOROIDAL CIRCULATION; RISK-FACTORS; PREVALENCE; MACULOPATHY;
   RETINOPATHY; EYE; ATHEROSCLEROSIS; CLASSIFICATION; ASSOCIATION; DISEASE
AB Purpose To elucidate the prevalence and risk factors of age-related macular degeneration (AMD) in people with diabetes.
   Methods Of the 5495 subjects >= 60 years of age recruited in the population-based study in south India, 4791 subjects with gradable images on 30 degrees three-field retinal photographs were analyzed. AMD and diabetic retinopathy (DR) were graded based on the International ARM Epidemiological Study Group classification and International Clinical Diabetic Retinopathy Disease Severity Scale, respectively. All subjects underwent a detailed history, physical examination, and a comprehensive ocular examination.
   Results Of the 4791 subjects, 1256 had diabetes. In those with diabetes, 166 (13.2%) had DR: of which, 9.6% had AMD. Of those with diabetes but no DR, 15.6% had AMD. Presence of DR (OR=0.57, 95% CI: 0.33-0.99, P=0.046) was a protective factor for AMD in diabetes. When adjusted for potential confounding factors, those with AMD and diabetes were from urban areas (OR=1.65, 95% CI: 1.09-2.49, P=0.018), had raised systolic blood pressure (OR=1.02, 95% CI: 1.00-1.03, P=0.01), higher BMI (OR=1.06, 95% CI: 1.02-1.10, P=0.005), and higher serum triglycerides (OR=1.00, 95% CI: 1.00-1.01, P=0.011). A higher level of highdensity lipoprotein (HDL) (OR=0.98, 95% CI: 0.96-0.99, P=0.038) was a protective factor for AMD in subjects with diabetes.
   Conclusions The presence of DR and higher serum HDL are protective factors whereas obesity and higher systolic blood pressure are risk factors for AMD in subjects with diabetes.
C1 [Srinivasan, S.; Swaminathan, G.; Kulothungan, V.; Ganesan, S.; Sharma, T.; Raman, R.] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
RP Raman, R (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM rajivpgraman@gmail.com
RI Raman, Rajiv/A-7234-2009
OI Raman, Rajiv/0000-0001-5842-0233
FU Jamsetji Tata Trust, Mumbai, India
FX This work has been funded by Jamsetji Tata Trust, Mumbai, India.
CR Agarwal S, 2005, OPHTHAL EPIDEMIOL, V12, P143, DOI 10.1080/09286580590932734
   American Diabetes Association, 2007, DIABETES CARE, V30, pS3
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Chen XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085716, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0087752, 10.1371/journal.pone.0091830]
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Dandona R, 1999, INVEST OPHTH VIS SCI, V40, P2810
   Dimitrova G, 2001, EYE, V15, P602, DOI 10.1038/eye.2001.193
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Goldstein DE, 2004, DIABETES CARE, V27, P1761, DOI 10.2337/diacare.27.7.1761
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Kulkarni SR, 2013, INDIAN J OPHTHALMOL, V61, P196, DOI 10.4103/0301-4738.99870
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Oakes JM, 2003, SOC SCI MED, V56, P769, DOI 10.1016/S0277-9536(02)00073-4
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Ramachandran A, 1999, DIABETES RES CLIN PR, V44, P207, DOI 10.1016/S0168-8227(99)00024-8
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Raman R, 2009, OPHTHALMOLOGY, V116, P311, DOI 10.1016/j.ophtha.2008.09.010
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Sander B, 2001, INVEST OPHTH VIS SCI, V42, P433
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 31
TC 13
Z9 13
U1 0
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2017
VL 31
IS 8
BP 1176
EP 1183
DI 10.1038/eye.2017.47
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FE3VE
UT WOS:000408143000010
PM 28387762
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Saksens, NTM
   Kersten, E
   Groenewoud, JMM
   van Grinsven, MJJP
   van de Ven, JPH
   Sanchez, CI
   Schick, T
   Fauser, S
   den Hollander, AI
   Hoyng, CB
   Boon, CJF
AF Saksens, Nicole T. M.
   Kersten, Eveline
   Groenewoud, Joannes M. M.
   van Grinsven, Mark J. J. P.
   van de Ven, Johannes P. H.
   Sanchez, Clara I.
   Schick, Tina
   Fauser, Sascha
   den Hollander, Anneke I.
   Hoyng, Carel B.
   Boon, Camiel J. F.
TI Clinical Characteristics of Familial and Sporadic Age-Related Macular
   Degeneration: Differences and Similarities
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; family history; clinical characteristics
ID FACTOR-H POLYMORPHISM; CARDIOVASCULAR RISK-FACTORS; CUTICULAR DRUSEN;
   TERM INCIDENCE; ASSOCIATION; MACULOPATHY; VARIANT; CAROTENOIDS; DISEASE;
   CONFERS
AB PURPOSE. We describe the differences and similarities in clinical characteristics and phenotype of familial and sporadic patients with age-related macular degeneration (AMD).
   METHODS. We evaluated data of 1828 AMD patients and 1715 controls enrolled in the European Genetic Database. All subjects underwent ophthalmologic examination, including visual acuity testing and fundus photography. Images were graded and fundus photographs were used for automatic drusen quantification by a machine learning algorithm. Data on disease characteristics, family history, medical history, and lifestyle habits were obtained by a questionnaire.
   RESULTS. The age at first symptoms was significantly lower in AMD patients with a positive family history (68.5 years) than in those with no family history (71.6 years, P = 1.9 x 10(-5)). Risk factors identified in sporadic and familial subjects were increasing age (odds ratio [OR], 1.08 per year; P = 3.0 x 10(-51), and OR, 1.15; P = 5.3 x 10(-36), respectively) and smoking (OR, 1.01 per pack year; P = 1.1 x 10(-6) and OR, 1.02; P = 0.005). Physical activity and daily red meat consumption were significantly associated with AMD in sporadic subjects only (OR, 0.49; P = 3.7 x 10(-10) and OR, 1.81; P = 0.001). With regard to the phenotype, geographic atrophy and cuticular drusen were significantly more prevalent in familial AMD (17.5% and 21.7%, respectively) compared to sporadic AMD (9.8% and 12.1%).
   CONCLUSIONS. Familial AMD patients become symptomatic at a younger age. The higher prevalence of geographic atrophy and cuticular drusen in the familial AMD cases may be explained by the contribution of additional genetic factors segregating within families.
C1 [Saksens, Nicole T. M.; Kersten, Eveline; van de Ven, Johannes P. H.; den Hollander, Anneke I.; Hoyng, Carel B.; Boon, Camiel J. F.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & Hlth Technol Assessment, NL-6525 ED Nijmegen, Netherlands.
   [van Grinsven, Mark J. J. P.; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Diagnost Image Anal Grp, NL-6525 ED Nijmegen, Netherlands.
   [Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, NL-2333 ZA Leiden, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; University of Cologne; Leiden University; Leiden
   University Medical Center (LUMC); Leiden University - Excl LUMC
RP Boon, CJF (通讯作者)，Leiden Univ, Med Ctr, Dept Ophthalmol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
EM C.J.F.Boon@lumc.nl
RI Gutiérrez, Clara Isabel Sánchez/B-3800-2014; Gutierrez, Clara Isabel
   Sanchez/N-3580-2014; Kersten, Eveline/P-8173-2015; Groenewoud, Hans
   JMM/R-3588-2017; Hollander, Anneke den/N-4911-2014; Hoyng,
   C.B./H-8050-2014; Boon, CJF/P-7534-2014
OI Gutiérrez, Clara Isabel Sánchez/0000-0001-9787-8319; Groenewoud, Hans
   JMM/0000-0002-4974-150X; Boon, CJF/0000-0002-6737-7932
FU Foundation Fighting Blindness USA [C-GE-0811-0548-RAD04]; Salentein
   fellowship; MD Fonds; Oogfonds; Algemene Nederlandse Vereniging ter
   Voorkoming van Blindheid; Stichting Nederlands Oogheelkundig Onderzoek;
   Gelderse Blindenstichting
FX Supported by Foundation Fighting Blindness USA (Grant
   C-GE-0811-0548-RAD04), Salentein fellowship, MD Fonds, Oogfonds,
   Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Stichting
   Nederlands Oogheelkundig Onderzoek, and Gelderse Blindenstichting. The
   authors alone are responsible for the content and writing of the paper.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barbazetto IA, 2007, OPHTHALMIC GENET, V28, P192, DOI 10.1080/13816810701538596
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   DUARA R, 1993, NEUROLOGY, V43, P1377, DOI 10.1212/WNL.43.7.1377
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Lerche W, 1975, Ber Zusammenkunft Dtsch Ophthalmol Ges, P439
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Luo L, 2008, VISION RES, V48, P494, DOI 10.1016/j.visres.2007.11.013
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Shastry BS, 2007, J HUM GENET, V52, P384, DOI 10.1007/s10038-007-0120-y
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Suvisaari JM, 1998, BRIT J PSYCHIAT, V173, P494, DOI 10.1192/bjp.173.6.494
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 44
TC 8
Z9 8
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2014
VL 55
IS 11
BP 7085
EP 7092
DI 10.1167/iovs.14-14659
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX9IR
UT WOS:000347217300008
PM 25301878
OA Green Published
DA 2022-11-30
ER

PT J
AU Muether, PS
   Hoerster, R
   Hermann, MM
   Kirchhof, B
   Fauser, S
AF Muether, Philipp S.
   Hoerster, Robert
   Hermann, Manuel M.
   Kirchhof, Bernd
   Fauser, Sascha
TI Long-term effects of ranibizumab treatment delay in neovascular
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Exudative age-related macular degeneration; Treatment delay; Spectral
   domain optical coherence tomography; Ranibizumab; Visual acuity; Central
   retinal thickness; Choroidal neovascularization
ID VISUAL-ACUITY; PARAMETERS
AB Intravitreal injections of ranibizumab are the standard of care for neovascular age-related macular degeneration (AMD). In clinical trials, comparable efficacy has been shown for either monthly injections or as needed injections upon monthly controls. Unlike in trial settings, treatment in clinical routine is often delayed by complex approval procedures of health insurance and limited short-term surgical capacities.
   Eighty-nine patients with neovascular AMD were followed for 12 months. Early treatment diabetic retinopathy study (ETDRS) visual acuity (VA), Radner reading VA and spectral domain optical coherence tomography were performed monthly, with additional fluorescein angiography if needed. After an initial loading phase of three consecutive monthly intravitreal injections with ranibizumab, re-injections were performed when recurrent activity of choroidal neovascularization (CNV) was detected.
   After an initial increase to a value of +5.0 +/- 11.87 ETDRS letters from baseline, VA constantly decreased over 12 months to a value of -0.66 +/- 16.82 ETDRS letters below baseline. Central retinal thickness (CRT) decreased from a value of 438.1 +/- 191.4 mu m at baseline to a value of 289.9 +/- 138.6 mu m after initial therapy and stabilized at a value of 322.4 +/- 199.5 mu m. Loss of VA during latency between indication to treat and treatment was significantly greater than re-gain of VA after re-initiation of therapy (-2.2 +/- 5.0 versus 0.4 +/- 7.4 letters; p = 0.046).
   Latency between indication to treat and treatment is responsible for irreversible VA deterioration. A successful PRN treatment regimen for neovascular AMD requires immediate access to therapy after indication.
C1 [Muether, Philipp S.; Hoerster, Robert; Hermann, Manuel M.; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne
RP Muether, PS (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM Philmuether@mac.com
FU Koeln Fortune Program, Faculty of Medicine, University of Cologne
FX Supported by the Koeln Fortune Program, Faculty of Medicine, University
   of Cologne
CR Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 9
TC 62
Z9 65
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2013
VL 251
IS 2
BP 453
EP 458
DI 10.1007/s00417-012-2038-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 086KT
UT WOS:000314683200004
PM 22573410
DA 2022-11-30
ER

PT J
AU Thi, HCT
   Querques, G
   Forzy, G
   Souied, EH
AF Thi Ha Chau Tran
   Querques, Giuseppe
   Forzy, Gerard
   Souied, Eric H.
TI Angiographic Regression Patterns After Intravitreal Ranibizumab
   Injections for Neovascular Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SUBGROUP ANALYSIS
AB BACKGROUND AND OBJECTIVE: To investigate the relation between visual gain, injection frequency, and the angiographic regression patterns after intravitreal ranibizumab on an as-needed basis in exudative age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Fifty-nine treatment-naive patients (68 eyes) were retrospectively analyzed. All patients received three consecutive monthly injections (induction phase) of ranibizumab (0.5 mg/0.05 mL). Based on fluorescein angiography (FA), the choroidal neovascularization (CNV) was judged to present either complete regression (pattern 1), partial regression (pattern 2), stabilization of the lesion size without leakage (pattern 3), stabilization of the lesion size with persistence of leakage (pattern 4), or increased angiographic size (pattern 5).
   RESULTS: Mean visual acuity (VA) significantly improved from 48 to 54.3 letters at 1 year after a mean of 5.5 injections (P < .001). Multiple linear regression revealed baseline VA as a predictor of visual gain and the angiographic pattern as a predictor of number of injections. Analysis of variance revealed a significant interaction (F-test [1.67] = 25, P < .001) between the number of injections at 12 months and the regression patterns, as evaluated by FA 1 month after the induction phase. Eyes showing complete CNV regression needed significantly fewer injections than eyes without any angiographic sign of CNV regression (3.4 injections in pattern 1 vs 5.6 injections in pattern 3 [P = .03], and 7 injections in pattern 4 [P < .001], 4.4 injections in pattern 2 vs 7 injections in pattern 4 [P < .001]).
   CONCLUSION: FA may represent a useful tool to adapt the rhythm of visits and intravitreal anti-vascular endothelial growth factor injections in exudative AMD.
C1 [Querques, Giuseppe] Univ Paris 12, Ctr Hosp Intercommunnal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Thi Ha Chau Tran] Hop St Vincent de Paul, Dept Ophthalmol, Lille, France.
   [Thi Ha Chau Tran; Forzy, Gerard] Univ No France, Fac Med, Lille, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite de Franche-Comte; Universite de Lille - ISITE; Universite de
   Lille
RP Querques, G (通讯作者)，Univ Paris 12, Ctr Hosp Intercommunnal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092; Querques,
   Giuseppe/0000-0002-3292-9581
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2007, J FR OPHTALMOL, V30, P330, DOI 10.1016/S0181-5512(07)89602-1
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Prenner JL, 2009, OPHTHALMOLOGY, V116, P1590, DOI 10.1016/j.ophtha.2009.04.007
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 16
TC 11
Z9 12
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD NOV-DEC
PY 2011
VL 42
IS 6
BP 498
EP 508
DI 10.3928/15428877-20110804-04
PG 11
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 959UZ
UT WOS:000305342500009
PM 21830744
DA 2022-11-30
ER

PT J
AU Gibran, S
   Romano, M
   Wong, D
AF Gibran, S. K.
   Romano, M. R.
   Wong, D.
TI Perfluorocarbon liquid assisted large retinal epithelium patching in
   sub-macular hemorrhage secondary to age related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Chorio-RPE patch; Exudative AMD; Large sub-macular hemorrhage;
   Full-thickness RPE patch graft
ID PIGMENT EPITHELIUM; SUBRETINAL HEMORRHAGE; CHOROID TRANSLOCATION;
   NEOVASCULAR MEMBRANES; TRANSPLANTATION; RETINOTOMY
AB We investigate the safety and feasibility of large retinal pigmentary epithelium (RPE)-Choroid-free graft after surgical drainage of massive sub-macular hemorrhage (SMH) due to age-related macular degeneration (ARMD).
   Four previously untreated patients (three females and one male) underwent to three port pars plana vitrectomy, induction of retinal detachment and peripheral temporal 180A degrees retinotomy. The retina was then folded nasally, to allow access for removal of sub-macular Hg and CNV complex. A full-thickness-large autologus Chorio-RPE patch was grafted. Silicone oil was used as endotemponade for approximately 12 weeks. After removal of silicone oil, the patients were followed-up for 6 months.
   SMH was completely removed in all cases. It was possible to graft a large RPE patch safely that is sufficiently large to cover the entire defect of macular RPE. At last follow-up, improvement in visual acuity (from 3 +/- 0.9 to 55 +/- 9 ETDRS letters) and recovery of central fixation was observed in all patients.
   Our surgical technique for large elevated SMH seems to be feasible and efficacious approach to harvest and relocate large RPE patch and to save limited vision in selected patients.
C1 [Gibran, S. K.; Romano, M. R.; Wong, D.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.
   [Gibran, S. K.] UTMB, Dept Ophthalmol & Visual Sci, Galveston, TX USA.
   [Wong, D.] Univ Hong Kong, D Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Texas System; University of Texas Medical Branch Galveston; University
   of Hong Kong
RP Romano, M (通讯作者)，Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.
EM romanomario@email.it
RI Wong, Sai Hung David/D-8482-2015; Romano, Mario R/I-8320-2012
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Chen FK, 2008, INVEST OPHTH VIS SCI, V49, P3143, DOI 10.1167/iovs.07-1648
   Maaijwee K, 2008, INVEST OPHTH VIS SCI, V49, P758, DOI 10.1167/iovs.07-0510
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
NR 13
TC 17
Z9 17
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2009
VL 247
IS 2
BP 187
EP 191
DI 10.1007/s00417-008-0958-5
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 384NE
UT WOS:000261750700006
PM 18925410
DA 2022-11-30
ER

PT J
AU Lai, KB
   Zhou, LJ
   Chong, XJ
   Huang, CX
   Gong, YJ
   Xu, FB
   Ma, L
   Chen, GD
   Chong, L
   Lu, L
   Jin, CJ
AF Lai, Kunbei
   Zhou, Lijun
   Chong, Xiaojin
   Huang, Chuangxin
   Gong, Yajun
   Xu, Fabao
   Ma, Li
   Chen, Guandi
   Chong, Lin
   Lu, Lin
   Jin, Chenjin
TI Morphological Difference of Choroidal Vasculature Between Polypoidal
   Choroidal Vasculopathy and Neovascular AMD on OCT: From the Perspective
   of Pachychoroid
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; SPECTRUM DISORDERS; RANIBIZUMAB;
   CLASSIFICATION; FEATURES; DISEASE; VERTEPORFIN
AB BACKGROUND AND OBJECTIVE: To investigate the morphological difference of choroidal vasculature between polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (nAMD) on optical coherence tomography (OCT).
   PATIENTS AND METHODS: One hundred eighty-nine patients with macula-involved PCV (n = 107) or nAMD (n = 82) were retrospectively reviewed. The subfoveal choroidal thickness (SFCT) and thickness of the Haller's layer were determined on enhanced depth imaging optical coherence tomography (EDIOCT). The mean diameters of subfoveal large choroidal vessels were also calculated.
   RESULTS: Both the SFCT (257.31 mu m +/- 100.50 mu m vs. 209.95 mu m +/- 97.51 mu m) (P < .01) and the thickness of the Haller's layer (213.68 mu m +/- 82.65 mu m vs. 159.67 mu m +/- 79.86 mu m) (P < .01) were greater in PCV patients than nAMD patients. The ratio of thickness of the Haller's layer to the SFCT was higher in the PCV group (0.83 +/- 0.07) than the nAMD group (0.7 5 +/- 0.11) (P < .01). The mean diameter of subfoveal large choroidal vessels was greater in PCV patients (163.55 +/- 62.23 mu m vs. 112.81 +/- 58.87 mu m) (P < .01).
   CONCLUSION: Choroidal thickening and dilation of large choroidal vessels were commonly seen in PCV patients, supporting that PCV belongs to the pachychoroid spectrum disorders and might be a different entity from nAMD.
C1 [Lai, Kunbei; Zhou, Lijun; Chong, Xiaojin; Huang, Chuangxin; Gong, Yajun; Xu, Fabao; Ma, Li; Chen, Guandi; Chong, Lin; Lu, Lin; Jin, Chenjin] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Jin, CJ (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM jinchj@mail.sysu.edu.cn
OI Cheng, Lin/0000-0002-4960-8186
FU Medical Scientific Research Foundation of Guangdong Province [A201633];
   Fundamental Research Funds of the State Key Laboratory of Ophthalmology
   [2016QN06]; Natural Science Foundation of Guangdong Province
   [2016A030310212]; National Natural Science Foundation of China
   [81670866]
FX Dr. Lai received grants from the Medical Scientific Research Foundation
   of Guangdong Province (A201633), the Fundamental Research Funds of the
   State Key Laboratory of Ophthalmology (2016QN06), and the Natural
   Science Foundation of Guangdong Province (2016A030310212). Dr. Jin
   received grants from National Natural Science Foundation of China
   (81670866). The remaining authors report no relevant financial
   disclosures.
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Azar G, 2017, ACTA OPHTHALMOL, V95, P421, DOI 10.1111/aos.13221
   Baillif-Gostoli S, 2010, GRAEF ARCH CLIN EXP, V248, P1845, DOI 10.1007/s00417-010-1328-7
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lau T, 2015, INDIAN J OPHTHALMOL, V63, P378, DOI 10.4103/0301-4738.159860
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Matsumiya W, 2015, OPHTHALMOLOGICA, V234, P33, DOI 10.1159/000431000
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park KA, 2014, AM J OPHTHALMOL, V158, P716, DOI 10.1016/j.ajo.2014.07.008
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Takkar B, 2016, AM J OPHTHALMOL, V163, P193, DOI 10.1016/j.ajo.2015.12.016
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 36
TC 5
Z9 5
U1 0
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD OCT
PY 2018
VL 49
IS 10
BP E114
EP E121
DI 10.3928/23258160-20181002-13
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GY8AM
UT WOS:000448839800001
PM 30395671
DA 2022-11-30
ER

PT J
AU Green-Simms, AE
   Fechtel, BM
   Agarwal, Z
   Bakri, SJ
AF Green-Simms, Amy E.
   Fechtel, Blake M.
   Agarwal, Zubin
   Bakri, Sophie J.
TI VISUAL AND ANATOMICAL OUTCOMES OF ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION AND
   VITREOMACULAR INTERFACE DISEASE Vitreomacular Adhesion and Epiretinal
   Membrane
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; Avastin; bevacizumab;
   epiretinal membrane; intravitreal; Lucentis; ranibizumab; vitreomacular
   adhesion; vitreomacular traction
ID OPTICAL COHERENCE TOMOGRAPHY; PHARMACOKINETICS; RANIBIZUMAB;
   BEVACIZUMAB; ACUITY; RISK
AB Purpose: To describe clinical and imaging features of eyes with and without vitreomacular interface disease (VMID) treated with intravitreal anti-vascular endothelial growth factor injections for exudative age-related macular degeneration, followed over an average of 2.5 years.
   Methods: Retrospective interventional case series involving 32 eyes with VMID and 146 eyes without traction. Best-corrected visual acuity (BCVA), manually measured central foveal thickness from optical coherence tomography imaging, and the number and timing of intravitreal anti-vascular endothelial growth factor injections were reviewed.
   Results: Eyes with VMID and exudative age-related macular degeneration received more intravitreal injections (mean 14.7) for 4 years than eyes without traction (mean 9.5) (P = 0.0224). Eyes with VMID had similar BCVA to eyes without traction at baseline (P = 0.8013) and Year 1 through Year 4 (P = 0.5417, 0.6275, 0.4574, 0.0570, respectively). Best BCVA showed significant improvement over baseline BCVA in eyes with (logarithm of the minimum angle of resolution 0.67-0.47, P = 0.0182) and without (logarithm of the minimum angle of resolution 0.61-0.44, P = 0.0001) VMID. Central foveal thickness was similar to eyes without traction at baseline and Year 1 through Year 3 and declined over time in eyes with VMID.
   Conclusion: In eyes with VMID, anti-vascular endothelial growth factor therapy resulted in improved BCVA and decreased central foveal thickness despite continued vitreomacular traction. Eyes with VMID required more intravitreal anti-vascular endothelial growth factor agents than eyes without VMID.
C1 [Green-Simms, Amy E.; Fechtel, Blake M.; Agarwal, Zubin; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
RI Agarwal, Zubin/AAY-9013-2020
OI Agarwal, Zubin/0000-0002-3619-9010
FU Research to Prevent Blindness, New York, NY
FX Supported by Research to Prevent Blindness, New York, NY.
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   DiLoreto DA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1586, DOI 10.1001/archopht.121.11.1586
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Sebag J, 2009, RETINA-J RET VIT DIS, V29, P871, DOI 10.1097/IAE.0b013e3181ac7b3c
NR 16
TC 3
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2013
VL 33
IS 7
BP 1359
EP 1364
DI 10.1097/IAE.0b013e3182845d18
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 300NN
UT WOS:000330470700009
DA 2022-11-30
ER

PT J
AU Mori, R
   Tanaka, K
   Haruyama, M
   Kawamura, A
   Furuya, K
   Yuzawa, M
AF Mori, Ryusaburo
   Tanaka, Koji
   Haruyama, Miho
   Kawamura, Akiyuki
   Furuya, Koichi
   Yuzawa, Mitsuko
TI Comparison of pro re nata versus Bimonthly Injection of Intravitreal
   Aflibercept for Typical Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Aflibercept; Typical neovascular age-related macular degeneration; pro
   re nata injection; Bimonthly injection
ID TERM EFFICACY; RANIBIZUMAB; BEVACIZUMAB
AB Purpose: The aim of this study was to clarify the 1-year outcomes of pro re nata (PRN) and bimonthly intravitreal injections of aflibercept (IVA) for typical neovascular age-related macular degeneration (tAMD) after the initial 3 monthly IVA. Methods: We conducted a prospective, interventional study. Fifty-eight treatment-naive patients with tAMD were randomly assigned to the PRN (30 patients) or the bimonthly (28 patients) treatment group. Both groups initially received 3 monthly IVA. Visual acuity, central macular retinal thickness (CRT), and central choroidal thickness (CCT) were evaluated at 12 months. Subanalysis was performed to identify factors associated with the best-corrected visual acuity (BCVA). Results: BCVA was significantly improved only in the bimonthly group at 12 months. CRT and CCT were significantly decreased in both groups. Subanalysis showed that the only factor associated with BCVA improvement at 12 months was the existence of pigment epithelial detachment at baseline. Conclusions: BCVA showed significant improvement only in the bimonthly group but not in the PRN group at 12 months. (C) 2017 S. Karger AG, Basel
C1 [Mori, Ryusaburo; Tanaka, Koji; Haruyama, Miho; Kawamura, Akiyuki; Furuya, Koichi; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol, 1-6 Kanda Surugadai Chiyoda Ku, Tokyo, 1018309, Japan.
C3 Nihon University
RP Tanaka, K (通讯作者)，Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol, 1-6 Kanda Surugadai Chiyoda Ku, Tokyo, 1018309, Japan.
EM tanaka.koji@nihon-u.ac.jp
RI Tanaka, Koji/H-3119-2019
OI Tanaka, Koji/0000-0003-3323-4148
FU Division of Companion Diagnostics, Department of Pathology of
   Microbiology, Nihon University School of Medicine, Tokyo, Japan
FX We thank all patients who participated in this study. This work was
   funded in part by the Division of Companion Diagnostics, Department of
   Pathology of Microbiology, Nihon University School of Medicine, Tokyo,
   Japan.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Okuma H, 2016, INT OPHTHALMOL, V36, P159, DOI 10.1007/s10792-015-0089-z
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Takahashi H, 2015, RETINA-J RET VIT DIS, V35, P1331, DOI 10.1097/IAE.0000000000000513
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 16
TC 8
Z9 10
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 1-2
BP 17
EP 22
DI 10.1159/000468950
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC1MB
UT WOS:000406600200003
PM 28402983
DA 2022-11-30
ER

PT J
AU Du, YY
   Kong, N
   Zhang, JB
AF Du, Yongyi
   Kong, Ning
   Zhang, Jibin
TI Genetic Mechanism Revealed of Age-Related Macular Degeneration Based on
   Fusion of Statistics and Machine Learning Method
SO FRONTIERS IN GENETICS
LA English
DT Article
DE AMD; GWAS; eQTL; SNPs; disease susceptibility
ID MENDELIAN RANDOMIZATION; RISK; ASSOCIATION; MACULOPATHY; PROGRESSION;
   PROTEIN; COMMON; RARE
AB Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the developed world which affects the quality of life for millions of elderly individuals worldwide. Genome-wide association studies (GWAS) have identified genetic variants at 34 loci contributing to AMD. To better understand the disease pathogenesis and identify causal genes for AMD, we applied random walk (RW) and support vector machine (SVM) to identify AMD-related genes based on gene interaction relationship and significance of genes. Our model achieved 0.927 of area under the curve (AUC), and 65 novel genes have been identified as AMD-related genes. To verify our results, a statistics method called summary data-based Mendelian randomization (SMR) has been implemented to integrate GWAS data and transcriptome data to verify AMD susceptibility-related genes. We found 45 genes are related to AMD by SMR. Among these genes, 37 genes overlap with those found by SVM-RW. Finally, we revealed the biological process of genetic mutations leading to changes in gene expression leading to AMD. Our results reveal the genetic pathogenic factors and related mechanisms of AMD.
C1 [Du, Yongyi; Kong, Ning] Panyu Cent Hosp, Dept Ophthalmol, Guangzhou, Peoples R China.
   [Zhang, Jibin] Panyu Cent Hosp, Dept Stomatol, Guangzhou, Peoples R China.
RP Zhang, JB (通讯作者)，Panyu Cent Hosp, Dept Stomatol, Guangzhou, Peoples R China.
EM kn13@tom.com
CR Allcock RJN, 2001, GENES CELLS, V6, P487, DOI 10.1046/j.1365-2443.2001.00435.x
   Claussnitzer M, 2015, NEW ENGL J MED, V373, P895, DOI 10.1056/NEJMoa1502214
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fernandez-Vega B, 2020, ACTA OPHTHALMOL, V98, pE282, DOI 10.1111/aos.14280
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Han XK, 2020, EUR J EPIDEMIOL, V35, P139, DOI 10.1007/s10654-019-00598-z
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Inoue A, 2010, REV ECON STAT, V92, P557, DOI 10.1162/REST_a_00011
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Katan MB, 2004, INT J EPIDEMIOL, V33, P9, DOI 10.1093/ije/dyh312
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lynch Michael, 1998
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Pierce BL, 2013, AM J EPIDEMIOL, V178, P1177, DOI 10.1093/aje/kwt084
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Schott G, 2021, RNA BIOL, V18, P640, DOI 10.1080/15476286.2020.1860388
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Smemo S, 2014, NATURE, V507, P371, DOI 10.1038/nature13138
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Winkler TW, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00760-7
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Zhao TY, 2020, BIOINFORMATICS, V36, P4466, DOI 10.1093/bioinformatics/btaa428
   Zhao TY, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa212
   Zhao TY, 2021, NUCLEIC ACIDS RES, V49, pD1413, DOI 10.1093/nar/gkaa838
   Zhao TY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00472
   Zhao TY, 2021, BRIEF BIOINFORM, V22, P2141, DOI 10.1093/bib/bbaa044
   Zhao TY, 2020, P NATL ACAD SCI USA, V117, P7568, DOI 10.1073/pnas.2000499117
   Zhao TY, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3124-7
NR 36
TC 1
Z9 1
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD AUG 5
PY 2021
VL 12
AR 726599
DI 10.3389/fgene.2021.726599
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA UD8BU
UT WOS:000687429100001
PM 34422023
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jiang, RF
   Dong, JP
   Joo, J
   Geller, NL
   Zheng, G
AF Jiang, Renfang
   Dong, Jianping
   Joo, Jungnam
   Geller, Nancy L.
   Zheng, Gang
TI Simple strategies for haplotype analysis of the X chromosome with
   application to age-related macular degeneration
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE case-control studies; GWAS; haplotype analysis; sex-linked genes
ID LINKAGE DISEQUILIBRIUM; ASSOCIATION; POLYMORPHISM; MARKER
AB For haplotype analysis of the X chromosome, haplotype-sharing (HS) statistics with sliding windows are defined for males and females separately, which are then combined to a single HS test for the X chromosome. When independent replication samples are not available, the training-testing sets approach is used to validate this procedure and a permutation method is used to obtain its P-value. We applied this method to the X chromosome (with 1804 SNPs) for age-related macular degeneration (AMD). We found a window of five SNPs over a 272 kb region associated with AMD after Bonferroni correction. An examination of the odds ratio and the population attributable risks revealed a disease-preventive haplotype, ATGAC, on these five SNPs. For elderly females without this haplotype, the likelihood of AMD is increased by a factor of 4.75 with a 95% confidence interval (1.43, 15.82). The frequency of ATGAC in HapMap CEU is 0.276. These five SNPs are covered by the gene DIAPH2, which is known to cause premature ovarian failure (POF) in females. Our results indicated that DIAPH2 may be a polygenic pleiotropy for POF and AMD. European Journal of Human Genetics (2011) 19, 801-806; doi:10.1038/ejhg.2011.35; published online 9 March 2011
C1 [Geller, Nancy L.; Zheng, Gang] NHLBI, Off Biostat Res, Bethesda, MD 20892 USA.
   [Jiang, Renfang; Dong, Jianping] Michigan Technol Univ, Dept Math Sci, Houghton, MI 49931 USA.
   [Joo, Jungnam] Natl Canc Ctr, Canc Biostat Branch, Geonggi Do, South Korea.
C3 National Institutes of Health (NIH) - USA; NIH National Heart Lung &
   Blood Institute (NHLBI); Michigan Technological University; National
   Cancer Center - Korea (NCC)
RP Zheng, G (通讯作者)，NHLBI, Off Biostat Res, 6701 Rockledge Dr,MSC 7913, Bethesda, MD 20892 USA.
EM zhengg@nhlbi.nih.gov
CR *AMA, 2004, ARCH OPHTHALMOL-CHIC, V122, P564, DOI 10.1001/archopht.122.4.564
   Bourgain C, 2000, ANN HUM GENET, V64, P255, DOI 10.1046/j.1469-1809.2000.6430255.x
   Clayton D, 1999, AM J HUM GENET, V65, P1161, DOI 10.1086/302566
   Clayton D, 2008, BIOSTATISTICS, V9, P593, DOI 10.1093/biostatistics/kxn007
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laan M, 2005, EUR J HUM GENET, V13, P452, DOI 10.1038/sj.ejhg.5201340
   Li Y, 2007, AM J HUM GENET, V80, P705, DOI 10.1086/513205
   Schaffner SF, 2004, NAT REV GENET, V5, P43, DOI 10.1038/nrg1247
   Smith JA, 2004, ARCH OPHTHALMOL-CHIC, V122, P151, DOI 10.1001/archopht.122.2.151
   Thorisson GA, 2005, GENOME RES, V15, P1592, DOI 10.1101/gr.4413105
   Toivonen HTT, 2000, AM J HUM GENET, V67, P133, DOI 10.1086/302954
   Tzeng JY, 2003, AM J HUM GENET, V72, P891, DOI 10.1086/373881
   Zhang SL, 2003, AM J HUM GENET, V73, P566, DOI 10.1086/378205
   Zheng G, 2007, GENET EPIDEMIOL, V31, P834, DOI 10.1002/gepi.20244
NR 16
TC 2
Z9 3
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD JUL
PY 2011
VL 19
IS 7
BP 801
EP 806
DI 10.1038/ejhg.2011.35
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 778DA
UT WOS:000291678400016
PM 21386871
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Gerth, C
   Delahunt, PB
   Alam, S
   Morse, LS
   Werner, JS
AF Gerth, C
   Delahunt, PB
   Alam, S
   Morse, LS
   Werner, JS
TI Cone-mediated multifocal electroretinogram in age-related macular
   degeneration - Progression over a long-term follow-up
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL SENSITIVITY; FELLOW EYES; DRUSEN; ABNORMALITIES; MACULOPATHY;
   AREAS; ERG
AB Objective: To evaluate the progression of change in the cone-driven multifocal electroretinogram (mfERG) responses in patients previously identified as having highrisk, soft drusen 63 mu m or greater.
   Methods: Seventeen eyes of 14 patients were reevaluated after 28 to 41 months. Fundus changes were graded depending on drusen size and extent. Each of the 103 mfERG responses was analyzed and compared with agematched normal controls and with the baseline measurement.
   Results: Stable visual acuity was found in 12 of the 17 eyes. Drusen size or extent was increased, decreased, and unchanged in 6, 3, and 8 eyes, respectively. The mfERG responses demonstrated a significant progression in the response density loss and in N1 and P1 implicit time delay compared with the baseline evaluation regardless of drusen change. The extent of response deterioration occurred over the entire retinal area tested. Eyes having decreased drusen at follow-up were typically associated with higher response delays at baseline and follow-up than eyes with stable or increased drusen.
   Conclusions: Early age-related macular degeneration is associated with a progressive loss in the cone-driven mfERG response despite stable visual acuity. The response deterioration extended beyond the visible drusen area. Implicit times seem to be an important predictor of drusen regression.
C1 Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   Univ Calif Davis, Dept Ophthalmol & Vis Sci, Davis, CA 95616 USA.
   Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA.
C3 University of Toronto; University Toronto Affiliates; Hospital for Sick
   Children (SickKids); University of California System; University of
   California Davis; University of California System; University of
   California Davis
RP Gerth, C (通讯作者)，Univ Toronto, Dept Ophthalmol & Vis Sci, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM chgerth@web.de
OI Gerth-Kahlert, Christina/0000-0001-6298-615X; Morse,
   Lawrence/0000-0002-1758-2348
FU NIA NIH HHS [AG04058, R37 AG004058-22, R37 AG004058, R01 AG004058]
   Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG004058,
   R37AG004058, R23AG004058] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Donders FC, 1855, ARCH OPHTHALMOL-CHIC, V1, P106
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gerth C, 2002, GRAEF ARCH CLIN EXP, V240, P202, DOI 10.1007/s00417-002-0442-6
   Han Y, 2004, INVEST OPHTH VIS SCI, V45, P948, DOI 10.1167/iovs.03-1101
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   MARMOR M, GUIDELINES BASIC MUL
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SARKS SH, 2001, RETINA, V2, P1064
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   SUTTER EE, 1991, SIAM J COMPUT, V20, P686, DOI 10.1137/0220043
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   TAKLURA K, 2001, INVESET OPHTHALMOL V, V42, pS73
   WERNER JS, 2002, ANN M ASS RES VIS OP
NR 36
TC 42
Z9 46
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2006
VL 124
IS 3
BP 345
EP 352
DI 10.1001/archopht.124.3.345
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 021GI
UT WOS:000235971300006
PM 16534054
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Pershing, S
   Chee, CP
   Asch, SM
   Baker, LC
   Boothroyd, D
   Wagner, TH
   Bundorf, MK
AF Pershing, Suzann
   Chee, Christine Pal
   Asch, Steven M.
   Baker, Laurence C.
   Boothroyd, Derek
   Wagner, Todd H.
   Bundorf, M. Kate
TI Treating Age-Related Macular Degeneration: Comparing The Use Of Two
   Drugs Among Medicare And Veterans Affairs Populations
SO HEALTH AFFAIRS
LA English
DT Article
ID HEALTH-CARE-SYSTEM; BEVACIZUMAB; RANIBIZUMAB; PATTERNS
AB While new biologics have revolutionized the treatment of age-related macular degeneration-the leading cause of severe vision loss among older adults-these new drugs have also raised concerns over the economic impact of medical innovation. The two leading agents are similar in effectiveness but vary greatly in price-up to $2,000 per injection for ranibizumab compared to $50 for bevacizumab. We examined the diffusion of these drugs in fee-for-service Medicare and Veterans Affairs (VA) systems during 2005-11, in part to assess the impact that differing financial incentives had on prescribing. Physicians treating Medicare patients have a direct financial incentive to prescribe the more expensive agent (ranibizumab), while VA physicians do not. Medicare injections of the more expensive ranibizumab peaked in 2007 at 47 percent. Beginning in 2009 the less expensive bevacizumab became the predominant therapy for Medicare patients, accounting for more than 60 percent of injections. For VA patients, the distribution of injections across the two drugs was relatively equal, particularly from 2009 to 2011. Our analysis indicates that there are opportunities in both the VA and Medicare to adopt more value-conscious treatment patterns and that multiple mechanisms exist to influence utilization.
C1 [Pershing, Suzann] Byers Eye Inst Stanford, Ophthalmol, Palo Alto, CA 94303 USA.
   [Pershing, Suzann] Vet Affairs VA Palo Alto Hlth Care Syst, Ophthalmol & Eye Care Serv, Palo Alto, CA USA.
   [Chee, Christine Pal] VA Hlth Econ Resource Ctr, Menlo Pk, CA USA.
   [Asch, Steven M.; Boothroyd, Derek] Stanford Univ, Sch Med, Med, Palo Alto, CA 94304 USA.
   [Asch, Steven M.] VA Palo Alto Hlth Care Syst, Hlth Serv Res, Palo Alto, CA USA.
   [Asch, Steven M.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Palo Alto, CA USA.
   [Baker, Laurence C.] Stanford Univ, Hlth Res & Policy, Cambridge, MA USA.
   [Baker, Laurence C.; Bundorf, M. Kate] Natl Bur Econ Res, Cambridge, MA 02138 USA.
   [Wagner, Todd H.] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Palo Alto, CA USA.
   [Wagner, Todd H.] Stanford Univ, Stanford, CA 94305 USA.
   [Bundorf, M. Kate] Stanford Univ, Sch Med, Hlth Res & Policy, Stanford, CA 94305 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Palo Alto Health Care System; Stanford University; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto
   Health Care System; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Palo Alto Health Care System; Stanford
   University; National Bureau of Economic Research; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto
   Health Care System; Stanford University; Stanford University
RP Pershing, S (通讯作者)，Byers Eye Inst Stanford, Ophthalmol, Palo Alto, CA 94303 USA.
EM bundorf@stanford.edu
OI Wagner, Todd/0000-0001-7625-3504; Boothroyd, Derek
   Brian/0000-0001-5387-6995; Bundorf, M. Kate/0000-0002-9824-4868; Baker,
   Laurence/0000-0001-5032-794X
FU Department of Veterans Affairs; Agency for Healthcare Research and
   Quality [5R01HS018434]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY
   [R01HS018434] Funding Source: NIH RePORTER
FX Laurence Baker, Derek Boothroyd, and Kate Bundorf received funding from
   the Department of Veterans Affairs for this work. Bundorf was also
   supported by the Agency for Healthcare Research and Quality, Grant No.
   5R01HS018434. The views, opinions, and content of this publication are
   those of the authors and do not necessarily reflect the views, opinions,
   or policies of the Department of Veterans Affairs.
CR [Anonymous], 2011, MED MED RES REV 20 S
   Bach PB, 2009, NEW ENGL J MED, V360, P626, DOI 10.1056/NEJMhpr0807774
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Department of Health and Human Services, 2012, MED PAYM DRUGS US TR
   Department of Veterans Affairs, 2014, PHARM BEN MAN SERV P
   El-Serag HB, 2006, ARCH INTERN MED, V166, P2202, DOI 10.1001/archinte.166.20.2202
   Glied S, 2014, ASPE ISSUE BRIEF M B
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Johnson D, 2013, CURR OPIN OPHTHALMOL, V24, P205, DOI 10.1097/ICU.0b013e32835f8ec0
   Kay C, 2013, VISN 21 PHARM PROPOS
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Levinson DR, 2011, REV MED B
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCarty S, 2014, SPECIALITY TIER PHAR
   McWilliams JM, 2014, ANN INTERN MED, V161, P794, DOI 10.7326/M14-0650
   Millman J., 2014, TOP 10 MEDICARE BILL
   National Center for Veterans Analysis and Statistics, 2014, WELC NCVAS
   NEWHOUSE JP, 1992, J ECON PERSPECT, V6, P3, DOI 10.1257/jep.6.3.3
   Petersen LA, 2003, NEW ENGL J MED, V348, P2209, DOI 10.1056/NEJMsa021725
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schenck AP, 2009, AM J PREV MED, V37, P1, DOI 10.1016/j.amepre.2009.03.009
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stein JD, 2013, AM J OPHTHALMOL, V155, P688, DOI 10.1016/j.ajo.2012.10.003
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Thomas K, 2014, NY TIMES, P1
   Wagner TH, 2009, J UROLOGY, V181, P2829, DOI 10.1016/j.juro.2009.02.058
   Yu XH, 2008, J UROLOGY, V180, P241, DOI 10.1016/j.juro.2008.03.039
NR 32
TC 9
Z9 9
U1 0
U2 2
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD FEB
PY 2015
VL 34
IS 2
BP 229
EP 238
DI 10.1377/hlthaff.2014.1032
PG 10
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA CE3HA
UT WOS:000351716100007
PM 25646102
OA Bronze
DA 2022-11-30
ER

PT J
AU Choi, CS
   Zhang, L
   Abramoff, MD
   Sonka, M
   Shifera, AS
   Kay, CN
AF Choi, Catherine S.
   Zhang, Li
   Abramoff, Michael D.
   Sonka, Milan
   Shifera, Amde Selassie
   Kay, Christine N.
TI Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related
   Macular Degeneration With OCT Segmentation Volumetric Analysis
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; BEVACIZUMAB; OUTCOMES; EYES
AB BACKGROUND AND OBJECTIVE: To use automated segmentation software to analyze spectral-domain optical coherence tomography (SD-OCT) scans and evaluate the effectiveness of aflibercept (Eylea; Regeneron, Tarrytown, NY) in the treatment of patients with exudative age-related macular degeneration (AMD) refractory to other treatments.
   PATIENTS AND METHODS: Retrospective chart review of 16 patients refractory to bevacizumab (Avastin; Genentech, South San Francisco, CA)/ranibizumab (Lucentis; Genentech, San Francisco, CA) treatment was conducted. Visual acuity, central foveal thickness (CFT), maximum fluid height, pigment epithelial detachment (PED) volume, subretinal fluid (SRF) volume, fluid-free time interval, and adverse effects were evaluated. Automated segmentation analysis was used to quantify improvement.
   RESULTS: With aflibercept treatment, there was a statistically significant improvement in visual acuity by 1 line (P = .020), in CFT by 74.02 mu m (P = .001), and in maximum fluid height by 31.9 mu m (P = .011). Total PED and SRF volume also decreased significantly by 1.50 mu m(3) x 108 mu m(3) (P = .013). Anatomic improvement was confirmed by automated segmentation analysis.
   CONCLUSION: This study demonstrates utility of automated segmentation software in quantifying anatomic improvement with aflibercept treatment in exudative AMD refractory to other anti-vascular endothelial growth factor treatments.
C1 [Choi, Catherine S.] Tufts Med Ctr, Dept Ophthalmol, Boston, MA USA.
   [Zhang, Li; Abramoff, Michael D.] Univ Iowa, Stephen A Wynn Inst Vis Res, Iowa City, IA USA.
   [Abramoff, Michael D.; Sonka, Milan] Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.; Sonka, Milan] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] Iowa City VA Med Ctr, Dept Vet Affairs, Iowa City, IA USA.
   [Shifera, Amde Selassie] Johns Hopkins Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD USA.
   [Kay, Christine N.] Vitreoretinal Associates PA, 4340 Newberry Rd,Suite 202, Gainesville, FL 32607 USA.
C3 Tufts Medical Center; University of Iowa; University of Iowa; University
   of Iowa; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Iowa City VA Health Care System; Johns Hopkins
   University; Johns Hopkins Medicine
RP Kay, CN (通讯作者)，Vitreoretinal Associates PA, 4340 Newberry Rd,Suite 202, Gainesville, FL 32607 USA.
EM christinenkay@gmail.com
RI Abramoff, Michael D/A-5836-2009
OI Abramoff, Michael D/0000-0002-3490-0037
FU Foundation Fighting Blindness; Arnold and Mabel Beckman Initiative for
   Macular Research; National Institutes for Health [R01-EY017066,
   R01-EY018853, R01-EB004640 EY018853]; NATIONAL EYE INSTITUTE
   [R01EY017066, R01EY019112, R01EY018853] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [R01EB004640] Funding Source: NIH RePORTER
FX Supported in part by a grant from Foundation Fighting Blindness (PI:
   Christine Kay); Arnold and Mabel Beckman Initiative for Macular
   Research, (PI: Abramoff); and National Institutes for Health
   R01-EY017066 and R01-EY018853 (PI: Abramoff and Sonka) and R01-EB004640
   EY018853 (PI: Sonka).
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 12
TC 4
Z9 4
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR
PY 2016
VL 47
IS 3
BP 245
EP 251
DI 10.3928/23258160-20160229-07
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9VF
UT WOS:000378844900008
PM 26985798
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gorczynska, I
   Srinivasan, VJ
   Vuong, LN
   Chen, RWS
   Liu, JJ
   Reichel, E
   Wojtkowski, M
   Schuman, JS
   Duker, JS
   Fujimoto, JG
AF Gorczynska, I.
   Srinivasan, V. J.
   Vuong, L. N.
   Chen, R. W. S.
   Liu, J. J.
   Reichel, E.
   Wojtkowski, M.
   Schuman, J. S.
   Duker, J. S.
   Fujimoto, J. G.
TI Projection OCT fundus imaging for visualising outer retinal pathology in
   non-exudative age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; HIGH-SPEED; THICKNESS
AB Aims: To demonstrate ultrahigh-resolution, three-dimensional optical coherence tomography (3D-OCT) and projection OCT fundus imaging for enhanced visualisation of outer retinal pathology in non-exudative age-related macular degeneration (AMD).
   Methods: A high-speed, 3.5 mu m resolution OCT prototype instrument was developed for the ophthalmic clinic. Eighty-three patients with non-exudative AMD were imaged. Projection OCT fundus images were generated from 3D-OCT data by selectively summing different retinal depth levels. Results were compared with standard ophthalmic examination, including fundus photography and fluorescein angiography, when indicated.
   Results: Projection OCT fundus imaging enhanced the visualisation of outer retinal pathology in non-exudative AMD. Different types of drusen exhibited distinct features in projection OCT images. Photoreceptor disruption was indicated by loss of the photoreceptor inner/outer segment (IS/OS) boundary and external limiting membrane (ELM). RPE atrophy can be assessed using choroid-level projection OCT images.
   Conclusions: Projection OCT fundus imaging facilities rapid interpretation of large 3D-OCT data sets. Projection OCT enhances contrast and visualises outer retinal pathology not visible with standard fundus imaging or OCT fundus imaging. Projection OCT fundus images enable registration with standard ophthalmic diagnostics and cross-sectional OCT images. Outer retinal alterations can be assessed and drusen morphology, photoreceptor impairment and pigmentary abnormalities identified.
C1 [Gorczynska, I.; Srinivasan, V. J.; Liu, J. J.; Fujimoto, J. G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Gorczynska, I.; Srinivasan, V. J.; Liu, J. J.; Fujimoto, J. G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Gorczynska, I.; Vuong, L. N.; Chen, R. W. S.; Reichel, E.; Duker, J. S.] Tufts Univ, New England Eye Ctr, Tufts Med Ctr, Boston, MA 02111 USA.
   [Wojtkowski, M.] Nicholas Copernicus Univ, Inst Phys, PL-87100 Torun, Poland.
   [Schuman, J. S.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, UPMC Eye Ctr, Pittsburgh, PA 15261 USA.
C3 Massachusetts Institute of Technology (MIT); Massachusetts Institute of
   Technology (MIT); Tufts Medical Center; Tufts University; Nicolaus
   Copernicus University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh
RP Fujimoto, JG (通讯作者)，MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave 36-345, Cambridge, MA 02139 USA.
EM jgfuji@mit.edu
RI Wojtkowski, Maciej/D-6822-2014; Gorczynska, Iwona M./P-9367-2015;
   Schuman, Joel S/K-7304-2012; Schuman, Joel S/M-2389-2019
OI Gorczynska, Iwona M./0000-0002-6120-8791; Schuman, Joel
   S/0000-0002-8885-3766; Schuman, Joel S/0000-0002-8885-3766; Wojtkowski,
   Maciej/0000-0003-0599-0878
FU National Institute of Health [R01-EY11289-23, R01-EY13178-09,
   R01-EY013516-06, P30-EY08098, P30-EY13078]; National Science Foundation
   [BES-0522845]; Air Force Office of Scientific Research; Medical Free
   Electron Laser Program [FA9550-07-1-0101, FA9550-07-1-0014]; The Eye and
   Ear Foundation (Pittsburgh); Massachusetts Lions Eye Research Fund;
   Research to Prevent Blindness; Medical Student Eye Research Fellowship;
   NATIONAL EYE INSTITUTE [R01EY013178, P30EY008098, R01EY011289,
   P30EY013078, R01EY013516] Funding Source: NIH RePORTER
FX National Institute of Health contracts R01-EY11289-23, R01-EY13178-09,
   R01-EY013516-06, P30-EY08098 and P30-EY13078; National Science
   Foundation contract BES-0522845; Air Force Office of Scientific
   Research, Medical Free Electron Laser Program contracts FA9550-07-1-0101
   and FA9550-07-1-0014; The Eye and Ear Foundation (Pittsburgh),
   Massachusetts Lions Eye Research Fund; unrestricted grants from Research
   to Prevent Blindness and Medical Student Eye Research Fellowship.
CR Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Hitzenberger CK, 2003, OPT EXPRESS, V11, P2753, DOI 10.1364/OE.11.002753
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Koozekanani D, 2001, IEEE T MED IMAGING, V20, P900, DOI 10.1109/42.952728
   Leitgeb R, 2003, OPT EXPRESS, V11, P889, DOI 10.1364/OE.11.000889
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Pircher M, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2358960
   Podoleanu AG, 2000, OPT EXPRESS, V7, P292, DOI 10.1364/OE.7.000292
   Podoleanu AG, 2004, J BIOMED OPT, V9, P86, DOI 10.1117/1.1627778
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   SCHUMAN JS, 1995, ARCH OPHTHALMOL-CHIC, V113, P586, DOI 10.1001/archopht.1995.01100050054031
   SHULIANG J, 2005, OPT EXPRESS, V13, P444
   SHULIANG J, 2006, OPT EXPRESS, V14, P3368
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Szkulmowski M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771569
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 25
TC 43
Z9 43
U1 2
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2009
VL 93
IS 5
BP 603
EP 609
DI 10.1136/bjo.2007.136101
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 438BE
UT WOS:000265530100011
PM 18662918
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lazic, R
   Gabric, N
   Dekaris, I
   Gavric, M
   Bosnar, D
AF Lazic, Ratimir
   Gabric, Nikica
   Dekaris, Iva
   Gavric, Morena
   Bosnar, Damir
TI Photodynamic therapy combined with intravitreal bevacizumab (avastin) in
   treatment of choroidal neovascularization secondary to age-related
   macular degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE bevacizumab; photodynamic therapy; choroidal neovascularization
ID TRIAMCINOLONE ACETONIDE; INJECTION
AB To evaluate photodynamic therapy with verteporfin combined with intravitreal bevacizumab in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. 46 eyes of 46 patients (mean age 74.5) included in this prospective, noncomparative, interventional case series. Median follow-up was 24 weeks (12-36). Verteporfin photodynamic therapy (PDT) was followed by 0.05 mL (1.25 mg) of bevacizumab injected intravitreally within 24 hours and again after 6 weeks. Whole procedure was repeated in 3-month intervals in case of leakage. Visual acuity (VA) improved in majority of patients (baseline VA 1.041 log MAR) by mean increase of 1.45 lines (last follow-up) (p=0.001). Central foveal thickness (CFT) and total macular volume (TMV) decreased by 53 mu m (p =0.03) and 1.04 mm(3) (p < 0.001) respectively. No serious complications were observed. Combined treatment may improve outcome of monotherapy. Significant improvement in VA, CFT and TMA was noted in majority of patients and maintained during follow-up.
C1 Eye Clin Svjetlost, Zagreb 10000, Croatia.
RP Lazic, R (通讯作者)，Eye Clin Svjetlost, Bukovacka 27, Zagreb 10000, Croatia.
EM ratimir.lazic@svjetlost.hr
RI Dekaris, Iva/AAM-8799-2020
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   He Aiwu Ruth, 2005, Clin Adv Hematol Oncol, V3, P555
   Ignoffo RJ, 2004, AM J HEALTH-SYST PH, V61, pS21, DOI 10.1093/ajhp/61.suppl_5.S21
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   WORMALD R, 2003, COCHRANE DB SYST REV
NR 18
TC 11
Z9 11
U1 0
U2 2
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD JAN
PY 2007
VL 31
SU 1
BP 71
EP 75
PG 5
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 143XD
UT WOS:000244758800018
PM 17469756
DA 2022-11-30
ER

PT J
AU Zhao, TT
   Guo, XJ
   Sun, Y
AF Zhao, Tantai
   Guo, Xiaojian
   Sun, Yun
TI Iron Accumulation and Lipid Peroxidation in the Aging Retina:
   Implication of Ferroptosis in Age-Related Macular Degeneration
SO AGING AND DISEASE
LA English
DT Review
DE iron; lipid peroxidation; ferroptosis; retina; age-related macular
   degeneration
ID PIGMENT EPITHELIAL-CELLS; TRANSFERRIN RECEPTOR 2; HANDLING PROTEINS
   FERRITIN; OXIDATIVE STRESS; NLRP3 INFLAMMASOME; MOUSE MODEL; RAT RETINA;
   PHOTOOXIDATIVE DAMAGE; MATRIPTASE-2 TMPRSS6; HEPCIDIN EXPRESSION
AB Iron is an essential component in many biological processes in the human body. It is critical for the visual phototransduction cascade in the retina. However, excess iron can be toxic. Iron accumulation and reduced efficiency of intracellular antioxidative defense systems predispose the aging retina to oxidative stress-induced cell death. Age-related macular degeneration (AMD) is characterized by retinal iron accumulation and lipid peroxidation. The mechanisms underlying AMD include oxidative stress-mediated death of retinal pigment epithelium (RPE) cells and subsequent death of retinal photoreceptors. Understanding the mechanism of the disruption of iron and redox homeostasis in the aging retina and AMD is crucial to decipher these mechanisms of cell death and AMD pathogenesis. The mechanisms of retinal cell death in AMD are an area of active investigation; previous studies have proposed several types of cell death as major mechanisms. Ferroptosis, a newly discovered programmed cell death pathway, has been associated with the pathogenesis of several neurodegenerative diseases. Ferroptosis is initiated by lipid peroxidation and is characterized by iron-dependent accumulation. In this review, we provide an overview of the mechanisms of iron accumulation and lipid peroxidation in the aging retina and AMD, with an emphasis on ferroptosis.
C1 [Zhao, Tantai; Guo, Xiaojian; Sun, Yun] Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha, Hunan, Peoples R China.
   [Zhao, Tantai; Guo, Xiaojian; Sun, Yun] Hunan Clin Res Ctr Ophthalm Dis, Changsha, Hunan, Peoples R China.
C3 Central South University
RP Sun, Y (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha, Hunan, Peoples R China.; Sun, Y (通讯作者)，Hunan Clin Res Ctr Ophthalm Dis, Changsha, Hunan, Peoples R China.
EM suny58@csu.edu.cn
FU National Natural Science Foundation of China [81900895]; Natural Science
   Foundation of Hunan Province [2020JJ5833]
FX This work is funded by the National Natural Science Foundation of China
   (Project No. 81900895) and Natural Science Foundation of Hunan Province
   (Project No. 2020JJ5833).
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Adler R, 1999, MOL VIS, V5
   Anandhan A, 2020, CELL CHEM BIOL, V27, P436, DOI 10.1016/j.chembiol.2020.03.011
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064
   Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701
   Arjunan P, 2016, INVEST OPHTH VIS SCI, V57, P1612, DOI 10.1167/iovs.15-17437
   Armstrong JS, 2004, INVEST OPHTH VIS SCI, V45, P4183, DOI 10.1167/iovs.04-0570
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Baath JS, 2008, RETINA-J RET VIT DIS, V28, P894, DOI 10.1097/IAE.0b013e3181679f67
   Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777
   Baksheeva VE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8010003
   Baksi S, 2016, FREE RADICAL BIO MED, V97, P292, DOI 10.1016/j.freeradbiomed.2016.06.025
   Baumann B, 2017, INVEST OPHTH VIS SCI, V58, P4223, DOI 10.1167/iovs.17-21743
   Baumann BH, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107728
   Bayir H, 2020, CELL CHEM BIOL, V27, P387, DOI 10.1016/j.chembiol.2020.03.014
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Belaidi AA, 2016, J NEUROCHEM, V139, P179, DOI 10.1111/jnc.13425
   Belavgeni A, 2020, CELL CHEM BIOL, V27, P448, DOI 10.1016/j.chembiol.2020.03.016
   Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2
   Bhoiwala DL, 2015, INVEST OPHTH VIS SCI, V56, P5344, DOI 10.1167/iovs.15-17026
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Bourdon E, 2003, BLOOD CELL MOL DIS, V31, P247, DOI 10.1016/S1079-9796(03)00161-X
   Bridges CC, 2001, INVEST OPHTH VIS SCI, V42, P47
   Brittenham GM, 2011, NEW ENGL J MED, V364, P146, DOI 10.1056/NEJMct1004810
   Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991
   Burdo JR, 2003, NEUROSCIENCE, V121, P883, DOI 10.1016/S0306-4522(03)00590-6
   Burkhart A, 2016, MOL NEUROBIOL, V53, P7237, DOI 10.1007/s12035-015-9582-7
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Cao JY, 2016, CELL MOL LIFE SCI, V73, P2195, DOI 10.1007/s00018-016-2194-1
   Cappellini MD, 2009, ANNU REV MED, V60, P25, DOI 10.1146/annurev.med.60.041807.123243
   Caro AA, 2015, BBA-GEN SUBJECTS, V1850, P2256, DOI 10.1016/j.bbagen.2015.08.005
   Ceci A, 2003, EXPERT OPIN PHARMACO, V4, P1763, DOI 10.1517/14656566.4.10.1763
   Charkoudian LK, 2006, J AM CHEM SOC, V128, P12424, DOI 10.1021/ja064806w
   Charkoudian LK, 2008, J INORG BIOCHEM, V102, P2130, DOI 10.1016/j.jinorgbio.2008.08.001
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen HY, 2009, NEUROBIOL AGING, V30, P1865, DOI 10.1016/j.neurobiolaging.2008.01.002
   Chen L, 2020, DEV GROWTH DIFFER, V62, P139, DOI 10.1111/dgd.12650
   Chen LJ, 2015, J BIOL CHEM, V290, P28097, DOI 10.1074/jbc.M115.680090
   Cheng ZY, 2007, CHEM REV, V107, P748, DOI 10.1021/cr040077w
   CHEVION M, 1991, FREE RADICAL RES COM, V12-3, P691, DOI 10.3109/10715769109145848
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Chua SYL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.32
   Coffman LG, 2009, P NATL ACAD SCI USA, V106, P570, DOI 10.1073/pnas.0812010106
   Cohen LA, 2010, BLOOD, V116, P1574, DOI 10.1182/blood-2009-11-253815
   Colak E, 2018, CURR EYE RES, V43, P659, DOI 10.1080/02713683.2018.1437452
   Conrad M, 2020, CELL CHEM BIOL, V27, P409, DOI 10.1016/j.chembiol.2020.03.012
   Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6
   Corradini E, 2009, GASTROENTEROLOGY, V137, P1489, DOI 10.1053/j.gastro.2009.06.057
   Cunha-Vaz J, 2017, OPHTHALMOLOGICA, V237, P1, DOI 10.1159/000455809
   Darshan D, 2009, BIOMETALS, V22, P77, DOI 10.1007/s10534-008-9187-y
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   De Domenico I, 2009, P NATL ACAD SCI USA, V106, P3800, DOI 10.1073/pnas.0900453106
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Di Nicola M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/249617
   Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Do Van B, 2016, NEUROBIOL DIS, V94, P169, DOI 10.1016/j.nbd.2016.05.011
   Dodson M, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2019.101107
   Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0
   Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/nchembio.2239, 10.1038/NCHEMBIO.2239]
   Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596
   Duce JA, 2010, CELL, V142, P857, DOI 10.1016/j.cell.2010.08.014
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Enami S, 2014, P NATL ACAD SCI USA, V111, P623, DOI 10.1073/pnas.1314885111
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Fagali N, 2009, CHEM PHYS LIPIDS, V159, P88, DOI 10.1016/j.chemphyslip.2009.03.001
   Feng HZ, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006203
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fisher SA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004839.pub3
   Galaris D, 2019, BBA-MOL CELL RES, V1866, DOI 10.1016/j.bbamcr.2019.118535
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   GANZ T, 2006, HEMATOL-AM SOC HEMAT, V507, P29, DOI DOI 10.1182/ASHEDUCATION-2006.1.29
   Ganz T, 2013, PHYSIOL REV, V93, P1721, DOI 10.1152/physrev.00008.2013
   Gao JW, 2009, CELL METAB, V9, P217, DOI 10.1016/j.cmet.2009.01.010
   Gao MH, 2018, CURR OPIN CELL BIOL, V51, P58, DOI 10.1016/j.ceb.2017.11.001
   Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95
   Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011
   Garcia-Castineiras S, 2010, EXP EYE RES, V90, P664, DOI 10.1016/j.exer.2010.03.003
   Gaschler MM, 2018, NAT CHEM BIOL, V14, P507, DOI 10.1038/s41589-018-0031-6
   Gascon S, 2016, CELL STEM CELL, V18, P396, DOI 10.1016/j.stem.2015.12.003
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Ghosh MC, 2015, NEUROBIOL DIS, V81, P66, DOI 10.1016/j.nbd.2015.02.026
   Giannetti AM, 2004, J BIOL CHEM, V279, P25866, DOI 10.1074/jbc.M401467200
   Glickstein H, 2005, BLOOD, V106, P3242, DOI 10.1182/blood-2005-02-0460
   Gnana-Prakasam JP, 2008, BIOCHEM J, V411, P79, DOI 10.1042/BJ20071377
   Gnana-Prakasam JP, 2014, MOL VIS, V20, P561
   Gnana-Prakasam JP, 2012, BIOCHEM J, V441, P599, DOI 10.1042/BJ20111148
   Gnana-Prakasam JP, 2011, INVEST OPHTH VIS SCI, V52, P3751, DOI 10.1167/iovs.10-6722
   Gnana-Prakasam JP, 2010, IUBMB LIFE, V62, P363, DOI 10.1002/iub.326
   Gnana-Prakasam JP, 2009, BIOCHEM J, V424, P243, DOI 10.1042/BJ20090424
   GOLDBERG L, 1962, BIOCHEM J, V83, P291
   Goralska M, 2001, INVEST OPHTH VIS SCI, V42, P1721
   Green DR, 2019, CELL, V177, P1094, DOI 10.1016/j.cell.2019.04.024
   Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343
   Guo LY, 2014, EXP EYE RES, V129, P31, DOI 10.1016/j.exer.2014.10.012
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2012, TRANSL VIS SCI TECHN, V1, DOI 10.1167/tvst.1.3.2
   Hadziahmetovic M, 2012, INVEST OPHTH VIS SCI, V53, P5231, DOI 10.1167/iovs.12-10204
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2004, MOL VIS, V10, P598
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Hambright WS, 2017, REDOX BIOL, V12, P8, DOI 10.1016/j.redox.2017.01.021
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Harned J, 2012, EXP EYE RES, V97, P90, DOI 10.1016/j.exer.2012.02.001
   Harned J, 2014, BBA-GEN SUBJECTS, V1840, P3138, DOI 10.1016/j.bbagen.2014.06.012
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028
   Hidajat RR, 2004, DOC OPHTHALMOL, V109, P273, DOI 10.1007/s10633-005-1336-9
   Hirayama T, 2019, FREE RADICAL BIO MED, V133, P38, DOI 10.1016/j.freeradbiomed.2018.07.004
   Hirota K, 2019, FREE RADICAL BIO MED, V133, P118, DOI 10.1016/j.freeradbiomed.2018.07.018
   Hirschhorn T, 2019, FREE RADICAL BIO MED, V133, P130, DOI 10.1016/j.freeradbiomed.2018.09.043
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Horackova M, 2000, CARDIOVASC RES, V47, P529, DOI 10.1016/S0008-6363(00)00088-2
   Hou W, 2016, AUTOPHAGY, V12, P1425, DOI 10.1080/15548627.2016.1187366
   HUNT RC, 1989, J CELL SCI, V92, P655
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jin ML, 2005, INVEST OPHTH VIS SCI, V46, P4311, DOI 10.1167/iovs.05-0353
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kakhlon O, 2002, FREE RADICAL BIO MED, V33, P1037, DOI 10.1016/S0891-5849(02)01006-7
   Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Karimi M, 2002, ACTA HAEMATOL-BASEL, V108, P79, DOI 10.1159/000064748
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kautz L, 2014, NAT GENET, V46, P678, DOI 10.1038/ng.2996
   Kautz L, 2009, BLOOD, V114, P2515, DOI 10.1182/blood-2009-02-206771
   Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826
   Kerins MJ, 2018, ANTIOXID REDOX SIGN, V29, P1756, DOI 10.1089/ars.2017.7176
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kidane TZ, 2006, AM J PHYSIOL-CELL PH, V291, pC445, DOI 10.1152/ajpcell.00505.2005
   Kim J, 2020, FREE RADICAL BIO MED, V152, P622, DOI 10.1016/j.freeradbiomed.2019.12.003
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Klimtova Ivona, 2003, Acta Medica (Hradec Kralove), V46, P163
   Kontoghiorghes GJ, 2007, EXPERT OPIN DRUG SAF, V6, P235, DOI 10.1517/14740338.6.3.235
   Kontoghiorghes GJ, 2000, TRANSFUS SCI, V23, P211, DOI 10.1016/S0955-3886(00)00089-8
   Kowoghiorghes GJ, 2003, DRUG SAFETY, V26, P553, DOI 10.2165/00002018-200326080-00003
   Kruszewski M, 2003, MUTAT RES-FUND MOL M, V531, P81, DOI 10.1016/j.mrfmmm.2003.08.004
   Kumar P, 2017, TOXICOLOGY, V392, P22, DOI 10.1016/j.tox.2017.10.005
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Kwon MY, 2015, ONCOTARGET, V6, P24393, DOI 10.18632/oncotarget.5162
   Lall MM, 2008, INVEST OPHTH VIS SCI, V49, P310, DOI 10.1167/iovs.07-1041
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Lee JJ, 2020, BIOCHEM BIOPH RES CO, V521, P414, DOI 10.1016/j.bbrc.2019.10.138
   Lewerenz J, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00214
   Li JY, 2009, DEV CELL, V16, P35, DOI 10.1016/j.devcel.2008.12.002
   Li LB, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020198
   Li YF, 2015, J BIOL CHEM, V290, P11918, DOI 10.1074/jbc.M115.645903
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lin L, 2005, BLOOD, V106, P2884, DOI 10.1182/blood-2005-05-1845
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu YX, 2014, J PHOTOCH PHOTOBIO B, V140, P85, DOI 10.1016/j.jphotobiol.2014.07.016
   Lu M, 2007, ARCH OPHTHALMOL-CHIC, V125, P1581, DOI 10.1001/archopht.125.11.1581
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148
   Marchette LD, 2010, FREE RADICAL BIO MED, V48, P16, DOI 10.1016/j.freeradbiomed.2009.08.005
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin PM, 2006, INVEST OPHTH VIS SCI, V47, P4238, DOI 10.1167/iovs.06-0026
   Masaldan S, 2019, FREE RADICAL BIO MED, V133, P221, DOI 10.1016/j.freeradbiomed.2018.09.033
   Masaldan S, 2018, REDOX BIOL, V14, P100, DOI 10.1016/j.redox.2017.08.015
   Maxwell PH, 1997, KIDNEY INT, V51, P393, DOI 10.1038/ki.1997.52
   Mayle Kristine M, 2012, Biochim Biophys Acta, V1820, P264, DOI 10.1016/j.bbagen.2011.09.009
   McGahan MC, 2005, AM J PHYSIOL-CELL PH, V288, pC1117, DOI 10.1152/ajpcell.00444.2004
   McKie AT, 2005, NAT GENET, V37, P1159, DOI 10.1038/ng1105-1159
   Mendes-Jorge L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106974
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Muckenthaler MU, 2017, CELL, V168, P344, DOI 10.1016/j.cell.2016.12.034
   Nag TC, 2017, EXP EYE RES, V165, P125, DOI 10.1016/j.exer.2017.09.014
   Nag TC, 2011, ANN ANAT, V193, P205, DOI 10.1016/j.aanat.2011.02.004
   Nag TC, 2019, ANN ANAT, V226, P35, DOI 10.1016/j.aanat.2019.06.007
   Neufeld EJ, 2006, BLOOD, V107, P3436, DOI 10.1182/blood-2006-02-002394
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Njie-Mbye YF, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00366
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Obolensky A, 2011, FREE RADICAL BIO MED, V51, P1482, DOI 10.1016/j.freeradbiomed.2011.07.014
   Oh IH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153624
   Ohgami RS, 2005, NAT GENET, V37, P1264, DOI 10.1038/ng1658
   Ohishi K, 2006, FREE RADICAL RES, V40, P799, DOI 10.1080/10715760600555027
   Pan Ying, 2010, Retin Cases Brief Rep, V4, P229, DOI 10.1097/ICB.0b013e3181af7b44
   Pariente A, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107746
   Park E, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2064-5
   Peslova G, 2009, BLOOD, V113, P6225, DOI 10.1182/blood-2009-01-201590
   Picard E, 2015, FREE RADICAL BIO MED, V89, P1105, DOI 10.1016/j.freeradbiomed.2015.08.018
   Picard E, 2010, MOL VIS, V16, P2612
   Puri C, 2009, J BIOL CHEM, V284, P34998, DOI 10.1074/jbc.M109.012328
   Ramey G, 2009, HAEMATOL-HEMATOL J, V94, P765, DOI 10.3324/haematol.2008.003541
   Ramsay AJ, 2009, HAEMATOL-HEMATOL J, V94, P840, DOI 10.3324/haematol.2008.001867
   Reed JC, 2012, CELL, V149, P963, DOI 10.1016/j.cell.2012.05.009
   Rice AE, 2009, J MOL BIOL, V386, P717, DOI 10.1016/j.jmb.2008.12.063
   Rodriguez IR, 2009, PHOTOCHEM PHOTOBIOL, V85, P1116, DOI 10.1111/j.1751-1097.2009.00568.x
   Rogers BS, 2007, INVEST OPHTH VIS SCI, V48, P438, DOI 10.1167/iovs.06-0528
   Roggia MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098864
   Rozanowska M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112799
   Sacca SC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060668
   Sakai O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130467
   Sakamoto K, 2018, EXP EYE RES, V171, P30, DOI 10.1016/j.exer.2018.03.008
   Santoro MM, 2020, CELL METAB, V31, P13, DOI 10.1016/j.cmet.2019.12.007
   Seibt TM, 2019, FREE RADICAL BIO MED, V133, P144, DOI 10.1016/j.freeradbiomed.2018.09.014
   Seo AY, 2008, AGING CELL, V7, P706, DOI 10.1111/j.1474-9726.2008.00418.x
   Sfera A, 2018, MECH AGEING DEV, V174, P63, DOI 10.1016/j.mad.2017.11.012
   Shah R, 2018, ACS CENTRAL SCI, V4, P387, DOI 10.1021/acscentsci.7b00589
   Shah YM, 2014, GASTROENTEROLOGY, V146, P630, DOI 10.1053/j.gastro.2013.12.031
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Shi HF, 2008, SCIENCE, V320, P1207, DOI 10.1126/science.1157643
   Shi L, 2017, FREE RADICAL BIO MED, V108, P904, DOI 10.1016/j.freeradbiomed.2017.04.368
   Shirai Y, 2015, BIOL PHARM BULL, V38, P1076, DOI 10.1248/bpb.b15-00185
   Shu WT, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101469
   Silva B, 2015, BBA-MOL BASIS DIS, V1852, P1347, DOI 10.1016/j.bbadis.2015.03.011
   Simunek T, 2005, J MOL CELL CARDIOL, V39, P345, DOI 10.1016/j.yjmcc.2005.05.008
   Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a
   Sohn YS, 2008, BLOOD, V111, P1690, DOI 10.1182/blood-2007-07-102335
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   Song DL, 2014, INVEST OPHTH VIS SCI, V55, P4525, DOI 10.1167/iovs.14-14568
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Steere AN, 2012, BBA-GEN SUBJECTS, V1820, P326, DOI 10.1016/j.bbagen.2011.06.003
   Stenirri S, 2012, CLIN CHEM LAB MED, V50, P1021, DOI 10.1515/cclm-2011-0854
   Sterling J, 2017, EXP EYE RES, V155, P15, DOI 10.1016/j.exer.2016.12.008
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Stoyanovsky DA, 2019, FREE RADICAL BIO MED, V133, P153, DOI 10.1016/j.freeradbiomed.2018.09.008
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P2392
   Tanito M, 2009, J LIPID RES, V50, P807, DOI 10.1194/jlr.M800170-JLR200
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Tawfik A, 2014, INVEST OPHTH VIS SCI, V55, P3616, DOI 10.1167/iovs.13-13677
   Testi C, 2019, BIOPHYS CHEM, V254, DOI 10.1016/j.bpc.2019.106242
   Theil EC, 2009, CHEM REV, V109, P4568, DOI 10.1021/cr900052g
   Theriot CA, 2016, NPJ MICROGRAVITY, V2, DOI 10.1038/npjmgrav.2016.14
   Theurl M, 2016, FASEB J, V30, P813, DOI 10.1096/fj.15-276758
   Tonnus W, 2019, CELL DEATH DIFFER, V26, P68, DOI 10.1038/s41418-018-0193-5
   Torii S, 2016, BIOCHEM J, V473, P769, DOI 10.1042/BJ20150658
   Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Truman-Rosentsvit M, 2018, BLOOD, V131, P342, DOI 10.1182/blood-2017-02-768580
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Turchi R, 2020, CELL DEATH DIS, V11, DOI [10.1038/s41419-020-2253-2, 10.1038/s41419-020-2347-x]
   Ueda K, 2018, P NATL ACAD SCI USA, V115, P4963, DOI 10.1073/pnas.1722601115
   Ueta T, 2012, J BIOL CHEM, V287, P7675, DOI 10.1074/jbc.M111.335174
   Ugarte M, 2018, BIOMETALS, V31, P1061, DOI 10.1007/s10534-018-0147-x
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wallace DF, 2009, HEPATOLOGY, V50, P1992, DOI 10.1002/hep.23198
   Wang H, 2017, HEPATOLOGY, V66, P449, DOI 10.1002/hep.29117
   Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825
   Wang RH, 2005, CELL METAB, V2, P399, DOI 10.1016/j.cmet.2005.10.010
   Wang XY, 2016, NEUROBIOL AGING, V47, P168, DOI 10.1016/j.neurobiolaging.2016.07.025
   Ward DM, 2019, ANNU REV PHYSIOL, V81, P453, DOI 10.1146/annurev-physiol-020518-114742
   Wessling-Resnick M, 2018, ANNU REV NUTR, V38, P431, DOI 10.1146/annurev-nutr-082117-051749
   Wilkinson N, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00176
   Wilkinson N, 2013, BLOOD, V122, P1658, DOI 10.1182/blood-2013-03-492454
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Wong BX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114174
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wood JPM, 1998, RESTOR NEUROL NEUROS, V12, P119
   Wooff Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58849-z
   Wu CH, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-88
   Wysokinski D, 2012, GRAEF ARCH CLIN EXP, V250, P1057, DOI 10.1007/s00417-012-1966-z
   Xia Y, 2008, BLOOD, V111, P5195, DOI 10.1182/blood-2007-09-111567
   Yamamoto N, 2012, J PHYS CHEM B, V116, P14178, DOI 10.1021/jp310008z
   Yanatori I, 2016, J BIOL CHEM, V291, P17303, DOI 10.1074/jbc.M116.721936
   Yanatori I, 2014, BIOCHEM J, V462, P25, DOI 10.1042/BJ20140225
   Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010
   Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113
   Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Yoo SE, 2012, FREE RADICAL BIO MED, V52, P1820, DOI 10.1016/j.freeradbiomed.2012.02.043
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Yumnamcha T, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01065
   Zadlo A, 2007, PIGM CELL RES, V20, P52, DOI 10.1111/j.1600-0749.2006.00350.x
   Zhang AS, 2008, J BIOL CHEM, V283, P17494, DOI 10.1074/jbc.M710527200
   Zhang DL, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00124
   Zhao LL, 2014, AM J PATHOL, V184, P2862, DOI 10.1016/j.ajpath.2014.07.008
   Zhao LL, 2014, INVEST OPHTH VIS SCI, V55, P5979, DOI 10.1167/iovs.14-15025
NR 286
TC 21
Z9 22
U1 12
U2 37
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD APR 1
PY 2021
VL 12
IS 2
BP 529
EP 551
DI 10.14336/AD.2020.0912
PG 23
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA RC6LA
UT WOS:000632909000016
PM 33815881
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Giocanti-Auregan, A
   Dubois, L
   Dourmad, P
   Cohen, SY
AF Giocanti-Auregan, Audrey
   Dubois, Lise
   Dourmad, Pauline
   Cohen, Salomon Y.
TI Impact of optical coherence tomography angiography on the non-invasive
   diagnosis of neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE OCT-angiography; Fluorescein angiography; Age-related macular
   degeneration
ID CHOROIDAL NEOVASCULARIZATION; TYPE-2 NEOVASCULARIZATION;
   QUANTITATIVE-ANALYSIS; SECONDARY; LESIONS; DOMAIN
AB Purpose To investigate the changes in imaging tool practice for the diagnosis of neovascular age-related macular degeneration (nAMD). Methods Retrospective analysis of consecutive patients diagnosed with nAMD in a tertiary care center, over a 6-month period in 2014, 2016, and 2018. Patient demographics were compared. Imaging modalities used in 2014 were fundus photography, fluorescein angiography (FA), and structural spectral-domain optical coherence tomography (SD-OCT), while OCT-angiography (OCT-A) was available from 2015. Imaging tools used in our practice were compared in the 3 cohorts. Results The 3 cohorts included 163, 99, and 167 patients, respectively. There was no difference in age or gender (mean age 81.7 years). OCT-A images were analyzable in 60.5% and 89.7% of patients respectively in 2016 and in 2018. In the 3 cohorts, all patients were imaged with fundus photography and structural OCT. FA was performed in 70.2, 28.8, and 22.1% of patients, respectively. Conclusion This study showed a shift in practice of imaging tools used for the diagnosis of nAMD, non-invasive tools being increasingly used as the first-line imaging, and FA as the second-line imaging.
C1 [Giocanti-Auregan, Audrey] Hop Avicenne, AP HP, Dept Ophthalmol, Bobigny, France.
   [Giocanti-Auregan, Audrey] Univ Paris 13, Bobigny, France.
   [Dubois, Lise; Dourmad, Pauline; Cohen, Salomon Y.] Ophthalmol Ctr Imaging & Laser, Paris, France.
   [Cohen, Salomon Y.] Univ Paris Est, Dept Ophthalmol, Creteil, France.
   [Cohen, Salomon Y.] Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Avicenne - APHP; Universite Paris 13; Universite Paris 13; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Cohen, SY (通讯作者)，Ophthalmol Ctr Imaging & Laser, Paris, France.; Cohen, SY (通讯作者)，Univ Paris Est, Dept Ophthalmol, Creteil, France.; Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Astroz P, 2018, RETINA-J RET VIT DIS, V38, P299, DOI 10.1097/IAE.0000000000001617
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Cohen SY, 2017, RETINA-J RET VIT DIS, V37, P1625, DOI 10.1097/IAE.0000000000001695
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Iafe NA, 2016, DEV OPHTHALMOL, V56, P45, DOI 10.1159/000442776
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Mrejen S, 2018, RETINA
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Wolff B, 2018, J FR OPHTALMOL, V41, P857, DOI 10.1016/j.jfo.2018.05.004
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   1994, ARCH OPHTHALMOL-CHIC, V112, P500, DOI DOI 10.1001/ARCHOPHT.1994.01090160076025
NR 33
TC 3
Z9 3
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2020
VL 258
IS 3
BP 537
EP 541
DI 10.1007/s00417-019-04581-y
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KN4JG
UT WOS:000514804400008
PM 31900638
DA 2022-11-30
ER

PT J
AU Pinheiro-Costa, J
   Freitas-da-Costa, P
   Falcao, MS
   Brandao, EM
   Falcao-Reis, F
   Carneiro, AM
AF Pinheiro-Costa, Joao
   Freitas-da-Costa, Paulo
   Falcao, Manuel S.
   Brandao, Elisete M.
   Falcao-Reis, Fernando
   Carneiro, Angela M.
TI Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of
   Neovascular Age-Related Macular Degeneration: Clinical Comparison
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Ranibizumab; Bevacizumab; Visual
   acuity
ID OPTICAL COHERENCE TOMOGRAPHY; AVASTIN; DISEASE; HEALTH
AB Objective: To compare outcomes after switching from intravitreal ranibizumab to bevacizumab in neovascular age-related macular degeneration (AMD). Methods: A retrospective review of 110 eyes treated in a 1+PRN (pro re nata) clinical setting with ranibizumab that were switched to bevacizumab. Patients analyzed had at least 3 ranibizumab injections followed by at least 3 bevacizumab injections. Changes in best-corrected visual acuity (BCVA), retinal thickness and frequency of injections were compared. Results: The mean duration of ranibizumab treatment was 18.1 months, followed by 12.2 months of bevacizumab. Mean injection rates per month were similar (0.54 and 0.56 respectively, p = 0.230). There were no significant differences between BCVA at baseline and at the time of the switch (52.4 and 54.8 letters, p = 0.059). After the switch, there was a statistically significant decrease in BCVA to 51.7 letters (p < 0.001). Conclusion: Switching patients to bevacizumab may have a minor negative effect on the initial gain obtained with ranibizumab; however the degenerative history of wet AMD could explain this small variation in visual acuity. (C) 2014 S. Karger AG, Basel
C1 [Pinheiro-Costa, Joao; Freitas-da-Costa, Paulo; Falcao, Manuel S.; Brandao, Elisete M.; Falcao-Reis, Fernando; Carneiro, Angela M.] Univ Porto, Fac Med, Hosp Sao Joao, Dept Ophthalmol, P-4200319 Oporto, Portugal.
   [Pinheiro-Costa, Joao; Freitas-da-Costa, Paulo] Univ Porto, Fac Med, Dept Anat, P-4200319 Oporto, Portugal.
   [Falcao, Manuel S.; Falcao-Reis, Fernando; Carneiro, Angela M.] Univ Porto, Fac Med, Dept Sense Organs, P-4200319 Oporto, Portugal.
C3 Sao Joao Hospital; Universidade do Porto; Universidade do Porto;
   Universidade do Porto
RP Pinheiro-Costa, J (通讯作者)，Univ Porto, Fac Med, Hosp Sao Joao, Dept Ophthalmol, P-4200319 Oporto, Portugal.
EM joaopinh@hotmail.com
RI Falcao/AAQ-8509-2020; Carneiro, Angela/N-9680-2013
OI Falcao/0000-0003-4718-0910; Carneiro, Angela/0000-0002-3370-7243;
   Freitas-da-Costa, Paulo/0000-0002-9567-4467; Falcao-Reis,
   Fernando/0000-0002-5995-9430
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ehlers JP, 2010, OPHTHAL SURG LAS IM, V41, P182, DOI 10.3928/15428877-20100303-05
   Grover S, 2010, INVEST OPHTH VIS SCI, V51, P2644, DOI 10.1167/iovs.09-4774
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Kent JS, 2012, CAN J OPHTHALMOL, V47, P159, DOI 10.1016/j.jcjo.2012.01.003
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
NR 25
TC 7
Z9 9
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 232
IS 3
BP 149
EP 155
DI 10.1159/000363422
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT9OC
UT WOS:000345255400004
PM 25196907
DA 2022-11-30
ER

PT J
AU McLaughlin, S
   Lockington, D
   Mansfield, D
AF McLaughlin, S.
   Lockington, D.
   Mansfield, D.
TI The importance of informed consent in patients with wet age-related
   macular degeneration considering intravitreal anti-vascular endothelial
   growth factor treatments
SO SCOTTISH MEDICAL JOURNAL
LA English
DT Article
DE macular degeneration; anti-VEGF; informed consent; RPE rips; pigment
   epithelial detachments
ID PIGMENT EPITHELIAL TEARS; BEVACIZUMAB INJECTION
AB Retinal pigment epithelial (RPE) tears are now a documented potential complication following the intravitreal injection of anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration. Patients are often not well consented regarding this risk and thus we retrospectively analyzed the data from all of our patients undergoing this treatment over a six month period. Our findings highlighted the fact that the three patients (out of thirty) who had developed this RPE tear complication were initially all diagnosed with a pigment epithelial detachment (which is a type of macular degeneration in question). Therefore, we have adjusted our informed consent procedure such that all patients with "wet" macular degeneration and especially those with pigment epithelial detachments are now fully consented regarding the risks of the intravitreal treatment, which could potentially damage their vision further.
C1 [McLaughlin, S.; Lockington, D.] Gartnavel Royal Hosp, Tennent Inst Ophthalmol, Glasgow G12 0YN, Lanark, Scotland.
   [Mansfield, D.] Inverclyde Royal Hosp, Greenock PA16 0XN, Scotland.
C3 Gartnavel Royal Hospital
RP McLaughlin, S (通讯作者)，Gartnavel Royal Hosp, Tennent Inst Ophthalmol, Glasgow G12 0YN, Lanark, Scotland.
EM sumona_m@hotmail.com
OI Lockington, David/0000-0001-7984-0958
CR Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
NR 8
TC 2
Z9 2
U1 0
U2 2
PU SCOTTISH MEDICAL JOURNAL
PI GLASGOW
PA MR K BURNSIDE, 12 BUCCLEUCH DRIVE, BEARSDEN, GLASGOW, G61 3LW, SCOTLAND
SN 0036-9330
J9 SCOT MED J
JI Scott. Med. J.
PD FEB
PY 2012
VL 57
IS 1
BP 48
EP 49
DI 10.1258/smj.2011.011290
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 927FD
UT WOS:000302891600011
PM 22408217
DA 2022-11-30
ER

PT J
AU Mones, J
AF Mones, Jordi
TI A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related
   Macular Degeneration and How to Translate It into Daily Practice
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Ranibizumab; MARINA; ANCHOR; EXCITE;
   SUSTAIN; PrONTO; PIER
AB The results of randomized controlled clinical trials of ranibizumab for the treatment of age-related macular degeneration established a new standard of care with the prospect of improved vision in many patients. Subsequent trials have explored different strategies to increase response rates and reduce treatment frequency. This review analyzes the key clinical trial data for ranibizumab on the basis of which the author proposes a new treatment regimen with the aim of rationalizing treatment frequency without compromising improvements in vision - the FUSION regimen. This consists of an initiation phase followed by pro re nata (PRN) retreatment combined with fixed injections after a period of disease inactivity of 2-4 months (depending on the time elapsed since the last injection). A randomized clinical trial is recommended for comparing monthly, PRN and the FUSION regimens. Copyright (C) 2010 S. Karger AG, Basel
C1 Ctr Med Teknon, Inst Macula & Retina, ES-08022 Barcelona, Spain.
RP Mones, J (通讯作者)，Ctr Med Teknon, Inst Macula & Retina, Vilana 12, ES-08022 Barcelona, Spain.
EM jmones@institutmacularetina.com
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160
CR Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   ELDEM MB, 2009, ASS RES VIS OPHTH AN
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holz FG, 2009, ASS RES VIS OPHTH AN
   MONES J, 2008, 25 M CLUB J GON ST M
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SINGER M, 2009, INVEST OPHTHALMOL VI, V50
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   VERBRAAK F, 2009, 9 EUR C NIC
NR 13
TC 12
Z9 12
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 2
BP 112
EP 119
DI 10.1159/000319906
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 666QN
UT WOS:000283132200007
PM 20938212
OA Bronze
DA 2022-11-30
ER

PT J
AU Guven, M
   Gorgun, E
   Unal, M
   Yenerel, M
   Batar, B
   Kucumen, B
   Dinc, UA
   Guven, GS
   Ulus, T
   Yuksel, A
AF Guven, Mehmet
   Gorgun, Ebru
   Unal, Mustafa
   Yenerel, Melda
   Batar, Bahadir
   Kucumen, Beril
   Dinc, Umut Asli
   Guven, Gulgun S.
   Ulus, Tumer
   Yuksel, Adnan
TI Glutathione S-Transferase M1, GSTT1 and GSTP1 Genetic Polymorphisms and
   the Risk of Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Glutathione S-transferase; Polymorphism; Age-related macular
   degeneration
ID MANGANESE SUPEROXIDE-DISMUTASE; RETINAL-PIGMENT EPITHELIUM; COMPLEMENT
   FACTOR-H; OXIDATIVE STRESS; TURKISH POPULATION; SUPERGENE FAMILY;
   DNA-DAMAGE; CANCER; GENOTYPES; GSTM1
AB Purpose: To determine the possible effects of glutathione S-transferase (GST) M1, GSTT1 and GSTP1 genetic polymorphisms on the risk of developing age-related macular degeneration (AMD). Patients and Methods: This case-control study included a total of 120 patients with AMD (65 with dry-type AMD and 55 with wet-type AMD) and 198 disease-free controls. GSTM1 and GSTT1 polymorphisms were analyzed by using a multiplex polymerase chain reaction (PCR), and GSTP1 polymorphism was detected by real-time PCR assay. Results: GSTM1-null genotype was significantly associated with the development of AMD (p = 0.01, OR = 1.82, 95% CI = 1.14-2.91). Stratification by AMD subtypes revealed a significant relationship between GSTM1-null genotype and dry-type AMD (p = 0.02, OR = 1.98, 95% CI = 1.10-3.53). In a stepwise regression model, only GSTM1-null genotype was significantly associated with the development of AMD (p = 0.01, OR = 1.77, 95% CI = 1.11-2.81). Conclusions: Our findings suggest that genetic polymorphisms of GST may have a role in the development of AMD. Copyright (C) 2011 S. Karger AG, Basel
C1 [Guven, Mehmet; Batar, Bahadir] Istanbul Univ, Cerrahpasa Fac Med, Dept Med Biol, Istanbul, Turkey.
   [Guven, Gulgun S.; Yuksel, Adnan] Istanbul Univ, Cerrahpasa Med Sch, Dept Med Genet, Istanbul, Turkey.
   [Ulus, Tumer] Istanbul Univ, Cerrahpasa Med Sch, Dept Publ Hlth, Istanbul, Turkey.
   [Gorgun, Ebru; Yenerel, Melda; Kucumen, Beril; Dinc, Umut Asli] Yeditepe Univ, Fac Med, Dept Ophthalmol, Istanbul, Turkey.
   [Unal, Mustafa] Akdeniz Univ, Fac Med, Dept Ophthalmol, TR-07058 Antalya, Turkey.
C3 Istanbul University; Istanbul University - Cerrahpasa; Istanbul
   University; Istanbul University - Cerrahpasa; Istanbul University;
   Istanbul University - Cerrahpasa; Yeditepe University; Akdeniz
   University
RP Unal, M (通讯作者)，Pinarbasi Mah 758 Sokak Nazlibahce Evleri C Blok, Antalya, Turkey.
EM mustafaunalmd@gmail.com
RI ÜNAL, MUSTAFA/C-7426-2016; Batar, Bahadir/F-4724-2018; GUVEN,
   MEHMET/C-9833-2019
OI Yuksel, Adnan/0000-0002-7275-8254; GUVEN, MEHMET/0000-0002-8749-1708
FU University of Istanbul [1153]; Akdeniz University Scientific Research
   Projects Unit
FX This work was supported by the Research Fund of the University of
   Istanbul (project No. 1153). M.U. was supported by Akdeniz University
   Scientific Research Projects Unit.
CR Abu-Amero KK, 2009, BRIT J OPHTHALMOL, V93, P1101, DOI 10.1136/bjo.2008.152983
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beer TM, 2002, PROSTATE CANCER P D, V5, P22, DOI 10.1038/sj/pcan/4500549
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Gotoh N, 2008, AM J OPHTHALMOL, V146, P146, DOI 10.1016/j.ajo.2008.03.017
   Guven M, 2007, CURR EYE RES, V32, P447, DOI 10.1080/02713680701338108
   Habdous M, 2004, ANN BIOL CLIN-PARIS, V62, P15
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hatagima A, 2008, ORAL ONCOL, V44, P200, DOI 10.1016/j.oraloncology.2007.02.001
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539
   Hirvonen A, 1997, ENVIRON HEALTH PERSP, V105, P755, DOI 10.2307/3433279
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kellen E, 2007, AM J EPIDEMIOL, V165, P1221, DOI 10.1093/aje/kwm003
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Rebbeck TR, 1997, CANCER EPIDEM BIOMAR, V6, P733
   Saadat M, 2006, OCCUP ENVIRON MED, V63, P503, DOI 10.1136/oem.2005.022343
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Unal M, 2007, BRIT J OPHTHALMOL, V91, P527, DOI 10.1136/bjo.2006.102418
   Wozniak K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/827562
   Xu SJ, 1998, J BIOL CHEM, V273, P3517, DOI 10.1074/jbc.273.6.3517
   ZIMNIAK P, 1994, EUR J BIOCHEM, V224, P893, DOI 10.1111/j.1432-1033.1994.00893.x
NR 37
TC 24
Z9 24
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2011
VL 46
IS 1
BP 31
EP 37
DI 10.1159/000321940
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 782TW
UT WOS:000292035800006
PM 21212706
DA 2022-11-30
ER

PT J
AU Grant, A
   Colman, I
   Freeman, EE
AF Grant, Alyssa
   Colman, Ian
   Freeman, Ellen E.
TI Impact of the Improper Adjustment for Age in Research on Age-Related
   Macular Degeneration: An Example Using Data from the Canadian
   Longitudinal Study on Aging
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Depression; age; residual confounding; nonlinear; CLSA
AB Purpose: Confounding is an important problem in observational research. Improper modeling of the confounder will lead to residual confounding that may distort results and impact inferences. An example of this will be presented from research on age-related macular degeneration and depression.
   Methods: A 3-year prospective cohort study was performed using data from the Canadian Longitudinal Study on Aging consisting of 30,097 individuals aged 45-85 years. Incident depression was assessed using the Center for Epidemiologic Studies Depression scale. Participants were asked if they had ever had a physician diagnosis of age-related macular degeneration (AMD). Multivariable Poisson regression was used. Age was modeled in four ways including as a linear term, as a 4-category variable, as a spline, and as a polynomial. Models were compared using the Akaike's Information Criteria (AIC) with lower scores indicating better performance.
   Results: The point estimates and inferences differed depending on how age was modeled. Age had a J-shape relationship with the incidence of depression. The model with the lowest AIC was when age was entered as a categorical variable. When age was modeled in this way, AMD was not significantly associated with the incidence of depression (relative risk (RR) = 1.21, 95% Confidence Interval (CI) 0.97, 1.53). By contrast, when age was modeled as a linear term, AMD was significantly associated with the incidence of depression (RR = 1.28, 95% CI 1.02, 1.61).
   Conclusions: Researchers should clearly report their adjustment strategies and should be cautious when modeling the relationship between age and depression in order to minimize residual confounding.
C1 [Grant, Alyssa; Colman, Ian; Freeman, Ellen E.] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada.
   [Colman, Ian] Norwegian Inst Publ Hlth, Ctr Fertil & Hlth, Oslo, Norway.
   [Freeman, Ellen E.] Ottawa Hosp Res Inst, Ottawa, ON, Canada.
C3 University of Ottawa; Norwegian Institute of Public Health (NIPH);
   University of Ottawa; Ottawa Hospital Research Institute
RP Freeman, EE (通讯作者)，Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada.
EM efreeman@uottawa.ca
OI Colman, Ian/0000-0001-5924-0277
FU Government of Canada through Canadian Institutes of Health Research
   (CIHR) [LSA 94473]; Canada Foundation for Innovation
FX This research was made possible using the data/biospecimens collected by
   the Canadian Longitudinal Study on Aging (CLSA). Funding for the
   Canadian Longitudinal Study on Aging (CLSA) is provided by the
   Government of Canada through the Canadian Institutes of Health Research
   (CIHR) under [grant reference: LSA 94473] and the Canada Foundation for
   Innovation. This research has been conducted using the CLSA dataset,
   Baseline Comprehensive Datasetversion 4.0, Follow-up 1 Comprehensive
   Dataset version 1.0, under Application Number 190212. The CLSA is led by
   Drs. Parminder Raina, Christina Wolfson and Susan Kirkland. The opinions
   expressed in this manuscript are the author's own and do not reflect the
   views of the Canadian Longitudinal Study on Aging.
CR ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   BRENNER H, 1997, EPIDEMIOLOGY, V8
   Celantano DD, 2019, GORDIS EPIDEMIOLOGY
   Grant A, 2021, OPHTHAL EPIDEMIOL, V28, P77, DOI [10.1080/09286586.2020.1823425CrossMarkLogoCrossMark, 10.1080/09286586.2020.1823425]
   Groenwold RHH, 2013, CAN MED ASSOC J, V185, P401, DOI 10.1503/cmaj.120592
   Guralnik JM, 1996, ANN EPIDEMIOL, V6, P376, DOI 10.1016/S1047-2797(96)00060-9
   KESSLER RC, 1992, PSYCHOL AGING, V7, P119, DOI 10.1037/0882-7974.7.1.119
   Raina P, 2019, INT J EPIDEMIOL, V48, P1752, DOI 10.1093/ije/dyz173
   Sutin AR, 2013, JAMA PSYCHIAT, V70, P803, DOI 10.1001/jamapsychiatry.2013.193
NR 9
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD JAN 2
PY 2021
VL 28
IS 1
BP 86
EP 89
DI 10.1080/09286586.2020.1853179
EA NOV 2020
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PH8YM
UT WOS:000594037900001
PM 33251871
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Cunningham, F
   Cahyadi, S
   Lengyel, I
AF Cunningham, Fiona
   Cahyadi, Sabrina
   Lengyel, Imre
TI A Potential New Role for Zinc in Age-Related Macular Degeneration
   through Regulation of Endothelial Fenestration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE zinc; fenestration; choroid; age-related macular degeneration; PV-1
ID RPE
AB Age-related macular degeneration (AMD) is a common blinding disease in the western world that is linked to the loss of fenestration in the choriocapillaris that sustains the retinal pigment epithelium and photoreceptors in the back of the eye. Changes in ocular and systemic zinc concentrations have been associated with AMD; therefore, we hypothesized that these changes might be directly involved in fenestrae formation. To test this hypothesis, an endothelial cell (bEND.5) model for fenestrae formation was treated with different concentrations of zinc sulfate (ZnSO4) solution for up to 20 h. Fenestrae were visualized by staining for Plasmalemmal Vesicle Associated Protein-1 (PV-1), the protein that forms the diaphragms of the fenestrated endothelium. Size and distribution were monitored by transmission electron microscopy (TEM). We found that zinc induced the redistribution of PV-1 into areas called sieve plates containing ~70-nm uniform size and typical morphology fenestrae. As AMD is associated with reduced zinc concentrations in the serum and in ocular tissues, and dietary zinc supplementation is recommended to slow disease progression, we propose here that the elevation of zinc concentration may restore choriocapillaris fenestration resulting in improved nutrient flow and clearance of waste material in the retina.
C1 [Cunningham, Fiona; Lengyel, Imre] Queens Univ, Wellcome Wolfson Inst Expt Med, Belfast BT9 7BL, Antrim, North Ireland.
   [Cahyadi, Sabrina; Lengyel, Imre] UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
C3 Queens University Belfast; University of London; University College
   London
RP Lengyel, I (通讯作者)，Queens Univ, Wellcome Wolfson Inst Expt Med, Belfast BT9 7BL, Antrim, North Ireland.; Lengyel, I (通讯作者)，UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
EM F.Cunningham@qub.ac.uk; sab.cahyadi@gmail.com; i.lengyel@qub.ac.uk
RI Lengyel, Imre/B-5217-2009
OI Lengyel, Imre/0000-0001-7467-2174
FU Mercer Fund from Fight for Sight; Bill Brown Charitable Trust
FX We thank the Mercer Fund from Fight for Sight, the Special Trustees of
   Moorfield's Eye Hospital, and the Bill Brown Charitable Trust for
   support.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   BEARER EL, 1985, J CELL BIOL, V100, P418, DOI 10.1083/jcb.100.2.418
   Bernal PJ, 2011, AM J PHYSIOL-LUNG C, V300, pL874, DOI 10.1152/ajplung.00328.2010
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144994
   Bozym RA, 2010, EXP BIOL MED, V235, P741, DOI 10.1258/ebm.2010.009258
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Emri E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103051
   Gilbert R, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801049
   Ioannidou S, 2006, P NATL ACAD SCI USA, V103, P16770, DOI 10.1073/pnas.0603501103
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SA, 2020, BIOCHEM BIOPH RES CO, V522, P240, DOI 10.1016/j.bbrc.2019.11.085
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Pao PJ, 2018, J TRACE ELEM MED BIO, V49, P184, DOI 10.1016/j.jtemb.2018.02.028
   Perrin L, 2017, ACS CHEM NEUROSCI, V8, P1490, DOI 10.1021/acschemneuro.6b00452
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
NR 19
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 21
AR 11974
DI 10.3390/ijms222111974
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XE1UI
UT WOS:000723180400001
PM 34769404
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ong, SS
   Proia, AD
   Whitson, HE
   Farsiu, S
   Doraiswamy, PM
   Lad, EM
AF Ong, Sally S.
   Proia, Alan D.
   Whitson, Heather E.
   Farsiu, Sina
   Doraiswamy, P. Murali
   Lad, Eleonora M.
TI Ocular amyloid imaging at the crossroad of Alzheimer's disease and
   age-related macular degeneration: implications for diagnosis and therapy
SO JOURNAL OF NEUROLOGY
LA English
DT Review
DE Alzheimer's disease; Amyloid beta; Optical coherence tomography; Retinal
   imaging
ID NERVE-FIBER LAYER; OPTICAL COHERENCE TOMOGRAPHY; MILD COGNITIVE
   IMPAIRMENT; SENSORLESS ADAPTIVE OPTICS; RETINAL-PIGMENT EPITHELIUM;
   TRANSGENIC MOUSE MODEL; PRECURSOR PROTEIN; BETA STIMULATION; THICKNESS;
   DEMENTIA
AB Alzheimer's disease (AD) and age-related macular degeneration (AMD) are important disorders of aging, but significant challenges remain in diagnosis and therapy. Amyloid-beta (A), found in the brain and a defining feature of AD, has also been observed in the retina in both AD and AMD. While current diagnostic modalities for detecting A in the brain are costly or invasive, A in the retina can be noninvasively and conveniently imaged using modern photonic imaging systems such as optical coherence tomography (OCT). Moreover, since many of these retinal changes occur before degenerative changes can be detected in the brain, ocular amyloid biomarkers could be utilized to detect AD as well as AMD in their earliest stages when therapy may be most effective in halting disease progression. Novel technologies to quantify retinal biomarkers have the potential to facilitate early diagnosis and noninvasive monitoring of disease progression with important therapeutic implications.
C1 [Ong, Sally S.; Farsiu, Sina; Lad, Eleonora M.] Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd,DUMC 3802, Durham, NC 27710 USA.
   [Proia, Alan D.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
   [Whitson, Heather E.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Farsiu, Sina] Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC USA.
   [Doraiswamy, P. Murali] Duke Univ, Med Ctr, Dept Psychiat, Div Translat Neurosci, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University; Duke University; Duke
   University
RP Lad, EM (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd,DUMC 3802, Durham, NC 27710 USA.
EM nora.lad@duke.edu
OI Whitson, Heather/0000-0002-8417-4846; Ong, Sally/0000-0003-3599-9021
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   [Anonymous], 2017, LANCET
   [Anonymous], 2014, ALZHEIMERS DEMENT, DOI DOI 10.1016/j.jalz.2014.04.341
   Armstrong RA, 1996, OPTOMETRY VISION SCI, V73, P677, DOI 10.1097/00006324-199611000-00001
   Ascaso FJ, 2014, J NEUROL, V261, P1522, DOI 10.1007/s00415-014-7374-z
   Bambo MP, 2014, ACTA OPHTHALMOL, V92, pe581, DOI 10.1111/aos.12374
   Baumann B, 2016, POLARIZATION PROPERT
   Bayer AU, 2002, AM J OPHTHALMOL, V133, P135, DOI 10.1016/S0002-9394(01)01196-5
   Bei L, 2015, EXP EYE RES, V140, P117, DOI 10.1016/j.exer.2015.03.010
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   Campbell MC, 2016, ALZHEIMERS DEMENT S, V12, P319
   Cedernaes J, 2014, EXP GERONTOL, V57, P104, DOI 10.1016/j.exger.2014.05.002
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   COGAN DG, 1985, AM J OPHTHALMOL, V100, P68, DOI 10.1016/S0002-9394(14)74985-2
   Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680
   CRONINGOLOMB A, 1991, ANN NEUROL, V29, P41, DOI 10.1002/ana.410290110
   Csincsik L, 2018, OPHTHALMIC RES, V59, P182, DOI 10.1159/000487053
   CURCIO CA, 1993, ANN NEUROL, V33, P248, DOI 10.1002/ana.410330305
   DAVIES DC, 1995, BRIT J OPHTHALMOL, V79, P596, DOI 10.1136/bjo.79.6.596
   De Strooper B, 2014, CELL, V159, P721, DOI 10.1016/j.cell.2014.10.016
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842
   Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889
   Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951
   Du LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135499
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Edwards MM, 2014, EXP EYE RES, V127, P252, DOI 10.1016/j.exer.2014.08.006
   Egan MF, 2018, NEW ENGL J MED, V378, P1691, DOI 10.1056/NEJMoa1706441
   Frost S, 2016, CURR ALZHEIMER RES
   Gharbiya M, 2014, J ALZHEIMERS DIS, V40, P907, DOI 10.3233/JAD-132039
   GILMORE GC, 1994, J GERONTOL, V49, pP52, DOI 10.1093/geronj/49.2.P52
   Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9
   Grossman I, 2010, EPMA J, V1, P293, DOI 10.1007/s13167-010-0024-3
   Gupta VK, 2016, NEUROSCI LETT, V623, P52, DOI 10.1016/j.neulet.2016.04.059
   Hale G, 2005, BEHAV NEUROSCI, V119, P884, DOI 10.1037/0735-7044.119.4.884
   He XF, 2012, INT J OPHTHALMOL-CHI, V5, P401, DOI 10.3980/j.issn.2222-3959.2012.03.30
   Hedges TR, 1996, ACTA OPHTHALMOL SCAN, V74, P271
   Helmer C, 2013, ANN NEUROL, V74, P171, DOI 10.1002/ana.23926
   HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804
   Ho CY, 2014, BRAIN PATHOL, V24, P25, DOI 10.1111/bpa.12070
   Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2
   Jiang JL, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00267
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Kerbage C, 2015, AM J ALZHEIMERS DIS, V30, P738, DOI 10.1177/1533317513520214
   Kesler A, 2011, CLIN NEUROL NEUROSUR, V113, P523, DOI 10.1016/j.clineuro.2011.02.014
   Kim S, 2016, BIOMED OPT EXPRESS, V7, P1400, DOI 10.1364/BOE.7.001400
   Knoll Brianna, 2016, Alzheimers Dement (Amst), V4, P85
   Koronyo Y, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93621
   Koronyo Y, 2012, NEURODEGENER DIS, V10, P285, DOI 10.1159/000335154
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Krasodomska K., 2010, ADV OPHTHALMOL, V121, P111, DOI [10.1007/s10633-010-9238-x, DOI 10.1007/S10633-010-9238-X]
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   La Morgia C, 2016, ANN NEUROL, V79, P90, DOI 10.1002/ana.24548
   Lad EM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192646
   Le Cudennec C, 2008, GENES BRAIN BEHAV, V7, P83, DOI 10.1111/j.1601-183X.2007.00374.x
   Leger F, 2011, J NEUROPATH EXP NEUR, V70, P63, DOI 10.1097/NEN.0b013e31820376cc
   Liu BQ, 2009, AM J PATHOL, V175, P2099, DOI 10.2353/ajpath.2009.090159
   Liu DC, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0268-6
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lu Y, 2010, NEUROSCI LETT, V480, P69, DOI 10.1016/j.neulet.2010.06.006
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Marziani E, 2013, INVEST OPHTH VIS SCI, V54, P5953, DOI 10.1167/iovs.13-12046
   Melov S, 2005, FREE RADICAL BIO MED, V38, P258, DOI 10.1016/j.freeradbiomed.2004.10.023
   Michael R, 2013, EXP EYE RES, V106, P5, DOI 10.1016/j.exer.2012.10.012
   Moncaster JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010659
   Mullard A, 2017, NAT REV DRUG DISCOV, V16, P3
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Nolan JM, 2014, J ALZHEIMERS DIS, V42, P1191, DOI 10.3233/JAD-140507
   Ong SY, 2012, ARCH OPHTHALMOL-CHIC, V130, P895, DOI 10.1001/archophthalmol.2012.152
   Ong SS, 2018, JAMA NEUROL
   Ong YT, 2015, NEUROSCI LETT, V584, P12, DOI 10.1016/j.neulet.2014.10.010
   Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8
   Pache M, 2003, AGE AGEING, V32, P422, DOI 10.1093/ageing/32.4.422
   Paquet C, 2007, NEUROSCI LETT, V420, P97, DOI 10.1016/j.neulet.2007.02.090
   Parisi V, 2001, CLIN NEUROPHYSIOL, V112, P1860, DOI 10.1016/S1388-2457(01)00620-4
   Parnell Miles, 2012, Int J Alzheimers Dis, V2012, P786494, DOI 10.1155/2012/786494
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   Polans J, 2017, BIOMED OPT EXPRESS, V8, P16, DOI 10.1364/BOE.8.000016
   Polans J, 2017, OPT LETT, V42, P17, DOI 10.1364/OL.42.000017
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Ritchie CW., 2011, INVEST OPHTH VIS SCI, V52, P6683
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   SADUN AA, 1990, OPHTHALMOLOGY, V97, P9
   Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839
   Salobrar-Garcia E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/636548
   Savonenko AV, 2012, NEUROPSYCHOPHARMACOL, V37, P261, DOI 10.1038/npp.2011.211
   Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124
   Schon C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053547
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323
   Tariot, 2014, JSM ALZHEIMERS DIS R, V1, P1008
   TSAI CS, 1991, ARCH OPHTHALMOL-CHIC, V109, P199, DOI 10.1001/archopht.1991.01080020045040
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Tsai YC, 2014, INVEST OPHTH VIS SCI, V55, P523, DOI 10.1167/iovs.13-12888
   Tsilis AG, 2014, CLIN OPHTHALMOL, V8, P2095, DOI 10.2147/OPTH.S69534
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Wang YJ, 2014, NAT REV NEUROL, V10, P188, DOI 10.1038/nrneurol.2014.44
   Whittaker KW, 2002, EYE, V16, P206, DOI 10.1038/sj/EYE/6700037
   Williams PA, 2013, NEUROBIOL AGING, V34, P1799, DOI 10.1016/j.neurobiolaging.2013.01.006
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 108
TC 20
Z9 19
U1 1
U2 16
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD JUL
PY 2019
VL 266
IS 7
BP 1566
EP 1577
DI 10.1007/s00415-018-9028-z
PG 12
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA IE7AX
UT WOS:000472527900002
PM 30155741
DA 2022-11-30
ER

PT J
AU Ao, J
   Wood, JPM
   Chidlow, G
   Gillies, MC
   Casson, RJ
AF Ao, Jack
   Wood, John P. M.
   Chidlow, Glyn
   Gillies, Mark C.
   Casson, Robert J.
TI Retinal pigment epithelium in the pathogenesis of age-related macular
   degeneration and photobiomodulation as a potential therapy?
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration (AMD); low light therapy; near infrared
   light; photobiomodulation; retinal pigment epithelium (RPE)
ID COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULAR MEMBRANES; ENDOTHELIAL
   GROWTH-FACTOR; MITOCHONDRIAL-DNA DAMAGE; IMPROVES VISUAL-ACUITY;
   LIGHT-INDUCED DAMAGE; ROD OUTER SEGMENTS; 670 NM LIGHT; OXIDATIVE
   STRESS; HUMAN RPE
AB The retinal pigment epithelium (RPE) comprises a monolayer of cells located between the neuroretina and the choriocapillaries. The RPE serves several important functions in the eye: formation of the blood-retinal barrier, protection of the retina from oxidative stress, nutrient delivery and waste disposal, ionic homeostasis, phagocytosis of photoreceptor outer segments, synthesis and release of growth factors, reisomerization of all-trans-retinal during the visual cycle, and establishment of ocular immune privilege. Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. Dysfunction of the RPE has been associated with the pathogenesis of AMD in relation to increased oxidative stress, mitochondrial destabilization and complement dysregulation. Photobiomodulation or near infrared light therapy which refers to non-invasive irradiation of tissue with light in the far-red to near-infrared light spectrum (630-1000 nm), is an intervention that specifically targets key mechanisms of RPE dysfunction that are implicated in AMD pathogenesis. The current evidence for the efficacy of photobiomodulation in AMD is poor but its safety profile and proposed mechanisms of action motivate further research as a novel therapy for AMD.
C1 [Ao, Jack; Wood, John P. M.; Chidlow, Glyn; Casson, Robert J.] Univ Adelaide, South Australian Inst Ophthalmol, Adelaide, SA, Australia.
   [Gillies, Mark C.] Univ Sydney, Save Sight Inst, Sydney Med Sch, Sydney, NSW, Australia.
C3 University of Adelaide; University of Sydney
RP Ao, J (通讯作者)，Univ Adelaide, Ophthalm Res Lab, WS7062-46,Level 7,Adelaide Hlth & Med Sci Bldg, Adelaide, SA 5000, Australia.
EM jack.ao36@gmail.com
RI Ao, Jack/GXM-9063-2022
OI Ao, Jack/0000-0002-8546-8598
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   ADLER AJ, 1992, OPHTHALMIC RES, V24, P243, DOI 10.1159/000267174
   Adler L, 2015, PHOTOCH PHOTOBIO SCI, V14, P1983, DOI 10.1039/c5pp00156k
   Ahuja P, 2001, NEUROREPORT, V12, P2951, DOI 10.1097/00001756-200109170-00039
   Albarracin R, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-125
   Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ban Y, 2000, DEV BRAIN RES, V119, P259, DOI 10.1016/S0165-3806(99)00183-2
   BARRETT DJ, 1985, BIOCHEM BIOPH RES CO, V131, P1086, DOI 10.1016/0006-291X(85)90202-5
   BAZAN NG, 1993, CAN J PHYSIOL PHARM, V71, P690, DOI 10.1139/y93-103
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   BAZAN NG, 1994, WORLD REV NUTR DIET, V75, P120
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   BOULTON M, 1998, RETINAL PIGMENT EPIT, P68
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459
   Chan D, 1998, OPTOMETRY VISION SCI, V75, P476, DOI 10.1097/00006324-199807000-00015
   Chang YG, 2007, J CELL SCI, V120, P3053, DOI 10.1242/jcs.006361
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen XD, 2017, INT J OPHTHALMOL-CHI, V10, P507, DOI 10.18240/ijo.2017.04.02
   Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cunha-Vaz JG, 1998, DOC OPHTH P, V62, P5
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Daruich A, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-77
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Desjardins DM, 2016, INVEST OPHTH VIS SCI, V57, P2706, DOI 10.1167/iovs.15-18397
   Desmettre T, 2003, LASER SURG MED, V33, P102, DOI 10.1002/lsm.10193
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Dibas Adnan, 2008, P157, DOI 10.1007/978-1-59745-375-2_9
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   EDELMAN JL, 1994, AM J PHYSIOL, V266, pC946, DOI 10.1152/ajpcell.1994.266.4.C946
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200
   Ferguson TA, 1997, IMMUNOL REV, V156, P167, DOI 10.1111/j.1600-065X.1997.tb00967.x
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   FONG SL, 1984, J BIOL CHEM, V259, P6534
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Fuma S, 2015, MOL VIS, V21, P883
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Geneva II, 2016, INT J OPHTHALMOL-CHI, V9, P145, DOI 10.18240/ijo.2016.01.24
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GUDAS LJ, 1994, RETINOIDS BIOL CHEM
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamann S, 1998, AM J PHYSIOL-CELL PH, V274, pC1332, DOI 10.1152/ajpcell.1998.274.5.C1332
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hosoya K, 2001, EXP EYE RES, V72, P163, DOI 10.1006/exer.2000.0941
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Huang YY, 2013, J BIOPHOTONICS, V6, P829, DOI 10.1002/jbio.201200157
   Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Ivandic BT, 2014, PHOTOMED LASER SURG, V32, P181, DOI 10.1089/pho.2013.3535
   Ivandic BT, 2012, PHOTOMED LASER SURG, V30, P167, DOI 10.1089/pho.2011.3089
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Karl MO, 2008, CELL SIGNAL, V20, P1159, DOI 10.1016/j.cellsig.2008.02.005
   Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002
   Karu T, 2010, PHOTOMED LASER SURG, V28, P159, DOI 10.1089/pho.2010.2789
   Karu TI, 2015, LASERS IN DENTISTRY: GUIDE FOR CLINICAL PRACTICE, P23
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KAUFMAN S, 1966, PHARMACOL REV, V18, P61
   KENYON E, 1994, AM J PHYSIOL-CELL PH, V267, pC1561, DOI 10.1152/ajpcell.1994.267.6.C1561
   KHATAMI M, 1986, EXP EYE RES, V43, P607, DOI 10.1016/S0014-4835(86)80027-6
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kirk DK, 2013, PROC SPIE, V8569, DOI 10.1117/12.981791
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kokkinopoulos I, 2013, J PHOTOCH PHOTOBIO B, V122, P24, DOI 10.1016/j.jphotobiol.2013.03.003
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   KUMAGAI AK, 1994, INVEST OPHTH VIS SCI, V35, P2887
   Kurtz JC, 1998, DOC OPHTH P, V62, P47
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lau LI, 2011, INVEST OPHTH VIS SCI, V52, P6832, DOI 10.1167/iovs.11-7815
   Lavey B.J., 2013, P MECH LOW LIGHT THE, P85690
   Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Maeda H, 1998, GRAEF ARCH CLIN EXP, V236, P207, DOI 10.1007/s004170050066
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Merry G., 2012, INVESTIG OPHTHALMOL, V53, P2049
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   MESTER E, 1971, AM J SURG, V122, P532, DOI 10.1016/0002-9610(71)90482-X
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Michaelides M, 2008, ARCH OPHTHALMOL-CHIC, V126, P320, DOI 10.1001/archopht.126.3.320
   MILLER SS, 1977, J MEMBRANE BIOL, V36, P337, DOI 10.1007/BF01868158
   MILLER SS, 1977, EXP EYE RES, V25, P235, DOI 10.1016/0014-4835(77)90090-2
   Natoli R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072135
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OLIVER PD, 1992, INVEST OPHTH VIS SCI, V33, P1909
   OSTWALD TJ, 1980, EXP EYE RES, V31, P351, DOI 10.1016/S0014-4835(80)80043-1
   Osusky R, 1997, OCUL IMMUNOL INFLAMM, V5, P43, DOI 10.3109/09273949709085049
   Park KH, 2009, MOL VIS, V15, P200
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Philp NJ, 1998, AM J PHYSIOL-REG I, V274, pR1824, DOI 10.1152/ajpregu.1998.274.6.R1824
   Qin S, 2007, DRUG DEVELOP RES, V68, P213, DOI 10.1002/ddr.20185
   Qin S, 2008, J INFLAMM RES, V1, P49
   Qu C, 2010, ADV EXP MED BIOL, V664, P365, DOI 10.1007/978-1-4419-1399-9_42
   Rizzolo LJ, 1999, INT REV CYTOL, V185, P195
   RIZZOLO LJ, 1990, EXP EYE RES, V51, P435, DOI 10.1016/0014-4835(90)90156-O
   RIZZOLO LJ, 1993, J CELL SCI, V106, P859
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rosenthal R, 2007, MOL VIS, V13, P443
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   Schuster K, 2013, MECH LOW LIGHT THERA, V8569
   SHADRACH KG, 2003, INVEST OPHTH VIS S1, V44
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   Spaide RF, 2014, INVEST OPHTH VIS SCI, V55
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stamer WD, 2003, INVEST OPHTH VIS SCI, V44, P2803, DOI 10.1167/iovs.03-0001
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   STREETEN BW, 1969, ARCH OPHTHALMOL-CHIC, V81, P383
   Sun H, 2011, INT REV CEL MOL BIO, V288, P1, DOI 10.1016/B978-0-12-386041-5.00001-7
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tang J, 2014, BRIT J OPHTHALMOL, V98, P1013, DOI 10.1136/bjophthalmol-2013-304477
   Tang J, 2013, INVEST OPHTH VIS SCI, V54, P3681, DOI 10.1167/iovs.12-11018
   TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413
   TARNOWSKI BI, 1988, INVEST OPHTH VIS SCI, V29, P291
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Ved N, 2017, CLIN SCI, V131, P1225, DOI 10.1042/CS20170102
   VERLANGIERI AJ, 1979, BLOOD VESSELS, V16, P177
   Walsh N, 2001, EXP EYE RES, V72, P495, DOI 10.1006/exer.2000.0984
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weng TX, 2002, AM J PHYSIOL-CELL PH, V283, pC839, DOI 10.1152/ajpcell.00445.2001
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wills NK, 2000, INVEST OPHTH VIS SCI, V41, P4247
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Xiao Qing, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P463, DOI 10.1007/s11596-006-0422-x
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   ZAVAZAVA N, 1991, CLIN EXP IMMUNOL, V84, P163
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
NR 181
TC 58
Z9 60
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2018
VL 46
IS 6
BP 670
EP 686
DI 10.1111/ceo.13121
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP5JZ
UT WOS:000440911000012
PM 29205705
OA Green Published
DA 2022-11-30
ER

PT J
AU Shinojima, A
   Kawamura, A
   Mori, R
   Yuzawa, M
AF Shinojima, Ari
   Kawamura, Akiyuki
   Mori, Ryusaburo
   Yuzawa, Mitsuko
TI MORPHOLOGIC FEATURES OF FOCAL CHOROIDAL EXCAVATION ON SPECTRAL DOMAIN
   OPTICAL COHERENCE TOMOGRAPHY WITH SIMULTANEOUS ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; central serous chorioretinopathy;
   choroidal neovascularization; fluorescein angiography; focal choroidal
   excavation; indocyanine angiography; polypoidal choroidal vasculopathy;
   spectral domain optical coherence tomography
ID CENTRAL SEROUS CHORIORETINOPATHY; MACULAR DEGENERATION; THICKNESS;
   VASCULOPATHY
AB Purpose: To reveal clinically relevant morphologic findings in patients with focal choroidal excavation (FCE) using enhanced depth imaging optical coherence tomography.
   Methods: Thirty-one FCE lesions in 29 eyes of 26 patients (21 men, 23 eyes; 5 women, 6 eyes) were studies. In all 26 patients, color fundus photographs were obtained, and fluorescein angiography and indocyanine green angiography with simultaneous enhanced depth imaging optical coherence tomography were performed. Twenty-five eyes also underwent angiographic video recording.
   Results: Focal choroidal excavation was detected in eyes with typical age-related macular degeneration, central serous chorioretinopathy, polypoidal choroidal vasculopathy, and idiopathic choroidal neovascularization, whereas in 8 eyes, FCE was considered to be idiopathic. Morphologically, FCE lesions were classified into 3 types: cone-shaped, bowl-shaped, and mixed. The cone-shaped type was detected in 17 lesions, bowl-shaped in 8, and mixed in 6, on optical coherence tomography findings. All bowl-shaped and mixed types had retinal pigment epithelial irregularities within the FCE lesion. The cone-shaped type was not observed in eyes with typical age-related macular degeneration.
   Conclusions: Morphologically, FCE lesions were classified into cone-shaped, bowl-shaped, and mixed types, based on optical coherence tomography findings. Focal choroidal excavation formation may be associated in part with chorioretinal diseases such as age-related macular degeneration and central serous chorioretinopathy, whereas some eyes are considered to have idiopathic FCE.
C1 [Shinojima, Ari; Kawamura, Akiyuki; Mori, Ryusaburo; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo 1018309, Japan.
C3 Nihon University
RP Kawamura, A (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, 1-8-13 Surugadai, Tokyo 1018309, Japan.
EM ariearly7@gmail.com
RI Shinojima, Ari/AAR-4442-2021
OI Shinojima, Ari/0000-0003-2322-0332
CR Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kuroda S, 2013, RETINA-J RET VIT DIS, V33, P302, DOI 10.1097/IAE.0b013e318263d11f
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Maruko I, 2012, INVEST OPHTH VIS SCI, V53, P3834, DOI 10.1167/iovs.12-9811
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Wakabayashi Y, 2010, ACTA OPHTHALMOL, V88, pe87, DOI 10.1111/j.1755-3768.2010.01895.x
NR 14
TC 32
Z9 36
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2014
VL 34
IS 7
BP 1407
EP 1414
DI 10.1097/IAE.0000000000000108
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK9UG
UT WOS:000338772600020
PM 24830823
DA 2022-11-30
ER

PT J
AU Klingel, R
   Fassbender, C
   Fischer, I
   Hattenbach, L
   Gumbel, H
   Pulido, J
   Koch, F
AF Klingel, R
   Fassbender, C
   Fischer, I
   Hattenbach, L
   Gumbel, H
   Pulido, J
   Koch, F
TI Rheopheresis for age-related macular degeneration: A novel indication
   for therapeutic apheresis in ophthalmology
SO THERAPEUTIC APHERESIS
LA English
DT Article
DE therapeutic apheresis; membrane differential filtration; rheopheresis;
   age-related macular degeneration; dry age-related macular degeneration;
   drusen
ID MEMBRANE DIFFERENTIAL FILTRATION; VITRONECTIN; MACULOPATHY; MODEL
AB Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in the elderly. Successful therapy is not yet available for the majority of patients, especially not for patients with dry AMD. AMD at cellular and molecular levels is at least in part a microcirculatory disorder of the retina. Rheopheresis is a safe and effective modality of therapeutic apheresis to treat microcirculatory disorders and represents a novel treatment option for patients with dry AMD. Elimination of a defined spectrum of high molecular weight proteins from human plasma including pathophysiologically relevant risk factors for AMD such as fibrinogen, cholesterol, von Willebrand factor, and alpha2-macroglobulin results in the reduction of blood and plasma viscosity as well as erythrocyte and thrombocyte aggregation. Pulses of lowering blood and plasma viscosity performed as a series of Rheopheresis treatments lead to rapid changes of blood flow, subsequently inducing sustained improvement of microcirculation and recovery of retinal function. Two controlled randomized clinical trials demonstrated the safety and efficacy of Rheopheresis for the treatment of AMD patients, especially for those with the dry form. Recently the interim analysis of the sham-controlled, double blind, randomized multicenter Multicenter Investigation of Rheopheresis for AMD (MIRA-1) trial confirmed these results. The framework of completed and still ongoing controlled clinical trials in combination with postcertification studies including the RheoNet registry represents a comprehensive quality management approach for this novel interdisciplinary therapy for AMD. The development and continuous update of guidelines for the precise indication of Rheopheresis for AMD follows the requirements of evidence-based medicine.
C1 Aphereis Res Inst, D-50935 Cologne, Germany.
   Mil Hosp Ulm, Clin Ophthalmol, Ulm, Germany.
   Goethe Univ Frankfurt, Dept Ophthalmol, D-6000 Frankfurt, Germany.
   Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
C3 Ulm University; Goethe University Frankfurt; University of Illinois
   System; University of Illinois Chicago; University of Illinois Chicago
   Hospital
RP Klingel, R (通讯作者)，Aphereis Res Inst, Stadtwaldguertel 77, D-50935 Cologne, Germany.
EM afi@apheresis-research.de
RI Hattenbach, Lars-Olof/AAC-5621-2020
OI Hattenbach, Lars-Olof/0000-0002-5275-8118; Fassbender, Dr.
   Cordula/0000-0001-6498-0210
CR Abdelgadir WS, 1998, INT J FOOD MICROBIOL, V44, P1, DOI 10.1016/S0168-1605(98)00090-7
   Berrouschot J, 1998, ACTA NEUROL SCAND, V97, P126
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brunner R, 1996, TRANSFUS SCI, V17, P493, DOI 10.1016/S0955-3886(96)90083-1
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Donauer J, 2000, AM J KIDNEY DIS, V36, P115, DOI 10.1053/ajkd.2000.8280
   Fell A., 2000, IOVS, V41, pS181
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   GODEHARDT E, 1993, TREATMENT SEVER DYSL, V4, P208
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   King GL, 2000, NEW ENGL J MED, V342, P349, DOI 10.1056/NEJM200002033420511
   KLINGEL R, 2001, CLIN HEMORHEOL MICRO, V24, P119
   Kost C, 1996, EUR J BIOCHEM, V236, P682, DOI 10.1111/j.1432-1033.1996.0682d.x
   KUSTNER E, 2001, KIDNEY BLOOD PRESS R, V24, P236
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Luke C, 2001, J CLIN APHERESIS, V16, P23, DOI 10.1002/jca.1004
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   PFAU N, 2000, SCHRIFTENREIHE IGSF, V84, P1
   PREISSNER KT, 1995, HISTOL HISTOPATHOL, V10, P239
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   SOUDAVAR F, 1998, INVEST OPHTH VIS SCI, V39, P386
   STOCKMANN A, 1993, J BIOL CHEM, V268, P22874
   Swartz M, 1999, INVEST OPHTH VIS SCI, V40, pS319
   Ueba H, 1997, ARTERIOSCL THROM VAS, V17, P1512, DOI 10.1161/01.ATV.17.8.1512
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Widder RA, 2002, INVEST OPHTH VIS SCI, V43, P2906
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 33
TC 20
Z9 22
U1 0
U2 1
PU BLACKWELL PUBLISHING INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148 USA
SN 1091-6660
J9 THER APHER
JI Therap. Apher.
PD AUG
PY 2002
VL 6
IS 4
BP 271
EP 281
DI 10.1046/j.1526-0968.2002.00418.x
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 582WH
UT WOS:000177373800007
PM 12164796
DA 2022-11-30
ER

PT J
AU Holz, FG
   Sadda, SR
   Staurenghi, G
   Lindner, M
   Bird, AC
   Blodi, BA
   Bottoni, F
   Chakravarthy, U
   Chew, EY
   Csaky, K
   Curcio, CA
   Danis, R
   Fleckenstein, M
   Freund, KB
   Grunwald, J
   Guymer, R
   Hoyng, CB
   Jaffe, GJ
   Liakopoulos, S
   Mones, JM
   Oishi, A
   Pauleikhoff, D
   Rosenfeld, PJ
   Sarraf, D
   Spaide, RF
   Tadayoni, R
   Tufail, A
   Wolf, S
   Schmitz-Valckenberg, S
AF Holz, Frank G.
   Sadda, SriniVas R.
   Staurenghi, Giovanni
   Lindner, Moritz
   Bird, Alan C.
   Blodi, Barbara A.
   Bottoni, Ferdinando
   Chakravarthy, Usha
   Chew, Emily Y.
   Csaky, Karl
   Curcio, Christine A.
   Danis, Ron
   Fleckenstein, Monika
   Freund, K. Bailey
   Grunwald, Juan
   Guymer, Robyn
   Hoyng, Carel B.
   Jaffe, Glenn J.
   Liakopoulos, Sandra
   Mones, Jordi M.
   Oishi, Akio
   Pauleikhoff, Daniel
   Rosenfeld, Philip J.
   Sarraf, David
   Spaide, Richard F.
   Tadayoni, Ramin
   Tufail, Adnan
   Wolf, Sebastian
   Schmitz-Valckenberg, Steffen
CA CAM Grp
TI Imaging Protocols in Clinical Studies in Advanced Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; QUANTITATIVE FUNDUS AUTOFLUORESCENCE;
   GEOGRAPHIC ATROPHY PROGRESSION; SCANNING LASER OPHTHALMOSCOPY;
   SUBRETINAL DRUSENOID DEPOSITS; INDOCYANINE GREEN ANGIOGRAPHY;
   RETINAL-PIGMENT EPITHELIUM; GROWTH-FACTOR THERAPY; CHOROIDAL
   NEOVASCULARIZATION; RETICULAR PSEUDODRUSEN
AB Purpose: To summarize the results of 2 consensus meetings (Classification of Atrophy Meeting [ CAM]) on conventional and advanced imaging modalities used to detect and quantify atrophy due to late-stage non-neovascular and neovascular age-related macular degeneration (AMD) and to provide recommendations on the use of these modalities in natural history studies and interventional clinical trials.
   Design: Systematic debate on the relevance of distinct imaging modalities held in 2 consensus meetings.
   Participants: A panel of retina specialists.
   Methods: During the CAM, a consortium of international experts evaluated the advantages and disadvantages of various imaging modalities on the basis of the collective analysis of a large series of clinical cases. A systematic discussion on the role of each modality in future studies in non-neovascular and neovascular AMD was held.
   Main Outcome Measures: Advantages and disadvantages of current retinal imaging technologies and recommendations for their use in advanced AMD trials.
   Results: Imaging protocols to detect, quantify, and monitor progression of atrophy should include color fundus photography (CFP), confocal fundus autofluorescence (FAF), confocal near-infrared reflectance (NIR), and high-resolution optical coherence tomography volume scans. These images should be acquired at regular intervals throughout the study. In studies of non-neovascular AMD (without evident signs of active or regressed neo-vascularization [NV] at baseline), CFP may be sufficient at baseline and end-of-study visit. Fluorescein angiography (FA) may become necessary to evaluate for NV at any visit during the study. Indocyanine-green angiography (ICG-A) may be considered at baseline under certain conditions. For studies in patients with neovascular AMD, increased need for visualization of the vasculature must be taken into account. Accordingly, these studies should include FA (recommended at baseline and selected follow-up visits) and ICG-A under certain conditions.
   Conclusions: A multimodal imaging approach is recommended in clinical studies for the optimal detection and measurement of atrophy and its associated features. Specific validation studies will be necessary to determine the best combination of imaging modalities, and these recommendations will need to be updated as new imaging technologies become available in the future. (C) 2017 by the American Academy of Ophthalmology
C1 [Holz, Frank G.; Lindner, Moritz; Fleckenstein, Monika; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Staurenghi, Giovanni; Bottoni, Ferdinando] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Bird, Alan C.] UCL, Inst Ophthalmol, London, England.
   [Blodi, Barbara A.; Danis, Ron] Univ Wisconsin, Sch Med & Publ Hlth, Fundus Photograph Reading Ctr, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Belfast, Antrim, North Ireland.
   [Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
   [Csaky, Karl] Texas Retina Associates, Dallas, TX USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [Freund, K. Bailey; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Grunwald, Juan] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Guymer, Robyn] Univ Melbourne, Dept Surg Ophthalmol, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Australia.
   [Hoyng, Carel B.] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Duke Reading Ctr, Durham, NC USA.
   [Liakopoulos, Sandra] Univ Cologne, Cologne Image Reading Ctr, Dept Ophthalmol, Cologne, Germany.
   [Mones, Jordi M.] Inst Macula & Barcelona Macula Fdn, Barcelona, Spain.
   [Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Tadayoni, Ramin] Univ Paris 07, Hop Lariboisiere, AP HP, Ophthalmol Dept,Sorbonne Paris Cite, Paris, France.
   [Tufail, Adnan] Moorfields Eye Hosp, London, England.
   [Wolf, Sebastian] Univ Bern, Univ Hosp Bern, Dept Ophthalmol, Bern, Switzerland.
C3 University of Bonn; Doheny Eye Institute; University of Milan; Luigi
   Sacco Hospital; University of London; University College London;
   University of Wisconsin System; University of Wisconsin Madison; Queens
   University Belfast; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); University of Alabama System; University
   of Alabama Birmingham; Vitreous Retina Macula Consultants of New York;
   University of Pennsylvania; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; Radboud
   University Nijmegen; Duke University; University of Cologne; St.
   Franziskus-Hospital; Bascom Palmer Eye Institute; University of Miami;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research
   Universities; Universite Paris Cite; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of Bern; University Hospital of Bern
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Frank.Holz@ukb.uni-bonn.de
RI Oishi, Akio/AAE-9996-2020; Wolf, Sebastian/B-8782-2008; mones,
   jordi/CAJ-2963-2022; Spaide, Richard/ABD-7368-2020; Lindner,
   Moritz/AAC-8639-2021; Freund, K. Bailey/V-7488-2018; Staurenghi,
   Giovanni/K-4388-2017
OI Oishi, Akio/0000-0002-0977-9458; Wolf, Sebastian/0000-0002-7467-7028;
   mones, jordi/0000-0003-3685-2160; Lindner, Moritz/0000-0002-4416-3421;
   Chakravarthy, Usha/0000-0002-2606-3734; bottoni,
   ferdinando/0000-0002-3737-0238; Freund, K. Bailey/0000-0002-7888-9773;
   Staurenghi, Giovanni/0000-0002-2299-5251; Guymer,
   Robyn/0000-0002-9441-4356; Tufail, Adnan/0000-0001-6131-7640;
   Fleckenstein, Monika/0000-0001-8321-8037
FU Jackstadt Fundation, Wuppertal, Germany
FX Supported by the Jackstadt Fundation, Wuppertal, Germany.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   [Anonymous], 2011, CTGTAC M 52 FDA CELL, V2016
   Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen Q, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.2
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coscas G, 2016, DEV OPHTHALMOL, V56, P1, DOI 10.1159/000442768
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Csutak A, 2010, EYE, V24, P1568, DOI 10.1038/eye.2010.85
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Domalpally A, 2014, INVEST OPHTH VIS SCI, V55
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Drexler W, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.7.071412
   Duisdieker V, 2015, OPHTHALMOLOGICA, V234, P218, DOI 10.1159/000439358
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P7274, DOI 10.1167/iovs.15-17371
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P3159, DOI 10.1167/iovs.14-16343
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P1471, DOI 10.1167/iovs.13-13834
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Friberg TR, 2014, INVEST OPHTH VIS SCI, V55
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Gorczynska I, 2016, BIOMED OPT EXPRESS, V7, P911, DOI 10.1364/BOE.7.000911
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz F.G., 2013, AGE RELATED MACULAR
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Huang D, 2016, DEV OPHTHALMOL, V56, P6, DOI 10.1159/000442770
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kuehlewein L, 2016, OSLI RETINA, V47, P224, DOI 10.3928/23258160-20160229-04
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Litts KM, 2016, INVEST OPHTH VIS SCI, V57, P2647, DOI 10.1167/iovs.16-19262
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mori K, 2005, RETINA-J RET VIT DIS, V25, P430, DOI 10.1097/00006982-200506000-00006
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Nehemy MB, 2015, OSLI RETINA, V46, P1056, DOI 10.3928/23258160-20151027-13
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Pang CE, 2014, AM J OPHTHALMOL, V158, P171, DOI 10.1016/j.ajo.2014.03.003
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schutze C, 2011, ACTA OPHTHALMOL, V89, P235, DOI 10.1111/j.1755-3768.2010.01955.x
   Slakter J S, 1995, Curr Opin Ophthalmol, V6, P25
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Stanga PE, 2016, DEV OPHTHALMOL, V56, P13, DOI 10.1159/000442771
   Staurenghi G, 2005, ARCH OPHTHALMOL-CHIC, V123, P244, DOI 10.1001/archopht.123.2.244
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Vujosevic S, 2007, GRAEF ARCH CLIN EXP, V245, P1453, DOI 10.1007/s00417-007-0574-9
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 111
TC 111
Z9 111
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2017
VL 124
IS 4
BP 464
EP 478
DI 10.1016/j.ophtha.2016.12.002
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ1ST
UT WOS:000397850600028
PM 28109563
DA 2022-11-30
ER

PT J
AU Ciulla, TA
   Rosenfeld, PJ
AF Ciulla, Thomas A.
   Rosenfeld, Philip J.
TI Anti-vascular endothelial growth factor therapy for neovascular ocular
   diseases other than age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE anti-vascular endothelial growth factor therapy; bevacizumab;
   neovascularization; pegaptanib sodium; ranibizumab
ID RETINAL VEIN OCCLUSION; INTRAVITREAL BEVACIZUMAB AVASTIN; OPTICAL
   COHERENCE TOMOGRAPHY; DIABETIC-RETINOPATHY; CHOROIDAL
   NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE; IRIS NEOVASCULARIZATION;
   VISUAL PROGNOSIS; EDEMA SECONDARY; VITREOUS LEVELS
AB Purpose of review Anti-vascular endothelial growth factor (anti-VEGF) therapies that arrest choroidal angiogenesis and reduce vascular permeability have revolutionized clinical practices for neovascular eye diseases. This review describes anti-VEGF strategies that are being evaluated in ocular diseases, other than neovascular age-related macular degeneration, in which neovascularization plays a critical role in pathogenesis.
   Recent findings Early studies of the anti-VEGF agents, pegaptanib sodium, ranibizumab, bevacizurnab, VEGF trap, and bevasiranib in the treatment of various neovascular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) have shown promising results. The efficacy and safety of these agents, either alone or combined with standard treatments (e.g., laser photocoagulation), anti-inflammatory agents, or other non-VEGF-based antiangiogenic therapies, is actively investigated. Non-VEGIF-driven pathways and growth factors other than VEGF may play important roles in pathogenesis and are included in certain combination therapies with VEGF inhibitors.
   Summary The discovery of VEGF-A's role in the pathogenesis of neovascular ocular disease provided a strong rationale for the development of anti-VEGF-based therapies. There is now ample evidence that anti-VEGF therapies are viable treatment options for these diseases. Nevertheless, large, randomized controlled trials are still awaited to confirm early safety and efficacy findings from small, open-label prospective studies.
C1 [Ciulla, Thomas A.] Midwest Eye Inst, Vitreoretinal Serv, Indianapolis, IN 46280 USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Ciulla, TA (通讯作者)，Midwest Eye Inst, Vitreoretinal Serv, 201 Penn Pkwy, Indianapolis, IN 46280 USA.
EM thomasciulla@yahoo.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
FU Genentech USA, Inc
FX Support for third-party medical writing assistance was provided by
   Genentech USA, Inc.
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Ahmadieh H, 2008, GRAEF ARCH CLIN EXP, V246, P483, DOI 10.1007/s00417-007-0688-0
   Aiello LP, 2008, NEW ENGL J MED, V359, P967, DOI 10.1056/NEJMcibr0804551
   Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1984, AM J OPHTHALMOL, V98, P271
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Avitabile T, 2005, AM J OPHTHALMOL, V140, P695, DOI 10.1016/j.ajo.2005.05.021
   Bakri SJ, 2006, EYE, V20, P1474, DOI 10.1038/sj.eye.6702364
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   BANDELLO F, 2008, 2008 ANN M ASS RES V
   BRESNICK GH, 1986, OPHTHALMOLOGY, V93, P989
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Chen E, 2006, RETINA-J RET VIT DIS, V26, P699, DOI 10.1097/01.iae.0000225351.87205.69
   Chen SDM, 2006, AM J OPHTHALMOL, V141, P876, DOI 10.1016/j.ajo.2005.12.011
   Chilov MN, 2007, CLIN EXP OPHTHALMOL, V35, P494, DOI 10.1111/j.1442-9071.2007.01521.x
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Cugati S, 2006, ARCH OPHTHALMOL-CHIC, V124, P726, DOI 10.1001/archopht.124.5.726
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   DAVID R, 1988, OPHTHALMOLOGICA, V197, P69, DOI 10.1159/000309923
   DO DV, 2007, 2007 ANN M ASS RES V
   DUGEL PU, 2006, 2006 ANN M AM AC OPH
   Dunavoelgyi R, 2007, CLIN EXP OPHTHALMOL, V35, P878, DOI 10.1111/j.1442-9071.2007.01632.x
   GABBAY KH, 1975, ANNU REV MED, V26, P521, DOI 10.1146/annurev.me.26.020175.002513
   Gheith ME, 2007, J OCUL PHARMACOL TH, V23, P487, DOI 10.1089/jop.2007.0036
   Gilbert RE, 1998, LAB INVEST, V78, P1017
   GIULIARI GP, 2008, 2008 ANN M ASS RES V
   GOMEZ YM, 2008, 2008 ANN M ASS RES V
   Gurwood A S, 1997, J Am Optom Assoc, V68, P309
   Hayreh SS, 2005, PROG RETIN EYE RES, V24, P493, DOI 10.1016/j.preteyeres.2004.12.001
   Honda S, 2008, GRAEF ARCH CLIN EXP, V246, P1061, DOI 10.1007/s00417-008-0786-7
   Hsu J, 2007, RETINA-J RET VIT DIS, V27, P1013, DOI 10.1097/IAE.0b013e318050ca7c
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Issa PC, 2007, OPHTHALMOLOGY, V114, P1736, DOI 10.1016/j.ophtha.2007.03.079
   Kelkar A S, 2007, Bull Soc Belge Ophtalmol, P43
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P513, DOI 10.1001/archopht.126.4.513
   Kockx M, 2008, ARTERIOSCL THROM VAS, V28, P1060, DOI 10.1161/ATVBAHA.108.164350
   Konareva-Kostianeva Marieta, 2005, Folia Med (Plovdiv), V47, P5
   Kong L, 2008, ARCH OPHTHALMOL-CHIC, V126, P1161, DOI 10.1001/archophthalmol.2008.1
   Kreutzer TC, 2008, BRIT J OPHTHALMOL, V92, P351, DOI 10.1136/bjo.2007.123513
   Kriechbaum K, 2008, BRIT J OPHTHALMOL, V92, P518, DOI 10.1136/bjo.2007.127282
   Krishnadas R, 2001, Community Eye Health, V14, P40
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Mandal S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1487, DOI 10.1001/archopht.125.11.1487
   Miller DG, 2006, OPTOMETRY VISION SCI, V83, P316, DOI 10.1097/01.opx.0000216019.88256.eb
   Minnella AM, 2008, ACTA OPHTHALMOL, V86, P683, DOI 10.1111/j.1600-0420.2007.01042.x
   Mintz-Hittner HA, 2008, RETINA-J RET VIT DIS, V28, P831, DOI 10.1097/IAE.0b013e318177f934
   Neubauer AS, 2007, OPHTHALMOLOGY, V114, P2096, DOI 10.1016/j.ophtha.2007.05.057
   Nguyen QD, 2008, AM J OPHTHALMOL, V145, P257, DOI 10.1016/j.ajo.2007.09.025
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Noma H, 2006, GRAEF ARCH CLIN EXP, V244, P309, DOI 10.1007/s00417-004-1087-4
   Noma H, 2005, AM J OPHTHALMOL, V140, P256, DOI 10.1016/j.ajo.2005.03.003
   Oleszczuk AK, 2006, INT J FERTIL WOMEN M, V51, P89
   Oshima Y, 2006, AM J OPHTHALMOL, V142, P155, DOI 10.1016/j.ajo.2006.02.015
   Ozdek Sengul C., 2005, International Ophthalmology, V26, P27, DOI 10.1007/s10792-006-0005-7
   PALMER EA, 1991, OPHTHALMOLOGY, V98, P1628
   PEER J, 1995, LAB INVEST, V72, P638
   PELITLIGURLU V, 2005, RETVITREOUS, V13, P39
   Pieramici Dante J, 2008, Ophthalmology, V115, pe47, DOI 10.1016/j.ophtha.2008.06.021
   Prasad Anita G, 2005, Curr Opin Ophthalmol, V16, P364, DOI 10.1097/01.icu.0000188321.61101.93
   Priglinger SG, 2007, RETINA-J RET VIT DIS, V27, P1004, DOI 10.1097/IAE.0b013e3180ed458d
   Querques G, 2008, EUR J OPHTHALMOL, V18, P138, DOI 10.1177/112067210801800125
   Querques G, 2008, GRAEF ARCH CLIN EXP, V246, P319, DOI 10.1007/s00417-007-0689-z
   Ramezani A, 2006, GRAEF ARCH CLIN EXP, V244, P1601, DOI 10.1007/s00417-006-0348-9
   Rehak J, 2008, CURR EYE RES, V33, P111, DOI 10.1080/02713680701851902
   Rishi P, 2008, GRAEF ARCH CLIN EXP, V246, P619, DOI 10.1007/s00417-007-0732-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2007, EUR J OPHTHALMOL, V17, P996, DOI 10.1177/112067210701700623
   RUIZMORENO JM, 2007, EYE
   Sachdev Nishant, 2007, Indian J Ophthalmol, V55, P457
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   SHAH SM, 2008, 2008 ANN M ASS RES V
   Shahid H, 2006, BRIT J OPHTHALMOL, V90, P627, DOI 10.1136/bjo.2005.068668
   Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334
   Shimura M, 2008, AM J OPHTHALMOL, V145, P854, DOI 10.1016/j.ajo.2007.12.031
   Simo R, 2008, DIABETOLOGIA, V51, P1574, DOI 10.1007/s00125-008-0989-9
   SISK RA, 2008, 2008 ANN M ASS RES V
   Soheilian M, 2007, RETINA-J RET VIT DIS, V27, P1187, DOI 10.1097/IAE.0b013e31815ec261
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Sonmez K, 2008, OPHTHALMOLOGY, V115, P1065, DOI 10.1016/j.ophtha.2007.08.050
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Stahl A, 2007, GRAEF ARCH CLIN EXP, V245, P1429, DOI 10.1007/s00417-007-0569-6
   Sun Y, 2007, GRAEF ARCH CLIN EXP, V245, P1387, DOI 10.1007/s00417-007-0559-8
   Tonello M, 2008, ACTA OPHTHALMOL, V86, P385, DOI 10.1111/j.1600-0420.2007.01056.x
   Vatavuk Z, 2007, EUR J OPHTHALMOL, V17, P269, DOI 10.1177/112067210701700220
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wilkinson-Berka JL, 2008, THESCIENTIFICWORLDJO, V8, P98, DOI 10.1100/tsw.2008.25
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yazdani S, 2007, J GLAUCOMA, V16, P437, DOI 10.1097/IJG.0b013e3180457c47
NR 101
TC 80
Z9 85
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2009
VL 20
IS 3
BP 166
EP 174
DI 10.1097/ICU.0b013e328329d173
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 446TN
UT WOS:000266144200004
PM 19381089
DA 2022-11-30
ER

PT J
AU Chong, EW
   Islam, FMA
   Robman, LD
   Aung, KZ
   Richardson, AJ
   Baird, PN
   Guymer, RH
AF Chong, Elaine W.
   Islam, Fakir M. Amirul
   Robman, Liubov D.
   Aung, Khin Zaw
   Richardson, Andrea J.
   Baird, Paul N.
   Guymer, Robyn H.
TI AGE-RELATED MACULAR DEGENERATION PHENOTYPES ASSOCIATED WITH MUTUALLY
   EXCLUSIVE HOMOZYGOUS RISK VARIANTS IN CFH AND HTRA1 GENES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; ARMS2; CFH; drusen location; HTRA1;
   phenotype; genes; genotype; predictor models
ID COMPLEMENT FACTOR-H; LOC387715; POLYMORPHISMS; CHALLENGES; MANAGEMENT;
   ALLELES; DRUSEN; AMD
AB Purpose: To determine age-related macular degeneration (AMD) phenotypes associated with mutually exclusive homozygotic risk variants in rs1061170 (CFH) and rs11200638 (HTRA1).
   Methods: Nested case-control study of 2,982 eyes (2,129 control, 809 drusen >= 125 mu m, 44 advanced AMD) homozygous for CFH [TT(-/-) or CC(+/+)] and HTRA1 [GG((-/-)) or AA((+/+))] were analyzed using logistic regression and generalized estimating equations specifically regards to homozygous risk variants in one but homozygous no-risk in the other gene.
   Results: In early AMD, [CFH+/+ HTRA1(-/-)] and [CFH-/- HTRA1(+/+)] were associated with central drusen (odds ratio [95% confidence interval] = 4.13 [2.97-5.73] and 3.65 [1.88-7.09], respectively). However, only [CFH+/+ HTRA1(-/-)] was associated with central drusen occupying >= 50% area (13.9 [2.97-64.7]). In advanced AMD, [CFH+/+ HTRA1(-/-)] was associated with geographic atrophy (4.04 [1.57-10.4]), whereas [CFH-/- HTRA1(+/+)] was associated with neovascular AMD (36.5 [8.3-160.9]). In doubly homozygous risk groups [CFH+/+ HTRA1(+/+)], odds ratios were multiplicative.
   Conclusion: Central but not peripheral drusen location was strongly associated with both [CFH+/+ HTRA1(-/-)] and [CFH-/- HTRA1(+/+)]. Only [CFH+/+ HTRA1(-/-)] was significantly associated with increased central drusen area.
C1 [Chong, Elaine W.; Islam, Fakir M. Amirul; Robman, Liubov D.; Aung, Khin Zaw; Richardson, Andrea J.; Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Islam, Fakir M. Amirul] Swinburne Univ Technol, Dept Psychol Sci & Stat, Hawthorn, Vic 3122, Australia.
   [Chong, Elaine W.] Singapore Natl Eye Ctr, Singapore, Singapore.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Swinburne University of Technology; Singapore
   National Eye Center
RP Chong, EW (通讯作者)，32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM elainechongwt@alumni.unimelb.edu.au
RI Islam, Fakir M Amirul/P-6665-2015
OI Islam, Fakir M Amirul/0000-0003-3897-3302; Baird,
   Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356
FU VicHealth; Cancer Council Victoria; National Health and Medical Research
   Council of Australia (NHMRC) [209057, 251533, 396414]; Ophthalmic
   Research Institute of Australia; American Health Assistance Foundation;
   John Reid Charitable Trust; Perpetual Foundation; NHMRC Centre for
   Clinical Research Excellence [529923]; NHMRC
FX The Melbourne Collaborative Cohort Study was supported by VicHealth, the
   Cancer Council Victoria, and the National Health and Medical Research
   Council of Australia (NHMRC program grant 209057, capacity-building
   grant 251533, and enabling grant 396414). The Ophthalmic Research
   Institute of Australia, the American Health Assistance Foundation, the
   John Reid Charitable Trust and the Perpetual Trustees, Perpetual
   Foundation funded the ophthalmic component. CERA is a recipient of the
   NHMRC Centre for Clinical Research Excellence Grant 529923 and
   Operational Infrastructure Support from the Victorian Government.
   Support was also provided through an NHMRC Practitioner Fellowship to R.
   H. Guymer, NHMRC Senior Research Fellowship to P. N. Baird, Wagstaff
   Fellowship to L. D. Robman. The sponsor or funding organization had no
   role in the design or conduct of this research.
CR Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2008, MOL VIS, V14, P1395
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Giles G G, 2002, IARC Sci Publ, V156, P69
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sambrook J, 1989, MOL CLONING LAB MANU, V1
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 30
TC 5
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2015
VL 35
IS 5
BP 989
EP 998
DI 10.1097/IAE.0000000000000417
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG6KI
UT WOS:000353408900021
PM 25627090
DA 2022-11-30
ER

PT J
AU Feigl, B
   Hutmacher, D
AF Feigl, Beatrix
   Hutmacher, Dietmar
TI Eyes on 3D-Current 3D Biomimetic Disease Concept Models and Potential
   Applications in Age-Related Macular Degeneration
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE Three-dimensional cell culture models; 3D disease concepts; age-related
   macular degeneration
ID ENDOTHELIAL GROWTH-FACTORS; CELL-CULTURE MODEL; 3-DIMENSIONAL COCULTURE;
   EXTRACELLULAR-MATRIX; COMPOSITE SCAFFOLDS; GENE-EXPRESSION;
   ANIMAL-MODELS; TISSUE; CANCER; SYSTEM
AB Three-dimensional cellular models that mimic disease are being increasingly investigated and have opened an exciting new research area into understanding pathomechanisms. The advantage of 3D in vitro disease models is that they allow systematic and in-depth studies of physiological and pathophysiological processes with less costs and ethical concerns that have arisen with animal models. The purpose of the 3D approach is to allow crosstalk between cells and microenvironment, and with cues from the microenvironment, cells can assemble their niche similar to in vivo conditions. The use of 3D models for mimicking disease processes such as cancer, osteoarthritis etc., is only emerging and allows multidisciplinary teams consisting of tissue engineers, biologist biomaterial scientists and clinicians to work closely together. While in vitro systems require rigorous testing before they can be considered as replicates of the in vivo model, major steps have been made, suggesting that they will become powerful tools for studying physiological and pathophysiological processes. This paper aims to summarize some of the existing 3D models and proposes a novel 3D model of the eye structures that are involved in the most common cause of blindness in the Western World, namely age-related macular degeneration (AMD).
C1 [Feigl, Beatrix; Hutmacher, Dietmar] Queensland Univ Technol QUT, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld 4059, Australia.
   [Feigl, Beatrix; Hutmacher, Dietmar] QUT, Sch Biomed Sci, Brisbane, Qld 4059, Australia.
   [Feigl, Beatrix] Queensland Eye Inst, South Brisbane, Qld 4101, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Queensland Eye Institute
RP Feigl, B (通讯作者)，Queensland Univ Technol QUT, Inst Hlth & Biomed Innovat, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
EM b.feigl@qut.edu.au; dietmar.hutmacher@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373; Hutmacher, Dietmar
   Werner/0000-0001-5678-2134
CR Ainscough SL, 2009, EXP EYE RES, V89, P629, DOI 10.1016/j.exer.2009.06.005
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2012, NATURE, V483, P373, DOI 10.1038/483373b
   Atala A, 2006, LANCET, V367, P1241, DOI 10.1016/S0140-6736(06)68438-9
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benton G, 2009, J CELL PHYSIOL, V221, P18, DOI 10.1002/jcp.21832
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Birgersdotter A, 2007, LEUKEMIA LYMPHOMA, V48, P2042, DOI 10.1080/10428190701573190
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burdett E, 2010, TISSUE ENG PART B-RE, V16, P351, DOI 10.1089/ten.TEB.2009.0676
   Carlson Mark W, 2008, Curr Protoc Cell Biol, VChapter 19, DOI 10.1002/0471143030.cb1909s41
   Carrier RL, 1999, BIOTECHNOL BIOENG, V64, P580, DOI 10.1002/(SICI)1097-0290(19990905)64:5<580::AID-BIT8>3.0.CO;2-X
   Chekhonin V. P., 2012, CURR CANC DRUG TARGE, V2012
   Daud MFB, 2012, BIOMATERIALS, V33, P5901, DOI 10.1016/j.biomaterials.2012.05.008
   Domansky K, 2005, P ANN INT IEEE EMBS, P7490, DOI 10.1109/IEMBS.2005.1616244
   Domansky K, 2010, LAB CHIP, V10, P51, DOI 10.1039/b913221j
   Ehrbar M, 2011, BIOPHYS J, V100, P284, DOI 10.1016/j.bpj.2010.11.082
   Elliott NT, 2011, J PHARM SCI-US, V100, P59, DOI 10.1002/jps.22257
   Eming SA, 2011, EXP DERMATOL, V20, P605, DOI 10.1111/j.1600-0625.2011.01309.x
   Eschenhagen T, 2005, CIRC RES, V97, P1220, DOI 10.1161/01.RES.0000196562.73231.7d
   Evans CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023434
   Evans HJ, 2003, AM J PHYSIOL-HEART C, V285, pH570, DOI 10.1152/ajpheart.01027.2002
   Feigl B, 2011, CURR MED RES OPIN, V27, P1745, DOI 10.1185/03007995.2011.603301
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Fletcher EL, 2011, PROG MOL BIOL TRANSL, V100, P211, DOI 10.1016/B978-0-12-384878-9.00006-6
   Fournier MV, 2006, J CELL PHYSIOL, V209, P625, DOI 10.1002/jcp.20787
   Gangatirkar P, 2007, NAT PROTOC, V2, P178, DOI 10.1038/nprot.2006.448
   Ghajar CM, 2010, TISSUE ENG PT A, V16, P2153, DOI [10.1089/ten.tea.2010.0135, 10.1089/ten.TEA.2010.0135]
   Ghosh K, 2007, BIOMATERIALS, V28, P671, DOI 10.1016/j.biomaterials.2006.09.038
   Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858
   Guillotin B, 2011, TRENDS BIOTECHNOL, V29, P183, DOI 10.1016/j.tibtech.2010.12.008
   Haberstroh K, 2010, J BIOMED MATER RES B, V93B, P520, DOI 10.1002/jbm.b.31611
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Harkin DG, 2011, BIOMATERIALS, V32, P2445, DOI 10.1016/j.biomaterials.2010.12.041
   Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khait L, 2008, J CARDIOVASC TRANSL, V1, P71, DOI 10.1007/s12265-007-9005-x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koeneman KS, 1999, PROSTATE, V39, P246
   Koh W, 2008, METHOD ENZYMOL, V443, P83, DOI 10.1016/S0076-6879(08)02005-3
   Kozel BA, 2006, J CELL PHYSIOL, V207, P87, DOI 10.1002/jcp.20546
   Langer R, 1995, Tissue Eng, V1, P151, DOI 10.1089/ten.1995.1.151
   Lee W, 2009, BIOMATERIALS, V30, P1587, DOI 10.1016/j.biomaterials.2008.12.009
   Leite S. B., 2012, TOXICOL SCI, DOI [10.1093/toxsci/kfs232, DOI 10.1093/T0XSCI/KFS232]
   Leite SB, 2011, TOXICOL IN VITRO, V25, P825, DOI 10.1016/j.tiv.2011.02.002
   Leonard F, 2010, MOL PHARMACEUT, V7, P2103, DOI 10.1021/mp1000795
   Leor J, 2000, CIRCULATION, V102, P56
   Li L, 2011, JOVE-J VIS EXP, DOI 10.3791/2937
   Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6
   MacNeil S, 2011, METHODS MOL BIOL, V695, P129, DOI 10.1007/978-1-60761-984-0_9
   Mithieux SM, 2013, ADV DRUG DELIVER REV, V65, P421, DOI 10.1016/j.addr.2012.06.009
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Oortgiesen DAW, 2012, TISSUE ENG PART C-ME, V18, P81, DOI [10.1089/ten.tec.2011.0367, 10.1089/ten.TEC.2011.0367]
   PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064
   Peyton SR, 2011, BIOTECHNOL BIOENG, V108, P1181, DOI 10.1002/bit.23027
   Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/NMAT2441, 10.1038/nmat2441]
   Powers MJ, 2002, BIOTECHNOL BIOENG, V78, P257, DOI 10.1002/bit.10143
   Powers MJ, 2002, TISSUE ENG, V8, P499, DOI 10.1089/107632702760184745
   Rethy A, 2010, J GASTROINTEST SURG, V14, P1969, DOI 10.1007/s11605-010-1283-y
   Rice J, 2012, NATURE, V484, pS9, DOI 10.1038/nature11102
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidt-Erfurth U, 2010, DEV OPHTHALMOL, V46, P21, DOI 10.1159/000320007
   Schumann Detlef, 2007, V140, P101
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Subramanian B, 2012, BIOMATERIALS, V33, P8383, DOI 10.1016/j.biomaterials.2012.08.020
   Subramanian B, 2010, TISSUE ENG PT A, V16, P2821, DOI [10.1089/ten.tea.2009.0595, 10.1089/ten.TEA.2009.0595]
   Taylor DA, 2009, CURR OPIN BIOTECH, V20, P598, DOI 10.1016/j.copbio.2009.10.016
   Tremolada G, 2012, EXP DIABETES RES, DOI 10.1155/2012/728325
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Vahidnezhad Hassan, 2009, Iranian Biomedical Journal, V13, P191
   Varley CL, 2011, METHODS MOL BIOL, V695, P197, DOI 10.1007/978-1-60761-984-0_13
   Wang RX, 2005, SEMIN CANCER BIOL, V15, P353, DOI 10.1016/j.semcancer.2005.05.005
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong C, 2012, JOVE-J VIS EXP, DOI 10.3791/4218
   Xu MG, 2010, BIOMATERIALS, V31, P3868, DOI 10.1016/j.biomaterials.2010.01.111
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Yates C, 2007, ADV CANCER RES, V97, P225, DOI 10.1016/S0065-230X(06)97010-9
   Yeo GC, 2011, ADV COLLOID INTERFAC, V167, P94, DOI 10.1016/j.cis.2010.10.003
   Zhau HE, 1997, IN VITRO CELL DEV-AN, V33, P375
NR 88
TC 10
Z9 11
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD JUL
PY 2013
VL 2
IS 7
BP 1056
EP 1062
DI 10.1002/adhm.201200445
PG 7
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Science & Technology - Other Topics; Materials Science
GA 267VX
UT WOS:000328127500017
PM 24000403
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Covert, DJ
   Han, DP
   Kim, JE
   Connor, TB
   Wirostko, WJ
   Moon, SJ
   Hamilton, R
AF Covert, Douglas J.
   Han, Dennis P.
   Kim, Judy E.
   Connor, Thomas B., Jr.
   Wirostko, William J.
   Moon, Suk J.
   Hamilton, Richard
TI Physician Assessment of Changing Lesion Size of Predominantly Classic
   Choroidal Neovascular Membranes in Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID PHOTODYNAMIC THERAPY; VISUAL-ACUITY; VERTEPORFIN; TAP; SECONDARY
AB BACKGROUND AND OBJECTIVE: To quantify the interpretation of fluorescein angiograms of evolving predominantly classic choroidal neovascularization in age-related macular degeneration.
   PATIENTS AND METHODS: Thirty-six fluorescein angiograms of predominantly classic choroidal neovascularization were used to define 22 fluorescein angiogram pairs. Imaging software was used to measure surface area and greatest linear dimension (GLD). Six retina physicians estimated the change in surface area and GLD for each pair before and after demarcation of the lesions' borders and GLD.
   RESULTS: For enlarging lesions, the smallest changes consistently detected by physicians were a 5% to 15% increase in surface area and a 5% to 15% increase in GLD; for shrinking lesions, they were a 5% to 15% decrease in surface area and a 5% to 15% decrease in GLD. Linear regression demonstrated moderate correlation between physician and software estimates of surface area and GLD change (r(2) = 0.50 and 0.67, respectively; P < .001), which was higher with lesion demarcation (r(2) = 0.91 and 0.93, respectively; P < .001).
   CONCLUSION: Computer-assisted demarcation of lesion surface area and GLD reduced variability in physicians' estimates of choroidal neovascularization size change and improved correlation with software measurements.
C1 [Covert, Douglas J.; Han, Dennis P.; Kim, Judy E.; Connor, Thomas B., Jr.; Wirostko, William J.; Moon, Suk J.; Hamilton, Richard] Med Coll Wisconsin, Inst Eye, Retina Serv, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin
RP Covert, DJ (通讯作者)，925 N 87th St, Milwaukee, WI 53226 USA.
FU Research to Prevent Blindness, Inc., New York, New York; Thomas M.
   Aaberg Retina Research Fund Milwaukee, Wisconsin
FX Supported in part by unrestricted grants from Research to Prevent
   Blindness, Inc., New York, New York, and the Thomas M. Aaberg Retina
   Research Fund Milwaukee, Wisconsin.
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
NR 7
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD NOV-DEC
PY 2009
VL 40
IS 6
BP 554
EP 560
DI 10.3928/15428877-20091030-04
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 529IY
UT WOS:000272510500005
PM 19928720
DA 2022-11-30
ER

PT J
AU Pennington, BO
   Clegg, DO
AF Pennington, Britney O.
   Clegg, Dennis O.
TI Pluripotent Stem Cell-Based Therapies in Combination with Substrate for
   the Treatment of Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; RPE-CHOROID SHEET; VISUAL FUNCTION; DIRECTED
   DIFFERENTIATION; SUBRETINAL IMPLANTATION; EFFICIENT GENERATION;
   EXTRACELLULAR-MATRIX; HUMAN FIBROBLASTS; SOMATIC-CELLS; TRANSPLANTATION
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the western world, which severely decreases the quality of life in the patients and places an economic burden on their families and society. The disease is caused by the dysfunction of a specialized cell layer in the back of the eye called the retinal pigmented epithelium (RPE). Pluripotent stem cells can provide an unlimited source of RPE, and laboratories around the world are investigating their potential as therapies for AMD. To ensure the precise delivery of functional RPE to the diseased site, some groups are developing a therapy composed of mature RPE monolayers on a supportive scaffold for transplantation as an alternative to injecting a single-cell suspension. This review summarizes methods of generating RPE from pluripotent stem cells, compares biodegradable and biostable materials as scaffolds, and describes the specific combination of human embryonic stem cell-derived RPE on Parylene-C membranes, which is scheduled to begin clinical trials in the United Sates in 2016. Stem cell-derived RPE monolayers on scaffolds hold great promise for the treatment of AMD and other retinal diseases.
C1 [Pennington, Britney O.; Clegg, Dennis O.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   [Clegg, Dennis O.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara
RP Clegg, DO (通讯作者)，Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
EM dennis.clegg@lifesci.ucsb.edu
FU Richard & Katherine Gee Breaux Fellowship in Vision Research; Garland
   Initiative for Vision; Fight for Sight; Sigma Xi; Foundation Fighting
   Blindness Wynn-Gund Translational Research Acceleration Program; UCSB
   Institute for Collaborative Biotechnologies from the U.S. Army Research
   Office [W911NF-09-0001]; California Institute for Regenerative Medicine
   [DR1-01444, CL1-00521, TG201151]; Major Facilities grant [FA1-00616]
FX This work was supported by the Richard & Katherine Gee Breaux Fellowship
   in Vision Research, Garland Initiative for Vision, Fight for Sight,
   Sigma Xi, The Foundation Fighting Blindness Wynn-Gund Translational
   Research Acceleration Program, the UCSB Institute for Collaborative
   Biotechnologies through grant W911NF-09-0001 from the U.S. Army Research
   Office, and the California Institute for Regenerative Medicine
   DR1-01444, CL1-00521, TG201151 (DOC), and Major Facilities grant
   FA1-00616. BOP was a fellow of the California Institute for Regenerative
   Medicine. The content of the information does not necessarily reflect
   the position or the policy of the Government, and no official
   endorsement should be inferred.
CR Anokye-Danso F, 2011, CELL STEM CELL, V8, P376, DOI 10.1016/j.stem.2011.03.001
   [Anonymous], 2009, SCH TECHN TECHN B
   Araki R, 2013, NATURE, V494, P100, DOI 10.1038/nature11807
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beach W.F., 2004, ENCY POLYM SCI TECHN, P587
   Binder S, 2011, BRIT J OPHTHALMOL, V95, P441, DOI 10.1136/bjo.2009.171926
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Butterwick A, 2009, EXP EYE RES, V88, P22, DOI 10.1016/j.exer.2008.09.018
   Caramoy A, 2011, BRIT J OPHTHALMOL, V95, P431, DOI 10.1136/bjo.2010.191882
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chang TY, 2007, LANGMUIR, V23, P11718, DOI 10.1021/la7017049
   Chen FK, 2008, INVEST OPHTH VIS SCI, V49, P3143, DOI 10.1167/iovs.07-1648
   Chung TW, 2006, J MICROENCAPSUL, V23, P15, DOI 10.1080/02652040500286110
   Cimadamore F, 2009, STEM CELLS, V27, P1772, DOI 10.1002/stem.107
   Clegg Dennis O., 2008, P1, DOI 10.1007/978-1-4020-8502-4_1
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Daar AS, 2007, J TISSUE ENG REGEN M, V1, P179, DOI 10.1002/term.20
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Dickens BM, 2008, MED LAW, V27, P179
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Feng Q, 2010, STEM CELLS, V28, P704, DOI 10.1002/stem.321
   Fujimura N, 2009, DEV BIOL, V334, P31, DOI 10.1016/j.ydbio.2009.07.002
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   Hageman G.S., 1995, ORIANIZATION RETINA
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARDY K, 1989, DEVELOPMENT, V107, P597
   Haruta Masathoshi, 2005, Semin Ophthalmol, V20, P17, DOI 10.1080/08820530590921846
   HERRON WL, 1969, INVEST OPHTH VISUAL, V8, P595
   Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ilic B, 2000, BIOMED MICRODEVICES, V2, P317, DOI 10.1023/A:1009911407093
   Ishida K, 2003, OCUL IMMUNOL INFLAMM, V11, P91, DOI 10.1076/ocii.11.2.91.15914
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Lee CJ, 2006, BIOMATERIALS, V27, P1670, DOI 10.1016/j.biomaterials.2005.09.008
   Li W, 2010, J MICROELECTROMECH S, V19, P735, DOI 10.1109/JMEMS.2010.2049985
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lindstrom Johnson S., 2013, J CRIMINOL-UK, V2013, P1, DOI [10.1155/2013/780460, DOI 10.1155/2013/780460]
   Liu J, 2015, EXP CELL RES, V338, P203, DOI 10.1016/j.yexcr.2015.08.004
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu B, 2011, PROC IEEE MICR ELECT, P505, DOI 10.1109/MEMSYS.2011.5734472
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Mandal PK, 2013, NAT PROTOC, V8, P568, DOI 10.1038/nprot.2013.019
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210
   Mellough C, 1 IPSC CLIN TRIALS T
   Melville H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-53
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Nistor G, 2010, J NEUROSCI METH, V190, P63, DOI 10.1016/j.jneumeth.2010.04.025
   O'Connor MD, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt169
   ORAHILLY R, 1975, EXP EYE RES, V21, P93, DOI 10.1016/0014-4835(75)90075-5
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Pera MF, 2011, NATURE, V471, P46, DOI 10.1038/471046a
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rolstad B, 2001, IMMUNOL REV, V184, P136, DOI 10.1034/j.1600-065x.2001.1840113.x
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SHEEDLO H J, 1991, Journal of Neural Transplantation and Plasticity, V2, P55
   Sipp D., 2013, PILOT CLIN STUDY IPS
   Song JS, 2009, J APPL POLYM SCI, V112, P3677, DOI 10.1002/app.29774
   Sridhar A, 2013, STEM CELL TRANSL MED, V2, P255, DOI 10.5966/sctm.2012-0101
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   SUMITA R, 1961, J ELECTRON MICROSC, V10, P111
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tan CP, 2010, MATERIALS, V3, P1803, DOI 10.3390/ma3031803
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thomson RC, 1996, BIOMATERIALS, V17, P321, DOI 10.1016/0142-9612(96)85570-0
   VEIS A, 1960, NATURE, V186, P720, DOI 10.1038/186720a0
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q
   Warre-Cornish K, 2014, STEM CELLS DEV, V23, P941, DOI 10.1089/scd.2013.0471
   Wei L., 2012, SPIE P BIOINSP BIOM, V8339
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Westenskow PD, 2010, INVEST OPHTH VIS SCI, V51, P5328, DOI 10.1167/iovs.09-5015
   Wright D, 2007, LAB CHIP, V7, P1272, DOI 10.1039/b706081e
   Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
NR 101
TC 24
Z9 25
U1 1
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUN
PY 2016
VL 32
IS 5
SI SI
BP 261
EP 271
DI 10.1089/jop.2015.0153
PG 11
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA DN9KW
UT WOS:000377399500005
PM 26889704
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Abdelfattah, NS
   Zhang, HY
   Boyer, DS
   Rosenfeld, PJ
   Feuer, WJ
   Gregori, G
   Sadda, SR
AF Abdelfattah, Nizar Saleh
   Zhang, Hongyang
   Boyer, David S.
   Rosenfeld, Philip J.
   Feuer, William J.
   Gregori, Giovanni
   Sadda, SriniVas R.
TI Drusen Volume as a Predictor of Disease Progression in Patients With
   Late Age-Related Macular Degeneration in the Fellow Eye
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular degeneration; geographic atrophy; wet macular degeneration;
   retinal drusen; choroidal neovascularization; optical coherence
   tomography; drusen volume
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; NATURAL-HISTORY;
   QUANTIFICATION; SEGMENTATION; PREVALENCE
AB PURPOSE. Increasing drusen volume was proposed to be a predictor of disease progression in age-related macular degeneration (AMD). In patients with late AMD in one eye, the fellow eyes without neovascularization are known to be at higher risk of developing exudative AMD. We evaluated the relationship between drusen volume in these fellow eyes and their progression to late AMD.
   METHODS. A retrospective analysis included fellow eyes with drusen associated with nonexudative AMD. All eyes with neovascular AMD were treated with intravitreal ranibizumab, aflibercept, and/or bevacizumab and followed for 2 years. All eyes were scanned with the Cirrus HD-OCT using a 512 x 128 scan pattern. Optical coherence tomography (OCT) data at baseline, month 12, and month 24 were collected using the advanced RPE analysis tool to quantify drusen volume within 3- and 5-mm-diameter circles centered on the fovea. Optical coherence tomography scans were also evaluated for the development of geographic atrophy (GA) or macular neovascularization (MNV).
   RESULTS. Eighty-nine patients who had neovascular AMD in only one eye were studied. Optical coherence tomography drusen volume in the absence of MNV could be measured in 61 participants (68.5%). After 12 months, 4 eyes (4.5%) developed MNV and 15 eyes (16.9%) developed GA. By 24 months of follow-up, an additional 5 eyes (7.1%) developed MNV and an additional 10 eyes (14.3%) developed GA. At month 24, the eyes that developed GA or MNV had baseline drusen volumes that were significantly larger than in eyes that did not develop late AMD. Patients with a drusen volume over 0.03 mm(3) had a greater than 4-fold increased risk for developing late AMD compared with those with lower drusen volumes.
   CONCLUSIONS. Baseline drusen volume appears to be an important predictor for the development of late AMD within 2 years in eyes that have fellow eyes being actively treated for MNV. This suggests that OCT-derived drusen volume measurements may be a useful biomarker to identify eyes at the highest risk for progression to late AMD.
C1 [Abdelfattah, Nizar Saleh; Zhang, Hongyang; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Abdelfattah, Nizar Saleh; Zhang, Hongyang; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Zhang, Hongyang] Guangdong Gen Hosp, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Rosenfeld, Philip J.; Feuer, William J.; Gregori, Giovanni] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Guangdong Academy of
   Medical Sciences & Guangdong General Hospital; Retina Vitreous
   Associates Medical Group; Bascom Palmer Eye Institute; University of
   Miami
RP Sadda, SR (通讯作者)，Doheny Image Reading Ctr, Ophthalmol, 1355 San Pablo St,Suite 100, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Abdelfattah, Nizar Saleh/H-6908-2019
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054
CR Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Diniz B, 2015, EYE, V29, P272, DOI 10.1038/eye.2014.260
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 29
TC 77
Z9 79
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 4
BP 1839
EP 1846
DI 10.1167/iovs.15-18572
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL8XY
UT WOS:000375926700042
PM 27082298
OA gold
DA 2022-11-30
ER

PT J
AU Corvi, F
   Srinivas, S
   Nittala, MG
   Corradetti, G
   Velaga, SB
   Stambolian, D
   Haines, J
   Pericak-Vance, MA
   Sadda, SR
AF Corvi, Federico
   Srinivas, Sowmya
   Nittala, Muneeswar Gupta
   Corradetti, Giulia
   Velaga, Swetha B.
   Stambolian, Dwight
   Haines, Jonathan
   Pericak-Vance, Margaret A.
   Sadda, SriniVas R.
TI Reproducibility of qualitative assessment of drusen volume in eyes with
   age related macular degeneration
SO EYE
LA English
DT Article
ID SEGMENTATION; PROGRESSION
AB Background Although an optical coherence tomography (OCT)-derived central drusen volume >= 0.03 mm(3) has been found to be a risk factor for progression to late age-related macular degeneration (AMD), this parameter is not currently available on most OCT devices or acquisition protocols. The purpose of this study was to evaluate the ability of human graders to qualitatively assess drusen volume by inspection of OCT B-scans. Methods 100 subjects (200 eyes) from the Amish Eye Study diagnosed with early or intermediate AMD underwent OCT imaging with both Cirrus OCT and Spectralis OCT. Drusen volume was automatically computed from the Cirrus OCT volumes using the Cirrus Advanced RPE Analysis software. Spectralis volume scans were reviewed by two independent, masked graders who were asked to determine whether the central drusen volume was >= 0.03 mm(3). Cohen's kappa coefficients were computed to assess the agreement. Results After excluding 11 eyes with poor image quality and 5 eyes used for training of the graders, the remaining 184 eyes were included in this analysis. The agreement between the graders and the automated evaluation of drusen volume by the Cirrus OCT was excellent with K = 0.88 for grader 1 and K = 0.82 for grader 2. The agreement between graders was also excellent with a K = 0.88. Conclusions The presence of a high central drusen volume can be assessed reliably by qualitative inspection of OCT B-scans. This approach may be useful in the assessment of risk for progression to late AMD.
C1 [Corvi, Federico; Srinivas, Sowmya; Nittala, Muneeswar Gupta; Corradetti, Giulia; Velaga, Swetha B.; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Corvi, Federico; Srinivas, Sowmya; Corradetti, Giulia; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Corvi, Federico] Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Haines, Jonathan] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of Milan;
   Luigi Sacco Hospital; University of Pennsylvania; Pennsylvania Medicine;
   Case Western Reserve University; University of Miami
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.; Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM ssadda@doheny.org
RI Corradetti, Giulia/Q-5400-2019; Corvi, Federico/AAD-7691-2021
OI Corradetti, Giulia/0000-0001-9213-5575; Corvi,
   Federico/0000-0002-2661-5500
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lamin A, 2020, OPHTHALMIC RES, V63, P375, DOI 10.1159/000505628
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nittala MG, 2019, RETINA-J RET VIT DIS, V39, P1540, DOI 10.1097/IAE.0000000000002210
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
NR 18
TC 3
Z9 3
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2021
VL 35
IS 9
BP 2594
EP 2600
DI 10.1038/s41433-020-01293-0
EA NOV 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UC8OV
UT WOS:000590945400001
PM 33214691
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Riusala, A
   Sarna, S
   Immonen, I
AF Riusala, A
   Sarna, S
   Immonen, I
TI Visual function index (VF-14) in exudative age-related macular
   degeneration of long duration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; LOW-VISION PATIENTS; CATARACT-SURGERY; IMPAIRMENT;
   OUTCOMES; IMPACT
AB PURPOSE: To evaluate the Visual Function Index (VF-14) questionnaire for its effectiveness in assessing visual function in patients with longstanding exudative age-related macular degeneration (AMD).
   DESIGN: Observational case series.
   METHODS: The records of 167 consecutive patients with recent neovascularization related to AMD between June 1990 and December 1994 at the Helsinki University Eye Clinic were analyzed in 1999. Of 121 patients still living, 74 (61%) attended the reexamination. After exclusions, data from 62 patients were analyzed. The VF-14 score, plus global assessment scores of satisfaction with vision and quality of vision, in which patients graded the subjective level of difficulty with their vision, best-corrected visual acuity (BCVA), contrast sensitivity, the area of the AMD lesion, and the shortest distance and direction from the center of the fovea to the edge of the subfoveal lesion, were analyzed.
   RESULTS: The VF-14 score correlated significantly with BCVA (P <.01), contrast sensitivity (P <.01), and global assessment scores (P <.01), showing stronger correlations with global assessment scores than did BCVA. In multivariate regression analysis, the global assessment scale of overall quality of vision and BCVA in the better eye were significant predictors (P <.001) of the variability in the VF-14 score.
   CONCLUSION: The VF-14 reflects visual function of patients with late AMD more effectively than BCVA measurement alone. The VF-14 can thus be used to compare the visual handicap of late AMD patients with that of patients with other eye diseases. (C) 2003 by Elsevier Science Inc. All rights reserved.
C1 Univ Helsinki Hosp, Dept Ophthalmol, Helsinki, Finland.
   Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki
RP Immonen, I (通讯作者)，Univ Helsinki Hosp, Dept Ophthalmol, Haartmaninkatu 4 C,JP 220, Helsinki, Finland.
OI Sarna, Seppo/0000-0003-3458-1627
CR Alonso J, 1997, OPHTHALMOLOGY, V104, P799, DOI 10.1016/S0161-6420(97)30230-9
   Alonso J, 1998, MED CARE, V36, P868, DOI 10.1097/00005650-199806000-00010
   Boisjoly H, 1999, AM J OPHTHALMOL, V128, P38, DOI 10.1016/S0002-9394(99)00071-9
   Brahma A, 2000, BRIT J OPHTHALMOL, V84, P60, DOI 10.1136/bjo.84.1.60
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   Castells X, 1999, OPHTHALMOLOGY, V106, P676, DOI 10.1016/S0161-6420(99)90150-1
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gresset J, 1997, CAN J OPHTHALMOL, V32, P31
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Lum F, 2000, OPHTHALMOLOGY, V107, P691, DOI 10.1016/S0161-6420(99)00184-0
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   MAGIONE CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Monestam E, 1997, ACTA OPHTHALMOL SCAN, V75, P569
   Musch DC, 1997, AM J OPHTHALMOL, V124, P1
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rose K, 2000, BRIT J OPHTHALMOL, V84, P1031, DOI 10.1136/bjo.84.9.1031
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   Uusitalo RJ, 1999, J CATARACT REFR SURG, V25, P989, DOI 10.1016/S0886-3350(99)00082-6
   Uusitalo RJ, 1998, J CATARACT REFR SURG, V24, P212, DOI 10.1016/S0886-3350(98)80202-2
NR 25
TC 40
Z9 48
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2003
VL 135
IS 2
BP 206
EP 212
AR PII S0002-9394(02)01832-9
DI 10.1016/S0002-9394(02)01832-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 640VV
UT WOS:000180709400012
PM 12566025
DA 2022-11-30
ER

PT J
AU Berlin, A
   Cabral, D
   Chen, L
   Messinger, JD
   Balaratnasingam, C
   Mendis, R
   Ferrara, D
   Freund, KB
   Curcio, CA
AF Berlin, Andreas
   Cabral, Diogo
   Chen, Ling
   Messinger, Jeffrey D.
   Balaratnasingam, Chandrakumar
   Mendis, Randev
   Ferrara, Daniela
   Freund, K. Bailey
   Curcio, Christine A.
TI Correlation of Optical Coherence Tomography Angiography of Type 3
   Macular Neovascularization With Corresponding Histology
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID CLINICOPATHOLOGICAL CORRELATION
AB IMPORTANCE By validating optical coherence tomography angiography (OCTA) in the analysis of type 3 macular neovascularization secondary to age-related macular degeneration, the overall value of clinical OCTA for disease observation, diagnosis, and staging is increased.
   OBJECTIVE To assess the association of in vivo OCTA of type 3 macular neovascularization secondary to age-related macular degeneration with corresponding ex vivo histology.
   DESIGN, SETTING, AND PARTICIPANTS This study included clinical imaging, laboratory microscopy, and eye-tracked clinicopathologic correlation of a single case from a community-based practice evaluated at a university-based research laboratory from 2014 to 2019.
   EXPOSURES Infrared reflectance and eye-tracked spectral-domain OCTA clinical imaging was correlated with ex vivo high-resolution histologic images of the preserved donor eye. Eye tracking, applied to the donor eye, enabled identification of histologic features corresponding with clinical OCTA signatures. Projection artifact removal based on 2-dimensional vessel-shape estimation and a Gaussian blur filter demonstrated a robust preservation of neovascular flow signal.
   MAIN OUTCOMES AND MEASURES Histology findings associated with clinical OCTA signatures. Three-dimensional view of neovascularization via video.
   RESULTS A White woman in her 90s with type 3 neovascularization secondary to age-related macular degeneration was treated with 37 intravitreal injections of ranibizumab and aflibercept in the right eye. The index lesion displayed a drusenoid pigment epithelium detachment, characteristic of type 3 neovascularization. OCTA decorrelation signal in the index lesion corresponded in histology to a collagen-ensheathed vascular complex contacting basal laminar deposit that outlasted the retinal pigment epithelium. The subretinal pigment epithelium-basal laminar space contained calcified material and glial processes. No connection between the choriocapillaris and this space was observed. Video showed a columnar tangle of flow signal in the outer nuclear layer, with inflow and outflow vessels connecting to the superficial artery and vein.
   CONCLUSIONS AND RELEVANCE While this study presents only 1 case in which a vascular connection between subretinal pigment epithelium-basal laminar space and choriocapillaris was undetected, these results support the potential value of OCTA for diagnosis. OCTA decorrelation signal of type 3 neovascularization corresponded with intraretinal neovessels on histology. Projection artifact removal based on 2-dimensional vessel-shape estimation and Gaussian blur filter demonstrated their potential value for further use in OCTA decorrelation signal processing.
C1 [Berlin, Andreas; Chen, Ling; Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
   [Berlin, Andreas] Univ Hosp Wurzburg, Wurzburg, Germany.
   [Cabral, Diogo; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Cabral, Diogo] Univ Nova Lisboa, CEDOC NOVA Med Sch, Lisbon, Portugal.
   [Chen, Ling] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Ophthalmol, Chongqing, Peoples R China.
   [Chen, Ling] Chongqing Eye Inst, Chongqing, Peoples R China.
   [Balaratnasingam, Chandrakumar] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
   [Balaratnasingam, Chandrakumar] Lions Eye Inst, Nedlands, WA, Australia.
   [Balaratnasingam, Chandrakumar] Sir Charles Gairdner Hosp, Dept Ophthalmol, Nedlands, WA, Australia.
   [Mendis, Randev] Canberra Retina Ctr, Canberra, ACT, Australia.
   [Ferrara, Daniela] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Wurzburg; Vitreous Retina Macula Consultants of New York;
   Universidade Nova de Lisboa; Chongqing Medical University; University of
   Western Australia; Lions Eye Institute; University of Western Australia;
   University of Western Australia; Roche Holding; Genentech; New York
   University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Fdn Alabama Vis Res Labs, Dept Ophthalmol & Visual Sci,EyeSight, 1670 Univ Blvd,Ste 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
FU Genentech/Hoffmann La Roche; Macula Foundation; Research to Prevent
   Blindness; EyeSight Foundation of Alabama; Werner Jackstadt Foundation
FX This work was supported by Genentech/Hoffmann La Roche, the Macula
   Foundation, unrestricted funds to the Department of Ophthalmology and
   Visual Sciences (University of Alabama at Birmingham) from Research to
   Prevent Blindness, and EyeSight Foundation of Alabama. Dr Berlin reports
   grants from theWerner Jackstadt Foundation. Purchase of the slide
   scanner was made possible by the Carl G. and Pauline Buck Trust.
CR [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373
   Balaratnasingam C, 2019, OPHTHALMOLOGY, V126, P1588, DOI 10.1016/j.ophtha.2019.05.022
   Balaratnasingam C, 2018, AM J OPHTHALMOL, V189, P55, DOI 10.1016/j.ajo.2018.02.007
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Borrelli E, 2022, CAN J OPHTHALMOL, V57, P228, DOI 10.1016/j.jcjo.2021.04.020
   Chaikitmongkol V., 2020, ALBERT JAKOBIECS PRI, P1
   Chen L, 2021, OPHTHALMOL RETINA, V5, P1085, DOI 10.1016/j.oret.2021.01.012
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Sharma A, 2021, GRAEF ARCH CLIN EXP, V259, P1381, DOI 10.1007/s00417-021-05164-6
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Xu XY, 2019, AM J OPHTHALMOL, V207, P363, DOI 10.1016/j.ajo.2019.06.009
   Yu PK, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.1.29
   Yu PK, 2018, INVEST OPHTH VIS SCI, V59, P108, DOI 10.1167/iovs.17-22542
NR 16
TC 1
Z9 1
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2022
VL 140
IS 6
BP 628
EP 633
DI 10.1001/jamaophthalmol.2022.0890
EA APR 2022
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2E7EA
UT WOS:000784945000005
PM 35446357
DA 2022-11-30
ER

PT J
AU Chen, W
   Xu, W
   Tao, QS
   Liu, J
   Li, XJ
   Gan, XM
   Hu, HL
   Lu, YX
AF Chen, Wen
   Xu, Wei
   Tao, Qiushan
   Liu, Juan
   Li, Xiaojing
   Gan, Xiumin
   Hu, Honglin
   Lu, Yunxia
TI Meta-analysis of the association of the HTRA1 polymorphisms with the
   risk of age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration (AMD); HTRA1; meta-analysis
ID JAPANESE POPULATION; VARIANT; SUSCEPTIBILITY; DISEASE
AB HTRA1 was considered as one of important age-related macular degeneration (AMD) candidate genes. However, due to population heterogeneity and bias from case-control study, the association between HTRA1 and AMD needs further confirmation across different studies in different population. In this study, a meta-analysis was performed in 14 case-control studies which were published before August 31, 2008. Effect of HTRA1 polymorphism with AMD was synthetically evaluated. The pooled odds ratio (OR) for heterozygous genotype GA versus wild homozygous genotype GG is 2.13 (95% CI: 1.90, 2.39), the OR of homozygous genotype AA versus GG is 6.92 (95% CI: 5.74, 8.34) and the OR of allele A carrier (GA + AA) versus GG is 3.02 (95% CI: 2.57, 3.53). Sub-analysis indicated that the risk of HTRA1 rs11200638 on wet AMD was stronger than dry AMD, and it seems that HTRA1 rs11200638 could increase the risk of AMD in all races. This study strengthens the hypothesis of association between rs11200638 in the promoter of HTRA1 polymorphism and AMD. The variant of HTRA1/625G -> A could be a potentially promising genetic biomarker of AMD. (c) 2008 Published by Elsevier Ltd.
C1 [Xu, Wei; Li, Xiaojing; Gan, Xiumin; Hu, Honglin; Lu, Yunxia] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430030, Hubei, Peoples R China.
   [Chen, Wen; Liu, Juan] Huazhong Univ Sci & Technol, Union Hosp, Dept Ophthalmol, Wuhan 430022, Hubei, Peoples R China.
   [Tao, Qiushan] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Peking University
RP Lu, YX (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430030, Hubei, Peoples R China.
EM luyunxia@mails.tjmu.edu.cn
RI Xu, Wei/AAE-2967-2020
OI Chen, Wen/0000-0001-8493-0157
FU NIH/FIC [D43 TW06176]; FOGARTY INTERNATIONAL CENTER [D43TW006176]
   Funding Source: NIH RePORTER
FX We thank the support from International Collaborative Genetic Research
   Training Grant, NIH/FIC, D43 TW06176 - International Collaborative
   Genetics Research Training Program.
CR Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Haines JL, 2007, P NATL ACAD SCI USA, V104, P16725, DOI 10.1073/pnas.0708151104
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Wang Yi-Qiang, 2005, Zhonghua Yan Ke Za Zhi, V41, P377
   *WHO, 2004, 282 WHO
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   ZHANG TY, 2005, CHIN J OPHTHALMOL, V15, P177
   ZHOU H, 2005, CHIN J OPHTHALMOL, V41, P15
NR 19
TC 28
Z9 29
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2009
VL 89
IS 3
BP 292
EP 300
DI 10.1016/j.exer.2008.10.017
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 484JZ
UT WOS:000269041900003
PM 19026638
DA 2022-11-30
ER

PT J
AU Ng, DSC
   Kwok, AKH
   Tong, JMK
   Chan, CWN
   Li, WWT
AF Ng, Danny Siu-Chun
   Kwok, Alvin Kwan-Ho
   Tong, Justin Man-Kit
   Chan, Clement Wai-Nang
   Li, Walton Wai-Tat
TI Bevacizumab for neovascular age-related macular degeneration in Chinese
   patients in a clinical setting
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; age-related macular degeneration; Chinese
ID ANTI-VEGF THERAPY; INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY;
   CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; RANIBIZUMAB TREATMENT;
   SUBGROUP ANALYSIS; AFLIBERCEPT; OUTCOMES; INJECTION
AB AIM: To determine the outcome of non-investigational treatment with intravitreal bevacizumab (IVB) in neovascular age-related macular degeneration (AMD) patients.
   METHODS: Retrospective chart review of 81 eyes with neovascular AMD followed-up for at least 12mo and received 3-monthly loading IVB injections. Re-treat was based upon the individual clinician's judgment. Best-corrected visual acuity (BCVA) and optical coherence tomography measurements of central foveal thickness outcomes were evaluated at 12, 24mo.
   RESULTS: Eighty-one eyes (of 75 patients) completed 12mo of follow-up and 44 eyes (of 41 patients) completed 24mo of follow-up. The mean baseline logMAR BCVA significantly improved from 0.94 +/- 0.69 to 0.85 +/- 0.68 at 12mo (P<0.001) and from 0.91 +/- 0.65 to 0.85 +/- 0.60 (P=0.004) at 24mo. The proportion of eyes that lost <15 logMAR letters at 12mo was 90.1% and at 24mo was 81.8%. IVB was effective in improving visual acuity in both treatment naive and previous photodynamic therapy (PDT)-treated subgroups. Treatment naive patients required significantly fewer injections than patients with prior PDT. Multiple regression analysis identified that poorer baseline visual acuity was associated with greater improvement in visual acuity (P=0.015).
   CONCLUSION: Fewer injections in clinical practice may result in suboptimal visual outcomes compared with clinical trials of IVB in neovascular AMD patients. Poor baseline visual acuity and prior PDT treatment may also improve vision after IVB. The safety and durability of effect was maintained at 24mo.
C1 [Ng, Danny Siu-Chun; Chan, Clement Wai-Nang] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Kwok, Alvin Kwan-Ho; Li, Walton Wai-Tat] Hong Kong Sanat & Hosp, Dept Ophthalmol, 5-F,Cent Block 2 Village Rd, Hong Kong, Hong Kong, Peoples R China.
   [Tong, Justin Man-Kit] United Christian Hosp, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; United Christian Hospital
RP Kwok, AKH (通讯作者)，Hong Kong Sanat & Hosp, Dept Ophthalmol, 5-F,Cent Block 2 Village Rd, Hong Kong, Hong Kong, Peoples R China.
EM alvinkwok@hksh.com
RI Ng, Danny Siu Chun/AAG-3081-2020
OI Ng, Danny Siu Chun/0000-0001-6566-1019
CR Ahfat FG, 2013, EYE, V27, P289, DOI 10.1038/eye.2013.1
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Jyothi S, 2010, EYE, V24, P1018, DOI 10.1038/eye.2009.266
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Ng DS, 2012, HONG KONG MED J, V18, P488
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 35
TC 0
Z9 1
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2016
VL 9
IS 3
BP 424
EP 430
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG0KB
UT WOS:000371752600017
PM 27158614
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Giansanti, F
   Bacherini, D
   Giacomelli, G
   Virgili, G
   Finocchio, L
   Fiore, T
   Vannozzi, L
   Menchini, U
AF Giansanti, Fabrizio
   Bacherini, Daniela
   Giacomelli, Giovanni
   Virgili, Gianni
   Finocchio, Lucia
   Fiore, Tito
   Vannozzi, Lorenzo
   Menchini, Ugo
TI Intravitreal anti-VEGF therapy for vascularized pigment epithelium
   detachment in age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Pigment epithelium
   detachment; Ranibizumab
ID OCCULT CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN PHOTODYNAMIC THERAPY;
   BEVACIZUMAB INJECTION; VISUAL-ACUITY; RANIBIZUMAB; TEARS;
   PHOTOCOAGULATION; SECONDARY
AB Purpose: To assess the efficacy of intravitreal anti-vascular endothelial growth factor (VEGF) treatment of vascularized pigment epithelial detachment (PED) due to age-related macular degeneration (AMD).
   Methods: A total of 26 patients with vascularized PED secondary to AMD were retrospectively analyzed and treated with anti-VEGF intravitreal injections according to a PRN regimen after 3 initial injections. Best-corrected visual acuity (BCVA), optical coherence tomography, and fluorescein angiography were performed at baseline and quarterly.
   Results: Mean follow-up ranged from 9 to 26 months (mean 13.5). There was a deterioration in mean BCVA from 0.46 at baseline to 0.79 logMAR at 12 months (p<0.001). The mean PED greatest linear diameter (GLD) increased from 4499 at baseline to 5206 pm at 1-year follow-up (p<0.001). The mean PED maximum height decreased from 669 pm at baseline to 305 pm at 1-year follow-up (p < 0.001). The mean central retinal thickness (CRT) was unchanged (from 277 to 209 pm at 1 year follow-up) (p = 0.099). No effect was seen on the change of VA according to groups of baseline predictors as defined by the medial value: baseline VA, PED height, and CRT (p>0.10).There was a borderline trend (p = 0.064) that GLD affected response to treatment. The mean number of injections was 5.5 (3 to 9). Seven out of 26 (27%) patients developed a retinal pigment epithelium (RPE) tear.
   Conclusions: Intravitreal anti-VEGF therapy, with a PRN regimen, did not prevent visual acuity loss or RPE tear.
C1 [Giansanti, Fabrizio; Bacherini, Daniela; Giacomelli, Giovanni; Virgili, Gianni; Finocchio, Lucia; Vannozzi, Lorenzo; Menchini, Ugo] Univ Florence, Eye Clin, Dept Translat Surg & Med, I-50134 Florence, Italy.
   [Fiore, Tito] Eye Clin, Dept Ophthalmol, Perugia, Italy.
C3 University of Florence
RP Giansanti, F (通讯作者)，Univ Florence, Eye Clin, Dept Translat Surg & Med, Largo Brambilla 2, I-50134 Florence, Italy.
EM fabrizio.giansanti@unifi.it
RI giacomelli, giovanni/ABC-6173-2020; Finocchio, Lucia/X-4835-2019;
   Bacherini, Daniela/T-6009-2019; Virgili, Gianni/P-6607-2014
OI Virgili, Gianni/0000-0002-9960-2989; Finocchio,
   Lucia/0000-0003-1986-045X
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Bashshur ZF, 2011, RETINA-J RET VIT DIS, V31, P636, DOI 10.1097/IAE.0b013e3181fe54ab
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P745
   Da Pozzo Stefano, 2001, International Ophthalmology, V24, P187, DOI 10.1023/A:1022539204849
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Goto S, 2012, AM J OPHTHALMOL, V154, P865, DOI 10.1016/j.ajo.2012.05.001
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P370, DOI 10.1089/jop.2006.22.370
   KOENIG F, 1989, J FR OPHTALMOL, V12, P775
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Lommatzsch A, 2010, OPHTHALMOLOGE, V107, P1115, DOI 10.1007/s00347-010-2143-6
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Parodi MB, 2013, AM J OPHTHALMOL, V155, P103, DOI 10.1016/j.ajo.2012.07.001
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal KB, 2008, OPHTHALMOLOGE, V105, P538, DOI 10.1007/s00347-007-1638-2
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
NR 44
TC 4
Z9 5
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2014
VL 24
IS 3
BP 402
EP 408
DI 10.5301/ejo.5000388
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ4NH
UT WOS:000337652600019
PM 24242217
DA 2022-11-30
ER

PT J
AU Paraoan, L
   Sharif, U
   Carlsson, E
   Supharattanasitthi, W
   Mahmud, NM
   Kamalden, TA
   Hiscott, P
   Jackson, M
   Grierson, I
AF Paraoan, Luminita
   Sharif, Umar
   Carlsson, Emil
   Supharattanasitthi, Wasu
   Mahmud, Nur Musfirah
   Kamalden, Tengku Ain
   Hiscott, Paul
   Jackson, Malcolm
   Grierson, Ian
TI Secretory proteostasis of the retinal pigmented epithelium: Impairment
   links to age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Retinal pigment epithelium RPE; Secretory proteostasis; Age-related
   macular degeneration AMD; Proteases; Cathepsins; Protease inhibitors;
   Cystatin C; Secretion; Leader sequence; ECM; Degeneration; Neurotrophic;
   Angiogenesis; Cytokine; Amyloid beta; Apical; Basolateral
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ENDOTHELIAL
   GROWTH-FACTOR; FACTOR PATHWAY INHIBITOR-2; MEMBRANE-ATTACK-COMPLEX;
   BETA-BINDING PROTEIN-2; PRECURSOR CYSTATIN-C; AMYLOID-BETA;
   INTERPHOTORECEPTOR MATRIX; TISSUE INHIBITOR
AB Secretory proteostasis integrates protein synthesis, processing, folding and trafficking pathways that are essential for efficient cellular secretion. For the retinal pigment epithelium (RPE), secretory proteostasis is of vital importance for the maintenance of the structural and functional integrity of apical (photoreceptors) and basal (Bruch's membrane/choroidal blood supply) sides of the environment it resides in. This integrity is achieved through functions governed by RPE secreted proteins, which include extracellular matrix modelling/remodelling, angiogenesis and immune response modulation. Impaired RPE secretory proteostasis affects not only the extracellular environment, but leads to intracellular protein aggregation and ER-stress with subsequent cell death. Ample recent evidence implicates dysregulated proteostasis as a key factor in the development of age-related macular degeneration (AMD), the leading cause of blindness in the developed world, and research aiming to characterise the roles of various proteins implicated in AMD-associated dysregulated proteostasis unveiled unexpected facets of the mechanisms involved in degenerative pathogenesis. This review analyses cellular processes unveiled by the study of the top 200 transcripts most abundantly expressed by the RPE/choroid in the light of the specialised secretory nature of the RPE. Functional roles of these proteins and the mechanisms of their impaired secretion, due to age and genetic-related causes, are analysed in relation to AMD development. Understanding the importance of RPE secretory proteostasis in relation to maintaining retinal health and how it becomes impaired in disease is of paramount importance for the development and assessment of future therapeutic advancements involving gene and cell therapies.
C1 [Paraoan, Luminita; Sharif, Umar; Carlsson, Emil; Supharattanasitthi, Wasu; Mahmud, Nur Musfirah; Hiscott, Paul; Grierson, Ian] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, William Henry Duncan Bldg 6,West Derby St, Liverpool L7 8TX, Merseyside, England.
   [Supharattanasitthi, Wasu] Mahidol Univ, Fac Pharm, Dept Physiol, Bangkok, Thailand.
   [Mahmud, Nur Musfirah; Kamalden, Tengku Ain] Univ Malaya, Fac Med, Eye Res Ctr, Dept Ophthalmol, Kuala Lumpur, Malaysia.
   [Jackson, Malcolm] Univ Liverpool, Inst Ageing & Chron Dis, Dept Musculoskeletal Biol, Liverpool, Merseyside, England.
C3 University of Liverpool; Mahidol University; Universiti Malaya;
   University of Liverpool
RP Paraoan, L (通讯作者)，Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, William Henry Duncan Bldg 6,West Derby St, Liverpool L7 8TX, Merseyside, England.
EM lparaoan@liverpool.ac.uk
RI KAMALDEN, TENGKU AIN FATHLUN TENGKU/B-9941-2010; Supharattanasitthi,
   Wasu/AAC-4704-2021; MAHMUD, NUR MUSFIRAH/AFN-9157-2022; Paraoan,
   Luminita/K-1066-2016
OI KAMALDEN, TENGKU AIN FATHLUN TENGKU/0000-0001-9810-5334; Paraoan,
   Luminita/0000-0001-7568-7116; Supharattanasitthi,
   Wasu/0000-0003-3789-8312
FU Humane Research Trust UK; Macular Society UK
FX The members of the Ocular Molecular Biology and Mechanisms of Disease
   group in the University of Liverpool gratefully acknowledge the
   continued generous support of The Humane Research Trust UK and The
   Macular Society UK.
CR Abid A, 2006, J MED GENET, V43, P378, DOI 10.1136/jmg.2005.035055
   Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Alcock F, 2009, J MOL BIOL, V385, P1032, DOI 10.1016/j.jmb.2008.11.045
   Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Zamarripa DA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13621-8
   Asthana A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08821-1
   Bachner Dietmar, 2002, Brain Res Gene Expr Patterns, V1, P159
   Bailey RW, 2001, BIOCHEMISTRY-US, V40, P11828, DOI 10.1021/bi010135x
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   BEDNAR A, 2013, INVEST OPHTH VIS SCI, V54
   Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677
   Bengtsson E, 2002, J BIOL CHEM, V277, P15061, DOI 10.1074/jbc.M108285200
   Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200
   Benussi L, 2003, NEUROBIOL DIS, V13, P15, DOI 10.1016/S0969-9961(03)00012-3
   Beuckmann CT, 1996, J NEUROSCI, V16, P6119
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Birke MT, 2014, GENE THER, V21, P507, DOI 10.1038/gt.2014.24
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Boelens WC, 2014, PROG BIOPHYS MOL BIO, V115, P3, DOI 10.1016/j.pbiomolbio.2014.02.005
   BOK D, 1993, J CELL SCI, P189
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bradshaw AD, 2009, J CELL COMMUN SIGNAL, V3, P239, DOI 10.1007/s12079-009-0062-6
   Bravo R, 2013, INT REV CEL MOL BIO, V301, P215, DOI 10.1016/B978-0-12-407704-1.00005-1
   BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273
   Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871
   Butler JM, 2015, HUM GENET, V134, P705, DOI 10.1007/s00439-015-1552-7
   Carlsson E., 2020, INVEST OPHTHALMOL VI, V28102
   Cavalli G., 2020, J MOL BIOL
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chand HS, 2005, THROMB HAEMOSTASIS, V94, P1122, DOI 10.1160/TH05-07-0509
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YM, 2013, J AM SOC NEPHROL, V24, P1223, DOI 10.1681/ASN.2012121149
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Coutinho MF, 2012, MOL GENET METAB, V105, P542, DOI 10.1016/j.ymgme.2011.12.012
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6
   Dempsey PJ, 2003, EXP CELL RES, V285, P159, DOI 10.1016/S0014-4827(03)00035-1
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Dinculescu A, 2018, ADV EXP MED BIOL, V1074, P61, DOI 10.1007/978-3-319-75402-4_8
   Do Carmo S, 2008, J NEUROSCI, V28, P10330, DOI 10.1523/JNEUROSCI.2644-08.2008
   DRAYNA D, 1986, J BIOL CHEM, V261, P6535
   Du SS, 2013, EXP EYE RES, V116, P151, DOI 10.1016/j.exer.2013.08.019
   Duga S, 2004, INT J BIOCHEM CELL B, V36, P1393, DOI 10.1016/j.biocel.2003.08.002
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Eletto D, 2014, MOL CELL, V53, P562, DOI 10.1016/j.molcel.2014.01.004
   Embree MC, 2010, AM J PATHOL, V176, P812, DOI 10.2353/ajpath.2010.090450
   Etique N, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/152163
   Fan YH, 2017, ONCOL REP, V38, P1149, DOI 10.3892/or.2017.5731
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Folsch H, 2009, TRAFFIC, V10, P972, DOI 10.1111/j.1600-0854.2009.00927.x
   Fritz BA, 1996, AM J PHYSIOL-GASTR L, V270, pG176, DOI 10.1152/ajpgi.1996.270.1.G176
   Frost LS, 2013, VISUAL NEUROSCI, V30, P55, DOI 10.1017/S0952523813000096
   Fthenou E, 2009, IN VIVO, V23, P69
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Ganfornina MD, 2008, AGING CELL, V7, P506, DOI 10.1111/j.1474-9726.2008.00395.x
   Gerakis Y, 2018, FEBS J, V285, P995, DOI 10.1111/febs.14332
   GHISO J, 1990, P NATL ACAD SCI USA, V87, P1288, DOI 10.1073/pnas.87.4.1288
   Gibson J, 2012, IMMUNOBIOLOGY, V217, P251, DOI 10.1016/j.imbio.2011.07.015
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Groenendyk J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004983
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hamada Y, 2003, BIOCHEM BIOPH RES CO, V310, P153, DOI 10.1016/j.bbrc.2003.09.001
   Hao X., 2018, MEDICINE, V97, pe11981
   Harned J, 2012, EXP EYE RES, V97, P90, DOI 10.1016/j.exer.2012.02.001
   Harter C, 1996, BBA-REV BIOMEMBRANES, V1286, P75, DOI 10.1016/0304-4157(96)00003-2
   Hatahet F, 2009, ANTIOXID REDOX SIGN, V11, P2807, DOI [10.1089/ars.2009.2466, 10.1089/ARS.2009.2466]
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403
   Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI13992
   Higuchi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009911
   HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527
   Hirai M, 2007, EMBO J, V26, P3283, DOI 10.1038/sj.emboj.7601768
   Hirani R, 2007, MATRIX BIOL, V26, P213, DOI 10.1016/j.matbio.2006.12.006
   Hollborn M, 2004, INVEST OPHTH VIS SCI, V45, P2033, DOI 10.1167/iovs.03-0656
   Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631
   Hollien J, 2009, J CELL BIOL, V186, P323, DOI 10.1083/jcb.200903014
   Hollyfield JG, 1999, INVEST OPHTH VIS SCI, V40, P2767
   Howard C, 2010, HISTOL HISTOPATHOL, V25, P1163, DOI 10.14670/HH-25.1163
   Hu H, 2016, CELL, V164, P433, DOI 10.1016/j.cell.2015.12.042
   Hua Y, 2012, INT J NEUROSCI, V122, P431, DOI 10.3109/00207454.2012.672502
   Huang CX, 2015, INVEST OPHTH VIS SCI, V56, P6196, DOI 10.1167/iovs.15-16795
   Huang Y, 2006, J BIOL CHEM, V281, P27398, DOI 10.1074/jbc.M603690200
   Hulleman JD, 2012, FASEB J, V26, P4548, DOI 10.1096/fj.11-202861
   Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Imamura Y, 1998, GENOMICS, V51, P293, DOI 10.1006/geno.1998.5357
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johansson H., 2016, THROMB VASC BIOL, V36, P122
   Jones RPO, 2010, INVEST OPHTH VIS SCI, V51, P2356, DOI 10.1167/iovs.09-4620
   Kaeser SA, 2007, NAT GENET, V39, P1437, DOI 10.1038/ng.2007.23
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kanekiyo T, 2013, J NEUROSCI, V33, P19276, DOI 10.1523/JNEUROSCI.3487-13.2013
   KATZ ML, 1989, MECH AGEING DEV, V49, P23, DOI 10.1016/0047-6374(89)90065-1
   Kaur I, 2010, P NATL ACAD SCI USA, V107, pE112, DOI 10.1073/pnas.1007476107
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Kheitan S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181667
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Kim HM, 2016, GENE, V584, P17, DOI 10.1016/j.gene.2016.03.002
   KISHIMOTO Y, 1992, J LIPID RES, V33, P1255
   KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5973, DOI 10.1167/iovs.10-6965
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Kunze A, 2010, OPHTHALMIC RES, V43, P108, DOI 10.1159/000247595
   La Venuta G, 2015, J BIOL CHEM, V290, P27015, DOI 10.1074/jbc.R115.689257
   Labbadia J, 2015, ANNU REV BIOCHEM, V84, P435, DOI 10.1146/annurev-biochem-060614-033955
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   Le Goff MM, 2012, J BIOL CHEM, V287, P28027, DOI 10.1074/jbc.M111.331157
   Le Goff MM, 2012, INVEST OPHTH VIS SCI, V53, P228, DOI 10.1167/iovs.11-8514
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li ZF, 2004, GENOMICS, V83, P1083, DOI 10.1016/j.ygeno.2003.12.005
   Liang XB, 2005, J NEUROCHEM, V92, P477, DOI 10.1111/j.1471-4159.2004.02870.x
   Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Locke CJ, 2014, EXP EYE RES, V129, P1, DOI 10.1016/j.exer.2014.10.010
   Loftus SK, 2009, PIGM CELL MELANOMA R, V22, P99, DOI 10.1111/j.1755-148X.2008.00518.x
   Longhurst HJ, 2015, CLIN EXP IMMUNOL, V180, P475, DOI 10.1111/cei.12584
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   LOU DA, 1987, HISTOCHEM J, V19, P431, DOI 10.1007/BF01675754
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lukas J, 2009, NUCLEIC ACIDS RES, V37, P3007, DOI 10.1093/nar/gkp179
   Lund SA, 2009, J CELL COMMUN SIGNAL, V3, P311, DOI 10.1007/s12079-009-0068-0
   Ma J, 2012, CYTOKINE, V59, P100, DOI 10.1016/j.cyto.2012.03.025
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mandal M.N.A., 2005, INVEST OPHTH VIS SCI
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Martin PM, 2006, INVEST OPHTH VIS SCI, V47, P4238, DOI 10.1167/iovs.06-0026
   Martinek N, 2007, J DENT RES, V86, P296, DOI 10.1177/154405910708600402
   Mercado G, 2016, BRAIN RES, V1648, P626, DOI 10.1016/j.brainres.2016.04.042
   Meyer RC, 2014, BRAIN RES, V1585, P1, DOI 10.1016/j.brainres.2014.08.022
   Mi W, 2007, NAT GENET, V39, P1440, DOI 10.1038/ng.2007.29
   Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200
   Mori H, 2019, GRAEF ARCH CLIN EXP, V257, P289, DOI 10.1007/s00417-018-4184-5
   MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nickel W, 2008, ANNU REV CELL DEV BI, V24, P287, DOI 10.1146/annurev.cellbio.24.110707.175320
   Nojima S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2420
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Obata R, 2005, EYE, V19, P464, DOI 10.1038/sj.eye.6701531
   Ogawa H, 2010, J BIOL CHEM, V285, P34155, DOI 10.1074/jbc.M110.109553
   Ouchi N, 2008, J BIOL CHEM, V283, P32802, DOI 10.1074/jbc.M803440200
   Padgett LC, 1997, EXP EYE RES, V64, P927, DOI 10.1006/exer.1997.0287
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Paraoan L, 2003, EXP EYE RES, V76, P753, DOI 10.1016/S0014-4835(03)00061-7
   Paraoan L, 2001, MOL MEMBR BIOL, V18, P229
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Paraoan L, 2009, FRONT BIOSCI-LANDMRK, V14, P2504, DOI 10.2741/3393
   Park S.Y., 2014, BIOSCIENCE REP, V34, pe00123
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Parsi MK, 2010, MATRIX BIOL, V29, P393, DOI 10.1016/j.matbio.2010.03.005
   Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701
   Peyvandi F, 2011, BLOOD TRANSFUS-ITALY, V9, pS3, DOI 10.2450/2011.002S
   Pilecki B, 2016, J BIOL CHEM, V291, P1103, DOI 10.1074/jbc.M115.681775
   Plate L, 2017, TRENDS CELL BIOL, V27, P722, DOI 10.1016/j.tcb.2017.05.006
   Prabakaran D, 1999, J CELL SCI, V112, P1247
   Prydz K, 2012, GLYCOSYLATION, P301, DOI 10.5772/48214
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Rabouille C, 2017, TRENDS CELL BIOL, V27, P230, DOI 10.1016/j.tcb.2016.11.007
   Rakoczy PE, 1997, BIOCHEM J, V324, P935, DOI 10.1042/bj3240935
   Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y
   Ratnayaka A, 2007, EXP EYE RES, V84, P1135, DOI 10.1016/j.exer.2006.01.030
   Ratnayaka A, 2007, INT J BIOCHEM CELL B, V39, P85, DOI 10.1016/j.biocel.2006.08.015
   Reinboth B, 2002, J BIOL CHEM, V277, P3950, DOI 10.1074/jbc.M109540200
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   ROHLICH P, 1970, EXP EYE RES, V10, P80, DOI 10.1016/S0014-4835(70)80013-6
   Roybal CN, 2005, INVEST OPHTH VIS SCI, V46, P3973, DOI 10.1167/iovs.05-0070
   Roybal CN, 2005, J BIOL CHEM, V280, P20331, DOI 10.1074/jbc.M411275200
   Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sagt CMJ, 1998, APPL ENVIRON MICROB, V64, P316
   Sagt CMJ, 2002, APPL ENVIRON MICROB, V68, P2155, DOI 10.1128/AEM.68.5.2155-2160.2002
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Sant'Anna R, 2016, FEBS LETT, V590, P644, DOI 10.1002/1873-3468.12093
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0
   Schneider R, 2010, J MOL BIOL, V401, P605, DOI 10.1016/j.jmb.2010.06.039
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8
   Sharif U, 2019, J CELL MOL MED, V23, P405, DOI 10.1111/jcmm.13944
   Sharif U, 2014, INVEST OPHTH VIS SCI, V55
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Stoops EH, 2014, J AM SOC NEPHROL, V25, P1375, DOI 10.1681/ASN.2013080883
   Storck SE, 2016, J CLIN INVEST, V126, P123, DOI 10.1172/JCI81108
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Supharattanasitthi W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36740-2
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Takayama K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8694641
   Tanaka T, 1997, J BIOL CHEM, V272, P15789, DOI 10.1074/jbc.272.25.15789
   Tanaka Y, 2004, INVEST OPHTH VIS SCI, V45, P245, DOI 10.1167/iovs.03-0230
   Tatti M, 2012, HUM MOL GENET, V21, P5159, DOI 10.1093/hmg/dds367
   TIEN LF, 1992, EXP EYE RES, V55, P297, DOI 10.1016/0014-4835(92)90194-W
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Tochio T, 2010, J DERMATOL SCI, V58, P123, DOI 10.1016/j.jdermsci.2010.02.012
   Toyofuku T, 2012, GENE DEV, V26, P816, DOI 10.1101/gad.184481.111
   Traub LM, 2005, BBA-MOL CELL RES, V1744, P415, DOI 10.1016/j.bbamcr.2005.04.005
   Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1
   Tsui SL, 2000, GENOMICS, V65, P266, DOI 10.1006/geno.2000.6169
   Tsuruma K, 2012, INVEST OPHTH VIS SCI, V53, P6729, DOI 10.1167/iovs.11-9378
   Tufvesson E, 2002, FEBS LETT, V530, P124, DOI 10.1016/S0014-5793(02)03439-7
   Twal WO, 2001, J CELL SCI, V114, P4587
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735
   Van den Berghe L, 2004, INVEST OPHTH VIS SCI, V45, P1297, DOI 10.1167/iovs.03-1048
   Vehvilainen P, 2003, J BIOL CHEM, V278, P24705, DOI 10.1074/jbc.M212953200
   Verma V, 2007, FASEB J, V21, pA763
   Volpert Katja N, 2009, J Ocul Biol Dis Infor, V2, P1, DOI 10.1007/s12177-009-9014-x
   Wagenaar-Bos IGA, 2006, IMMUNOL ALLERGY CLIN, V26, P615, DOI 10.1016/j.iac.2006.08.004
   WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Wang S, 2015, INVEST OPHTH VIS SCI, V56, P2971, DOI 10.1167/iovs.14-15874
   Wang Y, 2007, J BIOL CHEM, V282, P33247, DOI 10.1074/jbc.C700175200
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wei HY, 2012, ACTA OPHTHALMOL, V90, pe138, DOI 10.1111/j.1755-3768.2011.02283.x
   Weng CY, 2009, CURR EYE RES, V34, P867, DOI 10.3109/02713680903177890
   Westwood M, 2001, J BIOL CHEM, V276, P41668, DOI 10.1074/jbc.M102793200
   Wistow G, 2002, MOL VIS, V8, P205
   WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705
   Wyatt AR, 2013, ANNU REV BIOCHEM, V82, P295, DOI 10.1146/annurev-biochem-072711-163904
   Xie L, 2008, EXP BIOL MED, V233, P155, DOI 10.3181/0706-RM-167
   Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729
   Yan Q, 2005, INVEST OPHTH VIS SCI, V46, P4652, DOI 10.1167/iovs.05-0460
   Yang H, 2003, J CELL BIOCHEM, V89, P933, DOI 10.1002/jcb.10570
   Yang J, 2011, J ALZHEIMERS DIS, V27, P711, DOI 10.3233/JAD-2011-110725
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Yerbury JJ, 2007, FASEB J, V21, P2312, DOI 10.1096/fj.06-7986com
   Zhang Q, 2003, GENE, V318, P45, DOI 10.1016/S0378-1119(03)00753-4
   Zhang XY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03283-x
   Zhang ZX, 2016, BIOCHEMISTRY-MOSCOW+, V81, P574, DOI 10.1134/S0006297916060031
   Zhao PY, 2015, INVEST OPHTH VIS SCI, V56, P1916, DOI 10.1167/iovs.14-15738
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WH, 2018, MOL NEUROBIOL, V55, P1915, DOI 10.1007/s12035-017-0447-0
   Zinn KM, 1979, RETINAL PIGMENT EPIT
   Zlokovic BV, 2000, NAT MED, V6, P718, DOI 10.1038/77397
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 263
TC 7
Z9 7
U1 4
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2020
VL 79
AR 100859
DI 10.1016/j.preteyeres.2020.100859
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PH4OZ
UT WOS:000600395400004
PM 32278708
DA 2022-11-30
ER

PT J
AU Ward, E
   Wickens, RA
   O'Connell, A
   Culliford, LA
   Rogers, CA
   Gidman, EA
   Peto, T
   Knox, PC
   Burton, BJL
   Lotery, AJ
   Sivaprasad, S
   Donnelly, M
   Treanor, C
   Hogg, RE
   Reeves, BC
AF Ward, Elizabeth
   Wickens, Robin A.
   O'Connell, Abby
   Culliford, Lucy A.
   Rogers, Chris A.
   Gidman, Eleanor A.
   Peto, Tunde
   Knox, Paul C.
   Burton, Benjamin J. L.
   Lotery, Andrew J.
   Sivaprasad, Sobha
   Donnelly, Michael
   Treanor, Charlene
   Hogg, Ruth E.
   Reeves, Barnaby C.
TI Monitoring for neovascular age-related macular degeneration (AMD)
   reactivation at home: the MONARCH study
SO EYE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; SHAPE-DISCRIMINATION; HYPERACUITY; EYE;
   SECONDARY; DEVICE
AB Aims This study aims to quantify the diagnostic test-accuracy of three visual function self-monitoring tests for detection of active disease in patients with neovascular age-related macular degeneration (nAMD) when compared with usual care. An integrated qualitative study will investigate the acceptability of these home-based testing strategies. Methods All consenting participants are provided with an equipment pack containing an iPod touch with two vision test applications installed and a paper journal of reading tests. Participants self-monitor their vision at home each week with all three tests for 12-18 months. Usual care continues over this period. Key eligibility criteria are: age >= 50 years; at least one eye with AMD with >= 6-<= 42 months since first AMD treatment; and vision not worse than Snellen 6/60, LogMAR 1.04 or 33 letters. The primary outcome, and reference standard, is diagnosis of active disease during usual care monitoring in the Hospital Eye Service. Secondary outcomes include duration of study participation, ability of participants to do the tests, adherence to weekly testing and acceptability of the tests to participants. Conclusions Recruitment is in progress at five NHS centres. Challenges in procuring equipment, setting up the devices and transporting devices containing lithium batteries to participating sites delayed the start of recruitment. The study will describe the performance of the tests self-administered at home in detecting active disease compared to usual care monitoring. It will also describe the feasibility of the NHS implementing patient-administered electronic tests or similar applications at home for monitoring health.
C1 [Ward, Elizabeth; Wickens, Robin A.; O'Connell, Abby; Culliford, Lucy A.; Rogers, Chris A.; Gidman, Eleanor A.; Reeves, Barnaby C.] Univ Bristol, Bristol Royal Infirm, Bristol Trials Ctr CTEU, Bristol BS2 8HW, Avon, England.
   [Peto, Tunde; Donnelly, Michael; Treanor, Charlene; Hogg, Ruth E.] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
   [Knox, Paul C.] Univ Liverpool, Dept Eye & Vis Sci, Liverpool L7 8TX, Merseyside, England.
   [Burton, Benjamin J. L.] James Paget Univ Hosp NHS Fdn Trust, Norwich NR31 6LA, Norfolk, England.
   [Lotery, Andrew J.] Univ Southampton, Dept Clin & Expt Sci, Fac Med, Southampton SO16 6YD, Hants, England.
   [Sivaprasad, Sobha] Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr, London EC1V 2PD, England.
C3 Bristol Royal Infirmary; University of Bristol; Queens University
   Belfast; University of Liverpool; University of Southampton; University
   of London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust
RP Reeves, BC (通讯作者)，Univ Bristol, Bristol Royal Infirm, Bristol Trials Ctr CTEU, Bristol BS2 8HW, Avon, England.; Hogg, RE (通讯作者)，Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
EM r.e.hogg@qub.ac.uk; barney.reeves@bristol.ac.uk
RI Sivaprasad, S./D-6876-2015; Hogg, Ruth E./ABC-9602-2020; Peto,
   Tunde/M-2081-2013
OI Sivaprasad, S./0000-0001-8952-0659; Hogg, Ruth E./0000-0001-9413-2669;
   Burton, Ben/0000-0001-9579-9078; Wickens, Robin/0000-0003-4374-3747;
   Peto, Tunde/0000-0001-6265-0381; Reeves, Barnaby/0000-0002-5101-9487;
   culliford, lucy/0000-0002-9255-6617; O'Connell,
   Abby/0000-0001-7598-927X; Gidman, Eleanor/0000-0002-5261-5213; Knox,
   Paul/0000-0002-2578-7335
FU National Institute for Health Research, Health Technology Assessment
   (HTA) Programme [15/97/02]; Queen's University of Belfast, UK; National
   Institute for Health Research CTU
FX This project is funded by the National Institute for Health Research,
   Health Technology Assessment (HTA) Programme (ref 15/97/02). The views
   and opinions expressed are those of the author(s) and not necessarily
   reflect those of the HTA programme, NIHR, NHS or the Department of
   Health and Social Care. The study is sponsored by The Queen's University
   of Belfast, UK. This study was designed and is being delivered in
   collaboration with the Clinical Trials and Evaluation Unit (CTEU), a
   UKCRC registered clinical trials unit which, as part of the Bristol
   Trials Centre, is in receipt of National Institute for Health Research
   CTU support funding. The authors would like to acknowledge the Patient
   and Public Involvement group (PPI), the Macular Society and the Royal
   National Institute of Blind People for feedback on the study and the
   patient documents and the SSC for their oversight of the study. The
   independent SSC is chaired by a vision scientist, with two consultant
   ophthalmologists, an optometrist, a biostatistician, a vision scientist
   and patient and public involvement representatives; other SSC members
   with observer status represent the study management team and the
   Sponsor. The PPI group is formed of six public contributors.
CR Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   [Anonymous], 2017, MONITORING NEOVASCUL
   Bittner Ava K, 2014, J Clin Exp Ophthalmol, V5, P320
   Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1136/bmj.h5527, 10.1373/clinchem.2015.246280, 10.1148/radiol.2015151516]
   Braun V., 2013, SUCCESSFUL QUALITATI
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Luijkx K, 2015, INT J ENV RES PUB HE, V12, P15470, DOI 10.3390/ijerph121214999
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Obuchowski NA, 1997, STAT MED, V16, P1529, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1529::AID-SIM565>3.0.CO;2-H
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Pope C, 2006, ANAL QUAL DATA BMJ
   Smith D., 2002, QUALITATIVE RES ACTI, P17
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Trevino R, 2008, OPHTHAL PHYSL OPT, V28, P183, DOI 10.1111/j.1475-1313.2008.00561.x
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vazquez NP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207342
   Wang YZ, 2015, INVEST OPHTH VIS SCI, V56
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2009, OPTOMETRY VISION SCI, V86, P695, DOI 10.1097/OPX.0b013e3181a7b0ff
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Wang YZ, 2001, OPTOMETRY VISION SCI, V78, P447, DOI 10.1097/00006324-200106000-00019
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
   Winther C, 2015, ACTA OPHTHALMOL, V93, P481, DOI 10.1111/aos.12659
   Winther C, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/285463
   Yardley L, 2000, PSYCHOL HEALTH, V15, P215, DOI 10.1080/08870440008400302
NR 29
TC 10
Z9 10
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2021
VL 35
IS 2
BP 592
EP 600
DI 10.1038/s41433-020-0910-4
EA MAY 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA PX7VQ
UT WOS:000530278200002
PM 32367004
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kang, GY
   Bang, JY
   Choi, AJ
   Yoon, J
   Lee, WC
   Choi, S
   Yoon, S
   Kim, HC
   Baek, JH
   Park, HS
   Lim, HJ
   Chung, H
AF Kang, Gum-Yong
   Bang, Joo Young
   Choi, Ae Jin
   Yoon, Jeehyun
   Lee, Won-Chul
   Choi, Soyoung
   Yoon, Soojin
   Kim, Hyung Chan
   Baek, Je-Hyun
   Park, Hyung Soon
   Lim, Hyunjung Jade
   Chung, Hyewon
TI Exosomal Proteins in the Aqueous Humor as Novel Biomarkers in Patients
   with Neovascular Age-related Macular Degeneration
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium; exosome;
   aqueous humor; proteomics; biomarker; cathepsin D;
   epithelial-mesenchymal transition
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; PROTEOMIC
   ANALYSIS; OXIDATIVE STRESS; GEL-ELECTROPHORESIS; MASS-SPECTROMETRY;
   HEALTHY DONORS; MOUSE MODEL; CELL-LINE; AUTOPHAGY
AB Age-related macular degeneration (AMD) describes the progressive degeneration of the retinal pigment epithelium (RPE), retina, and choriocapillaris and is the leading cause of blindness in people over SO. The molecular mechanisms underlying this multifactorial disease remain largely unknown. To uncover novel secretory biomarkers related to the pathogenesis of AMD, we adopted an integrated approach to compare the proteins identified in the conditioned medium (CM) of cultured RPE cells and the exosomes derived from CM and from the aqueous humor (AH) of AMD patients by LC-ESI-MS/MS. Finally, LC-MRM was performed on the AH from patients and controls, which revealed that cathepsin D, cytokeratin 8, and four other proteins increased in the AH of AMD patients. The present study has identified potential biomarkers and therapeutic targets for AMD treatment, such as proteins related to the autophagy lysosomal pathway. and epithelial mesenchymal transition, and demonstrated a novel and effective approach to identifying AMD-associated proteins that might be secreted by RPE in vivo in the form of exosomes. The proteomics-based characterization of this multifactorial disease could help to match a particular marker to particular target-based therapy in AMD patients with various phenotypes.
C1 [Kang, Gum-Yong; Bang, Joo Young; Baek, Je-Hyun; Park, Hyung Soon] Diatech Korea Co Ltd, Seoul 138826, South Korea.
   [Choi, Ae Jin; Yoon, Jeehyun; Kim, Hyung Chan; Chung, Hyewon] Konkuk Univ, Sch Med, Dept Ophthalmol, Seoul 143701, South Korea.
   [Lee, Won-Chul] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul 151742, South Korea.
   [Choi, Soyoung; Lim, Hyunjung Jade] Konkuk Univ, Dept Biomed Sci & Technol, Seoul 143701, South Korea.
   [Choi, Soyoung; Lim, Hyunjung Jade; Chung, Hyewon] Konkuk Univ, Inst Biomed Sci & Technol, Seoul 143701, South Korea.
   [Yoon, Soojin] Konkuk Univ, Dept Mol Biotechnol, Seoul 143701, South Korea.
   [Kim, Hyung Chan; Chung, Hyewon] Konkuk Univ, Med Ctr, Dept Ophthalmol, Seoul 143729, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Seoul National
   University (SNU); Konkuk University; Konkuk University; Konkuk
   University; Konkuk University; Konkuk University Medical Center
RP Chung, H (通讯作者)，Konkuk Univ, Sch Med, Dept Ophthalmol, 120 Neungdong Ro, Seoul 143701, South Korea.
EM hchung@kuh.ac.kr
RI Lee, Won-Chul/D-5789-2012; Lim, Hyunjung J/D-5343-2011
OI Lee, Won-Chul/0000-0001-8052-2420; Lim, Hyunjung J/0000-0003-2191-666X;
   Park, Hyung Soon/0000-0003-0558-2874; Baek, Je-Hyun/0000-0003-4974-8397
FU National Research Foundation of Korea (NRF); Ministry of Science, ICT &
   Future Planning [2012M3A9B2028333, 2012R1A1A11012171]
FX This research was supported by the National Research Foundation of Korea
   (NRF) funded by the Ministry of Science, ICT & Future Planning
   (2012M3A9B2028333 and 2012R1A1A11012171).
CR Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703
   Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969
   Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1
   Bard MP, 2004, AM J RESP CELL MOL, V31, P114, DOI 10.1165/rcmb.2003-0238OC
   Bastos-Amador P, 2012, J PROTEOMICS, V75, P3574, DOI 10.1016/j.jprot.2012.03.054
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Businaro R, 2009, ATHEROSCLEROSIS, V207, P74, DOI 10.1016/j.atherosclerosis.2009.04.026
   Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267
   Carbone C, 2011, CLIN CANCER RES, V17, P5822, DOI 10.1158/1078-0432.CCR-11-1185
   Chowdhury UR, 2010, INVEST OPHTH VIS SCI, V51, P4921, DOI 10.1167/iovs.10-5531
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Colombo E, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00063
   Conde-Vancells J, 2008, J PROTEOME RES, V7, P5157, DOI 10.1021/pr8004887
   da Silveira JC, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.093252
   Dean DO, 1999, INVEST OPHTH VIS SCI, V40, P2952
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eriksson P, 2006, NEOPLASMA, V53, P285
   Escoffier P, 2010, J PROTEOME RES, V9, P789, DOI 10.1021/pr9006602
   Fader CM, 2008, TRAFFIC, V9, P230, DOI 10.1111/j.1600-0854.2007.00677.x
   Fang S, 2008, ACTA BIOCH BIOPH SIN, V40, P989, DOI 10.1111/j.1745-7270.2008.00484.x
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Funding M, 2005, ACTA OPHTHALMOL SCAN, V83, P31, DOI 10.1111/j.1600-0420.2005.00381.x
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Hegmans JPJJ, 2004, AM J PATHOL, V164, P1807, DOI 10.1016/S0002-9440(10)63739-X
   Hoffman EA, 2009, INVEST OPHTH VIS SCI, V50, P1313, DOI 10.1167/iovs.08-2326
   Izzotti A, 2010, J PROTEOME RES, V9, P4831, DOI 10.1021/pr1005372
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Kongara S, 2010, MOL CANCER RES, V8, P873, DOI 10.1158/1541-7786.MCR-09-0494
   Ku NO, 2007, HEPATOLOGY, V46, P1639, DOI 10.1002/hep.21976
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Lau ATY, 2007, CANCER RES, V67, P2107, DOI 10.1158/0008-5472.CAN-06-3771
   Lee H, 2010, INT J BIOL MACROMOL, V47, P104, DOI 10.1016/j.ijbiomac.2010.05.014
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Macknight ADC, 2000, CLIN EXP PHARMACOL P, V27, P100, DOI 10.1046/j.1440-1681.2000.03208.x
   Mathivanan S, 2010, MOL CELL PROTEOMICS, V9, P197, DOI 10.1074/mcp.M900152-MCP200
   Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876
   Ni M, 2005, EXP EYE RES, V81, P286, DOI 10.1016/j.exer.2005.01.027
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Ohguro H, 2002, AM J OPHTHALMOL, V134, P605, DOI 10.1016/S0002-9394(02)01633-1
   Panova IG, 2008, COMP BIOCHEM PHYS A, V151, P676, DOI 10.1016/j.cbpa.2008.08.020
   Perkumas KM, 2007, EXP EYE RES, V84, P209, DOI 10.1016/j.exer.2006.09.020
   Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Sabapatha A, 2006, AM J REPROD IMMUNOL, V56, P345, DOI 10.1111/j.1600-0897.2006.00435.x
   Sacca SC, 2012, INVEST OPHTH VIS SCI, V53, P4242, DOI 10.1167/iovs.11-8902
   Sakamoto T, 2001, GRAEF ARCH CLIN EXP, V239, P865, DOI 10.1007/s004170100373
   Sato T, 2008, INVEST OPHTH VIS SCI, V49, P4641, DOI 10.1167/iovs.08-2049
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Skriner K, 2006, ARTHRITIS RHEUM, V54, P3809, DOI 10.1002/art.22276
   Steindl-Kuscher K, 2009, INVEST OPHTH VIS SCI, V50, P4471, DOI 10.1167/iovs.08-3139
   Strauss K, 2010, J BIOL CHEM, V285, P26279, DOI 10.1074/jbc.M110.134775
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Taylor DD, 2006, J IMMUNOL, V176, P1534, DOI 10.4049/jimmunol.176.3.1534
   Taylor DD, 2011, METHODS MOL BIOL, V728, P235, DOI 10.1007/978-1-61779-068-3_15
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang ZH, 2013, CARCINOGENESIS, V34, P128, DOI 10.1093/carcin/bgs295
   Wu WC, 2007, EXP EYE RES, V85, P721, DOI 10.1016/j.exer.2007.08.005
   Xiao H, 2012, ANAL CHIM ACTA, V723, P61, DOI 10.1016/j.aca.2012.02.018
   Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   ZIMMERMAN WF, 1983, EXP EYE RES, V36, P151, DOI 10.1016/0014-4835(83)90098-2
NR 72
TC 95
Z9 102
U1 2
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD FEB
PY 2014
VL 13
IS 2
BP 581
EP 595
DI 10.1021/pr400751k
PG 15
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AA5UC
UT WOS:000331164100023
PM 24400796
DA 2022-11-30
ER

PT J
AU Ahmadieh, H
   Taei, R
   Riazi-Esfahani, M
   Piri, N
   Homayouni, M
   Daftarian, N
   Yaseri, M
AF Ahmadieh, Hamid
   Taei, Ramin
   Riazi-Esfahani, Mohammad
   Piri, Niloufar
   Homayouni, Mansour
   Daftarian, Narsis
   Yaseri, Mehdi
TI INTRAVITREAL BEVACIZUMAB VERSUS COMBINED INTRAVITREAL BEVACIZUMAB AND
   TRIAMCINOLONE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Six-Month
   Results of a Randomized Clinical Trial
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; triamcinolone acetonide
ID ENDOTHELIAL GROWTH-FACTOR; HUMAN CHOROIDAL NEOVASCULARIZATION; AVASTIN;
   ACETONIDE; SECONDARY; THERAPY; ENDOSTATIN
AB Purpose: To determine whether combined intravitreal bevacizumab (IVB) and triamcinolone (IVT) is more effective than IVB alone in neovascular age-related macular degeneration.
   Methods: This was a prospective, randomized clinical trial performed at two centers. Eligible eyes were assigned randomly to one of the two study arms. In the IVB group, 3 consecutive injections of 1.25 mg of bevacizumab were given 6 weeks apart, while in the IVB/IVT group, the first of the triple IVB injections was combined with 2 mg of IVB. A fourth IVB was injected in eyes demonstrating active choroidal neovascularization at Week 24.
   Results: Sixty and 55 eyes were in the IVB and IVB/IVT groups, respectively. Best-corrected visual acuity improved, and central macular thickness was reduced significantly in both groups at all time points. Visual improvement was more pronounced in the IVB/IVT group compared with the IVB group 6 weeks (8.5 +/- 14.4 vs. 3.8 +/- 8.9 letters, P = 0.04) and 12 weeks (11.8 +/- 16.6 vs. 6.2 +/- 10.8 letters, P = 0.03) after initiation of therapy. However, there was no significant difference in visual improvement at Week 24 (11.3 +/- 17.2 letters in the IVB/IVT group vs. 8.7 +/- 15.6 letters in the IVB group, P = 0.40). The IVB/IVT group showed significantly less need for a fourth injection at Week 24 (34.5% vs. 53.3% in the IVB/IVT and IVB groups, respectively, P = 0.04).
   Conclusion: Mandated therapy with IVB improved best-corrected visual acuity and decreased central macular thickness in neovascular age-related macular degeneration. The addition of low-dose IVT temporarily increased the therapeutic efficacy in the early postinjection period and resulted in fewer requirements for repeat IVB injections at 6 months; however, final levels of visual improvement were comparable in the 2 study groups. RETINA 31: 1819-1826, 2011
C1 [Ahmadieh, Hamid; Taei, Ramin; Homayouni, Mansour; Daftarian, Narsis; Yaseri, Mehdi] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Labbafinejad Med Ctr, Tehran 16666, Iran.
   [Riazi-Esfahani, Mohammad; Piri, Niloufar] Univ Tehran Med Sci, Eye Res Ctr, Farabi Eye Hosp, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Tehran University of
   Medical Sciences
RP Ahmadieh, H (通讯作者)，Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Labbafinejad Med Ctr, Pasdaran Ave,Boostan 9 St, Tehran 16666, Iran.
EM hahmadieh@hotmail.com
RI Daftarian, Narsis/AAW-5803-2020; Yaseri, Mehdi/I-1645-2018; Ahmadieh,
   Hamid/M-4853-2017
OI Daftarian, Narsis/0000-0001-5846-8739; Yaseri,
   Mehdi/0000-0002-4066-873X; Ahmadieh, Hamid/0000-0002-8139-2661; Piri,
   Niloofar/0000-0002-0685-028X
CR Ahmadieh H, 2008, GRAEF ARCH CLIN EXP, V246, P483, DOI 10.1007/s00417-007-0688-0
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Colucciello M, 2008, J OCUL PHARMACOL TH, V24, P15, DOI 10.1089/jop.2007.0080
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Koss MJ, 2010, OPHTHALMOLOGICA, V224, P72, DOI 10.1159/000235724
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Riazi-Esfahani Mohammad, 2008, J Ophthalmic Vis Res, V3, P95
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P207, DOI 10.1089/jop.2009.0131
   Tatar O, 2009, BRIT J OPHTHALMOL, V93, P159, DOI 10.1136/bjo.2008.138594
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P193, DOI 10.1001/archophthalmol.2007.40
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 27
TC 16
Z9 16
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2011
VL 31
IS 9
BP 1819
EP 1826
DI 10.1097/IAE.0b013e31820d58f2
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 825YR
UT WOS:000295318800012
PM 21555967
DA 2022-11-30
ER

PT J
AU Sharma, S
   Toth, CA
   Daniel, E
   Grunwald, JE
   Maguire, MG
   Ying, GS
   Huang, JY
   Martin, DF
   Jaffe, GJ
AF Sharma, Sumit
   Toth, Cynthia A.
   Daniel, Ebenezer
   Grunwald, Juan E.
   Maguire, Maureen G.
   Ying, Gui-Shuang
   Huang, Jiayan
   Martin, Daniel F.
   Jaffe, Glenn J.
CA Comparison Age-Related Macular Deg
TI Macular Morphology and Visual Acuity in the Second Year of the
   Comparison of Age-Related Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID EYES
AB Purpose: To describe the association between morphologic features on fundus photography (FP), fluorescein angiography (FA), and optical coherence tomography (OCT) and visual acuity (VA) in the second year of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
   Design: Prospective cohort study within a randomized clinical trial.
   Participants: Participants in the CATT.
   Methods: Study eye eligibility required angiographic and OCT evidence of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and VA between 20/25 and 20/320. Treatment was assigned randomly to ranibizumab or bevacizumab with 3 different dosing regimens over a 2-year period.
   Main Outcome Measures: Fluid type, location, and thickness; retina and subretinal tissue complex thickness on OCT; size and lesion composition on FP and FA; and VA.
   Results: Among 1185 CATT participants, 993 (84%) had fluid on OCT at baseline and completed 2 years of follow-up. At 2 years, intraretinal fluid (IRF), subretinal fluid (SRF), sub-retinal pigment epithelium (RPE) fluid, and subretinal tissue complex thickness decreased in all treatment groups. Ranibizumab monthly was best able to resolve each type of fluid. Eyes with SRF in the foveal center on OCT had better mean VA than eyes with no SRF (72.8 vs. 66.6 letters; P = 0.006). Eyes with IRF in the foveal center had worse mean VA than eyes without IRF (59.9 vs. 70.9 letters; P < 0.0001). Eyes with retinal thickness <120 mu m had worse VA compared with eyes with retinal thickness 120 to 212 and >212 mu m (59.4 vs. 71.3 vs. 70.3 letters; P < 0.0001). At 2 years, the mean VA (letters) of eyes varied substantially by the type of subfoveal pathology on FP and FA: 70.6 for no pathology; 74.1 for fluid only; 73.3 for CNV or pigment epithelial (RPE) detachment; 68.4 for nongeographic atrophy; and 62.9 for geographic atrophy, hemorrhage, RPE tear, or scar (P < 0.0001).
   Conclusions: The associations between VA and morphologic features identified through year 1 were maintained or strengthened during year 2. Eyes with foveal IRF, abnormally thin retina, greater thickness of the subretinal tissue complex on OCT, and subfoveal geographic atrophy or scar on FP/FA had the worst VA. Subretinal fluid was associated with better VA. (C) 2016 by the American Academy of Ophthalmology.
C1 [Sharma, Sumit; Toth, Cynthia A.; Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, 2351 Erwin Rd,Box 3802, Durham, NC 27710 USA.
   [Daniel, Ebenezer; Grunwald, Juan E.; Maguire, Maureen G.; Ying, Gui-Shuang; Huang, Jiayan] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Duke University; University of Pennsylvania; Cleveland Clinic Foundation
RP Jaffe, GJ (通讯作者)，Duke Univ, Dept Ophthalmol, 2351 Erwin Rd,Box 3802, Durham, NC 27710 USA.
EM jaffe001@mc.duke.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Losordo, Douglas/0000-0002-6857-7506;
   Vavvas, Demetrios/0000-0002-8622-6478
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland [U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, R21EY023689]; NATIONAL EYE
   INSTITUTE [U10EY017826, U10EY017823, R21EY023689, U10EY017828,
   U10EY017825] Funding Source: NIH RePORTER
FX Supported by cooperative agreements U10 EY017823, U10 EY017825, U10
   EY017826, U10 EY017828, and R21EY023689 from the National Eye Institute,
   National Institutes of Health, Department of Health and Human Services,
   Bethesda, Maryland. The funding organization participated in the design
   and conduct of the study and review of the manuscript.
   ClinicalTrials.gov identifier NCT00593450.
CR Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Stone TW, 2014, ASRS 2014 PREFERENCE
NR 11
TC 135
Z9 139
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2016
VL 123
IS 4
BP 865
EP 875
DI 10.1016/j.ophtha.2015.12.002
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH3WU
UT WOS:000372718300031
PM 26783095
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Park, SJ
   Lee, JH
   Woo, SJ
   Ahn, J
   Shin, JP
   Song, SJ
   Kang, SW
   Park, KH
AF Park, Sang Jun
   Lee, Ju Hyun
   Woo, Se Joon
   Ahn, Jeeyun
   Shin, Jae Pil
   Song, Su Jeong
   Kang, Se Woong
   Park, Kyu Hyung
CA Korean Ophthalmologic Soc
TI Age-Related Macular Degeneration Prevalence and Risk Factors from Korean
   National Health and Nutrition Examination Survey, 2008 through 2011
SO OPHTHALMOLOGY
LA English
DT Article
ID B SURFACE-ANTIGEN; MEDICAL PROGRESS; GENETIC-VARIANTS; OBESITY PARADOX;
   ANEMIA; HOMOCYSTEINE; MACULOPATHY; DEPOSITS; DRUSEN; FOLATE
AB Objective: To investigate the prevalence and risk factors of age-related macular degeneration (AMD) in the Korean population.
   Design: A cross-sectional study using a complex, stratified, multistage, probability-cluster survey, which can produce nationally representative estimates.
   Participants: Using the database of Korean National Health and Nutrition Examination Survey from 2008 through 2011, 14 352 participants 40 years of age or older with gradable fundus photographs were included.
   Methods: Age-related macular degeneration was determined by fundus photograph. Prevalences of AMDs were estimated. Risk factor analyses were conducted using logistic regression analyses (LRAs).
   Main Outcome Measures: Prevalence and risk factors of AMD.
   Results: The prevalence of AMD was 6.62% (95% confidence interval [CI], 6.15%-7.09%) in the Korean population: 6.02% (95% CI, 5.56%-6.48%) were early AMD and 0.60% (95% CI, 0.45%-0.75%) were late AMD. The prevalence of early AMD in women (6.73%; 95% CI, 6.11%-7.35%) was higher than that in men (5.25%; 95% CI, 4.61%-5.89%; P< 0.001), and the prevalence of late AMD in women (0.37%; 95% CI, 0.22%-0.52%) was lower than that in men (0.85%; 95% CI, 0.59%-1.12%; P<0.001). However, in multiple LRAs both early and late AMD had no association with gender, house income, residence, sun exposure, or systemic comorbidities, including hypertension, diabetes mellitus, and cardiovascular diseases. Early AMD had positive associations with older age groups (P<0.001), lower education (P = 0.027), occupation (P<0.001), anemia (P = 0.027), hepatitis B surface antigen carrier status (P<0.001), not being overweight (body mass index [BMI], P = 0.032; waist circumference, P = 0.041, in separate analyses), and higher serum high-density lipoprotein (HDL) level (P = 0.046), but not with smoking status. Late AMD had positive associations with age groups (P<0.001), current smokers (P = 0.022), and lower BMI (P = 0.037).
   Conclusions: The results suggest that there are 1.21 million individuals with early AMD and 121 000 individuals with late AMD in Korea. Nonoverweight status and higher HDL levels, generally assumed as positive health indicators, as well as anemia and hepatitis B infection had harmful associations with AMD in our study, implying a possible different pathophysiologic process of AMD in Asians compared with that of white persons. (C) 2014 by the American Academy of Ophthalmology.
C1 [Park, Sang Jun; Woo, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Songnam 463707, Gyeonggi Do, South Korea.
   [Lee, Ju Hyun] Seoul Natl Univ, Bundang Hosp, Med Res Collaborating Ctr, Songnam 463707, Gyeonggi Do, South Korea.
   [Ahn, Jeeyun] SMG SNU Boramae Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Shin, Jae Pil] Kyungpook Natl Univ, Dept Ophthalmol, Sch Med, Taegu, South Korea.
   [Song, Su Jeong] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
   [Kang, Se Woong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University Hospital; Kyungpook
   National University; Sungkyunkwan University (SKKU); Samsung Medical
   Center; Sungkyunkwan University (SKKU); Samsung Medical Center
RP Park, KH (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, 300 Gumi Dong, Songnam 463707, Gyeonggi Do, South Korea.
EM swkang@skku.edu; jiani4@snu.ac.kr
RI Park, Sang Jun/C-3234-2015
OI Park, Sang Jun/0000-0003-0542-2758; Ahn, Jeeyun/0000-0001-9017-1652
FU National Research Foundation of Korea - Ministry of Education, Science,
   and Technology [NRF-2012R1A1A2008943, NRF-2013R1A2A2A04015829]
FX Supported by the National Research Foundation of Korea, funded by the
   Ministry of Education, Science, and Technology (grant nos.:
   NRF-2012R1A1A2008943 and NRF-2013R1A2A2A04015829). The sponsor or
   funding organization had no role in the design or conduct of this
   research.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2007, VIS 2020 RIGHT SIGHT, P1
   Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   FRIBERG TR, 1983, AM J OPHTHALMOL, V95, P712, DOI 10.1016/0002-9394(83)90400-2
   Gatineau M, 2011, OBESITY ETHNICITY
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim BJ, 2012, NEUROLOGY, V79, P856, DOI 10.1212/WNL.0b013e318266fad1
   Kim Yangho, 2013, J Prev Med Public Health, V46, P96, DOI 10.3961/jpmph.2013.46.2.96
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   KOKSAL I, 1992, OPHTHALMOLOGICA, V204, P19
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Ma RCW, 2013, ANN NY ACAD SCI, V1281, P64, DOI 10.1111/nyas.12098
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Oreopoulos A, 2009, CLIN GERIATR MED, V25, P643, DOI 10.1016/j.cger.2009.07.005
   Oyeyemi GM, 2010, ASIAN J MATH STAT, V3, P33
   Pham TQ, 2009, OPHTHAL EPIDEMIOL, V16, P136, DOI 10.1080/09286580701299395
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Roy CN, 2010, HEMATOL-AM SOC HEMAT, P276, DOI 10.1182/asheducation-2010.1.276
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   SINGH VK, 1990, J IMMUNOL, V144, P1282
   SLEPOVA OS, 1994, VESTN OFTALMOL, V110, P27
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tefferi A, 2003, MAYO CLIN PROC, V78, P1274, DOI 10.4065/78.10.1274
   TEMEL A, 1990, ACTA OPHTHALMOL, V68, P205
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 52
TC 75
Z9 75
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2014
VL 121
IS 9
BP 1756
EP 1765
DI 10.1016/j.ophtha.2014.03.022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2KY
UT WOS:000341151800026
PM 24813632
DA 2022-11-30
ER

PT J
AU Lazreg, S
   Delcourt, C
   Zeggane, S
   Sanchezk, A
   Ziani, A
   Daghbouche, M
   Benmoussa, S
   Mokrani, K
   Mekki, MB
   Renault, D
   Parodi, MB
   Bandello, F
   Nouri, MT
AF Lazreg, Sihem
   Delcourt, Cecile
   Zeggane, Sihem
   Sanchezk, Alice
   Ziani, Assia
   Daghbouche, Mounir
   Benmoussa, Salaheddine
   Mokrani, Karim
   Mekki, Moatez Billah
   Renault, Didier
   Parodi, Maurizio Battaglia
   Bandello, Francesco
   Nouri, Mohamed Tahar
TI Age-Related Macular Degeneration and Its Risk Factors on North Africans
   Living on Algeria and Italy
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Macular degeneration; Epidemiology; Risk factors; North Africa
ID FATTY-ACIDS; MACULOPATHY; PREVALENCE; SMOKING; EYE; CONSUMPTION; LUTEIN;
   HEALTH
AB Purpose: To determine the risk factors for age-related macular degeneration (AMD) in Algerians, and compare these data with those on North Africans living in Italy. Methods: All patients over 55 years of age consulting one of the 23 involved Algerian ophthalmologists were invited to participate, and 1,183 patients were included. Data collection was standardized based on the Simplified Thea Risk Assessment Scale (STARS) questionnaire. A similar study was conducted in North Africans living in Italy (n = 1,011). Patients with only soft drusen and/or pigmentary abnormalities were classified as early AMD, and patients with geographic atrophy and/or neovascular AMD were classified as late AMD. Results: In the final multivariate model, risk for early and/or late AMD was significantly increased with older age, family history of AMD, Black ethnicity, atherosclerosis, beer consumption, high fruit consumption, cataract surgery, myopia, and hyperopia. High consumption of green vegetables was associated with lower risk for both early and late AMD. In comparison with North Africans from Italy, Algerians generally had a healthier profile (younger, less obesity, smoking, and cardiovascular diseases, and higher consumption of fruits and vegetables) and a lower risk for AMD. Conclusion: This study documents risk factors for AMD in North-African populations for the first time. (C) 2016 S. Karger AG, Basel
C1 [Zeggane, Sihem] Khemis Miliana Hosp, Dept Ophthalmol, Ain Delfa, Algeria.
   [Ziani, Assia] Beni Slimane Hosp, Dept Ophthalmol, Medea, Algeria.
   [Nouri, Mohamed Tahar] Beni Messous Univ Hosp, Dept Ophthalmol, Algiers, Algeria.
   [Delcourt, Cecile] Univ Bordeaux, ISPED, Bordeaux, France.
   [Delcourt, Cecile] INSERM, U1219, Bordeaux Populat Hlth Res Ctr, Bordeaux, France.
   [Sanchezk, Alice] Castries, Biostatem, Clermont Ferrand, France.
   [Renault, Didier] Lab Thea, Clermont Ferrand, France.
   [Parodi, Maurizio Battaglia; Bandello, Francesco] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
C3 UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite de Bordeaux; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele
RP Delcourt, C (通讯作者)，Univ Bordeaux, ISPED, Inserm U1219, 146 Rue Leo Saignat, FR-33076 Bordeaux, France.
EM cecile.delcourt@isped.fr
RI Delcourt, Cecile/I-2627-2013; Parodi, Maurizio Battaglia/K-7876-2016;
   bandello, francesco/AAH-2405-2019
OI Delcourt, Cecile/0000-0002-2099-0481; bandello,
   francesco/0000-0003-3238-9682; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
FU Laboratoires Thea
FX This study was supported by Laboratoires Thea. The sponsor participated
   in the design, analysis, and interpretation of results and writing of
   the manuscript. F. Bandello is a consultant for Alcon, Alimera,
   Allergan, Bausch + Lomb, Bayer, Genentech, Laboratoires Thea, Novagali
   Pharma, Novartis, Pfizer, Roche, and Sanofi-Aventis. C. Delcourt is a
   consultant for Allergan, Bausch + Lomb, Laboratoires Thea, and Novartis.
   D. Renaud is an employee of Laboratoires Thea. The other authors have no
   financial interests to disclose.
CR Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mathenge W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001393
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Rosenthal T, 2014, J AM SOC HYPERTENS, V8, P171, DOI 10.1016/j.jash.2013.12.007
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 38
TC 6
Z9 6
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 56
IS 3
BP 145
EP 154
DI 10.1159/000446844
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW0DI
UT WOS:000383310700005
PM 27410056
DA 2022-11-30
ER

PT J
AU Vedula, SS
   Krzystolik, MG
AF Vedula, S. S.
   Krzystolik, M. G.
TI Antiangiogenic therapy with anti-vascular endothelial growth factor
   modalities for neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB LUCENTIS; PEGAPTANIB SODIUM;
   VISUAL-ACUITY; PREVALENCE; SMOKING; MACULOPATHY; RISK
AB Background
   Age-related macular degeneration (AMD) is a common cause of severe vision loss in people 55 years and older.
   Objectives
   The objective of this review was to investigate the effects of anti-VEGF (vascular endothelial growth factor) modalities for treating neovascular AMD.
   Search strategy
   We searched CENTRAL, MEDLINE, EMBASE and LILACS. We handsearched ARVO abstracts for 2006, 2007 for ongoing trials.
   Selection criteria
   We included randomized controlled trials (RCTs).
   Data collection and analysis
   Two review authors independently extracted data. We contacted trial authors for additional data. We summarized outcomes as relative risks (RR), number needed to treat (NNT) and weighted mean differences.
   Main results
   We included five RCTs of good methodological quality. All five trials were conducted by pharmaceutical companies. An intention-to-treat analysis using the last observation carried forward method was done in most trials.
   Two trials compared pegaptanib versus sham. One trial compared ranibizumab versus sham, another compared ranibizumab/sham verteporfin PDT versus verteporfin PDT/sham ranibizumab, and the final trial compared ranibizumab plus verteporfin PDT versus verteporfin PDT alone.
   Fewer patients treated with pegaptanib lost 15 or more letters of visual acuity at one year follow-up compared to sham (pooled relative risk (RR) 0.71; 95% confidence interval (CI) 0.61 to 0.84). The NNT was 6.67 (95% CI 4.35 to 14.28) for 0.3 mg pegaptanib, 6.25 (95% CI 4.17 to 12.5) for 1 mg pegaptanib and 14.28 (95% CI 6.67 to 100) for 3 mg pegaptanib. In a trial of ranibizumab versus sham, RR for loss of 15 or more letters visual acuity at one year was 0.14 (95% CI 0.1 to 0.22) in favour of ranibizumab. The NNT was 3.13 (95% CI 2.56 to 3.84) for 0.3 mg ranibizumab and 3.13 (95% CI 2.56 to 3.84) for 0.5 mg ranibizumab. In a trial of ranibizumab versus verteporfin PDT, RR for loss of 15 or more letters at one year was 0.13 (95% CI 0.07 to 0.23) favouring ranibizumab. The NNT was 3.33 (95% CI 2.56 to 4.76) for 0.3 mg ranibizumab and 3.12 (95% CI 2.43 to 4.17) for 0.5 mg ranibizumab. In another trial of combined ranibizumab plus verteporfin PDT versus verteporfin PDT, RR for loss of 15 or more letters at one year favoured combined therapy (RR 0.3 (95% CI 0.15 to 0.60). The NNT was 4.35 (95% CI 2.78 to 11.11).
   Pooled RR for gain of 15 or more letters visual acuity at one year was 5.81 (95% CI 3.29 to 10.26) for ranibizumab versus sham, 6.79 (95% CI 3.41 to 13.54) for ranibizumab/sham verteporfin PDT versus verteporfin PDT/sham ranibizumab, and 4.44 ( 95% CI 1.40 to 14.08) for ranibizumab plus verteporfin PDT versus verteporfin PDT.
   Frequency of endophthalmitis in included studies was between 0.7% to 4.7% with ranibizumab and 1.3% with pegaptanib. Improvement in vision-specific quality of life was reported for both treatments.
   Authors' conclusions
   Pegaptanib and ranibizumab reduce the risk of visual acuity loss in patients with neovascular AMD. Ranibizumab causes gains in visual acuity in many eyes. Quality of life and cost will be important for treatment decisions. Other agents blocking VEGF are being tested in ongoing trials.
   PLAIN LANGUAGE SUMMARY
   Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration
   Age-related macular degeneration (AMD) is a common cause of severe vision loss in people 55 years and older. Neovascular AMD, which involves abnormal growth of blood vessels in the back of the eye, accounts for most AMD-related severe vision loss. Medications such as pegaptanib and ranibizumab that block this abnormal growth of blood vessels in the back of the eye are one way to treat this condition. Fewer patients treated with pegaptanib lost 15 or more letters visual acuity at one year. Ranibizumab alone and when combined with verteporfin photodynamic therapy (PDT) resulted in fewer patients losing 15 or more letters visual acuity at one year. Approximately seven patients need to be treated with 0.3 mg or 0.5 mg pegaptanib to prevent loss of 15 or more letters visual acuity in one patient. This number is about 14 for 3 mg pegaptanib. In contrast just over three patients need to be treated with either 0.3 mg or 0.5 mg doses of ranibizumab to prevent loss of 15 or more letters visual acuity. Very few patients treated with pegaptanib gained visual acuity. A greater proportion of patients treated with ranibizumab gained 15 of more letters visual acuity at one year compared with sham or verteporfin PDT. No trial directly compared pegaptanib and ranibizumab. Pegaptanib and ranibizumab are beneficial for treatment of neovascular AMD and their use is associated with few adverse effects. Trials on other agents that block abnormal growth of blood vessels in this condition are ongoing and will be included in updates of the review.
C1 [Vedula, S. S.; Krzystolik, M. G.] So New England Retina Associates, Providence, RI 02903 USA.
EM Magdalena_Krzystolik@brown.edu
FU NEI NIH HHS [N01EY21003, N01 EY21003] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [N01EY021003] Funding Source: NIH RePORTER
CR ABRAHAM P, 2006, 6 EVRS C JOINT ASRS
   Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P831, DOI 10.1111/j.1600-0420.2006.00764.x
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   *AREDS RES GROUP, 2001, ARCH OPHTHALMOL-CHIC, V119, P1414
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   BENZ MS, 2007, INVESTIGATIVE OPHTHA, V48
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, VISION SPECIFIC QUAL
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BROWN MM, 2007, OPHTHALMOLOGY   1031
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   CATT, COMP AG REL MAC DEG
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chang TS, 2006, INVESTIGATIVE OPHTHA, V47
   CHANG TS, RANIBIZUMAB LUCENTIS
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Deeks J, 2006, COCHRANE HDB SYSTEMA
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   *EYET PHARM INC, PEG SOD INJ TREATM N
   *EYET PHARM INC PF, PEG SOD INJ TREATM N
   FDA, MAC PEG SOD INJ TREA
   Fine SL, 2005, NAT REV DRUG DISCOV, V4, P187, DOI 10.1038/nrd1677
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   HARIPRASAD SM, 2007, INVESTIGATIVE OPHTHA, V48
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2005, AM SOC RET SPEC 23 A
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOLZ FG, 2007, INVESTIGATIVE OPHTHA, V48
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   *IVAN, RAND CONTR TRIAL ALT
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kim Rubin W., 2004, International Ophthalmology Clinics, V44, P41, DOI 10.1097/00004397-200404440-00005
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LEYS A, 2007, EYE             0622
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   Mieler WF, 2006, INVESTIGATIVE OPHTHA, V47
   Mills E, 2007, J CLIN EPIDEMIOL, V60, P456, DOI 10.1016/j.jclinepi.2006.09.001
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   NGUYEN QD, 2007, INVESTIGATIVE OPHTHA, V48
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   O'Shea JG, 1998, POSTGRAD MED J, V74, P203, DOI 10.1136/pgmj.74.870.203
   Patel PJ, 2007, INVESTIGATIVE OPHTHA, V48
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rakic JM, 2005, NEW ENGL J MED, V352, P1720
   Razavi S, 2002, J FR OPHTALMOL, V25, P747
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   SCOTT IU, 2007, EVIDENCE BASED OPHTH, V8, P100
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Slakter JS, 2007, INVESTIGATIVE OPHTHA, V48
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Sorbera LA, 2003, DRUG FUTURE, V28, P541, DOI 10.1358/dof.2003.028.06.738510
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   THOMPSON JT, 2006, AM AC OPHTH ANN M AB
   Tielsch JA, 1994, PREVENT BLINDNESS
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   STUDY EVALUATE RANIB
NR 98
TC 50
Z9 53
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2008
IS 2
AR CD005139
DI 10.1002/14651858.CD005139.pub2
PG 51
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 290JU
UT WOS:000255119900015
PM 18425911
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Violato, M
   Dakin, H
   Chakravarthy, U
   Reeves, BC
   Peto, T
   Hogg, RE
   Harding, SP
   Scott, LJ
   Taylor, J
   Cappel-Porter, H
   Mills, N
   O'Reilly, D
   Rogers, CA
   Wordsworth, S
AF Violato, M.
   Dakin, H.
   Chakravarthy, U.
   Reeves, B. C.
   Peto, T.
   Hogg, R. E.
   Harding, S. P.
   Scott, L. J.
   Taylor, J.
   Cappel-Porter, H.
   Mills, N.
   O'Reilly, D.
   Rogers, C. A.
   Wordsworth, S.
TI Cost-effectiveness of community versus hospital eye service follow-up
   for patients with quiescent treated age-related macular degeneration
   alongside the ECHoES randomised trial
SO BMJ OPEN
LA English
DT Article
ID OPTOMETRISTS; GLAUCOMA; OUTCOMES; DISEASE; VEGF
AB Objectives: To assess the cost-effectiveness of optometrist-led follow-up monitoring reviews for patients with quiescent neovascular age-related macular degeneration (nAMD) in community settings (including high street opticians) compared with ophthalmologist-led reviews in hospitals.
   Design: A model-based cost-effectiveness analysis with a 4-week time horizon, based on a 'virtual' non-inferiority randomised trial designed to emulate a parallel group design.
   Setting: A virtual internet-based clinical assessment, conducted at community optometry practices, and hospital ophthalmology clinics.
   Participants: Ophthalmologists with experience in the age-related macular degeneration service; fully qualified optometrists not participating in nAMD shared care schemes.
   Interventions: The participating optometrists and ophthalmologists classified lesions from vignettes and were asked to judge whether any retreatment was required. Vignettes comprised clinical information, colour fundus photographs and optical coherence tomography images. Participants' classifications were validated against experts' classifications (reference standard). Resource use and cost information were attributed to these retreatment decisions.
   Main outcome measures: Correct classification of whether further treatment is needed, compared with a reference standard.
   Results: The mean cost per assessment, including the subsequent care pathway, was 411 pound for optometrists and 397 pound for ophthalmologists: a cost difference of 13 pound (95% CI -18 pound to 45) pound. Optometrists were non-inferior to ophthalmologists with respect to the overall percentage of lesions correctly assessed (difference -1.0%; 95% CI -4.5% to 2.5%).
   Conclusions: In the base case analysis, the slightly larger number of incorrect retreatment decisions by optometrists led to marginally and non-significantly higher costs. Sensitivity analyses that reflected different practices across eye hospitals indicate that shared care pathways between optometrists and ophthalmologists can be identified which may reduce demands on scant hospital resources, although in light of the uncertainty around differences in outcome and cost it remains unclear whether the differences between the 2 care pathways are significant in economic terms.
C1 [Violato, M.; Dakin, H.; Wordsworth, S.] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.
   [Violato, M.] Univ Oxford, Natl Inst Hlth Res, Hlth Protect Res Unit Gastrointestinal Infect, Oxford, England.
   [Chakravarthy, U.; Hogg, R. E.; O'Reilly, D.] Queens Univ Belfast, Inst Clin Sci, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Reeves, B. C.; Scott, L. J.; Taylor, J.; Cappel-Porter, H.; Rogers, C. A.] Univ Bristol, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol, Avon, England.
   [Peto, T.] Moorfields Eye Hosp NHS Fdn Trust, NIHR BMRC, London, England.
   [Peto, T.] UCL Inst Ophthalmol, London, England.
   [Harding, S. P.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
   [Mills, N.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
C3 University of Oxford; University of Oxford; Queens University Belfast;
   University of Bristol; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; University of Liverpool; University of
   Bristol
RP Violato, M (通讯作者)，Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.; Violato, M (通讯作者)，Univ Oxford, Natl Inst Hlth Res, Hlth Protect Res Unit Gastrointestinal Infect, Oxford, England.
EM mara.violato@dph.ox.ac.uk
RI Hogg, Ruth E./ABC-9602-2020; Peto, Tunde/G-8812-2018
OI Hogg, Ruth E./0000-0001-9413-2669; Peto, Tunde/0000-0001-6265-0381;
   Mills, Nicola/0000-0002-2960-2940; Reeves, Barnaby/0000-0002-5101-9487;
   Chakravarthy, Usha/0000-0002-2606-3734; Dakin,
   Helen/0000-0003-3255-748X; Cappel-Porter, Heike/0000-0001-6320-4834;
   Violato, Mara/0000-0002-0484-7706
FU UK Health Technology Assessment Programme of the National Institute for
   Health Research; Economic and Social Research Council [ES/L007509/1]
   Funding Source: researchfish; Medical Research Council [MR/K025643/1,
   MC_CF023241] Funding Source: researchfish; National Institute for Health
   Research [NF-SI-0514-10114, 11/129/195] Funding Source: researchfish;
   Public Health Agency [STL/4918/13] Funding Source: researchfish; ESRC
   [ES/L007509/1] Funding Source: UKRI; MRC [MR/K025643/1] Funding Source:
   UKRI
FX The study was funded by the UK Health Technology Assessment Programme of
   the National Institute for Health Research. MV, SW and HD had full
   access to all the data in the study and the authors had final
   responsibility for the decision to submit for publication.
CR [Anonymous], 2013, GUID METH TECHN APPR
   Banes MJ, 2006, BRIT J OPHTHALMOL, V90, P579, DOI 10.1136/bjo.2005.082388
   Bowling B, 2005, BRIT J OPHTHALMOL, V89, P1102, DOI 10.1136/bjo.2004.064378
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Curtis L, 2013, UNIT COSTS HLTH SOCI
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Drummond MF, 2015, METHODS EC EVALUATIO, V4th
   Fenwick E, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-52
   Goudie C, 2014, OPHTHAL PHYSL OPT, V34, P628, DOI 10.1111/opo.12154
   Gray A., 2011, APPL METHODS COST EF
   Hau S, 2007, BRIT J OPHTHALMOL, V91, P437, DOI 10.1136/bjo.2006.105593
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Husereau D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-80
   Joint Formulary Committee, 2014, BRIT NATL FORMULARY
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mason J, 1995, CTR HLTH EC DISCUSSI
   Office of National Statistics, 2014, POP ENGL AG 50 YEARS
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Prasad S, 2001, EYE, V15, P595, DOI 10.1038/eye.2001.192
   Reeves BC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010685
   RNIB, 2009, FUT SIGHT LOSS UK 1
   Taylor J, 2016, EYE, V30, P68, DOI 10.1038/eye.2015.170
   Townsend D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007400
   Trikha S, 2012, EYE, V26, P1288, DOI 10.1038/eye.2012.120
NR 28
TC 5
Z9 5
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2016
VL 6
IS 10
AR e011121
DI 10.1136/bmjopen-2016-011121
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EG8JO
UT WOS:000391303200154
PM 27797985
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pellegrini, M
   Bernabei, F
   Mercanti, A
   Sebastiani, S
   Peiretti, E
   Iovino, C
   Casini, G
   Loiudice, P
   Scorcia, V
   Giannaccare, G
AF Pellegrini, Marco
   Bernabei, Federico
   Mercanti, Andrea
   Sebastiani, Stefano
   Peiretti, Enrico
   Iovino, Claudio
   Casini, Giamberto
   Loiudice, Pasquale
   Scorcia, Vincenzo
   Giannaccare, Giuseppe
TI Short-term choroidal vascular changes after aflibercept therapy for
   neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF; Choroidal vascularity
   index; Optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; VEGF TRAP-EYE; INTRAVITREAL RANIBIZUMAB;
   THICKNESS CHANGES; SUBFOVEAL; INJECTION; VASCULOPATHY; BEVACIZUMAB
AB Introduction The purpose of this study was to evaluate choroidal vascular changes in patients with neovascular age-related macular degeneration (nAMD) treated with aflibercept injection over a 3-month period. Methods Enhanced depth imaging optical coherence tomography scans of 60 eyes with treatment-naive nAMD and 60 unaffected fellow eyes were retrospectively analyzed. Data was collected at baseline and after 3 monthly intravitreal injections of aflibercept. The ImageJ software was used to binarize OCT scans and measure total choroid area (TCA), luminal area (LA), and stromal area (SA). Choroidal vascularity index (CVI) was defined as the ratio of LA to TCA. Results After treatment, subfoveal choroidal thickness (CT) in nAMD eyes significantly decreased from 210. 6 +/- 61.6 to 194.6 +/- 58.7 mu m (P< 0.001), TCA from 1.620 +/- 0.502 to 1.500 +/- 0.451 mm(2)(P< 0.001), LA from 1.075 +/- 0.335 to 0.985 +/- 0.307 mm(2)(P< 0.001), SA from 0.545 +/- 0.176 to 0.516 +/- 0.153 mm(2)(P= 0.005), and CVI from 66.36 +/- 2.89 to 65.46 +/- 2.87% (P= 0.009). The decrease of CVI after treatment was significantly correlated with baseline CVI (Rs = 0.466,P< 0.001), but not with the change in BCVA and presence of dry macula after treatment (alwaysP> 0.05). Conclusion Choroidal thickness and vascularity significantly decreased after treatment with aflibercept in nAMD eyes. Besides the pharmacologic effect on the neovascular lesion, aflibercept may induce vascular changes also on the underlying choroid.
C1 [Pellegrini, Marco; Bernabei, Federico; Giannaccare, Giuseppe] Univ Bologna, S Orsola Malpighi Univ Hosp, Ophthalmol Unit, Via Palagi 9, I-40138 Bologna, Italy.
   [Mercanti, Andrea; Sebastiani, Stefano] Infermi Hosp, Head & Neck Dept Ophthalmol, Ophthalmol Unit, Rimini, Italy.
   [Peiretti, Enrico] Univ Cagliari, Dept Surg Sci, Eye Clin, Cagliari, Italy.
   [Iovino, Claudio] Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Sci, Eye Clin, Naples, Italy.
   [Casini, Giamberto; Loiudice, Pasquale] Univ Pisa, Dept Surg Med Mol & Crit Area Pathol, Ophthalmol Unit, Pisa, Italy.
   [Scorcia, Vincenzo; Giannaccare, Giuseppe] Magna Graecia Univ Catanzaro, Dept Ophthalmol, Catanzaro, Italy.
C3 IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of
   Bologna; Hospital of Rimini; University of Cagliari; Universita della
   Campania Vanvitelli; University of Pisa; Magna Graecia University of
   Catanzaro
RP Pellegrini, M (通讯作者)，Univ Bologna, S Orsola Malpighi Univ Hosp, Ophthalmol Unit, Via Palagi 9, I-40138 Bologna, Italy.
EM marco.pellegrini@hotmail.it
RI Loiudice, Pasquale/W-2667-2019; Iovino, Claudio/O-7680-2019; Pellegrini,
   Marco/T-3694-2019; Bernabei, Federico/AAC-2293-2019
OI Loiudice, Pasquale/0000-0001-8529-9897; Iovino,
   Claudio/0000-0003-1984-0555; Pellegrini, Marco/0000-0002-6419-6941; 
FU Alma Mater Studiorum Universita di Bologna within the CRUI-CARE
   Agreement
FX Open access funding provided by Alma Mater Studiorum Universita di
   Bologna within the CRUI-CARE Agreement.
CR Agrawal R, 2017, ACTA OPHTHALMOL, V95, pe770, DOI 10.1111/aos.13442
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Gupta P, 2015, AM J OPHTHALMOL, V159, P293, DOI 10.1016/j.ajo.2014.10.034
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Iovino C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020595
   Kim H, 2015, RETINA-J RET VIT DIS, V35, P481, DOI 10.1097/IAE.0000000000000354
   Kim YK, 2016, RETINA-J RET VIT DIS, V36, P1516, DOI 10.1097/IAE.0000000000000952
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Minnella AM, 2016, BIODRUGS, V30, P353, DOI 10.1007/s40259-016-0179-0
   Mottet B, 2018, ACTA OPHTHALMOL, V96, pE783, DOI 10.1111/aos.13763
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Pellegrini M, 2021, OCUL IMMUNOL INFLAMM, V29, P340, DOI 10.1080/09273948.2019.1678650
   Pellegrini M, 2019, AM J OPHTHALMOL, V205, P43, DOI 10.1016/j.ajo.2019.03.028
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sansom LT, 2016, ACTA OPHTHALMOL, V94, pE157, DOI 10.1111/aos.12794
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
NR 38
TC 8
Z9 8
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2021
VL 259
IS 4
BP 911
EP 918
DI 10.1007/s00417-020-04957-5
EA OCT 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RH0XW
UT WOS:000577549000001
PM 33048236
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Dirani, A
   Ambresin, A
   Marchionno, L
   Decugis, D
   Mantel, I
AF Dirani, All
   Ambresin, Aude
   Marchionno, Laetitia
   Decugis, Doris
   Mantel, Irmela
TI Factors Influencing the Treatment Response of Pigment Epithelium
   Detachment in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL AFLIBERCEPT; VISUAL-ACUITY; ANATOMICAL OUTCOMES; FACTOR
   VEGF; RANIBIZUMAB; EYES; BEVACIZUMAB; EXPRESSION
AB PURPOSE: To study the effect of various baseline factors, particularly the type of drug (ranibizumab vs aflibercept), on the functional and anatomic response of treatment-naive pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (neovascular AMD), after 3 intravitreal injections.
   DESIGN: Retrospective consecutive case series.
   METHODS: This study included 102 patients (n = 115 eyes) with treatment-naive neovascular AMD and PED ( > 150 mu m), who were treated with either ranibizumab (n = 68 eyes) or aflibercept (n = 47 eyes). A multivariate analysis using stepwise linear regression was performed in order to assess factors influencing visual acuity improvement, as well as treatment response of PED height after 3 monthly injections.
   RESULTS: Multivariate analysis revealed that better visual improvement was associated with lower best-corrected visual acuity (BCVA) at baseline (P = .001), presence of subretinal fluid (P = .001), and retinal angiomatous proliferation (P = .001); PED reduction was associated with higher PED at baseline (P = .001), predominantly serous PED (P = .003), and the use of aflibercept (P = .022). Drug type was not associated with change in BCVA at 3 months.
   CONCLUSION: Eyes with neovascular AMID and PED showed significant functional and anatomic response after 3 monthly intravitreal anti-VEGF injections. The functional response depended on baseline BCVA, presence of subretinal fluid, and retinal angiomatous proliferation, while anatomic response was influenced by baseline PED height, degree of vascularization, and drug type. Drug type was not associated with change in BCVA, but had a weak effect on anatomic response. (C) 2015 by Elsevier Inc. All rights reserved.
C1 Univ Lausanne, Dept Ophthalmol, CH-1000 Lausanne 7, Switzerland.
   Fdn Asile Aveugles, Jules Gonin Eye Hosp, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, 15 Ave France Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
CR Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Bottomley MJ, 2000, CLIN EXP IMMUNOL, V119, P182, DOI 10.1046/j.1365-2249.2000.01097.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P474
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Wolf A, 2013, RETINA-J RET VIT DIS, V33, P1843, DOI 10.1097/IAE.0b013e318287d9be
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 36
TC 35
Z9 36
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2015
VL 160
IS 4
BP 732
EP 738
DI 10.1016/j.ajo.2015.06.025
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR7BR
UT WOS:000361503400015
PM 26144701
DA 2022-11-30
ER

PT J
AU Jackson, GR
   Scott, IU
   Kim, IK
   Quillen, DA
   Iannaccone, A
   Edwards, JG
AF Jackson, Gregory R.
   Scott, Ingrid U.
   Kim, Ivana K.
   Quillen, David A.
   Iannaccone, Alessandro
   Edwards, John G.
TI Diagnostic Sensitivity and Specificity of Dark Adaptometry for Detection
   of Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; dark adaptation; human; diagnostic
ID MACULOPATHY; ADAPTATION; ROD
AB PURPOSE. Difficulty with night vision is a common complaint of patients with age-related macular degeneration (AMD). Consistent with this complaint, dark adaptation (DA) is substantially impaired in these patients. Because of the severity of the deficit, measurement of DA has been suggested as a means for the diagnosis of AMD. Previous methods for measurement of DA were time intensive (>30 minutes), which made them unsuitable for clinical use. This study evaluated a rapid DA test (<= 6.5 minutes) for the detection of AMD.
   METHODS. Dark adaptation was measured by using the AdaptDx dark adaptometer in two groups: subjects with normal retinal health and subjects with AMD. Subjects were assigned to their group by clinical examination and grading of fundus photographs. Subjects were classified as having DA consistent with normal retinal health (rod intercept <= 6.5 minutes) or having dark adaptation consistent with AMD (rod intercept > 6.5 minutes).
   RESULTS. The eligible sample for analysis included 21 normal adults and 127 AMD patients. The rapid test was found to have a diagnostic sensitivity of 90.6% (P < 0.001) and specificity of 90.5% (P < 0.027). Thus, abnormal DA was detected in 115 of 127 AMD patients, and normal DA was found in 19 of 21 normal adults.
   CONCLUSIONS. The high diagnostic sensitivity and specificity compared favorably to long-duration research methods for the measurement of DA, and slit lamp biomicroscopy performed by a retina specialist. These results suggest that a rapid DA test is useful for the detection of AMD.
C1 [Jackson, Gregory R.; Scott, Ingrid U.; Quillen, David A.] Penn State Coll Med, Penn State Hershey Eye Ctr, Hershey, PA 17033 USA.
   [Kim, Ivana K.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Iannaccone, Alessandro] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA.
   [Edwards, John G.] MacuLogix Inc, Hummelstown, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Harvard University;
   Massachusetts Eye & Ear Infirmary; University of Tennessee System;
   University of Tennessee Health Science Center
RP Jackson, GR (通讯作者)，Penn State Coll Med, 500 Univ Dr,HU19, Hershey, PA 17033 USA.
EM gjackson@maculogix.com
RI Edwards, Jeff/P-9759-2016
OI Edwards, Jeff/0000-0001-7298-1889; Iannaccone,
   Alessandro/0000-0001-5737-8424; Scott, Ingrid/0000-0002-3908-7153; Kim,
   Ivana/0000-0003-0310-6129
FU National Institute on Aging at the National Institutes of Health [R44 AG
   26222-02]; NIA NIH HHS [R44 AG 26222-02, R44 AG026222] Funding Source:
   Medline; NATIONAL INSTITUTE ON AGING [R44AG026222] Funding Source: NIH
   RePORTER
FX Supported by the National Institute on Aging at the National Institutes
   of Health (R44 AG 26222-02). The authors alone are responsible for the
   content and writing of the paper.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Cervantes-Castaneda RA, 2008, EYE, V22, P777, DOI 10.1038/sj.eye.6702691
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Tikellis G, 2000, CLIN EXP OPHTHALMOL, V28, P367, DOI 10.1046/j.1442-9071.2000.00336.x
   U. S. Census Bureau, 2012, STAT ABSTR US
NR 17
TC 75
Z9 76
U1 0
U2 21
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2014
VL 55
IS 3
BP 1427
EP 1431
DI 10.1167/iovs.13-13745
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AD2BA
UT WOS:000333036500032
PM 24550363
OA Green Published
DA 2022-11-30
ER

PT J
AU Sabeti, F
   James, AC
   Essex, RW
   Maddess, T
AF Sabeti, Faran
   James, Andrew C.
   Essex, Rohan W.
   Maddess, Ted
TI Dichoptic multifocal visual evoked potentials identify local retinal
   dysfunction in age-related macular degeneration
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Multifocal; Visual evoked potentials; Age-related macular degeneration
ID FIELD DEFECTS; VEP; ELECTRORETINOGRAM; ABNORMALITIES; DELAYS; TESTS;
   TOPOGRAPHY; PERIMETRY; SCOTOMA
AB To evaluate the ability of multifocal visual evoked potentials (mfVEPs) to identify functional loss in patients with early and exudative age-related macular degeneration (AMD). A dichoptic multifocal stimulus presentation was employed to investigate the regional effects of AMD and the potential diagnostic utility in macular disease.
   MfVEP responses were recorded from 19 unilateral exudative AMD patients with non-exudative (n = 15) or normal (n = 4) presentations in the fellow eye and 28 age-matched controls. Root mean square (RMS) waveforms were pooled across selected EEG channels to produce global field RMS (gfRMS) waveforms. GfRMS amplitudes and response delays were analysed by multivariate linear models, and diagnostic capacity was measured using areas under the curve (AUC) of receiver operator characteristic plots.
   The mean gfRMS amplitude of the exudative eye of AMD patients was significantly reduced compared with the controls (-2.03 +/- A 0.08 dB, t = -12.9). Fellow non-exudative AMD eyes were less effected but still significantly reduced (-0.84 +/- A 0.07 dB, t = -11.5). No significant difference in mean gfRMS delay of AMD eyes across the central 46A degrees was observed. AUC values of 100 +/- A 0.0 % (mean +/- A SE) for exudative and 79.7 +/- A 6.5 % for non-exudative eyes were obtained for response amplitudes.
   The study demonstrated that mfVEP identified retinal dysfunction in both exudative AMD and fellow non-exudative AMD eyes, but mostly affecting the macular field. The reduced testing duration and good diagnostic accuracy suggest that dichoptic mfVEPs may be a sensitive tool for monitoring progression in AMD.
C1 [Sabeti, Faran; James, Andrew C.; Essex, Rohan W.; Maddess, Ted] Australian Natl Univ ANU, John Curtin Sch Med Res, ARC Ctr Excellence Vis Sci, Canberra, ACT 0200, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Canberra Hosp, Dept Ophthalmol, Canberra, ACT, Australia.
C3 Australian National University; John Curtin School of Medical Research;
   Australian National University; Canberra Hospital
RP Sabeti, F (通讯作者)，Australian Natl Univ ANU, John Curtin Sch Med Res, ARC Ctr Excellence Vis Sci, Canberra, ACT 0200, Australia.
EM faran.sabeti@anu.edu.au
RI James, Andrew C/C-9307-2009; Maddess, Teddy L/A-3200-2008; Sabeti,
   Faran/AAR-1767-2021
OI James, Andrew C/0000-0002-2447-8549; Maddess, Teddy
   L/0000-0003-4591-3658; SABETI, Faran/0000-0001-9187-7569; Essex,
   Rohan/0000-0001-5323-0334
FU Australian Research Council (ARC) through the ARC Centre of Excellence
   in Vision Science [CE0561903]
FX The authors thank Australian Research Council (ARC) through the ARC
   Centre of Excellence in Vision Science (CE0561903), AusIndustry and
   Seeing Machines Ltd, Canberra.
CR BASELER HA, 1994, ELECTROEN CLIN NEURO, V90, P65, DOI 10.1016/0013-4694(94)90114-7
   BASS SJ, 1985, INVEST OPHTH VIS SCI, V26, P1071
   Bell A, 2010, INVEST OPHTH VIS SCI, V51, P602, DOI 10.1167/iovs.09-3659
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   CAPPIN JM, 1975, ARCH OPHTHALMOL-CHIC, V93, P9
   Chen JY, 2006, INVEST OPHTH VIS SCI, V47, P4378, DOI 10.1167/iovs.06-0242
   Chrysostomou V, 2009, INVEST OPHTH VIS SCI, V50, P2407, DOI 10.1167/iovs.08-3003
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   FOLK JC, 1984, ARCH OPHTHALMOL-CHIC, V102, P1299
   Fortune B, 1999, INVEST OPHTH VIS SCI, V40, P2638
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Graham SL, 2000, J GLAUCOMA, V9, P10
   HAN DP, 1985, ARCH OPHTHALMOL-CHIC, V103, P394, DOI 10.1001/archopht.1985.01050030090029
   Hood DC, 2000, INVEST OPHTH VIS SCI, V41, P1580
   Ivers RQ, 2001, OPHTHALMOLOGY, V108, P968, DOI 10.1016/S0161-6420(00)00649-7
   James AC, 2003, INVEST OPHTH VIS SCI, V44, P879, DOI 10.1167/iovs.02-0608
   James AC, 2005, INVEST OPHTH VIS SCI, V46
   James AC, 2005, VISUAL NEUROSCI, V22, P45, DOI 10.1017/S0952523805221053
   JOHNSON LN, 1987, GRAEF ARCH CLIN EXP, V225, P123, DOI 10.1007/BF02160343
   LENNERSTRAND G, 1982, ACTA OPHTHALMOL, V60, P497
   Maddess T, 2005, VISUAL NEUROSCI, V22, P153, DOI 10.1017/S0952523805222046
   MARCUS M, 1983, ANN OPHTHALMOL, V15, P235
   MILNER BA, 1974, BRAIN, V97, P755, DOI 10.1093/brain/97.1.755
   Negishi C, 2001, ACTA OPHTHALMOL SCAN, V79, P271, DOI 10.1034/j.1600-0420.2001.790312.x
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   RADEMACHER J, 1993, CEREB CORTEX, V3, P313, DOI 10.1093/cercor/3.4.313
   REGAN D, 1969, J NEUROL NEUROSUR PS, V32, P479, DOI 10.1136/jnnp.32.5.479
   Rosli Y, 2008, INF TECHN INT S, P1
   Ruseckaite R, 2005, ANN NEUROL, V57, P904, DOI 10.1002/ana.20504
   Sabeti F, 2011, OPTOMETRY VISION SCI, V88, P1477, DOI 10.1097/OPX.0b013e318235af61
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   SHERMAN J, 1986, INVEST OPHTH VIS SCI, V27, P214
   Shimada Y, 1997, ACTA OPHTHALMOL SCAN, V75, P277
   SOKOL S, 1972, ARCH OPHTHALMOL-CHIC, V88, P619, DOI 10.1001/archopht.1972.01000030621010
   STENSAAS SS, 1974, J NEUROSURG, V40, P747, DOI 10.3171/jns.1974.40.6.0747
   Tarita-Nistor L, 2011, INVEST OPHTH VIS SCI, V52, P1887, DOI 10.1167/iovs.10-6059
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Walter P, 2000, OPHTHALMOLOGICA, V214, P312, DOI 10.1159/000027512
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   Wolff BE, 2010, DOC OPHTHALMOL, V121, P189, DOI 10.1007/s10633-010-9245-y
   Yu DY, 2004, INVEST OPHTH VIS SCI, V45, P2013, DOI 10.1167/iovs.03-0845
NR 43
TC 13
Z9 13
U1 1
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD APR
PY 2013
VL 126
IS 2
BP 125
EP 136
DI 10.1007/s10633-012-9366-6
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 119EC
UT WOS:000317079300006
PM 23238587
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Sun, C
   Tikellis, G
   Klein, R
   Steffens, DC
   Larsen, EKM
   Wong, TY
AF Sun, Cong
   Tikellis, Gabriella
   Klein, Ronald
   Steffens, David C.
   Larsen, Emily K. Marino
   Wong, Tien Y.
TI Depressive symptoms and age-related macular degeneration in older
   people: The cardiovascular health study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; depressive symptoms
ID CEREBROVASCULAR RISK-FACTORS; RETINAL MICROVASCULAR ABNORMALITIES;
   CORONARY-HEART-DISEASE; LATE-LIFE DEPRESSION; MYOCARDIAL-INFARCTION;
   COGNITIVE IMPAIRMENT; MAJOR DEPRESSION; BLOOD-PRESSURE; AMYLOID-BETA;
   MACULOPATHY
AB Purpose: To examine the association between age-related macular degeneration (AMD) and depressive symptoms. Methods: Population-based, cross-sectional study. A total of 2,194 persons aged 69-97 years were included in the current analyses. During the 1997-1998 examination, retinal photography from one randomly selected eye was graded for presence of early and late AMD using a modified Wisconsin AMD by Grading System. Depressive symptoms were assessed via a modified version of the Centers for Epidemiologic Studies Depression (CES-D) scale annually from 1989 through 1997-1998. Depressive symptoms were defined as a CES-D score of >9 (top quartile of CES-D score) at the 1997-1998 examination. Results: There were 338 (15.6%) individuals with early AMD and 29 (1.3%) with late AMD. Among them, 368 (16.8%) persons had depressive symptoms at the 1997-1998 examination. Depressive symptoms were not associated with early AMD (multivariable adjusted odds ratio [OR]: 0.97; 95% confidence intervals [Cl]: 0.69-1.36) or late AMD (OR: 1.15; 95% Cl: 0.38-3.46). Including persons using antidepressive medications did not alter these associations (OR: 0.98; 95% Cl: 0.74-1.32 for early AMD and OR: 0.97; 95% Cl: 0.35-2.67 for late AMD). There was no association in multinomial logistic regression models of increasing quartiles of the CES-D scores with early or late AMD status. Conclusions: Our study did not find an association between early AMD and depressive symptoms in older people.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
   Univ Washington, Dept Biostat, Seattle, WA USA.
   Natl Univ Singapore, Eye Res Inst, Singapore, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Wisconsin System; University of Wisconsin Madison; Duke University;
   University of Washington; University of Washington Seattle; National
   University of Singapore
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085079,
   N01HC085080, N01HC085082, N01HC085081, N01HC035129, N01HC085084,
   N01HC085086, N01HC015103, N01HC085083, N01HC085085] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL077166]
   Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-15103, N01-HC-35129,
   N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083,
   N01-HC-85084, N01-HC-85085, N01-HC-85086, R21-HL077166] Funding Source:
   Medline
CR Alexopoulos GS, 1997, AM J PSYCHIAT, V154, P562
   Alexopoulos GS, 2002, BIOL PSYCHIAT, V52, P543, DOI 10.1016/S0006-3223(02)01468-3
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   Ariyo AA, 2000, CIRCULATION, V102, P1773
   Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976
   Baune BT, 2006, PSYCHOTHER PSYCHOSOM, V75, P319, DOI 10.1159/000093955
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dentchev T, 2003, MOL VIS, V9, P184
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Green JG, 1998, MATURITAS, V29, P3
   Haas DC, 2005, AM J CARDIOL, V95, P547, DOI 10.1016/j.amjcard.2004.10.032
   HOUSE A, 1991, BRIT J PSYCHIAT, V158, P83, DOI 10.1192/bjp.158.1.83
   Irwin M, 1999, ARCH INTERN MED, V159, P1701, DOI 10.1001/archinte.159.15.1701
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Krishnan KRR, 2002, BIOL PSYCHIAT, V52, P559, DOI 10.1016/S0006-3223(02)01472-5
   Lyness JM, 1999, AM J GERIAT PSYCHIAT, V7, P252, DOI 10.1097/00019442-199908000-00010
   Lyness JM, 2000, AM J PSYCHIAT, V157, P1499, DOI 10.1176/appi.ajp.157.9.1499
   Lyness JM, 1998, AM J GERIAT PSYCHIAT, V6, P5
   McCabe MP, 2006, INT J GERIATR PSYCH, V21, P633, DOI 10.1002/gps.1538
   O'Brien J, 1998, BMJ-BRIT MED J, V317, P982, DOI 10.1136/bmj.317.7164.982
   Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   ROBBINS J, 1995, J AM GERIATR SOC, V43, P855, DOI 10.1111/j.1532-5415.1995.tb05526.x
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Rowan PJ, 2005, ANN EPIDEMIOL, V15, P316, DOI 10.1016/j.annepidem.2004.08.006
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Steffens DC, 1999, STROKE, V30, P2159, DOI 10.1161/01.STR.30.10.2159
   Steffens DC, 2002, STROKE, V33, P1636, DOI 10.1161/01.STR.0000018405.59799.D5
   Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9
   TELL GS, 1994, HYPERTENSION, V23, P59, DOI 10.1161/01.HYP.23.1.59
   Tiemeier H, 2004, ARCH GEN PSYCHIAT, V61, P369, DOI 10.1001/archpsyc.61.4.369
   Whyte EM, 2006, INT J GERIATR PSYCH, V21, P746, DOI 10.1002/gps.1555
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Wong TY, 2002, BRIT J OPHTHALMOL, V86, P1007, DOI 10.1136/bjo.86.9.1007
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 51
TC 10
Z9 10
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD MAY-JUN
PY 2007
VL 14
IS 3
BP 127
EP 133
DI 10.1080/09286580601186742
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 186MF
UT WOS:000247782100005
PM 17613847
DA 2022-11-30
ER

PT J
AU Ardeljan, D
   Meyerle, CB
   Agron, E
   Wang, JJ
   Mitchell, P
   Chew, EY
   Zhao, J
   Maminishkis, A
   Chan, CC
   Tuo, JS
AF Ardeljan, Daniel
   Meyerle, Catherine B.
   Agron, Elvira
   Wang, Jie Jin
   Mitchell, Paul
   Chew, Emily Y.
   Zhao, Jing
   Maminishkis, Arvydas
   Chan, Chi-Chao
   Tuo, Jingsheng
TI Influence of TIMP3/SYN3 polymorphisms on the phenotypic presentation of
   age-related macular degeneration
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE age-related macular degeneration; TIMP3; phenotype; single-nucleotide
   polymorphism; Blue Mountains Eye Study; Age-Related Eye Diseases Study
ID SORSBYS FUNDUS DYSTROPHY; BLUE MOUNTAINS EYE; TISSUE INHIBITOR;
   METALLOPROTEINASES-3 TIMP3; BRUCHS MEMBRANE; RISK-FACTORS; VISUAL-LOSS;
   MUTATION; DISEASE; AREDS
AB Age-related macular degeneration (AMD) is a leading cause of irreversible central visual loss in the elderly. A recent genome-wide association studies (GWAS) reported that rs9621532 near the tissue inhibitor of metalloproteinase 3 (TIMP3)/synapsin III (SYN3) region of 22q12.3 is associated with AMD. In this study, we characterize its phenotypic influence on AMD using three independent study cohorts: case-control studies from the National Eye Institute Clinical Center (NEI, n = 397) and the Age-Related Eye Disease Study (n = 523) as well as a nested case-control study from Blue Mountains Eye Study (BMES, n = 852). Comparisons between cases and controls show no association between rs9621532 and AMD in the three sample sets. However, stratifying NEI cases uncovers a moderate protective role of rs9621532 in neovascular AMD (nAMD) and the association adhered to a dominant model (odds ratios = 0.32; 95% CI: 0.11-0.89; P = 0.02). The BMES data followed the same pattern of association with nAMD as that seen in the NEI sample but did not reach statistical significance. Polychotomous logistic regression showed a trend that rs9621532 correlates with less severe disease, for example, with the majority of carriers having intermediate AMD rather than nAMD/geographic atrophy AMD. Functionally, rs9621532 influences TIMP3 mRNA expression in cultured primary human fetal retinal pigment epithelium (hfRPE) cells. In hfRPE donors carrying the protective rs9625132 allele, we measured a reduction in TIMP3 mRNA by quantitative RT-PCR. Our data suggest that rs9621532 carriers have a lower risk of developing nAMD, potentially because of decreased transcription of TIMP3.
C1 [Ardeljan, Daniel; Chan, Chi-Chao; Tuo, Jingsheng] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Meyerle, Catherine B.; Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW 2145, Australia.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Zhao, Jing; Maminishkis, Arvydas] NEI, Sect Epithelial & Retinal Physiol & Dis, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); University of Sydney; University of Sydney; Westmead
   Institute for Medical Research; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI)
RP Tuo, JS (通讯作者)，NEI, Immunol Lab, NIH, 10-10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM tuoj@nei.nih.gov
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; Ardeljan, Daniel/0000-0002-5593-421X;
   Maminishkis, Arvydas/0000-0003-3345-3375; Tuo,
   Jingsheng/0000-0002-1372-7810
FU Intramural Research Program of National Eye Institute, NIH; Australian
   National Health and Medical Research Council; NATIONAL EYE INSTITUTE
   [ZIAEY000526, ZIAEY000418, ZICEY000461, ZIAEY000222, ZIAEY000497,
   ZIAEY000419, ZIAEY000524, ZIAEY000523, ZIAEY000527] Funding Source: NIH
   RePORTER
FX We thank Angel Garced, Katherine Shimel, and Sun-min Ro, for their
   assistance in contacting study participants and collecting blood
   samples. We also thank the study participants and their families for
   enrolling in this study. This research was supported by the Intramural
   Research Program of National Eye Institute, NIH and the Australian
   National Health and Medical Research Council.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Dudbridge F, 2004, AM J HUM GENET, V75, P424, DOI 10.1086/423738
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Felbor U, 1996, J MED GENET, V33, P233, DOI 10.1136/jmg.33.3.233
   FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Li Zheng, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010045
   Macgregor AM, 2009, J HISTOCHEM CYTOCHEM, V57, P207, DOI 10.1369/jhc.2008.952531
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Xu PL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002689
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 31
TC 20
Z9 20
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD OCT
PY 2013
VL 21
IS 10
BP 1152
EP 1157
DI 10.1038/ejhg.2013.14
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 222JO
UT WOS:000324727200026
PM 23422939
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Berber, P
   Grassmann, F
   Kiel, C
   Weber, BHF
AF Berber, Patricia
   Grassmann, Felix
   Kiel, Christina
   Weber, Bernhard H. F.
TI An Eye on Age-Related Macular Degeneration: The Role of MicroRNAs in
   Disease Pathology
SO MOLECULAR DIAGNOSIS & THERAPY
LA English
DT Review
ID INDUCED CHOROIDAL NEOVASCULARIZATION; INDUCED RETINAL
   NEOVASCULARIZATION; PIGMENT EPITHELIAL-CELLS; CIRCULATING MICRORNAS;
   CELLULAR STRESS; DOWN-REGULATION; EXPRESSION; PROTEIN; MIRNAS; GENE
AB Age-related macular degeneration (AMD) is the primary cause of blindness in developed countries, and is the third leading cause worldwide. Emerging evidence suggests that beside environmental and genetic factors, epigenetic mechanisms, such as microRNA (miRNA) regulation of gene expression, are relevant to AMD providing an exciting new avenue for research and therapy. MiRNAs are short, non-coding RNAs thought to be imperative for coping with cellular stress. Numerous studies have analyzed miRNA dysregulation in AMD patients, although with varying outcomes. Four studies which profiled dysregulated circulating miRNAs in AMD yielded unique sets, and there is only minimal overlap in ocular miRNA profiling of AMD. Mouse models of AMD, including oxygen-induced retinopathy and laser-induced choroidal neovascularization, showed similarities to some extent with miRNA patterns in AMD. For example, miR-146a is an extensively researched miRNA thought to modulate inflammation, and was found to be upregulated in AMD mice and cellular systems, but also in human AMD retinae and vitreous humor. Similarly, mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae. These miRNAs are thought to regulate angiogenesis, apoptosis, phagocytosis, and inflammation. A promising avenue of research is the modulation of such miRNAs, as the phenotype of AMD mice could be ameliorated with antagomirs or miRNA-mimic treatment. However, before meaningful strides can be made to develop miRNAs as a diagnostic or therapeutic tool, reproducible miRNA profiles need to be established for the various clinical outcomes of AMD.
C1 [Berber, Patricia; Grassmann, Felix; Kiel, Christina; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
C3 University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
OI Weber, Bernhard H.F./0000-0002-8808-7723; Grassmann,
   Felix/0000-0003-1390-7528; Kiel, Christina/0000-0003-3154-4847
FU Freestate of Bavaria
FX The work and open access publication was funded in part by the
   institutional budget for Research and Teaching from the Freestate of
   Bavaria to BHFW.
CR Alexandrov PN, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00181
   AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891
   Anand Sudarshan, 2011, Genes Cancer, V2, P1134, DOI 10.1177/1947601911423032
   Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108
   Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016
   Balasubramanian SA, 2014, TRANSL RES, V164, P179, DOI 10.1016/j.trsl.2014.04.005
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   BRENNER S, 1974, GENETICS, V77, P71
   Carroll AP, 2013, J MOL CELL BIOL, V5, P73, DOI 10.1093/jmcb/mjt004
   CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8
   Choo KB, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0095-x
   Chung SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118949
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Derrick T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1367-8
   Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812
   Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005
   ECKHARDT H, 1979, J BIOL CHEM, V254, P1185
   Emde A, 2014, EMBO J, V33, P1428, DOI 10.15252/embj.201488142
   Ertekin S, 2014, MOL VIS, V20, P1057
   FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0
   Fichtlscherer S, 2010, CIRC RES, V107, P677, DOI 10.1161/CIRCRESAHA.109.215566
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Garcia TY, 2015, INVEST OPHTH VIS SCI, V56, P7480, DOI 10.1167/iovs.15-17251
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goldgraben MA, 2016, RNA, V22, P193, DOI 10.1261/rna.054072.115
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Grasso M, 2014, MOLECULES, V19, P6891, DOI 10.3390/molecules19056891
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Han S, 2016, CHINESE MED J-PEKING, V129, P709, DOI 10.4103/0366-6999.178013
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   He J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056647
   Hill JM, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00232
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   HORVITZ HR, 1980, GENETICS, V96, P435
   Howell JC, 2013, MOL VIS, V19, P544
   Huang HZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059482, 10.1371/journal.pone.0071808, 10.1371/journal.pone.0076982]
   Iyer A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044789
   JAYARAMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P1537, DOI 10.1073/pnas.78.3.1537
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Kim SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11872
   Kitanovski L, 2014, SUPPORT CARE CANCER, V22, P269, DOI 10.1007/s00520-013-1978-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kutty RK, 2013, MOL VIS, V19, P737
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lee Rosalind, 2004, Cell, VS116, pS89, DOI 10.1016/S0092-8674(04)00035-2
   Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027
   Li GM, 2008, CELL RES, V18, P1, DOI 10.1038/cr.2008.9
   Li PF, 2017, MOL NEUROBIOL, V54, P2901, DOI 10.1007/s12035-016-9842-1
   Li W, 2013, AGEING RES REV, V12, P1005, DOI 10.1016/j.arr.2013.05.006
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Liu GJ, 2014, BRAIN PATHOL, V24, P631, DOI 10.1111/bpa.12196
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Lyons A, 2007, J NEUROSCI, V27, P8309, DOI 10.1523/JNEUROSCI.1781-07.2007
   Malhotra S, 2007, SURGERY, V141, P520, DOI 10.1016/j.surg.2006.10.010
   Mavija M, 2014, MED ARCH, V68, P204, DOI DOI 10.5455/MEDARH.2014.68.204-208
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mitra R, 2015, RNA, V21, P1055, DOI 10.1261/rna.048132.114
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Muramatsu F, 2013, ONCOGENE, V32, P414, DOI 10.1038/onc.2012.68
   Naidoo A, 2014, ANTIVIR THER, V19, P161, DOI 10.3851/IMP2701
   Nakajima T, 2014, MOL VIS, V20, P864
   Orellana EA, 2015, CANCERS, V7, P1388, DOI 10.3390/cancers7030842
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689
   Pogue AI, 2009, J INORG BIOCHEM, V103, P1591, DOI 10.1016/j.jinorgbio.2009.05.012
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saxena K, 2015, INVEST OPHTH VIS SCI, V56, P1820, DOI 10.1167/iovs.14-15449
   Schober A, 2015, NAT REV CARDIOL, V12, P361, DOI 10.1038/nrcardio.2015.38
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   Semo J, 2014, EUR HEART J, V35, P3212, DOI 10.1093/eurheartj/eht041
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Smits M, 2012, FASEB J, V26, P2639, DOI 10.1096/fj.11-202820
   Song S, 2015, BIOCHEM BIOPH RES CO, V465, P299, DOI 10.1016/j.bbrc.2015.08.028
   Sun K, 2007, MOL VIS, V13, P2310
   Sundermeier TR, 2012, CELL MOL LIFE SCI, V69, P2739, DOI 10.1007/s00018-012-0976-7
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Turchinovich A, 2012, TRENDS BIOCHEM SCI, V37, P460, DOI 10.1016/j.tibs.2012.08.003
   Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210
   Vidigal JA, 2015, TRENDS CELL BIOL, V25, P137, DOI 10.1016/j.tcb.2014.11.004
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Weder N, 2014, J AM ACAD CHILD PSY, V53, P417, DOI 10.1016/j.jaac.2013.12.025
   Westenskow PD, 2013, J CLIN INVEST, V123, P4900, DOI 10.1172/JCI70230
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yallapu MM, 2012, DRUG DISCOV TODAY, V17, P71, DOI 10.1016/j.drudis.2011.09.009
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
   Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610
   Zhang HY, 2014, SCI WORLD J, DOI 10.1155/2014/645953
   Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010
   Zhao HP, 2013, STROKE, V44, P1706, DOI 10.1161/STROKEAHA.111.000504
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zong RR, 2016, INVEST OPHTH VIS SCI, V57, P1398, DOI 10.1167/iovs.15-17417
NR 114
TC 58
Z9 59
U1 1
U2 18
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1177-1062
EI 1179-2000
J9 MOL DIAGN THER
JI Mol. Diagn. Ther.
PD FEB
PY 2017
VL 21
IS 1
BP 31
EP 43
DI 10.1007/s40291-016-0234-z
PG 13
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA EI6UZ
UT WOS:000392634100004
PM 27658786
OA Green Published
DA 2022-11-30
ER

PT J
AU Rasmussen, A
   Brandi, S
   Fuchs, J
   Hansen, LH
   Lund-Andersen, H
   Sander, B
   Larsen, M
AF Rasmussen, Annette
   Brandi, Sara
   Fuchs, Josefine
   Hansen, Louise H.
   Lund-Andersen, Henrik
   Sander, Birgit
   Larsen, Michael
TI Visual outcomes in relation to time to treatment in neovascular
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE clinical setting; neovascular age-related macular degeneration;
   prognosis; visual acuity
ID INTRAVITREAL RANIBIZUMAB; EXUDATIVE AMD; PREDICTORS; ACUITY; DELAY
AB PurposeTo study the relation between the interval from diagnosis to initiation of intravitreal injection therapy and visual outcome in neovascular age-related macular degeneration (nAMD) and to report changes over time in fellow-eye status.
   MethodsRetrospective chart review. The study included 1185 eyes in 1099 patients who began vascular endothelial growth factor inhibitor treatment for nAMD during four separate periods in 2007, 2009, 2011 and 2012 using a fixed loading-dose regimen of three ranibizumab injections.
   ResultsMean best-corrected visual acuity (BCVA) at presentation remained within the range 0.23-0.24 Snellen and the median patient age within 79-80years, whereas BCVA at first visit after the third injection increased from 0.24 to 0.31 (p<0.0001) in concert with a shift in preferred practice from separate-day injection to same-day injection. This led to a reduction in the median time to treatment from 16days to 1day. The proportion of patients with fellow-eye BCVA 0.05 or worse at presentation with newly diagnosed wet AMD in the incident eye decreased from 38% to 22% (p<0.0018). The proportion of bilaterally treated patients increased during the study period.
   ConclusionIn this study, 2-week-earlier injection was associated with the equivalent of a 5-Early Treatment Diabetic Retinopathy Study letter-gain in mean visual acuity at 3months after presentation. The difference is larger than expected from the 2-week-longer duration of disease at the study end-point. The study supports that early diagnosis and treatment of nAMD is of value for functional outcomes.
C1 [Rasmussen, Annette; Brandi, Sara; Fuchs, Josefine; Hansen, Louise H.; Lund-Andersen, Henrik; Sander, Birgit; Larsen, Michael] Glostrup Cty Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   [Rasmussen, Annette; Fuchs, Josefine; Lund-Andersen, Henrik; Sander, Birgit; Larsen, Michael] Univ Copenhagen, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Rasmussen, A (通讯作者)，Glostrup Cty Hosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM annette.rasmussen@regionh.dk
RI Larsen, Michael/E-9620-2010
OI Larsen, Michael/0000-0002-5172-5891
FU VELUX Foundation; Lundbeck Foundation; Glostrup Hospital; Bayer;
   Novartis; Allergan; Pfizer; Novo Nordisk; GlaxoSmithKline
FX The study was supported by The VELUX Foundation, The Lundbeck Foundation
   and Glostrup Hospital. The funding organizations had no role in the
   design or conduct of this research.; A.R. has received travel support
   from Novartis and one lecture fee from Bayer. S.B. has received travel
   support and lecture fees from Novartis. J.F has received travel support
   from Novartis. L.H.H. is an advisory board member for Bayer and Novartis
   and has received travel support and lecture fees from Novartis, Bayer
   and Allergan. H.L-A has no financial disclosures. B.S has no financial
   disclosures. M.L. is an advisory board member for Novartis, Pfizer,
   Bayer, QLT, Thrombogenics and has received lecture fees from Novartis,
   Pfizer, Bayer, Novo Nordisk and GlaxoSmithKline.
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 19
TC 36
Z9 38
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2015
VL 93
IS 7
BP 616
EP 620
DI 10.1111/aos.12781
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU9UG
UT WOS:000363890500025
PM 26073051
OA Bronze
DA 2022-11-30
ER

PT J
AU Amore, FM
   Paliotta, S
   Silvestri, V
   Piscopo, P
   Turco, S
   Reibaldi, A
AF Amore, Filippo M.
   Paliotta, Silvia
   Silvestri, Valeria
   Piscopo, Paola
   Turco, Simona
   Reibaldi, Alfredo
TI Biofeedback stimulation in patients with age-related macular
   degeneration: comparison between 2 different methods
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID PREFERRED RETINAL LOCI; FIXATION STABILITY; VISION RESTORATION; RESIDUAL
   VISION; MP-1; REHABILITATION; REORGANIZATION; SCOTOMA; PERFORMANCE;
   PERIMETRY
AB Objective: To evaluate changes in patient's visual performance after rehabilitation training with 2 different biofeedback training programs offered by the MP-1 microperimeter. Spontaneous retinal location of preferred retinal loci (PRLs) and fixation stability are not always optimal for best visual performances. MP-1 microperimeter biofeedback techniques have been suggested as modalities for training for better fixation stability and to find a better location of the new PRL in a more useful area of the retina in nonoptimal cases. The MP-1 microperimeter offers different biofeedback strategies, such as acoustic biofeedback and structured light stimulus plus acoustic biofeedback.
   Design: Retrospective study.
   Participants: Thirty subjects affected by age-related macular degeneration with absolute central scotoma.
   Methods: A standard protocol of examination before and after visual rehabilitation training was performed on all study subjects. Assessment included demographics data, visual acuity, fixation stability, retinal sensitivity, and reading speed. Rehabilitation training was performed with standard and structured stimulus biofeedback. The whole sample was divided into 2 groups of 15 patients attending the 2 different stimulation training biofeedback.
   Results: Mean reading speed was found to be significantly increased for both groups (p < 0.05 and p < 0.01). Also, a statistically significant improvement of fixation stability was registered for both groups (p < 0.01). Only patients trained with the flickering pattern biofeedback stimulation increased retinal sensitivity (p < 0.01).
   Conclusions: Both regular biofeedback and flickering pattern biofeedback training seem to improve visual functions. More benefits seem to be accrued, however, with flickering pattern biofeedback training.
C1 [Amore, Filippo M.; Paliotta, Silvia; Silvestri, Valeria; Piscopo, Paola; Turco, Simona; Reibaldi, Alfredo] Italia Onlus, Int Agcy Prevent Blindness, Natl Ctr Serv & Res Prevent Blindness & Rehabilat, Rome, Italy.
RP Amore, FM (通讯作者)，Natl Ctr Serv & Res Prevent Blindness & Rehabilat, Largo A Gemelli 8, I-00168 Rome, Italy.
EM f.amore@iapb.it
RI Silvestri, Valeria/AAB-9530-2022; Piscopo, Paola/J-6504-2016
OI Piscopo, Paola/0000-0002-0693-4969; Silvestri,
   Valeria/0000-0002-8451-8901
CR Altpeter E, 2000, VISION RES, V40, P1539, DOI 10.1016/S0042-6989(00)00059-6
   Amore FM, 2013, OPHTHAL PHYSL OPT, V33, P611, DOI 10.1111/opo.12048
   Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   Buia C, 2006, J COMPUT NEUROSCI, V20, P247, DOI 10.1007/s10827-006-6358-0
   CARTER TL, 1994, GERIATRICS, V49, P37
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Contestabile MT, 2002, EYE, V16, P472, DOI 10.1038/sj.eye.6700046
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Giorgi D, 2005, APPL PSYCHOPHYS BIOF, V30, P389, DOI 10.1007/s10484-005-8424-1
   GOODRICH GL, 1977, AM J OPTOM PHYS OPT, V54, P312
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   HALL EC, 2001, J BEHAV OPTOM, V12, P87
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Lott LA, 2001, OPTOMETRY VISION SCI, V78, P316, DOI 10.1097/00006324-200105000-00015
   Markowitz SN, 2004, CAN J OPHTHALMOL, V39, P56, DOI 10.1016/S0008-4182(04)80053-X
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   RAYNER K, 1979, SCIENCE, V206, P468, DOI 10.1126/science.504987
   Rinaldi G, 2003, INVEST OPHTH VIS SCI, V44, pU315
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Sabel B A, 2000, Curr Opin Ophthalmol, V11, P430, DOI 10.1097/00055735-200012000-00008
   Sabel BA, 2004, RESTOR NEUROL NEUROS, V22, P399
   Sabel BA, 2011, PROG BRAIN RES, V192, P199, DOI 10.1016/B978-0-444-53355-5.00013-0
   Sawa M, 2006, JPN J OPHTHALMOL, V50, P111, DOI 10.1007/s10384-005-0292-y
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Schumacher EH, 2008, RESTOR NEUROL NEUROS, V26, P391
   Seiple W, 2004, J REHABIL RES DEV, V41, P359, DOI 10.1682/JRRD.2003.07.0111
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   Trauzettel-Klosinski S, 2010, J NEURO-OPHTHALMOL, V30, P73, DOI 10.1097/WNO.0b013e3181ce7e8f
   TrauzettelKlosinski S, 1996, NEURO-OPHTHALMOLOGY, V16, P241, DOI 10.3109/01658109609044632
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2013, APPL PSYCHOPHYS BIOF, V38, P11, DOI 10.1007/s10484-012-9203-4
   Vingolo EM, 2009, EYE VIS RES DEV, P249
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   Watson G, 1976, J Am Optom Assoc, V47, P1407
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 49
TC 25
Z9 26
U1 1
U2 14
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2013
VL 48
IS 5
BP 431
EP 437
DI 10.1016/j.jcjo.2013.07.013
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OM
UT WOS:000331149300030
PM 24093192
DA 2022-11-30
ER

PT J
AU Anastasopoulos, E
   Yu, F
   Coleman, AL
AF Anastasopoulos, Eleftherios
   Yu, Fei
   Coleman, Anne L.
TI Age-related macular degeneration is associated with an increased risk of
   hip fractures in the medicare database
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To explore the relationship between age-related macular degeneration (AMD) and incident hip fractures in the Medicare population.
   DESIGN: Prospective cohort study.
   METHODS: With a 5% random sample of Medicare beneficiaries in 1995, 8596 cases were coded with exudative AMD; 26,942 cases were coded with atrophic AMD, and 1,013,748 cases were coded without AMD. The Medicare claims from 1996 to 1999 were evaluated for hip fracture codes. The relationship between AMD and incident hip fractures was analyzed with multiple logistic regression models, with adjustment for baseline, ocular, and systemic covariates.
   RESULTS: In adjusted analyses, the risk of hip fractures was similar in cases that were coded with exudative AMD (odds ratio, 1.03; 95% confidence interval (CI), 0.95, 1.12) compared with cases with no AMD but was significantly higher in cases that were coded with atrophic AMD (odds ratio, 1.11; 95% CI, 1.06, 1.16).
   CONCLUSION: Medicare patients with a code for atrophic AMD had an 11 % greater risk of hip fractures than did patients without a code for AMD over a four-year follow-up period.
C1 Univ Calif Los Angeles, Jules Stein Eye Inst, Ctr Eye Epidemiol, Sch Med, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Coleman, AL (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, Ctr Eye Epidemiol, Sch Med, 100 Stein Plaza,Suite 2-118, Los Angeles, CA 90095 USA.
EM coleman@jsei.ucla.edu
CR Cox A, 2005, EYE, V19, P652, DOI 10.1038/sj.eye.6701610
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x
   FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
NR 7
TC 19
Z9 20
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2006
VL 142
IS 6
BP 1081
EP 1083
DI 10.1016/j.ajo.2006.06.058
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114MU
UT WOS:000242671100035
PM 17157603
DA 2022-11-30
ER

PT J
AU Zweifel, SA
   Engelbert, M
   Khan, S
   Freund, KB
AF Zweifel, Sandrine A.
   Engelbert, Michael
   Khan, Samira
   Freund, K. Bailey
TI RETROSPECTIVE REVIEW OF THE EFFICACY OF TOPICAL BROMFENAC (0.09%) AS AN
   ADJUNCTIVE THERAPY FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; topical bromfenac;
   nonsteroidal antiinflammatory drug; bevacizumab; ranibizumab; lucentis;
   avastin
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; VERTEPORFIN PHOTODYNAMIC THERAPY; RANDOMIZED
   CLINICAL-TRIAL; RANIBIZUMAB; COMBINATION; INJECTION
AB Purpose: The purpose of this study was to assess the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration demonstrating persistent exudation despite monthly intravitreal antivascular endothelial growth factor therapy.
   Methods: Twenty-one patients (22 eyes) who manifested persistent subretinal and/or intraretinal fluid after at least 3 monthly intravitreal injections of ranibizumab or bevacizumab were prescribed topical bromfenac (0.09%) ophthalmic solution twice daily for 2 months. The efficacy of topical bromfenac was evaluated by comparing visual acuity (logarithm of the minimal angle of resolution and Snellen equivalent), masked readings of spectral domain optical coherence tomography center-point retinal thickness, and the height of pigment epithelial detachment (when present) at baseline and at 1 month and 2 months after the initiation of combined treatment.
   Results: The mean visual acuity logarithm of the minimal angle of resolution (Snellen equivalent) at baseline was 0.55 +/- 0.35 (20/70), and it did not change significantly after 1 month (0.53 +/- 0.35; P = 0.41, paired Student's t-test) or 2 months (0.52 +/- 0.34; P = 0.26) after the initiation of combined treatment. The mean central retinal thickness was 311 mu m at baseline, 308 mu m (P = 0.73, paired Student's t-test) after 1 month, and 299 mu m (P = 0.34) after 2 months. In 20 eyes of 19 patients manifesting a pigment epithelial detachment, the mean pigment epithelial detachment height was 275 mu m at baseline, 271 mu m (P = 0.33, paired Student's t-test) at 1 month, and 274 mu m (P = 0.76) at 2 months. There were no adverse events associated with the extended administration of topical bromfenac.
   Conclusion: In patients with neovascular age-related macular degeneration manifesting persistent exudation despite monthly intravitreal antivascular endothelial growth factor therapy, we could not detect a beneficial effect of adding topical bromfenac (0.09%) twice daily over 2 months. RETINA 29:1527-1531, 2009
C1 [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Zweifel, Sandrine A.] Luesther T Mertz Retinal Res Ctr, New York, NY USA.
   [Engelbert, Michael] Columbia Univ, Edward S Harkness Eye Inst, New York, NY USA.
   [Khan, Samira] NYU, Dept Ophthalmol, Med Ctr, New York, NY 10016 USA.
   [Freund, K. Bailey] Univ Zurich Hosp, Dept Ophthalmol, CH-8032 Zurich, Switzerland.
C3 Vitreous Retina Macula Consultants of New York; Columbia University; New
   York University; University of Zurich; University Zurich Hospital
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave 5th, New York, NY 10022 USA.
EM vrmny@aol.com
RI Zweifel, Sandrine/AAX-5045-2020; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
CR Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Baklayan GA, 2008, J OCUL PHARMACOL TH, V24, P392, DOI 10.1089/jop.2007.0082
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   GRANT CA, 2008, INVEST OPHTHALMOL VI, V49
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Landa Gennady, 2009, International Ophthalmology, V29, P1, DOI 10.1007/s10792-007-9176-0
   LIE S, 2008, ACTA OPHTHALMOL 1111
   Lo Giudice G, 2008, EUR J OPHTHALMOL, V18, P652, DOI 10.1177/112067210801800429
   Michels S, 2002, OPHTHALMOLOGE, V99, P96, DOI 10.1007/s003470100532
   Piermarocchi S, 2008, ARCH OPHTHALMOL-CHIC, V126, P1367, DOI 10.1001/archopht.126.10.1367
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
NR 22
TC 17
Z9 18
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2009
VL 29
IS 10
BP 1527
EP 1531
DI 10.1097/IAE.0b013e3181b32f4c
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 519SH
UT WOS:000271787600021
PM 19898185
DA 2022-11-30
ER

PT J
AU Pyatova, Y
   Daibert-Nido, M
   Markowitz, SN
AF Pyatova, Yulia
   Daibert-Nido, Monica
   Markowitz, Samuel N.
TI Long term outcomes in dry age-related macular degeneration following low
   vision rehabilitation interventions
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Nystagmus disorders; neuro ophthalmology; age-related macular;
   degeneration; retina; macular hole; psychophysical testing; retina;
   medical therapies
ID BIOFEEDBACK
AB Background: Age-related macular degeneration (AMD) is the leading cause of loss of vision in the older age groups. In the absence of a known therapy, low vision rehabilitation aims at preserving residual functional vision at optimal levels. Long term functional outcomes from Low Vision Rehabilitation (LVR) in AMD cases were never scrutinized in the past. This study brings some clarification in this matter. Methods: This is a retrospective case series study including data up to 2 years following the baseline visit. Low Vision Assessments included microperimetry testing and recommendations for low vision devices for distance vision. Outcomes measures selected for this study were best corrected distance visual acuity, fixation stability and preferred retinal locus (PRL) topography and LVR interventions. Results: Data on 17 patients with an average age of 89.2 +/- 4.4 years was collected. In those with better vision than 20/400 loss of vision was about 1.4 letter per year as tested with ETDRS charts compared with losses of four letters per year in a population without LVR interventions. Fixation stability continued to deteriorate while PRL eccentricity seemed to remain the same. In about half of cases there was a change in the topographic location of the PRL to a different retinal quadrant. Conclusion: Long term, as expected, changes were noticed in visual acuity, fixation stability and PRL topography. However, it seems that LVR interventions for distance vision help patients retain significantly better functional vision at the 2 years follow up interval when compared to others.
C1 [Pyatova, Yulia; Daibert-Nido, Monica; Markowitz, Samuel N.] Univ Toronto, Univ Hlth Network Hosp, Dept Ophthalmol & Vision Sci, Low Vis Serv, 1225 Davenport Rd, Toronto, ON M6H2H1, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto
RP Markowitz, SN (通讯作者)，Univ Toronto, Univ Hlth Network Hosp, Dept Ophthalmol & Vision Sci, Low Vis Serv, 1225 Davenport Rd, Toronto, ON M6H2H1, Canada.
EM snm1@rogers.com
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Amoaku WM., 2015, BMJ CASE REP, V2015
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Kunzel SH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.63
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Markowitz SN, 2020, RETINA-J RET VIT DIS, V40, P1471, DOI 10.1097/IAE.0000000000002632
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 11
TC 1
Z9 1
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 296
EP 299
AR 1120672120973621
DI 10.1177/1120672120973621
EA NOV 2020
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000678276600001
PM 33222522
DA 2022-11-30
ER

PT J
AU Campa, C
   Hagan, R
   Sahni, JN
   Brown, MC
   Beare, NAV
   Heimann, H
   Harding, SP
AF Campa, Claudio
   Hagan, Richard
   Sahni, Jayashree N.
   Brown, Malcolm C.
   Beare, Nicholas A. V.
   Heimann, Heinrich
   Harding, Simon P.
TI Early Multifocal Electroretinogram Findings during Intravitreal
   Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL-ACUITY MEASUREMENTS; RETINAL FUNCTION; PHOTODYNAMIC THERAPY;
   BEVACIZUMAB AVASTIN; ERG; RELIABILITY; CHART
AB PURPOSE. To evaluate changes in the multifocal electroretinogram (mfERG) in patients with neovascular age-related macular degeneration (nAMD) undergoing ranibizumab treatment.
   METHODS. This was an observational, longitudinal, prospective study. Treatment-naive patients with nAMD who met the inclusion and exclusion criteria underwent a course of monthly injections of ranibizumab over 3 months. At baseline and month 3, each subject was evaluated with best corrected visual acuity (BCVA), contrast sensitivity (CS), fluorescein and indocyanine green angiography, optical coherence tomography (OCT), and mfERG. Additional mfERGs were performed at weeks 1 and 4 and BCVA and OCT at weeks 4 and 8.
   RESULTS. Eighteen patients were enrolled. Between baseline and week 12, median BCVA improved from 59 to 69 ETDRS letters (P = 0.001), median CS improved from 29 to 30 letters (P = 0.05), mean OCT central foveal subfield thickness (CFT) decreased from 294 to 199 mu m (P = 0.005), mean P1 amplitude density of the mfERG central zone increased from 35.85 to 51.55 nV/deg(2) (P = 0.009). The mfERG response correlated positively with BCVA (F = 22; P < 0.0001) and negatively with CFT (F = 12.73; P = 0.00078).
   CONCLUSIONS. Intravitreal ranibizumab therapy appears to induce an increase in mfERGs centrally in patients with nAMD at least in the short term. Longer term studies to investigate the prognostic value of mfERG responses to predict changes in visual acuity in nAMD and other diseases are warranted. (ClinicalTrials.gov number, NCT01023971.) (Invest Ophthalmol Vis Sci. 2011;52:3446-3451) DOI: 10.1167/iovs.10-6588
C1 [Campa, Claudio; Hagan, Richard; Sahni, Jayashree N.; Brown, Malcolm C.; Beare, Nicholas A. V.; Heimann, Heinrich; Harding, Simon P.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
   [Campa, Claudio; Sahni, Jayashree N.; Beare, Nicholas A. V.; Heimann, Heinrich; Harding, Simon P.] Univ Liverpool, Dept Eye & Vis Sci, Liverpool L69 3BX, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Liverpool
RP Campa, C (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Prescot St, Liverpool L7 8XP, Merseyside, England.
EM claudio.campa@yahoo.com
RI Beare, Nicholas/AAG-4946-2019; Heimann, Heinrich/AAP-8747-2020
OI Heimann, Heinrich/0000-0002-3298-4644; Beare,
   Nicholas/0000-0001-8086-990X; Harding, Simon/0000-0003-4676-1158
FU Foundation for the Prevention of Blindness
FX Supported by Foundation for the Prevention of Blindness
CR ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hagan RP, 2006, DOC OPHTHALMOL, V113, P21, DOI 10.1007/s10633-006-9009-x
   Harrison WW, 2009, DOC OPHTHALMOL, V119, P67, DOI 10.1007/s10633-009-9171-z
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   HUANG S, 2001, DOC OPHTHALMOL, V101, P115
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   Karanjia R, 2008, BRIT J OPHTHALMOL, V92, P1248, DOI 10.1136/bjo.2008.138800
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Mackay AM, 2007, DOC OPHTHALMOL, V115, P69, DOI 10.1007/s10633-007-9056-y
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Pedersen KB, 2010, RETINA-J RET VIT DIS, V30, P1025, DOI 10.1097/IAE.0b013e3181cafc8f
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosser DA, 2004, INVEST OPHTH VIS SCI, V45, P1076, DOI 10.1167/iovs.03-1320
   Ruther K, 2003, OPHTHALMOLOGE, V100, P459, DOI 10.1007/s00347-002-0757-z
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
NR 26
TC 10
Z9 15
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 3446
EP 3451
DI 10.1167/iovs.10-6588
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800CF
UT WOS:000293335400001
PM 21357390
DA 2022-11-30
ER

PT J
AU Shen, YC
   Hsia, NY
   Wu, WH
   Lin, CL
   Shen, TC
   Huang, WC
AF Shen, Yi-Chen
   Hsia, Ning-Yi
   Wu, Wan-Hua
   Lin, Cheng-Li
   Shen, Te-Chun
   Huang, Wei-Chien
TI Age-related macular degeneration and premorbid allergic diseases: a
   population-based case-control study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FACTOR-H POLYMORPHISM; HIGH-RISK; COMPLEMENT ACTIVATION; NASAL-MUCOSA;
   VARIANT; PREVALENCE; ALLELES; CONFERS; TAIWAN; C5A
AB Evidence indicates that age-related macular degeneration (AMD) is associated with the prior presence of allergic diseases; however, large-scale studies in the literature are limited. A case-control study was conducted to describe the relationship between premorbid allergic diseases and AMD using Taiwan's National Health Insurance database. Eligibility criteria for inclusion of new adult AMD cases from 2000 to 2013 were set up. We defined the year of diagnosis as the index year. Age-, gender-, index year- matched controls who were drawn from the same database. The case control ratio was 1:4. For all participants, all premorbid conditions staring 1996 to index year were documented. Binary logistic regression was used to describe factors related to AMD occurrence. The AMD group consisted of 10,911 patients, and the comparison group consisted of 43,644 individuals. Patients with AMD showed significant associations with premorbid allergic diseases (aOR 1.54, 95% CI 1.47-1.61), specifically with allergic conjunctivitis (aOR 2.07, 95% CI 1.94-2.20), allergic rhinitis (aOR 1.32, 95% CI 1.25-1.39), asthma (aOR 0.99, 95% CI 0.93-1.06), and atopic dermatitis (aOR 1.04, 95% CI 0.94-1.17). Further analyses indicated that patients with more concurrent allergic diseases have higher associations with AMD than those with fewer concurrent diseases. Patients with more annual medical visits for their allergic diseases also showed higher associations with AMD than those with fewer visits. AMD is significantly associated with premorbid allergic diseases. The underlying mechanisms must be further investigated.
C1 [Shen, Yi-Chen; Huang, Wei-Chien] China Med Univ, Coll Med, Grad Inst Biomed Sci, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
   [Shen, Yi-Chen; Shen, Te-Chun] China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, 2 Yude Rd, Taichung 404, Taiwan.
   [Hsia, Ning-Yi] China Med Univ Hosp, Dept Ophthalmol, 2 Yude Rd, Taichung 404, Taiwan.
   [Wu, Wan-Hua] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, 100,Jingmao 1st Rd, Taichung 404, Taiwan.
   [Lin, Cheng-Li] China Med Univ Hosp, Management Off Hlth Data, 2 Yude Rd, Taichung 404, Taiwan.
   [Shen, Te-Chun] China Med Univ, Coll Med, Sch Med, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
   [Shen, Te-Chun] Chu Shang Show Chwan Hosp, Dept Internal Med, 75,Sect 2,Jishan Rd, Nantou 557, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; China Medical University Taiwan;
   China Medical University Hospital - Taiwan; China Medical University
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan
RP Shen, TC (通讯作者)，China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, 2 Yude Rd, Taichung 404, Taiwan.; Shen, TC (通讯作者)，China Med Univ, Coll Med, Sch Med, 91 Hsueh Shih Rd, Taichung 404, Taiwan.; Shen, TC (通讯作者)，Chu Shang Show Chwan Hosp, Dept Internal Med, 75,Sect 2,Jishan Rd, Nantou 557, Taiwan.
EM chestshen@gmail.com
OI Shen, Te-Chun/0000-0002-9427-1068
FU Taiwan Ministry of Health and Welfare Clinical Trial and Research Center
   of Excellence [MOHW109-TDU-B-212-114004]; China Medical University
   Hospital [DMR-110-033]
FX This study is supported by Taiwan Ministry of Health and Welfare
   Clinical Trial and Research Center of Excellence
   (MOHW109-TDU-B-212-114004) and China Medical University Hospital
   (DMR-110-033).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   ANDERSSON M, 1994, ALLERGY, V49, P242, DOI 10.1111/j.1398-9995.1994.tb02656.x
   [Anonymous], SOURCES MACULAR DEGE
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gerard NP, 2002, CURR OPIN IMMUNOL, V14, P705, DOI 10.1016/S0952-7915(02)00410-7
   Gora N. V., 2014, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P15
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Jun SW, 2008, J ALLERGY CLIN IMMUN, V122, P119, DOI 10.1016/j.jaci.2008.04.028
   KAPP A, 1985, ACTA DERM-VENEREOL, P152
   KAPP A, 1985, ARCH DERMATOL RES, V277, P359, DOI 10.1007/BF00509233
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Laumonnier Y, 2011, CURR ALLERGY ASTHM R, V11, P122, DOI 10.1007/s11882-010-0171-6
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin CH, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969-016-0074-8
   Lynch AM, 2019, RETINA-J RET VIT DIS, V39, P656, DOI 10.1097/IAE.0000000000002023
   Mezei G, 2001, PEDIAT ALLERG IMM-UK, V12, P201, DOI 10.1034/j.1399-3038.2001.012004201.x
   MONDINO BJ, 1990, INVEST OPHTH VIS SCI, V31, P1945
   MONDINO BJ, 1981, ARCH OPHTHALMOL-CHIC, V99, P1430
   Moorthy S, 2011, AM J OPHTHALMOL, V151, P375, DOI 10.1016/j.ajo.2010.09.001
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sun YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030040
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wills-Karp M, 2005, CURR ALLERGY ASTHM R, V5, P362, DOI 10.1007/s11882-005-0007-y
   Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang X, 2010, EXPERT REV CLIN IMMU, V6, P269, DOI 10.1586/ECI.09.84
NR 38
TC 0
Z9 0
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 16
PY 2021
VL 11
IS 1
AR 16537
DI 10.1038/s41598-021-95937-0
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UC6WE
UT WOS:000686663200085
PM 34400678
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Heier, JS
   Brown, DM
   Chong, V
   Korobelnik, JF
   Kaiser, PK
   Nguyen, QD
   Kirchhof, B
   Ho, A
   Ogura, Y
   Yancopoulos, GD
   Stahl, N
   Vitti, R
   Berliner, AJ
   Soo, Y
   Anderesi, M
   Groetzbach, G
   Sommerauer, B
   Sandbrink, R
   Simader, C
   Schmidt-Erfurth, U
AF Heier, Jeffrey S.
   Brown, David M.
   Chong, Victor
   Korobelnik, Jean-Francois
   Kaiser, Peter K.
   Quan Dong Nguyen
   Kirchhof, Bernd
   Ho, Allen
   Ogura, Yuichiro
   Yancopoulos, George D.
   Stahl, Neil
   Vitti, Robert
   Berliner, Alyson J.
   Soo, Yuhwen
   Anderesi, Majid
   Groetzbach, Georg
   Sommerauer, Bernd
   Sandbrink, Rupert
   Simader, Christian
   Schmidt-Erfurth, Ursula
CA VIEW 1 VIEW Study Grp
TI Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   PHOTODYNAMIC THERAPY; RANIBIZUMAB; VERTEPORFIN; GROWTH; LESIONS
AB Objective: Two similarly designed, phase-3 studies (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular degeneration (AMD) compared monthly and every-2-month dosing of intravitreal aflibercept injection (VEGF Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) with monthly ranibizumab.
   Design: Double-masked, multicenter, parallel-group, active-controlled, randomized trials.
   Participants: Patients (n = 2419) with active, subfoveal, choroidal neovascularization (CNV) lesions (or juxtafoveal lesions with leakage affecting the fovea) secondary to AMD.
   Intervention: Patients were randomized to intravitreal aflibercept 0.5 mg monthly (0.5q4), 2 mg monthly (2q4), 2 mg every 2 months after 3 initial monthly doses (2q8), or ranibizumab 0.5 mg monthly (Rq4).
   Main Outcome Measures: The primary end point was noninferiority (margin of 10%) of the aflibercept regimens to ranibizumab in the proportion of patients maintaining vision at week 52 (losing <15 letters on Early Treatment Diabetic Retinopathy Study [ETDRS] chart). Other key end points included change in best-corrected visual acuity (BCVA) and anatomic measures.
   Results: All aflibercept groups were noninferior and clinically equivalent to monthly ranibizumab for the primary end point (the 2q4, 0.5q4, and 2q8 regimens were 95.1%, 95.9%, and 95.1%, respectively, for VIEW 1, and 95.6%, 96.3%, and 95.6%, respectively, for VIEW 2, whereas monthly ranibizumab was 94.4% in both studies). In a prespecified integrated analysis of the 2 studies, all aflibercept regimens were within 0.5 letters of the reference ranibizumab for mean change in BCVA; all aflibercept regimens also produced similar improvements in anatomic measures. Ocular and systemic adverse events were similar across treatment groups.
   Conclusions: Intravitreal aflibercept dosed monthly or every 2 months after 3 initial monthly doses produced similar efficacy and safety outcomes as monthly ranibizumab. These studies demonstrate that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:2537-2548 (C) 2012 by the American Academy of Ophthalmology.
C1 [Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Heier, Jeffrey S.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Brown, David M.] Retina Consultants Houston, Houston, TX USA.
   [Chong, Victor] Univ Oxford, Oxford Eye Hosp, Oxford, England.
   [Korobelnik, Jean-Francois] Univ Bordeaux 2, CHU Bordeaux, F-33076 Bordeaux, France.
   [Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH USA.
   [Quan Dong Nguyen] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Kirchhof, Bernd] Univ Cologne, D-50931 Cologne, Germany.
   [Ho, Allen] Wills Eye Hosp & Res Inst, Philadelphia, PA USA.
   [Ogura, Yuichiro] Nagoya City Univ, Nagoya, Aichi, Japan.
   [Yancopoulos, George D.; Stahl, Neil; Vitti, Robert; Berliner, Alyson J.; Soo, Yuhwen] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
   [Anderesi, Majid; Groetzbach, Georg; Sommerauer, Bernd; Sandbrink, Rupert] Bayer HealthCare, Berlin, Germany.
   [Sandbrink, Rupert] Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany.
C3 Medical University of Vienna; Ophthalmic Consultants of Boston; Tufts
   University; University of Oxford; CHU Bordeaux; UDICE-French Research
   Universities; Universite de Bordeaux; Johns Hopkins University; Johns
   Hopkins Medicine; University of Cologne; Jefferson University; Nagoya
   City University; Regeneron; Bayer AG; Bayer Healthcare Pharmaceuticals;
   Heinrich Heine University Dusseldorf
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI KOROBELNIK, Jean-Francois/A-5448-2016; Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X; Ho, Allen/0000-0003-3921-608X;
   Kaiser, Peter/0000-0001-5126-045X; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Simader, Christian/0000-0002-1784-2883
FU Alimera; Allergan; Fovea; Genentech; Genzyme; GlaxoSmithKline; Neovista;
   Regeneron Pharmaceuticals; Alcon; Eli Lilly; Novartis; Thrombogenics;
   Bayer; Pfizer; Ophthotech; Oraya; P.R.N.; Q.L.T.; Second Sight; Bayer
   HealthCare; Regeneron Pharmaceuticals, Inc, Tarrytown, New York; Bayer
   HealthCare, Berlin Germany
FX The author(s) have made the following disclosure(s): J.S.H. is a
   consultant to and has received research funding from Alimera, Allergan,
   Fovea, Genentech, Genzyme, GlaxoSmithKline, Neovista, and Regeneron
   Pharmaceuticals. He has also received travel support from Regeneron
   Pharmaceuticals. D. M. B. is a consultant to Alimera, Allergan, Bayer,
   Genentech/Roche, Novartis, Regeneron Pharmaceuticals, and Thrombogenics
   and has received research funding from Alcon, Alimera, Allergan, Eli
   Lilly, Genentech, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals,
   and Thrombogenics. He has also received travel support from Regeneron
   Pharmaceuticals and lecture fees from Genentech. V. C. is a consultant
   to Alimera and Bayer and has received research funding from Alcon,
   Allergan, Bayer, Novartis, and Pfizer. He is an advisory board member
   for Allergan and Novartis and has also received travel support from
   Bayer. J.-F.K. is a consultant to Alcon, Bayer, and Thea and an advisory
   board member for Allergan, Bayer, and Novartis. He has received travel
   support from Regeneron Pharmaceuticals. P. K. K. is a consultant to
   Bayer, Genentech, Novartis, and Regeneron Pharmaceuticals. He has
   received research funding from Regeneron Pharmaceuticals. Q.D.N. is a
   consultant to Bausch & Lomb and Santen and has received research funding
   from Genentech, Novartis, and Pfizer. B. K. has received travel support
   from Bayer. A. H. is a consultant to Alcon, Allergan, Centocor, Johnson
   & Johnson, Neovista, Merck, Ophthotech, Oraya, Paloma, P.R.N., Q. L. T.,
   Regeneron Pharmaceuticals, and Thrombogenics. He has received research
   funding and lecture fees from Alcon, Allergan, Genentech, Neovista,
   Ophthotech, Oraya, P.R.N., Q.L.T., Regeneron Pharmaceuticals, and Second
   Sight. Y.O. is a consultant to Alcon and Bayer and has received travel
   support from Bayer. G.D.Y., N.S., R. V., A.J.B., and Y.S. are employees
   of Regeneron Pharmaceuticals. MA, G. G., B. S., and R. S. are employees
   of Bayer HealthCare. C.S.'s institution has received payments from the
   Medical University of Vienna for data monitoring/reviewing and
   statistical analysis. U. S.-E. is a consultant to Alcon, Allergan, Bayer
   HealthCare, and Novartis, and an advisory board member for Alcon and
   Novartis. She has received travel support from Bayer HealthCare and
   lecture fees from Bayer HealthCare and Novartis.; Sponsored by Regeneron
   Pharmaceuticals, Inc, Tarrytown, New York, and Bayer HealthCare, Berlin
   Germany. The sponsors participated in the design and conduct of the
   study, analysis of the data, and preparation of the manuscript.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Yancopoulos GD, 2010, CELL, V143, P13, DOI 10.1016/j.cell.2010.09.028
NR 20
TC 1490
Z9 1541
U1 8
U2 180
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2012
VL 119
IS 12
BP 2537
EP 2548
DI 10.1016/j.ophtha.2012.09.006
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 049AL
UT WOS:000311954300017
PM 23084240
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Lynn, SA
   Keeling, E
   Munday, R
   Gabha, G
   Griffiths, H
   Lotery, AJ
   Ratnayaka, JA
AF Lynn, Savannah A.
   Keeling, Eloise
   Munday, Rosie
   Gabha, Gagandeep
   Griffiths, Helen
   Lotery, Andrew J.
   Ratnayaka, J. Arjuna
TI The complexities underlying age-related macular degeneration: could
   amyloid beta play an important role
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE amyloid beta (A beta); retinal neurons; retina; mouse models; age
   related macular degeneration (AMD)
ID IMPAIR SYNAPTIC PLASTICITY; RETINAL-PIGMENT EPITHELIUM;
   ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MOUSE MODEL; CONE PHOTORECEPTORS;
   GEOGRAPHIC ATROPHY; MOLECULAR-BIOLOGY; SEVERITY SCALE; CYSTATIN-C
AB Age-related macular degeneration (AMD) causes irreversible loss of central vision for which there is no effective treatment. Incipient pathology is thought to occur in the retina for many years before AMD manifests from midlife onwards to affect a large proportion of the elderly. Although genetic as well as non-genetic/environmental risks are recognized, its complex aetiology makes it difficult to identify susceptibility, or indeed what type of AMD develops or how quickly it progresses in different individuals. Here we summarize the literature describing how the Alzheimer's-linked amyloid beta (A) group of misfolding proteins accumulate in the retina. The discovery of this key driver of Alzheimer's disease in the senescent retina was unexpected and surprising, enabling an altogether different perspective of AMD. We argue that A fundamentally differs from other substances which accumulate in the ageing retina, and discuss our latest findings from a mouse model in which physiological amounts of A were subretinally-injected to recapitulate salient features of early AMD within a short period. Our discoveries as well as those of others suggest the pattern of A accumulation and pathology in donor aged/AMD tissues are closely reproduced in mice, including late-stage AMD phenotypes, which makes them highly attractive to study dynamic aspects of A-mediated retinopathy. Furthermore, we discuss our findings revealing how A behaves at single-cell resolution, and consider the long-term implications for neuroretinal function. We propose A as a key element in switching to a diseased retinal phenotype, which is now being used as a biomarker for late-stage AMD.
C1 [Lynn, Savannah A.; Keeling, Eloise; Munday, Rosie; Gabha, Gagandeep; Griffiths, Helen; Lotery, Andrew J.; Ratnayaka, J. Arjuna] Univ Southampton, Clin & Expt Sci, Fac Med, Southampton, Hants, England.
   [Lotery, Andrew J.] Univ Southampton NHS Trust, Eye Unit, Southampton, Hants, England.
C3 University of Southampton; University of Southampton
RP Ratnayaka, JA (通讯作者)，Univ Southampton, Clin & Expt Sci, Fac Med, Southampton, Hants, England.
EM J.Ratnayaka@soton.ac.uk
OI Munday, Rosie/0000-0003-2529-2735; Ratnayaka, J.
   Arjuna/0000-0002-1027-6938; Lotery, Andrew/0000-0001-5541-4305
FU National Centre for the Replacement Refinement & Reduction of Animals in
   Research (NC3R) [NC/L001152/1]; Macular Society, UK; National Eye
   Research Centre; Gift of Sight Appeal; National Institute for Health
   Research [NF-SI-0515-10020] Funding Source: researchfish; National
   Centre for the Replacement [NC/L001152/1] Funding Source: researchfish
FX This work was funded by the National Centre for the Replacement
   Refinement & Reduction of Animals in Research (NC3R: Grant #
   NC/L001152/1), the Macular Society, UK, National Eye Research Centre,
   and the Gift of Sight Appeal.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson PJB, 2009, CLIN OPHTHALMOL, V3, P235
   Armstrong RA, 2009, FOLIA NEUROPATHOL, V47, P289
   Atwood CS, 2003, BRAIN RES REV, V43, P1, DOI 10.1016/S0165-0173(03)00174-7
   Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bitan G, 2005, AMYLOID, V12, P88, DOI 10.1080/13506120500106958
   Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431
   Broersen K, 2011, PROTEIN ENG DES SEL, V24, P743, DOI 10.1093/protein/gzr020
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67
   Cunvong K, 2013, INVEST OPHTH VIS SCI, V54, P1516, DOI 10.1167/iovs.12-10821
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dias JRDO, 2017, RETINA-J RET VIT DIS, V37, P1499, DOI 10.1097/IAE.0000000000001385
   DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibson J, 2012, IMMUNOBIOLOGY, V217, P251, DOI 10.1016/j.imbio.2011.07.015
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Grandel H, 2006, DEV BIOL, V295, P263, DOI 10.1016/j.ydbio.2006.03.040
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Guo LY, 2014, EXP EYE RES, V129, P31, DOI 10.1016/j.exer.2014.10.012
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   He N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.437
   Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119
   Howlett DR, 2011, EXP BRAIN RES, V214, P185, DOI 10.1007/s00221-011-2819-4
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001
   Jefferies WA, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt230
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kim W, 2005, J BIOL CHEM, V280, P35069, DOI 10.1074/jbc.M505763200
   Kipfer-Kauer A, 2010, CURR EYE RES, V35, P828, DOI 10.3109/02713683.2010.494240
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Kuperstein I, 2010, EMBO J, V29, P3408, DOI 10.1038/emboj.2010.211
   Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007
   Lee J, 2011, NAT CHEM BIOL, V7, P602, DOI [10.1038/NCHEMBIO.624, 10.1038/nchembio.624]
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lynn SA, 2016, INVEST OPHTH VIS SCI, V57
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Mc Donald JM, 2010, BRAIN, V133, P1328, DOI 10.1093/brain/awq065
   McKay GJ, 2011, AM J EPIDEMIOL, V173, P1357, DOI 10.1093/aje/kwr015
   McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
   Minter MR, 2016, J NEUROCHEM, V136, P457, DOI 10.1111/jnc.13411
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Noguchi A, 2009, J BIOL CHEM, V284, P32895, DOI 10.1074/jbc.M109.000208
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   Perrin RJ, 2009, NATURE, V461, P916, DOI 10.1038/nature08538
   PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0
   Pow DV, 2007, EXP EYE RES, V84, P850, DOI 10.1016/j.exer.2007.01.005
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Ratnayaka A, 2007, EXP EYE RES, V84, P1135, DOI 10.1016/j.exer.2006.01.030
   Ratnayaka A, 2007, INT J BIOCHEM CELL B, V39, P85, DOI 10.1016/j.biocel.2006.08.015
   Ratnayaka A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1534
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Ratnayaka JA, 2016, ALZHEIMERS RELATED A, P85
   Reye P, 2002, J COMP NEUROL, V447, P323, DOI 10.1002/cne.10218
   Rich KA, 1997, J COMP NEUROL, V388, P47
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Selkoe DJ, 2008, BEHAV BRAIN RES, V192, P106, DOI 10.1016/j.bbr.2008.02.016
   Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782
   Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007
   Elias FTS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139556
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Soura V, 2012, BIOCHEM J, V441, P579, DOI 10.1042/BJ20110749
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sudo H, 2010, J NEUROSCI, V30, P7215, DOI 10.1523/JNEUROSCI.0048-10.2010
   TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0
   Taylor-Walker G, 2016, EXP EYE RES, V153, P110, DOI 10.1016/j.exer.2016.10.013
   Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025
   Townsend M, 2006, J PHYSIOL-LONDON, V572, P477, DOI 10.1113/jphysiol.2005.103754
   Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v
   Vaillant AR, 2002, NEURON, V34, P985, DOI 10.1016/S0896-6273(02)00717-1
   Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x
   Walsh DT, 2002, NEUROBIOL DIS, V10, P20, DOI 10.1006/nbdi.2002.0485
   Wang JQ, 2011, ANAT REC, V294, P1401, DOI 10.1002/ar.21438
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V424, P704, DOI 10.1016/j.bbrc.2012.07.014
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137
   Williams TL, 2010, LANGMUIR, V26, P17260, DOI 10.1021/la101581g
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
NR 127
TC 24
Z9 26
U1 0
U2 11
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD APR
PY 2017
VL 12
IS 4
BP 538
EP 548
DI 10.4103/1673-5374.205083
PG 11
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA EU3HO
UT WOS:000400920000006
PM 28553324
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Nomura, Y
   Yanagi, Y
AF Nomura, Yoko
   Yanagi, Yasuo
TI Intravitreal aflibercept for ranibizumab-resistant exudative age-related
   macular degeneration with choroidal vascular hyperpermeability
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal vascular hyperpermeability;
   Aflibercept
ID CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE GREEN ANGIOGRAPHY;
   VASCULOPATHY; BEVACIZUMAB; OUTCOMES; FLUID; EYES
AB Purpose To investigate anatomical responses and visual changes in cases of exudative age-related macular degeneration (AMD) with choroidal vascular hyperpermeability (CVH) that responded poorly to multiple ranibizumab injections and were treated with intravitreal aflibercept.
   Design Retrospective comparative study.
   Participants Twenty-five consecutive patients attending the outpatient clinic of the University of Tokyo Hospital who showed an insufficient response to multiple intravitreal ranibizumab injections and were switched to intravitreal aflibercept injections between March and June 2013. All patients were treated with intravitreal aflibercept in a treat-and-extend regimen and followed up for at least 12 months.
   Methods Presence or absence of CVH was determined by indocyanine green angiography. Changes of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at 12 months were compared between the CVH (+) AMD and CVH (-) AMD eyes.
   Results The improvement in logMAR BCVA at 12 months was larger in the CVH (-) AMD eyes than in the CVH (+) AMD eyes (-0.18 vs -0.026; P = 0.0089, t-test). The changes in CRT did not differ significantly between the groups (-122 +/- 101 mu m in the CVH (-) AMD eyes and -159 +/- 118 mu m in the CVH (+) AMD eyes; P = 0.44, t-test). The proportion of the eyes without intraretinal or subretinal fluid or hemorrhage was 88 % in the CVH (-) AMD and 67 % in the CVH (+) AMD (P = 0.21, t-test).
   Conclusions Compared with AMD without CVH, AMD with CVH showed poorer visual gain resulting from intravitreal aflibercept treatment.
C1 [Nomura, Yoko; Yanagi, Yasuo] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Nomura, Yoko; Yanagi, Yasuo] Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo; University of Tokyo
RP Yanagi, Y (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.org
RI Yanagi, Yasuo/AAF-2670-2020; Yanagi, Yasuo/AAA-5441-2022
OI Yanagi, Yasuo/0000-0002-0362-7285
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lafaut BA, GRAEFES ARCH CLIN EX
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Nomura Y, 2015, CLIN OPHTHALMOL, V9, P297, DOI 10.2147/OPTH.S78210
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
NR 20
TC 15
Z9 15
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2015
VL 59
IS 4
BP 261
EP 265
DI 10.1007/s10384-015-0387-z
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN1QI
UT WOS:000358194400009
PM 25983109
DA 2022-11-30
ER

PT J
AU Bakri, SJ
   Nickel, J
   Yoganathan, P
   Beer, PM
AF Bakri, Sophie J.
   Nickel, Jonathan
   Yoganathan, Pradeepa
   Beer, Paul M.
TI Photodynamic therapy for choroidal neovascularization associated with
   submacular hemorrhage in age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBRETINAL HEMORRHAGE; PNEUMATIC
   DISPLACEMENT; NATURAL-HISTORY; INJECTION; MANAGEMENT; REMOVAL
AB BACKGROUND AND OBJECTIVE: To describe visual acuity results after photodynamic therapy (PDT) with verteporfin for choroidal neovascularization in age-related macular degeneration (AMD) associated with large submacular hemorrhage (SMH).
   PATIENTS AND METHODS: Eyes that had AMD, at least 12 months' follow-up, and SMH of at least 2.5 mm 2, and had received no other treatment modality in conjunction with PDT, were divided into two groups: eyes with spontaneous SMH that was treated with PDT and eyes with SMH that occurred following PDT treatment. The presence of SMH did not preclude the patients from undergoing further PDT.
   RESULTS: Mean acuity of the spontaneous SMH group was 20/294 initially and 20/252 after 12 months. Mean acuity of the post-PDT SMH group was 20/336 initially and 20/406 after 12 months. Initial and 12-month acuities in both groups were not statistically different. Mean size of the hemorrhage was 11.5 mm(2) in the spontaneous SMH group and 17.8 mm(2) in the post-PDT SMH group. Subgroup analysis showed no statistically significant difference between initial and final visual acuities, regardless of the presence of blood under the fovea. Analysis by size of the SMH showed only the spontaneous SMH group with hemorrhages over 10 mm(2) to have a statistically significant difference in visual acuity at 12 months (P =.0001; initial acuity, 20/230; 12-month acuity, 20/456).
   CONCLUSION: Eyes treated with PDT for choroidal neovascularization associated with submacular hemorrhage and AMD maintained stable vision over 12 months.
C1 Albany Med Coll, Lions Eye Inst, Albany, NY 12208 USA.
   Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
C3 Albany Medical College; Mayo Clinic
RP Beer, PM (通讯作者)，Albany Med Coll, Lions Eye Inst, Albany, NY 12208 USA.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2001, OPHTHALMOLOGY, V108, P435, DOI 10.1016/S0161-6420(00)00666-7
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   DELLAPORTA AN, 1994, INT OPHTHALMOL, V18, P25, DOI 10.1007/BF00919410
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 19
TC 14
Z9 14
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JUL-AUG
PY 2006
VL 37
IS 4
BP 278
EP 283
DI 10.3928/15428877-20060701-03
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 070ZY
UT WOS:000239567600003
PM 16898387
DA 2022-11-30
ER

PT J
AU Ma, YB
   Fu, SY
   Ma, YH
   Liu, HL
AF Ma, Yan-Bo
   Fu, Shao-Ying
   Ma, Yan-Hua
   Liu, Hong-Ling
TI Relationship between SERPING1 rs2511989 polymorphism and age-related
   macular degeneration risk: A meta-analysis
SO MOLECULAR VISION
LA English
DT Article
ID C1 INHIBITOR; GENETIC-VARIANTS; ASSOCIATION
AB Purpose: We conducted a meta-analysis aiming to evaluate the relationship between a common polymorphism (rs2511989 G>A) in the SERPING1 gene and the risk of age-related macular degeneration (AMD).
   Methods: The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched for relevant articles published before November 1, 2013, without any language restrictions. A meta-analysis was conducted using STATA 12.0 software. We calculated a crude odds ratio (OR) with a 95% confidence interval (95% CI) to evaluate the relationships under five genetic models.
   Results: Seven case-control studies with a total of 7,159 patients with AMD and 5,797 healthy subjects met the inclusion criteria. The results of our meta-analysis showed that the SERPING1 rs2511989 polymorphism might be correlated with an increased risk of AMD (G allele versus A allele: OR = 1.09, 95% CI = 1.03-1.15, p = 0.020; GG + GA versus AA: OR = 1.14, 95% CI = 1.03-1.26, p = 0.014; GG versus GA+AA: OR = 1.10, 95% CI = 1.02-1.19, p = 0.012; GG versus AA: OR = 1.20, 95% CI = 1.07-1.34, p = 0.002; respectively). Results of subgroup analysis by ethnicity revealed positive correlations between the SERPING1 rs2511989 polymorphism and risk of AMD among Caucasians under five genetic models (all p<0.05), but not among Asians (all p>0.05).
   Conclusions: The current meta-analysis shows that the SERPING1 rs2511989 polymorphism may have a positive effect on the risk of AMD, especially among Caucasians.
C1 [Ma, Yan-Bo] Heilongjiang Prov Hosp, Dept Ophthalmol, Harbin, Peoples R China.
   [Fu, Shao-Ying; Liu, Hong-Ling] Harbin Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Harbin 150000, Peoples R China.
   [Ma, Yan-Hua] Liaoning Elect Power Spa Sanat, Xingcheng City, Peoples R China.
C3 Harbin Medical University
RP Liu, HL (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Youzheng St 23, Harbin 150000, Peoples R China.
EM liuhongling1219@126.com
CR Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Carter JG, 2011, ACTA OPHTHALMOL, V89, pE212, DOI 10.1111/j.1755-3768.2009.01788.x
   CARTER PE, 1991, EUR J BIOCHEM, V197, P301, DOI 10.1111/j.1432-1033.1991.tb15911.x
   Csuka D, 2013, MOL IMMUNOL, V54, P271, DOI 10.1016/j.molimm.2012.12.015
   Davis AE, 2004, DRUG NEWS PERSPECT, V17, P439, DOI 10.1358/dnp.2004.17.7.863703
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Gibson J, 2012, IMMUNOBIOLOGY, V217, P251, DOI 10.1016/j.imbio.2011.07.015
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lu F, 2010, MOL VIS, V16, P1
   McGwin G, 2011, BRIT J OPHTHALMOL, V95, P1616, DOI 10.1136/bjo.2011.204297
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Park KH, 2009, MOL VIS, V15, P200
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Wang W, 2010, DISCOV MED, V9, P13
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 19
TC 0
Z9 0
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 17
PY 2014
VL 20
BP 1434
EP 1442
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AS9MA
UT WOS:000344565600001
PM 25352749
DA 2022-11-30
ER

PT J
AU Yun, C
   Oh, J
   Ahn, SE
   Hwang, SY
   Kim, SW
   Huh, K
AF Yun, Cheolmin
   Oh, Jaeryung
   Ahn, Soh-Eun
   Hwang, Soon-Young
   Kim, Seong-Woo
   Huh, Kuhl
TI Peripapillary choroidal thickness in patients with early age-related
   macular degeneration and reticular pseudodrusen
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal thickness; Peripapillary choroidal thickness; Optical
   coherence tomography; Drusen; Pseudodrusen; Age-related macular
   degeneration
ID FELLOW-EYES; RISK-FACTOR; CIRCULATION; ATROPHY
AB The purpose of this study was to investigate peripapillary and macular choroidal thickness (CT) in patients with early age-related macular degeneration (AMD) with or without reticular pseudodrusen (RPD).
   We investigated the medical records of 89 patients (89 eyes) with early AMD. The eyes were grouped into three categories according to the extent of RPD: no RPD, localized RPD, and diffuse RPD. Peripapillary and macular CT were measured with images obtained by spectral domain optical coherence tomography. CT in the peripapillary and macular areas was compared among groups.
   Both RPD groups exhibited an older subject age and a greater female predominance compared to the non-RPD group (P = 0.007 and P = 0.030, respectively). Macular and peripapillary CT were different among the three groups (all, P < 0.001), and both RPD groups showed a thinner choroid in all areas compared to the non-RPD group after adjusting for age and sex (all, P a parts per thousand currency signaEuro parts per thousand 0.016). Temporal peripapillary and nasal macular CT at 500 mu m and 1500 mu m, respectively, from the fovea in eyes with diffuse RPD were significantly thinner than that in eyes with localized RPD (P = 0.008, P = 0.016 and P < 0.001, respectively).
   In addition to the macular area, the peripapillary CT, including the area outside the macula, was thinner in eyes with RPD than in those without RPD. Significant differences in the papillomacular choroid were observed based on RPD distribution type, which suggests that variation in CT is based on the extent of RPD.
C1 [Yun, Cheolmin; Oh, Jaeryung; Ahn, Soh-Eun; Kim, Seong-Woo; Huh, Kuhl] Korea Univ, Coll Med, Dept Ophthalmol, 126-1 Anam Dong 5-Ga, Seoul 136705, South Korea.
   [Hwang, Soon-Young] Korea Univ, Coll Med, Dept Biostat, Seoul 136705, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 126-1 Anam Dong 5-Ga, Seoul 136705, South Korea.
EM ojr4991@yahoo.co.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562; Kim, Seong-Woo/0000-0003-0073-5800
FU Korean Ministry of Environment [2012001350010]
FX This study was funded by the Korean Ministry of Environment through "the
   Environmental Health Action Program (2012001350010)".
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   GIUFFRE G, 1989, DOC OPHTHALMOL, V72, P175, DOI 10.1007/BF00156707
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Jonas Jost B, 2005, Curr Opin Ophthalmol, V16, P84, DOI 10.1097/01.icu.0000156135.20570.30
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Oh Jaeryung, 2013, Korean J Ophthalmol, V27, P172, DOI 10.3341/kjo.2013.27.3.172
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Shao L, 2014, AM J OPHTHALMOL, V158, P702, DOI 10.1016/j.ajo.2014.05.023
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, p[312, e301]
NR 32
TC 19
Z9 19
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2016
VL 254
IS 3
BP 427
EP 435
DI 10.1007/s00417-015-3054-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF3SK
UT WOS:000371267600003
PM 25971212
DA 2022-11-30
ER

PT J
AU Fasler, K
   Fu, DJ
   Moraes, G
   Wagner, S
   Gokhale, E
   Kortuem, K
   Chopra, R
   Faes, L
   Preston, G
   Pontikos, N
   Patel, PJ
   Tufail, A
   Lee, AY
   Balaskas, K
   Keane, PA
AF Fasler, Katrin
   Fu, Dun Jack
   Moraes, Gabriella
   Wagner, Siegfried
   Gokhale, Eesha
   Kortuem, Karsten
   Chopra, Reena
   Faes, Livia
   Preston, Gabriella
   Pontikos, Nikolas
   Patel, Praveen J.
   Tufail, Adnan
   Lee, Aaron Y.
   Balaskas, Konstantinos
   Keane, Pearse A.
TI Moorfields AMD database report 2: fellow eye involvement with
   neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   ranibizumab; aflibercept; anti-vascular endothelial growth factor;
   fellow eye; electronic medical record; visual acuity
ID QUALITY-OF-LIFE; RANIBIZUMAB; CONVERSION; THERAPY; VISION
AB Background/Aims
   Neovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on 'fellow eyes' have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) antivascular endothelial growth factor treatment and timelines for fellow eye involvement.
   Methods
   Retrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients/120 286 single entries with data extracted between 21 October 2008 and 9 August 2018. The data set for analysis consisted of 1180 sequential, 807 non-sequential and 3410 unilateral eyes.
   Results
   Mean VA (ETDRS letters +/- SD) of sequentially treated fellow eyes at baseline was significantly higher (63 +/- 13), VA gain over 2 years lower (0.37 +/- 14) and proportion of eyes with good VA (>= 70 letters) higher (46%) than the respective first eyes (baseline VA 54 +/- 16, VA gain at 2 years 5.6 +/- 15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at 2 years, and median time interval to fellow eye involvement was 71 (IQR: 27-147) weeks.
   Conclusion
   This report shows that sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years.
C1 [Fasler, Katrin; Fu, Dun Jack; Moraes, Gabriella; Wagner, Siegfried; Gokhale, Eesha; Kortuem, Karsten; Chopra, Reena; Faes, Livia; Preston, Gabriella; Pontikos, Nikolas; Patel, Praveen J.; Tufail, Adnan; Balaskas, Konstantinos; Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Fasler, Katrin; Fu, Dun Jack; Moraes, Gabriella; Wagner, Siegfried; Gokhale, Eesha; Kortuem, Karsten; Chopra, Reena; Faes, Livia; Preston, Gabriella; Pontikos, Nikolas; Patel, Praveen J.; Tufail, Adnan; Balaskas, Konstantinos; Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, UCL Inst Ophthalmol, London, England.
   [Fasler, Katrin] Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Kortuem, Karsten] Ludwig Maximilians Univ Munchen, Univ Eye Hosp, Munich, Germany.
   [Faes, Livia] Luzerner Kantonsspital, Dept Ophthalmol, Luzern, Switzerland.
   [Lee, Aaron Y.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of Zurich;
   University Zurich Hospital; University of Munich; Lucerne Cantonal
   Hospital; University of Washington; University of Washington Seattle
RP Keane, PA (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, London, England.
EM pearse.keane1@nhs.net
RI Pontikos, Nikolas/U-3642-2018; Lee, Aaron/AAT-2839-2020; Balaskas,
   Konstantinos/ABD-5979-2020
OI Pontikos, Nikolas/0000-0003-1782-4711; Balaskas,
   Konstantinos/0000-0002-7690-6277; Lee, Aaron/0000-0002-7452-1648;
   Gokhale, Eesha/0000-0002-8320-4548; Keane, Pearse/0000-0002-9239-745X;
   Tufail, Adnan/0000-0001-6131-7640; Kortuem, Karsten/0000-0001-9442-0708
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute
   of Ophthalmology; MRC [MC_PC_19005] Funding Source: UKRI
FX The research is supported by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology.
CR Barthelmes D, 2014, OPHTHALMOLOGY, V121, P2073, DOI 10.1016/j.ophtha.2014.05.007
   Bek T, 2018, GRAEF ARCH CLIN EXP, V256, P2061, DOI 10.1007/s00417-018-4100-z
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Chew JK, 2017, OPHTHALMOLOGICA, V238, P23, DOI 10.1159/000469652
   COHEN D, 2015, BMJ-BRIT MED J, V350, DOI [DOI 10.1136/BMJ.H1654, DOI 10.1136/bmj.h1654]
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Hambleton D, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5013
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Paulus YM, 2017, QUAL LIFE RES, V26, P2139, DOI 10.1007/s11136-017-1547-z
   Pezzullo L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2836-0
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   RAY WA, 1985, INVEST OPHTH VIS SCI, V26, P1186
   Rees GB, 2015, EYE, V29, P719, DOI 10.1038/eye.2015.38
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Sim PY, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017771
   The Royal College of Opthalmologists, CVI CERT VIS IMP
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 30
TC 16
Z9 16
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2020
VL 104
IS 5
BP 684
EP 690
DI 10.1136/bjophthalmol-2019-314446
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LL2KF
UT WOS:000531384100016
PM 31611234
OA Green Submitted, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Prettenhofer, U
   Haas, A
   Mayer, R
   Stranzl, H
   Oechs, A
   Hackl, A
AF Prettenhofer, U
   Haas, A
   Mayer, R
   Stranzl, H
   Oechs, A
   Hackl, A
TI Long-term results after external radiotherapy in age-related macular
   degeneration - A prospective study
SO STRAHLENTHERAPIE UND ONKOLOGIE
LA English
DT Article
DE age-related macular degeneration; external radiotherapy; prospective
   study; long-term results
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PATIENT INFORMATION;
   RADIATION-THERAPY; TELETHERAPY; MEMBRANES
AB Purpose: To prospectively evaluate the short- and Long-term efficacy of external radiotherapy (RT) in patients with age-related macular degeneration (AMD) by comparing two different dose schedules.
   Patients and Methods: In this prospective, nonrandomized, comparative study including 80 patients, the efficacy of external RT with a total dose of 14.4 Gy (group A, n = 40) and 25.2 Gy (group B, n = 40) was compared. Patients of group A were irradiated between September 1995 and July 1996, patients of group B between August 1996 and November 1997. 67 patients presented with occult choroidal neovascularization (CNV), 13 with classic subfoveal Lesions. Complete ophthalmologic investigation was performed before RT, at intervals of 3 months during the 1st year after RT, and of 6 months thereafter.
   Results: 12 months after RT, vision deteriorated in 85% (14.4 Gy) and 65% (25.2 Gy) of patients. Central, visual field decreased with both dose schedules. There was no morphological benefit in neovascular changes. After 48 months, complete follow-up was possible in 46 patients who showed a significant toss of vision similar to the natural course of AMD.
   Conclusion: External RT of AMD with 14.4 Gy as well as with the escalated dose of 25.2 Gy showed a poor beneficial outcome after 6 and 12 months, respectively. After a follow-up of 4 years, visual outcome in irradiated patients was similar to the natural course of the disease. A conspicuous efficacy of RT in prevention of blindness could not be demonstrated.
C1 Graz Univ, Sch Med, Dept Radiotherapy, A-8036 Graz, Austria.
   Graz Univ, Sch Med, Dept Ophthalmol, A-8036 Graz, Austria.
C3 University of Graz; University of Graz
RP Prettenhofer, U (通讯作者)，Graz Univ, Sch Med, Dept Radiotherapy, Auenbruggerpl 32, A-8036 Graz, Austria.
EM ulrike.prettenhofer@uni-graz.at
CR Anders N, 1998, OPHTHALMOLOGE, V95, P760, DOI 10.1007/s003470050349
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   BERGINK GJ, 1994, GRAEF ARCH CLIN EXP, V232, P591, DOI 10.1007/BF00193119
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eter N, 2002, INT OPHTHALMOL, V24, P13
   Gripp S, 2000, STRAHLENTHER ONKOL, V176, P131, DOI 10.1007/PL00002338
   Gripp S, 2002, INT J RADIAT ONCOL, V52, P489, DOI 10.1016/S0360-3016(01)02611-6
   GUYTON JS, 1948, ARCH OPHTHALMOL-CHIC, V40, P389, DOI 10.1001/archopht.1948.00900030397002
   Haas A, 2000, OPHTHALMOLOGY, V107, P1358, DOI 10.1016/S0161-6420(00)00154-8
   Haas A, 2000, J NEUROSURG, V93, P172, DOI 10.3171/jns.2000.93.supplement_3.0172
   Heyd R, 2003, STRAHLENTHER ONKOL, V179, P372, DOI 10.1007/s00066-003-0911-9
   Holloway TB, 1929, ARCH OPHTHALMOL-CHIC, V1, P219, DOI 10.1001/archopht.1929.00810010228005
   Lambooij AC, 2001, GRAEF ARCH CLIN EXP, V239, P539, DOI 10.1007/s004170100314
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Prettenhofer U, 1998, STRAHLENTHER ONKOL, V174, P613, DOI 10.1007/BF03038508
   Prettenhofer U., 1999, International Journal of Radiation Oncology Biology Physics, V45, P394, DOI 10.1016/S0360-3016(99)90495-9
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rodel F, 2002, STRAHLENTHER ONKOL, V178, P1, DOI 10.1007/s00066-002-0901-3
   Schafer C, 2002, STRAHLENTHER ONKOL, V178, P562, DOI 10.1007/s00066-002-0969-9
   Schittkowski M, 2001, STRAHLENTHER ONKOL, V177, P345, DOI 10.1007/PL00002417
   Schlund GH, 2001, STRAHLENTHER ONKOL, V177, P121, DOI 10.1007/PL00002391
   Seegenschmiedt MH, 1999, STRAHLENTHER ONKOL, V175, P541, DOI 10.1007/s000660050038
   Staar S, 1999, INT J RADIAT ONCOL, V45, P467, DOI 10.1016/S0360-3016(99)00186-8
   Thilmann C., 1997, Strahlentherapie und Onkologie, V173, P422
   Tholen AM, 1998, OPHTHALMOLOGE, V95, P691, DOI 10.1007/s003470050337
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
NR 28
TC 12
Z9 13
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0179-7158
EI 1439-099X
J9 STRAHLENTHER ONKOL
JI Strahlenther. Onkol.
PD FEB
PY 2004
VL 180
IS 2
BP 91
EP 95
DI 10.1007/s00066-004-1177-6
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 773AT
UT WOS:000188876100004
PM 14762661
DA 2022-11-30
ER

PT J
AU Palanker, D
   Le Mer, Y
   Mohand-Said, S
   Muqit, M
   Jose, S
AF Palanker, Daniel
   Le Mer, Yannick
   Mohand-Said, Saddek
   Muqit, Mahiul
   Jose, Sahel
TI Photovoltaic Restoration of Central Vision in Atrophic Age-Related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL GANGLION-CELLS; PROSTHESIS; THRESHOLDS; PREVALENCE; PROJECTION;
   DESIGN; TRIAL
AB Purpose: Loss of photoreceptors in atrophic age-related macular degeneration results in severe visual impairment, although some peripheral vision is retained. To restore central vision without compromising the residual peripheral field, we developed a wireless photovoltaic retinal implant (PRIMA; Pixium Vision, Paris, France) in which pixels convert images projected from video glasses using near-infrared light into electric current to stimulate the nearby inner retinal neurons.
   Design: We carried out a first-in-human clinical trial to test the safety and efficacy of the prosthesis in patients with geographic atrophy (ClinicalTrials.gov identifier, NCT03333954).
   Participants: Five patients with geographic atrophy zone of at least 3 optic disc diameters, no foveal light perception, and best-corrected visual acuity of 20/400 to 20/1000 in the worse-seeing study eye.
   Methods: The 2-mm wide, 30-mm thick chip, containing 378 pixels (each 100 mm in diameter), was implanted subretinally in the area of atrophy (absolute scotoma).
   Main Outcome Measures: Anatomic outcomes were assessed with fundus photography and OCT for up to 12 months of follow-up. Prosthetic vision was assessed by mapping light perception, bar orientation, letter recognition, and Landolt C acuity.
   Results: In all patients, the prosthesis was implanted successfully under the macula, although in 2 patients, it was implanted in unintended locations: within the choroid and off center by 2 mm. All 5 patients could perceive white-yellow prosthetic visual patterns with adjustable brightness in the previous scotomata. The 3 with optimal placement of the implant demonstrated prosthetic acuity of 20/460 to 20/550, and the patient with the off-center implant demonstrated 20/800 acuity. Residual natural acuity did not decrease after implantation in any patient.
   Conclusions: Implantation of the PRIMA did not decrease the residual natural acuity, and it restored visual sensitivity in the former scotoma in each of the 5 patients. In 3 patients with the proper placement of the chip, prosthetic visual acuity was only 10% to 30% less than the level expected from the pixel pitch (20/420). Therefore, the use of optical or electronic magnification in the glasses as well as smaller pixels in future implants may improve visual acuity even further. (C) 2020 by the American Academy of Ophthalmology.
C1 [Palanker, Daniel] Stanford Univ, Dept Ophthalmol, 452 Lomita Mall, Stanford, CA 94305 USA.
   [Palanker, Daniel] Stanford Univ, Hansen Expt Phys Lab, 452 Lomita Mall, Stanford, CA 94305 USA.
   [Le Mer, Yannick] Fdn Adolphe De Rothschild, Dept Ophthalmol, Paris, France.
   [Mohand-Said, Saddek] Quinze Vingts Natl Eye Hosp, Clin Invest Ctr, Paris, France.
   [Muqit, Mahiul] Moorfields Eye Hosp, Vitreoretinal Serv, London, England.
   [Muqit, Mahiul] UCL, Inst Ophthalmol, London, England.
   [Jose, Sahel] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
   [Mohand-Said, Saddek] Sorbonne Univ, CNRS, Inst Vis, INSERM, Paris, France.
C3 Stanford University; Stanford University; CHNO des Quinze-Vingts;
   UDICE-French Research Universities; Sorbonne Universite; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Centre National de la Recherche Scientifique (CNRS);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite
RP Palanker, D (通讯作者)，Stanford Univ, Dept Ophthalmol, 452 Lomita Mall, Stanford, CA 94305 USA.; Palanker, D (通讯作者)，Stanford Univ, Hansen Expt Phys Lab, 452 Lomita Mall, Stanford, CA 94305 USA.
EM palanker@stanford.edu
OI Muqit, Mahiul/0000-0003-1161-3956; Le Mer, Yannick/0000-0002-6925-3941;
   Palanker, Daniel/0000-0002-0480-3025
FU Pixium Vision, Paris, France; Sight Again Project (via Structural R&D
   Projects for Competitiveness and Investment for the Future); National
   Institutes of Health, Bethesda, Maryland [R01-EY027786]; Biomedical
   Research Centre at Moorfields Eye Hospital - National Institute for
   Health Research, United Kingdom; Clinical Investigation Center at the
   Quinze-Vingts National Hospital - Inserm-DHOS, France
FX Supported by Pixium Vision, Paris, France; the Sight Again Project (via
   Structural R&D Projects for Competitiveness and Investment for the
   Future funding managed by Bpifrance); the National Institutes of Health,
   Bethesda, Maryland (grant no.: R01-EY027786 [D.P.]); the Biomedical
   Research Centre at Moorfields Eye Hospital, which is supported in part
   by the National Institute for Health Research, United Kingdom; and the
   Clinical Investigation Center at the Quinze-Vingts National Hospital,
   which is supported in part by the Inserm-DHOS, France.
CR Ahuja AK, 2013, TRANSL VIS SCI TECHN, V2, DOI 10.1167/tvst.2.4.1
   Bach M, 1996, OPTOMETRY VISION SCI, V73, P49, DOI 10.1097/00006324-199601000-00008
   Behrend MR, 2011, IEEE T NEUR SYS REH, V19, P436, DOI 10.1109/TNSRE.2011.2140132
   Boinagrov D, 2016, IEEE T BIOMED CIRC S, V10, P85, DOI 10.1109/TBCAS.2014.2376528
   Castaldi E, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002569
   da Cruz L, 2013, BRIT J OPHTHALMOL, V97, P632, DOI 10.1136/bjophthalmol-2012-301525
   DRASDO N, 1974, BRIT J OPHTHALMOL, V58, P709, DOI 10.1136/bjo.58.8.709
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goetz GA, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/5/056021
   Ho E, 2019, J NEURAL ENG, V16, DOI 10.1088/1741-2552/ab34b3
   Ho E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21447-1
   Ho E, 2018, J NEUROPHYSIOL, V119, P389, DOI 10.1152/jn.00872.2016
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   Jensen RJ, 2006, EXP EYE RES, V83, P367, DOI 10.1016/j.exer.2006.01.012
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   LIEBERMAN HR, 1982, BEHAV RES METH INSTR, V14, P21, DOI 10.3758/BF03202110
   Lorach H, 2016, BIOMED OPT EXPRESS, V7, P13, DOI 10.1364/BOE.7.000013
   Lorach H, 2015, VISION RES, V111, P142, DOI 10.1016/j.visres.2014.09.007
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Loudin JD, 2007, J NEURAL ENG, V4, pS72, DOI 10.1088/1741-2560/4/1/S09
   Luo YHL, 2016, PROG RETIN EYE RES, V50, P89, DOI 10.1016/j.preteyeres.2015.09.003
   Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   Nanduri D, 2012, INVEST OPHTH VIS SCI, V53, P205, DOI 10.1167/iovs.11-8401
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Pearson J, 2015, TRENDS COGN SCI, V19, P278, DOI 10.1016/j.tics.2015.03.004
   Prevot PH, 2020, NAT BIOMED ENG, V4, P172, DOI 10.1038/s41551-019-0484-2
   Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445
   Stingl K, 2015, VISION RES, V111, P149, DOI 10.1016/j.visres.2015.03.001
   Stingl K, 2013, INVEST OPHTH VIS SCI, V54, P7658, DOI 10.1167/iovs.13-12835
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zrenner E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007399
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 36
TC 77
Z9 77
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2020
VL 127
IS 8
BP 1097
EP 1104
DI 10.1016/j.ophtha.2020.02.024
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MM6HW
UT WOS:000550256400021
PM 32249038
OA Green Accepted, hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Klein, ML
   Ferris, FL
   Francis, PJ
   Lindblad, AS
   Chew, EY
   Hamon, SC
   Ott, J
AF Klein, Michael L.
   Ferris, Frederick L., III
   Francis, Peter J.
   Lindblad, Anne S.
   Chew, Emily Y.
   Hamon, Sara C.
   Ott, Jurg
TI Progression of Geographic Atrophy and Genotype in Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; POOLED FINDINGS; GENETIC RISK; VARIANT; HTRA1;
   SUSCEPTIBILITY; LOC387715; POLYMORPHISM; DISEASE; EPIDEMIOLOGY
AB Purpose: We sought to determine whether genotype is associated with rate of growth of geographic atrophy (GA) in eyes with age-related macular degeneration (AMD).
   Design: Prospective analysis of participants in a randomized controlled clinical trial.
   Participants: We included 114 eyes of 114 participants in the Age-Related Eye Disease Study (AREDS).
   Methods: Fundus photographs from AREDS participants with GA from whom a DNA specimen had been obtained and serial photographs had been taken over a minimum of 2 years were evaluated for progression as determined by change in cumulative area of GA. All fundus photographs were scanned, digitized, and centrally graded longitudinally for area of GA. The relationship of GA progression with previously identified genetic variants associated with AMD was assessed.
   Main Outcome Measures: Genotype frequencies and change in cumulative area of GA.
   Results: The mean growth rate of GA for the 114 eyes was 1.79 mm(2)/year (range, 0.17-4.76). No association between growth rate and genotype was present for variants in the CFH, C2, C3, APOE, and TLR3 genes. For the single nucleotide polymorphism rs10490924 in LOC387715/ARMS2, there was a significant association of GA growth rate, both adjusted and unadjusted for initial lesion size, with the homozygous risk genotype as compared with the homozygous nonrisk genotype (unadjusted P = 0.002; Bonferroni-corrected P = 0.014) and for allelic association (Bonferroni-corrected P value = 0.011). Analyses of other measures of GA progression (progression to central GA from extrafoveal GA and development of bilateral GA in those initially with unilateral GA) showed no statistically significant association between progression and the LOC387715/ARMS2/HTRA1 genotype.
   Conclusions: Growth rates of GA calculated from digitized serial fundus photographs showed no association with variants in the CFH, C2, C3, APOE, or TLR3 genes. There was a nominally significant association with the LOC387715/ARMS2/HTRA1 genotype, although this finding was not supported by analyses of secondary measures of GA progression. Replication in other populations is needed to establish the existence of an association.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2010; 117: 1554-1559 (C) 2010 by the American Academy of Ophthalmology.
C1 [Klein, Michael L.; Francis, Peter J.] Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Casey Eye Inst, Portland, OR 97239 USA.
   [Klein, Michael L.; Francis, Peter J.] Devers Eye Inst, Portland, OR USA.
   [Ferris, Frederick L., III; Chew, Emily Y.] NEI, NIH, Dept Hlth & Human Serv, Bethesda, MD USA.
   [Lindblad, Anne S.] EMMES Corp, Rockville, MD USA.
   [Hamon, Sara C.; Ott, Jurg] Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   [Ott, Jurg] Chinese Acad Sci, Beijing Inst Gen, Beijing, Peoples R China.
C3 Oregon Health & Science University; Devers Eye Institute; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Emmes Corporation; Rockefeller University; Chinese Academy of Sciences;
   Beijing Institute of Genomics, CAS
RP Klein, ML (通讯作者)，Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM kleinm@ohsu.edu
RI Mitchell, Paul/P-1498-2014
OI Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [R01-EY12203]; China NSFC [30730057]; Casey Eye Institute;
   Research to Prevent Blindness, New York, New York; Foundation Fighting
   Blindness, Owings Mills, Maryland; NATIONAL EYE INSTITUTE [R01EY012203,
   ZIAEY000489] Funding Source: NIH RePORTER
FX Supported by contracts and grants from the National Eye Institute,
   National Institutes of Health, Bethesda, Maryland, R01-EY12203 (MLK),
   China NSFC grant 30730057 (JO), grants to the Casey Eye Institute,
   Oregon Health & Science University from Research to Prevent Blindness,
   New York, New York (PJF, MLK), the Foundation Fighting Blindness, Owings
   Mills, Maryland (PJF), and the Casey Eye Institute Macular Degeneration
   Fund (MLK and PJF). The authors have no proprietary interest in any
   materials or products discussed herein. No authors have any
   financial/conflicting interests to disclose.
CR Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Assink JJM, 2005, OPHTHALMOLOGY, V112, P482, DOI 10.1016/j.ophtha.2004.10.035
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Luo L, 2008, VISION RES, V48, P494, DOI 10.1016/j.visres.2007.11.013
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 45
TC 53
Z9 58
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2010
VL 117
IS 8
BP 1554
EP U117
DI 10.1016/j.ophtha.2009.12.012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 634QU
UT WOS:000280598900015
PM 20381870
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wang, YF
   Wang, MX
   Zhang, XQ
   Nie, J
   Zhang, M
   Liu, XH
   Ma, L
AF Wang, Yafeng
   Wang, Mingxu
   Zhang, Xiaoqing
   Nie, Jing
   Zhang, Ming
   Liu, Xiaohong
   Ma, Le
TI The Association between LIPC rs493258 Polymorphism and the
   Susceptibility to Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE age-related macular degeneration; LIPC; polymorphism; meta-analysis
ID GENOME-WIDE ASSOCIATION; GENETIC-VARIANTS; OXIDATIVE STRESS;
   PROGRESSION; PRODUCTS; RISK
AB The purpose of this study was to evaluate the association of the hepatic lipase (LIPC) rs493258 polymorphism and susceptibility to age-related macular degeneration (AMD). A systematic search in PubMed, EMBASE, and ISI web of science databases was performed to identify eligible published studies without language restrictions up to April 2016. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) in different stages of AMD were estimated under different genetic models using meta-analytic methods. Seven studies comprising 20,559 cases and 17,200 controls met the inclusion criteria and were included in the meta-analysis. The LIPC rs493258 polymorphism showed a significant association with a lower risk of AMD under the allelic model (OR = 0.87, 95% CI = 0.84-0.90). Significant relationships between the variant and AMD were also observed in other genetic models (OR ranging from 0.71 to 0.86, all p < 0.05). Stratified analysis based on ethnicity found that LIPC rs493258 polymorphism had a significant association with the decreased risk of the disease in the Caucasian population, but not in the Asian population. For late AMD, significant associations of the rs493258 polymorphism with a lower risk of this disease were also observed in the allelic genetic model (OR = 0.87, 95% CI = 0.83-0.90). This meta-analysis demonstrates that the T allele in the LIPC rs493258 polymorphism was significantly associated with the risk of any and late AMD. The associations of the locus with early and late AMD risk in various populations need further exploration.
C1 [Wang, Yafeng; Liu, Xiaohong] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian 710061, Peoples R China.
   [Wang, Yafeng] Xi An Jiao Tong Univ, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Coll Stomatol, Xian 710004, Peoples R China.
   [Wang, Yafeng; Wang, Mingxu; Ma, Le] Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Peoples R China.
   [Zhang, Xiaoqing] Xian Med Univ, Dept Publ Hlth, Xian 710021, Peoples R China.
   [Nie, Jing] Xi An Jiao Tong Univ, Sch Humanities, Xian 710049, Peoples R China.
   [Zhang, Ming] Xian Honghui Hosp, Dept Internal Med, Xian 710054, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University; Xi'an Medical University; Xi'an Jiaotong University
RP Liu, XH (通讯作者)，Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian 710061, Peoples R China.; Ma, L (通讯作者)，Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Peoples R China.; Zhang, M (通讯作者)，Xian Honghui Hosp, Dept Internal Med, Xian 710054, Peoples R China.
EM wyf.90.25.wyf@stu.xjtu.edu.cn; wangmx601@mail.xjtu.edu.cn;
   dyzhou@nwpu.edu.cn; boraisrighthere@sina.com; xgcgfd@126.com;
   liuxiaoh@mail.xjtu.edu.cn; male@mail.xjtu.edu.cn
RI wang, yafeng/J-4829-2017
OI ma, le/0000-0001-7592-9779
FU National Natural Science Foundation of China [NSFC-81202198,
   NSFC-81473059]; Natural Science Foundation of Shaanxi Province of China
   [2013JQ4008]; New-star Plan of Science and Technology of Shaanxi
   Province [2015LJXX-07]; China Postdoctoral Science Special Foundation
   [2015T81036]; Fundamental Research Funds for the Central Universities
   [qngz2016004]; China Postdoctoral Science Foundation [2014M560790]
FX This study was partially supported by grants from the National Natural
   Science Foundation of China (NSFC-81202198, NSFC-81473059), the Natural
   Science Foundation of Shaanxi Province of China (2013JQ4008), the
   New-star Plan of Science and Technology of Shaanxi Province
   (2015LJXX-07), the China Postdoctoral Science Special Foundation
   (2015T81036), the Fundamental Research Funds for the Central
   Universities (qngz2016004), and the China Postdoctoral Science
   Foundation Funded Project (2014M560790).
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bindu GH, 2011, CHOLESTEROL, DOI 10.1155/2011/274629
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Geirsdottir A, 2014, ACTA OPHTHALMOL, V92, P27, DOI 10.1111/aos.12294
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Koskela A, 2014, MOL VIS, V20, P760
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Millett GA, 2008, JAMA-J AM MED ASSOC, V300, P1674, DOI 10.1001/jama.300.14.1674
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Peter I., 2011, AM J OPHTHALMOL
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Song FJ, 1998, BRIT MED J, V316, P471
   Venza I, 2012, AGING CLIN EXP RES, V24, P530, DOI 10.3275/8477
   Wang Y. F., 2015, SCI REP
   Wells GA., NEWCASTLE OTTAWA SCA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 28
TC 3
Z9 3
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2016
VL 13
IS 10
AR 1022
DI 10.3390/ijerph13101022
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA EE4KF
UT WOS:000389570100089
PM 27763569
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Haas, P
   Steindl, K
   Schmid-Kubista, KE
   Aggermann, T
   Krugluger, W
   Hageman, GS
   Binder, S
AF Haas, P.
   Steindl, K.
   Schmid-Kubista, K. E.
   Aggermann, T.
   Krugluger, W.
   Hageman, G. S.
   Binder, S.
TI Complement factor H gene polymorphisms and Chlamydia pneumoniae
   infection in age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; complement factor H; polymorphism;
   chlamydia pneumoniae; infection; aetiology
ID NEOVASCULAR MEMBRANES; ASSOCIATION; VARIANT; RISK; SUSCEPTIBILITY;
   PATHOGENESIS; Y402H; PROGRESSION; ETIOLOGY; EXPOSURE
AB Purpose To investigate the association of the complement factor H gene (CFH) Y402H polymorphism and age-related macular degeneration (AMD) in the Austrian population (Caucasoid descent), and to determine whether there is an association between exposure to Chlamydia pneumoniae-responsible for up to 20% of community-acquired pneumoniae-and the AMD-associated CFH risk polymorphism.
   Methods Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism analysis in 75 unrelated AMD patients and compared with 75 healthy, age-matched control subjects. C. pneumoniae serum IgG was tested by ELISA (R&D) in both groups. The association between the CFH Y402H genetic polymorphism and the disease was examined by v 2-test and logistic regression.
   Results CFH Y402H genotype frequencies differed significantly between AMD patients and healthy controls (1277 TT, 22.7%; 1277 TC, 53.3%; and 1277 CC, 22.7% in the AMD group; 1277 TT, 48.0%; 1277 TC, 38.7%; and 1277 CC, 13.3% in the control group) showing a P-value <0.005 (OR: 2.920/3.811). No association was found between a positive C. pneumoniae titre and AMD (P = 0.192), nor was any association found between C. pneumoniae and the CFH Y402H polymorphism.
   Conclusions Our data confirm that the CFH Y402H polymorphism is a risk factor for AMD in the Austrian population with a higher frequency of the Y402 polymorphism in AMD patients. No association between preceding C. pneumoniae infection and diagnosed AMD was found. Eye (2009) 23, 2228-2232; doi:10.1038/eye.2008.422; published online 23 January 2009
C1 [Haas, P.; Steindl, K.; Binder, S.] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Schmid-Kubista, K. E.; Aggermann, T.; Binder, S.] Rudolf Fdn Clin, Dept Ophthalmol, Vienna, Austria.
   [Krugluger, W.] Rudolf Fdn Clin, Dept Clin Chem, Vienna, Austria.
   [Hageman, G. S.] Univ Iowa, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Haas, P (通讯作者)，Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM paulina.haas@wienkav.at
FU Burgermeisterfond, Vienna, Austria; NATIONAL EYE INSTITUTE [R24EY017404]
   Funding Source: NIH RePORTER
FX This study was supported by the Burgermeisterfond, Vienna, Austria
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kessler W, 2006, ACTA OPHTHALMOL SCAN, V84, P333, DOI 10.1111/j.1600-0420.2005.00591.x
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   SPAIDE RF, 2003, RETINA, P595
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Verkooyen RP, 1998, J CLIN MICROBIOL, V36, P2301, DOI 10.1128/JCM.36.8.2301-2307.1998
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 32
TC 13
Z9 14
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2009
VL 23
IS 12
BP 2228
EP 2232
DI 10.1038/eye.2008.422
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530JK
UT WOS:000272585500013
PM 19169230
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Xu, XY
   Liu, X
   Wang, XL
   Clark, ME
   McGwin, G
   Owsley, C
   Curcio, CA
   Zhang, YH
AF Xu, Xiaoyu
   Liu, Xing
   Wang, Xiaolin
   Clark, Mark E.
   McGwin, Gerald, Jr.
   Owsley, Cynthia
   Curcio, Christine A.
   Zhang, Yuhua
TI Retinal Pigment Epithelium Degeneration Associated With Subretinal
   Drusenoid Deposits in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER OPHTHALMOSCOPY; RETICULAR
   PSEUDODRUSEN; GEOGRAPHIC ATROPHY; ADAPTIVE OPTICS; CHOROIDAL THICKNESS;
   CLINICAL-FEATURES; FUNDUS; EYES; AUTOFLUORESCENCE
AB PURPOSE: To test whether increased light transmission (hypertransmission) through subretinal drusenoid deposits (SDD) into the choroid in age-related macular degeneration (AMD) represented retinal pigment epithelium (RPE) degeneration.
   DESIGN: Cross-sectional study.
   METHODS: Nineteen eyes of 12 patients with early- to intermediate-stage AMD and 18 eyes of 12 normal subjects were evaluated with color fundus photography, optical coherence tomography (OCT), and high-resolution adaptive optics scanning laser ophthalmoscopy (AOSLO) at baseline and 24 months later. SDD were classified using an OCT-based 3-stage grading system. Hypertransmission beneath SDD into the choroid was examined in OCT. SDD microstructure was assessed with AOSLO. To characterize the hypertransmission-associated chorioretinal degeneration, choroidal thickness and photoreceptor length were measured in OCT at 1 mm and 2 mm superior, inferior, temporal, and nasal to the foveal center.
   RESULTS: OCT disclosed hypertransmission beneath stage 3 SDD in 8 eyes. These lesions showed a distinctive regressing structure in AOSLO, compared with stage 3 lesions without hypertransmission. The phenomenon persisted at follow-up, and new hypertransmission developed as SDD advanced. In eyes with hypertransmission, choroids were thinner than those of normal eyes at all sites (by 44%-56%, P <= .0028) and those of eyes with SDD but without hypertransmission at superior and temporal sites (by 31%-46%, P <= .039). Photoreceptors were significantly shorter than those in normal eyes (by 6%-26%, P <= .0379).
   CONCLUSIONS: Hypertransmission into the choroid, accompanied with SDD regression and thinning of choroid and photoreceptor layers, indicates RPE degeneration associated with advanced stages in the SDD life cycle. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Xu, Xiaoyu; Liu, Xing] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Wang, Xiaolin; Clark, Mark E.; Owsley, Cynthia; Curcio, Christine A.; Zhang, Yuhua] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA.
C3 Sun Yat Sen University; University of Alabama System; University of
   Alabama Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Zhang, YH (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Volker Hall 390C,1670 Univ Blvd, Birmingham, AL 35294 USA.
EM zhanghua@uab.edu
OI Owsley, Cynthia/0000-0003-3424-011X
FU NIH [EY024378, AG04212, EY06109]; SCIENCE AND TECHnology Planning
   Project of Guangdong Province, China [2012B050600032]; Science and
   Technology Program of Guangzhou, China [2013J4500019]; International
   Program for PhD Candidates, Sun Yat-Sen University, China; Fundamental
   Research Funds of the State key Laboratory of Ophthalmology, China
   [2015KF03]; NATIONAL EYE INSTITUTE [R01EY006109, R01EY024378,
   P30EY003039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
FX THIS PROJECT WAS SUPPORTED IN PART BY NIH EY024378, NIH AG04212, NIH
   EY06109, SCIENCE AND TECHnology Planning Project of Guangdong Province,
   China, 2012B050600032; Science and Technology Program of Guangzhou,
   China, 2013J4500019, and International Program for PhD Candidates, Sun
   Yat-Sen University, China, Fundamental Research Funds of the State key
   Laboratory of Ophthalmology, China, 2015KF03, and institutional support
   from Research to Prevent Blindness, EyeSight Foundation of Alabama, and
   NIH P30 EY003039. The following authors have no financial disclosures:
   Xiaoyu Xu, Xing Liu, Xiaolin Wang, Mark E. Clark, Gerald McGwin Jr,
   Cynthia Owsley, Christine A. Curcio, and Yuhua Zhang. All authors attest
   that they meet the current ICMJE criteria for authorship.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitamura Y, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518170
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Mustafi D, 2011, FASEB J, V25, P3157, DOI 10.1096/fj.11-186767
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Vogel CR, 2006, OPT EXPRESS, V14, P487, DOI 10.1364/OPEX.14.000487
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2012, KLIN MONATSBL AUGENH, V229, P399, DOI 10.1055/s-0031-1299404
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 53
TC 28
Z9 28
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2017
VL 175
BP 87
EP 98
DI 10.1016/j.ajo.2016.11.021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EN4IK
UT WOS:000395971000013
PM 27986424
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Falsini, B
   Piccardi, M
   Minnella, A
   Savastano, C
   Capoluongo, E
   Fadda, A
   Balestrazzi, E
   Maccarone, R
   Bisti, S
AF Falsini, Benedetto
   Piccardi, Marco
   Minnella, Angelo
   Savastano, Cristina
   Capoluongo, Ettore
   Fadda, Antonello
   Balestrazzi, Emilio
   Maccarone, Rita
   Bisti, Silvia
TI Influence of Saffron Supplementation on Retinal Flicker Sensitivity in
   Early Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OXIDATIVE DAMAGE; MACULOPATHY; ANTIOXIDANTS; ELECTRORETINOGRAM;
   CAROTENOIDS; ADAPTATION; COMPONENT; SYSTEM; LUTEIN; LIGHT
AB PURPOSE. To evaluate the functional effect of short-term supplementation of saffron, a spice containing the antioxidant carotenoids crocin and crocetin, in early age-related macular degeneration (AMD).
   METHODS. Twenty-five patients with AMD were randomly assigned to oral saffron 20 mg/d or placebo supplementation over a 3-month period and then reverted to placebo or saffron for a further 3 months. Focal electroretinograms (fERGs) and clinical findings were recorded at baseline and after 3 months of saffron or placebo supplementation. fERGs were recorded in response to a sinusoidally modulated (41 Hz), uniform field presented to the macular region (18 degrees) at different modulations between 16.5% and 93.5%. Main outcome measures were fERG amplitude (in microvolts), phase (in degrees), and modulation thresholds.
   RESULTS. After saffron, patients' fERGs were increased in amplitude, compared with either baseline or values found after placebo supplementation (mean change after saffron, 0.25 log mu V; mean change after placebo, -0.003 log mu V; P < 0.01). fERG thresholds were decreased after saffron supplementation but not placebo, compared with baseline (mean change after saffron, -0.26 log units; mean change after placebo, 0.0003 log units).
   CONCLUSIONS. The results indicate that short-term saffron supplementation improves retinal flicker sensitivity in early AMD. Although the results must be further replicated and the clinical significance is yet to be evaluated, they provide important clues that nutritional carotenoids may affect AMD in novel and unexpected ways, possibly beyond their antioxidant properties. (ClinicalTrials.gov number, NCT00951288.) (Invest Ophthalmol Vis Sci. 2010;51:6118-6124) DOI:10.1167/iovs.094995
C1 [Falsini, Benedetto; Piccardi, Marco; Minnella, Angelo; Savastano, Cristina; Balestrazzi, Emilio] Univ Cattolica S Cuore, Dipartimento Sci Oftalmol & Otorinolaringol, I-00168 Rome, Italy.
   [Capoluongo, Ettore] Univ Cattolica S Cuore, Dipartmento Biochim & Biol Mol, I-00168 Rome, Italy.
   [Fadda, Antonello] Ist Super Sanita, Technol & Hlth Dept, I-00161 Rome, Italy.
   [Maccarone, Rita; Bisti, Silvia] Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy.
   [Bisti, Silvia] ARC Ctr Excellence Visual Sci, Canberra, ACT, Australia.
   [Bisti, Silvia] INBB, Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of
   L'Aquila
RP Falsini, B (通讯作者)，Univ Cattolica S Cuore, Dipartimento Sci Oftalmol & Otorinolaringol, Lgo F Vito 1, I-00168 Rome, Italy.
EM md0571@mclink.it
RI Falsini, Benedetto/V-1070-2019; Savastano, Maria Cristina/I-5355-2015;
   Piccardi, Marco/AAA-7849-2019; minnella, angelo maria/AAQ-6250-2020;
   Falsini, Benedetto/AAC-5907-2022; Fadda, Antonello/J-1560-2012
OI Falsini, Benedetto/0000-0002-1694-1062; Savastano, Maria
   Cristina/0000-0003-1397-4333; minnella, angelo
   maria/0000-0001-5896-5313; Fadda, Antonello/0000-0001-7004-5245;
   PICCARDI, Marco/0000-0002-9836-7534; CAPOLUONGO, Ettore
   Domenico/0000-0003-4402-8403; MACCARONE, Rita/0000-0003-0648-3771;
   Falsini, Benedetto/0000-0002-3569-4968
FU Ministero Universita e Ricerca Scientifica [ex 60%, PRIN06]
FX Supported in part by Ministero Universita e Ricerca Scientifica Grants
   ex 60% (BF) and PRIN06 (RM, SB).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   FIORENTINI A, 1981, INVEST OPHTH VIS SCI, V21, P490
   FISH GE, 1989, OPHTHALMOLOGY, V96, P109
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hammond BR, 1996, EXP EYE RES, V62, P713
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, pU68
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, pU403
   Kanakis CD, 2007, CELL BIOCHEM BIOPHYS, V49, P29, DOI 10.1007/s12013-007-0037-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Kondo M, 2001, INVEST OPHTH VIS SCI, V42, P305
   Laabich A, 2006, INVEST OPHTH VIS SCI, V47, P3156, DOI 10.1167/iovs.05-1621
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SCHALCH W, 1992, FREE RADICALS AGING, P280
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   SEIPLE W, 1992, VISION RES, V32, P2043, DOI 10.1016/0042-6989(92)90065-Q
   SEIPLE WH, 1993, INVEST OPHTH VIS SCI, V34, P2638
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
NR 40
TC 93
Z9 97
U1 0
U2 19
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2010
VL 51
IS 12
BP 6118
EP 6124
DI 10.1167/iovs.09-4995
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 688GJ
UT WOS:000284837500005
PM 20688744
DA 2022-11-30
ER

PT J
AU Kiser, AK
   Deschler, EK
   Dagnelie, G
AF Kiser, Ava K.
   Deschler, Emily K.
   Dagnelie, Gislin
TI Visual function and performance with blue-light blocking filters in
   age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; intraocular lens; scotopic
ID ABSORBING INTRAOCULAR-LENS; ADVANCED EYE DISEASE; CONTRAST SENSITIVITY;
   COLOR-VISION; DISCRIMINATION; VULNERABILITY; RELIABILITY; CONSISTENCY;
   MACULOPATHY; VARIABLES
AB Purpose: Some dispute has occurred over the use of blue-light-attenuating intraocular lenses in age-related macular degeneration (AMD), as they may reduce scotopic vision. This study aimed to determine if a blue blocking filter would affect performance during eye-hand coordination and mobility tasks in scotopic illumination, psychophysically measured scotopic sensitivity or colour discrimination in AMD patients.
   Methods: Scotopic measures performed with and without a blue-attenuating filter included a mobility obstacle course, manipulation of cylindrical blocks and a psychophysical dark-adapted full-field flash test. A navy and blue sock colour sorting task evaluated photopic colour discrimination. Subjects were 22 bilateral pseudophakes with early AMD and visual acuity > 6/24.
   Results: On average with the filter, there was a 13% increase in time during the block test. The differences in time and number of bumps with versus without the filter were not significant for the mobility course. Performance with and without the filter was well correlated for the blocks (r = 0.70), flash test (r = 0.83) and mobility (r = 0.66), and the regression slopes were not significantly different from unity. 77% of subjects misidentified at least one navy sock as black with the filter compared with 9% without, with a significant increase in such misidentifications with the filter.
   Conclusions: The difference in scotopic visual function or performance with versus without a blue-blocking filter most likely does not produce a clinically significant effect or risk; however, detection of navy colour may be impaired.
C1 [Kiser, Ava K.; Deschler, Emily K.; Dagnelie, Gislin] Johns Hopkins Univ, Wilmer Eye Inst, Lions Vis Ctr, Baltimore, MD 21218 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Kiser, AK (通讯作者)，550 N Broadway,6th Floor, Baltimore, MD 21205 USA.
EM abittne1@jhmi.edu
RI Bittner, Ava/AAK-8778-2021
OI Bittner, Ava/0000-0002-9498-2230
CR Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P733
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   ELFANT IL, 1977, AM J OCCUP THER, V31, P23
   Espindle D, 2005, J CATARACT REFR SURG, V31, P1952, DOI 10.1016/j.jcrs.2005.03.060
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Greenstein VC, 2007, J CATARACT REFR SURG, V33, P667, DOI 10.1016/j.jcrs.2006.12.012
   Guion R.M., 1965, PERSONNEL TESTING
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Kiser AK, 2006, INVEST OPHTH VIS SCI, V47, P444, DOI 10.1167/iovs.04-1146
   Kiser AK, 2005, OPTOMETRY VISION SCI, V82, P946, DOI 10.1097/01.opx.0000187863.12609.7b
   Kuyk T, 1998, OPTOMETRY VISION SCI, V75, P174, DOI 10.1097/00006324-199803000-00022
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Massof RW, 2005, ARCH PHYS MED REHAB, V86, P954, DOI 10.1016/j.apmr.2004.09.017
   MCMURDO MET, 1991, GERONTOLOGY, V37, P221
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P1736, DOI 10.1016/j.jcrs.2005.02.039
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tiffin J., 1968, PURDUE PEGBOARD EXAM
   Vuori ML, 2006, ACTA OPHTHALMOL SCAN, V84, P92, DOI 10.1111/j.1600-0420.2005.00579.x
   Werner JS, 2005, BRIT J OPHTHALMOL, V89, P1518, DOI 10.1136/bjo.2005.073734
NR 22
TC 18
Z9 20
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2008
VL 36
IS 6
BP 514
EP 520
DI 10.1111/j.1442-9071.2008.01824.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 359SS
UT WOS:000260009000005
PM 18954312
DA 2022-11-30
ER

PT J
AU Ma, YY
   Huang, JN
   Zhu, BJ
   Sun, Q
   Miao, YY
   Zou, HD
AF Ma, Yingyan
   Huang, Jiannan
   Zhu, Bijun
   Sun, Qian
   Miao, Yuyu
   Zou, Haidong
TI Cost-Utility Analyses of Cataract Surgery in Advanced Age-Related
   Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE advanced age-related macular degeneration; cataract surgery;
   cost-utility analysis; quality-adjusted life years; time trade-off
ID QUALITY-OF-LIFE; CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY;
   MACULOPATHY; EXTRACTION; VALUES; IMPACT
AB Purpose. To explore the cost-utility of cataract surgery in patients with advanced age-related macular degeneration (AMD).
   Methods. Patients who were diagnosed as having and treated for age-related cataract and with a history of advanced AMD at the Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, were included in the study. All of the participants underwent successful phacoemulsification with foldable posterior chamber intraocular lens implantation under retrobulbar anesthesia. Best-corrected visual acuity (BCVA) and utility value elicited by time trade-off method from patients at 3-month postoperative time were compared with those before surgery. Quality-adjusted life years (QALYs) gained in a lifetime were calculated at a 3% annual discounted rate. Costs per QALY gained were calculated using the bootstrap method, and probabilities of being cost-effective were presented using a cost-effectiveness acceptability curve. Sensitivity analyses were performed to test the robustness of the results.
   Results. Mean logarithm of the minimum angle of resolution BCVA in the operated eye increased from 1.37 +/- 0.5 (Snellen, 20/469) to 0.98 +/- 0.25 (Snellen, 20/191) (p < 0.001); BCVA in the weighted average from both eyes (= 75% better eye + 25% worse eye) was changed from 1.13 +/- 0.22 (Snellen, 20/270) to 0.96 +/- 0.17 (Snellen, 20/182) (p < 0.001). Utility values from both patients and doctors increased significantly after surgery (p < 0.001 and p = 0.007). Patients gained 1.17 QALYs by cataract surgery in their lifetime. The cost per QALY was 8835 Chinese yuan (CNY) (1400 U.S. dollars [USD]). It is cost-effective at the threshold of 115,062 CNY (18,235 USD) per QALY in China recommended by the World Health Organization. The cost per QALY varied from 7045 CNY (1116 USD) to 94,178 CNY (14,925 USD) in sensitivity analyses.
   Conclusions. Visual acuity and quality of life assessed by utility value improved significantly after surgery. Cataract surgery was a cost-effective intervention for patients with coexistent AMD.
C1 [Ma, Yingyan; Huang, Jiannan; Zou, Haidong] Shanghai Eye Hosp, Shanghai Eye Dis Prevent & Treatment Ctr, 380 KangDing Rd, Shanghai 200040, Peoples R China.
   [Ma, Yingyan; Huang, Jiannan; Zhu, Bijun; Sun, Qian; Miao, Yuyu; Zou, Haidong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zou, HD (通讯作者)，Shanghai Eye Hosp, Shanghai Eye Dis Prevent & Treatment Ctr, 380 KangDing Rd, Shanghai 200040, Peoples R China.
EM zouhaidong@263.net
OI Zou, Haidong/0000-0002-6831-7560
FU Shanghai Shenkang Hospital Development Center [SHDC12012104]; Shanghai
   Health Bureau [20114007]; Hong Kong K.C. Wong Education foundation;
   Cutting-Edge Technology Combined PR Project of the Shanghai Shen Kang
   Hospital Development Centre [SHDC12012104]
FX Supported by grants from the Shanghai Shenkang Hospital Development
   Center (no. SHDC12012104), the Shanghai Health Bureau (no. 20114007),
   the Hong Kong K.C. Wong Education foundation, and the Cutting-Edge
   Technology Combined PR Project of the Shanghai Shen Kang Hospital
   Development Centre (no. SHDC12012104).
CR Agarwal A, 2011, CURR OPIN OPHTHALMOL, V22, P15, DOI 10.1097/ICU.0b013e3283414f64
   [Anonymous], PHACOEMULSIFICATION
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Briggs AH, 1999, HEALTH TECHNOL ASSES, V3, DOI [10.3310/hta3020, DOI 10.3310/HTA3020]
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Busbee BG, 2003, OPHTHALMOLOGY, V110, P2310, DOI 10.1016/S0161-6420(03)00796-6
   Casparis H, 2012, COCHRANE DB SYST REV, V6
   Cataract in the Adult Eye PPP-2011, 2011, CAT AD EYE PPP 2011
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   de Jong PTVM, 2013, OPHTHALMOLOGY AGEING, P33
   Drummond MF, 2005, METHODS EC EVALUATIO
   El Mallah MK, 2001, OPTOMETRY VISION SCI, V78, P683, DOI 10.1097/00006324-200109000-00014
   Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Grixti A, 2014, ISRN OPHTHALMOL, V2014
   Gupta V, 2005, BRIT J OPHTHALMOL, V89, P1241, DOI 10.1136/bjo.2005.068858
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Lansingh VC, 2007, OPHTHALMOLOGY, V114, P1670, DOI 10.1016/j.ophtha.2006.12.013
   Lansingh VC, 2009, ARCH OPHTHALMOL-CHIC, V127, P1183, DOI 10.1001/archophthalmol.2009.113
   Lee TG, 2014, GRAEF ARCH CLIN EXP, V252, P1573, DOI 10.1007/s00417-014-2624-4
   Lundstrom M, 2005, BRIT J OPHTHALMOL, V89, P1017, DOI 10.1136/bjo.2005.065961
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   National Bureau of Statistics of China, 2012, GROSS DOM PROD
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Salomon JA, 2012, LANCET, V380, P2129, DOI 10.1016/S0140-6736(12)61680-8
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Stein Joshua D, 2004, Curr Opin Ophthalmol, V15, P238, DOI 10.1097/01.icu.0000120712.35941.ad
   *WHO, 2015, CHANG DEF BLINDN
   WHO Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E
   Zou H, 2005, QUAL LIFE RES, V14, P1633, DOI 10.1007/s11136-004-0026-5
   Zou H-d, 2005, ZHONG GUO SHI YONG Y, V23, P117
NR 39
TC 7
Z9 8
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD FEB
PY 2016
VL 93
IS 2
BP 165
EP 172
DI 10.1097/OPX.0000000000000772
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP2AE
UT WOS:000378289700008
PM 26605501
OA Green Published
DA 2022-11-30
ER

PT J
AU Daniel, E
   Shaffer, J
   Ying, GS
   Grunwald, JE
   Martin, DF
   Jaffe, GJ
   Maguire, MG
AF Daniel, Ebenezer
   Shaffer, James
   Ying, Gui-shuang
   Grunwald, Juan E.
   Martin, Daniel F.
   Jaffe, Glenn J.
   Maguire, Maureen G.
CA Comparison Age-Related Macular
TI Outcomes in Eyes with Retinal Angiomatous Proliferation in the
   Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL
   RANIBIZUMAB; PHOTODYNAMIC THERAPY; GEOGRAPHIC ATROPHY; RISK-FACTORS;
   SUBTYPES; NEOVASCULARIZATION; REPRODUCIBILITY; TRIAMCINOLONE
AB Purpose: To compare baseline characteristics, visual acuity (VA), and morphologic outcomes between eyes with retinal angiomatous proliferation (RAP) and all other eyes among patients with neovascular age-related macular degeneration (NVAMD) treated with antievascular endothelial growth factor (VEGF) drugs.
   Design: Prospective cohort study within the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
   Participants: Patients with NVAMD.
   Methods: Reading center staff evaluated digital color fundus photographs, fluorescein angiography (FA) images, and optical coherence tomography (OCT) scans of eyes with NVAMD treated with either ranibizumab or bevacizumab over a 2-year period. Retinal angiomatous proliferation was identified by the intense intra-retinal leakage of fluorescein in combination with other associated features.
   Main Outcome Measures: Visual acuity; fluorescein leakage; scar; geographic atrophy (GA) on FA; retinal thickness, fluid, and subretinal hyperreflective material (SHRM) on OCT; and the number of intravitreal anti-VEGF injections at 1 and 2 years.
   Results: Retinal angiomatous proliferation was present in 126 of 1183 (10.7%) study eyes at baseline. Mean VA improvement from baseline was greater (10.6 vs. 6.9 letters; P = 0.01) at 1 year, but similar at 2 years (7.8 vs. 6.2 letters; P = 0.34). At 1 year, eyes with RAP were more likely to have no fluid (46% vs. 26%; P < 0.001) on OCT, no leakage on FA (61% vs. 50%; P = 0.03), and greater reduction in foveal thickness (-240 mu m vs. -161 mu m; P < 0.001). They were more likely to demonstrate GA (24% vs. 15%; P = 0.01) and less likely to have scarring (17% vs. 36%; P < 0.001) or SHRM (36% vs. 48%; P = 0.01). These results were similar at 2 years. The mean change in lesion size at 1 year differed (-0.27 DA vs. 0.27 DA; P = 0.02), but was similar at 2 years (0.49 DA vs. 0.79 DA; P = 0.26). Among eyes treated PRN, eyes with RAP received a lower mean number of injections in year 1 (6.1 vs. 7.4; P = 0.003) and year 2 (5.4 vs. 6.6; P = 0.025).
   Conclusions: At both 1 and 2 years after initiation of anti-VEGF treatment in CATT, eyes with RAP were less likely to have fluid, FA leakage, scar, and SHRM and more likely to have GA than eyes without RAP. Mean improvement in VA was similar at 2 years. (C) 2016 by the American Academy of Ophthalmology.
C1 [Daniel, Ebenezer; Shaffer, James; Ying, Gui-shuang; Grunwald, Juan E.; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
C3 University of Pennsylvania; Cleveland Clinic Foundation; Duke University
RP Daniel, E (通讯作者)，Univ Penn, Fundus Photograph Reading Ctr, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM ebdaniel@mail.med.upenn.edu
OI Folk, James/0000-0002-6271-2906; Losordo, Douglas/0000-0002-6857-7506;
   Ciulla, Thomas/0000-0001-5557-6777; Daniel,
   Ebenezer/0000-0002-2027-2316; Vavvas, Demetrios/0000-0002-8622-6478
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828,
   R21EY023689]; NATIONAL EYE INSTITUTE [U10EY017828, R21EY023689,
   U10EY017826, U10EY017823] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (cooperative agreement nos.: U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, and R21EY023689).
CR Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Gharbiya M, 2009, RETINA-J RET VIT DIS, V29, P740, DOI 10.1097/IAE.0b013e3181a0be1d
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Inoue M, 2014, BRIT J OPHTHALMOL, V98, P956, DOI 10.1136/bjophthalmol-2013-304251
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kim JH, 2015, RETINA
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Martin D.F., 2011, NEW ENGL J MED, V364, P1897, DOI DOI 10.1056/NEJM0A1102673
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Parravano M, 2012, EUR J OPHTHALMOL, V22, P598, DOI 10.5301/ejo.5000087
   Reche-Frutos J, 2007, EUR J OPHTHALMOL, V17, P979, DOI 10.1177/112067210701700619
   Rouvas AA, 2012, RETINA-J RET VIT DIS, V32, P1181, DOI 10.1097/IAE.0b013e318235d8ce
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Shin JY, 2014, RETINA-J RET VIT DIS, V34, P2359, DOI 10.1097/IAE.0000000000000225
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 31
TC 67
Z9 68
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2016
VL 123
IS 3
BP 609
EP 616
DI 10.1016/j.ophtha.2015.10.034
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DE4UQ
UT WOS:000370626300036
PM 26681392
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Fang, AM
   Lee, AY
   Kulkarni, M
   Osborn, MP
   Brantley, MA
AF Fang, Amy M.
   Lee, Aaron Y.
   Kulkarni, Mukti
   Osborn, Melissa P.
   Brantley, Milam A., Jr.
TI Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related
   macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; RISK; ASSOCIATION;
   SUSCEPTIBILITY; VARIANT; C3; ANGIOGENESIS; INCREASES; KDR
AB Purpose: Genetic factors influence an individual's risk for developing neovascular age-related macular degeneration (AMD), a leading cause of irreversible blindness. Previous studies on the potential genetic link between AMD and vascular endothelial growth factor (VEGF), a key regulator of angiogenesis and vascular permeability, have yielded conflicting results. In the present case-control association study, we aimed to determine whether VEGF or its main receptor tyrosine kinase VEGFR-2 is genetically associated with neovascular AMD.
   Methods: A total of 515 Caucasian patients with neovascular AMD and 253 ethically-matched controls were genotyped for polymorphisms in the VEGFA and VEGFR-2 genes. A tagging single nucleotide polymorphism (tSNP) approach was employed to cover each gene plus two kilobases on each side, spanning the promoter and 3' untranslated regions. SNPs with a minimum allele frequency of 10% were covered by seven tSNPs in VEGFA and 20 tSNPs in VEGFR-2. Two VEGFA SNPs previously linked with AMD, rs1413711 and rs3025039, were also analyzed.
   Results: The 29 VEGFA and VEGFR-2 SNPs analyzed in our cohort demonstrated no significant association with neovascular AMD. A single rare haplotype in the VEGFR-2 gene was associated with the presence of neovascular AMD (p=0.034).
   Conclusions: This study is the first to investigate the association of VEGFR-2 polymorphisms with AMD and evaluates VEGFA genetic variants in the largest neovascular AMD cohort to date. Despite the angiogenic and permeability-enhancing effects of VEGF/VEGFR-2 signaling, we found minimal evidence of a significant link between polymorphisms in the VEGFA and VEGFR-2 genes and neovascular AMD.
C1 [Fang, Amy M.; Lee, Aaron Y.; Kulkarni, Mukti; Osborn, Melissa P.; Brantley, Milam A., Jr.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Brantley, Milam A., Jr.] Barnes Retina Inst, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Brantley, MA (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Campus Box 8096,660 S Euclid Ave, St Louis, MO 63110 USA.
EM Brantley@vision.wustl.edu
RI Lee, Aaron/AAT-2839-2020
OI Lee, Aaron/0000-0002-7452-1648
FU American Geriatrics Society; Carl M. & Mildred A. Reeves Foundation; NEI
   Core [5 P30 EY02687]; Research to Prevent Blindness to the Washington
   University School of Medicine Department of Ophthalmology and Visual
   Sciences; NATIONAL EYE INSTITUTE [P30EY002687] Funding Source: NIH
   RePORTER
FX The authors thank the Human Genetics Division Genotyping Core at the
   Washington University School of Medicine for assisting with genotyping
   and the physicians of the Barnes Retina Institute for generously
   contributing their time and patients to this study. This work was
   supported by the Jahnigen Career Development Award from the American
   Geriatrics Society (M. A. B.), the Carl M. & Mildred A. Reeves
   Foundation (M. A. B.), NEI Core Grant 5 P30 EY02687, and a grant from
   Research to Prevent Blindness to the Washington University School of
   Medicine Department of Ophthalmology and Visual Sciences.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Pau ECD, 2009, CANCER-AM CANCER SOC, V115, P1701, DOI 10.1002/cncr.24193
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Forsti A, 2007, BREAST CANCER RES TR, V101, P83, DOI 10.1007/s10549-006-9265-1
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P167
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mckay GJ, 2009, OPHTHALMOLOGY, V116, P1227, DOI 10.1016/j.ophtha.2009.01.008
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   PABST S, 2009, CHEST
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosen LS, 2005, ONCOLOGIST, V10, P382, DOI 10.1634/theoncologist.10-6-382
   Schneider BP, 2008, BREAST CANCER RES TR, V111, P157, DOI 10.1007/s10549-007-9755-9
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Veikkola T, 2000, CANCER RES, V60, P203
   Wang Y, 2007, J AM COLL CARDIOL, V50, P760, DOI 10.1016/j.jacc.2007.04.074
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   ZENG H, 2000, J BIOL CHEM, V159, P993
NR 34
TC 48
Z9 51
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 10
PY 2009
VL 15
IS 283-88
BP 2710
EP 2719
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 570PO
UT WOS:000275690400005
PM 20019880
DA 2022-11-30
ER

PT J
AU Ng, WT
   Goggin, M
AF Ng, WT
   Goggin, M
TI Awareness of and compliance with recommended dietary supplement among
   age-related macular degeneration patients
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related eye disease study supplement; age-related macular
   degeneration; awareness; compliance; public health
ID IRON SUPPLEMENTATION; ORAL ZINC; PREGNANCY; BLINDNESS; COSTS
AB Background: The age-related eye disease study suggested that taking zinc and anti-oxidants supplements could reduce the progression of age-related macular degeneration (AMD). In Australia, the available supplement is Macu-Vision. The study aimed to assess the awareness of and compliance with taking this supplement and the public health implication.
   Methods: The fundus photograph database of patients aged 55 years and older at the ophthalmology department of a public teaching hospital in Adelaide, Australia was reviewed. In total, 125 patients with category 3 and 4 AMD were identified. A total of 100 patients participated in this cross-sectional study.
   Results: In total, 53% of participants were aware of the availability of the formulae available in Australia, 38% were taking the supplement and only 1% were taking the correct dose. Of those taking the supplement 95% (36/38) were taking half the recommended dosage. Among those who were aware of the supplement but not taking it, cost was the most common reason (31%). Another 31% were not taking it because of actual side-effects experienced, fear of potential side-effect and/or fear of interaction with other medications. There was no predictive factor for failing to take the formulae available in Australia among age, sex, smoking status, living arrangement and category of AMD.
   Conclusions: Clinicians need to emphasize that the recommended dosage is twice that on the supplement label. If the trend demonstrated here of underutilizing the formulae available in Australia among public hospital patients continues, it is unlikely to have any major public health impact in similar settings in Australia.
C1 Univ Adelaide, Queen Elizabeth Hosp, Dept Ophthalmol, Woodville, SA 5011, Australia.
C3 University of Adelaide
RP Ng, WT (通讯作者)，Prince Wales Hosp, Eye Clin, Level 4 High St Bldg, Randwick, NSW 2031, Australia.
EM wengt@yahoo.com
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   *AUSTR BUR STAT, 2004, NAT REG PROF CENS 20
   *AUSTR BUR STAT, YB AUSTR 2002 INC WE
   *AUSTR BUR STAT, NAT REG PROF CENS 20
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Jampol LM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1634, DOI 10.1001/archopht.121.11.1634
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Knudsen VK, 2004, PUBLIC HEALTH NUTR, V7, P843, DOI 10.1079/PHN2004630
   *NAT ADV EYE COUNC, 1993, PUBL NIH
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nordeng H, 2003, EUR J CLIN PHARMACOL, V59, P163, DOI 10.1007/s00228-003-0599-x
   OMENN GS, 1994, NEW ENGL J MED, V330, P1150
   RICHER S, 2002, INVEST OPHTHALMOL VI
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Taylor HR, 2002, BRIT MED J, V325, P1
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Turner Perry, 2002, N Z Med J, V115, pU218
   Wright SE, 2000, CLIN EXP OPHTHALMOL, V28, P140, DOI 10.1046/j.1442-9071.2000.00296.x
   Wulff M, 2003, ACTA OBSTET GYN SCAN, V82, P628, DOI 10.1034/j.1600-0412.2003.00186.x
NR 25
TC 30
Z9 31
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2006
VL 34
IS 1
BP 9
EP 14
DI 10.1111/j.1442-9071.2006.01141.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 003EV
UT WOS:000234665300004
PM 16451252
DA 2022-11-30
ER

PT J
AU Pfau, M
   von der Emde, L
   Dysli, C
   Thiele, S
   Moller, PT
   Lindner, M
   Nadal, J
   Schmid, M
   Schmitz-Valckenberg, S
   Holz, FG
   Fleckenstein, M
AF Pfau, Maximilian
   von der Emde, Leon
   Dysli, Chantal
   Thiele, Sarah
   Moeller, Philipp T.
   Lindner, Moritz
   Nadal, Jennifer
   Schmid, Matthias
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Fleckenstein, Monika
TI Light Sensitivity Within Areas of Geographic Atrophy Secondary to
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE microperimetry; scotopic perimetry; geographic atrophy; age-related
   macular degeneration; AMD; GA
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM PHENOTYPES; OUTER
   RETINAL TUBULATION; FUNDUS AUTOFLUORESCENCE; MICROPERIMETRY;
   PROGRESSION; EVOLUTION; TRANSITION; PERIMETRY; DESIGN
AB PURPOSE. To investigate residual sensitivity within geographic atrophy (GA) secondary to age-related macular degeneration.
   METHODS. Mesopic and dark-adapted (DA) cyan and red light sensitivity (Goldmann III) were investigated using fundus-controlled perimetry (microperimetry). Test points were placed within GA along an "iso-hull'' with a distance of -0.645 degrees to the atrophy boundary. The false-positive response rate was determined with suprathreshold stimuli to the optic disc (Heijl-Krakau method) and used to compute the expected sensitivity measurements for the assumption of absolute scotomata. The outermost visible retinal layer on spectral-domain optical coherence tomography at the location of each test point was determined.
   RESULTS. Thirty eyes of 36 patients (75.55 +/- 7.93 years; 19 female) from the prospective natural history study Directional Spread in Geographic Atrophy (NCT02051998), with a total of 1380 threshold determinations were analyzed. The measured sensitivities were significantly (P < 0.01) higher than the expected values for absolute scotomata (mean +/- standard error of vertical bar 6.92 +/- 0.86 dB for mesopic, vertical bar 2.57 +/- 0.56 dB for DA cyan, and vertical bar 4.93 +/- 0.74 dB for DA red testing). For mesopic testing and DA red testing, the presence of a residual outer nuclear layer had a significant effect on this discrepancy (P < 0.001). There was no effect of fixation stability or any other reliability index on this discrepancy.
   CONCLUSIONS. Measured sensitivities within the inner junctional zone of GA may not be purely explained by patient-specific false-positive response rates or other reliability indices. The marked influence of the outer retinal configuration on measured sensitivity may be indicative of residual cone function within GA at the inner junctional zone.
C1 [Pfau, Maximilian; von der Emde, Leon; Dysli, Chantal; Thiele, Sarah; Moeller, Philipp T.; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Pfau, Maximilian; Thiele, Sarah; Moeller, Philipp T.; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] GRADE Reading Ctr, Bonn, Germany.
   [Dysli, Chantal] Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.
   [Dysli, Chantal] Bern Univ Hosp, Inselspital, Dept Clin Res, Bern, Switzerland.
   [Dysli, Chantal] Univ Bern, Bern, Switzerland.
   [Lindner, Moritz] Univ Oxford, Sleep & Circadian Neurosci Inst, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
   [Nadal, Jennifer; Schmid, Matthias] Univ Hosp Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
C3 University of Bonn; University of Bern; University Hospital of Bern;
   University of Bern; University Hospital of Bern; University of Bern;
   University of Oxford; University of Bonn
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM mfleckenstein@web.de
RI Lindner, Moritz/AAC-8639-2021
OI Lindner, Moritz/0000-0002-4416-3421; Schmid,
   Matthias/0000-0002-0788-0317
FU BONFOR Program of the Faculty of Medicine, University of Bonn
   [O-137.0022, O-137.0025]; Novartis Pharma GmbH, EYEnovative Forderpreis
   2017; German Research Foundation (DFG) [FL658/4-1, FL658/4-2]
FX Supported by the BONFOR Program of the Faculty of Medicine, University
   of Bonn, Grant No. O-137.0022 and O-137.0025 (MP); Novartis Pharma GmbH,
   EYEnovative Forderpreis 2017 (MP), and by the German Research Foundation
   (DFG), FL658/4-1 and FL658/4-2 (MF). CenterVue SpA (Padova, Italy) has
   provided research material (S-MAIA) for the conduct of this study.
   CenterVue had no role in the design or conduct of the experiments.
CR Arden GB., 1991, PRINCIPLES PRACTICE, P475
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272
   Chen FK, 2011, RETINA-J RET VIT DIS, V31, P371, DOI 10.1097/IAE.0b013e3181e46af3
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   HEIJL A, 1975, ACTA OPHTHALMOL, V53, P293
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Olsson J, 1997, ACTA OPHTHALMOL SCAN, V75, P181
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, P158, DOI 10.1167/iovs.17-21454
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sauer L, 2018, ACTA OPHTHALMOL, V96, P257, DOI 10.1111/aos.13587
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2017, OPHTHALMOLOGICA, V237, P11, DOI 10.1159/000455074
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   von der Emde L, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.7
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 55
TC 8
Z9 8
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2019
VL 60
IS 12
BP 3992
EP 4001
DI 10.1167/iovs.19-27178
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JB8RM
UT WOS:000488842600010
PM 31560765
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU De Koning-Backus, APM
   Buitendijk, GHS
   Jong, JCKD
   Colijn, JM
   Hofman, A
   Vingerling, JR
   Haverkort, EB
   Franco, OH
   Klaver, CCW
AF De Koning-Backus, Alexandra P. M.
   Buitendijk, Gabrielle H. S.
   Jong, Jessica C. Kiefte-De
   Colijn, Johanna M.
   Hofman, Albert
   Vingerling, Johannes R.
   Haverkort, Elizabeth B.
   Franco, Oscar H.
   Klaver, Caroline C. W.
TI Intake of Vegetables, Fruit, and Fish is Beneficia for Age-Related
   Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DIETARY ANTIOXIDANTS; GENETIC SUSCEPTIBILITY; BETA-CAROTENE;
   FATTY-ACIDS; VITAMIN-E; RISK; OMEGA-3-FATTY-ACIDS; MACULOPATHY;
   PROGRESSION; PREVALENCE
AB PURPOSE: What patients should eat to reduce their risk of age-related macular degeneration (AMD) is still unclear. We investigated the effect of a diet recommended by Health Councils on AMD.
   DESIGN: Prospective population-based cohort study.
   METHODS: Four thousand two hundred and two participants from the Rotterdam Study >= 55 years of age who were free of AMD at baseline were included and followed up for 9.1 +/- 5.8 years. Incident AMD was graded on fundus photographs. Dietary data were collected using a validated 170-item food frequency questionnaire, and food intakes were categorized into food patterns based on guidelines from Health Councils. Associations with incident AMD were analyzed using Cox proportional hazards models that were adjusted for age, sex, total energy intake, smoking, body mass index, hypertension, education, and income.
   RESULTS: Seven hundred fifty-four people developed incident AMD. Intake of the recommended amounts of vegetables (>= 200 g/day), fruit (2 x/day), and fish (2x/week) were 30.6%, 54.9%, and 12.5%, respectively. In particular, the intake of fish (2 x/week) decreased the risk of incident AMD (hazard ratio 0.76 [95% confidence interval 0.60-0.97]). Intake of the recommended amounts of all 3 food groups was only 3.7%, but adherence to this pattern showed a further reduction of the risk of incident AMD (hazard ratio 0.58 [95% confidence interval 0.36-0.93]). Younger age, higher income, and not smoking were associated with this food pattern, but the risk-lowering effects remained significant after additional adjustment for thecse factors.
   CONCLUSION: A diet of 200 grams per day of vegetables, fruit two times per day, and fish two times per week is associated with a significantly reduced risk of AMD. (C) 2018 Elsevier Inc. All rights reserved.
C1 [De Koning-Backus, Alexandra P. M.; Buitendijk, Gabrielle H. S.; Colijn, Johanna M.; Hofman, Albert; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus Univ, Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   [De Koning-Backus, Alexandra P. M.; Buitendijk, Gabrielle H. S.; Jong, Jessica C. Kiefte-De; Colijn, Johanna M.; Vingerling, Johannes R.; Franco, Oscar H.; Klaver, Caroline C. W.] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands.
   [De Koning-Backus, Alexandra P. M.; Haverkort, Elizabeth B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol, Amsterdam, Netherlands.
   [Hofman, Albert] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Haverkort, Elizabeth B.] Univ Appl Sci Utrecht, Res Grp Innovat Prevent Care, Res Ctr Innovat Hlth Care, Utrecht, Netherlands.
   [Jong, Jessica C. Kiefte-De] Leiden Univ, Coll The Hague, The Hague, Netherlands.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam;
   Harvard University; Harvard T.H. Chan School of Public Health; Leiden
   University; Leiden University - Excl LUMC; Radboud University Nijmegen
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI Franco, Óscar H/ABE-2305-2020; Kiefte-de Jong, Jessica/GLV-3216-2022
OI Franco, Óscar H/0000-0002-4606-4929; Kiefte-de Jong,
   Jessica/0000-0002-8136-0918; de Koning-Backus,
   Alexandra/0000-0001-5349-5500
FU UITZICHT (GRANT 2015-36); UITZICHT (VERENIGING BARTIMEUS Sonneheerdt);
   UITZICHT (Stichting Oogfonds); UITZICHT (Landelijke Stichting voor
   Blinden en Slechtzienden); UITZICHT (Algemene Nederlandse Vereniging ter
   voorkoming van Blindheid); UITZICHT (Novartis research foundation);
   UITZICHT (MaculaFonds); Stichting Erasmus Trustfonds; European Union's
   Horizon 2020 research and innovation program [634479]; Erasmus Medical
   Center; Erasmus University, Rotterdam, the Netherlands; Netherlands
   Organization for the Health Research and Development; Research Institute
   for Diseases in the Elderly; Ministry of Education,Culture and Science;
   Ministry for Health,Welfare and Sports; European Commission;
   Municipality of Rotterdam; UITZICHT (GRANT 2016-19)
FX THIS STUDY WAS SUPPORTED BY UITZICHT (GRANTS 2015-36 AND 2016-19;
   VERENIGING BARTIMEUS Sonneheerdt; Stichting Oogfonds; Landelijke
   Stichting voor Blinden en Slechtzienden; Algemene Nederlandse Vereniging
   ter voorkoming van Blindheid; Novartis research foundation;
   MaculaFonds), Stichting Erasmus Trustfonds, and the European Union's
   Horizon 2020 research and innovation program under grant agreement
   634479. The Rotterdam Study is funded by Erasmus Medical Center and
   Erasmus University, Rotterdam, the Netherlands, Netherlands Organization
   for the Health Research and Development, the Research Institute for
   Diseases in the Elderly, the Ministry of Education,Culture and Science,
   the Ministry for Health,Welfare and Sports, the European Commission, and
   the Municipality of Rotterdam. Sponsors and funding organizations had no
   role in the design or conduct of this research. All authors attest that
   they meet the current ICMJE criteria for authorship.
CR Beare R. J., 2001, J PURE APPL CHEM, V73, P685
   Brown MJ, 2004, AM J CLIN NUTR, V80, P396, DOI 10.1093/ajcn/80.2.396
   Buitendijk GHS, 2014, HANDBOOK OF NUTRITION, DIET, AND THE EYE, P55, DOI 10.1016/B978-0-12-401717-7.00006-X
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   Donders-Engelen M.R, 2003, MATEN GEWICHTEN CODE
   Food and Agriculture Organization of the United Nations, FOOD BAS DIET GUID
   GOLDBOHM RA, 1994, EUR J CLIN NUTR, V48, P253
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Health Council of the Netherlands, 2006, USITC PUBL, V2006
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hof KHV, 2000, J NUTR, V130, P503
   Hofman A, 2015, EUR J EPIDEMIOL, V30, P661, DOI 10.1007/s10654-015-0082-x
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klipstein-Grobusch K, 1998, EUR J CLIN NUTR, V52, P588, DOI 10.1038/sj.ejcn.1600611
   Laurenti G., 2007, 821 FAO, P429
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lima Veronica Castro, 2016, Int J Retina Vitreous, V2, P19
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   NEVO-tabel, 2011, DUTCH FOOD COMP DAT
   Roodenburg AJC, 2000, AM J CLIN NUTR, V71, P1187
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Lenthe FJ, 2015, BRIT J NUTR, V113, P1139, DOI [10.1017/S0007114515000288, 10.1017/S00]
   Wall CL, 2014, NEW ZEAL MED J, V127
   Widomska J, 2016, FOODS, V5, DOI 10.3390/foods5010007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Yang LG, 2016, LIPIDS, V51, P49, DOI 10.1007/s11745-015-4091-z
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 44
TC 28
Z9 28
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2019
VL 198
BP 70
EP 79
DI 10.1016/j.ajo.2018.09.036
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HK6MT
UT WOS:000458095500010
PM 30312575
DA 2022-11-30
ER

PT J
AU Invernizzi, A
   Agarwal, A
   Di Nicola, M
   Franzetti, F
   Staurenghi, G
   Viola, F
AF Invernizzi, Alessandro
   Agarwal, Aniruddha
   Di Nicola, Maura
   Franzetti, Fabio
   Staurenghi, Giovanni
   Viola, Francesco
TI Choroidal neovascular membranes secondary to intraocular tuberculosis
   misdiagnosed as neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Enhanced
   depth imaging optical coherence tomography; Indocyanine green
   angiography; Tuberculosis; Uveitis
ID SERPIGINOUS-LIKE CHOROIDITIS; PREVALENCE
AB Purpose: Intraocular tuberculosis (IOTB) can be complicated by choroidal neovascularization (CNV). However, when the CNV development is not accompanied by clear signs of inflammation, the etiology can be missed, especially in countries nonendemic for tuberculosis. We describe the clinical and imaging features of CNVs presenting as the first sign of IOTB initially misdiagnosed as exudative age-related macular degeneration (AMD).
   Methods: A retrospective review of clinical and imaging data of patients initially misdiagnosed with neovascular AMD later diagnosed with inflammatory CNV secondary to IOTB at tertiary referral centers was conducted. Features of fundus photography, fluorescein angiography, indocyanine green angiography, and enhanced depth imaging optical coherence tomography were analyzed. Distinguishing features between neovascular AMD and IOTB-associated CNV were evaluated.
   Results: Five patients over 55 years of age, erroneously diagnosed with exudative AMD, were included in the study. Multimodal imaging analysis allowed identification of peculiar choroidal alterations such as choroidal granulomas or choroiditis suggestive for posterior uveitis. Systemic workup for granulomatous uveitis including immunologic investigations such as tuberculin skin test or QuantiFERON TB Gold (R) and radiologic investigations revealed tubercular etiology in all the cases, allowing correct diagnosis and management of the uveitis and related CNV.
   Conclusions: Choroidal neovascularization represents a rare and unusual presenting sign of IOTB that can be misleading especially when it occurs in the elderly living in countries with low prevalence of the disease. Multimodal imaging can be helpful and should be employed, especially in atypical cases of CNV, in order to avoid misdiagnosis and/or diagnostic delays.
C1 [Invernizzi, Alessandro; Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Agarwal, Aniruddha] Postgrad Inst Med Educ & Res, Adv Eye Ctr, Chandigarh, India.
   [Di Nicola, Maura; Viola, Francesco] Univ Milan, IRCCS Ca Granda Fdn Osped Maggiore Policlin, Dept Clin Sci & Community Hlth, Ophthalmol Unit, Milan, Italy.
   [Franzetti, Fabio] Univ Milan, Luigi Sacco Hosp, Dept Clin Sci, Sect Infect & Trop Dis, Milan, Italy.
C3 University of Milan; Luigi Sacco Hospital; Post Graduate Institute of
   Medical Education & Research (PGIMER), Chandigarh; IRCCS Ca Granda
   Ospedale Maggiore Policlinico; University of Milan; University of Milan;
   Luigi Sacco Hospital
RP Invernizzi, A (通讯作者)，Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
EM alessandro.invernizzi@gmail.com
RI franzetti, fabio/AAK-9158-2020; viola, francesco/AAK-5583-2020
OI franzetti, fabio/0000-0001-9253-4453; viola,
   francesco/0000-0003-1208-913X; Di Nicola, Maura/0000-0002-6209-4191
CR Bansal R, 2017, OCUL IMMUNOL INFLAMM, V25, P554, DOI 10.3109/09273948.2016.1160128
   Bansal R, 2012, OPHTHALMOLOGY, V119, P2334, DOI 10.1016/j.ophtha.2012.05.034
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   CHUNG YM, 1989, ANN OPHTHALMOL, V21, P225
   Cimino Luca, 2009, International Ophthalmology, V29, P67, DOI 10.1007/s10792-007-9071-8
   D'Ambrosio E, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/450428
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Gupta Amod, 2005, International Ophthalmology Clinics, V45, P71, DOI 10.1097/01.iio.0000155934.52589.e3
   Gupta A, 2015, OCUL IMMUNOL INFLAMM, V23, P7, DOI 10.3109/09273948.2014.967358
   Gupta V, 2007, SURV OPHTHALMOL, V52, P561, DOI 10.1016/j.survophthal.2007.08.015
   Gupta V, 2015, OCUL IMMUNOL INFLAMM, V23, P14, DOI 10.3109/09273948.2014.986582
   Gupta V, 2011, AM J OPHTHALMOL, V152, P857, DOI 10.1016/j.ajo.2011.05.004
   Invernizzi A, 2015, RETINA-J RET VIT DIS, V35, P525, DOI 10.1097/IAE.0000000000000312
   Neri P, 2009, MIDDLE EAST AFR J OP, V16, P245, DOI 10.4103/0974-9233.58422
   Patel SS, 2013, JAMA OPHTHALMOL, V131, P752, DOI 10.1001/jamaophthalmol.2013.71
   Wolfensberger TJ, 1999, AM J OPHTHALMOL, V127, P350, DOI 10.1016/S0002-9394(98)00325-0
NR 16
TC 7
Z9 8
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2018
VL 28
IS 2
BP 216
EP 224
DI 10.5301/ejo.5001047
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF6FL
UT WOS:000432062400014
PM 29077184
DA 2022-11-30
ER

PT J
AU Karesvuo, P
   Elbaz, U
   Achiron, A
   Hecht, I
   Kaarniranta, K
   Tuuminen, R
AF Karesvuo, Petteri
   Elbaz, Uri
   Achiron, Asaf
   Hecht, Idan
   Kaarniranta, Kai
   Tuuminen, Raimo
TI Effect of cataract surgery on wet age-related macular degeneration
   activity
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age&#8208; related cataract; antivascular endothelial growth factor;
   cataract surgery; wet age&#8208; related macular degeneration
AB Background Wet age-related macular degeneration (AMD) and age-related cataract are often coexisting causes of visual impairment. Yet, the timing of cataract surgery in wet AMD patients is controversial.
   Methods One hundred and eleven eyes of 111 patients with wet AMD underwent cataract surgery at Helsinki University Hospital in Finland during 2014-2018. Best-corrected visual acuity and central subfield macular thickness (CSMT) were analysed at the time of wet AMD diagnosis, at the last recording prior to cataract surgery and at the first recording and at 1 year after surgery. The cumulative number of antivascular endothelial growth factor (anti-VEGF) injections at surgery, systemic and topical medication and postoperative anti-VEGF burden were recorded.
   Results Mean age was 78.9 +/- 5.6 years at the time of surgery. Central subfield macular thickness (CSMT) significantly decreased (280.1 +/- 75.0 mu m preoperatively to 268.6 +/- 67.6 mu m at the first postoperative recording, p = 0.001, and to 265.9 +/- 67.9 mu m at 1 year, p = 0.003), visual acuity improved (0.70 +/- 0.46 logMAR units preoperatively to 0.39 +/- 0.40 at the first postoperative recording, and to 0.33 +/- 0.34 at 1 year, p < 0.001 for both) and anti-VEGF treatment intervals lengthened despite the surgery (6.53 +/- 2.08 weeks prior to surgery to 7.03 +/- 2.23 weeks at 1 year, p = 0.246, and to 7.05 +/- 2.57 weeks at the last documented visit, p = 0.035). A CSMT increase of over 30% from the preoperative values was seen in only one case (1 out of 111 eyes, 0.9%). Macular status at surgery, wet AMD subtype, comorbidity of type II diabetes, systemic drugs and topical anti-inflammatory medication were not associated with macular changes nor with treatment intervals after surgery. The cumulative number of anti-VEGF injections correlated neither with CSMT change postoperatively (r = -0.051, p = 0.619) nor with CSMT change at 1 year (r = 0.091, p = 0.426).
   Conclusion Satisfactory visual outcomes and controlled disease activity were seen in patients with wet AMD undergoing cataract surgery. We found no evidence to support delaying surgery in patients who require it.
C1 [Karesvuo, Petteri; Hecht, Idan; Tuuminen, Raimo] Univ Helsinki, Helsinki Retina Res Grp, Helsinki, Finland.
   [Karesvuo, Petteri] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
   [Elbaz, Uri; Achiron, Asaf; Hecht, Idan] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Elbaz, Uri] Rabin Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
   [Achiron, Asaf] Wolfson Med Ctr, Dept Ophthalmol, Holon, Israel.
   [Achiron, Asaf] Bristol Eye Hosp, Bristol, Avon, England.
   [Hecht, Idan] Shamir Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
   [Tuuminen, Raimo] Kymenlaakso Cent Hosp, Dept Ophthalmol, Kotkantie 41, FI-48210 Kotka, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; Tel Aviv University; Sackler Faculty of Medicine;
   Rabin Medical Center; Bristol Eye Hospital; Shamir Medical Center (Assaf
   Harofeh); University of Eastern Finland; Kuopio University Hospital;
   University of Eastern Finland
RP Tuuminen, R (通讯作者)，Kymenlaakso Cent Hosp, Dept Ophthalmol, Kotkantie 41, FI-48210 Kotka, Finland.
EM raimo.tuuminen@helsinki.fi
OI Hecht, Idan/0000-0001-5634-0432; Elbaz, Uri/0000-0003-2706-6467;
   Tuuminen, Raimo/0000-0003-1550-8125
CR Achiron Asaf, 2021, Ophthalmology, V128, P410, DOI 10.1016/j.ophtha.2020.07.039
   Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chu CJ, 2016, OPHTHALMOLOGY, V123, P316, DOI 10.1016/j.ophtha.2015.10.001
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Daien V, 2018, AM J OPHTHALMOL, V190, P50, DOI 10.1016/j.ajo.2018.03.012
   Danni R, 2019, ACTA OPHTHALMOL, V97, P178, DOI 10.1111/aos.13911
   de Silva SR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008812.pub2
   Dong LM, 2003, OPHTHAL EPIDEMIOL, V10, P149, DOI 10.1076/opep.10.3.149.15080
   Ehmann DS, 2017, CURR OPIN OPHTHALMOL, V28, P58, DOI 10.1097/ICU.0000000000000331
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Hecht I, 2020, AM J OPHTHALMOL, V215, P104, DOI 10.1016/j.ajo.2020.02.007
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P755, DOI 10.1111/aos.13120
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Kessel L, 2014, OPHTHALMOLOGY, V121, P1915, DOI 10.1016/j.ophtha.2014.04.035
   Loriaut P, 2014, OPHTHALMIC RES, V52, P212, DOI 10.1159/000362881
   Malick H, 2021, EYE, V35, P685, DOI 10.1038/s41433-020-0863-7
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   OTHENINGIRARD P, 1994, J CATARACT REFR SURG, V20, P9, DOI 10.1016/S0886-3350(13)80036-3
   Porela-Tiihonen S, 2016, ACTA OPHTHALMOL, V94, P21, DOI 10.1111/aos.12755
   Rim TH, 2017, SEMIN OPHTHALMOL, V32, P466, DOI 10.3109/08820538.2015.1119861
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Small KW, 2017, RETINA-J RET VIT DIS, V37, P1630, DOI 10.1097/IAE.0000000000001475
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Starr MR, 2018, AM J OPHTHALMOL, V192, P91, DOI 10.1016/j.ajo.2018.05.014
   Taipale C, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-2020-965
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, P649, DOI 10.1111/aos.13341
   Wang JJ, 2016, OPHTHALMOLOGY, V123, P1829, DOI 10.1016/j.ophtha.2016.02.003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ylinen P, 2018, ACTA OPHTHALMOL, V96, P486, DOI 10.1111/aos.13670
NR 38
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2022
VL 100
IS 1
BP E262
EP E269
DI 10.1111/aos.14864
EA APR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YD6LB
UT WOS:000638684400001
PM 33838002
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Shi, Y
   Uji, A
   Balasubramanian, S
   Nassisi, M
   Sarraf, D
   Sadda, SR
AF Borrelli, Enrico
   Shi, Yue
   Uji, Akihito
   Balasubramanian, Siva
   Nassisi, Marco
   Sarraf, David
   Sadda, Srinivas R.
TI Topographic Analysis of the Choriocapillaris in Intermediate Age-related
   Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; SWEPT-SOURCE; MORPHOMETRIC-ANALYSIS;
   DRUSEN; IMAGE; EYES; DENSITY
AB PURPOSE: To quantitate regional differences in the choriocapillaris (CC) of patients with intermediate age-related macular degeneration (iAMD), using swept source optical coherence tomography angiography (SS-OCTA) imaging.
   DESIGN: Cross-sectional study.
   METHODS: Subjects were imaged with the SS-OCTA system (PLEX Elite 9000, Carl Zeiss Meditec Inc, Dublin, California, USA). The CC en face images were first compensated for the signal attenuation caused by drusen by using the structural information from the same slab. Subsequently, for each eye, 2 compensated CC en face images generated from 2 different OCTA volume scan sets were registered and averaged. The averaged CC images were then exported to Image) and binarized for subsequent quantitative analysis. In addition to the analysis of the whole averaged CC en face image in iAMD eyes, quantitative analysis was also performed in 3 different regions: (1) drusen region, (2) 150-mu m-wide ring around the drusen border, and (3) drusen-free region.
   RESULTS: Thirty eyes (30 patients) with iAMD and 30 healthy eyes from 30 controls were enrolled. Compared with controls, iAMD eyes displayed a lower number of signal voids (median and interquartile range [IQR]: 2561 and 2343-2746 vs 2734 and 2558-2834; P = .013), a greater signal void average size (median, IQR: 581.9 mu m(2), 466.1-726.9 mu m(2) vs 503.8 mu m(2), 429.1-576.8 mu m(2); P = .027), and a greater total signal void area (median, IQR: 26.0%, 22.1%-29.6% vs 23.8%, 21.2%-26.4%; P = .038). In multiple regression analysis, the presence of iAMD was not significantly associated with any of the CC variables. By contrast, the drusen region area was significantly associated with CC alterations. In the evaluation of the iAMD group, both the area underneath drusen and the 150-mu m-wide ring region around drusen were characterized by an increased total signal void area (P = .005 and P = .045, respectively) vs the drusen-free region.
   CONCLUSIONS: Intermediate AMD eyes demonstrated increased CC flow impairment, which co-localizes to the area of CC beneath and immediately surrounding drusen. (Am J Ophthalmol 2018;196:34-43. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Borrelli, Enrico; Shi, Yue; Uji, Akihito; Balasubramanian, Siva; Nassisi, Marco; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Borrelli, Enrico; Shi, Yue; Uji, Akihito; Balasubramanian, Siva; Nassisi, Marco; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA.
   [Borrelli, Enrico] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Chieti, Italy.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; G d'Annunzio University of Chieti-Pescara; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los
   Angeles Healthcare System
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Borrelli, Enrico/AAR-3693-2020; Nassisi, Marco/P-9939-2019
OI Borrelli, Enrico/0000-0003-2815-5031; Nassisi, Marco/0000-0002-9354-9005
CR Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Borrelli E, 2018, RETINA, DOI [10.1097/1AE.0000000000002123.2018.02.22, DOI 10.1097/1AE.0000000000002123.2018.02.22]
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 29
TC 83
Z9 84
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2018
VL 196
BP 34
EP 43
DI 10.1016/j.ajo.2018.08.014
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HD8MZ
UT WOS:000452812500010
PM 30118688
DA 2022-11-30
ER

PT J
AU Mitchell, SL
   Uppal, K
   Williamson, SM
   Liu, K
   Burgess, LG
   Tran, V
   Umfress, AC
   Jarrell, KL
   Bailey, JNC
   Agarwal, A
   Pericak-Vance, M
   Haines, JL
   Scott, WK
   Jones, DP
   Brantley, MA
AF Mitchell, Sabrina L.
   Uppal, Karan
   Williamson, Samantha M.
   Liu, Ken
   Burgess, L. Goodwin
   ViLinh Tran
   Umfress, Allison C.
   Jarrell, Kelli L.
   Bailey, Jessica N. Cooke
   Agarwal, Anita
   Pericak-Vance, Margaret
   Haines, Jonathan L.
   Scott, William K.
   Jones, Dean P.
   Brantley, Milam A., Jr.
TI The Carnitine Shuttle Pathway is Altered in Patients With Neovascular
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE metabolomics; age-related macular degeneration; long-chain
   acylcarnitines; carnitine shuttle
ID MASS-SPECTROMETRY; PLASMA ACYLCARNITINES; METABOLOMICS DATA; WIDE
   ASSOCIATION; METAANALYSIS; PHENOTYPES; EXPOSOME; PROFILE; RISK
AB PURPOSE. To identify metabolites and metabolic pathways altered in neovascular age-related macular degeneration (NVAMD).
   METHODS. We performed metabolomics analysis using high-resolution C18 liquid chromatography-mass spectrometry on plasma samples from 100 NVAMD patients and 192 controls. Data for mass/charge ratio ranging from 85 to 850 were captured, and metabolic features were extracted using xMSanalyzer. Nested feature selection was used to identify metabolites that discriminated between NVAMD patients and controls. Pathway analysis was performed with Mummichog 2.0. Hierarchical clustering was used to examine the relationship between the discriminating metabolites and NVAMD patients and controls.
   RESULTS. Of the 10,917 metabolic features analyzed, a set of 159 was identified that distinguished NVAMD patients from controls (area under the curve of 0.83). Of these features, 39 were annotated with confidence and included multiple carnitine metabolites. Pathway analysis revealed that the carnitine shuttle pathway was significantly altered in NVAMD patients (P = 0.0001). Tandem mass spectrometry confirmed the molecular identity of five carnitine shuttle pathway acylcarnitine intermediates that were increased in NVAMD patients. Hierarchical cluster analysis revealed that 51% of the NVAMD patients had similar metabolic profiles, whereas the remaining 49% displayed greater variability in their metabolic profiles.
   CONCLUSIONS. Multiple long-chain acylcarnitines that are part of the carnitine shuttle pathway were significantly increased in NVAMD patients compared to controls, suggesting that fatty acid metabolism may be involved in NVAMD pathophysiology. Cluster analysis suggested that clinically indistinguishable NVAMD patients can be separated into distinct subgroups based on metabolic profiles.
C1 [Mitchell, Sabrina L.; Williamson, Samantha M.; Burgess, L. Goodwin; Umfress, Allison C.; Jarrell, Kelli L.; Agarwal, Anita; Brantley, Milam A., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, 2311 Pierce Ave, Nashville, TN 37232 USA.
   [Uppal, Karan; Liu, Ken; ViLinh Tran; Jones, Dean P.] Emory Univ, Dept Med, Med Ctr, Atlanta, GA 30322 USA.
   [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Inst Computat Biol, Cleveland, OH 44106 USA.
   [Pericak-Vance, Margaret; Scott, William K.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
C3 Vanderbilt University; Emory University; Case Western Reserve
   University; University of Miami
RP Brantley, MA (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM milam.brantley@vumc.org
RI Cooke Bailey, Jessica Nicole/AFQ-5925-2022; Haines,
   Jonathan/C-3374-2012; Bailey, Jessica Cooke/Q-5062-2019
OI Cooke Bailey, Jessica Nicole/0000-0002-4001-8702; Haines,
   Jonathan/0000-0002-4351-4728; Bailey, Jessica Cooke/0000-0002-4001-8702;
   Mitchell, Sabrina/0000-0001-7930-2447; Scott,
   William/0000-0001-9336-6404
FU National Institutes of Health (NIH; Bethesda, MD, USA) [R01 EY22618, R01
   EY012118]; Research to Prevent Blindness; Clinical and Translational
   Science Collaborative of Cleveland from the National Center for
   Advancing Translational 419 Sciences (NCATS) component of the NIH
   [KL2TR000440]; NIH roadmap for Medical Research; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [KL2TR000440] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY022618] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008602]
   Funding Source: NIH RePORTER
FX Supported by National Institutes of Health (NIH; Bethesda, MD, USA)
   Grants R01 EY22618 (MAB) and R01 EY012118 (MP-V, JLH, WKS, and AA) and
   an unrestricted departmental award from Research to Prevent Blindness,
   and by the Clinical and Translational Science Collaborative of
   Cleveland, KL2TR000440 from the National Center for Advancing
   Translational 419 Sciences (NCATS) component of the NIH and NIH roadmap
   for Medical Research (JNCB).
CR Benton HP, 2010, BIOINFORMATICS, V26, P2488, DOI 10.1093/bioinformatics/btq441
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Burgess LG, 2015, INVEST OPHTH VIS SCI, V56, P5020, DOI 10.1167/iovs.15-16702
   Frediani JK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108854
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gevaert O, 2006, BIOINFORMATICS, V22, pE184, DOI 10.1093/bioinformatics/btl230
   Go YM, 2015, TOXICOL SCI, V148, P531, DOI 10.1093/toxsci/kfv198
   Guasch-Ferre M, 2016, AM J CLIN NUTR, V103, P1408, DOI 10.3945/ajcn.116.130492
   He ZY, 2010, COMPUT BIOL CHEM, V34, P215, DOI 10.1016/j.compbiolchem.2010.07.002
   Johnson JM, 2010, ANALYST, V135, P2864, DOI 10.1039/c0an00333f
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Li SZ, 2017, CELL, V169, P862, DOI 10.1016/j.cell.2017.04.026
   Li SZ, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003123
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Patel RM, 2015, TRANSFUSION, V55, P544, DOI 10.1111/trf.12884
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rist MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183228
   Roede JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077629
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Ruiz M, 2017, AM J PHYSIOL-HEART C, V313, pH768, DOI 10.1152/ajpheart.00820.2016
   Ruttkies C, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0115-9
   Sardell RJ, 2016, MOL VIS, V22, P1062
   Schymanski EL, 2014, ENVIRON SCI TECHNOL, V48, P2097, DOI 10.1021/es5002105
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sharma Shruti, 2009, Drug Discov Today Dis Mech, V6, pe31
   Slawski M, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-439
   Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Soltow QA, 2013, METABOLOMICS, V9, pS132, DOI 10.1007/s11306-011-0332-1
   Sumner LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/s11306-007-0082-2
   Sun L, 2016, DIABETES CARE, V39, P1563, DOI 10.2337/dc16-0232
   Tan SZ, 2016, EYE, V30, P773, DOI 10.1038/eye.2016.37
   Tautenhahn R, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-504
   Uppal K, 2017, ANAL CHEM, V89, P1063, DOI 10.1021/acs.analchem.6b01214
   Uppal K, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-15
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu TW, 2009, BIOINFORMATICS, V25, P1930, DOI 10.1093/bioinformatics/btp291
NR 42
TC 23
Z9 23
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2018
VL 59
IS 12
BP 4978
EP 4985
DI 10.1167/iovs.18-25137
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GX3IB
UT WOS:000447614900005
PM 30326066
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Liakopoulos, S
   Ongchin, S
   Bansal, A
   Msutta, S
   Walsh, AC
   Updike, PG
   Sadda, SR
AF Liakopoulos, Sandra
   Ongchin, Sharel
   Bansal, Alok
   Msutta, Sandeep
   Walsh, Alexander C.
   Updike, Paul G.
   Sadda, Srinivas R.
TI Quantitative Optical Coherence Tomography Findings in Various Subtypes
   of Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY;
   PHOTODYNAMIC THERAPY; RANIBIZUMAB; VERTEPORFIN; SUBANALYSIS
AB PURPOSE. To compare the volume of various spaces visible on optical coherence tomography (OCT) images in different angiographic lesion subtypes of neovascular age-related macular degeneration (AMD).
   METHODS. Sixty-six cases of previously untreated, active subfoveal choroidal neovascularization (CNV) associated with AMD were retrospectively collected. CNV lesions were classified as occult with no classic CNV, minimally classic CNV, predominantly classic CNV, or CNV lesions with associated retinal angiomatous proliferation ( RAP). Corresponding OCT image sets were analyzed by trained graders using previously validated custom software that allows manual placement of boundaries on OCT B-scans. Spaces delineated by these boundaries included the neurosensory retina, subretinal fluid, subretinal tissue, and pigment epithelial detachments (PEDs). Volume measurements were calculated by the software and compared among groups.
   RESULTS. Minimally and predominantly classic CNV membranes demonstrated subretinal tissue on OCT in all cases and appeared to show a significantly greater volume of subretinal tissue than did the occult membranes. Subretinal fluid was present in all the predominantly classic cases. A PED was visible in all the occult CNV cases in our study, demonstrating less retinal thickening and significantly greater PED volumes than minimally and predominantly classic CNV lesions. Lesions associated with RAP showed the highest percentage of cystoid spaces.
   CONCLUSIONS. OCT and angiography provide complementary information regarding CNV lesions. Quantitative analysis of OCT images allows for an improved understanding of the anatomic characteristics of angiographically defined CNV lesion subtypes. (Invest Ophthalmol Vis Sci. 2008;49:5048-5054) DOI:10.1167/iovs.08-1877
C1 [Liakopoulos, Sandra; Ongchin, Sharel; Bansal, Alok; Msutta, Sandeep; Walsh, Alexander C.; Updike, Paul G.; Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Liakopoulos, Sandra] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Cologne, Germany.
C3 Doheny Eye Institute; University of Southern California; University of
   Cologne
RP Sadda, SR (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, DEI 3623,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
FU National Eye Institute [EY03040, R01 EY014375]; Retino Vit Stiftung
   Cologne, Germany; NATIONAL EYE INSTITUTE [R01EY014375, R21EY015914,
   P30EY003040] Funding Source: NIH RePORTER
FX Supported in part by National Eye Institute Grants EY03040 and R01
   EY014375 and Retino Vit Stiftung Cologne, Germany.
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Fukuchi T, 2001, JPN J OPHTHALMOL, V45, P252, DOI 10.1016/S0021-5155(00)00381-6
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Submacular Surgery Trials Research Group, 2006, OPHTHALMOLOGY, V113
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
NR 19
TC 71
Z9 73
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2008
VL 49
IS 11
BP 5048
EP 5054
DI 10.1167/iovs.08-1877
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366RX
UT WOS:000260502200048
PM 18566473
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zawinka, C
   Ergun, E
   Stur, M
AF Zawinka, Claudia
   Ergun, Erdem
   Stur, Michael
TI Prevalence of patients presenting with neovascular age-related macular
   degeneration in an urban population
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; prevalence; photodynamic therapy;
   verteporfin; Vienna
ID 5-YEAR INCIDENCE; MACULOPATHY; RATIONALE; VISUDYNE; LESIONS
AB Purpose: To determine the number and type of new cases of neovascular age-related macular degeneration (AMD) present in a defined urban population and to establish the proportion that would be recommended for treatment with verteporfin or laser photocoagulation.
   Methods: Patients referred to an ophthalmic center in Vienna during a 10-week period because of recent deterioration in vision caused by newly diagnosed neovascular AMD were included.
   Results: Neovascular AMD was diagnosed in 168 eyes in 153 patients. One hundred one eyes (60.1 %) had lesions that were occult with no classic choroidal neovascularization (CNV); of these, 70 were subfoveal, 19 were juxtafoveal, and 12 were extrafoveal. Thirty-five eyes (20.8%) had predominantly classic lesions; of these, 27 were subfoveal, 6 were juxtafoveal, and 2 were extrafoveal. Thirty-two eyes (19.0%) had minimally classic lesions, of which 31 were subfoveal and 1 was extrafoveal. In accordance with consensus guidelines from a panel of experts and with American Academy of Ophthalmology's Preferred Practice Pattern guidelines, 33 lesions (17%) would be considered for treatment with verteporfin therapy. A further 37 subfoveal lesions with occult with no classic CNV and 7 juxtafoveal lesions with occult with no classic CNV might also benefit from verteporfin therapy if there is evidence of presumed recent disease progression. Five lesions (3.0%) could have been treated with laser photocoagulation according to Macular Photocoagulation Study criteria.
   Conclusions: These results suggest that verteporfin therapy substantially increases the number of patients with treatable neovascular AMD.
C1 Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   Univ Basel, Dept Ophthalmol, CH-4003 Basel, Switzerland.
C3 Medical University of Vienna; University of Basel
RP Stur, M (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20 8I, A-1090 Vienna, Austria.
EM michael.stur@meduniwien.ac.at
CR Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   Anderson R N, 2001, Natl Vital Stat Rep, V48, P1
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   *MACH PHOT STUD GR, 1996, ARCH OPHTHAMOL, V114, P400
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Rosenfeld PJ, 2001, INVEST OPHTH VIS SCI, V42, pS512
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stur M, 2001, INVEST OPHTH VIS SCI, V42, pS442
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   1999, BEV JAHRESDURCHSCHNI
NR 31
TC 18
Z9 19
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR-MAY
PY 2005
VL 25
IS 3
BP 324
EP 331
DI 10.1097/00006982-200504000-00012
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100QT
UT WOS:000241684400012
PM 15805910
DA 2022-11-30
ER

PT J
AU Brown, DM
   Michels, M
   Kaiser, PK
   Heier, JS
   Sy, JP
   Ianchulev, T
AF Brown, David M.
   Michels, Mark
   Kaiser, Peter K.
   Heier, Jeffrey S.
   Sy, Judy P.
   Ianchulev, Tsontcho
TI Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular
   Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
SO OPHTHALMOLOGY
LA English
DT Article
ID NATURAL-HISTORY
AB Objective: The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (ANCHOR) compared ranibizumab with verteporfin photodynamic therapy (PDT) in treating predominantly classic CNV.
   Design: Multicenter, international, randomized, double-masked, active-treatment-controlled clinical trial.
   Participants: Patients with predominantly classic, subfoveal CNV not previously treated with PDT or antiangiogenic drugs.
   Intervention: Patients were randomized 1:1:1 to verteporfin PDT plus monthly sham intraocular injection or to sham verteporfin PDT plus monthly intravitreal ranibizumab (0.3 mg or 0.5 mg) injection. The need for PDT (active or sham) retreatment was evaluated every 3 months using fluorescein angiography (FA).
   Main Outcome Measures: The primary, intent-to-treat efficacy analysis was at 12 months, with continued measurements to month 24. Key measures included the percentage losing <15 letters from baseline visual acuity (VA) score (month 12 primary efficacy outcome measure), percentage gaining :15 letters from baseline, and mean change over time in VA score and FA-assessed lesion characteristics. Adverse events were monitored.
   Results: Of 423 patients (143 PDT, 140 each in the 2 ranibizumab groups), the majority (>= 77% in each group) completed the 2-year study. Consistent with results at month 12, at month 24 the VA benefit from ranibizumab was statistically significant (P<0.0001 vs. PDT) and clinically meaningful: 89.9% to 90.0% of ranibizumab-treated patients had lost <15 letters from baseline (vs. 65.7% of PDT patients); 34% to 41.0% had gained >= 15 letters (vs. 6.3% of PDT group); and, on average, VA was improved from baseline by 8.1 to 10.7 letters (vs. a mean decline of 9.8 letters in PDT group). Changes in lesion anatomic characteristics on FA also favored ranibizumab (all comparisons P<0.0001 vs. PDT). Overall, there was no imbalance among groups in rates of serious ocular and nonocular adverse events. In the pooled ranibizumab groups, 3 of 277 (1.1%) patients developed presumed endophthalmitis in the study eye (rate per injection = 3/5921 [0.05%]).
   Conclusions: In this 2-year study, ranibizumab provided greater clinical benefit than verteporfin PDT in patients with age-related macular degeneration with new-onset, predominantly classic CNV. Rates of serious adverse events were low.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009;116:57-65 (C) 2009 by the American Academy of Ophthalmology.
C1 [Brown, David M.] Methodist Hosp, Vitreoretinal Consultants, Houston, TX 77030 USA.
   [Michels, Mark] Retina Care Specialists, Palm Beach Gardens, FL USA.
   [Kaiser, Peter K.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Sy, Judy P.; Ianchulev, Tsontcho] Genentech Inc, San Francisco, CA 94080 USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston;
   Cleveland Clinic Foundation; Ophthalmic Consultants of Boston; Roche
   Holding; Genentech
RP Brown, DM (通讯作者)，Vitreoretinal Consultants, Houston, TX 77030 USA.
EM dmbmd@houstonretina.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777; Gaudric, Alain/0000-0002-2486-4722;
   Kaiser, Peter/0000-0001-5126-045X
FU Genentech; Novartis Pharma
FX This Study wits funded by Genentech and Novartis Pharma.
CR Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   *NOV PHARM CORP, 2007, VIS PACK INS
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 12
TC 966
Z9 1015
U1 2
U2 87
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2009
VL 116
IS 1
BP 57
EP 65
DI 10.1016/j.ophtha.2008.10.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 392BA
UT WOS:000262276700010
PM 19118696
DA 2022-11-30
ER

PT J
AU Liu, YY
   Cai, QH
AF Liu, Yuanyuan
   Cai, Qinhua
TI Does Cataract Surgery Improve the Progression of Age-Related Macular
   Degeneration? A Meta-Analysis
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID RISK-FACTORS; BEAVER DAM; MACULOPATHY; ASSOCIATION; EXTRACTION; BIAS;
   INFLAMMATION; POPULATION; PREVALENCE
AB Purpose. Cataract and age-related macular degeneration (AMD) are the common causes of blindness in the elderly. Although cataract surgery is the most effective treatment for cataract, some clinicians suspect that such interventions may accelerate the progression of AMD. Therefore, we carried out this meta-analysis to focus on demonstrating the effectiveness and safety of cataract surgery in eyes with AMD.Methods. We performed a systematic literature search in the PubMed, EMBASE, and Cochrane Library databases, and the electronic databases were last searched in January 2019. We planned to include cohort trials of eyes affected by both cataract and AMD in which cataract surgery would be compared to no surgery. Two reviewers independently evaluated the search results against the inclusion and exclusion criteria. 8 trials were included for this meta-analysis.Results. We used the Stata/12.0 to integrate the data that was extracted from the articles. Eight cohort trials with data from different study populations were included. In random effects model, the relative risk (RR) for the progression of AMD is 1.194 (95% CI 0.897-1.591). As for those grouped according to the follow-up year, the RR for longer than five years was 1.372 (95% CI 1.062-1.772).Conclusion. We could draw out such a conclusion that there is still a positive correlation between cataract surgery and the progression of AMD, especially for the Asians. However, based on the current results, it is not possible to draw conclusions from existing studies on the impact of cataract surgery on early AMD development.
C1 [Liu, Yuanyuan; Cai, Qinhua] Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.
C3 Soochow University - China
RP Cai, QH (通讯作者)，Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.
EM liuyuanyuan2019@126.com; 3173695856@qq.com
RI liu, yuanyuan/GWZ-5838-2022
OI Cai, Qin hua/0000-0003-1707-9782; Liu, Yuanyuan/0000-0002-0665-4385
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Bailey JNC, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017186
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen J, 2012, NAT MED, V18, P658, DOI 10.1038/nm.2761
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Clifford TJ, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-18
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
   Ho JD, 2018, ACTA OPHTHALMOL, V96, pe213, DOI 10.1111/aos.13511
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hoy D, 2012, J CLIN EPIDEMIOL, V65, P934, DOI 10.1016/j.jclinepi.2011.11.014
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Kleinmann G, 2002, OPHTHALMOLOGY, V109, P334, DOI 10.1016/S0161-6420(01)00924-1
   Lazreg S, 2016, OPHTHALMIC RES, V56, P145, DOI 10.1159/000446844
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P927
   Nalwa HS, 2002, J NANOSCI NANOTECHNO, V2
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rim TH, 2017, SEMIN OPHTHALMOL, V32, P466, DOI 10.3109/08820538.2015.1119861
   Smith Bradley T, 2005, Curr Opin Ophthalmol, V16, P166, DOI 10.1097/01.icu.0000163030.33401.3d
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4
   Toyofuku N, 2002, J VISION, V2
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang J. J., 2008, AGING HLTH, V4, P597, DOI [10.2217/1745509x.4.6.5972-s2.0-58149164572, DOI 10.2217/1745509X.4.6.5972-S2.0-58149164572]
   Wang JJ, 2016, OPHTHALMOLOGY, V123, P1829, DOI 10.1016/j.ophtha.2016.02.003
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wilson ME, 2016, EYE, V30, P1187, DOI 10.1038/eye.2016.132
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
NR 50
TC 2
Z9 2
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD SEP 27
PY 2020
VL 2020
AR 7863987
DI 10.1155/2020/7863987
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OF7QB
UT WOS:000581396100002
PM 33062316
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lains, I
   Duarte, D
   Barros, AS
   Martins, AS
   Gil, J
   Miller, JB
   Marques, M
   Mesquita, TAN
   Kim, IK
   Cachulo, MD
   Vavvas, D
   Carreira, IM
   Murta, JN
   Silva, R
   Miller, JW
   Husain, D
   Gil, AM
AF Lains, Ines
   Duarte, Daniela
   Barros, Antonio S.
   Martins, Ana Sofia
   Gil, Joao
   Miller, John B.
   Marques, Marco
   Mesquita, Tania
   Kim, Ivana K.
   da Luz Cachulo, Maria
   Vavvas, Demetrios
   Carreira, Isabel M.
   Murta, Joaquim N.
   Silva, Rufino
   Miller, Joan W.
   Husain, Deeba
   Gil, Ana M.
TI Human plasma metabolomics in age-related macular degeneration (AMD)
   using nuclear magnetic resonance spectroscopy
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; NMR-SPECTROSCOPY; METABONOMICS; SIGNATURES;
   PREVALENCE; DISEASE; CANCER; EYE
AB Purpose
   To differentiate the plasma metabolomic profile of patients with age related macular degeneration (AMD) from that of controls, by Nuclear Magnetic Resonance (NMR) spectroscopy.
   Methods
   Two cohorts (total of 396 subjects) representative of central Portugal and Boston, USA phenotypes were studied. For each cohort, subjects were grouped according to AMD stage (early, intermediate and late). Multivariate analysis of plasma NMR spectra was performed, followed by signal integration and univariate analysis.
   Results
   Small changes were detected in the levels of some amino acids, organic acids, dimethyl sulfone and specific lipid moieties, thus providing some biochemical information on the disease. The possible confounding effects of gender, smoking history and age were assessed in each cohort and found to be minimal when compared to that of the disease. A similar observation was noted in relation to age-related comorbidities. Furthermore, partially distinct putative AMD metabolite fingerprints were noted for the two cohorts studied, reflecting the importance of nutritional and other lifestyle habits in determining AMD metabolic response and potential biomarker fingerprints. Notably, some of the metabolite changes detected were noted as potentially differentiating controls from patients diagnosed with early AMD.
   Conclusion
   For the first time, this study showed metabolite changes in the plasma of patients with AMD as compared to controls, using NMR. Geographical origins were seen to affect AMD patients A metabolic profile and some metabolites were found to be valuable in potentially differentiating controls from early stage AMD patients. Metabolomics has the potential of identifying biomarkers for AMD, and further work in this area is warranted.
C1 [Lains, Ines; Miller, John B.; Kim, Ivana K.; Vavvas, Demetrios; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA USA.
   [Lains, Ines; Gil, Joao; Marques, Marco; da Luz Cachulo, Maria; Carreira, Isabel M.; Murta, Joaquim N.; Silva, Rufino] Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.
   [Lains, Ines; Gil, Joao; Marques, Marco; Mesquita, Tania; da Luz Cachulo, Maria; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Lains, Ines; Gil, Joao; Marques, Marco; da Luz Cachulo, Maria; Murta, Joaquim N.; Silva, Rufino] CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Duarte, Daniela; Barros, Antonio S.; Martins, Ana Sofia; Gil, Ana M.] Univ Aveiro, Dept Chem, CICECO Aveiro Inst Mat, UA, Aveiro, Portugal.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Universidade de Coimbra; Universidade de Coimbra;
   Universidade de Coimbra; Universidade de Aveiro
RP Gil, AM (通讯作者)，Univ Aveiro, Dept Chem, CICECO Aveiro Inst Mat, UA, Aveiro, Portugal.
EM agil@ua.pt
RI Carreira, Isabel M/C-7711-2018; Murta, Joaquim/V-5494-2017; Barros,
   António S./B-5847-2009; Miller, John J/GZG-5663-2022; Silva, Rufino
   M/J-2817-2012; Duarte, Daniela/AAD-3491-2020; Gil, Ana/O-3871-2019
OI Carreira, Isabel M/0000-0001-6842-1707; Murta,
   Joaquim/0000-0001-8926-5176; Barros, António S./0000-0002-9103-5852;
   Silva, Rufino M/0000-0001-8676-0833; Duarte,
   Daniela/0000-0001-9460-1162; Gil, Ana/0000-0003-3766-4364; Cachulo,
   Maria Luz/0000-0002-0900-4548; Husain, Deeba/0000-0002-8494-0950;
   Vavvas, Demetrios/0000-0002-8622-6478; Martins, Ana
   Sofia/0000-0001-6865-5853; Quadrado Gil, Joao/0000-0001-9032-1008;
   Lains, Ines/0000-0002-8136-4724; Kim, Ivana/0000-0003-0310-6129
FU Portuguese Foundation for Science and Technology [HMSP-ICJ/0006/2013];
   Miller Retina Research Fund (MEE); Miller Champalimaud Award (MEE);
   CICECOAveiro Institute of Materials [POCI-01-0145FEDER-007679, UlD
   /CTM/50011/2013]; national funds through the FCT/MEC; FEDER; FCT funds;
   Fundacao para a Ciencia e a Tecnologia (FCT) [HMSP-ICJ/ 0006/2013];
   NATIONAL EYE INSTITUTE [R21EY023079, R01EY025362] Funding Source: NIH
   RePORTER
FX This project was funded by the Portuguese Foundation for Science and
   Technology (HMSP-ICJ/0006/2013), the Miller Retina Research Fund (MEE)
   and the Miller Champalimaud Award (MEE). This work was also developed
   within the scope of the project CICECOAveiro Institute of Materials,
   POCI-01-0145FEDER-007679 (FCT ref. UlD /CTM/50011/2013), financed by
   national funds through the FCT/MEC and when appropriate co-financed by
   FEDER under the PT2020 Partnership Agreement. We also acknowledge the
   Portuguese National NMR Network (RNRMN), supported by FCT funds. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; This project was
   funded by the Fundacao para a Ciencia e a Tecnologia (FCT) (HMSP-ICJ/
   0006/2013), the Miller Retina Research Fund (MEE) and the Miller
   Champalimaud Award (MEE). This work was also developed within the scope
   of the project CICECO-Aveiro Institute of Materials,
   POCI-01-0145-FEDER-007679 (FCT Ref. UID /CTM /50011/2013), financed by
   national funds through the FCT/MEC and when appropriate co-financed by
   FEDER under the PT2020 Partnership Agreement. AMG acknowledges the
   Portuguese National NMR Network (RNRMN), supported by FCT funds.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barba I, 2010, INVEST OPHTH VIS SCI, V51, P4416, DOI 10.1167/iovs.10-5348
   Burgess LG, 2015, INVEST OPHTH VIS SCI, V56, P5020, DOI 10.1167/iovs.15-16702
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Chen LY, 2016, DIABETES, V65, P1099, DOI 10.2337/db15-0661
   Chen LY, 2011, J PROTEOME RES, V10, P4876, DOI 10.1021/pr2004874
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Diaz SO, 2013, J PROTEOME RES, V12, P2946, DOI 10.1021/pr4002355
   Duarte IF, 2012, PROG NUCL MAG RES SP, V62, P51, DOI 10.1016/j.pnmrs.2011.11.002
   Duarte IF, 2010, VIRCHOWS ARCH, V457, P715, DOI 10.1007/s00428-010-0993-6
   Fiehn O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833
   Guo JG, 2014, GRAEF ARCH CLIN EXP, V252, P925, DOI 10.1007/s00417-014-2619-1
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hedges L.V., 1981, J EDUC STAT, V6, P107, DOI [10.3102/10769986006002107, DOI 10.3102/10769986006002107]
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Karamichos D, 2015, EXP EYE RES, V132, P1, DOI 10.1016/j.exer.2015.01.007
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Li M, 2014, MOL BIOSYST, V10, P1055, DOI 10.1039/c3mb70386j
   Li X, 2011, MOL BIOSYST, V7, P2228, DOI 10.1039/c0mb00341g
   Midelfart A, 2009, ACTA OPHTHALMOL, V87, P697, DOI 10.1111/j.1755-3768.2009.01516.x
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Naes T., 1992, MULTIVARIATE CALIBRA
   Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708
   Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Pinto J, 2014, ANALYST, V139, P1168, DOI 10.1039/c3an02188b
   Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957
   Rocha CM, 2011, J PROTEOME RES, V10, P4314, DOI 10.1021/pr200550p
   Sobrin L, 2013, PROG RETIN EYE RES
   Suhre K, 2012, NAT REV GENET, V13, P759, DOI 10.1038/nrg3314
   Tan SZ, 2016, EYE, V30, P773, DOI 10.1038/eye.2016.37
   Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695
   Ugurlu N, 2013, CURR EYE RES, V38, P497, DOI 10.3109/02713683.2013.774023
   Veselkov KA, 2009, ANAL CHEM, V81, P56, DOI 10.1021/ac8011544
   Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923
   WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Young Stephen P, 2009, J Ocul Biol Dis Infor, V2, P235
   Young SP, 2009, MOL VIS, V15, P1210
NR 40
TC 39
Z9 40
U1 1
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 18
PY 2017
VL 12
IS 5
AR e0177749
DI 10.1371/journal.pone.0177749
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EV3PV
UT WOS:000401672400075
PM 28542375
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, DI
   Yoon, CK
   Yu, HG
AF Kim, Dong Ik
   Yoon, Chang Ki
   Yu, Hyeong Gon
TI Unilateral Cilioretinal Artery and Advanced Age-Related Macular
   Degeneration: A Retrospective Cross-Sectional Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; PATHOGENESIS; RISK
AB PURPOSE: To investigate the association between the presence of a cilioretinal artery (CRA) and advanced age-related macular degeneration (AMD), including the prevalence of choroidal neovascularization (CNV) and geographic atrophy (GA).
   DESIGN: Retrospective cross-sectional study.
   METHODS: This was a single-center study. A total of 738 patients with AMD who underwent optical coherence tomography angiography (OCTA) were included in the study. Fundus photographs were reviewed to determine the presence of the CRA. In patients with a unilateral CRA, paired tests were performed between eyes with and without the CRA to compare AMD severity and prevalence of CNV and GA. The main outcomes of interest were AMD stage and prevalence of CNV and GA. Macular vasculature, including vessel density, perfusion density, and foveal avascular zone, were examined using OCTA.
   RESULTS: A total of 174 eyes from 87 patients with a unilateral CRA were examined. A total of 27.8% and 8.1% of patients had a CRA in 1 eye and both eyes, respectively. Eyes with a CRA showed lower AMD stage (4-step AREDS category; P = .037) and a lower prevalence of CNV (23.0% vs 41.4%; P = .024) than those without a CRA. The prevalence of GA and macular vessel density, perfusion density, and foveal avascular zone measured by OCTA were similar in both groups.
   CONCLUSIONS: In the eyes with a CRA, AMD stage and prevalence of CNV were lower than those in the eyes without a CRA. However, the effect of the CRA on the macular vascular system remains unclear. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, 103 Daehak Ro, Seoul 110799, South Korea.
   Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital
RP Yu, HG (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, 103 Daehak Ro, Seoul 110799, South Korea.
EM hgonyu@snu.ac.kr
OI Yoon, Chang Ki/0000-0003-4637-8044
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bavinger JC, 2019, JAMA OPHTHALMOL, V137, P1306, DOI 10.1001/jamaophthalmol.2019.3509
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hayreh SS, 2014, OCULAR VASCULAR OCCL, P55
   Inan UU, 2007, KLIN MONATSBL AUGENH, V224, P127, DOI 10.1055/s-2006-927316
   Ishii H, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.28
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rabiolo A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205773
   Scharf J, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040751
   Snyder K, 2018, JAMA OPHTHALMOL, V136, P1008, DOI 10.1001/jamaophthalmol.2018.2650
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Zhu XJ, 2020, OPHTHALMOL RETINA, V4, P965, DOI 10.1016/j.oret.2020.05.014
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2022
VL 237
BP 204
EP 210
DI 10.1016/j.ajo.2021.10.033
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3E8KI
UT WOS:000830227300022
PM 34780795
DA 2022-11-30
ER

PT J
AU Bilgic, A
   Kodjikian, L
   de Ribot, FM
   Vasavada, V
   Gonzalez-Cortes, JH
   Abukashabah, A
   Sudhalkar, A
   Mathis, T
AF Bilgic, Alper
   Kodjikian, Laurent
   March de Ribot, Francesc
   Vasavada, Vaishali
   Gonzalez-Cortes, Jesus H.
   Abukashabah, Amro
   Sudhalkar, Aditya
   Mathis, Thibaud
TI Real-World Experience with Brolucizumab in Wet Age-Related Macular
   Degeneration: The REBA Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; brolucizumab; exudation; switch therapy
ID RANIBIZUMAB; HORIZON; HOLE
AB The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. The REBA study (real-world experience with brolucizumab in wet AMD) was a retrospective, observational, multicentric study that included 78 consecutive patients (105 eyes), with neovascular AMD, who received brolucizumab therapy. Both treatment-naive and switch-therapy patients were included. Switch therapy was based either on fluid recurrence, fluid recalcitrance, or inability to extend beyond q4/q6. All relevant data were collected. The primary outcome measure was change in best-corrected visual acuity (BCVA) over time. Secondary outcome measures included determination of change in central subfield thickness (CST) and complications. The mean baseline BCVA was 49.4 +/- 5.4 letters and 40 +/- 3.2 letters, and corresponding mean BCVA gain was +11.9 +/- 3.9 letters (p = 0.011) and +10.4 +/- 4.8 letters (p = 0.014) in the treatment-naive and switch-therapy groups, respectively. The change in CST was significantly decreased in the treatment-naive (p = 0.021) and the switch-therapy (p = 0.013) groups. The mean follow-up was 10.4 months in both groups. One patient in the switch-therapy group developed vascular occlusion and another a macular hole after the fifth brolucizumab injection. Both patients recovered uneventfully. In conclusion, patients showed a very good anatomical and functional response to brolucizumab therapy in the real world, regardless of prior treatment status, until the end of the follow-up period. Two significant untoward events were noted.
C1 [Bilgic, Alper; Sudhalkar, Aditya] Alphavis Augenarztpraxis, D-27568 Bremerhaven, Germany.
   [Kodjikian, Laurent; Mathis, Thibaud] Univ Claude Bernard Lyon 1, Hosp Civils Lyon, CHU Croix Rousse, Serv Ophtalmol, F-69004 Lyon, France.
   [Kodjikian, Laurent; Mathis, Thibaud] CNRS, UMR 5510, Mateis, F-69004 Lyon, France.
   [March de Ribot, Francesc] Univ Autonoma Barcelona, Dept Ophthalmol, Barcelona 08003, Spain.
   [Vasavada, Vaishali] Raghudeep Eye Hosp, Ahmadabad 380054, Gujarat, India.
   [Gonzalez-Cortes, Jesus H.] Univ Autonoma Ciudad, Dept Ophthalmol, Mexico City 06720, DF, Mexico.
   [Abukashabah, Amro] King Abdulaziz Univ, Ophthalmol Dept, Rabigh 25732, Saudi Arabia.
   [Sudhalkar, Aditya] MS Sudhalkar Med Res Fdn, Baroda 390001, Gujarat, India.
C3 CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard
   Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS -
   Institute for Engineering & Systems Sciences (INSIS); Institut National
   des Sciences Appliquees de Lyon - INSA Lyon; Autonomous University of
   Barcelona; King Abdulaziz University
RP Sudhalkar, A (通讯作者)，Alphavis Augenarztpraxis, D-27568 Bremerhaven, Germany.; Sudhalkar, A (通讯作者)，MS Sudhalkar Med Res Fdn, Baroda 390001, Gujarat, India.
EM drbilgicalper@yahoo.com; laurent.kodjikian@chu-lyon.fr;
   marchfrancesc@gmail.com; vaishali@raghudeepeyeclinic.com;
   drjesusgzz@gmail.com; dr.heartaaa@hotmail.com;
   adityasudhalkar@yahoo.com; thibaud.mathis@chu-lyon.fr
RI ; kodjikian, laurent/A-3025-2015
OI March de Ribot, Francesc/0000-0002-9438-4740; kodjikian,
   laurent/0000-0002-3908-6716; Gonzalez-Cortes, Jesus
   Hernan/0000-0002-8936-5940
CR [Anonymous], NOVARTIS CONFIDENT B
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Baumal C.R., 2020, OPHTHALMOL RETINA, V7, P958
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bilgic A., 2021, RETINA-J RET VIT DIS, DOI [10.1097/IAE.0000000000003106, DOI 10.1097/IAE.0000000000003106]
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112425
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grigoropoulos V, 2010, EUR J OPHTHALMOL, V20, P469, DOI 10.1177/112067211002000235
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Kabanarou SA, 2017, CLIN INTERV AGING, V12, P911, DOI 10.2147/CIA.S135364
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Miura Masahiro, 2011, Retin Cases Brief Rep, V5, P149, DOI 10.1097/ICB.0b013e3181cd1da1
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Puxeddu I, 2016, CLIN EXP RHEUMATOL, V34, P129
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
NR 25
TC 12
Z9 12
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2021
VL 10
IS 13
AR 2758
DI 10.3390/jcm10132758
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TF9EN
UT WOS:000671017500001
PM 34201729
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pavelic, SK
   Klobucar, M
   Sedic, M
   Micek, V
   Gehrig, P
   Grossman, J
   Pavelic, K
   Vojnikovic, B
AF Pavelic, Sandra Kraljevic
   Klobucar, Marko
   Sedic, Mirela
   Micek, Vedran
   Gehrig, Peter
   Grossman, Jonas
   Pavelic, Kresimir
   Vojnikovic, Bozidar
TI UV-induced retinal proteome changes in the rat model of age-related
   macular degeneration
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Age-related macular degeneration; UV irradiation; Oxidative stress;
   Interphotoreceptor matrix; Retinal pigment epithelium; Proteomics
ID PIGMENT EPITHELIUM; CORNEAL OPACITY; LUMICAN; RISK; GLYCOLYSIS;
   PREVALENCE; DISRUPTION; EXPRESSION; RADIATION; GALECTINS
AB Age-related macular degeneration (AMD) is characterized by irreversible damage of photoreceptors in the central posterior part of the retina, called the macula and is the most common cause of vision loss in those aged over 50. A growing body of evidence shows that cumulative long-term exposure to UV radiation may be harmful to the retina and possibly leads to AMD irrespective of age. In spite of many research efforts, cellular and molecular mechanisms leading to UV-induced retinal damage and possibly retinal diseases such as AMD are not completely understood. In the present study we explored damage mechanisms accounting for IN-induced retinal phototoxicity in the rats exposed to UVA and UVB irradiation using a proteomics approach. Our study showed that UV irradiation induces profound changes in the retinal proteomes of the rats associated with the disruption of energy homeostasis, oxidative stress, DNA damage response and structural and functional impairments of the interphotoreceptor matrix components and their cell surface receptors such as galectins. Two small leucinerich proteoglycans, biglycan and lumican, were identified as phototoxicity biomarkers associated with UV-induced disruption of interphotoreceptor matrix (IPM). In addition, UVB induced activation of Src kinase, which could account for cytoskeletal rearrangements in the retina was observed at the proteomics level. Pharmacological intervention either to target Src kinase with the aim of preventing cytoskeletal rearrangements in the retinal pigment epithelium (RPE) and neuronal retina or to help rebuild damaged IPM may provide fresh avenues of treatment for patients suffering from AMD. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Pavelic, Sandra Kraljevic; Klobucar, Marko; Sedic, Mirela; Pavelic, Kresimir] Univ Rijeka, Dept Biotechnol, HR-51000 Rijeka, Croatia.
   [Pavelic, Sandra Kraljevic; Klobucar, Marko; Sedic, Mirela; Pavelic, Kresimir] Univ Rijeka, Ctr High Throughput Technol, HR-51000 Rijeka, Croatia.
   [Micek, Vedran] Inst Med Res & Occupat Hlth, HR-10001 Zagreb, Croatia.
   [Gehrig, Peter; Grossman, Jonas] Univ Zurich, ETH Zurich, Funct Genom Ctr Zurich, CH-8057 Zurich, Switzerland.
   [Vojnikovic, Bozidar] Univ Appl Sci Velika Gorica, Velika Gorica 10410, Croatia.
C3 University of Rijeka; University of Rijeka; Institute for Medical
   Research & Occupational Health (IMROH); Swiss Federal Institutes of
   Technology Domain; ETH Zurich; University of Zurich
RP Pavelic, SK (通讯作者)，Univ Rijeka, Dept Biotechnol, Radmile Matejcic 2, HR-51000 Rijeka, Croatia.
EM sandrakp@biotech.uniri.hr
RI Pavelić, Krešimir/T-2002-2018; Pavelić, Sandra Kraljević/J-3864-2012;
   Sedić, Mirela/R-4346-2018; Klobučar, Marko/S-4170-2018
OI Pavelić, Krešimir/0000-0001-7706-6858; Pavelić, Sandra
   Kraljević/0000-0003-0491-673X; Sedić, Mirela/0000-0003-4679-1541;
   Klobučar, Marko/0000-0002-8625-126X
FU FGCZ project [PRIME-XS-0000184]; University of Rijeka [511-21, 511-10,
   511-22]
FX Funding/support: Support from the FGCZ project "Proteomic profiling of
   retinal proteins from rat model of age-related macular degeneration"
   (PRIME-XS-0000184) and the University of Rijeka research projects
   (numbers 511-21,511-10 and 511-22) is highly acknowledged. Authors'
   contributions: SKP and MK declare equal contribution in preparation of
   the manuscript. SKP and MK performed the study design, literature
   search, results analysis, data presentation, writing of the manuscript,
   preparation of biological samples for proteomics analyses. MS performed
   literature search, results interpretation and manuscript writing, VM
   performed the in vivo study, PG performed mass spectrometry analyses, JG
   performed bioinformatics analyses, KP supervised the project, performed
   extensive literature search, and final proofreading of the manuscript BV
   performed UV-exposure of rats, collection of retina specimens and
   clinical interpretation of data
CR Alge CS, 2006, INVEST OPHTH VIS SCI, V47, P415, DOI 10.1167/iovs.05-0308
   Alge-Priglinger CS, 2011, BIOCHIMIE, V93, P477, DOI 10.1016/j.biochi.2010.10.021
   Ali SAM, 2011, J VET MED SCI, V73, P13, DOI 10.1292/jvms.10-0201
   Ali SAM, 2011, J VET MED SCI, V73, P439, DOI 10.1292/jvms.10-0464
   Amjadi S., 2013, ISRN OPHTHALMOL, V2013
   Austin BA, 2002, INVEST OPHTH VIS SCI, V43, P1695
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Byun K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037917
   Cachafeiro M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.303
   Cao Z, 2005, GLYCOBIOLOGY, V15, P1218
   Cao ZY, 2003, ARCH OPHTHALMOL-CHIC, V121, P82
   Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365
   Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Chung SH, 2013, INVEST OPHTH VIS SCI, V54, P6578, DOI 10.1167/iovs.13-12311
   Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979
   Ellen TP, 2008, CARCINOGENESIS, V29, P2, DOI 10.1093/carcin/bgm200
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Ghalayini AJ, 2002, J BIOL CHEM, V277, P1469, DOI 10.1074/jbc.M011432200
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hayashi Y, 2010, J CELL SCI, V123, P2987, DOI 10.1242/jcs.068221
   Hegde KR, 2010, MOL CELL BIOCHEM, V343, P101, DOI 10.1007/s11010-010-0503-9
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kall L, 2008, J PROTEOME RES, V7, P29, DOI 10.1021/pr700600n
   Kao WWY, 2006, EXP EYE RES, V82, P3, DOI 10.1016/j.exer.2005.08.012
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Moran SD, 2013, BIOCHEMISTRY-US, V52, P6169, DOI 10.1021/bi4008353
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   PIATIGORSKY J, 1989, FASEB J, V3, P1933, DOI 10.1096/fasebj.3.8.2656357
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Rastogi RP, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/592980
   Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Uehara F, 2001, INVEST OPHTH VIS SCI, V42, P2164
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P29
   Vojnikovic B, 2010, COLLEGIUM ANTROPOL, V34, P5
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Xia Z, 2013, SCI REP-UK, V3, DOI 10.1038/srep01560
   Yokosako K, 2014, OPEN OPHTHALMOL J, V8, P39, DOI 10.2174/1874364101408010039
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zuniga FI, 2010, INVEST OPHTH VIS SCI, V51, P4407, DOI 10.1167/iovs.10-5251
NR 52
TC 13
Z9 13
U1 1
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD SEP
PY 2015
VL 1852
IS 9
BP 1833
EP 1845
DI 10.1016/j.bbadis.2015.06.006
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CP5XQ
UT WOS:000359959100015
PM 26071645
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Krause, L
   Yousif, T
   Pohl, K
AF Krause, Lothar
   Yousif, Tarik
   Pohl, Karin
CA CAPTAIN Study Grp
TI An epidemiological study of neovascular age-related macular degeneration
   in Germany
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE AMD diagnosis; AMD epidemiology; AMD treatment; Neovascular age-related
   macular degeneration; Optical coherence tomography
ID BLUE MOUNTAINS EYE; INTRAVITREAL RANIBIZUMAB LUCENTIS; VISUAL
   IMPAIRMENT; RISK-FACTORS; PREVALENCE; MACULOPATHY; TRIAL; OLDER;
   POPULATION; ANCHOR
AB Objective:
   Neovascular or wet age-related macular degeneration (AMD) is one of the leading causes of blindness in industrialized countries; however, there is a lack of recent epidemiological data from Germany. The aim of this study was to collect epidemiological data from patients in Germany with suspected neovascular AMD and evaluate the diagnostic procedures performed and treatments used at clinics.
   Methods:
   This was a Germany-based, multicentre, retrospective review of data from patients with suspected neovascular AMD visiting ophthalmology clinics over an 18 month period in 2008-10. Clinical characteristics, functional symptoms and examination results were recorded. In addition, ophthalmologists completed a questionnaire on neovascular AMD diagnosis and treatment.
   Results:
   Ten sites collected data from 2498 patients (64.0% female) with a mean decimal visual acuity of 0.4 +/- 0.3 at the time of diagnosis of neovascular AMD. The mean age at the time of diagnosis was 76.9 +/- 8.9 years for patients with the right eye affected and 77.0 +/- 8.3 years for patients with the left eye affected. The most frequent pathological findings detected by routine ophthalmic examination were old lesions (31.2%), intra/subretinal fluid (18.1%), new lesions (13.0%), and intra/subretinal haemorrhage (11.4%). A confirmed diagnosis of neovascular AMD was most frequently based on fundoscopy (67.3%), fluorescein angiography (39.6%), and biomicroscopy (35.7%) tests but rarely on optical coherence tomography (8.9%). The most frequently documented comorbidity with neovascular AMD was hypertension and other cardiovascular diseases (57.5%). Seven ophthalmologists completed the questionnaire with the majority of ophthalmologists agreeing that regular ophthalmic examination can prevent the development of late-stage neovascular AMD.
   Conclusion:
   Neovascular AMD is a frequent diagnosis in German ophthalmology clinics. As visual acuity is already poor in most patients with suspected neovascular AMD, regular preventive ophthalmologic examinations should be considered in high risk patients.
   Study limitations:
   Limitations of the study include the lack of a comparator cohort, which limited the amount of analyses that could be performed. Additionally, a study eye was not defined and information was collected separately for each affected eye and therefore analysed separately. Furthermore, a small number of ophthalmologists completed the questionnaire, limiting the objectivity.
C1 [Krause, Lothar] Municipal Hosp Dessau, D-06847 Dessau, Germany.
   [Pohl, Karin] Novartis Pharma GmbH, Nurnberg, Germany.
C3 Dessau Medical Center; Novartis
RP Krause, L (通讯作者)，Municipal Hosp Dessau, Dept Ophthalmol, Auenweg 38, D-06847 Dessau, Germany.
EM lothar.krause@klinikum-dessau.de
FU Novartis Pharmaceuticals, Nuremberg, Germany
FX This study was sponsored by Novartis Pharmaceuticals, Nuremberg,
   Germany.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho M, 2010, BRIT J OPHTHALMOL, V94, P597, DOI 10.1136/bjo.2008.149724
   Current opinion of the German Ophthalmological Society and the Retina Society the Professional Association of German Ophthalmologists, 2012, CURRENT OPINION GERM
   Ernst Benjamin J., 2010, International Ophthalmology, V30, P267, DOI 10.1007/s10792-009-9324-9
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hawkins BS, 1999, MOL VIS, V5
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 24
TC 10
Z9 11
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD OCT
PY 2013
VL 29
IS 10
BP 1391
EP 1397
DI 10.1185/03007995.2013.832184
PG 7
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 220WZ
UT WOS:000324619300016
PM 23944372
DA 2022-11-30
ER

PT J
AU Chen, R
   Wu, B
AF Chen, Rui
   Wu, Bin
TI Cost-effectiveness of intravitreal conbercept versus other treatments
   for wet age-related macular degeneration
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Age-related macular degeneration (AMD); ranibizumab; conbercept;
   aflibercept; cost-effectiveness
ID RANIBIZUMAB; AFLIBERCEPT; UTILITY; CARE
AB Background: The potential benefits of conbercept, aflibercept, and ranibizumab has been reported in patients with wet age-related macular degeneration (wAMD). However, their economic outcomes are still unclear. The current study would assess the cost-effectiveness of conbercept, aflibercept and ranibizumab for patients with wAMD in a Chinese healthcare setting.
   Methods: A Markov model was constructed based on patient visual acuity. Five regimens were considered: usual care without active anti-vascular endothelial growth factor (VEGF) treatment, IVT-AFL (intravitreal aflibercept on a two-monthly basis following three initial monthly doses), RBZ q4 (ranibizumab monthly dosing), RBZ RPN (ranibizumab dose as needed) and IVT-CON (intravitreal conbercept on a three-monthly basis after three initial monthly doses). Clinical, cost, and utility data were collected from published literature.
   Results: In comparison with usual care, the IVT-AFL, RBZ q4, RBZ PRN, and IVT-CON strategies provided an additional 0.235, 0.338, 0.228, and 0.324 quality-adjusted life years (QALYs), respectively. They had marginal costs of $6,800, $10,084, $4,640, and $6,173, respectively. The strategies also produced incremental cost-effectiveness ratios (ICERs) of $28,892, $29,857, $20,338 and $19,028/QALY, respectively. One-way sensitivity analysis showed utility of blindness (best-corrected visual acuity <35) to have the greatest sensitivity of all the parameters. Probabilistic sensitivity analysis (PSA) indicated that IVT-CON yielded the greatest probabilities of cost-effectiveness (about 92%) compared with other strategies.
   Conclusions: Conbercept is a cost-effective option for the treatment of wAMD in a Chinese healthcare setting.
C1 [Chen, Rui] Second Peoples Hosp Foshan, Dept Ophthalmol, Foshan, Peoples R China.
   [Wu, Bin] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Med Decis & Econ Grp,Dept Pharm, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wu, B (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Pharm, Shanghai 200240, Peoples R China.
EM scilwsjtu-wb@yahoo.com
CR Alexander M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.11.20
   Bian W, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018756
   Cheng CY, 2020, BRIT J OPHTHALMOL, V104, P616, DOI 10.1136/bjophthalmol-2018-313308
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Elshout M, 2018, ACTA OPHTHALMOL, V96, P770, DOI 10.1111/aos.13824
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   Hodgson R, 2017, ADV THER, V34, P2360, DOI 10.1007/s12325-017-0620-x
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kyu HH, 2018, LANCET, V392, P1859, DOI [10.1016/S0140-6736(18)32335-3, 10.1016/s0140-6736(18)32335-3]
   Li Hong, 2018, Value Health Reg Issues, V15, P133, DOI 10.1016/j.vhri.2018.01.009
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Sun WH, 2015, J ENVIRON SCI-CHINA, V34, P63, DOI 10.1016/j.jes.2015.01.020
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Visser MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169816
   Wong TY, 2019, RETINA-J RET VIT DIS, V39, P537, DOI 10.1097/IAE.0000000000001986
   Wu B, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7689862
   Xiao J, 2017, Zhonghua Yu Fang Yi Xue Za Zhi, V51, P276, DOI 10.3760/cma.j.issn.0253-9624.2017.03.016
   Yanagi Y, 2017, J MED ECON, V20, P204, DOI 10.1080/13696998.2016.1245196
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhao M, 2015, VALUE HEALTH, V18, pA421, DOI 10.1016/j.jval.2015.09.558
NR 30
TC 2
Z9 3
U1 0
U2 4
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD AUG
PY 2020
VL 8
IS 15
AR 939
DI 10.21037/atm-20-1334
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA ND4SG
UT WOS:000561891400030
PM 32953739
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Denniss, J
   Astle, AT
AF Denniss, Jonathan
   Astle, Andrew T.
TI Modified images reflecting effects of age-related macular degeneration
   on perception of everyday scenes
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration vision; AMD vision; central vision
   loss; natural scene perception; scotoma perception
ID GLAUCOMA
AB Background: Depictions of vision with age-related macular degeneration (AMD) in public information material typically show a central region of absolute vision loss. Patients with early and moderate disease frequently do not report this. We aimed to measure how a group of people with AMD perceive everyday scenes in order to produce accurate depictions.
   Methods: We report on six people aged 65-82 years with monocular AMD (visual acuity +0.04 to +1.64 logMAR) and normal vision in the fellow eye. Participants viewed four images monocularly, alternating between eyes. The image was digitally altered to approximate participants' descriptions of their perception with the affected eye. The altered image was viewed with the unaffected eye, and compared with the original image viewed with the affected eye. This was repeated iteratively until a perceptual match was achieved between the modified image/unaffected eye and the original image/affected eye.
   Results: For five AMD participants with visual acuity +0.04 to +0.50 logMAR the modified images did not resemble those in current public information material. Image modifications required to achieve perceptual similarity with the affected eyes included localised distortion, contrast reduction and blur. Widespread colour desaturation was also required in some cases. One participant with advanced geographic atrophy reported an absolute positive scotoma, similar to existing depictions.
   Conclusions: Vision in people with AMD may not conform to the common depiction of a central region of absolute vision loss. The accurate representations of AMD patients' vision produced in this study will enable better understanding of the visual consequences of AMD.
C1 [Denniss, Jonathan; Astle, Andrew T.] Univ Nottingham, Sch Psychol, Visual Neurosci Grp, Nottingham, England.
   [Denniss, Jonathan] Univ Bradford, Fac Life Sci, Sch Optometry & Vis Sci, Bradford, W Yorkshire, England.
C3 University of Nottingham; University of Bradford
RP Denniss, J (通讯作者)，Univ Nottingham, Sch Psychol, Visual Neurosci Grp, Nottingham, England.; Denniss, J (通讯作者)，Univ Bradford, Fac Life Sci, Sch Optometry & Vis Sci, Bradford, W Yorkshire, England.
EM j.denniss@bradford.ac.uk
FU College of Optometrists Postdoctoral Award; National Institute for
   Health Research (NIHR) Postdoctoral Fellowship; NIHR
FX This work was supported by a College of Optometrists Postdoctoral Award
   (Jonathan Denniss and Andrew Astle). Andrew Astle is supported by a
   National Institute for Health Research (NIHR) Postdoctoral Fellowship.
   This report presents independent research funded by the NIHR. The views
   expressed are those of the authors and not necessarily those of the
   National Health Service, the NIHR or the Department of Health. The
   sponsor or funding organisation had no role in the design or conduct of
   this research.
CR Allen L, 2000, HOLE MY VISION ARTIS
   Anstis S, 1998, PERCEPTION, V27, P817, DOI 10.1068/p270817
   Barrett BT, 2003, INVEST OPHTH VIS SCI, V44, P1555, DOI 10.1167/iovs.02-0515
   Crabb DP, 2013, OPHTHALMOLOGY, V120, P1120, DOI 10.1016/j.ophtha.2012.11.043
   Crossland M., 2007, VISUAL IMPAIRMENT RE, V9, P59, DOI DOI 10.1080/13882350701643582
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Fletcher Donald C, 2012, Optom Vis Sci, V89, P1395, DOI 10.1097/OPX.0b013e318264cc77
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Marmor DJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P117, DOI 10.1001/archophthalmol.2009.366
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SPERDUTO RD, 1983, JAMA-J AM MED ASSOC, V250, P2506, DOI 10.1001/jama.250.18.2506
   THIBOS LN, 1987, J OPT SOC AM A, V4, P1524, DOI 10.1364/JOSAA.4.001524
NR 13
TC 3
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2018
VL 101
IS 5
BP 686
EP 691
DI 10.1111/cxo.12672
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR8PG
UT WOS:000442986200011
PM 29506321
DA 2022-11-30
ER

PT J
AU Wilde, C
   Patel, M
   Lakshmanan, A
   Morales, MA
   Dhar-Munshi, S
   Amoaku, WMK
AF Wilde, Craig
   Patel, Moneesh
   Lakshmanan, Arun
   Morales, Marco A.
   Dhar-Munshi, Sushma
   Amoaku, Winfried M. K.
TI Prevalence of reticular pseudodrusen in eyes with newly presenting
   neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Reticular drusen; Reticular macular
   disease; Reticular pseudodrusen; Subretinal drusenoid deposits
ID RETINAL ANGIOMATOUS PROLIFERATION; SUBRETINAL DRUSENOID DEPOSITS;
   GEOGRAPHIC-ATROPHY; FELLOW-EYES; CHOROIDAL NEOVASCULARIZATION; CLINICAL
   CHARACTERISTICS; JAPANESE PATIENTS; GRADING SYSTEM; RISK-FACTOR;
   MACULOPATHY
AB Purpose: To use multimodal imaging to evaluate the prevalence of reticular pseudodrusen (RPD) in eyes with newly presenting neovascular age-related macular degeneration (nAMD) in a UK population and explore associations with RPD and angiographic subtypes of nAMD.
   Methods: A retrospective review of all spectral-domain optical coherence tomography, color fundus photographs, red-free and blue channel images, and fundus fluorescein angiograms of 202 consecutive patients who presented to a rapid access macular clinic over a 4-year period was performed. All images were graded by at least 2 ophthalmologists for the presence of RPD and choroidal neovascular membrane (CNV) subtypes.
   Results: A total of 231 consecutive eyes were studied, of which 131 (56.7%) were in women. Of these, 51 eyes with CNV (22.1%) had identifiable RPD, with one or more imaging methods in that eye. A total of 30.3% of patients with newly presenting CNV in either or both eyes had identifiable RPD. The RPD were bilateral in 85.4% of patients and were identified more commonly in women than men (72.5% vs 27.5%), a difference that reached statistical significance (p = 0.011). No association between RPD and any particular CNV subtype was demonstrated, including for retinal angiomatous proliferations (RAP).
   Conclusions: Reticular pseudodrusen have a high prevalence in eyes presenting with nAMD (22.1%), although at rates much lower than that of conventional drusen. They are largely a bilateral finding, occurring more frequently in women. Unlike other previous reports, we found no difference in their occurrence between the different subtypes of CNV including RAPs.
C1 [Wilde, Craig; Morales, Marco A.; Amoaku, Winfried M. K.] Univ Nottingham, Div Clin Neurosci, Ophthalmol & Vis Sci, EENT Ctr,Queens Med Ctr, B Floor, Nottingham NG7 2RD, England.
   [Patel, Moneesh] Derby Hosp NHS Fdn Trust, Ophthalmol, Derby, England.
   [Lakshmanan, Arun] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Nottingham, England.
   [Dhar-Munshi, Sushma] Sherwood Forest Hosp NHS Fdn Trust, Sutton In Ashfield, England.
C3 University of Nottingham; Nottingham University Hospital NHS Trust;
   University of Nottingham
RP Amoaku, WMK (通讯作者)，Queens Med Ctr, Ophthalmol & Vis Sci, Div Clin Neurosci, EENT Ctr, B Floor,Derby Rd, Nottingham NG7 2UH, England.
EM Winfried.Amoaku@nottingham.ac.uk
OI Amoaku, Winfried/0000-0001-5028-7984
FU Macular Society UK
FX Supported by a research grant from the Macular Society UK.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 33
TC 16
Z9 16
U1 0
U2 1
PU WICHTIG PUBLISHING
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2016
VL 26
IS 2
BP 128
EP 134
DI 10.5301/ejo.5000661
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DN4PN
UT WOS:000377049800015
PM 26350997
DA 2022-11-30
ER

PT J
AU Tuo, JS
   Bojanowski, CM
   Zhou, M
   Shen, DF
   Ross, RJ
   Rosenberg, KI
   Cameron, DJ
   Yin, CY
   Kowalak, JA
   Zhuang, ZP
   Zhang, K
   Chan, CC
AF Tuo, Jingsheng
   Bojanowski, Christine M.
   Zhou, Min
   Shen, Defen
   Ross, Robert J.
   Rosenberg, Kevin I.
   Cameron, D. Joshua
   Yin, Chunyue
   Kowalak, Jeffrey A.
   Zhuang, Zhengping
   Zhang, Kang
   Chan, Chi-Chao
TI Murine Ccl2/Cx3cr1 deficiency results in retinal lesions mimicking human
   age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; BASAL LAMINAR DEPOSIT; ENDOPLASMIC-RETICULUM;
   FRACTALKINE RECEPTOR; PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULARIZATION;
   LIPOFUSCIN ACCUMULATION; INDUCED APOPTOSIS; DRUSEN FORMATION; TRANSGENIC
   MICE
AB PURPOSE. Senescent Ccl2(-/-) mice are reported to develop cardinal features of human age-related macular degeneration (AMD). Loss-of-function single-nucleotide polymorphisms within CX3CR1 are also found to be associated with AMD. The authors generated Ccl2(-/-) /Cx3cr1(-/-) mice to establish a more characteristic and reproducible AMD model.
   METHODS. Single Ccl2- and Cx3cr1-deficient mice were crossbred to obtain Ccl2(-/-) /Cx3cr1(-/-) mice. Funduscopy, histopathology, retinal A2E quantification, proteomics, RT-PCR gene expression assay, immunochemistry, and Western blotting were used to examine the retina and to evaluate gene expression within the retinal tissue.
   RESULTS. By 6 weeks of age, all Ccl2(-/-) /Cx3cr1(-/-) mice developed AMD-like retinal lesions, including drusen, retinal pigment epithelium alteration, and photoreceptor degeneration. Furthermore, choroidal neovascularization occurred in 15% of the mice. These degenerative lesions progressed with age. A2E, a major lipofuscin fluorophore that accumulated during AMD progression, was significantly higher in the Ccl2(-/-) /Cx3cr1(-/-) retina than in the wild-type retina. Complement cofactor was higher in the Ccl2(-/-) /Cx3cr1(-/-) RPE. Proteomics data indicated that four proteins were differentially expressed in Ccl2(-/-) /Cx3cr1(-/-) retina compared with control. One of these proteins, ERp29, an endoplasmic reticulum protein, functions as an escort chaperone and in protein folding.
   CONCLUSIONS. The authors concluded that Ccl2(-/-) /Cx3cr1(-/-) mice develop a broad spectrum of AMD abnormalities with early onset and high penetrance. These observations implicate certain chemokines and endoplasmic reticulum proteins in AMD pathogenesis. Similar to the mechanism of neurodegeneration caused by dysfunction of endoplasmic reticulum proteins, decreased chaperoning may cause misfolded protein accumulation, leading to drusen formation and retinal degeneration.
C1 NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.
   NIMH, Lab Neurotoxicol, NIH, Bethesda, MD 20892 USA.
   Univ Utah, John Moran Eye Ctr, Salt Lake City, UT USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Institute
   of Neurological Disorders & Stroke (NINDS); National Institutes of
   Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Utah
   System of Higher Education; University of Utah
RP Chan, CC (通讯作者)，NEI, Immunol Lab, NIH, 10-10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697; Tuo, Jingsheng/0000-0002-1372-7810
FU NATIONAL EYE INSTITUTE [Z01EY000418, Z01EY000461, Z01EY000222] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH000274]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL
   DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER;
   Intramural NIH HHS [Z01 EY000418-04] Funding Source: Medline
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Azfer A, 2006, AM J PHYSIOL-HEART C, V291, pH1411, DOI 10.1152/ajpheart.01378.2005
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476
   Bruno V, 2000, EUR J PHARMACOL, V399, P117, DOI 10.1016/S0014-2999(00)00367-8
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Carter DA, 2004, CURR EYE RES, V28, P427, DOI 10.1080/02713680490503778
   CHAN CC, 1985, CLIN IMMUNOL IMMUNOP, V35, P103, DOI 10.1016/0090-1229(85)90083-2
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chang ML, 2006, NEUROSCI RES, V54, P202, DOI 10.1016/j.neures.2005.11.010
   Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42
   Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Demmer J, 1997, FEBS LETT, V402, P145, DOI 10.1016/S0014-5793(96)01513-X
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELIZABETH RP, 2006, EXP EYE RES, V82, P741, DOI DOI 10.1016/J.EXER.2005.10.012
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Eugenin EA, 2003, J NEUROCHEM, V85, P1299, DOI 10.1046/j.1471-4159.2003.01775.x
   Fang IM, 2005, MOL VIS, V11, P443
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Green W R, 1999, Mol Vis, V5, P27
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455
   Hermann VM, 2005, J BIOL CHEM, V280, P13529, DOI 10.1074/jbc.M410889200
   Hubbard MJ, 2002, PROTEOMICS, V2, P1069, DOI 10.1002/1615-9861(200209)2:9<1069::AID-PROT1069>3.0.CO;2-R
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hulshof S, 2003, J NEUROPATH EXP NEUR, V62, P899, DOI 10.1093/jnen/62.9.899
   Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Karan G, 2005, MOL VIS, V11, P657
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Khan MZ, 2003, J NEUROVIROL, V9, P300, DOI 10.1080/13550280390201010
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Li DY, 2004, BIOCHEM BIOPH RES CO, V318, P253, DOI 10.1016/j.bbrc.2004.04.022
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   Mkrtchian S, 2006, ANTIOXID REDOX SIGN, V8, P325, DOI 10.1089/ars.2006.8.325
   Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925
   Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okamoto H, 2006, CANCER RES, V66, P10199, DOI 10.1158/0008-5472.CAN-06-0955
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Paschen W, 2003, CELL CALCIUM, V34, P365, DOI 10.1016/S0143-4160(03)00139-8
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Riley-Vargas RC, 2004, TRENDS IMMUNOL, V25, P496, DOI 10.1016/j.it.2004.07.004
   Roybal CN, 2005, INVEST OPHTH VIS SCI, V46, P3973, DOI 10.1167/iovs.05-0070
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Shen DF, 2006, OPHTHALMIC RES, V38, P71, DOI 10.1159/000090266
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   Sunnemark D, 2003, BRAIN PATHOL, V13, P617
   Tarzami ST, 2005, BIOCHEM BIOPH RES CO, V335, P1008, DOI 10.1016/j.bbrc.2005.07.168
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Zhang C, 2005, MOL VIS, V11, P887
NR 74
TC 155
Z9 165
U1 0
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2007
VL 48
IS 8
BP 3827
EP 3836
DI 10.1167/iovs.07-0051
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 199VF
UT WOS:000248722600052
PM 17652758
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Thibaut, M
   Tran, THC
   Szaffarczyk, S
   Boucart, M
AF Thibaut, Miguel
   Thi-Ha-Chau Tran
   Szaffarczyk, Sebastien
   Boucart, Muriel
TI Impact of age-related macular degeneration on object searches in
   realistic panoramic scenes
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE ageing; macular degeneration; scene perception; visual search
ID EYE-MOVEMENTS; VISUAL-SEARCH; FUNDUS AUTOFLUORESCENCE; READING
   PERFORMANCE; CONTOUR ENHANCEMENT; CENTRAL SCOTOMAS; VISION; PEOPLE;
   IDENTIFICATION; RECOGNITION
AB Background: This study investigated whether realistic immersive conditions with dynamic indoor scenes presented on a large, hemispheric panoramic screen covering 180 degrees of the visual field improved the visual search abilities of participants with age-related macular degeneration (AMD).
   Method: Twenty-one participants with AMD, 16 age-matched controls and 16 young observers were included. Realistic indoor scenes were presented on a panoramic five metre diameter screen. Twelve different objects were used as targets. The participants were asked to search for a target object, shown on paper before each trial, within a room composed of various objects. A joystick was used for navigation within the scene views. A target object was present in 24 trials and absent in 24 trials. The percentage of correct detection of the target, the percentage of false alarms (that is, the detection of the target when it was absent), the number of scene views explored and the search time were measured.
   Results: The search time was slower for participants with AMD than for the age-matched controls, who in turn were slower than the young participants. The participants with AMD were able to accomplish the task with a performance of 75 per cent correct detections. This was slightly lower than older controls (79.2 per cent) while young controls were at ceiling (91.7 per cent). Errors were mainly due to false alarms resulting from confusion between the target object and another object present in the scene in the target-absent trials.
   Conclusion: The outcomes of the present study indicate that, under realistic conditions, although slower than age-matched, normally sighted controls, participants with AMD were able to accomplish visual searches of objects with high accuracy.
C1 [Thibaut, Miguel; Thi-Ha-Chau Tran; Szaffarczyk, Sebastien; Boucart, Muriel] Univ Lille, CNRS, SCALab, Lille, France.
   [Thi-Ha-Chau Tran] Lille Catholic Univ, Dept Ophthalmol, Lille Grp Hosp, Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de Lille
   - ISITE; Universite de Lille
RP Boucart, M (通讯作者)，Univ Lille, CNRS, SCALab, Lille, France.
EM muriel.boucart@chru-lille.fr
FU French National Research Agency (program SHS2 ANR LowVision); Fondation
   Visio
FX The study was funded by a research grant from the French National
   Research Agency (program SHS2 ANR LowVision) and from the Fondation
   Visio to the last author. The sponsors played no role in the design or
   conduct of this research. Part of this study was presented as an invited
   talk at a meeting of the cross-sectional low vision group at the annual
   meeting of the Association for Research in Vision and Ophthalmology in
   Denver in May 2015.
CR Babu Raiju J, 2014, J Optom, V7, P229, DOI 10.1016/j.optom.2014.02.004
   Ball K., 1990, DEV ATTENTION RES TH, V69, P489, DOI DOI 10.1016/S0166-4115(08)60472-0
   Ball K, 2007, J GERONTOL B-PSYCHOL, V62, P19, DOI 10.1093/geronb/62.special_issue_1.19
   Bar M, 2004, NAT REV NEUROSCI, V5, P617, DOI 10.1038/nrn1476
   Belke E, 2008, PERCEPT PSYCHOPHYS, V70, P1444, DOI 10.3758/PP.70.8.1444
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   BIEDERMAN I, 1982, COGNITIVE PSYCHOL, V14, P143, DOI 10.1016/0010-0285(82)90007-X
   Bochsler TM, 2013, INVEST OPHTH VIS SCI, V54, P288, DOI 10.1167/iovs.12-10461
   Borges M, 2015, P EUR PAC JOINT C CO
   Boucart M, 2015, INVEST OPHTH VIS SCI, V56, P6832, DOI 10.1167/iovs.15-16758
   Calabrese A, 2014, INVEST OPHTH VIS SCI, V55, P3638, DOI 10.1167/iovs.13-13408
   Cheong AMY, 2008, VISION RES, V48, P577, DOI 10.1016/j.visres.2007.11.022
   Chung STL, 2014, VISION RES, V101, P167, DOI 10.1016/j.visres.2014.06.015
   Crabb DP, 2017, BEHAV BRAIN SCI, V40, P23, DOI 10.1017/S0140525X16000054
   Eperjesi F, 2007, OPHTHAL PHYSL OPT, V27, P93, DOI 10.1111/j.1475-1313.2006.00431.x
   Folk CL, 1996, EXP AGING RES, V22, P99, DOI 10.1080/03610739608254000
   Goh JO, 2010, NEUROIMAGE, V51, P336, DOI 10.1016/j.neuroimage.2010.01.107
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang AD, 2011, VISION RES, V51, P1192, DOI 10.1016/j.visres.2011.03.010
   Kabanarou SA, 2006, OPTOMETRY VISION SCI, V83, P789, DOI 10.1097/01.opx.0000238642.65218.64
   KOSNIK W, 1988, J GERONTOL, V43, pP63, DOI 10.1093/geronj/43.3.P63
   Kramer AF, 1996, J GERONTOL B-PSYCHOL, V51, pP201, DOI 10.1093/geronb/51B.4.P201
   Kuyk TK, 2005, VISION RES, V45, P3224, DOI 10.1016/j.visres.2005.07.019
   Kwon M, 2012, OPTOMETRY VISION SCI, V89, P1374, DOI 10.1097/OPX.0b013e3182678e52
   Lamoureux EL, 2008, OPHTHAL EPIDEMIOL, V15, P105, DOI 10.1080/09286580701840354
   MacKeben M, 2011, INVEST OPHTH VIS SCI, V52, P7603, DOI 10.1167/iovs.10-6728
   Madden DJ, 1996, PSYCHOL AGING, V11, P454, DOI 10.1037/0882-7974.11.3.454
   McIlreavy L, 2012, OPTOMETRY VISION SCI, V89, P1385, DOI 10.1097/OPX.0b013e318267a914
   Moores E, 2003, NAT NEUROSCI, V6, P182, DOI 10.1038/nn996
   Musel B, 2011, VISUAL NEUROSCI, V28, P529, DOI 10.1017/S0952523811000435
   Nuthmann A, 2014, J EXP PSYCHOL HUMAN, V40, P342, DOI 10.1037/a0033854
   Oliva A, 2000, COGNITIVE PSYCHOL, V41, P176, DOI 10.1006/cogp.1999.0728
   Oliveira AEA, 2009, AGR ISSUES POLICIES, P1
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Owsley C, 2011, VISION RES, V51, P1610, DOI 10.1016/j.visres.2010.10.020
   Pardhan S, 2011, OPHTHAL PHYSL OPT, V31, P233, DOI 10.1111/j.1475-1313.2010.00819.x
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Remy F, 2013, VISION RES, V91, P36, DOI 10.1016/j.visres.2013.07.006
   Roberts KL, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00039
   Satgunam P, 2012, OPTOMETRY VISION SCI, V89, pE1364, DOI 10.1097/OPX.0b013e318266f92f
   Scialfa CT, 2013, J GERONTOL B-PSYCHOL, V68, P522, DOI 10.1093/geronb/gbs086
   Scialfa CT, 1984, EXP AGING RES, V4, P337
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   SEKULER R, 1980, J GERONTOL, V35, P692, DOI 10.1093/geronj/35.5.692
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Sippel K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106089
   Smith ND, 2012, SEEING PERCEIVING, V25, P471, DOI 10.1163/187847612X634454
   Smith ND, 2011, OPHTHAL PHYSL OPT, V31, P225, DOI 10.1111/j.1475-1313.2011.00836.x
   Taylor DJ, 2017, INVEST OPHTH VIS SCI, V58, P1887, DOI 10.1167/iovs.16-21122
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   Thibaut M, 2015, OPHTHAL PHYSL OPT, V35, P336, DOI 10.1111/opo.12201
   Timberlake GT, 2011, INVEST OPHTH VIS SCI, V52, P2540, DOI 10.1167/iovs.10-6062
   Torralba A, 2006, PSYCHOL REV, V113, P766, DOI 10.1037/0033-295X.113.4.766
   Van der Stigchel S, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00579
   Vo MLH, 2010, J VISION, V10, DOI 10.1167/10.3.14
   Vo MLH, 2009, J VISION, V9, DOI 10.1167/9.3.24
   Wiecek E, 2012, INVEST OPHTH VIS SCI, V53, P6600, DOI 10.1167/iovs.12-10012
   Wolfe JM, 2011, TRENDS COGN SCI, V15, P77, DOI 10.1016/j.tics.2010.12.001
   Wood JM, 2016, CLIN EXP OPTOM, V99, P393, DOI 10.1111/cxo.12450
   Wu CC, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00054
   Yu DY, 2010, VISION RES, V50, P36, DOI 10.1016/j.visres.2009.10.005
NR 64
TC 6
Z9 6
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAY
PY 2018
VL 101
IS 3
BP 372
EP 379
DI 10.1111/cxo.12644
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE0OS
UT WOS:000430915000008
PM 29171100
DA 2022-11-30
ER

PT J
AU Limoli, PG
   Vingolo, EM
   Morales, MU
   Nebbioso, M
   Limoli, C
AF Limoli, Paolo Giuseppe
   Vingolo, Enzo Maria
   Morales, Marco Ulisses
   Nebbioso, Marcella
   Limoli, Celeste
TI Preliminary Study on Electrophysiological Changes After Cellular
   Autograft in Age-Related Macular Degeneration
SO MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; ADIPOSE-TISSUE;
   STROMAL CELLS; ELECTRORETINOGRAM; NEUROPROTECTION; REGENERATION;
   EXPRESSION; INHIBITOR; SECRETION
AB Evolving atrophic macular degeneration represents at least 80% of all macular degenerations and is currently without a standardized care. Autologous fat transplantation efficacy was demonstrated by several studies, as these cells are able to produce growth factors. The aim of the work was to demonstrate possible therapeutic effect of the joined suprachoroidal graft of adipocytes, adipose-derived stem cells (ADSCs) in stromal vascular fractions (SVFs) of adipose tissue, and platelet-rich plasma (PRP).
   Twelve eyes in 12 dry age-related macular degeneration (AMD) patients, aged 71.25 (SD +/- 6.8) between 62 and 80 years, were analyzed. A complete ocular evaluation was performed using best corrected visual acuity (BCVA), retinographic analysis, spectral-domain optical coherence tomography, microperimetry, computerized visual field, and standard electroretinogram (ERG). Each eye received a cell in graft between choroid and sclera of mature fat cells and ADSCs in SVF enriched with PRP by means of the variant second Limoli (Limoli retinal restoration technique [LRRT]). In order to test if the differences pre- and post-treatment were significant, the Wilcoxon signed-rank test has been performed.
   Adverse effects were not reported in the patients. After surgery with LRRT, the most significant increase in the ERG values was recorded by scotopic rod-ERG (answer coming from the rods), from 41.26 to 60.83 mu V with an average increase of 47.44% highly significant (P<0.05). Moderately significant was the one recorded by scotopic maximal ERG (answer coming from the rods and cones), from 112.22 to 129.68 mu V with an average increase of 15.56% (P < 0.1).
   Cell-mediated therapy based on growth factors used appears interesting because it can improve the retinal functionality responses in the short term. The ERG could, therefore, be used to monitor the effect of cell-mediated regenerative therapies.
C1 [Limoli, Paolo Giuseppe; Limoli, Celeste] Low Vis Res Milan, Milan, Italy.
   [Vingolo, Enzo Maria] A Fiorini Hosp, Dept Ophthalmol, Terracina, Italy.
   [Vingolo, Enzo Maria] Polo Pontino, Rome, Italy.
   [Morales, Marco Ulisses] CenterVue, Padua, Italy.
   [Nebbioso, Marcella] Univ Roma La Sapienza, Dept Sense Organs, Fac Med & Odontol, I-00161 Rome, Italy.
C3 Sapienza University Rome
RP Nebbioso, M (通讯作者)，Univ Roma La Sapienza, Dept Sense Organs, Electrophysiol Ctr, Policlin Umberto 1,Ocular, Vle Policlin 155, I-00161 Rome, Italy.
EM marcella.nebbioso@uniroma1.it
RI Nebbioso, Marcella/K-6878-2018; Vingolo, Enzo Maria/E-6674-2010; Limoli,
   Paolo/AAB-9828-2021
OI Nebbioso, Marcella/0000-0002-5512-0849; Vingolo, Enzo
   Maria/0000-0002-8363-5866; 
CR Bagchi M, 2013, FASEB J, V27, P3257, DOI 10.1096/fj.12-221812
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459
   Carron JA, 2000, INT J BIOCHEM CELL B, V32, P1137, DOI 10.1016/S1357-2725(00)00065-0
   Chaum E, 2003, J CELL BIOCHEM, V88, P57, DOI 10.1002/jcb.10354
   Chen GF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073673
   Coleman WP, 2001, J AM ACAD DERMATOL, V45, P438, DOI 10.1067/mjd.2001.117045
   Daftarian Narsis, 2010, J Ophthalmic Vis Res, V5, P250
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1
   FILATOV V P, 1951, Med Gen Fr, V11, P3
   Finkelstein SP, 2001, HEAD TRAUMA, P165
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Hauck SM, 2006, MOL CELL BIOL, V26, P2746, DOI 10.1128/MCB.26.7.2746-2757.2006
   Kevy S. V., 2001, T SOC BIOM 27 ANN M
   Khurana R, 2005, CIRCULATION, V111, P2828, DOI 10.1161/CIRCULATIONAHA.104.495887
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   La Vail MM, P NATL ACAD SCI US
   LAVAIL MM, 1991, ANN NY ACAD SCI, V638, P341
   Lawrence Naomi, 2002, J Am Acad Dermatol, V47, P105, DOI 10.1067/mjd.2002.122189
   Levine JP, 2009, RETINA-J RET VIT DIS, V29, P1074, DOI 10.1097/IAE.0b013e3181b09443
   Li Q, 2014, CELL BIOCHEM BIOPHYS, V69, P189, DOI 10.1007/s12013-013-9769-3
   Limoli P, 2014, RETINAL CELL NEURORE, V40, P159
   Limoli PG, 2011, INVEST OPHTH VIS SCI, V52, P437
   Limoli PG, 2012, INVEST OPHTH VIS SCI, V53, P277
   Luo S, 2013, TOHOKU J EXP MED, V231, P101, DOI 10.1620/tjem.231.101
   Mackay AM, 2007, DOC OPHTHALMOL, V115, P69, DOI 10.1007/s10633-007-9056-y
   Mao HY, 2011, HUM GENE THER, V22, P567, DOI 10.1089/hum.2010.140
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meduri R., 2007, ARVO 2007 ANN M FORT
   Nakagami H, 2006, J ATHEROSCLER THROMB, V13, P77, DOI 10.5551/jat.13.77
   Nebbioso M, 2010, CLIN EXP OPTOM, V94, P276
   NEMUNAITIS J, 1993, CRIT REV ONCOL HEMAT, V14, P153, DOI 10.1016/1040-8428(93)90022-V
   Okoye G, 2003, J NEUROSCI, V23, P4164
   Pelaez O, 1997, RETINITIS PIGMENTOSA
   Prunet-Marcassus B, 2006, EXP CELL RES, V312, P727, DOI 10.1016/j.yexcr.2005.11.021
   Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E
   Sakai T, 2007, INVEST OPHTH VIS SCI, V48, P3381, DOI 10.1167/iovs.06-1242
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Sansone L, 2013, J CELL PHYSIOL, V228, P1754, DOI 10.1002/jcp.24334
   Schaffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006-0589
   Scherer PE, 2006, DIABETES, V55, P1537, DOI 10.2337/db06-0263
   Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559
   SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759
   Sheibani N, 2000, BIOCHEM BIOPH RES CO, V267, P257, DOI 10.1006/bbrc.1999.1903
   Skaat A, 2011, ACTA OPHTHALMOL, V89, pe269, DOI 10.1111/j.1755-3768.2010.02005.x
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413
   Thanos C, 2005, EXPERT OPIN BIOL TH, V5, P1443, DOI 10.1517/14712598.5.11.1443
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Tischler Michael, 2002, N Y State Dent J, V68, P22
   Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194
   Ueki Y, 2013, GLIA, V61, P778, DOI 10.1002/glia.22472
   Vergara MN, 2009, MOL VIS, V15, P1000
   Wang P, 2008, J CELL PHYSIOL, V216, P3, DOI 10.1002/jcp.21386
   Wen R, ADV EXP MED BIOL
   Wen R, 2012, ADV EXP MED BIOL, V723, P93, DOI 10.1007/978-1-4614-0631-0_13
   Werko Lars, 2002, Lakartidningen, V99, P1552
   Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701
   Zack DJ, 2000, NEURON, V26, P285, DOI 10.1016/S0896-6273(00)81160-5
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 63
TC 22
Z9 23
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC
PY 2014
VL 93
IS 29
AR e355
DI 10.1097/MD.0000000000000355
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AX5RW
UT WOS:000346985700041
PM 25546695
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Coronado, BNL
   da Cunha, FBS
   de Oliveira, RM
   Nobrega, OD
   Ricart, CAO
   Fontes, W
   de Sousa, MV
   de Avila, MP
   Martins, AMA
AF Coronado, Bruno Nobre Lins
   da Cunha, Felipe Bruno Santos
   de Oliveira, Raphaela Menezes
   Nobrega, Otavio de Toledo
   Ricart, Carlos Andre Ornelas
   Fontes, Wagner
   de Sousa, Marcelo Valle
   de avila, Marcos Pereira
   Martins, Aline Maria Araujo
TI Novel Possible Protein Targets in Neovascular Age-Related Macular
   Degeneration: A Pilot Study Experiment
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE AMD (age-related macular degeneration); resistance; proteomics; mass
   spectrometry (MS); biomarkers; choroidal neo vascularization
ID RETINAL-PIGMENT EPITHELIUM; ANTI-VEGF THERAPY; APOLIPOPROTEIN-E; BRUCHS
   MEMBRANE; INFLAMMATORY RESPONSE; DRUSEN; PATHOGENESIS; IDENTIFICATION;
   ANGIOGENESIS; CHOLESTEROL
AB Age-related macular degeneration (AMD) is among the world's leading causes of blindness. In its neovascular form (nAMD), around 25% of patients present further anatomical and visual deterioration due to persistence of neovascular activity, despite gold-standard treatment protocols using intravitreal anti-VEGF medications. Thus, to comprehend, the molecular pathways that drive choroidal neoangiogenesis, associated with the vascular endothelial growth factor (VEGF), are important steps to elucidate the mechanistic events underneath the disease development. This is a pilot study, a prospective, translational experiment, in a real-life context aiming to evaluate the protein profiles of the aqueous humor of 15 patients divided into three groups: group 1, composed of patients with nAMD, who demonstrated a good response to anti-VEGF intravitreal injections during follow-up (good responsive); group 2, composed of patients with anti-VEGF-resistant nAMD, who demonstrated choroidal neovascularization activity during follow-up (poor/non-responsive); and group 3, composed of control patients without systemic diseases or signs of retinopathy. For proteomic characterization of the groups, mass spectrometry (label-free LC-MS/MS) was used. A total of 2,336 proteins were identified, of which 185 were distinctly regulated and allowed the differentiation of the clinical conditions analyzed. Among those, 39 proteins, including some novel ones, were analyzed as potential disease effectors through their pathophysiological implications in lipid metabolism, oxidative stress, complement system, inflammatory pathways, and angiogenesis. So, this study suggests the participation of other promising biomarkers in neovascular AMD, in addition to the known VEGF.
C1 [Coronado, Bruno Nobre Lins; Nobrega, Otavio de Toledo; Martins, Aline Maria Araujo] Univ Brasilia, Dept Med Sci, Fac Med, Brasilia, DF, Brazil.
   [Coronado, Bruno Nobre Lins] CESMAC Univ Ctr, Fac Med, Maceio, Alagoas, Brazil.
   [da Cunha, Felipe Bruno Santos; Martins, Aline Maria Araujo] Univ Ctr Brasilia UniCEUB, Sch Med, Dept Hlth Sci, Brasilia, DF, Brazil.
   [de Oliveira, Raphaela Menezes; Ricart, Carlos Andre Ornelas; Fontes, Wagner; de Sousa, Marcelo Valle] Univ Brasilia, Inst Biol Sci, Dept Cell Biol, Lab Prot Chem & Biochem, Brasilia, DF, Brazil.
   [de avila, Marcos Pereira] Univ Fed Goias, Fac Med, Goiania, Go, Brazil.
C3 Universidade de Brasilia; Centro Universitario de Brasilia (UniCEUB);
   Universidade de Brasilia; Universidade Federal de Goias
RP Coronado, BNL; Martins, AMA (通讯作者)，Univ Brasilia, Dept Med Sci, Fac Med, Brasilia, DF, Brazil.; Coronado, BNL (通讯作者)，CESMAC Univ Ctr, Fac Med, Maceio, Alagoas, Brazil.; Martins, AMA (通讯作者)，Univ Ctr Brasilia UniCEUB, Sch Med, Dept Hlth Sci, Brasilia, DF, Brazil.
EM brunonobrelins@gmail.com; alin3.m4rtins@gmail.com
RI Nobrega, Otavio T/J-7738-2012; Valle de Sousa, Marcelo/H-1838-2016
OI Nobrega, Otavio T/0000-0003-1775-7176; Valle de Sousa,
   Marcelo/0000-0002-2871-4430; Martins, Aline M A/0000-0001-9481-0327
CR Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Akahane T, 2004, EXP CELL RES, V301, P158, DOI 10.1016/j.yexcr.2004.08.002
   Ali K, 2005, CIRC RES, V97, P922, DOI 10.1161/01.RES.0000187467.67684.43
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Avila MP de., 2015, REV DIGIT OFTALMOL, V1, P1, DOI [10.17545/e-oftalmo.cbo/2015.18, DOI 10.17545/E-OFTALMO.CBO/2015.18]
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Brandl C, 2016, OPHTHALMOLOGE, V113, P735, DOI 10.1007/s00347-016-0341-6
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Catala Angel, 2011, Front Biosci (Schol Ed), V3, P52, DOI 10.2741/s131
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310
   Cioffi CL, 2015, J MED CHEM, V58, P5863, DOI 10.1021/acs.jmedchem.5b00423
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   de Carvalho JRL., PRECISION MED INVEST, P247
   Dentchev T, 2003, MOL VIS, V9, P184
   Dhiman K, 2019, CELL MOL LIFE SCI, V76, P1833, DOI 10.1007/s00018-019-03040-5
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Farnoodian M, 2018, J OPHTHAL VIS RES, V13, P470, DOI 10.4103/jovr.jovr_67_18
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Garcia-Onrubia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165934
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Glenn JV, 2012, GRAEF ARCH CLIN EXP, V250, P349, DOI 10.1007/s00417-011-1856-9
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Ito Y, 2013, CURR PHARM BIOTECHNO, V14, P400, DOI 10.2174/1389201011314040003
   Jensen EG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249752
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Kasim JK, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00472
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lores-Padin A, 2021, TALANTA, V221, DOI 10.1016/j.talanta.2020.121489
   Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110
   Lynch AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.12
   Lynch AM, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.14
   Ma B, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.100
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Mantel I, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.594087
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Mrowicka M, 2017, ACTA OPHTHALMOL, V95, P530, DOI 10.1111/aos.13289
   Nandi A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9613090
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pool FM, 2020, NPJ AGING MECH DIS, V6, DOI 10.1038/s41514-019-0039-5
   Pugazhendhi A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031170
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Rahimi N, 2006, EXP EYE RES, V83, P1005, DOI 10.1016/j.exer.2006.03.019
   Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sinha D, 2008, MOL CELL NEUROSCI, V37, P85, DOI 10.1016/j.mcn.2007.08.016
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tom I, 2020, P NATL ACAD SCI USA, V117, P9952, DOI 10.1073/pnas.1917608117
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   WAHNERROEDLER DL, 1992, AM J HEMATOL, V40, P56, DOI 10.1002/ajh.2830400112
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou HJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1004-y
NR 91
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JAN 27
PY 2022
VL 8
AR 692272
DI 10.3389/fmed.2021.692272
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YW8AO
UT WOS:000753635700001
PM 35155457
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Arpa, C
   Khalid, H
   Chandra, S
   Wagner, S
   Fasler, K
   Faes, L
   Pooprasert, P
   Chopra, R
   Moraes, G
   Balaskas, K
   Keane, PA
   Sivaprasad, S
   Fu, DJ
AF Arpa, Cristina
   Khalid, Hagar
   Chandra, Shruti
   Wagner, Siegfried
   Fasler, Katrin
   Faes, Livia
   Pooprasert, Pakinee
   Chopra, Reena
   Moraes, Gabriella
   Balaskas, Konstantinos
   Keane, Pearse A.
   Sivaprasad, Sobha
   Fu, Dun Jack
TI Ten-year survival trends of neovascular age-related macular degeneration
   at first presentation
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choroid; Degeneration; Macula; Retina; Treatment Medical
ID LONG-TERM OUTCOMES; GEOGRAPHIC ATROPHY; RANIBIZUMAB; GROWTH; MARINA;
   VERTEPORFIN; PROGRESSION; PROGNOSIS; THERAPY; ANCHOR
AB Background To describe 10-year trends in visual outcomes, anatomical outcomes and treatment burden of patients receiving antivascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD). Methods Retrospective cohort study of treatment-naive, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. The primary outcome was time to best-corrected visual acuity (BCVA) falling <= 35 ETDRS letters after initiating anti-VEGF therapy. Secondary outcomes included time to BCVA reaching >= 70 letters, proportion of eyes with BCVA >= 70 and <= 35 letters in 10 years, mean trend of BCVA and central retinal thickness over 10 years, and mean number of injections. Results For our cohort of 103 patients, Kaplan-Meier analyses demonstrated median time to BCVA reaching <= 35 and >= 70 letters were 37.8 (95% CI 22.2 to 65.1) and 8.3 (95% CI 4.8 to 20.9) months after commencing anti-VEGF therapy, respectively. At the final follow-up, BCVA was <= 35 letters and >= 70 letters in 41.1% and 21%, respectively, in first-affected eyes, while this was the case for 5.4% and 48.2%, respectively, in a patient's better-seeing eye. Mean injection number was 37.0 +/- 24.2 per eye and 53.6 +/- 30.1 at patient level (63.1% of patients required injections in both eyes). Conclusions The chronicity of nAMD disease and its management highlights the importance of long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA >= 70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet, one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes.
C1 [Arpa, Cristina; Khalid, Hagar; Chandra, Shruti; Wagner, Siegfried; Faes, Livia; Pooprasert, Pakinee; Chopra, Reena; Moraes, Gabriella; Balaskas, Konstantinos; Keane, Pearse A.; Sivaprasad, Sobha; Fu, Dun Jack] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Arpa, Cristina] Fdn IRCCS Policlin San Matteo, Ophthalmol Dept, Pavia, Italy.
   [Khalid, Hagar] Tanta Univ, Ophthalmol Dept, Tanta, Egypt.
   [Fasler, Katrin] Zurich Univ Hosp, Dept Ophthalmol, Zurich, Switzerland.
   [Faes, Livia] Cantonal Hosp Lucerne, Med Retina, Luzern, Switzerland.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; IRCCS Fondazione San Matteo; Egyptian Knowledge
   Bank (EKB); Tanta University; University of Zurich; University Zurich
   Hospital; Lucerne Cantonal Hospital
RP Keane, PA (通讯作者)，NHS Fdn Trust, Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM pearse.keanel@nhs.net
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Sivaprasad,
   Sobha/0000-0001-8952-0659; Faes, Livia/0000-0002-4159-3960; Keane,
   Pearse/0000-0002-9239-745X; Arpa, Cristina/0000-0001-9299-0061
CR Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boyce T, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004319
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Fasler K, 2020, BRIT J OPHTHALMOL, V104, P684, DOI 10.1136/bjophthalmol-2019-314446
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hamilton R, 2016, GUIDELINES INTRAVITR
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   R Core Team, 2021, R LANG ENV STAT COMP
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Starr MR, 2020, RETINA-J RET VIT DIS, V40, P1665, DOI 10.1097/IAE.0000000000002668
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 32
TC 5
Z9 5
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2021
VL 105
IS 12
BP 1688
EP 1695
DI 10.1136/bjophthalmol-2020-317161
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XJ6PS
UT WOS:000726907900015
PM 33011683
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Pfau, M
   Sahu, S
   Rupnow, RA
   Romond, K
   Millet, D
   Holz, FG
   Schmitz-Valckenberg, S
   Fleckenstein, M
   Lim, JI
   De Sisternes, L
   Leng, T
   Rubin, DL
   Hallak, JA
AF Pfau, Maximilian
   Sahu, Soumya
   Rupnow, Rawan Allozi
   Romond, Kathleen
   Millet, Desiree
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
   Fleckenstein, Monika
   Lim, Jennifer, I
   de Sisternes, Luis
   Leng, Theodore
   Rubin, Daniel L.
   Hallak, Joelle A.
TI Probabilistic Forecasting of Anti-VEGF Treatment Frequency in
   Neovascular Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE personalized medicine; machine-learning; age-related macular
   degeneration; anti-VEGF treatment; probabilistic prediction
ID GEOGRAPHIC ATROPHY SECONDARY; RANIBIZUMAB; OUTCOMES; AMD; LIFE
AB Purpose: To probabilistically forecast needed anti-vascular endothelial growth factor (anti-VEGF) treatment frequency using volumetric spectral domain-optical coherence tomography (SD-OCT) biomarkers in neovascular age-related macular degeneration from real-world settings.
   Methods: SD-OCT volume scans were segmented with a custom deep-learning-based analysis pipeline. Retinal thickness and reflectivity values were extracted for the central and the four inner Early Treatment Diabetic Retinopathy Study (ETDRS) subfields for six retinal layers (inner retina, outer nuclear layer, inner segments [IS], outer segments [OS], retinal pigment epithelium-drusen complex [RPEDC] and the choroid). Machine-learning models were probed to predict the anti-VEGF treatment frequency within the next 12 months. Probabilistic forecasting was performed using natural gradient boosting (NGBoost), which outputs a full probability distribution. The mean absolute error (MAE) between the predicted versus actual anti-VEGF treatment frequency was the primary outcome measure.
   Results: In a total of 138 visits of 99 eyes with neovascular AMD (96 patients) from two clinical centers, the prediction of future anti-VEGF treatment frequency was observed with an accuracy (MAE [95% confidence interval]) of 2.60 injections/year [2.25-2.96] (R-2 = 0.390) using random forest regression and 2.66 injections/year [2.31-3.01] (R-2 = 0.094) using NGBoost, respectively. Prediction intervals were well calibrated and reflected the true uncertainty of NGBoost-based predictions. Standard deviation of RPEDC-thickness in the central ETDRS-subfield constituted an important predictor across models.
   Conclusions: The proposed, fully automated pipeline enables probabilistic forecasting of future anti-VEGF treatment frequency in real-world settings.
   Translational Relevance: Prediction of a probability distribution allows the physician to inspect the underlying uncertainty. Predictive uncertainty estimates are essential to highlight cases where human-inspection and/or reversion to a fallback alternative is warranted.
C1 [Pfau, Maximilian; Rubin, Daniel L.] Stanford Univ, Dept Biomed Data Sci, Palo Alto, CA 94304 USA.
   [Pfau, Maximilian; Millet, Desiree; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Sahu, Soumya; Rupnow, Rawan Allozi; Romond, Kathleen; Lim, Jennifer, I; Hallak, Joelle A.] Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St,M-C 648, Chicago, IL 60612 USA.
   [Sahu, Soumya; Rupnow, Rawan Allozi] Univ Illinois, Sch Publ Hlth, Dept Epidemiol & Biostat, Chicago, IL 60612 USA.
   [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [de Sisternes, Luis] Carl Zeiss Meditec AG, Dublin, CA USA.
   [Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94304 USA.
C3 Stanford University; University of Bonn; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Utah System of Higher
   Education; University of Utah; Carl Zeiss AG; Stanford University
RP Hallak, JA (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St,M-C 648, Chicago, IL 60612 USA.
EM joelle@uic.edu
OI Pfau, Maximilian/0000-0001-9761-9640
FU Association of Rhine-Westphalian Ophthalmologists (RWA); German Research
   Foundation (DFG) [PF950/1-1]; BrightFocus Foundation [M2019155];
   Department of Ophthalmology and Visual Sciences, University of Illinois
   at Chicago, Chicago, IL [2P30EY001792]; Novartis Pharma GmbH, Germany;
   Research to Prevent Blindness, New York, NY; NIH [P30-EY026877]
FX Supported by the research award 2020 of the Association of
   Rhine-Westphalian Ophthalmologists (RWA) to MP, the German Research
   Foundation (DFG) grant PF950/1-1 to MP; a BrightFocus Foundation
   grantM2019155 to J.A.H., an Unrestricted Grant for Research to Prevent
   Blindness and a P30 Core Grant for Vision Research (2P30EY001792),
   Department of Ophthalmology and Visual Sciences, University of Illinois
   at Chicago, Chicago, IL (J.A.H., J.I.L.); and in part by Novartis Pharma
   GmbH, Germany (M.F.) and Unrestricted Grant from Research to Prevent
   Blindness, New York, NY, to the Department of Ophthalmology & Visual
   Sciences, University of Utah; and in part by an Unrestricted Grant from
   Research to Prevent Blindness, New York, NY, to the Department of
   Ophthalmology, Byers Eye Institute at Stanford, Stanford University
   School of Medicine and NIH grant P30-EY026877.
CR Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chen Q, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.2
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Duan T, 2019, ARXIV191003225
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Keenan TDL, 2021, AM J OPHTHALMOL, V224, P267, DOI 10.1016/j.ajo.2020.12.012
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Kokame GT, 2020, OPHTHALMOLOGICA, V243, P178, DOI 10.1159/000503834
   Kunzel SH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.63
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Liakopoulos S, 2020, BRIT J OPHTHALMOL, V104, P1573, DOI 10.1136/bjophthalmol-2019-315717
   Marz A., ARXIV PREPRINT ARXIV
   Mevik BH, 2007, J STAT SOFTW, V18, P1, DOI 10.18637/jss.v018.i02
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Pfau M, 2020, AM J OPHTHALMOL, V217, P162, DOI 10.1016/j.ajo.2020.04.003
   Puliafito CA, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00221-4
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Rosenfeld PJ, 2020, AM J OPHTHALMOL, V216, pA7, DOI 10.1016/j.ajo.2020.05.012
   von der Emde L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47565-y
   Wintergerst MWM, 2018, OPHTHALMOLOGE, V115, P1035, DOI 10.1007/s00347-017-0610-z
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 42
TC 5
Z9 5
U1 5
U2 13
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUN
PY 2021
VL 10
IS 7
AR 30
DI 10.1167/tvst.10.7.30
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TD3KJ
UT WOS:000669229500008
PM 34185055
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Park, JH
   Lee, S
   Yu, HG
   Kim, JI
   Seo, JS
AF Park, Jung Hyun
   Lee, Seungbok
   Yu, Hyeong Gon
   Kim, Jong-Il
   Seo, Jeong-Sun
TI Copy Number Variation of Age-Related Macular Degeneration Relevant Genes
   in the Korean Population
SO PLOS ONE
LA English
DT Article
ID SUBRETINAL NEOVASCULARIZATION; ASSOCIATION; RECEPTOR; RISK; EXPRESSION;
   VARIANTS; DISEASE; LINKAGE; FAMILY; VLDLR
AB Purpose: Studies that analyzed single nucleotide polymorphisms (SNP) in various genes have shown that genetic factors are strongly associated with age-related macular degeneration (AMD) susceptibility. Copy number variation (CNV) may be an additional type of genetic variation that contributes to AMD pathogenesis. This study investigated CNV in 4 AMD-relevant genes in Korean AMD patients and control subjects.
   Methods: Four CNV candidate regions located in AMD-relevant genes (VEGFA, ARMS2/HTRA1, CFH and VLDLR), were selected based on the outcomes of our previous study which elucidated common CNVs in the Asian populations. Real-time PCR based TaqMan Copy Number Assays were performed on CNV candidates in 273 AMD patients and 257 control subjects.
   Results: The predicted copy number (PCN, 0, 1, 2 or 3+) of each region was called using the CopyCaller program. All candidate genes except ARMS2/HTRA1 showed CNV in at least one individual, in which losses of VEGFA and VLDLR represent novel findings in the Asian population. When the frequencies of PCN were compared, only the gain in VLDLR showed significant differences between AMD patients and control subjects (p = 0.025). Comparisons of the raw copy values (RCV) revealed that 3 of 4 candidate genes showed significant differences (2.03 vs. 1.92 for VEGFA, p<0.01; 2.01 vs. 1.97 for CFH, p<0.01; 1.97 vs. 2.01, p<0.01 for ARMS2/HTRA1).
   Conclusion: CNVs located in AMD-relevant genes may be associated with AMD susceptibility. Further investigations encompassing larger patient cohorts are needed to elucidate the role of CNV in AMD pathogenesis.
C1 [Park, Jung Hyun; Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Park, Jung Hyun] Inje Univ, Seoul Paik Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Lee, Seungbok; Kim, Jong-Il; Seo, Jeong-Sun] Seoul Natl Univ, Med Res Ctr, GMI, Seoul, South Korea.
   [Lee, Seungbok; Kim, Jong-Il; Seo, Jeong-Sun] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul, South Korea.
   [Kim, Jong-Il; Seo, Jeong-Sun] Seoul Natl Univ, Coll Med, Dept Biochem, Seoul, South Korea.
   [Kim, Jong-Il; Seo, Jeong-Sun] Psoma Therapeut, Seoul, South Korea.
   [Seo, Jeong-Sun] Macrogen, Seoul, South Korea.
C3 Seoul National University (SNU); Inje University; Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University (SNU); Macrogen, Inc.
RP Park, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
EM hgonyu@snu.ac.kr; jongil@snu.ac.kr
RI KIM, JONG-IL/D-1019-2011; Yu, Hyeong Gon/J-2772-2012; Seo,
   Jeong-Sun/J-2763-2012
OI KIM, JONG-IL/0000-0002-7240-3744; Seungbok, Lee/0000-0002-3145-8714; Yu,
   Hyeong Gon/0000-0002-1795-202X
FU Ministry of Health & Welfare, the Republic of Korea [A080588]
FX This study was supported by a grant from the Korea Healthcare Technology
   R&D Project (A080588), Ministry of Health & Welfare, the Republic of
   Korea. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Ikeda M, 2010, BIOL PSYCHIAT, V67, P283, DOI 10.1016/j.biopsych.2009.08.034
   Ionita-Laza I, 2009, GENOMICS, V93, P22, DOI 10.1016/j.ygeno.2008.08.012
   Jiang AH, 2009, INVEST OPHTH VIS SCI, V50, P844, DOI 10.1167/iovs.08-2447
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Park H, 2010, NAT GENET, V42, P400, DOI 10.1038/ng.555
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678
   Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562
NR 27
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 15
PY 2012
VL 7
IS 2
AR e31243
DI 10.1371/journal.pone.0031243
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 925DP
UT WOS:000302741300048
PM 22355348
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Baseler, HA
   Gouws, A
   Crossland, MD
   Leung, C
   Tufail, A
   Rubin, GS
   Morland, AB
AF Baseler, Heidi A.
   Gouws, Andre
   Crossland, Michael D.
   Leung, Carmen
   Tufail, Adnan
   Rubin, Gary S.
   Morland, Antony B.
TI Objective Visual Assessment of Antiangiogenic Treatment for Wet
   Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE wet age-related macular degeneration (AMD); ranibizumab; functional MRI
   (fMRI); microperimetry
ID CORTICAL REORGANIZATION; FACE RECOGNITION; FUNCTIONAL MRI; LOW-VISION;
   CORTEX; MATTER; BRAIN; ORGANIZATION; MACULOPATHY; SCOTOMAS
AB Purpose. To assess cortical responses in patients undergoing antiangiogenic treatment for wet age-related macular degeneration (AMD) using functional magnetic resonance imaging (fMRI) as an objective, fixation-independent measure of topographic visual function.
   Methods. A patient with bilateral neovascular AMD was scanned using fMRI before and at regular intervals while undergoing treatment with intravitreal antiangiogenic injections (ranibizumab). Blood oxygenation level-dependent signals were measured in the brain while the patient viewed a stimulus consisting of a full-field flickering (6 Hz) white light alternating with a uniform gray background (18 s on and 18 s off). Topographic distribution and magnitude of activation in visual cortex were compared longitudinally throughout the treatment period (< 1 year) and with control patients not currently undergoing treatment. Clinical behavioral tests were also administered, including visual acuity, microperimetry, and reading skills.
   Results. The area of visual cortex activated increased significantly after the first treatment to include more posterior cortex that normally receives inputs from lesioned parts of the retina. Subsequent treatments yielded no significant further increase in activation area. Behavioral measures all generally showed an improvement with treatment but did not always parallel one another. The untreated control patient showed a consistent lack of significant response in the cortex representing retinal lesions.
   Conclusions. Retinal treatments may not only improve vision but also result in a concomitant improvement in fixation stability. Current clinical behavioral measures (e.g., acuity and perimetry) are largely dependent on fixation stability and therefore cannot separate improvements of visual function from fixation improvements. fMRI, which provides an objective and sensitive measure of visual function independent of fixation, reveals a significant increase in visual cortical responses in patients with wet AMD after treatment with antiangiogenic injections. Despite recent evidence that visual cortex degenerates subsequent to retinal lesions, our results indicate that it can remain responsive as its inputs are restored. (Optom Vis Sci 2011; 88: 1255-1261)
C1 [Baseler, Heidi A.; Gouws, Andre; Morland, Antony B.] Univ York, Dept Psychol, York Neuroimaging Ctr, York YO10 5DD, N Yorkshire, England.
   [Crossland, Michael D.; Tufail, Adnan; Rubin, Gary S.] UCL, Inst Ophthalmol, London, England.
   [Crossland, Michael D.; Tufail, Adnan; Rubin, Gary S.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Leung, Carmen; Morland, Antony B.] Hull York Med Sch, York, N Yorkshire, England.
C3 University of York - UK; University of London; University College
   London; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of Hull; University of York -
   UK
RP Morland, AB (通讯作者)，Univ York, Dept Psychol, York Neuroimaging Ctr, York YO10 5DD, N Yorkshire, England.
EM a.morland@psychology.york.ac.uk
RI Crossland, Michael D/B-5600-2008; Baseler, Heidi/AAI-7387-2020
OI Crossland, Michael D/0000-0001-6833-6043; Baseler,
   Heidi/0000-0003-0995-8453; Gouws, Andre/0000-0003-0674-7829; Morland,
   Antony/0000-0002-6754-5545; Tufail, Adnan/0000-0001-6131-7640
FU Medical Research Council [G0401339]; Department of Health; National
   Institute for Health Research; MRC [G0401339] Funding Source: UKRI;
   Medical Research Council [G0700729B] Funding Source: researchfish; Fight
   for Sight [1777/78] Funding Source: researchfish
FX This work was supported by the Medical Research Council (G0401339). AT,
   GSR, and MDC also received financial support from the Department of
   Health through an award made by the National Institute for Health
   Research to Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology for a Specialist Biomedical Research Centre
   for Ophthalmology.
CR Andrews TJ, 1997, J NEUROSCI, V17, P2859
   Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204
   Baseler HA, 2011, NAT NEUROSCI, V14, P649, DOI 10.1038/nn.2793
   Baseler HA, 2009, NEURO-OPHTHALMOLOGY, V33, P149, DOI 10.1080/01658100903050053
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Liu TT, 2010, INVEST OPHTH VIS SCI, V51, P6826, DOI 10.1167/iovs.09-4926
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   McKeefry DJ, 2009, NEUROSCIENTIST, V15, P489, DOI 10.1177/1073858409334424
   Noppeney U, 2005, CURR BIOL, V15, pR488, DOI 10.1016/j.cub.2005.06.053
   Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0
   Schumacher EH, 2008, RESTOR NEUROL NEUROS, V26, P391
   Smirnakis SM, 2005, NATURE, V435, P300, DOI 10.1038/nature03495
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Teo PC, 1997, IEEE T MED IMAGING, V16, P852, DOI 10.1109/42.650881
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   Vugler AA, 2010, RETINA-J RET VIT DIS, V30, P983, DOI 10.1097/IAE.0b013e3181e2a680
NR 26
TC 13
Z9 13
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD OCT
PY 2011
VL 88
IS 10
BP 1255
EP 1261
DI 10.1097/OPX.0b013e3182282f13
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 825YX
UT WOS:000295319400016
PM 21705938
DA 2022-11-30
ER

PT J
AU Jang, KH
   Do, YJ
   Son, D
   Son, E
   Choi, JS
   Kim, E
AF Jang, Ki-Hong
   Do, Yun-Ju
   Son, Dongwon
   Son, Eunji
   Choi, Jun-Sub
   Kim, Eunhee
TI AIF-independent parthanatos in the pathogenesis of dry age-related
   macular degeneration
SO CELL DEATH & DISEASE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; SODIUM IODATE; CELL-DEATH; POLY(ADP-RIBOSE)
   POLYMERASE-1; OXIDATIVE DAMAGE; APOPTOSIS; STRESS; ACTIVATION; NECROSIS;
   PARP-1
AB Cell death of retinal pigment epithelium (RPE) is characterized as an essential late-stage phenomenon of dry age-related macular degeneration (AMD). The aim of this study was to elucidate the molecular mechanism underlying RPE cell death after exposure to oxidative stress, which occurs often because of the anatomical location of RPE cells. ARPE-19, an established RPE cell line, exhibited necrotic features involving poly (ADP-ribose) polymerase-1 (PARP-1) activation in response to hydrogen peroxide (H2O2). ARPE-19 cells were resistant to H2O2 when PARP-1 was depleted using siRNA or inhibited by a pharmacological inhibitor of PARP-1, olaparib. Our data suggest a causal relationship between PARP-1 activation and ARPE-19 cell death in response to H2O2. Next, we investigated downstream molecular events in PARP-1 activation. Increased mitochondrial depolarization, mitochondrial fission and alterations of the cellular energy dynamics with reduced NAD+ and ATP were observed in H2O2-treated ARPE-19 cells. H2O2-triggered mitochondrial dysfunction was inhibited by olaparib. Nevertheless, translocation of apoptosis-inducing factor (AIF), a biochemical signature for PARP-1-dependent cell death (parthanatos), was not observed in our study. Moreover, the depletion of AIF did not affect the amplitude of cell death, demonstrating the lack of a role for AIF in the death of ARPE-19 cells in response to H2O2. This feature distinguishes the type of death observed in this study from canonical parthanatos. Next, we examined the in vivo role of PARP-1 in a dry AMD animal model system. Histological analysis of the outer nuclear layer in the mouse retina revealed protection against sodium iodate (SI) following treatment with olaparib. Moreover, retina fundus and electroretinograms also confirmed such a protective effect in the SI-treated rabbit. Collectively, we report that AIF-independent PARP-1-dependent necrosis constitutes a major mechanism of RPE cell death leading to retinal degeneration in dry AMD.
C1 [Jang, Ki-Hong; Do, Yun-Ju; Son, Dongwon; Son, Eunji; Kim, Eunhee] Chungnam Natl Univ, Dept Biol Sci, 99 Daehak Ro, Daejeon 305764, South Korea.
   [Choi, Jun-Sub] Catholic Univ Korea, Catholic Inst Visual Sci, 505 Banpo Dong, Seoul, South Korea.
   [Kim, Eunhee] Chungnam Natl Univ, Grad Sch New Drug Discovery & Dev, Daejeon, South Korea.
C3 Chungnam National University; Catholic University of Korea; Chungnam
   National University
RP Kim, E (通讯作者)，Chungnam Natl Univ, Dept Biol Sci, 99 Daehak Ro, Daejeon 305764, South Korea.
EM eunhee@cnu.ac.kr
RI Jang, Ki-Hong/AAR-2399-2021
OI Kim, Eunhee/0000-0002-7738-1222
FU Bio & Medical Technology Development Program of the National Research
   Foundation (NRF) - Korean government (MSIP) [NRF-2014M3A9A8064469]
FX This research was supported by the Bio & Medical Technology Development
   Program of the National Research Foundation (NRF) funded by the Korean
   government (MSIP) (No. NRF-2014M3A9A8064469).
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aredia F, 2014, BIOCHEM PHARMACOL, V92, P157, DOI 10.1016/j.bcp.2014.06.021
   BAICH A, 1992, PIGM CELL RES, V5, P394, DOI 10.1111/j.1600-0749.1992.tb00568.x
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   CLIFTON L, 1973, VISION RES, V13, P919, DOI 10.1016/0042-6989(73)90072-2
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   David KK, 2009, FRONT BIOSCI-LANDMRK, V14, P1116, DOI 10.2741/3297
   Degterev A, 2013, CELL DEATH DIFFER, V20, P366, DOI 10.1038/cdd.2012.133
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Douglas DL, 2014, J CELL SCI, V127, P4134, DOI 10.1242/jcs.128009
   Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416
   Ferraris DV, 2010, J MED CHEM, V53, P4561, DOI 10.1021/jm100012m
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galluzzi L, 2009, J MOL CELL BIOL, V1, P8, DOI 10.1093/jmcb/mjp007
   Giansanti V, 2013, J CELL MOL MED, V17, P103, DOI 10.1111/j.1582-4934.2012.01652.x
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200
   HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468
   Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaldarar-Pedotti S, 1979, Adv Ophthalmol, V39, P37
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1
   Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017
   Liu XB, 2015, INVEST OPHTH VIS SCI, V56, P2821, DOI 10.1167/iovs.14-15876
   Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247
   Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Mizota A, 1997, VISION RES, V37, P1859, DOI 10.1016/S0042-6989(97)00015-1
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Moubarak RS, 2007, MOL CELL BIOL, V27, P4844, DOI 10.1128/MCB.02141-06
   NILSSON SEG, 1977, ACTA OPHTHALMOL, V55, P994
   Njie-Mbye YF, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00366
   Park EJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.202
   PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0
   ROBSON JG, 1995, VISUAL NEUROSCI, V12, P837, DOI 10.1017/S0952523800009408
   Schroder E, 2008, CURR OPIN PHARMACOL, V8, P153, DOI 10.1016/j.coph.2007.12.012
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   TIAN N, 1995, VISION RES, V35, P1359, DOI 10.1016/0042-6989(95)98715-L
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Vandenabeele P, 2013, CELL DEATH DIFFER, V20, P185, DOI 10.1038/cdd.2012.151
   Wang YF, 2009, EXP NEUROL, V218, P193, DOI 10.1016/j.expneurol.2009.03.020
   WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509
   WEBSTER SH, 1957, J PHARMACOL EXP THER, V120, P171
   Winkler BS, 1999, MOL VIS, V5
   Wright KM, 2006, CELL CYCLE, V5, P1616, DOI 10.4161/cc.5.15.3129
   Yang P, 2007, INVEST OPHTH VIS SCI, V48, P3341, DOI 10.1167/iovs.06-1340
   Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221
   Zaremba T, 2007, ANTI-CANCER AGENT ME, V7, P515, DOI 10.2174/187152007781668715
   Zha X, 2015, CELL PHYSIOL BIOCHEM, V36, P2217, DOI 10.1159/000430186
   Zhang FJ, 2014, TOXICOL SCI, V140, P118, DOI 10.1093/toxsci/kfu073
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
NR 66
TC 42
Z9 43
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JAN
PY 2017
VL 8
AR e2526
DI 10.1038/cddis.2016.437
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EK1IM
UT WOS:000393679000012
PM 28055012
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Forte, R
   Panzella, L
   Cesarano, I
   Cennamo, G
   Eidenberger, T
   Napolitano, A
AF Forte, Raimondo
   Panzella, Lucia
   Cesarano, Ida
   Cennamo, Gilda
   Eidenberger, Thomas
   Napolitano, Alessandra
TI Epilutein for Early-Stage Age-Related Macular Degeneration: A Randomized
   and Prospective Study
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Lutein; Epilutein; Macular pigment
   optical density
ID PIGMENT OPTICAL-DENSITY; SPECTRAL FUNDUS REFLECTANCE; SERUM
   CONCENTRATIONS; ZEAXANTHIN SUPPLEMENTATION; LUTEIN; CAROTENOIDS; PLASMA;
   IDENTIFICATION; POPULATION; TRANSFORMATIONS
AB Purpose: The hypothesis that oral supplementation of the epilutein/lutein combination could augment the macular pigment optical density (MPOD) in patients with age-related macular degeneration (AMD) was tested. Methods: In a prospective randomized interventional study, 40 consecutive patients with early-stage AMD were recruited. After a 2-week run-in period, patients were randomly treated with a daily oral administration of 8 mg epilutein and 2 mg lutein (group 1) or 10 mg lutein (group 2) for 2 months. At baseline (BL) and 1-month (M1) and 2-month visits (M2), all patients underwent a complete ophthalmological examination, including measurement of MPOD in a 7 degrees area (Visucam 200; Carl Zeiss Meditec, Milan, Italy). Xanthophylls were quantified in plasma, as well as the HDL, non-HDL, and erythrocyte fractions at each study visit. Results: Twenty-one patients (mean age 69.4 +/- 6.7 years, 35 eyes) were included in group 1. Mean MPOD was 0.203 +/- 0.02 optical density units (ODU) at BL, and increased to 0.214 +/- 0.04 ODU at M1 (p = 0.008) and 0.206 +/- 0.03 ODU at M2 (p = 0.04). Sixteen patients (mean age 72.0 +/- 6.3 years, 29 eyes) were included in group 2. Mean MPOD was 0.215 +/- 0.03 at BL, which reduced to 0.202 +/- 0.03 ODU at M1 (p = 0.003) and 0.207 +/- 0.02 ODU at M2 (p < 0.001). A rise in the systemic level of total xanthophylls was observed at M1 for both groups. At M2, total xanthophylls were significantly increased only in group 1 and decreased in group 2. Conclusion: In patients with early-stage AMD, the administration of lutein in combination with epilutein was associated with an increased MPOD compared to the administration of lutein alone. (C) 2017 S. Karger AG, Basel
C1 [Forte, Raimondo; Cesarano, Ida; Cennamo, Gilda] Univ Naples Federico II, Dept Ophthalmol, Via Pansini 15, IT-80121 Naples, Italy.
   [Panzella, Lucia; Napolitano, Alessandra] Univ Naples Federico II, Dept Chem Sci, Naples, Italy.
   [Eidenberger, Thomas] Upper Austria Univ Appl Sci, Sch Engn & Environm Sci, AT-4600 Wels, Austria.
C3 University of Naples Federico II; University of Naples Federico II
RP Forte, R (通讯作者)，Univ Naples Federico II, Dept Ophthalmol, Via Pansini 15, IT-80121 Naples, Italy.; Eidenberger, T (通讯作者)，Upper Austria Univ Appl Sci, Sch Engn & Environm Sci, AT-4600 Wels, Austria.
EM raiforte@gmail.com; Thomas.Eidenberger@fh-wels.at
RI Napolitano, Alessandra/E-9761-2011
OI Napolitano, Alessandra/0000-0003-0507-5370
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Burrows T. L., 2015, Journal of Nutrition & Intermediary Metabolism, V2, P15, DOI 10.1016/j.jnim.2015.05.001
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Deli J, 2004, BIOORG MED CHEM LETT, V14, P925, DOI 10.1016/j.bmcl.2003.12.012
   Dragostinoff N, 2012, GRAEF ARCH CLIN EXP, V250, P1261, DOI 10.1007/s00417-012-1946-3
   Eidenberger T, 2009, patent US, Patent No. 7812198
   Eidenberger T, 2013, patent, Patent No. [US20110144200, 20110144200]
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   Hartmann D, 2004, AM J CLIN NUTR, V79, P410
   Ji YY, 2015, ACTA OPHTHALMOL, V93, pE550, DOI 10.1111/aos.12645
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5476, DOI 10.1167/iovs.06-0194
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Miyazawa T, 2013, J OLEO SCI, V62, P773, DOI 10.5650/jos.62.773
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Molnar P, 2006, LETT ORG CHEM, V3, P723, DOI 10.2174/157017806779025933
   Nakagawa K, 2008, ANAL BIOCHEM, V381, P129, DOI 10.1016/j.ab.2008.06.038
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Obana A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139257
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SCHIEDT K, 1985, PURE APPL CHEM, V57, P685, DOI 10.1351/pac198557050685
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Schweitzer D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3526358
   Tian Y, 2015, ACTA OPHTHALMOL, V93, P141, DOI 10.1111/aos.12535
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Vishwanathan R, 2010, NUTR RES, V30, P747, DOI 10.1016/j.nutres.2010.10.007
   Yoshizako H, 2016, ACTA OPHTHALMOL, V94, pE411, DOI 10.1111/aos.13106
NR 53
TC 4
Z9 4
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2017
VL 58
IS 4
BP 231
EP 241
DI 10.1159/000479930
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL1FD
UT WOS:000413959100007
PM 28957818
DA 2022-11-30
ER

PT J
AU Juel, HB
   Faber, C
   Munthe-Fog, L
   Bastrup-Birk, S
   Reese-Petersen, AL
   Falk, MK
   Singh, A
   Sorensen, TL
   Garred, P
   Nissen, MH
AF Juel, Helene Baek
   Faber, Carsten
   Munthe-Fog, Lea
   Bastrup-Birk, Simone
   Reese-Petersen, Alexander Lynge
   Falk, Mads Krueger
   Singh, Amardeep
   Sorensen, Torben Lykke
   Garred, Peter
   Nissen, Mogens Holst
TI Systemic and Ocular Long Pentraxin 3 in Patients with Age-Related
   Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; VISUAL IMPAIRMENT;
   PLASMA-LEVELS; DRUSEN; ACTIVATION; EXPRESSION; BIOMARKERS; BINDING;
   CELLS
AB Age-related macular degeneration (AMD) has been associated with both systemic and ocular alterations of the immune system. In particular dysfunction of complement factor H (CFH), a soluble regulator of the alternative pathway of the complement system, has been implicated in AMD pathogenesis. One of the ligands for CFH is long pentraxin 3 (PTX3), which is produced locally in the retinal pigment epithelium (RPE). To test the hypothesis that PTX3 is relevant to retinal immunohomeostasis and may be associated with AMD pathogenesis, we measured plasma PTX3 protein concentration and analyzed the RPE/choroid PTX3 gene expression in patients with AMD. To measure the ability of RPE cells to secrete PTX3 in vitro, polarized ARPE-19 cells were treated with activated T cells or cytokines (interferon (IFN)-gamma and/or tumor necrosis factor (TNF)-alpha) from the basolateral side; then PTX3 protein concentration in supernatants and PTX3 gene expression in tissue lysates were quantified. Plasma levels of PTX3 were generally low and did not significantly differ between patients and controls (P=0.307). No statistically significant difference was observed between dry and exudative AMD nor was there any correlation with hsCRP or CFH genotype. The gene expression of PTX3 increased in RPE/choroid with age (P=0.0098 macular; P=0.003 extramacular), but did not differ between aged controls and AMD patients. In vitro, ARPE-19 cells increased expression of the PTX3 gene as well PTX3 apical secretions after stimulation with TNF-alpha or activated T cells (P<0.01). These findings indicate that PTX3 expressed in the eye cannot be detected systemically and systemic PTX3 may have little or no impact on disease progression, but our findings do not exclude that locally produced PTX3 produced in the posterior segment of the eye may be part of the AMD immunopathogenesis.
C1 [Juel, Helene Baek; Faber, Carsten; Reese-Petersen, Alexander Lynge; Nissen, Mogens Holst] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
   [Faber, Carsten] Glostrup Cty Hosp, Dept Ophthalmol, Glostrup, Denmark.
   [Munthe-Fog, Lea; Bastrup-Birk, Simone; Garred, Peter] Copenhagen Univ Hosp, Dept Clin Immunol, Mol Med Lab, Rigshosp, Copenhagen, Denmark.
   [Falk, Mads Krueger; Singh, Amardeep; Sorensen, Torben Lykke] Copenhagen Univ Hosp, Dept Ophthalmol, Roskilde, Denmark.
   [Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen; Rigshospitalet;
   University of Copenhagen; University of Copenhagen; University of
   Copenhagen
RP Faber, C (通讯作者)，Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
EM carstenfaber@gmail.com
RI Juel, Helene/AAD-2843-2020; Nissen, Mogens/B-4825-2008; Faber,
   Carsten/N-3210-2019; Singh, Amardeep/ABI-4544-2020; Faber,
   Carsten/I-4150-2013; Bastrup-Birk, Annemarie/K-1937-2016
OI Nissen, Mogens/0000-0001-7729-8667; Faber, Carsten/0000-0002-2517-7270;
   Faber, Carsten/0000-0002-2517-7270; Munthe-Fog, Lea/0000-0003-1345-176X;
   Bastrup-Birk, Annemarie/0000-0002-8405-8538; Garred,
   Peter/0000-0002-2876-8586; Juel, Helene B/0000-0002-5763-8545; Bastrup
   Israelsen, Simone/0000-0002-0653-1289
FU Lundbeck Foundation; Danish Eye Research Foundation; Fight for Sight
   Denmark; Rigshospitalet; Medical Research Council; Novo Nordisk Research
   Foundation
FX This work was funded by The Lundbeck Foundation, The Danish Eye Research
   Foundation, Fight for Sight Denmark, Rigshospitalet, The Medical
   Research Council, and The Novo Nordisk Research Foundation. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Bastrup-Birk S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073119
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Doni A, 2012, IMMUNOBIOLOGY, V217, P1122, DOI 10.1016/j.imbio.2012.07.004
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Faber C, 2012, INVEST OPHTH VIS SCI, V53, P6324, DOI 10.1167/iovs.12-10385
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Lee HW, 2011, MOVEMENT DISORD, V26, P2364, DOI 10.1002/mds.23871
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Noma H, 2014, RETINA-J RET VIT DIS, V34, P352, DOI 10.1097/IAE.0b013e3182993d74
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Shimada Y, 2014, MOD RHEUMATOL, V24, P78, DOI 10.3109/14397595.2013.852837
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sofat R, 2010, ATHEROSCLEROSIS, V213, P184, DOI 10.1016/j.atherosclerosis.2010.07.021
   Trouw LA, 2011, CLIN EXP IMMUNOL, V166, P333, DOI 10.1111/j.1365-2249.2011.04482.x
   Uusitalo-Seppala R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053661
   Wang HH, 2013, MULT SCLER J, V19, P926, DOI 10.1177/1352458512457845
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Woo JM, 2013, MOL VIS, V19, P303
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
NR 48
TC 11
Z9 11
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 15
PY 2015
VL 10
IS 7
AR e0132800
DI 10.1371/journal.pone.0132800
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN1RL
UT WOS:000358197600161
PM 26176960
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Adamus, G
   Chew, EY
   Ferris, FL
   Klein, ML
AF Adamus, Grazyna
   Chew, Emily Y.
   Ferris, Frederick L.
   Klein, Michael L.
TI Prevalence of anti-retinal autoantibodies in different stages of
   Age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; AREDS; Autoantibodies; Enolase;
   Antibody signature; Biomarker; Retina; Macula; Smoking; Arthritis
ID CANCER-ASSOCIATED RETINOPATHY; PIGMENT EPITHELIAL-CELLS; COMPLEMENT
   FACTOR-H; ALPHA-ENOLASE; RHEUMATOID-ARTHRITIS; AUTOIMMUNE RETINOPATHY;
   CIGARETTE-SMOKING; RISK-FACTORS; INFLAMMATION; ANTIBODIES
AB Background: Age-related macular degeneration (AMD) is the leading cause of central vision loss in older adults. Anti-retinal autoantibodies (AAbs) have been found in individuals with AMD. The goal of the study was to determine the AAb specificity in different stages of AMD, and determine whether there is a prevalent AAb signature.
   Methods: Sera of 134 participants in the Age-related Eye Disease Study were analyzed for anti-retinal AAbs by western blotting. The subjects were classified by diagnostic subgroups based upon their clinical classification: No AMD, Intermediate AMD, and Late AMD -geographic atrophy (GA) and Late AMD -neovascular (NV).
   Results: The presence of anti-retinal AAb was detected in 58% patients with Intermediate and Late AMD, and 54% of those with no AMD. AAbs bound to fifteen different retinal antigens. Most individuals had 1 specific AAbs (67%), with the remainder having 2 to 4 different AAbs. Over 40% of patients with Intermediate AMD, and 46% of those with GA had anti-enolase AAbs, compared with 29% of individuals with NV and 29% with no AMD. Different AAbs signatures related to NV as compared to GA and/or Intermediate AMD were distinguished. Anti-40-kDa (10%) and 42-kDa (16%) autoantibodies were associated with Intermediate AMD, while anti-30-kDa AAbs (23%) were primarily present in GA. Anti-32-kDa (12%), 35-kDa (21%), and 60-kDa (8%) AAbs were more frequent in NV AMD.
   Conclusions: A unique AAb pattern for each of the disease subgroups was present when AMD progressed from the intermediate to the late forms of severity. Differences in the frequency of specific AAbs between AMD subgroups suggested that they may participate in pathogenicity of AMD. Further studies are necessary to confirm these observations in the larger cohort and individual AMD patients over time.
C1 [Adamus, Grazyna; Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Ocular Immunol Lab, Portland, OR 97239 USA.
   [Chew, Emily Y.; Ferris, Frederick L.] NEI, NIH, Bethesda, MD 20892 USA.
C3 Oregon Health & Science University; National Institutes of Health (NIH)
   - USA; NIH National Eye Institute (NEI)
RP Adamus, G (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Ocular Immunol Lab, L467AD,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM adamusg@ohsu.edu
OI Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute [EY13053, EY021532]; Macular Degeneration Center
   Research Fund [P30EY010572]; Foundation to Prevent Blindness; NATIONAL
   EYE INSTITUTE [ZIAEY000485, R01EY021532, R01EY013053, P30EY010572]
   Funding Source: NIH RePORTER
FX This work was supported in part by the National Eye Institute grants
   EY13053 (GA) and EY021532 (MK), the Macular Degeneration Center Research
   Fund (MK), core grant P30EY010572 and unrestricted grant to Casey Eye
   Institute from the Foundation to Prevent Blindness.
CR Adamus G, 1998, J AUTOIMMUN, V11, P671, DOI 10.1006/jaut.1998.0239
   Adamus G, 1996, CLIN IMMUNOL IMMUNOP, V78, P120, DOI 10.1006/clin.1996.0021
   Adamus G., 1997, Journal of Allergy and Clinical Immunology, V99, pS20
   Adamus G, 2013, J CLIN EXP OPHTHALMO, V4, P304
   Adamus Grazyna, 2004, BMC Ophthalmol, V4, P5, DOI 10.1186/1471-2415-4-5
   Adamus Grazyna, 2002, Int Rev Immunol, V21, P209, DOI 10.1080/08830180212068
   Adamus G, 2009, AUTOIMMUN REV, V8, P410, DOI 10.1016/j.autrev.2009.01.002
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arnson Y, 2010, J AUTOIMMUN, V34, pJ258, DOI 10.1016/j.jaut.2009.12.003
   Barud W, 2002, ATHEROSCLEROSIS, V164, P283, DOI 10.1016/S0021-9150(02)00069-2
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Butterfield DA, 2009, J NEUROCHEM, V111, P915, DOI 10.1111/j.1471-4159.2009.06397.x
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Cutolo M, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2630
   Deeg CA, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/39245
   Dhillon B, 2010, INVEST OPHTH VIS SCI, V51, P5858, DOI 10.1167/iovs.09-5124
   Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Heckenlively JR, 2008, SEMIN IMMUNOPATHOL, V30, P127, DOI 10.1007/s00281-008-0114-7
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Kennedy BN, 2003, EXP EYE RES, V76, P257, DOI 10.1016/S0014-4835(02)00308-1
   Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Kubicka-Trzaska A, 2012, ACTA OPHTHALMOL, V90, pE21, DOI 10.1111/j.1755-3768.2011.02237.x
   Kyger M, 2013, J NEUROIMMUNOL, V254, P91, DOI 10.1016/j.jneuroim.2012.10.007
   Lee J, 2012, J DENT RES, V91, P142, DOI 10.1177/0022034511421200
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Mahdi H, 2009, NAT GENET, V41, P1319, DOI 10.1038/ng.480
   MENZEL EJ, 1988, ARCH GERONTOL GERIAT, V7, P249, DOI 10.1016/0167-4943(88)90008-8
   Mooney LA, 2001, CANCER EPIDEM BIOMAR, V10, P641
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pikwer M, 2014, ANN RHEUM DIS, V73, P573, DOI 10.1136/annrheumdis-2012-202781
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Ren GY, 2004, J AUTOIMMUN, V23, P161, DOI 10.1016/j.jaut.2004.06.003
   Renganathan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076325
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon A, 1999, EUR J OPHTHALMOL, V9, P202, DOI 10.1177/112067219900900307
   Stolt P, 2003, ANN RHEUM DIS, V62, P835, DOI 10.1136/ard.62.9.835
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Terrier B, 2007, AUTOIMMUN REV, V6, P176, DOI 10.1016/j.autrev.2006.10.004
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   WIGGERT B, 1991, EXP EYE RES, V53, P389, DOI 10.1016/0014-4835(91)90245-A
   Zhu L, 2013, INVEST OPHTH VIS SCI, V54, P5675, DOI 10.1167/iovs.13-12050
NR 60
TC 26
Z9 27
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 8
PY 2014
VL 14
AR 154
DI 10.1186/1471-2415-14-154
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ4BF
UT WOS:000348166600001
PM 25488058
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Orozco, LD
   Chen, HH
   Cox, C
   Katschke, KJ
   Arceo, R
   Espiritu, C
   Caplazi, P
   Nghiem, SS
   Chen, YJ
   Modrusan, Z
   Dressen, A
   Goldstein, LD
   Clarke, C
   Bhangale, T
   Yaspan, B
   Jeanne, M
   Townsend, MJ
   Campagne, MV
   Hackney, JA
AF Orozco, Luz D.
   Chen, Hsu-Hsin
   Cox, Christian
   Katschke, Kenneth J., Jr.
   Arceo, Rommel
   Espiritu, Carmina
   Caplazi, Patrick
   Nghiem, Sarajane Saturnio
   Chen, Ying-Jiun
   Modrusan, Zora
   Dressen, Amy
   Goldstein, Leonard D.
   Clarke, Christine
   Bhangale, Tushar
   Yaspan, Brian
   Jeanne, Marion
   Townsend, Michael J.
   Campagne, Menno van Lookeren
   Hackney, Jason A.
TI Integration of eQTL and a Single-Cell Atlas in the Human Eye Identifies
   Causal Genes for Age-Related Macular Degeneration
SO CELL REPORTS
LA English
DT Article
ID STATIONARY NIGHT BLINDNESS; RNA-SEQ; EXPRESSION; TRPM1; TRANSCRIPTOME;
   COMPLEX; MELANOCYTES; MECHANISMS; VARIANTS; NEURONS
AB Age-related macular degeneration (AMD) is a leading cause of vision loss. To better understand disease pathogenesis and identify causal genes in GWAS loci for AMD risk, we present a comprehensive data-base of human retina and retinal pigment epithelium (RPE). Our database comprises macular and nonmacular RNA sequencing (RNA-seq) profiles from 129 donors, a genome-wide expression quantitative trait loci (eQTL) dataset that includes macula-specific retina and RPE/choroid, and single-nucleus RNA-seq (NucSeq) from human retina and RPE with subtype resolution from more than 100,000 cells. Using NucSeq, we find enriched expression of AMD candidate genes in RPE cells. We identify 15 putative causal genes for AMD on the basis of co-localization of genetic association signals for AMD risk and eye eQTL, including the genes TSPAN10 and TRPM1. These results demonstrate the value of our human eye database for elucidating genetic pathways and potential therapeutic targets for ocular diseases.
C1 [Orozco, Luz D.; Goldstein, Leonard D.; Clarke, Christine; Hackney, Jason A.] Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA.
   [Chen, Hsu-Hsin; Townsend, Michael J.] Genentech Inc, Dept Biomarker Discovery OMNI, San Francisco, CA 94080 USA.
   [Cox, Christian; Katschke, Kenneth J., Jr.; Jeanne, Marion; Campagne, Menno van Lookeren] Genentech Inc, Dept Immunol Discovery, San Francisco, CA 94080 USA.
   [Arceo, Rommel; Espiritu, Carmina; Caplazi, Patrick; Nghiem, Sarajane Saturnio] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA.
   [Chen, Ying-Jiun; Modrusan, Zora; Goldstein, Leonard D.] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA.
   [Dressen, Amy; Bhangale, Tushar; Yaspan, Brian] Genentech Inc, Dept Human Genet, San Francisco, CA 94080 USA.
   [Campagne, Menno van Lookeren] Amgen Res, Dept Inflammat & Oncol, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche
   Holding; Genentech
RP Hackney, JA (通讯作者)，Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA.; Townsend, MJ (通讯作者)，Genentech Inc, Dept Biomarker Discovery OMNI, San Francisco, CA 94080 USA.; Campagne, MV (通讯作者)，Genentech Inc, Dept Immunol Discovery, San Francisco, CA 94080 USA.; Campagne, MV (通讯作者)，Amgen Res, Dept Inflammat & Oncol, San Francisco, CA 94080 USA.
EM townsem1@gene.com; mvanlook@amgen.com; jasonah@gene.com
OI Townsend, Michael/0000-0003-0240-4562; Jeanne,
   Marion/0000-0001-7334-3061; Hackney, Jason/0000-0002-5922-563X; Clarke,
   Christine/0000-0002-2706-4448
FU Genentech
FX We thank Ashley Morganti and the Lion's Institute for retrieval of human
   donor eyes, Kyle Kuchinsky and Timothy Lee for their help with tissue
   dissections, Julie Hunkapiller for procuring the genotype data, the Next
   Generation Sequencing group at Genentech for their help with RNA-seq and
   NucSeq experiments, Yanli Hou for uploading data to GEO and Broad
   single-cell viewer, Brad Friedman for the pseudo-bulk method, Allison
   Bruce for creating the illustrations and artwork, Michal Biernacki for
   the user experience of the eQTL website, and Joshua Kaminker for
   scientific advice. This work was funded by Genentech.
CR Adato A, 2002, EUR J HUM GENET, V10, P339, DOI 10.1038/sj.ejhg.5200831
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Browning BL, 2016, AM J HUM GENET, V98, P116, DOI 10.1016/j.ajhg.2015.11.020
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Cannon ME, 2018, AM J HUM GENET, V103, P637, DOI 10.1016/j.ajhg.2018.10.001
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8
   Coughlin BA, 2017, VISION RES, V139, P93, DOI 10.1016/j.visres.2017.03.013
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146
   Farrar GJ, 2017, HUM MOL GENET, V26, pR2, DOI 10.1093/hmg/ddx185
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gao XR, 2019, HUM MOL GENET, V28, P1162, DOI 10.1093/hmg/ddy422
   Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
   Goldstein LD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156132
   Graham PS, 2018, BMC MED GENET, V19, DOI [10.1186/S12881-018-0587-8, 10.1186/s12881-018-0587-8]
   Grassi MA, 2011, HUM MOL GENET, V20, P2472, DOI 10.1093/hmg/ddr121
   Grindberg RV, 2013, P NATL ACAD SCI USA, V110, P19802, DOI 10.1073/pnas.1319700110
   Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506
   Habib N, 2017, NAT METHODS, V14, P955, DOI [10.1038/NMETH.4407, 10.1038/nmeth.4407]
   Haining EJ, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.416503
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hinrichs AS, 2006, NUCLEIC ACIDS RES, V34, pD590, DOI 10.1093/nar/gkj144
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hysi PG, 2018, NAT GENET, V50, P652, DOI 10.1038/s41588-018-0100-5
   Krishnaswami SR, 2016, NAT PROTOC, V11, P499, DOI 10.1038/nprot.2016.015
   Lake BB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04426-w
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Liu F, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000934
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Lu Y, 2015, COMP BIOCHEM PHYS C, V178, P86, DOI 10.1016/j.cbpc.2015.07.011
   Lun ATL, 2017, BIOSTATISTICS, V18, P451, DOI 10.1093/biostatistics/kxw055
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Meng WH, 2018, ACTA OPHTHALMOL, V96, pE811, DOI 10.1111/aos.13769
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Miller AJ, 2004, CANCER RES, V64, P509, DOI 10.1158/0008-5472.CAN-03-2440
   Morgan MD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07691-z
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Orozco LD, 2012, CELL, V151, P658, DOI 10.1016/j.cell.2012.08.043
   Peachey NS, 2012, J NEUROPHYSIOL, V108, P2442, DOI 10.1152/jn.00137.2012
   Peng YR, 2019, CELL, V176, P1222, DOI 10.1016/j.cell.2019.01.004
   Persad PJ, 2017, INVEST OPHTH VIS SCI, V58, P4027, DOI 10.1167/iovs.17-21734
   Plotnikov D, 2019, HUM GENET, V138, P723, DOI 10.1007/s00439-019-02022-8
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Rheaume BA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05134-3
   Romanoski CE, 2010, AM J HUM GENET, V86, P399, DOI 10.1016/j.ajhg.2010.02.002
   Rosenberg AB, 2018, SCIENCE, V360, P176, DOI 10.1126/science.aam8999
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sandmeyer LS, 2012, VET OPHTHALMOL, V15, P18, DOI 10.1111/j.1463-5224.2011.00903.x
   Sathyamurthy A, 2018, CELL REP, V22, P2216, DOI 10.1016/j.celrep.2018.02.003
   Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163
   Shah RL, 2018, HUM GENET, V137, P881, DOI 10.1007/s00439-018-1942-8
   Shekhar K, 2016, CELL, V166, P1308, DOI 10.1016/j.cell.2016.07.054
   Shulse CN, 2019, CELL REP, V27, P2241, DOI 10.1016/j.celrep.2019.04.054
   Stegle O, 2012, NAT PROTOC, V7, P500, DOI 10.1038/nprot.2011.457
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   Utz VM, 2018, JAMA OPHTHALMOL, V136, P389, DOI 10.1001/jamaophthalmol.2018.0185
   Voigt AP, 2019, EXP EYE RES, V184, P234, DOI 10.1016/j.exer.2019.05.001
   Wang AL, 2014, MOL VIS, V20, P1146
   Warrier V, 2013, BBA-MOL BASIS DIS, V1832, P1827, DOI 10.1016/j.bbadis.2013.03.017
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Wiggs JL, 2017, HUM MOL GENET, V26, pR21, DOI 10.1093/hmg/ddx184
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zeitz C, 2015, PROG RETIN EYE RES, V45, P58, DOI 10.1016/j.preteyeres.2014.09.001
   Zhiqi S, 2004, MELANOMA RES, V14, P509, DOI 10.1097/00008390-200412000-00011
   Zhu ZH, 2016, NAT GENET, V48, P481, DOI 10.1038/ng.3538
NR 70
TC 66
Z9 67
U1 1
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JAN 28
PY 2020
VL 30
IS 4
BP 1246
EP +
DI 10.1016/j.celrep.2019.12.082
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KG2LZ
UT WOS:000509775700025
PM 31995762
OA gold
DA 2022-11-30
ER

PT J
AU Shiba, T
   Takahashi, M
   Yoshida, I
   Taniguchi, H
   Matsumoto, T
   Hori, Y
AF Shiba, Tomoaki
   Takahashi, Mao
   Yoshida, Izumi
   Taniguchi, Hikari
   Matsumoto, Tadashi
   Hori, Yuichi
TI Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular
   Endothelial Growth Factor Drugs in Patients with Exudative Age-Related
   Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Intima-media thickness; Cardio-ankle
   vascular index; Anti-vascular endothelial growth factor drugs
ID ANKLE VASCULAR INDEX; INTIMA-MEDIA THICKNESS; PULSE-WAVE VELOCITY;
   VISUAL IMPAIRMENT; CANCER-PATIENTS; VASA VASORUM; CYSTATIN-C;
   RANIBIZUMAB; RISK; ATHEROSCLEROSIS
AB Purpose: The aim of this study was to determine whether multiple intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs for age-related macular degeneration (AMD) exacerbate systemic arteriosclerosis, using the cardio-ankle vascular index (CAVI) and intima-media thickness (IMT). Methods: We analyzed the data of 45 AMD patients who received intravitreal injections of anti-VEGF drugs (ranibizumab and/or aflibercept) and underwent systemic evaluations at baseline and after treatment. Reevaluation was conducted at >= 12 months from the initial treatment. Results: The total number of intravitreal injections of overall anti-VEGF drugs was significantly correlated with.serum cystatin C. The cumulative number of aflibercept injections was identified as an independent protective factor for.CAVI. An increase in the cumulative number of intravitreal injections of overall anti-VEGF drugs was identified as a protective factor for.mean IMT. Conclusion: Repeated intravitreal injections of an anti-VEGF drug for AMD may lead to morphological and functional changes in large arteries. (C) 2016 S. Karger AG, Basel
C1 [Shiba, Tomoaki; Matsumoto, Tadashi; Hori, Yuichi] Toho Univ, Sch Med, Dept Ophthalmol, Tokyo 1438541, Japan.
   [Takahashi, Mao] Toho Univ, Sakura Med Ctr, Ctr Cardiovasc, Chiba 2748510, Japan.
   [Yoshida, Izumi; Taniguchi, Hikari] Toho Univ, Sakura Med Ctr, Dept Ophthalmol, Chiba 2748510, Japan.
C3 Toho University; Toho University; Toho University
RP Shiba, T (通讯作者)，Toho Univ, Dept Ophthalmol, Sch Med, Ota Ku, 6-11-1 Omori Nishi, Tokyo 1438541, Japan.
EM tomoaki-s@med.toho-u.ac.jp
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bai XJ, 2010, GERONTOLOGY, V56, P129, DOI 10.1159/000262449
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Chambless LE, 2000, AM J EPIDEMIOL, V151, P478
   Dreilich M, 2005, MED ONCOL, V22, P29, DOI 10.1385/MO:22:1:029
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Hayashi K, 1975, Iyodenshi To Seitai Kogaku, V13, P293
   Herrmann J, 2001, CARDIOVASC RES, V51, P762, DOI 10.1016/S0008-6363(01)00347-9
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Ishikawa T, 2008, AM J HYPERTENS, V21, P413, DOI 10.1038/ajh.2007.77
   Ivan SI, 2012, OPHTHALMOLOGY, V119, P1399, DOI DOI 10.1016/J.0PHTHA.2012.04.015
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   Khurana R, 2005, CIRCULATION, V111, P2828, DOI 10.1161/CIRCULATIONAHA.104.495887
   Khurana R, 2004, CIRCULATION, V110, P2436, DOI 10.1161/01.CIR.0000145138.25577.F1
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103
   Pereg D, 2008, EUR HEART J, V29, P2325, DOI 10.1093/eurheartj/ehn384
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Shirai K, 1997, J CLIN LAB ANAL, V11, P82, DOI 10.1002/(SICI)1098-2825(1997)11:2&lt;82::AID-JCLA3&gt;3.0.CO;2-M
   Shirai K, 2006, J ATHEROSCLER THROMB, V13, P101, DOI 10.5551/jat.13.101
   Shirai K, 2011, J ATHEROSCLER THROMB, V18, P924
   Song SH, 2008, HYPERTENS RES, V31, P1895, DOI 10.1291/hypres.31.1895
   Stefanadis Christodoulos, 2006, Hellenic J Cardiol, V47, P7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Sun Y, 2002, ATHEROSCLEROSIS, V164, P89, DOI 10.1016/S0021-9150(02)00017-5
   Takiuchi S, 2004, J HUM HYPERTENS, V18, P17, DOI 10.1038/sj.jhh.1001628
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Xu JY, 2015, INT J MOL SCI, V16, P11574, DOI 10.3390/ijms160511574
   Yamamoto N, 2009, DEMENT GERIATR COGN, V28, P153, DOI 10.1159/000235642
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
NR 34
TC 5
Z9 5
U1 1
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 235
IS 4
BP 225
EP 232
DI 10.1159/000445388
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP9BR
UT WOS:000378792200007
PM 27082736
DA 2022-11-30
ER

PT J
AU Taylor, DJ
   Smith, ND
   Binns, AM
   Crabb, DP
AF Taylor, Deanna J.
   Smith, Nicholas D.
   Binns, Alison M.
   Crabb, David P.
TI The effect of non-neovascular age-related macular degeneration on face
   recognition performance
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Low vision; Face recognition; Age-related macular degeneration;
   Geographic atrophy; Visual function; Activities of daily living
ID QUALITY-OF-LIFE; VISUAL-ACUITY; OLDER-ADULTS; MEMORY TEST; MACULOPATHY;
   POPULATION; VISION; CLASSIFICATION; PROSOPAGNOSIA; QUESTIONNAIRE
AB There is a well-established research base surrounding face recognition in patients with age-related macular degeneration (AMD). However, much of this existing research does not differentiate between results obtained for 'wet' AMD and 'dry' AMD. Here, we test the hypothesis that face recognition performance is worse in patients with dry AMD compared with visually healthy peers.
   Patients (> 60 years of age, logMAR binocular visual acuity 0.7 or better) with dry AMD of varying severity and visually healthy age-related peers (controls) completed a modified version of the Cambridge Face Memory Test (CFMT). Percentage of correctly identified faces was used as an outcome measure for performance for each participant. A 90% normative reference limit was generated from the distribution of CFMT scores recorded in the visually healthy controls. Scores for AMD participants were then specifically compared to this limit, and comparisons between average scores in the AMD severity groups were investigated.
   Thirty patients (median [interquartile range] age of 76 [70, 79] years) and 34 controls (median age of 70 [64, 75] years) were examined. Four, seventeen and nine patients were classified as having early, intermediate and late AMD (geographic atrophy) respectively. Five (17%) patients recorded a face recognition performance worse than the 90% limit (Fisher's exact test, p = 0.46) set by controls; four of these had geographic atrophy. Patients with geographic atrophy identified fewer faces on average (+/- SD) (61% +/- 22%) than those with early and intermediate AMD (75 +/- 11%) and controls (74% +/- 11%).
   People with dry AMD may not suffer from problems with face recognition until the disease is in its later stages; those with late AMD (geographic atrophy) are likely to have difficulty recognising faces. The results from this study should influence the management and expectations of patients with dry AMD in both community practice and hospital clinics.
C1 [Taylor, Deanna J.; Smith, Nicholas D.; Binns, Alison M.; Crabb, David P.] City Univ London, Div Optometry & Visual Sci, Sch Hlth Sci, Northampton Sq, London EC1V 0HB, England.
C3 City University London
RP Crabb, DP (通讯作者)，City Univ London, Div Optometry & Visual Sci, Sch Hlth Sci, Northampton Sq, London EC1V 0HB, England.
EM david.crabb.1@city.ac.uk
OI Crabb, David/0000-0001-8754-3902; Taylor, Deanna/0000-0001-8261-5225
FU Roche Products Ltd. UK
FX This study was funded as part of an unrestricted investigator-initiated
   research grant from Roche Products Ltd. UK.
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Banerjee A, 2008, INDIAN J OPHTHALMOL, V56, P469
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Barnes CS, 2011, OPTOMETRY VISION SCI, V88, P188, DOI 10.1097/OPX.0b013e318205a17c
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   Bowles DC, 2009, COGN NEUROPSYCHOL, V26, P423, DOI 10.1080/02643290903343149
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Curriero FC, 2013, JAMA OPHTHALMOL, V131, P1420, DOI 10.1001/jamaophthalmol.2013.4471
   Dinon J-F, 2005, J VIS, V5, P985
   Duchaine B, 2006, NEUROPSYCHOLOGIA, V44, P576, DOI 10.1016/j.neuropsychologia.2005.07.001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Glen FC, 2013, VISION RES, V82, P42, DOI 10.1016/j.visres.2013.02.010
   Glen FC, 2012, INVEST OPHTH VIS SCI, V53, P3629, DOI 10.1167/iovs.11-8538
   Hart PM, 1998, EYE, V12, P124, DOI 10.1038/eye.1998.20
   Herzmann G, 2008, BEHAV RES METHODS, V40, P840, DOI 10.3758/BRM.40.3.840
   Hoddap E, 1993, CLIN DECISIONS GLAUC
   Loftus GR, 2005, PSYCHON B REV, V12, P43, DOI 10.3758/BF03196348
   Logan AJ, 2016, VISION RES, V119, P29, DOI 10.1016/j.visres.2015.11.003
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Pascalis O, 2009, PERSPECT PSYCHOL SCI, V4, P200, DOI 10.1111/j.1745-6924.2009.01119.x
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Schmier JK, 2006, OPHTHAL EPIDEMIOL, V13, P137, DOI 10.1080/09286580600573049
   Schoonjans F, 2011, EPIDEMIOLOGY, V22, P750, DOI 10.1097/EDE.0b013e318225c1de
   Sjostrand J, 2011, ACTA OPHTHALMOL, V89, P116, DOI 10.1111/j.1755-3768.2009.01653.x
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Wilmer JB, 2010, P NATL ACAD SCI USA, V107, P5238, DOI 10.1073/pnas.0913053107
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Yardley L, 2008, J PSYCHOSOM RES, V65, P445, DOI 10.1016/j.jpsychores.2008.03.013
NR 35
TC 14
Z9 14
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2018
VL 256
IS 4
BP 815
EP 821
DI 10.1007/s00417-017-3879-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FZ6HS
UT WOS:000427699300020
PM 29484559
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Sacu, S
   Stifter, E
   Vecsei-Marlovits, PV
   Michels, S
   Schutze, C
   Prunte, C
   Schmidt-Erfurth, U
AF Sacu, S.
   Stifter, E.
   Vecsei-Marlovits, P. V.
   Michels, S.
   Schuetze, C.
   Pruente, C.
   Schmidt-Erfurth, U.
TI Management of extensive subfoveal haemorrhage secondary to neovascular
   age-related macular degeneration
SO EYE
LA English
DT Article
DE subfoveal haemorrhage; recombinant tissue plasminogen activator; gas;
   avastin; lucentis
ID TISSUE-PLASMINOGEN ACTIVATOR; PARS-PLANA VITRECTOMY; SUBMACULAR
   HEMORRHAGE; SUBRETINAL HEMORRHAGE; INTRAVITREAL BEVACIZUMAB; SURGICAL
   DRAINAGE; INJECTION; GAS; REMOVAL; DISPLACEMENT
AB Background To evaluate the clinical outcomes of subfoveal haemorrhages secondary to neovascular age-related macular degeneration (AMD), which were treated with intravitreal recombinant tissue plasminogen activator (rTPA)/gas and anti-vascular endothelial growth factor (anti-VEGF) drug or with an intravitreal anti-VEGF monotherapy.
   Methods This is a retrospective pilot study. Patients who received intravitreal rTPA/gas and anti-VEGF injections (n = 20, bevacizumab or ranibizumab) were included in group A. Patients who refused prone positioning after rTPA/gas injections and were treated with an anti-VEGF monotherapy (bevacizumab) alone were included into group B (n = 10). Changes in baseline visual acuity (VA, Snellen), central retinal thickness (CRT) and haemorrhage size were analysed.
   Results Mean baseline VA was 0.15 +/- 0.2 and 0.25 +/- 0.17 in groups A and B, respectively. At month 4, significant improvement in mean VA was observed in group A (mean difference: +0.1 +/- 0.14; P = 0.003), and a stabilization in group B (mean difference: +0.008 +/- 0.2; P = 0.94). CRT decreased significantly by 70 mu m in group A (P = 0.001) and by 84 mu m in group B (P = 0.03). The mean size of subfoveal haemorrhage in groups A and B was 20.2 mm(2) and 19.1 mm(2) at baseline and 0.0 mm(2) and 2.0 mm(2) at month 4, respectively. The anti-VEGF treatmentrate was 1.6 in group A and 3.0 in group B.
   Conclusion In patients with extensive subfoveal haemorrhage secondary to neovascular AMD, the combination therapy of rTPA/pneumatic displacement and anti-VEGF results in mean improvement of VA and stabilization of morphological parameters. If rTPA and pneumatic displacement combination is contraindicated, an anti-VEGF monotherapy may be performed to prevent further visual loss. Eye (2009) 23, 1404-1410; doi:10.1038/eye.2008.267; published online 29 August 2008
C1 [Sacu, S.; Stifter, E.; Vecsei-Marlovits, P. V.; Schuetze, C.; Pruente, C.; Schmidt-Erfurth, U.] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Michels, S.] Univ Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 Medical University of Vienna; University of Zurich
RP Prunte, C (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM christian.pruente@meduniwien.ac.at
CR AIELLO LP, 2004, RETINA, V24, P3
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Claes C, 1996, Bull Soc Belge Ophtalmol, V261, P115
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HANSCOM TA, 1987, ARCH OPHTHALMOL-CHIC, V105, P1722
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2002, KLIN MONATSBL AUGENH, V219, P512, DOI 10.1055/s-2002-33584
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hesse L, 1997, ADV THER, V14, P275
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   Mozaffarieh M, 2006, GRAEF ARCH CLIN EXP, V244, P1421, DOI 10.1007/s00417-005-0232-z
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
NR 29
TC 49
Z9 50
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2009
VL 23
IS 6
BP 1404
EP 1410
DI 10.1038/eye.2008.267
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 457BP
UT WOS:000266900500026
PM 18756282
OA Bronze
DA 2022-11-30
ER

PT J
AU Qu, SC
   Xu, D
   Li, TT
   Zhang, JF
   Liu, F
AF Qu, Si-Chang
   Xu, Ding
   Li, Ting-Ting
   Zhang, Jing-Fa
   Liu, Fang
TI iTRAQ-based proteomics analysis of aqueous humor in patients with dry
   age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; protein biomarker; isobaric tags for
   relative and absolute quantification; differential expression of
   proteins; aqueous humor
ID QUANTITATIVE PROTEOMICS; RISK-FACTORS; PROTEIN; GLYCOPROTEIN;
   PREVALENCE; PATTERNS
AB AIM: To preliminarily test proteomics in aqueous humor in patients with dry age-related macular degeneration (AMD) by using the proteomic technology.
   METHODS: Aqueous humor samples were collected from patients with or without dry AMD, who underwent cataract surgery. The aqueous samples were analyzed with isobaric tags for relative and absolute quantification (iTRAQ) combined with liquid chromatography tandem mass spectrometry (LC-MS/MS) technology. The differential expressed proteins were analyzed with gene ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction (PPI) network analysis. The data were partly validated by ELISA and Western blot. False discovery rate (FDR) was used for statistical analysis.
   RESULTS: A total of 244 proteins were detected, in which 38 proteins were up-regulated and 51 were down-regulated significantly in patients with dry AMD compared with that in control groups (FDR value <1.0%). Several proteins, e.g., protein S100-A8 (S10A8), dystroglycan (DAG1), Ig alpha-1 chain C region (IGHA1), carbonic anhydrase 3 (CAH3) and alpha-1-acid glycoprotein (A1AG1) were increased more than 5 times of that in control group. The bioinformatics analysis showed that dry AMD is closely associated with inflammation or immune reaction, oxidative stress, blood coagulation and remodeling of extracellular matrix.
   CONCLUSION: iTRAQ-based proteomic analysis of aqueous humor demonstrate the differential expressions of proteins between dry AMD and control groups, providing the clues to understand the mechanisms and possible treatments of dry AMD.
C1 [Qu, Si-Chang; Xu, Ding; Li, Ting-Ting; Liu, Fang] Tongji Univ, Tongji Eye Inst, Shanghai Peoples Hosp 10, Dept Ophthalmol,Sch Med, 301 Yanchang Rd, Shanghai 200072, Peoples R China.
   [Zhang, Jing-Fa] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai Gen Hosp, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
C3 Tongji University; Shanghai Jiao Tong University
RP Liu, F (通讯作者)，Tongji Univ, Tongji Eye Inst, Shanghai Peoples Hosp 10, Dept Ophthalmol,Sch Med, 301 Yanchang Rd, Shanghai 200072, Peoples R China.; Zhang, JF (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai Gen Hosp, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM 13917311571@139.com; fangliu_2004@yahoo.com
FU National Natural Science Foundation of China [81570852]; Shanghai
   Municipal Health and Planning Commission Foundation [201540046]
FX Supported by National Natural Science Foundation of China (No.81570852);
   the Shanghai Municipal Health and Planning Commission Foundation
   (No.201540046).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Hochepied T, 2003, CYTOKINE GROWTH F R, V14, P25, DOI 10.1016/S1359-6101(02)00054-0
   Huang ZQ, 2013, CURR DRUG METAB, V14, P226
   Jin GM, 2018, BRIT J OPHTHALMOL, V102, P625, DOI 10.1136/bjophthalmol-2017-310368
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32548
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luo ZM, 2015, J PHYSIOL BIOCHEM, V71, P329, DOI 10.1007/s13105-015-0389-9
   Petrey AC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00101
   Pieragostino D, 2013, MOL BIOSYST, V9, P1108, DOI 10.1039/c3mb25463a
   Pollreisz A, 2013, EXP EYE RES, V108, P48, DOI 10.1016/j.exer.2012.11.010
   Raisanen SR, 1999, FASEB J, V13, P513, DOI 10.1096/fasebj.13.3.513
   Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200
   Roy P, 2010, FEBS J, V277, P441, DOI 10.1111/j.1742-4658.2009.07496.x
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Sun NN, 2015, INT J MOL SCI, V16, P25982, DOI 10.3390/ijms161125934
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 26
TC 12
Z9 14
U1 0
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD NOV 18
PY 2019
VL 12
IS 11
BP 1758
EP 1766
DI 10.18240/ijo.2019.11.15
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JN2MQ
UT WOS:000496735500015
PM 31741866
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hu, CC
   Ho, JD
   Lin, HC
   Kao, LT
AF Hu, C-C
   Ho, J-D
   Lin, H-C
   Kao, L-T
TI Association between open-angle glaucoma and neovascular age-related
   macular degeneration: a case-control study
SO EYE
LA English
DT Article
ID BRUCH MEMBRANE CHANGE; OCULAR BLOOD-FLOW; CHOROIDAL NEOVASCULARIZATION;
   EYE; PERFUSION; VESSELS
AB Purpose To investigate the relationship between previously diagnosed open-angle glaucoma (OAG) and neovascular age- related macular degeneration (AMD) using a routine insurance dataset.
   Methods This study retrieved data from the Taiwan Longitudinal Health Insurance Database 2005. We found 3282 patients with neovascular AMD as cases and 13 128 sex-and age-matched subjects without neovascular AMD as controls. Conditional logistic regressions were performed to evaluate the association of neovascular AMD with previously diagnosed OAG among the sampled patients.
   Results Of the 16 410 sampled patients, 2.55% had previously diagnosed OAG, 5.06 and 1.92% for the cases and controls, respectively. The logistic regression analysis showed that the odds ratio (OR) of previously diagnosed OAG for cases was 2.45 (OR: 2.45; 95% confidence interval: 1.99-3.01) compared with the controls after adjusting for potential confounders. In addition, the adjusted ORs for previously diagnosed OAG were similar for patients with AMD in both genders (with an adjusted OR of 2.49 for males and 2.39 for females). Furthermore, it shows that OAG was significantly associated with neovascular AMD regardless of sex even after adjusting for monthly income, geographic region, urbanisation level, and comorbidities (with adjusted ORs of 2.49 for males and 2.39 for females).
   Conclusions This study demonstrated that patients with neovascular AMD had a higher odds of previously diagnosed OAG compared with those patients without neovascular AMD regardless of sex.
C1 [Hu, C-C; Ho, J-D] Taipei Med Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hu, C-C] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hu, C-C] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan.
   [Lin, H-C] Taipei Med Univ, Sch Hlth Care Adm, Taipei, Taiwan.
   [Kao, L-T] Taipei Med Univ, Coll Med, Res Ctr Sleep Med, Taipei, Taiwan.
   [Kao, L-T] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.
C3 Taipei Medical University; Taipei Medical University Hospital; Shin Kong
   Wu Ho Su Memorial Hospital; Fu Jen Catholic University; Taipei Medical
   University; Taipei Medical University; National Defense Medical Center
RP Kao, LT (通讯作者)，Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.
EM kaoliting@gmail.com
RI Kao, Li-Ting/W-9287-2018
OI Kao, Li-Ting/0000-0003-0692-7408
FU Shin Kong Wu-Ho-Su Memorial Hospital [SKH-TMU-100-01]
FX This research was supported by a grant from Shin Kong Wu-Ho-Su Memorial
   Hospital (SKH-TMU-100-01).
CR Bjarnhall G, 2007, ACTA OPHTHALMOL SCAN, V85, P67, DOI 10.1111/j.1600-0420.2006.00780.x
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Delaney Y, 2006, OPTOMETRY VISION SCI, V83, P406, DOI 10.1097/01.opx.0000225877.13217.01
   Doucette LP, 2015, SURV OPHTHALMOL, V60, P310, DOI 10.1016/j.survophthal.2015.01.004
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Gao JL, 2015, SCI REP-UK, V5, DOI 10.1038/srep09585
   Griffith JF, 2015, CLIN OPHTHALMOL, V9, P1275, DOI 10.2147/OPTH.S85851
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Iglesias AI, 2015, EYE, V29, P1285, DOI 10.1038/eye.2015.160
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2005, OPHTHALMOLOGY, V112, P245, DOI 10.1016/j.ophtha.2004.08.015
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Piltz-Seymour IR, 2001, AM J OPHTHALMOL, V132, P63, DOI 10.1016/S0002-9394(01)00871-6
   Pinazo-Duran MD, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6215745
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Venkataraman ST, 2010, MICROCIRCULATION, V17, P568, DOI 10.1111/j.1549-8719.2010.00045.x
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
NR 30
TC 11
Z9 11
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2017
VL 31
IS 6
BP 872
EP 877
DI 10.1038/eye.2016.325
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX2ON
UT WOS:000403066000007
PM 28186508
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Javadzadeh, A
   Ghorbanihaghjo, A
   Bahreini, E
   Rashtchizadeh, N
   Argani, H
   Alizadeh, S
AF Javadzadeh, Alireza
   Ghorbanihaghjo, Amir
   Bahreini, Elham
   Rashtchizadeh, Nadereh
   Argani, Hassan
   Alizadeh, Samira
TI Plasma oxidized LDL and thiol-containing molecules in patients with
   exudative age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; HIGH-DOSE SUPPLEMENTATION; PIGMENT
   EPITHELIAL-CELLS; OXIDATIVE STRESS; RISK-FACTORS; CLINICAL-TRIAL;
   BETA-CAROTENE; NITRIC-OXIDE; EYE DISEASE; VISION LOSS
AB Purpose: It was proposed that total thiols (tSH) as powerful reducing agents and oxidized low-density lipoprotein (OX-LDL) may be associated with development of choroidal neovascularization in exudative age-related macular degeneration (E-ARMD).
   Methods: In a case-control study, 45 patients with E-ARMD were compared with 45 sex-and age-matched healthy controls. The levels of plasma homocysteine (Hcy) and OX-LDL as oxidant agents, and of tSH and glutathione (GSH) as antioxidant markers, were estimated in E-ARMD patients and controls.
   Results: The levels of Hcy (15.4 +/- 7.2 mu M versus 10.7 +/- 3.7 mu M; p = 0.001) and OX-LDL (52.2 +/- 13.8 U/l versus 37.8 +/- 10.8 U/l; p = 0.001) were statistically higher, while GSH (1.10 +/- 0.97 mu M versus 2.09 +/- 1.04 mu M; p = 0.001) and tSH (0.31 +/- 0.06 mM versus 0.35 +/- 0.05 mM; p = 0.001) were statistically lower, in the patients with E-ARMD than in the control group, respectively. The plasma OX-LDL concentration also exhibited a positive and significant correlation with Hcy (r = 0.719, p = 0.001) in patients with E-ARMD.
   Conclusions: Lower GSH and tSH as antioxidant and higher Hcy levels as oxidant agents in E-ARMD patients may have resulted in an oxidative environment that was associated with OX-LDL. Further studies with more cases are required to confirm the hypothesis.
C1 [Javadzadeh, Alireza; Ghorbanihaghjo, Amir; Bahreini, Elham; Alizadeh, Samira] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz 51664, Iran.
   [Rashtchizadeh, Nadereh; Argani, Hassan] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science
RP Ghorbanihaghjo, A (通讯作者)，Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz 51664, Iran.
EM ghorbaniamir@hotmail.com
RI Javadzadeh, Alireza/L-6424-2017; Rashtchizadeh, Nadereh/L-7691-2017;
   Argani, Hassan/AAD-8372-2019; Bahreini, Elham/AAT-7055-2021
OI Javadzadeh, Alireza/0000-0002-5151-6125; Rashtchizadeh,
   Nadereh/0000-0003-2878-3847; ghorbanihaghjo, amir/0000-0001-6742-0526;
   Bahreini, Elham/0000-0001-6823-8638; Alizadeh,
   Samira/0000-0001-6059-2181
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 2002, JAMA, V288, P2015
   Ashfaq S, 2006, J AM COLL CARDIOL, V47, P1005, DOI 10.1016/j.jacc.2005.09.063
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beltowski Jerzy, 2005, Postepy Hig Med Dosw (Online), V59, P392
   Biswas S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI 10.1016/j.bcp.2005.10.044
   Carrasco-Pozo C, 2006, EXP BIOL MED, V231, P1569, DOI 10.1177/153537020623100918
   Chatgilialoglu C, 2002, FREE RADICAL BIO MED, V33, P1681, DOI 10.1016/S0891-5849(02)01143-7
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Coral K, 2009, INVEST OPHTH VIS SCI, V50, P3607, DOI 10.1167/iovs.08-2667
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Feher J, 2003, OPHTHALMOLOGICA, V217, P351, DOI 10.1159/000071351
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   FUJIMOTO WY, 1988, JPN CIRC J, V52, P604, DOI 10.1253/jcj.52.604
   Ghaedi M, 2007, INT CARDIOVASC RES J, V1, P92
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HEINECKE JW, 1987, J BIOL CHEM, V262, P10098
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   HU ML, 1994, METHOD ENZYMOL, V233, P380
   Iciek M, 2004, ACTA BIOCHIM POL, V51, P815
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Johnston N, 2006, AM J CARDIOL, V97, P640, DOI 10.1016/j.amjcard.2005.09.123
   JONES BG, 1994, ATHEROSCLEROSIS, V105, P165, DOI 10.1016/0021-9150(94)90046-9
   Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kaplan M, 1999, CLIN CHEM LAB MED, V37, P777, DOI 10.1515/CCLM.1999.118
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kataoka H, 1999, CIRCULATION, V99, P3110, DOI 10.1161/01.CIR.99.24.3110
   Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x
   Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776
   MacDonald IM, 2005, CAN J OPHTHALMOL, V40, P288, DOI 10.1016/S0008-4182(05)80071-7
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Molloy AM, 2004, CURR OPIN LIPIDOL, V15, P49, DOI 10.1097/00041433-200402000-00010
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   Morris Martha Savaria, 2002, Nutr Clin Care, V5, P124, DOI 10.1046/j.1523-5408.2002.t01-1-00006.x
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859
   Ray Joel G, 2003, ACP J Club, V138, P78
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Suzuki M, 2007, MOL VIS, V13, P772
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   Ueland PM, 1996, J NUTR, V126, pS1281, DOI 10.1093/jn/126.suppl_4.1281S
   Vignini A, 2004, J CLIN ENDOCR METAB, V89, P4558, DOI 10.1210/jc.2004-0419
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Winkler BS, 1999, MOL VIS, V5
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499
   Wotherspoon F, 2006, DIABETIC MED, V23, P1350, DOI 10.1111/j.1464-5491.2006.01980.x
   Zappacosta B, 2001, FREE RADICAL RES, V35, P499, DOI 10.1080/10715760100301511
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zinellu A, 2006, CLIN CHEM, V52, P2054, DOI 10.1373/clinchem.2006.071142
NR 59
TC 23
Z9 23
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 6
PY 2010
VL 16
IS 275-76
BP 2578
EP 2584
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 697IA
UT WOS:000285505500001
PM 21151596
DA 2022-11-30
ER

PT J
AU Oishi, A
   Hata, M
   Shimozono, M
   Mandai, M
   Nishida, A
   Kurimoto, Y
AF Oishi, Akio
   Hata, Masayuki
   Shimozono, Masataka
   Mandai, Michiko
   Nishida, Akihiro
   Kurimoto, Yasuo
TI The Significance of External Limiting Membrane Status for Visual Acuity
   in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PHOTORECEPTOR
   STATUS; RETINAL THICKNESS; RESOLUTION; ASSOCIATION; PARAMETERS; IMAGES;
   EDEMA
AB PURPOSE: To evaluate status of the external limiting membrane (ELM) as a contributor of visual acuity (VA) in age-related macular degeneration (AMD).
   DESIGN: Hospital-based, cross-sectional study.
   METHODS: We retrospectively reviewed spectral-domain optical coherence tomography images of 158 patients with AMD who had undergone photodynamic therapy and classified them based on the status of the ELM: absent, discontinuous, or complete. We simultaneously assessed foveal thickness, presence or absence of subretinal fluid/mass, presence or absence of subretinal pigment epithelium fluid/mass, status of the inner segment/outer segment (IS/OS) junction, and status of the intermediate line between the IS/OS junction and retinal pigment epithelium. Correlation coefficients between each parameter and VA were analyzed.
   RESULTS: There was a strong correlation between ELM status and VA (r = -0.75, P < .001), and that was higher than that of the IS/OS (r = -0.69, P < .001). Multivariate analysis showed that ELM status is the most important factor for VA. Other parameters that correlated with VA included age, status of the intermediate line, and presence of subretinal or subretinal pigment epithelium fibrosis. Foveal thickness showed V-shaped correlation, with the dividing line around 200 mu m.
   CONCLUSION: ELM status may be more useful than is IS/OS status in evaluation of retinal morphology and function in patients with AMD. (Am J Ophthalmol 2010;150: 27-32. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Oishi, Akio] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, Kobe, Hyogo 6500046, Japan.
   [Mandai, Michiko] RIKEN, Lab Retinal Regenerat, Ctr Dev Biol, Kobe, Hyogo, Japan.
C3 Kobe City Medical Center General Hospital; RIKEN
RP Oishi, A (通讯作者)，Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Chuo Ku, 4-6 Minatojima Minamimachi, Kobe, Hyogo 6500046, Japan.
EM aquio@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; Mandai, Michiko/E-7986-2011
OI Oishi, Akio/0000-0002-0977-9458; 
CR Baba T, 2008, RETINA-J RET VIT DIS, V28, P453, DOI 10.1097/IAE.0b013e3181571398
   Coker J G, 1996, Curr Opin Ophthalmol, V7, P33, DOI 10.1097/00055735-199606000-00006
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P417, DOI 10.1097/00006982-200506000-00004
   Gloesmann M, 2003, INVEST OPHTH VIS SCI, V44, P1696, DOI 10.1167/iovs.02-0654
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE, P393
   Inoue M, 2009, GRAEF ARCH CLIN EXP, V247, P325, DOI 10.1007/s00417-008-0999-9
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Ko T. H., 2005, OPHTHALMOLOGY, V112, pe1
   Landa Gennady, 2009, International Ophthalmology, V29, P1, DOI 10.1007/s10792-007-9176-0
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Nguyen MHT, 2007, RETINA-J RET VIT DIS, V27, P414, DOI 10.1097/01.iae.0000246676.88033.25
   Oishi A, 2009, EYE, V23, P1411, DOI 10.1038/eye.2008.266
   Ruggeri M, 2007, INVEST OPHTH VIS SCI, V48, P1808, DOI 10.1167/iovs.06-0815
   Sakamoto A, 2009, GRAEF ARCH CLIN EXP, V247, P1325, DOI 10.1007/s00417-009-1107-5
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sandberg MA, 2005, INVEST OPHTH VIS SCI, V46, P3349, DOI 10.1167/iovs.04-1383
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Sayanagi K, 2008, AM J OPHTHALMOL, V145, P902, DOI 10.1016/j.ajo.2008.01.011
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Suh MH, 2009, AM J OPHTHALMOL, V147, P473, DOI 10.1016/j.ajo.2008.09.020
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
   Yamaike N, 2008, OPHTHALMOLOGY, V115, P355, DOI 10.1016/j.ophtha.2007.04.052
NR 29
TC 91
Z9 96
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2010
VL 150
IS 1
BP 27
EP 32
DI 10.1016/j.ajo.2010.02.012
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624FW
UT WOS:000279803200007
PM 20609705
DA 2022-11-30
ER

PT J
AU Fuse, N
   Miyazawa, A
   Mengkegale, M
   Yoshida, M
   Wakusawa, R
   Abe, T
   Tamai, M
AF Fuse, Nobuo
   Miyazawa, Akiko
   Mengkegale, MingGe
   Yoshida, Madoka
   Wakusawa, Ryosuke
   Abe, Toshiaki
   Tamai, Makoto
TI Polymorphisms in Complement factor H and Hemicentin-1 genes in a
   Japanese population with dry-type age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To determine whether polymorphisms in the Complement Factor H (CFH) gene and the Hemicentin-I gene at the ARMD1 locus are associated with dry age-related macular degeneration (AMD) in Japanese patients.
   DESIGN: Clinically relevant laboratory investigation.
   METHODS: Eighty unrelated Japanese patients with dry AMD and 196 Japanese control patients were studied. Two exons of the CFH gene and four exons of the Hemicentin-1 gene were amplified by polymerase chain reaction and sequenced directly.
   RESULTS: For the CFH gene, the frequency of the previously reported Tyr4021-fis variant was not significantly higher in the AMD group than in the control group (P = .31). In the Hemicentin-1 gene, three sequence alterations (Asp5088Val, IVS99-13C/T, and His5245Gln) were detected, and the originally reported Gln5346Arg was not detected.
   CONCLUSION: The CFH gene and Hemicentin-1 genes do not appear to be involved in a statistically significant fraction of dry AMD cases in the Japanese population.
C1 Tohoku Univ, Grad Sch Med, Dept Ophthalmol, Sendai, Miyagi 9808574, Japan.
C3 Tohoku University
RP Fuse, N (通讯作者)，Tohoku Univ, Grad Sch Med, Dept Ophthalmol, Sendai, Miyagi 9808574, Japan.
EM fusen@oph.med.tohoku.ac.jp
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   SEDDON JM, 2001, RETINA, P1039
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
NR 9
TC 54
Z9 56
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2006
VL 142
IS 6
BP 1074
EP 1076
DI 10.1016/j.ajo.2006.07.030
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114MU
UT WOS:000242671100032
PM 17157600
DA 2022-11-30
ER

PT J
AU Pang, CE
   Messinger, JD
   Zanzottera, EC
   Freund, KB
   Curcio, CA
AF Pang, Claudine E.
   Messinger, Jeffrey D.
   Zanzottera, Emma C.
   Freund, K. Bailey
   Curcio, Christine A.
TI The Onion Sign in Neovascular Age-Related Macular Degeneration
   Represents Cholesterol Crystals
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CLINICOPATHOLOGICAL CORRELATION; GRADING
   SYSTEM; DRUSEN; DEPOSITS; EYES; PROGRESSION; MICROGLIA; INSIGHTS;
   RUPTURE
AB Purpose: To investigate the frequency, natural evolution, and histologic correlates of layered, hyperreflective, subretinal pigment epithelium (sub-RPE) lines, known as the onion sign, in neovascular age-related macular degeneration (AMD).
   Design: Retrospective observational cohort study and experimental laboratory study.
   Participants: Two hundred thirty eyes of 150 consecutive patients with neovascular AMD and 40 human donor eyes with histopathologic diagnosis of neovascular AMD.
   Methods: Spectral-domain optical coherence tomography (SD OCT), near-infrared reflectance (NIR), color fundus images, and medical charts were reviewed. Donor eyes underwent multimodal ex vivo imaging, including SD OCT, before processing for high-resolution histologic analysis.
   Main Outcome Measures: Presence of layered, hyperreflective sub-RPE lines, qualitative analysis of their change in appearance over time with SD OCT, histologic correlates of these lines, and associated findings within surrounding tissues.
   Results: Sixteen of 230 eyes of patients (7.0%) and 2 of 40 donor eyes (5.0%) with neovascular AMD had layered, hyperreflective sub-RPE lines on SD OCT imaging. These appeared as refractile, yellow-gray exudates on color imaging and as hyperreflective lesions on NIR. In all 16 patient eyes, the onion sign persisted in follow-up for up to 5 years, with fluctuations in the abundance of lines and association with intraretinal hyperreflective foci. Patients with the onion sign disproportionately were taking cholesterol-lowering medications (P = 0.025). Histologic analysis of 2 donor eyes revealed that the hyperreflective lines correlated with clefts created by extraction of cholesterol crystals during tissue processing. The fluid surrounding the crystals contained lipid, yet was distinct from oily drusen. Intraretinal hyperreflective foci correlated with intraretinal RPE and lipid-filled cells of probable monocytic origin.
   Conclusions: Persistent and dynamic, the onion sign represents sub-RPE cholesterol crystal precipitation in an aqueous environment. The frequency of the onion sign in neovascular AMD in a referral practice and a pathology archive is 5% to 7%. Associations include use of cholesterol-lowering medication and intraretinal hyperreflective foci attributable to RPE cells and lipid-filled cells of monocyte origin. (C) 2015 by the American Academy of Ophthalmology.
C1 [Pang, Claudine E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Inst, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Messinger, Jeffrey D.; Zanzottera, Emma C.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Zanzottera, Emma C.] Univ Milan, Sacco Hosp, Dept Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York; University of Alabama
   System; University of Alabama Birmingham; University of Milan; Luigi
   Sacco Hospital; New York University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Alabama Vis Res Labs, Dept Ophthalmol,EyeSight Fdn, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation (New York, NY); LuEsther T. Mertz Retinal Research
   Center (New York, NY); National Institutes of Health (NIH), Bethesda,
   Maryland [R01 EY06109]; National Eye Institute, NIH [P30 EY003039];
   Research to Prevent Blindness, Inc., New York, New York; EyeSight
   Foundation of Alabama (Birmingham AL); International Retinal Research
   Foundation (Birmingham AL); Arnold and Mabel Beckman Initiative for
   Macular Research (Irvine CA); Edward N. and Della L. Thome Memorial
   Foundation (Boston MA); NATIONAL EYE INSTITUTE [P30EY003039,
   R01EY006109] Funding Source: NIH RePORTER
FX Supported by the Macula Foundation (New York, NY); the LuEsther T. Mertz
   Retinal Research Center (New York, NY); the National Institutes of
   Health (NIH), Bethesda, Maryland (grant no.: R01 EY06109), and the
   National Eye Institute, NIH (grant no.: P30 EY003039); Research to
   Prevent Blindness, Inc., New York, New York; EyeSight Foundation of
   Alabama (Birmingham AL); the International Retinal Research Foundation
   (Birmingham AL); and the Arnold and Mabel Beckman Initiative for Macular
   Research (Irvine CA). Project MACULA received additional support from
   the Edward N. and Della L. Thome Memorial Foundation (Boston MA), and
   the International Retinal Research Foundation (Birmingham AL). The
   funding organizations had no role in the design and conduct of this
   study.
CR Abela GS, 2010, J CLIN LIPIDOL, V4, P156, DOI 10.1016/j.jacl.2010.03.003
   Abela GS, 2006, SCANNING, V28, P1, DOI 10.1002/sca.4950280101
   Bagheri N, 2012, ADV EXP MED BIOL, V723, P479, DOI 10.1007/978-1-4614-0631-0_60
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Brown NH, 2009, GRAEF ARCH CLIN EXP, V247, P1069, DOI 10.1007/s00417-009-1044-3
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Christakopoulos C, 2013, ACTA OPHTHALMOL, V91, pE248, DOI 10.1111/aos.12000
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dotti MT, 2001, J INHERIT METAB DIS, V24, P696, DOI 10.1023/A:1012981019336
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Ford ES, 2010, INT J CARDIOL, V140, P226, DOI 10.1016/j.ijcard.2008.11.033
   FRIEDMAN E, 1966, ARCH OPHTHALMOL-CHIC, V75, P334
   Ghazi NG, 2006, AM J OPHTHALMOL, V141, P740, DOI 10.1016/j.ajo.2005.10.058
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Lammer J, 2014, INVEST OPHTH VIS SCI, V55, P1564, DOI 10.1167/iovs.13-13539
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lima LH, 2010, RETINA-J RET VIT DIS, V30, P542, DOI 10.1097/IAE.0b013e3181c713e4
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Liu LB, 2011, NAT MED, V17, P1010, DOI 10.1038/nm.2409
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Mukkamala S.K., 2012, ARCH OPHTHALMOL-CHIC, V130, P1
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Pennesi ME, 2010, RETINA-J RET VIT DIS, V30, P531, DOI 10.1097/IAE.0b013e3181c96a15
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   Ramirez AI, 2006, EXP EYE RES, V83, P1423, DOI 10.1016/j.exer.2006.07.023
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Salazar JJ, 2007, EXP EYE RES, V84, P412, DOI 10.1016/j.exer.2006.10.012
   Sallo FB, 2011, OPHTHALMOLOGY, V118, P2461, DOI 10.1016/j.ophtha.2011.05.022
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sarraf D, 2010, ARCH OPHTHALMOL-CHIC, V128, P685, DOI 10.1001/archophthalmol.2010.109
   SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Tearney GJ, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192697
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Uskokovic V, 2008, STEROIDS, V73, P356, DOI 10.1016/j.steroids.2007.12.005
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Vedre A, 2009, ATHEROSCLEROSIS, V203, P89, DOI 10.1016/j.atherosclerosis.2008.06.027
   Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18
   WILSON DJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P213, DOI 10.1001/archopht.1989.01070010219026
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yonetsu T, 2013, CIRC J, V77, P1933, DOI 10.1253/circj.CJ-13-0643.1
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 61
TC 66
Z9 66
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2015
VL 122
IS 11
BP 2316
EP 2326
DI 10.1016/j.ophtha.2015.07.008
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IQ
UT WOS:000363491800035
PM 26298717
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ivandic, BT
   Ivandic, T
AF Ivandic, Boris T.
   Ivandic, Tomislav
TI Low-level laser therapy improves vision in patients with age-related
   macular degeneration
SO PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
ID ETIOLOGY
AB Objective: The objective of this study of a case series was to examine the effects of low-level laser therapy (LLLT) in patients with age-related macular degeneration (AMD).
   Background Data: AMD affects a large proportion of the elderly population; current therapeutic options for AMD are limited, however.
   Patients and Methods: In total, 203 patients (90 men and 113 women; mean age 63.4 +/- 5.3 y) with beginning ("dry") or advanced ("wet") forms of AMD (n = 348 eyes) were included in the study. One hundred ninety-three patients (mean age 64.6 +/- 4.3 y; n = 328 eyes) with cataracts (n = 182 eyes) or without cataracts (n = 146 eyes) were treated using LLLT four times (twice per week). A semiconductor laser diode (780 nm, 7.5 mW, 292 Hz, continuous emission) was used for transconjunctival irradiation of the macula for 40 sec (0.3 J/cm(2)) resulting in a total dose of 1.2 J/cm(2). Ten patients (n = 20 eyes) with AMD received mock treatment and served as controls. Visual acuity was measured at each visit. Data were analyzed retrospectively using a t-test.
   Results: LLLT significantly improved visual acuity (p < 0.00001 versus baseline) in 162/182 (95%) of eyes with cataracts and 142/146 (97%) of eyes without cataracts. The prevalence of metamorphopsia, scotoma, and dyschromatopsia was reduced. In patients with wet AMD, edema and bleeding improved. The improved vision was maintained for 3-36 mo after treatment. Visual acuity in the control group remained unchanged. No adverse effects were observed in those undergoing therapy.
   Conclusion: In patients with AMD, LLLT significantly improved visual acuity without adverse side effects and may thus help to prevent loss of vision.
C1 [Ivandic, Boris T.] Heidelberg Univ, Otto Meyerhof Ctr, D-69120 Heidelberg, Germany.
   [Ivandic, Tomislav] Med Ctr, Munich, Germany.
C3 Ruprecht Karls University Heidelberg
RP Ivandic, BT (通讯作者)，Heidelberg Univ, Otto Meyerhof Ctr, Im Neuenheimer Feld 350, D-69120 Heidelberg, Germany.
EM boris.ivandic@med.uni-heidelberg.de
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Apte RS, 2001, OPHTHALMOLOGY, V108, P693, DOI 10.1016/S0161-6420(00)00653-9
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Desmettre T, 2003, LASER SURG MED, V33, P102, DOI 10.1002/lsm.10193
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Evans JR, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000254
   Holz F. G., 1996, Ophthalmologe, V93, P483
   Holz FG, 2003, OPHTHALMOLOGE, V100, P97, DOI 10.1007/s00347-002-0761-3
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   KARU TI, 1987, IEEE J QUANTUM ELECT, V23, P1703, DOI 10.1109/JQE.1987.1073236
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Pauleikhoff D., 1996, Ophthalmologe, V93, P299
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 16
TC 62
Z9 75
U1 2
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-5418
EI 1557-8550
J9 PHOTOMED LASER SURG
JI Photomed. Laser Surg.
PD JUN
PY 2008
VL 26
IS 3
BP 241
EP 245
DI 10.1089/pho.2007.2132
PG 5
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 327GU
UT WOS:000257718400011
PM 18588438
DA 2022-11-30
ER

PT J
AU Dong, Y
   Li, ZD
   Fang, XY
   Shi, XF
   Chen, S
   Tang, X
AF Dong, Yi
   Li, Ze-Dong
   Fang, Xin-Yu
   Shi, Xue-Feng
   Chen, Song
   Tang, Xin
TI Association between SERPING1 rs2511989 polymorphism and age-related
   macular degeneration: Meta-analysis
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; SERPING1; single nucleotide
   polymorphism; Meta-analysis
ID BODY-MASS INDEX; ENVIRONMENTAL ASSOCIATIONS; GENE; DISEASE; VARIANT;
   RISK; SMOKING; SUSCEPTIBILITY; MACULOPATHY; PREVALENCE
AB AIM: To investigate the association between SERPING1 rs2511989 (G>A) polymorphism and age-related macular degeneration (AMD).
   METHODS: A number of electronic databases (up to July 15, 2014) were searched independently by two investigators. A Meta -analysis was performed on the association between SERPING1rs2511989 polymorphism and AMD. Pooled odds ratios (ORs) with 95% confidence intervals (Cis) were estimated.
   RESULTS: Eight studies with 16 cohorts consisting of 9163 cases and 6813 controls were included in this Meta-analysis. There was no significant association between rs2511989 polymorphism and AMD under all genetic models in overall estimates (A vsG: OR= 0.938, 95%Cl = 0.858-1.025; AA vs GG:OR =0.871, 95%Cl =0.719-1.056; AG vs GG: OR =0.944, 95%Cl =0.845-1.054; AA +AG vs GG: OR =0.927, 95% Cl =0.823-1.044; AA vs AG +GG: OR =0.890, 95% Cl =0.780 -1.034). Cumulative Meta analyses also showed a trend of no association between rs2511989 polymorphism and AMD as information accumulated by year. Subgroup analysis and Meta regression analysis indicated that age -matching status was the main source of heterogeneity. Sensitivity analysis found the results in overall comparisons and subgroup comparisons of white subjects under the allele model were found to have significantly statistical differences after studies deviating from Hardy-Weinberg equilibrium (HWE) were excluded (overall: OR=0.918, 95% Cl = 0.844-0.999, P=0.049; whites: OR =0.901, 95%Cl = 0.817 -0.994, P =0.038). However, the results were not sufficiently robust for further sensitivity analysis and statistical differences disappeared on applying Bonferroni correction (with a significance level set at 0.05/25).
   CONCLUSION: This Meta -analysis indicates that SERPING1 rs2511989 polymorphism and AMD tend to have no association with each other. Age matching status is a big confounding factor, and more studies with subtle designs are warranted in future.
C1 [Dong, Yi; Li, Ze-Dong] Tianjin Med Univ, Tianjin 300070, Peoples R China.
   [Dong, Yi; Li, Ze-Dong; Shi, Xue-Feng; Chen, Song; Tang, Xin] Tianjin Med Univ, Tianjin Eye Hosp, Clin Coll Ophthalmol, Tianjin 300020, Peoples R China.
   [Fang, Xin-Yu] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Stat, Hefei 230032, Anhui, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Anhui Medical
   University
RP Tang, X (通讯作者)，Tianjin Med Univ, Tianjin Eye Hosp, Clin Coll Ophthalmol, 4 Gansu Rd, Tianjin 300020, Peoples R China.
EM tangprofessor@outlook.com
RI Dong, Yi/AAJ-9416-2020; Dong, Yi/AAG-2823-2020
OI Dong, Yi/0000-0002-0010-8172; 
FU Scientific and Technological Project of Tianjin Health Bureau [12KG123]
FX Supported by the Scientific and Technological Project of Tianjin Health
   Bureau (No.12KG123, website URL).
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Carter JG, 2011, ACTA OPHTHALMOL, V89, pE212, DOI 10.1111/j.1755-3768.2009.01788.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DerSimonian R, 1996, STAT MED, V15, P1237, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Falagas ME, 2008, J HOSP INFECT, V69, P101, DOI 10.1016/j.jhin.2008.01.013
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lu F, 2010, MOL VIS, V16, P1
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Middelberg RP, 2012, HUM MOL GENET, V21, P446, DOI 10.1093/hmg/ddr478
   Muellerleile P, 2006, AM J PUBLIC HEALTH, V96, P515, DOI 10.2105/AJPH.2003.036343
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Park KH, 2009, MOL VIS, V15, P200
   Scheetz TE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058657
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Slagboom PE, 2011, PHILOS T R SOC B, V366, P35, DOI 10.1098/rstb.2010.0284
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Synek S, 2010, COLLEGIUM ANTROPOL, V34, P25
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Soest SS, 2007, MOL VIS, V13, P1608
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wagenaar-Bos IGA, 2006, IMMUNOL ALLERGY CLIN, V26, P615, DOI 10.1016/j.iac.2006.08.004
   Wang X, 2014, GENE, V538, P306, DOI 10.1016/j.gene.2014.01.032
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 42
TC 3
Z9 4
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2015
VL 8
IS 2
BP 385
EP 394
DI 10.3980/j.issn.2222-3959.2015.02.31
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CF7RN
UT WOS:000352754100032
PM 25938061
DA 2022-11-30
ER

PT J
AU Bunce, C
   Zekite, A
   Walton, S
   Rees, A
   Patel, PJ
AF Bunce, C.
   Zekite, A.
   Walton, S.
   Rees, A.
   Patel, P. J.
TI Certifications for sight impairment due to age related macular
   degeneration in England
SO PUBLIC HEALTH
LA English
DT Article
DE Age related macular degeneration; Sight impairment; Severely sight
   impaired; Certification; Blind; Partial sight
ID RANIBIZUMAB; PEOPLE; WALES; BLIND
AB Objectives: To examine variability across England in certification rates for age related macular degeneration (AMD) between 1st April 2011 and 31st March 2012.
   Study design: Cross-sectional survey.
   Methods: An electronic version of the CVI, the ECVI, was used at the Certifications Office, London, to transfer information from paper based certificates into a database. The electronic certifications data set was queried for all certificates completed in England between April 1st 2011 and March 31st 2012 with the main cause of certifiable visual loss being AMD or with the main cause of certifiable visual loss being multiple pathology but a contributory cause being AMD. Data were explored by type of AMD, visual status, age and sex and then directly standardized rates were computed by English region.
   Results: The Certifications Office received 23,616 CVIs for England between April 2011 and March 2012, of which 10,481 (44%) were people certified severely sight-impaired (blind) (SSI) and 12,689 (54%) were certified as sight-impaired (partial sight) (SI). The remainder did not have visual status classified. AMD contributed to 11546 causes of certification on the CVI forms during this period, 53% of forms being for geographic atrophy (GA)/dry AMD which is currently mostly untreatable. The median (interquartile) age at certification for AMD was 86 (81, 90) years and women were more commonly certified than men (66%). Considerable variability was seen across English regions, although there was consistency in that GA was the more common form in all areas.
   Conclusions: There is considerable regional variability in CVI rates in England, which are not attributable to differences in age or sex. Reasons for such variability need examination yet this should not undermine the value of these data in terms of describing those newly registered with sight impairment due to AMD who are predominantly female and over 85 years of age. (C) 2015 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
C1 [Bunce, C.; Zekite, A.; Rees, A.; Patel, P. J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr Ophthalmol, London EC1V 2PD, England.
   [Bunce, C.; Zekite, A.; Rees, A.; Patel, P. J.] UCL Inst Ophthalmol, London EC1V 2PD, England.
   [Walton, S.] Knowledge & Intelligence Team West Midlands Publ, Birmingham, W Midlands, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Bunce, C (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr Ophthalmol, 162 City Rd, London EC1V 2PD, England.
EM c.bunce@ucl.ac.uk
OI Bunce, Catey/0000-0002-0935-3713
FU RNIB; NIHR; Department of Health
FX This study was supported by a grant from the RNIB and NIHR support. The
   views expressed in this paper are those of the author and not
   necessarily any funding body or the Department of Health. The data
   captured by the CVI are DH copyright and this work was made possible by
   collaboration with the Royal College of Ophthalmologists.
CR Boyce T, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004319
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Bunce C, 1998, BRIT J OPHTHALMOL, V82, P72, DOI 10.1136/bjo.82.1.72
   Department of Health and Social Security, 1979, REP PUBL HLTH MED SU, V129
   Evans J., 1995, STUDIES MED POPULATI, V57
   Government Statistical Service, 1988, CAUS BLIND PART SIGH
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Leamon S, 2012, VIS UK C
   Malik ANJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001496
   Rees A, 2014, EYE, V28, P832, DOI 10.1038/eye.2014.103
   Rees A, 2013, EYE, V27, P892, DOI 10.1038/eye.2013.82
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists, 2012, LOW VIS GUID OPHTH 2
   Sorsby A., 1953, CAUSES BLINDNESS ENG
   Sorsby A., 1966, REPORTS PUBLIC HLTH, V114
   Sorsby A., 1972, REPORTS PUBLIC HLTH, V128
   Sorsby A., 1956, BLINDNESS ENGLAND 19
NR 19
TC 7
Z9 7
U1 1
U2 2
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0033-3506
EI 1476-5616
J9 PUBLIC HEALTH
JI Public Health
PD FEB
PY 2015
VL 129
IS 2
BP 138
EP 142
DI 10.1016/j.puhe.2014.12.018
PG 5
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA CD7UU
UT WOS:000351300500009
PM 25677221
DA 2022-11-30
ER

PT J
AU Choi, EY
   Kim, MIN
   Lee, CS
   Byeon, SH
   Kim, SS
   Lee, MY
AF Choi, Eun young
   Kim, M. I. N.
   Lee, Christopher Seungkyu
   Byeon, Suk ho
   Kim, Sung soo
   Lee, Minyoung
TI Intermittent Fasting Is Associated With a Decreased Risk of Age-Related
   Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; PIGMENT EPITHELIAL-CELLS; OXIDATIVE
   STRESS; NATIONAL-HEALTH; PREVALENCE; PROGRESSION; OBESITY; TRIAL
AB PURPOSE: To investigate the association between in-termittent fasting and age-related macular degeneration (AMD) in the general older adult population. DESIGN: A cross-sectional study using a population -based, government-led survey data, Korean National Health and Nutrition Examination Survey (KN-HANES). METHODS: A total of 4504 individuals aged > 55 years with comprehensive data including meal frequency and fundus photography were selected using the KNHANES 2015-2018 database. Participants were divided into 2 groups based on breakfast frequency per week; intermit-tent fasting (nearly 0 time/week) and nonfasting (5-7 times/week) groups. Multiple logistic regression analysis was performed to determine the risk factors for AMD identified by fundus photography. RESULTS: AMD was identified in 25.1% of total par-ticipants. The intermittent fasting group had a decreased risk of AMD compared with the nonfasting group (ad-justed odds ratio [aOR] 0.413, 95% CI 0.203-0.841), especially in individuals with a younger age ( < 70 years, aOR 0.357, 95% CI 0.153-0.833), obesity (aOR 0.663, 95% CI 0.424-1.037), and urban residence (aOR 0.437, 95% CI 0.248-0.769). Increased age (aOR 1.058, 95% CI 1.041-1.076) and serum high-density lipoprotein lev-els (aOR 1.011, 95% CI 1.002-1.021) were also inde-pendent risk factors for AMD. CONCLUSIONS: Using the population-based survey data, we demonstrated that intermittent fasting by skip-ping breakfast was significantly associated with a reduced risk of AMD in a representative older adult population, especially in individuals with age < 70 years, obesity, and urban residence. (Am J Ophthalmol 2022;243: 1-9. (c) 2022 Elsevier Inc. All rights reserved.)
C1 [Choi, Eun young; Kim, M. I. N.] Yonsei Univ, Gangnam Severance Hosp, Inst Vis Res, Coll Med,Dept Ophthalmol, Seoul, South Korea.
   [Lee, Christopher Seungkyu; Byeon, Suk ho; Kim, Sung soo] Yonsei Univ, Severance Eye Hosp, Inst Vis Res, Coll Med,Dept Ophthalmol, Seoul, South Korea.
   [Lee, Minyoung] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Lee, Minyoung] Yonsei Univ, Coll Med, Inst Endocrine Res, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; Yonsei University; Yonsei University
   Health System; Yonsei University; Yonsei University Health System
RP Lee, MY (通讯作者)，Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
EM LMYCJ@yuhs.ac
RI Choi, Eun Young/Y-5204-2018
OI Choi, Eun Young/0000-0002-1668-6452
CR Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Bae HR, 2016, ONCOTARGET, V7, P66444, DOI 10.18632/oncotarget.12119
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cienfuegos S, 2020, CELL METAB, V32, P366, DOI 10.1016/j.cmet.2020.06.018
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Grajower MM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040873
   Guo XL, 2016, SCI REP-UK, V6, DOI 10.1038/srep33950
   Hainer V, 2013, DIABETES CARE, V36, pS276, DOI 10.2337/dcS13-2023
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Jung J, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56080396
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaul S, 2012, OBESITY, V20, P1313, DOI 10.1038/oby.2011.393
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim DS, 2021, DIABETES METAB J, V45, P799, DOI 10.4093/dmj.2021.0077
   Kong YXG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.026
   Korea Centers for Disease Control and Prevention, KOR NAT HLTH NUTR EX
   Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Mattson MP, 2014, P NATL ACAD SCI USA, V111, P16647, DOI 10.1073/pnas.1413965111
   McAllister MJ, 2022, J STRENGTH COND RES, V36, P2515, DOI 10.1519/JSC.0000000000003860
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rim TH, 2018, JAMA OPHTHALMOL, V136, P132, DOI 10.1001/jamaophthalmol.2017.5682
   Rowan S, 2018, BBA-MOL BASIS DIS, V1864, P3631, DOI 10.1016/j.bbadis.2018.08.036
   Russo R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1044-5
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2007, GLOB IN EL AV BLINDN
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2022
VL 243
BP 1
EP 9
DI 10.1016/j.ajo.2022.06.017
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4X7IK
UT WOS:000861011200001
PM 35809657
DA 2022-11-30
ER

PT J
AU Jung, JJ
   Chen, CY
   Mrejen, S
   Gallego-Pinazo, R
   Xu, LN
   Marsiglia, M
   Boddu, S
   Freund, KB
AF Jung, Jesse J.
   Chen, Christine Y.
   Mrejen, Sarah
   Gallego-Pinazo, Roberto
   Xu, Luna
   Marsiglia, Marcela
   Boddu, Sucharita
   Freund, K. Bailey
TI The Incidence of Neovascular Subtypes in Newly Diagnosed Neovascular
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION;
   ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; CLINICAL
   CHARACTERISTICS; TYPE-3 NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB;
   PHOTODYNAMIC THERAPY; GEOGRAPHIC ATROPHY; VISUAL-ACUITY
AB PURPOSE: To determine the frequency of neovascularization subtypes as determined by fluorescein angiography (FA) alone vs FA and optical coherence tomography (OCT) grading in age-related macular degeneration (AMD).
   DESIGN: Retrospective cohort.
   METHODS: PARTICIPANTS: Newly diagnosed neovascular AMD patients who initiated intravitreal anti-vascular endothelial growth factor therapy by 1 physician from October 1, 2005 to December 1, 2012. INTERVENTIONS: Two independent graders classified the baseline lesions using FA alone and FA + OCT. MAIN OUTCOME MEASURES: Analysis of the frequency of lesion subtypes by FA alone or FA + OCT and agreement between both classification systems was performed.
   RESULTS: A total of 232 patients (266 eyes) fit the inclusion criteria. Mean age was 86.3 years; 67.7% of eyes (180/266) were from female patients, and 95.5% (254/266) were from white patients. The distribution using FA alone was 49.6% (132/266), 12.0% (32/266), 28.6% (76/266), and 9.8% (26/266) among occult, classic, retinal angiomatous proliferation, and mixed choroidal neovascularization, respectively. With FA + OCT, 39.9% (106/266), 9.0% (24/266), 34.2% (91/266), and 16.9% (45/266) were type 1 (sub-retinal pigment epithelium), type 2 (subretinal), type 3 (intraretinal), and mixed neovascularization (NV), respectively. The K statistic was 0.65 (standard error +/- 0.37, P < .001) between the 2 classification systems, representing good agreement.
   CONCLUSION: With both FA-alone and FA + OCT grading, we found a higher incidence of type 3 NV in eyes with newly diagnosed neovascular AMD than that reported in prior studies. The kappa statistic between the 2 classification systems showed "good" agreement. The discrepancies are likely attributable to the identification of a higher frequency of type 3 and mixed NV and a lower frequency of type 1 NV with the aid of OCT. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Jung, Jesse J.; Boddu, Sucharita; Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Jung, Jesse J.; Chen, Christine Y.; Mrejen, Sarah; Gallego-Pinazo, Roberto; Marsiglia, Marcela; Freund, K. Bailey] Macula Consultants New York, Retina, Vitreous, New York, NY 10022 USA.
   [Jung, Jesse J.; Chen, Christine Y.; Mrejen, Sarah; Marsiglia, Marcela; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Jung, Jesse J.; Marsiglia, Marcela; Freund, K. Bailey] Columbia Univ, Coll Phys & Surg, Edward S Harkness Eye Inst, New York, NY USA.
   [Chen, Christine Y.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia.
   [Chen, Christine Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Valencia, Spain.
   [Xu, Luna] New York Eye & Ear Infirm, New York, NY 10003 USA.
C3 New York University; Vitreous Retina Macula Consultants of New York;
   Manhattan Eye Ear & Throat Hospital; Columbia University; Monash
   University; Centre for Eye Research Australia; University of Melbourne;
   New York Eye & Ear Infirmary of Mount Sinai
RP Freund, KB (通讯作者)，Macula Consultants New York, Retina, Vitreous, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Bayer Healthcare; Novartis; Heidelberg Engineering; Thea; Sensimed;
   LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and
   Throat Hospital, New York, NY; Macula Foundation Inc., New York, NY
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and the following were indicated:
   K.B.F.: consultant to Regeneron, Genentech, Bayer Health Care, and
   Heidelberg Engineering (honorarium for each); R.G.P.: consultant to Carl
   Zeiss Meditec, Bayer Health Care, and Novartis (honorarium for each);
   research support from Bayer Healthcare, Novartis, Heidelberg
   Engineering, Thea, Sensimed; D.T. (biostatistical consultant):
   consultant to Regeneron. This work was supported by a research grant
   from the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear,
   and Throat Hospital, New York, NY, and The Macula Foundation Inc., New
   York, NY. The funding organizations had no role in the design or conduct
   of this research. Contributions of authors: design of the study (J.J.J.,
   S.M., R.G.P., K.B.F.), conduct of the study (J.J.J., C.Y.C., S.M.,
   R.G.P., L.X., M.M., S.B., K.B.F.), collection of the data (J.J.J., S.M.,
   R.G.P., L.X., M.M., S.B.), management of the data (J.J.J., C.Y.C., S.M.,
   S.G.P., L.X., M.M., S.B., K.B.F.), analysis of the data (J.J.J., C.Y.C.,
   S.M., L.X., K.B.F.), interpretation of the data (J.J.J., C.Y.C., S.M.,
   R.G.P., L.X., M.M., K.B.F.), preparation of the manuscript (J.J.J.,
   C.Y.C.), review of the manuscript (J.J.J., C.Y.C., S.M., R.G.P., L.X.,
   M.M., S.B., K.B.F.), and approval of the manuscript (J.J.J., C.Y.C.,
   S.M., R.G.P., L.X., M.M., S.B., K.B.F.).
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   ClinicalTrials.gov, PHAS 3 SAF EFF STUD
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Querques G, 2013, J FR OPHTALMOL, V36, pE1, DOI 10.1016/j.jfo.2012.04.013
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 58
TC 126
Z9 130
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2014
VL 158
IS 4
BP 769
EP 779
DI 10.1016/j.ajo.2014.07.006
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ1PI
UT WOS:000342552900017
PM 25034111
DA 2022-11-30
ER

PT J
AU Akduman, L
   Kaderli, B
   Kim, M
   Brusatti, R
   Jones, M
AF Akduman, Levent
   Kaderli, Berkant
   Kim, Max
   Brusatti, Robert
   Jones, Michael
TI Pegaptanib Versus Combined Pegaptanib and Photodynamic Therapy for
   Neovascular Age-Related Macular Degeneration
SO TURKIYE KLINIKLERI TIP BILIMLERI DERGISI
LA English
DT Article
DE Choroidal neovascularization; pegaptanib; verteporfin
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   INTRAVITREAL BEVACIZUMAB; VERTEPORFIN THERAPY; RANIBIZUMAB; MEMBRANES;
   INJECTION; EFFICACY; TAP
AB Objective: The aim of this study is to review our experience with Pegaptanib in patients with neovascular age-related macular degeneration (AMD) and to determine whether outcomes would be improved by combining Pegaptanib with photodynamic therapy (PDT). Material and Methods: Institutional, retrospective case series. The charts of 20 patients with neovascular AMD who received Pegaptanib monotherapy or combined ocular PDT with Verteporfin were retrospectively reviewed. Main outcome measures consisted of the number of treatments applied, Snellen best-corrected visual acuity (BCVA), angiographic lesion characteristics and center field thickness (CFT) in optical coherence tomography (OCT). Results: Average follow-up time was 7.7 months (range, 3-12 months). Ten patients (50%) were in Pegaptanib monotherapy group (Group A) and 10 patients were in combination therapy with PDT group (Group B). Patients in both groups received 2 to 9 (mean, 5.2) Pegaptanib injections. Group B received 1 to 4 (mean, 1.8) PDT treatments. Initial BCVA ranged from 20/50 to 20/3200 (mean, 20/509), final BCVA ranged from 20/70 to 20/3200 (mean, 20/759). In group A, the mean initial and final BCVA were 20/650 and 20/617, respectively (p= 0.590). The corresponding numbers in group B were 20/398 and 20/1060, respectively (p= 0.062). Four of the 10 eyes (40%) in Group B lost three lines or more. None of the eyes in Group A lost three lines or more vision (p= 0.087). There was neither significant change in the lesion size (p= 0.513), nor in CFT (315 mu m to 268 mu m, p= 0.99). Conclusion: The results of this study suggest that combined ocular PDT and Pegaptanib treatment may not be superior to Pegaptanib alone in patients with neovascular AMD. Further studies are needed.
C1 [Kaderli, Berkant] Uludag Univ, Fac Med, Dept Ophthalmol, Bursa, Turkey.
   [Akduman, Levent; Kim, Max; Jones, Michael] St Louis Univ, Dept Ophthalmol, St Louis, MO 63103 USA.
   [Brusatti, Robert] ODonnell Eye Inst, St Louis, MO USA.
C3 Uludag University; Saint Louis University
RP Kaderli, B (通讯作者)，Uludag Univ, Fac Med, Dept Ophthalmol, Bursa, Turkey.
EM drkaderli@yahoo.com
FU Research to Prevent Blindness (RPB); Scientific and Technical Research
   Council of Turkey (TUBITAK)
FX The study was supported by the Research to Prevent Blindness (RPB) and
   Scientific and Technical Research Council of Turkey (TUBITAK).
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Calvo-Gonzalez C, 2008, BRIT J OPHTHALMOL, V92, P74, DOI 10.1136/bjo.2007.128942
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Ju M, 2008, INVEST OPHTH VIS SCI, V49, P662, DOI 10.1167/iovs.07-0195
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   MENTES J, 2006, TURKIYE KLINIKLERI C, V2, P30
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Sonmez K, 2006, TURKIYE KLINIKLERI C, V2, P38
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   TURGUT B, 2007, TURKIYE KLIN J OPHTH, V16, P38
NR 23
TC 1
Z9 1
U1 0
U2 7
PU ORTADOGU AD PRES & PUBL CO
PI ANKARA
PA TURKOCAGI CAD NO 30, BALGAT, ANKARA, 06520, TURKEY
SN 1300-0292
EI 2146-9040
J9 TURK KLIN TIP BILIM
JI Turk. Klin. Tip Bilim. Derg.
PD JUN
PY 2010
VL 30
IS 3
BP 978
EP 984
DI 10.5336/medsci.2008-9212
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 642ZV
UT WOS:000281262200021
OA hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Horster, R
   Ristau, T
   Sadda, SR
   Liakopoulos, S
AF Hoerster, Robert
   Ristau, Tina
   Sadda, Srinivas R.
   Liakopoulos, Sandra
TI Individual recurrence intervals after anti-VEGF therapy for age-related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Ranibizumab; Anti-VEGF
   therapy; Recurrence
ID RANIBIZUMAB; PREVALENCE; TRIAL
AB Background To assess the time interval to recurrent choroidal neovascular membrane (CNV) activity in eyes with neovascular age-related macular degeneration (AMD) after intravitreal anti-VEGF therapy.
   Methods Data from all patients who received intravitreal ranibizumab injections for neovascular AMD at the University of Cologne prior to February 2009 were retrospectively reviewed. Patients were treated on a pro re nata (PRN) basis and eyes with active CNV received three consecutive monthly injections. Recurrence of CNV activity was defined as recurrence of intra- or subretinal fluid on optical coherence tomography (OCT) or leakage on fluorescein angiography (FA) after initial resolution of fluid and leakage following anti-VEGF therapy. All eyes showing at least two documented recurrences of CNV activity during follow-up were included in this analysis. Recurrence intervals were calculated and were deemed to be regular or periodical if the difference between recurrence interval times was less than 50 days.
   Results Twenty-nine eyes of 28 patients met the inclusion criteria. Two to six recurrences were detected per case (mean 2.8 +/- A 1.1 recurrences). Recurrence intervals ranged from 41 days to 523 days (mean 5.5 A +/- 3.4 months, median 4.5 months). Twenty-two eyes (76%) showed at least two periodical recurrence intervals. In 12 eyes (41%), all recurrences occurred at regular intervals (2-4 recurrences, mean 2.3 +/- A 0.6 recurrences). Seven eyes (24%) showed irregular recurrence intervals (2-3 recurrences, mean 2.1 +/- A 0.4 recurrences). All 11 eyes with a classic CNV lesion component showed at least two periodical recurrence intervals. Eyes with occult CNV lesions showed periodical recurrence intervals in 11 out of 18 cases (61%).
   Conclusions Preliminary data indicate that periodical recurrences of CNV activity may be seen in eyes with neovascular AMD undergoing anti-VEGF therapy. Knowledge of individual recurrence interval times may allow for the development of an individualized treatment plan and prophylactic therapy.
C1 [Hoerster, Robert; Ristau, Tina; Liakopoulos, Sandra] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50924 Cologne, Germany.
   [Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Retina Inst, Doheny Eye Inst, Los Angeles, CA 90033 USA.
C3 University of Cologne; Doheny Eye Institute; University of Southern
   California
RP Liakopoulos, S (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sandra.liakopoulos@uk-koeln.de
CR Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GUPTA OP, 2010, OPHTHALMOLOGY   0629
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   MEYER CH, 2008, INVEST OPHTH VIS SCI, P273
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
NR 19
TC 28
Z9 28
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2011
VL 249
IS 5
BP 645
EP 652
DI 10.1007/s00417-010-1588-2
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 756SN
UT WOS:000290035100004
PM 21170547
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Ly, A
   Nivison-Smith, L
   Assaad, N
   Kalloniatis, M
AF Ly, Angelica
   Nivison-Smith, Lisa
   Assaad, Nagi
   Kalloniatis, Michael
TI Multispectral Pattern Recognition Reveals a Diversity of Clinical Signs
   in Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular disease; image analysis; multimodal; ocular imaging; drusen
ID RETINAL IMAGE-ANALYSIS; AMINO-ACID SIGNATURES; FUNDUS AUTOFLUORESCENCE;
   CLASSIFICATION; SENSITIVITY; ATROPHY
AB PURPOSE. To develop a proof-of-concept, computational method for the quantification and classification of fundus images in intermediate age-related macular degeneration (AMD).
   METHODS. Multispectral, unsupervised pattern recognition was applied to 184 fundus images from 10 normal and 36 intermediate AMD eyes. The imaging results of preprocessed, grayscale images from three modalities (infrared, green, and fundus autofluorescence scanning laser ophthalmoscopy) were automatically classified into various clusters sharing a common spectral signature, using a k-means clustering algorithm. Class separability was calculated by using transformed divergence (D-T). The classification results for large drusen, pigmentary abnormalities, and areas unaffected by AMD were compared against three expert observers for concordance, and to calculate sensitivity and specificity.
   RESULTS. Multispectral, unsupervised pattern recognition successfully identified a finite number of AMD-specific, statistically separable signatures in eyes with intermediate AMD. By using a correct classification criterion of >83% for identical clusters and a total of 1693 expert annotations, the sensitivity and specificity of multispectral pattern recognition for the detection of AMD lesions was 74% and 98%, respectively. Large drusen and pigmentary abnormalities were correctly classified in 75% and 68% of instances, respectively.
   CONCLUSIONS. We describe herein a novel approach for the classification of multispectral images in intermediate AMD. Automated classification of intermediate AMD, using multispectral pattern recognition, has moderate sensitivity and high specificity, when compared against clinical experts. The methods described may have a future role in AMD screening or monitoring.
C1 [Ly, Angelica; Nivison-Smith, Lisa; Assaad, Nagi; Kalloniatis, Michael] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
   [Ly, Angelica; Nivison-Smith, Lisa; Kalloniatis, Michael] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Assaad, Nagi] Prince Wales Hosp, Dept Ophthalmol, Randwick, NSW, Australia.
   [Assaad, Nagi] Sutherland Hosp, Dept Ophthalmol, Toren Point, NSW, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Kalloniatis, M (通讯作者)，Univ New South Wales, Fac Sci, Sch Optometry & Vis Sci, Ctr Eye Hlth, Sydney, NSW 2052, Australia.
EM m.kalioniatis@unsw.edu.au
RI Ly, Angelica/J-2070-2019
OI Ly, Angelica/0000-0001-7881-1522; Kalloniatis,
   Michael/0000-0002-5264-4639
FU Australian Government Research Training Program scholarship; National
   Health and Medical Research Council (NHMRC) [1033224]; NHMRC grant
FX Supported in part by an Australian Government Research Training Program
   scholarship and a National Health and Medical Research Council (NHMRC)
   Grant (No. 1033224). Guide Dogs NSW/ACT is a partner in the NHMRC grant
   and also provided a supplementary PhD scholarship for AL and support for
   LN-S.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREFE PRACT PATT GUI
   Anderson JR, 2009, PLOS BIOL, V7, P493, DOI 10.1371/journal.pbio.1000074
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Davis B, 2007, PROC SPIE, V6426, DOI 10.1117/12.701391
   DELORI FC, 1977, ARCH OPHTHALMOL-CHIC, V95, P861, DOI 10.1001/archopht.1977.04450050139018
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Dugel PU, 2016, OSLI RETINA, V47, P134, DOI 10.3928/23258160-20160126-06
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gorin MB, 2014, J CLIN MED, V3, P1335, DOI 10.3390/jcm3041335
   Hill E, 2001, CEREB CORTEX, V11, P679, DOI 10.1093/cercor/11.8.679
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lee N, 2010, IEEE ENG MED BIO, P5363, DOI 10.1109/IEMBS.2010.5626463
   Ly A, 2018, CLIN EXP OPTOM, V101, P172, DOI 10.1111/cxo.12624
   Ly A, 2018, CLIN EXP OPTOM, V101, P243, DOI 10.1111/cxo.12607
   Ly A, 2017, CLIN EXP OPTOM, V100, P718, DOI 10.1111/cxo.12528
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   Marc RE, 1998, INVEST OPHTH VIS SCI, V39, P1685
   MARC RE, 1995, J NEUROSCI, V15, P5106
   Muen Wisam J, 2011, JRSM Short Rep, V2, P64, DOI 10.1258/shorts.2011.011042
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Nivison-Smith L, 2014, INT J DEV NEUROSCI, V33, P62, DOI 10.1016/j.ijdevneu.2013.12.005
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Phu J, 2017, INVEST OPHTH VIS SCI, V58, P4863, DOI 10.1167/iovs.17-22371
   Quellec G, 2011, INVEST OPHTH VIS SCI, V52, P2976, DOI 10.1167/iovs.10-6232
   Richards J, 1993, REMOTE SENSING DIGIT, V2nd
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmitz-Valckenberg S, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.3
   Sun D, 2007, J COMP NEUROL, V505, P92, DOI 10.1002/cne.21478
   Swain PH, 1973, 39 LARS
   The Angiogenesis Foundation, 2012, ADV IMPR TREATM OUTC
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   WEBB RH, 1981, IEEE T BIO-MED ENG, V28, P488, DOI 10.1109/TBME.1981.324734
   Wintergerst MWM, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.10
   WOON WH, 1992, BRIT J OPHTHALMOL, V76, P470, DOI 10.1136/bjo.76.8.470
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yoshioka N, 2017, INVEST OPHTH VIS SCI, V58, P3086, DOI 10.1167/iovs.17-21450
NR 45
TC 6
Z9 6
U1 2
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2018
VL 59
IS 5
BP 1790
EP 1799
DI 10.1167/iovs.17-23076
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB5FH
UT WOS:000429088400012
PM 29610844
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Martins, MD
   Volpatto, E
   Emery, P
   Serracarbassa, PD
AF Martins, Mara de Franca
   Volpatto, Edio
   Emery, Paula
   Serracarbassa, Pedro Duraes
TI A study of the vitreoretinal interface in patients with age-related
   macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration/ultrasonography; Macula lutea; Tomography optical
   coherence/methods; Tissue adhesion
ID POSTERIOR VITREOMACULAR ADHESION; OPTICAL COHERENCE TOMOGRAPHY; FACTOR-H
   POLYMORPHISM; INTRAVITREAL INJECTION; PHOTODYNAMIC THERAPY; RISK;
   TRACTION; EYE
AB Purpose: To assess whether hyaloid adhesion is more prevalent in patients with age-related macular degeneration (AMD) than in control patients and to evaluate whether it is more prevalent in exudative AMD than in non-exudative AMD.
   Methods: This was a cross-sectional, controlled analytical study. Patients from the Ophthalmology Department of the Public Service Hospital of the State of Sao Paulo were included if they were diagnosed with AMD that was confirmed by fundus biomicroscopy and fluorescein angiography. Patients were divided into three groups: patients without a vitreoretinal disease (controls), patients with exudative AMD, and patients with non-exudative AMD. For the optimal study of the vitreoretinal interface, all patients were subjected to spectral-domain optical coherence tomography (SD-OCT; Cirrus HD-OCT, version 4000; Carl Zeiss Meditec) and ultrasonography (UltraScan (R), Alcon).
   Results with p values of <= 0.05 were considered statistically significant. Results: We assessed 75 eyes of 23 patients with AMD (14 women and nine men) and 15 the control patients (11 women and four men). In total, 33 eyes had AMD that was consistent with the inclusion criteria, of which 11 had the non-exudative form (non-atrophic) and 22 had the exudative form (11 active and 11 disciform scars). Adherence was observed in eight eyes in the control group (26.67%), in seven eyes with exudative AMD (31.82%), and in five eyes with non-exudative AMD (45.45%).
   Conclusion: Patients with exudative and non-exudative forms of AMD did not present with higher vitreoretinal adhesion than control patients as assessed by SD-OCT and ultrasound. Moreover, patients with exudative AMD (neovascular membrane and disciform scar) did not reveal a higher adherence than those with non-exudative AMD when evaluated by the same methods.
C1 [Emery, Paula; Serracarbassa, Pedro Duraes] HSPE, Hosp Servidor Publ Estado Sao Paulo, Dept Ophthalmol, Retina Sect, Sao Paulo, SP, Brazil.
C3 Instituto de Assistencia Medica ao Servidor Publico Estadual (IAMSPE)
RP Martins, MD (通讯作者)，Rua Capitao Souza Franco 95, BR-80730420 Curitiba, Parana, Brazil.
EM mairafranca@hotmail.com
CR [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green-Simms AE, 2011, SEMIN OPHTHALMOL, V26, P137, DOI 10.3109/08820538.2011.559512
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heier JS, 2014, OPHTHALMOLOGY, V121, pE5, DOI 10.1016/j.ophtha.2013.09.018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2014, OPHTHALMOLOGY, V121, pe5
   Heier JS, 2014, OPHTHALMOLOGY, V121, pe4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krebs I, 2009, SPEKTRUM AUGENHEILKD, V23, P2, DOI 10.1007/s00717-009-0309-x
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Morales-Canton V, 2013, AM J OPHTHALMOL, V155, P1000, DOI 10.1016/j.ajo.2013.01.015
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Sebag J, 2000, EUR J OPHTHALMOL, V10, P1
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Sternberg P, 2004, AM J OPHTHALMOL, V137, P483, DOI 10.1016/j.ajo.2003.11.023
   Traboulsi EI, 2005, AM J OPHTHALMOL, V139, P908, DOI 10.1016/j.ajo.2005.01.045
   Veloso CE, EFEITO ADESAO VITREO
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   1994, ARCH OPHTHALMOL, V112, P874
NR 33
TC 0
Z9 0
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JAN-FEB
PY 2016
VL 79
IS 1
BP 4
EP 8
DI 10.5935/0004-2749.20160003
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DD1BS
UT WOS:000369656700003
PM 26840157
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Baltu, F
   Sarici, AM
   Yildirim, O
   Mergen, B
   Bolat, E
AF Baltu, Fatih
   Sarici, Ahmet Murat
   Yildirim, Onur
   Mergen, Burak
   Bolat, Erkut
TI Investigation of vascular endothelial dysfunction in the patients with
   age-related macular degeneration
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Age-related macular degeneration; atherosclerosis; flow-mediated
   dilation; intima media thickness
ID CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS RISK; MEDIATED VASODILATION;
   BRACHIAL-ARTERY; GROWTH-FACTOR; MACULOPATHY; PREVALENCE; COMPLEMENT;
   THICKNESS; CORONARY
AB Purpose: This study aims to evaluate the association between age-related macular degeneration (AMD) and cardiovascular disease by using the noninvasive flow-mediated dilation (FMD) test to show endothelial dysfunction as an indicator of subclinical atherosclerosis. Method: Participants in this study included 30 dry AMD patients, 30 wet AMD patients, and 30 healthy controls without any systemic disease, including AMD. FMD and the intima media thickness (IMT) of the carotid artery were compared between the groups. Results: Comparison of FMD between the groups showed a 10.96% brachial artery dilation in the healthy controls, 3.99% in the dry AMD group, and 5.03% in the wet AMD group. While a significant difference was not observed between the wet and dry AMD groups, comparison of the control group to the wet and dry AMD groups yielded a significant difference. When brachial artery dilation below 7% was accepted as an abnormal FMD, 26.7% of the healthy controls, 66.7% of the dry AMD patients and 76.7% of the wet AMD patients were found to be abnormal. Similarly, while no significant difference was observed between the wet and dry AMD groups, comparison of the control group with the wet and dry AMD patients yielded a significant difference. When an IMT below 0.7 mm was accepted as abnormal, 26.7% of the healthy controls, 33.3% of the dry AMD, and 43.3% of the wet AMD were found to have an abnormal IMT. However, differences between the groups did not reach statistical significance. Conclusions: In this study, use of the FMD test showed endothelial dysfunction among AMD patients. No significant differences were found between the dry and wet AMD patient groups.
C1 [Baltu, Fatih; Sarici, Ahmet Murat; Mergen, Burak] Istanbul Univ, Cerrahpasa Med Fac, Dept Ophthalmol, Istanbul, Turkey.
   [Yildirim, Onur] Istanbul Univ, Cerrahpasa Med Fac, Dept Radiol, Istanbul, Turkey.
   [Bolat, Erkut] Istanbul Univ, Cerrahpasa Med Fac, Dept Biostat & Med Informat, Istanbul, Turkey.
C3 Istanbul University; Istanbul University - Cerrahpasa; Istanbul
   University; Istanbul University - Cerrahpasa; Istanbul University;
   Istanbul University - Cerrahpasa
RP Sarici, AM (通讯作者)，Istanbul Univ, Dept Ophthalmol, Cerrahpasa Med Fac, Goz Hastaliklari Anabilim Dali, TR-34098 Istanbul, Turkey.
EM ahmetsarici@gmail.com
RI Mergen, Burak/K-8464-2019; Mergen, Burak/P-2950-2018; Sarici,
   Ahmet/AAA-2565-2021; BOLAT, ERKUT/AAA-7024-2020
OI Mergen, Burak/0000-0002-8132-495X; Mergen, Burak/0000-0002-8132-495X;
   YILDIRIM, ONUR/0000-0002-1586-1933
CR Arifoglu HB, 2016, AGING CLIN EXP RES, V28, P853, DOI 10.1007/s40520-015-0377-5
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Blann AD, 1998, BLOOD COAGUL FIBRIN, V9, P297, DOI 10.1097/00001721-199806000-00001
   BURKE GL, 1995, STROKE, V26, P386, DOI 10.1161/01.STR.26.3.386
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Connell PP, 2018, J OPHTHALMOL, V2009, P1
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859
   Doshi SN, 2001, CLIN SCI, V101, P629, DOI 10.1042/CS20010033
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Inaba Y, 2010, INT J CARDIOVAS IMAG, V26, P631, DOI 10.1007/s10554-010-9616-1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lip PL, 2000, INVEST OPHTH VIS SCI, V41, P2115
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   McCarty CA, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-25
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Playford DA, 2018, CLIN EXP PHARM PHYSL, V25, P640
   Raitakari OT, 2000, BRIT J CLIN PHARMACO, V50, P397, DOI 10.1046/j.1365-2125.2000.00277.x
   Ras RT, 2013, INT J CARDIOL, V168, P344, DOI 10.1016/j.ijcard.2012.09.047
   Sakai T, 2011, OPHTHALMOLOGY, V118, P1217, DOI 10.1016/j.ophtha.2011.01.033
   Salonen JT, 2018, ARTERIOSCLER THROM A, V11, P1245
   Schroeder S, 1999, AM HEART J, V138, P731, DOI 10.1016/S0002-8703(99)70189-4
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Szeplaki G, 2009, MOL IMMUNOL, V46, P2784, DOI 10.1016/j.molimm.2009.04.028
   Takase B, 1998, AM J CARDIOL, V82, P1535, DOI 10.1016/S0002-9149(98)00702-4
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tsai WC, 2005, CLIN SCI, V109, P39, DOI 10.1042/CS20040307
   Ueda-Consolvo T, 2017, JPN J OPHTHALMOL, V61, P347, DOI 10.1007/s10384-017-0515-z
   Verhamme P, 2006, ACTA CLIN BELG, V61, P213, DOI 10.1179/acb.2006.036
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8212063
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Yan RT, 2005, J AM COLL CARDIOL, V45, P1980, DOI 10.1016/j.jacc.2004.12.079
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yeoh J, 2006, EXPERT OPIN PHARMACO, V7, P2355, DOI 10.1517/14656566.7.17.2355
   Zaliuniene D, 2008, EUR J OPHTHALMOL, V18, P384, DOI 10.1177/112067210801800312
NR 52
TC 1
Z9 1
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PD JAN 2
PY 2019
VL 38
IS 1
BP 29
EP 35
DI 10.1080/15569527.2018.1504056
PG 7
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA HJ2UV
UT WOS:000457026400006
PM 30037291
DA 2022-11-30
ER

PT J
AU Finger, RP
   Wickremasinghe, SS
   Baird, PN
   Guymer, RH
AF Finger, Robert P.
   Wickremasinghe, Sanjeewa S.
   Baird, Paul N.
   Guymer, Robyn H.
TI Predictors of anti-VEGF treatment response in neovascular age-related
   macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; anti-VEGF; risk gene; treatment
   response; ranibizumab; bevacizumab
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; VISION-RELATED FUNCTION;
   VARIABLE-DOSING RANIBIZUMAB; QUALITY-OF-LIFE; VISUAL-ACUITY;
   INTRAVITREAL RANIBIZUMAB; BEVACIZUMAB AVASTIN; SUBGROUP ANALYSIS;
   CLINICAL-TRIAL
AB Currently available evidence on predictors of anti-vascular endothelial growth factor (VEGF) treatment response in neovascular age-related macular degeneration was reviewed. No meta-analysis of results is possible because of a lack of controlled and randomized trials, varying treatment regimes and outcome measures used, as well as suboptimal reporting. For genetic factors, most evidence to date has been generated for single nucleotide polymorphisms (SNPs) in the complement factor H (CFH), and VEGF-A genes. Just under half of the SNPs assessed in the CFH gene and 15% of the SNPs assessed in the VEGF gene were found to be associated with visual outcomes or the number of injections required during follow-up. Some evidence suggests association of worse treatment outcomes as well as a younger age at treatment onset with an increasing number of risk alleles in known risk genes (CFH and ARMS2/HTRA1) and polymorphisms in the VEGF-A gene. Clinical factors such as higher age, a better visual acuity (VA), a larger choroidal neovascularization (CNV) lesion at baseline, and a delay between symptom onset and initiation of treatment of more than 3 weeks also impact outcomes. Conversely, a worse acuity at baseline predicted more gain in vision. Overall, patients presenting with good acuity at baseline were more likely to have good VA at follow up, but the gain afforded by treatment was impacted by a ceiling effect. Most available evidence suggests a strong association of clinical factors such as age, baseline VA, and CNV lesion size with anti-VEGF treatment outcomes. No behavioral factors such as smoking influence treatment outcomes. Based on the studies conducted so far, the evidence suggests that underlying genotype of known AMD risk associated genes or of the VEGF-A gene have a limited effect, whereas presenting clinical factors appear to be more important in determining treatment outcomes. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Finger, Robert P.; Wickremasinghe, Sanjeewa S.; Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Bonn
RP Finger, RP (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM robertfinger@gmx.net
OI Baird, Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356;
   Finger, Robert P/0000-0003-4253-7597
FU German Research Council [DFG FI 1540/5-5]; National Health and Medical
   Research Council (NHMRC) Australia; Centre for Clinical Research
   Excellence [529923]; NHMRC project [590205, 1008979]; NHMRC practitioner
   fellowship [529905]; NHMRC Fellowship [1028444]
FX This work was supported by the German Research Council (DFG FI 1540/5-5,
   grant to RPF) and by the National Health and Medical Research Council
   (NHMRC) Australia, Centre for Clinical Research Excellence grant 529923,
   and NHMRC project grants 590205 and 1008979, NHMRC practitioner
   fellowship (RHG, grant 529905), NHMRC Fellowship (PNB, grant 1028444).
   CERA receives Operational Infrastructure Support from the Victorian
   Government.
CR Abedi F, 2012, INVEST OPHTH VIS SCI, V53, P2931
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Amaro MH, 2011, INVEST OPHTH VIS SCI, V52, P4004
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bozorg S, 2011, INVEST OPHTH VIS SCI, V52, P5242
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543
   Centre for Eye Research Australia, 2004, CLEAR INS EC IMP COS
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen E, 2012, ARVO M, V53, P2032
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Franklin AJ, 2012, INVEST OPHTH VIS SCI, V53, P6507
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Guber J, 2012, INVEST OPHTH VIS SCI, V53, P5155
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, OPHTHALMOLOGE, V108, P124, DOI 10.1007/s00347-010-2210-z
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Ingleheam CF, 2012, INVEST OPHTH VIS SCI, V53, P3325
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Jeng DJ, 2010, INVEST OPHTH VIS SCI, V51
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang H, 2010, INVEST OPHTH VIS SCI, V51
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Kitchens JW, 2011, INVEST OPHTH VIS SCI, V52, P5259
   Kloeckener-Gruissem B, 2012, INVEST OPHTH VIS SCI, V53, P5168
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kolb S, 2012, KLIN MONATSBL AUGENH, V229, P343, DOI 10.1055/s-0031-1299250
   Kovach JL, 2011, INVEST OPHTH VIS SCI, V52, P5231
   Lad EM, 2012, INVEST OPHTH VIS SCI, V53, P5161
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Levine JP, 2009, RETINA-J RET VIT DIS, V29, P1074, DOI 10.1097/IAE.0b013e3181b09443
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menger JF, 2012, INVEST OPHTH VIS SCI, V53, P857
   Mettu PS, 2012, INVEST OPHTH VIS SCI, V53, P2654
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Noh DH, 2012, INVEST OPHTH VIS SCI, V53, P3328
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park U-C, 2012, INVEST OPHTH VIS SCI, V53, P3327
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Sabour-Pickett S, 2012, INVEST OPHTH VIS SCI, V53, P4397
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Suner IJ, 2012, ARVO M, V53, P3677
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Tannan A, 2010, INVEST OPHTH VIS SCI, V51
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tolentino MJ, 2010, INVEST OPHTH VIS SCI, V51
   Vedula SS, 2008, COCHRANE DB SYST REV, V16
   Wang VM, 2011, INVEST OPHTH VIS SCI, V52, P1231
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   Ying G-S, 2012, INVEST OPHTHALMOL VI, V53, P3681
NR 98
TC 98
Z9 104
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2014
VL 59
IS 1
BP 1
EP 18
DI 10.1016/j.survophthal.2013.03.009
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 275DL
UT WOS:000328656400001
PM 24332379
DA 2022-11-30
ER

PT J
AU Oishi, A
   Thiele, S
   Nadal, J
   Oishi, M
   Fleckenstein, M
   Schmid, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Oishi, Akio
   Thiele, Sarah
   Nadal, Jennifer
   Oishi, Maho
   Fleckenstein, Monika
   Schmid, Matthias
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Prevalence, Natural Course, and Prognostic Role of Refractile Drusen in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE calcified drusen; crystalline drusen; precursor; intermediate
   age-related macular degeneration; geographic atrophy; biomarker
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; BRUCHS
   MEMBRANE; RETICULAR PSEUDODRUSEN; GEOGRAPHIC-ATROPHY;
   MORPHOMETRIC-ANALYSIS; RISK-FACTOR; EYES; LESIONS
AB PURPOSE. To report prevalence, clinical characteristics, and prognostic significance of refractile drusen in eyes with intermediate age-related macular degeneration (AMD).
   METHODS. Presence of refractile drusen by color fundus photography (CFP), corresponding findings by multimodal imaging, and longitudinal changes with annual examinations for up to 4 years were analyzed within a prospective natural history study of 98 eyes with non-late AMD of 98 patients (Age-Related Eye Disease Study [AREDS] stages 3 and 4).
   RESULTS. A total of 115 refractile drusen were detected at baseline in 20 eyes (20.4%). Refractile drusen typically showed hyperreflectivity by infrared (80.9%) and blue (93.9%) reflectance imaging, appearing more distinct when compared to CFP. Laminar intense hyperreflectivity of Bruch's membrane was detected in 31 lesions by spectral-domain optical coherence tomography and was strongly related to atrophy development (23 out of 31 lesions). Presence of refractile drusen at baseline was overall associated with later development of geographic atrophy (GA) (9/20 eyes versus 6/78 eyes, P < 0.001). Spontaneous regression without evident atrophy occurred in seven lesions.
   CONCLUSIONS. Refractile drusen are a relative common phenotype in intermediate AMD and appear to confer risk for the development of late AMD. While not all lesions develop late AMD and regression may also occur, distinct subphenotypes as identified by multimodal imaging may not only be visible earlier but also be topographically associated with the risk for GA development. Recognizing the characteristic pattern on multimodal imaging would inform physicians for identification of the lesion and its clinical history.
C1 [Oishi, Akio; Thiele, Sarah; Oishi, Maho; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Nadal, Jennifer; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458; Fleckenstein,
   Monika/0000-0001-8321-8037; Schmid, Matthias/0000-0002-0788-0317
FU German Ministry of Education and Research (BMBF); Alexander von Humboldt
   Foundation, Bonn, Germany [FKZ 13N10349]; Alcon Japan, Tokyo, Japan
FX Supported by the German Ministry of Education and Research (BMBF). AO
   was supported by the Alexander von Humboldt Foundation (FKZ 13N10349),
   Bonn, Germany and Alcon Japan, Tokyo, Japan.
CR Agarwal A, 2012, GASS ATLAS MACULAR D, P63
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Steinberg JS, 2016, RETINA-J RET VIT DIS, V36, P1548, DOI 10.1097/IAE.0000000000000951
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
NR 28
TC 24
Z9 24
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2017
VL 58
IS 4
BP 2198
EP 2206
DI 10.1167/iovs.16-20781
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ET9SY
UT WOS:000400649600032
PM 28418494
OA gold
DA 2022-11-30
ER

PT J
AU Chatziralli, I
   Mitropoulos, P
   Parikakis, E
   Niakas, D
   Labiris, G
AF Chatziralli, Irini
   Mitropoulos, Panagiotis
   Parikakis, Efstratios
   Niakas, Dimitrios
   Labiris, Georgios
TI Risk Factors for Poor Quality of Life among Patients with Age-Related
   Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; EQ-5D; quality; SF-36; VFQ-25
ID VISUAL FUNCTION; MACULOPATHY; DEPRESSION; UTILITY; ACUITY
AB Purpose: The purpose of this study was to evaluate the quality of life in patients with age-related macular degeneration (AMD) and compare it with that of healthy controls. Additionally, our study aims to investigate the possible risk factors for poor quality of life in AMD patients. Methods: Participants in the study were 114 patients with AMD, 63 male and 51 female, mean-aged 76.5 +/- 6.1 years. Demographic data, lifestyle factors, and medical history were recorded. All patients underwent a routine examination for AMD, including best-corrected visual acuity measurement, dilated fundoscopy and optical coherence tomography, and completed three questionnaires assessing quality of life (SF-36, EQ-5D, NEI VFQ-25). In addition, 100 controls, adjusted for gender and age, were included in the study. Risk factors for quality of life in AMD patients were investigated. Univariate analysis was performed using SPSS 22.0. Results: Patients with AMD scored lower in vision-and health-related quality-of-life questionnaires compared to controls. Risk factors associated with quality of life in patients with AMD were found to be the female gender, alcohol consumption, the presence of hypertension, diabetes mellitus, cardiovascular diseases, myosceletal problems, migraine, anxiety/depression, subretinal or intraretinal fluid, pigment epithelium detachment, previous treatment for AMD, visual acuity, the stage of the disease, and the integrity of the ellipsoid zone. Conclusion: Patients with AMD presented lower quality of life in comparison with controls. Potential risk factors should be taken into account and clinicians should thus focus on the most vulnerable subgroups.
C1 [Chatziralli, Irini; Mitropoulos, Panagiotis; Parikakis, Efstratios] Second Dept Ophthalmol, Ophthalmiatr Athinon, Athens, Greece.
   [Chatziralli, Irini; Niakas, Dimitrios; Labiris, Georgios] Hellen Open Univ, Fac Social Sci, Patras, Greece.
   [Labiris, Georgios] Univ Hosp Alexandroupolis, Dept Ophthalmol, Alexandroupolis, Greece.
C3 Hellenic Open University
RP Chatziralli, I (通讯作者)，28 Papanastasiou St, Athens 17342, Greece.
EM eirchat@yahoo.gr
RI Chatziralli, Irini/AAG-4779-2020
OI Chatziralli, Irini/0000-0001-8523-1024; Niakas,
   Dimitris/0000-0003-0528-755X
CR Awdeh RM, 2010, BRIT J OPHTHALMOL, V94, P319, DOI 10.1136/bjo.2007.135913
   Aydin Kurna S, 2014, J OPHTHALMOL, V2014, DOI [10.1155/ 2014/ 694542, DOI 10.1155/2014/694542]
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cavar I, 2014, ACTA CLIN CROAT, V53, P79
   Chatziralli IP, 2013, GRAEF ARCH CLIN EXP, V251, P783, DOI 10.1007/s00417-012-2194-2
   Childs AL, 2004, AM J OPHTHALMOL, V137, P373, DOI 10.1016/S0002-9394(03)00911-5
   Chung SD, 2015, ACTA OPHTHALMOL, V93, pE176, DOI 10.1111/aos.12478
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Fuhs A, 2005, KLIN MONATSBL AUGENH, V222, P649, DOI 10.1055/s-2005-858367
   Gautam P, 2009, NEPAL J OPHTHALMOL, V1, P114
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kay S, 2014, OPHTHAL EPIDEMIOL, V21, P66, DOI 10.3109/09286586.2014.888456
   Kontodimopoulos N, 2008, VALUE HEALTH, V11, P1162, DOI 10.1111/j.1524-4733.2008.00356.x
   Labiris G, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-4
   Le Q, 2014, BMC OPHTHALMOL, V12, P22
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Pappa E, 2005, QUAL LIFE RES, V14, P1433, DOI 10.1007/s11136-004-6014-y
   Pesudovs K, 2010, J CATARACT REFR SURG, V36, P718, DOI 10.1016/j.jcrs.2009.11.019
   Rovner BW, 2011, ARCH OPHTHALMOL-CHIC, V129, P885, DOI 10.1001/archophthalmol.2011.146
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Synek S, 2010, COLLEGIUM ANTROPOL, V34, P25
   Turkoglu EB, 2015, J DIABETES COMPLICAT, V29, P540, DOI 10.1016/j.jdiacomp.2015.03.009
   Ware JE, 1994, SF 36 PHYS MENTAL HL
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 35
TC 13
Z9 15
U1 2
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2017
VL 32
IS 6
BP 772
EP 780
DI 10.1080/08820538.2016.1181192
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FS5EP
UT WOS:000419816800018
PM 27648680
DA 2022-11-30
ER

PT J
AU Chernykh, V
   Shevchenko, A
   Konenkov, V
   Prokofiev, V
   Eremina, A
   Trunov, A
AF Chernykh, Valeriy
   Shevchenko, Alla
   Konenkov, Vladimir
   Prokofiev, Viktor
   Eremina, Alena
   Trunov, Alexander
TI TNF-alpha gene polymorphisms: association with age-related macular
   degeneration in Russian population
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE tumor necrosis factor-alpha; genetic polymorphisms; age-related macular
   degeneration
ID NECROSIS-FACTOR-ALPHA; HAPLOTYPES
AB AIM: To study polymorphisms in promotor regions of tumor necrosis factor (TNF)-alpha TNF-863A/C (rs1800630), TNF-308A/G (rs1800629), and TNF-238A/G (rs361525) in patients with age-related macular degeneration (AMD) and associations of complex TNF-alpha genotypes with AMD.
   METHODS: One hundred and two patients (82 women, 20 men; mean age 64.2 +/- 1.2y) with AMD and 100 healthy age- and sex-matched controls (82 women, 18 men; 60 +/- 1.4y) were included in the study. All subjects were Caucasian, all subjects and their parents were inhabitants of Russia. Genomic DNA was obtained from EDTA-preserved blood using the standard phenol-chloroform method. Polymorphisms were detected by polymerase chain reaction followed by the restriction fragment length polymorphism method. The following TNF-alpha genotypes were studied: TNF-alpha-238 AA, GA, GG, TNF-alpha-308 AA, GA, GG, TNF-alpha-863 AA, CA, CC.
   RESULTS: Differences in TNF-alpha-863 and TNF-alpha-238 genotypes frequencies in patients with AMD and healthy controls were not found. The distribution of TNF-alpha-308 AA and TNF-alpha-308 GA genotypes was significantly different between the studied group and the controls [odds ratios (OR) =0.22, P=0.0287 and OR=2.91, P=0.0063, respectively]. TNF-863CC/TNF-308GA and TNF-308GA/TNF-238GG genotypes were associated with the increased risk of AMD (OR=2.48, P=0.0332 and OR=2.51, P=0.0187, respectively). Five genotypes combinations appeared to be protective.
   CONCLUSION: In the present study, single nucleotide polymorphisms and complex polymorphisms of one of the key inflammatory cytokines TNF-alpha, and a number of significant associations of these polymorphisms with AMD in Russian population have been shown. Complex analysis of genotypes could be important in AMD risk factors detection and studying pathogenesis.
C1 [Chernykh, Valeriy; Eremina, Alena; Trunov, Alexander] S Fyodorov Eye Microsurg Fed State, Novosibirsk Branch, Novosibirsk 630096, Russia.
   [Shevchenko, Alla; Konenkov, Vladimir; Prokofiev, Viktor] Sci Inst Clin & Expt Lymhol, Novosibirsk 630060, Russia.
RP Trunov, A (通讯作者)，10 Kolhidskaya St, Novosibirsk 630096, Russia.
EM trunov1963@yandex.ru
RI Shevchenko, Alla/K-2470-2018; Konenkov, Vladimir/U-3306-2019; Eremina,
   Alena/AAI-2929-2020; Chernykh, Valery/AAH-6121-2020; Trunov,
   Aleksandr/R-7867-2019
OI Trunov, Aleksandr/0000-0002-7592-8984; Konenkov, Vladimir
   I./0000-0001-7385-6270
CR Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Bonyadi Mohammad Hossein Jabbarpoor, 2015, J Ophthalmic Vis Res, V10, P155, DOI 10.4103/2008-322X.163781
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   El-Tahan RR, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3197-y
   Elahi MM, 2009, BBA-MOL BASIS DIS, V1792, P163, DOI 10.1016/j.bbadis.2009.01.007
   Fernandez-Vega B, 2016, CASE REP OPHTHAL, V7, P154, DOI 10.1159/000445102
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Jing LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097522
   Kazzi SNJ, 2008, PEDIATR RES, V64, P165, DOI 10.1203/PDR.0b013e31817758f4
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Qidwai T, 2011, SCAND J IMMUNOL, V74, P522, DOI 10.1111/j.1365-3083.2011.02602.x
   Stark AE, 2015, TWIN RES HUM GENET, V18, P399, DOI 10.1017/thg.2015.41
   Swaroop A, 2009, INVEST OPHTH VIS SCI, V50, P1614
   Tan JH, 2011, TISSUE ANTIGENS, V77, P100, DOI 10.1111/j.1399-0039.2010.01582.x
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tsiloulis AN, 2016, OPHTHALMIC GENET, V37, P339, DOI 10.3109/13816810.2015.1045525
   Wan L, 2010, RETINA-J RET VIT DIS, V30, P1595, DOI 10.1097/IAE.0b013e3181dc58a6
   Winham SJ, 2015, ATHEROSCLEROSIS, V241, P219, DOI 10.1016/j.atherosclerosis.2015.03.021
   Woo HJ, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2871-3
NR 22
TC 6
Z9 7
U1 1
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JAN 18
PY 2019
VL 12
IS 1
BP 25
EP 29
DI 10.18240/ijo.2019.01.04
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HH4EY
UT WOS:000455675300004
PM 30662836
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Stifter, E
   Michels, S
   Prager, F
   Georgopoulos, M
   Polak, K
   Hirn, C
   Schmidt-Erfurth, U
AF Stifter, Eva
   Michels, Stephan
   Prager, Franz
   Georgopoulos, Michael
   Polak, Kaija
   Hirn, Cornelia
   Schmidt-Erfurth, Ursula
TI Intravitreal bevacizumab therapy for neovascular age-related macular
   degeneration with large submacular hemorrhage
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBRETINAL HEMORRHAGE; INJECTION;
   MANAGEMENT; AVASTIN; GAS; DISPLACEMENT; SECONDARY; TOXICITY; SAFETY
AB PURPOSE: To evaluate functional and anatomic effects of intravitreal bevacizumab (Avastin; Roche Pharma, Vienna, Austria) in patients with neovascular age-related macular degeneration (AMD) with large submacular hemorrhages.
   DESIGN: Retrospective, clinical study.
   METHODS: Twenty-one eyes of 19 AMD patients with choroidal neovascularization and large submacular hemorrhage involving the fovea comprising more than 50% of the total lesion area were evaluated. All patients completed at least four months of follow-up; 12 patients fulfilled 12 months or more of follow-up. Patients were treated with up to six intravitreal bevacizumab injections (1 mg/0-04 ml) at a minimum of four-week intervals. Changes from baseline visual acuity (VA) scores, retinal measurements by optical coherence tomography (OCT), angiographic lesion characteristics, and hemorrhage size were analyzed. A safety assessment was performed at all visits.
   RESULTS: Intravitreal bevacizumab injections were well tolerated in all patients. At month 4, VA was stable or improved (visual loss of 3 acuity lines or fewer) in 100% and improved by at least 3 lines in 9.5%. Comparable results were found at month 12. On average, the central foveal thickness decreased significantly by 55 mu m four weeks after the first injection (P<.001) and by 52 mu m at month 4 (P=.002). A significant anatomic improvement also was found for maximum retinal thickness, minimum retinal thickness, and foveal volume (P<.05) and was maintained during four months of follow-up. Mean size of hemorrhage was significantly reduced from 19.7 mm(2) at baseline to 2.5 mm(2) at the four-month follow-up (P<.001).
   CONCLUSIONS: Intravitreal bevacizumab seems to be a promising therapeutic option in eyes with neovascular AMD and large submacular hemorrhages, with a stabilization in VA and anatomic improvement.
C1 Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 Medical University of Vienna
RP Michels, S (通讯作者)，Univ Zurich, Dept Ophthalmol, Frauenklinikstr 24, CH-8091 Zurich, Switzerland.
EM stephan.michels@usz.ch
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hattenbach LO, 2002, KLIN MONATSBL AUGENH, V219, P512, DOI 10.1055/s-2002-33584
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Schmidt-Erfurth U, 2005, SPEKTRUM AUGENHEILKD, V19, P68, DOI 10.1007/BF03163961
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
NR 37
TC 72
Z9 74
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2007
VL 144
IS 6
BP 886
EP 892
DI 10.1016/j.ajo.2007.07.034
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 238TI
UT WOS:000251470100012
PM 17916314
DA 2022-11-30
ER

PT J
AU Yang, HL
   Kim, JJ
   Kim, JH
   Kang, YK
   Park, DH
   Park, HS
   Kim, HK
   Kim, MS
AF Yang, Hyun-Lim
   Kim, Jong Jin
   Kim, Jong Ho
   Kang, Yong Koo
   Park, Dong Ho
   Park, Han Sang
   Kim, Hong Kyun
   Kim, Min-Soo
TI Weakly supervised lesion localization for age-related macular
   degeneration detection using optical coherence tomography images
SO PLOS ONE
LA English
DT Article
AB Age-related macular degeneration (AMD) is the main cause of irreversible blindness among the elderly and require early diagnosis to prevent vision loss, and careful treatment is essential. Optical coherence tomography (OCT), the most commonly used imaging method in the retinal area for the diagnosis of AMD, is usually interpreted by a clinician, and OCT can help diagnose disease on the basis of the relevant diagnostic criteria, but these judgments can be somewhat subjective. We propose an algorithm for the detection of AMD based on a weakly supervised convolutional neural network (CNN) model to support computer-aided diagnosis (CAD) system. Our main contributions are the following three things. (1) We propose a concise CNN model for OCT images, which outperforms the existing large CNN models using VGG16 and GoogLeNet architectures. (2) We propose an algorithm called Expressive Gradients (EG) that extends the existing Integrated Gradients (IG) algorithm so as to exploit not only the input-level attribution map, but also the high-level attribution maps. Due to enriched gradients, EG can highlight suspicious regions for diagnosis of AMD better than the guided-backpropagation method and IG. (3) Our method provides two visualization options: overlay and top-k bounding boxes, which would be useful for CAD. Through experimental evaluation using 10,100 clinical OCT images from AMD patients, we demonstrate that our EG algorithm outperforms the IG algorithm in terms of localization accuracy and also outperforms the existing object detection methods in terms of class accuracy.
C1 [Yang, Hyun-Lim; Kim, Min-Soo] DGIST, Dept Informat & Commun Engn, Daegu, South Korea.
   [Kim, Jong Jin; Kim, Jong Ho; Kang, Yong Koo; Park, Dong Ho; Park, Han Sang; Kim, Hong Kyun] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea.
C3 Daegu Gyeongbuk Institute of Science & Technology (DGIST); Kyungpook
   National University
RP Kim, MS (通讯作者)，DGIST, Dept Informat & Commun Engn, Daegu, South Korea.; Kim, HK (通讯作者)，Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea.
EM okeye@knu.ac.kr; mskim@dgist.ac.kr
RI Yang, Hyun-Lim/P-2597-2018
OI Yang, Hyun-Lim/0000-0003-2221-3042; Kim, Hong Kyun/0000-0002-9283-3506
FU Samsung Research Funding Center of Samsung Electronics [SRFC-IT1502-10]
FX This work was supported by Samsung Research Funding Center of Samsung
   Electronics under Project Number SRFC-IT1502-10 to MK. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aubert B., 2017, Medical Image Computing and Computer-Assisted Intervention, MICCAI 2017. 20th International Conference. Proceedings: LNCS 10434, P691, DOI 10.1007/978-3-319-66185-8_78
   Deng JJ, 2016, LECT NOTES COMPUT SC, V9730, P707, DOI 10.1007/978-3-319-41501-7_79
   Dong Yang, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10435, P498, DOI 10.1007/978-3-319-66179-7_57
   Glorot X, 2010, P 13 INT C ART INT S, P249, DOI DOI 10.1177/1753193409103364.
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   He KM, 2015, IEEE I CONF COMP VIS, P1026, DOI 10.1109/ICCV.2015.123
   Herm RJ, 2008, NEW ENGL J MED, V359, P1735
   Huang J, 2017, IEEE INT C INT ROBOT, P3296, DOI 10.1109/IROS.2017.8206166
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Rathke Fabian, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10433, P177, DOI 10.1007/978-3-319-66182-7_21
   Ren SQ, 2015, ADV NEUR IN, V28, DOI 10.1109/TPAMI.2016.2577031
   Samek W, 2017, IEEE T NEUR NET LEAR, V28, P2660, DOI 10.1109/TNNLS.2016.2599820
   Sandler M., 2018, ABS180104381 CORR
   Shrikumar A., 2017, PMLR, P3145, DOI DOI 10.1145/3292500.3330701
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Springenberg J.T., 2014, ICLR WORKSHOP TRACK, DOI DOI 10.48550/ARXIV.1412.6806
   Sundararajan M, 2017, PR MACH LEARN RES, V70
   Szegedy C., 2015, IEEE C COMP VIS PATT, P1, DOI DOI 10.1109/CVPR.2015.7298594
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Wei Liu, 2016, Computer Vision - ECCV 2016. 14th European Conference. Proceedings: LNCS 9905, P21, DOI 10.1007/978-3-319-46448-0_2
NR 22
TC 9
Z9 9
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2019
VL 14
IS 4
AR e0215076
DI 10.1371/journal.pone.0215076
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HR9NM
UT WOS:000463487500032
PM 30951557
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Eisenhauer, B
   Natoli, S
   Liew, G
   Flood, VM
AF Eisenhauer, Bronwyn
   Natoli, Sharon
   Liew, Gerald
   Flood, Victoria M.
TI Lutein and Zeaxanthin-Food Sources, Bioavailability and Dietary Variety
   in Age-Related Macular Degeneration Protection
SO NUTRIENTS
LA English
DT Review
DE lutein; zeaxanthin; xanthophylls; carotenoids; age-related macular
   degeneration; bioavailability
ID LONG-TERM INCIDENCE; NATIONAL-HEALTH; CAROTENOID INTAKE;
   OPTICAL-DENSITY; MESO-ZEAXANTHIN; VISUAL FUNCTION; BETA-CAROTENE; EYE
   DISEASE; VITAMIN-C; SUPPLEMENTATION
AB Lutein and zeaxanthin (L/Z) are the predominant carotenoids which accumulate in the retina of the eye. The impact of L/Z intake on the risk and progression of age-related macular degeneration (AMD), a leading cause of blindness in the developed world, has been investigated in cohort studies and clinical trials. The aims of this review were to critically examine the literature and evaluate the current evidence relating to L/Z intake and AMD, and describe important food sources and factors that increase the bioavailability of L/Z, to inform dietary models. Cohort studies generally assessed L/Z from dietary sources, while clinical trials focused on providing L/Z as a supplement. Important considerations to take into account in relation to dietary L/Z include: nutrient-rich sources of L/Z, cooking methods, diet variety and the use of healthy fats. Dietary models include examples of how suggested effective levels of L/Z can be achieved through diet alone, with values of 5 mg and 10 mg per day described. These diet models depict a variety of food sources, not only from dark green leafy vegetables, but also include pistachio nuts and other highly bioavailable sources of L/Z such as eggs. This review and the diet models outlined provide information about the importance of diet variety among people at high risk of AMD or with early signs and symptoms of AMD.
C1 [Eisenhauer, Bronwyn; Natoli, Sharon] Food & Nutr Australia, Sydney, NSW 2000, Australia.
   [Liew, Gerald] Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Dept Ophthalmol, Sydney, NSW 2145, Australia.
   [Flood, Victoria M.] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2141, Australia.
   [Flood, Victoria M.] Westmead Hosp, Western Sydney Local Hlth Dist, Westmead, NSW, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney; University of Sydney
RP Flood, VM (通讯作者)，Univ Sydney, Fac Hlth Sci, Sydney, NSW 2141, Australia.; Flood, VM (通讯作者)，Westmead Hosp, Western Sydney Local Hlth Dist, Westmead, NSW, Australia.
EM beisenhauer@foodnut.com.au; snatoli@foodnut.com.au;
   gerald.liew@sydney.edu.au; vicki.flood@sydney.edu.au
RI Flood, Victoria M/A-8732-2016; Liew, Gerald/AAB-6870-2022
OI Flood, Victoria M/0000-0001-5310-7221; 
FU Australian Egg Corporation Limited
FX Funding for the writing of this paper and the costs associated with
   publishing in open access was provided by the Australian Egg Corporation
   Limited.
CR Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Arteni AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135779
   Australian Bureau of Statistics, 2014, AUSTR HLTH SURV NUTR
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Blesso CN, 2013, FOOD FUNCT, V4, P213, DOI 10.1039/c2fo30154g
   Brown MJ, 2004, AM J CLIN NUTR, V80, P396, DOI 10.1093/ajcn/80.2.396
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cook T, 2001, COMP DATA FOOD NUTR
   Curran-Celentano JM, 2003, INVEST OPHTH VIS SCI, V44, pU78
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Druesne-Pecollo N, 2010, INT J CANCER, V127, P172, DOI 10.1002/ijc.25008
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Ghavami A, 2012, BRIT J NUTR, V107, P1350, DOI 10.1017/S000711451100451X
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Goltz SR, 2012, MOL NUTR FOOD RES, V56, P866, DOI 10.1002/mnfr.201100687
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Graydon R., 2012, BRIT J NUTR, V7, P1
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hobbs Ronald P, 2014, J Ophthalmic Vis Res, V9, P487, DOI 10.4103/2008-322X.150829
   Hof KHV, 2000, J NUTR, V130, P503
   Homero-Mendez D, 2007, INNOV FOOD SCI EMERG, V8, P407, DOI 10.1016/j.ifset.2007.03.014
   Johnson Elizabeth J, 2002, Nutr Clin Care, V5, P56, DOI 10.1046/j.1523-5408.2002.00004.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Kelly ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092659
   Kim J.E., 2015, FASEB J, V29, P1
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Manzi F, 2002, PUBLIC HEALTH NUTR, V5, P347, DOI 10.1079/PHN2002258
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Meyer zu Westrup V., 2016, INT J RETINA VITREOU, V2, P14
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nebeling LC, 1997, J AM DIET ASSOC, V97, P991, DOI 10.1016/S0002-8223(97)00239-3
   Nolan JM, 2013, EYE, V27, P899, DOI 10.1038/eye.2013.98
   Olmedilla B, 1997, CLIN CHEM, V43, P1066
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Pelz R, 1998, Z ERNAHRUNGSWISS, V37, P319, DOI 10.1007/s003940050032
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Rao AV, 2007, PHARMACOL RES, V55, P207, DOI 10.1016/j.phrs.2007.01.012
   Rasmussen HM, 2013, CLIN INTERV AGING, V8, P741, DOI 10.2147/CIA.S45399
   Reboul E, 2007, BRIT J NUTR, V97, P440, DOI 10.1017/S0007114507352604
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Riedl J, 1999, J NUTR, V129, P2170, DOI 10.1093/jn/129.12.2170
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Scott KJ, 1996, BRIT J NUTR, V75, P409, DOI 10.1079/BJN19960143
   Scripsema NK, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865179
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tian Y, 2015, ARCH BIOCHEM BIOPHYS, V572, P49, DOI 10.1016/j.abb.2015.01.019
   Tucker KL, 1999, J NUTR, V129, P438, DOI 10.1093/jn/129.2.438
   USDA, USDA NAT NUTR DAT ST
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Worsley D, 2015, NEW ZEAL MED J, V128, P44
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 78
TC 108
Z9 110
U1 5
U2 70
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD FEB
PY 2017
VL 9
IS 2
AR 120
DI 10.3390/nu9020120
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA EO9QL
UT WOS:000397023100033
PM 28208784
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Ueta, T
   Noda, Y
   Toyama, T
   Yamaguchi, T
   Amano, S
AF Ueta, Takashi
   Noda, Yasuo
   Toyama, Taku
   Yamaguchi, Takuhiro
   Amano, Shiro
TI Systemic Vascular Safety of Ranibizumab for Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; GROWTH-FACTOR INHIBITORS; CHOROIDAL
   NEOVASCULARIZATION; MYOCARDIAL-INFARCTION; CONTROLLED-TRIAL;
   CEREBROVASCULAR ACCIDENTS; COMBINATION THERAPY; PLUS RANIBIZUMAB; DOSING
   REGIMEN; ANTI-VEGF
AB Background: We conducted a meta-analysis of randomized trials of ranibizumab for age-related macular degeneration (AMD) to elucidate systemic vascular risk.
   Clinical Relevance: Although intravitreal vascular endothelial growth factor inhibitors are widely used to treat AMD, whether they produce systemic adverse effects remains uncertain.
   Methods: We searched MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials through March 2014 to identify the randomized trials that compared systemic safety among different intensities of ranibizumab treatment for AMD. The outcome measures were the incidence of cerebrovascular accidents (CVAs), myocardial infarctions, nonocular hemorrhages, overall arterial thromboembolic events (ATEs), and all-cause mortality. We calculated the Peto odds ratio (OR) with 95% confidence interval for the comparisons between different intensities of regimens in terms of dose and retreatment frequency.
   Results: Eleven trials comprising 6596 patients with AMD were included in the meta-analysis. A significant increase was observed in the following comparisons: 0.5 versus 0.3/0.0 mg for CVA (OR, 1.86; 95% CI, 1.05e3.29; P = 0.03), monthly versus pro re nata (PRN)/0.0 mg for CVA (OR, 1.89; 95% CI, 1.06-3.38; P = 0.03), and 0.3/0.5 versus 0.0 mg for nonocular hemorrhage (OR, 1.57; 95% CI, 1.01-2.44; P = 0.04). A nonsignificant increase was observed in the following comparisons: 0.5 versus 0.0 mg for CVA (OR, 2.27; 95% CI, 0.90-5.69; P = 0.08), monthly versus PRN for CVA (OR, 2.04; 95% CI, 0.94-4.45; P = 0.07), 0.5 versus 0.0 mg for nonocular hemorrhage (OR, 1.68; 95% CI, 0.98-2.88; P = 0.06), 0.3 versus 0.0 mg for nonocular hemorrhage (OR, 1.68; 95% CI, 0.95-2.98; P = 0.07), monthly versus PRN/0.0 mg for nonocular hemorrhage (OR, 1.54; 95% CI, 0.98-2.42; P = 0.06), monthly versus PRN for ATE (OR, 1.58; 95% CI, 0.96-2.61; P = 0.07), and monthly versus PRN/0.0 mg for ATE (OR, 1.42; 95% CI, 0.99-2.05; P - 0.06). Among the other analyses, no protective or harmful effects of ranibizumab were observed.
   Conclusions: In ranibizumab treatment for patients with AMD, a possible relationship of more intensive treatment to more systemic vascular adverse events was identified, but no relationship with mortality was identified. (C) 2014 by the American Academy of Ophthalmology.
C1 [Ueta, Takashi; Noda, Yasuo; Toyama, Taku; Amano, Shiro] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan.
   [Ueta, Takashi; Noda, Yasuo; Toyama, Taku; Amano, Shiro] Univ Tokyo, Fac Med, Tokyo 1138655, Japan.
   [Yamaguchi, Takuhiro] Univ Tokyo, Grad Sch Med, Div Biostat, Tokyo 1138655, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo
RP Ueta, T (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM ueta-tky@umin.ac.jp
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Beaumont PE, 2014, OPHTHALMOLOGY, V121, pE4, DOI 10.1016/j.ophtha.2013.09.020
   Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Center for Drug Evaluation and Research, MED REV
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cheng JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041325
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167
   Lundh A, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.MR000033.pub2, 10.1002/14651858.MR000033.pub3]
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Soderberg AC, 2012, BRIT J OPHTHALMOL, V96, P714, DOI 10.1136/bjophthalmol-2011-300721
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Ueta T, 2014, OPHTHALMOLOGY, V121, pE5, DOI 10.1016/j.ophtha.2013.09.019
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   Wong D, 2011, GRAEF ARCH CLIN EXP, V249, P161, DOI 10.1007/s00417-010-1574-8
NR 50
TC 44
Z9 50
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2014
VL 121
IS 11
BP 2193
EP 2203
DI 10.1016/j.ophtha.2014.05.022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS8DM
UT WOS:000344480400024
PM 25023760
DA 2022-11-30
ER

PT J
AU Sato, M
   Minami, S
   Nagai, N
   Suzuki, M
   Kurihara, T
   Shinojima, A
   Sonobe, H
   Akino, K
   Ban, N
   Watanabe, K
   Uchida, A
   Shinoda, H
   Tsubota, K
   Ozawa, Y
AF Sato, Maho
   Minami, Sakiko
   Nagai, Norihiro
   Suzuki, Misa
   Kurihara, Toshihide
   Shinojima, Ari
   Sonobe, Hideki
   Akino, Kunihiko
   Ban, Norimitsu
   Watanabe, Kazuhiro
   Uchida, Atsuro
   Shinoda, Hajime
   Tsubota, Kazuo
   Ozawa, Yoko
TI Association between axial length and choroidal thickness in early
   age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID VASCULOPATHY; MECHANISMS
AB The clinical course of age-related macular degeneration (AMD) is related to choroidal conditions, and can be determined by the evaluation of the central choroidal thickness (CCT). The aim of this study was to determine the association between the axial length (AL) and choroidal thickness in AMD by measuring these parameters in patients with and without AMD. Seventy eyes of 70 patients (34 men and 36 women; age, 64-88 years; mean age, 77.0 +/- 6.5 years) who underwent cataract surgery from February 2015 to March 2020 at the Department of Ophthalmology, Keio University School of Medicine were retrospectively analyzed. The AMD group (29 patients, 29 eyes) included eyes with early AMD, whereas the control group (41 patients, 41 eyes) included those without ocular diseases other than cataract. Optical coherence tomography images were used to measure the CCT and the choroidal vessel diameter (CVD). The IOL Master was used to measure the AL. The results revealed that mean CCT was greater in the AMD group (238.3 +/- 108.3 mu m) compared with the age-matched control group (187.2 +/- 66.8 mu m) (p = 0.03). The CCT was negatively correlated with AL in the overall sample (r = -0.42, p = 0.001), the AMD group (r = -0.42, p = 0.02), and the control group (r = -0.42, p = 0.006). Note that all eyes with CCT > 350 mu m were included in the AMD group. CCT and CVD were positively correlated in the overall sample (r = 0.76, p < 0.001) as well as in the individual groups (AMD: r = 0.82, p < 0.001; control: r = 0.76, p = 0.004). Given that CCT is an important parameter for predicting the prognosis of subfoveal diseases, routine evaluation of AL may be valuable for a better understanding of the pathogenesis of AMD.
C1 [Sato, Maho; Minami, Sakiko; Nagai, Norihiro; Suzuki, Misa; Kurihara, Toshihide; Shinojima, Ari; Sonobe, Hideki; Akino, Kunihiko; Ban, Norimitsu; Watanabe, Kazuhiro; Uchida, Atsuro; Shinoda, Hajime; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Nagai, Norihiro; Ozawa, Yoko] Keio Univ, Lab Retinal Cell Biol, Sch Med, Tokyo, Japan.
   [Ozawa, Yoko] St Lukes Int Hosp, Dept Ophthalmol, Tokyo, Japan.
   [Ozawa, Yoko] St Lukes Int Univ, Tokyo, Japan.
C3 Keio University; Keio University; St. Luke's International Hospital; St.
   Luke's International Hospital
RP Ozawa, Y (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.; Ozawa, Y (通讯作者)，Keio Univ, Lab Retinal Cell Biol, Sch Med, Tokyo, Japan.; Ozawa, Y (通讯作者)，St Lukes Int Hosp, Dept Ophthalmol, Tokyo, Japan.; Ozawa, Y (通讯作者)，St Lukes Int Univ, Tokyo, Japan.
EM ozawa@a5.keio.jp
RI Uchida, Atsuro/GVT-8593-2022; Shinojima, Ari/AAR-4442-2021
OI Shinojima, Ari/0000-0003-2322-0332
CR Chen HY, 2012, MOL VIS, V18, P816
   Cheung C.M.G., EYE
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cooper J, 2018, EYE CONTACT LENS, V44, P231, DOI 10.1097/ICL.0000000000000499
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Fan Qiao, 2017, J HUM GENET
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Gopinath T., 2019, SCI REP, V9, P1, DOI DOI 10.1038/s41598-018-37186-2
   Handy DE, 2011, CIRCULATION, V123, P2145, DOI 10.1161/CIRCULATIONAHA.110.956839
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Kishi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206646
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Mansour AM, 2019, BR J OPHTHALMOL
   McAfee PC, 2010, J SPINAL DISORD TECH, V23, P1, DOI 10.1097/BSD.0b013e31819e2ab8
   Michalewski J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/639160
   Morizane Y, 2019, JPN J OPHTHALMOL, V63, P26, DOI 10.1007/s10384-018-0623-4
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Stepanov A, 2018, CES SLOV OFTALMOL, V74, P3, DOI [10.31348/2018/1/1-1-2018, DOI 10.31348/2018/1/1-1-2018]
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Ulaganathan S, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107850
   Uyama M, 2000, OPHTHALMOLOGY, V107, P441, DOI 10.1016/S0161-6420(99)00141-4
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wallman J, 1995, NAT MED
   Wang P, 2016, SCI REP, V6, P1
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 29
TC 2
Z9 2
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2020
VL 15
IS 10
AR e0240357
DI 10.1371/journal.pone.0240357
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA OG3WA
UT WOS:000581817500002
PM 33035241
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Tao, Y
   Neumaier, M
   Findeisen, P
AF Jonas, Jost B.
   Tao, Yong
   Neumaier, Michael
   Findeisen, Peter
TI Cytokine concentration in aqueous humour of eyes with exudative
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE cytokines; epithelial growth factor; exudative age-related macular
   degeneration; intercellular adhesion molecule-1; monocyte
   chemoattractant protein-1
ID ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
   INTRAVITREAL TRIAMCINOLONE ACETONIDE; PROLIFERATIVE
   DIABETIC-RETINOPATHY; EPITHELIUM-DERIVED FACTOR; PIGMENT-EPITHELIUM;
   CHOROIDAL NEOVASCULARIZATION; BRUCHS MEMBRANE; EXPRESSION; BEVACIZUMAB
AB Purpose: To measure the concentration of cytokines in the aqueous humour of eyes with exudative age-related macular degeneration (AMD). Methods: The clinical interventional study included a study group of 18 patients with exudative AMD and a control group of 20 patients undergoing routine cataract surgery. Age did not vary significantly (p = 0.36) between study group (80.8 +/- 6.4 years) and control group (77.0 +/- 9.9 years), nor did gender (p = 0.75). During the interventions, aqueous humour samples were obtained, in which the concentration of cytokines was measured using a solid-phase chemiluminescence immunoassay. Macular thickness was measured by optical coherence tomography (OCT). Results: In the study group as compared to the control group, significantly higher concentrations were measured for epithelial growth factor (EGF) (p = 0.017), human growth factor (HGF) (p = 0.048), intercellular adhesion molecule-1 (ICAM1) (p = 0.028), interleukin 12p40 (IL12p40) (p = 0.009), interleukin 1a2 (IL1a2) (p = 0.01), interleukin 3 (IL3) (p = 0.02), interleukin 6 (IL6) (p = 0.006), interleukin 8 (IL8) (p = 0.02), monocyte chemoattractant protein-1 (MCP-1) (p = 0.048), monokine induced by interferon gamma (MIG) (p = 0.016), matrix metalloproteinase 9 (MMP9) (p = 0.004) and plasminogen activator inhibitor 1 (PAI1) (p = 0.006). Macular thickness was significantly associated with the concentrations of EGF (p = 0.001), HGF (p = 0.02), ICAM1 (p = 0.001), interleukin 12p40 (p = 0.006), IL 1a2 (p = 0.002), MIG (p = 0.001), MMP9 (p < 0.001) and PAI1 (p = 0.01). Interleukin 6 and MCP-1 showed significant associations with the height of retinal pigment epithelium detachment. Conclusions: Numerous cytokines are associated with the presence and the amount of exudative AMD.
C1 [Jonas, Jost B.] Univ Heidelberg, Univ Augenklin, Dept Ophthalmol, Med Fac Mannheim, D-68167 Mannheim, Germany.
   [Tao, Yong] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100871, Peoples R China.
   [Neumaier, Michael; Findeisen, Peter] Univ Heidelberg, Inst Clin Chem, Med Fac Mannheim, D-68167 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; Peking University; Ruprecht Karls
   University Heidelberg
RP Jonas, JB (通讯作者)，Univ Heidelberg, Univ Augenklin, Dept Ophthalmol, Med Fac Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@umm.de
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Cox OT, 2003, MOL VIS, V9, P665
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Funk M, 2010, RETINA-J RET VIT DIS, V30, P1412, DOI 10.1097/IAE.0b013e3181e095c0
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Funk M, 2009, INVEST OPHTH VIS SCI, V50, P1025, DOI 10.1167/iovs.08-2510
   Heidenkummer H.-P., 1995, Ophthalmologe, V92, P631
   Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P729, DOI 10.1001/archopht.121.5.729
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Jonas JB, 2007, CLIN EXP OPHTHALMOL, V35, P186, DOI 10.1111/j.1442-9071.2006.01437.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kamppeter BA, 2008, OPHTHALMOLOGY, V115, P1372, DOI 10.1016/j.ophtha.2008.01.019
   Katsura Y, 2005, DIABETES CARE, V28, P2252, DOI 10.2337/diacare.28.9.2252
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   King GL, 2000, NEW ENGL J MED, V342, P349, DOI 10.1056/NEJM200002033420511
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lau LI, 2010, INVEST OPHTH VIS SCI, V51, P5486, DOI 10.1167/iovs.10-5663
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2001
   Mullins RF, 2006, MOL VIS, V12, P224
   Nonobe NI, 2009, RETINA-J RET VIT DIS, V29, P579, DOI 10.1097/IAE.0b013e3181a3b848
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P3656, DOI 10.1167/iovs.02-1143
   Sato T, 2009, OPHTHALMOLOGY, V116, P1599, DOI 10.1016/j.ophtha.2008.12.023
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   VINORES SA, 1995, EXP EYE RES, V60, P607, DOI 10.1016/S0014-4835(05)80003-X
   Voskuil M, 2003, AM J PHYSIOL-HEART C, V284, pH1422, DOI 10.1152/ajpheart.00506.2002
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Wong TY, 2008, AM J OPHTHALMOL, V146, P656, DOI 10.1016/j.ajo.2008.07.048
   Yamada M, 2003, ARTERIOSCL THROM VAS, V23, P1996, DOI 10.1161/01.ATV.0000096208.80992.63
   Yokota T, 2003, DIABETES, V52, P838, DOI 10.2337/diabetes.52.3.838
NR 51
TC 110
Z9 113
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2012
VL 90
IS 5
BP e381
EP e388
DI 10.1111/j.1755-3768.2012.02414.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 980OV
UT WOS:000306903600008
PM 22490043
DA 2022-11-30
ER

PT J
AU Gonzalez, EG
   Tarita-Nistor, L
   Markowitz, SN
   Steinbach, MJ
AF Gonzalez, Esther G.
   Tarita-Nistor, Luminita
   Markowitz, Samuel N.
   Steinbach, Martin J.
TI Computer-based test to measure optimal visual acuity in age-related
   macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID REVERSED-CONTRAST CHARTS; PREFERRED RETINAL LOCI; CONTOUR INTERACTION;
   DESIGN PRINCIPLES; VISION; SUMMATION; FIXATION; IMPAIRMENT; LEGIBILITY;
   SELECTION
AB PURPOSE. The authors present a computer-based method for evaluating the visual acuity of patients with age-related macular degeneration (AMD). It incorporates four features known to improve visual acuity: high contrast, white optotypes on a black background to reduce intraocular scatter, proportional layout to reduce the effects of crowding, and multiple optotypes to minimize the effects of fixation instability and to maximize the likelihood of optotype detection.
   METHODS. Experiment 1 evaluated the best-eye acuity of 24 patients with AMD using the ETDRS chart and three versions of the Tumbling E acuity test: multiple black optotypes on a white background, single white optotype on a black background, and multiple white optotypes on a black background. Experiment 2 compared the two White E optotype tests with the ETDRS in patients with AMD, and Experiment 3 measured probability summation in persons with normal vision.
   RESULTS. Multiple white optotypes on a black background yielded the highest acuity estimates and the ETDRS the lowest. The Single E test yielded a lower estimate of acuity than the two Multiple E tests. The effect of polarity-white on black was better than black on white-was consistent with results found in persons with healthy retinas. For patients with AMD, acuity measured with the Multiple E test was independent of that measured with the ETDRS, but acuity measured with the Single E test decreased as acuity worsened. For the participants with normal vision, the differences between the Multiple and Single E tests were within the known limits of test-retest variability.
   CONCLUSIONS. The multiple-optotype, reversed-polarity test provides a measure of the optimal visual acuity of which a person is capable and, in this sense, may be a useful tool for assessing rehabilitation progress.
C1 Toronto Western Hosp, Vis Sci Res Program, Toronto, ON M5T 2S8, Canada.
   York Univ, Ctr Vis Res, Toronto, ON M3J 2R7, Canada.
   Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; York University - Canada; University of Toronto
RP Gonzalez, EG (通讯作者)，Toronto Western Hosp, Vis Sci Res Program, 399 Bathurst St,FP 6-212, Toronto, ON M5T 2S8, Canada.
EM gonzalez@yorku.ca
CR Altman A., 1952, Q REV OPHTHALMOL, V8, P4
   ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BARTLETT MS, 1949, BIOMETRICS, V5, P207, DOI 10.2307/3001936
   Betts LR, 2005, NEURON, V45, P361, DOI 10.1016/j.neuron.2004.12.041
   BLAKE R, 1973, PERCEPT PSYCHOPHYS, V14, P161, DOI 10.3758/BF03198631
   BLAKE R, 1981, PERCEPT PSYCHOPHYS, V30, P266, DOI 10.3758/BF03214282
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   CULHAM LE, 1993, CLIN VISION SCI, V8, P551
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Elliott DB, 2001, INVEST OPHTH VIS SCI, V42, P1945
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   FERRIS FL, 1993, AM J OPHTHALMOL, V116, P735
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7
   HARRIS MJ, 1985, OPHTHALMOLOGY, V92, P1550
   HEINEN SJ, 1992, VISION RES, V32, P365, DOI 10.1016/0042-6989(92)90145-9
   Horiguchi M, 2001, INVEST OPHTH VIS SCI, V42, P2765
   HOWARD I, 2002, BASIC MECH, V1, P83
   [ICO International Council of Ophthalmology Visual Functions Committee], 1988, ITALIAN J OPTH, VII, P1
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   LEVITT H, 1971, J ACOUST SOC AM, V49, P467, DOI 10.1121/1.1912375
   Liu L, 2002, OPTOMETRY VISION SCI, V79, P724, DOI 10.1097/00006324-200211000-00010
   Liu L, 2001, OPTOMETRY VISION SCI, V78, P50, DOI 10.1097/00006324-200101010-00014
   MAKEBEN M, 1999, VISION REHABILITATIO, P158
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pardhan S, 1997, NEURO-OPHTHALMOLOGY, V18, P59, DOI 10.3109/01658109709044118
   Pardhan S, 1996, CURR EYE RES, V15, P315, DOI 10.3109/02713689609007626
   Pelli DG, 2004, J VISION, V4, P1136, DOI 10.1167/4.12.12
   Pirenne MH, 1943, NATURE, V152, P698, DOI 10.1038/152698a0
   REGAN D, 1992, OPHTHAL PHYSL OPT, V12, P425, DOI 10.1016/0275-5408(92)90171-R
   Reich LN, 2000, OPTOMETRY VISION SCI, V77, P270, DOI 10.1097/00006324-200005000-00014
   Reich LN, 2002, OPTOMETRY VISION SCI, V79, P389, DOI 10.1097/00006324-200206000-00013
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Sceniak MP, 1999, NAT NEUROSCI, V2, P733, DOI 10.1038/11197
   Schneck ME, 2004, VISION RES, V44, P2317, DOI 10.1016/j.visres.2004.04.018
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   SCHUCHARD RA, 1992, CLIN VISION SCI, V7, P511
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tarita-Nistor L, 2006, VISION RES, V46, P2487, DOI 10.1016/j.visres.2006.01.035
   TAYLOR HR, 1978, AM J OPTOM PHYS OPT, V55, P348
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   TREUTWEIN B, 1995, VISION RES, V35, P2503, DOI 10.1016/0042-6989(95)00016-X
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Wang YZ, 2001, OPTOMETRY VISION SCI, V78, P447, DOI 10.1097/00006324-200106000-00019
   Westheimer G, 2003, OPTOMETRY VISION SCI, V80, P749, DOI 10.1097/00006324-200311000-00011
   Westheimer G, 2003, OPTOMETRY VISION SCI, V80, P745, DOI 10.1097/00006324-200311000-00010
   Wittich W, 2006, INVEST OPHTH VIS SCI, V47, P3690, DOI 10.1167/iovs.05-1307
   WOLFORD G, 1984, PERCEPT PSYCHOPHYS, V36, P457, DOI 10.3758/BF03207498
   Wood JM, 1996, OPHTHAL PHYSL OPT, V16, P507
NR 57
TC 21
Z9 21
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2007
VL 48
IS 10
BP 4838
EP 4845
DI 10.1167/iovs.06-1240
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214SE
UT WOS:000249757600058
PM 17898311
DA 2022-11-30
ER

PT J
AU Hogg, R
   Curry, E
   Muldrew, A
   Winder, J
   Stevenson, M
   McClure, M
   Chakravarthy, U
AF Hogg, R
   Curry, E
   Muldrew, A
   Winder, J
   Stevenson, M
   McClure, M
   Chakravarthy, U
TI Identification of lesion components that influence visual function in
   age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY
AB Aims: To explore the relation between lesion composition as assessed by fundus photography and fluorescein angiography with clinical measures of vision in eyes of patients with age related macular degeneration (AMD).
   Methods: A standardised visual function assessment along with colour stereo pair fundus photography was carried out in both eyes of 58 subjects with a confirmed clinical diagnosis of AMD. The size, location, and composition of the macular lesion (blood, exudate, subretinal fluid, pigment, membrane, atrophy, and fibrosis) were measured on the colour photographs using computer assisted image analysis. Of the 58 subjects, 44 also had concurrent fluorescein angiography. Classic and occult choroidal neovascularisation (CNV), blood, blocked fluorescence, fibrosis, geographic atrophy, and the total area of abnormal fluorescence were measured. Multiple linear regression was used to examine the relation between clinical measures of vision and the location and extent of lesion components identified by both colour and fluorescein image capture.
   Results: The composition of the macular lesion strongly influenced visual function, with atrophy (p=0.001) and fibrosis (p=0.002) accounting for most of the variation. When the location of the lesion with respect to the fovea was examined, fibrosis within the fovea significantly influenced all clinical measures of vision (p=0.008). The regression model selected the total area of abnormal fluorescence and a composite parameter (a semiquantitative measure of the following characteristics: atrophy, exudates, blood, and fibrosis) from colour photography (r(2)=0.52) as the variables that explained most of the variation in clinical measures of vision.
   Conclusions: The composition and extent of the macular lesion strongly influences visual function in eyes with AMD. Both colour photography and angiography yielded information, which together explained considerably more of the variation in the clinical measures of vision than either on its own.
C1 Queens Univ Belfast, Belfast BT12 6BA, Antrim, North Ireland.
   Univ Ulster, Coleraine BT52 1SA, Londonderry, North Ireland.
   Royal Grp Hosp, Belfast, Antrim, North Ireland.
C3 Queens University Belfast; Ulster University
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Belfast BT12 6BA, Antrim, North Ireland.
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Chakravarthy,
   Usha/0000-0002-2606-3734
CR BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378
   BERGINK GJ, 1998, RADIOTHERAPY SUBFOVE, P12
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
NR 16
TC 42
Z9 42
U1 0
U2 3
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2003
VL 87
IS 5
BP 609
EP 614
DI 10.1136/bjo.87.5.609
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 671MT
UT WOS:000182469100024
PM 12714405
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Cinici, E
   Caglar, O
   Arslan, ME
   Dilekmen, N
   Utlu, B
   Mardinoglu, A
   Turkez, H
AF Cinici, Emine
   Caglar, Ozge
   Arslan, Mehmet Enes
   Dilekmen, Nilay
   Utlu, Bahadir
   Mardinoglu, Adil
   Turkez, Hasan
TI Targeted Gene Candidates for Treatment and Early Diagnosis of
   Age-Related Macular Degeneration
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
AB Age-related macular degeneration (AMD) is an eye disease that impairs the sharp and central vision need for daily activities. Recent advances in molecular biology research not only lead to a better understanding of the genetics and pathophysiology of AMD but also to the development of applications based on targeted gene expressions to treat the disease. Clarification of molecular pathways that causing to development and progression in dry and wet types of AMD needs comprehensive and comparative investigations in particular precious biopsies involving peripheral blood samples from the patients. Therefore, in this investigation, dry and wet types of AMD patients and healthy individuals were aimed at investigating in regard to targeted gene candidates by using gene expression analysis for the first time. 13 most potent candidate genes involved in neurodegeneration were selected via in silico approach and investigated through gene expression analysis to suggest new targets for disease therapy. For the analyses, 30 individuals (10 dry and 10 wet types AMD patients and 10 healthy people) were involved in the study. SYBR-Green based Real-Time PCR analysis was performed on isolated peripheral blood mononuclear cells (PBMCs) to analyze differentially expressed genes related to these cases. According to the investigations, only the CRP gene was found to be upregulated for both dry and wet disease types. When the downregulated genes were analyzed, it was found that 11 genes were commonly decreased for both dry and wet types in the aspect of expression pattern. From these genes, CFH, CX3CR1, FLT1, and TIMP3 were found to have the most downregulated gene expression properties for both diseases. From these results, it might be concluded that these common upregulated and downregulated genes could be used as targets for early diagnosis and treatment for AMD.
C1 [Cinici, Emine] Ataturk Univ, Dept Ophthalmol, Fac Med, Erzurum, Turkey.
   [Caglar, Ozge; Arslan, Mehmet Enes] Erzurum Tech Univ, Dept Mol Biol & Genet, Fac Sci, Erzurum, Turkey.
   [Dilekmen, Nilay] Palandoken State Hosp, Dept Ophthalmol, TR-25100 Erzurum, Turkey.
   [Utlu, Bahadir] Hlth Sci Univ, Ophthalmol Reg Training & Res Hosp, Erzurum, Turkey.
   [Mardinoglu, Adil] KTH Royal Inst Technol, Sci Life Lab, SE-17121 Stockholm, Sweden.
   [Mardinoglu, Adil] Kings Coll London, Ctr Host Microbiome Interact, Fac Dent Oral & Craniofacial Sci, London SE1 9RT, England.
   [Turkez, Hasan] Ataturk Univ, Dept Med Biol, Fac Med, Erzurum, Turkey.
C3 Ataturk University; Erzurum Technical University; Palandoken State
   Hospital; University of Health Sciences Turkey; Royal Institute of
   Technology; University of London; King's College London; Ataturk
   University
RP Mardinoglu, A (通讯作者)，KTH Royal Inst Technol, Sci Life Lab, SE-17121 Stockholm, Sweden.; Mardinoglu, A (通讯作者)，Kings Coll London, Ctr Host Microbiome Interact, Fac Dent Oral & Craniofacial Sci, London SE1 9RT, England.
EM emine.cinici@atauni.edu.tr; ozge.caglar@erzurum.edu.tr;
   enes.aslan@erzurum.edu.tr; nilaydilekmen@yahoo.com;
   bahadirutlu@gmail.com; adilm@scilifelab.se; hasanturkez@yahoo.com
RI ARSLAN, MEHMET ENES/O-5498-2019; ARSLAN, MEHMET ENES/I-5823-2014; Çağlar
   Yıldırım, Özge/AAY-9490-2021; Mardinoglu, Adil/AAS-6360-2021
OI ARSLAN, MEHMET ENES/0000-0002-1600-2305; ARSLAN, MEHMET
   ENES/0000-0002-1600-2305; Çağlar Yıldırım, Özge/0000-0003-1412-8411;
   UTLU, BAHADIR/0000-0002-7129-2181; Mardinoglu, Adil/0000-0002-4254-6090
CR Afarid M, 2015, INT J OPHTHALMOL-CHI, V8, P991, DOI 10.3980/j.issn.2222-3959.2015.05.25
   Akkoyun I, 2014, TURK OFTALMOL DERG, V44, P476, DOI 10.4274/tjo.80008
   Altmuller J, 2001, AM J HUM GENET, V69, P936, DOI 10.1086/324069
   Amisten S, 2008, THROMB RES, V122, P47, DOI 10.1016/j.thromres.2007.08.014
   Andersson MK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-249
   Araya AV, 2008, ENDOCRINE, V33, P300, DOI 10.1007/s12020-008-9090-x
   Auer-Grumbach M, 2011, BRAIN, V134, P1839, DOI 10.1093/brain/awr076
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Cai H, 2006, ARCH OPHTHALMOL-CHIC, V124, P1276, DOI 10.1001/archopht.124.9.1276
   Calabro P, 2003, CIRCULATION, V108, P1930, DOI 10.1161/01.CIR.0000096055.62724.C5
   Chen D, 2020, AGING CELL, V19, DOI 10.1111/acel.13100
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Dagkalis A, 2009, IMMUNOLOGY, V128, P25, DOI 10.1111/j.1365-2567.2009.03046.x
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08
   Haab O., 1900, OPHTHALMOLOGICA, V3, P113, DOI [10.1159/000278125, DOI 10.1159/000278125]
   He SC, 2020, J AFFECT DISORDERS, V266, P671, DOI 10.1016/j.jad.2020.01.181
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang LP, 2018, MOL MED REP, V17, P1499, DOI 10.3892/mmr.2017.8021
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liutkeviciene R, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/9602949
   Lu PR, 2009, CORNEA, V28, P562, DOI 10.1097/ICO.0b013e3181930bcd
   Luthert Philip J, 2020, Netw Syst Med, V3, P105, DOI 10.1089/nsm.2020.0005
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Mechoulam H, 2005, INVEST OPHTH VIS SCI, V46, P4409, DOI 10.1167/iovs.05-0632
   Newton-Cheh C, 2005, MUTAT RES-FUND MOL M, V573, P54, DOI 10.1016/j.mrfmmm.2005.01.006
   Nielsen MK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.28
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Niki T, 2000, CLIN CANCER RES, V6, P2431
   Qiu H, 2007, BIOTECHNIQUES, V42, P355, DOI 10.2144/000112331
   Robertson DM, 2007, EXP EYE RES, V85, P492, DOI 10.1016/j.exer.2007.06.015
   Saruta J, 2012, ACTA HISTOCHEM CYTOC, V45, P211, DOI 10.1267/ahc.12005
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sharma K, 2017, J CELL BIOCHEM, V118, P2087, DOI 10.1002/jcb.25837
   Strunz T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102267
   Subhi Y, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0160-0
   Sun YW, 2020, SAUDI J BIOL SCI, V27, P2770, DOI 10.1016/j.sjbs.2020.06.037
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tekin MI, 2018, INVEST OPHTH VIS SCI, V59, P2833, DOI 10.1167/iovs.18-24030
   Telegina DV, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0493-8
   Turgut B., 2010, RETINA VITREUS, V18
   Uehara H, 2015, AM J OPHTHALMOL, V159, P92, DOI 10.1016/j.ajo.2014.09.036
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo THS, 1999, J MICROBIOL METH, V35, P23, DOI 10.1016/S0167-7012(98)00095-5
   Xu ZX, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015083
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhang SY, 2015, FREE RADICAL BIO MED, V85, P33, DOI 10.1016/j.freeradbiomed.2015.04.012
NR 62
TC 1
Z9 1
U1 1
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD FEB 2
PY 2021
VL 2021
AR 6620900
DI 10.1155/2021/6620900
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA QK1PS
UT WOS:000620153700004
PM 33604378
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Finger, R
   Hoffmann, AE
   Fenwick, EK
   Wolf, A
   Kampik, A
   Kernt, M
   Neubauer, AS
   Hirneiss, C
AF Finger, Robert
   Hoffmann, Andrea E.
   Fenwick, Eva K.
   Wolf, Armin
   Kampik, Anselm
   Kernt, Marcus
   Neubauer, Aljoscha S.
   Hirneiss, Christoph
TI Patients' preferences in treatment for neovascular age-related macular
   degeneration in clinical routine
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISION-RELATED FUNCTION; RANIBIZUMAB TREATMENT;
   SURGERY; UTILITY; ANCHOR; TRIAL
AB Purpose To assess the effect of ranibizumab treatment for neovascular age-related macular degeneration (nvAMD) on patients' preferences and vision-related quality of life (VRQoL) in a routine clinical setting. Methods 55 treatment naive patients were examined before and after the initial upload of three monthly injections of 0.5 mg ranibizumab. VRQoL was assessed using a Rasch-adjusted NEI-VFQ-25. Time trade-off (TTO), standard gamble, a visual analogue scale and the European Quality of Life Questionnaire (EQ-5D) were used to calculate utilities, and multiple logistic regression models were conducted to determine independent factors associated with utilities. Results Mean +/- SD age was 7567 years, and 40 patients (73%) were female. Mean +/- SD best-corrected visual acuity of the treated eye increased from 20/80 at baseline (logMAR 0.60 +/- 0.35) to 20/63 (logMAR 0.52 +/- 0.36; p=0.020) at follow-up after three injections. Utility score increases ranged from 2 utils (standard gamble anchored for death) up to 6.6 utils (EQ-5D German TTO, p=0.023) and visual functioning improved (Rasch adjusted composite NEI-VFQ score 50 +/- 21 to 54 +/- 21, p=0.042). Whether the worse or better eye was treated was not significantly associated with improvements in utility or VRQoL, whereas VA improvement in the treated eye was associated with an increase in utility (TTO, p=0.020). Conclusions TTO performed best in this sample of elderly nvAMD patients undergoing anti-VEGF therapy. Better or worse eye treatment was not associated with a change in reported utilities or visual functioning in patients with newly diagnosed nvAMD. Directly elicited, vision-specific utilities gained with TTO seem to be sensitive to a change in vision status.
C1 [Hoffmann, Andrea E.; Wolf, Armin; Kampik, Anselm; Kernt, Marcus; Neubauer, Aljoscha S.; Hirneiss, Christoph] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
   [Finger, Robert; Fenwick, Eva K.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Finger, Robert] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
C3 University of Munich; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne; University of Bonn
RP Hirneiss, C (通讯作者)，Univ Munich, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
EM christoph.hirneiss@med.uni-muenchen.de
OI Finger, Robert P/0000-0003-4253-7597
FU Novartis Pharma Germany; German Research Council [DFG FI 1540/5-1]
FX This work was supported by Novartis Pharma Germany (grant to CH) and the
   German Research Council (DFG FI 1540/5-1, grant to RF). CERA receives
   Operational Infrastructure Support from the Victorian government.
CR [Anonymous], 1990, HLTH POL, V16, P199
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Drummond MF, 2005, METHODS EC EVALUATIO
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P3613, DOI 10.1167/iovs.10-7127
   Hirneiss C, 2006, OPHTHALMOLOGE, V103, P109, DOI 10.1007/s00347-005-1252-0
   Hirneiss C, 2007, BRIT J OPHTHALMOL, V91, P481, DOI 10.1136/bjo.2006.102376
   KATZ JN, 1994, MED CARE, V32, P183, DOI 10.1097/00005650-199402000-00009
   Lee BS, 2008, OPHTHALMOLOGY, V115, P898, DOI 10.1016/j.ophtha.2007.06.008
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
NR 13
TC 21
Z9 21
U1 0
U2 9
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2012
VL 96
IS 7
BP 997
EP 1002
DI 10.1136/bjophthalmol-2011-301201
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 962WQ
UT WOS:000305579000016
PM 22535331
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Schmidt, S
   Haines, JL
   Postel, EA
   Agarwal, A
   Kwan, SY
   Gilbert, JR
   Pericak-Vance, MA
   Scott, WK
AF Schmidt, S
   Haines, JL
   Postel, EA
   Agarwal, A
   Kwan, SY
   Gilbert, JR
   Pericak-Vance, MA
   Scott, WK
TI Joint effects of smoking history and APOE genotypes in age-related
   macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; APOLIPOPROTEIN-E GENE; NITRIC-OXIDE PRODUCTION;
   CIGARETTE-SMOKING; EPSILON-4 ALLELE; BRUCHS MEMBRANE; E POLYMORPHISMS;
   DEFICIENT MICE; GRADING SYSTEM; RISK
AB Purpose: Age-related macular degeneration (AMD) is a leading cause of severe visual impairment in older adults worldwide. Cigarette smoking is one of the most consistently identified environmental risk factors for the disease. Several studies have implicated the apolipoprotein E (APOE) gene as modulating AMD risk. The purpose of this study was to investigate whether APOE genotypes modify the smoking-associated risk of AMD.
   Methods: Patients with early- and late-stage AMD (n=377) and a group of unrelated ethnically matched controls of similar age (n=198) were ascertained at two sites in the southeastern United States. Smoking history and APOE genotype distribution in cases and controls were compared by multivariable logistic regression.
   Results: All measures of smoking history showed a highly significant association with AMD, and odds ratio estimates were consistently higher when only patients with exudative AMD were compared to controls. Main effects of APOE genotypes in the overall analysis did not reach statistical significance. The analysis of exudative AMD patients suggested that the risk increase due to smoking was greatest in carriers of the APOE-2 allele, with genotype-specific odds ratios increasing from 1.9 for APOE-4 carriers (p=0.11) to 2.2 for APOE-3/3 homozygotes (p=0.007) to 4.6 (p=0.001) for APOE-2 carriers, compared to nonsmoking APOE-3/3 individuals. Measures of statistical interaction indicated more than additive, and possibly more than multiplicative, joint effects of APOE and smoking history, however, the interaction was not statistically significant on either scale.
   Conclusions: We hypothesize that a history of smoking is a stronger risk factor for exudative AMD in carriers of the APOE-2 allele, compared to carriers of APOE-4 and the most common APOE-3/3 genotype. To further clarify the association of AMD with APOE and smoking history, future studies should consider both factors simultaneously.
C1 Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC 27710 USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Nashville, TN USA.
C3 Duke University; Duke University; Vanderbilt University; Vanderbilt
   University
RP Schmidt, S (通讯作者)，Duke Univ, Med Ctr, Ctr Human Genet, Box 3445, Durham, NC 27710 USA.
EM silke.schmidt@duke.edu
RI Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NEI NIH HHS [U10EY012118, R03EY015216] Funding Source: Medline; NIA NIH
   HHS [P60AG011268] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R03EY015216, U10EY012118] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [P60AG011268] Funding Source: NIH RePORTER
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLOCK G, 1994, AM J EPIDEMIOL, V139, P1190, DOI 10.1093/oxfordjournals.aje.a116965
   Brown CM, 2002, FREE RADICAL BIO MED, V32, P1071, DOI 10.1016/S0891-5849(02)00803-1
   Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015
   Colton CA, 2002, ANN NY ACAD SCI, V962, P212, DOI 10.1111/j.1749-6632.2002.tb04070.x
   Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAYES C, 1995, AM J HUM GENET S, V57, P193
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   LU Q, 2004, ARVO ANN M APR 25 29
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Ota Y, 1997, ATHEROSCLEROSIS, V131, P195, DOI 10.1016/S0021-9150(97)06106-6
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Pezzini A, 2004, STROKE, V35, P438, DOI 10.1161/01.STR.0000112973.00867.98
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Schmidt S, 2000, MOL VIS, V6, P287
   SCHMIDT S, 2004, ARVO ANN M APR 25 29
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Skrondal A, 2003, AM J EPIDEMIOL, V158, P251, DOI 10.1093/aje/kwg113
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   vanLeeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P955
   WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250
   Wink DA, 2001, ANTIOXID REDOX SIGN, V3, P203, DOI 10.1089/152308601300185179
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 55
TC 36
Z9 38
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 4
PY 2005
VL 11
IS 113-15
BP 941
EP 949
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 984AU
UT WOS:000233275700001
PM 16288198
DA 2022-11-30
ER

PT J
AU Zhao, TT
   Wang, WF
   Gao, K
   Li, SM
   Jiang, Y
   Yang, ZF
   Liu, JN
   Wang, YL
   Peng, SM
AF Zhao, Tingting
   Wang, Wenfei
   Gao, Kun
   Li, Siming
   Jiang, Ye
   Yang, Zhifeng
   Liu, Jiannan
   Wang, Yanli
   Peng, Shaomin
TI Fibroblast growth factor-21 alleviates phenotypic characteristics of dry
   age-related macular degeneration in mice
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE FGF-21; Dry AMD; Complement; NF-kappa B pathway
ID COMPLEMENT FACTOR-H; EXPRESSION; PATHOGENESIS; BIOMARKERS; PATHWAY
AB Age-related macular degeneration (AMD) is the main cause of blindness in elderly individuals. As a metabolic regulator, fibroblast growth factor 21 (FGF-21) has been proven indicated to have an effect on wet AMD, but whether this cytokine has a therapeutic effect on dry AMD is unclear. The current study aimed to evaluate the preventive effects of FGF-21 against retinal degeneration in mice and provide mechanistic insights. FGF-21 -/- mice were raised to 10 months of age. Then, the morphological changes in the retinal pigment epithelium (RPE)/ choroid of the mice were observed by transmission electron microscopy (TEM), and iTRAQ was used to detect the variations in the protein profile. Next, FGF-21 -/- and wild-type mice of the same age were fed hydroquinone to generate a dry AMD mouse model to examine whether exogenous FGF-21 can interfere with the occurrence and development of dry AMD. In vivo studies revealed that following FGF-21 knockout, there was an increase in the expression of complement in the RPE/chomid concomitant with the occurrence of dry AMD-like pathological changes. Furthermore, exogenous FGF-21 administration effectively reversed this phenomenon. FGF-21 also demonstrated strong anti-inflammatory effects in the RPE/choroid by inhibiting the NF-kappa B pathway. In conclusion, the present study demonstrates that FGF-21 treatment presents a novel therapeutic approach for the prevention and development of dry AMD by reducing complement.
C1 [Zhao, Tingting; Liu, Jiannan; Peng, Shaomin] Cent South Univ, Aier Sch Ophthalmol, Changsha 410015, Peoples R China.
   [Wang, Wenfei; Gao, Kun; Jiang, Ye; Yang, Zhifeng; Wang, Yanli] Northeast Agr Univ, Sch Life Sci, Harbin 150030, Peoples R China.
   [Zhao, Tingting; Liu, Jiannan; Peng, Shaomin] Harbin Aier Eye Hosp, Harbin 150016, Peoples R China.
   [Peng, Shaomin] Aier Retina Inst, Changsha 410015, Peoples R China.
   [Li, Siming] Harbin Univ Commerce, Harbin 150076, Peoples R China.
C3 Central South University; Northeast Agricultural University - China;
   Harbin University of Commerce
RP Peng, SM (通讯作者)，Cent South Univ, Aier Sch Ophthalmol, Changsha 410015, Peoples R China.
EM tingtingzhaoeye@126.com; wangwenfei@neau.edu.cn; gk010610@163.com;
   1456382154@qq.com; yeri1025@163.com; 40942724@qq.com; lomicheal@126.com;
   wyl9951234@163.com; pengshaomin@aierchina.com
OI Zhao, Tingting/0000-0002-2762-3561
FU National Natural Science Foundation of China [81570867, 81903737];
   Clinical medical technology innovation guidance project in Hunan
   Province, China [2018SK50101, 2020SKC2001]; Science Research Foundation
   of Aier Eye Hospital Group. China [AF1901D1, AM1901D1]; Fundamental
   Research Funds for the Central Universities of Central South University
FX This work was supported by grants from the from National Natural Science
   Foundation of China (81570867; 81903737); Clinical medical technology
   innovation guidance project in Hunan Province. China (2018SK50101,
   2020SKC2001); Science Research Foundation of Aier Eye Hospital Group.
   China (AF1901D1, AM1901D1), Fundamental Research Funds for the Central
   Universities of Central South University.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Cheng SC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122957
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Feng TT, 2015, INT J CLIN EXP PATHO, V8, P9126
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fu ZJ, 2018, DIABETES, V67, P974, DOI 10.2337/db17-0830
   Fu ZJ, 2017, CELL REP, V18, P1606, DOI 10.1016/j.celrep.2017.01.014
   Geng LL, 2020, NAT REV ENDOCRINOL, V16, P654, DOI 10.1038/s41574-020-0386-0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1
   Kam JH, 2016, EXP EYE RES, V149, P116, DOI 10.1016/j.exer.2016.07.002
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lee JH, 2016, AM J TRANSL RES, V8, P4750
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Sprague AH, 2009, BIOCHEM PHARMACOL, V78, P539, DOI 10.1016/j.bcp.2009.04.029
   Tomita Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041188
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Wang N, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.002
   Wang WF, 2015, ENDOCRINE, V49, P119, DOI 10.1007/s12020-014-0433-5
   Wei W, 2019, ATHEROSCLEROSIS, V289, P132, DOI 10.1016/j.atherosclerosis.2019.08.017
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Youm YH, 2016, P NATL ACAD SCI USA, V113, P1026, DOI 10.1073/pnas.1514511113
   Yu Yin-hang, 2014, Yaoxue Xuebao, V49, P1000
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhang YM, 2018, MOL MED REP, V17, P1453, DOI 10.3892/mmr.2017.8100
   Zhang Y, 2012, ELIFE, V1, DOI 10.7554/eLife.00065
NR 37
TC 1
Z9 1
U1 2
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2022
VL 218
AR 109014
DI 10.1016/j.exer.2022.109014
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2Q3VK
UT WOS:000820354200003
PM 35245515
DA 2022-11-30
ER

PT J
AU Diack, C
   Schwab, D
   Cosson, V
   Buchheit, V
   Mazer, N
   Frey, N
AF Diack, Cheikh
   Schwab, Dietmar
   Cosson, Valerie
   Buchheit, Vincent
   Mazer, Norman
   Frey, Nicolas
TI A Baseline Score to Predict Response to Ranibizumab Treatment in
   Neovascular Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE BCVA; anti-VEGF; ranibizumab; meta-marker
ID VISION; DRUG
AB Purpose: What are the patient characteristics predictive of response to ranibizumab treatment?
   Methods: Model-based characterization of best-corrected visual acuity (BCVA) time profiles of patients with neovascular age-related macular degeneration under ranibizumab or sham treatment based on 24-month observations of BCVA in 2419 patients from randomized multicenter phase 3 trials of ranibizumab: ANCHOR, MARINA, PIER, and HARBOR. Goodness-of-fit plots and precision of parameter estimates were used for measure of accuracy.
   Results: The model incorporates a long-term effect on disease progression and an additive and more potent short-term effect of ranibizumab. Response to ranibizumab treatment and progression of the disease were found to be a function of seven baseline characteristics (visual acuity, age, leakage size, central retinal lesion thickness, presence or absence of cyst, type of choroidal neovascularization (CNV), and size of pigment epithelium detachment). A composite score of these seven baseline characteristics was derived and used to categorize response to ranibizumab treatment. The ranibizumab treatment arms of two proof-of-concept studies held out from the model development were used to validate the methodology.
   Conclusions: A composite score based on seven patient characteristics prior to treatment could be used to discriminate patients with predicted insufficient response to anti- vascular endothelial growth factor treatment.
   Translational Relevance: The method could be used to create a virtual ranibizumab treatment arm in clinical trials or to reduce the size of a ranibizumab active control arm.
C1 [Diack, Cheikh; Schwab, Dietmar; Cosson, Valerie; Buchheit, Vincent; Mazer, Norman; Frey, Nicolas] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Clin Pharmacol, Roche Innovat Ctr Basel,Pharmaceut Sci, Basel, Switzerland.
C3 Roche Holding
RP Diack, C (通讯作者)，F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Bldg 001-07,124 Grenzachestr, CH-4070 Basel, Switzerland.
EM cheikh.diack@roche.com
CR Adamis AP, 2020, EYE, V34, P1966, DOI 10.1038/s41433-020-0895-z
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burzykowski T, 2011, PHARM STAT, V10, P115, DOI 10.1002/pst.419
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Gonzalez-Buendia L, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0544-x
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Jacqmin P, 2007, J PHARMACOKINET PHAR, V34, P57, DOI 10.1007/s10928-006-9035-z
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Mulyukov Z, 2018, CPT-PHARMACOMET SYST, V7, P660, DOI 10.1002/psp4.12322
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Sheiner L, 1998, NONMEM USERS GUIDES
   Shirinifard A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002440
NR 18
TC 4
Z9 4
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2021
VL 10
IS 6
AR 11
DI 10.1167/tvst.10.6.11
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL4VP
UT WOS:000656917500015
PM 34111259
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU von der Emde, L
   Thiele, S
   Pfau, M
   Nadal, J
   Meyer, J
   Moller, PT
   Schmid, M
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF von der Emde, Leon
   Thiele, Sarah
   Pfau, Maximilian
   Nadal, Jennifer
   Meyer, Johanna
   Moeller, Philipp T.
   Schmid, Matthias
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Assessment of Exudative Activity of Choroidal Neovascularization in
   Age-Related Macular Degeneration by OCT Angiography
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Clinical
   research in AMD; OCT angiography; Quiescent choroidal
   neovascularizations; OCTA biomarkers; Anti-VEGF
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; GROWTH-FACTOR THERAPY; TYPE-2
   NEOVASCULARIZATION; QUANTITATIVE-ANALYSIS; RANIBIZUMAB; SECONDARY
AB Purpose: Based on exudative activity, choroidal neovascularization (CNV) in age-related macular degeneration (AMD) can be classified as "active" aCNV, pretherapied "silent" sCNV (i.e., a treatment-free interval >12 weeks), or treatment-naive "quiescent" qCNV. We evaluated the qualitative and quantitative optical coherence tomography angiography (OCTA) features of these CNV subgroups. Methods: The presence of small-caliber vessels, peripheral arcades, and a perilesional OCTA signal attenuation as well as values for vessel length, density, and branching index were evaluated for each CNV network in a 6 x 6 mm OCTA scan pattern. Results: Fifty-one eyes of 51 patients with AMD (age 75.9 +/- 7.5 years; 20 males [39.2%]) were included. The qCNV subgroup (n = 8) showed the highest prevalence of qualitative and quantitative values for OCTA activity criteria, reaching significance with regard to small-caliber vessels (p = 0.003), peripheral arcades (p = 0.039), vessel length (p = 0.020), and branching index (p < 0.001) when compared to the aCNV (n = 32) and sCNV (n = 11) subgroups. Qualitative criteria were inversely associated with the number of previous anti-VEGF injections (each p < 0.03), while quantitative metrics also suggested lower values. Conclusions: These findings suggest that OCTA may be supportive in the phenotypical differentiation of CNV lesions secondary to AMD, while the assessed structural changes appeared to be more indicative of previously administered anti-VEGF therapy than current exudative activity.
C1 [von der Emde, Leon; Thiele, Sarah; Pfau, Maximilian; Meyer, Johanna; Moeller, Philipp T.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
   [Thiele, Sarah; Pfau, Maximilian; Moeller, Philipp T.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, GRADE Reading Ctr, Bonn, Germany.
   [Nadal, Jennifer; Schmid, Matthias] Univ Hosp Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
C3 University of Bonn; University of Bonn; University of Bonn; Utah System
   of Higher Education; University of Utah
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukbonn.de
OI Schmid, Matthias/0000-0002-0788-0317; Meyer, Johanna/0000-0002-2092-6842
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Faatz H, 2017, KLIN MONATSBL AUGENH, V234, P1125, DOI 10.1055/s-0043-118346
   Fang PP, 2016, OPHTHALMOLOGE, V113, P6, DOI 10.1007/s00347-015-0184-6
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2016, INVEST OPHTH VIS SCI, V57, P6342, DOI 10.1167/iovs.16-19741
   Lupidi M, 2018, EUR J OPHTHALMOL, V28, P349, DOI 10.1177/1120672118766807
   Meyer JH, 2019, EXP EYE RES, V184, P162, DOI 10.1016/j.exer.2019.04.002
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Team RC, 2013, R LANG ENV STAT COMP
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   von der Emde L, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.7
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 32
TC 10
Z9 10
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAR
PY 2020
VL 243
IS 2
BP 120
EP 128
DI 10.1159/000503609
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LE6EW
UT WOS:000526817700006
PM 31665719
DA 2022-11-30
ER

PT J
AU Leveillard, T
   Philp, NJ
   Sennlaub, F
AF Leveillard, Thierry
   Philp, Nancy J.
   Sennlaub, Florian
TI Is Retinal Metabolic Dysfunction at the Center of the Pathogenesis of
   Age-related Macular Degeneration?
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE cone photoreceptor; inflammatory macrophage; aerobic glycolysis; lactate
   transporter; retinal degeneration; rod-derived cone viability factor
ID MEDIATED DARK-ADAPTATION; COMPLEMENT FACTOR-H; ANGIOMATOUS
   PROLIFERATION; SUCCINATE-DEHYDROGENASE; SUBRETINAL INFLAMMATION; CONE
   PHOTORECEPTORS; GEOGRAPHIC ATROPHY; CANCER METABOLISM; APOPTOTIC CELLS;
   PLASMA-MEMBRANE
AB The retinal pigment epithelium (RPE) forms the outer blood-retina barrier and facilitates the transepithelial transport of glucose into the outer retina via GLUT1. Glucose is metabolized in photoreceptors via the tricarboxylic acid cycle (TCA) and oxidative phosphorylation (OXPHOS) but also by aerobic glycolysis to generate glycerol for the synthesis of phospholipids for the renewal of their outer segments. Aerobic glycolysis in the photoreceptors also leads to a high rate of production of lactate which is transported out of the subretinal space to the choroidal circulation by the RPE. Lactate taken up by the RPE is converted to pyruvate and metabolized via OXPHOS. Excess lactate in the RPE is transported across the basolateral membrane to the choroid. The uptake of glucose by cone photoreceptor cells is enhanced by rod-derived cone viability factor (RdCVF) secreted by rods and by insulin signaling. Together, the three cells act as symbiotes: the RPE supplies the glucose from the choroidal circulation to the photoreceptors, the rods help the cones, and both produce lactate to feed the RPE. In age-related macular degeneration this delicate menage a trois is disturbed by the chronic infiltration of inflammatory macrophages. These immune cells also rely on aerobic glycolysis and compete for glucose and produce lactate. We here review the glucose metabolism in the homeostasis of the outer retina and in macrophages and hypothesize what happens when the metabolism of photoreceptors and the RPE is disturbed by chronic inflammation.
C1 [Leveillard, Thierry] Sorbonne Univ, Dept Genet, INSERM, CNRS,Inst Vis, 17 Rue Moreau, F-75012 Paris, France.
   [Philp, Nancy J.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.
   [Sennlaub, Florian] Sorbonne Univ, Dept Therapeut, INSERM, CNRS,Inst Vis, 17 Rue Moreau, F-75012 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Jefferson
   University; Centre National de la Recherche Scientifique (CNRS);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite
RP Leveillard, T (通讯作者)，Sorbonne Univ, Dept Genet, INSERM, CNRS,Inst Vis, 17 Rue Moreau, F-75012 Paris, France.
EM thierry.leveillard@inserm.fr; Nancy.Philp@jefferson.edu;
   florian.sennlaub@inserm.fr
RI Léveillard, Thierry/AAR-1804-2020; Sennlaub, Florian/F-2756-2017
OI Léveillard, Thierry/0000-0001-5692-8770; Sennlaub,
   Florian/0000-0003-4412-1341; Philp, Nancy/0000-0001-7028-0448
FU Inserm, Sorbonne University; Agence Nationale pour la Recherche (Labex
   Lifesenses)
FX This research was funded by Inserm, Sorbonne University and the Agence
   Nationale pour la Recherche (Labex Lifesenses).
CR Adijanto J, 2012, CURR TOP MEMBR, V70, P275, DOI 10.1016/B978-0-12-394316-3.00009-0
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Audo I, 2014, HUM MOL GENET, V23, P491, DOI 10.1093/hmg/ddt439
   Berg J., 2002, BIOCHEMISTRY-US, V2002, P5
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bisetto S, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00324
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Calippe B, 2014, CR BIOL, V337, P178, DOI 10.1016/j.crvi.2013.12.003
   Camacho ET, 2016, B MATH BIOL, V78, P1394, DOI 10.1007/s11538-016-0185-x
   Chen PW, 2017, P NATL ACAD SCI USA, V114, P580, DOI 10.1073/pnas.1614035114
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chinchore Y, 2017, ELIFE, V6, DOI 10.7554/eLife.25946
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cordes T, 2016, J BIOL CHEM, V291, P14274, DOI 10.1074/jbc.M115.685792
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Daniele LL, 2008, AM J PHYSIOL-CELL PH, V295, pC451, DOI 10.1152/ajpcell.00124.2008
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   De Jong PTVM, 2018, EYE, V32, P904, DOI 10.1038/eye.2017.298
   De Santa F, 2019, ANTIOXID REDOX SIGN, V30, P1553, DOI 10.1089/ars.2017.7420
   Doulias PT, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003252
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   El Kasmi KC, 2015, SEMIN IMMUNOL, V27, P267, DOI 10.1016/j.smim.2015.09.001
   Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flatt JF, 2011, BLOOD, V118, P5267, DOI 10.1182/blood-2010-12-326645
   Fridlich R, 2009, MOL CELL PROTEOMICS, V8, P1206, DOI 10.1074/mcp.M800406-MCP200
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galvan-Pena S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00420
   Gautier EL, 2013, BLOOD, V122, P2714, DOI 10.1182/blood-2013-01-478206
   Gentric G, 2017, ANTIOXID REDOX SIGN, V26, P462, DOI 10.1089/ars.2016.6750
   Ghazi NG, 2002, RETINA-J RET VIT DIS, V22, P509, DOI 10.1097/00006982-200208000-00023
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488
   HEBERT DN, 1992, J BIOL CHEM, V267, P23829
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Horton JC, 2015, SCI REP-UK, V5, DOI 10.1038/srep12364
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kobzik L, 2009, AM J RESP CELL MOL, V41, P9, DOI 10.1165/rcmb.2009-0156TR
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Leveillard T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8475125
   Leveillard T, 2017, CELL MOL LIFE SCI, V74, P3649, DOI 10.1007/s00018-016-2318-7
   Leveillard T, 2015, ONCOTARGET, V6, P32285, DOI 10.18632/oncotarget.5963
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liu XB, 2008, DIABETES, V57, P1651, DOI 10.2337/db07-1761
   Lu J, 2014, FREE RADICAL BIO MED, V66, P75, DOI 10.1016/j.freeradbiomed.2013.07.036
   Mathis T, 2017, AGING CELL, V16, P173, DOI 10.1111/acel.12540
   MCFADDEN BA, 1977, J BACTERIOL, V131, P136, DOI 10.1128/JB.131.1.136-144.1977
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mei X, 2016, ANTIOXID REDOX SIGN, V24, P909, DOI 10.1089/ars.2015.6509
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Michelucci A, 2013, P NATL ACAD SCI USA, V110, P7820, DOI 10.1073/pnas.1218599110
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitamura Y, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518170
   Monden I, 2001, BIOL CHEM, V382, P1551, DOI 10.1515/BC.2001.189
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   Nonnenmacher Y, 2018, CELL MOL LIFE SCI, V75, P2093, DOI 10.1007/s00018-018-2784-1
   Ochrietor JD, 2003, INVEST OPHTH VIS SCI, V44, P4086, DOI 10.1167/iovs.02-0995
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Palsson-McDermott EM, 2015, CELL METAB, V21, P65, DOI [10.1016/j.cmet.2014.12.005, 10.1016/j.cmet.2015.01.017]
   Philp NJ, 1998, AM J PHYSIOL-REG I, V274, pR1824, DOI 10.1152/ajpregu.1998.274.6.R1824
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Rajagopal R, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97076
   Rajala A, 2016, ONCOTARGET, V7, P46924, DOI 10.18632/oncotarget.10447
   Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532
   Roberts PA, 2017, J THEOR BIOL, V425, P53, DOI 10.1016/j.jtbi.2017.05.006
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schumann J, 2016, EUR J PHARMACOL, V785, P18, DOI 10.1016/j.ejphar.2015.04.057
   Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Moretti AIS, 2017, ARCH BIOCHEM BIOPHYS, V617, P106, DOI 10.1016/j.abb.2016.11.007
   SPOLARICS Z, 1994, J LEUKOCYTE BIOL, V56, P453, DOI 10.1002/jlb.56.4.453
   StClair EW, 1996, J EXP MED, V184, P1173, DOI 10.1084/jem.184.3.1173
   Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tan Z, 2015, J BIOL CHEM, V290, P46, DOI 10.1074/jbc.M114.603589
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang W, 2016, CELL REP, V15, P372, DOI 10.1016/j.celrep.2016.03.022
   Wei XC, 2016, NATURE, V539, P294, DOI 10.1038/nature20117
   Weinberg SE, 2015, IMMUNITY, V42, P406, DOI 10.1016/j.immuni.2015.02.002
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Yang JJ, 2017, AM J HUM GENET, V101, P404, DOI 10.1016/j.ajhg.2017.08.002
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 118
TC 46
Z9 48
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB 1
PY 2019
VL 20
IS 3
AR 762
DI 10.3390/ijms20030762
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HQ4WR
UT WOS:000462412500306
PM 30754662
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lau, JTF
   Lee, V
   Fan, D
   Lau, M
   Michon, J
AF Lau, JTF
   Lee, V
   Fan, D
   Lau, M
   Michon, J
TI Knowledge about cataract, glaucoma, and age related macular degeneration
   in the Hong Kong Chinese population
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; LENS OPACITIES; PREVALENCE; AUSTRALIA
AB Aims: Patients' knowledge and participation in their care are important in prevention of blindness from common eye diseases such as cataract, glaucoma, and age related macular degeneration (AMD). The aim of this study was to measure knowledge of these conditions in the Hong Kong Chinese population.
   Methods: Subjects aged 40 and above in the Shatin district of Hong Kong were randomly selected as part of a larger study of causes of adult visual loss. The subjects received eye examinations in which the primary cause of visual disability was recorded. The respondents were asked by trained interviewers in a standardised fashion about their knowledge of cataract, glaucoma, and AMD, Their answers were rated for accuracy by a senior ophthalmologist.
   Results: Out of the 2538 eyes examined, 7.0% had visual acuity less than 6/18. Fully 69.6% of the visual disability for those aged 60 or above was caused by cataract, AMD, or glaucoma. Awareness, of cataract in particular was high, in that over 90% of respondents had heard of it. However, only 22.9% of them could describe cataract symptoms correctly, and these percentages were even lower in glaucoma (10.2%) and AMD (<1%). Over 40% of subjects did not know that surgery was an appropriate treatment for cataract.
   Conclusion: This sample of the Hong Kong Chinese population had limited knowledge of common eye diseases. Educational programmes to enhance public awareness may be needed to improve the effectiveness of health promotion and thus prevent unnecessary blindness.
C1 Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27710 USA.
   Chinese Univ Hong Kong, Ctr Clin Trials & Epidemiol Res, Hong Kong, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Surg & Anat, Hong Kong, Hong Kong, Peoples R China.
   Hong Kong Adventist Hosp, Ctr Eye, Hong Kong, Hong Kong, Peoples R China.
C3 Duke University; Chinese University of Hong Kong; Chinese University of
   Hong Kong; University of Hong Kong
RP Michon, J (通讯作者)，Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27710 USA.
CR Coleman AL, 1999, LANCET, V354, P1803, DOI 10.1016/S0140-6736(99)04240-3
   Dandona R, 2001, B WORLD HEALTH ORGAN, V79, P96
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GARRAWAY WM, 1987, JAMA-J AM MED ASSOC, V258, P214, DOI 10.1001/jama.258.2.214
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Konstas AGP, 2000, EYE, V14, P752, DOI 10.1038/eye.2000.197
   KRAFT DP, 1988, J ALCOHOL DRUG EDUC, V34, P37
   Leske MC, 1997, ARCH OPHTHALMOL-CHIC, V115, P105, DOI 10.1001/archopht.1997.01100150107018
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780
   LOU JTF, 2002, BR J OPHTHALMOL, V86, P12
   Margo CE, 2002, OPHTHALMOLOGY, V109, P614, DOI 10.1016/S0161-6420(01)00820-X
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   *ROYAL AUSTR COLL, 1995, PREF PRACT PATT CAT
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   WORDEN JK, 1990, PREV MED, V19, P254, DOI 10.1016/0091-7435(90)90026-G
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 20
TC 57
Z9 61
U1 0
U2 4
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2002
VL 86
IS 10
BP 1080
EP 1084
DI 10.1136/bjo.86.10.1080
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 595YE
UT WOS:000178135200006
PM 12234882
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Hussain, AA
   Lee, Y
   Zhang, JJ
   Marshall, J
AF Hussain, Ali A.
   Lee, Yunhee
   Zhang, Jin-Jun
   Marshall, John
TI Disturbed Matrix Metalloproteinase Activity of Bruch's Membrane in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; TISSUE INHIBITOR; DARK-ADAPTATION;
   MATRIX-METALLOPROTEINASE-9 PROMOTER; HYDRAULIC CONDUCTIVITY; BASAL
   DEPOSITS; IV COLLAGENASE; OXIDANT INJURY; EXPRESSION; CELLS
AB PURPOSE. To evaluate the potential role of the matrix metalloproteinase (MMP) system of Bruch's membrane in the pathology of age-related macular degeneration.
   METHODS. Free and bound pools of gelatinase activity in Bruch's membrane-choroid preparations were isolated by phosphate-buffered saline (PBS) and sodium dodecyl sulfate (SDS) extraction, respectively. Individual MMP species were separated by gelatin-substrate zymography and the levels were quantified by densitometric techniques. Altogether, 13 control (age range, 71-99 years) and 6 AMD (age range, 71-95 years) donor eyes were used.
   RESULTS. All the gelatinase components normally present in control samples were also present in AMD tissue without any significant differences in their molecular masses. Total levels (bound plus free) of active MMP2 and -9 were significantly reduced in AMD donors (P < 0.05). The decrease in active MMP2 may be attributable to a similar reduction in the level of free pro-MMP2, the precursor to the active form. Reduction in active MMP9 occurred despite a nearly 3.5-fold increase in free pro-MMP9. The high-molecular-mass gelatinases denoted by HMW1 and -2 and comprising homo-and heteropolymers of pro-MMP2 and -9 were also raised in AMD (P < 0.05). The sequestration of free pro-MMP2 and -9 by these high-molecular-mass complexes may further contribute to reduced rates of activation of MMPs.
   CONCLUSIONS. The reduction in the levels of activated MMP2 and -9 may be responsible for impaired matrix degradation of Bruch's membrane, leading to the pathology associated with AMD. The degradation pathway is therefore a viable therapeutic target for future intervention. (Invest Ophthalmol Vis Sci. 2011;52:4459-4466) DOI:10.1167/iovs.10-6678
C1 [Hussain, Ali A.; Lee, Yunhee; Zhang, Jin-Jun; Marshall, John] Univ London, UCL Inst Ophthalmol, Div Mol Therapy, London EC1V 9EL, England.
C3 University of London; University College London
RP Hussain, AA (通讯作者)，Univ London, UCL Inst Ophthalmol, Div Mol Therapy, 11-43 Bath St, London EC1V 9EL, England.
EM alyhussain@aol.com
RI Mitchell, Paul/P-1498-2014
FU Fight for Sight UK; Guide Dogs for the Blind UK
FX Supported by Fight for Sight UK and Guide Dogs for the Blind UK.
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Alcazar O, 2007, INVEST OPHTH VIS SCI, V48, P5662, DOI 10.1167/iovs.07-0392
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FINI ME, 1995, INVEST OPHTH VIS SCI, V36, P622
   FIOTTI N, 2007, GENET MED, V4, P272
   Fornoni A, 2002, J AM SOC NEPHROL, V13, P2068, DOI 10.1097/01.ASN.0000022421.86757.8D
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   HAMLIN CR, 1971, BIOCHIM BIOPHYS ACTA, V236, P458, DOI 10.1016/0005-2795(71)90226-1
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   HUNT RC, 1993, INVEST OPHTH VIS SCI, V34, P3179
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Hussain AA, 2010, INVEST OPHTH VIS SCI, V51, P2363, DOI 10.1167/iovs.09-4259
   Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Kumar A, 2010, INVEST OPHTH VIS SCI, V51, P2664, DOI 10.1167/iovs.09-4195
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075
   MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455
   MURPHY G, 1995, METHOD ENZYMOL, V248, P470
   Nagai N, 2009, INVEST OPHTH VIS SCI, V50, P1903, DOI 10.1167/iovs.08-2383
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Peters DG, 1999, STROKE, V30, P2612, DOI 10.1161/01.STR.30.12.2612
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Shimajiri S, 1999, FEBS LETT, V455, P70, DOI 10.1016/S0014-5793(99)00863-7
   Smine A, 1997, CURR EYE RES, V16, P925, DOI 10.1076/ceyr.16.9.925.5044
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   STJEAN PL, 1995, ANN HUM GENET, V59, P17
   STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331
   VATER CA, 1979, BIOCHEM J, V181, P639, DOI 10.1042/bj1810639
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Ye S, 2000, MATRIX BIOL, V19, P623, DOI 10.1016/S0945-053X(00)00102-5
   Yoon S, 1999, BIOCHEM BIOPH RES CO, V265, P563, DOI 10.1006/bbrc.1999.1721
NR 54
TC 56
Z9 57
U1 2
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2011
VL 52
IS 7
BP 4459
EP 4466
DI 10.1167/iovs.10-6678
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800BP
UT WOS:000293332500072
PM 21498613
DA 2022-11-30
ER

PT J
AU Tamura, H
   Tsujikawa, A
   Yamashiro, K
   Akagi-Kurashige, Y
   Nakata, I
   Nakanishi, H
   Hayashi, H
   Ooto, S
   Otani, A
   Yoshimura, N
AF Tamura, Hiroshi
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Akagi-Kurashige, Yumiko
   Nakata, Isao
   Nakanishi, Hideo
   Hayashi, Hisako
   Ooto, Sotaro
   Otani, Atsushi
   Yoshimura, Nagahisa
TI Association of ARMS2 Genotype With Bilateral Involvement of Exudative
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   CIGARETTE-SMOKING; JAPANESE PATIENTS; FELLOW EYES; CFH Y402H;
   POLYMORPHISM; RISK; MACULOPATHY; LOC387715
AB PURPOSE: To study the association of ARMS2 A69S genotype with the development of exudative age-related macular degeneration (AMD) in the unaffected fellow eye and to estimate the duration until the development of AMD in the second eye.
   DESIGN: Retrospective cohort study.
   METHODS: We retrospectively reviewed 326 patients who had exudative AMD in at least 1 eye, genotyping of ARMS2 A69S, and a minimum follow-up of 2 years. Survival analysis and Cox proportional hazard regression analysis were used to examine the association between candidate factors and the duration until the development of AMD in the second eye.
   RESULTS: One hundred nineteen patients (36.5%) had bilateral exudative AMD at the initial visit. A risk allele of ARMS2 A69S was more frequently seen in patients with bilateral AMD (P = .0270) than in those with unilateral AMD. Of the 207 unilateral AMD patients, 23 (11.1%) had AMD in the fellow eye after a mean duration of 56.3 +/- 40.4 months. Fellow-eye involvement was associated with ARMS2 A69S genotype (hazard ratio [HR] 2.673; P = .0013), age (HR, 1.102; P = .0005), and smoking history (HR, 0.680; P = .3663). As HRs indicate, correlation of genotype (2.673) was as high as that of 10-year aging (1.102(10) = 2.641). Survival analysis revealed that patients with risk homozygous (TT) genotype had second-eye involvement significantly earlier than those with other genotypes (P = .0028). When the observation duration reached 120 months, second-eye involvement had developed in 50%, 6.6%, and 11.2% of the TT, GT, and GG cohorts, respectively.
   CONCLUSION: ARMS2 A69S genotype is associated with second-eye involvement of exudative AMD and with the period between first- and second-eye involvements. (Am J Ophthalmol 2012;154:542-548. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Tamura, Hiroshi] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tamura, H (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM htamura@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamashiro, Kenji/0000-0001-9354-8558
FU Pfizer; Topcon Corporation; Nidek; Canon; Japan Society for the
   Promotion of Science, Tokyo, Japan [22791655]; Japan National Society
   for the Prevention of Blindness, Tokyo, Japan
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF Interest. A. Tsujikawa has received grant
   support from Pfizer; N. Yoshimura is a consultant for Nidek and has
   received grant support and lecture fees from Topcon Corporation, Nidek,
   and Canon. Publication of this article was supported in part by
   grants-in-aid for scientific research (Nos. 22791655) from the Japan
   Society for the Promotion of Science, Tokyo, Japan; and the Japan
   National Society for the Prevention of Blindness, Tokyo, Japan. The
   funding organizations had no role in the design or conduct of this
   research. Involved in conception and design of study (H.T., AT., K.Y.,
   N.Y.); analysis and interpretation (H.T., AT., K.Y., Y.A.-K., I.N.);
   writing of the article (H.T.. K.Y.); critical revision of the article
   (AT., S.O., K.Y., N.Y.); final approval of the article (H.T., AT., K.Y.,
   Y.A.-K., IN., H.H., SO., A.O., N.Y.); and data collection (I-IT.,
   Y.A.-K., IN., H.N., H.H.). Both prospective protocol to collect DNA and
   retrospective protocol for the review of selected patients in the
   current study were approved by the Institutional Review Board (IRB) of
   Kyoto University Hospital and Kyoto University Graduate School of
   Medicine. All patients were fully informed of the purpose and procedure
   of this study, and written consent was obtained from each patient
   included in this study. All investigations in the current study adhered
   to the tenets of the Declaration of Helsinki.
CR Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Bessho H, 2011, MOL VIS, V17, P977
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Carlton J, 2008, Health Technol Assess, V12, pxi
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
NR 32
TC 14
Z9 15
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2012
VL 154
IS 3
BP 542
EP 548
DI 10.1016/j.ajo.2012.03.042
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 996SR
UT WOS:000308115600019
PM 22809783
OA Green Published
DA 2022-11-30
ER

PT J
AU Tiosano, L
   Corradetti, G
   Sadda, SR
AF Tiosano, Liran
   Corradetti, Giulia
   Sadda, Srinivas R.
TI Progression of choriocapillaris flow deficits in clinically stable
   intermediate age-related macular degeneration
SO EYE
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; SWEPT-SOURCE; DRUSEN; IMPACT; EYES
AB Purpose To evaluate the choriocapillaris (CC) flow deficit (FD) in eyes with stable intermediate age-related macular degeneration (AMD) eyes over 12 months of follow-up.
   Methods Thirty four patients with intermediate AMD were prospectively enrolled and evaluated by swept-source optical coherence tomography (SS-OCT) and OCT-angiography (OCTA) using the PLEX-Elite 9000. A 6 x 6 mm foveal-centered scan was used for both modalities and the study eyes were scanned twice to allow subsequent averaging. En face OCTA CC slabs (31-41 mu m below the RPE-band) were exported and compensated for signal attenuation. Two compensated CC en-face images were registered and averaged prior to binarization and CC FD computation. The CC FD of the entire 6 x 6 macular region was quantified at baseline and at 12-months. The presence of high-risk features, namely intraretinal hyper-reflective foci (HRF), subretinal drusenoid deposits (SDD), and hyporeflective-core-drusen, were evaluated using SS-OCT volume scans.
   Results Among the 34 eyes, 25 eyes from 25 patients were noted on exam and OCT to remain stable as intermediate AMD at 12-months without the development of late AMD. Eleven eyes had high-risk features at baseline compared to 14 eyes at the end of the follow-up (p = 0.094). The mean +/- SD FD% across the whole 6 x 6 macular region at baseline was 19.32 +/- 4.64% and significantly increased to 28.62 +/- 4.71% at the end of the study (p = 0.001). The CC FD progressed significantly both in non-HR and HR-eyes.
   Conclusions Choriocapillaris flow impairment significantly deteriorated over one year in relatively stable intermediate AMD. This might suggest that underlying progression of CC dysfunction occurs before structural changes appears on OCT and lead to the progression to late-stage AMD.
C1 [Tiosano, Liran; Corradetti, Giulia; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading & Res Lab, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Tiosano, Liran; Corradetti, Giulia; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Tiosano, Liran] Hadassah Hebrew Univ, Hebrew Univ Jerusalem, Dept Ophthalmol, Fac Med,Med Ctr, Jerusalem, Israel.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Hebrew University of
   Jerusalem; Hadassah University Medical Center
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading & Res Lab, 1355 San Pablo St, Los Angeles, CA 90033 USA.; Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM Sadda@doheny.org
RI Corradetti, Giulia/Q-5400-2019
OI Corradetti, Giulia/0000-0001-9213-5575
CR Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Borrelli E, 2018, RETINA, V39, P1216, DOI DOI 10.1097/IAE.0000000000002123
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Byon I, 2021, RETINA-J RET VIT DIS, V41, P393, DOI 10.1097/IAE.0000000000002906
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Eye TA, 2013, 8 AREDS, P119
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Tiosano L, 2020, GRAEF ARCH CLIN EXP, V258, P2353, DOI 10.1007/s00417-020-04837-y
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 32
TC 2
Z9 2
U1 0
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2021
VL 35
IS 11
BP 2991
EP 2998
DI 10.1038/s41433-020-01298-9
EA JAN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WJ3DG
UT WOS:000605901900003
PM 33414537
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Rinsky, B
   Beykin, G
   Grunin, M
   Amer, R
   Khateb, S
   Tiosano, L
   Almeida, D
   Hagbi-Levi, S
   Elbaz-Hayoun, S
   Chowers, I
AF Rinsky, Batya
   Beykin, Gala
   Grunin, Michelle
   Amer, Radgonde
   Khateb, Samer
   Tiosano, Liran
   Almeida, Diego
   Hagbi-Levi, Shira
   Elbaz-Hayoun, Sarah
   Chowers, Itay
TI Analysis of the Aqueous Humor Proteome in Patients With Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age- related macular degeneration; aqueous humor; retinal degeneration
ID PERIPHERAL-BLOOD MONOCYTES; EPITHELIUM-DERIVED FACTOR; CHOROIDAL
   NEOVASCULARIZATION; ASSOCIATION; GENE; INFLAMMATION; EXPRESSION; DRUSEN;
   SERUM; AMD
AB PURPOSE. Age-related macular degeneration (AMD) is associated with altered gene and protein expression in the retina. We characterize the aqueous humor (AH) proteome in AMD to gain insight into the pathogenesis of the disease and identify potential biomarkers.
   METHODS. AH was collected from age and gender matched neovascular AMD (nvAMD; n = 10) patients and controls (n = 10). AH was pooled to create two samples (nvAMD and control), followed by intensity-based label-free quantification (MS1). Functional and bioinformatic analysis were then performed. A validation set (20 controls, 15 atrophic AMD and 15 nvAMD) was tested via multiplex ELISA for nine differentially expressed proteins according to the MS1 findings.
   RESULTS. MS1 identified 674 proteins in the AH. 239 proteins were upregulated in nvAMD (nvAMD/control > 2, peptide tags (PT) > 2), and 86 proteins were downregulated (nvAMD/control < 0.5, PT > 2). Functional analysis of proteins upregulated in AMD demonstrated enrichment for platelet degranulation (enrichment score (ES):28.1), negative regulation of endopeptidase activity (ES:18.8), cellular protein metabolic process (ES:11.8), epidermal growth factor-like domain (ES:10.3), sushi/SCR/CCP (ES:10.1), and complement/coagulation cascades (ES:9.2). AMD protein clusters were upregulated for 3/6 (chi(2) < 0.05 compared to randomization). Validation via ELISA confirmed MS1 in 2/9 proteins (Clusterin and Serpin A4, P < 0.05), while 3/9 showed differential expression between aAMD and nvAMD (Clusterin, Serpin A4, and TF P < 0.05). Receiver operating characteristic curve calculation identified the area under the curve of 0.82 for clusterin as a biomarker for distinction of AMD.
   CONCLUSIONS. AH proteomics in AMD patients identified several proteins and functional clusters with altered expression. Further research should confirm if these proteins may serve as biomarkers or therapeutic target for the disease.
C1 [Rinsky, Batya; Beykin, Gala; Grunin, Michelle; Amer, Radgonde; Khateb, Samer; Tiosano, Liran; Almeida, Diego; Hagbi-Levi, Shira; Elbaz-Hayoun, Sarah; Chowers, Itay] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
C3 Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.; Chowers, I (通讯作者)，Hebrew Univ Jerusalem, Fac Med, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
FU Israel Science Foundation (ISF) [1006/13]
FX Supported in part by a grant from the Israel Science Foundation (ISF;
   Grant 1006/13).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baek JH, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0941-9
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Chen H, 2016, MOL VIS, V22, P1005
   Chowdhury UR, 2010, INVEST OPHTH VIS SCI, V51, P4921, DOI 10.1167/iovs.10-5531
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Grunin M, 2016, OPHTHALMIC GENET, V37, P285, DOI 10.3109/13816810.2015.1059456
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Hagbi-Levi S, 2017, NEUROBIOL AGING, V51, P71, DOI 10.1016/j.neurobiolaging.2016.11.018
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jackson John K., 2005, Angiogenesis, V8, P229, DOI 10.1007/s10456-005-9018-5
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kaeslin MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165314
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kim J, 2012, J REPROD IMMUNOL, V94, P190, DOI 10.1016/j.jri.2012.02.002
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kulaksizoglu S, 2016, CAN J DIABETES, V40, P115, DOI 10.1016/j.jcjd.2015.07.002
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Li B, 2019, HUM GENE THER, V30, P339, DOI 10.1089/hum.2018.084
   Nobl M, 2016, EXP EYE RES, V146, P107, DOI 10.1016/j.exer.2016.01.001
   Pollok-Kopp B, 2008, WIEN KLIN WOCHENSCHR, V120, P58
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Richardson MR, 2009, MOL VIS, V15, P2740
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Shalit T, 2015, J PROTEOME RES, V14, P1979, DOI 10.1021/pr501045t
   Silva JC, 2006, MOL CELL PROTEOMICS, V5, P144, DOI 10.1074/mcp.M500230-MCP200
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Wasmuth E. V., 2016, NUCLEIC ACIDS RES, V45, P1, DOI DOI 10.1093/NAR/GKW1152
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Zhu XJ, 2016, EXP EYE RES, V142, P13, DOI 10.1016/j.exer.2015.03.017
NR 40
TC 3
Z9 4
U1 4
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2021
VL 62
IS 10
AR 18
DI 10.1167/iovs.62.10.18
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UP2QS
UT WOS:000695230000018
PM 34406330
OA gold, Green Published
DA 2022-11-30
ER

EF